book,chapter,bullets,text,para_num_tokens,bullets_num_tokens,compression_ratio
9781905832729,ch_2,The bladder operates as a low-pressure high-volume system.,"Continence is maintained by a complex interaction between the bladder, the urethra, the pelvic floor muscles, the endopelvic fascia and the nervous system. The bladder operates as a low-pressure high-volume system, pressure increasing slowly and steadily as the bladder fills, normally at a rate of 0.5-5 mL/minute. It can usually hold 500-600 mL urine. A first need to void is felt when the bladder contains 250-300 mL. Continence is maintained as long as the urethral pressure exceeds the bladder pressure.",114,13,0.11403508771929824
9781905832729,ch_2,"Urine storage and voiding are controlled by reflex centers in the spinal cord, the micturition center in the midbrain and the somatic and parasympathetic nervous systems.","During normal voiding, voluntary relaxation of the striated musculature in and around the urethra precedes contraction of the detrusor (bladder) muscle. The bladder neck and proximal urethra (often referred to as the 'bladder outlet') become funnel shaped. This relaxation/contraction combination reduces outflow resistance and increases intravesical (in the bladder) pressure, causing the bladder to be emptied forcibly. Urine storage and voiding are controlled by reflex centers in the spinal cord and the micturition center in the midbrain. Both the autonomic and somatic nervous systems are involved. The innervation of the bladder is shown in Figure 1.2. The main neurological pathways that affect bladder contraction are parasympathetic. The sacral reflex center is situated in S2 to S4, and the pelvic nerve and its branches lead from here to the detrusor muscle. Excitation of these nerves stimulates the release primarily of acetylcholine, which acts on muscarinic receptors to cause detrusor contraction.",216,38,0.17592592592592593
9781905832729,ch_2,"Voiding requires a coordinated contraction of the detrusor (bladder smooth musculature), simultaneous opening of the bladder outlet (involuntary) and relaxation of the external urethral sphincter (voluntary). Continence requires the converse.","During normal bladder filling, there is no excitatory input from the micturition center in the brain to the sacral micturition center or from the sacral micturition center to the pelvic nerves. The detrusor (bladder) is quiescent. There is a gradual increase in the tone of the external sphincter (striated muscle), mediated through impulses via the pudendal nerve. Voiding depends on coordinated excitation of the sacral parasympathetic nerves and simultaneous opening of the bladder outlet (involuntary) and relaxation of the external urethral sphincter (voluntary); continence requires the converse (Table 1.1). Storage and voluntary emptying of the bladder are also influenced by psychological and sociocultural factors. Adults are trained to void in a socially acceptable place and women may not want or like to void in any other place than their homes because of concern about unsafe or unsanitary toilet facilities. Using a toilet away from home can cause psychological stress, suppression of the desire to void and infrequent voiding. Voiding position and posture (exempli gratia squatting or sitting) used by women to empty the bladder differs by cultures or by health status. Negative perceptions of the physical environment of toilets can alter toileting stance or suppress the desire to void.",279,54,0.1935483870967742
9781905832729,ch_3,"Lower urinary tract symptoms are key in the diagnosis of bladder disorders: onset, duration and severity should be recorded.","Urologic symptoms are clearly a key aspect in the diagnosis of urinary disorders, but may not be reliable when used alone; as many have stated, the bladder may be an unreliable witness. The onset of urinary symptoms, their duration and severity, and the time(s) when they occur, should be recorded. Symptoms can be divided into filling/storage, voiding/emptying and postmicturition. Filling symptoms.",88,22,0.25
9781905832729,ch_3,"Urinary symptoms can relate to filling (frequency, nocturia, urgency), storage (stress incontinence, urgency incontinence, nocturnal enuresis) or voiding/emptying (hesitancy, intermittent stream, slow stream, terminal dribble, incomplete emptying).","Urologic symptoms are clearly a key aspect in the diagnosis of urinary disorders, but may not be reliable when used alone; as many have stated, the bladder may be an unreliable witness. The onset of urinary symptoms, their duration and severity, and the time(s) when they occur, should be recorded. Symptoms can be divided into filling/storage, voiding/emptying and postmicturition. Filling symptoms. Frequency is the complaint of voiding too often by day and is usually defined as more than eight voids per 24 hours. Increased daytime frequency can occur with a normal bladder capacity where there is excessive fluid intake, or where the bladder capacity is affected by detrusor overactivity, impaired bladder compliance (compliance refers to the tonic change in bladder pressure during filling - usually, bladder compliance is normal if there is little or no change in detrusor pressure during filling) or increased bladder sensation (hypersensitivity). The causes of daytime frequency are shown in Table 2.1. Nocturia is the complaint of waking to void one or more times during the night. It may occur for the same reasons as daytime frequency, but may also occur in association with congestive heart failure (causing nocturnal polyuria) or because the normal circadian rhythm of antidiuretic hormone (ADH; desmopressin) secretion becomes reversed.",279,60,0.21505376344086022
9781905832729,ch_3,"Other assessments include cognitive and mobility evaluation, especially in the elderly.","The strength of the pelvic floor muscles (PFM) should be assessed and can be quantified using a validated grading system such as the Oxford 1-5 scale. Factors to be assessed include strength, duration and repeatability of contractions, and displacement of the pelvic floor. Low-tone pelvic floor dysfunction refers to the examination findings of an impaired ability to isolate and contract the pelvic floor musculature in the presence of weak and atrophic musculature and is seen in women with POP, urinary or fecal incontinence, and vaginal weakness. High-tone pelvic floor dysfunction refers to the clinical condition of hypertonic spastic PFM with resultant impairment of muscle isolation, contraction and relaxation and is seen in women with interstitial cystitis/bladder pain syndrome, voiding dysfunction, overactive bladder, pelvic pain and sexual dysfunction with dyspareunia.",176,13,0.07386363636363637
9781905832729,ch_3,The effect of symptoms on quality of life can be assessed using self-completion questionnaires.,"Quality of life. There are a number of ways to assess the impact of incontinence symptoms on a patient's quality of life. However, the only valid way to measure the patient's perception of their symptoms is through the use of psychometrically robust self-completion questionnaires, such as the International Continence Society's International Consultation on Incontinence modular questionnaire (ICIQ; Figure 2.2) A wide variety of questionnaires were assessed by the Continence Society the questionnaires recommended for the assessment of quality of life for patients with urinary incontinence alone or in the presence of lower urinary tract symptoms are listed in Table 2.2.",134,19,0.1417910447761194
9781905832729,ch_3,A frequency/volume bladder record (bladder diary) is a simple and practical method to record voiding and fluid intake.,"Frequency/volume bladder record. Use of a bladder record or diary is a simple and practical method to obtain information on a patient's normal voiding pattern, including frequency and amount of micturition and episodes of leakage, in addition to the time and volume of fluid ingested. The patient records the times and volumes of all voids over a specific time period, which should be at least 24 hours so that both day and night are included. Episodes of urinary incontinence are recorded and whether they are associated with, for example, urgency, straining or coughing. Eliciting an estimate of the volume of leakage during incontinence episodes is helpful. The following descriptions of urine leakage can be used.",144,25,0.1736111111111111
9781905832729,ch_3,"Dipstick urinalysis is essential for all patients with urinary incontinence, bladder or urethral pain and is good practice in those with voiding/emptying symptoms. Positive tests should be evaluated further.","Urinalysis and culture. Dipstick urinalysis is used to detect hematuria, glycosuria, pyuria and bacteriuria. It should be carried out for all patients presenting with urinary incontinence to exclude the possibility of infection, inflammation, urinary tract malignancy and diabetes. A positive dipstick test should be followed up by formal urine microscopy and culture to detect a urinary tract infection (UTI) before treatment and to allow antibiotic sensitivity to be evaluated. The presence of hematuria or red blood cells on microscopy should be investigated further with urine cytology, an imaging study of the upper tracts (kidneys and ureters) and endoscopic examination of the bladder and urethra to rule out malignancy, especially in a patient over 50 years of age with symptoms of bladder irritation. The investigation and management of hematuria are described in detail in Chapter 6.",184,44,0.2391304347826087
9781905832729,ch_3,"Urodynamic investigation can provide a wide variety of information, but is not necessarily indicated for all patients.","Many clinicians request urodynamic investigation for any patient, especially a woman, who complains of lower urinary tract symptoms; however, the clinician may have little appreciation of the clinical indications, what the test involves and its limitations. Urodynamic investigation is safe, but men in particular may experience some discomfort related to catheterization, which can last for up to 24 hours after the test. The incidence of culture-proven UTI following urodynamic testing is approximately 1%; prophylactic antibiotics should therefore be considered for patients who may be at risk (exempli gratia immunosuppression or prosthesis implanted within last 2 years).",130,21,0.16153846153846155
9781905832729,ch_3,"Physical examination is essential, and may include neurological examination, abdominal examination and examination of the genitals.","Before incontinence surgery. In our opinion, urodynamic information is essential if surgery to treat incontinence, especially stress incontinence, is contemplated. There is, however, some debate as to the need for urodynamic investigation before incontinence surgery. The UK's National Institute for Health and Clinical Excellence (NICE) has issued guidelines stating that preoperative urodynamic studies are not necessary for patients undergoing a primary procedure and whose symptoms and examination findings suggest simple stress incontinence. We disagree with this recommendation, as it has been claimed that surgery carried out on the basis of symptoms alone is inappropriate in up to 25% of cases. Furthermore, surgery for stress incontinence can lead to voiding dysfunction and de novo detrusor overactivity (the urodynamic term describing involuntary bladder contraction), or may exacerbate pre-existing symptoms, so it is important to perform a preoperative assessment.",186,19,0.10215053763440861
9781905832729,ch_4,Stress incontinence is the involuntary leakage of urine on exertion. It is far more common in women than in men.,"Urinary incontinence (UI), defined as the involuntary loss of urine, is the focus of this chapter. A classification of UI is given in Table 3.1. Stress urinary incontinence (SUI) is defined as the involuntary leakage of urine on effort or exertion. Urgency incontinence is the involuntary leakage of urine accompanied, or immediately preceded, by urgency, and is largely caused by involuntary detrusor contractions (called detrusor overactivity) during bladder filling/storage. This is discussed in more detail in Chapter 4. Mixed incontinence refers to the coexistence of stress incontinence with urgency incontinence symptoms.",135,26,0.1925925925925926
9781905832729,ch_4,"Risk factors for stress incontinence in women include pregnancy, childbirth, menopause and obesity. Prostatectomy is the main cause in men.","SUI is often divided etiologically, especially in women, into SUI due to urethral hypermobility and that due to intrinsic sphincter deficiency (ISD). Hypermobility-related SUI implies the outlet is closed at rest and opens because of the lack of a supporting scaffold underneath (backboard) against which the urethra is normally compressed during increases in intra-abdominal pressure. The lack of support and, therefore, compression is what causes the leakage and results in urethral hypermobility. ISD implies the bladder neck and proximal urethra are not normal at rest (lack the normal closure pressure necessary to prevent exertional leakage). The bladder outlet that is damaged or diseased and fixed in an entirely open position represents the most extreme form of ISD. In reality, some ISD must exist for SUI to occur and thus sphincteric incontinence in the woman is generally due to a combination of hypermobility (lack of support) and ISD in variable proportions. Pure ISD can exist in women, and it is generally the cause of postprostatectomy sphincter incontinence in men, in whom no counterpart of hypermobility or poor support exists.",258,32,0.12403100775193798
9781905832729,ch_4,Other alternatives in women are colposuspension and injection of bulking agents.,"SUI is often divided etiologically, especially in women, into SUI due to urethral hypermobility and that due to intrinsic sphincter deficiency (ISD). Hypermobility-related SUI implies the outlet is closed at rest and opens because of the lack of a supporting scaffold underneath (backboard) against which the urethra is normally compressed during increases in intra-abdominal pressure. The lack of support and, therefore, compression is what causes the leakage and results in urethral hypermobility. ISD implies the bladder neck and proximal urethra are not normal at rest (lack the normal closure pressure necessary to prevent exertional leakage). The bladder outlet that is damaged or diseased and fixed in an entirely open position represents the most extreme form of ISD. In reality, some ISD must exist for SUI to occur and thus sphincteric incontinence in the woman is generally due to a combination of hypermobility (lack of support) and ISD in variable proportions. Pure ISD can exist in women, and it is generally the cause of postprostatectomy sphincter incontinence in men, in whom no counterpart of hypermobility or poor support exists.",258,16,0.06201550387596899
9781905832729,ch_4,"Options for management in men include injection of bulking agent into the urethral sphincter, insertion of a perineal sling or artificial urinary sphincter.","SUI is often divided etiologically, especially in women, into SUI due to urethral hypermobility and that due to intrinsic sphincter deficiency (ISD). Hypermobility-related SUI implies the outlet is closed at rest and opens because of the lack of a supporting scaffold underneath (backboard) against which the urethra is normally compressed during increases in intra-abdominal pressure. The lack of support and, therefore, compression is what causes the leakage and results in urethral hypermobility. ISD implies the bladder neck and proximal urethra are not normal at rest (lack the normal closure pressure necessary to prevent exertional leakage). The bladder outlet that is damaged or diseased and fixed in an entirely open position represents the most extreme form of ISD. In reality, some ISD must exist for SUI to occur and thus sphincteric incontinence in the woman is generally due to a combination of hypermobility (lack of support) and ISD in variable proportions. Pure ISD can exist in women, and it is generally the cause of postprostatectomy sphincter incontinence in men, in whom no counterpart of hypermobility or poor support exists.",258,36,0.13953488372093023
9781905832729,ch_4,"Behavioral modification, including pelvic floor muscle exercises, is effective in women and men when taught correctly, and a number of devices are available to assist with training.","Pelvic floor muscle exercises. The pelvic floor muscles support the bladder neck, rectum and vagina (Figure 3.1). Exercises to strengthen the pelvic floor, and therefore improve support of the bladder neck, were first described by Dr Arnold Kegel in 1948. The aims are to promote patient awareness and to improve the contractility and coordination of pelvic floor muscles, especially in women with weak pelvic floor muscles. Exercise regimens concentrate on both contraction strength and muscle endurance. The exercises described in Table 3.3 should be taught by a healthcare professional who has expertise in behavioral treatment for pelvic floor disorders (exempli gratia nurse specialist, physiotherapist). A pelvic floor muscle assessment should be performed to ensure correct technique. Improvement should be observed within 2-4 months.",159,33,0.20754716981132076
9781905832729,ch_4,The surgical procedure of choice in women is insertion of a retropubic or transobturator tape mid-urethral sling to provide support for the urethra.,"Duloxetine hydrochloride is a combined serotonin and norepinephrine (noradrenaline) reuptake inhibitor which is approved in Europe for the treatment of stress incontinence in women. Duloxetine is thought to work by increasing the tone of the urethral sphincter during filling/storage via its action on serotonin and norepinephrine in the spinal cord. Duloxetine can be used to treat moderate-to-severe stress incontinence, and has been shown to reduce the frequency of episodes of leakage. It may be more effective if combined with pelvic floor muscle exercises. Duloxetine is approved for use in Europe but not in the USA.",144,36,0.25
9781905832729,ch_5,"Overactive bladder (OAB) describes a condition in which the patient experiences urgency, with or without urge incontinence, usually with frequency and nocturia.","The term 'overactive bladder' (OAB) is defined as urgency, with or without urgency incontinence, usually with frequency and nocturia. The incidence of symptomatic OAB varies with age, from about 5% in those aged 18-44 years to 20% in those over 44 years of age. Although historically thought of as a condition in women, the prevalence of OAB is in fact only slightly lower in men than in women. A greater proportion of women with OAB have urgency incontinence (OAB-wet) than do men, who predominantly have OAB without incontinence (OAB-dry). The term detrusor overactivity refers to a urodynamic observation of involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked. It can only be diagnosed after urodynamic investigation. Not all patients with symptoms of OAB will be found to have detrusor overactivity, and not all patients with detrusor overactivity will have symptoms of bladder overactivity.",212,33,0.15566037735849056
9781905832729,ch_5,Detrusor overactivity refers to involuntary detrusor contractions during filling; diagnosis is by urodynamic investigation.,"The term detrusor overactivity refers to a urodynamic observation of involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked. It can only be diagnosed after urodynamic investigation. Not all patients with symptoms of OAB will be found to have detrusor overactivity, and not all patients with detrusor overactivity will have symptoms of bladder overactivity. Overactivity can be the result of neurological abnormalities in which involuntary detrusor contractions (detrusor overactivity) occur in the presence of underlying neuropathy (exempli gratia multiple sclerosis, Parkinson's disease, stroke, spinal cord injury or spina bifida).",138,24,0.17391304347826086
9781905832729,ch_5,Bladder overactivity can be neurogenic or idiopathic. Idiopathic OAB can be associated with bladder outlet obstruction.,"Bladder overactivity can also be idiopathic, occurring in a neurologically normal individual. This is by far the most common category but, as the name implies, it is not fully understood. Overactivity is seen commonly in association with bladder outlet obstruction (id est together with prostatic obstruction in men, or after surgery for incontinence in women). It is important to exclude causes such as urinary tract infection (UTI), which can be detected with a urine dipstick test and culture if indicated. A frequency/volume bladder record or diary (see Figure 2.3) is a reliable method of quantifying urinary frequency and volume. It also gives a good indication of fluid intake. Diaries should be kept for at least 3 days to allow for variations in normal activities, but the ideal duration is not known. The diary for a patient with OAB will show frequent, irregular, small-volume voids.",186,28,0.15053763440860216
9781905832729,ch_5,A frequency/volume bladder record is useful in diagnosis.,"It is important to exclude causes such as urinary tract infection (UTI), which can be detected with a urine dipstick test and culture if indicated. A frequency/volume bladder record or diary (see Figure 2.3) is a reliable method of quantifying urinary frequency and volume. It also gives a good indication of fluid intake. Diaries should be kept for at least 3 days to allow for variations in normal activities, but the ideal duration is not known. The diary for a patient with OAB will show frequent, irregular, small-volume voids.",113,11,0.09734513274336283
9781905832729,ch_5,Initial management includes behavioral modification.,"Urodynamic studies are rarely indicated initially in patients who have symptoms suggestive of OAB, and most patients receive empirical treatment (drugs and or behavioral) whether or not urodynamic studies show detrusor overactivity. The only real role for these tests in patients with OAB symptoms is if conservative therapy fails and more invasive treatment is contemplated.",70,6,0.08571428571428572
9781905832729,ch_5,Other options for refractory OAB are neuromodulation and augmentation cystoplasty. Intradetrusor botulinum toxin injection is under investigation and seems promising for refractory cases.,"Bladder training with urgency suppression. Individuals with OAB symptoms usually void more frequently than normal (called 'defensive voiding') because of urgency, or to avoid situations where urgency is likely to cause a problem. A toileting program, such as bladder training, can help this frequency as it uses a progressive voiding schedule combined with techniques to control and suppress urgency. In bladder training, the individual actively attempts to increase the interval between the first desire to void and the actual void. Patients are instructed to use techniques that control or suppress urgency. Slow, deep breathing exercises relax the bladder, decrease the intensity of the urgency and delay voiding, while distraction methods involve patients in tasks that require mental concentration. The voiding interval should be increased by 15 to 30 minutes each week until an interval of at least 3 to 4 hours is achieved. Bladder training has been shown to be beneficial, and a course lasting for a minimum of 6 weeks, together with pelvic floor muscle training with exercises (see exercises in Table 3.3), should be offered as first-line treatment.",215,43,0.2
9781905832729,ch_5,Antimuscarinic drugs are a mainstay of conservative treatment.,"Antimuscarinic drugs are the mainstay of treatment for symptoms of OAB and detrusor overactivity (Table 4.3). These drugs were thought to act by blocking the muscarinic receptors on the detrusor muscle that are stimulated by acetylcholine released by activated parasympathetic nerves, thereby reducing the ability of the bladder to contract. It should be noted, however, that these drugs work mainly during the storage phase, decreasing urgency and increasing bladder capacity, when there is normally no parasympathetic input into the lower urinary tract. All these agents have been shown to decrease afferent (sensory) neural traffic during filling/storage. Current thinking is that these agents act primarily on the sensory side at lower dosages. As the dosage increases, actions on the motor side may become apparent.",167,13,0.07784431137724551
9781905832729,ch_6,"Voiding problems occur when normal smooth emptying of the bladder is impeded, through obstruction or impaired detrusor contractility.","Voiding problems. Voiding (emptying) problems occur when there is an impediment to the normal smooth emptying of the bladder. This may result from obstruction to the normal bladder outflow - the focus of this chapter - alone or in combination with impaired contractility of the detrusor muscle. Bladder outlet obstruction may occur at any point along the length of the urethra from the bladder neck to the urethral meatus. Etiology and risk factors. The likely causes of bladder outlet obstruction are listed in Table 5.1. The most common cause in men is benign prostatic enlargement (BPE) secondary to hyperplasia and in women, pelvic organ prolapse (POP), with kinking of the urethra. The patient may present with a variety of storage and voiding symptoms.",170,27,0.1588235294117647
9781905832729,ch_6,"Benign prostatic enlargement secondary to benign prostatic hyperplasia (BPH), a process of normal aging in men, is the most common cause of outlet obstruction. In women, pelvic organ prolapse (POP) can cause obstruction. Rarer causes include posterior urethral valves, urethral stricture and bladder neck obstruction, which may be congenital or secondary to increased voiding pressures as a result of urethral abnormality.","The likely causes of bladder outlet obstruction are listed in Table 5.1. The most common cause in men is benign prostatic enlargement (BPE) secondary to hyperplasia and in women, pelvic organ prolapse (POP), with kinking of the urethra. The patient may present with a variety of storage and voiding symptoms. Benign prostatic hyperplasia (BPH) refers to a regional nodular growth of varying combinations of glandular and stromal proliferation that occurs in almost all men who have testes and who live long enough (see Fast Facts: Benign Prostatic Hyperplasia). The term encompasses histological cellular proliferation (microscopic BPH) and consequent prostate enlargement (macroscopic BPH). The term BPE indicates benign prostatic enlargement, usually due to BPH, while BPO indicates benign prostatic obstruction, a common cause of bladder outlet obstruction. Microscopic BPH is seen in about 25% of men aged 40-50 years, 50% of men aged 50-60 years, 65% of men aged 60-70 years, 80% of men aged 70-80 years and 90% of men aged 80-90 years. It is estimated that 25-50% of men with microscopic and macroscopic BPH (BPE) will develop lower urinary tract symptoms due to BPO. However, far fewer men complain about these symptoms than of BPH, and even fewer seek help because of these symptoms. The cause of BPH is not fully understood. The hormonal theory postulates that estrogen-androgen synergism associated with aging drives prostatic growth. Posterior urethral valves are a congenital cause of bladder outlet obstruction in boys, which, if severe, can lead to hydronephrosis and renal failure. One in every 5000-8000 boys is born with posterior urethral valves.",387,92,0.23772609819121446
9781905832729,ch_6,"Obstruction due to BPH can be treated with alpha-1 adrenoceptor antagonists and 5alpha-reductase inhibitors. Surgery (transurethral resection, vaporization or incision of the prostate) may be needed.","Urethral stricture is an abnormal narrowing of the urethra that causes obstruction to the outflow of urine and may ultimately lead to back pressure on the bladder, ureters and kidneys. Strictures may be caused by inflammation or scarring as a result of surgery, disease or injury. The risk is increased in patients with sexually transmitted diseases, repeated episodes of urethritis or BPH. Instrumentation of the urethra (with a catheter or cystoscope) also increases the risk. Congenital strictures and true strictures occur rarely in women. Primary bladder neck obstruction is thought to occur as a result of congenital constriction, or failure to open that is not associated with the urethra. It is characterized by incomplete opening of the bladder neck during voluntary or involuntary voiding. It is found almost exclusively in young and middle-aged men, and is characterized by long-standing storage and voiding symptoms. These men typically have normal-sized prostate glands, and objective evidence of obstruction is easily obtained on urodynamic examination. Once obstruction is diagnosed, it may be located to the bladder neck by videourodynamic investigation. The diagnosis may also be made on the grounds of outlet obstruction in the absence of urethral stricture, prostatic enlargement or detrusor-sphincter dyssynergia (DSD).",280,48,0.17142857142857143
9781905832729,ch_6,Surgery is often required for bladder neck obstruction and urethral stricture.,"Primary bladder neck obstruction is thought to occur as a result of congenital constriction, or failure to open that is not associated with the urethra. It is characterized by incomplete opening of the bladder neck during voluntary or involuntary voiding. It is found almost exclusively in young and middle-aged men, and is characterized by long-standing storage and voiding symptoms. These men typically have normal-sized prostate glands, and objective evidence of obstruction is easily obtained on urodynamic examination. Once obstruction is diagnosed, it may be located to the bladder neck by videourodynamic investigation. The diagnosis may also be made on the grounds of outlet obstruction in the absence of urethral stricture, prostatic enlargement or detrusor-sphincter dyssynergia (DSD).",162,16,0.09876543209876543
9781905832729,ch_6,Uroflowmetry and urodynamic investigations are useful in the diagnosis of outlet obstruction but are not indicated for all men thought to have BPH. Transurethral ultrasonography and measurement of postvoid residual volume may also provide useful information. Videourodynamic investigations can be helpful in women with POP and suspected obstruction.,"In addition, urinalysis should be performed to detect hematuria (see Chapter 6) and signs of infection, and serum creatinine should be measured. Some men with BPH will have some degree of renal impairment. It is important to investigate this, as it affects clinical management. For example, a man with BPH and renal impairment may require more urgent surgical intervention and will need to be monitored more closely during and after surgery. There is some debate about whether the measurement of prostate-specific antigen (PSA) should be mandatory. This issue is beyond the scope of this book; however, it would seem sensible to consider measuring the serum PSA in all men with a life expectancy of more than 5 years and in whom the diagnosis of prostate cancer would influence treatment decisions. Ideally, the advantages and disadvantages of such testing should be explained to the patient. Uroflowmetry and urodynamic investigation. Measurement of urinary flow rate is an extremely useful investigation in patients with voiding dysfunction. The reduced flow rate characteristic of prostatic outlet obstruction is shown in Figure 2.4. Urodynamically, outlet obstruction is generally defined as high detrusor pressure accompanied by low urine flow rate. Once obstruction has been diagnosed, videourodynamic investigation can be useful to determine the site of the obstruction. Urodynamic studies are not indicated for all men suspected of having BPH. They are most useful to differentiate outlet obstruction from impaired detrusor contractility, and should be performed in patients with equivocal findings in whom invasive therapy is being considered. Videourodynamic studies, with reduction of the POP, are helpful in women.",333,66,0.1981981981981982
9781905832729,ch_7,Blood in the urine can originate from anywhere along the urinary tract and may indicate underlying pathology.,"Hematuria can originate from anywhere along the urinary tract and may be an indicator of underlying pathology. It can be microscopic or macroscopic (gross), but the investigation for each is similar. The prevalence of hematuria on urine dipstick testing in adults is estimated by various sources to be 2-16%. Dipstick testing is sensitive but is not specific, and it is sometimes difficult to distinguish between 'physiological' amounts of blood in the urine and blood that is the result of pathology.",101,18,0.1782178217821782
9781905832729,ch_7,Management depends on the underlying cause identified.,"Hematuria can originate from anywhere along the urinary tract and may be an indicator of underlying pathology. It can be microscopic or macroscopic (gross), but the investigation for each is similar.",40,8,0.2
9781905832729,ch_7,Dipstick testing is sensitive but does not distinguish between physiological and pathological amounts of blood.,"The prevalence of hematuria on urine dipstick testing in adults is estimated by various sources to be 2-16%. Dipstick testing is sensitive but is not specific, and it is sometimes difficult to distinguish between 'physiological' amounts of blood in the urine and blood that is the result of pathology. Urinary tract pathology is found in 2-10% of patients under the age of 50 years with microscopic hematuria. The most common pathologies are stones, infection, nephritis and, in men, prostate enlargement (see 5.i). Urinary tract malignancy is rarely seen in patients under 40 years of age. Over 50 years, 10-20% of patients with microscopic hematuria will have significant urinary tract pathology. Malignancy is more common in this age group when there is gross hematuria.",170,18,0.10588235294117647
9781905832729,ch_7,"The most common causes of hematuria are stones, infection, nephritis and prostate enlargement. Malignancy becomes more likely in patients over 50 years of age and who smoke. Some drugs can cause hematuria.","Urinary tract pathology is found in 2-10% of patients under the age of 50 years with microscopic hematuria. The most common pathologies are stones, infection, nephritis and, in men, prostate enlargement (see 5.i). Urinary tract malignancy is rarely seen in patients under 40 years of age. Over 50 years, 10-20% of patients with microscopic hematuria will have significant urinary tract pathology. Malignancy is more common in this age group when there is gross hematuria. In taking a history it is important to distinguish hematuria from rectal bleeding, and from vaginal bleeding in women. A history of urinary frequency and dysuria would suggest an infectious cause, which is the most common cause of hematuria in young women. Urinary tract calculi may present with pain. Glomerulonephritis or nephropathy may occur secondary to a recent upper respiratory tract infection, rash or edema.",198,46,0.23232323232323232
9781905832729,ch_7,The morphology of red blood cells may distinguish between glomerular and lower urinary tract causes.,"Microscopy. Hematuria identified by dipstick urinalysis should always be investigated further by urine microscopy. Microscopic hematuria is present if more than three red blood cells per high-power field are visible in urinary sediment from two out of three freshly voided, clean-catch midstream urine samples. The incidence of hematuria on microscopy varies from 0.2% to 16.1% in population-based studies. Microscopy can also provide further information about the morphology of the red blood cells. Misshapen red blood cells are usually glomerular in origin, whereas normal red blood cells generally come from the lower urinary tract. Red blood cell casts are almost always associated with glomerular disease.",150,18,0.12
9781905832729,ch_7,Unexplained hematuria should be followed up with repeat tests at a later date.,"Urine culture is vital to exclude infection as a cause of hematuria; hematuria should never be attributed to infection without a positive culture. In the case of urine infection, a specimen should be examined after treatment to exclude continuing hematuria. Biochemistry. Urine should be tested for proteinuria, which may be a sign of renal pathology or an extrarenal medical disorder. If proteinuria is identified, serum urea, creatinine and electrolytes should be measured.",99,19,0.1919191919191919
9781905832729,ch_7,"Ultrasonography is useful for identifying renal parenchymal disease and urinary tract obstruction. Radiography will identify stones. CT scanning is highly sensitive for detecting stones, renal masses and infections.","Intravenous urography (IVU) was traditionally the modality of choice for imaging the urinary tract, and some still consider it to be the best imaging test for the initial evaluation of microscopic hematuria. It has limited sensitivity for the detection of small renal masses and cannot differentiate between solid and cystic masses. CT is more sensitive for detecting small renal masses, and is the investigation of choice for detecting renal tract stones - it is extremely sensitive (94-98%) compared with IVU (52-59%) and ultrasonography (19%). CT is used to detect and characterize solid renal masses as well as renal and perirenal infections and associated complications. CT is therefore the most efficient investigation in differentiating the causes of hematuria and, if used as the investigation of first choice, would reduce the time taken to diagnose the underlying etiology. The sensitivity of CT with urographic follow through (CT urography) in detecting urothelial lesions compared with IVU is not yet established.",209,41,0.19617224880382775
9781905832729,ch_7,"Investigation of hematuria can be in a 'one-stop' clinic with facilities for cytology, ultrasonography and flexible cystoscopy so that diagnosis can be made in one visit.","CT is more sensitive for detecting small renal masses, and is the investigation of choice for detecting renal tract stones - it is extremely sensitive (94-98%) compared with IVU (52-59%) and ultrasonography (19%). CT is used to detect and characterize solid renal masses as well as renal and perirenal infections and associated complications. CT is therefore the most efficient investigation in differentiating the causes of hematuria and, if used as the investigation of first choice, would reduce the time taken to diagnose the underlying etiology. The sensitivity of CT with urographic follow through (CT urography) in detecting urothelial lesions compared with IVU is not yet established. Cystoscopy is recommended for the investigation of hematuria in adults. It allows for accurate detection of mucosal abnormalities and can be performed reliably with a flexible or rigid cystoscope under local anesthesia. It is possible to take bladder biopsies using a flexible cystoscope, although resection requires a rigid cystoscope and general anesthesia. 'One-stop' clinics. In European countries, the investigation of hematuria is often carried out in 'one-stop' clinics with facilities for cytology, ultrasonography and flexible cystoscopy, the aim being to make the diagnosis in a single outpatient visit.",270,41,0.15185185185185185
9781905832729,ch_8,Recurrent urinary tract infection (UTI) is defined as a further UTI after resolution of initial bacteriuria.,"Because of the increasing problem of bacterial resistance to antibiotics, it is important to rationalize treatment of asymptomatic bacteriuria. The majority of patients will not benefit from antibiotic treatment, and it is thus not indicated. However, it is important to treat asymptomatic infections in a small number of patient groups, as summarized in Table 7.1. Recurrent urinary tract infection. Recurrent UTI is defined as a UTI followed by a further infection after resolution of the initial bacteriuria. Often this reinfection is caused by repeated contamination of the urinary tract with perineal flora.",123,24,0.1951219512195122
9781905832729,ch_8,"At least 20-30% of women will have a UTI at some time, 25% of whom will develop recurrent UTI. UTIs are relatively rare in men and are more likely to have a significant cause than in women.","Diagnosis. Urinalysis, using dipstick tests for leukocytes and bacterial nitrite production, is quick and easy. A positive dipstick test result has sensitivity in the region of 70% and a specificity of 80% for finding significant pathogens in urine. Microscopy remains the gold standard for the diagnosis of UTI, and urine must be cultured in the presence of antimicrobials to determine sensitivities. Investigation. The extent to which recurrent UTI should be investigated is controversial; it does, however, make sense to rule out the common pathological abnormalities. It is important to note that UTIs are relatively rare in men and are therefore more likely to have a significant cause than in women. Tests performed can include an estimation of postvoid residual urine volume, outpatient cystoscopy and imaging of the upper urinary tract, usually with ultrasonography and plain radiography, looking for calculi, evidence of reflux and cortical scarring. However, such investigations will prove negative in the majority of patients, and a degree of clinical discretion is required to prevent the expense and distress caused by overinvestigation, particularly in young women in whom concurrent pathology is unlikely.",239,47,0.19665271966527198
9781905832729,ch_8,"Urinalysis is quick and easy. A positive test should be followed up by microscopy, and the urine cultured to determine antimicrobial sensitivity.","Diagnosis. Urinalysis, using dipstick tests for leukocytes and bacterial nitrite production, is quick and easy. A positive dipstick test result has sensitivity in the region of 70% and a specificity of 80% for finding significant pathogens in urine. Microscopy remains the gold standard for the diagnosis of UTI, and urine must be cultured in the presence of antimicrobials to determine sensitivities. Investigation. The extent to which recurrent UTI should be investigated is controversial; it does, however, make sense to rule out the common pathological abnormalities. It is important to note that UTIs are relatively rare in men and are therefore more likely to have a significant cause than in women.",144,29,0.2013888888888889
9781905832729,ch_8,Antibiotic treatment is recommended for recurrent UTI; prophylactic antibiotics and self-medication should also be considered.,"Antibiotic treatment is recommended for patients with recurrent UTIs. Acute infections should be treated with a short course of an appropriate antibiotic, the type depending on local resistance. The majority of uncomplicated lower UTIs respond to a 3-day course of trimethoprim or a 7-day course of amoxicillin or nitrofurantoin. However, urine culture before treatment is important, given the widespread resistance to antibiotics. Alternative antibiotics for resistant organisms include co-amoxiclav, oral cephalosporins or a quinolone.",115,26,0.22608695652173913
9781905832729,ch_8,"Bladder pain syndrome (BPS) is characterized by suprapubic pain relating to bladder filling, accompanied by other symptoms such as frequency, in the absence of a proven UTI or other pathology. The diagnosis of interstitial cystitis (IC) is confined to patients with bladder pain symptoms with characteristic cytoscopic and histological features.","Suppressing UTI in patients with bacterial colonization can be done using methenamine hippurate, a urinary antiseptic that releases formaldehyde and keeps colony counts low. The dosage is 1 g combined with vitamin C, 1 g, twice daily. Vaginal estrogen. There is some evidence that vaginal estrogen is beneficial in postmenopausal women with recurrent UTIs. It increases the cellular glycogen concentration and encourages recolonization with Lactobacilli spp., thus reducing the vaginal pH and therefore the concentration of pathogenic bacteria. Vaginal estrogens can be delivered locally via creams, tablets and a ring. Bladder pain syndrome and interstitial cystitis. Bladder pain syndrome (BPS) and interstitial cystitis (IC) are described in the American Urological Association IC/BPS guideline as a condition in which a patient experiences an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks' duration, in the absence of infection or other identifiable causes. BPS is the encompassing term. The diagnosis of IC is confined to patients with painful bladder symptoms who have characteristic cystoscopic and histological features. Epidemiology. There is no real agreement as to the true incidence of BPS or IC, as there are no formalized diagnostic criteria. Estimates of the incidence of the latter vary from 8 to 1600 per 100000.",295,69,0.23389830508474577
9781905832729,ch_8,The etiology of BPS/IC is largely unknown.,"Etiology. Despite extensive scientific effort, the precise etiology of BPS and IC has yet to be explained. The initial descriptions of IC by Guy Hunner in 1918 included loss of epithelium, with the underlying mucosa showing granulation tissue, increased capillaries, edema and chronic inflammatory cells, also involving the muscle coat and thickened peritoneum over the diseased area. Precisely what causes these changes is not known, and no causal agent has been found. These changes are generally considered to be late changes, and many patients with BPS/IC have no specific cystoscopic findings.",126,12,0.09523809523809523
9781905832729,ch_8,Treatment of UTIs is largely on the basis of symptoms and any underlying identified cause.,"Symptoms. The diagnosis of BPS/IC is based clinically on symptoms of urinary frequency, urgency and pain. Pain is an essential component of both conditions and is traditionally described as increasing pain on bladder filling that is relieved by voiding. It is recognized that pain may present as bladder, urethral, vaginal, vulval, rectal or pelvic pain, and it may be suprapubic, urethral, perineal or a combination. There are no criteria for the nature or location of the pain except that it must be chronic and have no other obvious cause.",118,18,0.15254237288135594
9781905832729,ch_8,"Management of BPS/IC is largely conservative, and includes dietary advice, behavioral therapies, and oral and intravesical medication.","Symptoms. The diagnosis of BPS/IC is based clinically on symptoms of urinary frequency, urgency and pain. Pain is an essential component of both conditions and is traditionally described as increasing pain on bladder filling that is relieved by voiding. It is recognized that pain may present as bladder, urethral, vaginal, vulval, rectal or pelvic pain, and it may be suprapubic, urethral, perineal or a combination. There are no criteria for the nature or location of the pain except that it must be chronic and have no other obvious cause.",118,26,0.22033898305084745
9781905832729,ch_8,The roles of cystoscopy and bladder biopsy in the diagnosis of BPS/IC are controversial.,"There is some disagreement about the role of cystoscopy and bladder biopsy in the diagnosis of IC. Some clinicians will diagnose IC in a patient who has a 3-month history of urinary urgency and frequency, bladder pain relieved by voiding and a negative urinary culture and cytology, whereas others will diagnose the condition only if the characteristic cystoscopic findings are present, preferably with histological confirmation. Biopsy is clinically indicated only if there is a suspicion of malignancy or as part of a clinical protocol.",104,22,0.21153846153846154
9781905832729,ch_9,"Treatment of primary nocturnal enuresis is rarely required, but can include modification of fluid intake, behavioral treatments and occasional use of ADH (desmopressin).","Primary nocturnal enuresis. Nocturnal enuresis is the involuntary passage of urine during sleep in children aged 5 years old and above. Primary nocturnal enuresis is urinary incontinence that occurs during sleep in a child who has never regularly been dry at night. It is often referred to as 'bed-wetting' and is a common condition that can cause difficulty for both child and family. Nocturnal enuresis occurs in approximately 20% of 5-year-olds, 10% of 10-year-olds and 1% of 15-year-olds. It is more prevalent among boys than girls. The majority of children affected are fully continent during the day. The condition is usually self-limiting and children generally become dry at night spontaneously as they get older.",163,36,0.22085889570552147
9781905832729,ch_9,Primary nocturnal enuresis is urinary incontinence that occurs at night in a child who has never been regularly dry at night.,"Nocturnal enuresis is the involuntary passage of urine during sleep in children aged 5 years old and above. Primary nocturnal enuresis is urinary incontinence that occurs during sleep in a child who has never regularly been dry at night. It is often referred to as 'bed-wetting' and is a common condition that can cause difficulty for both child and family. Nocturnal enuresis occurs in approximately 20% of 5-year-olds, 10% of 10-year-olds and 1% of 15-year-olds. It is more prevalent among boys than girls.",122,28,0.22950819672131148
9781905832729,ch_9,"It is a relatively common condition, but generally resolves spontaneously and rarely persists into adolescence.","Nocturnal enuresis is the involuntary passage of urine during sleep in children aged 5 years old and above. Primary nocturnal enuresis is urinary incontinence that occurs during sleep in a child who has never regularly been dry at night. It is often referred to as 'bed-wetting' and is a common condition that can cause difficulty for both child and family. Nocturnal enuresis occurs in approximately 20% of 5-year-olds, 10% of 10-year-olds and 1% of 15-year-olds. It is more prevalent among boys than girls.",122,17,0.13934426229508196
9781905832729,ch_9,The frequency/volume bladder record is the most useful investigative tool for primary nocturnal enuresis and also helps in monitoring treatment.,"Investigations. A comprehensive urologic history should be taken to exclude any associated conditions that may require treatment. Physical examination should be carried out, although abnormalities are unlikely to be detected. The specific gravity of an early-morning urine sample should be measured to identify those who may benefit from antidiuretic hormone (ADH; desmopressin) treatment. A frequency/volume bladder record (see 2.vi and Figure 2.3) is one of the most important tools in the investigation and management of primary nocturnal enuresis. It will provide detailed information about fluid intake and voided volumes during the day and episodes of bed-wetting during the night. It can be used to assess the severity of the problem and also provides a baseline against which the effects of treatment can be measured.",164,27,0.16463414634146342
9781905832729,ch_9,Nocturia - defined as waking from sleep to void - has a significant impact on quality of life and is a major cause of falls in the elderly.,"Nocturia is defined as waking from sleep once or more to void. The 'official' definition by the International Continence Society specifies that each void is preceded and followed by sleep. The threshold for bother is debatable: either two or three times. Prevalence estimates (referring to two or more episodes) are 2-17% in men aged 20-40 years, 4-18% in women aged 20-40 years, 29-59% in men over the age of 70, and 28-62% in women over 70. Nocturia may be associated with the following negative impacts: reduced quality of life and productivity; increased incidence of falls and fractures (particularly among the elderly); mood disturbances; increased daytime fatigue; and decreased alertness. The pathophysiology is shown in Figure 8.1.",166,31,0.18674698795180722
9781905832729,ch_9,"Treatment of nocturia is largely on the basis of the underlying cause. Loop diuretics in the afternoon may be useful if nocturia is related to congestive heart failure. ADH should be used with caution, as it can cause rapid hyponatremia. Antimuscarinics may prove useful only in patients with severe nocturnal detrusor overactivity.","Treatment of nocturia should be on the basis of identified underlying causes. Simple measures can be implemented, such as reducing evening and nighttime fluid intake. The frail elderly should be provided with a bedside commode or urinal, to minimize the risk of falls while going to the bathroom. An upright rail fixed to the bed to facilitate getting out safely is also important. Patients who have peripheral edema and vascular insufficiency may benefit from the use of support stockings during the day, leg elevation in the afternoon and reduction in salt intake. Treatment of sleep apnea can improve nocturia. Pharmacological treatment aims to shift the diuresis to the daytime. Reducing the volume overload associated with congestive heart failure with a dose of loop diuretic 6-8 hours before bed may be helpful. ADH (desmopressin) has been used successfully to reduce nocturnal urine output. However, it can cause hyponatremia, and there is a risk of exacerbating congestive cardiac failure, particularly in the elderly; some therefore consider it not generally suitable for patients over 65 years of age. If treatment is commenced, it is important to measure serum electrolytes beforehand and 1-3 days after commencing treatment, as hyponatremia can develop rapidly. A trial of antimuscarinic agent (see Table 4.3) is likely to be beneficial only if the nocturia is associated with significant nocturnal detrusor overactivity. Having a patient take the drug at bedtime may help to decrease nocturia.",319,79,0.2476489028213166
9781905832729,ch_10,"Neuropathic bladder dysfunction can be classified according to the site of the lesion as suprapontine, suprasacral spinal or peripheral.","Neuropathic bladder dysfunction. Most neurological diseases that affect the spinal cord and some that affect the brain will cause bladder dysfunction, which, if untreated, may lead to incontinence. Neuropathic bladder dysfunction (also referred to as neurogenic bladder) can be divided into three types of disorder according to the site of the lesion: suprapontine, suprasacral spinal and peripheral. Urodynamic investigation is required to distinguish between the different types of filling/storage and voiding dysfunction that may result. Lesion types. Suprapontine lesions tend to lead to detrusor overactivity, although coordinated sphincter function is preserved. These lesions can therefore result in frequency, urgency and urgency incontinence. The principal causes of suprapontine lesions are dementia, cerebrovascular accident, closed head injury and Parkinson's disease.",175,31,0.17714285714285713
9781905832729,ch_10,"Suprapontine lesions are largely associated with Parkinson's disease, dementia and cerebrovascular accident. They usually lead to detrusor overactivity but coordinated sphincter function is preserved.","Suprapontine lesions tend to lead to detrusor overactivity, although coordinated sphincter function is preserved. These lesions can therefore result in frequency, urgency and urgency incontinence. The principal causes of suprapontine lesions are dementia, cerebrovascular accident, closed head injury and Parkinson's disease. Suprasacral spinal lesions that interfere with reflex control of the bladder from the higher centers will produce detrusor overactivity. This is seen in many patients with neurological bladder dysfunction and is characterized by spontaneous involuntary detrusor contractions, with or without the sensation of urgency, leading to urinary incontinence. Detrusor overactivity may be associated with non-coordination of the external urethral sphincter, which contracts during detrusor contraction, termed detrusor-sphincter dyssynergia (DSD). This causes hypertrophy of detrusor smooth muscle (trabeculation) as a result of the frequent, high-pressure, sustained detrusor contractions in the presence of obstruction. Patients with detrusor overactivity and DSD not only experience urinary incontinence but may also develop long-term effects of high intravesical pressures, giving rise to ureteric reflux or obstruction, or both, and resulting in renal damage and failure.",274,40,0.145985401459854
9781905832729,ch_10,"Suprasacral spinal lesions are associated with spinal cord injury, spina bifida and tumors, and interfere with the reflex control of the bladder from higher centers, resulting in detrusor overactivity and detrusor-sphincter dyssynergia. Increased intravesical pressure can damage the ureters and, ultimately, the kidneys.","Suprasacral spinal lesions that interfere with reflex control of the bladder from the higher centers will produce detrusor overactivity. This is seen in many patients with neurological bladder dysfunction and is characterized by spontaneous involuntary detrusor contractions, with or without the sensation of urgency, leading to urinary incontinence. Detrusor overactivity may be associated with non-coordination of the external urethral sphincter, which contracts during detrusor contraction, termed detrusor-sphincter dyssynergia (DSD). This causes hypertrophy of detrusor smooth muscle (trabeculation) as a result of the frequent, high-pressure, sustained detrusor contractions in the presence of obstruction. Patients with detrusor overactivity and DSD not only experience urinary incontinence but may also develop long-term effects of high intravesical pressures, giving rise to ureteric reflux or obstruction, or both, and resulting in renal damage and failure. The causes of suprasacral spinal lesions include multiple sclerosis, spinal cord injury and infections (exempli gratia transverse myelitis), spina bifida and tumors that affect the suprasacral spinal cord. Peripheral lesions. Injury or disease that affects the nerve roots or peripheral nerves (spinal trauma, myelomeningocele, pelvic surgery, diabetes mellitus) causes bladder areflexia or acontractility and, as a result, the bladder fails to empty unless voiding is assisted by straining. In patients with such lesions, the external urethral sphincter may fail to relax (isolated distal sphincter obstruction) and may also be weakened, giving rise to stress incontinence.",366,74,0.20218579234972678
9781905832729,ch_10,"Peripheral lesions affecting the nerve roots cause bladder areflexia or acontractility, such that the bladder fails to empty without straining. Sphincteric weakness may also contribute to incontinence.","Peripheral lesions. Injury or disease that affects the nerve roots or peripheral nerves (spinal trauma, myelomeningocele, pelvic surgery, diabetes mellitus) causes bladder areflexia or acontractility and, as a result, the bladder fails to empty unless voiding is assisted by straining. In patients with such lesions, the external urethral sphincter may fail to relax (isolated distal sphincter obstruction) and may also be weakened, giving rise to stress incontinence. The diagnosis of neuropathic bladder disorders requires an understanding of the underlying neurological abnormality, which will be apparent in most patients. However, some patients will present with the symptoms of a neuropathic bladder but with no overt neurological cause. In this situation, it is important to consider the possibility of an undiagnosed neurological condition such as multiple sclerosis or spinal cord lesion, as neuropathic bladder may be the presenting symptom. In patients with cervical lesions, especially those with complete spinal cord transection, it may be difficult to assess symptoms as many will be atypical or unconscious rather than the classic 'urge' type symptoms.",237,42,0.17721518987341772
9781905832729,ch_10,"Management of detrusor overactivity aims to enable low-pressure storage of urine and bladder emptying without obstruction, achieved by antimuscarinic drugs, injection of botulinum toxin or surgery.","The aim of treating the neuropathic bladder is to enable low-pressure storage of urine and bladder emptying without obstruction. Treatment of detrusor overactivity is therefore focused on reducing detrusor muscle contractions and/or reducing the effect of DSD, if present, by lowering the resistance of the external urethral sphincter. Control of detrusor overactivity with antimuscarinic drugs or surgery is described in Chapter 4 (see 4.iii). If oral therapy cannot be tolerated, intravesical agents such as botulinum toxin or oxybutynin may be used. Reducing resistance in the external urethral sphincter can be achieved by a number of methods: sphincterotomy, sphincter stenting or injection of botulinum toxin. These procedures are only suitable for men, who should be counseled about the risk of continuous incontinence afterwards.",187,40,0.21390374331550802
9781905832729,ch_10,"Some patients require catheterization to ensure bladder emptying. Options are intermittent self-catheterization, if the bladder can store urine adequately without leaking (often achieved with antimuscarinic drugs), or a urethral or suprapubic indwelling catheter.","Catheterization. Despite these measures, some patients will continue to have problems with DSD and will require catheterization to empty the bladder and prevent the long-term complications associated with the condition. The options for these patients are intermittent self-catheterization, or long-term indwelling catheterization with a urethral or suprapubic catheter. Intermittent self-catheterization (ISC) is useful in any condition in which bladder emptying is impaired in association with adequate outlet resistance. Many patients catheterize themselves on a regular basis throughout the day (and night) to ensure bladder emptying. (Figure 9.1) In patients with neuropathic bladder, the number of catheterizations required will depend on factors such as fluid intake, ambient temperature, bladder capacity and social factors; most patients need to catheterize four or five times each day. If possible, the patient should void prior to catheterization. For self-catheterization to be successful in patients with neuropathic bladder dysfunction, the bladder must be able to store urine adequately without leaking, a condition that can be facilitated through the use of antimuscarinic medication (see Table 4.3). The patient must be physically able and motivated to perform catheterization, or a caregiver must be able to do it for them. Patients and caregivers need access to healthcare professionals who can teach them the technique and provide adequate support and appropriate catheters. Examples of catheters used for ISC are shown in Figure 9.2.",314,56,0.17834394904458598
9781905832729,ch_11,"The prevalence of urinary tract symptoms increases with age, and urinary incontinence is a frequent cause of institutionalization of the elderly.","The approach to treatment of these symptoms in the elderly is similar to that in younger people, as the underlying pathophysiology of bladder disorders, such as incontinence and overactive bladder (OAB) does not differ markedly. It is important to rule out or treat constipation and urinary tract infection (UTI) and discontinue inappropriate medication before embarking on extensive investigation. Urinary incontinence is a frequent cause of institutionalization in the elderly. The common causes of incontinence are similar to those found in younger people, namely bladder overactivity and sphincter weakness, but the effects of aging on the nervous system and the lower urinary tract exacerbate the symptoms.",137,26,0.1897810218978102
9781905832729,ch_11,"Identification of the cause is more important in the elderly than in younger patients, as elderly patients are likely to have multiple coexisting symptoms and pathologies. Polypharmacy may be a contributory factor.","Investigation. Finding the cause of urinary incontinence is more important in the elderly than in younger patients. The elderly are more likely to have multiple coexisting symptoms and may have multiple pathologies to account for them. In addition, the elderly are less likely to tolerate the adverse effects of antimuscarinic medications. Empirical treatment based on symptoms and a frequency/volume bladder record can be unsatisfactory. Investigation may involve urodynamic investigation, the indications for which are outlined in Chapter 2 (see 2.viii). Cystometry is well tolerated in the elderly. If cystometry is performed, prophylactic antibiotics should be considered, particularly in patients susceptible to UTIs. Treatment. If detrusor overactivity is identified, behavioral therapy and antimuscarinic medication can be commenced, taking into account other medications the patient is taking that may cause interactions, such as antidepressants. Treatment should be started with a low dose and the dose increased gradually until the required benefits are obtained with the minimum of adverse effects. Detrusor contractility decreases with age and therefore the incidence of urinary retention with antimuscarinic medications may be higher in the elderly. Also, in the elderly patient, antimuscarinic drugs may be more likely to cause drowsiness and cognitive impairment.",263,42,0.1596958174904943
9781905832729,ch_11,"Vesicovaginal fistula (VVF), which results in vaginal leakage of urine, is the most common fistula to cause urinary incontinence.","Voiding dysfunction. Poor detrusor contractility is common in the elderly and can impair voiding even in the absence of bladder outlet obstruction. Urinary retention may follow, which, if chronic, may be painless but can lead to overflow incontinence. It is also common for factors such as constipation, medication (such as antimuscarinics and alpha-adrenergic agonists) and bed rest to unmask subclinical voiding dysfunction and lead to retention. Neurological problems can lead to voiding dysfunction. These include spinal cord compression resulting from a tumor or vertebral collapse, stroke, sensory loss and Parkinson's disease. Stroke may initially cause retention, which is replaced by neurogenic detrusor overactivity. Parkinson's disease results in voiding dysfunction, primarily as a result of detrusor overactivity, bradykinesia of the striated sphincter or poor detrusor contractility. Sensory loss is most commonly caused by diabetes; it may lead to progressive bladder distension, voiding dysfunction and acontractility, resulting in overflow incontinence.",229,34,0.14847161572052403
9781905832729,ch_11,Urinary tract infection (UTI) is common in elderly women. Treatment of persistent UTI is with low-dose vaginal estrogen and prophylactic antibiotics.,"Urinary retention. The aims of initial management are to stop any implicated factors such as medication and to rectify any reversible factors, such as prolapse in women. If this fails then the treatment of choice is self-catheterization. However, this may not be feasible for the reasons outlined above, and long-term suprapubic catheterization may be the only option (see 9.iii). Urinary tract infections are common in elderly women, occurring in up to 46% over the course of a year. This is normally the result of multiple factors, such as impaired immunology, voiding dysfunction and urinary stasis, genital atrophy from decreased estrogen, fecal incontinence and low fluid intake. There is also an increased likelihood of intravesical pathology. Investigation with flexible cystoscopy is recommended in the case of recurrent UTIs. Treatment of UTIs in elderly women with no identifiable pathology is with low-dose vaginal estrogen and prophylactic antibiotics, as described in Chapter 7.",207,33,0.15942028985507245
9781905832729,ch_11,Lower urinary tract problems are common in pregnancy and usually resolve after delivery.,"Polypharmacy (the use of multiple medications concurrently) is common in the elderly, and incontinence is frequently a result of medications prescribed for other conditions. Drugs can adversely affect bladder function in a number of ways, summarized in Table 10.1. Lower urinary tract symptoms are common during pregnancy, and childbirth is often cited as a cause for subsequent urinary, colorectal and genital dysfunction. The hormonal effects of pregnancy also can be responsible for other urinary tract pathology such as hydronephrosis and UTIs.",106,14,0.1320754716981132
9781905832729,ch_11,"Vaginal delivery, especially associated with a long second stage of labor, forceps-assisted delivery and high birth weight, may damage the pelvic floor innervation and result in postnatal incontinence.","Urinary incontinence. Stress urinary incontinence in pregnancy is common - it has been reported in up to 85% of pregnant women. It is likely to be caused by pressure from the pregnant uterus, combined with relaxation of the pelvic ligaments and smooth musculature in response to the high levels of progesterone and other pregnancy hormones. Prenatal stress incontinence usually resolves spontaneously after delivery, and the mainstay of treatment is pelvic floor muscle exercises (see Table 3.3). However, at least 25% of women will persist with incontinence post-delivery and these women will benefit from a structured and supervised pelvic floor muscle training program. Intrapartum risk factors. A number of intrapartum events have been shown to contribute to postnatal urinary stress incontinence. Vaginal delivery, particularly in association with a prolonged second stage, assisted delivery, high birth weight and third-degree perineal tears can damage the pelvic floor innervation and increase pudendal nerve latency. Delivery with forceps appears to be associated with a higher incidence of stress incontinence than vacuum extraction and unassisted delivery.",232,41,0.17672413793103448
9781905832729,ch_11,"UTIs are common in pregnancy and are associated with preterm delivery and low birth weight. Pregnant women should therefore be screened for UTIs at all antenatal visits, and UTIs treated accordingly.","Urinary tract infections. The smooth muscle relaxation associated with high levels of progesterone in pregnancy may predispose women to UTIs by affecting bladder emptying and ureteric drainage. UTIs are known to be associated with preterm delivery and low birth weight, so screening for infection and administering correct treatment are important. Asymptomatic bacteriuria refers to the finding of more than 105 colony-forming units (CFU) per mL urine, which develops into pyelonephritis in 20-40% of pregnant women if left untreated, but only 1-2% if treated adequately. Pregnant women should be screened for UTI at all antenatal visits; if a UTI has been treated, the patient should be followed up closely for signs of recurrence. If recurrent UTIs occur, then appropriate low-dose prophylactic antibiotics may be used until delivery.",181,41,0.2265193370165746
9781905832729,ch_11,"In developed countries, VVF may be caused by pelvic malignancy, radiotherapy, trauma and gynecologic/urologic instrumentation. Obstetric trauma during unsupervised labor is a common cause of VVF in developing countries.","Etiology of VVF differs in various parts of the world. In developed countries, 75% of cases are iatrogenic, caused by injury to the bladder at the time of pelvic or gynecologic surgery. Obstetric trauma accounts for very few cases of VVF in developed countries, but is still a common cause in developing countries as a result of prolonged unsupervised labor. Other causes of VVF include pelvic malignancy, radiotherapy, trauma and gynecologic/urologic instrumentation. Diagnosis. A woman with a VVF will commonly complain of continuous drainage of urine from the vagina, although small fistulas can present with intermittent urine leakage that is positional in nature. If the fistula is large, the patient may not void normally at all and may have continuous leakage of urine into the vagina. A VVF that has occurred after surgery commonly presents upon removal of the urethral catheter or up to 3 weeks later with urinary drainage from the vagina. VVF caused by radiation therapy may present many months or even years after completion of radiotherapy.",226,51,0.22566371681415928
9781905832729,ch_11,Dye studies and imaging are required to determine the site of a fistula.,"Examination under anesthesia may be required to determine the presence of a fistula. It is also important to assess the mobility of the tissues and the accessibility of a fistula for surgical repair. Cystoscopy may also be carried out as part of this investigation. Although there is some debate as to the role of cystoscopy in the management of fistulas, it does enable the exact level of the fistula and its relation to the ureteric orifices and bladder neck to be assessed. In addition, a biopsy should be performed of the edge of any fistula that is related to radiotherapy or thought to be malignant.",132,16,0.12121212121212122
9781905832729,ch_11,Many fistulas heal spontaneously over 6-12 weeks with conservative management such as bladder draining or ureteric stenting. Premature surgery is likely to be unsuccessful because of tissue inflammation and sloughing.,"Conservative management. The initial management of most urinary tract fistulas is generally conservative. VVFs may heal spontaneously with continuous bladder drainage with an indwelling catheter, over a period of 6-8 weeks, and a ureterovaginal fistula may resolve if the affected ureter is stented for 6-12 weeks. During the period of conservative management, the patient should be provided with incontinence pads and with barrier cream to protect the vulval and perineal skin, which is at risk of dermatitis as a result of prolonged contact with urine. Surgical management. There is some debate as to the timing of surgical treatment of urinary tract fistulas. Early treatment is advocated by some because of the social and psychological benefits to women who are already distressed. However, fistulas may be associated with tissue inflammation and sloughing, and success rates are reduced if surgery is performed before this has resolved. It is therefore important not to be pressured by the patient into operating on a fistula too soon, as this may jeopardize the surgical outcome.",217,42,0.1935483870967742
9781908541024,ch_2,"Primary brain tumors and metastases have been diagnosed with increasing frequency over recent decades. This may reflect a true increase in incidence, but improved neuroimaging techniques and greater access to imaging account for part of this increase.","Brain metastases are much more common than primary intracranial tumors. Approximately 170000 people in the USA are diagnosed with brain metastases every year, while 62930 are diagnosed with a primary benign or malignant brain tumor. More than 13000 die each year as a result of a primary malignant brain tumor. In children and in men aged 20-39 years, brain tumors are the second leading cause of cancer-related death in the USA. Data from several studies suggest an increase in the incidence of both primary brain tumors, particularly primary central nervous system (CNS) lymphoma, and brain metastases since the 1970s. This may be partly due to a true increase in incidence, but it is also a consequence of greater access to and improvements in neuroimaging techniques. Epidemiological studies of brain tumors are limited as a result of ascertainment bias, small sample size and retrospective design. The best data suggest an annual worldwide incidence for primary brain tumors of 3-4/100000 person-years. The incidence of primary brain tumors varies by sex, race, age and geography. Men have a higher risk than women of developing most brain tumors, with the exception of meningiomas. Similarly, brain tumors are more common in white than other ethnic groups, with the exception of meningiomas and pituitary adenomas. Brain tumors are more common in developed countries.",283,43,0.1519434628975265
9781908541024,ch_2,Environmental risk factors for the development of brain tumors are poorly understood and are probably over-reported.,"Epidemiological studies of brain tumors are limited as a result of ascertainment bias, small sample size and retrospective design. The best data suggest an annual worldwide incidence for primary brain tumors of 3-4/100000 person-years. The incidence of primary brain tumors varies by sex, race, age and geography. Men have a higher risk than women of developing most brain tumors, with the exception of meningiomas. Similarly, brain tumors are more common in white than other ethnic groups, with the exception of meningiomas and pituitary adenomas. Brain tumors are more common in developed countries.",124,19,0.1532258064516129
9781908541024,ch_2,"Developments in molecular biology, genomics and proteomics are resulting in an exponential increase in our knowledge about all types of brain tumors.","An increasing number of molecular genetic alterations have been described in association with particular primary brain tumors (Table 1.3). For glioblastoma in particular, recent genetic studies have delineated at least three genetically distinct subgroups. In the majority of patients, it is likely that some combination of genetic and environmental factors leads to the development of a brain tumor. Developments in molecular biology, genomics and proteomics are resulting in an exponential increase in our knowledge about all types of brain tumors, and should lead to the development of novel therapeutic strategies.",110,27,0.24545454545454545
9781908541024,ch_3,Initial symptoms and signs of a brain tumor are often vague or non-specific; many patients will have a normal neurological examination.,"Patients with brain tumors typically develop neurological signs and symptoms over a period of weeks to months. Some will have an abrupt onset of signs and symptoms similar to that seen in patients with a cerebrovascular infarct. Occasionally, however, patients will have signs or symptoms, such as a chronic seizure disorder, for years prior to the diagnosis of a low-grade tumor. Symptoms and signs may result from increased intracranial pressure, tumor invasion, obstructive hydrocephalus, tumor secretions or secondary cerebral ischemia. Initial symptoms are often vague and non-specific (Table 2.1). The neurological examination may be normal. Hence, a high index of suspicion is necessary so that no clinical clues are disregarded.",149,25,0.16778523489932887
9781908541024,ch_3,"Headache, the most common symptom of a brain tumor, is also the most common neurological complaint in the general population. Therefore, attention to specific features of a patient's headache should guide the clinician's index of suspicion and diagnostic evaluation.","Symptoms and signs may result from increased intracranial pressure, tumor invasion, obstructive hydrocephalus, tumor secretions or secondary cerebral ischemia. Initial symptoms are often vague and non-specific (Table 2.1). The neurological examination may be normal. Hence, a high index of suspicion is necessary so that no clinical clues are disregarded. Some typical misleading scenarios include a sudden or insidious change in personality or mood that is misdiagnosed as depression but is refractory to therapy, or an unexplained change in a patient's usual headache pattern or the development of new headaches in an atypical age group (young children or older adults). The various neurological symptoms and signs caused by brain tumors may be generalized, localizing or falsely localizing. Headache is the most common symptom of a brain tumor. Typically, the headache is non-specific and occurs equally in patients with and without increased intracranial pressure. Since headache is also the most common neurological complaint in the general population, it is important to note specific features of a patient's headache, as these can assist the diagnostic evaluation. Features that should increase suspicion of a tumor include.",234,48,0.20512820512820512
9781908541024,ch_3,Seizures occur in one-third of patients and any adult with new onset seizures should be evaluated for an underlying brain tumor.,"Seizures occur in about one-third of patients; they are often the initial and only symptom. Up to 20% of adults with new-onset seizures will have an underlying brain tumor. Seizures are more common in low-grade than high-grade tumors. Focal seizures are common in situations where the tumor compresses cortex, especially adjacent to the motor strip. Patients with an abrupt or unexplained change in level of function may have non-convulsive status epilepticus; this is not always accompanied by a demonstrable change in level of consciousness and should be evaluated using electroencephalography.",123,26,0.21138211382113822
9781908541024,ch_3,"Improvements in neuroimaging may be most useful in assessing response to newer therapies, particularly targeted molecular strategies that may be cytostatic.","Magnetic resonance spectroscopy may also be useful in assessing the response to newer therapies, particularly targeted molecular strategies that may be cytostatic. CT is superior to MRI for visualizing calcification and may be useful in certain types of tumor, such as meningiomas or oligodendrogliomas, that are prone to calcification. CT scanning may also be helpful in determining the extent of bony destruction or hyperostosis related to tumor growth. Patients with a medical contraindication for MRI (exempli gratia cardiac pacemaker, ferromagnetic foreign body) should be imaged with CT.",126,28,0.2222222222222222
9781908541024,ch_3,"Although neuroimaging may suggest a specific diagnosis, tissue should be obtained for pathological review in all patients before instituting any therapy. The only exception to this rule is the patient with a typical infiltrating pontine glioma, where the risks of surgery outweigh the benefit.","Positron emission tomography (PET) is a nuclear medicine study that provides metabolic tumor imaging. A variety of different substances can be labeled with a positron-emitting isotope: 18-fluoro-2-deoxyglucose, the most common isotope, images glucose metabolism; 11-carbon-methionine, an amino acid, images DNA metabolism. Uptake is increased in proportion with tumor grade. PET scans are clinically useful in guiding stereotactic needle biopsy (Figure 2.3), or differentiating radiation necrosis from recurrent tumor. In the future, they may be important in determining response to newer classes of antitumor drugs such as antiangiogenic agents. Single photon emission computed tomography (SPECT) is a less technically demanding nuclear medicine image that is more widely available than PET. SPECT may be useful in differentiating tumor from radiation necrosis, and has been used extensively to differentiate between tumor and infection in HIV-positive patients. Definitive histopathological diagnosis is essential before administering specific antitumor therapy. The only exception is diffuse pontine glioma, as this diagnosis can usually be made on the basis of the characteristic MRI appearance, and the risk of neurological injury subsequent to biopsy outweighs any benefit. A neuropathologist should review all specimens; ideally, an intraoperative frozen section should be obtained and as large a sample as possible submitted for final review. Furthermore, the pathologist should be apprised of.",304,55,0.18092105263157895
9781908541024,ch_3,"Ideally, the clinician should review images and pathology information directly with the radiologist and neuropathologist.","prior therapy, including preoperative interventions such as embolization that may cause focal necrosis. These factors may be critical in the interpretation of pathological findings and guide the selection of appropriate immunohistochemical stains (Table 2.6) or other specialized studies (exempli gratia electron microscopy). Clinical correlation is critical to the interpretation of both neuroimaging and pathology. Ideally, the clinician should review images and pathology information directly with the radiologist and neuropathologist.",99,22,0.2222222222222222
9781908541024,ch_4,Image-guided surgery facilitates radical resection of intracranial tumors.,"The past decades have brought about remarkable advances in the technical aspects of tumor removal. One such advance has been the routine use of cortical mapping and stereotactic volumetric resections. Other improvements have been seen in the area of surgical equipment, including robotics, lasers and ultrasonic aspirators. Together, these developments have improved the surgeon's ability to perform radical resection of brain tumors, many of which had previously been considered inoperable.",89,15,0.16853932584269662
9781908541024,ch_4,"Stereotactic biopsy is a safe procedure for obtaining diagnostic tissue, but sampling error may result in the tumor grade being underestimated.","Stereotactic biopsy is a technique for obtaining diagnostic tissue using a small probe directed by anatomic and geometric guidance at an unseen target. Several factors are considered before a surgeon chooses stereotactic biopsy over craniotomy for diagnosing a brain lesion (Table 3.1). These include tumor-related factors such as accessibility of the lesion, and patient factors such as serious medical illness or advanced age, which might prohibit radical surgical intervention. Stereotactic biopsy is often considered for tumors situated deep within the cerebrum, the pineal region or posterior fossa.",120,27,0.225
9781908541024,ch_4,"MRI can suggest a diagnosis of a brain tumor, but surgery is always necessary to provide tissue for pathological diagnosis (except in the case of diffuse pontine glioma).","The basic technique involves the placement of a stereotactic frame, which is applied to the patient while using a local anesthetic. Subsequent CT or MRI identifies the coordinates of the target of interest. These coordinates are entered into a computer system, and an appropriate trajectory to the target is generated (Figure 3.2). The patient is taken to the operating theatre, where a burr hole or twist-drill hole is made, and a biopsy needle is inserted into the brain to the designated depth. The needle is rotated and gentle suction applied to obtain the biopsy; the tissue sample is then given to the pathologist for quick-section examination. Postoperatively, the patient is monitored for a few hours, and a postoperative CT is performed to ensure that there is no evidence of hemorrhage.",164,34,0.2073170731707317
9781908541024,ch_4,"Radiotherapy is associated with considerable brain side effects, including late toxicities such as dementia and cerebral radionecrosis.","Stereotactic biopsy is a relatively straightforward neurosurgical procedure. However, there are possible complications, such as intracranial hemorrhage, which occurs in 1.2-7% of patients. Situations associated with increased risk include stereotactic biopsy of highly vascular malignant lesions such as glioblastoma, and eloquent areas of the cerebrum where hemorrhage is more likely to be associated with neurological deficits. If a patient deteriorates significantly as a result of cerebral hemorrhage, immediate craniotomy for hematoma evacuation is mandated.",117,25,0.21367521367521367
9781908541024,ch_4,Elderly patients with poor neurological function are at highest risk of morbidity and mortality following craniotomy for tumor resection.,"Regional complications are classified as central nervous system (CNS) events that do not generally result in worsening of the neurological deficit. They occur in 3-5% of all patients undergoing craniotomy for tumor resection, and are more likely to be encountered in elderly patients in poor general health. Common regional complications include postoperative seizures, wound infections, meningitis, hydrocephalus and subgaleal effusions (Figure 3.4). Seizures in the early postoperative period occur in 0.5-5% of patients after supratentorial craniotomy even with anticonvulsant prophylaxis. Risk factors for postoperative seizures include a history of seizures, surgery adjacent to motor cortex, and postoperative hemorrhage or edema. Although prophylactic anticonvulsants are routinely used in patients undergoing craniotomy for tumor resection, there are no data from randomized trials to support this practice.",194,26,0.13402061855670103
9781908541024,ch_4,"Conformal radiotherapy, and stereotactic radiosurgery and radiotherapy are emerging techniques designed to provide maximal radiation dose to the tumor while sparing normal surrounding tissues.","Radiotherapy targets actively dividing cells, with tumor cell death being achieved via induction of DNA damage. The goal of radiotherapy is to achieve maximal tumor control while sparing normal structures from the toxicities of irradiation. The efficacy of radiotherapy depends on the delivery of adequate doses of radiation to the target tissue within the brain. The safety of radiotherapy depends on the relative exclusion of normal brain tissues and other critical structures from exposure to ionizing irradiation. Modern conventional external-beam megavoltage radiotherapy administers irradiation in fractionated doses, thereby allowing normal tissues adequate time to recover from radiation damage. Furthermore, the use of image-guided conformal techniques has enabled radiation oncologists to target the tumor with unprecedented accuracy, so as to minimize the exposure of surrounding normal tissues to ionizing radiation.",163,34,0.2085889570552147
9781908541024,ch_4,"Following surgery, radiotherapy is the most effective treatment for long-term control of most intracranial neoplasms.","Radiotherapy is one of the most effective treatments for brain tumors. It can be curative for some types of brain tumor, such as germinoma, and has a central role in the management of most primary brain tumors, including low-grade and malignant gliomas, where it can reduce the rate of tumor progression and prolong patient survival. Radiotherapy is also the primary palliative modality for the treatment of brain metastases from systemic cancers. Basic principles. Radiotherapy induces cellular damage by ionizing molecules in DNA, organelles and membranes. The generation of these free radicals can be accentuated by the presence of oxygen, or reversed by naturally occurring free-radical scavengers. The most important cellular target of radiotherapy is DNA, as ionizing irradiation can cause DNA crosslinks and breaks, as well as molecular damage to nucleotides. Although the cell is capable of repairing much of this damage using a variety of 'housekeeping' molecules, when a critical level of damage is reached a process of programmed cell death is triggered via a complicated signal transduction pathway.",222,25,0.11261261261261261
9781908541024,ch_4,"The chemotherapeutic agent temozolomide has revolutionized the treatment of gliomas, and is now firmly established as a component of initial management for glioblastoma.","The role of chemotherapy in the treatment of patients with brain tumors is expanding. Many pediatric intracranial tumors are treated primarily with chemotherapy for two reasons. First, tumors common in the pediatric population, such as medulloblastoma and primitive neuroectodermal tumors (PNETs), are highly chemosensitive. The addition of chemotherapy to the treatment of these neoplasms has significantly improved outcome and extended survival. Second, the toxic consequences of irradiation on the developing nervous system have stimulated the development of chemotherapy-based strategies that avoid or delay radiotherapy in the pediatric population. Chemotherapy is also assuming increasing importance in the management of adults with malignant brain tumors. For example, chemotherapy has recently been established as an essential component of the initial management of patients with glioblastoma, the most common primary brain tumor in adults. A recent international phase III trial has demonstrated a survival advantage conferred by the addition of concurrent and adjuvant temozolomide chemotherapy to radiotherapy for patients with newly diagnosed glioblastoma. This landmark trial has resulted in the widespread use of this regimen for glioblastoma and other malignant gliomas.",237,39,0.16455696202531644
9781908541024,ch_4,Inherent or acquired drug resistance and the blood-brain barrier are important factors limiting the efficacy of chemotherapy in patients with brain tumors.,"Basic principles. A number of inherent biological issues have hindered the development of effective chemotherapies for primary brain tumors. These issues include the cellular kinetics of brain tumors, inherent or acquired drug resistance, the blood-brain barrier and the potential toxicity of chemotherapy. Cellular kinetics. Chemotherapeutic agents affect dividing cells. In the normal adult brain, the only cells undergoing division are endothelial cells. For a given tumor, the proportion of cells undergoing division, the rate of this division and the rate of tumor cell death determine tumor growth. Theoretically, the most rapidly growing tumors should be most sensitive to the damaging effects of chemotherapy. Glioblastomas are the most rapidly growing gliomas, with 1-16% of the cells undergoing division at any point in time. Anaplastic and low-grade gliomas have much lower rates of division. Consequently, many chemotherapies have a limited capacity to kill glioma cells, because many are in a quiescent phase of the cell cycle and not susceptible to these agents.",216,26,0.12037037037037036
9781908541024,ch_4,Novel agents that target angiogenesis are the most promising of targeted therapies for malignant gliomas.,"New agents. Although there have been remarkable gains in outcome for patients with malignant gliomas with, in particular, the use of temozolomide, better anticancer drugs are needed to advance the management of primary brain tumors. Novel therapies that target growth factor signaling pathways, angiogenesis and tumor invasion are presently undergoing clinical investigation in patients with brain tumors. The most promising agents appear to target angiogenesis, and bevacizumab has been recently approved in some countries for the management of progressive glioblastoma. Other agents targeting vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are in development, and preliminary results appear very promising for this class of agents. Table 3.4 lists some of the agents that are being investigated for glioma and indicates their cellular targets. It is hoped that at least some of these novel theoretical strategies for combating cancer will be effective and soon become part of standard therapy for patients with malignant brain tumors.",202,22,0.10891089108910891
9781908541024,ch_5,"Improvements in therapy for systemic cancer have resulted in an increase in the number of patients living long enough to develop symptomatic brain metastasis. It is likely that this trend will continue. Therefore, new strategies to prevent and treat brain metastases will become increasingly important.","Improvements in therapy for systemic cancer have increased the number of patients living long enough to develop symptomatic brain metastases. Indeed, brain metastases are the most common intracranial tumor. In particular, human epidermal growth factor receptor-2-positive (Her2+) breast cancer patients with systemic disease controlled with trastuzumab appear to have an increased risk of developing brain metastases. Thus, the development of new strategies to prevent and treat brain metastases is increasingly important. Approximately 1 in 4 patients with cancer will develop a brain metastasis; patients with melanoma, lung or breast cancer are at the greatest risk (Table 4.1). Most patients present with headaches or focal neurological deficits; 20% or more present with or develop seizures. Radiographically, metastases are ring-enhancing lesions, most often located at the gray-white matter junction. There is often significant surrounding edema. About half are single lesions (Figure 4.1), with the remainder being multiple lesions (Figures 4.2 and 4.3). Skull and dural metastases are most commonly seen in association with prostate and breast cancer.",233,53,0.22746781115879827
9781908541024,ch_5,Patients with a new diagnosis of brain metastasis should be systemically restaged as appropriate for their primary tumor.,Patients with a new diagnosis of brain metastasis should be systemically restaged as appropriate for their primary tumor. The Radiation Therapy Oncology Group (RTOG) has delineated specific prognostic categories for patients with newly diagnosed brain metastases (Table 4.2). These may be helpful in determining appropriate treatment options and long-term plans (exempli gratia hospice care) for individual patients. A treatment algorithm for newly diagnosed brain metastasis is shown in Figure 4.4.,100,23,0.23
9781908541024,ch_5,"Although the average prognosis for an individual with brain metastasis is poor, selected patients will benefit significantly from aggressive local therapy or judicious use of chemotherapy.","Aggressive focused management of brain metastases may improve the prognosis for some patients. Those with a single brain metastasis located in a surgically accessible region clearly benefit from a combination of surgical resection and whole-brain radiotherapy. Stereotactic radiosurgery may also be helpful. In this patient group, the median survival with either of these approaches is 8-9 months. These results, while encouraging, have been obtained in highly selected patient populations, most of whom had a high Karnofsky performance status, limited systemic tumor burden and small brain metastases. Such patients have an inherently better prognosis, and consequently these results may not be easily extrapolated to all patients. (The Karnofsky performance status is scored from 0 to 100, with higher scores meaning a patient is better able to carry out daily activities.).",167,31,0.18562874251497005
9781908541024,ch_6,"The prognosis for patients with malignant gliomas is influenced most by histology, tumor grade and age. Increasingly, genetic aberrations are being identified at the molecular level in a variety of gliomas, and these abnormalities will assume substantial prognostic and therapeutic importance as greater knowledge of their significance is acquired.","Several systems exist for the pathological diagnosis of gliomas, the most frequently used of which is the WHO classification (Table 5.1). Astrocytic gliomas are the most common type, and include anaplastic astrocytomas and the highly malignant glioblastoma that can arise de novo or from a pre-existing low-grade astrocytoma. While some gliomas remain indolent, most have the potential to become highly aggressive neoplasms through a process of malignant degeneration caused by a series of genetic aberrations that are currently being defined (Table 5.2). The prognosis for patients with malignant gliomas is influenced most by histological grade and age. However, recently identified molecular prognostic factors are assuming increasing importance in the classification and treatment of selected gliomas. Glioblastoma is the most common and aggressive of all gliomas. This category of tumor accounts for 45-50% of all gliomas, arising most frequently in individuals aged 45-65 years. The male to female ratio is approximately 1.5:1. Glioblastomas usually arise in the deep white matter of the cerebrum, with the temporal and frontal lobes being the most common sites.",262,65,0.2480916030534351
9781908541024,ch_6,Glioblastoma is the most common and aggressive of all gliomas.,"Glioblastoma is the most common and aggressive of all gliomas. This category of tumor accounts for 45-50% of all gliomas, arising most frequently in individuals aged 45-65 years. The male to female ratio is approximately 1.5:1. Glioblastomas usually arise in the deep white matter of the cerebrum, with the temporal and frontal lobes being the most common sites.",88,17,0.19318181818181818
9781908541024,ch_6,Surgery is the principal initial treatment for gliomas. The benefit of extensive surgery versus limited resection or biopsy is controversial.,"Chemotherapy. The role of adjuvant chemotherapy is now established for glioblastoma. A recently completed randomized phase III study has demonstrated improved survival for patients receiving chemotherapy as part of their initial treatment. This trial demonstrated that daily temozolomide chemotherapy for the duration of radiotherapy (75 mg/kg/m /day for 42 consecutive days) followed by adjuvant temozolomide for 6 cycles (150-200 mg/m /day for days 1-5/28 days) was more effective than radiotherapy alone for patients with glioblastoma following surgery. In this study, more than 25% of patients who received temozolomide and radiotherapy had a 2-year survival compared with 10% for those receiving radiotherapy alone. Additionally, nearly 50% of patients who had tumors with a methylated phenotype had a 2-year survival following combined modality therapy. A recent analysis of this trial has shown prolonged survival and long-term control in a significant subset of patients, demonstrating that the benefit of this regimen can persist for years for some patients with this otherwise rapidly fatal cancer. Despite this very important therapeutic advance, most individuals with glioblastomas will experience tumor recurrence within 2 years of the initial diagnosis. Tumor recurrence is usually local and confined to the brain. At recurrence, further surgery and chemotherapy can extend life in a minority of patients.",288,27,0.09375
9781908541024,ch_6,Concurrent and adjuvant temozolomide chemotherapy with radiotherapy for glioblastoma is now the standard treatment for most patients with glioblastoma following surgery. This treatment is associated with significant long-term survival in responding patients. Patients who have tumors with hypermethylated O-methylguanine-DNA-methyltransferase promotor regions appear to benefit most from this treatment strategy. The role of this regimen is unclear in elderly patients or patients with poor performance status with glioblastoma. The use of this regimen in anaplastic gliomas is being investigated.,"Chemotherapy. The role of adjuvant chemotherapy is now established for glioblastoma. A recently completed randomized phase III study has demonstrated improved survival for patients receiving chemotherapy as part of their initial treatment. This trial demonstrated that daily temozolomide chemotherapy for the duration of radiotherapy (75 mg/kg/m /day for 42 consecutive days) followed by adjuvant temozolomide for 6 cycles (150-200 mg/m /day for days 1-5/28 days) was more effective than radiotherapy alone for patients with glioblastoma following surgery. In this study, more than 25% of patients who received temozolomide and radiotherapy had a 2-year survival compared with 10% for those receiving radiotherapy alone. Additionally, nearly 50% of patients who had tumors with a methylated phenotype had a 2-year survival following combined modality therapy. A recent analysis of this trial has shown prolonged survival and long-term control in a significant subset of patients, demonstrating that the benefit of this regimen can persist for years for some patients with this otherwise rapidly fatal cancer. Despite this very important therapeutic advance, most individuals with glioblastomas will experience tumor recurrence within 2 years of the initial diagnosis. Tumor recurrence is usually local and confined to the brain. At recurrence, further surgery and chemotherapy can extend life in a minority of patients. The most common chemotherapeutic agents in current use for malignant gliomas are listed in Table 5.3. A number of experimental treatments are under investigation for glioblastoma, including immunotherapy, viral therapy, signal-transduction inhibitors and antiangiogenic agents. The most promising new agent for glioblastoma is bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Bevacizumab is the most advanced of a variety of antiangiogenic therapies for cancer (see Table 3.4), and has recently been approved for the treatment of recurrent glioblastoma in several countries including the USA and Canada. When administered to patients with glioblastoma, bevacizumab has the potential to reduce cerebral edema (thereby reducing the need for corticosteroids), and to cause very dramatic reduction of tumor enhancement on MRI scans. While the use of bevacizumab can improve symptoms and delay progression in a significant fraction of patients with glioblastoma, the impact of this agent on survival remains unclear. Bevacizumab is generally well tolerated, with the most common toxicity being hypertension. It has the potential to interfere with wound healing and induce venous thromboembolism, intracranial hemorrhage and bowel perforation, though these serious complications are very uncommon. Studies are under way to further define the use of bevacizumab in patients with glioblastoma, including very large phase III trials in patients with newly diagnosed disease.",623,123,0.19743178170144463
9781908541024,ch_6,Chemotherapy is often administered for tumor recurrence or progression but is palliative and of limited benefit for most patients. More effective drugs are needed for this indication.,"Chemotherapy. The role of adjuvant chemotherapy is now established for glioblastoma. A recently completed randomized phase III study has demonstrated improved survival for patients receiving chemotherapy as part of their initial treatment. This trial demonstrated that daily temozolomide chemotherapy for the duration of radiotherapy (75 mg/kg/m /day for 42 consecutive days) followed by adjuvant temozolomide for 6 cycles (150-200 mg/m /day for days 1-5/28 days) was more effective than radiotherapy alone for patients with glioblastoma following surgery. In this study, more than 25% of patients who received temozolomide and radiotherapy had a 2-year survival compared with 10% for those receiving radiotherapy alone. Additionally, nearly 50% of patients who had tumors with a methylated phenotype had a 2-year survival following combined modality therapy. A recent analysis of this trial has shown prolonged survival and long-term control in a significant subset of patients, demonstrating that the benefit of this regimen can persist for years for some patients with this otherwise rapidly fatal cancer. Despite this very important therapeutic advance, most individuals with glioblastomas will experience tumor recurrence within 2 years of the initial diagnosis. Tumor recurrence is usually local and confined to the brain. At recurrence, further surgery and chemotherapy can extend life in a minority of patients.",288,33,0.11458333333333333
9781908541024,ch_6,"Anaplastic oligodendroglioma is a chemosensitive tumor. The appropriate timing of chemotherapy is controversial. Anaplastic oligodendroglial tumors that harbor co-deletion of 1p and 19q have a more favorable prognosis, and respond more consistently and durably to radiotherapy and chemotherapy.","Management. Anaplastic oligodendrogliomas have been reported to be particularly chemosensitive, with documented responses to numerous agents including nitrosoureas, temozolomide, procarbazine and the combination chemotherapeutic PCV regimen (procarbazine, lomustine [CCNU] and vincristine). Approximately 60-80% of anaplastic oligodendrogliomas have loss of heterozygosity of chromosome 1p and 19q (a translocation resulting in 1p/19q co-deletion) as a unique and defining genetic signature. This co-deletion is an early event in the development of these tumors, and is also present in the majority of low-grade oligodendrogliomas. Co-deletion of 1p and 19q occurs typically in oligodendroglial tumors that display classic histological features, and increasingly this genetic assessment is being used to assist the diagnosis of these tumors. Additionally, 1p/19q co-deletion is a molecular feature of favorable prognosis, in part because tumors with this feature are more radiosensitive and chemosensitive as a general rule. Consequently, both low-grade and anaplastic oligodendroglial tumors with co-deletion of 1p and 19q are being treated increasingly with chemotherapy first as a means of deferring cranial irradiation and its toxicities, although the best initial treatment strategy for these tumors remains unclear and is the focus of large phase III trials.",318,68,0.2138364779874214
9781908541024,ch_6,"Observation may be an appropriate initial strategy for patients with low-grade gliomas. The timing and extent of surgery for low-grade glioma is controversial. Increasingly, radiotherapy is deferred until clinically necessary, and lower doses are usually administered. The role of initial chemotherapy for low-grade gliomas is unclear, but is an option for a subset of patients with this diagnosis.","Management. Anaplastic oligodendrogliomas have been reported to be particularly chemosensitive, with documented responses to numerous agents including nitrosoureas, temozolomide, procarbazine and the combination chemotherapeutic PCV regimen (procarbazine, lomustine [CCNU] and vincristine). Approximately 60-80% of anaplastic oligodendrogliomas have loss of heterozygosity of chromosome 1p and 19q (a translocation resulting in 1p/19q co-deletion) as a unique and defining genetic signature. This co-deletion is an early event in the development of these tumors, and is also present in the majority of low-grade oligodendrogliomas. Co-deletion of 1p and 19q occurs typically in oligodendroglial tumors that display classic histological features, and increasingly this genetic assessment is being used to assist the diagnosis of these tumors. Additionally, 1p/19q co-deletion is a molecular feature of favorable prognosis, in part because tumors with this feature are more radiosensitive and chemosensitive as a general rule. Consequently, both low-grade and anaplastic oligodendroglial tumors with co-deletion of 1p and 19q are being treated increasingly with chemotherapy first as a means of deferring cranial irradiation and its toxicities, although the best initial treatment strategy for these tumors remains unclear and is the focus of large phase III trials. The PCV regimen has traditionally been the chemotherapy of choice for patients with anaplastic oligodendroglial tumors. Results of a recently completed phase III trial, in which patients with newly diagnosed anaplastic oligodendrogliomas were randomized to postoperative radiotherapy with or without PCV chemotherapy, failed to demonstrate a survival advantage of early versus delayed chemotherapy. However, adjuvant PCV chemotherapy was associated with an increased progression-free survival, and patients with co-deletion of 1p and 19q appeared to benefit most from adjuvant PCV chemotherapy. Despite these disappointing results, chemotherapy is still routinely administered as part of initial therapy of anaplastic oligodendroglioma, although temozolomide has become the treatment of choice in most instances.",479,80,0.16701461377870563
9781908541024,ch_6,Postoperative radiotherapy delays tumor progression and prolongs life for patients with malignant glioma.,"The PCV regimen has traditionally been the chemotherapy of choice for patients with anaplastic oligodendroglial tumors. Results of a recently completed phase III trial, in which patients with newly diagnosed anaplastic oligodendrogliomas were randomized to postoperative radiotherapy with or without PCV chemotherapy, failed to demonstrate a survival advantage of early versus delayed chemotherapy. However, adjuvant PCV chemotherapy was associated with an increased progression-free survival, and patients with co-deletion of 1p and 19q appeared to benefit most from adjuvant PCV chemotherapy. Despite these disappointing results, chemotherapy is still routinely administered as part of initial therapy of anaplastic oligodendroglioma, although temozolomide has become the treatment of choice in most instances.",161,20,0.12422360248447205
9781908541024,ch_7,"Meningiomas are the most common intracranial neoplasm. Most are low-grade and asymptomatic. Asymptomatic meningiomas may not require specific treatment, and can be observed by serial CT or MRI.","Meningiomas are neoplasms that arise from the coverings of the brain and spinal cord, the meninges. The annual incidence of meningiomas is at least 2 per 100000. They are the most common meningeal tumor and the most frequently encountered intracranial neoplasm. Meningiomas comprise approximately 20% of all brain tumors, and at least 90% are histologically benign or typical. However, a few are histologically atypical and aggressive, or frankly malignant. The WHO classification of meningiomas is presented in Table 6.1. There are many histological subtypes of benign meningiomas. With the exception of the papillary meningioma, which tends to be particularly aggressive, these subtypes are descriptive and without prognostic significance. Atypical meningiomas have frequent mitoses, large nuclei with prominent nucleoli, increased cellularity and necrosis. Malignant meningiomas have frankly malignant histological features, and invade blood vessels and brain.",214,51,0.2383177570093458
9781908541024,ch_7,"Surgery is the principal therapeutic modality for symptomatic meningiomas, but many meningiomas cannot be completely resected because of their location in high-risk areas.","Because meningiomas are frequently asymptomatic and tend to occur in elderly patients, the decision to treat is often a controversial one. When patients are diagnosed with an asymptomatic meningioma by CT or MRI, a period of observation of up to 1 year is often suggested before a decision is taken to treat the tumor. The decision to delay treatment is based on the indolent and very long natural history of most meningiomas. For patients who have meningiomas that cause persistent neurological deficits, or for patients whose tumors have unusual radiographic features or are causing significant cerebral edema, an immediate intervention is often recommended. Surgery is the best treatment for meningiomas and the goal should be complete resection, whenever possible. Surgical complications include hemorrhage, new or worsened neurological deficits, and infections. However, complications are uncommon, even though many patients with meningiomas are elderly. Meningiomas that are completely resected are associated with recurrence rates of approximately 3% at 5 years and 20% at 20 years.",220,38,0.17272727272727273
9781908541024,ch_7,Radiotherapy can achieve long-term growth stabilization of recurrent or enlarging meningiomas.,"Skull base meningiomas are particularly difficult to manage because they usually invade dura and compress vital blood vessels and cranial nerves. In addition, they can become very large and extensive without causing substantial symptoms. Surgery is problematic because morbidity, usually in the form of new or worsened cranial nerve deficits, is in the range of 30-40% even in the best surgical hands. For such tumors located in inaccessible areas, aggressive surgical approaches that are likely to cause considerable and permanent morbidity are now often replaced by limited surgical resection combined with postoperative confocal radiotherapy. Similarly, optic nerve sheath meningiomas cannot be resected without sacrificing vision, and should therefore be treated with stereotactic radiotherapy if they are progressive.",153,20,0.13071895424836602
9781908541024,ch_7,There are no effective medical therapies for recurrent or malignant meningiomas.,"There are limited therapeutic options for patients with meningiomas that are recurrent or progressive following maximal surgery and radiotherapy. Antiestrogenic and antiprogestational agents have been evaluated as potential treatments because meningiomas often express steroid receptors and the growth kinetics of some of these tumors are influenced by female sex hormones. However, these agents have no demonstrable efficacy.",76,16,0.21052631578947367
9781908541024,ch_8,Neuronal tumors are uncommon brain neoplasms typically diagnosed in children and young adults.,"Neuronal tumors are very uncommon brain neoplasms that tend to affect children and young adults (Table 7.1). There are often few signs and symptoms other than intractable epilepsy. The rarity of these neoplasms has been a source of considerable confusion and controversy, and it is only over the past two decades that many of these neoplasms have been recognized as distinct clinicopathological entities. General management guidelines are shown in Figure 7.1, and specific treatment issues are discussed below.",101,18,0.1782178217821782
9781908541024,ch_8,The behavior of these tumors can be unpredictable and remains poorly understood because of their rarity.,"The initial management of gangliogliomas and gangliocytomas is surgery, with the goal of gross total resection of all accessible hemispheric tumors. If it is possible only to achieve incomplete resection, most authors recommend close observation with regular neuroimaging. Resection of these tumors can improve epilepsy, and approximately 68% of patients with epilepsy who undergo complete resection of their tumors become seizure-free.",86,17,0.19767441860465115
9781908541024,ch_8,The principal management of neuronal tumors is surgical; total or subtotal resection can be associated with long-term tumor control.,"Patients typically present with an enlarged head and other features of hydrocephalus, and also seizures. These tumors are confined to the cerebral hemispheres, and MRI usually reveals a massive multicystic multilobulated mass with a solid component extending to the cortical surface. Enhancement with contrast is often seen within the solid elements and, rarely, in the walls of the cystic components. As with all glial-neuronal tumors, initial management comprises maximal surgical resection of the tumor. Subsequent management is not clear. Postoperative chemotherapy or radiotherapy has often been administered following subtotal resection, because the tumor has the potential for aggressive biological behavior. For patients undergoing macroscopically radical resections, further immediate therapy can be withheld because the prognosis associated with this tumor is usually good.",163,25,0.15337423312883436
9781908541024,ch_9,The wide range of tumor types that can arise in the pineal region makes histological diagnosis mandatory. The only exception is a patient with elevated cerebrospinal fluid (CSF) markers that indicate the presence of a malignant germ cell tumor.,"Pineal region tumors. It is useful to consider pineal region tumors as a group for the purposes of differential diagnosis. The tumors in this region include germ cell tumors, pineal parenchymal tumors, pineal region cysts, gliomas, meningiomas and Vein of Galen aneurysms (Table 8.1). The wide range of tumor types that can arise in the pineal region makes histological diagnosis mandatory. The only exception is a patient with elevated cerebrospinal fluid (CSF) markers that indicate the presence of a malignant germ cell tumor. Germ cell tumors. Germ cell tumors, the most common type of tumor in the pineal region, comprise a heterogeneous group of primary brain tumors arising from pluripotential germinal cells. The most common is the germinoma, accounting for 40-60% of all germ cell tumors. Other germ cell tumors include teratomas, and non-germinomatous germ cell tumors such as choriocarcinoma, endodermal sinus tumor and embryonal carcinoma. The different germ cell tumor markers are shown in Table 8.2.",242,50,0.2066115702479339
9781908541024,ch_9,Tumors of the pineal region often present with obstructive hydrocephalus.,"It is useful to consider pineal region tumors as a group for the purposes of differential diagnosis. The tumors in this region include germ cell tumors, pineal parenchymal tumors, pineal region cysts, gliomas, meningiomas and Vein of Galen aneurysms (Table 8.1). The wide range of tumor types that can arise in the pineal region makes histological diagnosis mandatory. The only exception is a patient with elevated cerebrospinal fluid (CSF) markers that indicate the presence of a malignant germ cell tumor.",118,17,0.1440677966101695
9781908541024,ch_9,CSF studies and spinal MRI should be obtained in all patients with a germ cell tumor or pineoblastoma.,"Neuroimaging characteristics may suggest the diagnosis. Germinomas tend to be homogeneous and isointense to white matter on T1-weighted MRI and slightly hyperintense on T2-weighted images. Gadolinium enhancement is intense and uniform (Figure 8.1). Teratomas and non-germinomatous germ cell tumors are notably heterogeneous on MRI, both pre- and post-contrast, and are more likely than pure germinomas to show evidence of infiltration into surrounding normal brain. Areas of previous hemorrhage are typical of choriocarcinoma (Figure 8.2). Although characteristic neuroimaging findings may suggest a particular diagnosis, definitive pathology should always be obtained. CSF studies and spinal MRI should also be obtained in all patients with a germ cell tumor.",166,23,0.13855421686746988
9781908541024,ch_10,"Symptoms arise from involvement of cranial nerves, compression of brainstem or basal cerebral structures, and obstruction of the pharynx, middle ear or nasal cavity.","Skull base tumors are neoplasms that arise from or involve theskull base. These tumors pose a surgical challenge because of their deep location within the cranium and close proximity to critical neurovascular structures. Recently, advances in neuroimaging, improved surgical tools and techniques, and new methods of stereotactically focusing radiotherapy have improved the prognosis in patients with cranial base tumors. Symptoms of skull base tumors arise from involvement of cranial nerves, compression of brainstem or basal cerebral structures, and obstruction of the pharynx, middle ear or nasal cavity. This chapter reviews the most common primary skull base tumors and discusses the principles of management in general and, in more detail, the management of pituitary tumors. Meningiomas are addressed in Chapter 6.",160,33,0.20625
9781908541024,ch_10,"Surgery can be curative if benign skull base tumors are resected completely. However, there is a relatively high risk of operative morbidity.","The decision to operate must be made on an individual basis, depending on the likelihood of benefit from tumor resection. Hence, surgery is most often offered to patients with progressive symptoms. It can be curative if benign skull base tumors are resected completely. Modern skull base surgery incorporates removal of non-critical skull base bone and has provided excellent access to deep-seated tumors, with reduced cerebral retraction. Consequently, it is now possible to carry out more radical surgery, with reduced morbidity. However, there are still risks associated with surgery, including cranial neuropathies, infections and cerebrospinal fluid (CSF) leakage.",131,30,0.22900763358778625
9781908541024,ch_10,Radiosurgery is an increasingly accepted alternative to surgery for small tumors in surgically high-risk areas.,"A number of radiotherapeutic modalities have been used to control tumor growth of skull base neoplasms with reasonable success and minimal complications. Conventional fractionated radiotherapy has been used to control benign tumors such as meningiomas and paragangliomas, as well as to provide palliative treatment for malignant tumors. Promising results have been obtained for relatively radioresistant tumors such as chordomas and chondrosarcomas with particle-beam therapy. Stereotactic radiosurgery is being used increasingly for small tumors, such as schwannomas or small meningiomas, in surgically high-risk areas, with promising results (Figure 9.1).",143,22,0.15384615384615385
9781908541024,ch_10,Particle-beam radiation can achieve long-term control of growth for radioresistant skull base tumors such as chordomas and chondrosarcomas.,"A number of radiotherapeutic modalities have been used to control tumor growth of skull base neoplasms with reasonable success and minimal complications. Conventional fractionated radiotherapy has been used to control benign tumors such as meningiomas and paragangliomas, as well as to provide palliative treatment for malignant tumors. Promising results have been obtained for relatively radioresistant tumors such as chordomas and chondrosarcomas with particle-beam therapy. Stereotactic radiosurgery is being used increasingly for small tumors, such as schwannomas or small meningiomas, in surgically high-risk areas, with promising results (Figure 9.1).",143,32,0.22377622377622378
9781908541024,ch_10,"Endocrine consultation is critical in the initial assessment and ongoing management of all patients with pituitary region tumors (adenomas, craniopharyngiomas and germ cell tumors).","Pituitary adenomas are the third most common type of primary intracranial tumor (after gliomas and meningiomas), accounting for 10-15% of all such tumors. Improvements in neuroimaging increasingly reveal incidental, usually asymptomatic, pituitary adenomas. These occult microadenomas have been reported on as many as 10-15% of routine MRIs. Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant disorder associated with tumors of the parathyroid, pancreatic islet cells and pituitary. A genetic mutation in the gene encoding aryl hydrocarbon receptor-interacting protein was recently described in 15-40% of patients and may provide functional insights critical to pituitary and other endocrine tumors. Patients with MEN-1 have about a 25% risk of developing a pituitary adenoma, usually a macroadenoma that secretes growth hormone (GH) or prolactin. These patients typically present at a younger age with larger tumors.",218,37,0.16972477064220184
9781908541024,ch_10,The goals of therapy for pituitary tumors include: reversal of endocrinopathy; elimination of mass effect with preservation or restoration of neurological function (particularly vision); and prevention of recurrence.,"The goals of therapy are to reverse endocrinopathy, to eliminate mass effects with preservation or restoration of neurological function (particularly vision), and to prevent recurrence. Table 9.4 summarizes treatment for pituitary adenomas. Prolactinomas are the most common subtype of pituitary adenomas, accounting for 30% of these tumors (Figure 9.3). In addition to the classic syndrome of amenorrhea/galactorrhea, patients often experience decreased libido, dyspareunia and headache. There is a significant risk of osteoporosis as a result of hypogonadism. Prolactin levels seen in association with a secreting adenoma are usually in excess of 200 ng/mL; levels in excess of 1000 ng/mL are indicative of invasive tumor. Moderate elevations of prolactin (20-150 ng/mL) may be seen with other pituitary adenomas as a result of pituitary stalk compression. Other medical conditions may also cause moderate prolactinemia (Table 9.5).",221,38,0.17194570135746606
9781908541024,ch_10,"Patients with prolactinomas should be managed medically; most other pituitary adenomas require surgery, with or without radiotherapy.","Medical management with a dopamine agonist (bromocriptine or cabergoline) is successful in normalizing prolactin levels, preserving fertility and decreasing tumor size in 50-100% of patients. Patients with microadenomas are particularly likely to respond well to medical treatment. However, lifelong therapy is required because most patients will have recurrent symptoms and tumor growth if the dopamine agonist is discontinued. Surgery is appropriate for patients with resistant tumors and for those unable to tolerate medical therapy, or simply for patient preference. Surgery is also undertaken to allow pregnancy without risk of tumor growth and to avoid the unknown risk of medications to the fetus.",128,29,0.2265625
9781908541024,ch_11,Primary central nervous system lymphoma (PCNSL) is increasing in incidence in the immunocompetent population.,"Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma confined to the central nervous system (CNS). This tumor is of interest for several reasons. First, it has increased in incidence in immunocompetent patients over the past few decades. This increase is independent of advances in neuroimaging or the general aging of the population. Therefore, it is an increasingly important consideration in the differential diagnosis of intracranial mass lesions. Second, unlike many primary brain tumors, PCNSL is exquisitely responsive to treatment and aggressive management may lead to prolonged remission or cure. Finally, the long-term consequences of aggressive therapy may cause significant delayed neurological toxicity.",147,24,0.16326530612244897
9781908541024,ch_11,The approach to diagnosis and treatment of PCNSL is significantly different from that for other primary brain tumors:,"The typical patient is 55-70 years old, and is likely to have had symptoms for only a few weeks before seeking medical attention. Cognitive and personality changes are the most common initial symptoms, reflecting involvement of the frontal lobes, corpus callosum and deep periventricular structures. PCNSL is often multifocal and may present with any focal neurological finding, such as hemiparesis or aphasia. Seizures are a presenting feature in only about 10% of cases, less common than in glioma or brain metastasis. The most important prognostic factors are age less than 50 years and an excellent performance status.",130,21,0.16153846153846155
9781908541024,ch_11,- stereotactic biopsy should be used for tissue diagnosis; complete resection is not indicated,"Evidence of leptomeningeal dissemination is found in up to 40% of patients, but concomitant clinical findings are uncommon. Therefore, cerebrospinal fluid (CSF) should be obtained from all newly diagnosed patients, and analyzed for cell count, protein, glucose and cytology. Flow cytometry may be particularly sensitive for the detection of CSF lymphoma and should be obtained where available. Primary leptomeningeal lymphoma is rare and usually presents with signs and symptoms of increased intracranial pressure, multifocal cranial neuropathies or nerve root involvement.",119,19,0.15966386554621848
9781908541024,ch_11,"Ideally, all patients with newly diagnosed PCNSL should be treated as part of a clinical trial or referred to an appropriate tertiary care center for evaluation and treatment.","Gadolinium-enhanced MRI is the standard neuroimaging technique for the evaluation of PCNSL. Most lesions are supratentorial and periventricular, often involving deep structures such as the corpus callosum and basal ganglia. Lesions may be hypointense or hyperintense on pre-contrast T1 imaging, with dense, homogeneous enhancement after the administration of gadolinium. Peritumoral edema and local mass effect are often less than expected with other intracranial lesions. Calcification, hemorrhage or cyst formation are rare. Table 10.1 summarizes the approaches to evaluating patients with newly diagnosed PCNSL. Ideally, all patients with newly diagnosed PCNSL should be treated as part of a clinical trial or referred to an appropriate tertiary care center for evaluation and treatment.",173,34,0.19653179190751446
9781908541024,ch_11,- steroids should be avoided prior to obtaining diagnostic tissue,"Table 10.1 summarizes the approaches to evaluating patients with newly diagnosed PCNSL. Ideally, all patients with newly diagnosed PCNSL should be treated as part of a clinical trial or referred to an appropriate tertiary care center for evaluation and treatment.",50,10,0.2
9781908541024,ch_11,"- optimal treatment includes methotrexate-based chemotherapy, with or without cranial radiotherapy","There has been increasing interest in using chemotherapy alone in order to minimize delayed neurological toxicity. In older patients (>= 60 years), methotrexate-based chemotherapy alone can achieve similar overall survival to that achieved with combined modality treatment. Importantly, older patients are able to tolerate aggressive chemotherapy without any excess acute morbidity. Typically, these patients improve during the course of chemotherapy, with resolution of neurocognitive deficits and improved performance status.",88,19,0.2159090909090909
9781908541024,ch_11,- older patients should be treated with chemotherapy alone to avoid treatment-related dementia.,"The prognosis at relapse is generally poor. However, prolonged survival is possible and some patients continue to be sensitive to salvage therapy despite multiple relapses. There is no standard salvage therapy. Success has been reported using methotrexate (including patients previously treated with methotrexate), high-dose chemotherapy with stem cell rescue, PCV (procarbazine, lomustine [CCNU] and vincristine), temozolomide and rituximab. Radiotherapy is particularly effective for ocular relapse. Older patients who defer initial radiotherapy remain responsive to this treatment modality, but are at high risk of developing subsequent neurotoxicity.",137,16,0.11678832116788321
9781908541024,ch_12,"There are several syndromes associated with an inherited predisposition to a variety of brain tumors. However, the vast majority of brain tumors are not inherited.","The vast majority of primary brain tumors occur sporadically, but a small number appear to be familial. The etiology of sporadic brain tumors is unknown, but environmental factors are suspected. Most patients with a family history of primary brain tumors have a hereditary disease that is known to be associated with such tumors, such as tuberous sclerosis, neurofibromatosis, familial polyposis or Li-Fraumeni syndrome. However, some patients do not have any underlying or obvious hereditary disorder that would predispose them to primary brain tumors, but nevertheless give a striking history of these tumors in first-degree relatives. Usually, the tumors are found to be high-grade gliomas.",139,31,0.22302158273381295
9781908541024,ch_12,Recognizing a familial brain tumor syndrome is valuable for appropriate surveillance of individuals at high risk of developing an occult brain tumor or associated disease and for genetic counseling.,"Although it is feasible that germline abnormalities could lead to the development of primary brain tumors in these families, there are a number of unusual demographic features suggesting an environmental rather than genetic explanation for brain tumor clustering. Most cases of confirmed familial cancers are multigenerational, and affected individuals are younger than average for the tumor. However, brain tumor families who do not have one of the recognized hereditary diseases usually involve parent-child and sibling-sibling cases; it is rare for more than two generations to be involved. In addition, the demographics suggest environmental rather than genetic causes in the parent-child and sibling-sibling clusters. These observations suggest that familial exposure to an environmental toxin or ionizing radiation may account for the clustering of primary brain tumors in these families. It is important for clinicians to enquire about any family history of brain tumors, and to be aware of the major syndromes with neoplastic manifestations in the nervous system, so that these diagnoses are not missed. Recognizing a familial brain tumor syndrome is valuable for appropriate patient surveillance for another occult brain tumor or associated disease, for screening family members, and for genetic counseling. Most patients presenting with primary brain tumors will, however, be sporadic cases and the etiology will remain unknown.",253,32,0.12648221343873517
9781908541024,ch_12,Recent advances in the molecular biology of familial brain tumor syndromes have suggested new therapies that have the potential to dramatically change the manifestations of these diseases.,"Although it is feasible that germline abnormalities could lead to the development of primary brain tumors in these families, there are a number of unusual demographic features suggesting an environmental rather than genetic explanation for brain tumor clustering. Most cases of confirmed familial cancers are multigenerational, and affected individuals are younger than average for the tumor. However, brain tumor families who do not have one of the recognized hereditary diseases usually involve parent-child and sibling-sibling cases; it is rare for more than two generations to be involved. In addition, the demographics suggest environmental rather than genetic causes in the parent-child and sibling-sibling clusters. These observations suggest that familial exposure to an environmental toxin or ionizing radiation may account for the clustering of primary brain tumors in these families.",155,30,0.1935483870967742
9781908541024,ch_12,"Cysts are common imaging findings; location, imaging characteristics and other features may help to establish the most likely diagnosis.","Several types of lesion, often cystic in nature, may be mistaken for a primary intracranial tumor and must therefore be considered in the differential diagnosis of suggestive MRI abnormalities (Table 11.1). Dermoid and epidermoid cysts account for about 1% of intracranial tumors and are most often found at the base of the brain, fourth ventricle or spine. They are midline tumors that arise from fetal neural and ectodermal tissues. There may be direct communication with the skin via a midline dermal tract.",114,23,0.20175438596491227
9781908541024,ch_12,Dermoids and epidermoids are benign congenital lesions that typically produce symptoms as they gradually increase in size. Total or subtotal resection is the treatment of choice.,"Rathke cleft cysts are usually small asymptomatic abnormalities found on MRI. They can arise in either the sellar or suprasellar region, with 70% of these cysts bridging these two compartments. The lack of calcification may help to distinguish these cysts from craniopharyngiomas. Rarely, Rathke cleft cysts cause pituitary dysfunction, headache or visual disturbance; in these cases, surgical resection is appropriate. Recurrence is rare. Arachnoid cysts are congenital malformations that are typically found in a superficial location, but may be intraventricular (Figure 11.7). They are usually asymptomatic, but occasionally have sufficient mass effect to cause headaches or seizures. Symptomatic lesions should be surgically drained. Neurenteric cysts are congenital epithelial cysts that occur in the spinal canal or posterior fossa. Most are asymptomatic; those causing compression or obstructing the flow of cerebrospinal fluid (CSF) should be resected or diverted.",225,36,0.16
9781908541024,ch_12,Colloid cysts should be resected using modern microneuro-surgical techniques.,"Arachnoid cysts are congenital malformations that are typically found in a superficial location, but may be intraventricular (Figure 11.7). They are usually asymptomatic, but occasionally have sufficient mass effect to cause headaches or seizures. Symptomatic lesions should be surgically drained. Neurenteric cysts are congenital epithelial cysts that occur in the spinal canal or posterior fossa. Most are asymptomatic; those causing compression or obstructing the flow of cerebrospinal fluid (CSF) should be resected or diverted.",120,19,0.15833333333333333
9781908541024,ch_13,Pathological diagnosis is critical to select appropriate therapy.,"Many intracranial tumors present with subacute cognitive decline over several weeks to months. In an elderly patient the differential diagnosis for this clinical presentation is lengthy, ranging from dementia and depression to cerebrovascular disease. Employing excellent neuroimaging early in the diagnostic evaluation usually allows diagnosis of an intracranial mass lesion. As each tumor requires a specific approach to management it is critical to obtain tissue for a pathological diagnosis to avoid administering incorrect and toxic therapies.",96,10,0.10416666666666667
9781908541024,ch_13,Aggressive therapy may improve outcome in elderly patients.,"Recent advances in the management of brain tumors raise a number of issues for older patients. First, older patients are often underrepresented in those clinical trials demonstrating the benefit of a new therapy and thus it is not known if the same benefit can be expected in the geriatric population. Further, the acute toxicity profile associated with a new therapy may be different in the elderly. Finally, the assessment of long-term toxicity associated with new therapies is often limited at the time of initial development and may present differently in older patients.",103,10,0.0970873786407767
9781908541024,ch_13,It may or may not be necessary to modify specific therapies for the elderly because of the risk of toxicity.,"Recent advances in the management of brain tumors raise a number of issues for older patients. First, older patients are often underrepresented in those clinical trials demonstrating the benefit of a new therapy and thus it is not known if the same benefit can be expected in the geriatric population. Further, the acute toxicity profile associated with a new therapy may be different in the elderly. Finally, the assessment of long-term toxicity associated with new therapies is often limited at the time of initial development and may present differently in older patients.",103,21,0.20388349514563106
9781908541024,ch_13,Neurocognitive outcome is of particular concern in elderly patients with brain tumors.,"The major limiting toxicity of high-dose methotrexate is renal toxicity. Assessment of renal function using creatinine clearance is a standard recommendation in geriatric oncology to guide chemotherapy dosing. Therefore, the best recommendation is to assess renal function using creatinine clearance (> 50 mL/h) to determine and modify the recommended methotrexate dose (> 3 g/m) in PCNSL. Several studies have specifically looked at delivering high-dose methotrexate to elderly patients with PCNSL (Table 12.2). Radiographic response rates of 90% or higher have been described and one study showed no difference in acute toxicity associated with methotrexate in older patients.",143,16,0.11188811188811189
9781908541024,ch_13,Clinical trials are needed to address issues specific to elderly patients with brain tumors.,"The major limiting toxicity of high-dose methotrexate is renal toxicity. Assessment of renal function using creatinine clearance is a standard recommendation in geriatric oncology to guide chemotherapy dosing. Therefore, the best recommendation is to assess renal function using creatinine clearance (> 50 mL/h) to determine and modify the recommended methotrexate dose (> 3 g/m) in PCNSL. Several studies have specifically looked at delivering high-dose methotrexate to elderly patients with PCNSL (Table 12.2). Radiographic response rates of 90% or higher have been described and one study showed no difference in acute toxicity associated with methotrexate in older patients.",143,16,0.11188811188811189
9781908541062,ch_2,"Dysregulation within any one of the tissues within the joint may precipitate specific pathologies, such as osteoarthritis or osteoporosis. In rheumatoid arthritis, the primary pathological target is the synovial membrane.","The normal joint. The synovial membrane lines the non-weight-bearing aspects of the synovial cavity and is divided into the lining layer or intima and sublining layer or subintima. It is the target tissue of the dysregulated inflammation and immunity that characterizes rheumatoid arthritis (RA) (Figure 1.1). The synovial membrane intima is just one or two cell layers thick and contains two major cell types: type A synoviocytes, which bear macrophage markers, and type B synoviocytes, which have fibroblastic characteristics. The intima lacks the typical features of an epithelium and does not possess a basement membrane or tight intercellular contacts between synoviocytes. The matrix of the intima is rich in proteoglycans and glycosaminoglycans, in particular hyaluronic acid. The subintima is a loose vascular connective tissue stroma containing blood vessels, lymphatics and nerve endings within a matrix comprising varying proportions of lipid, collagen fibrils and more organized fibrous tissue.",222,49,0.22072072072072071
9781908541062,ch_2,The joint is a complex organ composed of a number of specialized tissues.,"The synovial membrane lines the non-weight-bearing aspects of the synovial cavity and is divided into the lining layer or intima and sublining layer or subintima. It is the target tissue of the dysregulated inflammation and immunity that characterizes rheumatoid arthritis (RA) (Figure 1.1). The synovial membrane intima is just one or two cell layers thick and contains two major cell types: type A synoviocytes, which bear macrophage markers, and type B synoviocytes, which have fibroblastic characteristics. The intima lacks the typical features of an epithelium and does not possess a basement membrane or tight intercellular contacts between synoviocytes. The matrix of the intima is rich in proteoglycans and glycosaminoglycans, in particular hyaluronic acid.",176,14,0.07954545454545454
9781908541062,ch_3,Genetic and environmental factors both play a role in the etiology of RA. A number of genetic associations with RA have now been identified.,"Non-MHC genes. Genome-wide association studies (GWAS) have revolutionized our understanding of complex diseases such as RA. The human genome sequencing project highlighted the abundance of single nucleotide polymorphisms (SNPs) in human DNA. These are single base-pair differences in DNA sequence between different individuals, which do not usually change the function of the gene. The development of high-throughput genotyping technologies has enabled large-scale GWAS in which hundreds of thousands of SNPs that span the entire genome are rapidly compared in patients with a particular disease and matched controls. SNPs that appear more commonly in individuals with the disease in question should lie within or close to genes that are associated with the disease. The Wellcome Trust Case Control Consortium published the first GWAS of RA and, with subsequent studies, has identified and confirmed a number of genes associated with the disease. These include genes encoding proteins such as protein tyrosine phosphatase-22 (PTPN22), an important regulator of lymphocyte activation, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a downregulator of T cell activation, and STAT4, a signaling molecule downstream of the interleukin (IL)-12/IL-23 receptor. Table 2.1 lists genetic loci that have been reproducibly linked to RA in populations of European descent. It has been estimated that approximately 35% of the genetic risk for RA has now been established, most of which is attributable to the MHC. Consequently, many minor genetic influences await identification, including more recent concepts such as gene copy number variants.",332,28,0.08433734939759036
9781908541062,ch_3,"Smoking is an important environmental trigger that, in shared-epitope-positive individuals, stimulates the production of anti-citrullinated peptide antibodies (ACPAs).","A seminal study has irrefutably linked smoking to the etiology of RA in patients carrying a predisposing genotype. A healthy individual carrying two copies of the shared epitope (one on each chromosome 6, see 2.i) has an odds ratio (OR) of developing anti-citrullinated peptide antibody (ACPA)-positive RA that is about five times that of someone who is shared-epitope negative. If the individual smokes, the OR increases to approximately 23 times. PTPN22 also contributes to RA risk in this model, which clearly demonstrates the influence of smoking on RA development (Figure 2.3). Smoking appears to interact with the shared epitope, leading to the production of ACPA, perhaps via the citrullination of proteins in the lung, thereby increasing their immunogenicity. (Citrullination is the post-translational modification of an arginine to form citrulline [ see 6.i ].) Other airborne exposures, for example to silica dust and coal dust, have also been associated with the development of RA. The shared epitope and PTPN22 appear to be associated only with ACPA-positive RA, and seronegative disease appears to have a distinct, and much less well defined, etiology.",267,36,0.1348314606741573
9781908541062,ch_3,"Autoantibodies appear up to 15 years before clinical disease is manifest, suggesting a further influence of additional environmental triggers at a later time point.","A number of studies over the past 10 years have indicated that the process that culminates in RA may start up to 15 years before signs and symptoms appear. For example, autoantibodies (rheumatoid factor [RF] and ACPA) first appear in blood 10-15 years before clinical onset, suggesting that immune tolerance breaks down around that time. Similarly, inflammatory markers, cytokines and chemokines start to rise or appear in blood around 5 years before symptoms are evident. Whether all individuals who develop autoantibodies will ultimately develop RA is currently uncertain, but there may be important additional environmental triggers for disease onset.",128,29,0.2265625
9781908541062,ch_3,Subclinical inflammation starts to manifest approximately 5 years before disease onset.,"A number of studies over the past 10 years have indicated that the process that culminates in RA may start up to 15 years before signs and symptoms appear. For example, autoantibodies (rheumatoid factor [RF] and ACPA) first appear in blood 10-15 years before clinical onset, suggesting that immune tolerance breaks down around that time. Similarly, inflammatory markers, cytokines and chemokines start to rise or appear in blood around 5 years before symptoms are evident. Whether all individuals who develop autoantibodies will ultimately develop RA is currently uncertain, but there may be important additional environmental triggers for disease onset.",128,13,0.1015625
9781908541062,ch_4,"Dominant features are synovial inflammation, and proliferation and outgrowth of the synovial lining layer, with destruction of articular cartilage and bone.","Pro-inflammatory cytokines are abundant in the RA synovium. Prominent among these are tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6, but many others are present, including IL-12, IL-15, IL-17 and IL-18. The RA joint also contains anti-inflammatory cytokines, such as IL-10, IL-13 and transforming growth factor beta (TGFbeta), as well as high levels of cytokine-neutralizing factors, such as soluble TNF receptors and IL-1 receptor antagonist (IL-1ra). These data suggest that a cytokine imbalance, in favor of pro-inflammatory mediators, may be a key pathogenic mechanism in RA (Figure 3.4). A search for pivotal regulatory cytokines suggested that synovial TNF could orchestrate the expression of other pro-inflammatory mediators, and subsequent studies in animal models and then in humans have shown TNF blockade to be a useful therapeutic strategy for RA (see Chapter 9). Recently, however, IL-6 receptor blockade has proved to be as effective, emphasizing the complex interplay between distinct inflammatory mediators in RA. Other pro-inflammatory factors present within the RA synovium include the pleiotropic mediator nitric oxide, prostaglandins, leukotrienes and reactive oxygen intermediates. The accumulation of the last of these has been attributed to a form of reperfusion injury within the chronically inflamed joint secondary to elevated intra-articular pressure. The consequent hypoxia is one of a number of stimuli reported to promote neovascularization in rheumatoid synovitis. Others include soluble factors such as vascular endothelial growth factor (VEGF) and soluble vascular cell adhesion molecule-1 (VCAM-1), which stimulate endothelial cell growth.",380,32,0.08421052631578947
9781908541062,ch_4,Pro-inflammatory cytokines play a pivotal role in RA pathology.,"Pro-inflammatory cytokines are abundant in the RA synovium. Prominent among these are tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6, but many others are present, including IL-12, IL-15, IL-17 and IL-18. The RA joint also contains anti-inflammatory cytokines, such as IL-10, IL-13 and transforming growth factor beta (TGFbeta), as well as high levels of cytokine-neutralizing factors, such as soluble TNF receptors and IL-1 receptor antagonist (IL-1ra). These data suggest that a cytokine imbalance, in favor of pro-inflammatory mediators, may be a key pathogenic mechanism in RA (Figure 3.4). A search for pivotal regulatory cytokines suggested that synovial TNF could orchestrate the expression of other pro-inflammatory mediators, and subsequent studies in animal models and then in humans have shown TNF blockade to be a useful therapeutic strategy for RA (see Chapter 9). Recently, however, IL-6 receptor blockade has proved to be as effective, emphasizing the complex interplay between distinct inflammatory mediators in RA. Other pro-inflammatory factors present within the RA synovium include the pleiotropic mediator nitric oxide, prostaglandins, leukotrienes and reactive oxygen intermediates. The accumulation of the last of these has been attributed to a form of reperfusion injury within the chronically inflamed joint secondary to elevated intra-articular pressure. The consequent hypoxia is one of a number of stimuli reported to promote neovascularization in rheumatoid synovitis. Others include soluble factors such as vascular endothelial growth factor (VEGF) and soluble vascular cell adhesion molecule-1 (VCAM-1), which stimulate endothelial cell growth.",380,13,0.034210526315789476
9781908541062,ch_4,"The primary pathogenic event may reside within the immune system or in the synovial lining. However, data from genome-wide association studies and preclinical autoantibody development suggest primary immune dysregulation.","The role of B cells in rheumatoid synovitis has been revisited in recent years. In addition to producing autoantibodies, B cells secrete pro-inflammatory cytokines (including TNF and IL-6), and are also efficient antigen-presenting cells. There is good evidence that autoantibodies such as anti-citrullinated peptide antibody (ACPA; see 6.i) are produced locally in rheumatoid synovium, within the lymphoid follicles, and B cell depletion is now an established and effective therapy for RA (see Chapter 9). Macrophages are almost certainly the major 'factory' for pro-inflammatory cytokines in RA, and recently there has been renewed interest in the potential role of mast cells in the disease. Dendritic cells are the 'generals' of the immune system that, in large part, determine the outcome of T cell differentiation. They are also present in rheumatoid synovium and could play an important role in disease pathogenesis.",214,42,0.19626168224299065
9781908541062,ch_4,The inter-relationship between the immune system and bone is receiving increasing attention (osteoimmunology).,"Osteoimmunology is a relatively new field that studies the interactions between the immune system and bone. Bone destruction in RA is mediated by osteoclasts, which differentiate from monocyte precursors. A critically important molecule in this regard is receptor activator of nuclear factor B ligand [RANKL] (Figure 3.6). This is a transmembrane protein induced on fibroblast-like synoviocytes (FLS) and osteoblasts by pro-inflammatory cytokines, and a soluble form is secreted by activated T cells. By interacting with membrane receptor activator of nuclear factor B (RANK) on osteoclast precursors, RANKL results in their differentiation and activation, ultimately leading to bone destruction. Macrophage colony stimulating factor (M-CSF) is also necessary for osteoclast formation, whereas TNF, IL-1, IL-6 and IL-17 induce RANKL production, all contributing to both the periarticular and systemic osteoporosis characteristic of RA.",219,23,0.1050228310502283
9781908541062,ch_4,Accelerated cardiovascular disease in RA may be secondary to inflammation or intrinsic to the disease process.,"Cardiovascular disease (CVD) has been a well-recognized complication of RA for decades and accounts for at least 50% of the excess mortality seen in RA patients. Traditional risk factors (smoking, diabetes, hypertension, obesity and hyperlipidemia) cannot account for all of the excess CVD in RA and it is likely that inflammation and thrombogenic factors also contribute. Furthermore, it is now recognized that the pathology of atherosclerosis bears many resemblances to that of RA, in terms of cellular and pro-inflammatory mediators, as well as in the destructive enzymes that result in plaque rupture. Therefore, whether enhanced atherosclerosis is purely secondary to RA manifestations or intrinsically linked to its pathogenesis awaits further study. However, cardiovascular complications can occur in early RA, before downstream sequelae such as joint damage. Ultimately, RA may (and should) become generally recognized as a predisposing factor for atherosclerosis in much the same way as diabetes mellitus is currently.",200,19,0.095
9781908541062,ch_4,Rheumatoid arthritis (RA) is a disease initially localized to the joint lining.,"The symmetry of RA is highly suggestive of a neurological component to the disease, and RA synovium contains high levels of particular neuropeptides such as substance P. Furthermore, there is reduction in sympathetic innervations to the rheumatoid joint and local disruption of sex hormone metabolism and receptor expression. The relationship of these changes to the disease process remains unclear, but is reinforced by observations that include the sparing of paralyzed limbs in patients with neurological disorders such as strokes.",95,18,0.18947368421052632
9781908541062,ch_5,"Rheumatoid arthritis (RA) is a global disease, present in all populations studied.","Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and is a heterogeneous disease. There is no pathognomonic clinical sign or laboratory test, with diagnosis resting on a pattern of clinical and serological features. Classification criteria for RA have recently been updated jointly by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR). Compared with the previous 1987 criteria, more emphasis is now placed on autoantibodies (rheumatoid factor [RF] and anti-citrullinated peptide antibody [ACPA]) and acute phase reactants (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) (see Chapter 5).",155,19,0.12258064516129032
9781908541062,ch_5,"RA should not be viewed as a benign chronic disease of the elderly. The peak age of onset occurs during working life, severely reducing participation and productivity. Furthermore, mortality is increased and there is very significant comorbidity.","The peak age of onset varies between studies but is probably in the fifth decade of life. RA occurs in all societies, with no clear geographic or climatic influence. On the other hand there is variation between communities. For example, there is a high prevalence (approximately 5%) in some Native American populations such as the Pima Indians. Similarly, a low prevalence has been reported in certain rural Chinese and Japanese communities. In Africa, a lower prevalence was reported in a rural than in an urban community. This could reflect a genuine difference in prevalence but could also be explained by other factors, such as a lower mortality from RA-associated infections in the town-dwellers or differences in the age structure of the two communities. Historically, RA has been considered a chronic disabling disease that does not shorten lifespan. This is untrue, however, and various studies have reported a standardized mortality ratio of between 1.3 and 3.0 compared with the general population. Consequently, life expectancy in severe RA is reduced, on average, by 7 years for men and 4 years for women. Furthermore, the improvement in life expectancy seen in the general population over recent years does not appear to have extended to the RA population, resulting in a widening gap in mortality rates (Figure 4.1).",256,45,0.17578125
9781908541062,ch_5,The disease inflicts huge economic costs on both the individual and society. It is essential that total healthcare and societal costs are considered when the economic impact of new drugs is considered.,"The economic costs of an illness are categorized as direct, indirect and intangible. Direct costs are the costs of medicines, and primary and secondary care. For RA, these include the costs of inpatient care, either for rehabilitation or for complications of the disease and joint surgery. Indirect costs represent the consequences of unemployment and reduced productivity. Intangible costs reflect the psychosocial consequences of RA that impact on psychological wellbeing and quality of life. A recent analysis by the UK National Audit Office estimated the annual direct costs of RA to be in the region of 560 million, and total costs up to 4.8 billion per year. The direct costs divide approximately equally between primary and secondary care, with an increasing proportion of spend attributable to biological therapies (160 million annually).",153,35,0.22875816993464052
9781908541062,ch_5,It remains to be determined whether the new targeted biological therapies will reduce the mortality associated with RA.,"The cost-benefit equation. Several of the newer therapies for RA have been expensive to develop and are costly to manufacture; consequently, their price can exceed $15000 (10000)/patient/year. Furthermore, some require intravenous administration, which entails additional costs. If efficacy is high, however, the need for other therapies and surgery should be reduced. If, in addition, function and employment are retained, total direct, indirect and intangible costs will be significantly reduced. A recent estimate from the UK National Rheumatoid Arthritis Society suggests that the loss of productivity when a patient stops work because of RA equates to almost 300000.",130,19,0.14615384615384616
9781908541062,ch_6,Rheumatoid arthritis (RA) has a variety of articular and extra-articular manifestations.,"The pathological and etiologic heterogeneity of rheumatoid arthritis (RA) is reflected clinically, and RA can be difficult to diagnose in its earliest stages. Guidance from the UK's National Institute for Health and Clinical Excellence (NICE) states: refer for specialist opinion any person with suspected persist ent synovitis of undetermined cause. Refer urgently if any of the following apply: the small joints of the hands or feet are affected; more than one joint is affected; there has been a delay of 3 months or longer between onset of symptoms and seeking medical advice.",120,21,0.175
9781908541062,ch_6,The RA spectrum ranges from mild easily controlled disease to progressive destructive disease with organ- and life-threatening extra-articular complications.,"While this is the most common presentation of RA, there are many other possibilities. The disease can affect any synovial joint, and larger joints such as the elbows, shoulders or knees may also be involved. Unusual symptoms reflect the involvement of joints such as the crico-arytenoid joint of the larynx, with resultant hoarseness. Inflammation of synovium at extra-articular sites leads to tenosynovitis and bursitis. Tenosynovitis further compounds functional impairment, particularly of the hands and wrists. Bursitis causes pain at juxta-articular sites: for example, at the hip, where trochanteric bursitis is common. The tempo of onset is also variable, ranging from an acute dramatic presentation in up to one-third of cases to the classic insidious clinical picture, where symptoms may have been present for weeks or months before the patient sought medical advice. Fatigue and malaise may be prominent features and, in some cases, may overshadow the articular symptoms.",215,26,0.12093023255813953
9781908541062,ch_6,Extra-articular disease activity does not always parallel joint inflammation.,"Most extra-articular features of RA occur in RF-positive individuals with severe active joint disease. Occasionally, however, serious extra-articular involvement or even vasculitis arises in patients whose arthritis appears to have remitted or 'burnt out'. In particular, corneal 'melts' frequently arise in elderly patients with minimal inflammatory joint symptoms. There is no obvious explanation for this paradox, which emphasizes the importance of regular and systematic review of RA patients by a specialist throughout the course of their disease.",103,13,0.1262135922330097
9781908541062,ch_6,Patients require close and regular monitoring by a specialist clinician to treat their joint disease and also to promptly diagnose and manage extra-articular manifestations.,"Systemic features. The most common extra-articular manifestation is the rheumatoid nodule. These are usually subcutaneous and occur most commonly overlying pressure points. They are firm and non-tender unless infected, and range in size from a few millimeters in diameter to several centimeters. Common sites for nodules are the extensor surface of the forearms and over pressure points of the wrists, hands (see Figure 5.2a,b) and feet. Nodules may also occur at non-cutaneous sites. In the lungs, a solitary nodule may mimic a malignant tumor. In contrast, whilst less common now, massive and multiple nodules may be seen in ex-coal miners with pneumoconiosis (Caplan's syndrome). When localized to the sclera of the eye, nodules may cause thinning and, rarely, perforation of the globe (scleromalacia perforans). Nodules often improve with effective treatment of RA, but methotrexate may worsen nodulosis in some patients despite improvement in articular disease activity.",225,30,0.13333333333333333
9781908541062,ch_7,"There are no pathognomonic tests for rheumatoid arthritis (RA), and investigations may be completely normal at presentation.","Rheumatoid factor (RF) is an autoantibody with specificity for the Fc region of the immunoglobulin (Ig)G molecule (Figures 6.1 and 3.7). IgM RF is present in up to 75% of RA patients during the course of their disease, although it may be absent at presentation. In contrast, its presence may predate the onset of RA by several years (see 2.iii). Its precise role in the pathogenesis of RA is unclear, but it is associated with more aggressive disease and extra-articular manifestations. RF is not specific for RA, but may accompany other autoimmune diseases, various acute and chronic infections and certain malignancies (Table 6.2).",150,26,0.17333333333333334
9781908541062,ch_7,Anti-citrullinated peptide antibodies (ACPAs) are highly specific for RA and have a sensitivity of up to 75%.,"Unlike RF, autoantibodies directed at peptides containing the amino acid citrulline are highly specific for RA (>= 95%). They may also be present many years before symptomatic onset of RA (see Chapter 2), ultimately appearing in a similar proportion of patients as RF. Citrullinated epitopes are found in many peptides and proteins and are formed by the post-translational deimination of arginyl residues by the enzyme peptidyl arginine deiminase (PADI). Autoantibodies recognizing these epitopes are named anti-citrullinated peptide antibodies (ACPAs), and recognize targets that are potential RA autoantigens, such as citrullinated filaggrin, fibrin, fibrinogen, collagen, alpha-enolase and vimentin. The identification of the ACPA targets that are most closely associated with RA is an area of active research because this should provide clues to etiology and pathogenesis. Several commercial assays are now available for ACPA detection, most of which use second-generation cyclic citrullinated peptide mixtures (CCP2) as the substrate. The relationship between smoking, the shared epitope and the production of ACPA reflects an important gene-environment interaction in the etiology of RA (see Chapter 2).",277,27,0.09747292418772563
9781908541062,ch_7,"Conventional X-rays may provide diagnostic information but are less sensitive than MRI and high-resolution ultrasound (HRUS), although MRI and HRUS continue to be validated.","In contrast to conventional X-rays, high-resolution ultrasound (HRUS) and MRI may show significant abnormalities in the patient with a very recent onset of joint symptoms. Both modalities continue to be validated as diagnostic tools. MRI detects the water content of tissues, and readily demonstrates articular and periarticular structures (Figure 6.3). Additionally, MRI can capture structural information in several planes, and computer-generated three-dimensional reconstructions are possible. In the patient with early RA, inflamed synovium appears as a high signal on T2-weighted fat-suppressed images, and enhances further with the paramagnetic contrast agent gadolinium-DTPA. Bone marrow edema adjacent to the joint surface is a very early abnormality and appears to presage erosion development.",161,34,0.2111801242236025
9781908541062,ch_7,In the acute setting the investigation of polyarthritis is guided primarily by the differential diagnosis.,"A major disadvantage of MRI is the cost of the equipment and individual scans. It is also a relatively lengthy procedure, requiring the patient to lie still for a considerable period of time in a semi-enclosed space. This may be physically difficult, and some patients also find the procedure claustrophobic, although newer magnet designs are addressing some of these issues. For example, smaller MRI magnets are now available for the study of peripheral joints, providing high-resolution images in an office setting. MRI is the investigation of choice for imaging the rheumatoid cervical spine, however, where it provides high-resolution images of the spinal canal and cord. Similarly, osteonecrosis (avascular necrosis) is readily diagnosed using MRI, for example at the hip. This can occur as a complication of the RA disease process or secondary to therapy with corticosteroids.",175,18,0.10285714285714286
9781908541062,ch_7,"In the chronic setting, investigations are useful for determining disease activity, monitoring therapy and documenting and monitoring joint damage.","In established RA, investigations are aimed at determining disease activity, documenting damage and monitoring drug therapy. A normochromic normocytic anemia suggests poorly controlled disease, as does a low serum albumin. There is no indication to repeat RF titers or ACPA in a seropositive patient, because they do not necessarily correlate with disease activity, but a seronegative patient may convert to seropositivity during the course of their illness. Any patient with poorly controlled disease, particularly if taking glucocorticoid therapy, should be considered for osteoporosis screening by dual emission X-ray absorptiometry (DEXA) or an alternative modality. It is reasonable to repeat radiology of involved joints every 1-2 years to document stabilization or progression of joint damage. Other radiological investigations should be guided by the clinical picture. For example, HRUS is increasingly used to document the presence or absence of synovitis in some cases of established RA where the clinical picture is complicated by a second condition, such as fibromyalgia. The assessment of ongoing RA is discussed in more detail in Chapter 7.",231,22,0.09523809523809523
9781908541062,ch_8,"Rheumatoid arthritis can be assessed using objective clinical scores such as swollen-joint counts, biochemical and radiological parameters such as acute-phase response and joint X-rays, and subjective measures of pain, function and participation.","Composite scores. RA is a complex disease and cannot be assessed using a single measure. Therefore, in accordance with the variable manifestations and outcomes of RA, composite assessment criteria have been devised, although debate continues regarding the 'minimal data set' needed to provide a reliable picture of the individual patient. The ACR response criteria were designed for assessing outcomes in the clinical trials setting. These measure changes from baseline in the number of tender and swollen joints, acute-phase response, a functional measure (exempli gratia HAQ score), visual analog scale for pain, and global assessment of disease by patient and physician, also on a visual analog scale. A 20% improvement in swollen and tender joint counts, and in three of the remaining five parameters, represents an ACR20 response. This is the minimum required for efficacy in most trials. ACR50 and ACR70 responses are calculated in a similar fashion. While useful for monitoring clinical trials, these scores have not been validated in the routine clinical setting. Furthermore, they relate to a particular baseline, and a given improvement may be more difficult to achieve from a less active baseline. Thus, a 20% improvement from a baseline of five swollen joints may be more difficult to achieve than from a baseline of 20 swollen joints. In contrast, the disease activity score (DAS; Figure 7.3) provides a continuous variable which does not require reference to a baseline. The DAS is a complex measure that was derived by studying a number of disease activity criteria in patients with variable disease activity, and applying assorted statistical measures, including discriminant analysis and multiple regression analysis. Because of its continuous nature, a patient can be assigned a meaningful DAS at any stage of their disease, and inter-patient comparisons can also be made. Increasingly, the DAS is being used in the routine clinic setting. It provides a longitudinal quantitative measure of RA activity by which to judge the effectiveness of current management and the need for adjustment. In the clinical trial setting, improvement targets can be defined as both a reduction in DAS and also a target level of DAS, providing for good, moderate and nil improvements. The DAS28 is a modification based on 28 swollen and tender joints (see Figure 7.3).",454,47,0.10352422907488987
9781908541062,ch_8,"Quality of life is of overriding importance to the patient, and should always be considered during routine assessments.","While useful for monitoring clinical trials, these scores have not been validated in the routine clinical setting. Furthermore, they relate to a particular baseline, and a given improvement may be more difficult to achieve from a less active baseline. Thus, a 20% improvement from a baseline of five swollen joints may be more difficult to achieve than from a baseline of 20 swollen joints. In contrast, the disease activity score (DAS; Figure 7.3) provides a continuous variable which does not require reference to a baseline. The DAS is a complex measure that was derived by studying a number of disease activity criteria in patients with variable disease activity, and applying assorted statistical measures, including discriminant analysis and multiple regression analysis. Because of its continuous nature, a patient can be assigned a meaningful DAS at any stage of their disease, and inter-patient comparisons can also be made. Increasingly, the DAS is being used in the routine clinic setting. It provides a longitudinal quantitative measure of RA activity by which to judge the effectiveness of current management and the need for adjustment. In the clinical trial setting, improvement targets can be defined as both a reduction in DAS and also a target level of DAS, providing for good, moderate and nil improvements. The DAS28 is a modification based on 28 swollen and tender joints (see Figure 7.3).",269,20,0.07434944237918216
9781908541062,ch_8,Most information is captured in composite scores such as the disease activity score (DAS).,"Alternatives to the DAS include the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI). The former is a simple numerical sum of joint counts, patient and clinician global assessments and C-reactive protein (CRP); the latter removes CRP from the calculation, providing a 'bedside' composite score. An increasing emphasis is now being placed on patient-reported outcome measures (PROMs) to synergize with, or sometimes replace, these composite scores. Fatigue and sleep disturbance, as just two examples, are poorly captured by conventional outcome measures such as DAS28 and yet are some of the most disabling symptoms to patients. The Routine Assessment of Patient Index Data 3 (RAPID3) or Multi Dimensional Health Assessment Questionnaire (MDHAQ) is a patient-completed composite score that incorporates physical function, pain and patient global assessment that is simple to perform. Many patients can also reliably perform their own joint counts, providing further self-assessment information.",210,17,0.08095238095238096
9781908541062,ch_8,A number of patient-reported outcome measures (PROMs) are being developed that quantify symptoms such as fatigue and sleep.,"Alternatives to the DAS include the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI). The former is a simple numerical sum of joint counts, patient and clinician global assessments and C-reactive protein (CRP); the latter removes CRP from the calculation, providing a 'bedside' composite score. An increasing emphasis is now being placed on patient-reported outcome measures (PROMs) to synergize with, or sometimes replace, these composite scores. Fatigue and sleep disturbance, as just two examples, are poorly captured by conventional outcome measures such as DAS28 and yet are some of the most disabling symptoms to patients. The Routine Assessment of Patient Index Data 3 (RAPID3) or Multi Dimensional Health Assessment Questionnaire (MDHAQ) is a patient-completed composite score that incorporates physical function, pain and patient global assessment that is simple to perform. Many patients can also reliably perform their own joint counts, providing further self-assessment information.",210,25,0.11904761904761904
9781908541062,ch_9,Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids provide symptomatic relief but should almost never be used in isolation.,"The acute and chronic consequences of rheumatoid arthritis (RA) result from persistent, misdirected and inadequately controlled inflammation that causes tissue destruction and loss of function. Consequently, management strategies for RA have become highly refined over the past 10 years. The concept of long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids while awaiting a natural remission is no longer acceptable. Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as the diagnosis of RA is secure. Subsequently, therapy is aggressively adjusted until a state of low disease activity or remission is achieved. For this reason, it is critical that patients are referred for specialist assessment as soon as the diagnosis of RA is suspected, and even before the results of investigations are available. Early control of inflammation and the disease process is essential to minimize irreversible joint damage and functional disability. Most patients will commence therapy with methotrexate, either alone or ideally in combination with other DMARDs. With aggressive DMARD therapy a proportion of patients will achieve disease remission, and those who do not can now receive biological therapies (see Chapter 9) within a few months of diagnosis.",246,30,0.12195121951219512
9781908541062,ch_9,"Disease-modifying antirheumatic drugs (DMARDs) are the mainstay of pharmacological therapy, and their use in early rheumatoid arthritis (RA) reduces long-term irreversible joint damage.","The acute and chronic consequences of rheumatoid arthritis (RA) result from persistent, misdirected and inadequately controlled inflammation that causes tissue destruction and loss of function. Consequently, management strategies for RA have become highly refined over the past 10 years. The concept of long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids while awaiting a natural remission is no longer acceptable. Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as the diagnosis of RA is secure. Subsequently, therapy is aggressively adjusted until a state of low disease activity or remission is achieved. For this reason, it is critical that patients are referred for specialist assessment as soon as the diagnosis of RA is suspected, and even before the results of investigations are available. Early control of inflammation and the disease process is essential to minimize irreversible joint damage and functional disability. Most patients will commence therapy with methotrexate, either alone or ideally in combination with other DMARDs. With aggressive DMARD therapy a proportion of patients will achieve disease remission, and those who do not can now receive biological therapies (see Chapter 9) within a few months of diagnosis.",246,46,0.18699186991869918
9781908541062,ch_9,"Treatment-to-target strategies, including combination DMARD therapy, rapidly suppress inflammation and minimize long-term damage and disability.","The acute and chronic consequences of rheumatoid arthritis (RA) result from persistent, misdirected and inadequately controlled inflammation that causes tissue destruction and loss of function. Consequently, management strategies for RA have become highly refined over the past 10 years. The concept of long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids while awaiting a natural remission is no longer acceptable. Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as the diagnosis of RA is secure. Subsequently, therapy is aggressively adjusted until a state of low disease activity or remission is achieved. For this reason, it is critical that patients are referred for specialist assessment as soon as the diagnosis of RA is suspected, and even before the results of investigations are available. Early control of inflammation and the disease process is essential to minimize irreversible joint damage and functional disability. Most patients will commence therapy with methotrexate, either alone or ideally in combination with other DMARDs. With aggressive DMARD therapy a proportion of patients will achieve disease remission, and those who do not can now receive biological therapies (see Chapter 9) within a few months of diagnosis.",246,26,0.10569105691056911
9781908541062,ch_9,"Consequently, the patient with RA is optimally managed from disease onset by a rheumatologist and their multidisciplinary team.","The acute and chronic consequences of rheumatoid arthritis (RA) result from persistent, misdirected and inadequately controlled inflammation that causes tissue destruction and loss of function. Consequently, management strategies for RA have become highly refined over the past 10 years. The concept of long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids while awaiting a natural remission is no longer acceptable. Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as the diagnosis of RA is secure. Subsequently, therapy is aggressively adjusted until a state of low disease activity or remission is achieved. For this reason, it is critical that patients are referred for specialist assessment as soon as the diagnosis of RA is suspected, and even before the results of investigations are available. Early control of inflammation and the disease process is essential to minimize irreversible joint damage and functional disability. Most patients will commence therapy with methotrexate, either alone or ideally in combination with other DMARDs. With aggressive DMARD therapy a proportion of patients will achieve disease remission, and those who do not can now receive biological therapies (see Chapter 9) within a few months of diagnosis.",246,28,0.11382113821138211
9781908541062,ch_9,"Optimal therapy also includes access to allied health professionals such as nurse specialists, physiotherapists, occupational therapists and podiatrists.","The patient must be fully educated about treatment options and expectations from the outset, and decisions regarding drug therapy must be mutually agreed. Furthermore, the rheumatologist must serve as an advocate for the patient with regard to treatment and drug monitoring programs. In the USA this is particularly important, in light of potential restrictions due to changes in the healthcare reimbursement system and managed care. Economic considerations have also become important in the UK, although recent guidelines from the National Institute for Health and Clinical Excellence (NICE) have reduced some previous restrictions on the prescribing of biologics (see Chapter 9).",117,27,0.23076923076923078
9781908541062,ch_9,"DMARDs are generally safe with appropriate monitoring, but adverse events are potentially life-threatening if missed.","Side effects. Adverse events include bone marrow toxicity, reversible alopecia, skin rash, stomatitis, diarrhea, hypertension and elevation in liver enzymes. Routine monitoring of CBC, LFTs and blood pressure are required. Leflunomide is also teratogenic. It has an extremely long half-life and, if required, its elimination can be accelerated with cholestyramine or activated charcoal.",89,21,0.23595505617977527
9781908541062,ch_9,"The need for, and timing of, surgery requires skilled judgment.","The optimal timing of, and potential benefit to be gained from, orthopedic surgery in the RA patient requires skilled judgment. Similarly, both local and systemic disease activity must be optimally controlled perioperatively. It follows that pre- and postoperative assessment and care requires a multidisciplinary approach involving not only surgeon and rheumatologist, but also occupational therapist and physiotherapist. Most important of all, the patient must be absolutely clear as to the indication for surgery (relief of pain, preservation of function or both) and likely outcome. For example, pain-relieving elbow surgery may improve quality of life but not necessarily upper limb function.",133,13,0.09774436090225563
9781908541062,ch_10,"Biologics are expensive drugs, produced from living cells, that require parenteral (intravenous or subcutaneous) administration. They slow joint damage more effectively than traditional disease-modifying antirheumatic drugs.","Management - biological therapies. Advances in translational research have led to a better understanding of the pathogenesis of rheumatoid arthritis (RA). Combined with advances in biotechnology, this has led to the development of several biological therapies for RA. Biological therapies are produced from living cells rather than by chemical synthesis and, generally, are monoclonal antibodies (mAbs) or soluble derivatives of cell surface receptors. Those used to treat RA target specific molecules or receptors in the immune and/or inflammatory process (Table 9.1). Depending on their precise molecular structure mAbs can be chimeric (murine variable [V]-region, human constant [C]-region); humanized (human in sequence apart from murine complementarity determining regions); or fully human (derived from human B cells or gene libraries, or from transgenic mice with human immunoglobulin genes). Tumor necrosis factor antagonists. The development of drugs that target TNF has been an enormous advance. In the last 12 years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both approved five TNF antagonists for the treatment of RA: etanercept, infliximab, adalimumab, golimumab and certolizumab pegol (Figure 9.1).",269,48,0.17843866171003717
9781908541062,ch_10,"Nine biological therapies are now licensed for the treatment of RA. These block cytokines or their receptors (tumor necrosis factor [TNF], interleukin [IL]-1 and IL-6), deplete B cells or interfere with T cell activation.","Advances in translational research have led to a better understanding of the pathogenesis of rheumatoid arthritis (RA). Combined with advances in biotechnology, this has led to the development of several biological therapies for RA. Biological therapies are produced from living cells rather than by chemical synthesis and, generally, are monoclonal antibodies (mAbs) or soluble derivatives of cell surface receptors. Those used to treat RA target specific molecules or receptors in the immune and/or inflammatory process (Table 9.1). Depending on their precise molecular structure mAbs can be chimeric (murine variable [V]-region, human constant [C]-region); humanized (human in sequence apart from murine complementarity determining regions); or fully human (derived from human B cells or gene libraries, or from transgenic mice with human immunoglobulin genes). Tumor necrosis factor antagonists. The development of drugs that target TNF has been an enormous advance. In the last 12 years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both approved five TNF antagonists for the treatment of RA: etanercept, infliximab, adalimumab, golimumab and certolizumab pegol (Figure 9.1).",264,54,0.20454545454545456
9781908541062,ch_10,"Patients vary in their response to biologics, presumably reflecting important inter-patient differences in disease pathogenesis and drug pharmacokinetics.","These five TNF inhibitors show excellent effectiveness in both early and established RA. In addition to improvements in inflammation and joint damage, patients receiving TNF inhibitors also report important reductions in fatigue and malaise with significant quality-of-life benefits. Aside from differences in immunogenicity, half-life and route of administration, there are theoretical differences between the five TNF inhibitors. For example, etanercept also neutralizes lymphotoxin, although the contribution of this feature to effectiveness or toxicity is uncertain. Patients who may benefit. Not all RA patients respond to TNF antagonists and, at present, there are no factors that reliably predict effectiveness. Currently these drugs are licensed for use in patients who have failed one or more conventional DMARD (the precise license depends on geographic location). Their effectiveness approximates inversely with the duration of RA - thus they are more effective in early disease and least effective in very late disease.",187,28,0.1497326203208556
9781908541062,ch_10,Prolonged experience will be required to provide a true therapeutic ratio and an accurate economic evaluation of these drugs.,"Understanding why some patients do not respond to biological therapies remains a major challenge and provides opportunities for further dissection of the pathogenic mechanisms operative in RA. Factors predisposing to opportunistic or unusual infections also require clarification. Finally, the costs of these potent therapies will need to be evaluated in terms of their long-term benefit, with particular regard to work stability, the predicted reduction in joint replacements, and their potential to provide improved quality of life and lifespan (see Chapter 4). The question whether they should replace methotrexate or sulfasalazine as the DMARDs of first choice will be answered only as the use of these agents increases.",130,22,0.16923076923076924
9781908541062,ch_10,A major research agenda relates to how to target these drugs to the patients who will derive most benefit from them (personalized medicine).,"Understanding why some patients do not respond to biological therapies remains a major challenge and provides opportunities for further dissection of the pathogenic mechanisms operative in RA. Factors predisposing to opportunistic or unusual infections also require clarification. Finally, the costs of these potent therapies will need to be evaluated in terms of their long-term benefit, with particular regard to work stability, the predicted reduction in joint replacements, and their potential to provide improved quality of life and lifespan (see Chapter 4). The question whether they should replace methotrexate or sulfasalazine as the DMARDs of first choice will be answered only as the use of these agents increases. Now that we have nine biological therapies approved to treat RA, our major challenge over the next several years will be directed towards how to best use these in individual patients. Specifically, we need to develop biomarkers of the immune abnormalities in each patient so we can apply the most appropriate treatment (personalized medicine). In addition, we will need more research as to how to use these newer therapies in combination with more traditional medications such as methotrexate.",220,26,0.11818181818181818
9781908541062,ch_11,Signaling pathway inhibitors are orally active drugs with potencies similar to biological therapies. Their successful passage through phase III trials could have a major impact on RA management.,"Janus kinase inhibitors. The Janus kinase (JAK) family of tyrosine kinases (TYKs) comprises JAK1, JAK2, JAK3 and TYK2. All family members are expressed ubiquitously except for JAK3, which is expressed exclusively in leukocytes. JAK3 associates with the common gamma-chain, which is a component of the IL-2 receptor as well as other cytokine receptors (including IL-4, IL-7, IL-9, IL-15 and IL-21). JAK3 plays a crucial role in regulating leukocyte function, becoming activated following IL-2 binding to the IL-2 receptor. Once activated, JAK3 phosphorylates specific tyrosine residues on the receptor, leading to the recruitment of specific signal transducers and activators of transcription (STATs). The STATs are then phosphorylated and reorient as dimers; they are released from the receptor and translocate to the nucleus where they act as powerful regulators of gene transcription. Clinical trials of JAK inhibitors in patients with RA have yielded encouraging results, both from efficacy and toxicity standpoints. These are chemically synthesized orally bioavailable drugs, which provides a potential advantage over biological therapies. Phase III trials are in progress.",268,32,0.11940298507462686
9781908541062,ch_11,Mesenchymal stem cells have both immunomodulatory and tissue engineering potential. They could develop into an important cellular therapy for diseases such as RA.,"Mesenchymal stem cells (MSCs) are the precursors of osteoblasts, chondrocytes, myocytes and adipocytes. Rapid advances are being made in the isolation, expansion and culture of these cells, which could result in the generation of 'replacement parts' for joints in the laboratory. The main challenges are identifying optimal growth factors and conditions, and methods to guide the ultimate structure of laboratory-grown tissues, including the use of artificial scaffolds. Although such technology is likely to be applied initially to osteoarthritic joints, a role in RA may become evident, particularly if mesenchymal defects are shown to play a primary role in disease pathogenesis.",142,32,0.22535211267605634
9781908541062,ch_11,"A large number of drugs are currently in clinical trials for rheumatoid arthritis (RA); several target novel mediators and pathways, incorporating concepts such as epigenetic modification.","Chapter 2 highlighted that circulating autoantibodies appear many years before the onset of RA symptoms. Imaging studies have also indicated that synovitis can be present in joints for weeks to months before symptoms occur. Clinical trials of many therapies have demonstrated optimal results in early disease and attention is starting to turn to the preclinical phase of RA for two reasons. First, the likelihood of switching off disease and obtaining long-term remission, for example using tolerogenic therapies (see above), appears much higher before disease becomes established. Second, if it were possible to identify individuals with a high likelihood of developing RA, it may be possible to institute preventive measures. These could reflect lifestyle changes, such as smoking cessation or weight loss, or even mild therapeutic interventions such as hydroxychloroquine or a brief course of corticosteroids. Susceptible individuals might be identified either by screening family members for autoantibodies and tissue type, or even population screening for similar factors. A number of social and ethical issues need to be addressed before the adoption of such strategies, even in the trial setting, but this is an area of intense current interest.",228,35,0.15350877192982457
9781908541062,ch_11,"In the future, rheumatologists may identify and treat patients in the presymptomatic phase of RA, using approaches such as therapeutic tolerance induction.","Chapter 2 highlighted that circulating autoantibodies appear many years before the onset of RA symptoms. Imaging studies have also indicated that synovitis can be present in joints for weeks to months before symptoms occur. Clinical trials of many therapies have demonstrated optimal results in early disease and attention is starting to turn to the preclinical phase of RA for two reasons. First, the likelihood of switching off disease and obtaining long-term remission, for example using tolerogenic therapies (see above), appears much higher before disease becomes established. Second, if it were possible to identify individuals with a high likelihood of developing RA, it may be possible to institute preventive measures. These could reflect lifestyle changes, such as smoking cessation or weight loss, or even mild therapeutic interventions such as hydroxychloroquine or a brief course of corticosteroids. Susceptible individuals might be identified either by screening family members for autoantibodies and tissue type, or even population screening for similar factors. A number of social and ethical issues need to be addressed before the adoption of such strategies, even in the trial setting, but this is an area of intense current interest.",228,31,0.13596491228070176
9781908541086,ch_3,Anorexia nervosa is characterized by the refusal to maintain a normal bodyweight by self-starvation.,"Definition of anorexia nervosa. Anorexia nervosa is characterized by the refusal to maintain a bodyweight equal to or above a minimally normal weight for the individual's age and height. Bodyweight is at least 15% below the norm. The weight loss is self-induced by several means. use of laxatives or diuretics. self-induced vomiting. excessive exercise. Individuals with anorexia exhibit an overwhelming fear of putting on weight and a distorted view of the size and shape of their body. Postmenarcheal females experience amenorrhea, id est the absence of at least three consecutive menstrual cycles, or if the menstrual cycle occurs it does so only as a result of hormone administration.",147,22,0.14965986394557823
9781908541086,ch_3,Bulimia nervosa is characterized by significant binge-eating and subsequent purging to control bodyweight.,The specific diagnostic criteria for anorexia from the fourth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) are discussed in more detail in Chapter 4 - Diagnosis. Definition of bulimia nervosa. Bulimia nervosa is characterized by recurrent episodes of significant binge-eating - eating large amounts of food in a discrete amount of time and feeling a sense of a lack of control - followed by inappropriate compensatory behaviors to prevent weight gain. There are two subtypes of bulimia.,110,21,0.19090909090909092
9781908541086,ch_3,"Eating disorders often remain secret; sufferers experience shame and isolation, which can hinder recovery.","non-purging type, in which the individual does not regularly engage in purging behavior, but uses other inappropriate compensatory behaviors such as fasting or excessive exercising. Those who suffer from bulimia use their binge and purge cycles to prevent weight gain and to regulate other emotional difficulties. Unlike anorexia, bulimia does not generally result in significant weight loss and in many ways is a very secretive disease. The shame and isolation experienced by individuals suffering from this disorder can hinder recovery.",98,19,0.19387755102040816
9781908541086,ch_3,Other eating disorders include binge-eating disorder and night-eating syndrome.,"DSM-IV classifies both anorexia and bulimia under a specific diagnostic category entitled 'Eating Disorders', which also includes a third classification entitled 'eating disorders not otherwise specified' ('atypical eating disorder' in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems, tenth revision [ICD-10]). This last category includes binge-eating disorder and night-eating syndrome, discussed in Chapter 9 of this book, and may be used to describe eating disorders that meet some but not all of the diagnostic criteria for anorexia or bulimia: for example, an individual with almost all of the symptoms of anorexia but who still has a normal and regular menstrual cycle and/or a normal body mass index, or cases with overevaluation of weight and shape associated with purging behaviors at least twice a week but no binge-eating episodes ('eating disorder not otherwise specified' [EDNOS] purging type). Patients that present with subsyndromal criteria should be monitored in order to identify the development of a full-syndrome eating disorder. Primary care physicians should conduct a comprehensive assessment to uncover any significant risk factors in the patient's life that could rapidly lead to a full-syndrome eating disorder. The primary care physician may invite the patient for serial assessments to track symptoms over time, consulting or referring with a specialist if needed.",283,14,0.04946996466431095
9781908541086,ch_4,"Both anorexia and bulimia are more prevalent in Western industrialized nations of white ethnicity and in middle- to upper-class women, but the disorders are now affecting more diverse populations in terms of ethnicity and socioeconomic status.","Prepubescent onset (before menarche) is rare but further study of this age group is needed. Personality characteristics and eating disorder psychopathology are unique in this population and the course of the disorder in this group is particularly severe. Ethnic differences. Anorexia has long been considered as a disorder affecting mainly young women from middle to high economic classes in wealthy countries. While the disorder continues to be more prevalent in Western industrialized nations of white ethnicity and in middle- to upper-class women, there is an increasing diversity of those affected in terms of socioeconomic status and ethnicity, including African, Asian and Indian groups. In the USA, significant differences in the prevalence of anorexia were found by race in a geographically and economically diverse community sample of white and black 19-24-year-old women; none of the black women was found to have had anorexia (Figure 2.2).",181,45,0.24861878453038674
9781908541086,ch_4,"Eating disorders are more common in women than men, but disordered eating is increasingly being seen in male athletes and performers.","Sex differences. As with other eating disorders, bulimia has a much higher prevalence in women than in men. The reported lifetime prevalence of bulimia ranges from 1.0% to 2.8% among women, and is about 0.5% among men. In France, a two-stage screening for bulimia among 3527 unselected secondary-school students demonstrated higher rates in girls than boys with regard to overconcern with bodyweight and shape, dieting, bulimic binges, self-induced vomiting, use of laxatives and use of diet pills. From these data the researchers estimated prevalences for bulimia of approximately 1.1% in girls and 0.2% in boys.",147,25,0.17006802721088435
9781908541086,ch_4,"Bulimia is more common in adults than teenagers, while anorexia is more common in adolescent girls.","Sex differences. As with other eating disorders, bulimia has a much higher prevalence in women than in men. The reported lifetime prevalence of bulimia ranges from 1.0% to 2.8% among women, and is about 0.5% among men. In France, a two-stage screening for bulimia among 3527 unselected secondary-school students demonstrated higher rates in girls than boys with regard to overconcern with bodyweight and shape, dieting, bulimic binges, self-induced vomiting, use of laxatives and use of diet pills. From these data the researchers estimated prevalences for bulimia of approximately 1.1% in girls and 0.2% in boys.",147,22,0.14965986394557823
9781908541086,ch_4,Disordered eating is probably more common than classic eating disorders in adolescents and young adults.,"Epidemiological studies show that even in individuals who do not match the criteria for a specific eating disorder, patterns of 'disordered eating' are highly prevalent. 'Eating disorders not otherwise specified' (EDNOS; see 1.iii) are probably more common than classic eating disorders in young people. In the USA, the Centers for Disease Control and Prevention's 2005 Youth Risk Behavior Survey found that 30% of boys and 62% of girls in high school were trying to lose weight, although only 25% of boys and 38% of girls considered themselves to be overweight. Adolescents employ unhealthy weight control behaviors such as fasting (12%), diet supplements (6%) and even purging by vomiting or laxative abuse (5%). In both adolescents and adults, atypical eating disorders (EDNOS) account for more than 50% of cases in the community and in eating disorder treatment clinics.",182,17,0.09340659340659341
9781908541086,ch_5,"Parental attitudes and behaviors towards eating, weight and body shape have a strong influence on the development of a child's relationship with food and body image, both healthy and unhealthy.","Family functioning. Historically, the role of dysfunctional styles of family interaction was put forward in theories of the development of eating disorders. Unfortunately and unfairly, this has led to some parenting styles being blamed for causing eating disorders in children. Still, the type of relationships that children and adolescents develop with food and body image, both healthy and unhealthy, is strongly influenced by. parental attitudes toward eating, weight and body shape. parental eating and weight-related behavior modeled in the home. excessive parental control over a child's nutritional intake such that the child is unable to make independent food choices. Perceived pressure to be thin, family criticism regarding weight, and maternal investment in slenderness predict eating disturbances in adolescents. Parents also have a strong influence over their children's internalization of the aesthetic ideal.",159,35,0.22012578616352202
9781908541086,ch_5,"Clinicians and patients are best served by considering eating disorders from a bio-psycho-social perspective, unified in a framework of developmental psychopathology. All components are present, and interact to increase the risk for disorder as development proceeds. Disorder represents the crystallization of these interactions into syndromes which, in this case, are a developmental outcome, not simply the burgeoning of a latent biological deficit, as reductionist models of psychopathology would have it.","Societal influences. The preoccupation with body image and the drive to attain thinness that are characteristic of eating disorders relate to the idealized representation of the human figure within a given culture, and to the pressure to conform from peers and the media. In Western countries, the body dimensions of female cultural icons, such as fashion models and actresses, have become progressively thinner over the past decades, with a concomitant rise in disordered eating among women. Mounting evidence implicates the mass media in the promotion of body-image and eating disturbances, with the emphasis on dieting and other weight-control behaviors often targeted at women rather than men, thus paralleling the gender distribution of eating pathology. A longitudinal prospective study of ethnic Fijian adolescent girls demonstrated an increase in key indicators of disordered eating following novel prolonged television exposure to the aesthetic ideal. The internalization of societal pressures has been shown to have a clear effect on body dissatisfaction and eating dysregulation in population samples. The first diet in adolescent girls is most frequently triggered by comparison with others' appearance and their own self-ideal. Societal influences and internalization of the thin ideal may lead directly to body dissatisfaction and unhealthy eating, or may be mediated by more general psychological processes such as intrapersonal (self-esteem, mood, personality) or interpersonal functioning and/or emotional regulation and coping. Stressors and life events precipitate the onset of eating disorders in 70% of cases, and include parental neglect, abuse, indifference, loss and separation. In some studies, a high incidence of sexual abuse during childhood is reported by women with diagnosed eating disorders; rates of abuse are seemingly higher in bulimia than anorexia. In a US statewide representative sample, both sexual and physical abuse were strong independent risk factors for disordered eating in adolescent girls and boys. The nature of this relationship is difficult to assess because of differences in diagnostic criteria for abuse, a high base rate of sexual abuse in the general female population and a high rate of abuse associated with other psychiatric diagnoses. The issue is insufficiently explored in young people. Male university students who reported physical and sexual abuse in childhood were also at a greater risk for eating disorders.",444,92,0.2072072072072072
9781908541086,ch_5,"Stressors and life events, such as childhood abuse, separations or bereavement, may precipitate the onset of eating disorders.","Stressors and life events precipitate the onset of eating disorders in 70% of cases, and include parental neglect, abuse, indifference, loss and separation. In some studies, a high incidence of sexual abuse during childhood is reported by women with diagnosed eating disorders; rates of abuse are seemingly higher in bulimia than anorexia. In a US statewide representative sample, both sexual and physical abuse were strong independent risk factors for disordered eating in adolescent girls and boys. The nature of this relationship is difficult to assess because of differences in diagnostic criteria for abuse, a high base rate of sexual abuse in the general female population and a high rate of abuse associated with other psychiatric diagnoses. The issue is insufficiently explored in young people. Male university students who reported physical and sexual abuse in childhood were also at a greater risk for eating disorders.",168,27,0.16071428571428573
9781908541086,ch_5,Eating problems usually emerge in the context of pubertal change.,"Prepuberty and adolescence. Studies have also confirmed that eating problems emerge in response to pubertal change, especially fat accumulation. Girls who feel most negatively about their bodies at puberty are at a higher risk of developing eating difficulties. Several studies have identified associations between disturbed eating in adolescents and.",57,14,0.24561403508771928
9781908541086,ch_5,"Psychiatric comorbidities in both men and women with eating disorders include depression, anxiety, obsessive behavior and body-image disturbance.","Depression is one of the most salient psychiatric comorbidities in both men and women with eating disorders. Dysregulation in serotonin, a neurotransmitter involved in the regulation of both mood and satiety, has been implicated as a causal factor in depression and eating disorders. Antidepressants that selectively block serotonin reuptake are effective in the treatment of both depression and bulimia or binge-eating disorder. Anxiety and obsessive-compulsive behavior. Similarly, increased levels of anxiety and obsessiveness have been described in young people and adults with eating disorders. Premorbid overanxious disorder and obsessive-compulsive tendencies are seen significantly more often in patients with anorexia than in controls. Similarly, the risk for bulimia is increased by the presence of overanxious disorder or social phobia relative to controls. However, longitudinal studies in other fields indicate that premorbid anxiety disorders and negative affectivity are also risk factors for the development of other psychiatric conditions such as affective disorders and substance abuse.",204,27,0.1323529411764706
9781908541086,ch_5,"When treating a patient with either an eating disorder or substance-abuse problem, clinicians should always consider the possibility of comorbidity.","17% of bulimics report a current or past history of drug, substance or alcohol abuse and/or dependence, or treatment for any of the above. 20% of drug abusers report a current or past history of bulimia or bulimic behaviors. Among bulimics, the family history studies show alcoholism rates of 39%, and drug or substance use rates of 19%. When treating a patient with either an eating disorder or a substance-abuse problem, the clinician should always consider the possibility of a comorbid substance-abuse or eating problem.",113,27,0.23893805309734514
9781908541086,ch_6,Both DSM-IV and ICD-10 provide specific criteria for the diagnosis of bulimia and anorexia.,"The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition, (DSM-IV) criteria for anorexia and bulimia are highlighted in Tables 4.2 and 4.3, respectively. In the alternative diagnostic classification used in Europe - the World Health Organization's International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD-10) - eating disorders belong to a wider category entitled 'Behavioral syndromes associated with physiological disturbances and physical factors'. The ICD-10 criteria for anorexia and bulimia are consistent with those of DSM-IV, the only significant difference being the relationship between bulimia and anorexia. DSM-IV gives precedence to anorexia over bulimia, while the ICD-10 specifically excludes a diagnosis for anorexia if binge eating is present.",175,24,0.13714285714285715
9781908541086,ch_6,"Comorbid psychological problems include depression, anxiety and obsessive behavior, and substance misuse in patients with bulimia.","Behavioral signs associated with bulimia are shown in Table 4.6. Patients with bulimia often have features of depression, especially low self-esteem, and may have features of anxiety (30-70% present with depression or anxiety during their lifetime compared with a lifetime rate in the general population of 9% and 11% for mood disorders and anxiety disorders, respectively). Alcohol and substance misuse and deliberate self-harm are also common. Up to one out of two people with bulimia may report stealing.",105,23,0.21904761904761905
9781908541086,ch_6,"Patients with eating disorders are likely to present with profound weight loss or weight fluctuations, malnutrition and a number of medical complications associated with recurrent vomiting, as well as social problems.","Overtraining syndrome. Another presentation of disordered eating in athletes has been described as a state of exhaustion, depression and irritability in which athletes continue to train even as their athletic performance diminishes. Diagnosis in men. Men with eating disorders are less likely than women to seek professional help, as eating disorders are commonly viewed as a 'woman's disease'. However, the number of men seeking treatment for an eating disorder may be increasing. The most common diagnosis of eating disorders among men is 'eating disorders not otherwise specified' (EDNOS). Men also exhibit higher rates of psychiatric comorbidity and psychosocial morbidity than women. Notably, men with an eating disorder - particularly bulimia or binge-eating disorder - may be more likely to have a substance-abuse problem.",161,35,0.21739130434782608
9781908541086,ch_6,Structured interviews allow the reliable and valid assessment of the key behavioral features and associated psychopathology of eating disorders.,"Structured interviews enable the reliable and valid assessment of the key behavioral features and associated psychopathology of eating disorders. The main screening tools for assessment of eating disorders are shown in Table 4.8. Other screening tools include the Rating of Anorexia and Bulimia Interview-Revised Version (RAB-R) and the Multiaxial Assessment of Eating Disorders Symptoms (MAEDS). The shortest screening instrument is certainly the SCOFF questionnaire, which is a mnemonic for the words 'Sick, Control, One (as in one stone's worth of weight, in the UK), Fat, and Food' (Table 4.9). It is a five-item tool with a score of one point given for each question that is answered affirmatively; a total of two or more points suggests an eating disorder.",167,22,0.1317365269461078
9781908541086,ch_6,Laboratory tests may help to identify the degree of electrolyte imbalance caused by frequent purging and to determine overall nutritional status and need for hospitalization.,"Screening instruments for children include the child versions of the Eating Disorders Examination (EDE), the Eating Attitude Test (EAT), and the Eating Disorders Inventory (EDI) (see Table 4.8), as well as the Kids Eating Disorder Survey. In addition, various websites that screen for eating disorders have recently been promoted on college campuses in the USA. Data are not yet available to determine the success of these sites, but the approach is valued for its confidentiality and ease of access to younger students. Laboratory studies may be helpful to identify the degree of electrolyte imbalance caused by frequent purging and to determine the individual's nutritional status and state of overall health. Possible biochemical abnormalities are highlighted in Table 4.10. Laboratory profiles can be followed serially to monitor fluid balance and particularly to detect hypokalemia. An electrocardiogram may be useful to detect cardiac abnormalities (see 5.iii).",184,30,0.16304347826086957
9781908541086,ch_7,"The treatment of eating disorders requires a multidisciplinary team of healthcare professionals, involving the primary care physician, psychiatrist and nutritionist.","General management principles. The multidisciplinary team. Treatment of eating disorders requires a multidisciplinary team of professionals to provide the appropriate care for the patient. This team usually consists of a primary medical physician, a psychotherapist and/or psychiatrist and a dietitian. It is the responsibility of every team member to inform each other, as well as appropriate family members, of the patient's state. Together, the team decides what type of treatment is necessary along the continuum of care. outpatient therapy. partial hospitalization.",107,26,0.24299065420560748
9781908541086,ch_7,"Psychological health comprises: healthy eating behaviors with no restricting or purging; the elimination of obsessions regarding body image, bodyweight and food; normal adaptive functioning in school/work and interpersonal relationships; and coping with normative stressors.","to assess eating-disorder symptoms and behaviors. to monitor the patient's psychological status, including behavior shifts, cognitions, and emotions. to provide individual, family or group psychotherapy. The dietitian oversees the nutritional counseling of the patient, providing several important functions. to ensure adequate nutrient intake. to improve dietary variety. to establish structured normalized eating patterns to help address detrimental attitudes towards food and eating. to provide education regarding healthy nutrition and eating patterns. Treatment goals. The ultimate goal of treatment is both psychological and physical health. It is important to emphasize these definitions of recovery as opposed to defining recovery simply as weight gain or a temporary change in behavior. Psychological health involves the development of normal eating behaviors, without restricting or purging, and the elimination of obsessions with body image, bodyweight and food. The psychological aspects of treatment can be divided into three levels. interrupting pathological food-related behaviors. treating pathological coping and precipitating factors.",195,47,0.24102564102564103
9781908541086,ch_7,The ultimate goal of treatment is both psychological and physical health.,"The ultimate goal of treatment is both psychological and physical health. It is important to emphasize these definitions of recovery as opposed to defining recovery simply as weight gain or a temporary change in behavior. Psychological health involves the development of normal eating behaviors, without restricting or purging, and the elimination of obsessions with body image, bodyweight and food. The psychological aspects of treatment can be divided into three levels.",81,12,0.14814814814814814
9781908541086,ch_7,"There are many complications, acute and chronic, associated with eating disorders that require ongoing management.","chronic renal tubular disease. There are also potentially irreversible problems associated with chronic eating disorders (Table 5.1). Sudden death is also possible. Management of complications. Amenorrhea is a key feature of anorexia in particular. It is a consequence of a disturbance in the regulation of hypothalamic secretion of gonadotrophin-releasing hormone. This results in low levels of luteinizing hormone (LH), follicle-stimulating hormone and estradiol, a prepubertal pattern of LH pulsatile secretion, and a regression of uterus and ovary size. Prolonged amenorrhea can lead to osteopenia, which is a precursor to osteoporosis (see below).",149,18,0.12080536912751678
9781908541086,ch_7,Physical health is measured by the restoration of ideal bodyweight and return of menses.,"Amenorrhea is a key feature of anorexia in particular. It is a consequence of a disturbance in the regulation of hypothalamic secretion of gonadotrophin-releasing hormone. This results in low levels of luteinizing hormone (LH), follicle-stimulating hormone and estradiol, a prepubertal pattern of LH pulsatile secretion, and a regression of uterus and ovary size. Prolonged amenorrhea can lead to osteopenia, which is a precursor to osteoporosis (see below). Weight gain is important for the restoration of menses; 86% of patients who achieve 90% of their ideal bodyweight resume menses within 6 months.",145,17,0.11724137931034483
9781908541086,ch_7,Weight gain is crucial in order to restore menses and increase bone density.,"Osteopenia is the most serious, potentially irreversible complication of the low estrogen levels caused by prolonged amenorrhea. Nutritional factors also play an important role, as indicated by the more serious cases of osteopenia in anorexia compared with hypothalamic amenorrhea. In osteopenia, the level of markers of bone formation decrease and those of bone resorption increase. Osteopenia is defined by a bone mineral density (BMD) of 1.0-2.5 standard deviations (SDs) below the young adult reference mean. BMD is most commonly measured by means of dual-energy X-ray absorptiometry (DEXA). For children and adolescents, readings should be compared with the reference ranges for healthy young adults (T-scores) and age-matched children and adolescents (Z-scores) (Figure 5.1).",180,15,0.08333333333333333
9781908541086,ch_8,Up to 40% of patients with anorexia are readmitted to the hospital at least once for weight restoration and nutritional rehabilitation; the length of stay becomes longer with each successive hospitalization.,"Table 6.1 shows the indications for hospitalization of adolescents with anorexia. In the USA, under the influence of managed care and in the absence of a national health plan, the role of hospitalization for anorexia has changed dramatically over the past 10 years. In some EU countries and Australia, where national health plans are in operation, hospitalization has remained a major tool for weight rehabilitation and initial treatment. The average length of hospital stay in the USA is about 1-2 weeks, with inpatient treatment limited to brief acute weight restoration and nutritional rehabilitation (Table 6.2). Conversely, in other industrialized nations, it is not uncommon for patients to spend several weeks or even months in hospital in the initial treatment phase. Unfortunately, a low discharge weight may create an unnecessary risk for relapse and poor prognosis. Studies report that up to 40% of hospitalized patients with anorexia are readmitted at least once. The length of stay becomes longer with each successive hospitalization. Inpatient treatment studies of young adults suggest a continued role for hospitalization for severe cases. The Society of Adolescent Medicine's publication of medical treatment guidelines suggests a consistent pattern of acute hospitalization for patients with anorexia (see Table 6.1).",249,38,0.15261044176706828
9781908541086,ch_8,"Cognitive-behavior therapy and other psychotherapeutic techniques are an integral part of most multimodal treatment programs for anorexia, for both outpatients and inpatients.","Most clinicians base their interventions for adolescent patients on one of three models: individual psychodynamic therapy, family therapy and family-based treatment. The use of cognitive behavioral techniques is an integral part of most multimodal treatment programs for anorexia, whether on an outpatient or inpatient basis. However, rigorous efficacy treatment studies of intensive full-time or day treatment programs are few, especially in adolescents. Psychotherapy has been shown to be ineffective during the acute re-feeding stage of treatment, although a therapeutic alliance is helpful in increasing patient motivation. The therapeutic alliance has been broadly defined as the affective and collaborative bond between patient and therapist in which the patient feels positive about the therapist, perceives there to be a shared valuation of treatment tasks, and considers the intervention activities to be helpful. Psychotherapy is believed to be more helpful after weight restoration, although further formal study is needed.",177,38,0.21468926553672316
9781908541086,ch_8,"Patients with anorexia can be treated with antipsychotic medication in dire situations and in crises, as these medications become effective relatively quickly. Appropriate targets are the patient's obsession regarding weight and body shape (which often resemble a delusion), extreme anxiety regarding re-feeding, and psychotic states.","Antipsychotics. Patients with anorexia have long been treated with traditional antipsychotic medication because their obsession regarding weight and body shape seemed to resemble delusions. More recently, the atypical antipsychotics have been used for their anti-anxiety effect, as well as their higher ratio of serotonin-to-dopamine blockade, associated with a much more favorable side-effect profile, which often includes impressive weight gain. As yet, however, there have been only three small controlled studies supporting the efficacy of an atypical antipsychotic (olanzapine) in adults with anorexia, and only case reports and small series for adolescents with the disorder. It is best to consider the second-generation antipsychotics as treatments of last resort for extremely malnourished, severely ill patients with severe resistance to weight gain and severe obsessional thinking, often bordering on psychotic delusions and anxieties. The main problem is that the dopaminergic blockade produced by these medications often induces hyperphagia, leading to bulimic episodes that terrify the patient. In addition, the risk of cardiac complications such as QTc prolongation, tardive dyskinesia and other movement disorders, neuroleptic malignant syndrome and hyperprolactinemia may make the safe use of drugs difficult in this population. Treatment should be started under extremely close supervision, ideally in a hospital setting, and discontinued once weight rehabilitation has achieved some sustained momentum.",298,60,0.20134228187919462
9781908541086,ch_8,"Some second-generation atypical antipsychotics such as olanzapine, risperidone, quetiapine and aripiprazole have a more favorable side-effect profile than the traditional antipsychotics, including a higher ratio of serotonin-to-dopamine blockade and weight gain.","Antipsychotics. Patients with anorexia have long been treated with traditional antipsychotic medication because their obsession regarding weight and body shape seemed to resemble delusions. More recently, the atypical antipsychotics have been used for their anti-anxiety effect, as well as their higher ratio of serotonin-to-dopamine blockade, associated with a much more favorable side-effect profile, which often includes impressive weight gain. As yet, however, there have been only three small controlled studies supporting the efficacy of an atypical antipsychotic (olanzapine) in adults with anorexia, and only case reports and small series for adolescents with the disorder. It is best to consider the second-generation antipsychotics as treatments of last resort for extremely malnourished, severely ill patients with severe resistance to weight gain and severe obsessional thinking, often bordering on psychotic delusions and anxieties. The main problem is that the dopaminergic blockade produced by these medications often induces hyperphagia, leading to bulimic episodes that terrify the patient. In addition, the risk of cardiac complications such as QTc prolongation, tardive dyskinesia and other movement disorders, neuroleptic malignant syndrome and hyperprolactinemia may make the safe use of drugs difficult in this population. Treatment should be started under extremely close supervision, ideally in a hospital setting, and discontinued once weight rehabilitation has achieved some sustained momentum.",298,66,0.2214765100671141
9781908541086,ch_8,"Selective serotonin-reuptake inhibitors (SSRIs) can target anxiety and depression if efficacy is not of immediate concern. They have a more manageable side-effect profile than the atypical antipsychotics, but treatment should be monitored carefully for suicidality, weight gain or loss, emotional activation and agitation.","Antipsychotics. Patients with anorexia have long been treated with traditional antipsychotic medication because their obsession regarding weight and body shape seemed to resemble delusions. More recently, the atypical antipsychotics have been used for their anti-anxiety effect, as well as their higher ratio of serotonin-to-dopamine blockade, associated with a much more favorable side-effect profile, which often includes impressive weight gain. As yet, however, there have been only three small controlled studies supporting the efficacy of an atypical antipsychotic (olanzapine) in adults with anorexia, and only case reports and small series for adolescents with the disorder. It is best to consider the second-generation antipsychotics as treatments of last resort for extremely malnourished, severely ill patients with severe resistance to weight gain and severe obsessional thinking, often bordering on psychotic delusions and anxieties. The main problem is that the dopaminergic blockade produced by these medications often induces hyperphagia, leading to bulimic episodes that terrify the patient. In addition, the risk of cardiac complications such as QTc prolongation, tardive dyskinesia and other movement disorders, neuroleptic malignant syndrome and hyperprolactinemia may make the safe use of drugs difficult in this population. Treatment should be started under extremely close supervision, ideally in a hospital setting, and discontinued once weight rehabilitation has achieved some sustained momentum.",298,66,0.2214765100671141
9781908541086,ch_8,Further research is needed to establish the efficacy of SSRIs in preventing relapse in weight-restored individuals.,"Clinicians have increasingly turned to SSRIs over the past two decades. However, the research on treatment of anorexia with SSRIs has not been particularly promising. Additional research is needed to establish the possible efficacy of SSRIs in preventing relapse in weight-restored individuals with anorexia. Two compounds have been studied, fluoxetine and citalopram, with very mixed results. Fluoxetine. There is still no agreement regarding the efficacy of fluoxetine in anorexic patients. Studies have shown no significant benefits when prescribed during the weight restoration phase, but a study during the first year of weight maintenance after successful inpatient treatment demonstrated that fluoxetine, up to 60 mg/day, prevented relapse in women with anorexia. Another study showed no benefit following weight restoration, and fluoxetine was not found to be superior to placebo for inpatients with anorexia who were also receiving behavioral therapy.",199,22,0.11055276381909548
9781908541086,ch_8,"Tricyclic antidepressants are not recommended for the treatment of patients with anorexia because of the potential for arrhythmia at low bodyweight, a risk of lethal overdose and concern surrounding sudden death in young people.","Fluoxetine. There is still no agreement regarding the efficacy of fluoxetine in anorexic patients. Studies have shown no significant benefits when prescribed during the weight restoration phase, but a study during the first year of weight maintenance after successful inpatient treatment demonstrated that fluoxetine, up to 60 mg/day, prevented relapse in women with anorexia. Another study showed no benefit following weight restoration, and fluoxetine was not found to be superior to placebo for inpatients with anorexia who were also receiving behavioral therapy. Citalopram. During the weight restoration phase this SSRI may decrease the associated symptoms of depression and anxiety but it has not been shown to increase the rate of weight gain. One study demonstrated an alarming drop in bodyweight (mean 5.4 kg) and an overall response worse than placebo. If using this agent, clinicians should monitor the patient's weight closely. Tricyclic antidepressants such as amitriptyline and clomipramine should not be used in patients with anorexia. Randomized controlled trials have produced negative results. Underweight patients are particularly prone to the side effects of tricyclic antidepressants. There is a potential for arrhythmia at low bodyweight, plus a risk of lethal overdose and concern surrounding sudden death in young people. Additionally, prescription of tricyclic antidepressants should be avoided for suicidal patients and patients with cardiovascular concerns.",295,46,0.15593220338983052
9781908541086,ch_9,"The main goals of treatment for bulimia are abstinence from bingeing and purging, learning and maintaining healthy eating behaviors, and addressing any other psychological issues related to the condition.","Cognitive-behavior therapy comprises four distinct phases for patients with bulimia. Initially, a clinician makes an assessment of the patient's psychological, emotional and behavioral functioning by means of a clinical interview. The patient is also asked to self-monitor nutritional intake, and bingeing and purging behaviors. The patient is then educated about healthy regular eating patterns and is encouraged to resume or engage in nutritious eating. This is an attempt to normalize the sporadic and out-of-control dietary intake. CBT also seeks to restructure the patient's cognitive distortions about food, thinness, achievement and assertiveness. Finally, by continually discussing signs of relapse and focusing on preventative strategies, an emphasis is placed on the prevention of relapse. Therapy is slowly tapered when the patient shows consolidated signs of progress.",162,36,0.2222222222222222
9781908541086,ch_9,"Higher doses of selective serotonin-reuptake inhibitors are used for the treatment of bulimia than for depression, with careful monitoring of side effects.","Fluoxetine is commonly used for the treatment of bulimia; it is approved for use in bulimic patients in the UK and it is the only medication approved by the US Food and Drug Administration (FDA) for this eating disorder. Fluoxetine has been found to be a useful intervention for individuals with bulimia who had not responded to psychotherapy or who had relapsed after psychotherapy, producing short-term reductions in bulimic behaviors. However, more research is needed to determine the long-term effects of this drug and other antidepressants. In general, higher doses of SSRIs are used for the treatment of bulimia than for depression, with careful monitoring of side effects. A maximum daily dosage of 60 mg can be given. Lower doses are needed in adolescents. In those, the increased risk for psychomotor activation and suicidal events potentially associated with the use of SSRIs needs to be taken into account when deciding to start or increase medication, and close monitoring is warranted throughout treatment.",209,30,0.14354066985645933
9781908541086,ch_9,Fluoxetine is the only medication approved by the US Food and Drug Administration for the treatment of bulimia; it is also licensed for this use in the UK.,"Fluoxetine is commonly used for the treatment of bulimia; it is approved for use in bulimic patients in the UK and it is the only medication approved by the US Food and Drug Administration (FDA) for this eating disorder. Fluoxetine has been found to be a useful intervention for individuals with bulimia who had not responded to psychotherapy or who had relapsed after psychotherapy, producing short-term reductions in bulimic behaviors. However, more research is needed to determine the long-term effects of this drug and other antidepressants. In general, higher doses of SSRIs are used for the treatment of bulimia than for depression, with careful monitoring of side effects. A maximum daily dosage of 60 mg can be given. Lower doses are needed in adolescents. In those, the increased risk for psychomotor activation and suicidal events potentially associated with the use of SSRIs needs to be taken into account when deciding to start or increase medication, and close monitoring is warranted throughout treatment.",209,36,0.1722488038277512
9781908541086,ch_9,Psychological interventions are the mainstay of treatment; symptoms of bingeing and purging and other aspects of eating disorders respond better to psychotherapy than to medication alone.,"Up to 70% of patients with bulimia benefit from a combination of medication and cognitive-behavior interventions. Studies have demonstrated that the symptoms of bingeing, purging and other attitudes related to eating disorders respond better to psychotherapy than to medication alone. A combination of the two modalities has been shown to be more effective for some outcomes than either by itself. In one study, CBT produced better results than treatment with fluoxetine, and although a combination intervention showed some benefit, there was a high rate of attrition. In another study, intensive group cognitive psychotherapy demonstrated greater efficacy than imipramine for the treatment of bingeing, purging and the symptoms of depression. Although the combination of the treatments did not incrementally improve 'eating variables' such as fear of gaining weight, body-image distortion, bingeing and purging, it did reduce depression and anxiety.",179,33,0.18435754189944134
9781908541086,ch_9,Up to 70% of patients benefit from a combination of cognitive-behavior techniques and pharmacotherapy.,"Up to 70% of patients with bulimia benefit from a combination of medication and cognitive-behavior interventions. Studies have demonstrated that the symptoms of bingeing, purging and other attitudes related to eating disorders respond better to psychotherapy than to medication alone. A combination of the two modalities has been shown to be more effective for some outcomes than either by itself. In one study, CBT produced better results than treatment with fluoxetine, and although a combination intervention showed some benefit, there was a high rate of attrition. In another study, intensive group cognitive psychotherapy demonstrated greater efficacy than imipramine for the treatment of bingeing, purging and the symptoms of depression. Although the combination of the treatments did not incrementally improve 'eating variables' such as fear of gaining weight, body-image distortion, bingeing and purging, it did reduce depression and anxiety.",179,19,0.10614525139664804
9781908541086,ch_9,Regular moderate exercise may help patients to deal with the weight fluctuations that can be expected while their bodies adjust to new healthy eating patterns.,"Follow-up. Regular follow-up assessments may be beneficial to ensure that healthy eating patterns are being maintained and to assess the patient's long-term coping skills. Some patients find support groups helpful. Regular moderate exercise may help patients to deal with the weight fluctuations that can be expected while their bodies adjust to the new healthy eating patterns. Researchers in the UK suggest that, overall, readiness to change and the development of the therapeutic alliance are more strongly related to improvement than the specific type of treatment offered to patients with bulimia.",106,26,0.24528301886792453
9781908541086,ch_10,"Despite increasing research on short- and long-term outcomes of anorexia, the disease still has a relatively poor prognosis; the mortality rate is the highest of all psychiatric disorders, although it has decreased in recent years.","The course of anorexia is variable, with remission rates differing considerably across long-term outcome studies with follow-up periods of 1-30 years. In over 100 studies published in the second half of the 20th century, fewer than one half of anorexic patients recovered on average, whereas one-third improved, and 20% remained chronically ill. In seven studies published since 2004, most patients with anorexia ascertained through outpatient settings had achieved remission by 5-year follow-up, but inpatient samples had lower remission rates. In these most recent studies, rates of continued anorexia at follow-up ranged from 2% in a 9-year follow-up of patients at a community clinic, to 18% at 12 years for individuals from an inpatient center; other participants who did not achieve remission over the course of follow-up had moved to a diagnosis of either bulimia or eating disorder not otherwise specified (EDNOS). One consistent finding across long-term studies has been that a large proportion of anorexic patients followed over time suffered from additional psychiatric disorders, including anxiety disorders, affective disorders, substance-use disorders, obsessive-compulsive disorder and borderline or histrionic personality disorders; schizophrenia is only rarely observed at follow-up. There seems to be a critical threshold of duration of illness (of about 12 years) after which it is increasingly unlikely that patients will recover, regardless of the interventions used. As anorexia usually begins in mid-adolescence, this puts the critical age at about 30 years.",318,45,0.14150943396226415
9781908541086,ch_10,"Although results from long-term studies support optimism for most patients with eating disorders, approximately 30% of patients with bulimia and atypical eating disorders remain ill at 10-20 years following presentation.","The course of anorexia is variable, with remission rates differing considerably across long-term outcome studies with follow-up periods of 1-30 years. In over 100 studies published in the second half of the 20th century, fewer than one half of anorexic patients recovered on average, whereas one-third improved, and 20% remained chronically ill. In seven studies published since 2004, most patients with anorexia ascertained through outpatient settings had achieved remission by 5-year follow-up, but inpatient samples had lower remission rates. In these most recent studies, rates of continued anorexia at follow-up ranged from 2% in a 9-year follow-up of patients at a community clinic, to 18% at 12 years for individuals from an inpatient center; other participants who did not achieve remission over the course of follow-up had moved to a diagnosis of either bulimia or eating disorder not otherwise specified (EDNOS).",195,41,0.21025641025641026
9781908541086,ch_10,Anorexia can have serious effects on reproductive functioning and the health of neonates.,"Variables affecting outcome. In long-term outcome studies of anorexia nervosa, the findings regarding prognostic factors have also been very heterogeneous. Most studies indicated that a short duration of symptoms before treatment resulted in a favorable outcome, but findings are ambiguous regarding age at onset of illness. No definite conclusions could be drawn as to whether greater weight loss at presentation had long-term effects on outcome, but it is clear that vomiting, bulimia and purgative abuse imply an unfavorable prognosis. A few studies have also shown that premorbid development and clinical abnormalities, including eating disorders during childhood, have a negative prognostic significance. In contrast, a good parent-child relationship may protect the patient from a poor outcome. In addition, the data clearly show that chronicity leads to negative outcome, a finding that implies that there are cases of anorexia refractory to treatment. The features of coexisting obsessive-compulsive personality seem to add to chronicity.",198,17,0.08585858585858586
9781908541086,ch_10,"Bulimia usually persists for several years, and associated medical complications can result in intermittent hospitalization.","Medical complications that affect adolescents rather than adults are the potential for significant growth retardation, pubertal delay or interruption, and reduction in peak bone mass. Effects on reproductive functioning are shown in Table 8.1. Women who become pregnant should be considered to be at high risk of complications (Table 8.2) and monitored through pregnancy and postpartum. Compared with non-anorexic controls, women with anorexia are more likely to have postpartum depression, and low birth weight and feeding problems in their babies.",108,20,0.18518518518518517
9781908541086,ch_11,Eating disorders not otherwise specified is the category of diagnosis given to cases that do not fulfill all DSM-IV criteria for anorexia or bulimia; subtypes of this category include binge-eating disorder (BED) and night-eating syndrome (NES).,"Eating disorders not otherwise specified. As mentioned in Chapter 1, the classification of 'eating disorders not otherwise specified' (EDNOS), the third diagnostic category of eating disorders in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), is given to cases that do not fulfill the full criteria for anorexia or bulimia, and is the most frequently given diagnosis for eating disorders. Examples of EDNOS diagnoses are. female patients who meet all the criteria for anorexia yet menstruate regularly. individuals who meet all the criteria for anorexia but despite significant weight loss maintain weight in the normal range. individuals who display combinations of binge eating and inappropriate compensatory behaviors but at lower frequencies than those stipulated in the criteria. EDNOS also includes two subsets of disorders that have been defined by specific diagnostic criteria and have received increasing research interest: binge-eating disorder (BED) and night-eating syndrome (NES). Binge-eating disorder, or non-purging bulimia, is characterized as recurrent episodes of binge eating, accompanied by a sense of distress, and feelings of disgust, depression or guilt, without the subsequent inappropriate compensatory behaviors (purging or non-purging) associated with bulimia. Hence, BED is often associated with overweight or obesity. There is increasing consent in the literature to consider BED as its own diagnostic category because of its distinct features, treatment and prognosis compared with bulimia. The overall prevalence of BED has been estimated as 3.5% in women and 2.0% in men. Compared with anorexia and bulimia, the sex ratio is less uneven, with males making up about 40-50% of EDNOS diagnoses with a BED subcategory. Age of onset for BED is slightly higher than for bulimia, ranging from 17 to 32 years, with a mean of 25 years. BED has an overall better prognosis than bulimia, however, as it responds to a wider range of treatments that target both binge eating and weight reduction. Although the types of treatment are the same as those used for patients with bulimia, BED is more responsive to various subtypes of treatment such as medication and CBT.",467,54,0.11563169164882227
9781908541086,ch_11,There is a higher prevalence of BED than anorexia or bulimia in men.,"Binge-eating disorder, or non-purging bulimia, is characterized as recurrent episodes of binge eating, accompanied by a sense of distress, and feelings of disgust, depression or guilt, without the subsequent inappropriate compensatory behaviors (purging or non-purging) associated with bulimia. Hence, BED is often associated with overweight or obesity. There is increasing consent in the literature to consider BED as its own diagnostic category because of its distinct features, treatment and prognosis compared with bulimia. The overall prevalence of BED has been estimated as 3.5% in women and 2.0% in men. Compared with anorexia and bulimia, the sex ratio is less uneven, with males making up about 40-50% of EDNOS diagnoses with a BED subcategory. Age of onset for BED is slightly higher than for bulimia, ranging from 17 to 32 years, with a mean of 25 years. BED has an overall better prognosis than bulimia, however, as it responds to a wider range of treatments that target both binge eating and weight reduction. Although the types of treatment are the same as those used for patients with bulimia, BED is more responsive to various subtypes of treatment such as medication and CBT.",266,19,0.07142857142857142
9781908541086,ch_11,"The peak age of onset for BED is somewhat later than that for bulimia, and BED has an overall better prognosis.","Binge-eating disorder, or non-purging bulimia, is characterized as recurrent episodes of binge eating, accompanied by a sense of distress, and feelings of disgust, depression or guilt, without the subsequent inappropriate compensatory behaviors (purging or non-purging) associated with bulimia. Hence, BED is often associated with overweight or obesity. There is increasing consent in the literature to consider BED as its own diagnostic category because of its distinct features, treatment and prognosis compared with bulimia. The overall prevalence of BED has been estimated as 3.5% in women and 2.0% in men. Compared with anorexia and bulimia, the sex ratio is less uneven, with males making up about 40-50% of EDNOS diagnoses with a BED subcategory. Age of onset for BED is slightly higher than for bulimia, ranging from 17 to 32 years, with a mean of 25 years. BED has an overall better prognosis than bulimia, however, as it responds to a wider range of treatments that target both binge eating and weight reduction. Although the types of treatment are the same as those used for patients with bulimia, BED is more responsive to various subtypes of treatment such as medication and CBT.",266,28,0.10526315789473684
9781908541086,ch_11,"Individuals with NES wake several times throughout the night to eat, consuming over one-third of their total energy intake after their evening meal.","Night-eating syndrome is characterized by insomnia, excessive appetite (hyperphagia) in the evening and a lack of appetite in the morning. Individuals with NES wake several times throughout the night to eat, consuming over a third of their total energy intake after their evening meal. Binge eating or purging behaviors are generally not associated with this disorder, and these individuals can usually recall what they ate. In contrast, nocturnal eating/drinking syndrome is characterized by recurrent episodes of binge eating throughout the night with no, or partial, recollection of what was eaten. This syndrome is a combination of an eating, sleep and mood disorder. Limited research has been conducted on effective treatments for NES, but the SSRI sertraline has shown some benefit.",152,28,0.18421052631578946
9781908541086,ch_11,"Feeding disorders in young children are categorized as feeding disorder of infancy and childhood, rumination disorder or pica.","In young children, problems with eating are called feeding disorders. These disorders are believed to reflect the relationship between parent and child, as opposed to just the child or the adolescent as is the case with eating disorders. There is no extensive literature on this subject, but the typical dyad seems to be a single, young, socially isolated, anxious mother with a difficult infant. There are three DSM-IV categories of feeding disorders: feeding disorder of infancy and early childhood; rumination disorder; and pica.",101,23,0.22772277227722773
9781908541178,ch_4,"Palpation of key painful areas of the spine, facet joint areas, iliac crests, buttocks (sciatic outlet - piriformis region) and trochanteric bursae will often indicate the nature of the pain and/or significant areas of referred pain that may respond to different forms of therapy.","With over 60 different causes of low back pain, the differential diagnosis of this symptom spans the gamut from systemic inflammatory diseases like ankylosing spondylitis to localized disorders such as facet joint arthritis. The history you obtain from the patient and the observations from a physical examination are therefore essential in order to sift through the numerous possibilities and find the category of disorder that has the greatest likelihood of being the source of the patient's discomfort. The history should aim to elucidate the chronological development of the current episode of low back pain, its character and its response to treatment. Information about the quality of pain, id est localized (muscles) versus radicular (spinal nerve) pain, will help to specify potential sources. Determining alleviating (standing) and aggravating (sitting) positions can help to point investigation in the direction of mechanical disorders, such as a herniated disc with associated radiculopathy. Also, early in the history, assessment of the presence of 'red flags' (see below) can help to organize the speed and character of the low back pain evaluation. The extent of the inquiry should be appropriate to the severity and chronicity of the back pain problem, and should aim to identify relevant confounding factors, including systemic diseases, activities of daily living, work environment, recreation as well as psychological and litigation issues, smoking, and alcohol and analgesic abuse.",283,65,0.22968197879858657
9781908541178,ch_4,The pain drawing provides a simple way for the patient to indicate the region of the pain and often suggest etiology. A classic example involves groin tenderness as a marker of probable hip joint disease rather than a back-referred disorder.,"Two disorders that require emergency evaluation and possible surgical intervention include cauda equina compression syndrome and an expanding aortic aneurysm. In addition, rare disorders such as acromegaly or ochronosis, or rare manifestations of relatively common diseases such as gout, can occasionally affect the spinal structures. Pain intensity. It is usually very helpful to have the patient fill out a brief history and system-review questionnaire, and complete a pain drawing. A simple measure of pain intensity can be obtained using the visual analog scale (VAS). The VAS measures pain on a horizontal 10-cm line, where 0 is no pain and 10 cm is the greatest pain ever (Figure 1.1). The VAS can be repeated at subsequent visits to monitor progress. A pain drawing is also useful in determining the pattern of the pain and possibly its etiology (Figure 1.2). These two assessments are the simplest, least time-dependent and least threatening of the tests available. More detailed assessments of functional ability and of the patient's perception of the pain and its impact on his/her physical, psychological and socioeconomic functioning can be obtained using any of a large number of questionnaires of varying complexity, including.",244,47,0.19262295081967212
9781908541178,ch_4,The visual analog scale (VAS) is a simple linear scale to measure pain intensity and response to therapy.,"Pain intensity. It is usually very helpful to have the patient fill out a brief history and system-review questionnaire, and complete a pain drawing. A simple measure of pain intensity can be obtained using the visual analog scale (VAS). The VAS measures pain on a horizontal 10-cm line, where 0 is no pain and 10 cm is the greatest pain ever (Figure 1.1). The VAS can be repeated at subsequent visits to monitor progress. A pain drawing is also useful in determining the pattern of the pain and possibly its etiology (Figure 1.2). These two assessments are the simplest, least time-dependent and least threatening of the tests available.",135,22,0.16296296296296298
9781908541178,ch_4,"Ergonomic factors should be assessed, and this can often be readily done by observing the patient's movement in the clinic and during examination.","Psychological factors can be of no consequence or can play a major role in determining the patient's outcome and return to functional activity. The more chronic the low back pain disorder, the greater the impact of psychological factors is likely to be. A variety of tests can be used to categorize and document personality and cognitive behavioral functioning, exempli gratia whether the patient manifests inappropriate symptom amplification or other psychological disorders. One of the most widely used instruments for this purpose is the Minnesota Multiphasic Personality Inventory (MMPI). This is a comprehensive psychological test that characterizes hypochondriasis, depression and hysteria. The MMPI is useful in identifying psychological disorders that may accompany and complicate back pain and other organic diseases.",145,28,0.19310344827586207
9781908541178,ch_4,"The patient's gait and body motion can be observed in the clinic to detect sciatic scoliosis; short leg; hip, knee or foot arthritis or weakness; and/or foot drop as markers of relevant pathology.","Psychological factors can be of no consequence or can play a major role in determining the patient's outcome and return to functional activity. The more chronic the low back pain disorder, the greater the impact of psychological factors is likely to be. A variety of tests can be used to categorize and document personality and cognitive behavioral functioning, exempli gratia whether the patient manifests inappropriate symptom amplification or other psychological disorders. One of the most widely used instruments for this purpose is the Minnesota Multiphasic Personality Inventory (MMPI). This is a comprehensive psychological test that characterizes hypochondriasis, depression and hysteria. The MMPI is useful in identifying psychological disorders that may accompany and complicate back pain and other organic diseases. Although psychological assessment is carried out as an integral part of the clinical evaluation of patients with chronic low back pain, more detailed assessment may be indicated if an individual is resistant to improvement.",181,45,0.24861878453038674
9781908541178,ch_4,"'Red flags' are a set of findings that suggest that back pain is non-mechanical and may be due to fracture, malignancy, infection or systemic inflammatory disease","Gait can be assessed more fully, and with the patient feeling less self-conscious, during movement from one room to another; however, when patients are fully dressed some important observations may be obscured. Most obvious is a pain avoidance stride, permitting only brief weight-bearing on the affected side. A gait alteration due to a short leg, or a pronated foot, may also be less evident when the patient is clothed. Shuffling may be due to back pain avoidance; hip, knee or foot arthritis; peripheral neuropathy; Parkinson's disease; cardiac, cerebral or peripheral arteriosclerosis; spinal stenosis; visual impairment; or generalized debility and non-specific pain avoidance with depression and exhaustion. Limping. A limp favoring only one leg is a common consequence of low back pain, particularly when it is associated with neural impairment and lower extremity weakness. However, a unilateral limp can also be due to a number of other conditions, including arthritis of the foot, ankle, knee or hip; pes planus (flat foot); Morton's neuralgia; or hemiparesis.",223,36,0.16143497757847533
9781908541178,ch_5,"Identifiable radiographic abnormalities such as disc degeneration, disc protrusions and osteophytes are common in individuals over 40 years of age and almost universal in those over 50, but without corresponding clinical findings.","A significant proportion of individuals over 40 years of age show some disc space narrowing, osteophytic spurs or age-related spondylolisthesis on radiographs without corresponding clinical symptoms. Identifiable radiographic abnormalities are found in almost all individuals over 50 years old. In addition, disc bulges, protrusions or extrusions at one or more vertebral levels have been identified by magnetic resonance imaging (MRI) in over 50% of asymptomatic subjects. In geriatric patients, there are often many more abnormalities than necessary to explain the acute, subacute or chronic painful disorder. Further, when remission of symptoms occurs, in all likelihood the osseous abnormalities will remain unchanged, and even the soft-tissue disc-related lesions will still be present or little changed. This has been confirmed in several studies comparing a baseline MRI taken for a symptomatic disc derangement with a follow-up MRI.",189,42,0.2222222222222222
9781908541178,ch_5,"In geriatric patients, radiographic evidence of spinal degeneration is commonplace but may not be a source of back pain. In addition, geriatric radiographic abnormalities tend to persist after a patient goes into remission.","In contrast, significant radiographic findings are highly likely in a patient with low back pain and/or sciatica and evidence of any 'red flags' (see Table 1.1), or in a patient who has suffered a severe trauma capable of causing a fracture. Osteoporotic fractures can potentially occur in any part of the spine, though they are typically found in the thoracic and upper lumbar spine. They are less common in the lower lumbar vertebrae and rare in the cervical spine. A concern for low back pain associated with osteoporotic-associated lower lumbar fracture (L3-L5) is a possible neoplasm, either benign or malignant. Tumors may occur anywhere in the spine. Benign growths tend to affect the posterior vertebral elements, while malignant tumors preferentially involve the vertebral bodies. Vertebral tumors can be confused with atraumatic or traumatic osteoporotic fractures (Figure 2.1), but are most likely in patients with night pain or in those whose pain is not relieved by rest. Bony lesions in these patients may be better characterized by a computed tomography (CT) scan.",246,42,0.17073170731707318
9781908541178,ch_5,"In individuals over the age of 50, radiographic evaluation has a greater likelihood of identifying a tumor, osteoporotic fracture, infection or severe spinal stenosis.","In contrast, significant radiographic findings are highly likely in a patient with low back pain and/or sciatica and evidence of any 'red flags' (see Table 1.1), or in a patient who has suffered a severe trauma capable of causing a fracture. Osteoporotic fractures can potentially occur in any part of the spine, though they are typically found in the thoracic and upper lumbar spine. They are less common in the lower lumbar vertebrae and rare in the cervical spine. A concern for low back pain associated with osteoporotic-associated lower lumbar fracture (L3-L5) is a possible neoplasm, either benign or malignant. Tumors may occur anywhere in the spine. Benign growths tend to affect the posterior vertebral elements, while malignant tumors preferentially involve the vertebral bodies. Vertebral tumors can be confused with atraumatic or traumatic osteoporotic fractures (Figure 2.1), but are most likely in patients with night pain or in those whose pain is not relieved by rest. Bony lesions in these patients may be better characterized by a computed tomography (CT) scan.",246,33,0.13414634146341464
9781908541178,ch_5,"Discography is a relatively unreliable method of determining the locus of disc symptomatology, with numerous false positives.","Discography is the injection of a radiopaque substance under fluoroscopic guidance into the intradiscal space. Intradiscal contrast injections have been used as a diagnostic tool for disc-related pathologies for over 35 years, but the technique is associated with a high rate of both false-positive and false-negative findings. In a geriatric population and for patients with chronic pain, the specificity is only about 20%. The ability of patients to localize a specific disc derangement by pain-provoking stimulations during discography, and to relate the provoked pain to their symptoms, is also unreliable. The lack of correlation between this provocative test and clinical findings, and the potential for disc damage resulting in rapidly progressive disc degeneration, means that discography is rarely performed.",156,23,0.14743589743589744
9781908541178,ch_5,"When CT/MRI and the examination do not define the pathology, electromyography (EMG) may be helpful, but at best this has less than 80% accuracy in detecting a nerve root lesion.","When clinical testing for neurological defects is normal or equivocal, or when the radiological findings present too few or too many abnormalities to identify specifically the source of the neural abnormality, electrodiagnostic testing may add greater specificity. It can be particularly useful for distinguishing a unilateral distal peripheral neuropathy or entrapment from a disc-related nerve root impingement, or polyneuropathy from spinal stenosis. Although electrodiagnostic testing can confirm the presence of a nerve root lesion, it cannot indicate the precise level of the nerve root compression. Electrodiagnostic testing consists of sensory nerve conduction studies - sensory evoked potentials (SEPs) and sensory F-wave latencies - and electromyography (EMG), which may be used singly or in combination. Sensory evoked potentials measure sensory nerve conduction, which is most commonly affected by compression of nerve roots.",185,42,0.22702702702702704
9781908541178,ch_5,MRI is the most sensitive radiographic technique to identify anatomic alterations of the spinal elements.,"Electromyography is the most sensitive electrodiagnostic method for detecting nerve root lesions, with precision reported as high as 78%. Nonetheless, the precision of EMG in one study of patients with clinical and radiographic (CT) findings of nerve root compression was as low as 20% when the EMG was correlated with surgical findings. It is also important to note that 'benign' fibrillations (the EMG marker for denervation) can be seen in normal subjects. Thus, the interpretation of EMG abnormality is examiner dependent, and the skill of the electrodiagnostician can be the crucial variable in interpretation of the test findings.",131,18,0.13740458015267176
9781908541178,ch_5,"Laboratory tests usually are not needed for acute low back pain unless 'red flags' are present, or for patient monitoring to avoid potential hematologic, hepatic or renal drug-related complications.","For the most part, with the exception of patients with 'red flags' (see Table 1.1), laboratory testing for patients with low back pain disorders is of little value. Laboratory tests are indicated when a malignancy or infection is suspected. Blood tests are also indicated to identify the potential causes of vertebral osteoporotic fractures. Additionally, an HLA-B27 test and determination of erythrocyte sedimentation rate (ESR) may help to confirm a suspected diagnosis of spondyloarthropathy. Laboratory tests are most useful if medical complications such as renal and hepatic diseases, diabetes or drug sensitivities are suspected or have previously been confirmed. The most common indication for blood and urine laboratory testing is to monitor tolerance of pharmacological therapies and their potential side effects.",162,40,0.24691358024691357
9781908541178,ch_6,Acute pain must be resolved rapidly to prevent the modification of the central nervous system to a chronic pain status.,"Duration of pain is an important characteristic. Acute pain is a warning of acute injury. With acute injury, a specific array of prostaglandins, leukotrienes and other chemoattractants are released to alert the nervous system to damage and to initiate an inflammatory process to heal the traumatized structure. Therapies directed at control of acute pain, such as simple analgesics and NSAIDs, are effective. Importantly, the structure of the central nervous system has not been modified. When the injury has healed, the affected area returns to its usual status.",117,22,0.18803418803418803
9781908541178,ch_6,"All back pain is 'psychosomatic', because any somatic pain that is experienced must be experienced in the central nervous system and then processed by the individual to express its impact.","Any painful stimulus affecting the body is ultimately experienced in the central nervous system. There, it is modulated by genetically determined pain transmission and reception capabilities, familial and social conditioning, and increasingly by medicolegal and work-related socioeconomic factors and the possibility of malingering. All of these factors can be further modified by experiences of previous trauma, surgery and medication, as well as by general and specific health issues. Back pain occurs in an individual with a combination of physical, social and emotional concerns. All of these factors must be considered when evaluating the person who presents with the complaint of low back pain. Back pain is, in the truest sense, psychosomatic. Psychological issues must be addressed concurrently with the anatomic and pathological somatic aspects of low back pain-related disorders. Psychosocial issues must be prioritized, though they can often be readily handled by the patient and the practitioner. If this is not the case, they should be addressed promptly with appropriate psychiatric, psychological and/or social counseling according to need. Issues relating to drug habituation, depression, symptom amplification and chronic pain syndromes must be identified and addressed.",230,36,0.1565217391304348
9781908541178,ch_6,"Mechanical disorders - muscle strain, spondylolisthesis, herniated intervertebral disc, osteoarthritis, spinal stenosis - are the most common causes of low back pain.","Many anatomic factors can play a primary or a secondary role in the development and progression of low back pain syndromes. The most common causes of low back pain are mechanical in origin. Mechanical disorders of the lumbar spine are related to injury, overuse or deformity of a spinal structure. The most important traumatic factors in low back pain relate to soft tissue structures. Precise identification of the injured tissue, and the role of that injury in the consequent pain and dysfunction, can be frustratingly difficult. Problems occur in muscles, intervertebral discs, facet joints, ligaments or spinal nerves. Aging causes modification of these structures over time, and different parts of the spine tend to be at greater risk for change or injury during different decades of life. Early in life, muscle injuries are more frequent, while joint problems occur in the sixth decade of life (Table 3.1).",181,42,0.23204419889502761
9781908541178,ch_6,"Piriformis tenderness is an area of local tenderness deep to the gluteus maximus muscle, and tenderness palpated in that area most often represents a referred trigger point in the gluteus maximus muscle rather than specific piriformis sciatic nerve syndrome involvement.","The gluteal and piriformis muscles are shown in Figure 3.1. The primary functions of the gluteal muscles are to support, stabilize and mobilize the hips and lower extremities in relation to the pelvis and the trunk. Possibly the most common manifestation of lumbar and lumbosacral pain referral is to the mid-portion of the gluteal muscles (buttocks) that overlie the piriformis muscle. This is accompanied by a palpable localized region of deep, tender muscle induration. Because of the thickness of the overlying gluteus maximus muscle, the fibers of which are parallel to (and indistinguishable from) the piriformis muscle fibers, it is not possible to determine by palpation if the piriformis muscle per se is the source of the localized muscle tenderness. A 'piriformis syndrome' is therefore somewhat problematic to identify and must be carefully distinguished from the more common, spinal discogenic basis for sciatic radiculopathy. A piriformis syndrome may result from scarring after a fall on the buttocks or as a consequence of pelvic or hip surgeries. MRI can be used to visualize the tender area in the buttocks and help to identify selective piriformis entrapments of the sciatic nerve.",258,57,0.22093023255813954
9781908541178,ch_6,Facet arthritis and trochanteric bursal irritation both may produce symptomatology that mimics sciatic nerve involvement.,"Facet (zygapophyseal) joints (Figure 3.5) are synovial-lined, cartilage-surfaced diarthrodial joints that are connected by a ligamentous joint capsule. Facet joint malalignments and associated degenerative osteoarthritic changes (Figure 3.6) are commonly noted radiographically with or without, and before and after, any accompanying low back pain disorders. This does not preclude an abnormal facet joint being a causal factor of a low back pain syndrome. This can be confirmed by a selective joint injection of hypertonic saline under fluoroscopic visualization to attempt to reproduce the pain, followed by a local anesthetic injection to provide specific relief of the induced pain. The facet joint pain referral pattern thus elicited may not be limited to the lumbar region, and may radiate into the buttock and/or down the leg, mimicking a sciatic nerve root pain (facet syndrome).",194,26,0.13402061855670103
9781908541178,ch_6,"Radiographic spinal stenosis, facet arthrosis and disc protrusions are very common and correlate poorly with symptoms after age 50.","Although patients with spinal stenosis may complain of back discomfort and/or stiffness or pain with changing position or with activity, these are manifestations of associated lumbar or lumbosacral pathologies including facet arthritis, and are not due to the spinal stenosis per se. Examination of lower extremity pulses, particularly the dorsalis pedis and posterior tibial pulses, can help diagnose vascular claudication, but both spinal stenosis and arteriosclerosis can occur in the same patient. Spinal stenosis is most often a geriatric problem, and it can be symptomatically compounded by or confused with a number of conditions, including.",130,28,0.2153846153846154
9781908541178,ch_7,"Pain management during the acute first 4-week phase of low back pain should consist of RICE (rest, ice, corset/brace, exercise) unless 'red flags' are present. No X-ray or laboratory investigation is indicated unless 'red flags' are present.","In all phases of low back pain management, the patient must be given the responsibility and the tools to self-manage the disorder independently. In many acute lumbar strains nothing more than reassurance, cold compresses and analgesics may be required. In others, self-management requires educational materials and careful instruction to the patient or a family member by the physician or therapist to ensure that all aspects of home treatments can be carried out as prescribed. The specific exercise at each phase of the progression toward normal activity, work and exercise should be monitored to ensure that it is properly performed and well tolerated. An important principle to keep in mind is that the vast majority of individuals with the symptoms of low back pain with or without leg symptoms improve with non-surgical therapy. Only a small minority require surgical intervention to resolve their complaints. Principles of therapy. Therapeutic choices depend on both the chronicity and severity of the pain being treated. Chronicity is a measurable, time-dependent quantity (see Pain intensity, 1.i), whereas severity can be highly subjective from both the patient's and the physician's perspective. A suggested grading system is shown in Table 4.1. Primary care. The first 4 weeks of acute low back pain are generally managed by the primary care physician. For patients with acute, severe low back pain or an exacerbation of subacute or chronic pain and no 'red flags' (see Table 1.1), the first priority is pain control, which may be necessary even before more definitive diagnostic procedures are undertaken. In addition to analgesic medication, RICE treatment is initiated, which consists of. Rest, ranging from limited activities to 1-2 days of bed rest, but with the patient encouraged to be ambulatory as much as possible.",357,56,0.1568627450980392
9781908541178,ch_7,Corsets are of equivocal benefit for acute pain management and should be limited in their use.,"In all phases of low back pain management, the patient must be given the responsibility and the tools to self-manage the disorder independently. In many acute lumbar strains nothing more than reassurance, cold compresses and analgesics may be required. In others, self-management requires educational materials and careful instruction to the patient or a family member by the physician or therapist to ensure that all aspects of home treatments can be carried out as prescribed. The specific exercise at each phase of the progression toward normal activity, work and exercise should be monitored to ensure that it is properly performed and well tolerated. An important principle to keep in mind is that the vast majority of individuals with the symptoms of low back pain with or without leg symptoms improve with non-surgical therapy. Only a small minority require surgical intervention to resolve their complaints.",166,21,0.12650602409638553
9781908541178,ch_7,"Medications during the acute phase can include paracetamol (acetaminophen), non-steroidal anti-inflammatory drugs and muscle relaxants. Short-term opioids for severe pain can also be considered.","For patients with chronic, intractable, axial low back pain and/or leg pain, spinal cord stimulation using intraspinal canal implantable electrodes can provide pain relief that can be self-administered. Although it is not without risk, it may provide a reduced need for opioids and, for some, a relatively opioid-free pain control option. Although a few patients may request no medication, for almost all patients appropriate analgesic medication is the first priority. The US Agency for Health Care Policy and Research guidelines for medication use in low back pain are shown in Table 4.2. Analgesics. The initial choice is usually analgesic medication available without prescription, including paracetamol (acetaminophen), acetylsalicylic acid (ASA; aspirin) and a number of non-steroidal anti-inflammatory drugs (NSAIDs), exempli gratia ibuprofen and naproxen. These drugs in appropriate dosages are well tolerated, provided that known predisposing factors for side effects are recognized and avoided, such as.",214,42,0.19626168224299065
9781908541178,ch_7,Graduated and progressive home reconditioning along with pain control measures is indicated.,"Opioids are not uncommonly needed for short-term pain control, and intermittently (on an as-required basis) for patients with subacute low back pain. The decision to administer opioid analgesia to patients with chronic pain is more complex. The need for a moderate but effective dosage to control pain (rather than eliminate it) must be weighed against the risk of opioid dependency, causing withdrawal symptoms if the drug is abruptly discontinued, and the possibility of addiction.",95,17,0.17894736842105263
9781908541178,ch_7,Spinal manipulation once or twice weekly for up to 4 weeks may be helpful for acute low back pain. Evidence for the benefits of manipulation for chronic low back pain is lacking.,"Opioids are not uncommonly needed for short-term pain control, and intermittently (on an as-required basis) for patients with subacute low back pain. The decision to administer opioid analgesia to patients with chronic pain is more complex. The need for a moderate but effective dosage to control pain (rather than eliminate it) must be weighed against the risk of opioid dependency, causing withdrawal symptoms if the drug is abruptly discontinued, and the possibility of addiction. Tramadol, a non-scheduled, centrally acting analgesic for management of moderate to moderately severe pain, in combination with paracetamol, is effective for the treatment of patients with chronic low back pain. Clinical studies have demonstrated the efficacy and safety of a combination tablet containing tramadol, 37.5 mg, and paracetamol, 325 mg (Ultracet), as a 3-month treatment for chronic low back pain. This is an example of a combination of analgesics that provides improvement in quality-of-life measures related to physical and emotional functioning.",215,35,0.16279069767441862
9781908541178,ch_7,"Bed rest is rarely indicated, but restful postures and ergonomic considerations to promote comfortable ambulatory activities should be encouraged.","Psychiatric and skilled pain management assistance is often indicated for patients with intractable pain. Tricyclic antidepressants may be beneficial in patients with chronic pain and those suffering from fibromyalgia, particularly if night-time dosing minimizes daytime sedation while improving restful sleep. Selective serotonin reuptake inhibitors are not usually helpful in controlling low back pain, except in patients with both low back pain and unipolar or bipolar depressive mood disorders. In contrast, serotonin-norepinephrine reuptake inhibitors (SNRIs; duloxetine, milnacipran) have pain-relieving properties similar to those of tricyclics. Duloxetine is the first drug to be approved by the US Food and Drug Administration (FDA) with an indication for the treatment of chronic low back pain.",170,25,0.14705882352941177
9781908541178,ch_7,The visual analog scale (VAS) for measuring pain is very helpful.,"the Sickness Impact Profile (SIP). the Roland-Morris Disability Scale (see Table 1.2), derived from the SIP. the Oswestry Low Back Pain Disability Questionnaire. the visual analog scale (VAS) (see Figure 1.1). the Waddell Disability Index.",62,15,0.24193548387096775
9781908541178,ch_7,Acupuncture may be helpful. A trial of six to eight treatments should help determine acupuncture efficacy.,"Acupuncture is another non-pharmacological and non-surgical therapy that may provide a measure of relief for acute, subacute and chronic low back pain patients, particularly for those who do not tolerate medication. Acupuncturists often also use a variety of herbal and topical remedies in addition to acupressure massage. Six treatments over a 2-week period are usually sufficient to determine if acupuncture can provide any pain control for an individual patient.",93,19,0.20430107526881722
9781908541178,ch_7,"Treatment will depend on assessment of pain severity (severe, moderate, mild, minimal). Multidisciplinary treatment should be strongly considered in chronic pain management.","Back-reconditioning exercises are part of a multidisciplinary treatment program for chronic low back pain. Exercises are graded depending on the level of pain, and the patient is cautioned to stop if any of them cause pain. Sample programs for patients with moderate pain or mild pain are given in Tables 4.4 and 4.5, and Figures 4.8 - 4.24. The patients work towards performing these exercises twice daily, and then (those with moderate back pain initially) progressing to exercises for mild back pain and finally to maintenance exercises. Once the patient has reached a level of back conditioning suitable for his/her normal daily activities, a once-daily maintenance exercise program can be started (Table 4.6). Other forms of back-reconditioning exercises, such as core stability exercises, can also be useful.",170,31,0.18235294117647058
9781908541178,ch_8,Epidural and/or nerve root canal injections are safer and more reliable if done with fluoroscopic monitoring.,"The duration of full or partial remission following an epidural corticosteroid injection may be days to a few months. In the case of acute radiculopathy, this may be sufficient to permit nerve root and discal inflammation to subside sufficiently for healing to occur. In the case of spinal stenosis with associated neurogenic claudication, an epidural injection every few months may permit more comfortable walking and standing, an improved quality of life, and postpone or possibly rule out surgical interventions. Nerve root canal injections are performed under fluoroscopic visualization to enhance precision and minimize the risk of inadvertent needle placement. They are indicated for refractory nerve root impingement syndromes where conservative measures have proved inadequate, and where clinical, radiographic and electrodiagnostic procedures can, with reasonable precision, identify the locus of the root canal neural compression.",174,22,0.12643678160919541
9781908541178,ch_8,Intrabursal and trigger-point injections with low-dose steroids can often provide prompt pain reduction.,"Sacroiliac joint injection. Despite the ambiguities in the clinical assessment of sacroiliac dysfunctions, almost all patients with suspected non-inflammatory sacroiliac joint pain recover spontaneously or with non-surgical therapies. For those few who do not improve, sacroiliac corticosteroid joint injections can be performed under fluoroscopic guidance in a manner similar to that used for facet joint injection. In one study, the sacroiliac joint was injected with lidocaine after visualization of the joint with contrast medium. Those patients who showed a positive response in terms of pain reduction on moving the sacroiliac joint area then received injections of betamethasone and lidocaine. Physical therapy was continued, and if improvement was not sustained, a second injection was given. Although far from conclusive, this suggests that sacroiliac joint pain may be responsive to intra-articular corticosteroid injections. Intrabursal injection. Regardless of the precise pathogenesis, local corticosteroid injections into tender bursae can often provide prompt pain relief. Large doses of corticosteroids are not required, as these bursas respond to injections of as little as 5 mg of triamcinolone, or its equivalent, in 2-5 mL of 1% lidocaine.",271,21,0.07749077490774908
9781908541178,ch_8,Surgery is usually effective for refractory sciatica but is of equivocal benefit for low back pain. Approximately one-third of successful spine fusions provide pain relief for chronic low back pain.,"There is on average a 10-15% non-union rate for single-level, instrument-stabilized fusions, and this increases to 30-40% for three-level fusions. With predominant slippage at L4-L5, failure to fuse the L5-S1 resulted in only a 55% success rate for the surgical fusion. Even in surgically successful lumbar fusions, only about one-third of patients with L4-S1 degenerative spondylosis and chronic low back pain unresponsive to previous non-surgical therapies obtain some measure of pain relief, because the association of the mechanical and degenerative abnormalities and the pain is often not clear. Lumbar fusions are associated with significant complications, with an overall complication rate of 17% in one large series (related primarily to pedicle screw fixation), and with twice the mortality rate of non-fusion options.",189,42,0.2222222222222222
9781908541277,ch_4,Epilepsy is the most common serious neurological disorder.,"Epilepsy is the most common serious neurological condition. It affects nearly 70 million people in the world. In high-income countries, approximately 6 per 1000 people will develop epilepsy during their lifetime, and 45 people per 100000 will develop new-onset epilepsy each year. These figures are nearly twice as high in low- and middle-income countries, possibly as a consequence of more primitive obstetric services as well as the greater likelihood of cerebral infection and head trauma.",94,11,0.11702127659574468
9781908541277,ch_4,The incidence of epilepsy is highest in the elderly.,"Incidence varies greatly with age, with high rates in early childhood, low levels in early adult life and a second peak in people aged over 65 years (Figure 1.1). In recent years, there has been a fall in the number of children affected as well as a sharp rise in epilepsy in the elderly. Indeed, old age has now become the most common time in life to develop the condition.",81,10,0.12345679012345678
9781908541277,ch_4,Epilepsy can be controlled by antiepileptic drugs in the majority of patients.,"Most patients with epilepsy have a good prognosis. The prognosis is strongly influenced by the underlying cause. In many people - particularly children - the condition will remit, although a substantial proportion will have epilepsy all their lives. Overall, 60-70% of patients become seizure free after the start of treatment with antiepileptic drugs (AEDs). Some of these patients become and remain seizure free on the initiation of the first AED, while in others the disorder appears to follow a more fluctuating course. Some patients can remain in remission after subsequent drug withdrawal, implying that the epileptogenic causes have truly remitted. The other 30-40% of patients continue to have seizures with varying degrees of frequency and severity. It is also increasingly recognized that some patients can have a 'remitting-relapsing' course, fluctuating between periods of seizure freedom and recurrence. Factors that indicate a poor prognosis for seizure control include.",192,19,0.09895833333333333
9781908541277,ch_4,"In general, a person with epilepsy is two to three times more likely to have an untimely death than someone in the general population.","The standardized mortality ratio (the ratio of observed deaths to expected deaths) for patients with epilepsy is two to three times above that of the general population. In many cases, the cause of death is related to the underlying etiology, but sudden unexpected death in epilepsy (SUDEP) is believed to account for up to 17% of all epilepsy-related deaths. SUDEP has been defined as 'sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in patients with epilepsy, with or without evidence of a seizure, and excluding documented status epilepticus, in which postmortem examination does not reveal toxicological or anatomic cause of death'. The reported incidence of SUDEP ranges from 0.35 to 10 per 1000 patients per year. It is higher if the seizure disorder remains uncontrolled, suggesting that the majority of SUDEP is related to seizure activity. Other associated causes of death include drowning, burns, aspiration, pneumonia, status epilepticus and suicide.",201,28,0.13930348258706468
9781908541277,ch_5,A seizure is a symptom of brain dysfunction.,A seizure is a symptom and represents the clinical manifestation of an abnormal and excessive synchronized discharge of a set of cortical neurons in the brain. Establishing the type(s) of seizure experienced by the patient has important implications for.,46,9,0.1956521739130435
9781908541277,ch_5,"Depending on the pattern of onset, seizures are broadly classified into partial (focal) and generalized types; classification is important for identifying the underlying cause, prognosis and best approach to management.","Depending on the pattern of neuronal involvement, the clinical features of a seizure consist of a wide range of sudden and transitory abnormal phenomena, which may include alterations of consciousness, or motor, sensory, autonomic or psychic events. The widely used electroclinical classification of seizures established nearly three decades ago by the International League Against Epilepsy (ILAE) is the most widely adopted scheme. This classification system, viewed by the ILAE as a work in progress, divides seizures into two major groups: partial and generalized (Table 2.1). Partial (or focal) seizures originate in a focal region of the cortex (Figure 2.1). They can be subdivided into those that do not impair consciousness (simple partial) and those that do (complex partial), which is useful for identifying patients whose safety may be compromised by loss of consciousness from their seizures. Partial seizures can also be classified according to their clinical manifestations, such as focal motor, and can spread rapidly to other cortical areas through neuronal networks, resulting in secondary generalized tonic-clonic seizures (Figure 2.2).",218,38,0.1743119266055046
9781908541277,ch_5,"Epileptic syndromes are defined by clinical features, aided by appropriate investigations that include EEG and brain imaging.","In addition to the classification of seizures, there is a separate system for epilepsies and epileptic syndromes (Table 2.2) that has been in place for many years. These are defined by groups of characteristic clinical features related to age at onset of seizures, family history of epilepsy, seizure type(s) and associated neurological symptoms and signs, aided by appropriate investigations, including EEG and brain imaging with, for example, CT and MRI (see Chapter 3, Diagnosis).",98,23,0.23469387755102042
9781908541277,ch_5,Genetic mutations affecting ion channels have been identified in a range of rare idiopathic epilepsy syndromes.,"The accuracy of classification depends on the extent of investigation. With advances in technology, particularly in brain imaging, many subtle lesions can now be identified, making it possible to classify more of the epilepsies as symptomatic rather than cryptogenic. As with the classification of seizures, fueled by recent developments in diagnostic imaging and molecular genetics, the classification of epilepsy syndromes is also under revision by the ILAE. Some of the epilepsy syndromes that may be encountered by the primary care provider are described below.",103,23,0.22330097087378642
9781908541277,ch_5,Benign rolandic epilepsy occurs in otherwise neurologically normal children and generally has an excellent response to antiepileptic drugs (AEDs).,"The EEG shows high-amplitude central and mid-temporal spikes and sharp waves, particularly during light sleep (Figure 2.4). The prognosis for children with benign rolandic epilepsy is excellent. The seizures are generally very easy to control with AEDs. The most commonly employed AEDs tend to be carbamazepine (CBZ), sodium valproate (VPA) and benzodiazepines given at bedtime. Other useful agents include oxcarbazepine (OXC) and levetiracetam (LEV). However, many children with mild or infrequent seizures do not require prophylactic AED treatment. Nearly all patients outgrow the disorder by their teenage years.",148,31,0.20945945945945946
9781908541277,ch_5,Long-term AED treatment for children with simple febrile seizures is not recommended.,"Treatment of febrile convulsions is usually symptomatic, with sponge bathing and prompt administration of an antipyretic. Some physicians advocate prophylactic rectal diazepam when fever is present in children with a history of febrile convulsions. Most pediatric neurologists would not recommend long-term AED treatment for children with simple febrile seizures (id est generalized seizures lasting less than 15 minutes).",91,19,0.2087912087912088
9781908541277,ch_5,Mesial temporal lobe epilepsy is often drug resistant but may be successfully treated by temporal lobectomy.,"Mesial temporal lobe epilepsy is a syndrome characterized by hippocampal sclerosis, which is the most common pathology in drug-resistant temporal lobe epilepsy. Onset of seizures usually occurs before puberty, often with a history of prolonged febrile convulsions in childhood. A seizure typically begins with vegetative auras, such as an epigastric rising sensation, or affective symptoms (most commonly fear), but may consist of complex delusional experiences, hallucinations, or olfactory or gustatory sensations. When the complex partial seizure ensues, impairment of consciousness is usually heralded by behavioral arrest and stare, followed by oro-alimentary, gestural and reactive automatisms lasting 1-2 minutes, which the patient does not remember. Afterwards, the patient is confused for varying periods. Postictal dysphasia may occur if the seizure involves the language-dominant hemisphere. Secondary generalization is relatively uncommon.",187,20,0.10695187165775401
9781908541277,ch_6,Epilepsy has many underlying etiologies.,"Epilepsy is not a single disease but an extensive collection of conditions with a wide range of underlying etiologies and pathologies, all sharing the common and fundamental characteristic of recurrent, usually unprovoked, seizures. Figure 3.1 shows some common etiologies in relation to age.",59,10,0.1694915254237288
9781908541277,ch_6,A wide range of conditions can mimic epileptic seizures.,"A wide range of conditions can mimic epileptic seizures and must be considered in the differential diagnosis (Table 3.1). For example, syncopal attacks, sometimes with clonic movements and incontinence, are commonly misdiagnosed as epileptic seizures. Furthermore, non-epileptic psychogenic seizures (also called pseudoseizures) are estimated to occur in up to 45% of patients referred to specialist centers with apparently refractory epilepsy. This misidentification of non-epileptic conditions as epilepsy can lead to unnecessary treatments that are potentially harmful, and can delay the start of appropriate therapy. The temptation to attach a label of 'epilepsy' should be resisted if there is any doubt about the diagnosis despite a thorough evaluation. Both the physician and patient must simply await the passage of time before coming to a firm conclusion. Further challenges of diagnosis and management may arise in patients in whom non-epileptic events coexist with epileptic seizures or develop as a substitute for epileptic seizures once the epilepsy is controlled.",209,11,0.05263157894736842
9781908541277,ch_6,A witness's account is essential for accurate diagnosis of epilepsy and classification of seizures.,"Despite advances in investigational technologies, the diagnosis of epilepsy remains essentially clinical, and is based on a detailed description of the events experienced by the patient before, during and after a seizure. A witness's account of one or more of the episodes is an essential component of a confident diagnosis (Table 3.2).In addition to a full medical and social history, the patient should be asked about factors that may precipitate seizures by lowering the threshold for such an event (Table 3.3).",98,16,0.16326530612244897
9781908541277,ch_6,Electroencephalography can support diagnosis and help with the classification of seizures and syndromes.,"Electroencephalography can support the clinical diagnosis of epilepsy and help with the classification of partial-onset or generalized seizures. It is important to give the electroencephalographer detailed information concerning the patient's age, seizure behavior and response to AEDs. Routine EEGs are often insensitive - more than 50% of patients with epilepsy will have a normal trace. Activation techniques, including hyperventilation and photic stimulation (Figure 3.2),are helpful in uncovering abnormalities. Diagnostic yield can also be increased by repeat recordings. If the initial EEG is unremarkable and the diagnosis remains in doubt, a sleep-deprivation study is recommended.",135,20,0.14814814814814814
9781908541277,ch_6,Structural brain imaging is essential in the diagnostic work-up for patients with seizures suspected of having a focal onset.,"Structural imaging. Imaging studies of the brain to look for underlying structural abnormalities are essential for the appropriate diagnostic evaluation of most patients with epilepsy, particularly those presenting with partial-onset seizures. The imaging modality of choice is MRI. It has higher sensitivity and specificity than CT for identifying structural lesions such as malformations of cortical development (Figure 3.3a), hippocampal sclerosis, arteriovenous malformations, cavernous hemangioma (Figure 3.3b) and low-grade gliomas (Figure 3.3c). CT should be performed if MRI is unavailable and in patients for whom MRI is contraindicated (exempli gratia those with cardiac pacemakers, non-compatible aneurysm clips or severe claustrophobia).",160,23,0.14375
9781908541277,ch_6,MRI is the imaging modality of choice for detecting structural abnormalities in the brain.,"Structural imaging. Imaging studies of the brain to look for underlying structural abnormalities are essential for the appropriate diagnostic evaluation of most patients with epilepsy, particularly those presenting with partial-onset seizures. The imaging modality of choice is MRI. It has higher sensitivity and specificity than CT for identifying structural lesions such as malformations of cortical development (Figure 3.3a), hippocampal sclerosis, arteriovenous malformations, cavernous hemangioma (Figure 3.3b) and low-grade gliomas (Figure 3.3c). CT should be performed if MRI is unavailable and in patients for whom MRI is contraindicated (exempli gratia those with cardiac pacemakers, non-compatible aneurysm clips or severe claustrophobia).",160,16,0.1
9781908541277,ch_6,Functional neuroimaging techniques are mainly used as supplementary investigations in patients being considered for epilepsy surgery.,"Functional imaging can identify focal abnormalities in cerebral physiology even when structural imaging results are normal. Single photon emission computed tomography (SPECT) can demonstrate increased blood flow in brain regions in association with seizure activity. Epileptogenic areas can be detected as hypometabolic regions interictally by positron emission tomography (Figure 3.4). Magnetic resonance spectroscopy can measure changes in chemical compounds in the brain associated with neuronal loss in certain epileptogenic pathologies. Functional neuroimaging techniques have a limited role in routine diagnostic evaluation, but are useful adjuncts in the work-up for epilepsy surgery.",124,20,0.16129032258064516
9781908541277,ch_7,Patients reporting more than one unprovoked seizure usually require treatment; treatment after a single unprovoked seizure could be considered if the chance of recurrence is high.,"After a single seizure. Whether treatment should be started after a single episode remains controversial. Depending on study methods and inclusion criteria, the probability of recurrence over the next 5 years after a single unprovoked seizure ranges from 31% to 71%. As a substantial proportion of such patients will not have further episodes, most specialists do not routinely recommend treatment after a single seizure. Prospective randomized studies have shown that, compared with delaying treatment until a further episode, immediate treatment after a first generalized tonic-clonic seizure (GTCS) does not improve the long-term remission rate. However, treatment should be considered after the first seizure when the chance of recurrence is high - for instance, in the presence of an underlying cerebral lesion, an abnormal EEG or a strong family history of epilepsy, or if the patient has an epilepsy syndrome such as juvenile myoclonic epilepsy (JME) that is characterized by a high likelihood of seizure recurrence. In some instances, the patient may wish to start treatment after a single event because they are concerned about the potentially significant impact that recurrent seizures could have on their lifestyle, such as their ability to legally drive a car.",235,34,0.14468085106382977
9781908541277,ch_7,Combination AED therapy could be used after failure of two monotherapies in series or if the first AED is well tolerated but fails to completely control the seizures.,"After a single seizure. Whether treatment should be started after a single episode remains controversial. Depending on study methods and inclusion criteria, the probability of recurrence over the next 5 years after a single unprovoked seizure ranges from 31% to 71%. As a substantial proportion of such patients will not have further episodes, most specialists do not routinely recommend treatment after a single seizure. Prospective randomized studies have shown that, compared with delaying treatment until a further episode, immediate treatment after a first generalized tonic-clonic seizure (GTCS) does not improve the long-term remission rate. However, treatment should be considered after the first seizure when the chance of recurrence is high - for instance, in the presence of an underlying cerebral lesion, an abnormal EEG or a strong family history of epilepsy, or if the patient has an epilepsy syndrome such as juvenile myoclonic epilepsy (JME) that is characterized by a high likelihood of seizure recurrence. In some instances, the patient may wish to start treatment after a single event because they are concerned about the potentially significant impact that recurrent seizures could have on their lifestyle, such as their ability to legally drive a car.",235,35,0.14893617021276595
9781908541277,ch_7,"Patients should be referred to a specialist for definitive diagnosis and initiation of treatment, or when seizures prove refractory to medication, they are planning for pregnancy or hoping to stop treatment in the case of remission.","After a single seizure. Whether treatment should be started after a single episode remains controversial. Depending on study methods and inclusion criteria, the probability of recurrence over the next 5 years after a single unprovoked seizure ranges from 31% to 71%. As a substantial proportion of such patients will not have further episodes, most specialists do not routinely recommend treatment after a single seizure. Prospective randomized studies have shown that, compared with delaying treatment until a further episode, immediate treatment after a first generalized tonic-clonic seizure (GTCS) does not improve the long-term remission rate. However, treatment should be considered after the first seizure when the chance of recurrence is high - for instance, in the presence of an underlying cerebral lesion, an abnormal EEG or a strong family history of epilepsy, or if the patient has an epilepsy syndrome such as juvenile myoclonic epilepsy (JME) that is characterized by a high likelihood of seizure recurrence. In some instances, the patient may wish to start treatment after a single event because they are concerned about the potentially significant impact that recurrent seizures could have on their lifestyle, such as their ability to legally drive a car.",235,42,0.17872340425531916
9781908541277,ch_7,"First-line AEDs should be chosen according to the patient's seizure type(s) and/or epilepsy syndrome. Other important factors include the likelihood of side effects, lack of long-term sequelae, and a low potential for pharmacokinetic interactions.","The goal of treatment should be to enable the patient to lead as normal a lifestyle as possible, which generally requires complete seizure control without, or with minimal, side effects. Choosing the most suitable AED for an individual patient requires knowledge of the characteristics of the epilepsy, the patient and the available AEDs. The issues discussed below should be included in the decision-making process. Monotherapy. In comparison with combination therapy, monotherapy is associated with better compliance and fewer side effects. It is therefore also likely to be more cost-effective. For these reasons, in general, serial monotherapy trials of two AEDs that are appropriate first-line treatment for the patient's seizure type(s) should be undertaken before combinations are tried (Figure 4.1). The chance of remission is highest with the first drug - 60% of patients with newly diagnosed epilepsy achieve seizure control with the first or second AED. Substantial attention should therefore be given to choosing the most appropriate initial AED, taking into account a range of factors, including the seizure type(s) and/or epilepsy syndrome. Other relevant issues include age, sex, weight, psychiatric and other comorbidities, childbearing potential and concomitant medication.",249,53,0.21285140562248997
9781908541277,ch_7,"At the start of treatment, a single antiepileptic drug (AED) should be given at a low dose and slowly titrated to an effective dose.","Titration and monitoring. Approximately 50% of newly diagnosed patients will be able to tolerate and become seizure free with the first AED, often in low or moderate doses. In general, the AED should be started at a low dose, with increments over a number of weeks to establish an effective and tolerable regimen, although some agents, such as sodium valproate (VPA) and levetiracetam (LEV), can be commenced at effective doses with, or even without, a rapid titration phase. Slow titration will help avoid concentration-dependent side effects as with carbamazepine (CBZ) or topiramate (TPM), in particular central nervous system toxicity, the presence of which is likely to discourage the patient from persevering with therapy in the long term. An additional benefit of a cautious approach is that it allows the development of tolerance to sedation or cognitive impairment. Such a policy will also ensure early detection of potentially serious idiosyncratic reactions, such as rash, hepatotoxicity and blood dyscrasias (see Side effects). Slow titration with lamotrigine (LTG) has been shown to reduce the risk of skin rash.",241,34,0.14107883817427386
9781908541277,ch_7,"A small number of patients will demonstrate a sustained response to the fourth, fifth, sixth or even seventh regimen, and so drug-resistant epilepsy should never be viewed nihilistically.","Titration and monitoring. Approximately 50% of newly diagnosed patients will be able to tolerate and become seizure free with the first AED, often in low or moderate doses. In general, the AED should be started at a low dose, with increments over a number of weeks to establish an effective and tolerable regimen, although some agents, such as sodium valproate (VPA) and levetiracetam (LEV), can be commenced at effective doses with, or even without, a rapid titration phase. Slow titration will help avoid concentration-dependent side effects as with carbamazepine (CBZ) or topiramate (TPM), in particular central nervous system toxicity, the presence of which is likely to discourage the patient from persevering with therapy in the long term. An additional benefit of a cautious approach is that it allows the development of tolerance to sedation or cognitive impairment. Such a policy will also ensure early detection of potentially serious idiosyncratic reactions, such as rash, hepatotoxicity and blood dyscrasias (see Side effects). Slow titration with lamotrigine (LTG) has been shown to reduce the risk of skin rash.",241,35,0.14522821576763487
9781908541277,ch_7,"None of the newer AEDs has shown superior efficacy when tested against established agents for the treatment of partial seizures and generalized tonic-clonic seizures, although some may be better tolerated.","For partial seizures and GTCS (the most common seizure types), the established AEDs, with the exception of ethosuximide (ESM), appear to have similar efficacy. There is a possible small benefit of CBZ over VPA for partial seizures. Phenobarbital (PB) and primidone (PRM) have demonstrated higher withdrawal rates because of their sedative effects at higher dosages. None of the newer AEDs has shown superior efficacy when tested against the established agents for the treatment of partial seizures and GTCS, but some have demonstrated better tolerability, in particular fewer neurotoxic side effects (Table 4.5). Thus, LTG and OXC have shown better overall effectiveness than CBZ and PHT, respectively, for partial epilepsy whereas VPA may be more efficacious than LTG for some generalized epilepsies.",177,38,0.21468926553672316
9781908541277,ch_7,Drug-resistant epilepsy is defined as failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.,"The practical difficulty with combination therapy is that troublesome or disabling side effects are common at high doses, and complex pharmacokinetic interactions can occur. Consequently, it is advisable to combine drugs with different side-effect profiles and those that do not have the potential for deleterious drug interactions. Practical guidelines for prescribing AEDs are summarized in Table 4.9. Drug-resistant epilepsy. The International League Against Epilepsy (ILAE) defines drug-resistant epilepsy as 'a failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom'. An online classifier, intended to aid the application of the ILAE definition of drug-resistant epilepsy, is available at www.drugresistantepilepsy.com. Fulfillment of the definition in a patient should prompt a comprehensive review of the diagnosis and management, preferably by an epilepsy specialist.",191,39,0.20418848167539266
9781908541277,ch_7,The primary care physician should play an important role in coordinating professional care for people with epilepsy.,"Attending to the patient's psychosocial, cognitive, educational and vocational needs is an important part of caring for people with epilepsy. Both the primary care physician and the epilepsy specialist should work closely with other medical and social service professionals, and extend their roles beyond that of clinician to educator and advocate. Subsequent referral to a comprehensive epilepsy center for EEG monitoring, investigational drugs or devices, or consideration for epilepsy surgery is indicated for compliant patients whose seizures prove resistant to two or three reasonable attempts at pharmacological manipulation using new and established AEDs singly and in combination.",116,18,0.15517241379310345
9781908541277,ch_8,This wider choice of AEDs permits pharmacological treatment to be better matched to the individual patient's circumstances.,"Dosage. CBZ should be introduced at low doses (100-200 mg daily) with 100-200 mg increments every 3-14 days, depending on the urgency of the situation. Slow introduction facilitates tolerance to its central nervous system (CNS) side effects and allows hepatic auto-induction of CBZ metabolism to take place. The dose can be increased over the first month or two to a maintenance amount that completely controls the seizure disorder. A balance must be achieved in the individual patient between speed of seizure control and acceptance of temporary CNS toxicity. The final dose will depend on the extent to which CBZ induces its own metabolism (Figure 5.1).",135,22,0.16296296296296298
9781908541277,ch_8,Sixteen new antiepileptic drugs (AEDs) have been approved for the treatment of epilepsy since the late 1980s.,"After a hiatus of nearly 20 years, 16 new AEDs and two devices - the vagus nerve stimulator and deep brain stimulator - have received licenses for the adjunctive treatment of refractory epilepsy, the last so far only in Europe. Gabapentin (GBP), lacosamide (LCM), LTG, levetiracetam (LEV), oxcarbazepine (OXC), pregabalin (PGB), tiagabine (TGB), TPM and zonisamide (ZNS) are widely available for partial seizures. Rufinamide (RFN) has been licensed in Europe and the USA for adjunctive treatment of seizures in Lennox-Gastaut syndrome. Eslicarbazepine acetate (ESL) is licensed in Europe as adjunctive treatment for partial seizures with or without secondary generalization. Retigabine (RTG; ezogabine in the USA) and perampanel (PER) have recently been approved for use in Europe and the USA for the same indication. After 20 years of global experience, vigabatrin (VGB) has been approved in the USA for the treatment of infantile spasms and as add-on therapy for drug-resistant complex partial seizures. However, the use of VGB has also been markedly restricted because of reports of concentric visual field defects in up to 40% of patients. Stiripentol (STP) was licensed in 2001 for the adjunctive treatment of Dravet syndrome in Europe via the orphan drugs system. A similar arrangement has taken place in the USA for CLB in the treatment of Lennox-Gastaut syndrome. This drug has been available elsewhere in the world since the 1970s. The progress of felbamate (FBM) has been dramatically curtailed because of the unusual development of idiosyncratic life-threatening bone-marrow and liver toxicities. The advent of these newer agents has provided many more options in the management of refractory epilepsy, although whether overall outcomes have improved substantially is debatable.",431,28,0.06496519721577726
9781908541277,ch_8,"AEDs differ substantially in their mechanisms of action, spectra of activity, and pharmacokinetic and side-effect profiles.","After a hiatus of nearly 20 years, 16 new AEDs and two devices - the vagus nerve stimulator and deep brain stimulator - have received licenses for the adjunctive treatment of refractory epilepsy, the last so far only in Europe. Gabapentin (GBP), lacosamide (LCM), LTG, levetiracetam (LEV), oxcarbazepine (OXC), pregabalin (PGB), tiagabine (TGB), TPM and zonisamide (ZNS) are widely available for partial seizures. Rufinamide (RFN) has been licensed in Europe and the USA for adjunctive treatment of seizures in Lennox-Gastaut syndrome. Eslicarbazepine acetate (ESL) is licensed in Europe as adjunctive treatment for partial seizures with or without secondary generalization. Retigabine (RTG; ezogabine in the USA) and perampanel (PER) have recently been approved for use in Europe and the USA for the same indication. After 20 years of global experience, vigabatrin (VGB) has been approved in the USA for the treatment of infantile spasms and as add-on therapy for drug-resistant complex partial seizures. However, the use of VGB has also been markedly restricted because of reports of concentric visual field defects in up to 40% of patients. Stiripentol (STP) was licensed in 2001 for the adjunctive treatment of Dravet syndrome in Europe via the orphan drugs system. A similar arrangement has taken place in the USA for CLB in the treatment of Lennox-Gastaut syndrome. This drug has been available elsewhere in the world since the 1970s. The progress of felbamate (FBM) has been dramatically curtailed because of the unusual development of idiosyncratic life-threatening bone-marrow and liver toxicities. The advent of these newer agents has provided many more options in the management of refractory epilepsy, although whether overall outcomes have improved substantially is debatable.",431,26,0.060324825986078884
9781908541277,ch_9,"Patients should be referred for presurgical evaluation after failure of two or more regimens using antiepileptic drugs (AEDs), particularly if they have a resectable lesion.","Surgery should be considered for patients with drug-resistant seizures because of the increased mortality and progressive cognitive and psychosocial morbidities associated with uncontrolled seizures over many years. There is emerging consensus that once drug resistance is demonstrated, patients should be promptly referred to a specialty epilepsy center that offers surgery. In some situations, such as catastrophic epilepsy in children, patients should be referred urgently because of the risk of severe developmental disability. A case-by-case assessment is needed. In addition to results of diagnostic tests, the patient's and the family's perceptions of epilepsy severity despite optimal pharmacotherapy and their expectations for the future are key determinants in the decision to operate. Types of procedure. The type of surgical procedure performed depends on the indication (Table 6.1). The most common procedure is anterior temporal lobectomy for hippocampal or mesial temporal sclerosis. In well-selected cases, 70-80% of patients can become seizure free, with a surgical mortality close to 0% and less than 5% significant morbidity (exempli gratia hemiparesis, hemianopia).",219,40,0.182648401826484
9781908541277,ch_9,Most patients (70-80%) with mesial temporal sclerosis can become seizure free after anterior temporal lobectomy.,"Types of procedure. The type of surgical procedure performed depends on the indication (Table 6.1). The most common procedure is anterior temporal lobectomy for hippocampal or mesial temporal sclerosis. In well-selected cases, 70-80% of patients can become seizure free, with a surgical mortality close to 0% and less than 5% significant morbidity (exempli gratia hemiparesis, hemianopia). Some patients may be suitable candidates for a more limited resection known as amygdalohippocampectomy in which the epileptogenic hippocampus and amygdala are removed, while sparing the temporal neocortex.",128,22,0.171875
9781908541277,ch_9,"Essential presurgical evaluation includes long-term video-electroencephalogram (EEG) monitoring, MRI with a dedicated protocol, and neuropsychological assessment for language and memory functions.","Other potentially curative procedures include lesionectomy to resect discrete structural lesions such as glial tumors and vascular malformations. In a palliative procedure (exempli gratia hemispherectomy/functional hemispherotomy, corpus callosotomy, multiple subpial transection), the focus of the seizure is not resected. Instead, the aim of the operation is to disrupt the pathways important for the spread of epileptiform discharges in order to reduce the frequency and severity of the seizures. Corpus callosotomy is a treatment option for patients with severe generalized epilepsy, particularly atonic seizures with frequent falls and subsequent injuries. Multiple subpial transection is performed when the epileptogenic lesion cannot be removed because of its close proximity to the eloquent cortex, while hemispherectomy is a more drastic procedure in which an extensively diseased and epileptogenic cerebral hemisphere is removed, or left in place but functionally disconnected from other brain structures. Presurgical evaluation. There is no universally agreed protocol to identify potential surgical candidates. Presurgical evaluation aims to establish the presence of drug resistance, delineate the epileptogenic zone to be resected and demonstrate that its removal will not cause additional unacceptable neurological or cognitive deficits. In practice, the evaluation involves a number of processes. A thorough review of the patient's seizure history and AED trials. Sophisticated video-electroencephalogram (EEG) monitoring, which localizes the onset of a number of seizures that are typical for the particular patient. High-quality MRI with dedicated 'epilepsy surgery protocol' to increase diagnostic accuracy.",331,40,0.12084592145015106
9781908541277,ch_9,"Vagus nerve stimulation is a therapeutic option for patients with drug-resistant partial-onset seizures, particularly those with non-resectable seizure foci.","The introduction of vagus nerve stimulation (VNS) in 1997 provided a non-pharmacological approach to epilepsy treatment. The VNS Therapy (Cyberonics, Texas, USA) system has been implanted in tens of thousands of patients worldwide. It comprises an implantable multiprogrammable pulse generator that delivers electrical current to the vagus nerve with the aim of reducing the frequency and/or severity of epileptic seizures. VNS is approved in the USA for use as adjunctive therapy for adults and adolescents over 12 years of age whose partial-onset seizures are refractory to AEDs. In Canada and the EU, VNS is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to antiepileptic medications.",182,32,0.17582417582417584
9781908541277,ch_9,The ketogenic diet is effective adjunctive therapy for children with drug-resistant epilepsy.,"The ketogenic diet is a restrictive high-fat, low-protein and very-low-carbohydrate diet mostly given to children aged 5-10 years with medically intractable epilepsy. There is much less experience to guide its use in younger children, adolescents or adults. The diet mimics the biochemical changes associated with starvation, which creates ketosis. Its exact mechanism of seizure suppression remains unclear.",80,18,0.225
9781908541277,ch_9,The ketogenic diet should only be used under expert medical and nutritional supervision.,"The ketogenic diet is a restrictive high-fat, low-protein and very-low-carbohydrate diet mostly given to children aged 5-10 years with medically intractable epilepsy. There is much less experience to guide its use in younger children, adolescents or adults. The diet mimics the biochemical changes associated with starvation, which creates ketosis. Its exact mechanism of seizure suppression remains unclear.",80,15,0.1875
9781908541277,ch_9,"Up to one-third of patients with epilepsy take herbal or dietary supplements for general maintenance of health or the control of symptoms such as difficulty sleeping or depression. Thus, knowledge of the products taken by the patient may provide the clinician with information on AED side effects or comorbid mood disorders.","Herbal formulas have a centuries-old tradition in much of the world. Over-the-counter herbal and dietary supplements are increasingly popular with people in industrialized countries, especially patients with chronic illnesses such as epilepsy. In Japan, herbal medicines, called Kampo, are available by prescription from physicians. Surveys conducted in the USA and UK suggest that up to one-third of patients with epilepsy take herbal and/or dietary supplements, and that most of these patients do not discuss their herbal use with their physicians. Most patients take the alternative medicines for general maintenance of health or to control other symptoms - for example, valerian for difficulty sleeping, St John's wort for depression and Ginkgo biloba for memory disturbance. Thus, the particular products taken by a patient may be a clue to that patient's side effects from AEDs or comorbid disorders. Clinicians should take a thorough history regarding herbal and dietary supplements, and consult reliable databases for information on safety as well as possible effects on seizure frequency and serum AED concentrations. Certain herbs, such as St John's wort, can affect hepatic metabolism and therefore alter the serum concentrations of hepatically metabolized AEDs. In addition, anecdotal reports suggest that several herbal and dietary supplements, such as essential oils, evening primrose and borage, and stimulants such as ephedra (ma huang) and guarana exacerbate seizures.",289,60,0.20761245674740483
9781908541277,ch_9,"Clinicians must take a thorough history from patients regarding the use of alternative medicines, and check reliable databases for information on safety as well as possible effects on seizure frequency and serum AED concentrations.","Surveys conducted in the USA and UK suggest that up to one-third of patients with epilepsy take herbal and/or dietary supplements, and that most of these patients do not discuss their herbal use with their physicians. Most patients take the alternative medicines for general maintenance of health or to control other symptoms - for example, valerian for difficulty sleeping, St John's wort for depression and Ginkgo biloba for memory disturbance. Thus, the particular products taken by a patient may be a clue to that patient's side effects from AEDs or comorbid disorders. Clinicians should take a thorough history regarding herbal and dietary supplements, and consult reliable databases for information on safety as well as possible effects on seizure frequency and serum AED concentrations. Certain herbs, such as St John's wort, can affect hepatic metabolism and therefore alter the serum concentrations of hepatically metabolized AEDs. In addition, anecdotal reports suggest that several herbal and dietary supplements, such as essential oils, evening primrose and borage, and stimulants such as ephedra (ma huang) and guarana exacerbate seizures.",230,39,0.16956521739130434
9781908541277,ch_10,Emergency treatment should be given when a convulsive seizure has lasted more than 5-10 minutes.,"Traditionally, SE is diagnosed when the patient has continuous or repeated seizure activity without regaining consciousness for more than 30 minutes. This time frame is defined on the basis of decompensatory cerebral damage after 30 minutes of seizure activity when physiological changes fail to compensate for the increase in cerebral metabolism. In practice, however, most authorities would recommend emergency antiepileptic drug (AED) treatment when a seizure has lasted more than 5-10 minutes, excluding simple febrile seizures.",100,19,0.19
9781908541277,ch_10,Status epilepticus (SE) can be convulsive or non-convulsive.,"The most readily recognized type of SE is tonic-clonic SE, but it has been estimated that 25% of SE cases are 'non-convulsive' in nature. Diagnosis of the latter can only be established by concurrent EEG recording. Depending on the electrographic changes, non-convulsive SE is subdivided into complex partial and absence SE. SE is a neurological emergency that requires immediate treatment. SE may result from a variety of causes (Table 7.1), the commonest of which include non-compliance with antiepileptic medication, consumption of alcohol, metabolic problems, acute stroke and hypoxia.",128,17,0.1328125
9781908541277,ch_10,"Poor prognostic factors for SE include old age, acute symptomatic cause and long duration.","The most readily recognized type of SE is tonic-clonic SE, but it has been estimated that 25% of SE cases are 'non-convulsive' in nature. Diagnosis of the latter can only be established by concurrent EEG recording. Depending on the electrographic changes, non-convulsive SE is subdivided into complex partial and absence SE. SE is a neurological emergency that requires immediate treatment. SE may result from a variety of causes (Table 7.1), the commonest of which include non-compliance with antiepileptic medication, consumption of alcohol, metabolic problems, acute stroke and hypoxia.",128,18,0.140625
9781908541277,ch_10,"Benzodiazepine administration, orally or rectally, can be useful in patients experiencing clusters of seizures.","Most centers would initiate treatment with a benzodiazepine intravenously (most commonly lorazepam or diazepam), followed by phenytoin or fosphenytoin, or phenobarbital. If the seizure persists, the patient might be considered as having refractory SE and general anesthesia would be warranted. Although not tested in randomized control trials, AEDs with intravenous formulations (exempli gratia sodium valproate, levetiracetam, lacosamide) are often used when first-line therapies fail. Table 7.3 lists the schedules for treating resistant SE, as discussed at the first London Colloquium on Status Epilepticus on behalf of the Taskforce on Status Epilepticus of the International League Against Epilepsy in 2007. In persistent SE, it is important to watch for potential complications including hypothermia, acidosis, hypotension, rhabdomyolysis, renal failure, infection and cerebral edema. An underlying cause should continue to be investigated. Treatment response should be monitored clinically and with EEG.",222,21,0.0945945945945946
9781908541277,ch_10,Buccal midazolam is being increasingly used in place of rectal diazepam for the treatment of seizure clusters (acute repetitive seizures).,"During a seizure cluster, oral therapy in a child may be problematic and intravenous access is usually unavailable or difficult. Rectal diazepam administered by parents or other caregivers may be effective in this situation. Rectal diazepam is absorbed more rapidly than rectal lorazepam or oral diazepam because of its high lipid solubility. A gel-containing prefilled unit-dose rectal delivery system is commercially available. The doses used in clinical studies (0.5 mg/kg for children aged 2-5 years, 0.3 mg/kg for children aged 6-11 years, 0.2 mg/kg for those over 12 years) were effective and well tolerated, and did not produce respiratory depression. The most common side effect was somnolence. Buccal midazolam, available in Europe, is being increasingly used instead of rectal diazepam. In adults and children over 10 years of age, 10 mg can be given and repeated once if necessary. Lower amounts can be used in younger children. Nasal formulations of benzodiazepines are under development.",226,31,0.13716814159292035
9781908541277,ch_11,"Oral contraceptives containing at least 50 g of estrogen should be used when coadministered with carbamazepine, eslicarbazepine acetate, felbamate, oxcarbazepine, phenobarbital, phenytoin, primidone and rufinamide, and topiramate at doses over 200 mg daily, because these drugs induce the metabolism of female sex hormones.","Contraception. Carbamazepine (CBZ), eslicarbazepine acetate (ESL), felbamate (FBM), oxcarbazepine (OXC), phenobarbital (PB), phenytoin (PHT), primidone (PRM), rufinamide (RFN), and topiramate (TPM) at doses over 200 mg daily all induce the metabolism of female sex hormones. This metabolism can alter the menstrual cycle and increase turnover of the components of oral contraceptive pills and depot formulations of steroid hormones (Table 8.1). The risk of breakthrough pregnancy is not insignificant. An oral contraceptive formulation containing 50 g of estrogen, with subsequent adjustment depending on the presence or absence of breakthrough bleeding, can provide secure contraception, as can barrier methods. Other birth control measures must be taken until the pattern of menstruation has been stable for at least 3 months. Lamotrigine (LTG) reduces levonorgestrel levels by about 20%, which is a potentially significant decrease. Levonorgestrel implants are contraindicated in women taking enzyme-inducing antiepileptic drugs (AEDs) as they have an unacceptably high failure rate. This is also likely to be the case with the progesterone-only pill. Medroxyprogesterone injections appear to be effective, though they need to be given more frequently than is usually recommended. The morning-after contraceptive pill can be used after unprotected intercourse. The effectiveness of the hormonal method of emergency contraception is reduced by enzyme-inducing drugs; a copper intrauterine device may be offered, or the dose of levonorgestrel should be increased.",347,84,0.2420749279538905
9781908541277,ch_11,Intermittent clobazam just before and shortly after the onset of menstruation can be used in women who experience catamenial seizures.,"Menstruation. Up to 20% of women with epilepsy have abnormal ovarian function, including anovulatory menstrual cycles and polycystic ovaries. These problems may be more common in patients treated with sodium valproate (VPA). Some women find that their seizures worsen mid-cycle or around menstruation, a phenomenon known as catamenial epilepsy. This exacerbation is thought to be a consequence of an imbalance between the proconvulsant estrogen and anticonvulsant progestogen concentrations. Manipulating the cycle with hormonal preparations is often unsuccessful, however, and may cause unwanted effects such as weight gain and depression. Another option is intermittent clobazam (CLB) for the few days just before and shortly after the onset of menstruation.",154,30,0.19480519480519481
9781908541277,ch_11,"AED treatment is continued when necessary during pregnancy because seizures, especially convulsive seizures, are more harmful to the mother and fetus than the drugs themselves; however, treatment should be tapered to a minimally effective dose before pregnancy, if possible to a single AED.","Pregnancy. The fertility of women with treated epilepsy is one-quarter to one-third lower than that of the general population. However, when women do conceive, most can expect to undergo uneventful pregnancies and deliver healthy babies. During pregnancy, metabolic processes change and close attention needs to be given to AED concentrations. Total serum concentrations of some drugs will fall, particularly those of PHT (Figure 8.1) and LTG. Women whose epilepsy is well controlled usually remain seizure free during pregnancy and delivery. Conversely, those who continue to report seizures before conception may have increased seizures during pregnancy. Before conception. Although it would be ideal to withdraw AED treatment in women contemplating pregnancy, for many this would result in recurrence or exacerbation of seizures that could be dangerous for both mother and fetus. If the criteria for discontinuation are met (see Therapy withdrawal), the AED should be stopped over a suitable interval before conception. If AED therapy cannot be withdrawn completely, it should be tapered to a minimally effective dose of, if possible, a single drug. In addition, supplemental folic acid, 4-5 mg daily, should be started before conception in an attempt to prevent neural tube defects. Folate treatment should be continued for the first 5 weeks of gestation, and current advice is to continue taking it at least until the end of week 12. These and other guidelines for managing epilepsy in women who are contemplating pregnancy are set out in Table 8.2.",298,54,0.18120805369127516
9781908541277,ch_11,"Supplemental folic acid, 4-5 mg daily, should be administered before conception and continued at least until the end of week 12 of gestation.","Before conception. Although it would be ideal to withdraw AED treatment in women contemplating pregnancy, for many this would result in recurrence or exacerbation of seizures that could be dangerous for both mother and fetus. If the criteria for discontinuation are met (see Therapy withdrawal), the AED should be stopped over a suitable interval before conception. If AED therapy cannot be withdrawn completely, it should be tapered to a minimally effective dose of, if possible, a single drug. In addition, supplemental folic acid, 4-5 mg daily, should be started before conception in an attempt to prevent neural tube defects. Folate treatment should be continued for the first 5 weeks of gestation, and current advice is to continue taking it at least until the end of week 12. These and other guidelines for managing epilepsy in women who are contemplating pregnancy are set out in Table 8.2.",177,30,0.1694915254237288
9781908541277,ch_11,The risk of major malformations in babies exposed in utero seems to be greater with sodium valproate (VPA) than with other AEDs.,"There are no clear data indicating differences in safety among PHT, CBZ, PB and PRM. Current evidence suggests that the risk of major congenital malformations is two to four times higher with the use of VPA than with other AEDs such as CBZ and LTG. Absolute rates have ranged from 6% to 11%, although the risk may be minimized by keeping daily doses at or below 1000 mg. High-dose exposure to VPA in utero may impair later cognitive function. The teratogenic risk associated with LTG monotherapy is low and is similar to that associated with CBZ, although preliminary data suggest the possibility of greater risk of major malformations at higher dosage. There are still insufficient data regarding the safety of other modern AEDs.",158,33,0.2088607594936709
9781908541277,ch_11,"A witness's account is particularly important for the correct diagnosis of epilepsy in the elderly, in whom the presentation of seizures is often subtle.","Old age is now the most common time in life to develop epilepsy. Approximately 1.5% of the population over the age of 70 years is diagnosed with active epilepsy. The number of elderly people diagnosed with epilepsy is set to rise further with the aging of the population. Nearly all de-novo seizures in elderly people are partial-onset with or without secondary generalization. Underlying factors can be identified in a greater proportion of elderly patients than younger patients, and include cerebrovascular disease, dementia and tumor. New-onset idiopathic syndromes are rare.",119,27,0.226890756302521
9781908541277,ch_11,"Low doses of AEDs are recommended in the elderly in order to minimize adverse effects, particularly neurotoxicity. Preferred choices include lamotrigine (LTG) and levetiracetam (LEV).","Diagnosis of epilepsy can be challenging and may depend on a witnessed event. Complex partial seizures presenting as confusion may be misdiagnosed as psychiatric symptoms. Postictal confusion can be prolonged in the elderly and may contribute to physical injury sustained during a seizure. AEDs are the mainstay of treatment, and are effective in most patients. Complete seizure control can be expected in more than 70% of elderly patients. A subgroup, often with progressive neurodegenerative disease, will continue to have seizures despite all attempts at pharmacological prevention. Elderly patients are particularly sensitive to the adverse effects of AEDs, possibly because of age-related pharmacokinetic changes caused by the delay in gastric emptying, reduction in body fat, and decreased hepatic metabolism and renal elimination. Low doses are generally recommended in the elderly in order to minimize adverse effects.",174,43,0.2471264367816092
9781908541277,ch_11,"The teenage years are an appropriate time for counseling on contraception and other lifestyle issues including driving, social interactions and careers.","Children who develop epilepsy should be re-evaluated during their teenage years, and AED levels should be monitored. At puberty, hepatic metabolism slows to a rate similar to that in adults, which may lead to a rise in circulating AED concentrations. AED doses may, therefore, need to be reduced as a child grows older. However, such a rise is often offset by a teenage growth spurt. Falling AED levels may indicate imperfect compliance, a common occurrence in this age group. The teenage years are an appropriate time for counseling on contraception, clarifying the possible side effects of AEDs, and predicting prognosis and eventual drug withdrawal. Driving, social interactions and career advice are other issues that doctors caring for teenagers with epilepsy must address (see Chapter 9).",157,23,0.1464968152866242
9781908541277,ch_11,"Broad-spectrum AEDs (exempli gratia VPA, LTG, TPM, LEV, zonisamide) should be the treatment of choice in people with learning difficulties; barbiturates and benzodiazepines should be avoided.","Before the doctor's first visit, a great deal of useful information can be obtained from a home assessment by a specialist epilepsy nurse following an agreed protocol. The home assessment should include. description of the episodes. evaluation of IQ. details of concomitant medication. previous and current AED treatment. circulating AED levels if appropriate. details of the carer's concerns and so on. Home video recordings can help to confirm or refute the diagnosis of epilepsy. At the outset, a management plan, including outcome aims, should be formulated with the full involvement of the carer(s) and family. Numbers and doses of AEDs should be minimized as much as possible. Attention should be paid not only to seizure frequency and severity, but also to behavior, mood, appetite, communication, cooperation, alertness and sleep pattern. Broad-spectrum AEDs, such as VPA, LTG, TPM, zonisamide and LEV, should be the preferred choice, and barbiturates and benzodiazepines should be avoided. The endpoint need not always be freedom from seizures, but perhaps better control accompanied by improved alertness, mood and cooperation.",239,54,0.22594142259414227
9781908541277,ch_12,"Depression and anxiety are common in patients with epilepsy, and have a significantly negative impact on quality of life.","Depression is the most prevalent psychiatric condition in patients with epilepsy - up to 55% of patients in some studies - and has a greater negative impact on quality of life than seizure-specific variables such as seizure frequency and severity. Depression is under-recognized and, when diagnosed, often undertreated. Depression associated with epilepsy differs clinically from depressive disorders in non-epileptic patients. Accordingly, symptoms of depression in patients with epilepsy often fail to meet the diagnostic criteria for affective disorders set out in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV). Diagnosis may be further complicated if the patient minimizes their psychiatric symptoms, or if the clinician does not inquire about psychiatric symptoms or considers depression to be part of the normal adaptation to the diagnosis of epilepsy. Clinicians often inadequately treat depression because they are concerned that antidepressant therapy will increase seizure frequency. The consequence of underdiagnosis and undertreatment can be fatal. The overall suicide rate in depressed patients with epilepsy is five times higher than that in the general population and as much as 25 times higher in patients with complex partial seizures of temporal lobe origin.",233,22,0.0944206008583691
9781908541277,ch_12,The potential benefit of treating depression and anxiety pharmacologically outweighs the risk of increased seizures.,"Depression is under-recognized and, when diagnosed, often undertreated. Depression associated with epilepsy differs clinically from depressive disorders in non-epileptic patients. Accordingly, symptoms of depression in patients with epilepsy often fail to meet the diagnostic criteria for affective disorders set out in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV). Diagnosis may be further complicated if the patient minimizes their psychiatric symptoms, or if the clinician does not inquire about psychiatric symptoms or considers depression to be part of the normal adaptation to the diagnosis of epilepsy. Clinicians often inadequately treat depression because they are concerned that antidepressant therapy will increase seizure frequency. The consequence of underdiagnosis and undertreatment can be fatal. The overall suicide rate in depressed patients with epilepsy is five times higher than that in the general population and as much as 25 times higher in patients with complex partial seizures of temporal lobe origin.",188,18,0.09574468085106383
9781908541277,ch_12,"Psychosis is uncommon in patients with epilepsy, and generally occurs following a cluster of complex partial seizures.","Depression is under-recognized and, when diagnosed, often undertreated. Depression associated with epilepsy differs clinically from depressive disorders in non-epileptic patients. Accordingly, symptoms of depression in patients with epilepsy often fail to meet the diagnostic criteria for affective disorders set out in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV). Diagnosis may be further complicated if the patient minimizes their psychiatric symptoms, or if the clinician does not inquire about psychiatric symptoms or considers depression to be part of the normal adaptation to the diagnosis of epilepsy. Clinicians often inadequately treat depression because they are concerned that antidepressant therapy will increase seizure frequency. The consequence of underdiagnosis and undertreatment can be fatal. The overall suicide rate in depressed patients with epilepsy is five times higher than that in the general population and as much as 25 times higher in patients with complex partial seizures of temporal lobe origin.",188,20,0.10638297872340426
9781908541277,ch_12,"When psychotropic medications and antiepileptic drugs are coadministered, dosages may need to be adjusted because of potential pharmacokinetic interactions.","Depression is under-recognized and, when diagnosed, often undertreated. Depression associated with epilepsy differs clinically from depressive disorders in non-epileptic patients. Accordingly, symptoms of depression in patients with epilepsy often fail to meet the diagnostic criteria for affective disorders set out in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV). Diagnosis may be further complicated if the patient minimizes their psychiatric symptoms, or if the clinician does not inquire about psychiatric symptoms or considers depression to be part of the normal adaptation to the diagnosis of epilepsy. Clinicians often inadequately treat depression because they are concerned that antidepressant therapy will increase seizure frequency. The consequence of underdiagnosis and undertreatment can be fatal. The overall suicide rate in depressed patients with epilepsy is five times higher than that in the general population and as much as 25 times higher in patients with complex partial seizures of temporal lobe origin.",188,31,0.16489361702127658
9781908541277,ch_12,"Patients should be encouraged to work whenever possible, and to seek legal help if they encounter discrimination in the workplace.","Clinicians should encourage their patients to work whenever possible and to recommend they seek legal help if they encounter discrimination in the workplace. In the USA, the Americans with Disabilities Act, which was amended in 2008 to further protect the rights of persons with epilepsy, protects a person from being denied employment because of a medical condition if that person can perform the essential duties of that job. In the UK, in line with several other European countries, a similar Disabilities Discrimination Act was introduced in 1995 to protect people with disabilities from discrimination in employment. Whether patients should disclose their epilepsy before being hired is best dealt with on a case-by-case basis.",130,23,0.17692307692307693
9781908541277,ch_12,"Legal restrictions on driving for people with epilepsy vary; clinicians should be aware of the relevant laws in their place of practice, and must clearly document their discussion with patients.","Driving is often viewed as essential to holding a job and living independently. However, as driving is a privilege, applicants must meet the requirements established by their state, province or country to qualify for a driver's license. With reference to epilepsy, these requirements usually specify a seizure-free interval necessary for driving, the obligations of the patient and the physician to notify the authorities of the patient's status, and allowances that are made under certain circumstances such as seizures that only occur during sleep or seizures that occur during a physician-prescribed AED taper. Clinicians should be thoroughly familiar with the applicable laws where they practice, and should clearly document their discussions with patients. Clinicians should also remember that side effects of AEDs, especially sedation, may interfere with a patient's ability to safely operate a vehicle, and should advise patients accordingly.",170,33,0.19411764705882353
9781908541277,ch_12,Patients with epilepsy may have difficulty in finding affordable life insurance.,"Life insurance. Patients with epilepsy may be unable to find affordable life insurance, particularly if applying for an individual policy. Most insurance companies ascribe a globally higher risk of mortality to people with seizures, irrespective of the applicant's frequency or severity of seizures. Patients who obtain life insurance through their place of employment generally do not have a problem.",67,13,0.19402985074626866
9781908541277,ch_12,Patients should be counseled on lifestyle modifications that reduce the risk of provoking seizures without unduly limiting activities.,"Lifestyle considerations. Clinicians should counsel patients on lifestyle modifications that reduce the risk of provoking seizures and help maintain overall health without unduly limiting activities that bring enjoyment and fulfillment. Reducing or eliminating the consumption of alcohol, engaging in stress-reducing behaviors, eating regularly and getting adequate sleep may help to reduce seizure frequency. Regular aerobic exercise, especially conducted in such a way that having a seizure would not pose a safety risk, is important for general maintenance of health as well as bone health. Participation in organized sports is generally possible, though the possibility of concussion should be minimized and athletes should consider discussing their condition with team trainers and doctors in advance.",130,22,0.16923076923076924
9781908541406,ch_3,"Thrombin further promotes the stability of the platelet-fibrin hemostatic plug by activating platelets, FXIII (cross-linking fibrin strands) and thrombin activatable fibrinolytic inhibitor.","Platelet activation exposes the fibrinogen receptor glycoprotein alphaIIbbeta3, and there are also receptors for thrombin and thromboxane. Binding of these ligands to their receptors induces platelet activation and aggregation. Hemostatic proteins, such as VWF and fibrinogen, are released from alpha-granules (one of two unique types of granule found in platelets) and promote cross-linking between platelets to help the development of a platelet plug to stem hemorrhage. In addition, adenosine diphosphate (ADP) is released from the second type of granule (called platelet dense granules because of their calcium content), and promotes further aggregation of platelets by binding to platelet P2Y1 and P2Y12 receptors. The platelet membrane also has receptors for plasma coagulation factors (exempli gratia prothrombin and factors V, X and XI). Thus, the activated platelet membrane provides a surface on which the components of coagulation can gather very rapidly, leading to the development of a 'fibrin-reinforced' stable platelet plug.",242,49,0.2024793388429752
9781908541406,ch_3,The immediate arrest of hemorrhage depends on vasoconstriction together with the adhesion and aggregation of platelets at the site of vessel injury.,"Initiation phase. When the endothelium is damaged the subendothelial vessel wall components become exposed, and circulating VWF promotes adhesion of platelets to the exposed subendothelial connective tissue. P-selectin is exposed on activated endothelial cells and binds to P-selectin glycoprotein ligand on leukocytes and platelets, initiating the rolling of these cells on the endothelium toward the site of injury and the release of membrane microparticles (Figure 1.2). Tissue factor (TF), a transmembrane glycolipoprotein, is expressed by injured endothelium, subendothelial connective tissue and microparticles. At the site of injury, TF forms a complex with factor (F)VII (TF-FVIIa) on the surface of activated platelets. The TF-FVIIa complex activates FIX and FX, and the activated FX cleaves prothrombin to form small amounts of thrombin. Thrombin is a potent activator of platelets, which provide an enhanced catalytic surface on which further coagulation is promoted. The activated platelets release hemostatic factors (exempli gratia fibrinogen and VWF) and polyphosphate, which accelerate the activation of FXI by thrombin. Polyphosphate is also capable of activating FV, further enhancing thrombin formation.",290,29,0.1
9781908541406,ch_3,"The coagulation system is activated by tissue factor expression. This binds and converts factor (F)VII to FVIIa, which initiates a catalytic series of reactions leading to the rapid generation of small amounts of thrombin.","Initiation phase. When the endothelium is damaged the subendothelial vessel wall components become exposed, and circulating VWF promotes adhesion of platelets to the exposed subendothelial connective tissue. P-selectin is exposed on activated endothelial cells and binds to P-selectin glycoprotein ligand on leukocytes and platelets, initiating the rolling of these cells on the endothelium toward the site of injury and the release of membrane microparticles (Figure 1.2). Tissue factor (TF), a transmembrane glycolipoprotein, is expressed by injured endothelium, subendothelial connective tissue and microparticles. At the site of injury, TF forms a complex with factor (F)VII (TF-FVIIa) on the surface of activated platelets. The TF-FVIIa complex activates FIX and FX, and the activated FX cleaves prothrombin to form small amounts of thrombin. Thrombin is a potent activator of platelets, which provide an enhanced catalytic surface on which further coagulation is promoted. The activated platelets release hemostatic factors (exempli gratia fibrinogen and VWF) and polyphosphate, which accelerate the activation of FXI by thrombin. Polyphosphate is also capable of activating FV, further enhancing thrombin formation.",290,48,0.16551724137931034
9781908541406,ch_3,"Trace concentrations of thrombin trigger the explosive generation of a much larger quantity of thrombin by activating FXI, FVIII and FV in a positive feedback loop.","Initiation phase. When the endothelium is damaged the subendothelial vessel wall components become exposed, and circulating VWF promotes adhesion of platelets to the exposed subendothelial connective tissue. P-selectin is exposed on activated endothelial cells and binds to P-selectin glycoprotein ligand on leukocytes and platelets, initiating the rolling of these cells on the endothelium toward the site of injury and the release of membrane microparticles (Figure 1.2). Tissue factor (TF), a transmembrane glycolipoprotein, is expressed by injured endothelium, subendothelial connective tissue and microparticles. At the site of injury, TF forms a complex with factor (F)VII (TF-FVIIa) on the surface of activated platelets. The TF-FVIIa complex activates FIX and FX, and the activated FX cleaves prothrombin to form small amounts of thrombin. Thrombin is a potent activator of platelets, which provide an enhanced catalytic surface on which further coagulation is promoted. The activated platelets release hemostatic factors (exempli gratia fibrinogen and VWF) and polyphosphate, which accelerate the activation of FXI by thrombin. Polyphosphate is also capable of activating FV, further enhancing thrombin formation.",290,37,0.12758620689655173
9781908541406,ch_4,"Defects of primary hemostasis (id est platelet disorders and von Willebrand disease) present with mucosal bleeding (exempli gratia epistaxis, gastrointestinal hemorrhage and menorrhagia).","Site of bleed. Bruising, purpura, prolonged bleeding from superficial cuts, epistaxis, gastrointestinal bleeding and menorrhagia often reflect failure of the primary hemostatic system (as with a platelet abnormality or von Willebrand disease). Hemarthroses and muscle hematoma are associated with disorders of secondary hemostasis due to coagulation abnormalities. Recurrent bleeding from a single anatomic site (exempli gratia epistaxis from the same nostril) is most likely to result from a structural/vascular abnormality, whereas bleeding at many different sites suggests a generalized hemostatic defect. Duration of bleeding. Bleeding symptoms over a long period of time suggest a lifelong congenital bleeding disorder, while those of recent origin may be more in keeping with an acquired medical disorder (exempli gratia liver disease). Difficulties may arise in individuals with mild congenital bleeding disorders who only bleed after surgery and who may, therefore, remain undiagnosed until adulthood, especially now that circumcision, tonsillectomy and dental extractions are performed less often in childhood.",226,45,0.19911504424778761
9781908541406,ch_4,Defects of secondary hemostasis (id est coagulation disorders such as hemophilia) usually present with hemarthroses and muscle hematoma.,"Site of bleed. Bruising, purpura, prolonged bleeding from superficial cuts, epistaxis, gastrointestinal bleeding and menorrhagia often reflect failure of the primary hemostatic system (as with a platelet abnormality or von Willebrand disease). Hemarthroses and muscle hematoma are associated with disorders of secondary hemostasis due to coagulation abnormalities. Recurrent bleeding from a single anatomic site (exempli gratia epistaxis from the same nostril) is most likely to result from a structural/vascular abnormality, whereas bleeding at many different sites suggests a generalized hemostatic defect. Duration of bleeding. Bleeding symptoms over a long period of time suggest a lifelong congenital bleeding disorder, while those of recent origin may be more in keeping with an acquired medical disorder (exempli gratia liver disease). Difficulties may arise in individuals with mild congenital bleeding disorders who only bleed after surgery and who may, therefore, remain undiagnosed until adulthood, especially now that circumcision, tonsillectomy and dental extractions are performed less often in childhood.",226,35,0.15486725663716813
9781908541406,ch_4,All current and recent drugs should be reviewed as possible causes of a bleeding state.,"Family history. A positive family history of a bleeding disorder can be helpful in directing investigations (exempli gratia hemophilia). However, the absence of a family history does not exclude a heritable condition: one-third of individuals presenting with hemophilia have no family history and, in those with mild bleeding disorders, other affected relatives may not have been diagnosed. Furthermore, in a mild bleeding disorder the degree of bleeding symptoms may vary among different members of the family because of the co-inheritance of other causes of a mild bleeding state.",112,16,0.14285714285714285
9781908541406,ch_4,"Specific inquiry should be made about oral anticoagulants such as vitamin K antagonists, or inhibitors of thrombin or factor (F)Xa or other antithrombotic therapy (exempli gratia acetylsalicylic acid [ASA, aspirin]).","Systemic illness. Medical conditions that predispose to bleeding, such as renal or liver failure, paraproteinemia and collagenoses, should be considered. Some medical conditions (exempli gratia atrial fibrillation) are commonly treated with anticoagulants. Acutely ill patients often have multiple reasons for bleeding (exempli gratia septicemia, uremia and the effect of drugs). See Chapters 9. Drugs. A full drug history must be obtained. Non-steroidal anti-inflammatory drugs (NSAIDs) are in widespread use as analgesics and many inhibit platelet function. Acetylsalicylic acid (ASA, aspirin) is widely used as an antithrombotic; it induces a mild predisposition to bleeding in most individuals and may unmask an underlying lifelong mild bleeding disorder. It is important to inquire specifically about oral anticoagulant therapy (vitamin K antagonists [exempli gratia warfarin] as well as the newer anti-FXa and antithrombin drugs). In hospitalized patients, the prophylactic use of unfractionated or low-molecular-weight heparin against venous thromboembolism may predispose to bleeding.",258,57,0.22093023255813954
9781908541406,ch_4,A full and detailed history of personal and family bleeding symptoms often indicates the nature and severity of a potential bleeding diathesis.,"It is customary to begin with a full blood count, blood film and coagulation screen. If the history is not particularly suggestive of a bleeding disorder, these investigations may be sufficient (and will exclude most severe bleeding disorders). On the other hand, if the patient has a very convincing history but normal screening tests, it would be appropriate to consider measuring levels of the individual coagulation factors, usually beginning with FVIII and von Willebrand factor (VWF), as hemophilia A and von Willebrand disease are the most common congenital bleeding disorders (Table 2.1).",120,25,0.20833333333333334
9781908541406,ch_5,Henoch-Schnlein purpura in childhood may lead to complications in pregnancy and renal failure in adulthood.,"Clinical manifestations include vasculitic skin lesions and cutaneous ulcers (Figure 3.3), abdominal pain, arthopathy predominantly of the large joints, and nephritis. Renal involvement is characterized by a crescentic proliferative glomerulonephritis. In a series of 20 patients, seven (35%) who experienced severe Henoch-Schnlein purpura in childhood progressed to renal impairment in adulthood. In addition, women with a history of even mild renal symptoms were at risk of hypertension or proteinuria during pregnancy.",111,23,0.2072072072072072
9781908541406,ch_5,"Palpable purpura, renal disease, polyarthropathy and cryoglobulinemia are usually associated with hepatitis C infection.","Cryoglobulins are complexes of circulating immunoglobulins that precipitate in the cold. Type II cryoglobulinemia occasionally occurs in patients with hepatitis C virus (HCV) infection or lymphoma. The cryoglobulins are complexes of monoclonal IgM and polyclonal IgG. Deposition of these complexes on the endothelium of small vessels leads to vascular obstruction and hemorrhage. About 75% of patients have polyarthropathy and 50% develop renal involvement, usually glomerulonephritis. Deposition of immune complexes in skin venules is associated with a palpable purpura. The lesions are typically located on the lower legs (Figure 3.4).",147,29,0.19727891156462585
9781908541406,ch_5,Individuals with recurrent nosebleeds and a family history of epistaxis should be carefully evaluated for hereditary hemorrhagic telangiectasia.,"A different form of amyloid is found in the brain of patients with Alzheimer's disease, where it appears in plaques and in the walls of blood vessels. In an attempt to slow the progression of the disease, some patients were immunized with beta-amyloid peptide. Unfortunately, this led to an increase in cerebral microhemorrhages associated with amyloid-laden vessels; this phenomenon has been reproduced in a mouse model of Alzheimer's disease. The amyloid-laden vessels may be more sensitive to the inflammatory reaction accompanying the immunologic attack on the vascular amyloid. The presence of amyloid in cerebral vessels (found in 10% of those over 65 years of age and in 80% of patients with Alzheimer's disease) may also provide an explanation for the relatively high incidence of cerebral hemorrhage when these patients are treated with tissue plasminogen activator.",182,28,0.15384615384615385
9781908541406,ch_6,"Inhibitors of platelet function, such as acetylsalicylic acid (ASA, aspirin), should be avoided in individuals with disorders of platelet function and those with thrombocytopenia.","Defects in platelet storage organelles or granules. One form of platelet storage pool disease is due to the absence of dense bodies, which are organelles containing ADP, adenosine triphosphate (ATP), calcium and serotonin. Patients exhibit excessive bruising and bleeding after surgery or trauma as the platelets may fail to exhibit a secondary wave of aggregation in response to a variety of aggregating agents. The absence of dense bodies in the platelets can be demonstrated by electron microscopy or by measuring the intraplatelet levels of ADP and ATP. In some patients, this form of storage pool disease is inherited together with tyrosinase-positive oculocutaneous albinism and ceroid pigment deposition in various organs, including the kidney. This constellation is termed the Hermansky-Pudlak syndrome and is due to mutations in HPS1-8, genes affecting organelle biosynthesis and protein trafficking. Another form of storage pool disease, the gray platelet syndrome, is characterized by a lack of platelet alpha-granules and absence of platelet fibrinogen, fibronectin and thrombospondin. Dysfunction of cytosolic enzymes and other platelet constituents. Cyclooxygenase defects result in impaired platelet aggregation and release of ADP from dense granules in response to ADP and collagen, and are associated with a mild bleeding tendency. As acetylsalicylic acid (ASA, aspirin) inhibits cyclooxygenase and gives rise to similar clinical and laboratory features, cyclooxygenase deficiency is sometimes known as an 'aspirin-like defect'. A variety of other forms of inherited platelet dysfunction have been described; examples are platelet-type von Willebrand disease, collagen receptor deficiency and the Chediak-Higashi and Wiskott-Aldrich syndromes.",391,44,0.11253196930946291
9781908541406,ch_6,"Platelet transfusion has limited indications and should be used sparingly, because it may transmit infection or sensitize the recipient to platelet antigens.","Defects in platelet storage organelles or granules. One form of platelet storage pool disease is due to the absence of dense bodies, which are organelles containing ADP, adenosine triphosphate (ATP), calcium and serotonin. Patients exhibit excessive bruising and bleeding after surgery or trauma as the platelets may fail to exhibit a secondary wave of aggregation in response to a variety of aggregating agents. The absence of dense bodies in the platelets can be demonstrated by electron microscopy or by measuring the intraplatelet levels of ADP and ATP. In some patients, this form of storage pool disease is inherited together with tyrosinase-positive oculocutaneous albinism and ceroid pigment deposition in various organs, including the kidney. This constellation is termed the Hermansky-Pudlak syndrome and is due to mutations in HPS1-8, genes affecting organelle biosynthesis and protein trafficking. Another form of storage pool disease, the gray platelet syndrome, is characterized by a lack of platelet alpha-granules and absence of platelet fibrinogen, fibronectin and thrombospondin.",242,32,0.1322314049586777
9781908541406,ch_6,"Thrombocytopenia may occur with some inherited disorders of platelet function, such as the Bernard-Soulier, gray platelet and Wiskott-Aldrich syndromes.","Management. Patients with inherited platelet function defects should avoid ASA (aspirin) and other drugs that alter platelet function. In addition, chronic blood loss may necessitate iron supplementation. Women usually require hormonal therapy to control menorrhagia. Patients should carry documentation describing the nature of their bleeding defect with them at all times. Some of the inherited platelet disorders, such as the gray platelet syndrome, may respond temporarily to treatment with desmopressin. If platelet transfusions are needed, single-donor platelets are usually preferred. Patients with Glanzmann syndrome often become refractory to platelets because they develop anti-alphaIIbbeta3 and also anti-human leukocyte antigen (HLA) antibodies. Registries indicate that hemostasis has been secured in some of these patients with recombinant human factor (F)VIIa.",178,42,0.23595505617977527
9781908541406,ch_6,"Gestational thrombocytopenia is common and requires no treatment, but it must be distinguished from primary immune thrombocytopenia.","The American Society of Hematology's 2011 evidence-based guidelines do not recommend a bone marrow examination in patients newly diagnosed with primary immune thrombocytopenia, provided the history and physical examination are unremarkable and the blood count shows only thrombocytopenia and/or findings of iron deficiency. However, all patients should be tested for hepatitis C and HIV. Treatment. If the platelet count is greater than 50 x 10 /L, no treatment is required and patients may simply be observed at regular intervals. In children, primary immune thrombocytopenia is usually an acute self-limiting condition and, provided there is no frank or persistent bleeding, drug therapy may not be necessary. In adults, however, the thrombocytopenia may be more prolonged and specific treatment may be required. Table 4.5 shows some of the agents used for the management of symptomatic primary immune thrombocytopenia.",198,33,0.16666666666666666
9781908541406,ch_6,"In immune thrombocytopenia, bleeding is uncommon if the platelet count exceeds 10 x 10 /L and aggressive interventions (exempli gratia high-dose corticosteroids, splenectomy) are not usually indicated.","Steroids. If the platelet count is less than 30 x 10 /L or there is bleeding, prednisone (prednisolone), 1 mg/kg, is given. Patients with platelet counts of less than 20 x 10 /L are generally hospitalized; if there is considerable bleeding, methylprednisolone may be given intravenously. Once the platelet count has increased to over 30 x 10 /L, the dose of corticosteroid is tapered slowly to avoid a rapid relapse. The goal is to prevent recurrence of bleeding by maintaining the platelet count above 20 x 10 /L. If the dose of corticosteroid required to accomplish this is greater than 10-20 mg/day, other interventions, such as those listed below, may be required. Although a rise in the platelet count with oral steroids may not be observed for 5-7 days, bleeding often subsides within a day or two. Some physicians prescribe intravenous immunoglobulin, in addition to corticosteroids, to increase the platelet count more rapidly if there is significant or high potential for serious bleeding.",230,50,0.21739130434782608
9781908541406,ch_7,Tranexamic acid and -aminocaproic acid (EACA) are useful for the management of hemorrhage following trauma and surgery in many different clinical settings.,"At the site of blood vessel injury a platelet plug forms and this stems hemorrhage. The plug is consolidated by the deposition of fibrin strands, which maintains its integrity. Subsequently, the fibrin is dissolved by the fibrinolytic activity of plasmin, which is derived from its precursor plasminogen under the influence of tissue plasminogen activator (tPA) secreted by endothelial cells, and the plug disintegrates (see Chapter 1). One way in which the stability of the platelet plug can be enhanced is by inhibiting fibrinolysis. This can be achieved by inhibiting the activity of plasmin by aprotinin, or tPA by tranexamic acid or -aminocaproic acid (EACA). Tranexamic acid and EACA are synthetic lysine-containing amino acids. They have recently been found to reduce bleeding following trauma or surgery in a wide range of clinical settings. Desmopressin was initially developed to treat diabetes insipidus but when administered in larger doses it increases the concentration of von Willebrand factor (VWF) and factor (F)VIII and is therefore useful for reducing hemorrhage in mild hemophilia, von Willebrand disease and some platelet disorders. Topical products are available to augment wound hemostasis.",282,37,0.13120567375886524
9781908541406,ch_7,"Desmopressin will often provide effective hemostatic therapy in mild hemophilia A, von Willebrand disease and some platelet disorders. A fibrinolytic inhibitor may be given concomitantly to inhibit the activity of the released tissue plasminogen activator.","At the site of blood vessel injury a platelet plug forms and this stems hemorrhage. The plug is consolidated by the deposition of fibrin strands, which maintains its integrity. Subsequently, the fibrin is dissolved by the fibrinolytic activity of plasmin, which is derived from its precursor plasminogen under the influence of tissue plasminogen activator (tPA) secreted by endothelial cells, and the plug disintegrates (see Chapter 1). One way in which the stability of the platelet plug can be enhanced is by inhibiting fibrinolysis. This can be achieved by inhibiting the activity of plasmin by aprotinin, or tPA by tranexamic acid or -aminocaproic acid (EACA). Tranexamic acid and EACA are synthetic lysine-containing amino acids. They have recently been found to reduce bleeding following trauma or surgery in a wide range of clinical settings. Desmopressin was initially developed to treat diabetes insipidus but when administered in larger doses it increases the concentration of von Willebrand factor (VWF) and factor (F)VIII and is therefore useful for reducing hemorrhage in mild hemophilia, von Willebrand disease and some platelet disorders. Topical products are available to augment wound hemostasis.",282,59,0.20921985815602837
9781908541406,ch_7,Tranexamic acid or EACA should not be given to patients with disseminated intravascular coagulation or those who may be bleeding from the upper urinary tract.,"Bleeding in the urinary tract. Dissolution of clots forming in the urinary tract is promoted by the fibrinolytic enzyme urokinase, secreted by the kidney. This fibrinolytic activity in urine, however, tends to exacerbate any tendency to bleed, such as after prostatectomy or if a bladder polyp is present. In these circumstances, tranexamic acid inhibits urokinase and can reduce bleeding from the bladder. It should not be given systemically if there is a possibility of bleeding into the ureter or kidney, because clots forming in the ureter may not be lysed and cause obstructive uropathy and renal failure. To avoid this complication, the bladder can be irrigated and then tranexamic acid or EACA instilled to provide local inhibition of fibrinolysis.",177,35,0.1977401129943503
9781908541406,ch_7,The antidiuretic effect of desmopressin lasts for 24 hours and can lead to clinically significant water retention and hyponatremia. It should not be given to those with atherosclerosis because of the risk of precipitating a thrombosis.,"Desmopressin is usually given subcutaneously in a dose of 0.3 g/kg, although it can also be administered intranasally (which is especially useful for patients to use at home for treatment of minor bleeds or menorrhagia) and intravenously. FVIII and VWF levels peak after 30-60 minutes. Further doses can be given after 4-6 hours, but the response is usually diminished (tachyphylaxis). It is important to note that desmopressin also releases tPA; therefore, the concomitant administration of tranexamic acid or EACA is often considered. Desmopressin also has a place in the treatment of other congenital bleeding disorders (exempli gratia platelet storage pool disorder) and some acquired conditions (exempli gratia renal failure; see Chapter 9). Desmopressin should be used with caution. Water retention and consequent hyponatremia may complicate therapy and give rise to headache. In children, this water retention can lead to fits and so it is absolutely contraindicated for those under the age of 2 years. It is prudent to monitor the serum sodium if it is anticipated that more than one dose of the drug will be needed. Desmopressin should not be given to patients with clinical evidence of atherosclerosis because of the risk of thrombosis when raising the VWF/FVIII levels. Some clinicians consider it unwise to give it to anyone over the age of 60 years as they may have significant, but asymptomatic, arterial disease.",330,54,0.16363636363636364
9781908541406,ch_7,"Topical agents provide local hemostasis, but those that contain animal proteins or are prepared from human blood convey risks of antibody formation and infection transmission.","Desmopressin should be used with caution. Water retention and consequent hyponatremia may complicate therapy and give rise to headache. In children, this water retention can lead to fits and so it is absolutely contraindicated for those under the age of 2 years. It is prudent to monitor the serum sodium if it is anticipated that more than one dose of the drug will be needed. Desmopressin should not be given to patients with clinical evidence of atherosclerosis because of the risk of thrombosis when raising the VWF/FVIII levels. Some clinicians consider it unwise to give it to anyone over the age of 60 years as they may have significant, but asymptomatic, arterial disease. Topical hemostatic products. These agents are classified according to their mode of action. They may contain thrombin (either bovine or human), fibrinogen, gelatin, collagen, cellulose, polyethylene glycol or even glutaraldehyde. Their effectiveness is variable, depending on the extent and location of the wound and the intensity of bleeding. Preparations containing bovine thrombin have been associated with the development of antibodies to thrombin and FV, and those prepared from human blood may transmit infectious agents.",262,30,0.11450381679389313
9781908541406,ch_8,Repeated hemarthroses lead to joint destruction and it is therefore important to treat every bleed early and effectively.,"The causative mutations for hemophilia A and B are found in the genes for FVIII and FIX, respectively. The FVIII gene (also known as F8) is large at 186 kb in length and this may partly account for a greater risk of mutation (and therefore higher prevalence of hemophilia A) than that of FIX (also known as F9), which is only 34 kb. A large number of different mutations have been described that result in varying reductions in FVIII/FIX activity. Major disruption of either gene leads to severe hemophilia, whereas minor defects, such as a single base change, often result in a molecule that retains some of its functional activity and causes only mild hemophilia. About 50% of cases of severe hemophilia A result from a major inversion in intron 22 of the F8 gene, with a homologous region of the chromosome that lies 400 kb distant to the gene (known as the 'flip-tip' inversion, Figure 6.1). In those without a family history, this inversion may have occurred in meiosis during spermatogenesis in the patient's maternal grandfather. In the laboratory, with the current polymerase chain reaction (PCR) and gene sequencing techniques, it is now possible to characterize the specific mutation in each family. It is important to do this, because the clinical features are related to the mutation (exempli gratia the likelihood of an anti-FVIII antibody developing following treatment is higher with certain mutations), and because it makes identification of female carriers in the family much more straightforward.",327,24,0.07339449541284404
9781908541406,ch_8,"All licensed concentrates of FVIII and FIX, purified from pooled blood donor plasma, are virally attenuated, do not transmit HIV or hepatitis C virus and are safe and effective therapies. Recombinant clotting factor concentrates are being used increasingly as they are virally safe and equally effective.","In some patients with mild hemophilia, desmopressin, 0.3 g/kg (max 20 g), is capable of increasing FVIII to the necessary level, thereby avoiding the use of a clotting factor concentrate (see Chapter 5). In all other circumstances, a replacement concentrate of either FVIII or FIX (depending on the diagnosis) should be given. Concentrates are prepared either by purifying the clotting factors from pooled blood donor plasma, or synthetically by using recombinant DNA technology. Infused FVIII concentrate has a half-life of about 12 hours and FIX, 18 hours. To maintain therapeutic levels it is therefore necessary to administer FVIII twice daily, whereas daily injections of FIX are usually adequate (because of its longer half-life). About one-third of children with severe hemophilia A develop an inhibitory immunoglobulin (Ig)G antibody directed against FVIII. On average, this arises after 10-20 exposures to the concentrate. Many of the antibodies are transient, are present at low levels and spontaneously disappear after a short period, while others rise to high levels and persist. Treatment can be problematic in those patients with higher levels of antibody, because the infused FVIII is immediately neutralized and consequently therapy is ineffective. In such cases, recombinant FVIIa or activated prothrombin complex concentrate can be given. Both these concentrates contain 'activated' clotting factors that 'bypass' the FVIII-dependent step in the clotting mechanism and arrest hemorrhage. These treatments are not, however, as effective as FVIII in a patient without an inhibitor. In many patients who develop inhibitors, it is possible to induce tolerance to FVIII by giving regular daily infusions of this clotting factor, even in the absence of bleeding, and the antibody becomes undetectable after 6-12 months. Inhibitors are rare in patients with hemophilia B.",400,61,0.1525
9781908541406,ch_8,"In mild hemophilia A, desmopressin can often be effective and avoids the use of concentrate.","In some patients with mild hemophilia, desmopressin, 0.3 g/kg (max 20 g), is capable of increasing FVIII to the necessary level, thereby avoiding the use of a clotting factor concentrate (see Chapter 5). In all other circumstances, a replacement concentrate of either FVIII or FIX (depending on the diagnosis) should be given. Concentrates are prepared either by purifying the clotting factors from pooled blood donor plasma, or synthetically by using recombinant DNA technology. Infused FVIII concentrate has a half-life of about 12 hours and FIX, 18 hours. To maintain therapeutic levels it is therefore necessary to administer FVIII twice daily, whereas daily injections of FIX are usually adequate (because of its longer half-life).",160,22,0.1375
9781908541406,ch_8,Children with severe hemophilia should be treated with regular prophylactic injections of factor (F)VIII or FIX concentrate to prevent bleeding and preserve joint function.,"About one-third of children with severe hemophilia A develop an inhibitory immunoglobulin (Ig)G antibody directed against FVIII. On average, this arises after 10-20 exposures to the concentrate. Many of the antibodies are transient, are present at low levels and spontaneously disappear after a short period, while others rise to high levels and persist. Treatment can be problematic in those patients with higher levels of antibody, because the infused FVIII is immediately neutralized and consequently therapy is ineffective. In such cases, recombinant FVIIa or activated prothrombin complex concentrate can be given. Both these concentrates contain 'activated' clotting factors that 'bypass' the FVIII-dependent step in the clotting mechanism and arrest hemorrhage. These treatments are not, however, as effective as FVIII in a patient without an inhibitor. In many patients who develop inhibitors, it is possible to induce tolerance to FVIII by giving regular daily infusions of this clotting factor, even in the absence of bleeding, and the antibody becomes undetectable after 6-12 months. Inhibitors are rare in patients with hemophilia B.",240,34,0.14166666666666666
9781908541406,ch_8,"Patients should be tested regularly for the presence of inhibitors, and any patient who does not respond clinically to treatment with factor concentrate should be immediately tested for an inhibitory antibody.","Female carriers of hemophilia A and B can be identified from the family history alone. For example, a daughter of a hemophiliac, or a woman who has either two sons with hemophilia, or one son and another hemophiliac in her extended family, is an obligate carrier of hemophilia. Other women in families with a hemophiliac may be carriers; carrier status can be ascertained by assessing the presence or absence of the same mutation that is present in the affected family member. Alternatively, intragenic FVIII/FIX polymorphisms can be used to track the hemophilia gene in the family. For those women who are carriers, provided the X chromosome that carries the hemophilia gene can be distinguished from the X chromosome carrying the normal FVIII gene (by polymorphism or mutation studies), antenatal diagnosis in a male fetus can be undertaken at about 11 weeks' gestation by chorionic villus sampling. These women must be offered genetic counseling before testing. If the fetus is diagnosed as having hemophilia, a termination can be offered. If the woman does not wish to consider the option of a termination, antenatal diagnosis can be made later in pregnancy from an amniotic fluid sample. If the fetus has hemophilia it is becoming increasingly evident that a cesarean section birth is probably safer than a vaginal delivery, particularly in the case of severe hemophilia.",292,35,0.11986301369863013
9781908541406,ch_8,"All potential carriers of hemophilia A and B should be offered genetic counseling and, if appropriate, DNA testing to ascertain their carrier status.","Female carriers of hemophilia A and B can be identified from the family history alone. For example, a daughter of a hemophiliac, or a woman who has either two sons with hemophilia, or one son and another hemophiliac in her extended family, is an obligate carrier of hemophilia. Other women in families with a hemophiliac may be carriers; carrier status can be ascertained by assessing the presence or absence of the same mutation that is present in the affected family member. Alternatively, intragenic FVIII/FIX polymorphisms can be used to track the hemophilia gene in the family. For those women who are carriers, provided the X chromosome that carries the hemophilia gene can be distinguished from the X chromosome carrying the normal FVIII gene (by polymorphism or mutation studies), antenatal diagnosis in a male fetus can be undertaken at about 11 weeks' gestation by chorionic villus sampling. These women must be offered genetic counseling before testing. If the fetus is diagnosed as having hemophilia, a termination can be offered. If the woman does not wish to consider the option of a termination, antenatal diagnosis can be made later in pregnancy from an amniotic fluid sample. If the fetus has hemophilia it is becoming increasingly evident that a cesarean section birth is probably safer than a vaginal delivery, particularly in the case of severe hemophilia.",292,28,0.0958904109589041
9781908541406,ch_9,Desmopressin is safe and effective therapy for many patients.,"VWF protein is synthesized by endothelial cells and released into the plasma. It is also stored in endothelial cell Weibel-Palade bodies, from which it can be released by vigorous exercise, desmopressin and adrenergic stimulation. Bone marrow megakaryocytes synthesize VWF, which is packaged into the developing platelet alpha-granules. When platelets become activated at the site of vascular injury, they release VWF, which promotes platelet adhesion (via platelet glycoprotein Ib) and aggregation (via platelet glycoprotein IIb/IIIa). The mature VWF protein possesses a number of specific binding sites that are receptors for its functional ligands (Figure 7.1). VWF stabilizes FVIII in the circulation; in patients with von Willebrand disease, the half-life of FVIII is shortened and the plasma concentration of FVIII is decreased.",188,13,0.06914893617021277
9781908541406,ch_9,All patients with von Willebrand disease should be characterized by laboratory investigation as fully as possible.,"For a diagnosis of von Willebrand disease to be made, the plasma levels of normally functioning VWF must be reduced or a structurally abnormal molecule with altered function must be present. The VWF protein can be characterized by a number of different laboratory techniques that assess its concentration and function by a variety of methods. The primary hemostatic function of VWF is best assessed by its ability to support ristocetin-induced platelet aggregation in vitro, using the von Willebrand ristocetin cofactor (VWF:RCo) assay. Ristocetin was originally developed as an antibiotic, but it caused thrombocytopenia. Subsequently, it was discovered that ristocetin aggregates platelets via their glycoprotein Ib receptors; this aggregation requires the high-molecular-weight multimers of VWF (which are also the most important for hemostasis).",190,19,0.1
9781908541406,ch_9,"When a clotting factor concentrate is indicated, it should contain high-molecular-weight multimers of von Willebrand factor.","For a diagnosis of von Willebrand disease to be made, the plasma levels of normally functioning VWF must be reduced or a structurally abnormal molecule with altered function must be present. The VWF protein can be characterized by a number of different laboratory techniques that assess its concentration and function by a variety of methods. The primary hemostatic function of VWF is best assessed by its ability to support ristocetin-induced platelet aggregation in vitro, using the von Willebrand ristocetin cofactor (VWF:RCo) assay. Ristocetin was originally developed as an antibiotic, but it caused thrombocytopenia. Subsequently, it was discovered that ristocetin aggregates platelets via their glycoprotein Ib receptors; this aggregation requires the high-molecular-weight multimers of VWF (which are also the most important for hemostasis).",190,28,0.14736842105263157
9781908541406,ch_10,"Congenital hypofibrinogenemia predisposes to venous thromboembolism, postoperative and postpartum hemorrhage and placental abruption.","Although hemophilia A and B are the most common severe coagulation disorders, congenital and acquired deficiencies of all the other clotting factors occur and can lead to a range of bleeding states that may cause diagnostic and therapeutic difficulties. These uncommon disorders include deficiencies of factor (F)II, FV, FVII, FX, FXI and FXIII and multiple factor deficiencies of the vitamin-K-dependent factors. Most of these disorders have autosomal-recessive traits; heterozygote individuals are asymptomatic, with clotting factor levels of about 50%. In homozygous, or compound heterozygote, individuals the level of the deficient clotting factor is very low. Bleeding manifestations include perioperative hemorrhage, bleeding from the umbilical cord, hemoperitoneum during ovulation, hematomas and hemarthroses, and intracranial hemorrhage. The frequency of severe bleeding in these disorders is shown in Figure 8.1.",200,35,0.175
9781908541406,ch_10,Bleeding is uncommon in factor (F)VII heterozygotes.,"Although hemophilia A and B are the most common severe coagulation disorders, congenital and acquired deficiencies of all the other clotting factors occur and can lead to a range of bleeding states that may cause diagnostic and therapeutic difficulties. These uncommon disorders include deficiencies of factor (F)II, FV, FVII, FX, FXI and FXIII and multiple factor deficiencies of the vitamin-K-dependent factors. Most of these disorders have autosomal-recessive traits; heterozygote individuals are asymptomatic, with clotting factor levels of about 50%. In homozygous, or compound heterozygote, individuals the level of the deficient clotting factor is very low. Bleeding manifestations include perioperative hemorrhage, bleeding from the umbilical cord, hemoperitoneum during ovulation, hematomas and hemarthroses, and intracranial hemorrhage. The frequency of severe bleeding in these disorders is shown in Figure 8.1.",200,14,0.07
9781908541406,ch_10,Fibrinogen deficiency,"Fibrinogen deficiency. Fibrinogen deficiency comprises a group of disorders subdivided into those with afibrinogenemia (< 0.1 g/L), hypofibrinogenemia (0.1-1.5 g/L) and hypodysfibrinogenemia; the last have a reduced level of fibrinogen that can be demonstrated to be dysfunctional by laboratory testing. Inheritance is usually dominant. Deficiency is associated with both bleeding and venous thrombotic manifestations.",106,5,0.04716981132075472
9781908541406,ch_10,Factor VII deficiency,"The molecular basis for this condition has recently been found to be due to mutation in the genes encoding two proteins (lectin, mannose-binding, 1 [LMAN1] and multiple coagulation factor deficiency 2 [MCFD2]) of the Golgi endoplasmic reticulum that are involved in the intracellular transport of FV and FVIII. As no FV concentrate is available, treatment of FV deficiency is with fresh frozen plasma, while low level FVIII is treated with desmopressin or FVIII concentrate. Factor VII deficiency.",120,3,0.025
9781908541406,ch_10,Individuals with severe FVII deficiency are usually homozygous and originate from consanguineous marriages.,"Congenital FVII deficiency is an uncommon autosomal recessive disorder. Its prevalence is much higher in countries where consanguineous marriages are common. The severe phenotype is observed in individuals who are homozygous or doubly heterozygous for mutations that disrupt expression of the protein, whereas the majority of those with heterozygous mutations have missense mutations and are asymptomatic. However, the correlation between bleeding risk and FVII level is poor. Individuals with a moderate FVII deficiency (2-10% factor levels) often bleed from mucous membranes and have epistaxis, bleeding gums and menorrhagia, as well as perioperative hemorrhage. In patients with severe FVII deficiency (< 2% levels) bleeding into the CNS very early in life leads to a high morbidity and mortality. Hemarthroses have been reported in patients with severe FVII deficiency but, unlike in hemophilia A and B, they are not a regular feature.",199,21,0.10552763819095477
9781908541406,ch_10,FXI deficiency,"FXI deficiency is inherited as an autosomal disorder, and is sometimes known as hemophilia C. Ashkenazi Jews are particularly affected, with low levels of FXI found in up to 8% of this population. Several generations within a family may have reduced levels to different degrees (Figure 8.2). Individuals who are heterozygous for a mutation have a partial deficiency of FXI, whereas those who have a severe deficiency are either homozygous or compound heterozygotes. Of the original three mutations found in affected individuals, two mutations (types 2 and 3) account for most FXI deficiency. In type 2 deficiency, there is a stop codon in exon 5; in the homozygous state this results in a FXI level below 1 IU/dL. In type 3 deficiency Phe283 is replaced with Leu (coding in exon 9); in the homozygous condition this results in an FXI level of approximately 10 IU/dL. A compound heterozygote of these two mutations has an FXI level somewhere between less than 1% and 10%.",221,3,0.013574660633484163
9781908541406,ch_10,"Family members should be fully investigated for both FXI clotting activity and the mutation(s) in the gene, because compound heterozygotes are common.","FXI deficiency is inherited as an autosomal disorder, and is sometimes known as hemophilia C. Ashkenazi Jews are particularly affected, with low levels of FXI found in up to 8% of this population. Several generations within a family may have reduced levels to different degrees (Figure 8.2). Individuals who are heterozygous for a mutation have a partial deficiency of FXI, whereas those who have a severe deficiency are either homozygous or compound heterozygotes. Of the original three mutations found in affected individuals, two mutations (types 2 and 3) account for most FXI deficiency. In type 2 deficiency, there is a stop codon in exon 5; in the homozygous state this results in a FXI level below 1 IU/dL. In type 3 deficiency Phe283 is replaced with Leu (coding in exon 9); in the homozygous condition this results in an FXI level of approximately 10 IU/dL. A compound heterozygote of these two mutations has an FXI level somewhere between less than 1% and 10%.",221,31,0.14027149321266968
9781908541406,ch_10,"Bleeding is common in patients with severe FVII deficiency; it can be severe, and can include intracranial hemorrhage. Treatment with recombinant human FVIIa is effective and should be given prophylactically.","For those with a partial deficiency it may be appropriate to undertake surgery with only careful attention to hemostasis and to use tranexamic acid for dental extractions. The FXI level may need to be raised in those with a severe deficiency who are undergoing major surgery. As the half-life of FXI is approximately 45 hours, therapeutic infusions of plasma or concentrate should be given daily or on alternate days. Virally inactivated fresh frozen plasma can be used but solvent/detergent-treated plasma has a lower FXI content and is therefore relatively ineffective. FXI concentrates can be used, but these have been associated with both arterial and venous thromboembolism. They are therefore contraindicated in individuals with clinical atherosclerosis and in patients whose hemostatic mechanisms are activated, such as pregnant women and those with liver disease. Concentrates should not normally be used in doses above 30 IU/kg and the plasma level of FXI should not exceed 50-70 IU/dL. Fibrinolytic inhibitors should never be given concomitantly with a FXI concentrate, because of their propensity to predispose to thrombosis and DIC. Patients with the type 2 defect often develop inhibitory antibodies when exposed to normal FXI. Such antibodies may induce resistance to further treatment with FXI, in which case activated prothrombin complex concentrate or recombinant activated human FVIIa should be used to control bleeding.",299,47,0.15719063545150502
9781908541406,ch_10,"Unlike hemophilia A, the level of FXI is not a good predictor of bleeding risk.","For those with a partial deficiency it may be appropriate to undertake surgery with only careful attention to hemostasis and to use tranexamic acid for dental extractions. The FXI level may need to be raised in those with a severe deficiency who are undergoing major surgery. As the half-life of FXI is approximately 45 hours, therapeutic infusions of plasma or concentrate should be given daily or on alternate days. Virally inactivated fresh frozen plasma can be used but solvent/detergent-treated plasma has a lower FXI content and is therefore relatively ineffective. FXI concentrates can be used, but these have been associated with both arterial and venous thromboembolism. They are therefore contraindicated in individuals with clinical atherosclerosis and in patients whose hemostatic mechanisms are activated, such as pregnant women and those with liver disease. Concentrates should not normally be used in doses above 30 IU/kg and the plasma level of FXI should not exceed 50-70 IU/dL. Fibrinolytic inhibitors should never be given concomitantly with a FXI concentrate, because of their propensity to predispose to thrombosis and DIC. Patients with the type 2 defect often develop inhibitory antibodies when exposed to normal FXI. Such antibodies may induce resistance to further treatment with FXI, in which case activated prothrombin complex concentrate or recombinant activated human FVIIa should be used to control bleeding.",299,20,0.06688963210702341
9781908541406,ch_10,"FXI concentrates should be used with caution, because they predispose to arterial and venous thromboembolism. Fresh frozen plasma is often effective therapy, but exposure to normal FXI in plasma or concentrates carries a risk of inhibitor development in those with type 2 disease.","For those with a partial deficiency it may be appropriate to undertake surgery with only careful attention to hemostasis and to use tranexamic acid for dental extractions. The FXI level may need to be raised in those with a severe deficiency who are undergoing major surgery. As the half-life of FXI is approximately 45 hours, therapeutic infusions of plasma or concentrate should be given daily or on alternate days. Virally inactivated fresh frozen plasma can be used but solvent/detergent-treated plasma has a lower FXI content and is therefore relatively ineffective. FXI concentrates can be used, but these have been associated with both arterial and venous thromboembolism. They are therefore contraindicated in individuals with clinical atherosclerosis and in patients whose hemostatic mechanisms are activated, such as pregnant women and those with liver disease. Concentrates should not normally be used in doses above 30 IU/kg and the plasma level of FXI should not exceed 50-70 IU/dL. Fibrinolytic inhibitors should never be given concomitantly with a FXI concentrate, because of their propensity to predispose to thrombosis and DIC. Patients with the type 2 defect often develop inhibitory antibodies when exposed to normal FXI. Such antibodies may induce resistance to further treatment with FXI, in which case activated prothrombin complex concentrate or recombinant activated human FVIIa should be used to control bleeding.",299,59,0.19732441471571907
9781908541406,ch_10,"As fibrinogen has a long half-life of 5 days, effective prophylaxis can be readily achieved for surgery and throughout pregnancy.","Treatment. FXIII has a long half-life of about 11 days and, as it is only necessary to keep the level above about 2% of normal to prevent spontaneous bleeds, a single infusion is required only every 4 weeks. For surgery the level should be kept above 30%, and this can be accomplished with a virally inactivated plasma-derived FXIII concentrate. Because of the risk of intracranial hemorrhage in particular, it is customary to treat patients with monthly prophylactic infusions of 10-30 IU/kg, which are effective in preventing almost all spontaneous bleeds. A recombinant concentrate of the A subunit is under development.",136,30,0.22058823529411764
9781908541406,ch_11,Liver disorders,"Liver and kidney disorders. Liver disorders. The coagulation changes in patients with liver disease are complex and often arise as a result of several different mechanisms. The liver is the principal site for synthesis and clearance of many hemostatic and fibrinolytic proteins. Imbalances between procoagulants and anticoagulants are not infrequent, and may manifest as bleeding (from esophageal varices) or thrombosis (of the portal or peripheral veins), or both. The bleeding risk is also dependent on the platelet count, which is influenced by the degree of splenomegaly secondary to liver-induced portal hypertension.",138,3,0.021739130434782608
9781908541406,ch_11,Kidney disorders,"Liver and kidney disorders. Liver disorders. The coagulation changes in patients with liver disease are complex and often arise as a result of several different mechanisms. The liver is the principal site for synthesis and clearance of many hemostatic and fibrinolytic proteins. Imbalances between procoagulants and anticoagulants are not infrequent, and may manifest as bleeding (from esophageal varices) or thrombosis (of the portal or peripheral veins), or both. The bleeding risk is also dependent on the platelet count, which is influenced by the degree of splenomegaly secondary to liver-induced portal hypertension.",138,3,0.021739130434782608
9781908541406,ch_11,The risk of bleeding increases with the degree of renal failure.,"The coagulation changes in patients with liver disease are complex and often arise as a result of several different mechanisms. The liver is the principal site for synthesis and clearance of many hemostatic and fibrinolytic proteins. Imbalances between procoagulants and anticoagulants are not infrequent, and may manifest as bleeding (from esophageal varices) or thrombosis (of the portal or peripheral veins), or both. The bleeding risk is also dependent on the platelet count, which is influenced by the degree of splenomegaly secondary to liver-induced portal hypertension.",128,12,0.09375
9781908541406,ch_11,Acute and chronic liver disease can give rise to a variety of different hemostatic disorders; it is therefore important to assess each patient fully.,"Impaired g-carboxylation of factors II, VII, IX and X. Carboxylation of the inactive peptides for FII, FVII, FIX and FX, as well as proteins C and S by hepatocyte g-carboxylase, results in their conversion to clotting factors that can participate in hemostasis. Patients with chronic liver disease have reduced carboxylase activity, resulting in incomplete carboxylation of the precursor peptides. Furthermore, the carboxylation process depends on vitamin K; if vitamin K is lacking (exempli gratia in biliary obstruction), an assessment of clotting factor levels, particularly FVII, may underestimate the true capacity of the liver for synthesis. Therefore, before using the PT to assess liver function, the patient's vitamin K status should be evaluated, and if deficiency is suspected vitamin K supplementation should be given.",182,29,0.15934065934065933
9781908541406,ch_11,Vitamin K therapy should be given if there is any possibility of deficiency.,"Impaired g-carboxylation of factors II, VII, IX and X. Carboxylation of the inactive peptides for FII, FVII, FIX and FX, as well as proteins C and S by hepatocyte g-carboxylase, results in their conversion to clotting factors that can participate in hemostasis. Patients with chronic liver disease have reduced carboxylase activity, resulting in incomplete carboxylation of the precursor peptides. Furthermore, the carboxylation process depends on vitamin K; if vitamin K is lacking (exempli gratia in biliary obstruction), an assessment of clotting factor levels, particularly FVII, may underestimate the true capacity of the liver for synthesis. Therefore, before using the PT to assess liver function, the patient's vitamin K status should be evaluated, and if deficiency is suspected vitamin K supplementation should be given.",182,15,0.08241758241758242
9781908541406,ch_11,"Although many patients have abnormal clotting tests, it is usually only necessary to treat those patients who are actively bleeding or require surgical intervention.","Occasionally, a fibrinolytic inhibitor (exempli gratia tranexamic acid) may be used if diffuse bleeding is due to excessive fibrinolysis, but it also potentially predisposes to thrombosis or excessive fibrin deposition, which could impair organ function (exempli gratia induce renal failure). For patients with thrombosis, anticoagulants may be considered after evaluation for potential sites of vascular bleeding, such as varices. The older drugs, heparin and warfarin, require close monitoring, are difficult to control and often provoke bleeding. Newer oral agents such as rivaroxaban, apixaban and dabigatran, act independently of antithrombin and do not require monitoring, but are not readily reversible. Experience with these agents in patients with liver disease is limited.",178,27,0.15168539325842698
9781908541406,ch_11,Dialysis reduces the hemorrhagic risk.,"The bleeding observed in patients with renal failure, usually bruising and gastrointestinal hemorrhage, is generally attributed to defects in platelet adhesion and aggregation. It is intensified by concomitant morbidities such as anemia and hypertension, as well as the use of antithrombotic medications. Dialysis substantially reduces the risk of bleeding and is the mainstay of management to keep the hemorrhagic risk under control.",82,8,0.0975609756097561
9781908541406,ch_11,Correction of anemia in the short term by red cell transfusion or in the long term with regular erythropoietin injections reduces the risk of bleeding.,"Correction of anemia. Together with dialysis, correction of anemia is a mainstay of treatment to reduce the hemorrhagic risk. Regular red cell transfusions are effective in controlling hemostasis, but the accumulation of iron and the risk of acquiring infection make this approach unattractive. Recombinant erythropoietin raises the hematocrit effectively, but the dose needs to be carefully titrated because of the risk of stroke and other adverse events. It is recommended that treatment with erythropoietin be considered only if the hemoglobin is below 10 g/dL, and specifically with the goal of controlling bleeding and avoiding transfusions.",133,33,0.24812030075187969
9781908541406,ch_12,"Before attributing a platelet count of 100 x 10 /L or less to the benign condition of gestational thrombocytopenia of pregnancy, other causes of a reduced platelet count should be excluded.","The platelet count declines by 10% in pregnancy, partly as a result of the increase in plasma volume. Gestational thrombocytopenia. Although the platelet count declines in normal pregnancy, a fall below the lower limit of normal (150 x 10 /L) is uncommon. In about 10% of normal pregnancies, however, it falls to 100-150 x 10 /L without any coagulation disturbance or presence of other illness. This gestational or 'benign' thrombocytopenia of pregnancy is of unknown etiology and is of no clinical consequence. Babies born to mothers with this disorder have normal platelet counts. It is an entirely benign condition and the skill is to exclude other causes of thrombocytopenia and make a positive diagnosis. It is usually necessary to monitor the platelet count, because if it falls below 100 x 10 /L the diagnosis must be reviewed.",191,44,0.23036649214659685
9781908541406,ch_12,"In pregnancy, it is important to be aware of the complications that may be associated with severe coagulation disturbance (exempli gratia pregnancy-associated hypertension) and to monitor the blood count and coagulation screen in these patients.","Primary immune thrombocytopenia (previously known as idiopathic thrombocytopenic purpura) is a relatively common cause of isolated thrombocytopenia due to the presence of an antiplatelet antibody in the plasma (see Chapter 4). It is usually diagnosed by excluding other causes of a reduced platelet count (exempli gratia disseminated intravascular coagulation [DIC]). Pre-existing primary immune thrombocytopenia may be exacerbated during pregnancy, and the platelet count declines further to a level at which specific treatment may be required. The condition may also first present in pregnancy with a platelet count of less than 100 x 10 /L on routine blood examination, or with bleeding symptoms, which usually only occur when the platelet count is less than 20 x 10 /L. As in the non-pregnant state, it is important to exclude other causes of thrombocytopenia (see Chapter 4) and, in particular, to ensure that the patient does not have a primary bone marrow disorder (exempli gratia acute leukemia).",234,48,0.20512820512820512
9781908541406,ch_12,"In primary immune thrombocytopenia, the platelet count tends to fall as pregnancy progresses and treatment may be necessary to maintain it above about 50 x 10 /L. After delivery, the platelet count in the neonate should be monitored for about a week as it can fall profoundly in the first few days of life.","Primary immune thrombocytopenia (previously known as idiopathic thrombocytopenic purpura) is a relatively common cause of isolated thrombocytopenia due to the presence of an antiplatelet antibody in the plasma (see Chapter 4). It is usually diagnosed by excluding other causes of a reduced platelet count (exempli gratia disseminated intravascular coagulation [DIC]). Pre-existing primary immune thrombocytopenia may be exacerbated during pregnancy, and the platelet count declines further to a level at which specific treatment may be required. The condition may also first present in pregnancy with a platelet count of less than 100 x 10 /L on routine blood examination, or with bleeding symptoms, which usually only occur when the platelet count is less than 20 x 10 /L. As in the non-pregnant state, it is important to exclude other causes of thrombocytopenia (see Chapter 4) and, in particular, to ensure that the patient does not have a primary bone marrow disorder (exempli gratia acute leukemia). If the platelet count falls below about 30 x 10 /L, prednisone (prednisolone), 0.5-1.0 mg/kg/day, should be started and the response monitored. It may be necessary to increase the dose or give intravenous immunoglobulin, 0.4 g/kg/day for 5 days or 1 g/kg/day for 2 days, to maintain the platelet count above 30 x 10 /L.",330,68,0.20606060606060606
9781908541406,ch_13,A carefully taken history is the best screening test for a coagulation disorder.,"Nothing makes a surgeon happier than the knowledge that a patient does not have a bleeding tendency. Many laboratory tests have been developed to provide the surgeon with that assurance, but unfortunately none is as reliable as a carefully taken medical history. The normal hemostatic mechanism and routine assessment tests are discussed in Chapter 2; however, a normal coagulation screen does not exclude a bleeding disorder.",76,16,0.21052631578947367
9781908541406,ch_13,Thromboelastography may be useful in patients with massive bleeding.,"Laboratory testing should mainly be used to investigate clinical suspicions. If the history and physical examination do not suggest a bleeding disorder, laboratory studies are unlikely to be helpful. Often, extensive laboratory testing yields borderline abnormalities that do not predict bleeding and merely waste time. On the other hand, laboratory tests may be normal in patients with a clear history of previous bleeding; usually these patients have excessive surgical blood loss despite the normal tests. It is only when the history and the laboratory tests are congruent that an accurate diagnosis can be established, and appropriate measures implemented to avoid perioperative bleeding.",117,15,0.1282051282051282
9781908541406,ch_13,"If a bleeding tendency is suspected, the platelet function analyzer-100 test, the activated partial thromboplastin time (aPTT) and the prothrombin time (PT) may identify the cause.","Patients with a history of bleeding after surgery or trauma may have hemophilia or liver disease, which can be diagnosed by measuring the activated partial thromboplastin time (aPTT) and prothrombin time (PT) (Table 11.2). If the patient has a strong history suggestive of a bleeding disorder but normal screening tests, specific clotting factor levels should be measured or more detailed tests of platelet function performed. A prolonged aPTT with a normal PT is usually observed in patients receiving heparin, or when heparin contaminates a line being used for blood sampling. The presence of heparin may be readily suspected if the patient has a prolonged PT but a normal Reptilase time. Reptilase is a snake venom that clots fibrinogen and is not affected by heparin. Heparin may be inactivated by adding heparinase, Hepzyme (a commercially available enzyme that cleaves heparin) or protamine sulfate to the sample. A repeat aPTT will be normal if heparin is the culprit. In the absence of heparin, a prolonged aPTT with a normal PT indicates either hemophilia or a circulating anticoagulant. A mixing test (mixing equal volumes of the patient's plasma with normal plasma and determining the aPTT again) will exclude circulating anticoagulant. If the prolonged aPTT is due to a clotting factor deficiency, the aPTT should be corrected by the normal plasma to within 4 seconds of a simultaneously run control of normal plasma and buffer; otherwise a circulating anticoagulant should be suspected (see Chapter 13). Deficiencies of factor (F)VIII, FIX and FXI are associated with bleeding (see Chapters 6 and). Deficiencies of FXII, prekallikrein and high-molecular-weight kininogen are not associated with bleeding, even though the aPTT is prolonged.",410,47,0.11463414634146342
9781908541406,ch_13,Consider vitamin K therapy in every postoperative patient with a prolonged prothrombin time.,"A prolonged PT generally occurs with vitamin K deficiency, warfarin therapy or liver disease. Vitamin K deficiency occurs in individuals with extremely limited diets, fat malabsorption due to biliary tract obstruction, or pancreatic or intestinal disease. Administration of vitamin K, 5 mg by mouth, will correct the PT within 24 hours if the abnormal clotting is due to nutritional deficiency of the vitamin. If malabsorption is suspected parenteral vitamin K should be given. However, a prolonged PT in patients with hepatocellular liver disease will not be corrected by vitamin K supplementation. Patients with liver impairment have a complex coagulopathy, which includes low levels of clotting factors, defects in platelet function and abnormal fibrinolysis (see Chapter 9). Lastly, a high hematocrit, as in polycythemia, artifactually prolongs the clotting times, because the decreased volume of plasma in such samples results in a relative excess of citrate in the sample collection tube.",203,18,0.08866995073891626
9781908541406,ch_13,"The management of surgical bleeding includes meticulous local hemostatic measures, as well as replacement of red cells, fibrinogen and platelets.","Most surgical bleeding is due to local factors such as highly vascular tissues, anastomotic leaks, slipped ligatures or other technical problems, and poor wound healing. However, deficiencies or defects in circulating clotting factors may contribute. For example, oozing at the surgical site suggests impaired platelet function. This may be due to the use of a drug, such as the platelet inhibitor clopidogrel, taken before surgery and not discontinued until at least 10 to 14 days before the operation. It might also be due to postoperative analgesics such as ketorolac, an NSAID that inhibits platelet function. Very high intravenous doses of penicillin-type antibiotics, such as meticillin (methicillin) and carbenicillin, also impair platelet function. If packed red cells and plasma are given in large volumes, dilutional thrombocytopenia may occur, as these blood products lack platelets.",195,29,0.14871794871794872
9781908541406,ch_14,"Persistent oozing from venepuncture sites in a septic patient, or massive vaginal bleeding in an obstetric patient, suggests disseminated intravascular coagulation (DIC).","Bleeding is characteristic of acute DIC, and is often a persistent oozing from wounds or incisions. For example, the sudden appearance of wound bleeding in a patient receiving an intraoperative blood transfusion may suggest an acute hemolytic transfusion reaction and DIC. Other types of bleeding encountered include ecchymoses, epistaxis and hemorrhage from the gastrointestinal and genitourinary tracts. In patients with obstetric DIC, persistent uterine hemorrhage is often observed. Thrombosis generally occurs in chronic DIC, and may take the form of recurrent episodes of deep vein thrombosis or pulmonary emboli. Septic patients often develop purpura fulminans, a form of microvascular thrombosis affecting skin and extremities. Non-bacterial thrombotic endocarditis is a feature of the thrombophilia associated with malignancy.",184,38,0.20652173913043478
9781908541406,ch_14,"Hypofibrinogenemia usually indicates acute DIC, but the fibrinogen level is often normal or elevated in chronic DIC and it is not a reliable marker of the condition.","In many disorders that induce DIC, tissue-factor-bearing microparticles are released from the surface of monocytes, macrophages and endothelial cells. The consequence of this extensive exposure to tissue factor is a profound activation of coagulation and the generation of large amounts of thrombin (see Chapter 1). Thrombin promotes platelet activation and the platelet aggregates occlude the microvasculature. The consumption of platelets accounts for the thrombocytopenia that is typical of DIC. Thrombin activates factor (F)V and FVIII, and converts fibrinogen to fibrin, resulting in the depletion of these proteins and accounting for the prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) typical of acute DIC. Thrombin becomes bound to antithrombin and thrombomodulin, and these proteins are soon consumed. Following binding to thrombomodulin, thrombin activates the anticoagulant protein C, which also becomes depleted, predisposing to microvascular thrombosis. As part of the acute inflammatory reaction, raised levels of the C4B-binding protein result in the binding of more free protein S, and therefore render it unavailable as a cofactor of the anticoagulant protein C.",285,39,0.1368421052631579
9781908541406,ch_14,A DIC score >= 5 is indicative of overt DIC.,"A scoring system for the diagnosis of overt DIC has been developed by the DIC Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH), and is shown in Table 12.2; there is a second scoring system for non-overt DIC that includes measurements of antithrombin and protein C, as well as molecular markers of coagulation activation.",81,13,0.16049382716049382
9781908541406,ch_14,Treatment is directed toward the underlying cause of DIC; bleeding is controlled with cryoprecipitate and platelet infusions.,"A scoring system for the diagnosis of overt DIC has been developed by the DIC Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH), and is shown in Table 12.2; there is a second scoring system for non-overt DIC that includes measurements of antithrombin and protein C, as well as molecular markers of coagulation activation. Acute disseminated intravascular coagulation. The treatment of acute DIC is primarily directed toward the underlying cause. Antibiotics should be given for sepsis, volume expanders for shock and oxygen for hypoxia; evacuation of the uterus should be performed for obstetric accidents. Patients with acute DIC may have profound bleeding, usually because of hypofibrinogenemia. Table 12.3 lists agents used for the management of bleeding in such patients.",177,27,0.15254237288135594
9781908541406,ch_15,Pharmacological anticoagulants,"Anticoagulants and antithrombotic agents. A bleeding state may arise either because the patient develops a spontaneous pathological anticoagulant (often an antibody against one of the clotting factors) or, much more commonly, from therapy with an anticoagulant or antithrombotic drug.",66,8,0.12121212121212122
9781908541406,ch_15,Pathological anticoagulants,"Pathological anticoagulants. There are two main types of pathological anticoagulants (so-named because they prolong clotting times in vitro): those directed against a specific clotting factor; and those directed against phospholipid-binding proteins. The former are associated with bleeding and the latter with thrombosis. Almost all of these anticoagulants are antibodies, and most are considered to be autoimmune in origin.",91,7,0.07692307692307693
9781908541406,ch_15,Thrombolytic agents,"thrombolytic agents (streptokinase, urokinase, tissue plasminogen activator [tPA]).",28,6,0.21428571428571427
9781908541406,ch_15,"Serious bleeding associated with acetylsalicylic acid (aspirin) and other non-steroidal anti-inflammatory agents may be controlled by platelet transfusion and, if minor but troublesome, with desmopressin.","Inhibitors of platelet function. ASA (aspirin) and other non-steroidal anti-inflammatory drugs (NSAIDs) alter platelet function by inhibiting both cyclooxygenase-1 and -2. This results in impaired generation of thromboxane A and prostacyclin. Because thromboxane is a major inducer of platelet aggregation and vasoconstriction, treatment with ASA (aspirin) and NSAIDs inhibits platelet function. A meta-analysis of 287 studies involving 135 000 patients showed that antiplatelet therapy reduced the risk of having a recurrence of heart attack, stroke or peripheral arterial occlusion by at least 25%. Drugs used for the treatment of ischemic vascular disease are shown in Table 13.5. Bleeding risk. In the US National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES; 2007-2009), oral antiplatelet agents were implicated in 13.3% of more than 99 000 emergency hospitalizations. The regular use of ASA (aspirin) is associated with a twofold increase in the risk of upper gastrointestinal bleeding. In five large clinical trials comparing ASA (aspirin) with placebo, upper gastrointestinal bleeding increased from 1.1 (placebo) to 2.5 (ASA [aspirin]) major bleeds per 1000 patient-years, and the frequency of all bleeds was doubled. Therapy with other NSAIDs is also complicated by bleeding; some provoke more bleeding than others. For example, the risk with ibuprofen is 2.9, indometacin 6.3 and piroxicam 18.0. This risk may be modified by the concomitant use of proton pump inhibitors.",365,47,0.12876712328767123
9781908541406,ch_15,Thrombolytic agents are associated with a risk of intracranial hemorrhage of nearly 1%; they should be administered in intensive care units and stopped immediately if signs of bleeding appear.,"Bleeding risk. In the US National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES; 2007-2009), oral antiplatelet agents were implicated in 13.3% of more than 99 000 emergency hospitalizations. The regular use of ASA (aspirin) is associated with a twofold increase in the risk of upper gastrointestinal bleeding. In five large clinical trials comparing ASA (aspirin) with placebo, upper gastrointestinal bleeding increased from 1.1 (placebo) to 2.5 (ASA [aspirin]) major bleeds per 1000 patient-years, and the frequency of all bleeds was doubled. Therapy with other NSAIDs is also complicated by bleeding; some provoke more bleeding than others. For example, the risk with ibuprofen is 2.9, indometacin 6.3 and piroxicam 18.0. This risk may be modified by the concomitant use of proton pump inhibitors.",204,39,0.19117647058823528
9781908541406,ch_15,A pathological anticoagulant should be suspected when major unprovoked bleeding occurs in a previously well person.,"Bleeding risk. The risk of bleeding with coumarins is strongly related to the patient's vitamin K status. Patients on diets with a restricted vitamin K content, or those unable to eat because of recent surgery, neurological disease or other disorders, are very sensitive to even small doses of coumarins. In addition, those unable to absorb vitamin K because of diarrhea, biliary tract obstruction or malabsorption syndromes are at very high risk of bleeding, and coumarins should be administered cautiously. A prediction guide to assess the risk of warfarin-associated bleeding in patients with atrial fibrillation (ATRIA) weighs anemia and severe renal disease with 3 points each, age of 75 years and older with 2 points, and hypertension and past hemorrhage with 1 point each. A score of 3 or lower indicates low risk, and a score of 5 or more high risk. The event rates per 100 person-years in a cohort with 32 888 person-years of warfarin exposure were 0.76 for those with low scores and 5.8 for those with high scores, demonstrating good predictability for major hemorrhages.",233,23,0.09871244635193133
9781908541406,ch_15,"Coumarins should be used cautiously, if at all, in patients with poor oral intake.","Bleeding risk. The risk of bleeding with coumarins is strongly related to the patient's vitamin K status. Patients on diets with a restricted vitamin K content, or those unable to eat because of recent surgery, neurological disease or other disorders, are very sensitive to even small doses of coumarins. In addition, those unable to absorb vitamin K because of diarrhea, biliary tract obstruction or malabsorption syndromes are at very high risk of bleeding, and coumarins should be administered cautiously. A prediction guide to assess the risk of warfarin-associated bleeding in patients with atrial fibrillation (ATRIA) weighs anemia and severe renal disease with 3 points each, age of 75 years and older with 2 points, and hypertension and past hemorrhage with 1 point each. A score of 3 or lower indicates low risk, and a score of 5 or more high risk. The event rates per 100 person-years in a cohort with 32 888 person-years of warfarin exposure were 0.76 for those with low scores and 5.8 for those with high scores, demonstrating good predictability for major hemorrhages.",233,20,0.08583690987124463
9781908541406,ch_15,"The direct factor Xa and thrombin inhibitors currently available do not have specific antidotes and should be used cautiously in patients at risk for bleeding (those with renal failure, liver disease, previous stroke or history of hemorrhage).","Bleeding risk. The risk of bleeding with coumarins is strongly related to the patient's vitamin K status. Patients on diets with a restricted vitamin K content, or those unable to eat because of recent surgery, neurological disease or other disorders, are very sensitive to even small doses of coumarins. In addition, those unable to absorb vitamin K because of diarrhea, biliary tract obstruction or malabsorption syndromes are at very high risk of bleeding, and coumarins should be administered cautiously. A prediction guide to assess the risk of warfarin-associated bleeding in patients with atrial fibrillation (ATRIA) weighs anemia and severe renal disease with 3 points each, age of 75 years and older with 2 points, and hypertension and past hemorrhage with 1 point each. A score of 3 or lower indicates low risk, and a score of 5 or more high risk. The event rates per 100 person-years in a cohort with 32 888 person-years of warfarin exposure were 0.76 for those with low scores and 5.8 for those with high scores, demonstrating good predictability for major hemorrhages.",233,46,0.19742489270386265
9781908541406,ch_15,A decline in hemoglobin in a patient receiving an anticoagulant should prompt an exhaustive search for a source of bleeding.,"Streptokinase and urokinase activate both free and fibrin-bound plasminogen, while tPA mainly activates fibrin-bound plasminogen. Unfortunately, the expectation that tPA would be associated with less bleeding has not been borne out by clinical practice. A meta-analysis demonstrated bleeding complications in 29% of patients receiving streptokinase, 15% receiving tPA and 10% receiving urokinase. In another study of patients with myocardial infarction treated with tPA, the incidence of intracranial bleeding was 0.95%; 53% died during hospitalization and another 25% had residual neurological deficits. A study that compared tPA with streptokinase showed more strokes in the tPA group (1.33% vs 0.94%). The major risk factors for bleeding are older age, systolic blood pressure above 140 mmHg and history of stroke. Any interruption of vascular integrity may lead to hemorrhage; for example, placement of a femoral sheath for catheter insertion or a venepuncture to obtain blood samples. Spontaneous bleeding from the gastrointestinal tract or into the retroperitoneum also occurs, but the main concern is the unpredictability of intracranial bleeding.",259,26,0.10038610038610038
9781908541420,ch_3,"Asthma is a chronic inflammatory condition of the conducting airways. It is characterized by recurrent episodes of airflow limitation which, depending on the severity of the attack, can cause breathlessness, wheezing, chest tightness, cough and, rarely, death","Asthma is a chronic inflammatory condition of the airways. It is characterized by recurrent episodes of airflow limitation which, depending on the severity of the attack, produce symptoms such as breathlessness, wheezing, chest tightness and cough. Acute exacerbations can be rapid or gradual in onset, and may be severe and potentially life-threatening. Autopsy studies of patients who have died from asthma show hyperinflated lungs, with both large and small airways blocked by plugs containing a mixture of mucus, serum proteins, inflammatory cells and cell debris. Microscopic examination reveals extensive inflammatory infiltration of the airways (Figure 1.1), with edema due to vasodilatation and blood vessel engorgement, and epithelial disruption. Biopsy studies have shown increased numbers of leukocytes, particularly eosinophils, mast cells and T lymphocytes, in the airways together with increases in the markers of lymphocyte activation. Structural changes resulting from chronic inflammation include bronchial smooth muscle hypertrophy and hyperplasia, new vessel formation, interstitial matrix deposition resulting in basement membrane thickening, and airway wall remodeling.",237,51,0.21518987341772153
9781908541420,ch_3,"The structural abnormalities in asthma include thickened basement membrane, mucus hypersecretion, smooth muscle hypertrophy, and mast cells within the airway smooth muscle.","The IgE produced by the stimulated B lymphocytes binds to mast cells and, possibly, other cells involved in inflammation (exempli gratia eosinophils), leading to the release of inflammatory mediators. Antigens can also provoke T-cell activation, cytokine and chemokine release, and production of inflammatory mediators. A characteristic finding in asthma, reported only recently, is the presence of mast cells distributed within airway smooth muscle. Moreover, in contrast to the mast cells in the mucosa, which are T-cell-dependent and enriched for the granule enzyme tryptase (MC T), the mast cells in smooth muscle are of the connective-tissue type, enriched in chymase as well as tryptase (MC TC). Stimulation of mast cells through IgE-antigen binding or other mechanism results in the release of these mediators together with histamine, and newly generated bronchoconstrictors such as prostaglandin D and cysteinyl leukotrienes LTC and LTD. As asthma becomes more severe, the number of MC TC increases in the mucosa at the expense of MC T. This may be important as MC TC are more dependent on stem cell factor (ckit ligand) from mesenchymal and epithelial cells and less responsive to Th2 cytokines and programmed cell death induced by corticosteroids.",287,33,0.11498257839721254
9781908541420,ch_3,"Airway inflammation in people with asthma is not uniform: in most it is eosinophil predominant, but in others neutrophil cell types predominate.","The IgE produced by the stimulated B lymphocytes binds to mast cells and, possibly, other cells involved in inflammation (exempli gratia eosinophils), leading to the release of inflammatory mediators. Antigens can also provoke T-cell activation, cytokine and chemokine release, and production of inflammatory mediators. A characteristic finding in asthma, reported only recently, is the presence of mast cells distributed within airway smooth muscle. Moreover, in contrast to the mast cells in the mucosa, which are T-cell-dependent and enriched for the granule enzyme tryptase (MC T), the mast cells in smooth muscle are of the connective-tissue type, enriched in chymase as well as tryptase (MC TC). Stimulation of mast cells through IgE-antigen binding or other mechanism results in the release of these mediators together with histamine, and newly generated bronchoconstrictors such as prostaglandin D and cysteinyl leukotrienes LTC and LTD. As asthma becomes more severe, the number of MC TC increases in the mucosa at the expense of MC T. This may be important as MC TC are more dependent on stem cell factor (ckit ligand) from mesenchymal and epithelial cells and less responsive to Th2 cytokines and programmed cell death induced by corticosteroids.",287,34,0.11846689895470383
9781908541420,ch_3,Structural changes also occur in the airways; these are particularly evident in those with severe and chronic asthma.,"However, the inflammatory cell profile in the airways defines other disease subtypes such as neutrophilic and paucigranulocytic (in which there is a normal cellular profile). Such patients tend to express lower levels of epithelial and sputum cell Th2 genes and have fewer corticosteroid-responsive cytokine inflammatory pathways; the non-eosinophilic inflammatory pathways are associated with relative corticosteroid resistance. In individual cases, the definition of the asthmatic inflammatory phenotype is being used to guide therapy and has shown effectiveness in reducing exacerbations. Such stratification of asthma, particularly in those with more severe disease, has implications for targeting therapy to those most responsive.",142,22,0.15492957746478872
9781908541420,ch_3,"Genetic factors determine susceptibility to environmental factors, and it is the interaction between these that leads to clinical disease.","Genetics. Clearly, genetic influences can modify the risk of an individual developing atopy and asthma. While no single gene has been identified as being causative for asthma, several genetic loci have been associated with increased asthma risk, particularly in certain environments resulting in a gene-environment interaction. It is likely that several of these may work synergistically to cause asthma in individuals exposed to appropriate environmental factors. In particular, variants of the genes ADAM33, PHF11, HLA-G, NPSR1 (also known as GPRA and GPR154), IRAK3 (also known as IRAK-M), HLA-DQ, YKL-40 (also known as CHI3L1), ORMDL3, GSDMB, SMAD3 and IL33 are associated with an increased risk of asthma. However, it is important to recognize that each genetic variant contributes only a small amount to the asthma phenotype, with complex gene-gene and gene-environment interactions being involved.",207,22,0.10628019323671498
9781908541420,ch_3,The most prominent risk factors are allergen exposure in genetically susceptible individuals and maternal cigarette smoking.,"Causal factors. The relevance of different causes of asthma depends on individual exposure and when it occurs. In early childhood, inhaled allergens and infection appear to be important causal factors for asthma. In adults, cigarette smoking and exposure to occupational allergens are more likely to be important causal factors. Inhaled allergens. Common indoor sources of inhaled allergens include domestic mites, cats, dogs and fungi. Outdoor pollens from grasses, trees and wind-pollinated weeds are also common inhaled allergens. Allergen exposure leads to the activation of specific T lymphocytes and the production of specific IgE by B lymphocytes, which sensitizes the individual to subsequent exposure. There is a strong correlation between the prevalence of asthma and long-term exposure to allergen, and asthma often improves when the allergen is removed, although this is not always feasible.",180,19,0.10555555555555556
9781908541420,ch_4,Asthma is one of the most common chronic diseases worldwide. The highest prevalence is seen in affluent westernized populations.,"Asthma is one of the most common chronic diseases worldwide. The reported prevalence depends on the definition of asthma used, whether relying on self-report of symptoms, or whether these are further validated by lung function testing or doctor diagnosis. The prevalence of asthma also depends on the age, geographic region and socioeconomic status of the population studied, and the study design. Several large international trials have studied asthma prevalence in adults and children. Childhood. The International Study of Asthma and Allergies in Childhood (ISAAC) has provided cross-sectional data from many global sites since 1993, with the most recent survey in 2003. In this study, the prevalence of asthma in populations of children aged 13-14 years and 6-7 years is, on average, 13.7% and 11.6%, respectively. However, in some nations, particularly in high-income countries, prevalence in the 13-14 years age group exceeds 20%, indicating very large regional differences in asthma prevalence (Figure 2.1). Studies have consistently shown that the prevalence of asthma increased worldwide through the 1980s and 1990s. However, in countries with a very high prevalence of asthma historically, particularly English-speaking countries, the rates have stabilized or are even falling. In contrast, the prevalence in developing countries appears to be increasing, particularly in some parts of Asia, Africa and South America.",273,23,0.08424908424908426
9781908541420,ch_4,"In many countries asthma, along with other allergic disorders, continues to increase in prevalence, especially in children and young adults.","Childhood. The International Study of Asthma and Allergies in Childhood (ISAAC) has provided cross-sectional data from many global sites since 1993, with the most recent survey in 2003. In this study, the prevalence of asthma in populations of children aged 13-14 years and 6-7 years is, on average, 13.7% and 11.6%, respectively. However, in some nations, particularly in high-income countries, prevalence in the 13-14 years age group exceeds 20%, indicating very large regional differences in asthma prevalence (Figure 2.1). Studies have consistently shown that the prevalence of asthma increased worldwide through the 1980s and 1990s. However, in countries with a very high prevalence of asthma historically, particularly English-speaking countries, the rates have stabilized or are even falling. In contrast, the prevalence in developing countries appears to be increasing, particularly in some parts of Asia, Africa and South America.",189,24,0.12698412698412698
9781908541420,ch_4,Death from asthma reflects poor access to healthcare in many countries.,"Asthma death rates not only vary between nations but have also fluctuated over time. In many countries, a marked increase in asthma deaths occurred in the 1960s, after which mortality decreased. In the UK, the mortality rate increased slightly during the 1980s, but the most recent data indicate that death rates are now falling. The greatest increase in mortality during the late 1970s and 1980s was seen in New Zealand (Figure 2.5). The reasons for this are unclear; the use of high doses of short-acting beta -agonists (SABAs), especially high-dose fenoterolin, has been associated with the increased mortality, but the evidence is inconclusive. Ethnic and socioeconomic factors may be at least partly responsible. In New Zealand, a large proportion of the increased mortality occurred in Maoris, and during the same period a similar increase occurred among black Americans living in inner-city areas of the USA. Studies of asthma deaths during this time suggested that a majority were preventable with the best available current treatment, and that factors such as poor access to healthcare may have been partly responsible. In countries that have introduced effective guidelines for asthma management (exempli gratia UK, Australia and Scandinavian countries), mortality has declined and is now reasonably stable.",254,12,0.047244094488188976
9781908541420,ch_4,"Asthma can occur at any time in life, although it most commonly develops in infancy and childhood.","Asthma can occur at any time in life, although it most commonly develops in infancy and childhood. The natural history of the condition varies according to the age at onset, and possibly according to the causative factors. Infancy (0-3 years). Wheezing is common in the early years of life and recent studies have enabled the identification of several distinct phenotypes. The most common are.",80,20,0.25
9781908541420,ch_4,"There is evidence that early life events, including those that occur in the womb, may be important in the initiation of childhood asthma in those genetically at risk.","Lung growth is relatively normal in most children with mild asthma, but may be reduced in children with severe persistent symptoms. This is important - long-term studies show that, although asthma disappears in 30-50% of children during puberty, it often recurs in adulthood. Furthermore, lung function often remains impaired even when clinical signs of asthma have disappeared, and 5-10% of children with mild asthma develop severe asthma later in life. In general, children with mild asthma are likely to have a good prognosis, but those with moderate or severe asthma are more likely to show some degree of bronchial hyperresponsiveness and to be at risk for the persistence of asthma and progressive decline in lung function throughout life. Although counterintuitive based on the inflammatory concept of asthma, there is no evidence that regular use of powerful inhaled corticosteroids in early life alters the natural history of asthma even though these drugs are highly effective in disease control, and reduce the burden of symptoms and exacerbations. There is evidence that eczema is a major risk for the persistence of childhood asthma into adult life. As both diseases have defects in barrier function, a causative link is implied, possibly through an enhanced opportunity for allergens to penetrate and sensitize.",251,31,0.12350597609561753
9781908541420,ch_4,"Although asthma disappears in 30-50% of children during puberty, it often recurs in adulthood.","Lung growth is relatively normal in most children with mild asthma, but may be reduced in children with severe persistent symptoms. This is important - long-term studies show that, although asthma disappears in 30-50% of children during puberty, it often recurs in adulthood. Furthermore, lung function often remains impaired even when clinical signs of asthma have disappeared, and 5-10% of children with mild asthma develop severe asthma later in life. In general, children with mild asthma are likely to have a good prognosis, but those with moderate or severe asthma are more likely to show some degree of bronchial hyperresponsiveness and to be at risk for the persistence of asthma and progressive decline in lung function throughout life.",144,20,0.1388888888888889
9781908541420,ch_4,"There is no evidence that regular use of corticosteroids in early life alters the natural history of asthma, though these medications are highly effective in disease control.","Lung growth is relatively normal in most children with mild asthma, but may be reduced in children with severe persistent symptoms. This is important - long-term studies show that, although asthma disappears in 30-50% of children during puberty, it often recurs in adulthood. Furthermore, lung function often remains impaired even when clinical signs of asthma have disappeared, and 5-10% of children with mild asthma develop severe asthma later in life. In general, children with mild asthma are likely to have a good prognosis, but those with moderate or severe asthma are more likely to show some degree of bronchial hyperresponsiveness and to be at risk for the persistence of asthma and progressive decline in lung function throughout life. Although counterintuitive based on the inflammatory concept of asthma, there is no evidence that regular use of powerful inhaled corticosteroids in early life alters the natural history of asthma even though these drugs are highly effective in disease control, and reduce the burden of symptoms and exacerbations. There is evidence that eczema is a major risk for the persistence of childhood asthma into adult life. As both diseases have defects in barrier function, a causative link is implied, possibly through an enhanced opportunity for allergens to penetrate and sensitize.",251,32,0.12749003984063745
9781908541420,ch_5,"The clinical diagnosis of asthma is often based on the presence of symptoms, such as breathlessness (often episodic), wheezing, chest tightness and coughing.","Diagnosis and classification. Although asthma is one of the most common chronic disorders it is often underdiagnosed, especially in older people. Because of the intermittent and non-specific nature of symptoms, patients may accept the effects of their condition and delay seeking treatment. They may also be incorrectly diagnosed when they do seek medical advice: asthma is often misdiagnosed as bronchitis or 'wheezy' bronchitis, particularly in children and the elderly, and is treated inappropriately with antibiotics. An accurate diagnosis is essential for effective asthma control. The clinical diagnosis of asthma is often based on the presence of symptoms such as. breathlessness - often episodic.",134,33,0.2462686567164179
9781908541420,ch_5,"Although asthma is one of the most common chronic disorders, it is often underdiagnosed or misdiagnosed.","Although asthma is one of the most common chronic disorders it is often underdiagnosed, especially in older people. Because of the intermittent and non-specific nature of symptoms, patients may accept the effects of their condition and delay seeking treatment. They may also be incorrectly diagnosed when they do seek medical advice: asthma is often misdiagnosed as bronchitis or 'wheezy' bronchitis, particularly in children and the elderly, and is treated inappropriately with antibiotics. An accurate diagnosis is essential for effective asthma control.",104,22,0.21153846153846154
9781908541420,ch_5,Measurement of bronchial responsiveness and allergy status can aid diagnosis as well as identify possible exacerbating factors.,"Measurement of bronchial responsiveness can be useful in the diagnosis of asthma, although there is some overlap between the range of values found in patients with asthma and in those with rhinitis or other causes of lower airway obstruction, such as chronic obstructive pulmonary disease (COPD). The most usual tests are performed in a lung function laboratory and involve the patient inhaling incremental doses of a bronchoconstricting substance, such as histamine, methacholine, hypertonic saline, adenosine 5'-monophosphate (AMP) or mannitol. Tests using the last three measure 'indirect' bronchial responsiveness and take into account the inflammatory cell priming that is a crucial component of the disease. These tests are said to be more specific as diagnostic tools. Whichever agonist is applied, spirometry is used to follow the changes in airway caliber. Airway responsiveness is usually defined as that dose (D) or concentration (C) of the agonist that reduces the FEV by 20% of the starting volume (id est PD20 or PC20). A standardized exercise test has also found use, especially in young children with suspected asthma.",241,22,0.0912863070539419
9781908541420,ch_5,"A key feature is variation of symptoms over time, especially diurnal variation.","The most usual tests are performed in a lung function laboratory and involve the patient inhaling incremental doses of a bronchoconstricting substance, such as histamine, methacholine, hypertonic saline, adenosine 5'-monophosphate (AMP) or mannitol. Tests using the last three measure 'indirect' bronchial responsiveness and take into account the inflammatory cell priming that is a crucial component of the disease. These tests are said to be more specific as diagnostic tools. Whichever agonist is applied, spirometry is used to follow the changes in airway caliber. Airway responsiveness is usually defined as that dose (D) or concentration (C) of the agonist that reduces the FEV by 20% of the starting volume (id est PD20 or PC20). A standardized exercise test has also found use, especially in young children with suspected asthma.",182,15,0.08241758241758242
9781908541420,ch_5,Attempts should be made to assess disease control to guide treatment.,"Skin-prick tests with allergens or detection of allergen-specific immunoglobulin (Ig)E in the circulation are the most common diagnostic tests for allergy. For the diagnosis of asthma, the results should always be interpreted in relation to the patient's history and the relationship between asthma symptoms and allergen exposure, because up to 45% of the population may exhibit atopy but only a proportion of these individuals will have asthma. Nevertheless, the identification of allergens that may be contributing to persistent asthma and exacerbations is important in order to provide advice on allergen avoidance or other treatment strategies. New molecular-level characterization of IgE specificity to a large number of allergens in a single test is an exciting new diagnostic development. However, a positive response to any single allergen must be interpreted in the clinical context and not in isolation.",175,12,0.06857142857142857
9781908541420,ch_5,"The diagnosis of asthma may be difficult in certain patient groups, particularly those who smoke and the very young or old.","The diagnosis of asthma may be difficult in certain patient groups, especially smokers and the extremely young or old, who may have difficulty performing lung function tests. Individuals with other lung disease may also provide a mixed pattern on spirometry testing. Infants may have recurrent wheezing due to acute viral respiratory infections; the first episode of wheezing in infants under the age of 6 months is usually due to viral bronchiolitis, whereas asthma is more likely to be the cause of wheezing after 18 months of age. After a viral infection, symptoms may persist in children with atopic asthma and a positive interaction between virus infection and sensitization to aeroallergens has been shown in genetically susceptible children. Similarly, older children may show asthma symptoms in association with viral infections (exacerbation) or exercise; asthma should be considered if the child has a persistent nocturnal cough, or if colds go to the chest easily or take longer than 10 days to resolve.",197,23,0.116751269035533
9781908541420,ch_5,Objective measures of lung function are important in order to establish asthma as a diagnosis and to assess response to treatment.,"A combination of symptom measurements and lung function tests can be used to classify asthma according to its severity (Figure 3.5). These clinical measures of disease severity have been shown to correlate well with pathological markers of airway inflammation such as eosinophil numbers. However, classification of asthma by severity is not necessarily predictive of the amount or types of treatment required to achieve best asthma outcomes. Recent research using non-hierarchical and cluster approaches to diagnosis are identifying multiple disease phenotypes with varying inflammatory and cytokine profiles and differing physiological features, responses to treatment and natural histories. This level of complexity has yet to translate into treatment strategies, leaving us with treatment algorithms based on asthma control: an assessment of daytime and night-time symptoms, limitation of activities, the need for rescue reliever therapy, lung function, and exacerbation frequency and severity (see Chapter 4).",174,23,0.13218390804597702
9781908541420,ch_6,Controllers (exempli gratia inhaled corticosteroids) are the mainstay of asthma therapy. Increased use of relievers (short-acting beta -agonists) indicates inadequate disease control.,"Inhaled corticosteroids, such as beclometasone (beclomethasone) dipropionate, budesonide, fluticasone propionate, mometasone, fluticasone furoate and ciclesonide, are the most effective anti-inflammatory agents currently available for asthma management. They are the mainstay of effective asthma treatment, improving symptoms and preventing exacerbations, and their use is associated with protection from asthma deaths. Studies have consistently shown that these agents reduce pathological signs of airway inflammation, so that lung function and symptoms improve, bronchial hyperresponsiveness decreases, and the frequency and severity of exacerbations are reduced. Corticosteroids interrupt the signaling pathways for pro-inflammatory molecules by decreasing the expression of genes for a variety of inflammatory mediators and by increasing the expression of genes for anti-inflammatory mediators.",181,41,0.2265193370165746
9781908541420,ch_6,Drugs used in the management of asthma can be classified as controllers (preventers) or relievers: controllers are taken daily on a long-term basis to control persistent asthma; relievers are used to rapidly reverse the bronchoconstriction and associated symptoms during acute attacks.,"Relievers (sometimes referred to as rescue medication) are used to rapidly reverse the bronchoconstriction and associated symptoms during acute attacks (see Table 4.2). They include SABAs, LABAs with a rapid onset of action, short-acting theophylline and short-acting anticholinergic agents. The most effective forms are those that are delivered by inhalation directly to the airways. Short-acting beta -agonists. Inhaled SABAs, such as salbutamol and terbutaline, are used to control bronchoconstriction, and are the treatment of choice for the management of acute exacerbations and the prophylaxis of exercise-induced asthma. Oral preparations are also available and may be suitable for patients who are unable to use inhaled medication. In general, oral administration is less desirable than inhaled administration because systemic side effects such as tachycardia are more pronounced when the drug is delivered orally. Concern has been expressed over the long-term safety of repeatedly inhaling short-acting beta -bronchodilators. Several points are worth making in relation to the use of these quick relievers. They are certainly the best drugs for relieving acute bronchospasm and associated symptoms, but their increased use by a patient is a sign of worsening asthma and the need for greater use of controller (preventer) drugs. The use of one canister of a metered-dose inhaler per month should certainly sound alarm bells. Regular use of SABAs is not recommended, as a refractory response may develop, and it has been suggested that asthma may worsen. In addition, it is now known that genetic beta -adrenoceptor polymorphisms influence the effectiveness of these drugs, particularly with regard to tachyphylaxis or the development of refractoriness; therefore SABAs should only be used for quick relief on an 'as-required' basis.",398,57,0.14321608040201006
9781908541420,ch_6,Asthma therapy should be tailored to disease severity; current management guidelines recommend a stepwise approach to treatment.,"The second aim of asthma control is prevention of exacerbations. While achieving control of asthma symptoms is likely to lead to prevention of exacerbations in most, for some patients asthma exacerbations are the predominant feature of their asthma. As asthma exacerbations can be life-threatening and are inevitably disruptive to patients and their carers, in these instances prevention of exacerbations should be the major focus of treatment. Factors indicating a high risk for future exacerbations include a past history of severe or life-threatening asthma attack, exacerbation occurring despite adequate preventative treatment, impaired interval lung function and cigarette smoke exposure. Current management guidelines recommend a stepwise approach to asthma treatment, depending on disease control (Table 4.5), in both adults and children (Figure 4.6). All patients should aim to have well-controlled asthma, and treatment should be stepped up or down, as appropriate, every 1-3 months to achieve and maintain asthma control.",187,21,0.11229946524064172
9781908541420,ch_6,"If recommended treatment fails, adherence and diagnosis should be re-examined before treatment is escalated.","Recommended management strategies suggest five treatment steps. Patients should be started on therapy appropriate to the initial level of symptoms: step 2 is appropriate for most patients who are receiving no, or only as-needed, bronchodilator treatment for asthma, and step 3 is appropriate for those with more uncontrolled symptoms and reduced lung function at the start of treatment. Depending on symptom severity and the presence of exacerbations, treatment should be continued at a given level for 1-3 months before considering escalation or reduction. Generally, after 3 months of well-controlled asthma a step down to a lower level of treatment should be considered.",123,20,0.16260162601626016
9781908541420,ch_6,Any exacerbation should prompt a review of maintenance medications.,"Step 5. The highest level of treatment, step 5, involves the addition of oral corticosteroid treatment and/or anti-IgE therapy for patients with uncontrolled asthma despite the use of high-dose controller inhaled corticosteroids and LABAs. Such unresponsive asthma symptoms should prompt a consideration of the diagnosis of asthma and the exclusion of other factors that may be worsening asthma. It is also appropriate to seek specialist referral at this stage. Oral corticosteroids should be used at the lowest dose and for the minimum time required to gain asthma symptom control. Immunosuppressants such as methotrexate, cyclophosphamide, ciclosporin, tacrolimus and azathioprine are occasionally used as oral corticosteroid-sparing agents.",163,11,0.06748466257668712
9781908541420,ch_6,All patients with asthma should have a written asthma action plan.,"Written treatment plan. All patients with asthma should have a written plan that describes their current step of asthma treatment and advises on treatment adjustments to accommodate worsening asthma (see Chapter 6). For many patients, such a plan will also involve instructions to take oral corticosteroids or seek medical advice for prescription of oral corticosteroid treatment.",67,12,0.1791044776119403
9781908541420,ch_7,Refractory asthma is characterized by uncontrolled symptoms and/or frequent exacerbations despite maximal inhaled medication including high-dose inhaled corticosteroids and long-acting beta-agonists.,"Current therapies, particularly inhaled corticosteroids and long-acting bronchodilators, have excellent efficacy in controlling symptoms and preventing asthma exacerbations in nearly all people with asthma. In studies of asthma in the community, asthma symptoms are frequently poorly controlled, but this is most usually due to lack of availability of, or failure to take, recommended asthma controller therapies. However, not all patients achieve complete control of symptoms. For instance in a dose-escalation study using fluticasone dipropionate and salmeterol, only 72% of individuals achieved complete control of symptoms with high-dose inhaled therapy, although most of these had partially controlled asthma symptoms. However, some individuals with asthma suffer from severe symptoms or may have progressive loss of lung function, together with frequent exacerbations despite optimal inhaled therapy. These individuals are considered to have refractory asthma.",178,38,0.21348314606741572
9781908541420,ch_7,Refractory asthma is present in less than 5% of people with asthma.,"Current therapies, particularly inhaled corticosteroids and long-acting bronchodilators, have excellent efficacy in controlling symptoms and preventing asthma exacerbations in nearly all people with asthma. In studies of asthma in the community, asthma symptoms are frequently poorly controlled, but this is most usually due to lack of availability of, or failure to take, recommended asthma controller therapies. However, not all patients achieve complete control of symptoms. For instance in a dose-escalation study using fluticasone dipropionate and salmeterol, only 72% of individuals achieved complete control of symptoms with high-dose inhaled therapy, although most of these had partially controlled asthma symptoms.",137,16,0.11678832116788321
9781908541420,ch_7,The first step in assessing refractory asthma is to assess adherence to current treatment.,"Once medication is prescribed and acquired, patients then need to use their device effectively. Many people, especially the young and very old, find the manipulation of inhaled devices difficult. A major part of consultation with a patient who is not successful in achieving good asthma control should be a review of inhaler use and technique, as this can be a significant barrier to effective treatment. Routinely, the substitution of a spacer device with an MDI can improve medication delivery and consequently asthma control. A further consideration is in those with low lung function and consequent poor inspiratory flows who may not reach required inspiratory flow to achieve drug deposition with dry powder devices. So the first step in uncontrolled or poorly controlled asthma is the assessment of medication use and adherence. For the majority of individuals with uncontrolled asthma this will rectify the problem. In some instances measurement of blood corticosteroid levels can be performed, or dose counters used to formally assess adherence to medications where this is in doubt.",197,17,0.08629441624365482
9781908541420,ch_7,Before making a diagnosis of refractory asthma other conditions such as COPD and allergic bronchopulmonary aspergillosis should be excluded.,"Some diagnoses to consider are listed in Table 5.1. Important features on history are the onset of asthma, the presence of cough and sputum, a history of cigarette smoking and a history of infectious symptoms such as fever. Physical examination may point to a different pulmonary abnormality such as interstitial lung disease or pulmonary hypertension. In these instances chest imaging, such as an X-ray, CT scan or echocardiography may be relevant. Allergic bronchopulmonary aspergillosis is a condition that complicates severe asthma due to airway colonization by fungi, leading to an exuberant immunologic response. Patients often present with fevers, cough and sputum as well as worsening asthma. Laboratory investigations including tests for blood specific immunoglobulin (Ig)E to Aspergillus spp. and total IgE are important in suggesting this diagnosis.",182,31,0.17032967032967034
9781908541420,ch_7,Assessment of airway inflammation is a very useful step for guiding treatment in refractory asthma.,"Non-invasive measurement of airway inflammation. The presence of severe, refractory asthma is an indication for establishment of airway inflammatory phenotype. Cellular analysis of induced sputum can enable the diagnosis of eosinophilic airway inflammation which is much more likely to respond to corticosteroid treatments than a predominantly neutrophilic, or non-inflammatory sputum inflammatory pattern. Exhaled nitric oxide measurements may also be useful for the determination of the nature of airway inflammation, guiding further treatment options (see page 44). Treatment algorithms that use measures of airway inflammation suggest that there are some patients with high symptom burden but little evidence of inflammation: a dose reduction of anti-inflammatory therapies may be considered in this group (Figure 5.2).",156,20,0.1282051282051282
9781908541420,ch_8,"Asthma exacerbations are one of the major causes of morbidity in asthma, resulting in loss of work time in adults or school absence in children, and emergency hospital presentation and admission.","Asthma exacerbations remain one of the major causes of morbidity in asthma. They represent a significant burden of disease to patients and also to emergency healthcare providers. In children, asthma exacerbations remain one of the most common causes of school absence and hospital admission. In adults, exacerbations are responsible for loss of work time, emergency asthma attendances to primary care practitioners and hospital presentation and admission. A major indicator of risk for emergency asthma attendance is previous emergency attendance, indicating that preventive strategies should be applied for such individuals to prevent future severe and even life-threatening episodes. Fear of acute severe asthma is a major burden for many who live with severe asthma, and is a further reason for taking steps to prevent severe attacks. Any patient with asthma can suffer from an acute asthma episode, often described as an asthma attack. Viral respiratory infections are the most common cause, accounting for at least 50% of hospital admissions for asthma in adults and over 80% in children. Such infections can be responsible for a rapid decline in lung function, which may not be entirely prevented by regular inhaled controller (preventer) therapy.",224,37,0.16517857142857142
9781908541420,ch_8,"Causes of acute asthma include viral respiratory infections, acute allergen exposure, food allergies and some medications such as acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs.","Other causes of acute asthma include acute allergen exposure, when an allergic person is exposed to an allergen not usually encountered in the environment. Examples of this include 'thunderstorm asthma' in people who usually have allergic rhinitis due to grass pollens, or individuals with allergy to molds. Inhalation of small allergen particles into the lower respiratory tract can cause a severe asthma episode and weather patterns can lead to epidemics of asthma in such circumstances. Similarly, severe food allergies (exempli gratia to peanuts or shellfish) may trigger asthma. While individuals with such a food allergy often present with signs of anaphylaxis, acute asthma is a major component of a severe food reaction for some and it requires recognition and treatment in its own right. Some medications, such as beta-blockers - even in eye drops - may also be responsible for an acute exacerbation of asthma. Individuals with acetylsalicylic acid (ASA; aspirin)-sensitive asthma may have severe asthma after taking ASA or other non-steroidal anti-inflammatory drug (NSAID) that has cyclooxygenase (COX)-1 activity such as indometacin, ibuprofen, naproxen, piroxicam, and nabumetone. The mechanism probably relates to inhibition of formation of protective prostaglandins such as prostaglandin E (PGE). COX-2 inhibitors such as celecoxib are much less likely to cause reactions. NSAID reactions are most often described in individuals with non-allergic asthma who have nasal polyposis. Individuals with this type of asthma should avoid ASA and preferably all NSAIDs, although if absolutely necessary (exempli gratia a patient with severe rheumatoid arthritis and asthma), a supervised trial of a COX-2 inhibitor might be considered. It is important to be aware of other preventable causes of exacerbations such as occupational and sometimes unusual allergen exposures.",405,44,0.10864197530864197
9781908541420,ch_8,Acute exacerbations of asthma usually respond well to inhaled beta -agonists and a course of oral corticosteroid.,"Other causes of acute asthma include acute allergen exposure, when an allergic person is exposed to an allergen not usually encountered in the environment. Examples of this include 'thunderstorm asthma' in people who usually have allergic rhinitis due to grass pollens, or individuals with allergy to molds. Inhalation of small allergen particles into the lower respiratory tract can cause a severe asthma episode and weather patterns can lead to epidemics of asthma in such circumstances. Similarly, severe food allergies (exempli gratia to peanuts or shellfish) may trigger asthma. While individuals with such a food allergy often present with signs of anaphylaxis, acute asthma is a major component of a severe food reaction for some and it requires recognition and treatment in its own right.",159,25,0.15723270440251572
9781908541420,ch_8,"After hospital admission, patients should receive appropriate medication, a written plan of what to do if their asthma worsens and a follow-up medical appointment for ongoing management and measurement of lung function.","For asthma exacerbations, 8-12 puffs of a beta -agonist with a spacer device is approximately equivalent to 5 mg of salbutamol delivered by a nebulizer. This method of short-acting beta -agonist delivery may be preferred for reasons of infection control or community use. Familiarity with the delivery of salbutamol by metered-dose inhaler (MDI) and spacer will also assist people with asthma and their carers to deliver care for asthma exacerbations following discharge from hospital. Ongoing review in hospital ensures recovery and introduces patients to their ongoing preventative medication and the management plan likely to be required following a hospital admission for asthma. The time in hospital presents an ideal opportunity for formal asthma education; interventions that provide in-hospital asthma education have shown benefits in terms of reduced re-admission rates. All patients should leave hospital with medication, a written plan of what to do if their asthma worsens and a follow-up medical appointment for ongoing management. Oral corticosteroid therapy should be continued for at least 5 days following hospital discharge. It is important that asthma control is assessed following a hospital admission and that ongoing maintenance medication is adjusted accordingly.",243,38,0.15637860082304528
9781908541420,ch_9,Preventing asthma attacks is the most effective means of controlling asthma.,"Preventing asthma attacks. Preventing asthma attacks is the most effective means of controlling asthma. Effective prevention involves identifying and avoiding risk factors and asthma triggers, together with effective patient education and adherence to a medication regimen. Patient partnerships. Included in the goals of good asthma management is the need to meet patients' goals and expectations as well as those of the health practitioners. Good asthma management means that a partnership should be established between the patient and health professional, with shared treatment goals noted in a jointly written and agreed self-management plan. This eases the pressure on healthcare personnel resources by helping patients to take responsibility for their health and improves asthma outcomes.",132,14,0.10606060606060606
9781908541420,ch_9,"Identifying risk factors that trigger asthma attacks and removing allergens and irritants from the patient's environment can reduce the frequency of symptoms and hospitalizations for asthma, and decrease the need for medication.","Included in the goals of good asthma management is the need to meet patients' goals and expectations as well as those of the health practitioners. Good asthma management means that a partnership should be established between the patient and health professional, with shared treatment goals noted in a jointly written and agreed self-management plan. This eases the pressure on healthcare personnel resources by helping patients to take responsibility for their health and improves asthma outcomes. Identifying the risk factors that trigger asthma attacks and removing the appropriate allergens and irritants from the patient's environment can reduce the frequency of symptoms and hospitalizations for asthma, and the need for medication. Appropriate avoidance behaviors are shown in Table 7.1. However, allergens should only be avoided when there is evidence that the patient is indeed allergic to that specific allergen. Patients with a true allergy will have both a history of symptoms on exposure to an allergen and immunologic evidence of sensitivity, for example a positive skin-prick test or blood-specific immunoglobulin (Ig)E test. If these are not present then allergen avoidance is not recommended.",226,39,0.17256637168141592
9781908541420,ch_9,A written self-management plan empowers patients to manage their asthma optimally.,"Included in the goals of good asthma management is the need to meet patients' goals and expectations as well as those of the health practitioners. Good asthma management means that a partnership should be established between the patient and health professional, with shared treatment goals noted in a jointly written and agreed self-management plan. This eases the pressure on healthcare personnel resources by helping patients to take responsibility for their health and improves asthma outcomes.",84,16,0.19047619047619047
9781908541420,ch_9,- specific allergens can be shown to be causative,"Identifying the risk factors that trigger asthma attacks and removing the appropriate allergens and irritants from the patient's environment can reduce the frequency of symptoms and hospitalizations for asthma, and the need for medication. Appropriate avoidance behaviors are shown in Table 7.1. However, allergens should only be avoided when there is evidence that the patient is indeed allergic to that specific allergen. Patients with a true allergy will have both a history of symptoms on exposure to an allergen and immunologic evidence of sensitivity, for example a positive skin-prick test or blood-specific immunoglobulin (Ig)E test. If these are not present then allergen avoidance is not recommended.",142,11,0.07746478873239436
9781908541420,ch_9,Immunotherapy is helpful in some patients when one of the following applies:,"Cockroach allergen is a major cause of asthma in some areas, particularly in inner city environments. It can be reduced by regular cleaning of the home and by the use of pesticides. If pesticide sprays are used, however, the patient should not be present while spraying is in progress, and the home should be aired thoroughly before the patient returns.",72,15,0.20833333333333334
9781908541420,ch_9,- allergen avoidance is not possible,"Specific immunotherapy, aimed at treating the underlying allergy, has been shown to be effective in patients with asthma caused by house dust mite, grass or other pollens, and animal dander. Such treatment may be useful in patients for whom allergen avoidance is not possible or whose symptoms are poorly controlled by conventional medication, or where a single allergen is especially problematic. Allergen immunotherapy is usually delivered by subcutaneous or sublingual routes by a specialist medical practitioner. Considerable effort is now being spent on improving the tolerogenicity of allergens and reducing their anaphylactogenic effects. This type of treatment probably works by inducing a subset of regulatory T lymphocytes (Treg) that secrete inhibitory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)beta. However, there is increasing evidence to support the use of sublingual immunotherapy. As immunotherapy is relatively contraindicated in those with unstable asthma and those with abnormal lung function, it is practically limited to those with milder disease, especially those who suffer from allergic rhinitis. There is some evidence that immunotherapy can prevent the progression of allergic rhinitis to asthma.",249,8,0.0321285140562249
9781908541420,ch_9,- symptoms are not controlled by conventional medication.,"Specific immunotherapy, aimed at treating the underlying allergy, has been shown to be effective in patients with asthma caused by house dust mite, grass or other pollens, and animal dander. Such treatment may be useful in patients for whom allergen avoidance is not possible or whose symptoms are poorly controlled by conventional medication, or where a single allergen is especially problematic. Allergen immunotherapy is usually delivered by subcutaneous or sublingual routes by a specialist medical practitioner. Considerable effort is now being spent on improving the tolerogenicity of allergens and reducing their anaphylactogenic effects. This type of treatment probably works by inducing a subset of regulatory T lymphocytes (Treg) that secrete inhibitory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)beta. However, there is increasing evidence to support the use of sublingual immunotherapy. As immunotherapy is relatively contraindicated in those with unstable asthma and those with abnormal lung function, it is practically limited to those with milder disease, especially those who suffer from allergic rhinitis. There is some evidence that immunotherapy can prevent the progression of allergic rhinitis to asthma.",249,9,0.03614457831325301
9781908541420,ch_9,Failure to respond to treatment may result from non-adherence to the prescribed treatment. Attention must be paid to the patient's ability to take their inhaled therapy correctly. Identifying problems surrounding care and creating a patient partnership with agreed treatment goals can facilitate adherence.,"Specific immunotherapy, aimed at treating the underlying allergy, has been shown to be effective in patients with asthma caused by house dust mite, grass or other pollens, and animal dander. Such treatment may be useful in patients for whom allergen avoidance is not possible or whose symptoms are poorly controlled by conventional medication, or where a single allergen is especially problematic. Allergen immunotherapy is usually delivered by subcutaneous or sublingual routes by a specialist medical practitioner. Considerable effort is now being spent on improving the tolerogenicity of allergens and reducing their anaphylactogenic effects. This type of treatment probably works by inducing a subset of regulatory T lymphocytes (Treg) that secrete inhibitory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)beta. However, there is increasing evidence to support the use of sublingual immunotherapy. As immunotherapy is relatively contraindicated in those with unstable asthma and those with abnormal lung function, it is practically limited to those with milder disease, especially those who suffer from allergic rhinitis. There is some evidence that immunotherapy can prevent the progression of allergic rhinitis to asthma.",249,52,0.20883534136546184
9781908541420,ch_10,Exercise-induced asthma is defined as a transient increase in airway resistance that follows vigorous exercise.,"Exercise-induced asthma is defined as a transient increase in airway resistance that follows vigorous exercise. Many people complain of shortness of breath while exercising, and this symptom is often magnified in people with asthma. A history of developing wheeze, shortness of breath and sometimes cough both during and after exercise should prompt a clinician to consider a diagnosis of exercise-induced asthma. Exercise-induced asthma is particularly common in children and approximately 80% of children with asthma will have evidence of exercise-induced bronchoconstriction. For some individuals with brittle asthma, the response to exercise can be severe and may be a strong disincentive to exercise.",133,20,0.15037593984962405
9781908541420,ch_10,It appears to be more common in those with atopy and to be seen more often on exercise in very cold weather.,"Exercise-induced asthma appears to be more common in those with allergies to inhaled substances and often occurs on exercise in very cold weather. A feature of exercise-induced asthma is a refractory period, whereby induction of exercise-induced asthma appears to be protective for further episodes for a period of several hours. Thus, individuals who experience a bout of exercise-induced asthma can undertake subsequent exercise with relative protection from further episodes. Some people with asthma use this strategy to manage exercise-induced symptoms by undertaking a warm-up to exercise of short, high-intensity exercise bursts. The refractory period can be inhibited by anti-inflammatory medications such as indometacin.",136,24,0.17647058823529413
9781908541420,ch_10,Induction of exercise-induced asthma appears to be protective for further episodes for a period of several hours.,"Exercise-induced asthma appears to be more common in those with allergies to inhaled substances and often occurs on exercise in very cold weather. A feature of exercise-induced asthma is a refractory period, whereby induction of exercise-induced asthma appears to be protective for further episodes for a period of several hours. Thus, individuals who experience a bout of exercise-induced asthma can undertake subsequent exercise with relative protection from further episodes. Some people with asthma use this strategy to manage exercise-induced symptoms by undertaking a warm-up to exercise of short, high-intensity exercise bursts. The refractory period can be inhibited by anti-inflammatory medications such as indometacin.",136,21,0.15441176470588236
9781908541420,ch_10,Exercise testing or other direct or indirect challenges are used in diagnosis.,"Indirect challenges. Exercise challenge testing is an indirect challenge relying on airway responses to exercise, such as airway drying and cooling, to cause smooth muscle contraction. Because of the difficulties of replicating field exercise in the laboratory to achieve consistency of diagnosis, a number of surrogate challenges for exercise have been developed. Chief among these is the eucapnic voluntary hyperventilation challenge, in which the individual is asked to breathe a mixture of dry air with 5% carbon dioxide at 85% of their maximal ventilation (approximately 30 times FEV) for 6 minutes, and their FEV is monitored after challenge. This surrogate challenge has been shown to correlate very well with actual exercise challenge and is suitable for use by athletes. A fall in FEV of 10% following the eucapnic voluntary hyperventilation challenge has been adopted by the International Olympic Committee as the preferred criterion for confirmation of an asthma diagnosis in elite athletes.",185,14,0.07567567567567568
9781908541420,ch_10,"In elite athletes, direct airway challenges may not reveal exercise-induced asthma, so indirect surrogate challenges must be used to confirm diagnosis.","The high prevalence of exercise-induced asthma in elite athletes has been an issue of concern. Escalating use of bronchodilator treatments by elite athletes has prompted rulings from the International Olympic Committee so that diagnosis of asthma in elite competition must be confirmed by lung function abnormality or challenge testing. Some elite cold-weather athletes, such as cross-country skiers, are very likely to develop exercise-induced asthma (so called 'skier's asthma'). In summer athletes, a high occurrence of asthma has been reported in elite swimmers. In both these instances, training for prolonged periods at high ventilatory workloads and consequent high exposure to very cold or chlorinated air, respectively, is thought to contribute to an airway injury that may lead to exercise-induced asthma. The finding that older athletes and those from sports that are predominantly aerobic are more likely to have exercise-induced asthma supports this theory.",185,27,0.14594594594594595
9781908541468,ch_3,Proteinuria and hematuria should always be investigated.,"One of the most common causes of low-level proteinuria is inflammation in the lower urinary tract, which is usually caused by urinary tract infection (UTI) (Table 1.1). Women are at increased risk of UTI because of renal tract dilatation leading to urinary stasis, and this should be treated promptly according to bacterial sensitivity.",70,12,0.17142857142857143
9781908541468,ch_3,"Proteinuria should be quantified by means of an albumin:creatinine ratio or 24-hour collections, since the result will guide management.","Timed and spot urine samples. Proteinuria may be formally quantified using timed urine samples, usually a 24-hour specimen. The upper end of the normal range is 150 mg/24 hours. As collecting 24-hour urine samples is difficult and unreliable, measurement of the albumin:creatinine or protein:creatinine ratio from a spot urine sample is increasingly being used, because it correlates well with 24-hour albumin or protein excretion. In conventional units an albumin:creatinine ratio of 1 equates to 1 g/24 hours of albumin excretion, and in SI units a ratio of 120 mg/mmol equates to 1 g/24 hours albuminuria. Albuminuria of more than 1 g/24 hours, in the absence of an obvious cause, should prompt further investigation, which might include kidney biopsy. Albuminuria of more than 3.5 g/24 hours is commonly associated with nephrotic syndrome (see Chapter 6).",203,31,0.15270935960591134
9781908541468,ch_3,"Hematuria may have a medical or surgical cause, and this should be assessed before starting investigations.","Timed and spot urine samples. Proteinuria may be formally quantified using timed urine samples, usually a 24-hour specimen. The upper end of the normal range is 150 mg/24 hours. As collecting 24-hour urine samples is difficult and unreliable, measurement of the albumin:creatinine or protein:creatinine ratio from a spot urine sample is increasingly being used, because it correlates well with 24-hour albumin or protein excretion. In conventional units an albumin:creatinine ratio of 1 equates to 1 g/24 hours of albumin excretion, and in SI units a ratio of 120 mg/mmol equates to 1 g/24 hours albuminuria. Albuminuria of more than 1 g/24 hours, in the absence of an obvious cause, should prompt further investigation, which might include kidney biopsy. Albuminuria of more than 3.5 g/24 hours is commonly associated with nephrotic syndrome (see Chapter 6).",203,21,0.10344827586206896
9781908541468,ch_3,Serum creatinine alone is an unreliable guide to kidney function; an assessment of glomerular filtration rate is more useful.,"Kidney function is assessed most simply by measuring the serum concentrations of metabolites excreted by the kidney, most commonly urea and creatinine. The serum urea concentration is influenced more by dietary intake of protein, the state of hydration, liver function and various drugs. Serum creatinine is, therefore, a more reliable measure, but is related directly to muscle mass; thus, a small elderly woman may have a normal serum creatinine with a markedly reduced glomerular filtration rate (GFR). Changes in serum creatinine (especially a rise) can be a useful guide to deteriorating kidney function; absolute values do not correlate well with GFR.",138,28,0.2028985507246377
9781908541468,ch_3,No fall in serum creatinine during pregnancy can indicate significant renal functional impairment.,"Serum creatinine in pregnancy. During a normal pregnancy in a woman with normal kidneys, renal plasma flow and GFR both increase (by >= 50%), leading to a reduction in the mean serum creatinine during the first and second trimesters from 73 mol/L (0.8 mg/dL) to 51 mol/L (0.5 mg/dL). No fall in serum creatinine during pregnancy can indicate significant renal functional impairment.",95,16,0.16842105263157894
9781908541468,ch_4,Electrolyte disturbances are very common and often iatrogenic.,"Electrolyte disturbances and acid-base disorders. Plasma electrolyte and acid-base disturbances are common clinical problems. Perturbations may result in morbidity and mortality, particularly in the elderly and young children, and in those with other comorbid states, such as sepsis, coronary heart disease and heart failure.",68,15,0.22058823529411764
9781908541468,ch_4,All electrolye disturbances require an accurate assessment of fluid balance.,"Treatment. Particular care must be taken when correcting hyponatremia in premenopausal women, children and those with very low plasma sodium levels (< 120 mmol/L). Severe symptomatic hyponatremia may require treatment with hypertonic (3%) sodium chloride. The sodium concentration should be monitored frequently. The optimal correction rate should be 0.5-1 mmol/L/hour, with a total correction of plasma sodium of 10-12 mmol over the first 24 hours. A more aggressive correction rate of 2.0 mmol/L/hour may be considered in patients with seizures or severe neurological symptoms attributable to hyponatremia. However, an overly rapid correction rate carries the risk of precipitating central pontine myelinolysis.",157,12,0.07643312101910828
9781908541468,ch_4,Correction should generally be cautious.,"Treatment. Particular care must be taken when correcting hyponatremia in premenopausal women, children and those with very low plasma sodium levels (< 120 mmol/L). Severe symptomatic hyponatremia may require treatment with hypertonic (3%) sodium chloride. The sodium concentration should be monitored frequently. The optimal correction rate should be 0.5-1 mmol/L/hour, with a total correction of plasma sodium of 10-12 mmol over the first 24 hours. A more aggressive correction rate of 2.0 mmol/L/hour may be considered in patients with seizures or severe neurological symptoms attributable to hyponatremia. However, an overly rapid correction rate carries the risk of precipitating central pontine myelinolysis.",157,6,0.03821656050955414
9781908541468,ch_4,"Intake and excretion of solutes, and drugs, must be considered when trying to identify causes.","Treatment. In general, patients with a calcium level corrected to below 1.75 mmol/L (7 mg/dL) or those with tetany, seizures and/or ECG abnormalities should be treated. Patients who are asymptomatic with a chronically low calcium level can be treated with oral calcium salts, vitamin D and the use of a thiazide to reduce renal excretion of calcium; calcium carbonate contains more elemental calcium than other salts. Patients with symptomatic and severe hypocalcemia must be given intravenous calcium with a bolus of calcium gluconate (10 mL of 10% calcium gluconate), under cardiac monitoring. Calcium gluconate is preferable to calcium chloride, because calcium chloride can cause tissue necrosis if accidentally extravasated.",161,21,0.13043478260869565
9781908541468,ch_5,Acute kidney injury (AKI) is common and often reversible if diagnosed promptly.,"The incidence of severe AKI (serum creatinine > 5.7 mg/dL [500 mol/L]) is about 140/million/year. AKI may result from poor perfusion of the kidneys (prerenal), intrinsic renal disease or urinary tract obstruction (postrenal). In general, prerenal AKI will recover rapidly once kidney perfusion is re-established. However, reversible prerenal AKI overlaps with, and may lead to, established AKI owing to acute tubular necrosis (ATN). In ATN, the degree of tubular damage is such that kidney recovery is often delayed for 2 weeks or longer. ATN is by far the most common cause of AKI, and is often seen in postoperative patients in a hospital setting, and in those with severe infections or multisystem disease (Table 3.2).",180,17,0.09444444444444444
9781908541468,ch_5,Recognition and management of volume depletion or overload is crucial in the early management of AKI.,"Established AKI is most often due to ATN. The most common cause of ATN is prolonged renal ischemia due to reduced kidney perfusion, which may be a result of volume depletion, septicemia, cardiac failure or renal artery obstruction. Tubular damage is often caused by exogenous toxins, such as non-steroidal anti-inflammatory drugs (NSAIDs), heavy metals and contrast agents. Endogenous tubular toxins, such as myoglobin (in rhabdomyolysis), hemoglobin (in hemolysis) or immunoglobulin light chains (in myeloma), are also important causes. It is essential to look for hematuria, urinary casts and proteinuria, which suggest a diagnosis of glomerulonephritis or tubulointerstitial nephritis. In these circumstances, kidney biopsy may be indicated. When the cause of AKI is unclear, a number of blood tests may be helpful (Table 3.3).",197,20,0.10152284263959391
9781908541468,ch_5,Drug doses often need to be modified.,"Established AKI is most often due to ATN. The most common cause of ATN is prolonged renal ischemia due to reduced kidney perfusion, which may be a result of volume depletion, septicemia, cardiac failure or renal artery obstruction. Tubular damage is often caused by exogenous toxins, such as non-steroidal anti-inflammatory drugs (NSAIDs), heavy metals and contrast agents. Endogenous tubular toxins, such as myoglobin (in rhabdomyolysis), hemoglobin (in hemolysis) or immunoglobulin light chains (in myeloma), are also important causes. It is essential to look for hematuria, urinary casts and proteinuria, which suggest a diagnosis of glomerulonephritis or tubulointerstitial nephritis. In these circumstances, kidney biopsy may be indicated. When the cause of AKI is unclear, a number of blood tests may be helpful (Table 3.3).",197,8,0.04060913705583756
9781908541468,ch_5,"Patients require frequent re-assessment and measurement of physiological parameters (including urine output), and daily measurement of serum electrolytes.","Patients with ATN lose the ability both to concentrate and dilute the urine, and will pass a constant volume with inappropriate osmolality. Accurate measurement of urine output is essential to prevent volume overload or depletion. Most patients are oliguric and, in general, should be provided with a volume of fluid equal to the output on the previous day, plus at least an extra 500 mL if pyrexia is present. The situation may change rapidly and requires frequent clinical assessment together with CVP monitoring and measurement of body weight. Although diuretics do not alter the course or outcome of AKI, high-dose diuretics may convert oliguric AKI to non-oliguric AKI, which is worthwhile if dialysis is not readily available. There is no evidence in favor of using low-dose dopamine infusions; indeed, there is good evidence of a lack of benefit.",184,26,0.14130434782608695
9781908541468,ch_5,"Acute tubular necrosis has no specific treatment other than volume control, and there is no benefit in the routine use of dopamine or furosemide.","Patients with ATN lose the ability both to concentrate and dilute the urine, and will pass a constant volume with inappropriate osmolality. Accurate measurement of urine output is essential to prevent volume overload or depletion. Most patients are oliguric and, in general, should be provided with a volume of fluid equal to the output on the previous day, plus at least an extra 500 mL if pyrexia is present. The situation may change rapidly and requires frequent clinical assessment together with CVP monitoring and measurement of body weight. Although diuretics do not alter the course or outcome of AKI, high-dose diuretics may convert oliguric AKI to non-oliguric AKI, which is worthwhile if dialysis is not readily available. There is no evidence in favor of using low-dose dopamine infusions; indeed, there is good evidence of a lack of benefit.",184,32,0.17391304347826086
9781908541468,ch_5,AKI is a risk factor for the subsequent development of chronic kidney disease.,"Most patients with ATN should recover kidney function, provided that they survive the underlying illness. However, increasingly it is being recognized that AKI is a risk factor for the subsequent development of CKD. Similarly, most patients will recover from acute interstitial nephritis. Recovery from crescentic glomerulonephritis is more variable; patients usually recover if treated early, but are likely to remain dependent on dialysis if treated late or inadequately.",92,15,0.16304347826086957
9781908541468,ch_6,"Chronic kidney disease is very common, especially the early stages.","Chronic kidney disease (CKD) is common and underrecognized. It can be defined as kidney damage present for at least 3 months, with either structural or functional abnormalities of the kidney with or without decreased glomerular filtration rate (GFR). In the early stages of CKD, evidence of kidney damage (exempli gratia proteinuria, cysts, biopsy changes) may be seen in the presence of a normal GFR (> 60 mL/minute/1.73 m), while the later stages are characterized by greater functional impairment, with the GFR falling to below 60 mL/minute/1.73 m (Table 4.1).",137,13,0.0948905109489051
9781908541468,ch_6,Anemia and bone disease may require treatment before dialysis is necessary.,"The incidence of CKD leading to dialysis varies worldwide; the number of patients per million population starting dialysis each year is 300 in the USA compared with 230 in Japan and 110 in the UK. The prevalence of end-stage kidney disease (ESKD) also varies; in the USA, 1 in 1000 of the population are receiving treatment for ESKD (dialysis or transplantation) and, overall, the number of patients per million population is 1131 compared with 1397 in Japan, 690 in Canada, 634 in France, 530 in Australia, 498 in the UK and 223 in Poland. Reasons for this wide variation include both patient factors (exempli gratia the prevalence of diabetes) and external factors (exempli gratia the availability of dialysis and the number of nephrologists).",168,14,0.08333333333333333
9781908541468,ch_6,Early interventions can prevent a progressive decline in kidney function and complications.,"CKD is generally a progressive disease (Figure 4.2), though the rate of decline in kidney function varies between patients. In the last decade, it has become clear that, regardless of the underlying cause of the kidney disease, the factors that will determine the likelihood of progression to ESKD are.",62,13,0.20967741935483872
9781908541468,ch_6,"Blood pressure control is crucial, and very low targets should be set.","The management of CKD is summarized in Tables 4.2 and 4.3. Blood pressure targets are extremely low and some drugs are undoubtedly more beneficial than others (exempli gratia angiotensin-converting enzyme [ACE] inhibitors in patients with albuminuria), though in reality all classes of drug need to be used for blood-pressure control, and most patients will require at least three or four drugs. Evidence suggests that for patients with CKD and albuminuria the target blood pressure should be between 125/75 mmHg and 130/80 mmHg, whereas in patients with CKD but no albuminuria, aiming for a blood pressure of less than 140/90 mmHg is recommended. Patients with diabetes undoubtedly benefit from renin-angiotensin blockade with either an ACE inhibitor or an angiotensin-receptor blocker (ARB). Combining both an ACE inhibitor and an ARB is no longer recommended for most patients. For patients on dialysis, the most important factor in controlling blood pressure is to control salt (and water) intake and body fluid volume. A full discussion of hypertension and kidney disease can be found in Chapter 5.",241,14,0.058091286307053944
9781908541468,ch_6,Cardiovascular risk factors need aggressive management.,"The risk factors for cardiovascular disease in CKD are summarized in Table 4.6; the risks increase as kidney function deteriorates. The major cardiovascular outcomes include stroke, sudden death, arrhythmia, myocardial infarction, ischemic heart disease, cardiac arrest, hypertension, pericarditis, left ventricular hypertrophy and vascular calcification (Figure 4.3).",80,8,0.1
9781908541468,ch_7,Blood pressure targets are less than 130/80 mmHg or lower in the presence of albuminuria (> 500 mg/day) and less than 140/90 mmHg in the absence of albuminuria.,"Management. Antihypertensive therapy is beneficial in reducing both cardiovascular and renal events, as well as lowering mortality. In patients with CKD, treating hypertension is important in slowing disease progression and in reducing cardiovascular risk. In patients with ESKD, the focus should be directed towards reducing cardiovascular morbidity. Patients with albuminuric CKD (> 500 mg albumin/24 hours) require aggressive management of blood pressure, with a target of less than 130/80 mmHg. A more relaxed target of less than 140/90 mmHg is recommended for patients who are normoalbuminuric. First-line therapy should comprise lifestyle changes, such as reducing salt intake, moderating alcohol intake, stopping smoking and taking regular exercise, which together can lower blood pressure by 10/5 mmHg. An angiotensin-converting enzyme (ACE) inhibitor or an angiotensin- receptor blocker (ARB) is recommended as first-line therapy in patients with CKD (Figure 5.2). However, usually more than one drug is required, and a beta-blocker, a calcium-channel blocker or a diuretic agent can be added. The key features of several commonly used antihypertensive drug classes are shown in Table 5.2. The choice of drugs can be influenced by comorbid conditions, as shown in Table 5.3.",283,44,0.15547703180212014
9781908541468,ch_7,"For optimal renal protection in patients with chronic kidney disease, angiotensin blockade with an ACE inhibitor or an ARB is recommended.","Renovascular disease is a remediable form of hypertension and should be excluded in high-risk patients, such as elderly hypertensives with evidence of diffuse atherosclerosis, in refractory or malignant hypertension, in those with 'flash' pulmonary edema and in individuals with an abdominal bruit. In young women with hypertension of recent onset, fibromuscular renal artery disease should be excluded. The preferred diagnostic tests include magnetic resonance angiography and ACE-inhibitor renography. Duplex ultrasonography with Doppler flow measurements can be a useful screening test but is rather operator dependent, and in many patients the renal arteries cannot be visualized. The definitive diagnostic tests in almost all patients are still digital subtraction angiography or arteriography (Figure 5.3), but both carry a risk of contrast nephropathy and cholesterol embolization. Magnetic resonance angiography with gadolinium is not recommended in patients with an estimated glomerular filtration rate (GFR) of less than 60 mL/min/1.73m because of the risk of gadolinium-associated nephrogenic skin fibrosis, although the risk is very small and possibly dependent on the type of gadolinium used.",255,27,0.10588235294117647
9781908541468,ch_7,Hypertension is both an important cause and a consequence of renal disease.,"Hypertension during pregnancy is defined as any rise in systolic blood pressure of more than 30 mmHg or a rise in diastolic blood pressure of more than 15 mmHg above baseline, or the use of antihypertensive agents. It is classified according to its presentation (Table 5.5). Chronic hypertension is more common in multiparous women, and is present at the first antenatal visit. On the other hand, pre-eclampsia is more common in primigravidas (in 10% of first pregnancies), and represents an important cause of maternal and perinatal mortality. It usually presents only after 20 weeks of gestation, with or without proteinuria and a raised serum urate. Elevated levels of soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) and endoglin have been reported in pre-eclampsia and have been implicated in disease pathogenesis. Pre-eclampsia may progress to full-blown eclampsia, which is characterized by seizures and also associated with acute kidney injury (AKI). Management of eclampsia comprises immediate delivery, and magnesium sulfate, anticonvulsant and antihypertensive therapy.",261,15,0.05747126436781609
9781908541468,ch_7,"Pregnant women with significant renal impairment are likely to have hypertension, pre-eclampsia and premature labor.","Hypertension during pregnancy is defined as any rise in systolic blood pressure of more than 30 mmHg or a rise in diastolic blood pressure of more than 15 mmHg above baseline, or the use of antihypertensive agents. It is classified according to its presentation (Table 5.5). Chronic hypertension is more common in multiparous women, and is present at the first antenatal visit. On the other hand, pre-eclampsia is more common in primigravidas (in 10% of first pregnancies), and represents an important cause of maternal and perinatal mortality. It usually presents only after 20 weeks of gestation, with or without proteinuria and a raised serum urate. Elevated levels of soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) and endoglin have been reported in pre-eclampsia and have been implicated in disease pathogenesis. Pre-eclampsia may progress to full-blown eclampsia, which is characterized by seizures and also associated with acute kidney injury (AKI). Management of eclampsia comprises immediate delivery, and magnesium sulfate, anticonvulsant and antihypertensive therapy.",261,24,0.09195402298850575
9781908541468,ch_7,"Medications, particularly antihypertensive agents, require careful review in pregnant women with renal disease.","Antihypertensive agents must be reviewed in women with renal disease who wish to get pregnant. Methyldopa, labetalol, hydralazine and nifedipine are all safe drugs for treating hypertension in pregnancy, but diuretics should be avoided. ACE inhibitors are contraindicated from the second trimester, but may be important in controlling the progression of CKD. Women may therefore continue to take these as they plan a pregnancy but must stop when pregnant.",100,20,0.2
9781908541468,ch_7,"The earliest clinical evidence of nephropathy is microalbuminuria, which can be tested by an increased albumin:creatinine ratio in a spot urine sample (> 2.5 mg/mol in men or 3.5 mg/mol in women).","Diabetic nephropathy is defined by the presence of albuminuria. Overt nephropathy is characterized by albuminuria of more than 300 mg/24 hours or 200 g/minute; in addition, hypertension and kidney dysfunction, with a progressive decline in kidney function over time, may be present. The pathology of nephropathy in type 1 and type 2 diabetes is identical and comprises glomerular hypertrophy, glomerular basement membrane thickening, mesangial matrix accumulation and nodular glomerulosclerosis (Figure 5.5). Natural history (Table 5.6). The earliest clinical evidence of nephropathy is the appearance of microalbuminuria, which is a low but abnormal amount of albumin in the urine (> 30 mg/24 hours or 20 g/minute). Microalbuminuria can also be detected by an increased albumin:creatinine ratio in a spot urine sample (> 2.5 mg/mmol in men or 3.5 mg/mmol in women), which avoids the need for timed urine collections. Patients with early disease have incipient nephropathy and without specific interventions may progress to overt or clinical albuminuria over a period of 2-10 years. Most patients will also develop hypertension, which initially manifests as the absence of a nocturnal dip in blood pressure, but later becomes sustained hypertension.",283,53,0.1872791519434629
9781908541468,ch_7,"All patients with type 2 diabetes should be screened for incipient or established diabetic nephropathy, as microalbuminuria is present in about 25% of patients at diagnosis.","Type 2 diabetes. All patients with type 2 diabetes should be screened for incipient or established diabetic nephropathy, because microalbuminuria is present at diagnosis in approximately 25% of patients. If urinalysis is positive for protein (in the absence of infection), it is very likely that the patient has clinical albuminuria (> 300 mg/24 hours), which has important implications in terms of the progression of renal disease and overall cardiovascular risks. Positive urinalysis should be confirmed quantitatively (exempli gratia spot urine albumin:creatinine ratio), and patients in whom urinalysis is negative for protein require quantitative assessment for microalbuminuria. Type 1 diabetes. In contrast, microalbuminuria is rarely present at the time of diagnosis of type 1 diabetes or before puberty, and therefore screening should begin with the onset of puberty or 5 years after the diagnosis and be performed annually.",184,36,0.1956521739130435
9781908541468,ch_7,"Microalbuminuria is rarely present at diagnosis in type 1 diabetes; these patients should therefore be screened at the onset of puberty or 5 years after diagnosis, then annually.","Type 2 diabetes. All patients with type 2 diabetes should be screened for incipient or established diabetic nephropathy, because microalbuminuria is present at diagnosis in approximately 25% of patients. If urinalysis is positive for protein (in the absence of infection), it is very likely that the patient has clinical albuminuria (> 300 mg/24 hours), which has important implications in terms of the progression of renal disease and overall cardiovascular risks. Positive urinalysis should be confirmed quantitatively (exempli gratia spot urine albumin:creatinine ratio), and patients in whom urinalysis is negative for protein require quantitative assessment for microalbuminuria. Type 1 diabetes. In contrast, microalbuminuria is rarely present at the time of diagnosis of type 1 diabetes or before puberty, and therefore screening should begin with the onset of puberty or 5 years after the diagnosis and be performed annually.",184,34,0.18478260869565216
9781908541468,ch_7,The major risk factor for development of diabetic nephropathy is hyperglycemia.,Risk factors. The major factor influencing the development of diabetic nephropathy is hyperglycemia. Persistent hyperglycemia leads to the development of glycosylated macromolecules and their conversion to advanced glycosylation end products. This process results in thickening of the basement membranes (including the glomerular basement membrane) and accumulation of matrix proteins within the glomeruli.,83,18,0.21686746987951808
9781908541468,ch_7,"Treatment strategies for diabetic nephropathy include aggressive glycemic control, angiotensin blockade, blood pressure control, protein restriction and smoking cessation.","Although genetic factors predispose individuals to develop diabetes, whether they also influence the rate of progression of the nephropathy remains controversial. The racial and familial distribution of diabetes also suggests a role for as yet undetermined polygenic influences. Other risk factors include male sex and smoking. Apart from glycemic control, the other major factor determining progression through diabetic nephropathy is hypertension. Prevention and treatment. Aggressive intervention in patients with either incipient or established nephropathy has been shown unequivocally to prevent progression of renal disease. Strategies include aggressive glycemic control, angiotensin blockade, blood pressure control, protein restriction and smoking cessation (Figure 5.6 and Table 5.8).",141,31,0.2198581560283688
9781908541468,ch_7,Aggressive intervention in patients with incipient or established nephropathy unequivocally prevents progression of renal disease.,"Prevention and treatment. Aggressive intervention in patients with either incipient or established nephropathy has been shown unequivocally to prevent progression of renal disease. Strategies include aggressive glycemic control, angiotensin blockade, blood pressure control, protein restriction and smoking cessation (Figure 5.6 and Table 5.8). The US Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have clearly shown that intensive therapy can significantly reduce the risk of the development of microalbuminuria and overt nephropathy in individuals with diabetes. In the UKPDS, there was a 75% reduction in the relative risk of doubling serum creatinine over 12 years.",145,21,0.14482758620689656
9781908541468,ch_8,Urgent investigations are needed to determine the precise type.,"Mesangiocapillary glomerulonephritis (MCGN) is also known as membranoproliferative glomerulonephritis. There is proliferation of mesangial cells, an increase in mesangial matrix and thickening of the glomerular basement membrane. MCGN can be subdivided according to the appearance on electron microscopy. Type 1 has electron dense subendothelial deposits of immunoglobulin and complement, while type 2 has characteristic linear 'dense deposits' along the glomerular basement membrane.",113,11,0.09734513274336283
9781908541468,ch_8,Treatments are available for most categories of glomerulonephritis.,"Crescentic glomerulonephritis (Figure 6.2) may occur as part of the evolution of certain forms of primary glomerulonephritis (exempli gratia IgA nephropathy or MCGN), but is more often seen in conditions such as Goodpasture's syndrome and systemic vasculitis. A condition previously described as idiopathic crescentic glomerulonephritis is now recognized as generally being due to renal limited vasculitis. The immunofluorescence findings are most informative in the diagnosis of crescentic glomerulonephritis (Table 6.1).",129,16,0.12403100775193798
9781908541468,ch_8,Crescentic glomerulonephritis requires urgent and aggressive immunosuppression.,"Crescentic glomerulonephritis (Figure 6.2) may occur as part of the evolution of certain forms of primary glomerulonephritis (exempli gratia IgA nephropathy or MCGN), but is more often seen in conditions such as Goodpasture's syndrome and systemic vasculitis. A condition previously described as idiopathic crescentic glomerulonephritis is now recognized as generally being due to renal limited vasculitis. The immunofluorescence findings are most informative in the diagnosis of crescentic glomerulonephritis (Table 6.1).",129,18,0.13953488372093023
9781908541468,ch_8,Glomerulonephritis should be considered in all patients with urine abnormalities.,"Crescentic glomerulonephritis should be treated according to the underlying cause. So-called idiopathic crescentic glomerulonephritis is now widely regarded as a form of antineutrophil cytoplasm antibody (ANCA)-positive vasculitis limited to the kidney. It presents with the clinical syndrome of rapidly progressive glomerulonephritis. Without treatment, the disease progresses to ESKD within a few weeks or months, but prednisolone and cyclophosphamide are generally effective in patients before severe kidney damage occurs. The addition of plasma exchange or pulse doses of methylprednisolone is recommended in patients with advanced renal disease. Indeed, evidence suggests that plasma exchange may be the more effective approach.",156,16,0.10256410256410256
9781908541468,ch_9,"Systemic lupus erythematosus (SLE) commonly causes kidney disease, which can be severe and requires immunosuppression.","Glomerular or tubular involvement may be a major feature of systemic autoimmune diseases, and may result from the deposition of abnormal proteins in dysproteinemias. Diabetic nephropathy is becoming the commonest cause of kidney failure in developed countries; this is discussed in Chapter 5. Systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is most common in young women and often affects the joints, skin, nervous system and kidneys. Approximately 50% of patients with SLE will eventually develop kidney disease. This may affect the glomeruli directly, small blood vessels within the kidney or the interstitium. A variety of forms of lupus nephritis can be identified by standard light microscopy.",169,31,0.1834319526627219
9781908541468,ch_9,Vasculitis is common in the elderly and can be successfully treated if diagnosed early.,"Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is most common in young women and often affects the joints, skin, nervous system and kidneys. Approximately 50% of patients with SLE will eventually develop kidney disease. This may affect the glomeruli directly, small blood vessels within the kidney or the interstitium. A variety of forms of lupus nephritis can be identified by standard light microscopy.",98,18,0.1836734693877551
9781908541468,ch_9,Atheromatous renal vascular disease is very common and reflects widespread arterial pathology.,"Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is most common in young women and often affects the joints, skin, nervous system and kidneys. Approximately 50% of patients with SLE will eventually develop kidney disease. This may affect the glomeruli directly, small blood vessels within the kidney or the interstitium. A variety of forms of lupus nephritis can be identified by standard light microscopy.",98,18,0.1836734693877551
9781908541468,ch_9,Long-term treatment is usually needed for both vasculitis and SLE with kidney involvement.,"Treatment. Most patients respond well to treatment with prednisolone and cyclophosphamide. Recent studies suggest that rituximab is as effective as cyclophosphamide for induction therapy. Once remission has been induced (generally within 3 months), cyclophosphamide may be replaced by azathioprine for maintenance therapy. Mycophenolate mofetil can be used in those intolerant of azathioprine. Patients with severe kidney failure or other life-threatening features of disease are generally treated with additional intravenous methylprednisolone and/or plasma exchange. There is evidence that plasma exchange may be more effective than methylprednisolone in salvaging kidney function in patients with advanced kidney failure. With aggressive treatment, most patients, even those on dialysis, will recover kidney function.",167,19,0.11377245508982035
9781908541468,ch_10,Autosomal-dominant polycystic kidney disease is a common inherited disease.,"Inherited kidney disease. Autosomal-dominant polycystic kidney disease. Autosomal-dominant polycystic kidney disease (APKD) is a common inherited multisystem disease in which patients develop multiple bilateral kidney cysts, cysts in other organs and non-cystic renal manifestations (Figure 8.1).",70,17,0.24285714285714285
9781908541468,ch_10,Liver cysts are the most common extrarenal manifestation.,"Clinical features of APKD are summarized in Table 8.1. APKD affects about 1 in 1000 people, making it one of the commonest inherited diseases. It is a common cause of end-stage kidney disease (ESKD); however, progression is slow in most patients, and not inevitable.",64,13,0.203125
9781908541468,ch_10,"Progression to end-stage kidney disease is slow, and does not occur in all patients.","Clinical features of APKD are summarized in Table 8.1. APKD affects about 1 in 1000 people, making it one of the commonest inherited diseases. It is a common cause of end-stage kidney disease (ESKD); however, progression is slow in most patients, and not inevitable. Diagnosis. Cysts are easily identified by ultrasound examination. Cysts are not commonly seen in the fetus or in children. They are, however, found in a number of conditions other than APKD, such as simple cysts, tuberous sclerosis and von Hippel-Lindau disease. The absence of cysts in young people does not exclude the diagnosis, because they can form late in life, and screening of asymptomatic individuals is therefore not recommended before the age of 20 years. If negative, a scan should then be repeated at 5-yearly intervals in individuals with a family history. Genetic diagnosis by mutation analysis or linkage analysis is possible, but not always available, and may require blood samples from family members.",213,19,0.0892018779342723
9781908541468,ch_10,Alport's syndrome is an important but rare cause of hematuria.,"Hereditary nephritis is a group of rare genetic disorders that affects 2 in 100 000 people, and accounts for 3% of children and 0.2% of adults with ESKD in developed countries. It is caused by mutations in type IV collagen, which result in structurally defective glomerular (and other) basement membranes. Hereditary nephritis presents with hematuria and proteinuria, causes deafness and ocular changes, and in some individuals progresses to chronic kidney failure (CKD), but with a wide variation in phenotype.",113,15,0.13274336283185842
9781908541468,ch_10,Deafness and eye abnormalities are common in men with Alport's syndrome.,"Management. No specific treatments are available. Priorities are management of hypertension, slowing the progression of CKD and prevention of complications. Ultimately, many patients progress to ESKD, requiring dialysis or transplantation. Transplant survival rates are similar to those for patients with other diagnoses (see Chapter 12). Anti-glomerular basement membrane nephritis involving the kidney allograft may occur in a recipient with hereditary nephritis, because an immune response develops to a hitherto unseen type IV collagen antigen; however, this is rare and affects only 3-4% of male transplant recipients. Surgical repair of cataracts or repair of the anterior lenticonus is possible. Loss of hearing is likely to be permanent. Young men with Alport's syndrome should use hearing protection in noisy environments.",160,16,0.1
9781908541468,ch_11,"Uncomplicated cystitis in women, diagnosed by history and pyuria, can be treated empirically with short courses of antibiotics.","Recurrent cystitis in young women. Up to 20% of young women with acute cystitis develop recurrent UTIs. Hematuria and pyuria are almost always present. It is important to perform a urine culture to differentiate between relapse (infection with the same organism) and recurrence (infection with different organisms). Multiple infections caused by the same organism require longer courses of antibiotics and possibly further diagnostic tests. In contrast, infections caused by different organisms are generally not associated with underlying anatomic abnormalities and do not require further investigation of the genitourinary tract. A negative urinalysis or Gram stain does not exclude cystitis in women with low bacterial counts.",137,27,0.19708029197080293
9781908541468,ch_11,"Recurrent cystitis in women may require longer courses of, or prophylactic, antibiotics.","Recurrent cystitis in young women. Up to 20% of young women with acute cystitis develop recurrent UTIs. Hematuria and pyuria are almost always present. It is important to perform a urine culture to differentiate between relapse (infection with the same organism) and recurrence (infection with different organisms). Multiple infections caused by the same organism require longer courses of antibiotics and possibly further diagnostic tests. In contrast, infections caused by different organisms are generally not associated with underlying anatomic abnormalities and do not require further investigation of the genitourinary tract. A negative urinalysis or Gram stain does not exclude cystitis in women with low bacterial counts.",137,21,0.15328467153284672
9781908541468,ch_11,Cystitis in men generally requires a formal urologic assessment.,"Acute cystitis in young men is most commonly associated with underlying urologic abnormalities. In younger men, however, UTI may result from unprotected anal intercourse, an uncircumcised penis, unprotected intercourse with a woman whose vagina is colonized with uropathogens and in those men with HIV infection and a CD4+ T-cell count below 200/L. The commonest urologic abnormalities that predispose to UTI are prostatic disease and outlet obstruction (see Chapter 11) and urinary tract instrumentation.",110,14,0.12727272727272726
9781908541468,ch_11,Pyelonephritis usually requires intravenous antibiotics as initial treatment.,"Between 2-10% of pregnancies are complicated by UTI; if left untreated, 25-30% of the women affected will develop pyelonephritis. Pregnancies that are complicated by pyelonephritis have been associated with low-birth-weight and premature infants. Thus, pregnant women should be screened for bacteriuria by urine culture at 12-16 weeks of gestation. Bacteriuria of more than 10 CFU/mL of urine is considered significant. Pregnant women with asymptomatic bacteriuria should be treated with a 3-7-day course of antibiotics (see Table 9.5), and the urine should subsequently be cultured to ensure cure and to avoid relapse. As E. coli is now commonly resistant to ampicillin, amoxicillin and cefalexin, treatment should be based on the results of susceptibility tests. Nitrofurantoin or trimethoprim-sulfamethoxazole may be used, but in the third trimester sulfonamides compete with bilirubin binding in the newborn.",222,14,0.06306306306306306
9781908541468,ch_12,Kidney stones are common and are most often associated with hypercalciuria.,"Kidney stones are a common cause of morbidity in the Western world, affecting 10-20% of the population during their lifetime and leading to hospitalization for 1 in 1000 of the general population each year. Over 80% of kidney stones occur in white men; they are much rarer in women and black people. The peak age of onset for kidney stone formation is 20-30 years, and the recurrence rate is high - up to 50% within 5 years.",95,16,0.16842105263157894
9781908541468,ch_12,"Stones may require surgical intervention, but recurrence after surgery is common.","Kidney stones are a common cause of morbidity in the Western world, affecting 10-20% of the population during their lifetime and leading to hospitalization for 1 in 1000 of the general population each year. Over 80% of kidney stones occur in white men; they are much rarer in women and black people. The peak age of onset for kidney stone formation is 20-30 years, and the recurrence rate is high - up to 50% within 5 years.",95,15,0.15789473684210525
9781908541468,ch_12,Stones can be asymptomatic or cause a variety of clinical problems.,"The most common stones contain calcium salts, and may be calcium oxalate, calcium phosphate or a mixture of both. Magnesium ammonium phosphate stones (struvite stones) mostly occur in association with an underlying urease-splitting bacterial infection of the urinary tract (exempli gratia Proteus). These stones often recur and are most often seen in patients with an associated anatomic abnormality.",85,16,0.18823529411764706
9781908541468,ch_12,Thiazide diuretics and potassium citrate are used in some patients.,Magnesium ammonium phosphate stones (struvite stones) mostly occur in association with an underlying urease-splitting bacterial infection of the urinary tract (exempli gratia Proteus). These stones often recur and are most often seen in patients with an associated anatomic abnormality. Pure uric acid stones usually occur in the context of hyperuricemia among patients with a gouty diathesis or a hematologic malignancy. Uric acid stones have a high recurrence rate.,106,16,0.1509433962264151
9781908541468,ch_12,High fluid intake and a low-salt and low-oxalate diet are the mainstays of management.,"Initially, management is directed towards optimal pain control, hydration and urologic consultation for potential removal of an obstructing stone, and subsequently to the underlying predisposing factors and prevention of further episodes. Medical management of a non-obstructing stone requires increasing fluid intake to generate a urine output of more than 2 liters/day, dietary modification and treatment targeted at changing urinary pH (Tables 10.4 and 10.5). Low-calcium diets are to be avoided.",98,24,0.24489795918367346
9781908541468,ch_12,Low-calcium diets should be avoided.,"Initially, management is directed towards optimal pain control, hydration and urologic consultation for potential removal of an obstructing stone, and subsequently to the underlying predisposing factors and prevention of further episodes. Medical management of a non-obstructing stone requires increasing fluid intake to generate a urine output of more than 2 liters/day, dietary modification and treatment targeted at changing urinary pH (Tables 10.4 and 10.5). Low-calcium diets are to be avoided.",98,9,0.09183673469387756
9781908541468,ch_13,An infected obstructed urinary system is a urologic emergency.,"Urinary tract obstruction or obstructive uropathy is defined as complete or partial obstruction of the flow of urine at any level of the urinary tract from the kidneys to the urethral meatus. Urinary tract obstruction is a relatively common cause of community-acquired acute kidney injury (AKI) (10% of cases) with an incidence of 23 cases per million population. Urinary tract obstruction has a bimodal age distribution, and is common in children and the elderly (> 60 years of age). In children, congenital abnormalities of the urinary tract are particularly common, and include pelviureteric junction obstruction and vesicoureteric junction obstruction, such as an ectopic ureter, ureterocele or posterior urethral valves. In adults, the commonest causes are benign prostatic hyperplasia (BPH) in men and pelvic malignancies in women.",187,13,0.06951871657754011
9781908541468,ch_13,Urinary tract obstruction is common and can lead to irreversible kidney failure if not recognized.,"Pathophysiology. Three main points of physiological narrowing of the urinary tract present a high risk for obstruction: the pelviureteric junction, the crossing of the ureter over the common iliac vessels at the pelvic brim and the vesicoureteric junction (Figure 11.1). The functional effects of urinary tract obstruction are influenced by the level, severity and duration of obstruction. Short-term complete infravesical obstruction is invariably associated with AKI together with an enlarged bladder, hydroureter and hydronephrosis. These abnormalities are reversible and rarely associated with long-term sequelae if diagnosed and treated early. Long-term complete infravesical obstruction may result in AKI or subacute kidney failure coupled with structural changes that are often irreversible.",162,17,0.10493827160493827
9781908541468,ch_13,Targeted therapies are expanding the treatment options for both benign and malignant kidney tumors.,"Once a diagnosis of urinary obstruction has been made, further investigations are necessary to establish the underlying cause (Table 11.3, Figure 11.2). Contrast medium for intravenous urography or CT may lead to kidney dysfunction in patients with existing renal impairment and should be administered with caution. In most circumstances, after kidney ultrasonography, a CT scan followed by either antegrade or retrograde pyelography is the best approach. Assessment of lower tract obstruction to distinguish functional from mechanical causes may include uroflowmetry (to measure the speed of urine flow), postvoid residual urine measurement (to determine the amount of urine left in the bladder after urination) and filling cystometry (to determine the presence of uninhibited detrusor contractions).",153,17,0.1111111111111111
9781908541468,ch_13,"Renal cell carcinoma often presents late, while transitional cell carcinoma of the kidney pelvis causes obstruction and presents early.","Renal cell carcinomas are relatively rare and account for only 1-3% of all visceral cancers. They occur most typically in males over 50 years of age. The clinical presentation is variable; tumors may be picked up incidentally or may present with hematuria, loin pain, as a mass or as a paraneoplastic syndrome (hypercalcemia, hypertension or polycythemia). Renal cell cancers often present late and have a relatively poor prognosis. In the absence of metastatic disease, 5-year survival is 70%, but with renal vein involvement or extension into perinephric fat, the 5-year survival is only 20%. Risk factors for renal cell carcinoma include smoking, obesity, acetaminophen (paracetamol) use, gasoline exposure, kidney stones and von Hippel-Lindau disease (approximately 30-50% of all patients).",180,25,0.1388888888888889
9781908541468,ch_14,"Not all patients with end-stage kidney disease (ESKD) need or want dialysis, and some may be managed conservatively.","Renal replacement therapy and transplantation. Three choices for renal replacement therapy are available for patients with end-stage kidney disease (ESKD). conservative care and symptom control. dialysis (either peritoneal or hemodialysis). kidney transplant (from a living or cadaveric donor). In general, all patients should be offered all suitable choices, and be fully counseled as to the advantages and disadvantages of each. In reality, however, not all options are available in all centers, and patient-related factors can be limiting. Conservative care.",114,28,0.24561403508771928
9781908541468,ch_14,"Peritoneal dialysis is an excellent modality for many patients, especially early in ESKD.","Dialysis may not improve quality of life in patients with extensive comorbidities. Indeed, there is some evidence that very elderly patients, with only limited comorbid illnesses, may not even have the length of their lives prolonged by dialysis. In these circumstances, many patients opt for symptom control without dialysis, using erythropoietin, vitamin D analogs, dietary control, antipruritics and antiemetics as necessary. Such patients often have significantly better quality of life, fewer hospital admissions (exempli gratia from dialysis-related complications), and are more likely to die finally at home rather than in hospital than patients receiving dialysis.",137,21,0.15328467153284672
9781908541468,ch_14,Hemodialysis requires excellent vascular access; problems with access cause significant morbidity.,"Patients need excellent vascular access, and access problems are a major cause of morbidity (Table 12.1). Access is obtained through either a fistula created between a peripheral artery and vein (usually radial or brachial), or a permanent plastic catheter inserted into an internal jugular or subclavian vein (Figure 12.2). Hemodialysis can be carried out in a main hospital center, a satellite unit (often staffed only by nurses) or in the patient's home. Home hemodialysis offers patients the most autonomy, but requires a suitable house with a water supply, space (for the machine and supplies), a reasonably technically competent patient and usually a trained helper who will be present during each dialysis session. Patients dialysing at home often have the best quality of life. Dialysis is usually performed three times each week for about 4 hours. Some patients opt for daily hemodialysis (usually 6 days/week), which provides the best control of fluid balance and biochemistry, but is intensive. Patients can dialyse overnight while they sleep either at home or in dialysis centers. It is difficult to determine the optimum amount of dialysis a patient requires, and various methods are in use.",251,18,0.07171314741035857
9781908541468,ch_14,"Transplantation offers the best long-term outcomes, but at the expense of long-term side effects from immunosuppression, including cancers and cardiovascular disease.","Hemodialysis can be carried out in a main hospital center, a satellite unit (often staffed only by nurses) or in the patient's home. Home hemodialysis offers patients the most autonomy, but requires a suitable house with a water supply, space (for the machine and supplies), a reasonably technically competent patient and usually a trained helper who will be present during each dialysis session. Patients dialysing at home often have the best quality of life. Dialysis is usually performed three times each week for about 4 hours. Some patients opt for daily hemodialysis (usually 6 days/week), which provides the best control of fluid balance and biochemistry, but is intensive. Patients can dialyse overnight while they sleep either at home or in dialysis centers. It is difficult to determine the optimum amount of dialysis a patient requires, and various methods are in use.",181,33,0.18232044198895028
9781908541468,ch_14,Most patients will require several modalities of renal replacement therapy in their lifetime.,"When to start dialysis. The question of when to start dialysis remains controversial. In general, patients should begin dialysis when estimated glomerular filtration rate (GFR) is in the range of 8-10 mL/minute/1.73m. There is no good evidence that starting dialysis earlier is of any benefit to patients. If dialysis is delayed for too long, however, patients can become very malnourished. Nevertheless, there are excellent data suggesting that earlier referral for nephrological care before renal replacement therapy is required can significantly delay the need for dialysis, and reduce early morbidity and mortality.",131,15,0.11450381679389313
9781908541468,ch_14,"Most women on dialysis are infertile. Fertility is restored after transplantation, but pregnant transplant recipients have an increased risk of hypertension, miscarriage in the first trimester and premature delivery.","Common complications. Routine postoperative problems, such as deep-vein thrombosis, pulmonary embolism and pneumonia, can occur. Specific problems include opportunistic infections (viral, fungal, bacterial), malignancies (especially skin cancers), drug toxicity, recurrence of the original disease in the transplant, cardiovascular disease, hypertension, dyslipidemia and graft failure (Table 12.6). Patients should be followed up for life and undergo annual screening for cancers, drug toxicity and cardiovascular disease in addition to routine clinic visits. Most patients with a transplant will die from cardiovascular disease, which should, therefore, be aggressively managed. Fertility is usually restored in women after a kidney transplant, but transplant recipients have a high risk of hypertension during pregnancy, and an increased risk of miscarriage in the first trimester and premature delivery. Some immunosuppressants (exempli gratia mycophenolate mofetil) also pose a risk to the fetus.",198,39,0.19696969696969696
9781908541666,ch_2,"The prevalence of diabetes is increasing around the world, reflecting the massive societal changes in dietary habits, with energy overconsumption, an increase in sedentary lifestyle and obesity.","National data have demonstrated an alarming increase in the prevalence of diabetes mellitus in the developed world. According to the US 2011 National Diabetes Fact Sheet, the prevalence of diabetes in the US population is 8.3%, with estimates ranging from 5.8% in Vermont to 11.3% in Mississippi. Prevalence varies from 7.1% in non-Hispanic whites to 12.6% in non-Hispanic blacks (with even higher rates in Mexican Americans). This equates to 18.8 million people with diabetes (and 7.0 million with undiagnosed diabetes). Data from Diabetes UK reveals that 4.45% of the UK population had diabetes in 2011, equating to 2.9 million people. This figure is expected to grow to 5 million people by 2025. With increasing urbanization in India there has been an explosive increase in the prevalence of diabetes, which has now reached 8.0%, with 50 million people with type 2 diabetes. In China, diabetes has become a major public health problem, with an estimated prevalence of 9.7%.",214,34,0.1588785046728972
9781908541666,ch_2,Different ethnic groups are particularly susceptible to diabetes.,"Globally, most people with diabetes are in the age range 40-59 years, a time in which productivity at work and contribution to family life is anticipated. Illness, disability and premature death in this age group profoundly affect personal and family life, communities and national productivity. IDF data show that preventable complications of diabetes account for an additional 23 million years of life lost through disability and reduced quality of life.",83,9,0.10843373493975904
9781908541666,ch_2,The impact of diabetes and its complications will have the greatest burden on resource-poor nations with limited access to insulin and renal replacement (dialysis and transplantation).,"In terms of the population-based burden of diabetes, China has the highest number of people affected, based on 2013 data collected by the IDF, followed by India and the USA (Table 1.2). Rapid changes in lifestyle associated with westernization have led to large increases in the prevalence of diabetes throughout Asia. Of concern, recent data show no sign that the rate is slowing. People of Asian descent develop diabetes at lower degrees of obesity and at younger ages. There are also data to suggest Asian people suffer longer from diabetes complications and die earlier than people in other regions. An accelerating factor appears to be childhood obesity, which is increasing at alarming rates in Asia.",132,32,0.24242424242424243
9781908541666,ch_2,The obesity epidemic is impacting on earlier development of both type 1 and type 2 diabetes.,"Type 1 diabetes develops in about 79 000 children under the age of 14 every year. Recent data indicate the rate of new cases of type 1 diabetes is increasing by 3% every year, promoted by, among other factors, escalating rates of childhood obesity. About 25% of all cases of type 1 diabetes are in South East Asia, with about 20% in Europe. Finland, Sweden and Norway have the highest incidence of type 1 diabetes. Rates of type 1 diabetes also appear to be increasing in eastern European countries. The rate of type 2 diabetes is also increasing in children, though more data are required.",120,17,0.14166666666666666
9781908541666,ch_3,Screening for diabetes should be undertaken annually with a fasting glucose level.,"The glucose tolerance test is a useful provocation test that can be used for early detection of diabetes in the at-risk patient (see Table 2.2). It is also diagnostically useful in women with impaired fasting glucose (fasting glucose 5.6-6.9 mmol/L [100-125 mg/dL]), for whom the fasting glucose test is less sensitive for diabetes.",78,14,0.1794871794871795
9781908541666,ch_3,"Always consider diabetes mellitus in high-risk populations, including those with a family history, the obese, corticosteroid recipients and transplantation recipients.","In those diagnosed with diabetes, it is important to distinguish between the different types. This is simple in those cases of lean children, adolescents or adults who present with sudden onset of polyuria and polydipsia, who clearly have type 1 diabetes. Similarly, it may be relatively clear cut in the obese middle-aged person with multiple family members who have lifestyle- or tablet-managed type 2 diabetes. It can be less clear cut in some situations, however. Latent autoimmune diabetes in adults (LADA) provides a good example. It may appear identical to type 2 diabetes but be difficult to manage with standard oral medications, with patients progressing to insulin therapy. Recent studies show that early instigation of insulin therapy in this diabetes subgroup is associated with better glycemic control than use of sulfonylureas; a large randomized study is currently under way.",173,31,0.1791907514450867
9781908541666,ch_4,Type 1 diabetes results from an absolute deficiency of insulin.,Type 1 diabetes differs from type 2 in many ways; the key features of type 1 diabetes are illustrated in Table 3.2. In clinical practice it can sometimes be difficult to determine whether an individual patient has type 1 or type 2 diabetes when classic features are not present. Testing for autoimmune markers of type 1 diabetes and insulin secretory reserve helps to distinguish the two conditions.,74,11,0.14864864864864866
9781908541666,ch_4,"Environmental factors that cause the condition are unknown, but possibly include viral infection.","Although the precise cause or causes of type 1 diabetes remain to be elucidated, the best working model is that something in the environment triggers autoimmune damage in a person genetically prone to the disease (Figure 3.2). An increase in the incidence of cases of type 1 diabetes is being observed in many areas of the world. As this is unlikely to be related to a change in the gene pool, it suggests that some unidentified environmental factor or factors is triggering the increase. Children who develop type 1 diabetes are often heavier in early childhood and tend to be taller. Some have speculated that the increasing prevalence of obesity in childhood is the cause of the increasing incidence of type 1 diabetes (the 'accelerator hypothesis'), but this theory remains far from proven.",149,15,0.10067114093959731
9781908541666,ch_4,Autoimmune processes lead to beta cell destruction and a decline in beta cell mass.,"Mumps and Coxsackie viruses may cause acute pancreatitis and Coxsackie virus infection may lead to inflammatory destruction of beta cells. A significant association between enterovirus infection detected by molecular methods and autoimmune type 1 diabetes has been demonstrated. The precise temporal relationship remains to be elucidated. Coxsackie B viruses have been isolated from the pancreases of patients with new-onset type 1 diabetes. Viruses (such as Coxsackie) may directly attack the beta cell or may act by initiating autoimmune destruction of the beta cell. The only certain association is between rubella infection during pregnancy and increased risk of the neonate developing type 1 diabetes. Despite this and the longstanding suspicion of a relationship between type 1 diabetes and preceding viral infection, the precise role of viral infections in the etiology of type 1 diabetes is not yet clear.",173,16,0.09248554913294797
9781908541666,ch_4,Multiple inherited genetic factors influence both disease susceptibility and resistance.,"Type 1 diabetes is a complex genetic trait. Multiple inherited genetic factors influence both susceptibility and resistance to the disease. Familial clustering of type 1 diabetes is suggested by an average risk in siblings of 6%, compared with 0.4% in the general population.",52,11,0.21153846153846154
9781908541666,ch_4,"Osmotic symptoms at onset include thirst, polydipsia and polyuria.","Hyperglycemia produces the classic symptoms with which people with type 1 diabetes present. Patients usually consult their doctor with osmotic symptoms of intense thirst, polydipsia and polyuria and complain of unintentional weight loss. Blurring of vision is very common at the time of diagnosis and is caused by osmotic effects on the lens of the eye. Rarely, and sadly, cases still present in diabetic ketoacidosis because the diagnosis of acute-onset type 1 diabetes has not been considered.",103,17,0.1650485436893204
9781908541666,ch_5,"As the pancreatic secretion of insulin starts to fail, glucose levels progressively rise due to dysregulation of hepatic gluconeogenesis.","This sets up a cascade of phosphorylation steps of subcellular enzymes that are controlled by key regulators. The eventual result is the movement of a glucose transporter, glucose transporter 4 (GLUT4), from the cell cytosol to the cell surface, and this permits glucose uptake into the cell (Figure 4.1). Within this complex pathway, there are many points at which signaling may be perturbed. Overall, such perturbation results in a reduced glucose-uptake response to insulin (insulin resistance). The body attempts to override this by producing more insulin (hyperinsulinemia). When the pancreatic beta cells can no longer produce sufficient insulin to overcome insulin resistance, blood glucose levels start to rise.",146,26,0.1780821917808219
9781908541666,ch_5,"Nutrient excess and obesity contribute to insulin resistance, through mechanisms that include cell signaling defects, lipotoxicity and inflammation.","In addition, low-grade systemic inflammation is often found in obesity; disturbed adipose tissue secretion of molecules called adipokines (such as adiponectin, tumor necrosis factor alpha [TNFalpha], interleukin-6) can contribute to this. Adipokines can interfere with insulin action through a number of specific pathways involving intracellular inflammation signal transduction pathways that link in to insulin signaling pathways. These disturbances in inflammation add to the metabolic disturbances in the regulation of insulin signaling and contribute to insulin resistance.",108,24,0.2222222222222222
9781908541666,ch_5,"Type 2 diabetes results from a relative deficiency of insulin, often in the context of insulin resistance.","Lipotoxicity in type 2 diabetes is found in the muscle cells, where glucose is the major substrate. However, it has also been reported in the pancreas, where the effects of excess lipid can contribute to damage to insulin-secreting beta cells. Thus, in the situation of nutrient excess and obesity, where there are excess amounts of circulating fatty acids, lipotoxicity can increase insulin resistance (and the demand for insulin) and diminish the ability to respond by worsening beta cell impairment (see Figure 4.2).",107,19,0.17757009345794392
9781908541666,ch_6,Onset of hyperglycemia without ketoacidosis in non-obese individuals under 25 years of age is suggestive of monogenic diabetes (more commonly referred to as maturity onset diabetes of youth - MODY). A positive family history of diabetes in two to three generations should raise this suspicion.,"Monogenic forms of diabetes account for 1-2% of diabetes. These forms of diabetes result from mutations affecting the genes that regulate beta cell function. They are commonly referred to as maturity onset diabetes of youth (MODY), though the more correct name is monogenic diabetes. It is important to consider these forms of diabetes, as their treatment requirements can differ and they can be misclassified as type 1 or 2 diabetes. Monogenic diabetes is generally characterized by the onset of hyperglycemia at an early age (under 25 years) without ketoacidosis. The family history is usually positive for diabetes in two to three generations, which should raise the suspicion. Other suggestive features include the absence of autoantigens such as glutamic acid decarboxylase (GAD) or islet cell antibodies and detectable C-peptide. The lack of signs suggestive of insulin resistance - obesity, acanthosis nigricans and polycystic ovary syndrome - should also raise suspicion. Monogenic diabetes can be distinguished into types detected at birth and types detected later in life. About 10-15% of children diagnosed with diabetes are negative for autoantibodies. Monogenic diabetes should be considered as a cause in these children if there is a family history of diabetes. The commonest forms of monogenic diabetes are listed in Table 5.2.",274,60,0.21897810218978103
9781908541666,ch_6,"Conditions such as cystic fibrosis, hemochromatosis and pancreatic carcinoma can cause hyperglycemia.","Conditions affecting the integrity of the pancreas can damage beta cells and result in hyperglycemia. These conditions include cystic fibrosis, hemochromatosis and pancreatic carcinoma. A patient may already have the diagnosis, as in the case of cystic fibrosis, or a condition such as hemochromatosis can be considered at diagnosis, particularly if there are features of skin pigmentation, hepatomegaly and a history of fatigue and degenerative joint disease. Pancreatic carcinoma should be considered in the older individual who also has weight loss.",118,26,0.22033898305084745
9781908541666,ch_6,Glucocorticoids can unmask a susceptibility to type 2 diabetes or cause hyperglycemia at high doses. Anti-HIV drugs increase insulin resistance. Pentamidine can cause ketosis-prone diabetes.,"Glucocorticoids reduce insulin action, even at low doses. Glucocorticoids can unmask an underlying susceptibility to type 2 diabetes, but can also induce hyperglycemia if used at high enough doses. Glucocorticoid-induced hyperglycemia can have a characteristic pattern of normal (or even low) fasting glucose levels and pronounced hyperglycemia by mid-afternoon (in those patients receiving morning doses). It usually ameliorates in the days or weeks after glucocorticoid cessation. Anti-HIV drugs also increase insulin resistance. They include the protease inhibitors and nucleoside reverse transcriptase inhibitors. Studies indicate that within each of these drug classes, different drugs are more likely to worsen insulin resistance. HIV infection treated with combined antiretroviral therapy (cART) is associated with an increased risk of diabetes, with some studies indicating a fourfold increase.",190,45,0.23684210526315788
9781908541666,ch_6,"Renal, cardiac and lung transplantation increases the risk of diabetes.","Solid organ transplantation is also associated with diabetes mellitus and can be attributed to glucocorticoid use; however, some of the immunosuppressants used in transplantation have also been implicated. Recipients of renal and cardiac transplantation appear particularly susceptible. Lung recipients (particularly those with underlying cystic fibrosis) are also at higher risk because of underlying damage to the exocrine pancreas.",84,14,0.16666666666666666
9781908541666,ch_7,Insulin treatment of type 1 diabetes attempts to keep plasma glucose levels as near normal as possible without causing hypoglycemia.,"A diagnosis of type 1 diabetes changes the lives of affected patients for ever. Many face the prospect of injecting themselves with insulin for the rest of their lives with considerable dread. In time, however, virtually all patients accommodate to the prospect of daily self-injection with a degree of fortitude; indeed, it is the minority of patients who live their lives in complete resentment of their condition. Insulin treatment for type 1 diabetes aims to lower glucose levels in the blood to as near to the normal (non-diabetic) range as possible (Figure 6.1) without causing significant hypoglycemia. The objectives of this strategy are to.",130,25,0.19230769230769232
9781908541666,ch_7,Most young patients are treated with a basal-bolus regimen incorporating rapid-acting insulin analogs at mealtimes and a basal long-acting insulin analog.,"Animal-derived insulins (both porcine and bovine) are used by a diminishing minority of patients with a long duration of diabetes. Most patients with type 1 diabetes are treated with a variety of human insulin preparations or, increasingly, recombinant insulin analogs. Patients using animal insulins sometimes maintain that using human insulin produced either by enzymatic modification or recombinant-DNA technology is associated with lack of awareness of hypoglycemia. However, this phenomenon has not been reported in the USA and the hypothesis has largely been patient driven. There is no scientific evidence to support this contention, though current practice is to support patients who choose to continue using animal insulin as no material harm will ensue. Only a few manufacturers continue to produce insulin derived from animals. No major world insulin producer continues to do so. If patients using animal insulins report hypoglycemia unawareness, the cause of this (other than insulin type) should be explored and appropriate corrective action taken.",201,32,0.15920398009950248
9781908541666,ch_7,Insulin therapy confers the need to perform self-monitoring of blood glucose levels.,"Rapidly acting insulins such as the insulin analog insulin lispro (Humalog) have an onset of action of 5-10 minutes and a duration of action of 3-4 hours. Intermediate-acting insulins such as the isophane insulins act within 30-60 minutes and continue to act for 9-12 hours. Insulin glargine (Lantus), a more truly basal insulin, has an onset of action after 5 hours and will act for more than 24 hours in most cases, while insulin detemir (Levemir) acts after 60 minutes and lasts for 24 hours. The biphasic insulin analogs have an onset of action of 10-20 minutes and a duration of up to 24 hours. Insulin degludec is a new basal ultra-long-acting insulin analog available uniquely in two strengths (100 units/mL and 200 units/mL). It has a half-life of 24 hours and a 42-hour duration of effect, which enables day-to-day flexibility as to when degludec is injected. Rapidly acting insulin analogs can be injected just as the meal is eaten, but it is preferable to inject the other insulins 30-40 minutes before eating in order to match the absorption of insulin into the bloodstream with the rise in blood glucose levels on eating. Table 6.1 lists some common insulin preparations.",288,18,0.0625
9781908541666,ch_7,Twice-daily fixed-mixture regimens may be useful for children and the elderly.,"Twice-daily fixed-mixture regimens comprise injections of a biphasic insulin, such as biphasic insulin lispro (25% insulin lispro, 75% insulin lispro protamine [Humalog Mix25]) or biphasic insulin aspart (30% insulin aspart, 70% insulin aspart protamine [NovoMix 30]) at breakfast and at the evening meal. Clearly this insulin regimen has the advantage of simplicity and hence it has been popular with children and the elderly. However, the lack of flexibility of this regimen means it does not lend itself well to young active patients, particularly those with an irregular lifestyle where the basal-bolus regimen confers considerable advantage.",145,19,0.1310344827586207
9781908541666,ch_7,Pancreatic and islet cell transplantation may be offered to highly selected type 1 patients.,"Novel insulin analogs continue to be developed to help 'fine tune' the treatment by subcutaneous insulin injections. As mentioned above, insulin degludec has an ultra-long-acting profile attributable to the formation of soluble multihexamers at the injection site that degrade, leading to the slow release and subsequent absorption of insulin monomers. To date, studies have shown that this insulin is associated with a reduced incidence of nocturnal hypoglycemia in both type 1 and type 2 diabetes patients.",104,20,0.19230769230769232
9781908541666,ch_7,Pump therapy is a very effective and safe mode of treatment for some patients.,"Insulin pump therapy is recommended as a treatment for children under 12 years of age when multiple injection treatment is considered impractical or inappropriate. Patient choice is another valid reason for pump treatment, but this may pose a problem in some countries where funding may not be available on these grounds. Some patients decline the choice of treating their diabetes with a pump for a variety of reasons. One frequently cited reason is that the physical presence of the pump, although small, is a constant reminder of the diabetic condition. It is estimated that 10-15% of patients would fulfill the criteria for pump therapy, although without conditions patient choice might drive this figure much higher.",129,16,0.12403100775193798
9781908541666,ch_7,Diabetes education programs help diabetic patients to manage their condition more effectively.,"Blood glucose meters measure the concentration of glucose by a variety of methods, but all require the collection of a very small quantity of capillary blood, usually from a fingertip. This is delivered on to a measuring strip that is then inserted into the meter for measurement. Blood glucose meters have become smaller, quicker and ever more sophisticated (an example is shown in Figure 6.8), but the technique of pricking a finger to produce a small sample of blood remains an unpleasant experience that is usually considered more painful than subcutaneous injection of insulin. Not surprisingly, this inhibits some patients from performing the requisite number of blood tests to manage their diabetic condition effectively. Although blood glucose meters achieve clinically acceptable standards of accuracy and precision under laboratory conditions, patients (and indeed doctors and nurses) may not replicate such standards, and this emphasizes the need for proper instruction in the technique of blood glucose measurement and regular assessment of quality control.",183,14,0.07650273224043716
9781908541666,ch_7,Diabetes control is assessed by regular measurement of glycated hemoglobin (HbA 1c ).,"Further to the problems associated with self-monitoring of blood glucose outlined above, HbA 1c measurement has long been the gold standard for the assessment of diabetes control. Glycated (or glycosylated) hemoglobin refers to a series of minor hemoglobin components (HbA 1a, HbA 1b and HbA 1c) formed by the adduction of glucose to normal adult hemoglobin.",88,20,0.22727272727272727
9781908541666,ch_8,"Type 2 diabetes management requires patient education on the fundamentals of self-care, including monitoring of glucose levels, dietary management - with an emphasis on weight reduction in the overweight or obese - increased physical activity and reduced sedentariness.","Treatment of people with type 2 diabetes requires consideration of several aspects of the patient's health, and the range of areas is summarized in Table 7.1. Ideally, an individualized approach that considers the patient holistically is encouraged, with the patient becoming skilled in self-management of most aspects of their diabetes care. Each patient will have varying levels of diabetic complications, cardiovascular risk, risk from hypoglycemia and so on, and thus diabetes care should be tailored to individual needs. It is important to consider care for the patient with type 2 diabetes from the perspective of a multidisciplinary team, with contributions from medical practitioners, nurse educators, dietitians and podiatrists. Psychologists can contribute substantially when appropriate. At diagnosis, the patient should be given simple and clear messages about diabetes and how it may affect health with regard to complications and cardiovascular risk. Importantly, patients should be encouraged that, with excellent glucose, lipid and blood pressure control and smoking cessation, risks of complications and cardiovascular events can be reduced substantially.",207,46,0.2222222222222222
9781908541666,ch_8,"Cardiovascular risk factors must be treated to targets, including lipids and blood pressure. Consideration should be given to acetylsalicylic acid (ASA; aspirin) therapy where appropriate.","The fundamentals of history and examination are critical in assessment for clinical comorbidities. Are there any clues to indicate the duration of diabetes? If present, when did the symptoms of hyperglycemia start? These signals may be as simple as fatigue or sleepiness after eating. Studies show type 2 diabetes is often present for 5 years prior to diagnosis. A family history of diabetic complications or heart disease is useful, as this may signpost a genetic predisposition to nephropathy or cardiovascular disease that helps identify patients for more aggressive prevention (for example, blood pressure normalization and excellent glucose and lipid control in those with a family history of diabetic nephropathy with chronic renal failure). A prior history or family history of myocardial infarction or heart disease mandates therapeutic targets of perfect lipids and blood pressure control, together with acetylsalicylic acid (ASA; aspirin) or anticoagulant as required.",190,39,0.20526315789473684
9781908541666,ch_8,"Glycemic treatment targets aim for an HbA 1c that ranges from 6.0% to 7.0%, depending on the age of the patients and their risk for hypoglycemia.","Over the longer term, HbA 1c levels can be used to measure whether glycemic control is acceptable. Generally, a target of HbA 1c between 6.0% and 7.0% (42 and 53 mmol/mol) is considered adequate control. There has been significant debate as to how tight glycemic control should be in type 2 diabetes, based on large studies such as the UK Prospective Diabetes Study (UKPDS) and intervention studies such as Action in Diabetes and Vascular Disease (ADVANCE) and Action to Control Cardiovascular Risk in Diabetes (ACCORD). While consensus has not been reached, a sensible approach is to consider the individual patients and their unique health needs but with an overall aim of reaching an HbA 1c below 7.0% (53 mmol/mol). In patients who are at risk of hypoglycemia, such as the elderly, a reasonable HbA 1c target is 6.5-7.0% (48-53 mmol/mol) or higher.",212,41,0.19339622641509435
9781908541666,ch_8,Bariatric surgery should be considered in the obese with type 2 diabetes and poor glycemic control.,"Over the longer term, HbA 1c levels can be used to measure whether glycemic control is acceptable. Generally, a target of HbA 1c between 6.0% and 7.0% (42 and 53 mmol/mol) is considered adequate control. There has been significant debate as to how tight glycemic control should be in type 2 diabetes, based on large studies such as the UK Prospective Diabetes Study (UKPDS) and intervention studies such as Action in Diabetes and Vascular Disease (ADVANCE) and Action to Control Cardiovascular Risk in Diabetes (ACCORD). While consensus has not been reached, a sensible approach is to consider the individual patients and their unique health needs but with an overall aim of reaching an HbA 1c below 7.0% (53 mmol/mol). In patients who are at risk of hypoglycemia, such as the elderly, a reasonable HbA 1c target is 6.5-7.0% (48-53 mmol/mol) or higher.",212,20,0.09433962264150944
9781908541666,ch_8,"Medications are often required for glucose control. There are multiple classes of glucose-lowering medications, including metformin, sulfonylureas, thiazolidinediones, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose transporter-2 inhibitors and insulin.","Thiazoledinediones act by stimulating a transcriptional factor, peroxisomal proliferator receptor gamma, resulting in at least several actions that improve insulin sensitivity and glucose control. The thiazoledinediones are generally given once or twice daily. Adverse effects include weight gain and fluid retention, which can precipitate cardiac failure in patients with underlying cardiac disease; rosiglitazone has been implicated in increased coronary risk, although this remains controversial.. There is also an increased risk of fracture. Most recently, some controversial data have suggested a potential increased risk of bladder cancer with prolonged use, though further data are awaited. Incretin therapy refers to two classes of hypoglycemic agent that act by mimicking or increasing circulating levels of gut peptides such as glucagon-like peptide-1 (GLP-1). The GLP-1 analogs are considered to act directly on the beta cells to stimulate insulin secretion; the dipeptidyl peptidase-4 (DPP4) inhibitors act by reducing breakdown of endogenous GLP-1, thereby boosting its systemic half-life and action. These drugs are associated with modest weight loss. Sodium-glucose transporter-2 inhibitors. This relatively new class of glucose-lowering medications selectively inhibit the subtype 2 of the sodium-glucose transport proteins in the kidney. These proteins are responsible for the bulk of glucose reabsorption in the renal tubules. With these medications, excess blood glucose can be somewhat offloaded through excretion in the urine, inducing a modest reduction in blood glucose and possibly also modest weight reduction. alpha-Glucosidase inhibitors. The glucosidase inhibitor acarbose induces a modest reduction in postprandial glucose excursions by reducing dissacharide breakdown and monosaccharide absorption in the gut. Side effects include abdominal distention and flatus.",387,84,0.21705426356589147
9781908541666,ch_8,All patients with type 2 diabetes who smoke must receive smoking cessation intervention(s).,"Smoking cessation is critical in reducing macrovascular disease in patients with diabetes. Patients who smoke should be supported with psychological strategies and, where appropriate, drug therapy to stop smoking. See Fast Facts: Smoking Cessation. Hypertension. Blood pressure should ideally be normalized in patients with diabetes. Weight reduction and increased physical activity may have some benefit; multiple drugs are often necessary. A target of 120/80 mmHg is appropriate, even lower in those with microalbuminuria. See Fast Facts: Hypertension.",107,16,0.14953271028037382
9781908541666,ch_8,"Open dialogue between healthcare professionals and patients is important in order to identify factors that may be undermining self-care, and to rectify poor glucose control early.","It is therefore important to develop an open dialogue with patients and to inquire into factors that may be undermining their self-care. As well as personal factors such as forgetfulness or complacency, or underlying depression that may require intervention, look for external factors such as long working hours or travel times, which may limit opportunities for physical activity or cooking of healthy meals. Are there underlying stresses, such as interpersonal tensions with partners or other family members? Is someone undermining the efforts made at lifestyle change? For example, someone else may be responsible for the food shopping or cooking. Table 7.4 provides a number of questions that may help to reveal aspects of an individual patient's life that need to be addressed in order to facilitate improved diabetes self-care and/or improve glycemic and other healthcare targets.",160,31,0.19375
9781908541666,ch_9,"Suitable management plans for people with diabetes will include addressing nutrition and physical activity, using the skill sets of allied health professionals including dietitians and exercise physiologists, where available. If these specialists are not available or easily accessible, others involved in patient care, including general practitioners, diabetes educators and endocrinologists are ideally placed to provide lifestyle advice to people with diabetes.","Balance of macronutrients. More recently, it has been accepted that different dietary approaches are also appropriate in type 2 diabetes. Specifically, accepted macronutrient content has become more flexible. The first change was the acceptance that different types of fats were not necessarily as harmful as saturated fat. Studies have shown that a higher intake of fat from monounsaturated fat sources improves the glycemic and lipid profiles. Sources of monounsaturated fats include olive and canola oil, avocados and some nuts. Individual need should be considered again: if obesity is an issue and weight loss is desired, energy intake reduction may be compromised if there is increased energy intake by increased consumption of fat, even if it is of high quality. The second change has been the acceptance that lower carbohydrate and higher protein intakes are acceptable and beneficial in type 2 diabetes. Protein sources should remain low in saturated fat. In the patient with excellent or tight glycemic control, insulin or hypoglycemic drugs may require dose reduction with carbohydrate intake reduction, particularly if omitted from any particular meal. Several studies have now shown certain nutrients, including fish oils and monounsaturated fats in the form of olive oil, have cardioprotective effects in people with heart disease. While such studies have not been performed specifically in people with diabetes, it would nevertheless seem prudent to advise that people with diabetes add fish-based meals to their diet and use olive oil as the main oil or fat in the diet.",296,74,0.25
9781908541666,ch_9,Increased physical activity and reduced sedentariness are fundamental to physical health and healthy weight in diabetes control.,"The second change has been the acceptance that lower carbohydrate and higher protein intakes are acceptable and beneficial in type 2 diabetes. Protein sources should remain low in saturated fat. In the patient with excellent or tight glycemic control, insulin or hypoglycemic drugs may require dose reduction with carbohydrate intake reduction, particularly if omitted from any particular meal. Several studies have now shown certain nutrients, including fish oils and monounsaturated fats in the form of olive oil, have cardioprotective effects in people with heart disease. While such studies have not been performed specifically in people with diabetes, it would nevertheless seem prudent to advise that people with diabetes add fish-based meals to their diet and use olive oil as the main oil or fat in the diet.",148,21,0.14189189189189189
9781908541666,ch_9,Diet for healthy weight and optimized glucose control is one of the cornerstones of diabetes self-care.,"Insulin-treated patients (type 1 or type 2 diabetes) receiving meal-time quick-acting insulin (either singly or in a premixed form) need to eat carbohydrate at that meal. It is useful to refer to standard portion sizes or exchanges of carbohydrates for patients, and ensure the premeal insulin dose covers the carbohydrate sufficiently to prevent postmeal hyperglycemia or hypoglycemia. Postmeal glucose testing can help to determine the appropriate premeal insulin dose. It is outside the scope of this chapter to discuss carbohydrate portion size extensively. Patients treated with premeal insulin should receive specific counseling from a dietitian skilled in management of insulin-treated patients.",135,21,0.15555555555555556
9781908541666,ch_10,"Many different types of neuropathy affect diabetic patients, with some being very debilitating.","Neuropathy in diabetes is common and may have many and varied manifestations. The types of neuropathy seen in diabetic patients are set out in Table 9.2. The risk of developing neuropathy is directly linked to the duration of diabetes: after 20 years of diabetes, about 40% of patients have neuropathy (though equally, and interestingly, some 60% will not). The precise cause of diabetic neuropathy is not completely understood. There seems no doubt that it is related to hyperglycemia, with the possibility of mild neuropathy associated with impaired glucose tolerance being present before the development of frank diabetes. However, the development of diabetic neuropathy is thought to depend on many factors in addition to hyperglycemic exposure, including hyperlipidemia, hypertension, smoking, increased height and alcohol.",160,16,0.1
9781908541666,ch_10,"Neuropathy and ischemia increase the risk of foot ulceration, which is associated with enormous healthcare costs.","Neuropathy in diabetes is common and may have many and varied manifestations. The types of neuropathy seen in diabetic patients are set out in Table 9.2. The risk of developing neuropathy is directly linked to the duration of diabetes: after 20 years of diabetes, about 40% of patients have neuropathy (though equally, and interestingly, some 60% will not). The precise cause of diabetic neuropathy is not completely understood. There seems no doubt that it is related to hyperglycemia, with the possibility of mild neuropathy associated with impaired glucose tolerance being present before the development of frank diabetes. However, the development of diabetic neuropathy is thought to depend on many factors in addition to hyperglycemic exposure, including hyperlipidemia, hypertension, smoking, increased height and alcohol.",160,24,0.15
9781908541666,ch_10,Chronic complications of diabetes may be microvascular or macrovascular.,"Chronic insidious sensorimotor neuropathy, often accompanied by asymptomatic motor impairment, is the most frequent abnormality of nerve function seen in diabetes. It may be present at the time of first diagnosis in patients with type 2 diabetes, reflecting the duration of the disorder before formal detection. Patients may have few symptoms or complain of paresthesias, numbness, discomfort or pain accompanied by demonstrable distal sensory loss, loss of vibration sense and loss of deep-tendon reflexes. Motor nerves tend to be affected later, which may result in distal weakness and atrophy, though this is much less common than the sensory symptoms. Once established, this type of neuropathy is usually resistant to treatment other than the use of drugs for symptomatic pain relief. Aside from the unpleasant symptoms, the significance of this type of neuropathy is that once severe, sensory loss - together with lower-limb ischemia - becomes a major risk factor for the development of neuropathic ulceration and a Charot joint.",209,15,0.07177033492822966
9781908541666,ch_10,All diabetic patients must be screened for the presence of retinopathy and referred for ophthalmic review where necessary. Intravitreal injections with anti-VEGF agents are now considered the gold standard of therapy for eyes with center-involving macular edema and reduced vision.,"Laser photocoagulation is used to treat proliferative diabetic retinopathy and maculopathy (Figure 9.10). New vessels are photocoagulated and, in cases of more severe proliferative retinopathy, panretinal photocoagulation is performed (id est laser burns to the entire retina, sparing the central macular area). The strategy for treating macular edema depends on the type and extent of vessel leakage. With focal leakage, microaneurysms are treated directly with laser photocoagulation. With non-specific foci of leakage, a grid of laser burns is applied. Photocoagulation aims to destroy hypoxic retinal tissue and may decrease the overproduction of vasoactive factors such as VEGF. Vitrectomy may be necessary to treat vitreous hemorrhage that fails to resolve spontaneously. Anti-VEGF agents. VEGF has been identified as having a major role in the genesis of diabetic retinopathy, and many ophthalmologists use intravitreal injections of anti-VEGF agents to treat diabetic macular edema based on their success in the treatment of age-related macular edema. This is an invasive technique that requires skilled operators; frequent repeat injections are usually required. Anti-VEGF agents include pegaptamib sodium, ranibizumab, bevacizumab and aflibercept. Although the effectiveness and safety of anti-VEGF agents continue to be investigated in several clinical trials, they are now considered to be the new gold standard of therapy for eyes with center-involving macular edema and reduced vision.",336,58,0.17261904761904762
9781908541666,ch_10,Diabetic nephropathy is the leading cause of chronic renal failure in western societies.,"Diabetic nephropathy has become the leading cause of chronic renal failure in the USA and other western societies. It accounts for 30-40% of cases of end-stage renal failure in the USA. Proteinuria occurs in 15-40% of patients with type 1 diabetes and rarely develops before 10 years' duration. In patients with type 2 diabetes the prevalence is highly variable, ranging from 5% to 20%. Nephropathy is frequently associated with the development of type 1 diabetes before the age of 15 years. The incidence of nephropathy peaks after 10-20 years of type 1 diabetes and declines thereafter, suggesting a possible genetic predisposition to this complication. Although diabetic nephropathy is less common in type 2 diabetes, as this type of diabetes is much more prevalent, most patients with diabetes-related chronic kidney disease will have type 2 diabetes. An increase in patients with end-stage renal disease from type 2 diabetes has been observed even in countries with a low incidence of type 2 diabetes.",203,18,0.08866995073891626
9781908541666,ch_10,Treatment of diabetic nephropathy with blood-pressure reduction and angiotensin-converting enzyme (ACE) inhibitors slows disease progression.,"Treatment. Intensive glycemic control has been shown in several studies to slow the progression of diabetic nephropathy. Dietary protein restriction (0.3-0.8 g/kg/day) has also been shown to have a beneficial effect, though is difficult to maintain. In the presence of hypertension, vigorous blood pressure reduction attenuates the decline in renal function and delays progression to end-stage renal failure. A target blood pressure of 120/70 mmHg is usual. Antihypertensive therapy irrespective of the agent used will slow the development of diabetic nephropathy; however, the use of ACE inhibitors to lower blood pressure has been associated with superior clinical benefit in this context, probably because ACE inhibitors reduce intraglomerular capillary pressure, leading to a reduction in proteinuria. Treatment with ACE inhibitors also delays the development of diabetic nephropathy in patients with microalbuminuria. ACE inhibitors have also been demonstrated to have a beneficial effect on diabetic retinopathy. Superiority over conventional agents has also been proven for AR2Bs.",218,30,0.13761467889908258
9781908541666,ch_10,Major vascular disease accounts for more than half of all deaths in diabetes.,"In the WHO Multinational Study of Vascular Disease in Diabetes, cardiovascular disease was the most common cause of death, accounting for 44% of deaths in type 1 diabetes and 52% of deaths in type 2 diabetes. Diabetes is associated with a two- to fourfold increase in the risk of coronary artery disease, cerebrovascular disease and peripheral-limb ischemia (Figure 9.14). Diabetic patients, particularly women, have an increased risk of dying from coronary artery disease and an increased mortality from peripheral vascular disease. Of all lower-limb amputations, 50% are performed on diabetic patients. Atherosclerosis is more severe and widespread in diabetic patients, and consequently coronary artery disease may present at a younger age than in the non-diabetic population. Diabetic patients have more multivessel disease of the coronary arteries. They also have an increase in left ventricular mass. While this may be partly related to the increased prevalence of hypertension in this population, diabetes appears to be an independent contributor to left ventricular mass. This fact and other considerable pathological, epidemiological and clinical data point to the existence of a specific diabetic cardiomyopathy.",235,14,0.059574468085106386
9781908541666,ch_10,Lowering of blood pressure to 130/80 mmHg is associated with a considerable reduction in vascular morbidity and microvascular disease.,"In the UK Prospective Diabetes Study (UKPDS), each 10 mmHg decrease in mean systolic pressure was associated with a reduction in risk of 12% for any complication related to diabetes, 15% for risk of death related to diabetes, 11% for risk of myocardial infarction and 13% for risk of microvascular complications. In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril reduced the rates of death, myocardial infarction and stroke in a broad range of high-risk patients, 40% of whom had diabetes. In the Hypertension Optimal Treatment (HOT) study, intensive treatment of blood pressure to achieve a target of 140/81 mmHg was associated with a 66% reduction in mortality in people with diabetes. Multiple drug therapy was necessary to achieve this target. This study also showed that in people with diabetes, blood pressure needed to be lowered further than in those without diabetes to achieve equivalent benefit on mortality. Table 9.8 shows the risk reductions for macro- and microvascular outcomes associated with intensive blood pressure reduction in the UKPDS.",231,28,0.12121212121212122
9781908541666,ch_10,Failure of erection occurs in 38-55% of men with diabetes.,"Failure of erection is a common complication of diabetes in men (see Fast Facts: Erectile Dysfunction). It occurs with an estimated prevalence of 38-55%. Erectile dysfunction is now viewed, in most cases, as a vascular complication of diabetes. It is most likely to result from a defect in nitric-oxide-mediated smooth-muscle relaxation as a consequence of autonomic nerve damage and endothelial dysfunction. Large-vessel disease may also play a role.",97,14,0.14432989690721648
9781908541666,ch_10,"It is important to recognize psychological stress and depression in patients with diabetes, as lifestyle changes associated with the condition can be overwhelming for some.","Management considerations. It is important to recognize psychological stress and depression in people with diabetes, and to consider how as healthcare professionals we may offer support. Strategies to prevent weight gain in people with major mental illness include lifestyle interventions, such as supported eating and exercise regimens, when antipsychotic drugs are initiated. Short-term studies also show that metformin can be of benefit. It is also important to consider the unique vulnerability and needs of people with a double diagnosis of diabetes and severe mental illness. Studies have shown that this group is particularly vulnerable to complications of diabetes, with documented disparities in diabetes care delivery, poorer glycemic control, lower screening rates for complications and poorer cardiovascular risk factor control. As such, prevention of diabetes in this group remains paramount, and supported engaged treatment must be provided if diabetes develops.",162,27,0.16666666666666666
9781908541666,ch_11,Hypoglycemia is a barrier to the achievement of tight glycemic control.,"Acute hypoglycemia potentially threatens the quality of life on a daily basis for people with type 1 diabetes. It may also affect patients with type 2 diabetes, especially those who are treated with sulfonylureas or insulin. Hypoglycemia represents a considerable barrier to the goal of achievement of near-normal blood glucose levels in insulin-treated patients. It is feared by patients with diabetes treated with insulin and has the capacity to seriously disrupt their lives.",93,16,0.17204301075268819
9781908541666,ch_11,Frequent hypoglycemia may lead to the development of hypoglycemia unawareness.,"Acute hypoglycemia potentially threatens the quality of life on a daily basis for people with type 1 diabetes. It may also affect patients with type 2 diabetes, especially those who are treated with sulfonylureas or insulin. Hypoglycemia represents a considerable barrier to the goal of achievement of near-normal blood glucose levels in insulin-treated patients. It is feared by patients with diabetes treated with insulin and has the capacity to seriously disrupt their lives.",93,19,0.20430107526881722
9781908541666,ch_11,There are many and varied causes of hypoglycemia.,"The symptoms of hypoglycemia are listed in Table 10.1. The initial symptoms of hypoglycemia are caused by sympathoadrenal activation. Such symptoms include sweating, shakiness, palpitation, anxiety and a sensation of hunger. Patients come to recognize their own hypoglycemic symptoms, which are often highly individualized. If hypoglycemia is not reversed promptly then patients may go on to develop symptoms due to neuroglycopenia (resulting from brain neuronal glucose deprivation) and these symptoms include behavioral changes, cognitive dysfunction and even seizures and coma.",117,12,0.10256410256410256
9781908541666,ch_11,Symptomatic hypoglycemia is common in patients with type 1 diabetes.,"People with type 1 diabetes experience symptomatic hypoglycemia on average twice per week, with significant disabling hypoglycemia occurring approximately once a year. Hypoglycemia is much less common in people with type 2 diabetes but frequently goes unrecognized. In the UK Hypoglycaemia Study Group, there was a low incidence of hypoglycemia in those taking oral hypoglycemic drugs, but an appreciable incidence in those on insulin therapy. The glucose threshold that triggers hypoglycemia in diabetic patients is different from that in people without diabetes. Hypoglycemia may be experienced at a higher plasma glucose threshold in patients with poorly controlled diabetes, while patients with tightly controlled diabetes may tolerate remarkably low plasma glucose levels without experiencing hypoglycemic symptoms.",152,16,0.10526315789473684
9781908541666,ch_11,Death from hypoglycemia is rare.,"Death from hypoglycemia is rare, but it may follow excess alcohol consumption or deliberate insulin overdose. Occasionally, tragically unexpected deaths happen in young patients with type 1 diabetes; these often occur in bed and it has been speculated that they may result from hypoglycemia-induced cardiac dysrhythmias.",62,9,0.14516129032258066
9781908541666,ch_12,Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 diabetes.,"Diabetic ketoacidosis (DKA) is a serious life-threatening complication of type 1 diabetes. DKA occurs more often in adults than in children, but it can occur at any age. Most commonly seen in young adults, it is the main cause of death in type 1 diabetic patients under the age of 20 years. DKA may also be encountered in people with type 2 diabetes, particularly in those of Afro-Caribbean descent. When DKA occurs in type 2 diabetes, it is the physiological stress caused by the underlying illness that precipitates the acute metabolic decompensation.",120,21,0.175
9781908541666,ch_12,"DKA is characterized by hyperglycemia, hyperketonemia and acidosis.","Of the infective causes, urinary tract infection and pneumonia predominate. Other common medical conditions such as myocardial infarction, acute stroke, pancreatitis and trauma may precipitate DKA. Alcohol or drug abuse may also contribute. Newly diagnosed, previously unknown type 1 diabetes causes about 15% of cases. Missed insulin injections account for about 25% of cases. Often, psychological factors are implicated if there has been deliberate insulin omission or non-compliance with insulin therapeutic regimens. Frequent recurrent DKA in one individual is a commonly encountered clinical scenario - it is usually the consequence of a psychosocial problem that may be very difficult to delineate. The incidence of DKA is slightly greater in females than in males. Recurrent DKA in young women is frequently caused by insulin omission. Eating disorders can be an important contributory factor. However, no definite cause is found in a large proportion of cases of DKA. Clinical presentation. DKA is characterized by hyperglycemia, hyperketonemia and metabolic acidosis, which occur as a consequence of insulin deficiency or ineffectiveness, accompanied by increased circulating concentrations of counter-regulatory hormones (cortisol, growth hormone, glucagon and catecholamines) (Figure 11.1).",258,18,0.06976744186046512
9781908541666,ch_12,Infection is the most common precipitating factor in DKA.,"Of the infective causes, urinary tract infection and pneumonia predominate. Other common medical conditions such as myocardial infarction, acute stroke, pancreatitis and trauma may precipitate DKA. Alcohol or drug abuse may also contribute. Newly diagnosed, previously unknown type 1 diabetes causes about 15% of cases. Missed insulin injections account for about 25% of cases. Often, psychological factors are implicated if there has been deliberate insulin omission or non-compliance with insulin therapeutic regimens. Frequent recurrent DKA in one individual is a commonly encountered clinical scenario - it is usually the consequence of a psychosocial problem that may be very difficult to delineate. The incidence of DKA is slightly greater in females than in males. Recurrent DKA in young women is frequently caused by insulin omission. Eating disorders can be an important contributory factor. However, no definite cause is found in a large proportion of cases of DKA.",189,14,0.07407407407407407
9781908541666,ch_12,Treatment of HHS is similar to the treatment of DKA.,"Of the infective causes, urinary tract infection and pneumonia predominate. Other common medical conditions such as myocardial infarction, acute stroke, pancreatitis and trauma may precipitate DKA. Alcohol or drug abuse may also contribute. Newly diagnosed, previously unknown type 1 diabetes causes about 15% of cases. Missed insulin injections account for about 25% of cases. Often, psychological factors are implicated if there has been deliberate insulin omission or non-compliance with insulin therapeutic regimens. Frequent recurrent DKA in one individual is a commonly encountered clinical scenario - it is usually the consequence of a psychosocial problem that may be very difficult to delineate. The incidence of DKA is slightly greater in females than in males. Recurrent DKA in young women is frequently caused by insulin omission. Eating disorders can be an important contributory factor. However, no definite cause is found in a large proportion of cases of DKA.",189,13,0.06878306878306878
9781908541666,ch_12,"Treatment of DKA is by fluid and electrolyte replacement, intravenous insulin and treatment of the underlying cause, when known.","Treatment. Immediate treatment of any identifiable cause of the DKA should be undertaken without delay. Until recently, standard management of DKA focused on reducing blood glucose levels with insulin and intravenous fluids. There is still universal agreement that the initial cornerstone of treatment is fluid replacement and insulin administration. The intravascular volume should be expanded to correct a typical deficit of 100 mL/kg of water with intravenous isotonic saline, which will also improve renal perfusion. Infusion rates of 1 L per hour for the first hour, 1 L for the next 2 hours and 1 L over the next 4 hours are usually adequate except in those patients with profound hypovolemia and hypotension, who may need twice this amount (Table 11.3). If the initial systolic blood pressure is below 90 mmHg, 500 mL of normal saline should be given over 15 minutes. In the presence of significant hypernatremia, isotonic saline can be replaced with 0.45% saline. The aim is to replace total body deficits of water and electrolytes, with half the estimated deficit being replaced in 12-24 hours (see Table 11.3). Once the blood glucose has fallen to about 14 mmol/L (252 mg/dL), saline should be replaced with 5% dextrose (or an infusion of 10% glucose given at 125 mL/hour started alongside the infusion of normal saline to correct circulatory volume) to allow continued insulin administration to suppress ketogenesis while avoiding hypoglycemia.",305,26,0.08524590163934426
9781908541666,ch_12,The overall mortality of DKA is 3-4%.,"Prognosis. The prognosis of DKA is usually determined by the precipitating cause. The overall mortality is 3-4%. Cerebral edema is a rare life-threatening complication usually encountered in children with DKA (around 1% of episodes). It carries a mortality of 40-90% and manifests as a decreasing level of consciousness, with headache, seizures, papilledema, bradycardia and respiratory arrest. Treatment is with intravenous mannitol. Mechanical ventilation may help to reduce swelling of the brain. In the UK, 70-80% of diabetes-related deaths in children under 12 years of age are caused by cerebral edema.",134,11,0.08208955223880597
9781908541666,ch_12,"HHS is similar to DKA, but without ketosis and acidosis.","Hyperosmolar hyperglycemic state (HHS) is one of the two serious metabolic derangements in diabetes that may be life-threatening. It is less common than DKA, but carries a higher mortality rate (10-20%). Other terms used to describe the condition include diabetic hyperosmolar non-ketoacidotic coma, hyperosmolar hyperglycemic non-ketotic coma and hyperosmolar non-ketotic state. HHS is characterized by severe hyperglycemia, dehydration and hyperosmolarity in the absence of ketonemia/ketonuria and acidosis (Table 11.4).",131,16,0.12213740458015267
9781908541666,ch_12,Hyperosmolar hyperglycemic state (HHS) occurs in older patients with type 2 diabetes.,"HHS usually occurs in middle-aged or elderly patients with type 2 diabetes (often undiagnosed). The absence of ketoacidosis in HHS is not fully explained but may be because such individuals have insulin levels low enough to cause hyperglycemia but adequate to inhibit lipolysis and ketogenesis because of the differential effect of insulin on lipolysis and glucose uptake. HHS occurs in patients with type 2 diabetes in the presence of a concomitant illness that leads to reduced fluid intake. Infection (commonly urinary tract infection and pneumonia) is the preceding illness in 30-60% of cases. Other relatively frequent causes include myocardial infarction, stroke and concomitant drug use such as thiazide diuretics or corticosteroids.",157,21,0.1337579617834395
9781908541666,ch_13,Diabetic pregnancy is associated with fetal morbidity.,"Diabetic pregnancy is associated with an increased risk of adverse outcome for the fetus, but there is little excess mortality among diabetic women. Pregnancy may be complicated by type 1 diabetes, gestational diabetes mellitus (GDM) and, increasingly, by type 2 diabetes. Occasionally, both types 1 and 2 may be diagnosed for the first time during pregnancy. Of all pregnancies in the USA, 3-10% are complicated by diabetes (90% are cases of GDM). Prevalence is higher in certain ethnic groups such as Asian, Afro-Caribbean and Hispanic groups. The fetal morbidity associated with diabetes is shown in Table 12.1.",133,10,0.07518796992481203
9781908541666,ch_13,"GDM is becoming increasingly common, particularly in certain ethnic groups.","Diabetic pregnancy is associated with an increased risk of adverse outcome for the fetus, but there is little excess mortality among diabetic women. Pregnancy may be complicated by type 1 diabetes, gestational diabetes mellitus (GDM) and, increasingly, by type 2 diabetes. Occasionally, both types 1 and 2 may be diagnosed for the first time during pregnancy. Of all pregnancies in the USA, 3-10% are complicated by diabetes (90% are cases of GDM). Prevalence is higher in certain ethnic groups such as Asian, Afro-Caribbean and Hispanic groups. The fetal morbidity associated with diabetes is shown in Table 12.1.",133,13,0.09774436090225563
9781908541666,ch_13,Treatment of GDM is associated with improved fetal outcome.,"Diabetic pregnancy is associated with an increased risk of adverse outcome for the fetus, but there is little excess mortality among diabetic women. Pregnancy may be complicated by type 1 diabetes, gestational diabetes mellitus (GDM) and, increasingly, by type 2 diabetes. Occasionally, both types 1 and 2 may be diagnosed for the first time during pregnancy. Of all pregnancies in the USA, 3-10% are complicated by diabetes (90% are cases of GDM). Prevalence is higher in certain ethnic groups such as Asian, Afro-Caribbean and Hispanic groups. The fetal morbidity associated with diabetes is shown in Table 12.1.",133,12,0.09022556390977443
9781908541666,ch_13,Miscarriage rates are high in diabetic pregnancy.,"There is a miscarriage rate of 9-14% among women with pre-existing diabetes. Higher rates are seen in those with very poor glycemic control. The risk of a structural anomaly in the fetus is four to eight times the rate in the normal population. The congenital malformation rate in diabetic pregnancy is 5.1-9.8%. Two-thirds of the birth defects affect the cardiovascular and central nervous systems, with neural tube defects being particularly common. The achievement of meticulous preconception glycemic control can reduce the incidence of malformation to near normal.",113,11,0.09734513274336283
9781908541666,ch_13,The congenital malformation rate is 5.1-9.8%.,"There is a miscarriage rate of 9-14% among women with pre-existing diabetes. Higher rates are seen in those with very poor glycemic control. The risk of a structural anomaly in the fetus is four to eight times the rate in the normal population. The congenital malformation rate in diabetic pregnancy is 5.1-9.8%. Two-thirds of the birth defects affect the cardiovascular and central nervous systems, with neural tube defects being particularly common. The achievement of meticulous preconception glycemic control can reduce the incidence of malformation to near normal.",113,15,0.13274336283185842
9781908541666,ch_13,Strict glycemic control improves the outcome of diabetic pregnancy.,"There is a miscarriage rate of 9-14% among women with pre-existing diabetes. Higher rates are seen in those with very poor glycemic control. The risk of a structural anomaly in the fetus is four to eight times the rate in the normal population. The congenital malformation rate in diabetic pregnancy is 5.1-9.8%. Two-thirds of the birth defects affect the cardiovascular and central nervous systems, with neural tube defects being particularly common. The achievement of meticulous preconception glycemic control can reduce the incidence of malformation to near normal.",113,12,0.10619469026548672
9781908541666,ch_13,Both growth restriction and growth acceleration may complicate diabetic pregnancy.,"Diabetic pregnancy is linked with the development of large-for-gestational-age babies, but growth restriction in patients with pre-existing type 1 diabetes may also occur, particularly when the diabetes is associated with vascular complications. Fetal macrosomia (affecting 15-45% of babies born to diabetic women) is a frequent complication of diabetic pregnancy and increases the likelihood of birth injuries such as shoulder dystocia and brachial plexus trauma. Perinatal mortality has fallen greatly in diabetic pregnancies but remains approximately twice that observed in non-diabetic pregnancies, with serious congenital malformations accounting for a large proportion of fetal loss.",134,11,0.08208955223880597
9781908541666,ch_13,Fetal macrosomia increases the likelihood of birth injury.,"Diabetic pregnancy is linked with the development of large-for-gestational-age babies, but growth restriction in patients with pre-existing type 1 diabetes may also occur, particularly when the diabetes is associated with vascular complications. Fetal macrosomia (affecting 15-45% of babies born to diabetic women) is a frequent complication of diabetic pregnancy and increases the likelihood of birth injuries such as shoulder dystocia and brachial plexus trauma. Perinatal mortality has fallen greatly in diabetic pregnancies but remains approximately twice that observed in non-diabetic pregnancies, with serious congenital malformations accounting for a large proportion of fetal loss.",134,13,0.09701492537313433
9781908541666,ch_13,Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset during pregnancy.,"GDM is defined as glucose intolerance with onset or first recognition during pregnancy. Previously there were no uniformly accepted international standards for the diagnosis of GDM. New evidence has emerged to change practice. The large multinational Hyperglycemia and Pregnancy Outcome (HAPO) study has demonstrated a linear relationship between maternal hyperglycemia and birth weight, with no apparent threshold effect between maternal glycemia and pregnancy outcome. The Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) has established that treatment of GDM with insulin improves pregnancy outcomes (such as birth weight, macrosomia and shoulder dystocia). The International Association of Diabetes and Pregnancy Study Groups (IADPSG) has attempted to achieve an international consensus on screening and diagnosis of gestational diabetes. It recommends a 75 g oral glucose tolerance test (OGTT) for all women who are not known to be diabetic at 24-28 weeks. Gestational diabetes is diagnosed when one or more threshold values are exceeded (fasting >= 5.1 mmol/L [92 mg/dL), 1-hour >= 10.0 mmol/L [180 mg/dL], 2-hour >= 8.5 mmol/L [153 mg/dL]). Other guidelines (for example, those from the Scottish Intercollegiate Guidelines Network [SIGN]) advocate a more selective approach to screening on the basis of risk factors (for example, obesity, a first-degree relative with diabetes, ethnicity, advanced maternal age, previous GDM and a previous macrosomic baby).",314,20,0.06369426751592357
9781908541680,ch_2,The initial approach is crucial: an individual can be permanently engaged or alienated depending on the opening gambit.,"Not to broach the subject of excess weight with a patient is a dereliction of duty as a health professional. Obesity is often considered to be a 'heart sink' condition: reluctance to address the issue may be due to time constraints, lack of training on obesity or in conducting sensitive conversations, anxiety about patient attitudes to raising a personal issue and/or concerns that the individual did not present asking for their global metabolic risk to be reduced. In children, the specter of anorexia and malnutrition loom large in clinicians' perception, as does the risk of upsetting angry parents by the inadvertent suggestion that the blame lies with their flawed upbringing skills. The initial approach taken is crucial, however, as an individual can be permanently engaged or alienated depending on the opening gambit.",156,21,0.1346153846153846
9781908541680,ch_2,The best initial screening method is to look at the patient: an obese abdomen is a simple physical sign to pick up but can be indicative of potentially serious underlying disease.,"Not to broach the subject of excess weight with a patient is a dereliction of duty as a health professional. Obesity is often considered to be a 'heart sink' condition: reluctance to address the issue may be due to time constraints, lack of training on obesity or in conducting sensitive conversations, anxiety about patient attitudes to raising a personal issue and/or concerns that the individual did not present asking for their global metabolic risk to be reduced. In children, the specter of anorexia and malnutrition loom large in clinicians' perception, as does the risk of upsetting angry parents by the inadvertent suggestion that the blame lies with their flawed upbringing skills. The initial approach taken is crucial, however, as an individual can be permanently engaged or alienated depending on the opening gambit.",156,33,0.21153846153846154
9781908541680,ch_2,Decreased waist circumference in the absence of weight loss can keep a patient motivated.,"A patient attending a diabetes or cardiovascular clinic can be asked whether they have lost or gained weight recently. Any patient can be offered a 'well patient check' during a consultation, which will include measurement of weight, height and waist circumference. 'Best practice in weight management' can be performed in the last 2 minutes of any consultation, provided that appropriate follow-up is offered. These 2 minutes are the most important part of the entire weight-loss program.",91,16,0.17582417582417584
9781908541680,ch_2,"Whatever the reason for a patient's presentation, the presence of obesity should be acknowledged and tackled.","The examination should include measurement of height, weight and waist circumference (see Assessment of body fat). Body fat analysis is optional but is useful for identifying patients with a normal body mass index (BMI) but high percentage of fat and for monitoring progress, in particular providing encouragement to patients who are improving their health by increased activity but who fail to lose weight. A general visual assessment of a person's fat distribution and body morphology is useful to define a central, peripheral or mixed pattern of fat distribution. The presence of any dysmorphic features should be noted, as these may suggest the presence of an obesity syndrome.",122,19,0.1557377049180328
9781908541680,ch_2,Waist circumference is directly proportional to the amount of visceral fat. It has gained recognition as a more accurate indicator of cardiometabolic risk than body mass index and is being increasingly embraced in routine medical practice.,"Waist circumference is directly proportional to the amount of visceral fat and is therefore an accurate marker of cardiometabolic risk. Correct measurement is shown in Figure 1.1. Measurements are reproducible with little practice and provide a tangible figure: 102 cm (40 inches) is a meaningful term compared with the abstract score of BMI. Patients can easily measure waist circumference themselves. Waist circumference has gained recognition as a more accurate indicator of cardiometabolic risk than BMI, and is being increasingly embraced in routine medical practice. Definitions of overweight and obesity in terms of waist circumference are given in Table 1.3. A degree of abdominal obesity is usually recognizable as soon as a patient enters the clinic, and may well represent potentially serious underlying pathology that requires identification and management. Even if the patient's BMI is normal, the clinician has a responsibility to undertake appropriate risk management. Measurement of blood pressure and evaluation of the blood lipid profile and blood glucose is mandatory in such individuals.",196,42,0.21428571428571427
9781908541680,ch_3,Physiological and genetic influences that promoted survival of our ancestors now promote obesity and comorbid disease.,"For our prehistoric ancestors, the rules for survival were simple: eat whenever possible, and rest to conserve energy for times when it was needed to preserve life. Those that could store energy efficiently as fat when food was available survived times of fast and famine. In today's environment, eating for survival and conserving vital energy have transformed into overeating and underactivity. This, combined with food processing that increases the energy density and decreases the nutrient and fiber content of food, and the consumption of sugared drinks instead of water for hydration, predispose individuals to serious chronic disease and premature death.",119,20,0.16806722689075632
9781908541680,ch_3,"Most causes of adult obesity are within the grasp of an individual to control, but babies and children rely on their parents and carers to provide an appropriate environment.","Basal metabolic rate reflects the energy expended on the basic metabolic processes necessary for life and constitutes 45-70% of total energy expenditure in adults. It can be measured accurately using indirect calorimetry in the morning after 8 hours' rest and 12 hours after a meal, while supine and awake. Calorimetric measurement requires abstinence from strenuous physical activity the day before, a state of mental relaxation and an ambient environmental temperature that does not evoke shivering or sweating. It is therefore perhaps more appropriately termed 'resting energy expenditure'. Resting energy expenditure is higher in men than women, and in both sexes it depends on fat-free mass, fat mass and age. Fat-free mass is the best predictor of resting energy expenditure and accounts for most of the variability between individuals; however, a large fat mass will also contribute significantly to resting energy expenditure. It is now also recognized that humans have deposits of active brown adipose tissue that generate heat in cold environments, although the extent to which these deposits affect BMR in thermoneutral environments is uncertain. Various factors may increase resting energy expenditure, including thyroid hormone, growth hormone and activation of the sympathetic nervous system.",236,32,0.13559322033898305
9781908541680,ch_3,"Iatrogenic causes of obesity should be considered. The effect on weight of managing comorbid conditions is important, particularly diabetes in which weight gain is potentially catastrophic.","Basal metabolic rate reflects the energy expended on the basic metabolic processes necessary for life and constitutes 45-70% of total energy expenditure in adults. It can be measured accurately using indirect calorimetry in the morning after 8 hours' rest and 12 hours after a meal, while supine and awake. Calorimetric measurement requires abstinence from strenuous physical activity the day before, a state of mental relaxation and an ambient environmental temperature that does not evoke shivering or sweating. It is therefore perhaps more appropriately termed 'resting energy expenditure'. Resting energy expenditure is higher in men than women, and in both sexes it depends on fat-free mass, fat mass and age. Fat-free mass is the best predictor of resting energy expenditure and accounts for most of the variability between individuals; however, a large fat mass will also contribute significantly to resting energy expenditure. It is now also recognized that humans have deposits of active brown adipose tissue that generate heat in cold environments, although the extent to which these deposits affect BMR in thermoneutral environments is uncertain. Various factors may increase resting energy expenditure, including thyroid hormone, growth hormone and activation of the sympathetic nervous system.",236,34,0.1440677966101695
9781908541680,ch_3,Transformation of our food habits has been a key factor in the increase of obesity and diabetes: energy-dense processed food is readily available in bigger and cheaper portions than ever before.,"A landmark paper published in the British Medical Journal in 1995 entitled 'Obesity in Britain: gluttony or sloth?' concluded that reduction in physical activity, rather than increased energy intake, was the fundamental cause of the obesity epidemic. A decline in activity was possibly the major feature of the early rise in obesity levels in the 1960s to 1980s. Certainly, the ready availability of labor-saving devices and technology has contributed to this, as have more sedentary occupations and leisure time based around sedentary activities such as watching television and online/computer-based activities. Current thinking, however, is that transformation of our food habits has been the major amplifier of the high prevalence of obesity and diabetes, largely in response to intense industry competition. Processing of food is now common but profoundly alters nutritional balance, increases energy density and potentially creates exposure to a variety of chemicals. Also, food is available day and night in supermarkets and fast-food outlets at almost any geographic location, and in bigger, cheaper and unhealthier portions than ever.",207,37,0.178743961352657
9781908541680,ch_3,Genetic influences act alongside environmental factors to promote obesity.,"'Obesity genes'. Genetic factors can determine whether a person is prone to gaining weight, and the likely magnitude of the weight gain, as shown by overfeeding studies in twins. It is estimated that 50-70% of the variation in fat mass between individuals has a genetic basis, due to polygenic environmental interactions rather than individual 'obesity genes'.",71,11,0.15492957746478872
9781908541680,ch_4,Obesity significantly affects cardiometabolic status and risk.,"Definition of the metabolic syndrome is of value because it ensures that any patient with a single cardiovascular risk factor, including obesity, is screened for the others, as their presence is statistically highly likely and coexistent cardiometabolic risks multiply the overall risk. It also ensures that a patient with multiple risk factors, even those considered borderline, is managed as a high-risk individual. The aim of management is to tackle the syndrome as a whole, and obesity in particular. Management of single or even multiple cardiometabolic risk factors, for example hypertension or hyperlipidemia alone, or even the combination of hyperlipidemia, hyperglycemia and hypertension, is insufficient; the fundamental issues of excess and pathologically distributed body fat, exercise deficiency and a nutritionally poor diet require attention.",160,12,0.075
9781908541680,ch_4,The metabolic syndrome defines the clustering of cardiovascular risk factors under the umbrella of obesity.,"Definition of the metabolic syndrome is of value because it ensures that any patient with a single cardiovascular risk factor, including obesity, is screened for the others, as their presence is statistically highly likely and coexistent cardiometabolic risks multiply the overall risk. It also ensures that a patient with multiple risk factors, even those considered borderline, is managed as a high-risk individual. The aim of management is to tackle the syndrome as a whole, and obesity in particular. Management of single or even multiple cardiometabolic risk factors, for example hypertension or hyperlipidemia alone, or even the combination of hyperlipidemia, hyperglycemia and hypertension, is insufficient; the fundamental issues of excess and pathologically distributed body fat, exercise deficiency and a nutritionally poor diet require attention.",160,17,0.10625
9781908541680,ch_4,"Weight loss rapidly and effectively reduces cardiovascular risk and the burden of atrial fibrillation, and improves cardiac function.","Is weight loss always beneficial? Obesity, particularly when severe, is associated with an increase in mortality. The Framingham Heart Study estimated a reduced life expectancy of 5.8 and 7.1 years in 40-year-old obese men and women (non-smokers), respectively. The lowest mortalities occur in people who are normal weight or overweight and remain weight stable. For people who are overweight, gaining more weight increases mortality. Weight loss in cohort studies, particularly in older populations, has been associated with an increase in all-cause mortality but these data may be confounded by individuals with unintentional weight loss caused by an underlying disease process. Conversely, in controlled clinical trials, 5% weight loss as part of a healthy lifestyle intervention in people over the age of 65 has been associated with a reduction in mortality. It appears, therefore, that weight loss in and of itself may not necessarily confer benefit independent of an underlying condition, or adopting healthy eating behaviors and regular physical activity.",196,23,0.11734693877551021
9781908541680,ch_4,Type 2 diabetes mellitus is the comorbidity most closely linked with obesity. Weight loss prevents the disease in those at risk and improves glycemic control when it is present.,"The lag phase between the onset of uncomplicated obesity (BMI > 30 kg/m) and the development of diabetes can be 10-12 years. However, the underlying pathological changes are already developing when the patient is overweight, even though outward signs and symptoms may remain undetected, and therefore the possibility of disordered glucose metabolism must be considered and looked for. Type 2 diabetes mellitus is a preventable disease. Moreover, recent data have clearly shown that aggressive early management confers the best chance to prevent, or at the very least substantially delay, both progression of the disease and emergence of cardiovascular and other complications. Once complications are established very tight control is less beneficial. Also see Fast Facts: Diabetes Mellitus.",145,36,0.2482758620689655
9781908541680,ch_4,Lipid disorders and hypertension are exacerbated by obesity and add to cardiovascular risk.,"Mechanism of obesity-related hypertension. Increased renal sodium reabsorption and blood volume expansion are central features in the development of obesity-related hypertension. Hyperinsulinemia leads to renal salt retention. Overweight is also associated with increased sympathetic activity, an effect that may be mediated by leptin, a protein expressed in and secreted by adipocytes (see Chapter 2). The renin-angiotensin-aldosterone system has also been causally implicated in obesity-related hypertension, partly because of activation by increased sympathetic activity, and perhaps also because angiotensinogen is expressed in and secreted by adipose tissue. Low levels of the adipocyte-derived cytokine adiponectin, high circulating levels of free fatty acids and increased vascular production of endothelin-1 have also been implicated in mediating the effect of obesity to increase blood pressure, although recent studies have suggested that BMI, in the absence of diabetes, does not affect plasma adiponectin levels.",200,16,0.08
9781908541680,ch_5,Obesity is associated with potentially serious physical and psychological consequences; almost every system in the body may be affected (see The health risks of excess weight ).,"Plasma testosterone. Obesity, particularly when visceral and accompanied by impairment of glucose metabolism, is associated with low plasma total testosterone. This may substantially reflect the decrease in sex hormone binding globulin (SHBG), and the free testosterone level may be normal. Severe obesity may, however, be associated with secondary hypogonadism at a hypothalamic level. Both total testosterone and SHBG should be measured. A low testosterone level should prompt screening for the metabolic complications of obesity and OSA. Weight loss, reversal of the metabolic abnormalities and treatment of OSA will improve plasma testosterone levels. Erectile dysfunction is a marker of cardiovascular risk. It is a consequence of visceral obesity and the associated metabolic abnormalities that induce endothelial dysfunction. OSA is also associated with erectile dysfunction. Weight loss through a lifestyle modification program is associated with improvements in erectile dysfunction in obese men.",176,30,0.17045454545454544
9781908541680,ch_5,The distribution of excess body fat determines the nature of the adverse consequences of obesity.,"Colorectal cancer. Bodyweight and BMI increase the risk of colon cancer in men, but not in women. This discrepancy may be related to differences in fat distribution between the sexes or the use of hormone replacement therapy (HRT) in women, which lowers the risk of colon cancer. In contrast, waist circumference, a marker of abdominal obesity, is associated with colon cancer risk in men and women, although this too may vary depending on HRT use in postmenopausal women. Also see Fast Facts: Colorectal Cancer.",109,16,0.14678899082568808
9781908541680,ch_5,The metabolic consequences of excess weight may respond to as little as 5-10% weight loss; much greater weight loss is required for other comorbidities (exempli gratia obstructive sleep apnea).,"Osteoarthritis is the third leading cause of life-years lost due to disability. Obesity and joint injury are important potentially modifiable risk factors for the development of osteoarthritis. Obesity is also an important predictor of osteoarthritis progression. Overweight at any time is related to knee osteoarthritis. A moderate increase in BMI, even within the normal weight range, is significantly related to knee osteoarthritis among men. Obesity is also strongly related to hip osteoarthritis, back pain and osteoarthritis in other joints, for example thumb carpometacarpal osteoarthritis, in both sexes. Each pound (454 g) of weight lost results in a fourfold reduction in the load exerted on the knee per step during daily activities. An intensive weight-loss program that involves an energy-deficit diet and exercise training improves physical function in older obese adults with osteoarthritis of the knee. Greatest improvements in function are seen in those with the greatest weight loss. Surgically induced weight loss (see Chapter 8) is an effective, rapid and dependable means of reversing the radiological signs of early changes associated with osteoarthritis. Joint replacement surgery. Total knee replacement improves mobility, enhancing the success of subsequent weight-loss therapy. However, successful treatment of lower-extremity arthritis may not lead to weight loss, and obesity should be treated as an independent disease that is not necessarily the result of inactivity from arthritis.",302,43,0.1423841059602649
9781908541680,ch_5,"Consider and manage obesity in all patients presenting with problems that may be related to obesity, or where obesity may confer a risk (surgery, pregnancy).","Community samples of adolescents and adults indicate that depressive symptoms and psychiatric morbidity are not significantly higher in obese than normal-weight groups. However, the prevalence of psychiatric morbidity, most commonly depression, is increased in patients seeking treatment for obesity (40-60%). Extreme obesity is associated with an increased risk for depression, and obese individuals in weight-loss trials experience reductions in symptoms of depression. Obesity in adolescence may be associated with depression in young adulthood. In women, being overweight or obese in both adolescence and adulthood may be a risk for later depression. In men, abdominal obesity may be closely related to concomitant depression.",125,30,0.24
9781908541680,ch_5,Obese patients should be assessed for obesity-related comorbidities.,"All surgery, but abdominal surgery in particular, is associated with increased morbidity and mortality in the obese. Table 4.3 shows the main complications of surgery in obese patients. Every effort should be made to identify and reduce obesity-related comorbidities, as well as weight (if necessary using a very-low-calorie diet; see Chapter 5), before surgery. It is particularly important to identify and appropriately manage significant OSA. Ask the patient about loud snoring, daytime somnolence, frequent nocturia and morning headaches; if present, obtain a sleep study.",119,15,0.12605042016806722
9781908541680,ch_6,"Weight loss requires a negative energy balance, which for most people is achieved more readily by caloric restriction than by increased physical activity.","Energy that is in excess of requirements is stored as fat. A negative energy balance, regardless of how it is achieved, will result in a reduction in fat mass. A specified negative energy balance results in comparable magnitudes of weight loss whether it is achieved entirely by caloric restriction or by a combination of caloric restriction and physical activity. Most people achieve a negative energy balance more easily by reducing their caloric intake than by increasing physical activity. For example, a 300 kcal reduction in energy can be achieved by eliminating a small packet of potato chips (crisps), or by substituting two diet sodas for two regular sodas; the alternative is to run 5 km (3 miles) or cycle 8 km in 30 minutes.",143,25,0.17482517482517482
9781908541680,ch_6,"A reduction in bodyweight through caloric restriction will result in lower daily energy expenditure, and maintenance of weight loss will then depend on physical activity.","Energy that is in excess of requirements is stored as fat. A negative energy balance, regardless of how it is achieved, will result in a reduction in fat mass. A specified negative energy balance results in comparable magnitudes of weight loss whether it is achieved entirely by caloric restriction or by a combination of caloric restriction and physical activity. Most people achieve a negative energy balance more easily by reducing their caloric intake than by increasing physical activity. For example, a 300 kcal reduction in energy can be achieved by eliminating a small packet of potato chips (crisps), or by substituting two diet sodas for two regular sodas; the alternative is to run 5 km (3 miles) or cycle 8 km in 30 minutes. A caloric deficit of 500-1000 kcal/day will promote a weight loss of 0.5-1 kg per week. The easiest way to reduce energy intake is to reduce the energy density of the diet. Reducing bodyweight by caloric restriction will result in a lower daily energy expenditure because of lower BMR and a lower energy cost associated with moving a smaller body mass. Maintenance of weight loss is therefore critically dependent on physical activity.",230,28,0.12173913043478261
9781908541680,ch_6,"Dietary adherence is more important than the specific dietary pattern; choice of diet should therefore consider the particular patient's characteristics in terms of culture, lifestyle, understanding, sex, age etc.","Dietary adherence is more important than the specific dietary pattern, but overall adherence to all of the diets described below has been found to be low. To persuade a patient to stick to a particular nutritional regimen, the chosen regimen must actually induce weight loss and reduce health-related risk factors. It is also important to work within the parameters that accommodate the characteristics of a particular patient - culture, lifestyle, level of understanding, sex, age etc. Key factors in promoting dietary adherence include convenience, choice and an ongoing behavioral support program. Motivational interviewing as a technique for improving weight loss outcomes is increasing in popularity, but lacks compelling evidence for its use. Information technology such as short messaging services have also been used in an attempt to improve concordance with weight loss and other lifestyle regimens, but very little evidence exists to support its use.",169,38,0.22485207100591717
9781908541680,ch_6,"Important factors in promoting dietary adherence include convenience, choice and an ongoing behavioral support program.","Dietary adherence is more important than the specific dietary pattern, but overall adherence to all of the diets described below has been found to be low. To persuade a patient to stick to a particular nutritional regimen, the chosen regimen must actually induce weight loss and reduce health-related risk factors. It is also important to work within the parameters that accommodate the characteristics of a particular patient - culture, lifestyle, level of understanding, sex, age etc. Key factors in promoting dietary adherence include convenience, choice and an ongoing behavioral support program.",106,17,0.16037735849056603
9781908541680,ch_6,"Healthy diets focus on fruit and vegetables, whole grains and lean unprocessed meat, chicken and seafood. Up to 30% of energy may come from fat but intake of saturated (animal) fat should be very limited. The predominant fats consumed should be of plant origin such as monounsaturated fatty acids (exempli gratia from olive oil) and long-chain polyunsaturated fatty acids, and omega-3 fatty acids from seafood.","Standard calorie-restricted diet. Ultimately, caloric restriction is the most important element of any diet (Table 5.2), as evidenced by a meta-analysis of randomized clinical trials that compared diets of different macronutrient composition and found no difference in weight loss between diet groups. High-fat foods are relatively less satiating than iso-energetic portions of high-protein foods or carbohydrate-containing foods with a high fiber content. Many epidemiological studies have shown that a relatively high intake of dietary fat, in particular saturated (animal) fat, corresponds with increased obesity. Reducing intake of saturated fat and refined carbohydrates facilitates weight loss and forms the basis of the most standard dietary approach. Fats. Up to 30% of calories may come from fat, but saturated (animal) fat should comprise less than 7% of total calories. The fats consumed should be predominantly of plant origin, for example monounsaturated fatty acids (MUFA; from olive oil) and long-chain polyunsaturated fatty acids (PUFA). A high intake of omega-3 fatty acids (long-chain PUFA mainly from seafood), particularly when intake of saturated fatty acids is low, may be associated with lower rates of diabetes and heart disease and less inflammation. Complex carbohydrates from vegetables, fruits and whole grains should be the main source of carbohydrate, enabling a daily fiber intake of 20-30 g. Protein and dairy products. Other constituents of a healthy calorie-restricted diet should include lean unprocessed meat, chicken and seafood, and low-fat dairy products. Fluids. Water rather than fruit juice or soft drinks is the optimum fluid for hydration. Epidemiological data have linked sugar-sweetened beverages to adult and childhood obesity. At both a population and individual level, a reduction in sugar-sweetened beverages (including fruit juice and flavored milks) may be the best single prescription to reduce caloric intake without compromising the intake of essential nutrients.",393,91,0.23155216284987276
9781908541680,ch_6,Sugared beverages should be avoided; water is the ideal drink for hydration.,"Fluids. Water rather than fruit juice or soft drinks is the optimum fluid for hydration. Epidemiological data have linked sugar-sweetened beverages to adult and childhood obesity. At both a population and individual level, a reduction in sugar-sweetened beverages (including fruit juice and flavored milks) may be the best single prescription to reduce caloric intake without compromising the intake of essential nutrients.",79,17,0.21518987341772153
9781908541680,ch_6,Changing to a healthy diet has benefits for cardiometabolic health irrespective of weight loss.,"Meal replacements. Another approach is to substitute one or more meals with a sachet of a commercially available VLCD or other nutritionally complete meal replacement. This is often a useful approach for people who avoid breakfast (which leads to overconsumption later in the day). Use of meal replacements provides structure with portion control and convenience - which are important factors for the maintenance of weight loss (Table 5.6) - and allows prudent additional meals and snacks. In obese subjects, diets with meal replacements have proven more effective than conventional diets. Meal replacements offer a promising strategy for treating obese patients with type 2 diabetes.",124,18,0.14516129032258066
9781908541680,ch_7,Physical activity is a key component of weight management and is important for maintaining weight lost by any method of treatment.,"Sedentary behavior and obesity are closely linked but are not necessarily concurrent in the same individual and should be considered independent risk factors for disease. Inactivity, for example prolonged sitting, carries a risk irrespective of bodyweight. Lack of physical activity is a risk factor for stroke, coronary artery disease and type 2 diabetes mellitus and causes a twofold increase in risk for all-cause mortality, hard on the heels of smoking and hypertension in terms of damage done (Figure 6.1).",97,22,0.2268041237113402
9781908541680,ch_7,"Physical activity is beneficial regardless of weight loss, as it reduces cardiometabolic risk, insulin resistance and cancer risk.","It is difficult to lose weight by physical activity alone but exercise reduces the adverse effects of overweight and obesity even if weight is not lost (Table 6.1). Increasing physical activity is as beneficial to general health as giving up smoking. Maximum benefits come from a combination of resistance and aerobic activity. An increase in muscle bulk at the expense of fat has multiple benefits: apart from reduction in cardiovascular disease and diabetes, it reduces the risk of cancer and loss of cognitive function, improves mood and sense of well-being, facilitates better sleep, and reduces the risk of frailty, falls and dependence in older age.",121,24,0.19834710743801653
9781908541680,ch_7,"Although the amount of weight loss induced by exercise alone may be disappointing, there are beneficial changes in fat distribution and body composition.","Maximum benefits come from a combination of resistance and aerobic activity. An increase in muscle bulk at the expense of fat has multiple benefits: apart from reduction in cardiovascular disease and diabetes, it reduces the risk of cancer and loss of cognitive function, improves mood and sense of well-being, facilitates better sleep, and reduces the risk of frailty, falls and dependence in older age. The waist circumference of someone who becomes fitter by increasing levels of activity will decrease, although their weight may change little. Encouraging patients who exercise. Individuals who attempt weight loss by physical activity alone should be congratulated on increased fitness, and should be encouraged to monitor their waist circumference; otherwise they may become frustrated and demoralized by lack of change in weight or body mass index (BMI).",154,25,0.16233766233766234
9781908541680,ch_7,An increase in physical activity can be achieved by modifications to the daily routine; multiple short bouts are just as beneficial as the equivalent amount of activity performed in one session.,"Long-term medical conditions may affect a person's ability to achieve meaningful levels of activity, and appropriate advice must take this into account. For an obese person with chronic bronchitis, a few steps in the garden every hour may represent a significant increase in activity; a patient with asthma may need to be advised to use their salbutamol inhaler before exercising; a slow stroll on even ground may be appropriate for someone with severe vascular disease; advice to stand up while talking on the phone may be helpful for someone with severe physical limitations. The US Surgeon General's report recommends wheeling oneself in a wheelchair for 40 minutes as being a reasonable level of activity for health benefits, whereas a patient with lower-limb orthopedic problems may be advised to perform low-impact activities, or even arm exercises alone. Elderly patients often suffer from low muscle mass (sarcopenia), so increased physical activity of any degree and particularly with a resistance component should be vigorously promoted for anyone with severe physical limitations.",204,33,0.16176470588235295
9781908541680,ch_7,"Some aerobic activity that leads to shortness of breath each day provides additional benefit, and some resistance exercise should also be included.","Long-term medical conditions may affect a person's ability to achieve meaningful levels of activity, and appropriate advice must take this into account. For an obese person with chronic bronchitis, a few steps in the garden every hour may represent a significant increase in activity; a patient with asthma may need to be advised to use their salbutamol inhaler before exercising; a slow stroll on even ground may be appropriate for someone with severe vascular disease; advice to stand up while talking on the phone may be helpful for someone with severe physical limitations. The US Surgeon General's report recommends wheeling oneself in a wheelchair for 40 minutes as being a reasonable level of activity for health benefits, whereas a patient with lower-limb orthopedic problems may be advised to perform low-impact activities, or even arm exercises alone. Elderly patients often suffer from low muscle mass (sarcopenia), so increased physical activity of any degree and particularly with a resistance component should be vigorously promoted for anyone with severe physical limitations.",204,25,0.12254901960784313
9781908541680,ch_8,"Behavioral therapy, alongside diet and lifestyle advice, is one of the three key components of obesity management.","Behavioral therapy - the collective name for the various methods and strategies used to bring about changes in lifestyle - is universally credited as being one of the three main pillars of weight management, alongside dietary modification and increased physical activity (Chapters 5 and). Bringing about a change in behavior is an important part of clinical care; the ability to foster such change in patients is fundamental to the skill base of any health professional. Changing patients' habits and attitudes using cognitive behavioral therapy (CBT) is key to long-term obesity management.",106,22,0.20754716981132076
9781908541680,ch_8,"Techniques include goal setting, self-monitoring and stimulus control.","Goal setting: the agreement of realistic weight-loss targets, at a realistic rate of improvement. Self-monitoring: increasing self-awareness of eating patterns and physical activity behavior, which is an essential precursor for change. Stimulus control: avoiding situations that lead to harmful behavior, and promoting situations that influence healthy activity.",65,14,0.2153846153846154
9781908541680,ch_8,A person's degree of motivation and expectations should be assessed.,"A food and activity diary should clarify eating patterns and behaviors, particularly events that trigger eating, with a view to changing those patterns once they have been identified, for instance by planning ahead. Once the pattern of eating has been established, the diary can be used as part of the treatment plan, by recording progress towards dietary goals. Long-term weight management has been shown to improve when food records are used.",81,12,0.14814814814814814
9781908541680,ch_8,Binge eating disorder and night eating syndrome are specific eating disorders and should be treated accordingly.,"Binge eating disorder (BED) is specifically recognized in its own right in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the broadly accepted manual for mental illness classification, published by the American Psychiatric Association. Patients with BED display the features of bulimia nervosa but without the purging, abnormal exercise regimens or other compensatory behavior to induce weight loss (see also Fast Facts: Eating Disorders). The condition was largely ignored when it was first recognized in 1959 but has recently gained greater prominence.",111,18,0.16216216216216217
9781908541680,ch_9,Pharmacotherapy is more effective for the maintenance than induction of weight loss but must be used on an ongoing basis to maintain the effect.,"Pharmacotherapy may be a useful adjunct for the control of bodyweight, inducing a 5-10% greater weight loss than can be achieved with lifestyle measures alone, and is particularly useful for the maintenance of weight loss. Despite considerable effort and investment, however, only one agent - orlistat - remains widely marketed and is of limited efficacy. Phentermine and bupropion are available in some countries and the new long-acting phentermine/topiramate combination and lorcaserin only in the USA. Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) that may have some benefits in terms of weight loss in patients with eating disorders. Rimonabant, a cannabinoid receptor antagonist, was withdrawn from the market following unacceptable problems associated with depression and aggression. Sibutramine, which has combined serotonergic and noradrenergic mechanisms of action, was withdrawn because of concerns about cardiovascular safety in the SCOUT trial, although a post hoc study demonstrated a reduction in mortality in those who responded to the drug.",215,27,0.12558139534883722
9781908541680,ch_9,Pharmacotherapy improves the cardiovascular risk factors associated with obesity.,"Pharmacotherapy may be a useful adjunct for the control of bodyweight, inducing a 5-10% greater weight loss than can be achieved with lifestyle measures alone, and is particularly useful for the maintenance of weight loss. Despite considerable effort and investment, however, only one agent - orlistat - remains widely marketed and is of limited efficacy. Phentermine and bupropion are available in some countries and the new long-acting phentermine/topiramate combination and lorcaserin only in the USA. Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) that may have some benefits in terms of weight loss in patients with eating disorders. Rimonabant, a cannabinoid receptor antagonist, was withdrawn from the market following unacceptable problems associated with depression and aggression. Sibutramine, which has combined serotonergic and noradrenergic mechanisms of action, was withdrawn because of concerns about cardiovascular safety in the SCOUT trial, although a post hoc study demonstrated a reduction in mortality in those who responded to the drug.",215,12,0.05581395348837209
9781908541680,ch_9,Pharmacotherapy should only be used as an adjunct to lifestyle modification.,"Managing expectations. Weight-loss drugs should only be used as part of a comprehensive weight management program, as this is when they are most effective. For many patients, the modest weight loss associated with the use of weight-loss pharmacotherapy may seem disappointing, leading to frustration and limiting adherence to the overall weight management program. In order to avoid this, it is essential at the outset that clinicians spend time counseling patients and managing their expectations. The aim should be to improve well-being and reduce cardiometabolic risk. It has been shown that modest weight loss induced by orlistat can reduce the incidence of diabetes mellitus over and above that achieved by lifestyle modification alone.",136,14,0.10294117647058823
9781908541680,ch_9,"Orlistat has been shown to be safe and effective, and to prevent the onset of type 2 diabetes mellitus, over a 4-year period.","Managing expectations. Weight-loss drugs should only be used as part of a comprehensive weight management program, as this is when they are most effective. For many patients, the modest weight loss associated with the use of weight-loss pharmacotherapy may seem disappointing, leading to frustration and limiting adherence to the overall weight management program. In order to avoid this, it is essential at the outset that clinicians spend time counseling patients and managing their expectations. The aim should be to improve well-being and reduce cardiometabolic risk. It has been shown that modest weight loss induced by orlistat can reduce the incidence of diabetes mellitus over and above that achieved by lifestyle modification alone.",136,31,0.22794117647058823
9781908541680,ch_9,Bariatric surgery is among the most clinically effective and cost-effective procedures in medicine.,"Bariatric surgery is among the most clinically effective procedures in medicine. 'Bariatric surgery' refers to surgical procedures that lead directly to weight loss, used in the management of obesity and related comorbidities. The surgical treatment of obesity is cost-effective and may be the only means by which certain individuals can lose significant amounts of weight and maintain weight loss long term, accompanied by reversal or significant improvement in comorbidities. Recent technological advances in surgical techniques have led to safer, better and cheaper operations, so although the surgical option is still limited to a relatively small number of obese people, for such patients it can be a vital means of improving health and quality of life.",138,18,0.13043478260869565
9781908541680,ch_9,"Adjustable gastric banding, sleeve gastrectomy and Roux-en-Y gastric bypass are performed laparoscopically.","Restrictive surgery reduces the functional size of the stomach so that smaller quantities of food induce a feeling of fullness. Food eaten in excess of this amount can result in discomfort or bloating and may be regurgitated or vomited. Examples include gastric stapling and laparoscopic gastric banding. After passing through the restricted portion of the stomach, food passes through the rest of the bowel normally. Restrictive procedures have the advantages of lower cost, technical ease, low surgical risk and the absence of any long-term malabsorption, but compared to Roux-en-Y gastric bypass (RYGB) the amount and durability of weight loss are limited and reversal or improvement of complications less frequent; with bands, late complications may be significant and irreversible.",157,29,0.18471337579617833
9781908541680,ch_9,The majority of cases of diabetes resolve after bariatric surgery.,"The UK's National Bariatric Surgery Register examined all bariatric procedures undertaken in the year 2009-10 and assessed clinical outcomes and cost-economics for the first time internationally. The register examined 86 hospitals and 8710 operations: 3817 RYGB, 2132 gastric bands and 588 sleeve gastrectomies. The general complication rate for primary surgery was 2.6%, far lower than anticipated. The overall operative mortality rate was 0.1% and for gastric bypass was 0.2%, making it safer than gall-bladder surgery. Average weight loss after 12 months was 57.8% of excess weight (67.8% for gastric bypass), and diabetes resolved in 85.5% of patients. Outcomes for sleeve gastrectomies, which are not reversible, approach those for RYGB, while bands have the poorest outcomes for reduction of weight and reversal of comorbidities and are now infrequently performed in many countries. Economic modeling has shown that bariatric surgery can pay for itself within 18 months to 3 years - depending on the nature of the operation - based on clinical costs alone. The UK Office of Health Economics published a document entitled Shedding the Pounds, which looked at the wider economic benefits of bariatric surgery. It concluded that the additional paid work patients were able to undertake following bariatric surgery off-set the costs 1 year after surgery; there were also savings through reductions in benefits paid to individuals. If 5% of eligible patients received bariatric surgery, savings to the UK Government at 3 years (not including clinical cost savings) would be 382 million. If 25% underwent surgery, the figure would be 1.295 billion.",342,12,0.03508771929824561
9781908541680,ch_10,Pregnancy is a crucial stage both for the mother and the fetus in preventing and managing future obesity.,"Causes of childhood obesity are multifactorial. There is a strong genetic component, and if both parents are obese the risk is magnified. Other risk factors include excessive maternal weight gain during pregnancy, absence of breast-feeding, excessive caloric intake (particularly from snack foods and sugared drinks such as fruit juice), a sedentary lifestyle (television viewing and time in front of the computer), lack of physical activity and insufficient sleep. Sociodemographic factors, including migration, low education and income, and single mothers also confer an increased risk.",111,20,0.18018018018018017
9781908541680,ch_10,An elderly person at any given body mass index or waist circumference is always likely to have a higher percentage of fat.,"Lack of physical activity. A child's natural inclination is to be active, but the modern developed world offers more instantly gratifying sedentary pursuits: computer games that require hours of dedicated practice to 'win', and televisions with a plethora of channels to view that many children watch on their own sets in their bedrooms. More children are being driven to school than ever before under the pretext of safety and convenience. Children are being conditioned to be inactive from infancy. Unhealthy eating. Children's eating habits reflect those of adults, compounded by the promotion of unhealthy foods to children. Teenagers who eat at fast-food restaurants consume more unhealthy foods and are more likely to have a higher body mass index (BMI) than those teenagers who don't. Those exposed to more takeaway foods at home eat more frequently at fast-food restaurants and eat lower quantities of vegetables and raw fruit.",176,23,0.13068181818181818
9781908541680,ch_10,Management of obesity is different for different age groups; individualization of care with informed patient choice is important.,"Physical activity. Increasing sustainable physical activity is crucial in the management of childhood obesity. The NICE guidelines for childhood obesity recommend that children and adolescents spend at least 60 minutes a day on moderate-intensity physical activity (although this may not be enough to prevent obesity), and should take part in activities that improve bone health, muscle strength and flexibility at least twice a week. NICE points out, however, that the amount of activity that children and young people need to prevent obesity is unclear. The RCPCH/NOF guidelines emphasize tailoring activity to the individual child and family.",116,21,0.1810344827586207
9781908541680,ch_10,In childhood obesity the aim is usually to attenuate weight gain rather than induce weight loss.,"Management. For overweight elderly individuals in good health, there is no good evidence to show that weight loss reduces mortality risk. Specific weight-loss recommendations may be unnecessary even among overweight persons with one or more obesity-related health condition (exempli gratia hypertension, dyslipidemia, insulin resistance, glucose intolerance), which can be ameliorated independently of weight loss. In the overweight (but not obese) elderly, weight fluctuation in any direction and irrespective of intention, may increase the risk for mobility limitation. It is desirable to prevent weight gain, particularly among the obese, and weight loss, particularly among the non-obese.",130,18,0.13846153846153847
9781908541680,ch_10,Weight loss is not always an appropriate outcome in an individual; overweight or obesity may provide a protective influence.,"Diet. In general, it is not appropriate to advise caloric restriction as the sole modality to induce weight loss. The overall diet must be balanced and contain adequate protein and sufficient micronutrients. It is generally appropriate to advise a reduction in intake of saturated fat and an increase in fiber. There are clear benefits in optimizing the intake of vitamin D and calcium in the elderly. Omega-3 fatty acids reduce the risk of cardiovascular events, and may have benefits for the maintenance of cognitive function; several clinical trials are under way and preliminary data are promising.",112,21,0.1875
9781908541680,ch_11,"There are successful models for every stage of obesity, including prevention, childhood obesity and the treatment and management of adult obesity.","Managing obesity in clinical practice is often complex and time consuming. A plethora of online tools, publications and weight-loss programs are available for the management of obesity at both an individual level in clinical practice and on a larger scale within the community, and evidence of their effectiveness is beginning to emerge. MEND (www.mendcentral.org) is a community multidisciplinary program for overweight and obese children and their families, currently in use in the USA. It places equal emphasis on (M)ind, (E)xercise, (N)utrition and (D)iet (although the 'D' now stands for 'do it!'), combining all the elements known to be vital in treating and preventing overweight or obesity in children, including family involvement, practical education in nutrition and diet, increasing physical activity and behavioral change.",169,24,0.14201183431952663
9781908541680,ch_11,There is robust evidence indicating the effectiveness of the MEND program for children and the Counterweight program for adults.,"The objective of the Counterweight program is to achieve and maintain a medically valuable weight loss of 5-10% for as many people as possible, starting with lifestyle intervention. Patients can choose between a goal-setting approach, a structured eating plan or a group program, all based on 500-600 kcal daily energy deficit. Patients also receive advice on increasing physical activity, and behavioral strategies are a core component of the model. The program is flexible and can be delivered individually or to families or groups, depending on need and resources. Nine appointments of 10-30 minutes in the first year are recommended.",119,22,0.18487394957983194
9781908541680,ch_11,"Since water is the appropriate drink for hydration, a tax on all sugar-containing/carbonated drinks is probably the most logical fiscal measure that governments could implement to tackle obesity.","These initiatives are a good start, but do not constitute a sufficiently comprehensive policy response to effectively address the increasing prevalence of severe obesity and associated complications. In recent years, many governments have intensified their health promotion efforts. Coordinated national programs have been launched; for example, 'Let's Move' in the USA, 'Change4Life' in the UK and 'Actionsant' in Switzerland. There has also been increasing interest in the use of fiscal measures to limit the consumption of foods high in fat, sugar and salt. In 2011, taxes were introduced in Denmark on foods containing more than 2.3% saturated fats, only to be withdrawn subsequently. In Hungary, selected manufactured foods with high sugar, salt or caffeine content have specific taxes applied, as do confectionery products in Finland. A tax on carbonated sugary drinks, all carbonated drinks, and all drinks containing sugar are among measures currently being implemented or under consideration in a number of places around the world. Since water is the appropriate drink for hydration a tax on all sugar-containing/carbonated drinks is probably the most logical fiscal measure with the most theoretical if not empirical evidence to support it.",236,36,0.15254237288135594
9781908541680,ch_11,"The obesity prevention program EPODE has had proven success with a whole-community approach to the integration of healthier lifestyles into daily life, including the addition of nutritional education to school curriculums.","EPODE is an obesity prevention program that aims to integrate healthier lifestyles into daily life. The aim is engagement of all relevant local stakeholders in a coordinated whole-community approach to promote healthy behaviors, and to minimize unhealthy behaviors, through environmental change, supported by a positive, concrete and stepwise learning process. The integration of nutritional education into the school curriculum, for example, can change the dietary behavior of children and their families. By creating changes in group dynamics, changes in social norms occur, leading to healthier lifestyles. Since 2004, EPODE has been implemented in more than 500 communities in six countries. Involvement of, and part funding by, industry stakeholders has been controversial but not problematic and a strict ethical charter is adhered to. Evaluation. While recent data in France indicate stabilization in the prevalence of childhood overweight and obesity, data for 2005-09 from the French EPODE pilot towns showed a significant decrease of 9.12% (p<0.0001). Over the same time period there was a decrease of 2% (p=0.3845) in the prevalence of overweight and obesity in children attending schools in deprived areas, an interesting contrast to the increase in prevalence in deprived areas at national level.",245,38,0.15510204081632653
9781908541680,ch_11,"Health professionals have an ethical and moral obligation, and the opportunity, to promote public health as well as taking care of individual patients.","Evaluation. While recent data in France indicate stabilization in the prevalence of childhood overweight and obesity, data for 2005-09 from the French EPODE pilot towns showed a significant decrease of 9.12% (p<0.0001). Over the same time period there was a decrease of 2% (p=0.3845) in the prevalence of overweight and obesity in children attending schools in deprived areas, an interesting contrast to the increase in prevalence in deprived areas at national level. In light of the encouraging experiences and results of the EPODE methodology and the EPODE European Network (www.epode-european-network.com), the EPODE International Network (www.epode-international-network.com) was created in 2011 to share best practices and benefit from EPODE methodology and experience. Public health advocacy. Health professionals have an ethical and moral obligation, and the opportunity, to promote public health as well as taking care of individual patients. This can be achieved by.",201,26,0.12935323383084577
9781908541703,ch_2,Age is the greatest risk factor.,"Age is by far the greatest risk factor for breast cancer in women. Of the approximately 60% of breast cancers for which identifiable risk factors can be found, age accounts for more than half. The incidence of breast cancer increases with age; approximately 50% of breast cancers occur in women aged 50-64 years, and a further 30% occur in women over the age of 70 years.",77,7,0.09090909090909091
9781908541703,ch_2,"Hormonal factors, such as menstrual and obstetric history and exogenous hormones affect the risk of breast cancer.","A meta-analysis involving over 150 000 women examined the influence of oral contraceptive use on the risk of breast cancer. The relative risk was slightly increased (1.24) in women who had used oral contraceptives within 10 years, but no excess risk was seen in those who had used oral contraceptives more than 10 years previously. The risk is particularly high when oral contraceptives are taken before the first full-term pregnancy. Although the incidence of breast cancer was increased in oral contraceptive users, mortality from the disease remained constant because the cancers tended to be of a more favorable type. The slight increase in risk associated with oral contraceptives should, however, be viewed in the context of women's health in general. It is very likely that oral contraceptives substantially diminish the risk of ovarian and endometrial carcinoma. They are also highly effective as a form of contraception and as a means of relieving menses-related morbidity. There is no evidence to indicate how current formulations of oral contraceptives affect breast cancer risk. However, this will not be known for certain for another 30 years, since the cohort of women who have taken the pill (particularly low-dose preparations) are only now reaching the age at which they are at risk of breast cancer.",246,22,0.08943089430894309
9781908541703,ch_2,Mammographic breast density is an independent and powerful risk factor that is not yet fully explained.,"There is increasing and compelling evidence that mammographic breast density correlates directly with the risk of breast cancer, with a relative risk of up to 4 between the most and least dense breasts. While this finding is not very well explained, it remains an independent risk factor. The addition of breast density significantly improves the discriminatory power of conventional risk-predicting models. Interestingly, recent alcohol intake, particularly of beer and white wine (as opposed to red wine), has been found to correlate directly with mammographic breast density; also, women living in urban areas have been found to have a higher breast density.",119,19,0.15966386554621848
9781908541703,ch_2,"Mutations in the breast cancer genes BRCA1 and BRCA2 denote high risk but account for only a small proportion of cancers. Mutations in several other genes, including CHEK2, TP53 and EMSY, are also involved.","BRCA1 and BRCA2. The breast cancer susceptibility genes BRCA1 (17q21) and BRCA2 (13q14) are associated with a high risk of breast cancer, even in the absence of a family history. Mutations in these genes are implicated in approximately 4% of all breast cancers and in up to 25% of patients diagnosed before the age of 40 years; they are also linked to ovarian cancers. The breast cancer risk associated with mutations in BRCA2 appears to be less than that with mutations in BRCA1, but the presence of the gene mutation carries additional smaller risks of male breast and prostate cancers and perhaps others. Neither BRCA1 nor BRCA2 should be considered 'breast-cancer specific' in the sense that a single mutation leads directly to disease, as in sickle-cell disease, for example. Both genes represent large segments on specific chromosomes where a number of deviations from the base sequence of DNA in the normal population are concentrated. It is believed that some of these changes result in inappropriate cellular proliferation, or are linked to a failure of DNA repair as a final common pathway. BRCA1 does not appear to be a classic tumor suppressor gene and, somewhat paradoxically, it is not associated with sporadic cancers. However, there is some evidence that the gene may act in a novel way to suppress the function of other inhibitors of proliferation.",291,52,0.17869415807560138
9781908541703,ch_2,"Diet, exercise, alcohol and smoking are modifiable risk factors. It is arguable whether the use of oral contraceptives and hormone replacement therapy, early childbearing and long-term breast-feeding are modifiable in a modern society.","BRCA1 and BRCA2 are not the only genes implicated in breast cancer. One of the common DNA-sequence variants that confers a small increase in breast cancer risk is CHEK2. It is a component of the machinery that recognizes and repairs damaged DNA, and seems to activate BRCA1. Germline mutations in TP53, which encodes tumor protein p53 (Li-Fraumeni syndrome), usually lead to childhood cancers, but girls who reach adulthood have a risk of breast cancer as high as 90%. EMSY, a newly identified gene that is overexpressed in sporadic breast cancers, produces a protein that interacts with BRCA2. Mutations in other genes that raise the risk of breast cancer are ATM (ataxia telangiectasia mutated), PTEN (Cowden syndrome), CDH1 (hereditary diffuse gastric cancer) and STK11 (Peutz-Jeghers syndrome).",194,47,0.2422680412371134
9781908541703,ch_3,Risk is a poorly understood concept - it has negative connotations when in reality it is neutral.,"Risk is a measurement of likelihood, or how often an event takes place. It is a proportional quantity. Implicit in the concept is a comparison of the number of times an event might occur with the number of times it actually does occur. For example, if the risk of falling off a mountain is estimated to be 1/10 000, then for every 10 000 individual mountain-climbing excursions, one person falls. The term 'risk' carries a negative connotation, though in fact it is intended to be a neutral term; conversely 'odds' has a more positive implication (exempli gratia the odds of winning).",132,20,0.15151515151515152
9781908541703,ch_3,Risk is a proportional quantity; change in risk can be expressed in absolute or relative terms.,"Risk is a measurement of likelihood, or how often an event takes place. It is a proportional quantity. Implicit in the concept is a comparison of the number of times an event might occur with the number of times it actually does occur. For example, if the risk of falling off a mountain is estimated to be 1/10 000, then for every 10 000 individual mountain-climbing excursions, one person falls. The term 'risk' carries a negative connotation, though in fact it is intended to be a neutral term; conversely 'odds' has a more positive implication (exempli gratia the odds of winning).",132,19,0.14393939393939395
9781908541703,ch_3,Decision-making involves balancing of risks and considering trade-offs.,"People have some sense of the total effect of a specific risk. However, there is no metric for identifying, summing and weighing all hazards and consequences. The event risks are constantly changing. The consequences vary with time and circumstance, and individuals making personal choices change their internal evaluation strategies over time. The best approach is to give a clear explanation of the basic principles and to set individual risk/consequence discussions in the context of the other hazards that exist. Thus, when explaining the concept of risk to a patient, there are a number of points worth considering.",112,14,0.125
9781908541703,ch_3,Consequence represents the severity of effect of an event.,"Consequence or harm represents the severity of the effect of the risk event should it happen, which also carries a negative connotation. The total effect of a given risk is the product of the risk and the consequence. Numerous studies have shown that people tend to pay more attention to negative consequences than positive ones, particularly when the former are seen as gruesome, refractory to treatment and poorly understood.",80,12,0.15
9781908541703,ch_3,Risk measures the likelihood that an event will take place.,"Other adverse events. There are two important further considerations. First, the data from which these recommendations derive are generally specific for the risk of breast cancer; competing adverse risks, including the toxicity of treatment, are not considered. In that respect, the data may overestimate benefit. Secondly, in contrast to the benefit being calculated against the number of adverse events, the toxicity of treatment affects the entire population treated and not solely those who experience an adverse event. Thus, if the risk of an adverse event is 25%, then 1 in 4 of those who receive the treatment will experience the effect. If only 3 in 100 benefit from a reduction in the recurrence risk, it might be said that 25 people experience side effects in order that 3 accrue a benefit. However, this is a simplification that can lead to erroneous conclusions such as 'but I could be one of those 3, or one of those 25 - then it is 50-50'. But it is not that way at all; every woman faces those outcomes at the respective probabilities, and understanding this concept is fundamental to understanding risks versus benefits.",220,12,0.05454545454545454
9781908541703,ch_4,Breast cancer is becoming understood as a constantly evolving series of defects in cellular regulation and control.,"Malignant change. It is, perhaps, a truism to suggest that breast cancer is the result of a subtle imbalance in the complex regulatory cycles to which breast tissue is exposed. Sex hormones, epidermal growth factors and other agents that influence normal growth and function do so by up- and down-regulating genetic pathways, leading to cell proliferation and regression. The induction and promotion of breast cancer is a multifactorial and multistep process, in which a series of defenses must be overcome over a period of time, though not necessarily in a rigidly defined order. As this process develops from an early genetic predisposition, each defect in the regulatory system contributes to a cascade. In time, and in the face of numerous external stimuli, the family of defects expands, eventually leading to cellular immortalization and the molecular expression of the drivers of the classic malignant triad of growth, invasion and metastasis (Figure 3.2).",189,19,0.10052910052910052
9781908541703,ch_4,"Growth, invasion and metastasis are related but distinct regulatory processes. The mix determines the clinical course in an individual.","The subtle dividing line between benign and malignant changes is seen in ductal carcinoma in situ. There is now evidence that, in this situation, tumor sensitivity to growth hormones is increased, but the tumor lacks the abnormal ability to traverse the basement membrane, and thus may reach a considerable size yet remain localized. The subsequent emergence of the ability of the tumor to cross the basement membrane, apparently characterized by the production of specific gene products such as hyaluronidase, heralds invasion and increased risk of systemic disease. It is likely that each step in the triad of growth, invasion and metastasis is controlled by specific proteins secreted by the tumor or surrounding tissue. Thus, while the tissues from different patients may have the same histopathological appearance, the genetic and metabolic machinery of the surrounding tissue, as well as the rest of the body, will differ. It is the combination of such 'host' and tumor factors that will determine the clinical pattern of the disease.",196,24,0.12244897959183673
9781908541703,ch_4,New evidence is emerging that the systemic response to the trauma of surgery may induce angiogenesis at the site of latent/occult distant metastases. This may well be amenable to perioperative manipulation of the tumor microenvironment.,"The subtle dividing line between benign and malignant changes is seen in ductal carcinoma in situ. There is now evidence that, in this situation, tumor sensitivity to growth hormones is increased, but the tumor lacks the abnormal ability to traverse the basement membrane, and thus may reach a considerable size yet remain localized. The subsequent emergence of the ability of the tumor to cross the basement membrane, apparently characterized by the production of specific gene products such as hyaluronidase, heralds invasion and increased risk of systemic disease. It is likely that each step in the triad of growth, invasion and metastasis is controlled by specific proteins secreted by the tumor or surrounding tissue. Thus, while the tissues from different patients may have the same histopathological appearance, the genetic and metabolic machinery of the surrounding tissue, as well as the rest of the body, will differ. It is the combination of such 'host' and tumor factors that will determine the clinical pattern of the disease.",196,47,0.23979591836734693
9781908541703,ch_4,"Most breast lumps are benign, especially those in women younger than 50 years of age.","Although a lump is the first symptom in 80-90% of cases of breast cancer, about 80% of lumps are due to benign breast disease (Table 3.1). Benign breast disease affects up to 30% of women; fibroadenomas and diffuse nodularity are most common in young women (< 30 years of age), whereas cysts are more common over the age of 40 years (Figure 3.6). Of note, dimpling of the skin is an almost pathognomic sign of cancer, being caused by the contracture of Cooper's ligaments by cicatrization.",122,18,0.14754098360655737
9781908541703,ch_4,"Staging of breast cancer, including examination of lymph nodes, is a prognosis-estimating procedure. Axillary surgery is both diagnostic as well as therapeutic as it achieves local control.","Nomenclature of breast cancer. The traditional adjective used to describe breast cancer - 'invasive' - is a tautology and is unnecessary. It is not used for other cancers: colon cancer is not called invasive colon cancer! In the same vein, the term 'ductal' or 'lobular carinoma in situ' (DCIS and LCIS) should not be used to refer to preinvasive lesions. By definition they cannot spread and are cured by local excision (as long as there is no breach of the basement membrane) so do not qualify as 'carcinoma'. Lumps are seldom detectable, and most such tumors are detected by mammographic screening of the breast or as chance findings after a biopsy of a benign lesion. Ductal intraepithelial neoplasia (DIN) would be the preferred name and would remove the unnecessary taboo of cancer when these lesions are diagnosed.",191,37,0.193717277486911
9781908541703,ch_4,Gene array techniques are bringing modern molecular biology into the clinic.,"Gene array technology, which allows the genetic activity in different tissues to be characterized and compared, is now beginning to influence clinical medicine. Malignancies, particularly leukemias and lymphomas, are being classified by gene-expression patterns in addition to conventional light microscopy and flow cytometry. Patterns of gene expression appear to correlate with light-microscopic diagnosis. Moreover, data are accumulating to allow clinicians to estimate the risk of relapse, its likely pattern and its response to specific treatments with greater precision. The current challenge is to make the technique sufficiently robust and reproducible for wider use.",119,12,0.10084033613445378
9781908541703,ch_5,All suspicious findings on MRI require pathological confirmation.,"Bleeding from the nipple is a rare symptom of breast cancer; fewer than 3% of women report bleeding as a first symptom. The likelihood of cancer is increased if a lump is found on examination. In the absence of a lump, the most common cause of bleeding or bloodstained discharge is benign duct papilloma. In postmenopausal women, discharges from the nipple that are not bloodstained are usually due to duct ectasia. Discharges may also occur during early pregnancy, after breastfeeding and during treatment with certain drugs, such as oral contraceptives, some antihypertensive agents and some antidepressants. Persistent discharge from a single duct in the nipple needs to be investigated, especially if a dipstick is positive for blood. The usual method is microdochectomy (removal of a single duct), or in older women, total duct excision; the value of ductoscopy is being investigated, and some advocate using MRI to identify any pathology far from the usual limits of duct excision.",202,9,0.04455445544554455
9781908541703,ch_5,A logical process for assessing breast pain or masses will greatly enhance diagnostic accuracy.,"Algorithms used for general screening or for incidental findings may not apply to patients who present with a well-defined abnormality. A much higher level of accuracy is required for patients with symptomatic lumps: the risk of a false negative is too high (1-10%) with two assessments only (exempli gratia physical examination and imaging), so a tissue sample (preferable to cytology) should be taken in any patient with a clinically or radiologically identifiable lesion. Triple assessment, comprising clinical examination, imaging and pathological evaluation (preferably a core biopsy) will provide a confident diagnosis in 95% of patients with suspected breast cancer, and should be carried out before the patient is discharged.",145,15,0.10344827586206896
9781908541703,ch_5,Triple assessment - clinical examination plus imaging plus cytological or histopathological examination - represents the diagnostic gold standard.,"Algorithms used for general screening or for incidental findings may not apply to patients who present with a well-defined abnormality. A much higher level of accuracy is required for patients with symptomatic lumps: the risk of a false negative is too high (1-10%) with two assessments only (exempli gratia physical examination and imaging), so a tissue sample (preferable to cytology) should be taken in any patient with a clinically or radiologically identifiable lesion. Triple assessment, comprising clinical examination, imaging and pathological evaluation (preferably a core biopsy) will provide a confident diagnosis in 95% of patients with suspected breast cancer, and should be carried out before the patient is discharged.",145,23,0.15862068965517243
9781908541703,ch_5,No test is pathognomonic. Clinical judgment has high value.,"Pathology. If a discrete lump is present, and clinical examination and ultrasound suggests that it is a cyst, it can be aspirated with a 10/20-mL syringe and venipuncture (blue hub) needle. Aspiration of non-bloody fluid confirms the diagnosis of a benign cyst and the fluid need not be sent for further examination. Such aspiration will provide immediate relief and reassurance. Biochemical examination of the fluid, albeit interesting, has no clinical relevance; and cytological examination can yield non-specific changes that can sometimes lead to unnecessary anxiety.",117,14,0.11965811965811966
9781908541703,ch_5,Breast screening programs have modest utility. Their greatest value may be in increasing patient self-awareness and in the improved organization of clinical services.,"Small breast cancers detected by mammography may be biologically different from those detected clinically. Approximately 20% of cancers detected by mammography are carcinomas in situ, of which some would never progress to invasive disease if left undetected, and the optimal treatment for such tumors is unknown. If these cancers are treated in the same way as invasive cancers, some women may undergo unnecessarily extensive surgery. Conversely, in other women, delaying treatment of asymptomatic disease may ultimately compromise the chance of cure. Furthermore, there is good evidence that screening leads to overdiagnosis. Many invasive cancers detected by screening would never have progressed to clinical disease.",126,28,0.2222222222222222
9781908541703,ch_5,"Breast self-examination can no longer be recommended, though women should be aware of normal physiological changes and thus be alerted to the first chance observation of a pathological change.","Breast self-examination. In the latter part of the 20th century, several large-scale programs were established to teach self-examination techniques and encourage women to examine their breasts each month. Although this approach does appear to lead to the detection of smaller tumors, there is no evidence that it improves long-term survival. Indeed, two large-scale randomized controlled trials performed in St Petersburg and China found no difference in breast cancer mortality rates between women trained in breast self-examination and a control group. In these trials, compliance with the instructions was very high and could not be the reason for the absence of benefit. An adverse effect of self-examination training was the disproportionate number of women presenting with lumpy breasts who were then subjected to futile biopsies. The self-examination approach also has a potential problem in that random biopsies among premenopausal women may disclose ductal carcinoma in situ or lobular carcinoma in situ, the natural history of which is unknown. Such findings may result in inappropriate radical surgery or, at the very least, a lifetime of uncertainty and anxiety for the patient.",223,34,0.15246636771300448
9781908541703,ch_6,Mastectomy and lumpectomy/wide local excision plus radiation are therapeutically equivalent for most women.,"Surgery may consist of either mastectomy or conservative procedures, so-called 'lumpectomy' in the USA and wide local excision in the UK (Table 5.1). Mastectomy. The most commonly used mastectomy procedures are total mastectomy and axillary clearance. In many cases, axillary clearance can be avoided if the sentinel node is found to be negative. Simple mastectomy. The entire breast tissue, including the axillary tail, is removed together with the skin, nipple and areola (Figure 5.1). Samples from the lowest axillary lymph nodes are usually also taken.",125,23,0.184
9781908541703,ch_6,Breast reconstruction is viable and can be offered as an immediate or a delayed procedure.,"Subcutaneous mastectomy. In a small number of women, it is possible to remove most of the breast tissue while leaving the skin and nipple intact. The breast can then be reconstructed immediately with an implant. This procedure is, however, mainly used in women with high-risk precancerous conditions, such as carcinoma in situ. Intraoperative radiotherapy is being tested in an attempt to reduce the risk of a cancer in the retained nipple and early results are encouraging. However, several large series have been reported, particularly from Japan, in which the risk of a recurrence is exceedingly low when the operation removes most of the subareolar tissue, although this does increase the risk of ischemic necrosis of the nipple.",148,17,0.11486486486486487
9781908541703,ch_6,"Given adequate information, women can choose equally between mastectomy and breast conservation approaches.","The indications for axillary surgery and the extent to which it should be carried out in women with operable breast cancer remain controversial; the dogma of axillary clearance is now being replaced by a dogma for sentinel node biopsy. Clinicians who have observed uncontrolled axillary disease are cautious of taking any steps that could risk such an outcome. In terms of local control, however, there may be little to choose between the success of surgery and the success of radiotherapy, balanced against the relatively rare, but significant, morbidity of either approach. It is likely that axillary clearance will have a decreasing role in the future, partly because of the earlier presentation of breast cancer and partly because of improvements in the prognostic value of tumor markers.",148,16,0.10810810810810811
9781908541703,ch_6,"In the future, selected patients may be able to avoid the 3-6 weeks of conventional postoperative radiotherapy by receiving a single dose of intraoperative radiotherapy during lumpectomy.","It is worth noting again that for every four recurrences prevented at 5 years, one life is saved at 15 years. This 4:1 ratio appears to be true particularly when the reduction in recurrence is more than 10%, and the effect may be 10:1 or even lower in tumors with a good prognosis if the reduction by radiotherapy is less than 10%. Hypofractionated radiotherapy. A large trial in Canada and the Standardisation of Radiotherapy (START) trials in the UK have shown that the breast is more sensitive to fraction size than previously thought. The START Trial B found that local recurrence rates at 5-year follow-up were equivalent in patients who received a 3-week regimen as those who received a conventional 6-week regimen. This has prompted the 'faster radiotherapy for breast cancer patients' trial that is testing whether 1 week of therapy can be as good and without side effects. Of course, the ultimate hypofractionation is to give the radiotherapy in a single dose intraoperatively and targeted to the tumor bed.",218,37,0.16972477064220184
9781908541703,ch_7,Adjuvant hormonal treatment and chemotherapy reduces the risk of recurrence of breast cancer by 33% and improves survival. The absolute benefit for an individual woman depends on her initial risk.,"Tamoxifen was developed as a fertility drug in the 1970s and has subsequently become the mainstay of treatment for breast cancer. Treatment with tamoxifen for 5 years reduces the relative risk of dying from breast cancer in both pre- and postmenopausal women (see below). Tamoxifen works as a selective estrogen receptor modulator (SERM), and has effects both as an estrogen agonist and antagonist depending on the tissue and receptor type. Mechanism of action. In breast tissue, tamoxifen blocks the peripheral actions of estrogen (Figure 6.1). Tamoxifen binds competitively with 17-b-estradiol at the receptor site, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen, causing cells to remain in the G0 and G1 phases of the cell cycle. Tamoxifen is a prodrug, which is metabolized in the liver by the cytochrome P450 isoform CYP2 D6 and CYP3a4 into active metabolites, such as 4-hydroxytamoxifen and endoxifen, which have 30-100 times greater affinity for the ER than tamoxifen itself.",242,36,0.1487603305785124
9781908541703,ch_7,Trial evidence supports a further 5 years of hormone therapy in patients who have already received 5 years of tamoxifen -tamoxifen for premenopausal women and an aromatase inhibitor for postmenopausal women.,"Placebo-controlled clinical trials to explore this area were stopped when the comparative benefit of the aromatase inhibitor became clear. So the questions of how long to extend adjuvant treatment with an aromatase inhibitor after 5 years of tamoxifen or when the aromatase inhibitor should be started in relation to tamoxifen remain unanswered. In the trials, patients started an aromatase inhibitor any time after they had taken tamoxifen for 4 years. Some analyses have suggested that patients may still benefit even if there is an interval of up to 12 months after completion of tamoxifen; these analyses could, however, be completely explained by a simple selection bias and there may be no benefit. The ATLAS trial has provided further evidence to support an additional 5 years of hormone therapy in premenopausal women who have already received 5 years of tamoxifen - a continuation of tamoxifen in women who are still premenopausal and an aromatase inhibitor in postmenopausal women.",206,47,0.22815533980582525
9781908541703,ch_7,Well-designed and managed clinical trials remain the preferred context for treatment.,"Placebo-controlled clinical trials to explore this area were stopped when the comparative benefit of the aromatase inhibitor became clear. So the questions of how long to extend adjuvant treatment with an aromatase inhibitor after 5 years of tamoxifen or when the aromatase inhibitor should be started in relation to tamoxifen remain unanswered. In the trials, patients started an aromatase inhibitor any time after they had taken tamoxifen for 4 years. Some analyses have suggested that patients may still benefit even if there is an interval of up to 12 months after completion of tamoxifen; these analyses could, however, be completely explained by a simple selection bias and there may be no benefit.",145,14,0.09655172413793103
9781908541703,ch_7,"For women with strongly estrogen-receptor(ER) positive breast cancer, endocrine treatment is the mainstay of treatment, and the additional benefit of chemotherapy should be calculated.","Selection. There is little doubt that postmenopausal women with ER positive breast cancer should receive an aromatase inhibitor as part of their adjuvant therapy. It could be argued that an aromatase inhibitor should be an upfront treatment, as some patients (particularly those at high risk) may relapse early and, if denied an aromatase inhibitor for 2-3 years, may not get the opportunity to benefit. Conversely, patients with ER positive disease may be at low and protracted risk of relapse and may therefore benefit from extended therapy; at present, this would be tamoxifen followed by an aromatase inhibitor, as there are no data to support the use of aromatase inhibitor monotherapy for more than 5 years. Economics may also be a consideration, as aromatase inhibitors are currently more expensive than tamoxifen, and patient preference and comorbidity (exempli gratia osteoporosis) should be taken into account. The gynecologic side-effect profile of tamoxifen may also influence the decision in favor of aromatase inhibitors, as significantly fewer gynecologic interventions are required.",232,35,0.15086206896551724
9781908541703,ch_7,Postmenopausal women with ER positive breast cancer should be offered an aromatase inhibitor as part of standard adjuvant treatment.,"Selection. There is little doubt that postmenopausal women with ER positive breast cancer should receive an aromatase inhibitor as part of their adjuvant therapy. It could be argued that an aromatase inhibitor should be an upfront treatment, as some patients (particularly those at high risk) may relapse early and, if denied an aromatase inhibitor for 2-3 years, may not get the opportunity to benefit. Conversely, patients with ER positive disease may be at low and protracted risk of relapse and may therefore benefit from extended therapy; at present, this would be tamoxifen followed by an aromatase inhibitor, as there are no data to support the use of aromatase inhibitor monotherapy for more than 5 years. Economics may also be a consideration, as aromatase inhibitors are currently more expensive than tamoxifen, and patient preference and comorbidity (exempli gratia osteoporosis) should be taken into account. The gynecologic side-effect profile of tamoxifen may also influence the decision in favor of aromatase inhibitors, as significantly fewer gynecologic interventions are required.",232,26,0.11206896551724138
9781908541703,ch_7,Women with human epidermal growth factor receptor 2 (HER2) positive breast cancer should be offered anti-HER2-targeted therapy (provided there are no medical contraindications) as part of standard adjuvant treatment.,"Selection. There is little doubt that postmenopausal women with ER positive breast cancer should receive an aromatase inhibitor as part of their adjuvant therapy. It could be argued that an aromatase inhibitor should be an upfront treatment, as some patients (particularly those at high risk) may relapse early and, if denied an aromatase inhibitor for 2-3 years, may not get the opportunity to benefit. Conversely, patients with ER positive disease may be at low and protracted risk of relapse and may therefore benefit from extended therapy; at present, this would be tamoxifen followed by an aromatase inhibitor, as there are no data to support the use of aromatase inhibitor monotherapy for more than 5 years. Economics may also be a consideration, as aromatase inhibitors are currently more expensive than tamoxifen, and patient preference and comorbidity (exempli gratia osteoporosis) should be taken into account. The gynecologic side-effect profile of tamoxifen may also influence the decision in favor of aromatase inhibitors, as significantly fewer gynecologic interventions are required.",232,48,0.20689655172413793
9781908541703,ch_7,Taxane-based chemotherapy is recommended for women at high risk (node positive and high-risk node negative).,"Taxanes. Two taxanes are in common use: paclitaxel and docetaxel. An overview analysis of taxane trials has confirmed the benefit of these drugs over anthracycline treatment alone, but debate continues as to whether this benefit is equal for the population as a whole or whether some women benefit more than others. Most of the trials have involved women at relatively high risk (exempli gratia node-positive patients), though some have included high-risk node-negative patients. There is some concern that patients with ER positive disease derive less benefit than patients with ER negative disease. This may lead to different regimens being employed according to perceived risk level.",138,22,0.15942028985507245
9781908541703,ch_8,"Conventional belief in the need for intensive follow-up after treatment for primary breast cancer is being challenged, but it may have non-measurable benefits to the patient and their doctors and nurses.","It should be remembered that regular and intensive follow-up does not improve the success rates for treatment of a recurrence. However, it may serve other purposes. The patient's perceived need for follow-up may mean that visiting her doctor regularly for reassurance (even if it is sometimes proven false) will improve her personal well-being. Physicians may also gain more job satisfaction by regularly seeing so many patients doing well rather than seeing only those patients who have had a recurrence. As neither of these possible benefits has been tested in randomized trials, it would be prudent to explain to the patient that regular follow-up, though offered, is not necessarily of proven value. In fact, the UK's National Institute for Health and Clinical Excellence (NICE) has recommended that follow-up for breast cancer patients should stop after 3 years in England and Wales.",171,40,0.23391812865497075
9781908541703,ch_8,Attention must be paid to both physical and psychological rehabilitation.,"Other tests. The routine use of tumor markers or imaging tests in the search for distant metastases is not recommended. None of these tests has a high specificity, and the patient can therefore experience repeated false alarms. Moreover, even if the results are truly positive for asymptomatic metastases, this merely provides the patient with 6 months' additional notice of impending death, during which time the reintroduction of systemic therapy is of unproven value. Patients undergoing surgery for primary breast cancer require rehabilitation to address the physical and psychological consequences of surgery. Physical rehabilitation.",112,12,0.10714285714285714
9781908541703,ch_8,"Simple physical exercises, initiated early, accelerate and improve rehabilitation.","Breast prostheses are an important aspect of physical rehabilitation after mastectomy, and can also strongly influence psychological rehabilitation. A light, temporary prosthesis can be used for the first few weeks until the wound has healed. A suitable permanent prosthesis can then be selected from the wide range available, according to the required size, shape and adherence to the chest wall. New developments in materials technology have overcome many of the disadvantages of traditional silicone prostheses (exempli gratia Duette, which uses two different types of silicone to produce more natural movement, and Harmony, which has a silky surface). Many hospitals have a nurse or physiotherapist trained in the use of breast prostheses.",138,12,0.08695652173913043
9781908541703,ch_8,Short- and long-term emotional and spiritual support should not be overlooked.,"Psychological rehabilitation. Breast cancer imposes considerable psychological stress and trauma. The initial diagnosis and preparation for surgery can produce a period of emotional turmoil in which rapid mood swings are accompanied by immense disruption to the woman's lifestyle. By contrast, the patient may be euphoric during the immediate postoperative period, possibly due to relief of uncertainty and anticipation of a return to normal life. This initial reaction is, however, transient, and many women experience a period of shock and denial followed by anxiety about 2-3 months after surgery. Most women eventually develop coping skills, enabling them to live a normal lifestyle. Approximately 20-30% of women, however, have persistent psychological or sexual problems 1-2 years after surgery, compared with 10% of age-matched women without breast cancer. This does not seem to be related to the type of operation; anxiety and depression appear to be as common in women undergoing conservative surgery as in women undergoing mastectomy.",188,15,0.0797872340425532
9781908541703,ch_9,"Site of recurrence, extent, time to recurrence and evaluation of comorbidities are critical determinants of prognosis and treatment.","Aims of treatment. Conventionally, metastatic breast cancer is incurable. However, the prognosis for patients with metastases has improved and about 20% of patients will be alive 5 years from diagnosis. It is important to have a clear view of the aim of treatment. In clinical trials, this is measured in terms of response rates, time to progression and survival; outside trials and in clinical practice, however, the benefits of treatment are more commonly assessed by relief of symptoms and maintained quality of life. It is important to consider patients holistically in light of their comorbidities, social environment and their own and their family's wishes.",130,28,0.2153846153846154
9781908541703,ch_9,"Systemic treatment can improve symptoms and, in some cases, prolong survival.","Systemic treatment can improve symptoms in 30-70% of patients and may delay disease progression. With newer combination regimens, particularly those given in combination with targeted therapy, there may be an opportunity to improve overall survival. For patients whose initial disease was steroid hormone-receptor-positive, the preferred initial treatment for metastases is hormonal, provided that the characteristics of the disease are not aggressive (id est long disease-free interval, hormone-receptor-positive disease, bone-only disease). Chemotherapy is reserved for steroid hormone-receptor-negative disease and disease that fails to respond to hormonal treatment. Patients with human epidermal growth factor receptor 2 (HER2) positive disease should receive anti-HER2 targeted therapy as their main treatment, usually in combination with chemotherapy.",158,15,0.0949367088607595
9781908541703,ch_9,Oncological emergencies must be anticipated and recognized.,"Overexpression of HER2 in hormone-receptor-positive breast cancer. Retrospective analyses have shown that metastatic steroid hormone-receptor-positive breast cancer with concurrent overexpression of HER2 is less responsive to endocrine treatment, especially tamoxifen. This may be explained by 'in vitro' data, which have indicated that the presence of HER2 downregulates estrogen-receptor production, thereby rendering cells less responsive to anti-estrogen therapy. In a phase III trial comparing anastrozole plus trastuzumab with anastrozole alone as first-line therapy, progression-free survival was poor (< 4 months) in both treatment arms, though an improvement in progression-free survival in favor of trastuzumab was seen in the combination arm. In a phase II trial of letrozole and trastuzumab, the overall response rate to the combination in patients who had previously received tamoxifen was 26%, with median time to disease progression of 5.8 months; however, a large number of patients in this trial also experienced early progressive disease, indicating overlapping resistance. A study of the oral tyrosine kinase inhibitor lapatinib in combination with letrozole has demonstrated superior response rates and time to progression in favor of the combination. There are several ongoing trials combining hormonal treatment and other targeted therapy with the anti-HER2 agent, farnesyl transferase, and angiogenesis inhibitors. It should be recognized, however, that patients with hormone-receptor-positive disease who have overexpression of HER2 do badly and should perhaps be considered for chemotherapy at an early stage in their metastatic disease.",346,10,0.028901734104046242
9781908541703,ch_9,Effective pain management is almost always possible.,"Bone metastases occur in over 70% of patients with metastatic breast cancer and may be solitary or multiple. They are usually identified because of pain, or during staging after metastatic disease has been identified at other sites. An isotope bone scan with plain radiographs can be used to identify bone destruction. MRI will determine the cause of any neurological symptoms. Management is outlined in Table 8.4.",80,8,0.1
9781908541703,ch_9,It is essential to set clearly defined goals of therapy for both the patient and healthcare professionals.,"It is essential that healthcare professionals recognize the need for spiritual and emotional support for the dying patient. While all doctors should, of course, be taught the skills of listening and counseling, no breast cancer team is complete without access to a professionally trained counselor or the appropriate ministers of religion. Coming to terms with the inevitability of death may have a calming influence and may even reduce the need for pharmacological support. The hospice movement, pioneered in the UK, is an example of this ethos at work and has now been copied in many countries around the world.",111,18,0.16216216216216217
9781908541703,ch_10,The well-conducted clinical trial remains the benchmark of both therapy and medical progress.,"The clinical trial process may be our most powerful analytical tool for developing and testing new treatments. There is also good evidence that the trial process itself raises the quality of care. However, a good trial must ask a good question and be structured to provide a reasonable chance of getting a good answer. Bad questions and poor execution defeat the purpose. It must also be remembered that no trial can supplant good clinical observation, the insight that develops a new hypothesis or the basic scientific discovery or technological advance that prompts the trial.",102,17,0.16666666666666666
9781908541703,ch_10,The clinical trial process needs to be encouraged within routine clinical practice.,"The clinical trial process may be our most powerful analytical tool for developing and testing new treatments. There is also good evidence that the trial process itself raises the quality of care. However, a good trial must ask a good question and be structured to provide a reasonable chance of getting a good answer. Bad questions and poor execution defeat the purpose. It must also be remembered that no trial can supplant good clinical observation, the insight that develops a new hypothesis or the basic scientific discovery or technological advance that prompts the trial.",102,13,0.12745098039215685
9781908541703,ch_10,The patient must be an informed and willing participant in the study.,"The trial must address a legitimate question to which the answer is currently unclear. In a randomized trial, this introduces the concept of 'equipoise', which means that each arm of the study has equal merit in advance of the experiment. The patient must be an informed and willing participant in the study.",60,13,0.21666666666666667
9781908541703,ch_10,Patient safety is of primary concern in a trial.,"Patient safety is of primary concern in a trial. It is possible that a new treatment may harbor an unanticipated disadvantage or that the treatments compared may have much greater differences in effect than anticipated. Such concerns are addressed by the interim analysis of blinded data, with rules to shut down a trial and make the results public if either of these events occurs. These are not easy systems to design or execute. There is great pressure from all directions to get the data early. The risk is the loss of important long-term information. This issue is particularly important in the adjuvant setting, where much breast cancer research and treatment is concentrated. The trial designer must give very careful thought to all the outcomes in a trial and to the early estimators used. It is our view that the referring physician, consultant and patient must understand these stopping rules, at least in outline.",173,11,0.06358381502890173
9781908541727,ch01,Carry out a basic eye assessment by:- identifying the presenting symptoms- taking a complete patient history- performing as thorough an examination as you can with the equipment you have available.,"Basic eye assessment: history and examination. You only have a few minutes with each patient who comes to see you with an eye complaint, and (if you're a general practitioner) you probably have very little eye examination equipment. A careful history of the patient's eye symptoms plus looking for a few critical signs of serious disease will help you identify how urgently the patient should be referred to an ophthalmologist, or whether you can treat them yourself. Always remember to examine both eyes. Eye anatomy. The eye, its surrounding structures and the brain's visual pathways can be affected by a wide spectrum of clinical conditions. Fortunately, the cornea and the ocular media are transparent, so most of the eyeball can be observed directly for signs of abnormality. Figure 1.1 depicts the essential components of the eye's optical system, many of which are referred to throughout this book. The main stages of an eye assessment are listed in Table 1.1 and are discussed in more detail below.",199,35,0.17587939698492464
9781908541727,ch01,"Use your patients' eye symptoms and signs to triage them according to their need for referral to an ophthalmologist: those with serious eye emergencies who require urgent referral, those with non-urgent problems who require routine referral and those whom you can observe or treat yourself.","Basic eye assessment: history and examination. You only have a few minutes with each patient who comes to see you with an eye complaint, and (if you're a general practitioner) you probably have very little eye examination equipment. A careful history of the patient's eye symptoms plus looking for a few critical signs of serious disease will help you identify how urgently the patient should be referred to an ophthalmologist, or whether you can treat them yourself. Always remember to examine both eyes. Eye anatomy. The eye, its surrounding structures and the brain's visual pathways can be affected by a wide spectrum of clinical conditions. Fortunately, the cornea and the ocular media are transparent, so most of the eyeball can be observed directly for signs of abnormality. Figure 1.1 depicts the essential components of the eye's optical system, many of which are referred to throughout this book. The main stages of an eye assessment are listed in Table 1.1 and are discussed in more detail below. Taking a history. When a patient presents with an eye complaint, you will need to find out the exact nature and severity of the problem. Questions to ask include.",232,56,0.2413793103448276
9781908541727,ch01,- identifying the presenting symptoms,"You only have a few minutes with each patient who comes to see you with an eye complaint, and (if you're a general practitioner) you probably have very little eye examination equipment. A careful history of the patient's eye symptoms plus looking for a few critical signs of serious disease will help you identify how urgently the patient should be referred to an ophthalmologist, or whether you can treat them yourself. Always remember to examine both eyes.",89,5,0.056179775280898875
9781908541727,ch01,- taking a complete patient history,"You only have a few minutes with each patient who comes to see you with an eye complaint, and (if you're a general practitioner) you probably have very little eye examination equipment. A careful history of the patient's eye symptoms plus looking for a few critical signs of serious disease will help you identify how urgently the patient should be referred to an ophthalmologist, or whether you can treat them yourself. Always remember to examine both eyes.",89,6,0.06741573033707865
9781908541727,ch01,- performing as thorough an examination as you can with the equipment you have available.,"You only have a few minutes with each patient who comes to see you with an eye complaint, and (if you're a general practitioner) you probably have very little eye examination equipment. A careful history of the patient's eye symptoms plus looking for a few critical signs of serious disease will help you identify how urgently the patient should be referred to an ophthalmologist, or whether you can treat them yourself. Always remember to examine both eyes.",89,16,0.1797752808988764
9781908541727,ch01,"Eye disease cannot be accurately diagnosed without a slit-lamp microscope examination. If in any doubt, refer the patient.","Eye injury. It is important to get a clear idea of the mechanism of injury. If something hit the eye, find out what it was and with what velocity it struck the eye. Patients who give a history of being struck in the eye with a fragment of high-speed metal (such as when hammering metal), or those who have received sharp trauma to the eye, need urgent referral for a slit-lamp examination and an X-ray to determine whether a perforating injury, with or without an intraocular foreign body, is present, even if the results of your examination are normal.",121,24,0.19834710743801653
9781908541727,ch01,Test visual acuity (VA) in every patient who complains of blurred vision.,"Visual acuity. Every general practice should have a distance VA chart for testing the sharpness of vision at 6 m (20 ft) (Figure 1.2), and every patient complaining of blurred vision should ideally have their VA tested. VA is tested one eye at a time (occlude the other eye), with the patient wearing their 'distance' glasses or contact lenses to provide a measure of 'best corrected visual acuity' (BCVA).",90,16,0.17777777777777778
9781908541727,ch01,Test the visual field to confrontation to detect disease that would be missed by testing for VA alone.,"Visual field to confrontation. There is a lot more to vision than just visual acuity. Testing the visual field (the entire sideways extent of vision for each eye) is also important, as this can lead to the detection of disease that would be missed if VA alone were tested. For example, a patient with a pituitary tumor can have a bitemporal hemianopia but still retain normal VA in each eye.",85,19,0.2235294117647059
9781908541727,ch01,"Perform the 'swinging light test' to check for a relative afferent pupillary defect (RAPD) in all patients who complain of blurred vision, flashes, floaters or visual field loss. The presence of an RAPD signifies serious retinal or optic nerve disease.","We do not have room in this book for a full discussion of eye movement testing, but you should ask the patient to keep their head still and follow a slowly moving target with their eyes (right, up and right, up, up and left, left, down and left, down, down and right), while you look for any restriction in the normal range of movement of one or both eyes. Pupils. It is important to note the pupil size in each eye and whether each pupil constricts briskly to a bright light in a dimly lit room. However, the most important test is the 'swinging light test', which is used to look for a relative afferent pupillary defect (RAPD) (Figure 1.4). This should be performed for all patients complaining of blurred vision, flashes, floaters or visual field loss. Dim the room lights and use a bright light source (such as a bright flashlight or an ophthalmoscope); ask the patient to stare at a distant target and swing the light repeatedly but slowly between the two eyes, shining it for 1-2 seconds in each eye. A normal response is for each pupil to constrict when the light is shone on each eye in turn. An RAPD (the abnormal response) occurs when one pupil dilates, rather than constricts, when the light is shone on it. If an RAPD is found, serious retinal or optic nerve disease on the same side is likely.",300,56,0.18666666666666668
9781908541727,ch01,"In patients with red eye/s, the use of a blue light and fluorescein drops may identify a corneal ulcer that is invisible with white light alone.","Blue light and fluorescein drops. For cases of red eye, it is useful to administer the orange dye fluorescein (unless you think the patient has a penetrating injury, in which case no drops should be used). Instill a drop of fluorescein in the eye, or put a drop of saline on a fluorescein paper strip and touch it to the lower conjunctiva. Then examine the corneal and conjunctival surface with a bright blue light in a dark room (Figure 1.5b). If you don't have a commercial blue filter for your flashlight, blue cellophane held over the flashlight can be used instead. A corneal ulcer or abrasion will show up as a fluorescent yellow-green area on the cornea (see page 103). Ulcers that are invisible under white light can be detected by this procedure.",181,36,0.19889502762430938
9781908541727,ch01,"Although useful for viewing the optic disc, the commonly available handheld direct ophthalmoscope is not a particularly good instrument for examining the retina. Patients who exhibit 'normal fundoscopy' with the direct ophthalmoscope can still have serious disease that is detectable only by examination with the slit-lamp microscope and retinal lenses.","Optic discs, retinal blood vessels and macula. Move close to the patient and view the optic disc in each eye, noting whether the disc looks normal or abnormal (Figure 1.7); trace the retinal blood vessels away from the disc. View as much of the peripheral retina as possible by asking the patient to look up, down, right and left in turn. Finally, ask the patient to look directly at the light to view the macula. It is important to remember to examine the optic discs by direct ophthalmoscopy in all patients complaining of headache to see if bilateral disc swelling caused by raised intracranial pressure (papilledema) is present. Remember that although the direct ophthalmoscope gives good images of the optic discs it has only a very small field of view; a 'normal' direct ophthalmoscope examination therefore does not exclude the possibility of serious intraocular disease. It is sometimes difficult to identify subtle optic nerve swelling through the ophthalmoscope because you are viewing the image with only one eye. Depth perception and optic nerve swelling is better appreciated when viewing with both eyes (binocular viewing), such as when using a table-mounted slit-lamp. Slit-lamp examination is required to determine whether an eye is definitely 'normal'. A slit-lamp microscope provides a highly magnified three-dimensional view of the eye surface, anterior chamber, lens and, with handheld fundus lenses, the vitreous, retina and optic disc (Figure 1.8). There are many eye diseases, for example iritis, which can only be diagnosed with the slit lamp. Again, examination with this instrument is best taught in practice.",347,69,0.1988472622478386
9781908541727,ch02,"If a patient presents with a red eye of unknown cause, with one or more of the 'five Ps' (see page 22 ), they have a 'bad' red eye.","Red eye is one of the most common eye symptoms your patients will complain of. Many diseases can result in a red eye, ranging from harmless but irritating complaints such as conjunctivitis, which you can treat yourself, to severe sight-threatening diseases such as acute glaucoma, which can be permanently blinding if you don't immediately refer the patient for emergency treatment. You must be able to recognize the severity of a red eye (that is, distinguish between a 'good' and 'bad' red eye), as outlined below. For red eye due to trauma (including corneal foreign body), see Chapter 11. 'Bad' red eye. 'Bad' red eye is defined as one red eye (rarely bilateral) of unknown cause with one or more of the 'five Ps', as detailed in Table 2.1. The underlying cause of a 'bad' red eye, such as acute glaucoma or iritis, can only be diagnosed by a careful slit-lamp examination and measurement of intraocular pressure.",211,36,0.17061611374407584
9781908541727,ch02,Do not prescribe any treatment for a 'bad' red eye.,"Red eye is one of the most common eye symptoms your patients will complain of. Many diseases can result in a red eye, ranging from harmless but irritating complaints such as conjunctivitis, which you can treat yourself, to severe sight-threatening diseases such as acute glaucoma, which can be permanently blinding if you don't immediately refer the patient for emergency treatment. You must be able to recognize the severity of a red eye (that is, distinguish between a 'good' and 'bad' red eye), as outlined below. For red eye due to trauma (including corneal foreign body), see Chapter 11.",126,13,0.10317460317460317
9781908541727,ch02,"Underlying causes of 'bad' red eye include acute glaucoma, iritis, infective corneal ulcer, scleritis and endophthalmitis.","Red eye is one of the most common eye symptoms your patients will complain of. Many diseases can result in a red eye, ranging from harmless but irritating complaints such as conjunctivitis, which you can treat yourself, to severe sight-threatening diseases such as acute glaucoma, which can be permanently blinding if you don't immediately refer the patient for emergency treatment. You must be able to recognize the severity of a red eye (that is, distinguish between a 'good' and 'bad' red eye), as outlined below. For red eye due to trauma (including corneal foreign body), see Chapter 11. 'Bad' red eye. 'Bad' red eye is defined as one red eye (rarely bilateral) of unknown cause with one or more of the 'five Ps', as detailed in Table 2.1. The underlying cause of a 'bad' red eye, such as acute glaucoma or iritis, can only be diagnosed by a careful slit-lamp examination and measurement of intraocular pressure.",211,38,0.18009478672985782
9781908541727,ch02,"You can treat these patients yourself; however, they should be referred if they do not begin to improve within 2 weeks, or if their condition worsens.","'Good' red eye. 'Good' red eye is diagnosed when one or both eyes are red, but. there is no pain, photophobia or blurred vision. both eyes are otherwise completely normal on examination. You can assess these patients for treatment yourself, or refer non-urgently to an ophthalmologist. The underlying cause could be viral, allergic or bacterial conjunctivitis, dry eyes or blepharitis. However, you should refer any patient with 'good' red eye if the eye has not improved within 2 weeks, or if it turns into 'bad' red eye at any stage.",125,31,0.248
9781908541727,ch02,"Underlying causes of 'good' red eye/s include bacterial, viral and allergic conjunctivitis, subconjunctival hemorrhage, episcleritis, dry eyes and blepharitis.","both eyes are otherwise completely normal on examination. You can assess these patients for treatment yourself, or refer non-urgently to an ophthalmologist. The underlying cause could be viral, allergic or bacterial conjunctivitis, dry eyes or blepharitis. However, you should refer any patient with 'good' red eye if the eye has not improved within 2 weeks, or if it turns into 'bad' red eye at any stage. Prescribing eye drops. There will be numerous occasions when you are challenged with a decision to treat a patient's eye condition with medication or to refer to an ophthalmologist. (It is difficult to make these decisions and monitor the eye condition without an ophthalmic slit-lamp.). 'Safe' topical treatment. The only eye drops you should prescribe without an ophthalmologist's opinion are artificial tears for dry eyes, antihistamine and mast-cell stabilizers for allergic conjunctivitis, and antibiotic eye drops for bacterial conjunctivitis.",206,42,0.20388349514563106
9781908541727,ch02,"The only eye drops you should prescribe without an ophthalmologist's opinion are artificial tears, antibiotics (for bacterial conjunctivitis) or mast-cell inhibitors (for allergic conjunctivitis).","You can assess these patients for treatment yourself, or refer non-urgently to an ophthalmologist. The underlying cause could be viral, allergic or bacterial conjunctivitis, dry eyes or blepharitis. However, you should refer any patient with 'good' red eye if the eye has not improved within 2 weeks, or if it turns into 'bad' red eye at any stage. Prescribing eye drops. There will be numerous occasions when you are challenged with a decision to treat a patient's eye condition with medication or to refer to an ophthalmologist. (It is difficult to make these decisions and monitor the eye condition without an ophthalmic slit-lamp.). 'Safe' topical treatment. The only eye drops you should prescribe without an ophthalmologist's opinion are artificial tears for dry eyes, antihistamine and mast-cell stabilizers for allergic conjunctivitis, and antibiotic eye drops for bacterial conjunctivitis. Don't ever prescribe the following eye drops.",206,41,0.19902912621359223
9781908541727,ch02,Refer all patients with 'bad' red eye immediately and urgently - emergency treatment can often save the patient's sight.,"For the conditions described in this section, urgent treatment by an ophthalmologist can often save the patient's sight. If referral is delayed, even by a few days, permanent visual loss can occur. Iritis (anterior uveitis) is inflammation in the anterior chamber of the eye that can only be diagnosed by slit-lamp examination. Patients are usually young or middle-aged adults who present with one or more of: blurred vision (although vision can be normal early on), red eye (also mild in early cases), eye pain and photophobia. The pupil may look normal, be irregular or be distorted. On slit-lamp examination, white cells can be seen in the anterior chamber and clumps of white cells (keratic precipitates) may be seen on the inside of the cornea (Figure 2.1).",170,23,0.13529411764705881
9781908541727,ch02,"If a patient presents with one or two red eyes, but without pain, photophobia or blurred vision, and the eyes are otherwise normal on examination, they have 'good' red eye/s.","Iritis (anterior uveitis) is inflammation in the anterior chamber of the eye that can only be diagnosed by slit-lamp examination. Patients are usually young or middle-aged adults who present with one or more of: blurred vision (although vision can be normal early on), red eye (also mild in early cases), eye pain and photophobia. The pupil may look normal, be irregular or be distorted. On slit-lamp examination, white cells can be seen in the anterior chamber and clumps of white cells (keratic precipitates) may be seen on the inside of the cornea (Figure 2.1). Acute glaucoma is a sudden rise in intraocular pressure: normal pressure is less than 22 mmHg, but in acute glaucoma it is usually above 40 mmHg. Symptoms include eye ache or pain (which can be severe, can cause nausea or vomiting, and can be mistaken for migraine) and blurred vision, sometimes with haloes around lights.",207,40,0.1932367149758454
9781908541727,ch02,"Do not prescribe steroid eye drops without advice from an ophthalmologist, as they can exacerbate infections, and cause cataracts and glaucoma.","Allergic conjunctivitis most commonly occurs in patients with asthma, eczema or hay fever, although it can occur in isolation. The predominant symptom is itching of one or both eyes. There is either no discharge, or a watery or scant, sticky discharge (Figure 2.9a); lid eversion may show papillae (Figure 2.9b). The condition can be acute and severe (often in association with a hay fever attack), seasonal (in spring or summer) or chronic. If the patient wears contact lenses, they should see their contact lens prescriber for a check-up. If not, prescribe mast-cell inhibitor drops to see whether they help. Warn the patient that they may need to use the drops for several weeks before they notice any improvement. Steroid eye drops will make the eyes feel much better, but should only be prescribed on the advice of an ophthalmologist, as long-term use can cause glaucoma and cataracts.",202,32,0.15841584158415842
9781908541727,ch03,"Most patients with blurred vision have benign, slowly progressive conditions and can be referred routinely to an ophthalmologist. However, blurred vision may also be the first symptom of potentially sight- or life-threatening disease, and patients suspected of having a serious cause of blurred vision must be referred urgently.","Blurred vision. The most common causes of blurred vision are refractive error (in the young) and cataract (in the elderly). However, blurred vision can also be the presenting symptom of potentially blinding intraocular disease such as retinal detachment, or potentially fatal extraocular disease such as vasculitis, brain tumor or stroke. It is essential to be able to clinically triage your patients with blurred vision into the majority for whom routine written referral to an ophthalmologist is appropriate and the minority who require urgent referral (to be seen the same day). Delay in referral of urgent cases, of even a few days, can cost the patient their sight. Patients with none of the features requiring urgent referral may be referred routinely, but should be advised to contact you if there are any major changes in their symptoms while they are waiting to be seen by the ophthalmologist. Causes of acute visual loss. Patients suspected of having any of the diseases outlined in this section should be referred urgently, as immediate ophthalmic medical or surgical treatment may be able to recover or stabilize sight. Retinal detachment. The retina lines the inner aspect of the back wall of the eye and consists of specialist cells called rods and cones (photoreceptors). These cells convert the focused light falling upon the retina to electrical energy to send to the brain to give us vision. The retina also contains the retinal pigment epithelium, which lies beneath the photoreceptors and helps them function, and the neural connections above the photoreceptors which form the optic nerve.",318,59,0.18553459119496854
9781908541727,ch03,All people over 40 should be encouraged to have regular eye checks by their optometrist to look for early signs of glaucoma and other eye disease. Chronic glaucoma is usually asymptomatic until it is very advanced.,"Chronic glaucoma causes slow, painless loss of vision, which is usually not noticed by the patient because peripheral vision is lost first. Central vision loss signifies severe disease and can occur if the condition is not detected early by routine population screening. Chronic glaucoma is common, and risk increases with age. People with a family history of glaucoma are at increased risk and may develop the disease at a younger age. Regular examination by an optometrist every 2 years is recommended from the age of 40 to look for signs of glaucoma. If there is a strong family history of glaucoma, annual examination from an earlier age may be required. The examination should include an eye pressure test, optic disc examination and automated visual fields. The eyes of a patient with chronic glaucoma appear entirely normal on examination, apart from raised intraocular pressure (in most but not all patients) and characteristic 'cupping' of one or both optic discs (Figure 3.7). Do not confuse this condition with acute glaucoma, which is much rarer and presents with a painful red eye and blurred vision (see Chapter 2).",237,49,0.20675105485232068
9781908541727,ch03,Please check that all your practice's diabetic patients are enrolled for regular eye screening to detect diabetic eye disease. Diabetic retinopathy is best treated at an asymptomatic stage to prevent visual loss.,"Diabetic maculopathy. All of your practice's diabetic patients should be enrolled for regular (usually annual) diabetic retinopathy screening. The right time to treat diabetic maculopathy (or proliferative retinopathy) is in its early stages, before it becomes symptomatic. Laser treatments, slow-release steroid injections and anti-VEGF injections are used for this condition. Patients who have advanced diabetic maculopathy that has not been detected by screening complain of blurred vision and metamorphopsia. Early diabetic maculopathy is very difficult to see with the direct ophthalmoscope, particularly without the aid of dilating drops. Advanced cases may show microaneurysms (small red dots) and hard exudates (yellow lipid deposits from leaky microaneurysms) at or near the macula (Figure 3.8).",175,41,0.2342857142857143
9781908541727,ch03,Always consider temporal arteritis if a patient over 50 complains of sudden loss of vision or transient blurring of vision.,"'Dry' age-related macular degeneration ('dry' AMD). In the elderly, age-related changes in the macula often cause gradual, usually mild-to-moderate, loss of vision, although in some cases it can also cause severe visual loss. In the early stages of macular degeneration patients are aware that they need more light to read and it takes longer to adjust from light to dark environments and vice versa. Patients complain of increasing difficulty reading and blurred central vision with preserved peripheral vision. The macula is very difficult to examine with the direct ophthalmoscope, especially if dilating drops are not used, but drusen (small yellow spots from the waste products of cell metabolism) or areas of pigment atrophy and/or black pigment clumps may be seen (Figure 3.9). Superimposed on this gradual decline of vision, a minority of patients also experience a sudden loss of central vision with distortion due to the development of 'wet' AMD.",202,23,0.11386138613861387
9781908541727,ch04,"Urgently refer all patients (of any age) with new-onset double vision to an ophthalmologist, ideally to be seen the same day.","The clinical assessment of a patient with double vision (diplopia) is complex, and it is very difficult for non-ophthalmologists to accurately differentiate between serious and non-serious causes. For this reason, all patients with new-onset transient or persisting double vision require urgent referral to an ophthalmologist, ideally to be seen the same day. Causes of double vision. If a patient has double vision they see two images of a single object. Many adults with double vision have an ischemic third, fourth or sixth nerve palsy, which will usually resolve spontaneously within a few months. However, the fact that a patient has risk factors for an ischemic nerve palsy (such as diabetes or hypertension) is no reassurance that more serious pathology is absent.",161,32,0.19875776397515527
9781908541727,ch04,"Double vision may be due to disease of the orbit, extraocular muscles, neuromuscular junction, ocular motor nerves or brain. It is often very difficult to accurately diagnose the cause on examination.","If a patient has double vision they see two images of a single object. Many adults with double vision have an ischemic third, fourth or sixth nerve palsy, which will usually resolve spontaneously within a few months. However, the fact that a patient has risk factors for an ischemic nerve palsy (such as diabetes or hypertension) is no reassurance that more serious pathology is absent. New-onset double vision is also a common presenting symptom of potentially fatal brain aneurysms, brain tumors, stroke, myasthenia gravis or temporal arteritis. Brain aneurysms in particular can rupture, causing a subarachnoid hemorrhage, and may kill the patient within hours of the onset of double vision if they are not immediately diagnosed and treated. As outlined in the following sections, double vision can result from disease of the orbit, extraocular muscles, neuromuscular junction, ocular motor nerves or brain.",193,41,0.21243523316062177
9781908541727,ch04,"Overall, the most common cause of diplopia in adults is ischemic third, fourth or sixth cranial nerve palsy. Temporal arteritis should always be excluded.","Neuromuscular junction disease (myasthenia gravis) is a relatively common cause of diplopia and/or ptosis (drooping upper eyelid/s) in adults of all ages. Most patients with myasthenia say that their double vision varies from day to day, and is often worst at the end of the day. The patient may also complain of systemic symptoms such as dysphagia (difficulty in swallowing), shortness of breath and dysarthria (impaired speech). Cranial nerve palsies (CN 3, 4 and/or 6). The most common cause of diplopia in patients over 50 is an ischemic third, fourth or sixth nerve palsy; this is usually due to diabetes or atherosclerosis. Another important cause in this age group, which should be excluded, is temporal arteritis.",177,36,0.2033898305084746
9781908541727,ch04,Brain aneurysms - which can be fatal if they are not urgently diagnosed and treated - are a not infrequent cause of double vision in adults; patients often present with partial or complete third nerve palsy. Pupil size is not a reliable indicator of whether an aneurysm is present.,"Third cranial nerve (oculomotor nerve) palsy. The palsy may be partial (affecting one or more of the medial rectus, superior rectus, inferior rectus, inferior oblique or upper-lid levator muscles) or complete (completely paralyzing all these muscles). In either of these presentations, the pupil constrictor muscle, which is also innervated by the third nerve, may be affected (causing a dilated pupil that constricts poorly to light) or unaffected. Partial third nerve palsy may not be obvious, as it can present as a subtle vertical muscle imbalance (one eye higher than the other) or one eye turned out with horizontal, vertical or oblique double vision. A complete third nerve palsy presents with a complete ptosis (the eyelid is closed) (Figure 4.2). When the lid is lifted, the eye is seen to be turned out (by the action of the intact sixth nerve on the lateral rectus) and cannot move in any direction except further out towards the ear. In addition, the pupil is dilated. Posterior communicating artery aneurysm causes up to a third of all third nerve palsies (partial or complete). A 'spared' (normal size) or enlarged pupil is not a reliable indication of whether an aneurysm is present.",280,62,0.22142857142857142
9781908541727,ch05,A combination of flashing lights and floating spots may indicate a retinal tear or detachment.,"A combination of new-onset flashing lights and and new-onset floaters signals a higher likelihood of a retinal tear or detachment. Flashing lights. Patients with migraine often see flashing or sparkling lights before the onset of their headache; sometimes they experience these symptoms without their usual headache (acephalgic migraine). Flashing lights that are not the prodrome of migraine are most commonly due to an age change in the vitreous called posterior vitreous detachment, in which the vitreous jelly pulls away from the retina. The resultant minor retinal traction causes retinal neurons to fire, and the patient then sees flashing lights. However, in a minority of patients the flashing lights are caused by significant retinal traction resulting in a retinal tear or detachment, which requires urgent laser or surgical treatment.",164,17,0.10365853658536585
9781908541727,ch05,Any of the following symptoms require urgent ophthalmic referral:- flashing lights (other than the visual prodrome of migraine)- new-onset floating spots- visual field loss- visual distortion- photophobia (sensitivity to light)- pain in the eye (even if vision is normal and the eye is not red)- symptoms of temporal arteritis (if the patient is over 50).,"Flashing lights that are not the prodrome of migraine are most commonly due to an age change in the vitreous called posterior vitreous detachment, in which the vitreous jelly pulls away from the retina. The resultant minor retinal traction causes retinal neurons to fire, and the patient then sees flashing lights. However, in a minority of patients the flashing lights are caused by significant retinal traction resulting in a retinal tear or detachment, which requires urgent laser or surgical treatment. Floating spots. Most of us, when looking at a blue sky or a white wall, can see small clear or gray floaters in our vision; these are normal imperfections in the vitreous jelly. However, new-onset floaters (gray, black or red spots, cobwebs or blobs) can be due to a retinal tear, retinal detachment or vitreous hemorrhage, and require urgent assessment. Visual field loss. Table 5.1 outlines the different types of visual field defect in terms of how they are perceived by the patient, the anatomic site at which they occur and the causes of each type of defect. Persisting visual field loss is always due to serious eye, optic nerve or brain disease. Some patients will spontaneously mention that their vision is bad only in a certain area (exempli gratia only out to the side) in one or both eyes. Others will realize (if you ask them) that their blurred vision is only in part of the visual field (Figure 5.1), and some patients may be asymptomatic and the field defect only noted on examination.",329,76,0.23100303951367782
9781908541727,ch05,- flashing lights (other than the visual prodrome of migraine),"Flashing lights that are not the prodrome of migraine are most commonly due to an age change in the vitreous called posterior vitreous detachment, in which the vitreous jelly pulls away from the retina. The resultant minor retinal traction causes retinal neurons to fire, and the patient then sees flashing lights. However, in a minority of patients the flashing lights are caused by significant retinal traction resulting in a retinal tear or detachment, which requires urgent laser or surgical treatment.",99,13,0.13131313131313133
9781908541727,ch05,- new-onset floating spots,"Floating spots. Most of us, when looking at a blue sky or a white wall, can see small clear or gray floaters in our vision; these are normal imperfections in the vitreous jelly. However, new-onset floaters (gray, black or red spots, cobwebs or blobs) can be due to a retinal tear, retinal detachment or vitreous hemorrhage, and require urgent assessment.",90,7,0.07777777777777778
9781908541727,ch05,- visual field loss,"Visual field loss. Table 5.1 outlines the different types of visual field defect in terms of how they are perceived by the patient, the anatomic site at which they occur and the causes of each type of defect.",44,4,0.09090909090909091
9781908541727,ch05,- pain in the eye (even if vision is normal and the eye is not red),"Persisting visual field loss is always due to serious eye, optic nerve or brain disease. Some patients will spontaneously mention that their vision is bad only in a certain area (exempli gratia only out to the side) in one or both eyes. Others will realize (if you ask them) that their blurred vision is only in part of the visual field (Figure 5.1), and some patients may be asymptomatic and the field defect only noted on examination.",96,18,0.1875
9781908541727,ch05,Visual distortion is almost always a symptom of serious macular disease.,"Visual distortion (metamorphopsia) is almost always a symptom of macular (central retinal) disease (Figure 5.3). If onset is sudden in elderly patients, it may be a warning sign of 'wet' age-related macular degeneration (AMD). There are also many other macular diseases.",66,13,0.19696969696969696
9781908541727,ch05,- visual distortion,"Visual distortion (metamorphopsia) is almost always a symptom of macular (central retinal) disease (Figure 5.3). If onset is sudden in elderly patients, it may be a warning sign of 'wet' age-related macular degeneration (AMD). There are also many other macular diseases.",66,3,0.045454545454545456
9781908541727,ch05,Photophobia or eye pain may indicate early iritis or acute glaucoma.,"Photophobia (sensitivity to light) can be the earliest symptom of iritis, before the eye becomes red or the vision becomes blurred. It is also important to check for non-ocular causes of photophobia (exempli gratia meningitis). Eye pain or eye ache can occur in early acute glaucoma, scleritis or iritis, before the eye becomes red.",83,18,0.21686746987951808
9781908541727,ch05,- photophobia (sensitivity to light),"Photophobia (sensitivity to light) can be the earliest symptom of iritis, before the eye becomes red or the vision becomes blurred. It is also important to check for non-ocular causes of photophobia (exempli gratia meningitis).",53,9,0.16981132075471697
9781908541727,ch05,Urgent referral of patients with symptoms of temporal arteritis could save their sight or their life.,"The only clinical sign of temporal arteritis (other than signs of its complications) is tenderness and/or non-pulsatility of the temporal arteries on palpation; however, this is often unreliable. Blood tests usually reveal an elevated erythrocyte sedimentation rate (ESR), plasma viscosity (PV) and C-reactive protein (CRP) level. Even if no visual symptoms are present initially, patients with untreated temporal arteritis can suddenly go permanently blind in one or both eyes, usually from anterior ischemic optic neuropathy. If, however, the disease is suspected early, and the patient is referred urgently and is treated with high-dose steroids, visual loss and life-threatening complications can usually be prevented.",153,19,0.12418300653594772
9781908541727,ch05,- symptoms of temporal arteritis (if the patient is over 50).,"Even if no visual symptoms are present initially, patients with untreated temporal arteritis can suddenly go permanently blind in one or both eyes, usually from anterior ischemic optic neuropathy. If, however, the disease is suspected early, and the patient is referred urgently and is treated with high-dose steroids, visual loss and life-threatening complications can usually be prevented.",73,14,0.1917808219178082
9781908541727,ch06,"Most patients with gritty, itchy or watery eyes do not need urgent referral, unless serious abnormalities are found when taking a history or on examination. You can treat many patients with these conditions yourself, as described in the chapter.","Gritty, itchy or watery eyes. Gritty, itchy or watery eyes are very common complaints, and in general are annoying to the patient rather than dangerous. Routine referral is appropriate for patients with gritty, itchy or watery eyes if their discomfort persists or worsens. Patients with these symptoms do not require urgent referral, unless you discover another abnormality when taking a history or during examination. Gritty eyes or foreign body sensation. Causes of a gritty eye include a corneal or conjunctival foreign body, corneal ulcers (infective and non-infective corneal ulcers, such as marginal keratitis), corneal abrasions, dry eye, blepharitis, inturned eyelashes, ectropion and entropion. The most common causes of gritty sore eyes are dry eye and blepharitis or a combination of the two.",186,46,0.24731182795698925
9781908541727,ch06,"Remember to evert the upper eyelid in patients complaining of a 'gritty' feeling or foreign body sensation, to look for a foreign body under the lid.","Causes of a gritty eye include a corneal or conjunctival foreign body, corneal ulcers (infective and non-infective corneal ulcers, such as marginal keratitis), corneal abrasions, dry eye, blepharitis, inturned eyelashes, ectropion and entropion. The most common causes of gritty sore eyes are dry eye and blepharitis or a combination of the two. Foreign body in the eye. If a patient complains 'there is something in my eye' (foreign body sensation), they may well have a foreign body on the cornea (see Chapter 11) or conjunctiva, or between the upper or lower eyelid and the eyeball. If a foreign body is not visible, remember to evert the upper and lower lid (see Chapter 1) and look for a foreign body under the lid.",183,33,0.18032786885245902
9781908541727,ch06,It is important to use a blue light and fluorescein drops to examine the cornea to exclude a corneal ulcer. Occasionally a viral dendritic corneal ulcer will present with a gritty or irritated eye (no pain is felt because the virus makes the eye numb). Always refer these patients urgently to an ophthalmologist and do not prescribe steroid eye drops.,"Corneal ulcer. Corneal examination with fluorescein and blue light will usually reveal the ulcer by staining. Causes may be infective (viral, bacterial, fungal or protozoan) or non-infective. These patients require urgent (same day) referral to an ophthalmologist. Be aware that a dendritic corneal ulcer, which is caused by the herpes simplex virus (HSV), may present as a gritty eye rather than a red painful eye, because the virus makes the cornea partially numb. However, the patient will often complain of blurred vision and will have mildly reduced visual acuity; corneal examination with fluorescein and blue light will usually reveal the typical branch-like ulcer. Do not prescribe steroid drops for this condition. Dry eye may cause a slightly red eye, or the patient may have normal-looking eyes. Corneal abnormalities caused by dry eye are only visible on slit-lamp examination. Dry eye should be suspected if the patient complains that their eyes feel 'dry' or 'burning', or if the sensation worsens during reading (due to the decreased blink rate we all have while reading). Prescribe artificial tears to be administered frequently (every 2 hours) and then reduce the frequency as the symptoms improve. If the eyes are uncomfortable or 'stuck down' on waking, a lubricating ointment at night as well as drops during the day can help. Refer routinely if the eye drops do not help. Blepharitis is a chronic inflammation of the eyelid margins (often with crusting at the base of the lashes and redness of the lid margins) that can occur at any age. Patients commonly complain of chronic eye irritation, grittiness and itching. Patients with blepharitis are also predisposed to the development of chalazia (eyelid lumps caused by inflammation of the oil glands; see page 85) and marginal keratitis (small peripheral corneal ulcers).",417,79,0.18944844124700239
9781908541727,ch07,- acute red eye with proptosis (forward movement of one or both eyes) (possible orbital cellulitis),"Proptosis is a condition in which one or both eyes become pushed forwards due to enlargement of the orbital contents, vascular engorgement or an orbital tumor (Figure 7.1). Causes according to presentation are as follows. Acute proptosis with pain and a red eye is caused by orbital cellulitis, autoimmune orbital inflammation and carotid-cavernous fistula. Subacute or gradually progressive unilateral or bilateral proptosis with red eye/s is most commonly caused by thyroid eye disease (associated with Graves' disease).",110,24,0.21818181818181817
9781908541727,ch07,"It is very important to perform ophthalmoscopy, looking for optic disc swelling, on all patients who complain of headache; bilateral disc swelling may be the first and only sign of a brain tumor.","Swollen disc/s. The optic discs are normally flat and pink, with a paler central 'cup'. When the intracranial pressure is raised significantly (due to tumor, hemorrhage or hydrocephalus) both optic discs swell (papilledema) (Figure 7.3). The brain's subarachnoid space normally extends forwards around the optic nerves. If intracranial pressure is raised the high-pressure cerebrospinal fluid squeezes both nerves, causing disc swelling. Both optic discs are usually obviously swollen if intracranial pressure is very high, but in less severe cases disc swelling may be mild and subtle, asymmetric or even unilateral. The absence of disc swelling does not exclude raised intracranial pressure. It is also possible for unilateral or bilateral disc swelling to occur with normal intracranial pressure, as a result of unilateral or bilateral optic nerve disease of any cause (exempli gratia inflammation, ischemia or infiltration with tumor).",204,40,0.19607843137254902
9781908541727,ch07,- bilateral optic disc swelling (possible papilledema from brain tumor or accelerated hypertension),"It is also possible for unilateral or bilateral disc swelling to occur with normal intracranial pressure, as a result of unilateral or bilateral optic nerve disease of any cause (exempli gratia inflammation, ischemia or infiltration with tumor). Bilateral disc swelling can also be seen in accelerated hypertension, so it is essential to check the patient's blood pressure in this situation.",76,18,0.23684210526315788
9781908541727,ch07,Urgently refer patients who present with any of the following signs:- acute red eye with proptosis (forward movement of one or both eyes) (possible orbital cellulitis)- bilateral optic disc swelling (possible papilledema from brain tumor or accelerated hypertension)- unequal pupils plus double vision (possible partial third nerve palsy from posterior communicating artery aneurysm)- an abnormal (dull or white) red reflex and/or white pupil in children (possible retinoblastoma or congenital cataract).,"Iris disease. The second most common cause of unequal pupil size is previous iritis, trauma or operation. Mechanical damage to the iris caused by these events may result in a pupil that is smaller or larger than normal, or that has a distorted rather than circular shape. Third nerve palsy. It is very rare for partial third nerve palsy from a tumor or aneurysm to cause an enlarged pupil in isolation (without double vision, ptosis or a visible abnormality of eye movement). The presence of an enlarged pupil in a patient with double vision from partial third nerve palsy indicates a high risk of serious underlying disease such as nerve compression by a posterior communicating artery aneurysm. Urgent referral is mandatory. Horner's syndrome is the combination of miosis (a smaller than usual pupil), slight ptosis (a drooping upper lid) and hemifacial anhidrosis (absence of sweating) on the affected side of the face (Figure 7.5). These signs can be subtle and easily missed. Horner's syndrome occurs as a result of damage to the sympathetic nerve supply to the eye and eyelid; it may be caused by disease in the brainstem, cervical spinal cord, brachial plexus, lung apex, neck, base of skull or cavernous sinus. Such diseases include internal carotid artery dissection (spontaneous or following head or neck trauma), apical lung tumor (Pancoast syndrome) and tumors of the brain, skull base or neck; however, in many cases no cause is identified. Adie's tonic pupil is a benign condition in which one pupil is enlarged (rarely both pupils), without ptosis or diplopia. Patients may complain of blurred vision, because they lose the ability to focus on near objects. The affected pupil shows sluggish or absent constriction to a bright light, but still constricts slowly when the patient is asked to focus on a near object (known as light-near dissociation). The patient may also have depressed limb tendon reflexes of unknown cause (Holmes-Adie syndrome). Dilating eye drops are a common cause of abnormal sized pupils. Always try to exclude this before referring the patient.",452,107,0.23672566371681417
9781908541727,ch07,- unequal pupils plus double vision (possible partial third nerve palsy from posterior communicating artery aneurysm),"Third nerve palsy. It is very rare for partial third nerve palsy from a tumor or aneurysm to cause an enlarged pupil in isolation (without double vision, ptosis or a visible abnormality of eye movement). The presence of an enlarged pupil in a patient with double vision from partial third nerve palsy indicates a high risk of serious underlying disease such as nerve compression by a posterior communicating artery aneurysm. Urgent referral is mandatory.",92,23,0.25
9781908541727,ch07,- an abnormal (dull or white) red reflex and/or white pupil in children (possible retinoblastoma or congenital cataract).,"Normally, a patient's pupils look black on casual observation. Red reflex examination by direct ophthalmoscopy will produce a diffuse red or orange glow that fills the pupils; this is the reflection from the back of the eye seen through the ophthalmoscope (the cause of 'red eye' in flash photographs). Red reflex examination is an essential part of every neonate's initial examination after birth. If a child's red reflex is noted to be dark, absent or white (Figure 7.6), on one or both sides, a life-threatening retinoblastoma or sight-threatening congenital cataract could be present. An abnormal red reflex is not as important a sign in adults, but can be seen in patients with advanced cataract, severe vitreous hemorrhage or advanced retinal detachment.",167,33,0.19760479041916168
9781908541727,ch08,Ensure that all your diabetic patients are enrolled for regular retinal screening examinations - these can save their sight.,"Diabetic retinopathy. Regular retinal screening of your diabetic patients by an ophthalmologist or via an accredited retinal screening service is essential for picking up the signs of early maculopathy or proliferative retinopathy. If detected early, the progression of both of these diseases can usually be halted with appropriate treatment, and the patient's sight can be saved. The best time to detect and treat serious diabetic retinopathy is before the patient develops blurred vision.",95,22,0.23157894736842105
9781908541727,ch08,"Hypertensive patients do not require eye screening, but if they develop a vein occlusion as a complication of hypertension, urgent referral is indicated.","Hypertensive patients do not require specific eye screening for this condition in the way that diabetic patients do. Although the presence of hypertensive retinopathy is a useful indication that marked hypertension has been present for some time, it does not usually cause vision problems in itself. The only time hypertensive retinopathy results in visual symptoms is in cases of acute accelerated hypertension, which may cause severe bilateral disc swelling and macular edema, a macro-aneurysm that may leak or bleed into the retina, or arteriovenous (AV) nipping inducing retinal vein occlusions.",121,30,0.24793388429752067
9781908541727,ch08,"If patients present with an eye problem that has no apparent cause, it is worth reviewing the patient's systemic medications, as a number of systemic agents may have ocular side effects.","When patients present with an eye problem that has no apparent cause, it is worth considering whether the condition could be caused by a systemic medication they are taking. Some of the key culprits are highlighted below in a brief 'A-Z' overview of systemic drugs and their effects on the eye. Alpha-blockers (doxazosin and tamsulosin) are used to treat blood pressure and prostatic symptoms. These agents have an effect on the iris that makes it floppy during cataract surgery. The ophthalmologist must be made aware of alpha-blocker use in order to take measures to avoid this problem. Amiodarone commonly causes vortex keratopathy (a whorl-like pattern on the surface of the cornea). The corneal changes are usually asymptomatic but, rarely, the drug can cause optic neuropathy. Referral is indicated if vision is affected.",189,36,0.19047619047619047
9781908541727,ch09,"Refer within 1 week, any patient with suspected eyelid skin cancer, or entropion with eyelashes abrading the cornea.","It is essential to differentiate orbital cellulitis from preseptal cellulitis. Orbital cellulitis is a sight- and life-threatening infection of the deep soft tissues of the orbit around and behind the eye. By contrast, preseptal cellulitis is an infection in front of the orbital septum of the eyelid skin, and is harmless provided it does not progress to orbital cellulitis. Fortunately, it is usually possible to make the distinction between the two conditions on clinical grounds. Orbital cellulitis. A patient with eyelid redness and swelling plus one or more of the signs shown in Table 9.1 has orbital cellulitis (Figure 9.1) until proven otherwise.",141,28,0.19858156028368795
9781908541727,ch09,"- preseptal cellulitis in a child, or in an adult if it does not settle with the use of oral antibiotics","It is essential to differentiate orbital cellulitis from preseptal cellulitis. Orbital cellulitis is a sight- and life-threatening infection of the deep soft tissues of the orbit around and behind the eye. By contrast, preseptal cellulitis is an infection in front of the orbital septum of the eyelid skin, and is harmless provided it does not progress to orbital cellulitis. Fortunately, it is usually possible to make the distinction between the two conditions on clinical grounds. Orbital cellulitis. A patient with eyelid redness and swelling plus one or more of the signs shown in Table 9.1 has orbital cellulitis (Figure 9.1) until proven otherwise.",141,26,0.18439716312056736
9781908541727,ch09,- acute unilateral or bilateral eyelid swelling with red eye and proptosis (possible orbital cellulitis),"Patients with suspected orbital cellulitis require urgent admission for intravenous antibiotics (and sometimes surgery). Orbital cellulitis may be mimicked by several other conditions, all of which are also serious (exempli gratia carotid-cavernous fistula). Preseptal cellulitis usually starts with an infected pimple or stye. None of the symptoms or signs of orbital cellulitis already described are present, and although there is localized eyelid redness and swelling (Figure 9.2) the patient is otherwise well and the eye looks normal and moves with ease on lifting the lid.",121,22,0.18181818181818182
9781908541727,ch09,- any of the other signs of orbital cellulitis (see pages 79 - ),"Preseptal cellulitis usually starts with an infected pimple or stye. None of the symptoms or signs of orbital cellulitis already described are present, and although there is localized eyelid redness and swelling (Figure 9.2) the patient is otherwise well and the eye looks normal and moves with ease on lifting the lid.",68,16,0.23529411764705882
9781908541727,ch09,"- acute onset of unilateral or bilateral ptosis with double vision, unequal pupils, body muscle weakness or problems with breathing or swallowing (possible myasthenia gravis or partial third nerve palsy from aneurysm or tumor)","Ptosis, in which the upper eyelid is too low ('drooping' upper lid; Figure 9.3), has a number of serious causes, including myasthenia, Horner's syndrome and third nerve palsy. However, the most common cause in middle-aged or elderly patients is age-related weakening of the levator muscle's insertion in the upper eyelid (aponeurotic ptosis). In adults with ptosis, the prime concern is to exclude any serious underlying cause; once this has been achieved surgery can be performed. Rarely, children are born with a unilateral or bilateral congenital ptosis; these children should be referred to an ophthalmologist as the drooping lid/s can prevent normal visual development. Ectropion, in which the lower eyelid is turned out, is most commonly due to age-related degeneration and stretching of the eyelid tissues (Figure 9.4); however, rarely, the condition can be due to seventh nerve palsy or scarring. The lower lid hangs away from the eye and can cause chronic irritation and watering. Patients with ectropion should be referred routinely for corrective surgery. Patients with mild ectropion and mild discomfort can be treated with ocular lubricants if they do not wish to have surgery.",264,48,0.18181818181818182
9781908541727,ch09,- new-onset seventh nerve palsy of any cause.,"Ptosis, in which the upper eyelid is too low ('drooping' upper lid; Figure 9.3), has a number of serious causes, including myasthenia, Horner's syndrome and third nerve palsy. However, the most common cause in middle-aged or elderly patients is age-related weakening of the levator muscle's insertion in the upper eyelid (aponeurotic ptosis). In adults with ptosis, the prime concern is to exclude any serious underlying cause; once this has been achieved surgery can be performed.",113,13,0.11504424778761062
9781908541727,ch09,"Refer urgently (the same day), patients with one or more of:- acute unilateral or bilateral eyelid swelling with red eye and proptosis (possible orbital cellulitis)- any of the other signs of orbital cellulitis (see pages 79 - )- preseptal cellulitis in a child, or in an adult if it does not settle with the use of oral antibiotics- acute onset of unilateral or bilateral ptosis with double vision, unequal pupils, body muscle weakness or problems with breathing or swallowing (possible myasthenia gravis or partial third nerve palsy from aneurysm or tumor)- herpes zoster ophthalmicus (shingles around the eye)- new-onset seventh nerve palsy of any cause.","Entropion, in which the lower eyelid is turned in, is also usually due to age-related changes in the lid (Figure 9.5). The lower eyelid rolls inwards, which sometimes causes the eyelashes to abrade the cornea and create foreign body sensation. If severe, this can cause a corneal ulcer. Patients with entropion should be referred urgently if a corneal abrasion or ulcer is present; otherwise prompt referral for corrective surgery is appropriate. Seventh nerve palsy, whether idiopathic or of known cause (tumor, infection, inflammation, traumatic, postsurgical), can result in decreased orbicularis muscle function and poor eyelid closure (Figure 9.6). Patients with seventh nerve palsy need to be seen urgently by an ophthalmologist (not referred routinely), as all patients with poor lid closure are at high risk of developing an exposure corneal ulcer. Blepharospasm is an intermittent or constant eyelid spasm that results in too much eyelid closure. If on one side only, the condition is usually associated with lower facial spasm on the same side (hemifacial spasm); or spasm can occur bilaterally without lower facial involvement (bilateral blepharospasm). All these patients should see an ophthalmologist to rule out an ocular or neurological cause for the spasm. Many patients benefit from botulinum toxin injections to relax the contracting muscles. Skin rashes around the eye. The skin around the eyes is susceptible to most rashes that can occur elsewhere on the skin. However, two of the most common periocular rashes are herpes zoster ophthalmicus (shingles around the eye) and contact allergic rashes. Herpes zoster ophthalmicus (HZO) is caused by the varicella zoster virus and presents as shingles in the distribution of the ophthalmic division of the trigeminal nerve (V1). A vesicular rash (often severe) appears on half the forehead and scalp; the rash sometimes affects the eyelids (Figure 9.7). If the rash involves the tip of the nose, there is an increased incidence of eye involvement. (The nasociliary branch of the trigeminal nerve supplies both the cornea and the tip of the nose.) Any patient can also develop involvement of the eyeball itself, with corneal ulcers, iritis and optic nerve or orbital complications, and therefore all need to be seen by an ophthalmologist. It is important that these patients begin a course of oral antiviral treatment (exempli gratia aciclovir or valaciclovir) as soon as possible, as this shortens the course of the disease and reduces the risk of serious eye complications. Neuralgic pain, which may be persistent and severe, is common after the rash resolves. (Post-herpetic neuralgia can be controlled by medication, and this should be offered to these patients.).",627,151,0.24082934609250398
9781908541727,ch09,- herpes zoster ophthalmicus (shingles around the eye),"The skin around the eyes is susceptible to most rashes that can occur elsewhere on the skin. However, two of the most common periocular rashes are herpes zoster ophthalmicus (shingles around the eye) and contact allergic rashes. Herpes zoster ophthalmicus (HZO) is caused by the varicella zoster virus and presents as shingles in the distribution of the ophthalmic division of the trigeminal nerve (V1). A vesicular rash (often severe) appears on half the forehead and scalp; the rash sometimes affects the eyelids (Figure 9.7). If the rash involves the tip of the nose, there is an increased incidence of eye involvement. (The nasociliary branch of the trigeminal nerve supplies both the cornea and the tip of the nose.) Any patient can also develop involvement of the eyeball itself, with corneal ulcers, iritis and optic nerve or orbital complications, and therefore all need to be seen by an ophthalmologist.",217,16,0.07373271889400922
9781908541727,ch10,"- squint ('turned eye', strabismus) or nystagmus (constantly moving eyes) not yet assessed by an ophthalmologist","Children's eye problems. In some ways, children's eye problems may have greater consequences than eye problems in adults, because some conditions, if neglected, may cause amblyopia ('lazy eye') which can reduce the vision in one or both eyes for the whole of the patient's life. In addition, life-threatening problems such as eye or brain tumors can, rarely, present with a squint ('turned eye'), poor red reflex or poor vision in an infant or child. Prompt referral to an ophthalmologist when indicated is essential if the potentially serious consequences of children's eye problems are to be avoided. Routine referral is appropriate for.",132,33,0.25
9781908541727,ch10,- an infant or child with ptosis,"In some ways, children's eye problems may have greater consequences than eye problems in adults, because some conditions, if neglected, may cause amblyopia ('lazy eye') which can reduce the vision in one or both eyes for the whole of the patient's life. In addition, life-threatening problems such as eye or brain tumors can, rarely, present with a squint ('turned eye'), poor red reflex or poor vision in an infant or child.",92,8,0.08695652173913043
9781908541727,ch10,"- red eye/s with normal vision and no pain or photophobia, which persists for longer than 2 weeks","In some ways, children's eye problems may have greater consequences than eye problems in adults, because some conditions, if neglected, may cause amblyopia ('lazy eye') which can reduce the vision in one or both eyes for the whole of the patient's life. In addition, life-threatening problems such as eye or brain tumors can, rarely, present with a squint ('turned eye'), poor red reflex or poor vision in an infant or child.",92,22,0.2391304347826087
9781908541727,ch10,"- an infant or child with photophobia, constant tearing (epiphora), corneal enlargement or cloudy cornea (possible congenital glaucoma)","an infant with persisting eye watering or a slight sticky discharge from one or both eyes, with no eye redness, photophobia or corneal clouding or enlargement (likely to be congenital nasolacrimal duct obstruction). a child with a head tilt or turn (possible congenital fourth nerve palsy). Eye discharge or watering. Most infants and children with 'watery' eyes have harmless congenital nasolacrimal duct obstruction; however, be careful not to miss the rare sight-threatening condition of congenital glaucoma, and the sight- and life-threatening disease ophthalmia neonatorum. Ophthalmia neonatorum. In contrast with viral or bacterial conjunctivitis in children or adults, in whom the disease is annoying but rarely dangerous; conjunctivitis within the first few weeks of life (ophthalmia neonatorum) may be the first sign of a sight- or life-threatening systemic infection due to a sexually transmitted disease that the infant acquired during delivery.",210,35,0.16666666666666666
9781908541727,ch10,"- a child with red eye with pain, photophobia or blurred vision (possible corneal ulcer, iritis or endophthalmitis)","an infant with persisting eye watering or a slight sticky discharge from one or both eyes, with no eye redness, photophobia or corneal clouding or enlargement (likely to be congenital nasolacrimal duct obstruction). a child with a head tilt or turn (possible congenital fourth nerve palsy). Eye discharge or watering. Most infants and children with 'watery' eyes have harmless congenital nasolacrimal duct obstruction; however, be careful not to miss the rare sight-threatening condition of congenital glaucoma, and the sight- and life-threatening disease ophthalmia neonatorum. Ophthalmia neonatorum. In contrast with viral or bacterial conjunctivitis in children or adults, in whom the disease is annoying but rarely dangerous; conjunctivitis within the first few weeks of life (ophthalmia neonatorum) may be the first sign of a sight- or life-threatening systemic infection due to a sexually transmitted disease that the infant acquired during delivery.",210,33,0.15714285714285714
9781908541727,ch10,- an infant or child with preseptal or orbital cellulitis,"an infant with persisting eye watering or a slight sticky discharge from one or both eyes, with no eye redness, photophobia or corneal clouding or enlargement (likely to be congenital nasolacrimal duct obstruction). a child with a head tilt or turn (possible congenital fourth nerve palsy).",67,14,0.208955223880597
9781908541727,ch10,- an infant or child with a history of eye trauma or possible shaken baby syndrome.,"an infant with persisting eye watering or a slight sticky discharge from one or both eyes, with no eye redness, photophobia or corneal clouding or enlargement (likely to be congenital nasolacrimal duct obstruction). a child with a head tilt or turn (possible congenital fourth nerve palsy). Eye discharge or watering.",72,17,0.2361111111111111
9781908541727,ch10,"Refer urgently, to be seen the same day, if your patient is:- a neonate with red eyes and eye watering or discharge (possible ophthalmia neonatorum)- a neonate or child with an abnormal red reflex (possible retinoblastoma or congenital cataract)- an infant or child with photophobia, constant tearing (epiphora), corneal enlargement or cloudy cornea (possible congenital glaucoma)- a child with red eye with pain, photophobia or blurred vision (possible corneal ulcer, iritis or endophthalmitis)- an older child with double vision (causes include brain tumor or aneurysm)- a child of any age with swollen optic disc/s on ophthalmoscopy (possible brain tumor or hydrocephalus).- an infant or child with preseptal or orbital cellulitis- an infant or child with ptosis- an infant or child with a history of eye trauma or possible shaken baby syndrome.","Causative organisms include gonorrhea, chlamydia and herpes simplex virus (HSV) type II, which can also cause meningitis, encephalitis and other systemic infections. For this reason, neonates suspected of having ophthalmia neonatorum should be managed as an emergency by both a neonatologist and an ophthalmologist. Conjunctivitis alone (without systemic infection) can also be due to common, less virulent bacteria. Congenital glaucoma is a rare but serious eye condition in which the child is born with persistent high pressure in one or both eyes. Congenital glaucoma does not cause red eyes, but does result in corneal and eye enlargement. Corneal clouding may develop, and the child may have constant watering of the eye/s and photophobia (aversion to bright lights). Prompt surgical treatment can save the child's sight. Congenital nasolacrimal duct obstruction is very common. It presents as persistent watering or sticky discharge from one or both eyes, without eye redness, photophobia, or corneal enlargement or clouding. This often corrects itself within the first year to 18 months of life. Nasolacrimal duct probing under general anesthetic by an ophthalmologist can be performed after this time if the problem has not spontaneously resolved. Conjunctivitis. Children of all ages may develop the usual types of conjunctivitis (viral, allergic and bacterial; see Chapter 2). Suspected poor vision. Young children are unable to complain of poor vision themselves, but parents may notice that their child is not looking at them or reacting to their facial expressions, or is having problems navigating and bumps into furniture. A normal and healthy infant usually makes eye contact with the parent in the first 8-12 weeks of life. Poor vision in one or both eyes may also present with a noticeable squint or nystagmus (see below). Assessing children's vision before they can talk may be difficult, but you can present them with various toys of different sizes and note their reaction, and observe how well they visually fix and follow the targets, as well as observing their general visual behavior. A critical difference between childhood and adult vision is that children less than 9 years old with poor vision in one or both eyes from any cause, or one eye constantly turned from squint, will not develop normal connections between the affected eye/s and the developing visual cortex. This poor connection will result in permanent poor vision from amblyopia, even if the original eye problem is later corrected. If, however, the cause of poor vision (exempli gratia congenital cataract) is identified and treated urgently, permanent blindness from amblyopia may be prevented. The earlier a child with poor vision in one or both eyes is referred to an ophthalmologist, the better the chance of preventing permanent visual loss. In the case of a squint, amblyopia may often be partially or fully corrected by patching the 'good' eye under close ophthalmic supervision. For these reasons, the ophthalmic assessment of children with poor vision is a matter of some urgency. Abnormal red reflex or 'white pupil'. The normal red reflex seen with a direct ophthalmoscope in a dark room is a diffuse orange or red glow from both pupils. Do not forget that you see the red reflex by looking though the direct ophthalmoscope a few feet away from the patient. You can check both red reflexes at the same time in the same field of view because of this distance from the patient. This also allows a direct comparison of the red reflex in both eyes at the same time. A red reflex test should be performed on any child with a squint, apparently poor vision or any other eye problem. If the red reflex on one or both sides is abnormal (Figure 10.1), a serious intraocular abnormality such as congenital cataract (dull or absent red reflex) or retinoblastoma (white reflex) is likely. Alternatively, you or the parents may notice that one or both pupils looks white or gray, rather than black.",861,210,0.24390243902439024
9781908541727,ch10,"Refer within 1 week, any child with:- squint ('turned eye', strabismus) or nystagmus (constantly moving eyes) not yet assessed by an ophthalmologist- visual field loss, or a relative afferent pupillary defect (RAPD) on the swinging light test (potentially serious optic nerve or brain disease)- suspected poor vision, or decreased visual acuity in one or both eyes, which cannot be completely corrected with glasses- red eye/s with normal vision and no pain or photophobia, which persists for longer than 2 weeks- pale optic disc/s on ophthalmoscopy.","Congenital glaucoma is a rare but serious eye condition in which the child is born with persistent high pressure in one or both eyes. Congenital glaucoma does not cause red eyes, but does result in corneal and eye enlargement. Corneal clouding may develop, and the child may have constant watering of the eye/s and photophobia (aversion to bright lights). Prompt surgical treatment can save the child's sight. Congenital nasolacrimal duct obstruction is very common. It presents as persistent watering or sticky discharge from one or both eyes, without eye redness, photophobia, or corneal enlargement or clouding. This often corrects itself within the first year to 18 months of life. Nasolacrimal duct probing under general anesthetic by an ophthalmologist can be performed after this time if the problem has not spontaneously resolved. Conjunctivitis. Children of all ages may develop the usual types of conjunctivitis (viral, allergic and bacterial; see Chapter 2). Suspected poor vision. Young children are unable to complain of poor vision themselves, but parents may notice that their child is not looking at them or reacting to their facial expressions, or is having problems navigating and bumps into furniture. A normal and healthy infant usually makes eye contact with the parent in the first 8-12 weeks of life. Poor vision in one or both eyes may also present with a noticeable squint or nystagmus (see below). Assessing children's vision before they can talk may be difficult, but you can present them with various toys of different sizes and note their reaction, and observe how well they visually fix and follow the targets, as well as observing their general visual behavior. A critical difference between childhood and adult vision is that children less than 9 years old with poor vision in one or both eyes from any cause, or one eye constantly turned from squint, will not develop normal connections between the affected eye/s and the developing visual cortex. This poor connection will result in permanent poor vision from amblyopia, even if the original eye problem is later corrected. If, however, the cause of poor vision (exempli gratia congenital cataract) is identified and treated urgently, permanent blindness from amblyopia may be prevented. The earlier a child with poor vision in one or both eyes is referred to an ophthalmologist, the better the chance of preventing permanent visual loss. In the case of a squint, amblyopia may often be partially or fully corrected by patching the 'good' eye under close ophthalmic supervision. For these reasons, the ophthalmic assessment of children with poor vision is a matter of some urgency.",561,129,0.22994652406417113
9781908541727,ch10,- a neonate with red eyes and eye watering or discharge (possible ophthalmia neonatorum),"Congenital glaucoma is a rare but serious eye condition in which the child is born with persistent high pressure in one or both eyes. Congenital glaucoma does not cause red eyes, but does result in corneal and eye enlargement. Corneal clouding may develop, and the child may have constant watering of the eye/s and photophobia (aversion to bright lights). Prompt surgical treatment can save the child's sight.",95,22,0.23157894736842105
9781908541727,ch10,"- suspected poor vision, or decreased visual acuity in one or both eyes, which cannot be completely corrected with glasses","Young children are unable to complain of poor vision themselves, but parents may notice that their child is not looking at them or reacting to their facial expressions, or is having problems navigating and bumps into furniture. A normal and healthy infant usually makes eye contact with the parent in the first 8-12 weeks of life. Poor vision in one or both eyes may also present with a noticeable squint or nystagmus (see below). Assessing children's vision before they can talk may be difficult, but you can present them with various toys of different sizes and note their reaction, and observe how well they visually fix and follow the targets, as well as observing their general visual behavior.",137,23,0.1678832116788321
9781908541727,ch10,- a neonate or child with an abnormal red reflex (possible retinoblastoma or congenital cataract),"The normal red reflex seen with a direct ophthalmoscope in a dark room is a diffuse orange or red glow from both pupils. Do not forget that you see the red reflex by looking though the direct ophthalmoscope a few feet away from the patient. You can check both red reflexes at the same time in the same field of view because of this distance from the patient. This also allows a direct comparison of the red reflex in both eyes at the same time. A red reflex test should be performed on any child with a squint, apparently poor vision or any other eye problem. If the red reflex on one or both sides is abnormal (Figure 10.1), a serious intraocular abnormality such as congenital cataract (dull or absent red reflex) or retinoblastoma (white reflex) is likely. Alternatively, you or the parents may notice that one or both pupils looks white or gray, rather than black.",195,26,0.13333333333333333
9781908541727,ch10,- a child of any age with swollen optic disc/s on ophthalmoscopy (possible brain tumor or hydrocephalus).,"The normal red reflex seen with a direct ophthalmoscope in a dark room is a diffuse orange or red glow from both pupils. Do not forget that you see the red reflex by looking though the direct ophthalmoscope a few feet away from the patient. You can check both red reflexes at the same time in the same field of view because of this distance from the patient. This also allows a direct comparison of the red reflex in both eyes at the same time. A red reflex test should be performed on any child with a squint, apparently poor vision or any other eye problem. If the red reflex on one or both sides is abnormal (Figure 10.1), a serious intraocular abnormality such as congenital cataract (dull or absent red reflex) or retinoblastoma (white reflex) is likely. Alternatively, you or the parents may notice that one or both pupils looks white or gray, rather than black.",195,27,0.13846153846153847
9781908541727,ch10,"- visual field loss, or a relative afferent pupillary defect (RAPD) on the swinging light test (potentially serious optic nerve or brain disease)","The normal red reflex seen with a direct ophthalmoscope in a dark room is a diffuse orange or red glow from both pupils. Do not forget that you see the red reflex by looking though the direct ophthalmoscope a few feet away from the patient. You can check both red reflexes at the same time in the same field of view because of this distance from the patient. This also allows a direct comparison of the red reflex in both eyes at the same time. A red reflex test should be performed on any child with a squint, apparently poor vision or any other eye problem. If the red reflex on one or both sides is abnormal (Figure 10.1), a serious intraocular abnormality such as congenital cataract (dull or absent red reflex) or retinoblastoma (white reflex) is likely. Alternatively, you or the parents may notice that one or both pupils looks white or gray, rather than black.",195,32,0.1641025641025641
9781908541727,ch10,- an older child with double vision (causes include brain tumor or aneurysm),"Poor vision itself (including serious causes such as malignant retinoblastoma in one or both eyes, or congenital cataracts) can cause squint. Conversely, squint can cause poor vision, because an eye that is constantly turned will develop amblyopia. Children with squints usually do not (if they are old enough to talk) complain of double vision, because their brain 'switches off' the image from the deviated eye.",93,19,0.20430107526881722
9781908541727,ch10,- pale optic disc/s on ophthalmoscopy.,Optic disc abnormalities. Abnormal optic discs in children always require ophthalmic assessment. Swollen discs may represent papilledema due to a brain tumor or hydrocephalus. Pale discs may be associated with other congenital brain abnormalities or a tumor of the anterior visual pathway.,56,12,0.21428571428571427
9781908541727,ch11,"Refer urgently, to be seen by an ophthalmologist the same day, if your patient with eye trauma has:- been hit in the eye by a high-speed metal fragment; even if you find a corneal foreign body or find no abnormality on examination, the patient needs an X-ray to exclude the presence of an intraocular foreign body- unexplained eye pain, blurred vision, photophobia, flashes, floaters, field loss or double vision- an unexplained decrease in visual acuity (VA), field defect to confrontation, relative afferent pupillary defect, unexplained red eye, visible abnormality of the cornea, abnormal pupil shape or size, absent red reflex or swollen optic disc/s- blood in the anterior chamber (hyphema)- eyelids that are swollen shut, so that you cannot test VA (an ultrasound or computed tomography scan may be needed to confirm that the eyeball is intact)- chemical (do not delay immediate eye irrigation) or thermal burn to the eyes- a suspected infectious ulcer that has developed around a corneal foreign body- a non-infectious corneal abrasion that has not healed within 3 days.","A patient suspected of having any of these injuries requires urgent referral. Penetrating eye injury. It is important to suspect a penetrating injury in any patient with a suggestive history such as hammering metal, which may, for example, cause a high velocity small fragment of metal to penetrate the eye. Even if the eye looks normal on examination, you must refer the patient urgently to an ophthalmologist because of the risk of intraocular infection or retinal toxicity to a metallic intraocular foreign body. Direct trauma with a sharp object may lacerate the cornea or sclera (Figure 11.1). Ocular structures are often damaged at the time, but there is also a high risk of intraocular infection that can cause blindness and loss of the eye within days. Injuries range from the eye being struck with the sharp tip of a palm frond while gardening, which may result in an eye with normal vision that has a barely visible corneal laceration, to a patient whose eye has been severely lacerated with broken glass. Warning symptoms and signs (which are not always present) to watch out for include. eye pain, photophobia (sensitivity to light), blurred vision, floaters or field loss after a suspicious-sounding injury. a distorted pupil (teardrop shape with the point due to iris prolapse at the site of penetration). hyphema (blood in the anterior chamber). Telephone an ophthalmologist immediately if you suspect your patient has a penetrating eye injury. Intraocular foreign body is most commonly caused by a small piece of high-speed metal striking the eye, often in metalworkers whilst hammering. You need to maintain a high index of suspicion even if the eye looks normal to you and even if you find a corneal foreign body, as a second piece of metal could be inside the eye. An urgent slit-lamp examination and X-ray of the orbit should be carried out in any patient who says they have been hit in the eye with a high-speed fragment. If an intraocular foreign body is not detected and surgically removed early, loss of the eye through infection, toxicity or retinal detachment can occur. Hammering metal is the classic cause of an intraocular foreign body; fragments from grinding metal more commonly result in superficial corneal foreign bodies. Ruptured globe. Severe blunt trauma may split the sclera open, but because the overlying conjunctiva may remain intact this type of injury is often not directly visible on examination. The patient usually complains of severe pain, blurred vision and often floaters (due to vitreous hemorrhage) or field loss (due to retinal detachment). Intraocular pressure is often low. Hyphema is blood in the anterior chamber (between the cornea and the iris) (Figure 11.2). Hyphema may be seen after blunt trauma that has caused no other damage to the eye, or it may be a sign of penetrating eye injury, intraocular foreign body or ruptured globe. The major risk to sight after isolated hyphema (with no other eye damage) is high intraocular pressure, which can cause damage to the optic nerve head or retinal vascular occlusion. Permanent corneal blood staining can also occur with high eye pressure. Orbital fracture. The most common fracture is an orbital floor 'blowout' fracture, which is often seen on an X-ray or CT scan as a fluid level in the maxillary sinus, or as soft tissue protruding into the sinus from the orbital floor (Figure 11.3). Air in the orbit may also be seen. This injury should be suspected in any patient with blunt facial trauma who admits to double vision or a numb cheek or numb upper teeth on the side of the injury. They should be advised to not blow their nose after the injury as air can pass into the soft tissues. Chemical burn by acid, alkali (strong alkalis in particular) or other substances such as snake venom may cause devastating damage to the eye. Alkali disrupts cell membranes allowing ease of penetration of the alkali into the eye. Acid-coagulated protein can sometimes provide a barrier to further penetration of acid. Acid and alkali burns can, however, often result in blindness or loss of the eye. It may help the ophthalmologist if the patient brings along information about the substance that may have entered the eye (substance name and chemical classification, or a sealed container of the substance), but obtaining such information should not in any way delay immediate and prolonged irrigation of the eye. Mild chemical burns are more common (exempli gratia from shampoo, washing detergent and so on); these cause mild discomfort but are not dangerous.",973,238,0.2446043165467626
9781908541727,ch11,"- an unexplained decrease in visual acuity (VA), field defect to confrontation, relative afferent pupillary defect, unexplained red eye, visible abnormality of the cornea, abnormal pupil shape or size, absent red reflex or swollen optic disc/s","A patient suspected of having any of these injuries requires urgent referral. Penetrating eye injury. It is important to suspect a penetrating injury in any patient with a suggestive history such as hammering metal, which may, for example, cause a high velocity small fragment of metal to penetrate the eye. Even if the eye looks normal on examination, you must refer the patient urgently to an ophthalmologist because of the risk of intraocular infection or retinal toxicity to a metallic intraocular foreign body. Direct trauma with a sharp object may lacerate the cornea or sclera (Figure 11.1). Ocular structures are often damaged at the time, but there is also a high risk of intraocular infection that can cause blindness and loss of the eye within days. Injuries range from the eye being struck with the sharp tip of a palm frond while gardening, which may result in an eye with normal vision that has a barely visible corneal laceration, to a patient whose eye has been severely lacerated with broken glass.",212,50,0.2358490566037736
9781908541727,ch11,"- unexplained eye pain, blurred vision, photophobia, flashes, floaters, field loss or double vision","Penetrating eye injury. It is important to suspect a penetrating injury in any patient with a suggestive history such as hammering metal, which may, for example, cause a high velocity small fragment of metal to penetrate the eye. Even if the eye looks normal on examination, you must refer the patient urgently to an ophthalmologist because of the risk of intraocular infection or retinal toxicity to a metallic intraocular foreign body. Direct trauma with a sharp object may lacerate the cornea or sclera (Figure 11.1). Ocular structures are often damaged at the time, but there is also a high risk of intraocular infection that can cause blindness and loss of the eye within days. Injuries range from the eye being struck with the sharp tip of a palm frond while gardening, which may result in an eye with normal vision that has a barely visible corneal laceration, to a patient whose eye has been severely lacerated with broken glass. Warning symptoms and signs (which are not always present) to watch out for include. eye pain, photophobia (sensitivity to light), blurred vision, floaters or field loss after a suspicious-sounding injury.",242,21,0.08677685950413223
9781908541727,ch11,- a suspected infectious ulcer that has developed around a corneal foreign body,"Penetrating eye injury. It is important to suspect a penetrating injury in any patient with a suggestive history such as hammering metal, which may, for example, cause a high velocity small fragment of metal to penetrate the eye. Even if the eye looks normal on examination, you must refer the patient urgently to an ophthalmologist because of the risk of intraocular infection or retinal toxicity to a metallic intraocular foreign body. Direct trauma with a sharp object may lacerate the cornea or sclera (Figure 11.1). Ocular structures are often damaged at the time, but there is also a high risk of intraocular infection that can cause blindness and loss of the eye within days. Injuries range from the eye being struck with the sharp tip of a palm frond while gardening, which may result in an eye with normal vision that has a barely visible corneal laceration, to a patient whose eye has been severely lacerated with broken glass.",199,16,0.08040201005025126
9781908541727,ch11,"- been hit in the eye by a high-speed metal fragment; even if you find a corneal foreign body or find no abnormality on examination, the patient needs an X-ray to exclude the presence of an intraocular foreign body","Intraocular foreign body is most commonly caused by a small piece of high-speed metal striking the eye, often in metalworkers whilst hammering. You need to maintain a high index of suspicion even if the eye looks normal to you and even if you find a corneal foreign body, as a second piece of metal could be inside the eye. An urgent slit-lamp examination and X-ray of the orbit should be carried out in any patient who says they have been hit in the eye with a high-speed fragment. If an intraocular foreign body is not detected and surgically removed early, loss of the eye through infection, toxicity or retinal detachment can occur. Hammering metal is the classic cause of an intraocular foreign body; fragments from grinding metal more commonly result in superficial corneal foreign bodies. Ruptured globe. Severe blunt trauma may split the sclera open, but because the overlying conjunctiva may remain intact this type of injury is often not directly visible on examination. The patient usually complains of severe pain, blurred vision and often floaters (due to vitreous hemorrhage) or field loss (due to retinal detachment). Intraocular pressure is often low.",248,49,0.1975806451612903
9781908541727,ch11,- blood in the anterior chamber (hyphema),"Hyphema is blood in the anterior chamber (between the cornea and the iris) (Figure 11.2). Hyphema may be seen after blunt trauma that has caused no other damage to the eye, or it may be a sign of penetrating eye injury, intraocular foreign body or ruptured globe. The major risk to sight after isolated hyphema (with no other eye damage) is high intraocular pressure, which can cause damage to the optic nerve head or retinal vascular occlusion. Permanent corneal blood staining can also occur with high eye pressure.",119,11,0.09243697478991597
9781908541727,ch11,- chemical (do not delay immediate eye irrigation) or thermal burn to the eyes,"Chemical burn by acid, alkali (strong alkalis in particular) or other substances such as snake venom may cause devastating damage to the eye. Alkali disrupts cell membranes allowing ease of penetration of the alkali into the eye. Acid-coagulated protein can sometimes provide a barrier to further penetration of acid. Acid and alkali burns can, however, often result in blindness or loss of the eye. It may help the ophthalmologist if the patient brings along information about the substance that may have entered the eye (substance name and chemical classification, or a sealed container of the substance), but obtaining such information should not in any way delay immediate and prolonged irrigation of the eye.",143,16,0.11188811188811189
9781908541727,ch11,- a non-infectious corneal abrasion that has not healed within 3 days.,"If you are confident that an isolated corneal abrasion is present, with no signs of infection (the corneal substance underneath the abrasion remains completely clear, rather than cloudy or white as occurs in infectious ulcers), apply antibiotic ointment and an eye pad. You will need to review and re-pad the eye daily until it has healed. Some smaller abrasions can heal with regular use of ointment (4 times a day) without having to pad the eye. If the abrasion does not heal completely within 3 days, refer urgently.",117,20,0.17094017094017094
9781908541727,ch11,"- eyelids that are swollen shut, so that you cannot test VA (an ultrasound or computed tomography scan may be needed to confirm that the eyeball is intact)","'Black eye' is bruising of the eyelids due to blunt trauma. It is not serious and will resolve spontaneously; however, it is possible to miss an underlying serious eye injury, such as hyphema or ruptured globe, because of difficulty examining the eye (the eyelids may be so swollen that they prevent eye examination, or the patient may be drunk or uncooperative). It is essential that you measure VA in every patient with a 'black eye', and carry out as full an eye examination as is possible. Even if the eyelids are severely swollen it is usually possible to prise them apart with cotton swabs (cotton buds) to obtain a VA measurement. If the initial examination reveals no serious eye injury, review the patient for re-examination in a few days. On repeat visits, check that the patient is not experiencing double vision (this may only be noticed as lid swelling recedes).",185,34,0.1837837837837838
9781908541796,chapter1,"The epidemiology of lymphoma is difficult to study owing to the existence of so many different subtypes of the disease, each with its own epidemiology and associated causative factors.","Lymphoma is a malignancy of lymphocytes and their progenitors. The term lymphoma encompasses a broad range of lymphoid malignancies, which is reflected in the complexity of the classification systems (see Appendix, page 131). Although the current World Health Organization (WHO) classification system is clinically useful, it is now recognized that many of the broader categories, such as diffuse large B-cell lymphoma, include several distinct entities, each of which may have its own unique epidemiological and etiologic profile. Consequently, it is difficult to present an all-encompassing overview of the epidemiology of lymphoma. Incidence and relevant factors. In the USA, Europe and Australasia the incidence of non-Hodgkin lymphoma (NHL) is approximately 20 per 100 000 of the population, with a slightly higher incidence in men than in women. This makes lymphoma the sixth or seventh most common cancer worldwide.",191,36,0.18848167539267016
9781908541796,chapter1,"An understanding of the epidemiology has, in some instances, led to an understanding of causative factors such as human T-cell lymphotropic virus infection causing adult T-cell leukemia/lymphoma.","Lymphoma is a malignancy of lymphocytes and their progenitors. The term lymphoma encompasses a broad range of lymphoid malignancies, which is reflected in the complexity of the classification systems (see Appendix, page 131). Although the current World Health Organization (WHO) classification system is clinically useful, it is now recognized that many of the broader categories, such as diffuse large B-cell lymphoma, include several distinct entities, each of which may have its own unique epidemiological and etiologic profile. Consequently, it is difficult to present an all-encompassing overview of the epidemiology of lymphoma. Incidence and relevant factors. In the USA, Europe and Australasia the incidence of non-Hodgkin lymphoma (NHL) is approximately 20 per 100 000 of the population, with a slightly higher incidence in men than in women. This makes lymphoma the sixth or seventh most common cancer worldwide.",191,41,0.21465968586387435
9781908541796,chapter1,The incidence of non-Hodgkin lymphoma increased dramatically during the 1980s and 1990s but has plateaued in recent years.,"Relatively uncommon risk factors with high relative risk. Immuno-deficiency states are the most obvious examples of a relatively uncommon risk factor that carries a high relative risk. It has been suggested that the rising incidence of lymphoma during the 1980s and 1990s reflected an increasing incidence of immunodeficiency, most obviously due to the emergence of HIV and AIDS. Indeed, HIV/AIDS has been shown to be a major risk factor for the development of lymphoma, but it accounts for less than 50% of the increase in incidence seen in the West. Furthermore, since the advent of highly active antiretroviral therapy (HAART), the incidence of AIDS-associated lymphoma has declined.",141,28,0.19858156028368795
9781908541796,chapter1,Large cohort studies are required to verify many of the potential causative factors.,"Common risk factors with low relative risk. Many environmental factors have been implicated in the development of lymphoma (see below). Most of these have been identified using case-control retrospective analyses, which have disadvantages, such as recall and selection bias, that can reduce the validity of the results. Further large prospective cohort studies are needed, some of which are ongoing. However, it must be remembered that a relatively innocuous environmental exposure that carries only a marginally raised relative risk of developing lymphoma can contribute substantially to a rising incidence if a sufficiently large number of people are exposed. Nevertheless, it is not possible to test for every environmental exposure that carries only a marginally raised relative risk.",133,15,0.11278195488721804
9781908541796,chapter1,"Various other subtypes of lymphoma have been linked with infection, particularly immunosuppression-related lymphomas caused by Epstein-Barr virus (EBV) infection and mucosa-associated lymphoid tissue (MALT) lymphomas caused by various bacterial infections.","Inflammatory conditions. Certain inflammatory conditions predispose to the development of NHL and particularly extranodal marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas, which are associated with organ-specific autoimmune conditions. For example, Sjgren syndrome (an autoimmune condition affecting the salivary and lacrimal glands) is associated with a 15-fold increased risk of developing salivary or lacrimal MALT lymphomas, and Hashimoto disease (an autoimmune condition affecting the thyroid gland) predisposes to thyroid MALT lymphoma. Pesticide/herbicide exposure has been implicated in the etiology of NHL in numerous studies. Agents include organophosphates, phenoxyacetic acid herbicides and triazine herbicides. However, the results are inconsistent with wide variations in the estimates of risk. Presumably this is because most investigations have been case-control studies in which the estimation of risk is fraught with difficulty. Some studies have also demonstrated an association between specific pesticides and herbicides and NHL subtypes but, again, the results are inconsistent.",222,54,0.24324324324324326
9781908541796,chapter2,The different types of lymphoma probably arise from different stages of the lymphocyte life cycle.,"Each lymphoma arises from a single abnormal lymphocyte. Genetic changes within the lymphocyte lead to an accumulation of cells, every one of which has arisen from a single cell (a clonal population). Different types of lymphoma are thought to exist as a result of genetic changes in lymphocytes at different stages of their life cycle. Therefore, to understand lymphoma classification it is important to have some knowledge of the life cycle of B and T lymphocytes.",91,18,0.1978021978021978
9781908541796,chapter2,Lymphocytes are formed in an antigen-independent stage in the bone marrow (and thymus for T cells) but need an encounter with antigen in secondary lymphoid tissue to develop further.,"Antigen-independent development takes place predominantly in the bone marrow, which is one of two primary lymphoid organs. The earliest recognizable cell in the B-cell lineage is called the pro-B cell. This matures to produce the pre-B cell, which expresses immunoglobulin internally within the cytoplasm (along with a receptor on the surface called the pre-B-cell receptor). This in turn develops into the immature B cell, which expresses intact immunoglobulin (IgM or IgD) on the surface of the cell. The main molecular event during the antigen-independent phase is rearrangement of the heavy- and light-chain genes that code for the immunoglobulin receptor, thereby generating a vast range of B-cell receptors capable of recognizing large numbers of new antigens. B cells then travel via the bloodstream to the spleen where they undergo further development (in the form of transitional B cells) to result in mature (though still antigen naive) B cells.",206,39,0.18932038834951456
9781908541796,chapter2,"Lymphomas are cancers of lymphocytes, the major cellular components of the adaptive immune response.","Antigen-dependent development takes place within the germinal center of secondary lymphoid organs, which are the sites of interaction between the adaptive immune system and invading microorganisms. Within the germinal center, specialized follicular dendritic cells present the foreign antigen of the invading microorganism to B cells (Figure 2.3); if the B cells recognize the foreign antigen they are rescued from cell death by the intervention of T cells, allowing a population of B cells to survive that are capable of recognizing foreign organisms and producing antibodies that attack them.",111,19,0.17117117117117117
9781908541796,chapter2,Lymphomas arise because of several complex genetic changes involving activation of oncogenes or inactivation of tumor suppressor genes.,"Any cancer can be considered as a process characterized by unregulated cell division, cell growth and impaired cellular maturation. These processes are normally carefully controlled by a complex interplay of genes and their protein products but, because of damage to the genetic structure, they are fundamentally disturbed in a cancer cell. Cancer can, therefore, be considered a genetic disease. This does not mean it is hereditary, but rather is due to the accumulation of a number of acquired genetic changes that cause the transformation of a normal cell into a malignant cell. The genetic changes result in either over- or underexpression of the genes involved. There are two main classes of gene involved: oncogenes and tumor suppressor genes (Table 2.2).",147,26,0.17687074829931973
9781908541796,chapter3,The most essential components in diagnosis are suspicion of lymphoma from the clinical presentation and the taking of an adequate biopsy.,"Accurate diagnosis is essential in order to successfully treat any disease. This is a major issue in the case of lymphoma because of the different subtypes, many of which respond differently to a given treatment modality. Advances in cellular and molecular techniques have revolutionized our understanding of lymphoma as a disease and have paved the way for improved diagnosis and treatment. The most essential stages in diagnosis, however, still require suspicion of lymphoma from the clinical presentation and the taking of an adequate biopsy (such as an excision node biopsy or core biopsy) with basic histology and immunohistochemistry.",123,24,0.1951219512195122
9781908541796,chapter3,New molecular and cellular techniques have revolutionized the diagnosis of lymphoma.,"Accurate diagnosis is essential in order to successfully treat any disease. This is a major issue in the case of lymphoma because of the different subtypes, many of which respond differently to a given treatment modality. Advances in cellular and molecular techniques have revolutionized our understanding of lymphoma as a disease and have paved the way for improved diagnosis and treatment. The most essential stages in diagnosis, however, still require suspicion of lymphoma from the clinical presentation and the taking of an adequate biopsy (such as an excision node biopsy or core biopsy) with basic histology and immunohistochemistry.",123,14,0.11382113821138211
9781908541796,chapter3,An increased understanding of the molecular and cellular basis of lymphomas may lead to improved targeting of treatment.,"Accurate diagnosis is essential in order to successfully treat any disease. This is a major issue in the case of lymphoma because of the different subtypes, many of which respond differently to a given treatment modality. Advances in cellular and molecular techniques have revolutionized our understanding of lymphoma as a disease and have paved the way for improved diagnosis and treatment. The most essential stages in diagnosis, however, still require suspicion of lymphoma from the clinical presentation and the taking of an adequate biopsy (such as an excision node biopsy or core biopsy) with basic histology and immunohistochemistry.",123,20,0.16260162601626016
9781908541796,chapter3,Immunophenotyping and immunohistochemistry analyze the expression of proteins on the cell surface (or sometimes within the cytoplasm or nucleus).,"To determine the proteins expressed on the cell surface, the cells are first mixed with an antibody specific to the protein (antigen) in question. This antibody is linked to a fluorescent marker, which will emit light if it is bound to the cell when it passes through the flow cytometer. The strength of the emitted light is measured by a detector, which then provides information about the relative amount of antigen expressed on the cell surface. More than one protein can be assessed at the same time, as different antibodies can be linked to markers emitting light of different frequencies. The process of using antibodies to define the phenotype of a cell is called immunophenotyping. The immunophenotypes of normal mature T cells and B cells are listed in Table 3.1.",151,31,0.2052980132450331
9781908541796,chapter3,Karyotyping and fluorescent in-situ hybridization (FISH) reveal the chromosomal changes in the cell.,"Karyotyping is conducted on cells in the metaphase (id est the stage in the cell cycle when the cell is about to divide). Cells for analysis are obtained from a blood sample, or a bone-marrow or lymph-node biopsy. The cells are stimulated to grow using a chemical called a mitogen, and a drug is then added that prevents the completion of mitosis, therefore enhancing the yield of cells in metaphase. The nucleus of the cell is made to swell, enabling a more detailed look at the chromosomes.",109,25,0.22935779816513763
9781908541796,chapter3,Gene-expression profiling has led to subtyping cases of diffuse large B-cell lymphomas and may improve the diagnosis of Burkitt lymphoma.,"In lymphoma, the major impact so far has been in subtyping cases of diffuse large B-cell lymphoma (DLBCL). This group of lymphomas is likely to represent several different entities with distinct epidemiological and etiologic factors. They may also confer a different prognosis to the patient; there is emerging evidence that different subtypes of DLBCL use different signaling pathways and that patients may therefore benefit from different targeted therapies according to their 'molecular subtype'. Expression microarray studies have identified two major groups of DLBCL, which are associated with different outcomes. The first group has a gene-expression signature that suggests the cells have originated from a germinal-center B cell (see page 19). This group is therefore called germinal-center B-cell (GCB) type and has a relatively good 5-year survival rate. The second group is rather more heterogeneous and is often termed the activated B-cell (ABC) type. These lymphomas have a significantly worse 5-year survival rate.",213,30,0.14084507042253522
9781908541796,chapter4,Extranodal lymphomas must be monitored during and after treatment to assess response to therapy.,"Recognizing that lymphomas may affect sites outside the lymph nodes is important, because it has a direct bearing on their management. Extranodal sites must be monitored during and after treatment to assess response to therapy. Involvement of two or more extranodal sites confers a worse prognosis and is reflected by a higher score in the International Prognostic Index (see pages 54 and).",82,19,0.23170731707317074
9781908541796,chapter4,Fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning is a valuable staging investigation for patients with many subtypes of lymphoma.,"Imaging. CT scanning of the chest, abdomen and pelvis has been the standard imaging technique for lymphoma for many years. Fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning has been shown to be a valuable staging investigation for patients with many subtypes of lymphoma. Several studies suggest that it is more sensitive than CT scanning and 'upstages' a significant proportion of patients. Many centers are now adopting CT/PET as part of their standard staging work up. Bone-marrow biopsy and aspirate are a standard staging investigation for most types of lymphoma. There are certain situations, such as low-risk early-stage Hodgkin lymphoma, where the routine use of bone-marrow biopsy is not recommended as the likelihood of bone involvement is so low. Studies have suggested that patients with advanced Hodgkin lymphoma who have extensive disease on CT/PET do not need to undergo bone-marrow biopsy as its result does not influence subsequent management.",207,36,0.17391304347826086
9781908541796,chapter4,Staging is mandatory in the management of lymphoma.,"Bone-marrow biopsy and aspirate are a standard staging investigation for most types of lymphoma. There are certain situations, such as low-risk early-stage Hodgkin lymphoma, where the routine use of bone-marrow biopsy is not recommended as the likelihood of bone involvement is so low. Studies have suggested that patients with advanced Hodgkin lymphoma who have extensive disease on CT/PET do not need to undergo bone-marrow biopsy as its result does not influence subsequent management.",102,11,0.10784313725490197
9781908541796,chapter4,"When staging investigations have been completed, the patient and relatives must be fully informed of the nature of the condition and the likely treatment plan, and given opportunities to ask questions.","objectively documented fever. more than 10% weight loss in 6 months. night sweats that drench and wake the patient. Absence of B symptoms makes the patient stage A. So, for example, if a patient has drenching night sweats, and has lymphoma in the supraclavicular and mediastinal lymph nodes, but nothing below the diaphragm, the stage is IIB. Management principles. Once the diagnosis is established and the staging investigations are completed, the patient and relatives need to be fully informed of the nature of the condition and the likely treatment plan. It is important to provide the following. verbal and written information about the disorder and its treatment.",139,34,0.2446043165467626
9781908541796,chapter4,Patients who relapse should be considered for re-biopsy and complete restaging.,"Indolent lymphomas, such as follicular lymphoma, are not thought to be curable with conventional chemotherapy. However, there is extensive evidence to show that the survival for patients with indolent lymphomas has improved in the last two decades, possibly because of the introduction of monoclonal antibody therapy. In view of this, the treatment paradigm for patients with indolent lymphomas is changing. Historically, treatment was considered palliative, aimed at reducing symptoms and preventing critical organ failure (see Chapter 6). It was entirely reasonable to monitor the patient (often known as active surveillance) and to intervene only when symptoms appeared. This approach is still widely used and still appropriate for many patients with indolent lymphoma, especially those who are elderly or who have major comorbidities that limit the use of chemotherapy. For younger fitter patients, the advent of new therapies has improved survival and a more active approach to therapy is typical for these patients now (see below). Single-agent oral chemotherapy, for example with an alkylating agent, can be effective in inducing a partial response and thereby improves the patient's symptoms and general wellbeing. Combination chemotherapy with rituximab will induce a higher response rate and a higher complete remission rate, which appears to translate into increased overall survival.",265,17,0.06415094339622641
9781908541796,chapter4,Neutropenic sepsis is a life-threatening complication of chemotherapy and requires urgent assessment.,"Fertility. The impact of chemotherapy on fertility is important and must be discussed before treatment starts. All men receiving chemotherapy who may wish to have children should be given the option of sperm storage. For women, preserving fertility is more complex and is a function of age, the nature of the underlying disease and properties of the specific chemotherapy regimen. The most commonly used method of preserving fertility for women is cryopreservation of fertilized ova. However, this technique requires 2 weeks of hormonal stimulation and is therefore only possible in those cases in which treatment can be delayed. Furthermore, the technique requires the presence of a willing partner. Other techniques under investigation include oocyte storage, cryopreservation of ovarian tissue and hormone suppression therapy.",146,20,0.136986301369863
9781908541796,chapter4,Fertility is an important consideration in any patient of childbearing age receiving chemotherapy or radiotherapy.,"Fertility. The impact of chemotherapy on fertility is important and must be discussed before treatment starts. All men receiving chemotherapy who may wish to have children should be given the option of sperm storage. For women, preserving fertility is more complex and is a function of age, the nature of the underlying disease and properties of the specific chemotherapy regimen. The most commonly used method of preserving fertility for women is cryopreservation of fertilized ova. However, this technique requires 2 weeks of hormonal stimulation and is therefore only possible in those cases in which treatment can be delayed. Furthermore, the technique requires the presence of a willing partner. Other techniques under investigation include oocyte storage, cryopreservation of ovarian tissue and hormone suppression therapy.",146,19,0.13013698630136986
9781908541796,chapter4,Chemotherapy is the mainstay of management.,"The response to chemotherapy determines the subsequent management of the patient. For any curative strategy, a complete response is required. However, as new techniques emerge, response definitions change. The most recent response criteria adopted for lymphomas include the use of functional imaging, with PET scans for patients in clinical trials. The use of PET scans in 'standard of care' management is still unclear. Some studies have suggested that PET scanning after a few cycles of chemotherapy can predict the likely result of treatment - patients whose PET scan is positive after one or two cycles of chemotherapy appear to have a poorer prognosis than those with a negative scan. In view of this, many clinical trials are exploring whether a change of treatment for patients who are 'PET-positive' will improve their outcome.",153,9,0.058823529411764705
9781908541796,chapter5,The commonest aggressive B-cell lymphoma is diffuse large B-cell lymphoma (DLBCL).,"The aggressive B-cell lymphomas (also known as high-grade B-cell lymphomas) include diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma, Burkitt lymphoma, and lymphoblastic lymphoma or acute lymphoblastic leukemia (see page 80). It can sometimes be difficult for pathologists to distinguish DLBCL from Burkitt lymphoma. Another subtype of lymphoma has therefore been identified, known for now as 'aggressive B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma'. Other terms sometimes used for particularly aggressive types of DLBCL include ' c-Myc -positive DLBCL' and 'double hit' and 'triple hit' lymphomas, depending on the number of BCL2 and MYC translocations. Left untreated, these tumors can rapidly be fatal. Treatment aims to provide a cure. Relapse is associated with a poor prognosis.",198,22,0.1111111111111111
9781908541796,chapter5,Burkitt lymphoma and the c-Myc -positive DLBCL subtype have high proliferation rates and should be treated with sequential chemotherapy incorporating central nervous system prophylaxis.,"The aggressive B-cell lymphomas (also known as high-grade B-cell lymphomas) include diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma, Burkitt lymphoma, and lymphoblastic lymphoma or acute lymphoblastic leukemia (see page 80). It can sometimes be difficult for pathologists to distinguish DLBCL from Burkitt lymphoma. Another subtype of lymphoma has therefore been identified, known for now as 'aggressive B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma'. Other terms sometimes used for particularly aggressive types of DLBCL include ' c-Myc -positive DLBCL' and 'double hit' and 'triple hit' lymphomas, depending on the number of BCL2 and MYC translocations. Left untreated, these tumors can rapidly be fatal. Treatment aims to provide a cure. Relapse is associated with a poor prognosis.",198,38,0.1919191919191919
9781908541796,chapter5,"Most DLBCL express CD20, which is the target for rituximab; approximately 50% of DLBCL are curable with R-CHOP.","The most common aggressive lymphoma is DLBCL, which accounts for approximately 30% of all cases of non-Hodgkin lymphoma (NHL). Typically, the cells are large (Figure 5.1) and express B-cell markers. While there are a few recurring cytogenetic and molecular abnormalities, they are not particularly helpful diagnostically (Table 5.1). Importantly for treatment, most DLBCL express CD20, which is the target for rituximab. The condition may present at any age, but is increasingly common in later life. Pathology. The most common finding is sheets of large cells, which stain with the B-cell markers CD19, CD79a and CD20. Molecular profiling using expression microarrays (see page 37) has identified two main types of DLBCL, namely those derived from germinal-center B cells (GCB subtype) and those derived from a more differentiated stage in the B-cell life cycle - activated B-cell (ABC) type.",214,35,0.16355140186915887
9781908541796,chapter5,"Patients who relapse require salvage chemotherapy and, if chemosensitive, will benefit from high-dose chemotherapy and stem-cell rescue.","Relapse or progressive disease. The prognosis for patients who relapse after treatment is generally poor, with only 20-30% of patients rescued with salvage/relapse protocols. Most patients destined to relapse will do so in the first 2 years after initial treatment. Salvage protocols vary, but are usually based on regimens containing platinum. The key consideration is response, because patients achieving a satisfactory response may then benefit from high-dose therapy and peripheral stem-cell rescue (Figure 5.2). The following salvage/relapse regimens are used.",110,27,0.24545454545454545
9781908541796,chapter6,"Some low-grade lymphomas, such as follicular and mantle cell lymphomas, have characteristic immunophenotypes and cytogenetics that enable clear diagnosis.","6 Indolent B-cell lymphomas. Indolent lymphoma (also known as low-grade lymphoma) is generally considered to be incurable and treatment is used to reduce systemic symptoms or debulk a high tumor burden. Nearly all low-grade lymphomas are of B-cell origin although occasional T-cell lymphomas, such as angio-immunoblastic lymphoma, can behave in an indolent fashion. The most common low-grade B-cell lymphomas are. follicular lymphoma. mantle cell lymphoma. marginal zone lymphoma. lymphoplasmacytoid lymphoma.",131,31,0.2366412213740458
9781908541796,chapter6,Knowledge of the cause of the lymphoma has in some cases led to improved treatments (exempli gratia Helicobacter pylori infection and gastric mucosa-associated lymphoid tissue lymphoma).,"One of the many difficulties in managing follicular lymphoma is its uncertain prognosis: some patients survive for more than 10 years, while others die within 2 or 3 years of presentation. The uncertainty surrounding the prognosis of follicular lymphoma has been clarified by the development of the Follicular Lymphoma International Prognostic Index-2 (FLIPI-2), which has been successfully validated in patients treated uniformly with R-CHOP chemotherapy (bloodref.com/lymphoid/lymphoma/flipi2). Unlike the original FLIPI, which measured survival from diagnosis, the FLIPI-2 is applied at the time of treatment and takes into consideration the availability of rituximab therapy. This clinical scoring system helps to determine which patients are at higher risk and may therefore be eligible for experimental or aggressive therapy. The FLIPI-2 adds one point for each of the following five risk factors.",192,43,0.22395833333333334
9781908541796,chapter6,Low-grade B-cell lymphomas are more common in the elderly and treatment is usually aimed at alleviating symptoms rather than curing the disease.,"Early-stage disease. For patients with early-stage follicular lymphoma (stage IA or IIA), radiotherapy is an option. Most low-grade lymphomas are remarkably radiosensitive, so this may be the treatment of choice for patients with localized disease. In fact, some studies suggest that radiotherapy alone may be curative in about 50% of patients with early-stage disease. However, radiotherapy is thought to reduce the chance of successful future stem-cell harvesting, so it is best avoided in younger patients who may need high-dose therapy later. Patients who progress after first-line therapy can be treated again with the same regimen provided that the duration of their initial response was favorable. Patients whose disease is refractory to first-line therapy will require a second-line treatment, such as CHOP or a fludarabine-containing regimen; the addition of rituximab may also be beneficial.",189,29,0.15343915343915343
9781908541796,chapter6,Other low-grade lymphomas are hard to diagnose definitively because of the lack of specific markers (exempli gratia marginal zone and lymphoplasmacytoid lymphoma).,"Pathology. The diagnosis is usually made from either lymph-node or bone-marrow biopsy. The abnormal neoplastic lymphoid cells have a marked propensity for plasma cell differentiation and an excess of mast cells is often present, which is a helpful diagnostic feature (Figure 6.4). There are almost no specific diagnostic markers for this disease. The cells express CD19 and CD20, but lack CD5 and CD23, which distinguishes them from B-cell CLL, and CD10, which usually excludes follicular lymphoma. An IgM paraprotein, or more rarely another class of paraprotein, is usually found in cases of LPL. There are no specific chromosomal translocations associated with the condition; 6q deletions are perhaps the most commonly reported abnormality. Distinguishing these lymphomas from marginal zone lymphomas is difficult and some authors would consider LPL a variant of marginal cell lymphoma.",187,36,0.1925133689839572
9781908541796,chapter7,T-cell lymphomas comprise only 5% of non-Hodgkin lymphoma cases in Western countries.,"In Europe and the USA, T-cell lymphomas represent about 5% of cases of non-Hodgkin lymphoma. Most T-cell lymphomas are aggressive except for the primary cutaneous forms, such as mycosis fungoides, which can have a protracted and indolent course if they remain localized to the skin. As with B-cell lymphomas, T-cell lymphomas are divided into different clinicopathological entities in terms of cell lineage, immunophenotype, cytogenetics and molecular profile. Tumors derived from natural killer (NK) cells are very rare and tend to present in the nose and adjacent structures, though occasionally they can present as a frank leukemia.",143,23,0.16083916083916083
9781908541796,chapter7,T-cell lymphomas often involve the skin.,"In Europe and the USA, T-cell lymphomas represent about 5% of cases of non-Hodgkin lymphoma. Most T-cell lymphomas are aggressive except for the primary cutaneous forms, such as mycosis fungoides, which can have a protracted and indolent course if they remain localized to the skin. As with B-cell lymphomas, T-cell lymphomas are divided into different clinicopathological entities in terms of cell lineage, immunophenotype, cytogenetics and molecular profile. Tumors derived from natural killer (NK) cells are very rare and tend to present in the nose and adjacent structures, though occasionally they can present as a frank leukemia.",143,10,0.06993006993006994
9781908541796,chapter7,Most T-cell lymphomas are aggressive and often progress during treatment.,"In Europe and the USA, T-cell lymphomas represent about 5% of cases of non-Hodgkin lymphoma. Most T-cell lymphomas are aggressive except for the primary cutaneous forms, such as mycosis fungoides, which can have a protracted and indolent course if they remain localized to the skin. As with B-cell lymphomas, T-cell lymphomas are divided into different clinicopathological entities in terms of cell lineage, immunophenotype, cytogenetics and molecular profile. Tumors derived from natural killer (NK) cells are very rare and tend to present in the nose and adjacent structures, though occasionally they can present as a frank leukemia.",143,14,0.0979020979020979
9781908541796,chapter7,"Peripheral T-cell lymphomas present with widespread small-volume lymphadenopathy, but with marked systemic symptoms.","Clinical presentation. Most patients are middle-aged or elderly and typically present with widespread, often relatively small-volume, lymphadenopathy with marked systemic symptoms, particularly fever and weight loss. Treatment is with CHOP or equivalent chemotherapy. In many patients, however, disease progression occurs during treatment, and salvage chemotherapy proceeding to high-dose therapy is required. Some centers treat peripheral T-cell lymphomas with high-dose therapy as part of first-line treatment in view of the poor prognosis. Some data suggest that chemotherapy regimens that include drugs such as etoposide or gemcitabine are more effective in the first-line treatment of this condition, and clinical trials are in progress to assess these combinations as well as the inclusion of some newer T-cell 'specific' drugs such as pralatrexate and romidepsin.",173,24,0.13872832369942195
9781908541796,chapter8,Immunosuppression is a major risk factor for the development of B-cell lymphoma.,"In practice, the malignant potential of such lymphoproliferations (post-transplant lymphoproliferative disorders [PTLDs]) is variable; some cases are clinically aggressive, however, and may be thought of as a form of high-grade lymphoma. The incidence of PTLDs following solid-organ or bone-marrow transplantation depends on a number of factors including the depth of immunosuppression achieved. In renal transplantation, the incidence is thought to be about 2%. In heart and lung transplantation, it is a little higher, but in T-cell-depleted bone-marrow transplants, the incidence has been reported to be as high as 40-60% in some series (Table 8.1). There is a bimodal distribution of incidence. EBV-positive PTLDs are most common within the first year of transplantation (especially in EBV-negative patients with an EBV-positive donor), whereas EBV-negative disease peaks at 10 years. Overall, approximately 60% of PTLD cases are EBV-positive.",224,20,0.08928571428571429
9781908541796,chapter8,"Viruses, such as Epstein-Barr virus (associated with post-transplant lymphoproliferative disorder, Burkitt lymphoma and diffuse large B-cell lymphoma) and human herpes virus 8 (associated with primary effusion lymphoma) are often implicated.","In practice, the malignant potential of such lymphoproliferations (post-transplant lymphoproliferative disorders [PTLDs]) is variable; some cases are clinically aggressive, however, and may be thought of as a form of high-grade lymphoma. The incidence of PTLDs following solid-organ or bone-marrow transplantation depends on a number of factors including the depth of immunosuppression achieved. In renal transplantation, the incidence is thought to be about 2%. In heart and lung transplantation, it is a little higher, but in T-cell-depleted bone-marrow transplants, the incidence has been reported to be as high as 40-60% in some series (Table 8.1). There is a bimodal distribution of incidence. EBV-positive PTLDs are most common within the first year of transplantation (especially in EBV-negative patients with an EBV-positive donor), whereas EBV-negative disease peaks at 10 years. Overall, approximately 60% of PTLD cases are EBV-positive.",224,56,0.25
9781908541796,chapter8,Treatment should target the lymphoma and the cause of the immunosuppression (id est highly active antiretroviral therapy in lymphomas associated with HIV and a reduction in therapeutic immunosuppression in post-transplant lymphoproliferative disorder).,"In practice, the malignant potential of such lymphoproliferations (post-transplant lymphoproliferative disorders [PTLDs]) is variable; some cases are clinically aggressive, however, and may be thought of as a form of high-grade lymphoma. The incidence of PTLDs following solid-organ or bone-marrow transplantation depends on a number of factors including the depth of immunosuppression achieved. In renal transplantation, the incidence is thought to be about 2%. In heart and lung transplantation, it is a little higher, but in T-cell-depleted bone-marrow transplants, the incidence has been reported to be as high as 40-60% in some series (Table 8.1). There is a bimodal distribution of incidence. EBV-positive PTLDs are most common within the first year of transplantation (especially in EBV-negative patients with an EBV-positive donor), whereas EBV-negative disease peaks at 10 years. Overall, approximately 60% of PTLD cases are EBV-positive.",224,54,0.24107142857142858
9781908541796,chapter8,Improved HIV treatment is leading to a falling incidence of HIV-associated lymphoma.,"The most common presentation is systemic lymphoma of diffuse large B-cell lymphoma (DLBCL) or Burkitt type. Extranodal disease is more common than in HIV-negative patients. As with other forms of HIV-associated lymphoma, EBV positivity is a frequent finding. Primary CNS lymphoma may occur in the context of very low CD4 counts. Clearly, with better HIV treatment the incidence of this form of HIV-associated lymphoma is diminishing.",97,16,0.16494845360824742
9781908541796,chapter8,The use of rituximab in HIV-associated B-cell lymphomas is generally considered standard in those with well-controlled infection.,"Treatment of HIV-associated lymphoma is directed by its pathological subtype. DLBCL is usually treated with R-CHOP, whereas Burkitt lymphoma is treated with R-CODOX-M/R-IVAC or other similar regimens including dose-adjusted-EPOCH-R. These patients are at risk of CNS involvement and will receive intrathecal or high-dose methotrexate/cytarabine. All patients should receive highly active antiretroviral therapy (HAART) during chemotherapy. The addition of rituximab is somewhat controversial as some trials have demonstrated a benefit but others have shown an increase in serious infections when rituximab is combined with chemotherapy. Particularly in patients in whom the HIV infection is well controlled, however, rituximab is generally considered to be important. The International Prognostic Index applies to HIV-associated lymphomas; in addition, a low CD4 count confers a poorer prognosis.",204,29,0.14215686274509803
9781908541796,chapter9,There are two main types with distinct immunophenotypes and clinical pictures: classic Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL).,"Hodgkin lymphoma is subdivided into classic Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL). Classic Hodgkin lymphoma is divided according to the pattern of reactive tissue into nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-deplete subtypes; nodular sclerosis is by far the most common type. The diagnosis rests on the finding of HRS cells in an appropriate cellular background of inflammatory and other reactive cells. These cells can be identified by a simple hematoxylin-eosin stain and confirmed by immunostaining as they are typically negative for B-cell markers (CD19, CD20, CD79a), but positive for CD15 and CD30 (Figure 9.1). However, most cells in a biopsy from Hodgkin lymphoma are not HRS cells but reactive polyclonal cells such as T cells, eosinophils and macrophages.",204,41,0.20098039215686275
9781908541796,chapter9,"Diagnosis is by biopsy and identification of Hodgkin/Reed-Sternberg (HRS) cells in cHL, or lymphocytic and histiocytic cells (LandH) in nLPHL. HRS cells are typically CD15+ and CD30+; LandH cells have a characteristic B-cell phenotype.","Classic Hodgkin lymphoma is divided according to the pattern of reactive tissue into nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-deplete subtypes; nodular sclerosis is by far the most common type. The diagnosis rests on the finding of HRS cells in an appropriate cellular background of inflammatory and other reactive cells. These cells can be identified by a simple hematoxylin-eosin stain and confirmed by immunostaining as they are typically negative for B-cell markers (CD19, CD20, CD79a), but positive for CD15 and CD30 (Figure 9.1). However, most cells in a biopsy from Hodgkin lymphoma are not HRS cells but reactive polyclonal cells such as T cells, eosinophils and macrophages. The cause of cHL is unknown, although Epstein-Barr virus (EBV; see Figure 1.3, page 15) can be found within the HRS cells in about 40% of cases in the USA and UK. A study in Scandinavia showed that glandular fever caused by EBV does increase the risk of subsequently developing EBV-positive cHL; the delay from glandular fever to the peak in incidence was 4 years. Immunosuppression due to infection with HIV or post-transplant immunosuppression also increases the risk of developing cHL, though this is by no means as great as the increase in risk of developing a high-grade non-Hodgkin lymphoma (NHL).",315,71,0.2253968253968254
9781908541796,chapter9,Hodgkin lymphoma is a relatively common form of lymphoma that predominantly affects young people and is curable.,"Classic Hodgkin lymphoma. Around 1800 new cases of Hodgkin lymphoma are diagnosed every year in the UK, with young people aged 15-35 years usually affected. In the USA, the incidence is 2.7/100000, with an estimated 9190 new cases in 2014. In Australia in 2010, 572 new cases were diagnosed. Like other forms of lymphoma, Hodgkin lymphoma typically presents with, or with symptoms caused by, enlarged lymph nodes (Table 9.1). A particularly characteristic presentation is with enlarged mediastinal lymph nodes resulting in cough and breathlessness, particularly on lying flat. Superior vena caval obstruction is unusual. Pruritus is also a common symptom. Interestingly, alcohol-induced pain at sites of disease is a striking and characteristic feature of classic Hodgkin lymphoma, though somewhat rare. The presence of B symptoms (weight loss, night sweats or fevers) and bulky disease (>10 cm in diameter) are generally accepted to be associated with a poorer prognosis (Table 9.2).",209,24,0.11483253588516747
9781908541796,chapter9,"Treatment of early-stage cHL involves two to four courses of combination chemotherapy (usually ABVD), often with involved-field radiotherapy.","Classic Hodgkin lymphoma. Until relatively recently, early-stage disease was treated with extended-field radiotherapy alone. However, such treatment was associated with a significant relapse rate and serious late toxicities. In particular, it was noted that second cancers could develop within the radiotherapy field. This was especially marked in women who had irradiation involving the breasts and in smokers who had irradiation involving the lungs. The other major long-term toxicity was found to be coronary heart disease in patients who had radiotherapy involving the heart. Most centers now treat favorable disease with two to four cycles of combination chemotherapy (usually ABVD), followed by radiotherapy to only those areas directly affected by the disease (involved-field or involved-site radiotherapy). Trials are ongoing as to whether it is safe to omit the radiotherapy entirely in patients who respond very well to chemotherapy as judged by a negative PET scan after two or three courses of ABVD.",188,29,0.15425531914893617
9781908541796,chapter9,Treatment of late-stage cHL involves six to eight courses of combination chemotherapy (usually ABVD).,"Late-stage disease can be considered as stages IIB-IV. Improvements in treatment have led to increased survival (Figure 9.3). Most centers treat late-stage disease with six to eight cycles of combination chemotherapy, usually ABVD, together with radiotherapy to sites of bulky disease. The ABVD regimen is particularly favored because it results in good cure rates, does not usually impair fertility and is not associated with a high rate of second cancers or hematologic disorders. There is evidence that the more intensive escalated BEACOPP regimen cures a higher proportion of patients but is associated with higher rates of toxicity, including reduced fertility. It is unclear whether this regimen results in better overall survival rates, as patients relapsing after ABVD can often be successfully treated.",154,21,0.13636363636363635
9781908541796,chapter9,The cure rate is 90-95% for early-stage disease and 75-80% for late-stage disease.,"In view of the fact that HRS cells express CD30, the antibody-drug conjugate brentuximab vedotin has been evaluated in patients with relapsed Hodgkin lymphoma and has been shown to produce high response rates. Its use as a component of first-line therapy is now being explored, as well as its role as a maintenance treatment for patients who undergo high-dose therapy and stem cell transplantation. The cure rate for early-stage disease is generally excellent and approaches 95%. In late-stage disease the cure rate is 75-80%. although in those with a particularly poor prognosis it is 60-65%.",131,24,0.183206106870229
9781908541796,chapter9,"Because of the high cure rates, a major aim of future treatment strategies is to reduce the long-term effects of treatment, such as secondary cancers and heart disease.","As the prognosis for young patients with Hodgkin lymphoma improves, concern is now shifting to the long-term toxicities associated with treatment. As outlined previously, these include secondary cancers and heart disease. An analysis of survival data from Hodgkin patients over the past few decades shows that, after 15-20 years, patients are more likely to die of these late toxicities than from relapse of their lymphoma. More modern chemotherapy regimens are expected to reduce these late effects, but concern remains that a significant proportion of patients with Hodgkin lymphoma may be being overtreated. Although studies often implicate radiotherapy as being particularly associated with late toxicity, the higher-dose chemotherapy regimens (exempli gratia escalated BEACOPP) may carry a significant risk of myelodysplasia.",163,33,0.20245398773006135
9781908541796,chapter10,"Some side effects are common to all chemotherapy agents, such as fatigue, nausea and bone-marrow suppression, but some are agent specific.","General side effects. Chemotherapy has a number of general side effects (Table 10.1). Most of these effects can be explained by the action of chemotherapy on the relatively few healthy cells that normally have an active cell cycle. Cells in hair follicles, the gut lining, the testicle and the bone marrow fall into this category. Although these are general side effects of chemotherapy, they occur to differing extents according to the chemotherapy agent, regimen and dose. For example, oral chlorambucil seldom causes significant hair loss or mucositis, whereas the ABVD regimen causes hair loss but rarely causes significant suppression of fertility.",126,28,0.2222222222222222
9781908541796,chapter10,"Chemotherapy is administered orally, intravenously, subcutaneously or intrathecally.","Some drugs may only be given by one route: for example, vincristine is given intravenously. Other drugs such as fludarabine may have an oral and an intravenous preparation. Only two drugs are commonly administered intrathecally: methotrexate and cytarabine. Administering certain drugs (exempli gratia vincristine) intrathecally would rapidly lead to coma and death.",90,18,0.2
9781908541796,chapter10,"For complex chemotherapy regimens, indwelling venous catheters are often used but they carry the risks of infection and thrombosis.","Complications. Although indwelling lines are convenient for administering intravenous chemotherapy and taking blood samples, they have associated complications. Any indwelling foreign object can act as a source of infection, and a common reason for removal of a line is persistent fever. Also, the tip of the line can act as a focus for the formation of a thrombus. Although it is extremely rare for a thrombus to break off and cause a significant pulmonary embolus, it can cause local complications such as phlebitis or venous congestion in the associated limb. In addition, a PICC can cause a superficial phlebitis affecting the arm, but this is usually amenable to treatment with a topical corticosteroid cream.",151,30,0.1986754966887417
9781908541796,chapter10,Side effects of radiotherapy include damage to local tissues in the radiation field and an increased risk of secondary cancers. These effects are minimized by using fractions (which also increases efficacy) and by careful planning.,"External-beam radiotherapy is by far the most common radiotherapy for lymphomas. Careful planning is essential for safety. The aim is to ensure that the entire target area is included in the radiation field, while normal organs receive as little radiation as possible. To achieve this, several X-ray, CT and MRI studies are usually carried out. The patient is then put into a simulator, which is almost identical to the radiotherapy machine but does not actually deliver therapy. Information from the scans and from the simulator is then used to calculate the optimum radiation field, and the number and direction of the beams. To ensure that the radiation is delivered to exactly the same place every time, very small tattoos are made on the patient's skin, which act as landmarks for the radiographers. Intensity-modulated radiotherapy (IMRT) involves the use of multiple beams to limit the dose of radiotherapy to normal tissue. Its use requires special planning and more intensive input from medical physicists.",198,40,0.20202020202020202
9781908541796,chapter10,"Monoclonal antibody therapy with rituximab (anti-CD20) has revolutionized the treatment of both high- and low-grade lymphomas, and indications for this agent are likely to expand.","Rituximab. The most commonly used monoclonal antibody is rituximab, which binds to the CD20 molecule. CD20 is found on normal B lymphocytes and many types of B-cell non-Hodgkin lymphoma (NHL). When rituximab binds to target cells, it sensitizes them to chemotherapy and recruits components of the immune system (Figure 10.5). Rituximab has been shown to be effective in both high- and low-grade B-cell NHL. It also has the advantage of having relatively few side effects, with the most problematic being fever and chills during the initial infusion. When rituximab was first introduced, there was concern that the resulting depletion of normal B cells would lead to an increase in the rate of serious infection, but this has not yet been observed in extensive clinical trials.",184,44,0.2391304347826087
9781908541796,chapter10,"The treatment of lymphoma often involves multiple modalities: chemotherapy, radiotherapy, immunotherapy and/or high-dose therapy with stem-cell support.","In general, the higher the dose of chemotherapy or radiotherapy, the greater the number of lymphoma cells that is destroyed. However, it is also true that the higher the dose, the worse the side effects. The major dose-limiting side effect is bone-marrow suppression. Although most forms of chemotherapy cause some degree of bone-marrow suppression, this usually lasts for only a few days. With high doses, however, significant anemia, thrombocytopenia and leukopenia can last for weeks or months. The main risk during this time is overwhelming infection with bacteria or fungi. To reduce the duration of marrow failure with high doses of chemotherapy with or without radiotherapy, stem cells can be infused into the bloodstream 1 or 2 days after the completion of treatment. Stem cells previously obtained from the bone marrow (called hematopoietic stem cells) have the ability to return to the bone marrow, grow, divide and produce all the cellular constituents of the blood. Such a procedure can reduce the duration of marrow suppression from months to 7-10 days.",222,31,0.13963963963963963
9781908541796,chapter10,High-dose therapy with autologous stem-cell support is useful for patients with certain types of relapsed lymphoma and may be indicated as part of first-line therapy for very aggressive lymphomas.,"Autologous stem-cell transplantation is most frequently used in the treatment of lymphoma. The most common indications (Table 10.4) are relapsed Hodgkin lymphoma and certain types of NHL (id est in second or subsequent remissions). As the success of an autograft relies on the action of chemotherapy, it is important to determine whether the lymphoma is still chemosensitive. Transplantation in chemoresistant disease is generally unsuccessful. For the transplant procedure (Figure 10.6), patients first receive high-dose chemotherapy with or without radiotherapy. This is followed 1 or 2 days after the last dose of treatment by infusion of the stem cells in a process similar to a blood transfusion. About 2-4 days after the stem cell infusion, the patient's blood counts drop and an infection often develops. The blood counts normally start to recover 7-10 days later, but full recovery may take weeks or months and the total hospital stay is typically 4-6 weeks.",201,41,0.20398009950248755
9781908541796,chapter10,Radiotherapy kills cells by causing damage to the DNA.,"Allogeneic stem-cell transplantation, like autologous transplantation, uses chemotherapy or radiotherapy to kill the lymphoma cells. However, allogeneic stem-cell transplantation also uses the graft-versus-lymphoma effect to attack any residual cells. When stem cells from a donor repopulate the bone marrow of a patient, the immune system formed by the donor marrow has the potential to recognize the patient's body as foreign. When this happens, the immune system starts to attack the patient's body (graft-versus-host disease) and may also attack any residual lymphoma cells. Although this graft-versus-lymphoma effect may result in a reduced relapse rate, this is unfortunately partly offset by the risk of graft-versus-host disease.",162,12,0.07407407407407407
9781908541796,chapter10,"High-dose therapy with allogeneic stem-cell transplantation is a toxic procedure, but it may result in cure, particularly in cases of low-grade non-Hodgkin lymphoma.","Allogeneic stem-cell transplantation, like autologous transplantation, uses chemotherapy or radiotherapy to kill the lymphoma cells. However, allogeneic stem-cell transplantation also uses the graft-versus-lymphoma effect to attack any residual cells. When stem cells from a donor repopulate the bone marrow of a patient, the immune system formed by the donor marrow has the potential to recognize the patient's body as foreign. When this happens, the immune system starts to attack the patient's body (graft-versus-host disease) and may also attack any residual lymphoma cells. Although this graft-versus-lymphoma effect may result in a reduced relapse rate, this is unfortunately partly offset by the risk of graft-versus-host disease. Previously, allogeneic stem-cell transplantation always used very high doses of chemotherapy and radiotherapy before infusing the stem cells. This was termed myeloablative, because it destroyed the patient's bone marrow. The procedure alone carried a high mortality (up to 40% in some cases), and its use was restricted to patients under about 40 years of age. More recently, efforts have been made to reduce the intensity of conditioning treatment and to rely more on the graft-versus-lymphoma effect. These transplants are called reduced-intensity conditioning transplants. This approach has reduced mortality due to the procedure and has widened its use to older patients.",296,41,0.13851351351351351
9781908541796,chapter10,"A number of small-molecule pathway inhibitors are currently in development, several of which show very encouraging activity.","Several small-molecule pathway inhibitors are in clinical trials and are showing very encouraging activity in a number of lymphoma subtypes. A number of these drugs target the intracellular signaling pathway that is constitutively active in B cells, which express an immunoglobulin molecule on their cell surface. One constituent enzyme in this pathway is Bruton's tyrosine kinase (BTK). When the gene encoding this enzyme is congenitally mutated, the result is an absolute deficiency of B cells. Perhaps not surprisingly then, when this enzyme is chemically inhibited, B-cell depletion also occurs. Ibrutinib is the first drug in this class and is showing very encouraging activity in mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia.",164,23,0.1402439024390244
9781908541796,chapter11,Supportive care is aimed at managing the complications of treatment for lymphoma or of the lymphoma itself.,"Supportive care is a vital component of lymphoma management, and indeed the management of all cancers, because it underpins all other treatment modalities. It can be defined as treatment aimed at alleviating symptoms and complications caused by the underlying cancer (Table 11.1) or its management (see Chapter 10). Good supportive care is multidisciplinary and involves, among others, oncologists, hematologists, specialist nurses, palliative care physicians, primary care physicians, physiotherapists, dietitians, counselors and psychologists; effective communication between everyone involved in patient care is essential. Complementary therapies may also play a role depending on the wishes of the individual patient, and may include aromatherapy, acupuncture, reflexology, massage and homeopathy. This chapter outlines the traditional approaches to the management of some of the more common problems.",172,21,0.12209302325581395
9781908541796,chapter11,"Effective supportive care involves a multidisciplinary and holistic approach, with consideration of psychosocial and physical factors.","Supportive care is a vital component of lymphoma management, and indeed the management of all cancers, because it underpins all other treatment modalities. It can be defined as treatment aimed at alleviating symptoms and complications caused by the underlying cancer (Table 11.1) or its management (see Chapter 10). Good supportive care is multidisciplinary and involves, among others, oncologists, hematologists, specialist nurses, palliative care physicians, primary care physicians, physiotherapists, dietitians, counselors and psychologists; effective communication between everyone involved in patient care is essential. Complementary therapies may also play a role depending on the wishes of the individual patient, and may include aromatherapy, acupuncture, reflexology, massage and homeopathy. This chapter outlines the traditional approaches to the management of some of the more common problems.",172,22,0.12790697674418605
9781908541796,chapter11,"Effective analgesia and antiemesis has revolutionized supportive care, but fatigue remains debilitating, common and hard to manage.","Supportive care is a vital component of lymphoma management, and indeed the management of all cancers, because it underpins all other treatment modalities. It can be defined as treatment aimed at alleviating symptoms and complications caused by the underlying cancer (Table 11.1) or its management (see Chapter 10). Good supportive care is multidisciplinary and involves, among others, oncologists, hematologists, specialist nurses, palliative care physicians, primary care physicians, physiotherapists, dietitians, counselors and psychologists; effective communication between everyone involved in patient care is essential. Complementary therapies may also play a role depending on the wishes of the individual patient, and may include aromatherapy, acupuncture, reflexology, massage and homeopathy. This chapter outlines the traditional approaches to the management of some of the more common problems.",172,24,0.13953488372093023
9781908541796,chapter11,Anemia may be treated with recombinant human erythropoietin or blood transfusions.,"It must be borne in mind that pain often cannot be wholly assigned to a single physical cause. Pain is a complex physiological and emotional experience, and not simply a sensation. Anxiety or depression may lower the threshold for physical pain and such psychological problems may also be caused by persistent pain, leading to a vicious circle. In addition, pain may cause social isolation, interfere with social functioning, make work difficult or impossible and lead to difficulties with relationships. A holistic approach to pain management is important, with attention being paid to the doctor-patient or carer-patient relationship.",113,20,0.17699115044247787
9781908541796,chapter11,"Bone-marrow suppression is a common complication of lymphoma therapy and results in anemia, a low platelet count with bleeding, and a low white cell count and infection risk.","Infections. Bone-marrow suppression leads to a low white cell count with resulting immunosuppression. Neutrophils have a particular role in the defense against bacteria and fungi, and a lymphoma patient with a low neutrophil count (neutropenia) is particularly susceptible to serious infection. Such an infection is termed neutropenic sepsis and is a medical emergency. Although a normal neutrophil count is 1.5-4.0 x 10 /L, the risk of infection is only increased greatly when the count falls to below 0.5 x 10 /L. In this situation, a number of steps should be taken to prevent neutropenic sepsis developing (Table 11.4).",150,37,0.24666666666666667
9781908541796,chapter11,The treatment of neutropenic sepsis is a medical emergency and requires prompt assessment by a medical team with rapid administration of broad-spectrum antibiotics.,"Infections. Bone-marrow suppression leads to a low white cell count with resulting immunosuppression. Neutrophils have a particular role in the defense against bacteria and fungi, and a lymphoma patient with a low neutrophil count (neutropenia) is particularly susceptible to serious infection. Such an infection is termed neutropenic sepsis and is a medical emergency. Although a normal neutrophil count is 1.5-4.0 x 10 /L, the risk of infection is only increased greatly when the count falls to below 0.5 x 10 /L. In this situation, a number of steps should be taken to prevent neutropenic sepsis developing (Table 11.4).",150,31,0.20666666666666667
9781908541796,chapter11,"If sufficiently severe, a low platelet count may be treated with platelet transfusions.","Serious bleeding is often prevented by monitoring the platelet count and giving a platelet transfusion when the count falls below a given cut-off value. The normal platelet count is 150-400 x 10 /L, but prophylactic platelet transfusions are seldom given unless the count falls below 20 x 10 /L or even 10 x 10 /L. In addition, the following steps help to reduce the incidence of bleeding.",89,18,0.20224719101123595
9781908541796,chapter11,Tumor lysis syndrome is a serious complication of aggressive lymphomas. Recognizing patients at high risk and implementing effective preventive measures is the mainstay of treatment.,"Avoid anti-platelet medication (exempli gratia acetylsalicylic acid [ASA; aspirin], non-steroidal anti-inflammatory agents such as ibuprofen and diclofenac). Avoid intramuscular injections, which may result in painful intramuscular hematomas. Ensure the platelet count is sufficiently high to cover any planned invasive procedures. Tumor lysis syndrome. Tumor lysis syndrome is a potentially devastating complication of aggressive lymphomas and their treatment. It can be defined as the metabolic consequence of a rapidly proliferating malignancy and can occur before or, more usually, after the onset of initial treatment. When a cell dies, it results in the release of.",152,33,0.21710526315789475
9781908541901,ch_3,"The common underlying mechanism of acute coronary syndromes (ACS) is atherosclerotic plaque rupture or erosion, with differing degrees of superimposed thrombosis and distal embolization.","Pathological and imaging observations indicate that the common underlying mechanism of ACS is atherosclerotic plaque rupture or erosion followed by superimposed thrombosis formation and distal embolization. These processes result in myocardial hypoperfusion. Atherosclerosis is a chronic inflammatory disease involving large and medium-sized arteries. Although it begins early in life, the speed of progression is non-linear, unpredictable and varies markedly between individuals. Dysfunctional endothelium. Atherosclerosis starts with the development of dysfunctional endothelium in the presence of cardiovascular risk factors (Table 1.1). Under normal conditions, healthy vascular endothelium prevents adhesion of platelets to the endothelium and platelet activation by producing antithrombotic factors, including ectoADPase (CD39), prostaglandin I, nitric oxide, matrix metalloproteinase (MMP)-9, protein S, thrombomodulin and tissue-type plasminogen activator (t-PA). However, in the presence of numerous risk factors (see Table 1.1), the normal endothelium loses its antithrombotic properties, which results in the generation of dysfunctional enodothelium.",253,41,0.16205533596837945
9781908541901,ch_3,"Although atherosclerosis starts with the development of dysfunctional endothelium in the presence of cardiovascular risk factors early in life, the speed of progression is non-linear, unpredictable and varies markedly between individuals.","Pathological and imaging observations indicate that the common underlying mechanism of ACS is atherosclerotic plaque rupture or erosion followed by superimposed thrombosis formation and distal embolization. These processes result in myocardial hypoperfusion. Atherosclerosis is a chronic inflammatory disease involving large and medium-sized arteries. Although it begins early in life, the speed of progression is non-linear, unpredictable and varies markedly between individuals. Dysfunctional endothelium. Atherosclerosis starts with the development of dysfunctional endothelium in the presence of cardiovascular risk factors (Table 1.1). Under normal conditions, healthy vascular endothelium prevents adhesion of platelets to the endothelium and platelet activation by producing antithrombotic factors, including ectoADPase (CD39), prostaglandin I, nitric oxide, matrix metalloproteinase (MMP)-9, protein S, thrombomodulin and tissue-type plasminogen activator (t-PA). However, in the presence of numerous risk factors (see Table 1.1), the normal endothelium loses its antithrombotic properties, which results in the generation of dysfunctional enodothelium.",253,40,0.15810276679841898
9781908541901,ch_3,"A vulnerable plaque is prone to rupture or erosion and consists of a thin-capped fibroatheroma that is enriched in cholesterol debris, a large number of inflammatory cells (especially macrophages, some activated T cells), and smooth muscle cells.","A vulnerable plaque is prone to rupture or erosion, leading to platelet-rich thrombosis generation and subsequently to ACS. Histologically, a vulnerable plaque consists of a thin-capped fibroatheroma that is enriched in cholesterol debris, a large number of inflammatory cells - especially macrophages, some activated T cells, and smooth muscle cells. Plaque vulnerability is influenced by a dynamic balance between collagen synthesis and degradation by MMPs. Together, the leukocytes and endothelial cells proliferate at the plaque site and secrete extracellular matrix components and MMPs that degrade collagen and cause plaque erosion (see below). Similarly, macrophages can also elicit apoptosis of the smooth muscle cells of the plaque that may further affect the collagen synthesis and ensure thinning of the fibrous cap. Large amounts of hyaluronan (an anionic non-sulfated glycosaminoglycan that is present in both eroded and ruptured plaques) promote thrombosis by enhancing local adherence of platelets and leukocytes.",215,50,0.23255813953488372
9781908541901,ch_3,"The major determinants of thrombus generation are those of the classic 'triad of Virchow': thrombogenicity of the exposed plaque material (plaque vulnerability), local flow disturbances (vessel vulnerability), and systemic thrombotic propensity (blood vulnerability).","Plaque rupture is more common among men (78%) than women (60%), and is less frequently observed in premenopausal women. The major determinants of thrombus generation are those of the classic 'triad of Virchow'. thrombogenicity of the exposed plaque material (plaque vulnerability). local flow disturbances (vessel vulnerability). systemic thrombotic propensity (blood vulnerability). Whatever the cause of endothelial denudation (plaque vulnerability), it may be a weaker thrombogenic stimulus, whereas flow disturbances (stasis, turbulence), platelet hyperreactivity, hypercoagulability, inflammation and depressed fibrinolysis (blood vulnerability) play major roles. In addition, atherosclerotic lesion development and thrombotic complications are confined to areas characterized by low shear rate and/or flow disturbances (exempli gratia narrow vessels, bifurcations and branching points) (Figure 1.5). The underlying mechanisms of vulnerable plaque development (fibrous cap thinning and propensity to rupture) and thrombus generation at the site of plaque rupture are poorly understood. It is estimated that frank plaque rupture is responsible for about 75% of coronary thromboses, whereas endothelial erosion without frank plaque rupture, which is more common in women, accounts for 20%. Erosions around calcium nodules, rapid plaque expansion and intraplaque hemorrhage account for the remaining occurrences of thrombosis and vessel occlusions. It has been demonstrated that only a small percentage of plaque ruptures occur at sites of severe arterial stenoses, and in most cases high-grade coronary arterial stenoses are preceded by multiple healed plaque ruptures.",351,56,0.15954415954415954
9781908541901,ch_3,Mural platelet-rich 'white' thrombi most often incompletely block coronary blood flow and are present in unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI).,"Finally, thrombin converts fibrinogen to fibrin leading to the formation of an extensive fibrin network and a stable occlusive platelet-fibrin clot. In addition to the prothrombotic properties resulting from heightened platelet reactivity, a procoagulant and antifibrinolytic environment in the presence of a dysfunctional endothelium and plaque rupture markedly enhances clot formation and stability. The clinical manifestation of thrombus generation at the site of plaque rupture depends on the extent and duration of thrombotic occlusion. Mural platelet-rich 'white' thrombi most often incompletely block coronary blood flow and are present in UA and NSTEMI. STEMI is often characterized by the complete obstruction of coronary vessels by 'red thrombi' rich in red blood cells and fibrin that overlay platelet-rich thrombi (see Figure 1.1). In contrast to UA/NSTEMI, STEMI more often results in abrupt and persistent ischemia which, if left untreated, can cause sudden cardiac death.",226,49,0.2168141592920354
9781908541901,ch_3,"ST-segment elevation MI (STEMI) is often characterized by the complete obstruction of coronary vessels by thrombi rich in red blood cells and fibrin, which overlay platelet-rich thrombi.","Finally, thrombin converts fibrinogen to fibrin leading to the formation of an extensive fibrin network and a stable occlusive platelet-fibrin clot. In addition to the prothrombotic properties resulting from heightened platelet reactivity, a procoagulant and antifibrinolytic environment in the presence of a dysfunctional endothelium and plaque rupture markedly enhances clot formation and stability. The clinical manifestation of thrombus generation at the site of plaque rupture depends on the extent and duration of thrombotic occlusion. Mural platelet-rich 'white' thrombi most often incompletely block coronary blood flow and are present in UA and NSTEMI. STEMI is often characterized by the complete obstruction of coronary vessels by 'red thrombi' rich in red blood cells and fibrin that overlay platelet-rich thrombi (see Figure 1.1). In contrast to UA/NSTEMI, STEMI more often results in abrupt and persistent ischemia which, if left untreated, can cause sudden cardiac death.",226,44,0.19469026548672566
9781908541901,ch_4,"Clinical recognition of acute coronary syndromes (ACS) requires a careful assessment of the clinical presentation and history, application of appropriate imaging techniques and measurement of biomarkers.","Clinical recognition of ACS requires a careful assessment of the clinical presentation and history, application of appropriate imaging techniques and measurement of biomarkers. The most important factors to consider when taking the patient's history are the nature of the angina symptoms (see below), a history of coronary artery disease (CAD) (in up to 80% of patients), male gender, older age and a number of traditional cardiovascular risk factors such as smoking, family history, hyperlipidemia, diabetes and hypertension. These last traditional risk factors are poor predictors of the likelihood of ACS, but they may be associated with poorer outcomes. Chest pain. The hallmark symptom of ACS is pain in the center (substernal) or left of the chest, with radiation to the left shoulder and arm, neck and jaw (Table 2.1); pain in the arm is usually on the inner (ulnar) aspect. Most often, pain in the chest feels like a pressure or heaviness lasting for more than 20 minutes. It may or may not be severe. Chest pain in the setting of ST-segment elevation myocardial infarction (STEMI) usually occurs at rest, while in the setting of unstable angina/non-ST-segment elevation MI (UA/NSTEMI) chest pain often occurs during activity and stops at rest.",270,35,0.12962962962962962
9781908541901,ch_4,"A patient's symptom description is a critical diagnostic step, and typical symptoms such as chest heaviness, oppression and retrosternal burning are important angina symptoms.","The most important factors to consider when taking the patient's history are the nature of the angina symptoms (see below), a history of coronary artery disease (CAD) (in up to 80% of patients), male gender, older age and a number of traditional cardiovascular risk factors such as smoking, family history, hyperlipidemia, diabetes and hypertension. These last traditional risk factors are poor predictors of the likelihood of ACS, but they may be associated with poorer outcomes. Chest pain. The hallmark symptom of ACS is pain in the center (substernal) or left of the chest, with radiation to the left shoulder and arm, neck and jaw (Table 2.1); pain in the arm is usually on the inner (ulnar) aspect. Most often, pain in the chest feels like a pressure or heaviness lasting for more than 20 minutes. It may or may not be severe. Chest pain in the setting of ST-segment elevation myocardial infarction (STEMI) usually occurs at rest, while in the setting of unstable angina/non-ST-segment elevation MI (UA/NSTEMI) chest pain often occurs during activity and stops at rest.",243,32,0.13168724279835392
9781908541901,ch_4,"A 12-lead ECG should be performed and reviewed by an experienced clinician in all patients with suspected ACS within 10 minutes of first medical contact (id est on first contact with emergency medical services either outside or in hospital). If the likelihood of ACS is high but the 12-lead ECG is normal, a 17-lead ECG may be performed to reveal 'true posterior' ST-segment elevation myocardial infarction (STEMI).","The physical examination should include an assessment of vital signs, jugular venous pressure, heart sounds and murmurs, and peripheral perfusion. Auscultation of the chest may provide evidence of congestive heart failure. The abdomen should also be examined (a palpable abdominal mass indicates aortic aneurysm) and skin color assessed. The neurological examination should focus on the level of patient alertness and any evidence of stroke. Patients with ACS frequently exhibit anxiety and restlessness, diaphoresis and skin pallor. The patient may have a variable heart rate, depending on the degree of anxiety, concomitant arrhythmias and hemodynamic compromise. Body temperature is likely to be normal in patients with UA but elevated during MI. Respiratory rate may be normal or elevated because of pain, anxiety or left ventricular (LV) dysfunction. An abnormal cardiac examination will be observed more often in patients with MI than in those with UA. A resting 12-lead ECG should be performed and reviewed by an experienced clinician in all patients with suspected ACS within 10 minutes of first medical contact. If the likelihood of ACS is high but the 12-lead ECG is normal, a 17-lead ECG may be performed to reveal 'true posterior' STEMI (usually caused by occlusion of the circumflex artery or upper marginal branch of the circumflex artery). Without this, 8-10% of STEMIs may be misdiagnosed as NSTEMIs. Since ECGs provide only a 'snap shot' of myocardial ischemia, continuous monitoring and serial ECG tracings are recommended. Continuous monitoring provides vital information about arrhythmias or the development of recurrent ischemia. European (ESC) guidelines recommend that an ECG should be recorded at least 6 and 24 hours after presentation and if/when symptoms recur. It is important to compare current and previous ECG findings, as patients with no ECG changes have a lower risk of complications than those with ECG changes.",411,92,0.22384428223844283
9781908541901,ch_4,Early risk stratification is strongly recommended. Optimal risk stratification requires a multivariable approach. Clinical validated risk-stratification models such as the TIMI or GRACE risk scores are useful for assisting in management strategies and timing of invasive treatment in patients with suspected ACS.,"The GRACE risk score. In the GRACE risk model, eight variables are used to predict whether a patient will die or have a MI in the hospital or in the next 6 months. Each variable is assigned a numeric score on the basis of a specific value, and the eight scores are added to yield a total score, which is applied to a reference nomogram to determine the patient's risk (www.outcomes-umassmed.org/grace/acs_risk/acs_risk_content.html, last accessed 04 November 2013). GRACE uses variables derived from a registry of consecutive ACS patients, rather than patients in randomized trials (as in other scores) with specific inclusion-exclusion criteria. GRACE also includes renal function as a variable, since this is known to influence long-term prognosis. Application of risk scores. Ischemic risk scores assist risk stratification at the time of hospital admission, help to identify patients suitable for early invasive management and predict short- and long-term adverse cardiac events. Table 2.7 shows predicted in-hospital and short-term (14-day), as well as long-term (6-month), outcomes in patients with ACS using the TIMI risk score and GRACE.",253,56,0.22134387351778656
9781908541901,ch_4,"Invasive and non-invasive management strategies for ACS reduce the recurrence of ischemic events, but are associated with an increased risk of bleeding.","Invasive and non-invasive management strategies for ACS reduce the recurrence of ischemic events, but are associated with an increased risk of bleeding. Importantly, major bleeding and the need for transfusion are associated with an increased risk of in-hospital mortality as well as a long-term risk of death or MI. Gastrointestinal and femoral access site bleeding during coronary angiography are the most frequent bleeding complications. A variety of definitions for 'major' and 'minor' bleeding have been used in published clinical studies. In general, however, major bleeds can be considered those that are fatal or life-threatening, cause severe symptoms in a critical area or organ (exempli gratia intracranial, intraocular, intra-articular) or consume major healthcare resources. The International Society on Thrombosis and Haemostasis also gives a fall in hemoglobin level of 2.0 g/L (1.24 mmol/L) or more, or the need for transfusion of two or more units of whole or red blood cells, as a guideline for major bleeding in non-surgical patients. Minor bleeding can be considered any bleeding that requires medical intervention but does not cause hemodynamic compromise or require transfusion.",256,31,0.12109375
9781908541901,ch_4,Major bleeding and the need for transfusion are associated with an increased risk of in-hospital mortality as well as a long-term risk of death or MI; gastrointestinal and femoral access site bleeding are the most frequent bleeding complications.,"Invasive and non-invasive management strategies for ACS reduce the recurrence of ischemic events, but are associated with an increased risk of bleeding. Importantly, major bleeding and the need for transfusion are associated with an increased risk of in-hospital mortality as well as a long-term risk of death or MI. Gastrointestinal and femoral access site bleeding during coronary angiography are the most frequent bleeding complications. A variety of definitions for 'major' and 'minor' bleeding have been used in published clinical studies. In general, however, major bleeds can be considered those that are fatal or life-threatening, cause severe symptoms in a critical area or organ (exempli gratia intracranial, intraocular, intra-articular) or consume major healthcare resources. The International Society on Thrombosis and Haemostasis also gives a fall in hemoglobin level of 2.0 g/L (1.24 mmol/L) or more, or the need for transfusion of two or more units of whole or red blood cells, as a guideline for major bleeding in non-surgical patients. Minor bleeding can be considered any bleeding that requires medical intervention but does not cause hemodynamic compromise or require transfusion.",256,46,0.1796875
9781908541901,ch_5,"The preferred approach to revascularization depends on the extent and severity of the lesions, potential infarct complications and the patient's condition and comorbidities.","Coronary revascularization. The preferred approach to revascularization - percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) - depends on the extent and severity of the lesions as identified by coronary angiography, potential infarct complications, the patient's condition and comorbidities. Percutaneous coronary intervention. The majority of PCIs are performed with the implantation of a stent(s) (Figure 3.1). The procedure. During PCI, access into the femoral artery in the leg (or the radial artery or brachial artery in the arm) is created by a device called an 'introducer needle'. Once access is gained, a sheath is placed in the opening to keep the artery open and control bleeding. A long, flexible, soft plastic tube called a guiding catheter is advanced through the sheath over a guidewire. The tip of the guiding catheter is placed at the origin of the coronary artery. The guiding catheter also allows for iodine-based radiopaque dyes to be injected into the coronary artery, so that lesion location and severity can be precisely assessed using real-time radiographic visualization. This enables the cardiologist to estimate the size of the coronary artery and select the type of balloon catheter and coronary guidewire to use. A heparin or direct thrombin inhibitor is given to prevent clotting and maintain blood flow. A coronary guidewire, which is an extremely thin wire with a radiopaque flexible tip, is then inserted through the guiding catheter and into the coronary artery. Still using real-time radiographic visualization, the wire is guided through the coronary artery to the site of the stenosis or blockage. The tip of the wire is then passed across the blockage. The cardiologist controls the movement and direction of the guidewire by gently twisting the end that sits outside the patient.",396,33,0.08333333333333333
9781908541901,ch_5,The use of drug-eluting stents is preferred as they reduce the risk of reintervention compared with bare-metal stents.,"Type of stent. Numerous factors affect the decision to use a bare-metal or a drug-eluting stent, including coronary anatomic features, clinical characteristics (exempli gratia diabetes), likely patient adherence to long-term dual antiplatelet therapy (DAPT), risk of bleeding with prolonged DAPT and the potential need for future surgical or other procedures that would require discontinuation of DAPT. Several randomized clinical trials, which included patients with STEMI, have shown that drug-eluting stents reduce the risk of re-intervention compared with bare-metal stents, without having a significant impact on the risk of stent thrombosis, recurrent MI or death.",144,28,0.19444444444444445
9781908541901,ch_5,"Percutaneous coronary intervention (PCI) is associated with superior restoration of myocardial blood flow, lower rates of reinfarction and mortality and less intracranial bleeding than pharmacological intervention with fibrinolytic therapy.","PCI is associated with superior restoration of myocardial blood flow, lower rates of reinfarction and mortality and less intracranial bleeding than pharmacological intervention with fibrinolytic therapy. Choice of approach. The femoral approach has been widely adopted for PCI in the past. However, the radial approach has been increasingly favored in recent years because of potentially important advantages, including lower risk of major vascular complications and major bleeding, reduced length of stay after the procedure, reduced use of resources, and possibly lower mortality in high-risk patients such as those with STEMI. Moreover, the radial artery is superficial, which enables hemostasis to be achieved more readily. Bleeding at the site of radial access, radial artery injury and occlusion, increased radiation exposure, and the significant learning curve that is required to master the procedure before implementation of the radial approach as the standard method to achieve access in STEMI, are important considerations that need to be addressed when using the radial approach.",200,49,0.245
9781908541901,ch_5,Approximately 10% of patients with acute coronary syndromes undergo coronary artery bypass grafting during initial hospitalization.,"Choice of approach. The femoral approach has been widely adopted for PCI in the past. However, the radial approach has been increasingly favored in recent years because of potentially important advantages, including lower risk of major vascular complications and major bleeding, reduced length of stay after the procedure, reduced use of resources, and possibly lower mortality in high-risk patients such as those with STEMI. Moreover, the radial artery is superficial, which enables hemostasis to be achieved more readily. Bleeding at the site of radial access, radial artery injury and occlusion, increased radiation exposure, and the significant learning curve that is required to master the procedure before implementation of the radial approach as the standard method to achieve access in STEMI, are important considerations that need to be addressed when using the radial approach. Coronary artery bypass grafting. Approximately 10% of patients with acute coronary syndromes (STEMI and NSTEMI) undergo CABG during initial hospitalization (Figure 3.2).",201,23,0.11442786069651742
9781908541901,ch_6,"Although the in-hospital mortality is higher in patients with STEMI than those with UA/NSTEMI, the 6-month mortality rates are similar and the 4-year mortality rates are two times higher in patients with UA/NSTEMI.","Unstable angina/non-ST-segment elevation myocardial infarction. Surveys and registries suggest that the current incidence of unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI), collectively known as non-ST-segment elevation acute coronary syndromes (NSTE-ACS), is higher than ST-segment elevation myocardial infarction (STEMI; see Chapter 5). Although the in-hospital mortality is higher in STEMI than UA/NSTEMI (7% vs 5%), the 6-month mortality rates are similar (12% vs 13%) and the 4-year mortality rates are two times higher in patients with UA/NSTEMI. In STEMI, most events occur before or shortly after presentation, but in UA/NSTEMI ischemic events continue over a longer period of time, possibly because patients with UA/NSTEMI tend to be older and have more comorbidities (Table 4.1).",215,50,0.23255813953488372
9781908541901,ch_6,Early invasive strategy followed promptly by revascularization is increasingly preferred over conservative strategy.,"Increasingly, physicians are initiating an early invasive strategy in patients without contraindications, with coronary angiography within 24 hours of admission followed promptly by revascularization (see Chapter 3). The rationale for this more aggressive approach is the protective effect of revascularization on ischemic outcomes in high-risk patients. The decision to initiate a conservative strategy is guided by the absence of high-risk features, with angiography reserved for patients with recurrent ischemia or a high-risk stress test despite medical therapy.",107,16,0.14953271028037382
9781908541901,ch_6,"Antithrombotic therapy is a fundamental strategy in patients with UA/NSTEMI; however, proper risk assessment is essential to determine an optimal strategy that achieves a maximum anti-ischemic effect associated with an acceptable bleeding risk.","Bleeding risk. Although pre-treatment with a triple or dual antiplatelet regimen may cause increased bleeding in the individual patient, a recent meta-analysis suggests that surgery-related bleeding decreases in these patients as surgical experience increases. In patients who require emergency surgery before the washout period of antiplatelet agents is completed, platelet transfusions, antifibrinolytics, off-pump CABG and use of recombinant factor VII (in extreme cases) may be employed to curtail bleeding. Antithrombotic therapy. Since platelet function and coagulation play pivotal roles in the generation of a clot at the site of plaque rupture (see Chapter 1) and in subsequent ischemic events, a combination of antiplatelet and anticoagulant agents (together known as antithrombotic therapy) is the cornerstone of treatment for patients with ACS (Figure 4.3). However, the choice, initiation and duration of treatment depend on the severity of CAD, comorbid diseases, the clinical setting of intervention (elective, acute or urgent intervention) and the type of stenting (bare-metal or drug-eluting). Proper risk assessment is essential to determine an optimal antithrombotic strategy that achieves a maximal antithrombotic effect associated with an acceptable bleeding risk (see Chapter 2).",273,48,0.17582417582417584
9781908541901,ch_6,"Dual antiplatelet therapy with acetylsalicylic acid (ASA; aspirin) and a P2Y receptor blocker is the standard of care in patients with UA/NSTEMI; however, optimal duration of therapy is controversial.","Since platelet function and coagulation play pivotal roles in the generation of a clot at the site of plaque rupture (see Chapter 1) and in subsequent ischemic events, a combination of antiplatelet and anticoagulant agents (together known as antithrombotic therapy) is the cornerstone of treatment for patients with ACS (Figure 4.3). However, the choice, initiation and duration of treatment depend on the severity of CAD, comorbid diseases, the clinical setting of intervention (elective, acute or urgent intervention) and the type of stenting (bare-metal or drug-eluting). Proper risk assessment is essential to determine an optimal antithrombotic strategy that achieves a maximal antithrombotic effect associated with an acceptable bleeding risk (see Chapter 2). Antiplatelet therapy. Currently approved antiplatelet strategies for ACS include acetylsalicylic acid (ASA; aspirin), P2Y receptor inhibitors and GPIIb/IIIa inhibitors. Simultaneous inhibition of cyclo-oxygenase (COX)-1 and P2Y by ASA and clopidogrel, respectively, has been shown in both preclinical and large-scale clinical studies to have a more potent antithrombotic effect than ASA alone. These pivotal findings form the basis for current therapeutic recommendations in ACS. However, with improved invasive technologies and concomitant treatments that address modifiable cardiovascular risk factors, ischemic event rates are falling in clinical trials and therefore the efficacy of treatment strategies that uniformly employ more potent platelet inhibition may also decrease in the future.",326,48,0.147239263803681
9781908541901,ch_6,"The benefits of triple therapy of ASA, P2Y receptor blocker and warfarin/oral anticoagulant have not been clearly established. The role of direct oral anticoagulants for long-term therapy is being studied in large-scale trials.","In the EARLY ACS trial, high-risk NSTE-ACS patients were randomized to receive either early routine administration of eptifibatide (double bolus followed by standard infusion) or delayed provisional eptifibatide at the time of PCI in addition to ASA and clopidogrel. There was no difference in the primary endpoint at 96 hours (9.3% vs 10%, OR: 0.92; p=0.23) and a non-significant decrease in the secondary endpoint (all-cause death or MI within 30 days) in patients in the early therapy arm versus patients in the delayed GPIIb/IIIa inhibitor arm. However, early routine eptifibatide administration was associated with a greater risk of TIMI major or minor bleeding, increased severe or moderate bleeding on the GUSTO bleeding scale and increased rates of red blood cell transfusion. The lack of significant efficacy and increased bleeding in the trial have affected recent guidelines for routine early GPIIb/IIIa inhibitor administration in NSTE-ACS patients. The choice of upstream or deferred administration remains controversial, because true early administration (id est at the time of emergency department presentation) has never been achieved in a clinical trial despite the goal of testing the utility of 'early' administration. Various studies have indicated that GPIIb/IIIa inhibitors should only be used concomitantly with ASA and/or heparin in acute settings of ACS. The increasing use of the new antiplatelet agents prasugrel or ticagrelor in NSTE-ACS may further reduce the need for GPIIb/IIIa receptor blockers but this has not yet been addressed in specific randomized controlled trials. Novel strategies such as intracoronary administration, bolus-only strategy or short infusion of GPIIb/IIIa inhibitors are being studied, and evidence so far has suggested a benefit in reducing bleeding complications.",396,54,0.13636363636363635
9781908541901,ch_6,Guidelines uniformly recommend starting all UA/NSTEMI patients (without contraindications) on an anticoagulant as soon as possible after presentation.,Inhibitors of the renin-angiotensin-aldosterone system. The mortality benefits observed with the administration of angiotensin-converting enzyme (ACE) inhibitors favor the use of these drugs in all patients with UA/NSTEMI. ACE inhibitors should be administered within 24 hours to patients with congestive heart failure or an ejection fraction less than 40%. Long-term use of ACE inhibitors is also indicated in patients with high-risk chronic CAD. Angiotensin receptor blockers (ARBs) are generally reserved for patients who are intolerant to ACE inhibitors. Valsartan and captopril are equally effective for patients at high risk of cardiovascular events after MI.,141,33,0.23404255319148937
9781908541901,ch_6,"Since patients with UA/NSTEMI have a high risk of recurrent ischemic events, active long-term management strategies are crucial.","Patients with diabetes mellitus. Nearly one quarter of patients with UA/NSTEMI have diabetes. CAD is more severe among patients with diabetes and accounts for 75% of all deaths in this group. Moreover, diabetic patients have more extensive comorbidities such as hypertension, heart failure, LV hypertrophy, obesity and renal failure compared with non-diabetic patients. Diabetes is also an independent risk factor for recurrent ischemic events (death, MI or readmission for UA at 1 year: RR=4.9) in UA/NSTEMI patients.",116,28,0.2413793103448276
9781908541901,ch_7,"In the European guidelines, bivalirudin is the anticoagulant of choice during primary PCI, while enoxaparin has its merits as an adjuvant to thrombolytic therapy. Whereas, in the US guidelines there is no general preference for bivalirudin over unfractionated heparin and there is no recommendation for enoxaparin.",Reperfusion should be performed as soon as possible in patients with ST elevation of at least 2 mm (0.2 mV) in two contiguous precordial leads or 1 mm in two adjacent limb leads or a presumed new LBBB. Patients without ST-segment elevation are not candidates for immediate pharmacological reperfusion but should receive anti-ischemic therapy and catheter-based therapy. The goal for mechanical reperfusion is to achieve intracoronary balloon inflation within 90 minutes of the patient's arrival at hospital or first contact with the medical system (door [or FMC]-to-balloon time) (Figure 5.2). The goal of pharmacological reperfusion is to initiate fibrinolytic therapy within 30 minutes (door-to-needle time). It is recommended that early reperfusion (preferably primary PCI) should be performed within 12 hours of symptom onset in patients with the clinical presentation of STEMI (Figure 5.3) and for those with persistent ST-segment elevation or new or presumed new LBBB. There is no consensus as to whether PCI is beneficial in patients who present more than 12 hours after the onset of ischemia without clinical and/or ECG evidence of ongoing ischemia. Early mortality risk assessment can be based on the TIMI (Thrombolysis in Myocardial Infarction) risk score for STEMI. High-risk patients with cardiogenic shock or a very high TIMI risk (> 7) are likely to benefit from primary PCI more than fibrinolysis since there is evidence of a poorer lytic effect in the presence of hemodynamic compromise.,344,79,0.22965116279069767
9781908541901,ch_7,"The selection of reperfusion strategy in STEMI (pharmacological versus invasive) is critically dependent on the time from onset of symptoms, mortality risk of STEMI and bleeding risk.","Worse clinical outcomes have been observed in both randomized studies and registries when long delays have occurred before the primary PCI, id est increased time from symptom onset to first medical contact (FMC  ECG-confirmed diagnosis of STEMI), time from FMC to arrival in the cath laboratory, time from FMC to sheath insertion, and time from FMC to balloon inflation. The 'PCI-related time delay' is the theoretical difference between the time of FMC to balloon inflation minus the time from FMC to start of fibrinolytic therapy ('door-to-balloon' minus 'door-to-needle'; see Figure 5.2). The extent to which the PCI-related time delay (which may be between 60 and 120 minutes) diminishes the advantages of PCI over fibrinolysis has been the subject of many analyses and debates. Therefore, primary PCI (balloon inflation) should optimally be performed within 2 hours of FMC. In patients presenting early, with a large amount of myocardium at risk, the delay should be less than 60 minutes from FMC. Although much emphasis has been given to achieving lower FMC-to-balloon time in general practice, in-hospital and short-term mortality has remained virtually unaffected despite a significantly increased percentage of patients meeting the criteria of FMC-to-balloon time of 90 minutes or less (recently reported results from a registry of 95 007 STEMI patients).",301,37,0.12292358803986711
9781908541901,ch_7,Primary percutaneous coronary intervention (PCI) is the preferred choice of revascularization in STEMI patients if it can be offered within 90-120 minutes of diagnosis.,"Worse clinical outcomes have been observed in both randomized studies and registries when long delays have occurred before the primary PCI, id est increased time from symptom onset to first medical contact (FMC  ECG-confirmed diagnosis of STEMI), time from FMC to arrival in the cath laboratory, time from FMC to sheath insertion, and time from FMC to balloon inflation. The 'PCI-related time delay' is the theoretical difference between the time of FMC to balloon inflation minus the time from FMC to start of fibrinolytic therapy ('door-to-balloon' minus 'door-to-needle'; see Figure 5.2). The extent to which the PCI-related time delay (which may be between 60 and 120 minutes) diminishes the advantages of PCI over fibrinolysis has been the subject of many analyses and debates. Therefore, primary PCI (balloon inflation) should optimally be performed within 2 hours of FMC. In patients presenting early, with a large amount of myocardium at risk, the delay should be less than 60 minutes from FMC. Although much emphasis has been given to achieving lower FMC-to-balloon time in general practice, in-hospital and short-term mortality has remained virtually unaffected despite a significantly increased percentage of patients meeting the criteria of FMC-to-balloon time of 90 minutes or less (recently reported results from a registry of 95 007 STEMI patients).",301,35,0.11627906976744186
9781908541901,ch_7,Immediate recognition of STEMI with timely initiation of reperfusion therapies is associated with improved outcomes.,"Fibrinolytic therapy. An overview of the nine trials performed by the Fibrinolytic Therapy Trialists' Collaborative Group shows that approximately 30 early deaths are prevented per 1000 patients within 35 days for those treated with fibrinolytic therapy, and 20 deaths are prevented per 1000 patients when treatment is given 7-12 hours after symptom onset. These benefits were observed in patients with ST-segment elevation or LBBB at the time of presentation, irrespective of age, gender, blood pressure, heart rate or history of MI or diabetes. The available data support prehospital initiation of fibrinolytic treatment if reperfusion is indicated. Early fibrinolytic therapy is associated with similar outcomes to primary PCI, if early angiography and PCI were performed in those patients who needed intervention. The principal goal of fibrinolysis is prompt restoration of normal myocardial blood flow. Indications for fibrinolytic therapy are shown in Table 5.2.",203,20,0.09852216748768473
9781908541901,ch_7,Prasugrel and ticagrelor have superseded clopidogrel as the gold standard in dual antiplatelet therapy.,"Prasugrel. A loading dose of 60 mg followed by a maintenance dose of 10 mg, in combination with ASA, showed a statistical reduction of the combined primary endpoint and cardiovascular mortality when compared with clopidogrel in STEMI patients. Major bleeding complications were equal in the two study groups. In STEMI patients referred for primary PCI, international guidelines recommend that prasugrel should be administered as soon as possible. Although early use of a 60-mg loading dose (exempli gratia in the ambulance on the way to the catheter-equipped tertiary hospital) has not yet been investigated, this strategy has become standard practice in many STEMI networks.",136,29,0.21323529411764705
9781908541901,ch_8,"Patients with acute coronary syndromes, particularly NSTEMI, remain at heightened risk for long-term recurrent cardiovascular events.","Despite reduced mortality during the acute phase of acute coronary syndromes (ACS) because of improved and timely reperfusion strategies, patients with coronary artery disease (CAD), particularly patients with non-ST-segment elevation myocardial infarction (NSTEMI), remain at heightened risk for long-term recurrent cardiovascular events. The potential underlying mechanisms include advancing age, ischemic complications caused by residual or progressive atherosclerotic CAD, arrhythmias resulting from the trigger of latent ischemia or arising from the re-entrant substrate provided by the infarct scar, and heart failure.",126,26,0.20634920634920634
9781908541901,ch_8,"The goal of secondary prevention strategies is to reduce cardiovascular death, recurrent myocardial infarction, the burden of angina, and other ischemic events.","Despite reduced mortality during the acute phase of acute coronary syndromes (ACS) because of improved and timely reperfusion strategies, patients with coronary artery disease (CAD), particularly patients with non-ST-segment elevation myocardial infarction (NSTEMI), remain at heightened risk for long-term recurrent cardiovascular events. The potential underlying mechanisms include advancing age, ischemic complications caused by residual or progressive atherosclerotic CAD, arrhythmias resulting from the trigger of latent ischemia or arising from the re-entrant substrate provided by the infarct scar, and heart failure. The goal of secondary prevention strategies is to reduce cardiovascular death, recurrent myocardial infarction (MI), the burden of angina and other ischemic events. Numerous hospital-based (cardiac rehabilitation) and cost-effective home-based secondary prevention programs have been shown to improve processes of care, coronary risk factor profiles and quality of life. However, internationally, patient access to these programs is low (around 30%), particularly in those groups with the greatest need for risk factor reduction, id est those with diabetes, dyslipidemia, hypertension, obesity, smoking or a family history of CAD.",248,33,0.13306451612903225
9781908541901,ch_8,"More than 90% of the risk of coronary artery disease (CAD) is associated with modifiable risk factors. Secondary prevention trials are therefore mainly targeting the modifiable risk factors such as diabetes, dyslipidemia, hypertension, obesity and smoking.","The goal of secondary prevention strategies is to reduce cardiovascular death, recurrent myocardial infarction (MI), the burden of angina and other ischemic events. Numerous hospital-based (cardiac rehabilitation) and cost-effective home-based secondary prevention programs have been shown to improve processes of care, coronary risk factor profiles and quality of life. However, internationally, patient access to these programs is low (around 30%), particularly in those groups with the greatest need for risk factor reduction, id est those with diabetes, dyslipidemia, hypertension, obesity, smoking or a family history of CAD. More than 90% of the risk of CAD is associated with modifiable risk factors, and detailed US and European guidelines are available for the long-term management of specific coronary risk factors and left ventricular dysfunction (see Key references). Nevertheless, patients with CAD do not achieve treatment targets regarding lifestyle changes, risk factor modification and therapeutic strategies, and there are huge gaps in applying current evidence to routine practice. Non-adherence to secondary prevention guidelines is a major problem. Measures to improve adherence to medications and healthy lifestyle choices, improved awareness and education programs targeting both patients and healthcare providers are needed.",240,50,0.20833333333333334
9781908541901,ch_8,"Despite many secondary prevention programs, patients with CAD do not achieve treatment targets regarding lifestyle changes, risk factor modification and therapeutic strategies, and there are huge gaps in applying evidence to routine practice.","The goal of secondary prevention strategies is to reduce cardiovascular death, recurrent myocardial infarction (MI), the burden of angina and other ischemic events. Numerous hospital-based (cardiac rehabilitation) and cost-effective home-based secondary prevention programs have been shown to improve processes of care, coronary risk factor profiles and quality of life. However, internationally, patient access to these programs is low (around 30%), particularly in those groups with the greatest need for risk factor reduction, id est those with diabetes, dyslipidemia, hypertension, obesity, smoking or a family history of CAD. More than 90% of the risk of CAD is associated with modifiable risk factors, and detailed US and European guidelines are available for the long-term management of specific coronary risk factors and left ventricular dysfunction (see Key references). Nevertheless, patients with CAD do not achieve treatment targets regarding lifestyle changes, risk factor modification and therapeutic strategies, and there are huge gaps in applying current evidence to routine practice. Non-adherence to secondary prevention guidelines is a major problem. Measures to improve adherence to medications and healthy lifestyle choices, improved awareness and education programs targeting both patients and healthcare providers are needed.",240,37,0.15416666666666667
9781908541901,ch_8,"Strict adherence to medications, improved awareness and education programs targeting patient and healthcare providers are needed.","More than 90% of the risk of CAD is associated with modifiable risk factors, and detailed US and European guidelines are available for the long-term management of specific coronary risk factors and left ventricular dysfunction (see Key references). Nevertheless, patients with CAD do not achieve treatment targets regarding lifestyle changes, risk factor modification and therapeutic strategies, and there are huge gaps in applying current evidence to routine practice. Non-adherence to secondary prevention guidelines is a major problem. Measures to improve adherence to medications and healthy lifestyle choices, improved awareness and education programs targeting both patients and healthcare providers are needed.",118,19,0.16101694915254236
9781908541963,chapter1,"Increases in serum bilirubin occur for many reasons, but generally indicate severe disease.","Liver disorders are encountered frequently in general practice. In the UK, while mortality rates from other major causes of disease are falling, mortality from liver disease continues to increase, and accounts for approximately 2% of all deaths in England. In the USA, recent data suggest that 5.5 million people have chronic liver disease. Many asymptomatic patients will have elevated liver test results, although the incidence varies considerably between populations with differing risk profiles. The goals of the physician's investigation are to understand the origin of the liver injury, to correct its cause and to prevent permanent organ dysfunction (id est cirrhosis). An organized approach to investigating liver abnormalities allows the physician to reach conclusions promptly, and avoids excessive cost or risk to the patient.",148,18,0.12162162162162163
9781908541963,chapter1,Elevated levels of aspartate aminotransferase and alanine aminotransferase suggest injury to hepatocytes.,"Liver enzymes. The liver typically responds to injury by releasing enzymes from hepatocytes and/or biliary epithelium. Elevated levels of enzymes of hepatocellular origin, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), suggest injury to hepatocytes. Elevations in alkaline phosphatase suggest injury to the function or structure of the biliary system. Aminotransferases (transaminases). AST is a mitochondrial enzyme found in the liver and other tissues, such as skeletal and myocardial muscle. ALT is a cytoplasmic enzyme found primarily in the liver. Both AST and ALT are released from injured hepatocytes, and elevated levels are found in the blood of patients with liver disease of diverse etiologies. In most liver disorders, ALT is higher than AST. When AST is higher than ALT (particularly if the ratio is greater than 2), ALD should be strongly suspected.",207,30,0.14492753623188406
9781908541963,chapter1,An elevated level of alkaline phosphatase suggests injury to structures of the biliary tree.,"Liver enzymes. The liver typically responds to injury by releasing enzymes from hepatocytes and/or biliary epithelium. Elevated levels of enzymes of hepatocellular origin, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), suggest injury to hepatocytes. Elevations in alkaline phosphatase suggest injury to the function or structure of the biliary system.",91,19,0.2087912087912088
9781908541963,chapter1,Prothrombin time (after vitamin K) and serum albumin are used to assess the liver's ability to synthesize proteins.,"Prothrombin time. Most clotting factors are produced by the liver. Thus, measurement of PT is a reliable marker of liver function. Because the clotting proteins require vitamin K as a cofactor, vitamin K deficiency must be ruled out as a cause of an increased PT. Parenteral administration of vitamin K to patients with vitamin K deficiency usually corrects the PT within 12-24 hours, whereas vitamin K has a negligible effect in liver failure. Occasionally, vitamin K deficiency and liver disease coincide. With cholestatic liver disorders, such as primary biliary cirrhosis and primary sclerosing cholangitis, the absorption of fat-soluble vitamins such as vitamin K can be impaired. Thus, administering vitamin K to a patient with an elevated PT is reasonable. However, repeated daily injections of vitamin K when there is no apparent improvement in PT are not helpful.",180,27,0.15
9781908541963,chapter1,A liver biopsy is the gold standard for evaluation of liver disease.,"Biopsy. A liver biopsy is the gold standard for evaluation of liver disease. Although patients approach biopsy with trepidation, it is safe and quite simple to perform. Most liver biopsies are now performed under ultrasound guidance on an outpatient basis. Generally, a biopsy is safe provided that the PT is prolonged by no more than a few seconds and the platelet count is greater than 70 000 x 10 -6 /L. A liver biopsy usually allows a definitive diagnosis of the underlying liver disorder and staging of the disease (severity of permanent liver injury; fibrosis; cirrhosis).",124,14,0.11290322580645161
9781908541963,chapter2,"Attempt to classify acute liver disease as hepatitis (most common), cholestatic (intermediate) or vascular (unusual).","Acute liver disease. Acute liver disease refers to diseases of less than 6 months' duration at the time of presentation. This category of disease excludes first presentations of cirrhosis, with a few exceptions, such as when hepatitis B or Wilson's disease present with the syndrome of acute liver failure. There are three major categories of acute liver disease. vascular disease. The associated symptoms and biochemical profiles differentiate between these patterns of disease (Table 2.1). Jaundice is the typical presentation of both hepatitis and cholestasis; the sudden onset of ascites is the most common presentation of vascular disease.",123,26,0.21138211382113822
9781908541963,chapter2,Simple blood tests and an ultrasound examination provide most of the information required.,"Extrahepatic biliary obstruction is the cause of most cases of cholestasis (Table 2.4). The presence of pain points to gallstone disease; conversely, the absence of pain suggests malignant disease, especially in older patients. Biliary obstruction causes dilation of the bile ducts and is easily detected on ultrasound examination, which is the initial screening procedure. More precise definition of the site of the obstruction is then obtained by endoscopic or magnetic resonance cholangiography.",102,14,0.13725490196078433
9781908541963,chapter2,"Hypoglycemia, coagulopathy and any evidence of confusion indicate a high risk of acute liver failure and the need for specialist care.","Paracetamol (acetaminophen) overdose induces a distinct pattern of acute liver failure. Acidosis may be an early feature, and failure to reverse the acidosis within 24 hours of drug ingestion is associated with a very high mortality. Patients at risk of acute liver failure are identified by the development of a coagulopathy, and encephalopathy typically develops on the third or fourth day after the overdose. Renal failure is more common and earlier than with other causes of acute liver failure. Progression to acute liver failure is usually prevented by the administration of N -acetylcysteine within 16-24 hours of the overdose. Later administration of N -acetylcysteine may also modify the severity of the disease.",148,29,0.19594594594594594
9781908541963,chapter2,Coagulopathy in cholestatic disorders responds to parenteral vitamin K.,"Intrahepatic causes of cholestasis should be considered when there is no evidence of duct dilation on ultrasound examination. The dominant clinical features are jaundice and pruritus. Other features include dark urine and pale stools, and weight loss may be considerable. The liver function profile comprises elevated serum bilirubin, serum alkaline phosphatase and GGT but no features that distinguish intrahepatic from extrahepatic biliary obstruction. There may be an abnormality in coagulation tests in protracted cases, but this is corrected rapidly by parenteral administration of vitamin K. There is no specific therapy other than symptomatic relief, particularly of the pruritus - colestyramine (cholestyramine), ursodeoxycholic acid, rifampicin (rifampin). The duration of the cholestatic episode is variable but it can last for many months.",193,19,0.09844559585492228
9781908541963,chapter3,Alcoholic liver disease (ALD) is a common cause of end-stage liver disease.,"Alcoholic liver disease (ALD) is a common cause of end-stage liver disease, resulting in substantial morbidity and mortality throughout the world. In the USA, approximately 2 million people suffer from an alcohol-induced liver disorder. In the UK in 2012, ALD accounted for 63% (4425) of all alcohol-related deaths, an 18% increase on 2002. Medical costs associated with caring for these patients are enormous.",88,19,0.2159090909090909
9781908541963,chapter3,"Early intervention prevents permanent injury, but interrupting alcoholism can be difficult.","Alcohol-related liver injury presents a spectrum of disease, including asymptomatic hepatic steatosis (fatty liver), steatosis accompanied by inflammation (steatohepatitis or alcoholic hepatitis), cirrhosis with liver failure, variceal bleeding, ascites and even the development of hepatocellular carcinoma. Intervention for patients presenting with the early stages of liver injury helps to prevent further permanent liver injury. Interrupting alcoholism is the key, but this is not an easy task and frustrates many primary care providers, families and patients.",116,14,0.1206896551724138
9781908541963,chapter3,"Patients with ALD typically have mild to moderate elevations in aminotransferases, with AST > ALT.","Liver function tests. Examination of laboratory results is helpful in diagnosing ALD. The aminotransferases are elevated and have a characteristic pattern in patients with ALD: the aspartate aminotransferase (AST) is almost always higher than the alanine aminotransferase (ALT) level, and the greater the ratio the more likely that the liver disease is due to alcohol. Alkaline phosphatase and serum bilirubin levels may be increased, the prothrombin time (PT) prolonged and the albumin level depressed. The last two are good markers of the severity of ALD. However, it should also be noted that liver function tests may be entirely normal in the presence of cirrhosis, particularly if the patient has achieved sobriety.",167,26,0.15568862275449102
9781908541963,chapter3,Patients with ALD are often malnourished; improving nutrition is an important treatment goal.,"Nutrition. Alcoholics are usually malnourished, and improving nutrition is associated with improved outcomes. This is particularly important for patients with alcoholic hepatitis. Anorexia may prevent adequate nutrition and feeding via an enteral tube is sometimes required. Most alcoholics need protein. Unfortunately, however, a few patients with advanced liver disease develop hepatic encephalopathy when given large amounts of protein. Consultation with dietitians may be beneficial.",89,20,0.2247191011235955
9781908541963,chapter3,Patients with severe alcoholic hepatitis may benefit from corticosteroids or pentoxifylline.,"Corticosteroids. Alcoholic hepatitis is an inflammatory condition. Thus, corticosteroids are a logical treatment for ALD. However, despite many studies that have investigated the role of corticosteroids in the treatment of alcoholic hepatitis, there is no clear consensus on their efficacy. Most hepatologists believe that patients with the most severe forms of alcoholic hepatitis - id est those with a Maddrey's discriminant function (DF) score greater than 32 - will benefit from a course of corticosteroids. The DF score is calculated with the simple formula.",114,20,0.17543859649122806
9781908541963,chapter4,Drug-induced liver injury is common and usually mild.,"The liver is uniquely positioned, both anatomically and metabolically, to receive the brunt of potential insults; thus, medications have the potential to induce liver disease, and at least 1000 drugs have been implicated. Medications appear to be the cause of 50% of cases of acute liver failure in the USA, and as pharmacotherapy advances the treatment of many disorders, drug-induced liver injury (DILI) may also rise. The growing use of herbal preparations and traditional medicines is also of great concern. Whereas all approved medications have been evaluated at least superficially for hepatotoxicity, the majority of 'natural' remedies have not.",129,11,0.08527131782945736
9781908541963,chapter4,Determining the temporal relationship between starting a drug and the development of symptoms and signs of liver disease is important.,"Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) reduce cardiovascular morbidity and mortality in patients with and without cardiovascular disease. These drugs are so effective that they are in very common use. As a group the statins are very safe, with fewer than 2% of patients enrolled in clinical trials discontinuing the medications for any reason. Nevertheless, elevation of the aminotransferases (greater than three times normal) occurs in approximately 1% of exposed patients. Lesser elevations in the aminotransferases are more common (id est about 3%). The effect appears to be dose-related and usually occurs in the first few months of therapy. Most patients are asymptomatic and have no signs suggestive of liver dysfunction on physical examination. Severe liver injury has been reported but is rare.",184,23,0.125
9781908541963,chapter4,Discontinuation of offending agents usually results in prompt resolution of hepatic injury.,"Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) reduce cardiovascular morbidity and mortality in patients with and without cardiovascular disease. These drugs are so effective that they are in very common use. As a group the statins are very safe, with fewer than 2% of patients enrolled in clinical trials discontinuing the medications for any reason. Nevertheless, elevation of the aminotransferases (greater than three times normal) occurs in approximately 1% of exposed patients. Lesser elevations in the aminotransferases are more common (id est about 3%). The effect appears to be dose-related and usually occurs in the first few months of therapy. Most patients are asymptomatic and have no signs suggestive of liver dysfunction on physical examination. Severe liver injury has been reported but is rare.",184,17,0.09239130434782608
9781908541963,chapter4,"Monitoring for hepatotoxicity may be appropriate for some medications, such as statins and isoniazid.","Isoniazid is a mainstay of treatment for both active and latent tuberculosis. Two types of hepatotoxicity are recognized. The first, and by far most common, is a transient mild elevation in the aminotransferases within a few months of beginning therapy. This occurs in approximately 20% of patients, who remain asymptomatic. Isoniazid should be continued and the patient monitored for symptoms and worsening liver tests. Often the liver test abnormalities will resolve despite continuing isoniazid.",104,23,0.22115384615384615
9781908541963,chapter5,Autoimmune hepatitis (AIH) is potentially treatable if diagnosed before the development of cirrhosis.,"Autoimmune liver diseases. Three liver diseases are categorized as autoimmune in etiology. autoimmune hepatitis (AIH), which targets the hepatocyte. primary biliary cirrhosis (PBC), which affects the microscopic bile ducts. primary sclerosing cholangitis (PSC), which can involve any elements of the intrahepatic and extrahepatic biliary system. AIH and PBC are predominantly autoimmune diseases, but the categorization is less clear-cut with PSC. The classic immunologic profiles associated with these conditions are shown in Table 5.1. Some diagnostic confusion can occur because of the existence of 'overlap syndromes' or histological progression from apparent AIH to either PBC or PSC.",153,21,0.13725490196078433
9781908541963,chapter5,Autoimmune liver disease can target the hepatocyte or any element of the bile duct system.,"AIH and PBC are predominantly autoimmune diseases, but the categorization is less clear-cut with PSC. The classic immunologic profiles associated with these conditions are shown in Table 5.1. Some diagnostic confusion can occur because of the existence of 'overlap syndromes' or histological progression from apparent AIH to either PBC or PSC. Autoimmune hepatitis. AIH is a chronic inflammatory liver disease of at least 6 months' duration. The target cell for the immunologic response is the hepatocyte, and the dominant effector cells are lymphocytes and plasma cells. Two types of AIH are defined by classic autoantibody profiles.",134,19,0.1417910447761194
9781908541963,chapter5,Primary sclerosing cholangitis is strongly associated with ulcerative colitis and is unpredictable; late disease can be managed effectively with liver transplantation unless complicated by cholangiocarcinoma.,"These antibodies are associated with hypergammaglobulinemia, with a dominant elevation in the immunoglobulin (Ig) G fraction in untreated disease. Histological verification and staging of the disease is mandatory. The classic finding on liver histology is portal inflammation, with plasma cells and lymphocytes spilling over into the lobule in a pattern called interface hepatitis (Figure 5.1). Fibrosis or cirrhosis may be established by the time of presentation or may develop during follow-up despite apparently adequate therapy. Clinical features. There is a strong gender association, with 70% of cases occurring in women. The age at presentation has a bimodal distribution, with peaks during the second decade and the fourth and fifth decades. AIH can present as an acute hepatitis-like illness, with jaundice and a laboratory profile showing hyperbilirubinemia and a marked elevation in serum aminotransferases (transaminases). A liver biopsy will show the characteristic features, with or without fibrosis or cirrhosis. Alternatively, patients may present with established cirrhosis in the absence of any previous episode of jaundice or other symptoms alerting to the presence of chronic hepatitis. These patients may present with liver failure or complications of portal hypertension. As with all causes of cirrhosis, there is a risk of hepatocellular carcinoma, but this risk is at the lower end of the spectrum in this condition.",298,43,0.14429530201342283
9781908541963,chapter5,"Primary biliary cirrhosis (PBC) is a slowly progressive disease, with a presymptomatic period of up to 20 years.","PBC is a progressive disease with an asymptomatic phase that may last for 15-20 years. The asymptomatic phase is being increasingly recognized, however, with the detection of increased alkaline phosphatase levels on routine blood tests. The diagnosis is effectively established by the detection of positive antimitochondrial antibodies (AMA), usually of the M2 subtype. The IgM fraction of the serum gammaglobulins is normally raised. The combination of elevated alkaline phosphatase, positive AMA and elevated IgM is now considered diagnostic of PBC; histological verification is no longer necessary. However, a liver biopsy may be of value in staging the severity of the disease.",145,29,0.2
9781908541963,chapter5,Liver transplantation is an excellent treatment for end-stage AIH and PBC.,"Liver transplantation is still the only effective treatment for advanced PBC. The indications for transplantation are liver failure, defined by the Model for End-Stage Liver Disease (MELD) as a disease severity score ranging from 4 to 40, typically above 20; severe and intractable pruritus; and hepatocellular carcinoma The results of liver transplantation for PBC are excellent. There is evidence that PBC recurs in the transplanted liver, but this phenomenon appears to be of little clinical relevance in the first 10-15 years after transplantation.",116,18,0.15517241379310345
9781908541963,chapter6,"Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder, most often seen in obese or diabetic patients.","Non-alcoholic fatty liver disease (NAFLD) is a group of disorders of diverse etiology (Table 6.1) and presents as a spectrum of disease ranging from apparently innocuous deposition of fat in the liver to cirrhosis with liver failure. Once thought to be uncommon and benign, NAFLD is now recognized as one of the most common forms of serious liver disease in Western populations. The growing prevalence of disorders associated with NAFLD (particularly diabetes, obesity and hyperlipidemia) suggests that fatty liver disease will be an important cause of morbidity and even mortality in the future. This discussion focuses on steatosis associated with insulin resistance.",134,27,0.20149253731343283
9781908541963,chapter6,NAFLD is a spectrum of conditions from simple steatosis to cirrhosis with liver failure.,"Non-alcoholic fatty liver disease (NAFLD) is a group of disorders of diverse etiology (Table 6.1) and presents as a spectrum of disease ranging from apparently innocuous deposition of fat in the liver to cirrhosis with liver failure. Once thought to be uncommon and benign, NAFLD is now recognized as one of the most common forms of serious liver disease in Western populations. The growing prevalence of disorders associated with NAFLD (particularly diabetes, obesity and hyperlipidemia) suggests that fatty liver disease will be an important cause of morbidity and even mortality in the future. This discussion focuses on steatosis associated with insulin resistance.",134,21,0.15671641791044777
9781908541963,chapter6,"When associated with obesity, NAFLD is best treated with weight loss.","Treatment. Weight reduction is the mainstay of treatment for NAFLD. Patients should be strongly encouraged to lose weight slowly, as there is some evidence to suggest that rapid weight loss may provoke inflammation and even liver failure. Unfortunately, weight loss is extraordinarily difficult for most patients and success is often not achieved. However, the patient should be encouraged with the knowledge that weight loss is almost always associated with an improvement in liver tests and perhaps liver function (see Fast Facts: Obesity). Careful control of diabetes and hyperlipidemia is recommended, although this may not affect the underlying liver disease (see Fast Facts: Diabetes Mellitus and Fast Facts: Hyperlipidemia).",135,15,0.1111111111111111
9781908541963,chapter6,Hemochromatosis is easily treatable but underdiagnosed.,"Screening for hemochromatosis. Because hemochromatosis is an easily treatable autosomal dominant disorder but has potentially devastating consequences, screening for the disorder is appealing. Early diagnosis allows for reduction of iron overload before injury occurs. Close relatives of patients identified with hemochromatosis should be screened by measuring transferrin saturation and genetic markers.",72,15,0.20833333333333334
9781908541963,chapter6,It is reasonable to screen patients at risk of hemochromatosis by measuring the transferrin saturation in early middle age.,"Screening for hemochromatosis. Because hemochromatosis is an easily treatable autosomal dominant disorder but has potentially devastating consequences, screening for the disorder is appealing. Early diagnosis allows for reduction of iron overload before injury occurs. Close relatives of patients identified with hemochromatosis should be screened by measuring transferrin saturation and genetic markers. There is currently no consensus on screening the general population for hemochromatosis, although it appears logical to screen populations with the highest prevalence of the disease (those of northern European decent). A single measurement of transferrin saturation at 30 years of age in men and 40 years of age in women may be appropriate in these groups.",138,25,0.18115942028985507
9781908541963,chapter7,Hepatitis B and C virus are the most common causes of chronic liver disease and hepatocellular carcinoma worldwide.,Chronic infection with the hepatitis B (HBV) or C (HCV) virus is the most common cause of chronic liver disease worldwide (Table 7.1). There are an estimated 300 million hepatitis B carriers worldwide and the prevalence of hepatitis B ranges from 0.1 to 20%. The prevalence of hepatitis C also varies geographically and ranges from 0.5 to 15%. Hepatitis is considered chronic when the infection is present for more than 6 months. The prevalence of hepatitis B infection varies worldwide; the highest rates are seen in Asia. The risk factors for acquisition of the virus are discussed in Chapter 1 (page 9).,126,26,0.20634920634920634
9781908541963,chapter7,Hepatitis B is preventable with vaccination and is treatable in 40-60% of cases.,"Liver transplantation is indicated for patients developing liver failure and those found to have small HCCs (typically 1-3 nodules with diameters not exceeding 5 cm on radiological evaluation). Liver decompensation associated with active viral replication has the potential to be dramatically reduced with effective suppression of viral replication, and patients apparently in need of liver transplantation can recover and defer the need for transplantation for many years. The overall burden of hepatitis B on transplant resources is therefore decreasing. Passive immunoprophylaxis using hepatitis B immunoglobulin, possibly in combination with an oral agent, is successful in preventing reinfection of the liver in 80% or more cases where the HBV DNA is negative at the time of liver transplantation. In the absence of reinfection, the results of liver transplantation for hepatitis B are comparable to those for other patient subgroups.",177,22,0.12429378531073447
9781908541963,chapter7,Liver transplantation may be required for end-stage chronic liver disease and small hepatocellular carcinoma.,"Liver transplantation is indicated for patients developing liver failure and those found to have small HCCs (typically 1-3 nodules with diameters not exceeding 5 cm on radiological evaluation). Liver decompensation associated with active viral replication has the potential to be dramatically reduced with effective suppression of viral replication, and patients apparently in need of liver transplantation can recover and defer the need for transplantation for many years. The overall burden of hepatitis B on transplant resources is therefore decreasing.",96,23,0.23958333333333334
9781908541963,chapter7,"There is no vaccine for hepatitis C, but it is treatable in up to 85% of cases with interferon-based regimens or the new oral therapy sofosbuvir.","Hepatitis D (delta) virus is an incomplete virus that can exist only in association with hepatitis B infection. It can be acquired with hepatitis B or can be superimposed on established disease. It seems to lead to more aggressive liver disease, even though, paradoxically, it suppresses the replication of HBV. The incidence of hepatitis D appears to be decreasing. Currently, there are no good treatments available other than interferon. Hepatitis C virus is an RNA virus. The recognized means of acquisition involves contact with blood, and the virus was commonly transmitted via blood products before the introduction of screening for hepatitis C in 1990-91. Intravenous drug use was associated with an infection rate of approximately 70%, and tattooing has resulted in infection with hepatitis C in up to 30% of cases. Sexual and vertical transmission are possible but unusual.",176,39,0.2215909090909091
9781908541963,chapter7,"Hepatitis C almost invariably recurred after liver transplantation and was problematic, but the availability of additional therapeutic options is likely to change this.","Liver transplantation. Liver disease associated with hepatitis C is now the most common indication for liver transplantation in most countries. Unlike hepatitis B, the burden of hepatitis C on transplant resources is increasing and is not expected to peak for another 10-15 years. The indications for liver transplantation are the same as for hepatitis B. However, unlike hepatitis B, reinfection of the graft is almost inevitable as no immunoprophylaxis is currently available. Nevertheless, a proportion of patients who are HCV RNA negative at the time of transplantation following antiviral therapy do not develop recurrent infection. Developments in antiviral strategies are expected to be of special benefit to these patients, particularly the significant minority (20-30%) who were at risk of accelerated disease, with cirrhosis developing as early as 3-5 years after transplantation. As a result, the survival rate for hepatitis C was lower than for other indications 8 years and more after liver transplantation. A number of risk factors for accelerated disease have been identified (Table 7.4).",212,30,0.14150943396226415
9781908541963,chapter8,Diagnostic paracentesis is mandatory in any patient with new ascites.,"Diagnostic paracentesis is mandatory for all patients with new ascites (Table 8.2). Fluid obtained during paracentesis should be sent for measurement of albumin levels, cell count, cytology and culture (ascites should be inoculated into blood culture bottles at the bedside for optimal yield). A peripheral albumin level should be determined. The calculation of the serum-ascites albumin gradient (SAAG) has proved useful for distinguishing ascites associated with portal hypertension from other causes, and is 97% accurate. The SAAG is calculated by subtracting the ascites albumin level from the serum albumin level. If the difference is greater than or equal to 1.1 g/dL, the ascites is a consequence of portal hypertension. Amylase and triglyceride levels may be determined to evaluate ascites due to pancreatic disease or lymphatic disruption, respectively.",184,16,0.08695652173913043
9781908541963,chapter8,Salt restriction and diuretics are effective in most patients with ascites. Repeated large-volume paracentesis and transjugular intrahepatic portosystemic shunts may be required for refractory cases.,"Spontaneous bacterial peritonitis should be suspected in a patient with ascites who is not doing well. The clinical findings associated with spontaneous bacterial peritonitis may be subtle: fever and abdominal pain or tenderness are not common. Vague changes in mental status, electrolyte abnormalities or renal insufficiency may be the only signs and should prompt a diagnostic paracentesis. An ascitic neutrophil count above 250 cells/mm suggests infection and mandates immediate antibiotic treatment, before cultures are available. A third-generation cephalosporin or ampicillin/sulbactam offers good empiric coverage for typical organisms. Hepatorenal syndrome. Hepatorenal syndrome is a feared complication of cirrhosis, sometimes seen in patients with advanced liver disease and ascites. The kidney responds exuberantly to a relatively low intravascular volume by intense renovascular constriction. Oliguria and azotemia develop. Clinically, the situation appears similar to pre-renal azotemia. Intravenous fluids should be administered to rule out this condition. Midodrine, octreotide and intravenous volume support with albumin may help. Unfortunately, the prognosis is poor but liver transplant may be an option.",257,46,0.17898832684824903
9781908541963,chapter8,"Patients with cirrhosis should be screened for varices. If these are present, prophylactic treatment with beta-blockers is recommended.","Primary prevention. Patients with cirrhosis should be screened for varices by endoscopy. If varices of significant size are identified, prophylactic treatment should be started (Table 8.4). The mainstays of prophylactic treatment are non-selective beta-blockers: propranolol (starting dose 20 mg twice daily) or nadolol (40 mg daily) reduce the incidence of bleeding for patients with medium or large esophageal varices. The dosages are increased until the patient's heart rate is 50-60 beats per minute. Endoscopic band ligation may benefit patients who cannot tolerate beta-blockers. Additional research is required before prophylaxis with nitrates can be recommended, and sclerotherapy is not recommended.",161,31,0.19254658385093168
9781908541963,chapter8,"Acute variceal bleeding is best treated with endoscopic techniques; however, pharmacotherapy also has a limited role.","Pharmacological control. Much attention has been devoted to the use of pharmacological agents for the control of acute variceal bleeding. Somatostatin and terlipressin control bleeding in approximately 75% of patients, but neither drug is available in the USA. Octreotide, a long-acting analog of somatostatin with few side effects, has become the agent of choice in the USA, although available evidence regarding efficacy is controversial. The role of octreotide is undefined and it is best regarded as an adjunct to endoscopic techniques.",112,24,0.21428571428571427
9781908541963,chapter8,"Hepatic encephalopathy is a diagnosis of exclusion. Lactulose, rifaximin and correction of precipitating factors are the mainstays of treatment.","The mainstay of treatment is the non-absorbable disaccharide lactulose. Lactulose induces catharsis and acidifies the bowel lumen, resulting in the reduction of absorbable neurotoxins (ammonia). Oral lactulose, 15-30 mL one to three times a day, is given to stable patients to produce two or three soft bowel movements per day. Profuse diarrhea may contribute to renal insufficiency and should be avoided. Patients who are acutely encephalopathic often benefit from aggressive dosing until they have bowel movements. Tap-water enemas containing lactulose are used for patients unable to take oral lactulose. Rifaximin, a non-absorbed oral antibiotic, is effective in controlling hepatic encephalopathy in cirrhotic patients and is usually added at a dose of 550 mg twice daily to therapy with lactulose. A recent multicenter study has indicated that long-term treatment with rifaximin reduces the recurrence of overt hepatic encephalopathy and the rate of hospitalization without any increase in adverse events. In addition, audits in the UK demonstrated significant cost impact by the reduction of hospital admissions and length of stay.",248,35,0.14112903225806453
9781908541963,chapter9,Benign liver lesions are relatively common.,"The use of ultrasonography in the investigation of abdominal symptoms and abnormal liver function tests has greatly increased the detection of benign liver lesions (Table 9.1), although the lesions identified are often not relevant to the issue under investigation. Because the detection of focal lesions in the liver can precipitate considerable anxiety until they are characterized as benign, appropriate investigations are warranted and occasionally therapeutic intervention is indicated.",78,8,0.10256410256410256
9781908541963,chapter9,Most lesions identified are unrelated to the symptoms under investigation.,"The use of ultrasonography in the investigation of abdominal symptoms and abnormal liver function tests has greatly increased the detection of benign liver lesions (Table 9.1), although the lesions identified are often not relevant to the issue under investigation. Because the detection of focal lesions in the liver can precipitate considerable anxiety until they are characterized as benign, appropriate investigations are warranted and occasionally therapeutic intervention is indicated.",78,11,0.14102564102564102
9781908541963,chapter9,Hemangiomas and focal nodular hyperplasia are managed conservatively.,"Focal nodular hyperplasia is the most frequent of the benign solid liver tumors and is most commonly encountered in women during their reproductive years. There is a weak association with exposure to the oral contraceptive pill. The typical lesion is solitary, measures 3-5 cm in diameter and has a characteristic central scar that may be visualized on scanning. About 15% of patients report vague abdominal pain and the remainder are asymptomatic. Unlike adenomas, there is no risk of rupture or malignant transformation and these lesions do not need specific therapy.",112,17,0.15178571428571427
9781908541963,chapter9,Adenomas are closely linked to hormone therapy and require surveillance and occasionally surgical resection.,"Adenomas are rare - about 300 are diagnosed annually in the USA - but are the most clinically relevant of the benign tumors. The development of adenoma is closely linked to use of the oral contraceptive pill in women and androgen therapy in men. Regression after cessation of exposure to the hormonal stimulus may occur but is not consistent. Unlike focal nodular hyperplasia, these lesions have the potential to grow, hemorrhage and rupture. The last two complications may present with severe abdominal pain. Pregnancy increases the risk of rupture, so regular ultrasound surveillance is recommended.",115,18,0.1565217391304348
9781908541963,chapter10,Hepatocellular carcinoma is a worrisome complication of advanced liver disease.,"Hepatocellular carcinoma (hepatoma, HCC) is a malignancy of hepatocytes. HCC is a common cause of mortality in the developing world. Although currently less common in the developed world, the incidence is expected to rise as patients with cirrhosis due to chronic hepatitis C age. Marked geographic variation in incidence is largely due to variation in the risk factors that predispose an individual to the tumor (Table 10.1). Most cases of HCC occur in liver that is already cirrhotic. Thus, patients with advanced viral hepatitis, hemochromatosis or alcoholic liver disease are at risk. Hepatitis B presents a unique risk, as there is evidence that a tumor may develop in the absence of cirrhosis - presumably via direct integration of viral DNA into the host genome.",168,16,0.09523809523809523
9781908541963,chapter10,Hepatocellular carcinoma should be suspected in patients with an unexpected worsening of liver disease.,"Hepatocellular carcinoma (hepatoma, HCC) is a malignancy of hepatocytes. HCC is a common cause of mortality in the developing world. Although currently less common in the developed world, the incidence is expected to rise as patients with cirrhosis due to chronic hepatitis C age. Marked geographic variation in incidence is largely due to variation in the risk factors that predispose an individual to the tumor (Table 10.1). Most cases of HCC occur in liver that is already cirrhotic. Thus, patients with advanced viral hepatitis, hemochromatosis or alcoholic liver disease are at risk. Hepatitis B presents a unique risk, as there is evidence that a tumor may develop in the absence of cirrhosis - presumably via direct integration of viral DNA into the host genome.",168,20,0.11904761904761904
9781908541963,chapter10,"Screening for hepatocellular carcinoma is of unclear utility, but is widely practiced. Regular checking of serum alpha fetoprotein levels and hepatic ultrasound scanning areacceptable.","Hepatocellular carcinoma (hepatoma, HCC) is a malignancy of hepatocytes. HCC is a common cause of mortality in the developing world. Although currently less common in the developed world, the incidence is expected to rise as patients with cirrhosis due to chronic hepatitis C age. Marked geographic variation in incidence is largely due to variation in the risk factors that predispose an individual to the tumor (Table 10.1). Most cases of HCC occur in liver that is already cirrhotic. Thus, patients with advanced viral hepatitis, hemochromatosis or alcoholic liver disease are at risk. Hepatitis B presents a unique risk, as there is evidence that a tumor may develop in the absence of cirrhosis - presumably via direct integration of viral DNA into the host genome.",168,37,0.22023809523809523
9781908541963,chapter10,"Radiofrequency ablation, percutaneous ethanol injection, transarterial chemoembolization and systemic chemotherapy are all treatment options.","Alpha fetoprotein. Immature (fetal) liver cells synthesize alpha fetoprotein (AFP). Malignant hepatocytes resemble immature hepatocytes, and AFP is an important marker for HCC. A sudden rise in serum AFP or absolute levels greater than 500 ng/mL are highly suggestive of HCC. Lower levels can be seen with any liver disease that provokes hepatocyte regeneration (ongoing hepatitis, cirrhosis). AFP is also produced during pregnancy and by some germ-cell tumors. Unfortunately, not all HCCs produce AFP; 30-40% of patients with HCC have normal AFP levels, which considerably limits the usefulness of AFP for screening.",135,27,0.2
9781908541963,chapter10,Hepatocellular carcinoma often has few specific symptoms orsigns.,"Available data do not strongly support the efficacy of screening for HCC. Nevertheless, because there are few symptoms or objective signs of the tumor before it progresses to an incurable stage, and because screening is associated with few risks, many practitioners offer screening to their patients. Patients with established cirrhosis, particularly from viral hepatitis or hemochromatosis, are at the highest risk for HCC. It is therefore reasonable that these candidates be screened, typically with an ultrasound scan and AFP measurement every 6 months. An algorithm for investigating a liver nodule found on hepatic ultrasound is shown in Figure 10.1.",123,17,0.13821138211382114
9781908541963,chapter10,"Curative treatment by resection or transplantation is an option, but not always possible.","Surgery. If tumors are small, there is no evidence of extrahepatic spread and the patient has preserved liver function, surgical resection may be considered. Unfortunately, however, few patients with HCC have resectable tumors or sufficient hepatic reserve to tolerate a partial hepatectomy, and approximately 50% of tumors will have recurred at 5 years. Liver transplantation may be an option for some patients, provided there is no evidence of extrahepatic spread and the patient is an otherwise good candidate for transplantation (see Chapter 12). The prognosis is best for patients with either a single small tumor (less than 5 cm) or no more than three lesions, each smaller than 3 cm.",145,18,0.12413793103448276
9781908541963,chapter11,Pregnancy is surprisingly well tolerated by women with chronic liver disease.,"management of established chronic liver disease during pregnancy. coincidental acute liver disease. Physiological changes. Pregnancy produces cutaneous signs associated with chronic liver disease, including palmar erythema and spider nevi. The majority of the laboratory parameters of liver function remain normal, but.",58,13,0.22413793103448276
9781908541963,chapter11,Cholestasis of pregnancy is a recurrent disorder which is associated with increased fetal mortality.,Cholestasis of pregnancy complicates up to 1% of pregnancies and accounts for 20% of cases of jaundice during pregnancy. It typically presents with itch in the second and third trimesters. Jaundice subsequently develops in association with pale stools and dark urine. The liver function profile shows a marked increase in serum alkaline phosphatase and possibly hyperbilirubinemia. A vitamin-K-responsive coagulopathy may be a manifestation of decreased absorption of fat-soluble vitamins. Management involves control of the pruritus with colestyramine (cholestyramine) or ursodeoxycholic acid. Cholestasis is likely to recur in subsequent pregnancies and with subsequent use of the oral contraceptive pill.,156,18,0.11538461538461539
9781908541963,chapter11,"Three classic syndromes of liver dysfunction are associated with late pregnancy: acute fatty liver, hypertension/eclampsia-related dysfunction and HELLP syndrome, but considerable overlap exists between them.","Hypertension and eclampsia. Hypertension is a key element of pre-eclampsia and eclampsia, with additional features including proteinuria, edema and seizures. The frequency and severity of liver dysfunction increase with the severity of the syndrome. The dominant abnormality is in the serum aminotransferases, which may be very high and in the range associated with acute hepatitis. The mechanism of injury is fibrinoid necrosis; in severe cases, focal areas of ischemia are identified on biopsy and radiological assessment. Acute liver failure, hepatic infarction and rupture are all recognized complications. Renal failure and thrombocytopenia are other common features of severe disease. Management involves control of the hypertension and early termination of the pregnancy. Emergency liver transplantation may be indicated.",174,39,0.22413793103448276
9781908541963,chapter12,"Thorough assessment is mandatory and must cover physiological, social and psychiatric comorbidity.","Liver transplantation may be a viable option for patients with advanced liver disease of almost any etiology. In the USA, the most common indications for transplantation resulting from chronic liver disease are viral hepatitis and alcoholic liver disease (ALD) (Table 12.1). Severe liver disease that has resulted from acute disorders may also require liver transplantation (Table 12.2). It is important to select candidates who can tolerate the significant physiological, emotional and social stressors that often accompany liver transplantation. An extensive pretransplant evaluation is required to assess the patient's physiological, social and psychiatric reserves (Table 12.3). Accepted contraindications are listed in Table 12.4.",139,18,0.12949640287769784
9781908541963,chapter12,Limitations to lifestyle after transplantation are remarkably few.,"It is important to select candidates who can tolerate the significant physiological, emotional and social stressors that often accompany liver transplantation. An extensive pretransplant evaluation is required to assess the patient's physiological, social and psychiatric reserves (Table 12.3). Accepted contraindications are listed in Table 12.4.",64,11,0.171875
9781908541963,chapter12,Liver transplantation is effective for a wide range of liver diseases.,"With regard to chronic liver disease, it is best to select patients for liver transplant whose survival would otherwise be dramatically limited. It must be noted, however, that advanced liver disease itself causes systemic changes that may limit the success of liver transplantation. Thus, the clinician must select patients who are most in need of liver transplant, and are likely to survive the procedure. The Child's score (Table 12.6) predicts survival for patients with advanced cirrhosis. Patients with a score greater than 7 are likely to benefit from consultation at a liver transplant center. The model for end-stage liver disease (MELD) score predicts survival of patients with cirrhosis using serum bilirubin and creatinine levels and the international normalized ratio (INR). (Calculators are available on the internet, for example at www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/meld-model-unos-modification). In interpreting the MELD score in hospitalized patients, the 3-month mortality is.",223,14,0.06278026905829596
9781908541963,chapter12,"Careful attention to the complications of immunosuppression is of great importance; possible opportunistic infections, drug interactions and side effects can occur.","Diarrhea is another frequent problem and is usually the result of drug toxicity or common infections. The latter are generally well tolerated, and management is as standard for immunocompetent individuals. However, diarrhea may also be the presentation of an opportunistic infection. Clostridium difficile is common in the early post-transplant period when exposure to broad-spectrum antibiotics is high. Reactivation of the infection can occur in the community, and a stool sample should be screened in patients known to have had previous infection. Cytomegalovirus can cause gastroenteritis, and this should be considered in patients with high fevers, abdominal pain or rectal bleeding.",139,29,0.20863309352517986
9781908541963,chapter12,"Many diseases recur after transplantation, but with variable consequences.","Disease recurrence. Many liver diseases have the potential to recur after liver transplantation (Table 12.9). The liver transplant center will normally screen for recurrent disease, but some diseases may first become apparent to the primary care physician (exempli gratia ALD), whereas others may be co-managed in the community (exempli gratia hepatitis C).",76,13,0.17105263157894737
9781908541994,ch01,Acne (acne vulgaris) typically occurs around adolescence.,"Acne (acne vulgaris) can affect all age groups, including neonates, infants, prepubescent children, adolescents and mature adults. However, the disease is most prevalent and most severe in adolescents; it is present to some degree in 85% of all teenagers. Once regarded as a transient disease of puberty, acne now starts earlier and lasts longer (Figure 1.1). The earlier onset of acne mirrors an earlier average age of puberty, but the reasons for persistent acne are not clear.",101,13,0.12871287128712872
9781908541994,ch01,"Acne can present in the neonate, and may persist beyond adolescence in susceptible individuals.","Pre-adolescent acne. Acne before the onset of puberty is not common. Descriptive terms used for acne in pre-adolescent children are generally based on age; a recent classification of acne in children based on expert consensus included five subtypes according to age: neonatal, infantile, mid-childhood, pre-adolescent and adolescent. However, the distinction between pre-adolescence and adolescence by age can be challenging, so the term prepubertal acne is frequently used. In addition, defining acne by age does not necessarily identify children that are at risk of treatable forms of virilization. A focused history and examination should be adopted to ensure underlying hormonal abnormalities and adrenal or gonadal tumors are identified.",151,18,0.11920529801324503
9781908541994,ch01,Midfacial comedones in prepubertal acne correlate with relatively worse prognosis.,"Pre-adolescent acne. Acne before the onset of puberty is not common. Descriptive terms used for acne in pre-adolescent children are generally based on age; a recent classification of acne in children based on expert consensus included five subtypes according to age: neonatal, infantile, mid-childhood, pre-adolescent and adolescent. However, the distinction between pre-adolescence and adolescence by age can be challenging, so the term prepubertal acne is frequently used. In addition, defining acne by age does not necessarily identify children that are at risk of treatable forms of virilization. A focused history and examination should be adopted to ensure underlying hormonal abnormalities and adrenal or gonadal tumors are identified.",151,18,0.11920529801324503
9781908541994,ch01,Patients with infantile acne may experience resurgence at puberty.,"A history of a sibling with infantile acne may be notable, and a family history of severe acne is not uncommon. Patients with infantile acne may develop a resurgence of their acne as teenagers, and parents should be advised accordingly. The central cheeks are frequently affected, and lesions embrace a combination of inflamed papules/pustules with open and closed comedones. The presentation is usually more widespread than neonatal acne.",85,12,0.1411764705882353
9781908541994,ch01,"There may be a link between geographic location and the prevalence of acne, with lower prevalence of acne in rural compared with urban populations.","Acne occurs earlier in females than males, reaching peak severity in females at about 17 years, compared with 19 or 20 years in males. In a randomized sample of 2491 students (aged 4-18 years) from schools in Victoria, Australia, acne was found to be less prevalent among boys aged 10-12 years than girls of the same age (14.9% vs 40.7%), but by 16-18 years the prevalence was similar in both sexes (97.8% boys vs 89.8% girls). Moderate to severe acne was present in 24% of boys and 11% of girls. Adult female acne is seen more commonly in dermatology clinics than adult male acne. Although acne is a universal condition, studies suggest a link between geographic environment and prevalence, with an intrinsically lower prevalence in people living in rural locations than those living in urban environments. Acne in patients over 40 years of age may be a product of modern urban lifestyles. Further investigation is required to confirm this.",200,26,0.13
9781908541994,ch02,Acne is a hormonally mediated disease.,"Increased sebum production. Acne is a hormonally mediated disease, with androgens contributing to an increase in sebum production from sebaceous glands. Increased sebum production, which presents as seborrhea, correlates well with acne severity.",51,10,0.19607843137254902
9781908541994,ch02,Four main factors are implicated in the etiology of acne:- high sebum production- hyperkeratinization of the intrafollicular duct- colonization by Propionibacterium acnes- inflammation.,"Inflammation. Inflammatory lesions are thought to develop from comedones following the influx of inflammatory cells and/or rupture of the follicular wall. Recent studies have demonstrated the involvement of inflammatory responses even in the very earliest phases of acne lesion development. Inflammatory mediators stimulate vasodilatation and neutrophil chemotaxis into the pores, which may result in papules and pustules. Papules and pustules may evolve into tender inflammatory nodules or 'cysts' as the extent of the inflammation increases. Inflammatory acne may produce scarring. Atrophic scars (Figures 2.2 and 2.3) are caused by a loss of tissue, while hypertrophic or fibrotic scars (Figure 2.4) are due to an increase in tissue.",164,41,0.25
9781908541994,ch02,"There are many myths about the factors that influence acne; patients should be made aware of the appropriate facts (see Table 8.1, pages 83-4 ).","Myths still remain about factors that might influence the disease and the appropriate facts should be shared with the patient. For example, acne is frequently worse before the menstrual period. Stress may worsen acne; in turn, acne certainly and frequently causes more stress. The role of diet in acne is controversial. Factors that have been implicated include 'glycemic load', the intake of dairy products, skim milk, chocolate and whey, obesity, reduced intake of fish, lack of omega-3 fatty acids and others. Epidemiological studies suggest a possible link with intake of skim milk, while clinical trials in very small numbers of patients suggest that a diet with a low glycemic index may be beneficial in patients with acne, as summarized in recent systematic reviews on this topic.",151,32,0.2119205298013245
9781908541994,ch03,"Diagnosis is based on an accurate history, evaluation of clinical features, assessment of severity and recognition of psychological or social issues. Further investigations are rarely required.","The diagnosis of acne involves taking a history and physical examination to determine the type of acne (see clinical features of the different types of acne below), an assessment of severity (see page 38), and an assessment of psychosocial effect (see Chapter 4). Other investigations are not normally necessary; however, occasionally an underlying endocrinological disorder may necessitate further tests (see Adult female acne, pages 26-9). Table 3.1 outlines the key elements in developing an accurate acne history. Acne vulgaris. Acne vulgaris is the most common type of acne. The individual lesions of acne vulgaris (Figure 3.1) can be characterized as.",133,32,0.24060150375939848
9781908541994,ch03,Postinflammatory hyperpigmentation may persist for many months in type IV-VI skins following the resolution of acne.,"Postinflammatory erythema and/or pigmentary changes. In some patients, particularly those with skin of color and Fitzpatrick skin types IV-VI, hyper- (Figure 3.7) or hypopigmented macules may persist following resolution of inflammatory acne lesions. Patients may think that these resolving lesions are active acne lesions and may have the erroneous impression that their acne is not improving. It is important to reassure patients that these dark areas are healing lesions and not active acne.",97,23,0.23711340206185566
9781908541994,ch03,"Drugs, industrial agents and friction may all contribute to acne.","Postinflammatory erythema and/or pigmentary changes. In some patients, particularly those with skin of color and Fitzpatrick skin types IV-VI, hyper- (Figure 3.7) or hypopigmented macules may persist following resolution of inflammatory acne lesions. Patients may think that these resolving lesions are active acne lesions and may have the erroneous impression that their acne is not improving. It is important to reassure patients that these dark areas are healing lesions and not active acne.",97,13,0.13402061855670103
9781908541994,ch03,Acne presents with both inflammatory and comedonal lesions in most patients.,"Acne conglobata is a very severe form of inflammatory acne characterized by grouped comedones, cysts, abscesses, draining sinus tracts and scars (Figure 3.8). The majority of affected patients are males who present with lesions on the back, buttocks, chest and face. The axilla and inguinal areas can also be involved. The grouped comedones often have multiple openings. The inflammatory lesions are large, tender and red to violaceous in color; they often drain a serous or purulent material. Deep-seated sinus tracts often develop, as does keloidal scarring. Secondary infection with staphylococci or streptococci can occur, although many lesions are colonized by Propionibacterium acnes (P. acnes) only.",164,14,0.08536585365853659
9781908541994,ch03,Acne scarring is a very common sequel to acne.,"Acne fulminans is a very severe form of inflammatory acne associated with systemic signs and symptoms, including fever, arthralgias and/or osteolytic lesions of the clavicles or ribs. It usually occurs in boys aged 13-18 years and can be very acute in its onset. Investigations frequently demonstrate leukocytosis, elevated erythrocyte sedimentation rate and/or proteinuria. Clinically, acne fulminans is characterized by multiple intensely inflamed nodules, cysts and plaques (Figure 3.9). Large nodules can ulcerate, drain and become necrotic. Hemorrhagic crusting is common. A polyarthritis of large joints such as the sacroiliac, hips, knees, shoulders, elbows and ankles may be present. The etiology of acne fulminans is unknown.",177,12,0.06779661016949153
9781908541994,ch03,Late-onset acne in females may relate to hyperandrogenism. Further investigations should be carried out to determine if there is an underlying endocrinological problem.,"Hyperandrogenism. If an adult woman has sudden-onset severe acne, acne accompanied by signs of hyperandrogenism or acne that is refractory to conventional therapy, a medical history and physical examination directed towards eliciting symptoms or signs of hyperandrogenism should be performed. Investigations to rule out an underlying endocrine abnormality should also be carried out in these cases (Table 3.3); note, however, that most cases of adult female acne do not require an endocrine work-up. Screening tests for hyperandrogenism include serum dehydroepiandrosterone sulfate (DHEAS), total testosterone, free testosterone, and luteinizing hormone and follicle-stimulating hormone. These tests should be obtained in the luteal phase of the menstrual cycle. Women should be advised not to take oral contraceptives for at least 1 month before laboratory testing, as these drugs can mask an underlying endocrine abnormality.",194,33,0.17010309278350516
9781908541994,ch03,"Differential diagnoses of acne include drug-induced acneiform eruptions, rosacea, pyoderma faciale, gram-negative folliculitis and perioral dermatitis.","The differential diagnosis of acne includes drug-induced acneiform eruptions, rosacea, pyoderma faciale, gram-negative folliculitis and perioral dermatitis. Drug-induced acne. A number of drugs cause or worsen acne or can induce an acneiform eruption (Table 3.5). The latter account for about 1% of all drug-induced skin eruptions. A diagnosis of acne vulgaris is defined by the presence of closed comedones, papules and pustules. In contrast, most drug-induced 'acnes' represent acne-like eruptions embracing monomorphic inflammatory lesions in the absence of comedones, often presenting abruptly outside the most frequent age range for acne and extending over areas not commonly affected by acne. The face and upper trunk are most frequently affected.",163,38,0.2331288343558282
9781908541994,ch03,"Acne severity can be determined according to the type, number, distribution or location of lesions, or a combination of each of these. There are many scales available for this, but no gold standard at present.","Perioral (periorificial) dermatitis (Figure 3.17) is characterized by erythema, scaling and small papules and pustules, most commonly around the mouth and on the chin. It often occurs in adult women, especially in the context of stress. Topical corticosteroids can cause or exacerbate the condition and should be avoided. Oral tetracycline is the treatment of choice. Assessing acne severity. Defining acne severity helps with the selection of the most suitable initial therapy and enables response to treatment to be monitored. There are many scales available for assessing the severity of acne, but no consensus on a gold standard. Severity can be determined according to the type, number, distribution or location of lesions, or a combination of each of these. Acne can be classified as comedonal, mild, moderate or severe based on the type of lesions (Table 3.6). Alternatively, an assessment tool such as the Leeds Revised Acne Grading System allows grading of severity based on photographic comparisons of acne on the face (Figure 3.18), back and chest.",225,42,0.18666666666666668
9781908541994,ch04,"Psychological changes should be noted, assessed and taken into account when managing acne.","Acne often occurs at an age when an individual is experiencing significant psychological and social changes. It is therefore not surprising that acne often leads to loss of self-esteem, anxiety, problems mixing with peers and, at times, significant depression. It is common for acne to produce a loss of motivation in carrying out day-to-day activities such as shopping, socializing and going away for a weekend or holiday. Television commercials and the media may exacerbate this, as a cosmetically acceptable appearance is often portrayed as being inherently linked to social success.",110,16,0.14545454545454545
9781908541994,ch04,Perception studies have identified that people with acne and/or scarring are perceived more negatively.,"Acne often occurs at an age when an individual is experiencing significant psychological and social changes. It is therefore not surprising that acne often leads to loss of self-esteem, anxiety, problems mixing with peers and, at times, significant depression. It is common for acne to produce a loss of motivation in carrying out day-to-day activities such as shopping, socializing and going away for a weekend or holiday. Television commercials and the media may exacerbate this, as a cosmetically acceptable appearance is often portrayed as being inherently linked to social success. Patients with acne also have greater employment difficulties than the general population; in one survey, 22% of respondents believed that they had been turned down for a job because of their skin. Studies assessing independent reactions to photographs of patients with acne and acne scarring, versus no acne or acne scarring, have identified that people with acne and scars are perceived more negatively.",183,19,0.10382513661202186
9781908541994,ch04,Acne may be associated with anorexia nervosa.,"In some studies of patients with severe acne, the levels of social, psychological and emotional problems were as great as those reported by patients with conditions such as chronic disabling asthma, epilepsy, diabetes, back pain or arthritis. Acne may also be a predisposing factor for anorexia; vulnerable teenagers may adopt an extreme diet in an attempt to control their acne. Depression and suicidal ideation have been studied in patients with a variety of skin conditions, including acne. The incidence of suicidal ideation found in 72 patients with mild-to-moderate acne was 5.6%; the incidence among general medical patients is 2.4-3.3%.",129,12,0.09302325581395349
9781908541994,ch04,Validated and recognized questionnaires are available to assess the psychological disability caused by acne.,Assessing psychosocial effect. Several simple generic and dermatology-specific questionnaires are available to better understand the psychosocial effect of acne on the patient's life and wellbeing. Quality of life (QoL) measures help to identify patients vulnerable to psychological complications by capturing the complete effect of acne and treatment on the patient's life. Adopting a QoL measure as an integral part of acne management is recommended.,87,17,0.19540229885057472
9781908541994,ch04,Acne and scarring can cause significant psychosocial disability.,"Acne scarring (see pages 22-3) can cause significant disfigurement and correlates with psychological problems; it is also very difficult to treat. The identification of scarring is an important part of initial assessment. When scarring is evident, early and effective therapy must be implemented to minimize further scarring; this requires urgent specialist attention.",69,13,0.18840579710144928
9781908541994,ch04,A small number of patients with body dysmorphic disorder have acne as their prime dysmorphic symptom. The acne in these patients is usually mild or non-existent and the patient's complaint does not correlate with the physical signs.,"Body dysmorphic disorder. A small number of patients with body dysmorphic disorder (BDD) have acne as their prime dysmorphic symptom. The acne is usually mild or non-existent and the patient's complaint does not correlate with the physical signs. These patients are often depressed or have obsessive compulsive disorder (OCD) behaviors, anxiety and depression. A significant risk of suicide in these patients has been reported. Treatment. Patients with BDD require significant support and expert dermatological and psychiatric management, as many have global mental disorders. Patients for whom BDD is the only behavioral symptom may gain relief by treating their mild acne aggressively. Isotretinoin has been given in this context but relapse, either real or perceived, is common and requests for further isotretinoin are frequent. Acne excorie is a self-inflicted skin condition in which the affected individual compulsively picks real or imagined acne lesions, predominantly on the face (Figure 4.2). The disorder can develop into dermatitis artefacta. Acne excorie is predominantly seen in adolescent girls and young women, although the incidence also appears to be increasing in mature females who have apparent late-onset acne. It is frequently seen in the context of anxiety and stress. A personality or psychological problem, such as OCD or body-focused anxiety, frequently underlies the condition.",279,46,0.16487455197132617
9781908541994,ch04,"Acne excorie may be alleviated by psychotropic drug treatments, psychological therapy, hypnosis or habit reversal therapy.","Some patients with acne excorie may just need to break the habit of picking, whilst others may have a compulsive skin picking disorder that requires psychological therapy or psychotropic drug treatments. In those with virtually no acne spots, trifluoperazine hydrochloride, 5-30 mg/day; pimozide, 2 mg twice a day; and olanzapine, 2.5-5 mg/day, have all been used with some success in conjunction with psychotherapeutic support. Doxepin and selective serotonin-reuptake inhibitors (SSRIs) such as fluoxetine and sertraline have also been reported as helpful. Hypnosis and habit reversal techniques may also be effective treatment options.",151,25,0.16556291390728478
9781908541994,ch05,Topical therapy is a key component of nearly all acne regimens.,"Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical antibiotics.",100,14,0.14
9781908541994,ch05,Topical antibiotics can lead to the development of antimicrobial resistance.,"The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product to enhance adherence.",61,13,0.21311475409836064
9781908541994,ch05,Topical antibiotics should not be used as single agents for the treatment of acne.,"The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains.",171,16,0.0935672514619883
9781908541994,ch05,Topical retinoids are useful as first-line agents.,"The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product to enhance adherence.",61,13,0.21311475409836064
9781908541994,ch05,"Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent the development of antibiotic-resistant strains of P. acnes.","Sodium sulfacetamide is a sulfonamide, which is thought to inhibit the growth of P. acnes through competitive antagonism of para-aminobenzoic acid, an essential requirement for bacterial growth. Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or without tint. Topical tetracycline is available in Italy, but not the UK or USA. Antibiotic resistance. Since the 1970s, P. acnes has developed resistance to both topical and oral antibiotics. It is important to bear this in mind when prescribing antibiotics. P. acnes resistance has been shown to affect clinical outcomes of acne treatment. In addition, overuse of antibiotics can drive resistance in other commensal bacteria. For these reasons, the use of topical antibiotics as single agents for acne is to be discouraged. Topical retinoids and BPO are useful as first-line agents. Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO.",222,46,0.2072072072072072
9781908541994,ch05,Combining therapies or using fixed combination topical products improves efficacy by targeting more than one pathogenic feature and enhancing treatment adherence.,"Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the disease and may also increase treatment adherence among patients. Combination products that include BPO offer excellent bactericidal effects and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes (see pages 51 and). A fixed combination of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics. Other combinations include topical tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in the USA).",168,24,0.14285714285714285
9781908541994,ch05,Topical therapy should be selected to help achieve medical adherence. Realistic expectations of therapy should be explained.,"Moisturizers. Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment. Thus, recommendations regarding effective ways of managing facial dryness should be an integral part of any acne treatment plan. Regular use of moisturizers is especially important, but the clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne. These patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and are labeled 'non-comedogenic'. Studies show that moisturizers applied before or after topical retinoids do not alter efficacy.",137,21,0.15328467153284672
9781908541994,ch06,Systemic antibiotics remain useful therapy for inflammatory acne.,"While topical treatment may be perfectly adequate for mild localized acne, more inflamed moderate-to-severe acne often requires systemic treatment. In addition, applying topical therapy to the back or to large areas is often impractical. Effective systemic therapies for moderate-to-severe types of acne include antibiotics, hormonal therapies for women and isotretinoin.",68,10,0.14705882352941177
9781908541994,ch06,Oral isotretinoin is teratogenic; careful monitoring is mandatory.,"Lymecycline breaks down into tetracycline, lysine and formaldehyde in the gastrointestinal tract. It is indicated for moderate and moderate-to-severe acne. The advised dosage is 300-600 mg daily for 12 weeks. Studies have demonstrated that lymecycline is as effective as oral minocycline and has a lower side-effect profile. The concurrent use of lymecycline with the fixed topical combination of adapalene and BPO is beneficial in patients with moderate-to-severe acne vulgaris. The incidence of P. acnes resistance to lymecycline mirrors that of tetracycline, which is low but can occur in up to 1 in 5 cases depending on the country.",159,16,0.10062893081761007
9781908541994,ch06,"Antibiotic-resistant Propionibacterium acnes is an emerging problem, and prescribing should take this important factor into account.","Minocycline is an effective treatment for moderate and moderate-to-severe inflammatory acne, and is often effective in cases of acne that have not responded to treatment with other oral antibiotics. However, based on concerns about its safety compared with other tetracyclines, a recent Cochrane review found no reliable evidence to consider minocycline as a first-line oral antibiotic therapy in patients with acne. While there is still no evidence of superiority of minocycline to other commonly used therapies, there are fewer reports of P. acnes resistance to minocycline than with tetracycline and doxycycline. However, this may be changing and a reduced response to minocycline should be suspected in patients from whom isolates are tetracycline resistant, because minocycline minimum inhibitory concentrations are raised for such isolates.",178,27,0.15168539325842698
9781908541994,ch06,Antiandrogen hormonal therapy may be helpful in female patients.,"Minocycline is an effective treatment for moderate and moderate-to-severe inflammatory acne, and is often effective in cases of acne that have not responded to treatment with other oral antibiotics. However, based on concerns about its safety compared with other tetracyclines, a recent Cochrane review found no reliable evidence to consider minocycline as a first-line oral antibiotic therapy in patients with acne. While there is still no evidence of superiority of minocycline to other commonly used therapies, there are fewer reports of P. acnes resistance to minocycline than with tetracycline and doxycycline. However, this may be changing and a reduced response to minocycline should be suspected in patients from whom isolates are tetracycline resistant, because minocycline minimum inhibitory concentrations are raised for such isolates.",178,12,0.06741573033707865
9781908541994,ch06,Oral isotretinoin should be considered in patients with severe scarring acne and those who have relapsed or are not responding to conventional therapy.,"Hormonal therapy can be very effective in women with acne, whether or not their serum androgens are abnormal; although women with acne may have higher serum androgens than those without acne, these levels are often still within the normal range. Patients with acne have more sebocytes and keratinocytes of the pilosebaceous follicles than individuals without acne, and these cells have more sensitive androgen receptors. In addition, patients with acne have the enzymatic machinery required to produce testosterone locally via acetate and cholesterol. The objectives of hormonal therapy are to decrease androgen production by the ovaries and adrenal and pituitary glands, and to inhibit the activity of androgen nuclear receptors on sebocytes and keratinocytes. The most commonly administered hormonal treatments for patients with acne are.",160,30,0.1875
9781908541994,ch06,"Mood changes, depression and suicidal ideation have been described in patients taking isotretinoin, but the drug has not been shown to be the cause; nevertheless, patients should be informed of the possibility.","Contraindications. Spironolactone is contraindicated in pregnancy because of the potential for feminization of the male fetus in the third trimester. Increased potassium levels may occur in up to 15% of cases but they do not generally reach clinical relevance. Patients taking this drug are usually young and healthy and do not tend to experience hyperkalemia, so monitoring is not indicated. However, if patients are also receiving, for example, an angiotensin-converting enzyme (ACE) inhibitor, then great caution should be adopted. Side effects are dose related and include potential hyperkalemia, irregular menstrual periods, breast tenderness, headache and fatigue. Postural hypertension has been described in young females. Although breast tumors have been reported in rodent models treated with spironolactone, the drug has not been directly linked to the development of cancer in humans. As this medication is an antiandrogen, there is a risk of feminization of male fetuses if taken during pregnancy.",205,42,0.2048780487804878
9781908541994,ch07,"Macrocomedones frequently require surgical treatment with cautery, as pharmacological therapeutic options are unhelpful.","Photodynamic therapy. A recent review has assessed the effects and safety of photodynamic therapy (PDT) for the treatment of acne: 492 patients from 14 randomized controlled trials (RCTs) were evaluated. Light sources included red light, intense pulsed light (IPL), pulsed dye laser (PDL), long-pulsed dye laser (LPDL) and green light. Photosensitizers included methylaminolevulinate (MAL), aminolevulinic acid (ALA), and indole-3-acetic acid (IAA). Many combinations of light sources and photosensitizers have produced positive results in patients with inflammatory and non-inflammatory acne lesions; in some cases, these treatments have also reduced sebum production. However, the evidence for PDT as a good treatment option for acne, producing positive results with acceptable side effects, is limited. ALA plus red light seems to be the optimal choice. More RCTs are needed to determine the best types and concentrations of photosensitizers and light sources, and the duration of light activation and incubation in order to obtain the best results.",235,22,0.09361702127659574
9781908541994,ch07,Acne nodules/cysts respond well to intralesional triamcinolone injection or cryotherapy.,Intralesional injection of corticosteroids such as triamcinolone can dramatically decrease the size of inflammatory cysts and nodules. Triamcinolone can be used in concentrations of 2.5-10 mg/mL. Often a volume of 0.05-0.25 mL per lesion is used. Repeat injection after 3-4 weeks may be needed. This mode of therapy is a useful adjuvant to treatment with oral antibiotics or isotretinoin. It is particularly helpful in patients who develop these lesions only rarely and who are not candidates for treatment with isotretinoin.,125,24,0.192
9781908541994,ch07,Laser therapy may be helpful for acne scarring.,Intralesional injection of corticosteroids such as triamcinolone can dramatically decrease the size of inflammatory cysts and nodules. Triamcinolone can be used in concentrations of 2.5-10 mg/mL. Often a volume of 0.05-0.25 mL per lesion is used. Repeat injection after 3-4 weeks may be needed. This mode of therapy is a useful adjuvant to treatment with oral antibiotics or isotretinoin. It is particularly helpful in patients who develop these lesions only rarely and who are not candidates for treatment with isotretinoin.,125,11,0.088
9781908541994,ch07,"Acne scarring is common, and the best approach is prevention by early effective therapy.","The treatment of atrophic acne scars is based on type, distribution and depth. Deep scars should be treated singularly in order to make them superficial. Appropriate techniques include fillers, subcision, punch elevation, punch grafting, surgery and chemical reconstruction of skin scars (CROSS), a method that uses a high concentration of trichloroacetic acid localized on the depth of a single scar. The first dermal filler for acne scars has now been approved by the FDA. Comprised of 80% purified bovine collagen and 20% polymethylmethacrylate microspheres, it is indicated for the correction of moderate-to-severe atrophic facial acne scars on the cheeks in patients over 21 years of age. It has been shown to add volume to the skin and lift and smooth pitted acne scars to the level of the surrounding areas. Superficial and widely distributed scars may benefit from laser therapy, peelings, dermarolling and dermabrasion.",203,18,0.08866995073891626
9781908541994,ch08,"A clinical history must be carefully taken, including family history, previous treatments and response to therapy (see Table 3.3, page 19 ).","Initial assessment should include a thorough history (see Table 3.1, page 19) and take into account clinical presentation, extent and overall severity of the patient's acne (graded using a system such as The Leeds Acne Grading Scale; see Chapter 3). The type of treatment may be dictated by the predominant type of lesion, so good lighting is required for the physical examination in order to detect non-inflamed lesions, which can easily be missed. Clinicians must also take into consideration the psychosocial effects of the condition, using questionnaires such as Assessment of the Psychosocial Effects of Acne (APSEA), the Cardiff Acne Diability Index (CADI) or the Dermatology Life Quality Index (DLQI) (see Chapter 4), along with the presence of and potential for scarring, and failure to respond to previous therapy.",177,28,0.15819209039548024
9781908541994,ch08,"The clinician must have a thorough discussion about the disease with the patient to dispel myths, instill realistic expectations and improve adherence.","Dispel myths. Dispelling popular myths about acne can have a positive effect on a person's motivation to cope with the condition, improve adherence to treatment and stop the patient from adopting unnecessary or potentially harmful behavior (see page 17). Myths about the disease should be dispelled in a frank and thorough discussion with the patient. For example, certain foods do not cause acne, acne is not infectious and excessive washing does not help manage the disease (see Table 8.1). Inform about treatment duration and response. It should be stressed that acne is a chronic disease and that no response will be seen before a minimum of 4 weeks of therapy. This is especially important for teenage patients, who often become discouraged if results are not seen quickly despite the fact that they have been following their prescribed regimen.",159,26,0.16352201257861634
9781908541994,ch08,"The patient must be carefully examined, noting acne lesion type, extent and severity as well as acne scarring.","In all cases, the choice of a specific agent or agents should depend on the type and severity of acne lesions as well as the presence of scarring and/or psychological disability. Clinicians should seek to achieve maximum efficacy and tolerability with minimum risk of adverse effects. With the exception of early comedonal acne in prepubertal children, it is rare for a patient to present with a single type of acne lesion. For this reason, combination therapy is the mainstay of acne treatment. For example, different topical therapies may be alternated morning and evening, or formulations containing a stable combination of products may be prescribed. Therapeutic agents should be chosen to match the type and severity of lesions observed in each individual patient.",147,23,0.1564625850340136
9781908541994,ch08,Early effective therapy is likely to reduce the significant clinical and psychological morbidity associated with acne.,"Prevention. Early treatment of acne is likely, although not proven, to prevent or modify development of the disease; thus, early use of appropriate topical therapy in mild acne (see below) may well prevent development of moderate acne. Recognizing predictive factors for severity (see page 38) is important. A family history of acne and scarring should be taken into account when implementing therapy to prevent significant disease. Scarring has been shown to develop with more prolonged disease and the duration of inflammation appears to be relevant. Hence, early targeted therapy is associated with better prognosis.",114,18,0.15789473684210525
9781908541994,ch08,Prescribers should be aware of the emergence of antibiotic-resistant Propionibacterium acnes and the potential link to reduced clinical response. Studies have shown that the improvement in acne achieved with oral antibiotics plus a topical retinoid or retinoid/benzoyl peroxide (BPO) fixed combination can be maintained with continued use of the topical retinoid or retinoid/BPO combination after the antibiotic is discontinued.,"Oral antibiotics. Second-generation tetracycline antibiotics (see pages 59-64) should be the systemic treatment of choice for those patients who can tolerate them. Second-generation tetracyclines are absorbed more rapidly, are more rapidly efficacious and achieve better adherence than first-generation tetracyclines. They are usually administered as capsules. If minocycline is used (not as first-line treatment, see pages 61-2), it is available as aqueous film-coated tablets. Patients who crush their tablets because they are unable to swallow entire pills may not absorb an adequate amount of antibiotic. Minocycline is thought to be associated with the lowest incidence of P. acnes resistance but development of resistance to oral tetracyclines is a potential problem in patients with acne. Resistance should be suspected if a patient's acne fails to respond, or improves then worsens after 3 months of treatment. In such cases, an alternative agent should be chosen. Erythromycin is now used only as a substitute for tetracyclines in women who 'may become' pregnant. The third-line treatment is oral trimethoprim (see page 65). Maintenance therapy. Global overutilization of antibiotics and the resulting emergence of antibacterial resistance (see pages 91-3) have led to calls to limit the use of oral antibiotics in acne treatments. Three well-designed trials indicate that the benefit achieved with a 12-week course of antibiotics plus a retinoid or retinoid/BPO fixed combination can be maintained with continued use of the retinoid or retinoid/BPO combination after the course of antibiotics. This approach limits the long-term use of antibiotics, thus minimizing the ongoing selective pressure for development of antibiotic-resistant strains of bacteria. Since microcomedones are thought to be the precursor lesions of both inflammatory and non-inflammatory acne, a topical retinoid regimen aimed at reducing microcomedones may be useful as maintenance therapy following treatment with oral antibiotics or isotretinoin (see below).",423,91,0.21513002364066194
9781908541994,ch08,"Patients with severe nodulocystic acne, an unusual variant of acne or an underlying endocrinological problem should be referred urgently to a dermatologist for treatment with isotretinoin or hormonal therapy, as appropriate.","Young men with highly inflammatory or cystic acne are at particular risk of developing a severe flare, and in some cases exuberant lesions similar to pyogenic granulomas may develop. It is strongly recommended that patients with severe inflammatory cystic acne who are at risk of complications such as these be referred to a dermatologist for treatment with isotretinoin and possibly a concomitant course of oral corticosteroids. Successful use of isotretinoin requires careful patient selection and education, personalization of the dosage (according to factors such as age, sex and bodyweight) and appropriate monitoring and follow-up on the part of an experienced dermatologist. Patients should be given immediate access to a dermatologist if any problem with therapy arises or if they fail to respond adequately to the drug. Expected response. Since its inception, the use of oral isotretinoin treatment has been responsible for a dramatic improvement in the appearance and psychological wellbeing of numerous individuals affected by moderate-to-severe acne. By the end of an adequate course of treatment, acne will have cleared in the majority of patients.",223,44,0.19730941704035873
9781908541994,ch08,"Patients with moderate acne that has failed to respond to treatment, those at risk of developing scarring, and pregnant women with acne should also be referred to a dermatologist.","Young men with highly inflammatory or cystic acne are at particular risk of developing a severe flare, and in some cases exuberant lesions similar to pyogenic granulomas may develop. It is strongly recommended that patients with severe inflammatory cystic acne who are at risk of complications such as these be referred to a dermatologist for treatment with isotretinoin and possibly a concomitant course of oral corticosteroids. Successful use of isotretinoin requires careful patient selection and education, personalization of the dosage (according to factors such as age, sex and bodyweight) and appropriate monitoring and follow-up on the part of an experienced dermatologist. Patients should be given immediate access to a dermatologist if any problem with therapy arises or if they fail to respond adequately to the drug.",161,35,0.21739130434782608
9781908541994,ch08,Patients with acne who have associated social or psychological problems should also be referred for specialist treatment.,"Young men with highly inflammatory or cystic acne are at particular risk of developing a severe flare, and in some cases exuberant lesions similar to pyogenic granulomas may develop. It is strongly recommended that patients with severe inflammatory cystic acne who are at risk of complications such as these be referred to a dermatologist for treatment with isotretinoin and possibly a concomitant course of oral corticosteroids.",85,19,0.2235294117647059
9781910797006,ch01,Combinations of these pathological changes to varying degrees in different individuals with COPD contribute to the airflow limitation.,"In chronic obstructive pulmonary disease (COPD), pathological changes occur in the central conducting airways, the peripheral airways, the lung parenchyma and the pulmonary vasculature (Figure 1.1). Current concepts suggest that inflammation induced by cigarette smoke underlies most pathological lesions associated with COPD. The inflammation damages lung structures, and individuals who are unable to repair this damage develop tissue alterations and functional compromise. Inflammation also contributes to recurrent exacerbations of COPD, in which acute inflammation is superimposed on the chronic disease. There is now good evidence that all smokers develop lung inflammation; however, some individuals are more susceptible to the effects of cigarette smoke and are more severely affected. The pathogenesis of COPD in non-smokers has not been studied as much, but inflammation secondary to air pollution or other substances is likely to play a key role. The extent of the pathological changes in the different lung compartments varies between individuals and results in the clinical and pathophysiological heterogeneity seen in patients with COPD.",208,21,0.10096153846153846
9781910797006,ch01,Chronic bronchitis is defined clinically as the production of sputum on most days for at least 3 months a year over at least 2 consecutive years.,"Chronic bronchitis is defined clinically by the American Thoracic Society and the UK Medical Research Council as: 'the production of sputum on most days for at least 3 months in at least 2 consecutive years'. This chronic hypersecretion of mucus results from changes in the central airways - the trachea, bronchi and bronchioles over 2-4 mm in internal diameter. Mucus is produced by mucus glands, which are present mainly in the larger airways, and by goblet cells, found in the airway epithelium (see Figure 1.1). In chronic bronchitis, hypertrophy of mucus glands, mainly in the larger bronchi, is associated with infiltration of the glands by inflammatory cells (Figure 1.2). In healthy never-smokers, goblet cells make up 10% of the columnar epithelial cells in the proximal airways, but their numbers decrease in more distal airways and are normally absent in the terminal or respiratory bronchioles. In smokers, however, goblet cells are not only present in increased numbers but also extend more peripherally. Metaplastic or dysplastic changes in the surface epithelium may replace the goblet cells of the normal respiratory epithelium in some smokers and thus may reduce the number of goblet cells in the proximal airways. The clinical significance of these varied anatomic alterations is unknown.",299,32,0.10702341137123746
9781910797006,ch01,"Once COPD is established, the inflammatory process persists even after smoking cessation.","Bronchial biopsies taken from patients during mild exacerbations of chronic bronchitis indicate increased numbers of eosinophils in the bronchial wall, though far fewer than are present in exacerbations of asthma; increased numbers of neutrophils are also observed. Eosinophils may not be prominent in severe exacerbations. Several studies using bronchoalveolar lavage, spontaneous or induced sputum, have demonstrated intraluminal inflammation in the airspaces of patients with chronic bronchitis with or without airway obstruction. In stable chronic bronchitis, the high percentage of intraluminal neutrophils is associated with the presence of neutrophil chemotactic factors, including interleukin-8 (IL-8) and leukotriene B4, and other inflammatory mediators. There is also evidence that the airspace inflammation in patients with chronic bronchitis persists following smoking cessation if the production of sputum persists, though cough and sputum are reduced in most smokers who quit. A subset of COPD patients with eosinophils in their sputum has been described; these patients are more responsive to inhaled glucocorticoids.",250,15,0.06
9781910797006,ch01,"Inflammation occurs in large and small airways, and in the alveolar space, most commonly involving a number of cells including neutrophils, macrophages and T lymphocytes, particularly CD8+ lymphocytes.","The smaller bronchi and bronchioles less than 2 mm in diameter are a major site of airway obstruction in COPD. Inflammation in the small airways is one of the earliest changes in asymptomatic cigarette smokers, and considerable changes in these airways can occur without giving rise to symptoms or alteration in spirometry measurements. Thus, this region in the lung has been referred to as the 'silent zone', as abnormalities are not easily detected by conventional pulmonary function testing. The pattern of inflammatory cell changes in the small airways resembles that in the larger airways, including a predominance of CD8+ lymphocytes and an increase in the CD8:CD4 ratio. The mechanisms leading to the increase in peripheral airway resistance include several distinct processes: destruction of alveolar support, loss of elastic recoil in the parenchyma that contributes to this support and provides driving pressure for alveolar emptying, and structural narrowing of the airway lumen. The lumen may be occluded by mucus and cells. Mucosal ulceration, goblet cell hyperplasia and squamous cell metaplasia may be present in addition to fibrosis and mesenchymal cell accumulation. As the condition progresses, structural remodeling may occur, characterized by increased collagen content and formation of scar tissue, which narrows the airways and produces fixed airway obstruction (Figure 1.3). With severe disease, the number of small airways is reduced.",304,46,0.1513157894736842
9781910797006,ch01,"Centriacinar (centrilobular) emphysema is the most common form of emphysema, particularly in smokers, and is distributed mainly in the upper zones of the lungs. Panacinar (panlobular) emphysema has a more diffuse distribution, predominantly in the lower zones of the lungs, and is associated with alpha1-antitrypsin deficiency; it can also occur in some smokers.","Centriacinar and panacinar emphysema can occur alone or in combination. Whether the two types represent different disease processes and thus have different etiologies, or whether panacinar emphysema is a progression from centriacinar emphysema is still subject to debate. The association with cigarette smoking is certainly clearer for centriacinar than panacinar emphysema, though smokers can develop both types. Those with centriacinar emphysema appear to have more abnormalities in their small airways than those with predominantly panacinar emphysema. Centriacinar emphysema is characterized by initial clustering of the enlarged airspaces around the terminal bronchiole. It is more prominent in the upper zones of the upper and lower lobes and is the type most commonly seen in smokers. Panacinar emphysema. The enlarged airspaces are distributed throughout the acinar unit. The destruction of the acinus is more uniform, and all of the acini within the secondary lobule are involved. In contrast to centriacinar emphysema, panacinar emphysema appears to be more severe in the lower lobe, but can be found anywhere in the lungs. It is associated with alpha1-proteinase inhibitor deficiency, but it can also be found in cases where no clear-cut genetic abnormality has been identified. Periacinar (paraseptal or distal acinar) emphysema is the least common of the three main types. It is characterized by enlargement of the airspaces along the edge of the acinar unit, but only where it abuts a fixed structure, such as the pleura or a vessel. Periacinar emphysema is now a recognized emphysema pattern in smokers. It can be associated with pneumothorax.",386,91,0.23575129533678757
9781910797006,ch01,Bullae are emphysematous spaces over 1 cm in diameter.,"Bullae are localized areas of emphysema that are overdistended. Conventionally, only lesions over 1 cm in size are described as bullae. Bullae arise in areas of lung that have been locally destroyed, though this destruction does not have to be a result of emphysema; the damage can also result from lytic or traumatic causes. They have been described in patients with tuberculosis, sarcoidosis, AIDS and trauma. The origins of bullae remain obscure. In around 20% of cases the surrounding lung is normal, but most bullae are associated with more generalized emphysema and chronic airway obstruction.",130,15,0.11538461538461539
9781910797006,ch01,"The lungs of patients with COPD show an amplified and persistent inflammatory response to the inhalation of particles and gases, particularly those in cigarette smoke. A protease:antiprotease and oxidant:antioxidant imbalance is part of this amplified inflammatory response.","Bullae are localized areas of emphysema that are overdistended. Conventionally, only lesions over 1 cm in size are described as bullae. Bullae arise in areas of lung that have been locally destroyed, though this destruction does not have to be a result of emphysema; the damage can also result from lytic or traumatic causes. They have been described in patients with tuberculosis, sarcoidosis, AIDS and trauma. The origins of bullae remain obscure. In around 20% of cases the surrounding lung is normal, but most bullae are associated with more generalized emphysema and chronic airway obstruction. Pulmonary vasculature. The vasculature of the lung may be affected in several ways. The development of chronic alveolar hypoxia in patients with COPD results in hypoxic vasoconstriction of the small pulmonary arteries and, consequently, an inflammatory response in the arteries similar to that in the lungs. This leads to remodeling of the pulmonary arteries. As a result, early in COPD the intima may become thickened, followed by an increase in the amount of smooth muscle and infiltration of the vessel wall with inflammatory cells. As the disease progresses, the amounts of smooth muscle, proteoglycans and collagen present in the vessel wall increase and cause it to thicken. Right ventricular hypertrophy and pulmonary hypertension are common in patients with advanced COPD who have chronic hypoxemia. Functional compromise of the pulmonary circulation can also be caused by dynamic hyperinflation, which increases intrathoracic pressure, restricts blood flow and may contribute to impaired diastolic filling of the heart.",338,53,0.15680473372781065
9781910797006,ch01,COPD results from pathological changes in the large and small airways (bronchiolitis) and in the alveolar space (emphysema).,"The pathological changes in patients with COPD are complex and may occur to varying extents in the large and small airways, and in the alveolar compartment. It is difficult to determine clinically or by respiratory function tests the relative contributions made to airway obstruction by the different pathological changes. In general, it is thought that the smaller bronchi and bronchioles less than 2 mm in diameter are the major sites of airway obstruction in COPD. Symptoms and physiological abnormalities in a given individual may be due to different combinations of lesions at different stages. Narrowing of small airways can result from the formation of peribronchiolar scars and consequent contraction. Consistent with this, decreased airway circumference correlates well with airflow limitation, as does reduced numbers of small airways in patients with moderately severe COPD when assessed on specimens removed surgically.",175,34,0.19428571428571428
9781910797006,ch01,"Small-airways disease or bronchiolitis can result in inflammation and eventually scarring of the small airways; this is an important pathological change in COPD, which is difficult to assess by respiratory function tests, but may be a major source of airway obstruction.","The pathological changes in patients with COPD are complex and may occur to varying extents in the large and small airways, and in the alveolar compartment. It is difficult to determine clinically or by respiratory function tests the relative contributions made to airway obstruction by the different pathological changes. In general, it is thought that the smaller bronchi and bronchioles less than 2 mm in diameter are the major sites of airway obstruction in COPD. Symptoms and physiological abnormalities in a given individual may be due to different combinations of lesions at different stages. Narrowing of small airways can result from the formation of peribronchiolar scars and consequent contraction. Consistent with this, decreased airway circumference correlates well with airflow limitation, as does reduced numbers of small airways in patients with moderately severe COPD when assessed on specimens removed surgically. Emphysema leads to decreased expiratory airflow by different mechanisms. Loss of elastic recoil of the lungs, due to loss of alveolar attachments to the smaller airways, decreases the driving pressure that empties the alveoli and reduces the intraluminal pressure within the terminal airways. Because of this and because of destruction of alveolar attachments that tether the small airways in an open position, small airways can collapse during forced exhalation, resulting in effort-independent limitation of expiratory airflow.",284,55,0.1936619718309859
9781910797006,ch02,"Cigarette smoking is the most important risk factor for COPD; about 80% of patients with COPD are, or have been, smokers.","Fortunately, great gains have been made in understanding the pathogenesis, physiology, clinical features and management of COPD. While cigarette smoking, itself now regarded as a disease, is the major risk factor, COPD also occurs in non-smokers and individuals vary greatly in their susceptibility to smoke. Cigarette smoking is the most important etiologic factor for the development of COPD. There is a highly significant dose and duration effect, with smokers having lower lung function the more and longer they smoke. There is, however, considerable individual variation. Some non-smokers, for example, have impaired lung function. Approximately 20% of patients with COPD are lifelong non-smokers. Conversely, some heavy smokers are able to maintain normal lung function (Figure 2.1).",157,30,0.1910828025477707
9781910797006,ch02,Almost all smokers develop impaired lung function.,"Cigarette smoking is the most important etiologic factor for the development of COPD. There is a highly significant dose and duration effect, with smokers having lower lung function the more and longer they smoke. There is, however, considerable individual variation. Some non-smokers, for example, have impaired lung function. Approximately 20% of patients with COPD are lifelong non-smokers. Conversely, some heavy smokers are able to maintain normal lung function (Figure 2.1).",98,8,0.08163265306122448
9781910797006,ch02,"Early life events, including compromised lung development and growth, are likely to contribute to the risk of developing COPD later.","It is likely that smoking contributes to the development of COPD in several distinct ways and at several different periods over the lifespan of the individual (Table 2.1). Furthermore, the adverse effects of smoking on lung function are likely to be greater the earlier an individual is exposed. Exposure to other substances, including indoor and outdoor pollution, can also contribute to the development of COPD. Passive exposure to cigarette smoke is an important risk factor and may contribute to the development of COPD in non-smokers. Individuals exposed to dusts and fumes who also smoke cigarettes have the highest risk of developing COPD.",122,24,0.19672131147540983
9781910797006,ch02,"Other influences, including air pollution and occupational exposures, contribute to COPD risk.","Exposure to other substances, including indoor and outdoor pollution, can also contribute to the development of COPD. Passive exposure to cigarette smoke is an important risk factor and may contribute to the development of COPD in non-smokers. Individuals exposed to dusts and fumes who also smoke cigarettes have the highest risk of developing COPD.",67,16,0.23880597014925373
9781910797006,ch02,Asthma may contribute to COPD risk in some individuals.,"Exposure to other substances, including indoor and outdoor pollution, can also contribute to the development of COPD. Passive exposure to cigarette smoke is an important risk factor and may contribute to the development of COPD in non-smokers. Individuals exposed to dusts and fumes who also smoke cigarettes have the highest risk of developing COPD.",67,12,0.1791044776119403
9781910797006,ch02,"Many individuals with COPD are undiagnosed, as symptoms of dyspnea can be minimized by restricting activity, which leads patients to discount their functional compromise.","Mechanisms of effect. The mechanisms by which cigarette smoke leads to COPD are under intensive study, as they offer potential opportunities for therapeutic intervention. Smoke is capable of inducing an inflammatory response through a number of mechanisms. It induces release of proinflammatory mediators from epithelial cells present in the lower respiratory tract, as well as from resident macrophages. It can also activate complement. Thus, the inflammation that is characteristically present in the lungs of smokers probably results from activation of multiple pathways. The mediators released by inflammatory cells and parenchymal cells recruited and stimulated by cigarette smoke are capable of inducing lung damage. These mediators include reactive oxygen species, active proteinases and toxic peptides. In addition, cigarette smoke can decrease levels of antioxidants and antiproteinases that serve to mitigate damage caused by these toxic moieties. These effects therefore tip the balance in the lung toward tissue damage both by increasing the production of toxic mediators and by decreasing defenses.",195,33,0.16923076923076924
9781910797006,ch02,Individual genetic susceptibility probably accounts for the heterogeneity of COPD risk.,"Heterogeneous susceptibility. The complex interactions between cigarette smoke and the lungs of smokers suggest multiple steps at which individual susceptibility may vary. Consistent with this, smokers show considerable heterogeneity in their susceptibility to developing COPD and strong genetic components appear to be present. Both smoking and non-smoking siblings of individuals with established COPD are at greatly increased risk of lower lung function than are siblings of individuals without COPD. It is likely that a number of specific genetic factors will affect susceptibility to COPD (see pages 27 -).",104,13,0.125
9781910797006,ch02,It is likely that many specific genetic factors will contribute to COPD risk; alpha1-proteinase inhibitor deficiency is the best characterized of these.,"alpha1-proteinase inhibitor is a major inhibitor of serine proteinases, including neutrophil elastase; thus, it is postulated that alpha1-proteinase inhibitor deficiency results in excess activity of neutrophil elastase and therefore tissue destruction and emphysema. However, only some non-smokers with alpha1-proteinase inhibitor deficiency develop emphysema. Some maintain normal lung function throughout life. This indicates the importance of other factors. Additional genetic associations that may contribute to COPD risk and that are more common than alpha1-proteinase inhibitor deficiency have been identified, although these are likely to increase the risk of COPD only modestly. Interestingly, many of these candidate genes can affect proteinase or oxidant balance, suggesting mechanisms of action analogous to those in alpha1-proteinase inhibitor deficiency.",171,29,0.1695906432748538
9781910797006,ch03,"Usually (in 80% of patients) there is a significant smoking history of at least 20 pack-years. For those with lesser smoking histories or for younger individuals, consider an alternative diagnosis or a genetic predisposition (exempli gratia alpha1-antitrypsin deficiency).","The characteristic symptom of COPD is breathlessness on exertion, sometimes accompanied by wheeze and cough, which is often, but not invariably, productive. Breathlessness is the symptom that commonly` causes the patient to seek medical attention, and it is usually the most disabling. Patients often date the onset of their illness from an episode of worsening cough with sputum production, which leaves them with a degree of chronic breathlessness. However, close questioning will often reveal the presence of a 'smoker's cough' over a period of years, along with the production of small amounts (usually < 60 mL/day) of mucoid sputum, usually predominantly in the morning. Most patients (80%) with COPD will have a smoking history of at least 20 pack-years (1 pack-year is equivalent to smoking 20 cigarettes [1 pack] per day for 1 year or 10 a day for 2 years) before symptoms are recognized, commonly in the fifth decade. However, COPD may occur in the non-smoker and is more frequently missed in this setting. It is characteristic of patients with COPD to progress through the clinical stages of mild, moderate and severe disease. Symptoms and signs therefore vary in any individual depending on the stage of the disease. Considerable loss of lung function can occur before symptoms become apparent, and many patients may seek medical attention when the disease is at an advanced stage, since COPD is a slowly progressive disorder and patients gradually adapt their lives to their disability. Most smokers accept cough and shortness of breath, so they often dismiss these symptoms of progressive airflow limitation as a normal consequence of their smoking habit and the aging process.",337,58,0.17210682492581603
9781910797006,ch03,The most common symptom in COPD is breathlessness on exertion.,"The characteristic symptom of COPD is breathlessness on exertion, sometimes accompanied by wheeze and cough, which is often, but not invariably, productive. Breathlessness is the symptom that commonly` causes the patient to seek medical attention, and it is usually the most disabling. Patients often date the onset of their illness from an episode of worsening cough with sputum production, which leaves them with a degree of chronic breathlessness. However, close questioning will often reveal the presence of a 'smoker's cough' over a period of years, along with the production of small amounts (usually < 60 mL/day) of mucoid sputum, usually predominantly in the morning.",139,14,0.10071942446043165
9781910797006,ch03,"Clinical indicators include signs of overinflation, prominent use of accessory muscles of respiration, weight loss, expiratory wheeze, cyanosis, peripheral edema and raised jugular venous pressure. These are usually apparent only in severe disease.","It is characteristic of patients with COPD to progress through the clinical stages of mild, moderate and severe disease. Symptoms and signs therefore vary in any individual depending on the stage of the disease. Considerable loss of lung function can occur before symptoms become apparent, and many patients may seek medical attention when the disease is at an advanced stage, since COPD is a slowly progressive disorder and patients gradually adapt their lives to their disability. Most smokers accept cough and shortness of breath, so they often dismiss these symptoms of progressive airflow limitation as a normal consequence of their smoking habit and the aging process. Breathlessness is the symptom that causes most disability and is associated with loss of lung function over time. In good health, the body meets the increased oxygen demand produced by exercise by using some of the inspiratory reserve volume of the lungs to increase tidal volume and by increasing respiratory rate (Figure 3.1). In COPD, because the expiratory airflow is reduced, the lungs empty slowly. As a result, the lungs become overinflated with air trapped in the alveoli, particularly when the respiratory rate increases. This hyperinflation compromises the use of the inspiratory reserve volume and breathlessness worsens. As the diaphragm flattens when the lungs are overinflated, the accessory muscles of respiration become increasingly important. The loss of alveolar/capillary surface in COPD, particularly in emphysema, increases the ventilation required to excrete the carbon dioxide that is generated during exercise, and this further increases the sensation of breathlessness.",318,52,0.16352201257861634
9781910797006,ch03,"Dyspnea may be discounted by patients until disease is severe, as breathlessness can be avoided by restricting activity.","The perception of breathlessness varies greatly between individuals with the same degree of ventilatory capacity. Breathlessness can be assessed using the modified Borg Scale (Table 3.1), a visual analog scale, the modified Medical Research Council (mMRC) Dyspnea Scale (Table 3.2), or the Dyspnea-12 scale. Mood is an important determinant of the perception of breathlessness in patients with COPD. When the FEV has fallen to 30% or less of the predicted value (equivalent in an average man to an FEV of around 1 liter), breathlessness is usually present on minimal exertion. Severe breathlessness is often affected by changes in temperature and by exposure to dust and fumes. Position has a variable effect on breathlessness. Some patients have severe orthopnea, relieved by leaning forward, whereas others find the greatest ease when lying flat.",179,24,0.1340782122905028
9781910797006,ch03,"COPD occurs, though less commonly, in those who do not smoke.","Wheeze is common in COPD, but is not universally present and is a non-specific symptom. It is not easy to evaluate because of its intermittent nature and the difficulties patients experience in understanding this symptom. Wheeze is due to turbulent airflow through the larger airways as a result of various causes including bronchial smooth muscle contraction, structural airway narrowing and the presence of excess airway secretions. Wheeze does not usually wake patients with COPD at night as it does those with asthma. The absence of signs of wheeze on auscultation of the chest does not exclude a diagnosis of COPD.",129,16,0.12403100775193798
9781910797006,ch03,Physical signs often present only at an advanced stage of the disease.,"Many smokers accept the development of exertional dyspnea and cough with sputum production as an inevitable consequence of the smoking habit, and therefore often present to their doctor when the disease is at a fairly advanced stage. Relatively few patients are diagnosed early in the course of the disease. All smokers should quit. However, repeated spirometry over the course of several years will identify smokers with a rapid decline in FEV whose function may still be normal, who could be targeted for smoking cessation and early therapeutic intervention.",103,13,0.1262135922330097
9781910797006,ch03,The systemic effects of COPD result in a number of comorbidities that impact on the morbidity and mortality of the disease.,"Traditionally, COPD is regarded as a disease of the lungs characterized by progressive symptoms and a decline in lung function. Therapeutic strategies such as bronchodilators and inhaled glucocorticosteroids have therefore been used for relieving symptoms in association with improving airflow limitation. However, COPD is also associated with a number of systemic effects and common comorbidities (see Table 3.3), which may be present at any stage of the disease. Some of these comorbidities arise independent of COPD, whereas others appear to be causally related, either as a result of shared risk factors or the influence of COPD on the development of another condition. Systemic inflammation in COPD may be the link between COPD and some of its comorbidities.",162,27,0.16666666666666666
9781910797006,ch03,The full spectrum of COPD can now be better identified using new classifications of disease that take into account symptoms and exacerbation risk in addition to airflow limitation.,"Many national and international guidelines for COPD have used a simple classification of disease severity based on spirometry. However, because FEV only partially captures the severity of COPD, recent recommendations suggest assessing additional measures. The most recent classification from the Global initiative for chronic Obstructive Lung Disease (GOLD) takes into account symptoms and exacerbation risk in addition to airflow limitation (Figure 3.2). First, the patient's symptoms are assessed using the COPD assessment test (CAT) or the modified MRC score (mMRC) for dyspnea (see Table 3.2). The CAT is the preferred test as it provides a comprehensive assessment of symptoms (www.catestonline.org). A CAT score of 10 or more indicates a high level of symptoms. Exacerbation risk is then assessed in three ways: by the severity of airflow limitation as indicated by spirometry grade, with a GOLD classification of 3 or 4 indicating high risk (see Table 4.1); by the patient's history of exacerbations, with two or more exacerbations in the preceding year indicating high risk; and by the patient's history of hospitalization in the preceding year. The highest risk parameter should be recorded for the purposes of this assessment. Alternatively, the COPD Foundation Guide recommends assessing seven independent domains of severity (Table 3.4).",270,32,0.11851851851851852
9781910797006,ch04,"Spirometry is the most important measurement in COPD and is essential for diagnosis. Forced expiratory volume in 1 second (FEV ) and forced vital capacity (FVC) are recorded in absolute values (liters) and also as a percentage of the predicted values for the individual depending on age, height, sex and ethnic origin.","FEV and FVC are expressed in absolute values in liters and also as a percentage of the predicted values for the individual depending on their age, height, sex and ethnic origin. Values within +- 20% of the predicted values are considered to be within the normal range. Thus, an FEV of over 80% of the predicted value is considered to be normal. Under normal circumstances, 70-80% of the total volume of the air in the lungs (the FVC) should be exhaled in the first second. In other words, the FEV :FVC ratio is normally 0.7-0.8. When airflow through the airways is obstructed, it is not possible to exhale so much air in the first second, and the FEV :FVC ratio falls. A ratio of less than 0.7 indicates airflow obstruction (Figure 4.2). A post-bronchodilator FEV :FVC ratio below 0.7 indicates chronic airflow limitation and is a diagnostic criterion for COPD. The use of a fixed FEV :FVC ratio as a diagnostic criterion for chronic airflow limitation is a pragmatic approach, as reference values for FEV :FVC are unavailable. However, the fixed ratio has limitations because the ratio declines with age, with the potential for overdiagnosis of COPD in the elderly. It also has the potential to underdiagnose disease in younger individuals. The lower limit of normal (LLN) is an alternative approach to the fixed ratio to determine the presence of COPD. The LLN threshold is defined as the fifth percentile of the normal population distribution of FEV /FVC. If an individual's FEV :FVC falls below this fifth percentile, the individual is defined as having COPD.",361,69,0.19113573407202217
9781910797006,ch04,An FEV over 80% of the predicted value is considered to be normal. This does not exclude the presence of disease.,"FEV and FVC are expressed in absolute values in liters and also as a percentage of the predicted values for the individual depending on their age, height, sex and ethnic origin. Values within +- 20% of the predicted values are considered to be within the normal range. Thus, an FEV of over 80% of the predicted value is considered to be normal. Under normal circumstances, 70-80% of the total volume of the air in the lungs (the FVC) should be exhaled in the first second. In other words, the FEV :FVC ratio is normally 0.7-0.8. When airflow through the airways is obstructed, it is not possible to exhale so much air in the first second, and the FEV :FVC ratio falls. A ratio of less than 0.7 indicates airflow obstruction (Figure 4.2). A post-bronchodilator FEV :FVC ratio below 0.7 indicates chronic airflow limitation and is a diagnostic criterion for COPD.",212,25,0.1179245283018868
9781910797006,ch04,A post-bronchodilator FEV :FVC ratio below 0.7 indicates chronic airflow limitation and is a diagnostic criterion for COPD.,"FEV and FVC are expressed in absolute values in liters and also as a percentage of the predicted values for the individual depending on their age, height, sex and ethnic origin. Values within +- 20% of the predicted values are considered to be within the normal range. Thus, an FEV of over 80% of the predicted value is considered to be normal. Under normal circumstances, 70-80% of the total volume of the air in the lungs (the FVC) should be exhaled in the first second. In other words, the FEV :FVC ratio is normally 0.7-0.8. When airflow through the airways is obstructed, it is not possible to exhale so much air in the first second, and the FEV :FVC ratio falls. A ratio of less than 0.7 indicates airflow obstruction (Figure 4.2). A post-bronchodilator FEV :FVC ratio below 0.7 indicates chronic airflow limitation and is a diagnostic criterion for COPD.",212,32,0.1509433962264151
9781910797006,ch04,Peak expiratory flow rate is not the best assessment of airway obstruction in COPD and may underestimate the degree of airway obstruction.,"Peak expiratory flow (PEF) can either be read directly from the flow-volume loop (see page 60) or measured with a handheld peak flow meter. It is a simple, quick and inexpensive way of measuring airflow obstruction, and has been particularly useful for repeated measurements in patients with asthma to reveal spontaneous diurnal variation or variations in response to therapy. The PEF meter measures the maximal flow rate that can be maintained over 10 ms; it is most effective for monitoring changes in airflow in an individual over time, but should not be used in the diagnosis of COPD. In COPD, there is little daily change in PEF and many of the variations are often within the error range of the measurement. Although repeated measurements of PEF can replace measurement of FEV, single measurements are not as useful as the variation is so high. There are several theoretical reasons why FEV is a better measurement than PEF in the diagnosis and assessment of COPD (Table 4.3). However, for clinicians who lack office spirometry, performance of a PEF may be useful in deciding whom to refer for the more definitive testing needed for diagnosis.",232,29,0.125
9781910797006,ch04,"There is no standard assessment of reversibility; generally, however, an improvement in FEV of both 200 mL and 12% over the baseline is interpreted as a positive result.","The use of bronchodilator testing in patients with COPD is limited by the variability of the FEV measurement itself, and by the fact that, by definition, patients with COPD may have only a small degree of reversibility, which is often within the error of the measurement. Bronchodilator reversibility tests can also vary from day to day depending on the degree of bronchomotor tone. A change in FEV that exceeds 170 mL can be considered not to have occurred by chance. Most guidelines recommend that changes should be considered significant only if they exceed 200 mL. In addition to this absolute change in FEV, a percentage change of 12% over baseline has been suggested as significant in the American Thoracic Society and the GOLD guidelines, whereas an improvement of 15% over baseline FEV and a 200 mL absolute change is recommended in the European Respiratory Society and British Thoracic Society guidelines.",188,35,0.18617021276595744
9781910797006,ch04,Reversibility testing to bronchodilators is useful in differential diagnosis to distinguish those with marked reversibility indicative of asthma.,"Reversibility testing with a bronchodilator is generally indicated only at the time of diagnosis. Bronchodilator testing should usually be undertaken only in patients with COPD at stage II (moderate) and above, and reversibility testing should be conducted during a period of clinical stability, with a high dose of bronchodilator in order not to miss a significant response. The high dose can be delivered by means of a nebulizer. An alternative method is to deliver a smaller dose of the drug by giving repeated doses from a metered-dose inhaler through a large-volume spacer. The usual recommended protocol for testing bronchial reversibility is shown in Table 4.4. Improvement of lung function to normal suggests a diagnosis of asthma without the presence of COPD.",162,26,0.16049382716049382
9781910797006,ch04,A standardized technique must be employed in spirometry assessment. It is critical that the expiratory flow trace reaches a plateau to prove that the patient has reached the FVC.,"Flow-volume loops. Many spirometers plot expiratory flow rate throughout the entire expiration at the same time as a standard volume-time trace. The PEF, which is sustained for 10 ms, represents the flow only in the larger airways. However, the flow-volume trace interprets flow from all generations of the airways and may be more helpful than PEF in detecting early airway narrowing in smaller airways (Figure 4.5). Expiratory flow rates at 75% or 50% of VC have been used as a measure of airflow limitation, and provide complementary information to that obtained from the usual volume-time plot. There are problems with the reproducibility of these measurements, so that values must fall below 50% of the predicted values to be considered abnormal. Flows at lung volumes below 50% of VC were previously considered to be an indicator of small-airways dysfunction, but probably provide no more clinically useful information than measurement of FEV. Examples of flow-volume loops in airflow obstruction are shown in Figure 4.6.",214,35,0.16355140186915887
9781910797006,ch04,Further tests of lung volumes and the diffusing capacity in the lung for carbon monoxide may be helpful in some cases.,"Gas transfer by the lungs can be measured using carbon monoxide as a tracer gas. Following inhalation of a small amount of carbon monoxide, some of the inhaled marker is transferred from the lungs into the pulmonary capillary blood where it binds to hemoglobin. Reductions in the concentration of carbon monoxide in the exhaled gas can therefore be used to gauge the efficiency of gas transfer within the lung. Some of the reduction in carbon monoxide level is also due to diffusion into the residual volume of the lung. Thus, values for the diffusing capacity in the lung for carbon monoxide (DLco; TLco in the UK) are generally corrected using helium, which diffuses into the residual volume but is not absorbed into the pulmonary capillary blood. This technique yields the ventilated alveolar volume (V A), which provides the carbon monoxide transfer coefficient Kco (DLco/V A).",185,24,0.12972972972972974
9781910797006,ch05,"No features on plain chest radiography are specific for COPD. The features usually described are those of severe emphysema, but no abnormality may be visible, even in patients with marked disability.","No features specific for COPD are seen on a plain posterior-anterior chest radiograph. The features usually described are those of severe emphysema. However, there may be no abnormalities, even in patients with very appreciable disability. Recent improvements in imaging techniques, particularly the advent of CT and, more recently, high-resolution CT (HRCT), have provided more sensitive means of diagnosing emphysema in life. Plain chest radiography. The most reliable radiographic signs of emphysema can be classified by their causes of overinflation, vascular changes and bullae. Overinflation of the lungs results in the following radiographic features. a low flattened diaphragm (Figure 5.1): the diaphragm is abnormally low if the border of the diaphragm in the midclavicular line is at or below the anterior end of the seventh rib; and the diaphragm is flattened if the perpendicular height from a line drawn between the costal and cardiophrenic angles to the border of the diaphragm is less than 1.5 cm.",230,41,0.1782608695652174
9781910797006,ch05,"CT scans can be used to quantify emphysema, either by visual assessment of high-resolution scanning or by CT lung density measurements.","CT scanning has been used to detect and quantify emphysema. Techniques can be divided into those that use visual assessment of low-density areas on the CT scan, which can be either semiquantitative or quantitative, and those that use CT lung density to quantify areas of low X-ray attenuation. These two techniques are usually employed to measure macroscopic or microscopic emphysema, respectively. Use of inspiratory and expiratory phases during CT scanning helps to determine air-trapping and small airways disease. Visual assessment of emphysema on CT scanning (Figure 5.2) reveals.",126,28,0.2222222222222222
9781910797006,ch05,CT scanning is the best way to detect and assess bullous disease.,"CT scanning has been used to detect and quantify emphysema. Techniques can be divided into those that use visual assessment of low-density areas on the CT scan, which can be either semiquantitative or quantitative, and those that use CT lung density to quantify areas of low X-ray attenuation. These two techniques are usually employed to measure macroscopic or microscopic emphysema, respectively. Use of inspiratory and expiratory phases during CT scanning helps to determine air-trapping and small airways disease.",108,14,0.12962962962962962
9781910797006,ch05,CT scanning is the standard way to assess patients for volume reduction surgery.,"It is possible to distinguish the various types of emphysema using HRCT, particularly when the changes are not severe. The distinction depends on the distribution of the lesions: those of centrilobular emphysema are patchy and prominent in the upper zones; whereas those of panlobular emphysema are diffuse throughout the lung zones (see Figure 5.2). It is generally acceptable to select patients with upper lung zone emphysema for volume reduction surgery by visual inspection of an HRCT by an experienced radiologist and surgeon.",113,14,0.12389380530973451
9781910797006,ch05,"Echocardiography, particularly continuous-wave Doppler echocardiography, can be used to assess pulmonary arterial pressure in patients with COPD.","Pulsed-wave Doppler echocardiography has been used to assess the ejection flow dynamics of the right ventricle in patients with pulmonary hypertension. The parameters measured include: acceleration time (in milliseconds), which is defined as the time between the onset of ejection to peak velocity; right ventricular pre-ejection time (in milliseconds), which is the interval from the Q wave of the ECG to the beginning of the forward flow; and right ventricular ejection time (in milliseconds), which is the interval between the onset and termination of flow in the right ventricular outflow tract. Although the pulsed-wave Doppler technique is useful in differentiating patients with an elevated pulmonary arterial pressure from those with normal pulmonary arterial pressure, it is not as accurate as the continuous-wave Doppler technique in assessing pulmonary arterial pressure.",178,34,0.19101123595505617
9781910797006,ch06,Smoking should be regarded as a primary chronic relapsing disease.,"Smoking should not be oversimplified as merely a lifestyle choice, but, owing to the addiction, should be considered as a primary disease entity in itself. In this context, smoking is properly classified as a chronic, often relapsing, disease. Smoking cessation is thus not simply a matter of personal choice, but is a legitimate therapeutic intervention, the goal of which is to induce a 'remission' in smoking.",85,14,0.16470588235294117
9781910797006,ch06,Repeated efforts by the physician are required to provide sufficient motivation for a quit attempt.,"Behavioral support. Data show clearly that the more behavioral support offered the more likely a smoker is to quit. Many smokers, however, will not attend intensive behavioral programs. Brief behavioral help is therefore appropriate for most individuals and a number of approaches are shown in Table 6.4. The efficacy of widely available telephone quit lines has been well demonstrated. In addition, some studies have suggested efficacy for the many internet-based interventions that have been developed. However, many of these do not have supporting evidence.",101,17,0.16831683168316833
9781910797006,ch06,All serious attempts to quit should be maximally supported with behavioral and pharmacological interventions.,Pharmacological treatment. All smokers making a serious attempt to quit should be offered pharmacological treatment (in the absence of contraindications). Treatment with first-line medicines for smoking cessation can double or triple quit rates compared with those achieved without pharmacological support. Second-line treatments should be considered for smokers who have failed first-line treatment.,70,17,0.24285714285714285
9781910797006,ch06,"Relapses are common, and should engender repeated attempts.","Intensive interventions are more elaborate than the brief interventions described above. Generally speaking, they require trained counselors and can be conducted either as individual or group sessions. Most often, multiple sessions are necessary. Only a minority of smokers referred for intensive programs will attend. Such programs can, however, provide important support for many smokers, and every practitioner should be able to refer patients for intensive intervention.",77,12,0.15584415584415584
9781910797006,ch06,Smoking cessation activities should be an integrated part of every medical practice.,"Cigarette smoking should be regarded as a primary disease, and its treatment should be integrated into each healthcare system. This should include adequate training of personnel to interview patients for smoking status as a 'vital sign'. The healthcare system should also provide adequate support for smoking cessation efforts and personnel at all levels should be active participants in smoking cessation interventions. Data show that quit rates increase when more personnel at more levels participate in smoking cessation therapy.",87,14,0.16091954022988506
9781910797006,ch07,Optimum clinical benefits require an integrated program combining pulmonary rehabilitation with pharmacotherapy.,"Clinical monitoring. In view of the above, all patients with COPD should be treated initially and aggressively with bronchodilators to control symptoms. Their response should be monitored with objective measures of airflow and on the basis of clinical outcomes, such as symptoms and performance. Adequate assessment of clinical response may require exercise challenge. It is common for patients with COPD to restrict their level of activity progressively as the disease worsens. This reduces dyspnea, but at the cost of an increasingly sedentary existence. Treatment with bronchodilators alone is often insufficient to treat such patients. Usually, improvements in physiological function can benefit the patient only if the bronchodilator treatment is used together with an aggressive rehabilitation program (see pages 113 -). Thus, though bronchodilators form first-line therapy in COPD, for their use to be successful they must be integrated into an appropriate management plan, such as that suggested in the GOLD strategy document (see Table 7.2) or the COPD Foundation Guide (see Table 7.1).",216,15,0.06944444444444445
9781910797006,ch07,Bronchodilators are the first-line treatment in COPD; they can be effectively used concurrently and also have beneficial non-bronchodilator effects.,"beta -agonists act as bronchodilators by acting on the beta -subclass of beta-agonist receptors in airway smooth muscle, thereby increasing cyclic adenosine monophosphate (cAMP) levels (Figure 7.1), which in turn decreases airway smooth muscle tone. beta-agonists can act on beta-receptors on other cell types as well (exempli gratia the heart). By relaxing vascular smooth muscle, they can increase blood flow to relatively poorly ventilated areas and may thus cause a reduction in oxygenation in some settings. Effects on airway epithelial cells and inflammatory cells may be beneficial (see below), but the clinical importance of all these non-bronchodilator effects remains uncertain.",153,35,0.22875816993464052
9781910797006,ch07,"Short courses (7-14 days) of systemic corticosteroids may help following exacerbations, but should not be used over the long term.","Glucocorticosteroids. Oral corticosteroids should be avoided if at all possible in the management of stable COPD. Corticosteroid-induced side effects are relatively common and can be devastating in patients with COPD. Corticosteroid myopathy may further compromise individuals already relatively unable to exercise. Corticosteroid-induced osteoporosis may lead to fractures, which not only compromise mobility but also, if they occur in the spine or ribs, may lead to chest-wall splinting and an increased risk of pneumonia. Chronic administration of oral corticosteroids has been associated with increased mortality in patients with COPD. However, systemic corticosteroids may be of benefit during COPD exacerbations (Table 7.7). Treatment should be stopped after 7-14 days.",165,30,0.18181818181818182
9781910797006,ch07,Inhaled glucocorticosteroids can improve airflow modestly and can reduce the frequency and severity of exacerbations.,"Inhaled corticosteroids also reduce the frequency and severity of exacerbations. This decrease appears to be associated with a beneficial effect on health status (quality of life), which is reasonable, as COPD exacerbations are associated with a worsening in health status. Several large studies have demonstrated a statistically significant benefit in terms of both exacerbations and health status. The effect on exacerbations is generally due to the effect in the most severely affected patients who experience the most frequent exacerbations, although milder cases may also benefit. Inhaled glucocorticosteroids should therefore be considered for patients with more severe airflow limitation (FEV < 60% predicted) who experience frequent exacerbations, particularly if they are already receiving maximal bronchodilator therapy.",153,25,0.16339869281045752
9781910797006,ch07,Influenza vaccination is recommended for patients with COPD; there is also some evidence to support pneumococcal vaccination.,"Vaccines. Influenza vaccination is recommended for all elderly patients since it can reduce mortality from influenza by around 50%. Vaccines that contain killed or live inactivated viruses are particularly recommended for elderly patients with COPD. The vaccine is adjusted each year to be effective against the appropriate strains of the virus, and the vaccination is usually given once a year in the autumn (or twice a year in the autumn and winter in some countries). Recent strategies have also advocated immunization of individuals likely to transmit influenza to patients with COPD.",106,24,0.22641509433962265
9781910797006,ch07,"Rehabilitation has been shown to be beneficial in terms of improving exercise tolerance, symptoms of breathlessness and fatigue in patients with COPD.","Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, and pneumococcal infection is more common in adults over the age of 50. Pneumococcal vaccination has been shown to be beneficial in reducing mortality from streptococcal pneumonia in an elderly population and, by extrapolation, might be expected to be effective in patients with COPD. While data regarding the specific use of pneumococcal vaccination in patients with COPD are limited, vaccination is recommended for those aged 65 or older and younger patients with COPD with significant comorbid conditions such as cardiac disease or severe airflow limitation (FEV < 40% predicted).",132,28,0.21212121212121213
9781910797006,ch07,Surgical removal of large bullae and lung volume reduction surgery may improve lung function and symptoms in carefully selected patients.,"Lung volume reduction surgery has been shown to improve FEV, decrease total lung capacity, and improve exercise tolerance and quality of life; these effects may last for more than 2 years. In addition, longer-term follow-up has shown that lung volume reduction surgery leads to an improvement in maximal work capacity and health-related quality of life, a reduction in exacerbation frequency and improved survival. These beneficial effects are largely seen in those patients with predominant upper-zone emphysema and poor exercise tolerance. The efficacy of surgical and bronchoscopic lung volume reduction also depends on the presence of collateral ventilation to the diseased lobe (detected by the presence of an incomplete fissure between the lung lobes on CT scanning). Lung volume reduction surgery is expensive and should be reserved for carefully selected patients.",162,23,0.1419753086419753
9781910797006,ch07,"Lung transplantation in patients with very advanced COPD improves health status and functional capacity, though it does not convey a survival benefit.","Lung volume reduction surgery has been shown to improve FEV, decrease total lung capacity, and improve exercise tolerance and quality of life; these effects may last for more than 2 years. In addition, longer-term follow-up has shown that lung volume reduction surgery leads to an improvement in maximal work capacity and health-related quality of life, a reduction in exacerbation frequency and improved survival. These beneficial effects are largely seen in those patients with predominant upper-zone emphysema and poor exercise tolerance. The efficacy of surgical and bronchoscopic lung volume reduction also depends on the presence of collateral ventilation to the diseased lobe (detected by the presence of an incomplete fissure between the lung lobes on CT scanning). Lung volume reduction surgery is expensive and should be reserved for carefully selected patients. Lung transplantation. In patients with very advanced COPD, lung transplantation has been shown to improve health status and functional capacity, though it does not convey a survival benefit. The main criteria for lung transplantation are a Bode index (Body mass index, Obstruction, Dyspnea, Exercise; see Table 4.2) of 7-10 and one of the following.",240,27,0.1125
9781910797006,ch08,Acute exacerbations of COPD are common and place a huge burden on healthcare resources.,"Acute exacerbations of chronic obstructive pulmonary disease (COPD), particularly those that result in hospitalization, place a large burden on healthcare resources. It has been estimated that, in an average UK Health Authority with a population of 250 000, there will be 14 200 consultations with a primary care physician and 680 hospital admissions for exacerbations of COPD each year. In the UK, respiratory admissions account for 25% of all acute emergency admissions, and COPD accounts for more than half of these, representing more than 200 000 hospital admissions per year. Recent studies have suggested that up to 50% of patients do not report exacerbations, so the true frequency is much higher than the number of consultations with primary care physicians suggests. Thus, the healthcare burden imposed by exacerbations of COPD is enormous. Annual costs in the USA are estimated at nearly $29.5 billion and $20.4 billion in direct and indirect costs, respectively. The comparable annual figure in the EU is 80 billion in total costs.",204,18,0.08823529411764706
9781910797006,ch08,"The main etiologic factors in acute exacerbations are bacterial infection, respiratory viruses and air pollution.","The main etiologic factors in exacerbations of COPD are thought to be bacterial and viral infections, and air pollutants. Other factors associated with exacerbations of COPD are social deprivation and changes in temperature. However, in around 30% of exacerbations of COPD, no obvious etiologic factor is found. Bacteria. Between 30% and 50% of patients with exacerbations of COPD have a positive sputum culture for bacteria. However, around 20-30% of clinically stable patients also have a positive bacterial culture from sputum. Bronchoscopic protected specimen brush biopsies show that bacteria are present in the lower airways in greater numbers during exacerbations than in the stable clinical state, suggesting infection. The main organisms present in sputum in exacerbations of COPD are Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Gram-negative bacteria, such as Pseudomonas aeruginosa, are less common during exacerbations of COPD, but occur with increasing frequency in patients with severe airflow limitation. In some studies, atypical bacterial pathogens such as Chlamydia pneumoniae have been found during exacerbations of COPD. Changes in bacterial strain have also been associated with acute exacerbations.",263,20,0.07604562737642585
9781910797006,ch08,"Most exacerbations of COPD are managed at home, but those with suspected respiratory failure should be admitted to hospital.","Management at home. Most exacerbations of COPD are treated in primary care; only a minority of patients are admitted to hospital. Bronchodilators. The dose and the frequency of use of bronchodilators are increased in home management of exacerbations of COPD. If not already used, therapy with multiple bronchodilator classes may be added if symptoms are not improving. In the most severe cases, high-dose nebulized bronchodilators can be given on a regular or as-required basis for several days. However, there is evidence that the use of multiple doses of bronchodilators by metered-dose inhaler with a spacer device has an effect similar to that of nebulized bronchodilators in exacerbations of COPD. When a nebulizer is used, it is probably safer to use air as the driving gas, rather than oxygen, and to continue oxygen therapy via nasal prongs. The long-term use of nebulized therapy after acute exacerbations of COPD is not routinely recommended.",219,23,0.1050228310502283
9781910797006,ch08,"Treatment includes oxygen, increased use of bronchodilators, antibiotics and short-term oral glucocorticosteroids.","Bronchodilators. The dose and the frequency of use of bronchodilators are increased in home management of exacerbations of COPD. If not already used, therapy with multiple bronchodilator classes may be added if symptoms are not improving. In the most severe cases, high-dose nebulized bronchodilators can be given on a regular or as-required basis for several days. However, there is evidence that the use of multiple doses of bronchodilators by metered-dose inhaler with a spacer device has an effect similar to that of nebulized bronchodilators in exacerbations of COPD. When a nebulizer is used, it is probably safer to use air as the driving gas, rather than oxygen, and to continue oxygen therapy via nasal prongs. The long-term use of nebulized therapy after acute exacerbations of COPD is not routinely recommended.",193,27,0.13989637305699482
9781910797006,ch08,Exacerbations can be prevented by inhaled corticosteroids and vaccination against influenza.,"Bronchodilators. The dose and the frequency of use of bronchodilators are increased in home management of exacerbations of COPD. If not already used, therapy with multiple bronchodilator classes may be added if symptoms are not improving. In the most severe cases, high-dose nebulized bronchodilators can be given on a regular or as-required basis for several days. However, there is evidence that the use of multiple doses of bronchodilators by metered-dose inhaler with a spacer device has an effect similar to that of nebulized bronchodilators in exacerbations of COPD. When a nebulizer is used, it is probably safer to use air as the driving gas, rather than oxygen, and to continue oxygen therapy via nasal prongs. The long-term use of nebulized therapy after acute exacerbations of COPD is not routinely recommended.",193,18,0.09326424870466321
9781910797006,ch08,Non-invasive ventilation has been shown to reduce mortality in patients with acute-on-chronic respiratory failure.,"Glucocorticosteroids have been shown to reduce symptoms and improve lung function effectively in patients with acute exacerbations of COPD. Currently, systemic corticosteroid, 40 mg/day for 5 days, is recommended for all patients with an acute exacerbation in the absence of significant contraindications. Oral corticosteroids are preferable. Nebulized budesonide is an alternative to oral corticosteroid treatment in exacerbations without respiratory failure and is associated with a reduction in complications, such as hyperglycemia. Corticosteroids should be discontinued after the acute episode; clinical improvement with corticosteroids during the exacerbation does not indicate the need for long-term treatment with oral or inhaled corticosteroids.",153,23,0.1503267973856209
9781910797082,ch01,"Psoriasis affects up to 3% of the population; however, there is considerable interracial variation in prevalence.","Psoriasis is a common chronic, disfiguring inflammatory skin disease that affects up to 3% of the population. Several clinical variants exist (see Chapter 2) of which chronic plaque psoriasis (psoriasis vulgaris) is the most common form (85-90% of all cases). Effects of ethnicity. Although all races are affected, there is considerable interracial variation. For example, psoriasis is relatively common in white people but appears to be very uncommon in American Indians and in Japanese people. Prevalence appears to be highest in Scandinavian countries and northern Europe.",118,23,0.19491525423728814
9781910797082,ch01,The usual age of onset is 20-35 years.,"Effects of gender and age. Men and women are affected equally. The usual age of onset is 20-35 years, with 75% of all cases occurring for the first time before 40 years of age. However, psoriasis can occur at any age, including childhood (often signifying a more severe clinical course) and old age.",68,11,0.16176470588235295
9781910797082,ch01,"The impact of psoriasis on the patient's quality of life is similar - physically and emotionally - to that of ischemic heart disease, diabetes or chronic obstructive pulmonary disease.","Socioeconomic burden. Psoriasis severely affects a patient's quality of life in terms of both psychological and physical well-being. Studies comparing psoriasis with other important chronic diseases have shown that the impact of psoriasis on the patient's quality of life is at least as great as that of ischemic heart disease, diabetes and chronic obstructive pulmonary disease. Psoriasis is therefore a disease of major socioeconomic importance; in the USA alone, the annual cost to society has been estimated at US$3.5 billion. Furthermore, there is increasing evidence of an association between psoriasis and important comorbidities including cardiovascular and psychiatric disease; evidence suggests that patients with moderate and severe disease have a high mortality due to cardiovascular events (see Chapter 2).",155,37,0.23870967741935484
9781910797082,ch01,A family history of psoriasis is found in approximately 30% of patients.,"Genetics. In 1963, Gunnar Lomholt, a pioneer in the epidemiology of psoriasis, stated in his classic thesis that the disease 'is capricious and refuses to part with its innermost secret', but also wrote: 'that psoriasis is genetically conditioned is beyond doubt'. The validity of this statement has been borne out by population and family studies and research in twins, all of which suggest an important genetic component to the disease. For example, in terms of types I and II psoriasis (see page 7), approximately 80% of patients with type I psoriasis are positive for the HLA-Cw6 gene, compared with only 20% of those with type II psoriasis. Approximately 30% of patients with psoriasis will have a known family history of the disease.",168,16,0.09523809523809523
9781910797082,ch01,"Three key events characterize the pathophysiology of psoriasis: epidermal hyperproliferation, angiogenesis and accumulation of inflammatory cells.","There have been a number of key genetic advances in recent years: first, the chromosomal localization (on 6p21.3) of the major psoriasis genetic locus, psoriasis susceptibility 1 (PSORS1), which contributes up to 50% of the genetic risk; and secondly, the discovery of several genes that, while conferring a low genetic risk, point to specific biological pathways for the disease. To date, approximately 35 genetic loci have been associated with psoriasis. Interesting candidate genes at each of these loci cluster around specific biological pathways involved in the epidermal barrier, innate immunity and adaptive immune response. They suggest a key role for host defenses against microbes, which involve interferon. Intriguingly, these genetic findings indicate a key role for tumor necrosis factor (TNF)alpha in disease pathogenesis, thus supporting therapy targeted at TNF. Furthermore, when combined with immunologic studies, they define the key T-cell subset in psoriasis pathogenesis as T helper (Th)-17 cells (see below). This explains the highly effective treatments designed to block Th17 cells or prevent their differentiation through inhibition of interleukin (IL)-23 (see Chapter 8).",249,30,0.12048192771084337
9781910797082,ch01,"Important environmental triggers include infection, drugs, and physical and psychological stress.","Environmental factors also play a key etiologic role. For example, in 60% of patients with guttate psoriasis (see page 18), the disease is precipitated by systemic, usually upper respiratory tract, streptococcal infection. Other important environmental factors include drugs, particularly lithium and antimalarials, and physical or psychological stress. Excessive alcohol intake is also associated with disease deterioration and makes management more difficult.",87,14,0.16091954022988506
9781910797082,ch01,Evidence indicates that psoriasis is primarily an immunologic T-cell-driven disease requiring participation of both innate and T-cell-mediated mechanisms.,"Immunologic changes. Evidence that psoriasis is primarily an immunologic disease comes from many different sources. In evolving lesions, lymphocytes infiltrate the skin early, before epidermal and other changes. Psoriasis is associated with certain HLA antigens, particularly HLA-Cw6, which are cell-surface molecules critical to the regulation of T-lymphocyte function. Experimentally, psoriasis can be induced in non-lesional skin transplanted onto mice by injection of lymphocytes from the same patient. Finally, psoriasis responds rapidly to treatments designed to inhibit T-lymphocyte function, such as ciclosporin (cyclosporine), as well as to specific biological agents targeting key cytokines (IL17, TNFalpha, etc.) involved in its immunopathogenesis.",169,30,0.17751479289940827
9781910797082,ch02,Psoriasis is a clinical diagnosis; there is no blood test specific for this disease.,"Chronic plaque psoriasis (psoriasis vulgaris) accounts for approximately 85% of all cases of psoriasis. Most patients develop clinical signs of psoriasis before the age of 35 years and about 10% of patients develop the condition during childhood. A history of long-standing dandruff, scaling in the ears, pruritus ani or vulvae, arthralgias or the presence of other autoimmune diseases, such as inflammatory bowel disease, diabetes or thyroid disease, may be clues to the diagnosis (Table 2.1). There is no specific blood test for psoriasis.",124,18,0.14516129032258066
9781910797082,ch02,Chronic discoid plaque psoriasis is the most common subtype of psoriasis.,"Chronic plaque psoriasis (psoriasis vulgaris) accounts for approximately 85% of all cases of psoriasis. Most patients develop clinical signs of psoriasis before the age of 35 years and about 10% of patients develop the condition during childhood. A history of long-standing dandruff, scaling in the ears, pruritus ani or vulvae, arthralgias or the presence of other autoimmune diseases, such as inflammatory bowel disease, diabetes or thyroid disease, may be clues to the diagnosis (Table 2.1). There is no specific blood test for psoriasis.",124,19,0.1532258064516129
9781910797082,ch02,"Psoriasis can sometimes be triggered by infection, trauma, stress or medications.","Guttate lesions, approximately 1 cm in diameter, often follow a streptococcal infection in younger patients. Multiple drop-like lesions occur (Figure 2.4) and are typically distributed on the trunk; they may develop rapidly over a period of 1 week. Larger plaques may be seen in areas such as the lumbar-sacral region, and often involve the natal (gluteal) cleft with extension to perianal areas. Guttate psoriasis can be a one-off event or it may recur as further guttate episodes or (in about 50% of cases) as chronic plaque psoriasis.",135,16,0.11851851851851852
9781910797082,ch02,"The scalp, elbows, knees and sacrum are the areas most commonly affected by psoriasis.","Recent studies have indicated that pustular forms of psoriasis may be genetically distinct from chronic plaque psoriasis. This fits well with the intermittent nature of the disease and the poorer response of pustular forms to standard treatments. Distribution of psoriatic lesions is highly symmetrical in most cases except when modified, for example, by chronic scratching on the back or sides of the scalp. Regions commonly involved include the thicker areas of the skin, such as the scalp, elbows, knees, sacral area and knuckles on the hand dorsa.",112,20,0.17857142857142858
9781910797082,ch02,Psoriasis is associated with a number of comorbidities that have important health and socioeconomic implications.,"It is becoming increasingly clear that a multitude of diseases is associated with psoriasis. This observation has strong clinical implications and suggests that the management of patients with psoriasis should take into account factors other than the severity of the skin disease. For example, management planning should incorporate measures to recognize and prevent cardiovascular disease and other consequences of the metabolic syndrome, and should take into account the fact that some treatments for moderate and severe disease, particularly methotrexate and the tumor necrosis factor (TNF)alpha blockers, may be associated with a reduction in various parameters of cardiovascular disease. Thus, the treatment of psoriasis should involve not just patient-driven factors, such as a desire to improve quality of life, but also parameters, such as decreased morbidity/mortality, which have important health and socioeconomic implications.",165,21,0.12727272727272726
9781910797082,ch03,"Various dermatological disorders can resemble psoriasis, including other inflammatory dermatoses, infections and neoplasms.","Although diagnosis is relatively straightforward, a number of other dermatological entities may be confused with psoriasis (Table 3.1). A careful medical and family history and physical examination, together with laboratory findings, will usually reveal the correct diagnosis. Candidiasis. In flexural areas, peripheral pustules are characteristic of Candida infection. The presence of yeast and pseudohyphae in Gram-stained microscopy specimens will confirm infection.",89,22,0.24719101123595505
9781910797082,ch03,"Medical and family history and physical examination, along with laboratory findings, are all important in establishing the correct diagnosis.","Although diagnosis is relatively straightforward, a number of other dermatological entities may be confused with psoriasis (Table 3.1). A careful medical and family history and physical examination, together with laboratory findings, will usually reveal the correct diagnosis. Candidiasis. In flexural areas, peripheral pustules are characteristic of Candida infection. The presence of yeast and pseudohyphae in Gram-stained microscopy specimens will confirm infection.",89,22,0.24719101123595505
9781910797082,ch04,Patient assessment should include reference to important comorbidities.,"Factors in the patient's social history can contribute to disease severity or affect treatment outcome and, although sometimes difficult to change, it is important to recognize such factors in terms of overall disease management. Lifestyle advice regarding the benefits of exercise, avoiding excess alcohol intake and following a healthy diet may be useful. However, despite multiple claims, no one specific diet has been shown to be more beneficial than another. Patients should be advised to avoid trauma, friction and scratching (including shaving trauma in men and women, scratching of ear canals, harsh shampooing and picking of crusts on the scalp). In addition, providing information about stress reduction and management is often of value.",134,13,0.09701492537313433
9781910797082,ch04,"Before beginning therapy, the patient should have a realistic expectation of the outcome.","Managing patient expectations. Before beginning therapy, the patient should have a realistic expectation of the outcome. In practice, this means explaining that treatment will be lengthy and is not curative, and that the psoriasis is likely to relapse if therapy is discontinued. In addition, it is crucial to spend sufficient time explaining practical aspects, such as.",69,15,0.21739130434782608
9781910797082,ch04,All systemic medications used for psoriasis can have limiting side effects and toxicities.,"An impressive array of treatments for all forms of psoriasis, whether mild, moderate or severe, is now available. By convention, topical therapy is the preferred first-line treatment for psoriasis. At present, if the response to topical therapy is inadequate, most dermatologists try phototherapy next. However, particularly in the UK and Europe, systemic drugs are now being introduced earlier in treatment algorithms. This partly reflects growing concerns about phototherapy carcinogenicity, but also the increasing realization that psoriasis is a systemic disease (see pages 26 -) and as such requires systemic management. Psoriasis is a chronic disease that requires long-term therapy, which raises the potential problem of cumulative toxicities. Rotational, combination and sequential therapeutic strategies have potential advantages in terms of reduced side effects and increased efficacy, while maintaining longer-term control and reducing the frequency of inevitable relapses.",179,17,0.09497206703910614
9781910797082,ch04,"Rotational, combination and sequential therapeutic strategies can reduce side effects and increase efficacy, while maintaining longer-term control of the psoriasis and reducing the frequency and severity of inevitable relapses.","An impressive array of treatments for all forms of psoriasis, whether mild, moderate or severe, is now available. By convention, topical therapy is the preferred first-line treatment for psoriasis. At present, if the response to topical therapy is inadequate, most dermatologists try phototherapy next. However, particularly in the UK and Europe, systemic drugs are now being introduced earlier in treatment algorithms. This partly reflects growing concerns about phototherapy carcinogenicity, but also the increasing realization that psoriasis is a systemic disease (see pages 26 -) and as such requires systemic management. Psoriasis is a chronic disease that requires long-term therapy, which raises the potential problem of cumulative toxicities. Rotational, combination and sequential therapeutic strategies have potential advantages in terms of reduced side effects and increased efficacy, while maintaining longer-term control and reducing the frequency of inevitable relapses.",179,38,0.2122905027932961
9781910797082,ch04,Psoriasis is a chronic disease requiring long-term therapy.,"Psoriasis is a chronic disease that requires long-term therapy, which raises the potential problem of cumulative toxicities. Rotational, combination and sequential therapeutic strategies have potential advantages in terms of reduced side effects and increased efficacy, while maintaining longer-term control and reducing the frequency of inevitable relapses.",60,13,0.21666666666666667
9781910797082,ch05,"A wide variety of topical therapies is available; topical corticosteroids and vitamin D analogs, or a combination of both in a single preparation, are considered first-line therapy for most patients.","Topical therapy. Patients with mild-to-moderate chronic plaque psoriasis comprise the majority of those requiring treatment. In general, most of those who remain adherent to their topical therapy can be managed successfully. Those with more extensive chronic plaque disease may also benefit from topical therapy, usually in combination with phototherapy, systemic or biological therapy, though the logistics of application become difficult and more time-consuming. A large number of different topical preparations are available (Table 5.1); topical corticosteroids and vitamin D analogs are considered first-line therapy for most patients. When deciding which product to prescribe, therapeutic efficacy must be balanced against the cosmetic acceptability and the local side-effect profile, particularly as most treatments take several weeks to reach their maximum benefit. Previous therapy. Tried and tested treatments that the patient has previously found helpful are likely to be the best choice again. However, patients commonly cite previous therapy as unhelpful, so it is important to establish the reasons for this and the way in which the treatment failed. Sometimes expectations are unrealistic; if the patient was hoping for a cure, disappointment will ensue if the psoriasis relapses off therapy. Always ensure that the treatment duration has been adequate and the patient has adhered to the treatment plan. For example, calcipotriol and tazarotene therapy needs to be continued for 8-12 weeks to achieve maximum benefit. Local side effects and poor cosmetic acceptability are the most frequent reasons for patient dissatisfaction with previous therapy. These may be overcome by using a different formulation of the active ingredient or changing the frequency or time of application.",328,40,0.12195121951219512
9781910797082,ch05,Approximately 70% of patients (those with mild or moderate disease) can be managed using topical therapy alone.,"Patients with mild-to-moderate chronic plaque psoriasis comprise the majority of those requiring treatment. In general, most of those who remain adherent to their topical therapy can be managed successfully. Those with more extensive chronic plaque disease may also benefit from topical therapy, usually in combination with phototherapy, systemic or biological therapy, though the logistics of application become difficult and more time-consuming. A large number of different topical preparations are available (Table 5.1); topical corticosteroids and vitamin D analogs are considered first-line therapy for most patients. When deciding which product to prescribe, therapeutic efficacy must be balanced against the cosmetic acceptability and the local side-effect profile, particularly as most treatments take several weeks to reach their maximum benefit.",151,22,0.1456953642384106
9781910797082,ch05,"Consideration should be given to the body site being treated, since this influences which active ingredient and formulation to prescribe.","Tried and tested treatments that the patient has previously found helpful are likely to be the best choice again. However, patients commonly cite previous therapy as unhelpful, so it is important to establish the reasons for this and the way in which the treatment failed. Sometimes expectations are unrealistic; if the patient was hoping for a cure, disappointment will ensue if the psoriasis relapses off therapy. Always ensure that the treatment duration has been adequate and the patient has adhered to the treatment plan. For example, calcipotriol and tazarotene therapy needs to be continued for 8-12 weeks to achieve maximum benefit. Local side effects and poor cosmetic acceptability are the most frequent reasons for patient dissatisfaction with previous therapy. These may be overcome by using a different formulation of the active ingredient or changing the frequency or time of application.",170,23,0.13529411764705881
9781910797082,ch05,Efficacy and cosmetic acceptability are key determinants of patients' adherence to therapy.,"Side effects, safety and cosmetic acceptability. Topical corticosteroids are popular with patients, and remain first-line therapy in the USA, because of their immediate efficacy and cosmetic acceptability. They are available in a host of different bases including creams, lotions, gels, sprays, foams, ointments and shampoos. It is important for physicians to outline the problems associated with continuous long-term therapy and to monitor prescriptions carefully to avoid excessive use.",99,18,0.18181818181818182
9781910797082,ch05,Time spent detailing the practicalities of topical therapy with patients is crucial to achieving a successful therapeutic outcome.,"Efficacy. Compared with placebo, both the 0.05% and 0.1% preparations produce a significant reduction in scaling and plaque elevation and improvement in global severity scores in mild-to-moderate plaque psoriasis; there is little difference between the two preparations. Tazarotene has the advantage of requiring only once-daily application. Few studies have compared tazarotene with other topical therapies. In terms of overall treatment success, both concentrations of tazarotene gel have similar efficacy to twice-daily fluocinonide (0.05%) cream, a potent topical corticosteroid, following 12 weeks' therapy. Predictably, patients treated with the topical corticosteroid relapsed quickly after cessation of therapy, whereas the therapeutic benefit of tazarotene was sustained during the 12-week follow-up period. The drop-out rate for patients using tazarotene was higher than for those using the corticosteroid. Combining tazarotene with a topical corticosteroid enhances speed of response and overall efficacy, and also reduces retinoid-induced skin irritation.",228,20,0.08771929824561403
9781910797082,ch06,"Phototherapy (broad-band UVB and narrow-band UVB) is widely used for extensive chronic plaque psoriasis and sebo-psoriasis, and persistent guttate psoriasis.","The beneficial effects of natural sunlight on psoriasis are well documented. Phototherapy involves whole-body exposure to artificial sources of ultraviolet (UV) radiation and is being widely and increasingly used for the treatment of extensive psoriasis resistant to topical therapy. Natural UV radiation is subdivided into UVC (below 280 nm), which is screened from the Earth's surface by ozone, UVB (280-320 nm) and UVA (320-400 nm) radiation. UVB radiation is absorbed mainly by the epidermis and is an effective treatment for psoriasis. UVA, however, penetrates the deeper layers of the dermis and is largely ineffective in psoriasis unless given in combination with a photosensitizer (see page 68). Administration. Two sources of UV radiation are used to administer UVB phototherapy: conventional broad-band UVB (emission spectrum 270-350 nm) and the newer, more effective, narrow-band UVB via the TL-01 fluorescent lamp (emission spectrum 311-313 nm) or via the excimer laser. Recently, pulsed dye lasers have also been shown to produce significant clinical responses.",235,42,0.17872340425531916
9781910797082,ch06,"Burning and, rarely, photosensitive rashes complicate phototherapy in the short term.","Short-term risks. Most dosage protocols aim to provide suberythema UVB to minimize short- and long-term toxicity. However, mild erythema is common and may in fact improve clearance rates. Acute sunburn can be avoided by careful dosimetry. Narrow-band UVB may be less likely to produce burning than broad-band UVB, though both are probably associated with a long-term risk of skin cancer. Xerosis (dry skin) and consequent itching usually respond to simple emollients. Rarely, photosensitive rashes such as polymorphic light eruption, lupus erythematosus and photosensitive psoriasis may be precipitated in vulnerable individuals.",147,18,0.12244897959183673
9781910797082,ch06,"Short-term risks of PUVA include nausea (following oral ingestion of methoxsalen), itching and phototoxic reactions.","Short-term risks. Most dosage protocols aim to provide suberythema UVB to minimize short- and long-term toxicity. However, mild erythema is common and may in fact improve clearance rates. Acute sunburn can be avoided by careful dosimetry. Narrow-band UVB may be less likely to produce burning than broad-band UVB, though both are probably associated with a long-term risk of skin cancer. Xerosis (dry skin) and consequent itching usually respond to simple emollients. Rarely, photosensitive rashes such as polymorphic light eruption, lupus erythematosus and photosensitive psoriasis may be precipitated in vulnerable individuals.",147,27,0.1836734693877551
9781910797082,ch06,There is a small increase in the risk of non-melanoma skin cancer with long-term phototherapy.,"Long-term risks. As with any form of chronic UV exposure, it is likely that phototherapy carries an increased risk of non-melanoma skin cancers, which increases with cumulative exposure. Broad-band UVB is probably associated with a small increase in the risk of squamous cell carcinomas, particularly in patients receiving high-level exposure (more than 300 treatments). Narrow-band UVB phototherapy has now been in clinical use for long enough to determine the associated risk precisely. On the basis of cancer-risk calculations from mouse models and efficacy data, it seems likely that the risk is at least as great as that associated with broad-band UVB, but probably less than that associated with PUVA. In view of this, phototherapy may be relatively contraindicated for patients with pre-existing risk factors for skin cancer, such as individuals who work outside, those who have already had significant amounts of phototherapy, patients with very fair skin, and those with multiple melanocytic or atypical nevi.",209,23,0.11004784688995216
9781910797082,ch06,Long-term risks of PUVA include premature skin aging and skin cancer (non-melanoma and melanoma).,"Long-term risks. As with any form of chronic UV exposure, it is likely that phototherapy carries an increased risk of non-melanoma skin cancers, which increases with cumulative exposure. Broad-band UVB is probably associated with a small increase in the risk of squamous cell carcinomas, particularly in patients receiving high-level exposure (more than 300 treatments). Narrow-band UVB phototherapy has now been in clinical use for long enough to determine the associated risk precisely. On the basis of cancer-risk calculations from mouse models and efficacy data, it seems likely that the risk is at least as great as that associated with broad-band UVB, but probably less than that associated with PUVA. In view of this, phototherapy may be relatively contraindicated for patients with pre-existing risk factors for skin cancer, such as individuals who work outside, those who have already had significant amounts of phototherapy, patients with very fair skin, and those with multiple melanocytic or atypical nevi.",209,24,0.11483253588516747
9781910797082,ch06,"Photochemotherapy (PUVA) is indicated for patients with moderate-to-severe psoriasis involving more than 10% of the body surface area, and those whose psoriasis does not respond to topical therapy.","The dose of methoxsalen is based on the patient's weight; the most effective dose is 0.3-0.4 mg/kg. The initial dose of UVA can be increased by 0.5-1 J/cm at every second treatment, or until a minor degree of erythema is achieved with each session. It is essential that the dosage of UVA and, if necessary, oral methoxsalen, is adjusted depending on the individual patient's sensitivity and skin type. Patients with skin type I (always burns, never tans) require lower doses than patients with types V or VI (moderately or heavily pigmented skin). Patients are usually treated twice a week. If nausea and vomiting or ocular problems develop secondary to ingestion of the sensitizing drug, or patients do not like wearing ocular protection, the drug may be administered during bathing. The patient soaks in water containing measured amounts of the sensitizing drug before UVA exposure. Indications. PUVA is indicated for patients with psoriasis resistant to topical therapies or with moderate-to-severe psoriasis affecting more than 10% of the body surface area. PUVA may also be beneficial for more localized recalcitrant disease (exempli gratia palmar-plantar psoriasis), often in combination with retinoids. Caution must be exercised in patients with inflammatory psoriasis.",287,44,0.15331010452961671
9781910797082,ch06,"In patients who already have risk factors for skin cancer, phototherapy and PUVA should be prescribed only with extreme caution.","Patients who have received large cumulative doses of PUVA (in excess of 2000 J/cm or more than 260 treatments) are at greater risk of squamous cell carcinoma, particularly if they are fair-skinned. There is a smaller increase in the incidence of basal cell carcinoma. Most squamous cell carcinomas associated with PUVA are non-invasive, though cases with metastases have been reported. In addition, an increased incidence of malignant melanoma has been reported in a special cohort of 1370 patients followed over 20 years by numerous centers in the USA. These findings have not been confirmed in Europe, however. To reduce the overall risk of skin cancer, PUVA is often combined with systemic retinoids or topical therapy, such as vitamin D and vitamin A derivatives, so that fewer treatments are needed and the cumulative UVA dose is reduced. As with phototherapy, PUVA is relatively contraindicated in patients who already have risk factors for skin cancer. It should therefore be prescribed for these patients only with extreme caution.",211,24,0.11374407582938388
9781910797082,ch07,Conventional systemic therapies can be extremely helpful in the short- and long-term management of psoriasis.,"There are several important factors to consider before starting systemic therapy (Table 7.1). To ensure appropriate safety and maximal efficacy, it is essential that a coordinated approach is adopted by the dermatologist, primary care physician, specialist dermatology nurse, physician assistant, nurse practitioner and other staff. Patient education is also important before embarking on any form of systemic therapy, particularly as all available treatments are associated with potential short- and long-term side effects. The benefits of disease clearance or improvement must be balanced against the risk of these side effects.",108,22,0.2037037037037037
9781910797082,ch07,Teratogenicity limits the use of methotrexate and acitretin.,"Various agents are used in the systemic treatment of psoriasis (Table 7.2). With the exception of retinoids, all are associated with varying degrees of immunosuppression. Certain groups of patients (exempli gratia those with cancer or those with HIV) may be especially vulnerable to this effect of treatment. Therefore, the risks of systemic therapy need to be carefully considered. Many patients in the USA are routinely assessed for HIV status before systemic therapy, including receptor-targeted therapies (see Chapter 8). This is not the case in the UK, but patients are provided with information leaflets indicating that those at risk of infection should inform the prescribing doctor. Methotrexate has been used to treat psoriasis for over 40 years and remains the gold standard. Accepted guidelines for the use of methotrexate have evolved worldwide during this time.",175,18,0.10285714285714286
9781910797082,ch07,Close monitoring and adherence to guidelines are key to minimizing toxicity.,"While debate exists, many suggest that the risk of long-term hepatotoxicity (fibrosis and ultimately cirrhosis) is increased when the total cumulative dose reaches 4 g, especially in those who are obese, have diabetes and/or have a current or past history of drinking alcohol to excess. US guidelines recommend a liver biopsy after approximately 3.5-4 g (2-3 years) of continuous methotrexate treatment. In some countries, particularly in the UK, measurement of procollagen III, a serological measure of fibrosis, has been adopted to improve monitoring of liver toxicity while minimizing the need for liver biopsy. When levels are within normal range, hepatic fibrosis is extremely unlikely. Newer non-invasive measures of liver fibrosis are under evaluation.",162,12,0.07407407407407407
9781910797082,ch07,"Side effects of systemic therapies for psoriasis include myelosuppression, hepatotoxicity and nephrotoxicity.","Ciclosporin, which was approved for the treatment of psoriasis in the UK in 1993 and in the USA in 1997, has proved to be an excellent therapy for widespread recalcitrant psoriasis and is well tolerated by most patients. It is probably best used as interventional therapy, with slow tapering of the dose once adequate control is obtained. Wherever possible, therapy should be limited to short periods of up to 1 year, with rotation to other systemic agents, phototherapy or biological therapy in order to avoid long-term nephrotoxicity.",115,25,0.21739130434782608
9781910797082,ch08,"Receptor-targeted therapies ('biologics') target specific molecules involved in the immunopathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease and ankylosing spondylitis.","Initial skin activation is required for APCs to migrate from the skin and interact with T cells (proinflammatory state). Similarly, chemokines and proinflammatory cytokines are needed for T cells to enter the skin. These chemokines and cytokines are derived from endogenous skin cells (exempli gratia dendritic cells, macrophages, keratinocytes) as well as recruited cells. The T cells in psoriatic lesions secrete proinflammatory cytokines of the Th-1 and Th-17 type, including IL-12, IL-23, IL-2, interferon gamma and tumor necrosis factor (TNF)alpha. These cytokines induce epidermal and vascular changes that lead to the clinical changes seen in psoriatic plaques (see page 11). As specific details of the immunopathogenesis of psoriasis have been elucidated, new therapies have been developed that target the aberrant immune cells and molecules that trigger the development of psoriatic plaques. Receptor-targeted therapies have been in clinical studies and usage for a wide range of immune-mediated inflammatory disorders since 1997, but for psoriasis since 2003. They are designed specifically to interfere with T-cell activation and effector function in order to prevent the inflammatory effects characteristic of this group of diseases. There are several important factors to consider before starting biological therapy (Table 8.1); for example, many of these drugs are also effective in treating psoriatic arthritis, a debilitating inflammatory arthritis that affects around 30% of patients with moderate-to-severe psoriatic skin disease (see Chapter 9).",328,62,0.18902439024390244
9781910797082,ch08,"The biologics currently available or in clinical trials are all given by injection (subcutaneous, intramuscular or intravenous).","The T cells in psoriatic lesions secrete proinflammatory cytokines of the Th-1 and Th-17 type, including IL-12, IL-23, IL-2, interferon gamma and tumor necrosis factor (TNF)alpha. These cytokines induce epidermal and vascular changes that lead to the clinical changes seen in psoriatic plaques (see page 11). As specific details of the immunopathogenesis of psoriasis have been elucidated, new therapies have been developed that target the aberrant immune cells and molecules that trigger the development of psoriatic plaques. Receptor-targeted therapies have been in clinical studies and usage for a wide range of immune-mediated inflammatory disorders since 1997, but for psoriasis since 2003. They are designed specifically to interfere with T-cell activation and effector function in order to prevent the inflammatory effects characteristic of this group of diseases.",186,28,0.15053763440860216
9781910797082,ch08,A number of exciting new agents are in various stages of development and clinical trials.,"As specific details of the immunopathogenesis of psoriasis have been elucidated, new therapies have been developed that target the aberrant immune cells and molecules that trigger the development of psoriatic plaques. Receptor-targeted therapies have been in clinical studies and usage for a wide range of immune-mediated inflammatory disorders since 1997, but for psoriasis since 2003. They are designed specifically to interfere with T-cell activation and effector function in order to prevent the inflammatory effects characteristic of this group of diseases.",105,16,0.1523809523809524
9781910797082,ch08,Evidence to date suggests that biologics have fewer organ-specific toxic effects than traditional systemic agents.,"Receptor-targeted therapies have revolutionized the treatment of moderate-to-severe psoriasis since their introduction in 2003. They have the advantage over traditional therapies of producing significantly less organ (exempli gratia renal and hepatic) toxicity. Individual drugs may prove to induce sustained drug-free remission rates that are generally longer than with the three traditional agents; likewise, rebound after discontinuation is significantly less evident.",85,20,0.23529411764705882
9781910797082,ch08,Reduction in the inflammatory systemic components of other organs (exempli gratia joints and heart) is a positive development.,"Receptor-targeted therapies have revolutionized the treatment of moderate-to-severe psoriasis since their introduction in 2003. They have the advantage over traditional therapies of producing significantly less organ (exempli gratia renal and hepatic) toxicity. Individual drugs may prove to induce sustained drug-free remission rates that are generally longer than with the three traditional agents; likewise, rebound after discontinuation is significantly less evident. Long-term safety data (up to 10 years) for the three TNFalpha agents have shown no new areas of concern. On the contrary, it is likely that they may help ameliorate the cardiovascular inflammatory component of the disease as well as the skin and joint inflammation, and therefore potentially reduce cardiovascular events in the psoriasis population. Five-year safety data are now available for ustekinumab, with over 70 000 patients having been exposed to this biological agent since its introduction. No longer-term negative issues have been noted.",197,25,0.12690355329949238
9781910797082,ch08,Cost and long-term safety will be important in determining the future role of biologics in the treatment of psoriasis.,"Long-term safety data (up to 10 years) for the three TNFalpha agents have shown no new areas of concern. On the contrary, it is likely that they may help ameliorate the cardiovascular inflammatory component of the disease as well as the skin and joint inflammation, and therefore potentially reduce cardiovascular events in the psoriasis population. Five-year safety data are now available for ustekinumab, with over 70 000 patients having been exposed to this biological agent since its introduction. No longer-term negative issues have been noted. Pharmacogenomics in the future will hopefully allow for more precise targeting of individual drugs for individual patients, singly or in combination. While the goal for patients is long-term disease-free remissions and improved quality of life, overall cost and long-term safety will be key issues in determining the significance of biological therapies in the treatment of psoriasis.",185,26,0.14054054054054055
9781910797082,ch08,"Biosimilar agents, soon to be introduced, could help to reduce cost issues considerably.","Long-term safety data (up to 10 years) for the three TNFalpha agents have shown no new areas of concern. On the contrary, it is likely that they may help ameliorate the cardiovascular inflammatory component of the disease as well as the skin and joint inflammation, and therefore potentially reduce cardiovascular events in the psoriasis population. Five-year safety data are now available for ustekinumab, with over 70 000 patients having been exposed to this biological agent since its introduction. No longer-term negative issues have been noted.",112,18,0.16071428571428573
9781910797082,ch09,"Psoriatic arthritis is often underdiagnosed and undertreated; however, it is important to recognize this disease because advances in therapy offer the prospect of more complete disease control.","Psoriatic arthritis is a common autoimmune inflammatory condition affecting the joints and entheses (insertion sites of tendons and ligaments) of patients with psoriasis. Clinical manifestations are heterogeneous and vary widely in severity. The disease is underdiagnosed and often undertreated. Recent advances in therapy offer the prospect of more complete disease control, including the prevention of joint destruction. It is therefore important for a correct diagnosis to be reached promptly. History and classification. An association between psoriasis and a form of inflammatory arthritis was first suggested in the 1850s. However, the characterization of psoriatic arthritis as a distinct form of arthritis was not fully articulated until the early 1960s by Wright, Baker and others. Until that time, it was considered to be a variant of rheumatoid arthritis seen in individuals with concomitant psoriasis.",172,35,0.20348837209302326
9781910797082,ch09,Traditional oral therapies may be effective for some clinical domains of psoriatic arthritis.,"Although psoriatic arthritis may present in adolescence, onset is most common in patients in their 20s or 30s. Men and women are equally affected. In 75% of cases, onset of skin disease precedes the development of arthritis, often by a decade or more. In 15% of cases, the onset of skin and joint disease is simultaneous and, in approximately 10% of cases, the joint manifestations precede the appearance of skin lesions. It is especially challenging for the clinician to make an accurate diagnosis of psoriatic arthritis when joint manifestations appear before signs of skin disease. In such cases, confirmatory diagnosis may be delayed until skin lesions appear, even when there is strong suspicion based on clinical and radiographic appearance. Table 9.2 lists the disorders that should be considered in the differential diagnosis of psoriatic arthritis.",168,16,0.09523809523809523
9781910797082,ch09,"New therapies with a different mechanism of action from TNF inhibition, ustekinumab and apremilast, have been approved for the treatment of psoriatic arthritis; other promising therapies are in development.","As in rheumatoid arthritis, the etiology of psoriatic arthritis is unknown, but is generally felt to occur as a result of genetic and immunologic factors. Many similar immunologic cellular and cytokine pathways are activated in the skin and joint, promoting migration of immune cells to the site of inflammation and upregulating cellular activation at this site. As in psoriasis, there has been speculation regarding the possibility of infectious antigenic triggering in some cases of psoriatic arthritis. The treatment of psoriatic arthritis has been revolutionized by the recent development and use of receptor-targeted therapies, especially anti-TNF medications, for patients with moderate-to-severe disease. These agents have yielded significant advances in the effective treatment of symptoms and signs of both arthritis and enthesitis. Furthermore, evidence of inhibition or slowing of radiological signs of disease progression suggests that these drugs may have the potential to alter the natural history of psoriatic arthritis. Since not all patients respond to these agents or have side effects, or the agents lose efficacy, newer receptor-targeted therapies are being introduced and studied.",226,44,0.19469026548672566
9781910797082,ch09,The classification criteria for psoriatic arthritis are highly specific and sensitive.,"The treatment of psoriatic arthritis has been revolutionized by the recent development and use of receptor-targeted therapies, especially anti-TNF medications, for patients with moderate-to-severe disease. These agents have yielded significant advances in the effective treatment of symptoms and signs of both arthritis and enthesitis. Furthermore, evidence of inhibition or slowing of radiological signs of disease progression suggests that these drugs may have the potential to alter the natural history of psoriatic arthritis. Since not all patients respond to these agents or have side effects, or the agents lose efficacy, newer receptor-targeted therapies are being introduced and studied.",127,14,0.11023622047244094
9781910797082,ch09,"All available anti-tumor necrosis factor (TNF) agents have been approved for the treatment of psoriatic arthritis and demonstrate significant ability to control signs and symptoms, improve function and quality of life, and inhibit progression of structural damage of joints.","Ustekinumab, an inhibitor of IL-12/23/p40, which targets both Th1 and Th17 cell pathways, has now been approved for both psoriasis and psoriatic arthritis, the latter based on two Phase 3 trials that showed efficacy in multiple clinical domains including joints, skin, enthesitis, dactylitis, function and quality of life. As in psoriasis, after a loading dose the drug is administered subcutaneously once every 3 months in a weight-based approach: 45 mg subcutaneously for patients who weigh less than 100 kg and 90 mg for those who weigh more. The second Phase 3 trial included patients previously treated with anti-TNF therapy, and in these individuals the treatment effects of ustekinumab were smaller than in those who had not experienced such therapy. The safety profile is similar to that seen in psoriasis, for example the rare potential for serious infection. Apremilast, an oral inhibitor of phosphodiesterase 4 (PDE4), has been approved for the treatment of psoriatic arthritis. It appears to work by decreasing the conversion of cyclic adenosine monophosphate (cAMP) to AMP in potentially immunologically active cells, thus diminishing their ability to generate pro-inflammatory cytokines. The approved dose is 30 mg twice daily. In several Phase 3 trials, the drug showed consistent efficacy in treating arthritis, enthesitis, dactylitis and skin disease, and improved function and quality of life. The safety profile was good, showing a paucity of serious adverse events. A proportion of patients may experience nausea, diarrhea and headache. The gastrointestinal side effects were generally mild to moderate and resolved in most patients with continued use, suggesting that an initial upward titration of dose might improve tolerability. A good position for this agent is early in the treatment ladder, especially for patients who appreciate the drug's safety profile and oral format.",400,52,0.13
9781910797082,ch09,"Optimal management requires a team approach between dermatologist, rheumatologist and primary care provider.","Given that some drugs are able to treat both the skin and the joint manifestations of psoriatic arthritis, it is advantageous for the primary care physician, dermatologist and rheumatologist to work together to manage both skin and joints optimally, synchronize therapeutic approaches and appropriately manage important comorbidities such as metabolic syndrome. Many patients with psoriatic arthritis are managed primarily by a dermatologist - or in some situations by their primary care physician - for the skin manifestations of their disease. These physicians therefore have a unique opportunity to recognize joint disease and potentially initiate treatment. At the very least, it is imperative that all the physicians involved remain alert to the possibility of joint disease since, in a proportion of patients, progressive joint destruction will occur in the absence of effective therapy. This progression may now be ameliorated or prevented with the use of older disease-modifying agents, but especially with the receptor-targeted therapies.",188,20,0.10638297872340426
9781910797105,ch01,Schizophrenia was first clearly identified in the 1890s.,"In the first part of the 19th century, the foundations for the modern concept of schizophrenia were established (Table 1.1). An early diagnostic system emerged and various mental illnesses were described, including epilepsy, melancholia, mania and the dementing psychotic disorders, which included schizophrenia. However, the system lacked a general approach that could integrate the diverse manifestations of mental illness into distinct clinical syndromes. The situation was complicated by the overlap in the clinical presentation of these disorders. Furthermore, the clinical presentation of an individual could change over time, and patients with the same symptoms could have different outcomes.",120,12,0.1
9781910797105,ch01,Its characteristic features were an early onset and a chronic course.,"In the first part of the 19th century, the foundations for the modern concept of schizophrenia were established (Table 1.1). An early diagnostic system emerged and various mental illnesses were described, including epilepsy, melancholia, mania and the dementing psychotic disorders, which included schizophrenia. However, the system lacked a general approach that could integrate the diverse manifestations of mental illness into distinct clinical syndromes. The situation was complicated by the overlap in the clinical presentation of these disorders. Furthermore, the clinical presentation of an individual could change over time, and patients with the same symptoms could have different outcomes.",120,12,0.1
9781910797105,ch01,Kraepelin described two characteristic psychopathological processes.,"In differentiating dementia praecox from manic-depressive disorder, Kraepelin emphasized the early onset and what he believed to be the inevitable deteriorating course of dementia praecox, compared with the relatively good outcome of manic-depressive illness. Kraepelin also described what he thought were the two main pathological processes in patients with schizophrenia.",69,11,0.15942028985507245
9781910797105,ch01,Bleuler introduced the concept of primary and secondary symptoms.,"In 1911, Eugen Bleuler (Figure 1.3), recognizing that dementia was not a necessary characteristic of dementia praecox, suggested the term 'schizophrenia' (splitting of the mind) for the disorder. Bleuler believed that schizophrenia represented a syndrome consisting of several disorders that shared a common psychopathology. He also introduced the concept of primary and secondary symptoms of schizophrenia. His four primary symptoms (the four 'A's) were abnormal associations, autistic behavior and thinking, abnormal affect and ambivalence. Of these four symptoms, Bleuler viewed as central to the illness the loss of association between thought processes and that between thought, emotion and behavior.",134,11,0.08208955223880597
9781910797105,ch02,"There are three major symptom clusters: positive symptoms (hallucinations and delusions), negative symptoms and behavioral disorganization.","Positive symptoms include hallucinations, defined as perceptions in the absence of an external stimulus, and delusions, defined as unshakable false beliefs not explainable by religious or cultural background. In the 1930s, the German psychiatrist Kurt Schneider reviewed many case records and listed eight symptoms that he considered diagnostic of schizophrenia. These specific types of delusions and hallucinations became known as 'Schneider's first-rank symptoms' (Table 2.2), although they also occasionally occur in other serious psychiatric disorders.",98,24,0.24489795918367346
9781910797105,ch02,"It is important to rate social and functional outcomes, as well as symptoms.","It is important to distinguish between primary and enduring negative symptoms or deficit symptoms, which are indisputably part of the illness, and secondary negative symptoms. The latter can be similar in quality but result from a superimposed anxious or depressed mood, an impoverished understimulating environment or the adverse effects of antipsychotic medication.",64,15,0.234375
9781910797105,ch02,"The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Diseases, Tenth Edition (ICD-10) provide the two principal diagnostic systems used to diagnose people with schizophrenia.","The loosening of the diagnostic boundaries in schizophrenia became a concern in the early 1970s. After a series of studies in the 1970s showed that clinicians varied widely in their diagnosis of schizophrenia (which was made twice as often in North America as in Europe), operational diagnostic criteria were developed, such as the Research Diagnostic Criteria of Endicott and Spitzer, initially for use in research to try to standardize diagnosis. This approach gives a menu of possible symptoms and specifies that a certain number should be present for a minimum duration before a diagnosis can be made. Current classification systems. The two main classification systems in use worldwide are the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and the tenth edition of the World Health Organization's International Classification of Diseases (ICD-10) (Tables 2.3 and 2.4). The ICD-10 is mainly used outside North America; ICD-11 is expected in 2017. In their definitions of schizophrenia, the two systems are similar. Both diagnose schizophrenia with inter-rater reliabilities of at least 0.8, which compares well with those for many other medical disorders.",242,46,0.19008264462809918
9781910797105,ch02,Cognitive impairments and negative symptoms have the greatest prognostic importance for functional outcome.,"Symptoms. The Positive and Negative Syndrome Scale (PANSS) is now the most widely used of the symptom rating scales (Table 2.7). It comprises 30 items in three subscales that rate positive, negative and general symptoms, respectively. It takes about 20 minutes to administer. Symptomatic patients typically score between 60 and 120, and a score reduction of 20% is clinically meaningful. Alternatively, the Brief Psychiatric Rating Scale (BPRS) and Scales for the Assessment of Positive/Negative Symptoms (SAPS/SANS) may be used to track changes in positive, negative and general symptoms. The Calgary Depression Scale (CDS) is specifically designed to assess depressive symptoms in people with schizophrenia, and has been shown to be reliable and to have good construct validity.",159,17,0.1069182389937107
9781910797105,ch03,The incidence of new cases of schizophrenia is 1-2 per 10000 population per year.,"The incidence of schizophrenia is the number of new cases, expressed either annually or as lifetime risk. The prevalence of schizophrenia is the total number of cases, either at a particular point in time (point prevalence) or over a particular period (exempli gratia lifetime prevalence). Incidence studies of epidemiological samples show that there are approximately two new cases of ICD schizophrenia, or approximately one new case of DSM schizophrenia, per 10000 population each year.",90,17,0.18888888888888888
9781910797105,ch03,"The condition exists in all countries and cultures, but incidence and prevalence rates vary markedly. Rates are higher in ethnic minority groups.","The incidence of schizophrenia is the number of new cases, expressed either annually or as lifetime risk. The prevalence of schizophrenia is the total number of cases, either at a particular point in time (point prevalence) or over a particular period (exempli gratia lifetime prevalence). Incidence studies of epidemiological samples show that there are approximately two new cases of ICD schizophrenia, or approximately one new case of DSM schizophrenia, per 10000 population each year. Schizophrenia exists in all cultures in all countries. Until relatively recently, it was believed that incidence rates were similar around the globe, based on results from large-scale studies carried out by the World Health Organization. A fivefold difference in incidence rates around the globe is now known to exist, with higher rates in developed countries than in developing countries. The median lifetime risk is between 0.5% and 1%.",173,25,0.14450867052023122
9781910797105,ch03,Urban environments in childhood appear unexpectedly important in causing schizophrenia.,"It has long been known that rates of schizophrenia are higher in urban than in rural areas. Early surveys seemed to show that this was due to the drift of people into urban areas after the illness started, rather than to higher rates of new cases in cities. However, large studies have confirmed that new cases arise more commonly in cities, with the rates being proportional to the degree of urbanization. This appears to be an unexpectedly large effect. The relative risk for large-city dwellers compared with that for rural residents is only two- to threefold (see Table 5.2, page 44) but, because much of the population lives in cities, the proportion of schizophrenia that can be explained by this factor is about one-third. Being brought up in a city appears to be the critical factor, and the risk increases the more childhood years spent in an urban environment. The factors associated with city life that lead to this higher incidence remain to be clarified. The data suggest that those with a genetic vulnerability are most at risk of the effects of urban upbringing.",211,11,0.052132701421800945
9781910797105,ch03,Onset is usually in early adult life; 20% will recover completely.,"The best-designed outcome studies are those that prospectively follow a cohort of consecutive first-episode patients, ideally from a defined geographic area, for at least 5 years. However, such studies are rare. Summarizing the best long-term studies available, there is a consensus that 15-20% of patients will make a complete recovery without relapse. At the other extreme, about 15% will effectively never recover from their first episode, remaining symptomatic and needing long-term, high levels of social and medical input. Between these two poles, most patients will recover at least partly from their first episode, but will not return to their premorbid level of functioning, or will suffer future relapses, or both (Figure 3.2).",150,15,0.1
9781910797105,ch03,"Life expectancy in people with schizophrenia is 15 years less than the general population, mainly because of increased cardiometabolic disease.","Mortality in people with schizophrenia is increased threefold, and life expectancy is reduced by about 15 years, compared with the general population. This effect can be partially attributed to a tenfold increase in suicide rates: young men in the first 3 years of their illness are most at risk. However, much of the increased mortality is due to the deleterious effect of poor diet, obesity, smoking and lack of exercise, all of which are more common among the population with schizophrenia. Worryingly, the general trend for healthier lifestyles in the population at large does not extend to people with schizophrenia, so that the mortality gap is widening.",127,25,0.1968503937007874
9781910797105,ch04,Having a close relative with schizophrenia increases one's own risk 15-fold.,"The most straightforward studies in population genetics are family studies. Usually, a series of individuals with schizophrenia, known as probands or index cases, is selected and rates of schizophrenia are assessed in their biological families. These rates are compared with rates in the families of control probands, usually healthy volunteers. To express the results as rates, the number of affected relatives is divided by the total number and is age-corrected for relatives who are too young to have the disorder or are not yet through the age range at highest risk.",105,15,0.14285714285714285
9781910797105,ch04,Identical twins show a 45% concordance rate.,"Studies in twins involve probands with schizophrenia who are either identical (monozygotic: MZ) or non-identical (dizygotic: DZ). MZ twins share 100% of their genes and DZ twins share about 50%. Concordance rates in the two types of twins are compared by looking at the rate at which co-twins also have schizophrenia. The consensus from population-based studies is that concordance rates are about 45% for MZ co-twins and 15% for DZ co-twins. The fact that concordance is less than 100% in MZ twins suggests that non-genetic, environmental factors are also involved. However, the offspring of the unaffected MZ co-twins in discordant pairs are at increased risk of schizophrenia, suggesting that the co-twins still carry a genetic predisposition for the disease.",181,12,0.06629834254143646
9781910797105,ch04,"Individual vulnerability genes exist, which are each of small effect and interact with other genes and with environmental factors.","Most of the genes found by genome-wide association studies to be implicated in schizophrenia do seem plausible in that they are known to exert effects on neuronal systems and particularly synaptic function. It appears too that different genes give different symptom profiles; for example, ZNF804A is associated with better cognition, NRG1 with preserved affect and the dysbindin gene (DTNBP1) with IQ. Examples are being uncovered of synergistic gene-gene interactions, and of how specific genes interact with specific environmental risk factors (Table 4.4). Studies looking at patterns of gene expression in the postmortem brain suggest changes in particular functional gene groups in schizophrenia, such as those related to oligodendrocyte and myelin development and synaptic transmission.",151,21,0.1390728476821192
9781910797105,ch04,"A growing number of susceptibility genes have been identified, some of which also predispose to bipolar disorder.","It is only since 2008 that the significance of CNVs for neuropsychiatry has been realized. They are usually, but not always, sporadic (arising de novo) duplications or deletions of stretches of DNA several thousand to a million base pairs long. They exist in everyone, at all locations in the genome, and may or may not be passed on. Rates of CNVs have been shown to be higher in schizophrenia as well as in other neurodevelopmental disorders such as autism (Table 4.5). It is thought that approximately 2% of people with schizophrenia have CNVs. Some CNVs for schizophrenia are associated with other neurodevelopmental disorders; for example, duplications at 15q13.3 are also the region for the commonest duplications in autism and Prader-Willi syndrome.",165,20,0.12121212121212122
9781910797105,ch04,Copy number variants are rare major genetic risk factors for schizophrenia and other neurodevelopmental disorders.,"It is only since 2008 that the significance of CNVs for neuropsychiatry has been realized. They are usually, but not always, sporadic (arising de novo) duplications or deletions of stretches of DNA several thousand to a million base pairs long. They exist in everyone, at all locations in the genome, and may or may not be passed on. Rates of CNVs have been shown to be higher in schizophrenia as well as in other neurodevelopmental disorders such as autism (Table 4.5). It is thought that approximately 2% of people with schizophrenia have CNVs. Some CNVs for schizophrenia are associated with other neurodevelopmental disorders; for example, duplications at 15q13.3 are also the region for the commonest duplications in autism and Prader-Willi syndrome.",165,18,0.10909090909090909
9781910797105,ch05,"Like genetic factors, environmental factors are many and varied.","Some established risk factors act early in life (Table 5.2). Obstetric complications generally appear to increase the risk of schizophrenia. During pregnancy, risk factors include rubella and influenza infections in the first or second trimester and antepartum bleeding. Asphyxia and low birth weight, especially with intrauterine growth retardation, are risk factors at birth, as are certain brain insults and infections in childhood.",84,11,0.13095238095238096
9781910797105,ch05,Birth complications increase the child's risk of schizophrenia in later life fourfold.,"Some established risk factors act early in life (Table 5.2). Obstetric complications generally appear to increase the risk of schizophrenia. During pregnancy, risk factors include rubella and influenza infections in the first or second trimester and antepartum bleeding. Asphyxia and low birth weight, especially with intrauterine growth retardation, are risk factors at birth, as are certain brain insults and infections in childhood.",84,15,0.17857142857142858
9781910797105,ch05,Psychosocial risk factors are being re-established as important risk factors.,"Some established risk factors act early in life (Table 5.2). Obstetric complications generally appear to increase the risk of schizophrenia. During pregnancy, risk factors include rubella and influenza infections in the first or second trimester and antepartum bleeding. Asphyxia and low birth weight, especially with intrauterine growth retardation, are risk factors at birth, as are certain brain insults and infections in childhood.",84,15,0.17857142857142858
9781910797105,ch05,Cannabis use increases the risk of schizophrenia as well as relapse.,"Use of cannabis and amphetamine-like drugs has long been known to be an important trigger of relapse, but had not been thought to directly cause the onset of illness. However, several cohort studies since 2000 have shown that use of cannabis doubles the risk of developing schizophrenia. The risk is further increased if minor psychotic symptoms pre-exist and if cannabis use starts early in adolescence. Research suggests that this effect of cannabis may be mediated by a particular gene. Those with a specific version of the catechol- O -methyltransferase (COMT) gene, carried by about a quarter of the general population, appear to be especially prone to psychosis after cannabis use. Delta-9-THC, the active component of cannabis, disrupts learning and recall in schizophrenia.",154,14,0.09090909090909091
9781910797105,ch05,"Early neurodevelopmental, non-genetic risk factors exist for schizophrenia.","The risk is further increased if minor psychotic symptoms pre-exist and if cannabis use starts early in adolescence. Research suggests that this effect of cannabis may be mediated by a particular gene. Those with a specific version of the catechol- O -methyltransferase (COMT) gene, carried by about a quarter of the general population, appear to be especially prone to psychosis after cannabis use. Delta-9-THC, the active component of cannabis, disrupts learning and recall in schizophrenia. Psychosocial risk factors. There is emerging evidence for the role of non-biological risk factors in schizophrenia, such as the effects of urban upbringing and of ethnicity, as noted in Chapter 3.",140,15,0.10714285714285714
9781910797105,ch05,Evidence for specific gene-environment interactions is beginning to emerge.,"The risk is further increased if minor psychotic symptoms pre-exist and if cannabis use starts early in adolescence. Research suggests that this effect of cannabis may be mediated by a particular gene. Those with a specific version of the catechol- O -methyltransferase (COMT) gene, carried by about a quarter of the general population, appear to be especially prone to psychosis after cannabis use. Delta-9-THC, the active component of cannabis, disrupts learning and recall in schizophrenia.",100,12,0.12
9781910797105,ch06,"People with schizophrenia exhibit gray matter reductions in the prefrontal, superior temporal and inferior parietal heteromodal cortices.","Morphological findings. MRI studies confirmed the previous findings of enlarged ventricles, with patients exhibiting about a one-third increase in ventricular volume compared with controls (Figure 6.1), and increased sulcal widening (Figure 6.2). MRI studies demonstrated for the first time the involvement of cortical and subcortical gray matter structures. Specifically, people with schizophrenia were shown to exhibit decreased volume of the neocortex, by about 5%, with specific gray matter reductions in the prefrontal, superior temporal and inferior parietal heteromodal cortices. These brain regions are the neuroanatomic substrate for the complex cognitive behaviors that are disrupted in schizophrenia. In addition to volume reductions in these areas, several studies have found that people with schizophrenia have a reversal or loss of the normal asymmetry of these structures.",163,24,0.147239263803681
9781910797105,ch06,Men with schizophrenia have been found to have greater volume reductions in the temporal lobes than women.,"Morphological findings. MRI studies confirmed the previous findings of enlarged ventricles, with patients exhibiting about a one-third increase in ventricular volume compared with controls (Figure 6.1), and increased sulcal widening (Figure 6.2). MRI studies demonstrated for the first time the involvement of cortical and subcortical gray matter structures. Specifically, people with schizophrenia were shown to exhibit decreased volume of the neocortex, by about 5%, with specific gray matter reductions in the prefrontal, superior temporal and inferior parietal heteromodal cortices. These brain regions are the neuroanatomic substrate for the complex cognitive behaviors that are disrupted in schizophrenia. In addition to volume reductions in these areas, several studies have found that people with schizophrenia have a reversal or loss of the normal asymmetry of these structures.",163,19,0.1165644171779141
9781910797105,ch06,"People with schizophrenia have decreased volume of subcortical structures, including the amygdala, hippocampus, parahippocampus and thalamus.","MRI studies have also documented decreased volume of limbic system structures such as the amygdala, hippocampus and parahippocampus (Figure 6.3). These structures are involved in the regulation of emotions and various forms of memory. The magnitude of these changes is relatively small (Table 6.1), but the observations have been shown to be highly reliable, especially for the hippocampus. MRI studies have also documented decreased volume of specific thalamic nuclei and total volume of the thalamus. Thalamic nuclei play a central role in gating the flow of information to the cerebral cortex and in regulating the activation of specific cortical brain areas in response to external or internal stimuli or signals. These MRI results are consistent with postmortem study reports documenting decreased volume of the medial dorsal and pulvinar thalamic nuclei.",165,29,0.17575757575757575
9781910797105,ch06,A subgroup of patients may exhibit progressive changes in brain structure over the course of their illness.,"Progression of brain changes. A series of longitudinal studies involving multiple MRI has evaluated whether schizophrenia is a neurodevelopmental disorder, with fixed morphological abnormalities, or a neurodegenerative disorder, with progressive changes in brain structure. These studies, conducted in childhood-onset, first-episode and chronic patient populations, have consistently demonstrated 2-10% decreases in cortical and subcortical gray matter volumes and 5-10% increases in ventricular volume. The extent to which these results apply to a subgroup or to the total schizophrenia population is unknown. The possible progression of brain changes would be consistent with increased functional disability and cognitive decrements observed in a proportion of people with schizophrenia. Recent studies have shown consistently that superior and medial frontal structural changes occur in young people at clinical high risk if they make the transition to full psychosis compared with those who do not.",174,19,0.10919540229885058
9781910797105,ch06,"Hallucinations, delusions and positive formal thought disorder are associated with decreased volume of the superior temporal gyrus.","Morphological changes associated with specific symptoms. Several studies have observed an association between decreased volume of the superior temporal gyrus (STG) gray matter and hallucinations and delusions or positive formal thought disorder. Hallucinations and delusions are more frequently associated with decreased volume of the anterior STG, and positive formal thought disorder with decreased volume of the posterior STG. MRI has also been used to show that people with schizophrenia have a loss of the normal asymmetry of the cerebral hemispheres, especially of the planum temporale, a region of the brain involved in audition and language. These observations have led to the development of etiologic hypotheses concerning abnormalities in the normal process of brain lateralization.",140,22,0.15714285714285714
9781910797105,ch06,Diffusion tensor imaging studies support the hypothesis that schizophrenia is characterized by abnormal connections among cortical and subcortical structures.,"Diffusion tensor imaging (DTI) is based on the diffusion of water through different brain tissues and allows for the evaluation of white matter integrity. In addition, DTI may be used to identify and measure specific white matter fiber tracts (Figure 6.4). DTI studies have documented widespread reductions in fractional anisotropy (a measure of white matter integrity) in the white matter of people with schizophrenia, but the localization of the abnormalities has differed across studies. In addition, multiple fiber tracts have been shown to be characterized by reduced fractional anisotropy. Several studies have suggested that people with schizophrenia with persistent negative symptoms have decreased fractional anisotropy in fiber tracts associated with social cognition. In combination with functional imaging, genetic and postmortem studies, DTI studies support the hypothesis that schizophrenia is a dysconnection syndrome, characterized by abnormal connectivity among the different cortical and subcortical brain regions.",186,25,0.13440860215053763
9781910797105,ch07,People with schizophrenia exhibit subtle neurocognitive impairments prior to the onset of florid psychotic symptoms.,"Do cognitive deficits predate the illness? The results of high-risk and large-scale birth cohort studies and studies of military inductees who have developed schizophrenia provide compelling evidence that people with schizophrenia exhibit subtle neurocognitive impairments prior to the onset of more florid psychotic symptoms (Table 7.2). Studies of IQ test scores obtained routinely during childhood show that those children who later develop schizophrenia, but not bipolar disorder, have significantly lower mean scores than either age- or social-class-matched children or siblings who do not develop schizophrenia. There is a dose-response relationship, such that for every point decrease in IQ, the risk of later schizophrenia increases by 4%. At the time of onset of positive psychotic symptoms, there is usually a further decline in IQ score.",155,21,0.13548387096774195
9781910797105,ch07,Neurocognitive impairments are a major determinant of poor social and occupational functioning.,"How do deficits relate to symptoms and outcome? Patients with negative symptoms are more likely to exhibit clinically significant neurocognitive impairments than patients without these symptoms. Patients with negative symptoms have also exhibited the most impairment on tasks requiring self-generated, rather than stimulus-driven, activity. In contrast, disorganized patients are characterized by impaired performance on measures of distractibility, and they are also more likely to show an inability to inhibit inappropriate behavioral responses. Impairments of verbal memory, language, vigilance and executive function have been shown to be major determinants of poor social and community function in people with schizophrenia. Impairments of memory and executive and processing speed have been related to poor occupational outcome.",139,18,0.12949640287769784
9781910797105,ch07,Positive psychotic symptoms correlate with hippocampal activation and frontostriatal disconnectivity.,"Negative symptoms, or the psychomotor poverty syndrome, correlate with decreased activity in the dorsolateral prefrontal cortex, particularly on the left. Interestingly, this pattern also appears in severe depressive illness with psychomotor retardation, thus indicating a final common cortical deficit underlying psychomotor poverty in schizophrenia and psychomotor retardation in depression. Positive psychotic symptoms correlate with hippocampal activation and with a distributed network of frontal, temporal and subcortical sites.",94,17,0.18085106382978725
9781910797105,ch07,Negative symptoms correlate with decreased activity in the dorsolateral prefrontal cortex.,"Negative symptoms, or the psychomotor poverty syndrome, correlate with decreased activity in the dorsolateral prefrontal cortex, particularly on the left. Interestingly, this pattern also appears in severe depressive illness with psychomotor retardation, thus indicating a final common cortical deficit underlying psychomotor poverty in schizophrenia and psychomotor retardation in depression.",69,15,0.21739130434782608
9781910797105,ch07,The disorganization syndrome correlates with increased activity in the anterior cingulate gyrus.,"In some cases, the link between a specific symptom and a functional abnormality emerges only under particular conditions. Compared with controls, patients with persecutory delusions show increased activation in the amygdala in situations of possible threat. Patients with auditory hallucinations show right-sided temporoparietal and parahippocampal deficits during inner speech tasks, which again suggest an internal monitoring problem. The disorganization syndrome correlates with increased activity in the dorsal anterior cingulate gyrus, a region involved in selective attention.",100,18,0.18
9781910797105,ch08,Disturbances in the cholinergic and GABAergic systems have been hypothesized to underlie cognitive impairments in schizophrenia.,"Neurochemical abnormalities, including changes to the activity of neurotransmitters, are the link between underlying causal factors, either genetic or environmental, and the signs and symptoms of the illness. Over the last 50 years, multiple neurotransmitter systems have been hypothesized to be involved in the neurochemistry of schizophrenia. These hypotheses have fallen in and out of vogue as our knowledge of the brain and our methods for investigating brain neurobiology have become more sophisticated. The major neurochemical pathophysiological hypotheses continue to involve the traditional neurotransmitters, although this situation is changing as novel molecular biological techniques are applied to the study of schizophrenia.",125,24,0.192
9781910797105,ch08,The dopamine hypothesis remains the major neurochemical hypothesis of schizophrenia.,"In the early 1960s, the Swedish pharmacologist Arvid Carlsson (Figure 8.2) posited the dopamine hypothesis of schizophrenia, in which he stated that schizophrenia was caused by an excess of dopaminergic activity, either an excess of dopamine release and/or hypersensitivity of dopamine receptors. The hypothesis was built on three observations. First was the recognition of a schizophrenia-like psychosis in people who misused amphetamine, a drug known to increase the release of dopamine. Second was the emergence of adverse effects of the recently discovered antipsychotic chlorpromazine, which mimicked Parkinson's disease, itself thought to be due to faulty dopamine transmission. Third was the observation that all effective antipsychotic agents were dopamine receptor antagonists. In the following 15 years, while several experiments provided compelling, but circumstantial, evidence in further support of the importance of the dopamine D receptor in schizophrenia, there remained known shortcomings in the dopamine hypothesis and a lack of direct evidence. In addition, the prediction that untreated patients should have increased numbers of dopamine receptors received no firm support from postmortem assays nor, more critically, from studies using positron emission tomography (PET), which imaged the binding of radiolabeled antipsychotic drugs to receptors.",251,12,0.04780876494023904
9781910797105,ch08,Positive symptoms are hypothesized to be due to increased activity of the mesolimbic dopamine pathway.,"Four developments have helped to revive the dopamine hypothesis. First, the hypothesis was reformulated to predict the existence of both hyperdopaminergic and hypodopaminergic activity in people with schizophrenia. The reformulation states that positive symptoms are due to increased activity of the mesolimbic dopamine pathway, whereas negative symptoms are due to decreased activity of the mesocortical dopamine pathway (see Figure 8.1).",84,20,0.23809523809523808
9781910797105,ch08,Negative symptoms are hypothesized to be due to decreased activity of the mesocortical dopamine pathway.,"Four developments have helped to revive the dopamine hypothesis. First, the hypothesis was reformulated to predict the existence of both hyperdopaminergic and hypodopaminergic activity in people with schizophrenia. The reformulation states that positive symptoms are due to increased activity of the mesolimbic dopamine pathway, whereas negative symptoms are due to decreased activity of the mesocortical dopamine pathway (see Figure 8.1).",84,20,0.23809523809523808
9781910797105,ch08,Altered glutamate activity may be involved in the pathophysiology of negative and positive symptoms and cognitive impairments.,"Evidence to support a glutamate hypothesis is growing. Postmortem studies have documented abnormal NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate receptor binding in the prefrontal and temporal cortex, and abnormal NMDA and AMPA messenger RNA receptor expression in the hippocampus. Perhaps the most compelling evidence comes from clinical trials that have examined the efficacy of agents that modify the activity of the NMDA receptor. Some, but not all, of these studies have shown that glycine and D-cycloserine, which bind to the glycine site of the NMDA receptor, may be effective treatments for negative symptoms. They have also shown that both positive and negative symptoms may be treated by D-serine, which also binds to the glycine site of the NMDA receptor, and by sarcosine, which inhibits glycine reuptake. Glycine transporter type 1 inhibitors, such as bitopertin, prevent reuptake of synaptic glycine and so enhance NMDA receptor function, but have not been shown to be effective for negative symptoms or cognitive impairments.",235,22,0.09361702127659574
9781910797105,ch09,Assertive community treatment is the most effective model of community care.,"Multidisciplinary teams are the core of community-based services for people with schizophrenia (Table 9.1). These are effective when a case management model is used, so that one care coordinator develops and oversees the patient's entire care package. Different models of care management exist, but systematic reviews have shown that it is most effective when combined with assertive community treatment. This involves proactive community follow-up and delivery of as much care as possible in the individual's home setting.",95,14,0.14736842105263157
9781910797105,ch09,Urgent specialist referral and multidisciplinary assessment are needed for first-episode psychosis.,"First-episode psychosis. A first episode of psychosis requires urgent referral to a specialist mental health team or an early intervention team for assessment within 2 weeks. Admission to inpatient status may be needed. Full diagnostic assessment should include a physical and neurological examination, an assessment of physical health (Table 9.2) and evaluation of substance abuse status.",68,17,0.25
9781910797105,ch09,Maintaining and improving physical health is vital.,"A first episode of psychosis requires urgent referral to a specialist mental health team or an early intervention team for assessment within 2 weeks. Admission to inpatient status may be needed. Full diagnostic assessment should include a physical and neurological examination, an assessment of physical health (Table 9.2) and evaluation of substance abuse status.",63,10,0.15873015873015872
9781910797105,ch09,Cognitive therapy should be offered in addition to drug treatments.,"Therapeutic response should be carefully monitored, ideally using a recognized rating scale such as the Positive and Negative Syndrome Scale (PANSS; Table 2.7, page 21). In addition, psychological support and treatment should be initiated, ideally cognitive therapy for 16 weeks in addition to drug treatment. Side effects and weight should be monitored weekly for the first 6 weeks.",73,12,0.1643835616438356
9781910797105,ch09,m-health approaches are becoming increasingly important.,"Connected health refers to approaches such as telehealth, telecare, electronic health (e-health) and mobile health (m-health). This is a growing area of activity, especially around the potential of web- and smartphone-based monitoring and interventions to help people with schizophrenia to better manage their own illness (exempli gratia www.clintouch.com) (Table 9.5). Remote, ambulant, symptom monitoring with wireless real-time data uploads to a central server, enabling better collaborative management in the form of early intervention and personalized management.",116,9,0.07758620689655173
9781910797105,ch09,Clozapine should be considered early in treatment resistance.,"About 30% of people will not respond adequately to two adequate trials of drug treatment of different classes. In these cases, diagnostic review, and exclusion of significant substance use and non-adherence should be undertaken. If it is not already being used, adjunctive cognitive therapy should be considered. Clozapine should be the next step in drug treatment. In those 30-40% who do not improve with clozapine at an optimized dose with therapeutic plasma levels, augmentation with a second antipsychotic can be tried.",108,12,0.1111111111111111
9781910797105,ch10,The long-acting injectable (depot) forms of FGAs and SGAs are useful for patients who are non-adherent to their medications.,"The first-generation antipsychotics (FGAs) are all dopamine D receptor antagonists. This property is hypothesized to be the basis of their antipsychotic mechanism of action. There are four major classes of these drugs (Table 10.1). Both oral and injectable long-acting depot forms of FGAs are available. Their primary indication is for positive symptoms, such as hallucinations, delusions and positive formal thought disorder. They have limited efficacy for negative symptoms or cognitive impairments in people with schizophrenia. Efficacy. In the treatment of acute psychotic episodes, these drugs usually begin to improve symptoms within the first week. The long-standing notion that antipsychotic drugs take 2-4 weeks to start working is false: at least half of the therapeutic effect on core psychotic symptoms occurs in the first 7 days. If there is no response within 7 days, there is only a 20% chance of symptoms responding by 6 weeks. Improvement will continue to accrue over the following few months of treatment, with most improvement during the first 4-6 weeks of treatment.",213,31,0.14553990610328638
9781910797105,ch10,Clozapine is the only SGA that is effective for positive symptoms resistant to other antipsychotics.,"Indications. Clozapine is the only SGA that has been approved for the treatment of positive symptoms resistant to other antipsychotics (Case history 10.1). It is also effective for alleviating negative symptoms secondary to positive symptoms, EPS or dysphoric affect. Clozapine has not been shown to be effective for primary negative symptoms. Clozapine has been found to reduce suicidal ideation in schizophrenia and to reduce symptoms of hostility and violent behaviors. The unique pharmacological properties of clozapine may be related to its superior efficacy for positive symptoms and other illness dimensions.",120,22,0.18333333333333332
9781910797105,ch10,First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are effective treatments for the acute phase and maintenance treatment of schizophrenia.,"Other second-generation antipsychotics share the property of potent 5-HT 2a antagonism, but differ in the degree to which they share the other pharmacological properties of clozapine. All SGAs share with clozapine the reduced proclivity for causing EPS and TD, though some are associated with increased risk of akathisia and other EPS at higher doses. The substantially reduced risk of EPS at low to moderate doses has played a major role in their supplanting the FGAs as first-line treatments for acute psychotic episodes and maintenance therapy. However, none of the other SGAs has yet been shown to be as effective as clozapine for treatment-resistant positive symptoms. There is little evidence to suggest that these agents are effective for primary negative symptoms, though they may be of some benefit for treating secondary negative symptoms. Several of the SGAs are known to cause substantial weight gain and disruption of glucose and lipid metabolism (see Table 10.3; Case history 10.2).",204,34,0.16666666666666666
9781910797105,ch10,SGAs other than clozapine have become the first-line treatments for acute psychotic episodes and maintenance therapy.,"Other second-generation antipsychotics share the property of potent 5-HT 2a antagonism, but differ in the degree to which they share the other pharmacological properties of clozapine. All SGAs share with clozapine the reduced proclivity for causing EPS and TD, though some are associated with increased risk of akathisia and other EPS at higher doses. The substantially reduced risk of EPS at low to moderate doses has played a major role in their supplanting the FGAs as first-line treatments for acute psychotic episodes and maintenance therapy. However, none of the other SGAs has yet been shown to be as effective as clozapine for treatment-resistant positive symptoms. There is little evidence to suggest that these agents are effective for primary negative symptoms, though they may be of some benefit for treating secondary negative symptoms. Several of the SGAs are known to cause substantial weight gain and disruption of glucose and lipid metabolism (see Table 10.3; Case history 10.2).",204,23,0.11274509803921569
9781910797105,ch10,FGAs and SGAs are relatively effective for treating secondary negative symptoms but are not effective in treating primary negative symptoms and have limited effects on the cognitive impairments of schizophrenia.,"The treatment of negative symptoms is a major challenge facing clinicians. FGAs and SGAs are relatively effective for treating secondary negative symptoms, but leave untouched the primary avolitional syndrome described so eloquently by Kraepelin (see Chapter 1). The limited efficacy of antipsychotics has led to the investigation of alternative treatments for negative symptoms. Various approaches have been attempted based on specific neurochemical hypotheses of the pathophysiology of negative symptoms. One of the more frequently investigated strategies has been the use of agents that increase the level of activity of the N -methyl- D -aspartate (NMDA) receptor. As described in Chapter 8, this approach is based on the proposition that negative symptoms are due to decreased glutamatergic activity secondary to NMDA receptor hypofunction. Glycine, D-serine and D-cycloserine all bind to the glycine site of the NMDA receptor and are required for NMDA receptor response to glutamate. In pilot studies, these agents were shown to be effective in ameliorating persistent negative symptoms. However, in a large multicenter study, neither glycine nor D-cycloserine was found to be more effective than placebo for these symptoms.",245,34,0.13877551020408163
9781910797105,ch10,Add-on treatments for people with residual positive symptoms have not been clearly demonstrated to be effective.,"As described in Chapter 8, despite the advent of clozapine, a large percentage of people with schizophrenia continue to experience considerable residual positive symptoms. A number of agents have been used in combination with ongoing antipsychotic treatment in an attempt to alleviate these symptoms. The agents most commonly used in this regard are antiseizure medications (exempli gratia lamotrigine), antidepressants, benzodiazepines and minocycline. However, although there are reports of small subgroups of patients who may benefit from combination therapy with one of these agents, there has not been a consistent demonstration of enhanced positive symptom efficacy when these drugs have been used in combination with antipsychotics. Antiepileptics, antidepressants and benzodiazepines may be more effective for the treatment of persistent symptoms of anxiety, depression, hostility or mania.",172,19,0.11046511627906977
9781910797105,ch11,Cognitive behavioral therapy (CBT) administered in addition to drug treatment reduces persistent positive symptoms. CBT can also abort relapses if targeted at early signs.,"The idea that cognitive behavioral treatments that are effective in people with major depression might be effective in treating positive psychotic symptoms dates from the 1990s. Traditionally, these symptoms were viewed, in the words of the psychiatrist and phenomenologist Karl Jaspers, as 'un-understandable'. Coupled with the failure of psychoanalytical treatments for schizophrenia in the 1950s and 1960s, this view left a legacy of skepticism about psychological approaches. Since the mid-1990s, however, randomized controlled trials have shown that cognitive behavioral therapy (CBT) can be effective for persistent psychotic symptoms in chronic schizophrenia when given in addition to routine care (Case history 11.1). The effect size is about the same as that for clozapine. Secondary analyses of these trials suggest that as important as the actual CBT is the patient-rated 'therapeutic alliance' - the positive feelings of the patient towards the therapist. Components of CBT are shown in Table 11.3. It has yet to be clarified which of these components is the most important.",213,32,0.15023474178403756
9781910797105,ch11,"Cognitive remediation is effective in reducing cognitive impairments, although generalization to global functioning is an issue.","Cognitive remediation involves processes such as repeated practice and scaffolding, a learning technique in which the therapist helps the patient to solve problems by providing support for aspects of the task that the patient cannot accomplish, while removing assistance in areas in which the patient is competent. These processes take place over days and weeks to train up key cognitive functions in chronic schizophrenia. It has been shown to deliver cognitive improvements that persist beyond the end of treatment, although generalization to improved functioning is more likely if an overall rehabilitation program is also given. Computer- and web-based cognitive remediation approaches are now available.",119,22,0.18487394957983194
9781910797105,ch12,Duration of untreated psychosis is usually 3-6 months.,"First episodes of psychosis can go undetected and untreated for long periods of time. The median duration of positive psychotic symptoms before detection is 12-24 weeks, but in many cases symptoms endure for much longer before detection, particularly if negative symptoms are taken into account. The duration of untreated psychosis (DUP) is strongly associated with response to treatment and speed to remission in the first episode, although it is still disputed whether this is truly a causal link. Nonetheless, this observation is the main impetus behind the increased focus on early detection and treatment of the first episode of schizophrenia.",114,11,0.09649122807017543
9781910797105,ch12,"The longer the delay in treatment, the worse the clinical outcome.","First episodes of psychosis can go undetected and untreated for long periods of time. The median duration of positive psychotic symptoms before detection is 12-24 weeks, but in many cases symptoms endure for much longer before detection, particularly if negative symptoms are taken into account. The duration of untreated psychosis (DUP) is strongly associated with response to treatment and speed to remission in the first episode, although it is still disputed whether this is truly a causal link. Nonetheless, this observation is the main impetus behind the increased focus on early detection and treatment of the first episode of schizophrenia.",114,13,0.11403508771929824
9781910797105,ch12,Early detection has been shown to be possible.,"The answer to the first question is almost certainly yes. Some of the reasons for delayed detection are given in Table 12.1. Public education, training of family physicians and youth workers in recognizing early signs, and specialist rapid assessment teams have been shown in pilot early-intervention services to reduce median DUP to 6 weeks, with a concomitant reduction in symptom severity by the time treatment is initiated.",80,9,0.1125
9781910797105,ch12,Second generation drugs are preferred.,"Patients in the first episode are responsive to relatively low doses of antipsychotic drugs, and treatment should be started with the equivalent of haloperidol, 2 mg daily, or less. Similarly, first-episode patients are sensitive to the neurological and metabolic adverse effects of drugs. Added cognitive behavioral therapy speeds remission and helps maintain recovery.",68,6,0.08823529411764706
9781910797105,ch12,Treatment of prodromal cases with cognitive behavioral or drug therapy may prevent or delay schizophrenia.,"Overall, follow-up studies of individuals seeking help for these symptoms show that a significant proportion develop schizophrenia or a related psychotic disorder over the following 12 months. Early follow-up studies of clinical-high-risk cases suggested rates of transition of 40%, although more recent studies suggest that 10-15% is more representative. If effective drug or psychological interventions are given at this prodromal stage, it may be feasible to prevent, delay or at least ameliorate subsequent psychosis in such cases (Case history 12.1). Randomized trials have shown that second-generation antipsychotic drug treatments reduce rates of transition to schizophrenia and that cognitive therapy may also do so.",135,19,0.14074074074074075
9781910797150,ch01,It is estimated that 80-100% of patients receiving chemotherapy without antiemetic prophylaxis will experience some level of chemotherapy-induced nausea and vomiting.,"It is estimated that 80-100% of patients receiving chemotherapy without antiemetic prophylaxis will experience some level of chemotherapy-induced nausea and vomiting (CINV). The sensation of nausea and the act of vomiting are protective reflexes that rid the intestine and stomach of toxic substances. Nausea. The experience of nausea is subjective. It is a difficult-to-describe sick or queasy sensation, usually perceived as being in the stomach. Nausea and vomiting are not necessarily on a continuum. Although nausea may be considered a prodromal phase to the act of vomiting, patients may experience significant nausea without vomiting. Conversely, patients may have sudden emesis without nausea. Nausea has been assumed to be the conscious awareness of unusual sensations in the 'vomiting center' of the brainstem (see below), but the existence of such a center and its relationship to nausea remain controversial.",185,32,0.17297297297297298
9781910797150,ch01,"Nausea and vomiting are triggered when afferent impulses from the cerebral cortex, chemoreceptor trigger zone (CTZ), pharynx and vagal afferent fibers of the gastrointestinal (GI) tract travel to the vomiting center (VC) in the central nervous system.","The mechanisms of nausea and vomiting are not well defined. Vomiting is a reflex activated by toxic substances such as chemotherapy drugs, which may directly affect areas in the cerebral cortex and the medulla oblongata, or may stimulate the small intestine via the vagus nerve. Afferent impulses, triggered from the cerebral cortex, chemoreceptor trigger zone (CTZ), pharynx and vagal afferent fibers of the gastrointestinal (GI) tract, then travel to the vomiting center (VC) - termed the 'central pattern generator' by some authors - in the lateral reticular formation of the medulla (Figure 1.1). The VC is the primary structure that coordinates the mechanisms of nausea and vomiting; it is sensitive to several neurotransmitters (serotonin, dopamine, substance P), which are released through these pathways. Each individual may require a different level of stimulation to the VC to reach the threshold for nausea or vomiting, such that individuals will experience different responses to the same stimuli. The mechanism that is best supported by research involves an effect on the upper small intestine. When rapidly dividing enterochromaffin cells in the GI tract are damaged, serotonin is released and binds to vagal afferent receptors in the wall of the bowel that activate the VC and stimulate emesis either directly or indirectly through the CTZ. The CTZ is situated in the area postrema of the medulla near the fourth ventricle. It is strongly suspected that the nucleus tractus solitarius (NTS) neurons, which lie ventrally to the area postrema, initiate emesis. This medullary area is a convergence point for projections arising from the area postrema and the vestibular and vagal afferent. The NTS is a good candidate for the site of action of centrally acting antiemetics.",370,55,0.14864864864864866
9781910797150,ch01,The main approach to the control of emesis has been to identify the active neurotransmitters (serotonin and substance P) and their receptors (5-hydroxytryptamine-3 [5-HT ] and neurokinin-1 [NK-1]) in the CNS and the GI tract that mediate the afferent inputs to the VC.,"The mechanism that is best supported by research involves an effect on the upper small intestine. When rapidly dividing enterochromaffin cells in the GI tract are damaged, serotonin is released and binds to vagal afferent receptors in the wall of the bowel that activate the VC and stimulate emesis either directly or indirectly through the CTZ. The CTZ is situated in the area postrema of the medulla near the fourth ventricle. It is strongly suspected that the nucleus tractus solitarius (NTS) neurons, which lie ventrally to the area postrema, initiate emesis. This medullary area is a convergence point for projections arising from the area postrema and the vestibular and vagal afferent. The NTS is a good candidate for the site of action of centrally acting antiemetics. Activation of the VC produces efferent impulses that travel from the VC to the abdominal muscles, salivation center, cranial nerves and respiratory center, causing vomiting. Nausea is thought to be mediated by the autonomic nervous system. Control of CINV. The main approach to the control of emesis has been to identify the active neurotransmitters (Figure 1.2) and their receptors in the CNS and the GI tract that mediate the afferent inputs to the VC. The receptors associated with serotonin and substance P are 5-hydroxytryptamine-3 (5-HT) and neurokinin-1 (NK-1), respectively. The study of these serotonin and substance P receptors has guided the development of antagonists, with relative success in controlling emesis (Table 1.1) (also see Chapter 3).",340,72,0.21176470588235294
9781910797150,ch01,Several 5-HT and NK-1 receptor antagonists have been developed for the prevention of chemotherapy-induced emesis.,"Control of CINV. The main approach to the control of emesis has been to identify the active neurotransmitters (Figure 1.2) and their receptors in the CNS and the GI tract that mediate the afferent inputs to the VC. The receptors associated with serotonin and substance P are 5-hydroxytryptamine-3 (5-HT) and neurokinin-1 (NK-1), respectively. The study of these serotonin and substance P receptors has guided the development of antagonists, with relative success in controlling emesis (Table 1.1) (also see Chapter 3).",122,23,0.1885245901639344
9781910797150,ch02,"Chemotherapy agents vary in their emetogenicity; for example, cisplatin has high emetogenic potential and causes CINV in almost all patients who do not receive antiemetic prophylaxis.","Delayed CINV is arbitrarily defined as nausea and/or vomiting that develops more than 24 hours after chemotherapy administration. It is important to emphasize that there is no clear break for when acute CINV ends and delayed CINV starts and the definitions for both should be considered an approximation. Delayed CINV is typically associated with the administration of cisplatin, doxorubicin or cyclophosphamide and can occur days 2 to 7 after chemotherapy. It can persist for as long as 5-7 days, with maximal intensity 48-72 hours after drug administration. It is more common in those who experience acute emesis/nausea. Other predictive factors include the dose and the emetogenicity of the chemotherapeutic agent (see Chapter 4), patient sex and age, and protection against nausea and vomiting in previous cycles of chemotherapy. For cisplatin, which has been most extensively studied, delayed emesis reaches peak intensity 2-3 days after chemotherapy administration and can last up to a week if not treated.",212,44,0.20754716981132076
9781910797150,ch02,The different types of CINV are classified according to the time interval at which nausea and vomiting occurs in relation to the administration of chemotherapy.,"Anticipatory CINV. Patients who experience CINV may develop a conditioned response known as anticipatory nausea and/or vomiting before the administration of chemotherapy in future chemotherapy cycles. This is attributed to the adverse memory of previous CINV. Incidence rates for this type of nausea and vomiting range from 10% to 45%, with nausea occurring more frequently., - Anticipatory CINV can be triggered by a variety of tastes, odors, sights, thoughts or anxiety associated with the chemotherapy treatment. It is more challenging to control and treat than acute or delayed CINV.",119,28,0.23529411764705882
9781910797150,ch02,"Despite guideline-directed antiemetic prophylaxis, CINV can occur with relatively high frequency in high-risk patients (20-25% acute CINV, 50-70% delayed CINV, 50% breakthrough CINV and 30% refractory CINV).","Treatment risk factors. The potential for CINV may be influenced by the following features of the chemotherapy being administered. the emetogenicity of chemotherapy agents (see Tables 4.1 and 4.2, pages 54-7). the doses of chemotherapy administered (see Table 4.3, page 59). the route of administration (see Table 4.1, page 54). the infusion duration. the combination of chemotherapy agents. Patient characteristics also influence the potential for CINV (Table 2.2). Young women with a history of motion sickness, emesis during pregnancy and no history of alcohol consumption have the highest risk of developing significant CINV. These patients should receive the most effective prophylactic antiemetic regimen available based on the international antiemetic guidelines (see Chapter 4). Incidence in high-risk patients. Despite the use of guideline-directed prophylactic antiemetics, CINV can occur with relatively high frequency in high-risk patients (20-25% acute, 50-70% delayed, 50% breakthrough and 30% refractory). Patients who are scheduled to receive their first course of chemotherapy should be individually evaluated for their specific risk factors and prescribed appropriate antiemetics (see Chapter 7).",255,61,0.23921568627450981
9781910797150,ch02,Important individual patient characteristics contribute to the risk of developing CINV.,"Patient characteristics also influence the potential for CINV (Table 2.2). Young women with a history of motion sickness, emesis during pregnancy and no history of alcohol consumption have the highest risk of developing significant CINV. These patients should receive the most effective prophylactic antiemetic regimen available based on the international antiemetic guidelines (see Chapter 4).",76,14,0.18421052631578946
9781910797150,ch02,The guideline-directed use of antiemetic agents has been shown to prevent emesis in approximately 50-70% of patients receiving highly or moderately emetogenic chemotherapy.,"Incidence in high-risk patients. Despite the use of guideline-directed prophylactic antiemetics, CINV can occur with relatively high frequency in high-risk patients (20-25% acute, 50-70% delayed, 50% breakthrough and 30% refractory). Patients who are scheduled to receive their first course of chemotherapy should be individually evaluated for their specific risk factors and prescribed appropriate antiemetics (see Chapter 7). Treatment effectiveness. The use of antiemetic agents, as recommended by international guidelines, has been shown to prevent emesis in approximately 50-70% of patients receiving either highly or moderately emetogenic chemotherapy. - The prevention of nausea has been much less successful with currently approved agents., New agents and new combinations of agents are necessary to adequately prevent chemotherapy-induced nausea.",167,34,0.20359281437125748
9781910797150,ch02,The prevention of nausea has been much less successful with currently approved agents.,"The use of antiemetic agents, as recommended by international guidelines, has been shown to prevent emesis in approximately 50-70% of patients receiving either highly or moderately emetogenic chemotherapy. - The prevention of nausea has been much less successful with currently approved agents., New agents and new combinations of agents are necessary to adequately prevent chemotherapy-induced nausea.",71,14,0.19718309859154928
9781910797150,ch03,"Serotonin (5-HT ) receptor antagonists (RAs) (ondansetron, granisetron, tropisetron, dolasetron and palonosetron) have their main antiemetic effect during the acute CINV phase.","In the early 1990s, treatment for CINV included the corticosteroid dexamethasone. Management was further improved by the use of agents that disrupt signals from the brain, sent by specific neurotransmitters that cause nausea and vomiting, to matching receptors in the body. In particular, the discovery of the 5-hydroxytryptamine (5-HT) receptor and the development of 5-HT receptor antagonists (RAs) (ondansetron, granisetron, tropisetron, dolasetron, palonosetron) significantly advanced the treatment of CINV. CINV control was further improved by combining the 5-HT RAs with dexamethasone. Over the past decade, discovery of the role of the neurokinin-1 (NK-1) receptor in the pathogenesis of delayed CINV and the development of NK-1 RAs (aprepitant, netupitant, rolapitant) have led to significant developments in the management of emetogenic anticancer treatment. Despite these milestone achievements, nausea in particular (60% of patients), and vomiting (30% of patients) remain clinically significant problems for patients undergoing highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). The effect of CINV on patients' quality of life can be devastating, and patients who experience uncontrollable nausea and vomiting associated with their therapy may be reluctant to continue with additional chemotherapy. Proper administration of antiemetics reduces CINV and improves patients' quality of life, such that patients are more likely to undergo subsequent chemotherapy cycles.",334,55,0.16467065868263472
9781910797150,ch03,"Neurokinin (NK)-1 receptor antagonists (aprepitant, fosaprepitant, rolapitant and netupitant) have their main antiemetic effect during the delayed CINV phase.","In the early 1990s, treatment for CINV included the corticosteroid dexamethasone. Management was further improved by the use of agents that disrupt signals from the brain, sent by specific neurotransmitters that cause nausea and vomiting, to matching receptors in the body. In particular, the discovery of the 5-hydroxytryptamine (5-HT) receptor and the development of 5-HT receptor antagonists (RAs) (ondansetron, granisetron, tropisetron, dolasetron, palonosetron) significantly advanced the treatment of CINV. CINV control was further improved by combining the 5-HT RAs with dexamethasone. Over the past decade, discovery of the role of the neurokinin-1 (NK-1) receptor in the pathogenesis of delayed CINV and the development of NK-1 RAs (aprepitant, netupitant, rolapitant) have led to significant developments in the management of emetogenic anticancer treatment.",218,44,0.2018348623853211
9781910797150,ch03,"5-HT RAs, NK-1 RAs and corticosteroids are not very effective in the prophylaxis of chemotherapy-induced nausea. Nausea control remains a challenge in the management of CINV.","Palonosetron exhibits allosteric interactions and positive cooperativity with the 5-HT receptor, characteristics not observed in the first-generation 5-HT RAs (granisetron, ondansetron, tropisetron, dolasetron). The binding of palonosetron elicits receptor internalization, which results in prolonged inhibition of serotonin signaling. In addition, palonosetron inhibits cross-talk between serotonin/5-HT and NK-1/substance P signaling pathways. These properties enable palonosetron to maintain adequate 5-HT receptor blockade even when it is no longer detectable in plasma, making it more effective and convenient than the first-generation RAs. Dosage. The recommended dose is 0.25 mg intravenously or 0.5 mg orally. The oral formulation is not available in the USA. Efficacy. A meta-analysis of 16 randomized clinical trials was performed comparing palonosetron to other 5-HT RAs, involving 2896 patients who received palonosetron and 3187 patients randomized to other 5-HT RAs. The meta-analysis showed that palonosetron was statistically superior to the other 5-HT RAs in the acute, delayed and overall phases of CINV. Essentially, when given without an NK-1 RA, palonosetron is more effective than other 5-HT RAs in the management of CINV in patients receiving both MEC and HEC.",311,47,0.15112540192926044
9781910797150,ch03,"A combination of a triple antiemetic regimen of a 5-HT RA, an NK-1 RA and a corticosteroid is very effective in antiemetic prophylaxis for patients receiving cispatin, AC (anthracycline and cyclophosphamide)-based and highly emetogenic chemotherapy (HEC) regimens.","Efficacy in MEC. In a global, randomized, double-blind, active-controlled, parallel group, phase III study, 1322 MEC- and HEC-naive patients were randomized to receive oral rolapitant, 180 mg, or placebo approximately 30 minutes before administration of MEC. It is important to clarify that there were two cohorts receiving either AC-based (703 patients) or non-AC-based (629 patients) chemotherapy regimens, and at the time of protocol development AC-based regimens were classified as MEC; they are now classified as HEC. The primary endpoint of complete response consisting of no emesis or rescue treatment in the delayed phase (after 24 to 120 hours) was successfully achieved. Treatment with rolapitant resulted in a significantly higher complete response rate in the delayed phase (71.3% vs 61.6%, p <0.001) than control treatment. The trial demonstrated the advantage of adding an NK-1 RA to active control for the prevention of CINV in patients receiving both AC-based and non-AC-based MEC. A pre-specified exploratory logistic regression analysis, which adjusted for sex, region, age and use of AC-based chemotherapy confirmed the primary analysis. When analyzed by chemotherapy subgroups, treatment with rolapitant demonstrated significantly higher complete response rates than control treatment in the delayed phase in patients who received AC-based (66.9% vs 59.5%; p =0.05) and non-AC-based (76.1% vs 63.8%; p <=0.001) MEC. It is important to highlight that the randomization of the AC and non-AC groups was done prospectively with a prespecified endpoint. These data clearly show that rolapitant is active in CINV prophylaxis in patients receiving non-AC-based MEC.",387,72,0.18604651162790697
9781910797150,ch03,"Recent data have shown that a combination of a triple antiemetic regimen of a 5-HT RA, an NK-1 RA and a corticosteroid is very effective in the prophylaxis of moderately emetogenic chmeotherapy (MEC) regimens, in particular carboplatin-based treatment.","Efficacy in MEC. In a global, randomized, double-blind, active-controlled, parallel group, phase III study, 1322 MEC- and HEC-naive patients were randomized to receive oral rolapitant, 180 mg, or placebo approximately 30 minutes before administration of MEC. It is important to clarify that there were two cohorts receiving either AC-based (703 patients) or non-AC-based (629 patients) chemotherapy regimens, and at the time of protocol development AC-based regimens were classified as MEC; they are now classified as HEC. The primary endpoint of complete response consisting of no emesis or rescue treatment in the delayed phase (after 24 to 120 hours) was successfully achieved. Treatment with rolapitant resulted in a significantly higher complete response rate in the delayed phase (71.3% vs 61.6%, p <0.001) than control treatment. The trial demonstrated the advantage of adding an NK-1 RA to active control for the prevention of CINV in patients receiving both AC-based and non-AC-based MEC. A pre-specified exploratory logistic regression analysis, which adjusted for sex, region, age and use of AC-based chemotherapy confirmed the primary analysis. When analyzed by chemotherapy subgroups, treatment with rolapitant demonstrated significantly higher complete response rates than control treatment in the delayed phase in patients who received AC-based (66.9% vs 59.5%; p =0.05) and non-AC-based (76.1% vs 63.8%; p <=0.001) MEC. It is important to highlight that the randomization of the AC and non-AC groups was done prospectively with a prespecified endpoint. These data clearly show that rolapitant is active in CINV prophylaxis in patients receiving non-AC-based MEC.",387,65,0.16795865633074936
9781910797150,ch03,"Corticosteroids (dexamethasone in particular) have a significant role in the prophylaxis of acute and delayed CINV, and are an essential part of almost all antiemetic regimens in clinical practice.","Although the mechanism of action of corticosteroids in CINV is unknown, they are effective agents in the management of acute and delayed CINV both as monotherapy and in combination with other agents (either with a 5-HT RA alone or as part of a triple-drug regimen with an NK-1 RA). They have remained valuable agents even since the development of NK-1 RAs and the first second-generation 5-HT RA, palonosetron, and remain the backbone of most CINV prophylactic regimens. Dexamethasone is the most broadly used corticosteroid in the management of CINV. Although dexamethasone is not approved as an antiemetic, it plays a significant role in the prophylaxis of acute and delayed CINV, and is an essential part of almost all antiemetic regimens in clinical practice. Safety and tolerability. Corticosteroids used in CINV as either monotherapy or in combination with other agents are very well tolerated. The most common side effects are transient elevations in glucose, insomnia, anxiety and gastric upset., In most settings, the duration of therapy with a corticosteroid is short and side effects can be managed, and the benefits are considered to offset any adverse effects. Uncommonly, these agents can decompensate diabetes, cause psychosis, or reactivate an ulcer. Importantly, when combined with aprepitant, the dose of dexamethasone should be reduced, as dexamethasone is a sensitive substrate of the cytochrome P450 [CYP] 3A4 enzyme.",340,50,0.14705882352941177
9781910797150,ch04,Outcomes are improved by following international guidelines when selecting the antiemetic regimen to use in relation to emetogenicity of the type of chemotherapy involved.,"It is essential that oncologists and oncology practitioners take significant time and effort to prepare patients adequately for their first course of chemotherapy. Clinicians have a wide variety of antiemetics to choose from for the prevention of chemotherapy-induced nausea and vomiting (CINV), and patients should receive the most effective antiemetic agents available. Outcomes are improved by following the recommendations of national or international guidelines for CINV. Both the Multinational Association for Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) and American Society of Clinical Oncology (ASCO) guidelines concur that the primary goal of CINV therapy is not to manage nausea and vomiting but to prevent these symptoms from happening in the first place. - All of the guidance for managing CINV in this book adheres to these international guidelines.",176,31,0.17613636363636365
9781910797150,ch04,The primary goal of CINV therapy is the prevention of nausea and vomiting.,Outcomes are improved by following the recommendations of national or international guidelines for CINV. Both the Multinational Association for Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) and American Society of Clinical Oncology (ASCO) guidelines concur that the primary goal of CINV therapy is not to manage nausea and vomiting but to prevent these symptoms from happening in the first place. - All of the guidance for managing CINV in this book adheres to these international guidelines.,107,16,0.14953271028037382
9781910797150,ch04,Patients should be individually evaluated for their specific risk factors as well as the level of anxiety present before the first course of treatment.,"Patients should be individually evaluated for their specific risk factors (see Table 2.2, page 18), as well as the level of anxiety present before the first course of treatment (see page 72). If the patient has a high level of anxiety before the first course of chemotherapy, serious consideration should be given to adding an antianxiety agent to the antiemetic regimen. To select the optimal antiemetic regimen, the emetogenic potential of the individual chemotherapy agents (Table 4.1) and overall emetogenicity of the chemotherapy regimen (Table 4.2) must be taken into consideration, according to the well-established antiemetic guidelines described above.",135,26,0.1925925925925926
9781910797150,ch04,"The final choice of antiemetic agent will depend on efficacy, toxicity and cost. To determine overall cost-effectiveness of any given regimen, the acquisition cost of the antiemetic agent should be weighed against the probability and cost of post-chemotherapy visits to the clinic or emergency department and/or admissions to hospital.","International guidelines recommend the use of palonosetron as the preferred agent because of its higher efficacy compared with ondansetron or granisetron (see above). If the use of palonosetron results in better control of CINV with fewer visits to the clinic or the emergency department after chemotherapy and fewer admissions to the hospital for control of CINV, then its use may be cost-effective despite its initial higher acquisition cost. Choice of NK-1 RA. Aprepitant, fosaprepitant, netupitant and rolapitant have all been shown to be safe and effective in phase III clinical trials, with few adverse events (see Chapter 3). Aprepitant, fosaprepitant and netupitant are metabolized by the liver enzyme CYP3A4 and are moderate inhibitors of CYP3A4, potentially resulting in drug interactions, although few, if any, clinical adverse events attributable to CYP3A interactions have been reported. Rolapitant does not induce CYP3A4. To date, no definitive clinical trials have directly compared the efficacy and safety of the various NK-1 RAs. One of the netupitant-palonosetron (NEPA) clinical trials involving patients receiving HEC included a comparative arm of oral aprepitant plus intravenous ondansetron. All patients in both arms received standard doses of dexamethasone. There appeared to be no significant differences in adverse events or in the prevention of CINV between NEPA and the aprepitant-ondansetron combination. A formal statistical comparison of the NEPA and aprepitant/ondansetron arms was not reported. For the present, the choice among these agents may be based on cost and the availability of oral or intravenous forms.",376,66,0.17553191489361702
9781910797150,ch04,"The triple-drug regimen of a NK-1 receptor antagonist (RA), 5-HT RA and dexamethasone is recommended for patients receiving highly emetogenic chemotherapy.","Prophylactic control of carboplatin-based CINV requires a triple-drug combination of a NK-1 RA, a 5-HT RA and dexamethasone before chemotherapy is administered on day 1. If aprepitant, 125 mg, is used on day 1, aprepitant, 80 mg, is recommended on days 2-3 for the prevention of delayed CINV. If another NK-1 RA is used on day 1, no additional NK-1 prophylaxis for delayed CINV prevention is recommended (Figure 4.4). At present there is no consensus as to whether to administer dexamethasone on days 2-3. Prophylactic control of CINV induced by a multiple-day cisplatin regimen comprises a 5-HT RA, dexamethasone and an NK-1 RA (aprepitant or fosaprepitant) for acute nausea and vomiting, and dexamethasone and an NK-1 RA (aprepitant or fosaprepitant) for delayed nausea and vomiting (Figure 4.5). However, it should be noted that there are only limited data on the use of aprepitant in this setting and, given the few studies to date in this patient population, the optimal doses of aprepitant and fosaprepitant still need to be determined. Some clinicians add 2 days of aprepitant to the regimen after completion of multiple-day chemotherapy to control the delayed nausea and vomiting that may occur after the final day of chemotherapy. There are no data for rolapitant or netupitant in patients receiving multiple-day cisplatin treatment, and the optimal doses of 5-HT RA and dexamethasone have yet to be determined.",362,36,0.09944751381215469
9781910797150,ch04,The two-drug combination of palonosetron and dexamethasone is recommended for patients receiving moderately emetogenic chemotherapy.,"Prophylactic control of carboplatin-based CINV requires a triple-drug combination of a NK-1 RA, a 5-HT RA and dexamethasone before chemotherapy is administered on day 1. If aprepitant, 125 mg, is used on day 1, aprepitant, 80 mg, is recommended on days 2-3 for the prevention of delayed CINV. If another NK-1 RA is used on day 1, no additional NK-1 prophylaxis for delayed CINV prevention is recommended (Figure 4.4). At present there is no consensus as to whether to administer dexamethasone on days 2-3.",140,28,0.2
9781910797150,ch04,A single 8-mg dose of dexamethasone before chemotherapy is recommended for patients receiving low emetogenic chemotherapy; no antiemetic should be administered routinely for patients receiving minimally emetogenic chemotherapy.,"Prophylactic control of CINV induced by a multiple-day cisplatin regimen comprises a 5-HT RA, dexamethasone and an NK-1 RA (aprepitant or fosaprepitant) for acute nausea and vomiting, and dexamethasone and an NK-1 RA (aprepitant or fosaprepitant) for delayed nausea and vomiting (Figure 4.5). However, it should be noted that there are only limited data on the use of aprepitant in this setting and, given the few studies to date in this patient population, the optimal doses of aprepitant and fosaprepitant still need to be determined. Some clinicians add 2 days of aprepitant to the regimen after completion of multiple-day chemotherapy to control the delayed nausea and vomiting that may occur after the final day of chemotherapy. There are no data for rolapitant or netupitant in patients receiving multiple-day cisplatin treatment, and the optimal doses of 5-HT RA and dexamethasone have yet to be determined. Furthermore, the 20-mg dose of dexamethasone that is often used on each day of chemotherapy has only been studied in patients receiving single-day higher doses of cisplatin-based chemotherapy (>= 50 mg/m). It is not known whether a lower dexamethasone dose administered on days 1-5 would be equivalent to a 20-mg dose. Low or minimally emetogenic chemotherapy. Limited evidence from clinical studies support the choice of antiemetic therapy or of any treatment at all for patients receiving low or minimally emetogenic chemotherapy. Of the patients who receive low or minimally emetogenic chemotherapy, it is hard to categorize those at risk of developing nausea and vomiting.",368,43,0.11684782608695653
9781910797150,ch04,The incidence and severity of CINV in children is similar ito that in adults. The use of antiemetics in children should follow the same principles as those used to treat adults.,"The incidence and severity of CINV in the pediatric age group is similar to that in adults. The use of antiemetics should follow the same principles as those used to treat adults. The literature on the use of specific agents for particular chemotherapy regimens in children is not as well developed as that in adults, mainly because the phase III clinical trials performed for the approval of 5-HT and NK-1 RAs were performed in adults only. The main antiemetics administered to children have been the 5-HT RAs (ondansetron, granisetron, palonosetron) with or without the use of corticosteroids. The use of corticosteroids has depended on the risk:benefit ratio in specific age groups and the particular chemotherapy regimen being used.",161,38,0.2360248447204969
9781910797150,ch05,Breakthrough CINV within 5 days of chemotherapy administration remains a significant clinical problem despite the development of effective agents for the prevention of CINV. Olanzapine has been shown in a phase III clinical trial to be an effective treatment.,"Even with improved control of acute and delayed CINV and adequate antiemetic prophylaxis, breakthrough CINV within 5 days of chemotherapy administration (see page 17) remains a significant clinical problem. Management principles. Breakthrough CINV usually requires immediate treatment or 'rescue' with additional antiemetics. Clinicians should provide patients with a prescription for rescue antiemetic treatment before the patient leaves the clinic or hospital, so that in the event of breakthrough CINV occurring, treatment can be started immediately. As patients may or may not derive some benefit from the original antiemetic regimen, this may or may not be continued. It is very unlikely that breakthrough nausea and vomiting will respond to an agent in the same drug class, and therefore with the same mechanism of action, as that already used unsuccessfully for prophylaxis. Agents that are found to effectively treat a patient's breakthrough CINV should be given routinely for at least 3 days rather than on an as-needed basis.",203,49,0.2413793103448276
9781910797150,ch05,A change in the prophylactic antiemetic regimen should be considered for those patients who develop refractory CINV.,"A change in the prophylactic antiemetic regimen should be considered for those patients who develop CINV during subsequent cycles of chemotherapy when antiemetic prophylaxis has not been successful in controlling CINV in earlier cycles. Treatment options. Few studies have examined CINV in this setting. If anxiety is considered to be a major patient factor in CINV, a benzodiazepine such as lorazepam or alprazolam can be added to the prophylactic regimen.",108,27,0.25
9781910797150,ch05,"If the patient has a poor experience with CINV in the first cycle, anticipatory CINV may develop requiring behavioral therapy.","If CINV is effectively controlled during the first cycle of chemotherapy, the patient is likely to have effective control during subsequent cycles of the same chemotherapy. If the patient has a poor experience with CINV in the first cycle, it may be more difficult to control CINV in subsequent cycles, and refractory and/or anticipatory CINV may develop. The earlier anticipatory CINV is identified, the more likely treatment will be effective. Management principles. To prevent the occurrence of anticipatory CINV (see pages 17-18), patients should be counseled about their 'expectations' of CINV before the initial course of treatment. Patients should be informed that very effective prophylactic antiemetic regimens will be used and that 70-75% of patients have a complete response (id est no emesis and no use of rescue medications). For optimum control of CINV during the first course of chemotherapy, each patient should receive the most effective prophylactic antiemetic regimen based on the specific type of chemotherapy (see Tables 4.1 and 4.2, pages 54-7) and their individual risk factors (see Table 2.2, page 18) before the first course of chemotherapy.",254,27,0.1062992125984252
9781910797150,ch05,"Optimum control of CINV during the first course of chemotherapy may prevent breakthrough, refractory and anticipatory CINV. Each patient should receive the most effective prophylactic antiemetic regimen based on the specific type of chemotherapy and their individual risk factors before the first course of chemotherapy.","Management principles. To prevent the occurrence of anticipatory CINV (see pages 17-18), patients should be counseled about their 'expectations' of CINV before the initial course of treatment. Patients should be informed that very effective prophylactic antiemetic regimens will be used and that 70-75% of patients have a complete response (id est no emesis and no use of rescue medications). For optimum control of CINV during the first course of chemotherapy, each patient should receive the most effective prophylactic antiemetic regimen based on the specific type of chemotherapy (see Tables 4.1 and 4.2, pages 54-7) and their individual risk factors (see Table 2.2, page 18) before the first course of chemotherapy. Treatment options. The use of anti-anxiety medications such as lorazepam or another benzodiazepine may be considered for excess anxiety prior to the first course of chemotherapy in order to obtain an optimum outcome and prevent anticipatory CINV. If anticipatory CINV occurs despite the use of guideline-directed prophylactic antiemetics, additional antiemetic drugs do not seem to be effective. Behavioral therapy should be considered instead. A number of behavioral interventions have been investigated (Table 5.2).",269,61,0.22676579925650558
9781910797150,ch06,"Current data from multiple large studies suggest that neither the 5-HT receptor antagonists (RAs) nor the NK-1 RAs are effective in the prevention of nausea in patients receiving either moderately or highly emetogenic chemotherapy, despite marked improvement in the control of emesis.","Conventional antiemetics are more successful at preventing emesis than nausea. Current data from multiple large studies suggest that neither first- nor second-generation 5-hydroxytryptamine-3 (5-HT) receptor antagonists (RAs) are effective in the control of nausea in patients receiving either moderately or highly emetogenic chemotherapy (MEC or HEC, respectively), despite marked improvement in the control of emesis. - Multiple large phase III trials have also shown that although the neurokinin (NK)-1 RA aprepitant is effective for the control of emesis, it is not effective in controling nausea in patients receiving MEC or HEC. Similarly, phase III clinical trial data indicate that the new neurokinin (NK)-1 RAs netupitant and rolapitant are not effective antinausea agents,, although rolapitant may have some effect in patients receiving cisplatin HEC. These studies suggest that the serotonin (5-HT) and substance P (NK-1) receptors may not be important in the mediation of nausea, despite their important role in chemotherapy-induced emesis (see page 11). - New studies using novel agents and using nausea as the primary endpoint need to be performed.",252,55,0.21825396825396826
9781910797150,ch06,Phase III clinical studies suggest that olanzapine may be an important agent in the prevention of chemotherapy-induced nausea and in the treatment of breakthrough CINV.,"These studies suggest that the serotonin (5-HT) and substance P (NK-1) receptors may not be important in the mediation of nausea, despite their important role in chemotherapy-induced emesis (see page 11). - New studies using novel agents and using nausea as the primary endpoint need to be performed. Olanzapine appears to have high potential for the control of both emesis and nausea in patients receiving MEC or HEC (Table 6.1). Phase III studies suggest that olanzapine may be an important agent in the control of chemotherapy-induced nausea. - Olanzapine is known to affect a wide variety of receptors including dopamine D, 5-HT 2C, histaminic and muscarinic receptors. At present, there is still a substantial lack of understanding of the pathogenesis of chemotherapy-induced nausea, and any or all of these receptors may be important mediators.",187,34,0.18181818181818182
9781910797150,ch06,"Non-pharmacological measures for the control of chemotherapy-induced nausea include avoidance of strong odors, eating small amounts of spicy food, avoiding smoking and caffeine, and acupuncture.","Olanzapine appears to have high potential for the control of both emesis and nausea in patients receiving MEC or HEC (Table 6.1). Phase III studies suggest that olanzapine may be an important agent in the control of chemotherapy-induced nausea. - Olanzapine is known to affect a wide variety of receptors including dopamine D, 5-HT 2C, histaminic and muscarinic receptors. At present, there is still a substantial lack of understanding of the pathogenesis of chemotherapy-induced nausea, and any or all of these receptors may be important mediators. The addition of olanzapine to the 5-HT RA azasetron and dexamethasone has been shown to improve nausea and emesis compared with azasetron and dexamethasone alone in patients receiving MEC and HEC. Olanzapine, palonosetron and dexamethasone has been shown to improve the control of nausea compared with aprepitant, palonosetron and dexamethasone in patients receiving HEC. Breakthrough nausea and emesis was controlled with olanzapine in patients receiving HEC and guideline-directed prophylactic antiemetics. The addition of olanzapine to aprepitant, a 5-HT RA and dexamethasone significantly improved nausea and emesis compared with aprepitant, a 5-HT RA and dexamethasone alone in patients receiving HEC. Olanzapine is available as a generic.",322,36,0.11180124223602485
9781910797150,ch07,"Issues that may reduce the effectiveness of CINV control by healthcare professionals include underestimation of the incidence of CINV, concerns about the adverse effects and cost of antiemetic agents, and insufficient following up after chemotherapy.","Better prescribing. Incorporating antiemetic guidelines in electronic medical record prescribing orders may help to ensure prescription of optimal antiemetic regimens. Studies have shown that oncology nurses and nurse practitioners can have a key role in influencing the selection of the antiemetic regimen, and it is important that they are aware of the latest antiemetic guidelines and the factors that put patients at risk for CINV. In a multidisciplinary team, communication between oncology nurses, palliative care nurses, pharmacists and clinicians about the antiemetic regimen and the patient's progress is essential. Patient education. Clinicians should reassure patients that the incidence or severity of CINV is not an indicator of the effectiveness of their chemotherapy and that nausea and vomiting should not be considered a normal part of treatment. Furthermore, it is important to discuss the likelihood and management of adverse effects of antiemetic treatment and emphasize the importance of continuing the medications at home and completing the full course of treatment. Minimizing the pill burden and eliminating the requirement to swallow medication can also improve patient adherence to treatment.",223,46,0.2062780269058296
9781910797150,ch07,Incorporating antiemetic guidelines in electronic medical record prescribing orders may help to ensure prescription of optimal antiemetic regimens by healthcare professionals.,"Better prescribing. Incorporating antiemetic guidelines in electronic medical record prescribing orders may help to ensure prescription of optimal antiemetic regimens. Studies have shown that oncology nurses and nurse practitioners can have a key role in influencing the selection of the antiemetic regimen, and it is important that they are aware of the latest antiemetic guidelines and the factors that put patients at risk for CINV. In a multidisciplinary team, communication between oncology nurses, palliative care nurses, pharmacists and clinicians about the antiemetic regimen and the patient's progress is essential.",122,30,0.2459016393442623
9781910797150,ch07,Patient factors that may reduce the effectiveness of CINV control include under-reporting of symptoms and poor adherence to medications.,"Patient education. Clinicians should reassure patients that the incidence or severity of CINV is not an indicator of the effectiveness of their chemotherapy and that nausea and vomiting should not be considered a normal part of treatment. Furthermore, it is important to discuss the likelihood and management of adverse effects of antiemetic treatment and emphasize the importance of continuing the medications at home and completing the full course of treatment. Minimizing the pill burden and eliminating the requirement to swallow medication can also improve patient adherence to treatment.",101,25,0.24752475247524752
9781910797150,ch07,Clinicians must emphasize the importance of continuing medications at home and completing the full course of treatment.,"Patient education. Clinicians should reassure patients that the incidence or severity of CINV is not an indicator of the effectiveness of their chemotherapy and that nausea and vomiting should not be considered a normal part of treatment. Furthermore, it is important to discuss the likelihood and management of adverse effects of antiemetic treatment and emphasize the importance of continuing the medications at home and completing the full course of treatment. Minimizing the pill burden and eliminating the requirement to swallow medication can also improve patient adherence to treatment.",101,20,0.19801980198019803
9781910797150,ch07,Telephone follow-up by oncology nurses with patients 24-48 hours after chemotherapy will provide important patient information.,"Patient education. Clinicians should reassure patients that the incidence or severity of CINV is not an indicator of the effectiveness of their chemotherapy and that nausea and vomiting should not be considered a normal part of treatment. Furthermore, it is important to discuss the likelihood and management of adverse effects of antiemetic treatment and emphasize the importance of continuing the medications at home and completing the full course of treatment. Minimizing the pill burden and eliminating the requirement to swallow medication can also improve patient adherence to treatment. Improved follow-up. It is important to assess symptoms throughout therapy, as patient response to antiemetic treatment may change over time and may require adjustment of the antiemetic regimen. Telephone follow-up by oncology nurses with patients 24-48 hours after chemotherapy will provide important patient information as well as suggested treatment for unreported breakthrough CINV.",173,24,0.13872832369942195
9781910797181,ch01,Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff.,"One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation (Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco.",162,20,0.12345679012345678
9781910797181,ch01,Smokers absorb an average 1-2 mg of nicotine per cigarette (more when cigarettes are smoked more intensively).,"One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation (Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco.",162,23,0.1419753086419753
9781910797181,ch01,"Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide.","Many smokers, particularly older smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA and EU.",192,17,0.08854166666666667
9781910797181,ch01,Smokers' intake of tar and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes.,"Many smokers, particularly older smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA and EU.",192,31,0.16145833333333334
9781910797181,ch01,Nicotine is rapidly metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence.,"Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide. These appear to be largely inactive and are further metabolized and excreted in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1). Duration of withdrawal symptoms. All nicotine is cleared from the body within a day or two of abstinence. Some people think that this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks.",189,35,0.18518518518518517
9781910797181,ch01,"The nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.","Duration of withdrawal symptoms. All nicotine is cleared from the body within a day or two of abstinence. Some people think that this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating nicotine intake. Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly accurate picture of total intake over a day. Measurement of its metabolite, cotinine, is used instead. Cotinine has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair. Saliva samples are simple to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake.",215,50,0.23255813953488372
9781910797181,ch02,Smoking prevalence is higher in men than in women in almost every country.,"In countries such as the UK and the USA, rates are relatively low overall, and rates for women are slightly lower than those for men. However, in Asian and African countries the prevalence of smoking is much higher in men than in women. Socioeconomic factors. Within countries, smoking prevalence varies according to socioeconomic status and level of education. In high-income countries such as the UK and the USA, smoking rates are higher among less affluent and less well-educated groups. Figure 2.2 shows the trends in Australia, and the pattern is similar in the UK and USA.",116,15,0.12931034482758622
9781910797181,ch02,"In industrialized English-speaking countries (which have all implemented tobacco control measures), smoking prevalence has declined markedly, and in countries such as the UK and Australia with strong anti-tobacco policies it continues to decline.","In countries such as the UK and the USA, rates are relatively low overall, and rates for women are slightly lower than those for men. However, in Asian and African countries the prevalence of smoking is much higher in men than in women. Socioeconomic factors. Within countries, smoking prevalence varies according to socioeconomic status and level of education. In high-income countries such as the UK and the USA, smoking rates are higher among less affluent and less well-educated groups. Figure 2.2 shows the trends in Australia, and the pattern is similar in the UK and USA. In the UK, the main cause of the socioeconomic gradient in smoking prevalence is a difference in the success of attempts to stop smoking. Thus, low-income smokers make the same number of quit attempts and want to stop just as much as higher-income smokers, but they are less likely to succeed. In other countries, different patterns may hold true.",186,43,0.23118279569892472
9781910797181,ch02,"Smoking prevalence varies across countries from less than 20% to more than 60% in men, and from less than 5% to more than 30% in women.","Ethnic differences in smoking prevalence are often accompanied by sex differences. In general, women from Asian backgrounds are subject to strong cultural taboos against smoking, so that prevalence in women is much lower than in men. Among British Asians, smoking prevalence is highest in those of Bangladeshi descent, moderate in those of Pakistani descent and low in those of Indian descent. In the UK, there is also a high prevalence of smoking in people of African-Caribbean descent. In the USA, native American communities have particularly high smoking rates (Figure 2.3). Changes in smoking prevalence. In many developed countries, smoking prevalence has fallen dramatically from a peak in the middle of the last century. At that time, most of the population smoked, whereas prevalence is now 20-30%. Figure 2.4 shows the decrease in smoking in men and women in Japan, the UK and the USA since the 1960s.",182,33,0.1813186813186813
9781910797181,ch02,"In western industrialized countries, smoking prevalence is greater among people with lower educational level and greater socioeconomic disadvantage.","Ethnic differences in smoking prevalence are often accompanied by sex differences. In general, women from Asian backgrounds are subject to strong cultural taboos against smoking, so that prevalence in women is much lower than in men. Among British Asians, smoking prevalence is highest in those of Bangladeshi descent, moderate in those of Pakistani descent and low in those of Indian descent. In the UK, there is also a high prevalence of smoking in people of African-Caribbean descent. In the USA, native American communities have particularly high smoking rates (Figure 2.3).",112,20,0.17857142857142858
9781910797181,ch02,"Most smokers smoke every day, and in the USA and the UK 70% smoke within 30 minutes of waking.","The majority of smokers smoke every day. In England, just under 90% of smokers smoke daily. In the USA, the proportion of non-daily smokers has increased to around 25%, and is highest in states with the lowest smoking prevalence and most active tobacco control policies. The application of regulations that prevent smoking in indoor public areas may partly account for this increase, but there are probably other factors as well, including the changing social acceptability of smoking.",90,22,0.24444444444444444
9781910797181,ch02,Most smokers start during adolescence; initial take-up and transition to regular smoking are linked to both genetic and social factors.,"In the USA and the UK, people most commonly start smoking at 13-16 years of age. The reasons why young people become smokers are complex. Peer influence certainly plays a role and it is possible, though not established, that more distant role models (exempli gratia music and movie stars) may have an effect too. Personal characteristics are also important. In many western countries, those with an antisocial personality and/or lacking engagement with social values are more likely to take up smoking, as are those with a tendency toward sensation- or thrill-seeking (a characteristic common in teenagers). There is also evidence that children who suffer from depression are more likely to begin smoking, but the reverse is also true - non-depressed children who start to smoke are more likely to become depressed subsequently. This suggests that there may be a causal link in both directions, or that there is a common underlying mechanism.",183,24,0.13114754098360656
9781910797181,ch02,"In most developed countries, most smokers want to stop smoking, usually because of health concerns and cost, and try to do so many times.","Smokers' attitudes and attempts to stop smoking. Surveys in Europe and the USA consistently show that the majority of smokers would like to stop. Approximately 80% have made at least one attempt to do so, and 30-50% make at least one attempt in any given year. The main reasons for wanting to stop are shown in Table 2.1. At the top of the list in both the USA and the UK are concerns about health and the cost of cigarettes. Some smokers report that pressure from their children or spouse is a factor in the decision to try to stop.",117,28,0.23931623931623933
9781910797181,ch03,"In western countries, smoking is more prevalent in people with mental health problems, those with alcohol- and drug-related problems, the homeless and criminals.","There is a strong link between smoking and many psychiatric disorders, including mood disorders, schizophrenia and substance abuse. Smoking is also prevalent among homeless people, many of whom suffer from mental health disorders. Not only are persons with psychiatric disorders more likely to smoke, but they are also likely to smoke more heavily than others. It has yet to be established why these links exist: whether smoking causes or exacerbates these conditions, whether a disorder makes it more likely that a patient will smoke and be unable to stop, or whether there is a common underlying cause. It is widely thought that smoking is particularly closely linked to schizophrenia, but in fact the dominant factors are the severity of the psychiatric disorder and whether the patient is institutionalized (Figure 3.1). Thus, discussion about whether specific links exist between smoking behavior and the mechanisms that underlie schizophrenia or its treatment are somewhat premature.",173,30,0.17341040462427745
9781910797181,ch03,"Smoking prevalence is strongly influenced by social norms and the financial cost. High-intensity and sustained mass media campaigns and mass quitting events, such as Stoptober, have an important effect in promoting smoking cessation and reducing smoking prevalence. Banning tobacco marketing and bans on smoking in indoor public areas probably also play a role.","In countries such as the UK, smokers support these kinds of policies, presumably because they recognize that they can provide an added incentive to stop - which is what they mostly want to do. Taxation has to be linked to effective countermeasures against illicit supply. It is important to structure it to prevent tobacco companies using pricing policies to undermine its deterrent effect. Not all of the decrease in consumption involves smokers giving up altogether; in some cases smokers merely reduce the number of cigarettes they smoke. The health benefits of this action may be undermined, however, because smokers tend to smoke each cigarette more intensively. It is also not fully known how reductions in consumption translate into health benefits. Nevertheless, it is clear that increasing the cost of smoking is, potentially, an important public health measure. Mass media campaigns can be effective in promoting smoking cessation and reducing smoking prevalence. The size of the effect is related to the intensity of the campaign (as indexed by viewing numbers) and whether it is sustained. Specific quitting events, for example the UK's 'No Smoking Day' and 'Stoptober' (a mass quitting event that challenges smokers to be smoke-free for a month as a stepping stone to permanent cessation), and the US 'Great American Smokeout' (which encourages quitting for a day), have been evaluated as a highly cost-effective way of promoting smoking cessation.",272,64,0.23529411764705882
9781910797181,ch04,"Nicotine binds to nicotinic acetylcholine receptors and acts, among other things, as a central nervous system stimulant. Nicotine at the level associated with smoking has relatively few adverse health effects and does not cause cancer.","The irritancy of nicotine and other components of smoke in the airways usually causes coughing and sore throat on initial exposure. For many people this is accompanied by nausea and dizziness caused by the action of nicotine on the central nervous system (CNS) and by the anoxic effect of inhaling carbon monoxide. There may also be a sensation of cooling in the hands and feet, palpitations, sweating and tremor. Some first-time smokers experience a pleasurable sensation as well. Adaptation to the acute unpleasant effects of smoking occurs quickly, and within a few weeks or months novice smokers are able to tolerate as much nicotine from each cigarette as habitual smokers. Long-term health effects of smoking. Long-term smoking has disastrous effects on most body systems, resulting in the death of half of smokers who do not manage to stop (Table 4.1); it kills an estimated 6 million people worldwide each year. Those who are killed by smoking die an average of 20 years sooner than they would have done otherwise. Smoking also causes long-term disability, both in those who are eventually killed by cigarette smoking and in those who ultimately die from some other cause. The average smoker who fails to stop can expect to develop diseases of old age many years earlier than a non-smoker. The following sections discuss some of the more common causes of death associated with smoking.",275,46,0.16727272727272727
9781910797181,ch04,"Smoking causes substantial mortality and morbidity, killing anestimated 6 million people worldwide each year.","Long-term smoking has disastrous effects on most body systems, resulting in the death of half of smokers who do not manage to stop (Table 4.1); it kills an estimated 6 million people worldwide each year. Those who are killed by smoking die an average of 20 years sooner than they would have done otherwise. Smoking also causes long-term disability, both in those who are eventually killed by cigarette smoking and in those who ultimately die from some other cause. The average smoker who fails to stop can expect to develop diseases of old age many years earlier than a non-smoker. The following sections discuss some of the more common causes of death associated with smoking.",133,21,0.15789473684210525
9781910797181,ch04,"The main causes of death from smoking are lung cancer, cardiovascular disease and chronic obstructive pulmonarydisease.","Lung cancer kills about 150 000 people a year in the USA and 30 000 in the UK. Although a variety of new techniques are being tested to detect lung cancer in its early stages, in practice the disease is usually fatal. Smoking accounts for the vast majority of cases of lung cancer worldwide. Indeed, lung cancer was almost never seen before manufactured cigarettes became popular at the beginning of the 1900s. Since then, it has reached epidemic proportions. The risk of lung cancer is 15 times greater for a smoker than for a non-smoker. The risk accumulates over time and is related to both daily cigarette consumption and duration of smoking. Starting young - before 15 years of age - is particularly hazardous. About 1 in 8 smokers who do not quit will die from lung cancer.",156,23,0.14743589743589744
9781910797181,ch04,"Smoking also increases the risk of a wide range of disabling conditions, such as age-related blindness, deafness and dementia.","Fertility is impaired by smoking in both women and men. Smoking is also an important cause of miscarriage, the risk being several times higher than in non-smokers when other known risk factors are controlled for. In addition, smoking increases the risk of placental abruption (in which the placenta detaches from the wall of the uterus), which jeopardizes the lives of both the baby and the mother. It is important for pregnant smokers to understand that, even if the baby is born apparently healthy, this does not mean that no damage has been done. Children of smokers are more likely to suffer from intellectual impairment and behavioral problems and delinquency, although we cannot be sure that smoking is the cause. Also, there is evidence that smoking (and possibly any form of nicotine use) during pregnancy increases the subsequent risk of sudden infant death syndrome (crib or cot death).",177,26,0.14689265536723164
9781910797181,ch04,Smoking impairs fertility and increases the risk of fetal and neonatal death.,"Fertility is impaired by smoking in both women and men. Smoking is also an important cause of miscarriage, the risk being several times higher than in non-smokers when other known risk factors are controlled for. In addition, smoking increases the risk of placental abruption (in which the placenta detaches from the wall of the uterus), which jeopardizes the lives of both the baby and the mother. It is important for pregnant smokers to understand that, even if the baby is born apparently healthy, this does not mean that no damage has been done. Children of smokers are more likely to suffer from intellectual impairment and behavioral problems and delinquency, although we cannot be sure that smoking is the cause. Also, there is evidence that smoking (and possibly any form of nicotine use) during pregnancy increases the subsequent risk of sudden infant death syndrome (crib or cot death).",177,16,0.0903954802259887
9781910797181,ch04,"Smoking cessation causes temporary withdrawal symptoms, such as irritability, restlessness, depressed mood, difficulty concentrating and increased appetite.","When smokers abstain, even for a few hours, they experience physical and psychological changes, most of which are unpleasant (Table 4.4). Most or all are attributable to cessation of nicotine intake. However, not all of them should be regarded as part of a withdrawal syndrome. Such a syndrome involves signs and symptoms that arise when an individual abstains from a drug, because the body has adapted to the presence of the drug and needs a period of adjustment once the drug is no longer in the system. Thus, a key feature of a withdrawal syndrome is that it is temporary. While this is clearly the case for many of the subjective symptoms, such as depressed mood and irritability, it does not seem to be the case for some of the physical changes, which appear to be permanent and may simply reflect a return to a level that would have been the case if the individual had never smoked.",179,25,0.13966480446927373
9781910797181,ch04,Many smokers experience permanent weight gain when they stop smoking.,"The core of the nicotine withdrawal syndrome is mood disturbance. The temporary mood changes that smokers experience when they stop are often unpleasant and disruptive; they have been compared with the effects of psychiatric disorders. Particular concern has been expressed about the increase in depressed mood, which has been linked in some studies (but not others) to subsequent relapse to smoking. However, there is no clear evidence that stopping smoking places smokers at greater risk of developing depression.",88,11,0.125
9781910797181,ch04,Stopping smoking reduces the risks; a healthy smoker who stops before 35 years of age has a near-normal life expectancy.,"Quitting has substantial health benefits at any age. The greatest benefit is achieved in those who stop while they are relatively young, and before they develop a smoking-related disease, but all smokers stand to gain by quitting. In fact, a healthy adult who stops smoking before 35 years of age can have a near-normal life expectancy. Someone who stops in their forties or fifties can expect to gain an average of 6 years of healthy life. Table 4.5 shows the main health benefits and how long they take to materialize. Every year after the age of about 35 years that a smoker delays smoking cessation costs an average of 2-3 months of life and every day that smoking continues costs 4-6 hours of life expectancy.",149,25,0.16778523489932887
9781910797181,ch05,"Cigarette addiction stems primarily from nicotine dependence.- Repeated rapid intake of nicotine from cigarettes sets up a powerful association between smoking and situations in which smoking typically occurs.- It also creates 'nicotine hunger' so that when brain nicotine levels fall, the smoker experiences a need to smoke.- It creates unpleasant withdrawal symptoms, including mood disturbance, because of physiological adaptation.","Nicotine hunger. A second likely mechanism is the development of a kind of 'nicotine hunger'. Repeated intake of nicotine from cigarettes over a period of months or years changes the way that the pathway described above operates, so that if nicotine concentrations in the brain fall below a certain level, the activity in the pathway falls to abnormally low levels; this creates a kind of 'acquired drive', a hunger for nicotine, that is often experienced as craving. Like hunger for food, at low levels this feeling does not reach consciousness until something reminds us of its presence. At higher levels it is persistent and insistent, trying in some sense to motivate the smoker to do something to relieve it. It is a need. Withdrawal symptoms. A third mechanism involves learning that smoking a cigarette helps to alleviate feelings of anxiety, depression, irritability, restlessness, and difficulty concentrating. These are all withdrawal symptoms resulting from physiological adaptation to repeated nicotine intake. Thus, nicotine does not alleviate these problems in people who do not smoke. Unfortunately, such discomfort can occur for all kinds of reasons, and the smoker's brain is not good at discriminating adverse mood states that arise from nicotine withdrawal from those arising from other causes. This means that smokers learn to associate adverse mood states and difficulty concentrating with smoking, and come to believe that smoking helps them to cope, even though it does so only because they are experiencing the problem because they have not smoked for a while. Unfortunately, as long as they believe that smoking helps to relieve adverse mood and other symptoms, smokers will be at risk of relapse when they try to stop.",322,72,0.2236024844720497
9781910797181,ch05,"The withdrawal symptoms are relieved by smoking, thus generating the feeling of a need to smoke whenever these symptoms are experienced, even if they are caused by something else.","Withdrawal symptoms. A third mechanism involves learning that smoking a cigarette helps to alleviate feelings of anxiety, depression, irritability, restlessness, and difficulty concentrating. These are all withdrawal symptoms resulting from physiological adaptation to repeated nicotine intake. Thus, nicotine does not alleviate these problems in people who do not smoke. Unfortunately, such discomfort can occur for all kinds of reasons, and the smoker's brain is not good at discriminating adverse mood states that arise from nicotine withdrawal from those arising from other causes. This means that smokers learn to associate adverse mood states and difficulty concentrating with smoking, and come to believe that smoking helps them to cope, even though it does so only because they are experiencing the problem because they have not smoked for a while. Unfortunately, as long as they believe that smoking helps to relieve adverse mood and other symptoms, smokers will be at risk of relapse when they try to stop.",178,32,0.1797752808988764
9781910797181,ch05,"Cigarette addiction involves powerful motivations to smoke that undermine and overwhelm the desire to avoid smoking because of its social, financial and health costs.","The sum of motivations. Putting all this together, we can see that there are probably at least three ways in which repeated ultra-rapid intake of nicotine from cigarettes creates powerful motivations to smoke, which undermine and overwhelm the resolve not to. Different smokers probably experience each of these three elements of nicotine dependence to differing degrees. Thus, some smokers clearly have a strong nicotine hunger and smoke as soon as they wake up in the morning and whenever the opportunity arises during the day. Others may not need to smoke for much of the day but experience powerful urges to smoke in particular situations, such as when socializing; this is particularly true of non-daily smokers. For some smokers the nicotine withdrawal syndrome is relatively mild, while others experience severe adverse mood states when not smoking.",153,28,0.1830065359477124
9781910797181,ch05,Addiction to cigarettes is demonstrated by the fact that fewer than 5% of serious attempts to stop smoking succeed without behavioral support or pharmacological treatment.,"Combining time to first cigarette of the day and number of cigarettes smoked provides what is known as the Heaviness of Smoking Index (HSI), which is probably the measure of choice for very quickly assessing cigarette addiction (Table 5.1). The diagnosis can also be made based on clinical evidence. If a patient has tried to stop smoking and failed because the urge to smoke is too strong, the need for a cigarette is overwhelming, or the withdrawal symptoms are too much to bear, that patient is addicted to cigarettes. Equally, if a patient has never tried to stop smoking because the prospect of going without cigarettes is too much to contemplate, even though he or she is concerned about the damage that smoking is doing to his or her health, that patient is addicted.",154,29,0.18831168831168832
9781910797181,ch06,Smoking is an essential vital sign; it is imperative that patients' smoking status be recorded and the record kept up to date.,Smoking is linked to so many diseases that recording it is imperative in the diagnosis of a condition and in deciding its management. Failing to record smoking status and acting on the result is considered by leading professional organizations such as the UK's Royal College of Physicians and the American Medical Association to be tantamount to negligence. Smoking history is important in the diagnosis of chronic obstructive pulmonary disease (COPD). It can also be useful in the preliminary diagnosis of other smoking-related diseases and where a hidden psychiatric disorder is suspected.,105,26,0.24761904761904763
9781910797181,ch06,A physician's advice on smoking has a positive effect and need take as little as 30 seconds.,"It is now recognized that all clinicians have a role to play in encouraging and aiding smoking cessation. This need not be time-consuming or confrontational if undertaken properly. Research has shown that brief opportunistic advice from a physician can trigger an attempt to stop smoking in about 40% of cases. If the smoker then attempts to quit with no treatment, he or she has only a 5% chance of long-term success. Hence, the overall effect of the physician's advice alone (without assistance) is to create one long-term ex-smoker for about every 50 people advised. This may seem like a very low figure, but when one considers that the advice can take as little as 30 seconds, that the cost, taking into account the physician's time, is no more than 10 or US$15, and that stopping smoking yields an average of up to 10 extra years of healthy life, then, bearing in mind that some smokers who stop will relapse and others who did not respond will stop later, the cost per healthy life-year gained can be as little as 1000 or US$1500. Taking into account the cost savings on smoking-related illness and time off work, brief advice to stop smoking actually results in a cost saving.",251,19,0.07569721115537849
9781910797181,ch06,"The advice should focus, taking a small amount of time in routine consultations at least once a year, on telling all smokers about the best ways of stopping rather than berating smokers or just advising them to stop.","It is now recognized that all clinicians have a role to play in encouraging and aiding smoking cessation. This need not be time-consuming or confrontational if undertaken properly. Research has shown that brief opportunistic advice from a physician can trigger an attempt to stop smoking in about 40% of cases. If the smoker then attempts to quit with no treatment, he or she has only a 5% chance of long-term success. Hence, the overall effect of the physician's advice alone (without assistance) is to create one long-term ex-smoker for about every 50 people advised. This may seem like a very low figure, but when one considers that the advice can take as little as 30 seconds, that the cost, taking into account the physician's time, is no more than 10 or US$15, and that stopping smoking yields an average of up to 10 extra years of healthy life, then, bearing in mind that some smokers who stop will relapse and others who did not respond will stop later, the cost per healthy life-year gained can be as little as 1000 or US$1500. Taking into account the cost savings on smoking-related illness and time off work, brief advice to stop smoking actually results in a cost saving.",251,42,0.16733067729083664
9781910797181,ch07,"Sustained-release bupropion hydrochloride (Zyban) and nicotine-replacement therapy (NRT, in the form of chewing gum, transdermal patches, nasal spray, inhalator, lozenges, sublingual tablets, mouth spray or dissolvable oral strips) increase smokers' chances of stoppingconsiderably.","Treatments to aid smoking cessation. Optimal treatment. Structured behavioral support combined with medication (nicotine-replacement therapy [NRT], bupropion [formerly amfebutamone] or varenicline) is the treatment of choice to aid smokers who want to quit. This combination can improve the chances of success of a quit attempt from 5% when unaided to more than 20% (Figure 7.1). In the absence of an available program of structured behavioral support, medication plus limited behavioral support, such as might be feasible in routine consultations via a telephone quitline or through the internet, is an important treatment option. Behavioral support. Research has consistently shown that a structured behavioral support program, whether conducted with groups of smokers, one-to-one (face-to-face) with a specialist or by telephone with a trained counselor, can significantly increase a smoker's chances of long-term success in stopping smoking. Many different face-to-face behavioral support programs are available, including some inpatient programs (though the incremental value of an inpatient program has not been demonstrated). Most follow a pattern of one or two pre-quit sessions, followed by regular sessions in the 4-6 weeks following the quit date. Figure 7.2 shows a treatment plan in a typical smokers' clinic. The key elements are. sessions before the quit date. a specified quit date.",288,72,0.25
9781910797181,ch07,A structured behavioral support program involving several sessions concentrated in the first few weeks after the quit date can significantly increase smokers' chances of stoppingpermanently.,"Research has consistently shown that a structured behavioral support program, whether conducted with groups of smokers, one-to-one (face-to-face) with a specialist or by telephone with a trained counselor, can significantly increase a smoker's chances of long-term success in stopping smoking. Many different face-to-face behavioral support programs are available, including some inpatient programs (though the incremental value of an inpatient program has not been demonstrated). Most follow a pattern of one or two pre-quit sessions, followed by regular sessions in the 4-6 weeks following the quit date. Figure 7.2 shows a treatment plan in a typical smokers' clinic. The key elements are.",138,31,0.2246376811594203
9781910797181,ch07,A combination of behavioral support and medication quadruples the chances of a successful quit attempt; these treatments are among the most cost-effective life-preserving interventions available to health professionals.,"Assessment session. Behavioral support programs typically begin with an assessment session in which the smoker's commitment to making a serious attempt to stop smoking is confirmed, his or her level of dependence is gauged and the schedule of sessions is explained. Smokers may be asked to observe or monitor their smoking patterns in order to anticipate situations in which they may face temptations to smoke. At the assessment session a quit date, or date and time when the attempted abstinence will begin, is decided; this is usually 1-2 weeks in the future. Where medications (see below) are available and not contraindicated, they will usually form an integral element of the treatment package and the most appropriate form of medication will be determined during the assessment session. Several studies have demonstrated a benefit to initiating NRT for 1-2 weeks before the quit date, so NRT may be initiated at this stage. Bupropion and varenicline also need to be initiated before the quit date in order to build up to adequate blood levels.",206,36,0.17475728155339806
9781910797181,ch07,"Hypnotherapy and acupuncture have received little research attention in relation to smoking cessation; to date, no specific effect in aiding smoking cessation has been found.","Varenicline (brand name Chantix in the USA, Champix elsewhere) was specifically designed to aid smoking cessation. It is modeled on the plant extract cytisine (discussed below) and is a partial agonist at the alpha beta nicotinic acetylcholine (ACh) receptor believed to be involved in nicotine dependence. As a partial agonist, it increases activation in downstream neural pathways. This is sufficient to reduce the urge to smoke and the withdrawal symptoms but it does not reward or induce dependence itself. By binding to that receptor, varenicline prevents nicotine from attaching to it, thereby probably reducing the rewarding effect of smoking. In head-to-head trials, varenicline has been found to be more effective than bupropion. It has few contraindications, although close monitoring has been suggested when it is given to smokers with psychiatric conditions. It is more expensive than bupropion but, because it is more effective, the cost-effectiveness in terms of cost per life-year saved is similar to that for bupropion.",220,30,0.13636363636363635
9781910797181,ch07,"Electronic cigarettes have become very popular and may help many smokers to stop smoking. They are much safer than conventional cigarettes, even if used long term. Concerns exist around the way some of them are being marketed and the variability in quality.","Smokers are advised to use 9-20 pieces of gum per day initially, tapering the frequency after 6 weeks. Although it is usually recommended that the gum is used at regular intervals rather than at the onset of craving (in response to a cue), it has been shown that the gum can help relieve acute craving when taken in response. In practice, many smokers use far too little gum to be of much benefit. This may be partly because the gum causes some irritation in the mouth and throat, and can produce nausea. It may also be because smokers are worried about absorbing too much nicotine. It is important to reassure smokers on both counts: the irritancy and nausea quickly resolve, and pure nicotine in these doses is not harmful. Another concern for many smokers is that they will become dependent on the gum. In practice, persistent use of the gum is uncommon, and dependence is quite rare, probably because the gum releases nicotine much more slowly than cigarettes. People who appear to have difficulty coming off the gum are typically those who were more dependent on cigarettes than other smokers and would almost certainly have gone back to smoking without the aid of the gum. In these cases, evidence shows that gum use tapers over a period of months or sometimes years. It is important to remember that the gum is relatively harmless, and even if users continue to chew it for many years, the health effects would be minimal, and certainly far smaller than the effects of smoking.",290,48,0.16551724137931034
9781910797181,ch07,Nortriptyline and cytisine are both effective at helping smokers to stop and are very cheap. Cytisine (available in much of Central and Eastern Europe for several decades and available over the counter) offers a safe and effective low-cost treatment that can be given with minimal supervision. It has yet to receive a marketing license in most of the world.,"Smokers are advised to use 9-20 pieces of gum per day initially, tapering the frequency after 6 weeks. Although it is usually recommended that the gum is used at regular intervals rather than at the onset of craving (in response to a cue), it has been shown that the gum can help relieve acute craving when taken in response. In practice, many smokers use far too little gum to be of much benefit. This may be partly because the gum causes some irritation in the mouth and throat, and can produce nausea. It may also be because smokers are worried about absorbing too much nicotine. It is important to reassure smokers on both counts: the irritancy and nausea quickly resolve, and pure nicotine in these doses is not harmful. Another concern for many smokers is that they will become dependent on the gum. In practice, persistent use of the gum is uncommon, and dependence is quite rare, probably because the gum releases nicotine much more slowly than cigarettes. People who appear to have difficulty coming off the gum are typically those who were more dependent on cigarettes than other smokers and would almost certainly have gone back to smoking without the aid of the gum. In these cases, evidence shows that gum use tapers over a period of months or sometimes years. It is important to remember that the gum is relatively harmless, and even if users continue to chew it for many years, the health effects would be minimal, and certainly far smaller than the effects of smoking. Nicotine lozenges are available in two formulations. One formulation from GlaxoSmithKline has been clinically proven and is available in 2 mg and 4 mg lozenges. Novartis market a 1 mg lozenge which is yet to undergo clinical trials. The nicotine is absorbed through the lining of the mouth, as it is from nicotine gum. The 2 mg and 4 mg lozenges deliver more nicotine than gum of the corresponding doses, because all the nicotine is released. The 4 mg lozenge has been tested only with more-dependent smokers (those who light up within 30 minutes of waking), while the 2 mg lozenge has been tested only with less-dependent smokers (those who first light up more than 30 minutes after waking). In both cases, the lozenges proved effective. The lozenges have also been shown to be effective in both light (<= 15 cigarettes per day; 2 mg lozenge) and heavy (>= 40 cigarettes per day; 4 mg lozenge) smokers.",499,73,0.1462925851703407
9781910797181,ch07,"NRT, varenicline and bupropion are among the safest medicines available, although bupropion carries a small risk of seizure and allergic reaction (about 1/1000).","Smokers and health workers sometimes believe that if a smoker has tried a medication once, without success, they have demonstrated themselves to be unresponsive, and should not try the same medication again. However, both varenicline and NRT have been shown to be effective even in those smokers who previously failed on the treatment, and the same may be true of bupropion. Varenicline and NRT have also been helpful to smokers who have not decided exactly when they will quit but are intending to quit at some point in the next few weeks. In addition, they have been found to be very effective in promoting cessation in patients who are not willing to quit in the next month but are willing to reduce their smoking with a view to quitting at some point in the next 3 months. Importantly, the efficacy of varenicline and NRT is not limited to highly dependent smokers; they have been demonstrated to help a wide range of daily smokers. Efficacy with non-daily smokers has not yet been demonstrated.",207,37,0.178743961352657
9781910797181,ch07,The highest quit rates can be achieved with either varenicline (Chantix/Champix) or dual-form NRT (patch plus one of the other forms of NRT).,"The major problem appears to be that many pregnant smokers are reluctant to admit to health professionals that they smoke, and only a small proportion are willing to receive behavioral support. Ideally, clinicians should ask about smoking in a way that enables women to admit to it without fear of stigmatization, and behavioral support services should be made as accessible as possible. One approach is to ask whether the mother-to-be has recently stopped smoking, and to recommend behavioral support to new 'ex-smokers' as well as current smokers. Given the health gains if a pregnant smoker manages to stop, it would even be cost-effective to deliver behavioral support in the woman's own home. Importantly, even among women who stop during pregnancy, there is a very high risk of relapse after birth; accordingly, such women should be provided with behavioral support and, if necessary, pharmacological treatment to avoid relapse. As noted earlier, NRT has not been found in clinical trials to improve cessation rates but there is evidence from a large non-randomized comparative study that dual form NRT (transdermal patch plus one of the other products) may improve success rates.",230,39,0.16956521739130434
9781910797181,ch08,"In countries that have comprehensive smoking cessation programs, such as the UK and the USA, the main challenge is to ensure that smokers make full use of such services.","Unfortunately, the health services in most countries have not been geared up to provide evidence-based support for quitting, even very low-cost clinical programs that could be incorporated into existing clinical services. In countries that do have comprehensive smoking cessation programs, the challenge is in ensuring that smokers make full use of these services. Preventing young people from taking up smoking is also vital, although an impact on death rates will not become apparent for several decades. While research on improving treatments for smoking-related disorders continues, smoking cessation remains our best hope for reducing the burden of tobacco-related death and disease over the next 50 years. If higher rates of smoking cessation are to be achieved, concerted action is required on all fronts: fiscal, legislative, educational and clinical. The challenge for physicians is to.",157,32,0.20382165605095542
9781910797181,ch08,Price increases and mass media campaigns play a crucial role in motivating attempts to stop smoking.,"If higher rates of smoking cessation are to be achieved, concerted action is required on all fronts: fiscal, legislative, educational and clinical. The challenge for physicians is to. develop clinical interventions that improve on the success rates of existing methods. encourage more attempts to stop smoking. make greater use of effective treatments so that the proportion of attempts that are successful increases considerably.",73,17,0.2328767123287671
9781910797181,ch08,"If the pandemic of death from lung disease and cardiovascular disease is to be controlled, millions of smokers must quit.","It seems reasonable to suppose that if a pure nicotine delivery system could be found that was almost as efficient as the cigarette and also as palatable, it would be more effective than the current generation of nicotine-replacement therapy (NRT) products in helping smokers to quit. However, it also seems likely that smokers would transfer their dependence to this product. Nevertheless, even if smokers continued to use such a product indefinitely, there would be minimal health risks, so this is an important area for development.",100,23,0.23
9781910797181,ch08,"In many countries, affordable and scalable systems need to be developed to ensure that smokers are offered evidence-based support for stopping as a matter of routine.","Ensuring effective use of nicotine-replacement therapy. There is now evidence that in countries where it has been studied, such as the UK, use of NRT bought over the counter and used without any professional support is not improving smokers' success rates. There is an urgent need to find out why and to take steps to ensure that smokers gain the benefit they expect. It is possible that these smokers are not using enough of the product or not using it for long enough for it to be effective. In that case, cheap scalable interventions to improve adherence to medication instructions could make a substantial difference.",120,30,0.25
9781910797181,ch08,"More effective treatments, and treatments to help smokers who are not currently being helped, are focuses for current and future research.","There is now evidence that in countries where it has been studied, such as the UK, use of NRT bought over the counter and used without any professional support is not improving smokers' success rates. There is an urgent need to find out why and to take steps to ensure that smokers gain the benefit they expect. It is possible that these smokers are not using enough of the product or not using it for long enough for it to be effective. In that case, cheap scalable interventions to improve adherence to medication instructions could make a substantial difference.",108,24,0.2222222222222222
9781910797181,ch08,Effective treatments are available to support quit attempts; a major challenge lies in finding ways to get these treatments to the majority of smokers.,"The commercial success of varenicline, NRT and bupropion has prompted many pharmaceutical companies to examine other medications that may help smokers to quit. The cannabinoid antagonist rimonabant showed some efficacy in aiding smoking cessation, its main feature being that it appeared to reduce post-cessation weight gain. Unfortunately, the clinical trials showed some evidence of cardiac toxicity and the drug has not been brought to market. However, the principle of action has been established and may spawn other drugs. Work is also under way on a number of nicotine 'vaccines' that aim to prevent nicotine being taken up into the CNS, in order to dampen its effects there and thus make quitting or staying abstinent easier. To date, no vaccine has been found to be effective in clinical trials but the principle is intriguing and research continues.",165,26,0.15757575757575756
9781910797211,ch01,"Patients may experience unexplained symptoms for years before diagnosis: prodromal non-motor symptoms, such as impaired sense of smell, constipation and rapid eye movement sleep behavior disorder, develop in the majority of patients.","The Parkinson's journey may begin long before diagnosis, as Parkinson's disease is now recognized to have a prodromal period dominated by a number of non-motor symptoms. These are late-onset hyposmia or anosmia, rapid eye movement (REM) behavior disorder, episodes of major depression or anxiety, and excessive daytime sleepiness. This prodromal period could last up to 20 years before awareness of the motor symptoms that mark the initial or 'stable' period of the condition. Those who have the non-motor prodrome will have had unexplained symptoms for years, while those with a dominant motor presentation may have had symptoms for only a few months. For the clinician, diagnosis is based on clinical presentation, as there is still no reliable diagnostic test. While the cardinal motor symptoms and signs of rest tremor, akinesia and rigidity remain the mainstay of diagnosis, the prodrome of non-motor symptoms described above develops in the majority of patients. At least half of all patients experience mood disturbance with anxiety or depression at some stage of the illness, including in the prodromal phase.",228,44,0.19298245614035087
9781910797211,ch01,"Care must be taken in delivering the diagnosis. It is best if the patient is accompanied by a spouse, partner or other family member, and information may need to be repeated 2-3 weeks later when the shock has subsided.","For the clinician, diagnosis is based on clinical presentation, as there is still no reliable diagnostic test. While the cardinal motor symptoms and signs of rest tremor, akinesia and rigidity remain the mainstay of diagnosis, the prodrome of non-motor symptoms described above develops in the majority of patients. At least half of all patients experience mood disturbance with anxiety or depression at some stage of the illness, including in the prodromal phase. Delivering the diagnosis. Care must be taken in how the diagnosis is delivered. Patients are often fearful and may come to the clinician with preconceptions based on information overload from the internet, or a limited understanding or experience of the disease from the media or a relative. It is best to break the news of a patient's diagnosis in the presence of their spouse, partner or other family members. Often, little information is retained from that first consultation and it is necessary to meet again within 2-3 weeks when the patient's initial shock has subsided. Satisfaction with the initial explanation of the diagnosis has been shown to continue to have an independent effect on quality of life even much later in the illness. Reinforcing the diagnosis and the steps made to confirm it should be followed by provision of information and advice. A sense of optimism must be encouraged.",263,46,0.17490494296577946
9781910797211,ch01,"All patients will eventually experience motor (and often non-motor) fluctuations, with a 'wearing off' of the benefit of their initial medication.","For the clinician, diagnosis is based on clinical presentation, as there is still no reliable diagnostic test. While the cardinal motor symptoms and signs of rest tremor, akinesia and rigidity remain the mainstay of diagnosis, the prodrome of non-motor symptoms described above develops in the majority of patients. At least half of all patients experience mood disturbance with anxiety or depression at some stage of the illness, including in the prodromal phase. Delivering the diagnosis. Care must be taken in how the diagnosis is delivered. Patients are often fearful and may come to the clinician with preconceptions based on information overload from the internet, or a limited understanding or experience of the disease from the media or a relative. It is best to break the news of a patient's diagnosis in the presence of their spouse, partner or other family members.",171,31,0.18128654970760233
9781910797211,ch01,"It is important to address both non-motor and motor symptoms, and to treat both social and motor disability.","Major research efforts are in force to discover additional therapies and, of course, a cure. Regardless of the stage of the disease, non-motor symptoms, in particular depression or mood disturbance, dominate as the predictor of quality of life. It is useful to guide the patient to a viewpoint whereby the focus is maintaining quality of life, rather than defining themselves by their Parkinson's disease, and it is therefore important to address both non-motor and motor symptoms, and to treat both social and motor disability.",102,23,0.22549019607843138
9781910797211,ch01,"Maintaining an active lifetyle, both physically and mentally, is important.","Regardless of the stage of the disease, non-motor symptoms, in particular depression or mood disturbance, dominate as the predictor of quality of life. It is useful to guide the patient to a viewpoint whereby the focus is maintaining quality of life, rather than defining themselves by their Parkinson's disease, and it is therefore important to address both non-motor and motor symptoms, and to treat both social and motor disability.",84,17,0.20238095238095238
9781910797211,ch01,Early treatment is important; quality of life deteriorates in those who delay treatment.,"Patients who may not have fully accepted the diagnosis may be fearful of treatment. It is important to acknowledge this, and to help the patient deal with their fear and denial. Evidence shows that quality of life deteriorates in those who delay treatment compared with those who start it straight away. In early Parkinson's disease, motor and non-motor symptoms can be controlled in a stable fashion with relatively simple medication regimens.",84,16,0.19047619047619047
9781910797211,ch01,Patients should be reassured that the increasing motor disability and complications of late-stage Parkinson's disease do not tend to occur until the eighth or ninth decade of life; not all patients will reach this stage of Parkinson's disease.,"As Parkinson's disease progresses, some of the motor symptoms that once were levodopa responsive (exempli gratia fine motor skills, postural reflexes, freezing of gait) become only partially or occasionally levodopa responsive. This can result in increasing motor disability and complications such as frequent falls. Cognitive impairment or dementia can develop, as well as psychiatric manifestations such as hallucinations without insight, or even psychosis. Fortunately, it is increasingly recognized that the major risk factor for these complications is age, rather than simply the duration of Parkinson's disease. Patients should be reassured that regardless of when their Parkinson's disease developed (fifth, sixth or seventh decade), these complications do not tend to occur until patients enter their eighth or ninth decade, so not all patients will reach this stage of Parkinson's disease. Specialist care. Treatment of this stage of the disease remains the greatest challenge in the modern era. Treatments that can provide some maintenance or enhancement of quality of life are available, but the therapeutic options for many symptoms are limited. It is important that people with Parkinson's disease continue to experience care from a specialist, who can best help navigate the route between over- and under-treatment.",239,45,0.18828451882845187
9781910797211,ch02,"Parkinson's disease is one of the most common neurodegenerative diseases, with a prevalence of approximately 200 per 100 000 individuals.","Parkinson's disease is one of the most common neurodegenerative diseases, but estimating its incidence and prevalence is problematic as there is no 'in-life' marker for idiopathic Parkinson's disease; the diagnosis can only be made with certainty if Lewy bodies (intracytoplasmic aggregations of misfolded protein in the brain) are found in the substantia nigra and other brain regions after death (see pages 19 -). Case ascertainment in community studies is difficult, and often other parkinsonian syndromes may be included.",116,27,0.23275862068965517
9781910797211,ch02,The incidence and prevalence of Parkinson's disease increases sharply with age.,"Age, sex and ethnicity. Both the incidence and prevalence of Parkinson's disease increase with age, and the prevalence may be as high as 1 in 50 for patients over the age of 80 years. The disease is estimated to affect 1% of 70-year-olds, but is also seen in younger people, with 10% of cases occurring before the age of 50.",74,13,0.17567567567567569
9781910797211,ch02,Men are 1.5 times more likely than women to develop the disease.,"Age, sex and ethnicity. Both the incidence and prevalence of Parkinson's disease increase with age, and the prevalence may be as high as 1 in 50 for patients over the age of 80 years. The disease is estimated to affect 1% of 70-year-olds, but is also seen in younger people, with 10% of cases occurring before the age of 50. Men are 1.5 times more likely than women to develop the condition.",89,15,0.16853932584269662
9781910797211,ch02,"Pathologically, Parkinson's disease is characterized by widespread neurodegeneration including that of neuromelanin-containing neurons, as well as deficits in the serotonergic, cholinergic and noradrenergic systems that result in the manifestation of motor and non-motor symptoms. Lewy bodies in the remaining nigral neurons are a pathological hallmark of the disease after death.","The confusion regarding mortality in Parkinson's disease may be partly because the disease itself is not a primary or direct cause of death. In the USA, the average annual age-adjusted Parkinson's disease mortality between 1962 and 1984 was estimated as 2 deaths per 100 000 for white men and 1 death per 100 000 for non-white men, 1 death per 100 000 for white women and less than 1 death per 100 000 for non-white women. Mortality increased for persons aged 75 years and older, but declined for those younger than 70 years. Overall, published evidence suggests that mortality for Parkinson's disease increases in the older age groups but decreases for younger ages. The cause of death in Parkinson's disease is most commonly a secondary comorbid disorder. A Japanese study showed that the most common cause of death for all patients, regardless of age, was pneumonia. Economic burden. Studies suggest that Parkinson's disease adversely affects the health-related quality of life of patients and imposes a significant economic burden on society comparable with that of other chronic conditions such as congestive heart failure, diabetes and stroke. Although it is difficult to measure the specific economic cost of Parkinson's disease, in the UK the annual direct cost of managing patients with Parkinson's disease at home is estimated at around 4189; the cost rises to 19 338 for full-time institutionalization. Furthermore, the total direct cost of Parkinson's disease in patients in 'good health' is three times lower than for those in 'poor health'. These figures do not take into account hidden indirect costs such as loss of income from premature retirement, for both the patient and carer. The main pathological feature of Parkinson's disease is the degeneration of neuromelanin-containing neurons in the pars compacta of the substantia nigra (Figure 2.1). Examination with the naked eye reveals pallor of this area, which is confirmed microscopically by a marked decrease in the number of neuromelanin-containing cells and the presence of Lewy bodies in the remaining nigral neurons.",412,78,0.18932038834951456
9781910797211,ch02,"Braak has suggested that the condition may begin in the olfactory bundle and lower brainstem, and studies are under way to identify specific non-motor biomarkers of the prodromal phase of Parkinson's disease.","After examining a large number of brains, both clinically normal and with Parkinson's disease, Braak et al. suggested that stage 1 of the disease begins at induction sites in the olfactory system and the dorsal vagal nucleus, with degeneration of the olfactory bulb and the anterior olfactory nucleus. This presents clinically as olfactory dysfunction. Stage 2 reflects progression of the pathological process to the nuclei of the caudal brainstem (the locus ceruleus and other nuclei). The lower brainstem nuclei are key areas mediating a myriad of non-motor symptoms such as sleep homeostasis, depression, fatigue, cognitive problems, pain, constipation and a reduction in central autonomic vagal control. Several of these symptoms are now recognized as possible prodromal features of Parkinson's disease. However, clinical Parkinson's disease tends to be recognized by healthcare professionals only when the condition reaches stage 3, which involves the substantia nigra. Stages 4 to 6 represent further pathological progression to the cortex (Figure 2.3).",216,45,0.20833333333333334
9781910797211,ch02,The cause of neuronal degeneration is uncertain.,"Neuronal degeneration. The cause of neuronal degeneration in Parkinson's disease is unknown. The susceptible neurons are located in astroglial-poor regions such as the ventral tier. Glia may offer neuroprotection by providing neurotrophic factors that prevent cell death. Several hypotheses for neuronal degeneration have been proposed, including.",67,9,0.13432835820895522
9781910797211,ch02,"Rapid eye movement behavior disorder (RBD), late-onset hyposmia, constipation and major depression are all risk factors for Parkinson's disease.","Latest thinking. It is now widely believed that the clinical symptoms of Parkinson's disease are not only due to the loss of a single monoamine neurotransmitter, dopamine, but also the effects of widespread Lewy body disease. This results in a convergence of deficits in multiple transmitter pathways, including the cholinergic, noradrenergic and serotonergic systems, which underpin many of the non-motor symptoms that are integral to Parkinson's disease (Figure 2.7). In addition, glial pathology, neuroimmune responses and proinflammatory cytokines are likely to play a key pathogenic role. Non-motor symptoms that become evident in the prodromal phase of the disease, such as late-onset hyposmia, RBD, constipation and depression, are all risk factors for Parkinson's disease. Forebrain cholinergic system dysfunction is present in non-demented Parkinson's disease and worsens with dementia.",189,32,0.1693121693121693
9781910797211,ch02,"At present, there are no guidelines for genetic testing in Parkinson's disease. Genetic tests for common mutations such as LRRK2 Gly2019Ser mutations in at-risk individuals (European, North African and Ashkenazi Jewish), glucocerebrosidase ( GBA ) mutations, or Parkin (autosomal recessive) are usually available if they are thought to be clinically relevant and necessary. Where possible, advice from a genetic counselor must be obtained before genetic testing.","However, the SNCA and PARK3 mutations have not been found in many families with autosomal-dominant Parkinson's disease or sporadic Parkinson's disease. Other mutations are being discovered elsewhere (see Table 2.2); mutation in PARK7 is linked to autosomal-recessive early-onset Parkinson's disease, and was identified in a Dutch and an Italian family, while leucine-rich repeat kinase (LRRK2; also known as PARK8), with a locus on chromosome 12, was identified in a Japanese family (see below). Autosomal-recessive juvenile parkinsonism has been studied mainly in Japan. The gene associated with juvenile parkinsonism, PARK2, has been mapped to chromosome 6q. The same genetic mutation has been found in European families in individuals with juvenile or young-onset Parkinson's disease. PARK2 has a 30% homology with the gene that encodes ubiquitin, and is expressed in various regions of the brain (including the substantia nigra) and in liver, heart, testis and skeletal muscle. PARK2 encodes parkinson protein 2, E3 ubiquitin protein ligase (parkin), which is involved in protein degradation. The PARK2 mutation appears to lead to defective protein ubiquination, leading to protein aggregation and cell death. Recent findings in the genetics of Parkinson's disease include the identification of mutations in LRRK2, which is involved in mitochondrial functioning, the powerhouse of cells. LRRK2 is part of the Roco family of genes. Mutation in LRRK2 has been associated with familial late-onset Parkinson's disease and a few cases of sporadic late-onset Parkinson's disease. The phenotype appears to be identical to sporadic Parkinson's disease, but is associated with behavioral disorders, leg tremor, sleep disturbances and slight cognitive decline. One case of an Ile1371Val substitution in LRRK2 has been reported, with the typical Lewy body pathology that stained positive for ubiquitin and alpha-synuclein and symptoms identical to idiopathic sporadic Parkinson's disease. The most common LRRK2 substitution is Gly2019Ser, which accounts for 2% of sporadic and 5% of familial cases. This substitution is identified more frequently in North African Arabs and Ashkenazi Jews, while a Gly2385Arg mutation has been described in the Chinese/Taiwanese population.",494,99,0.20040485829959515
9781910797211,ch03,"Most cases of Parkinson's disease are recognizable at an early stage, but can be misdiagnosed if tremor is absent.","When, in 1817, James Parkinson first described the features of paralysis agitans in 6 patients, he did not refer to the typical cogwheel rigidity, and mistook bradykinesia for paralysis. Nevertheless, his description of the tremor, posture (Figure 3.1) and clinical course of the disease has stood the test of time and remains valid today. Most cases of Parkinson's disease are easily recognizable at an early stage, but many are missed if tremor is absent; gradual slowing in performance may be instead attributed to aging or aches and pains, and loss of function may be ascribed to other causes.",128,25,0.1953125
9781910797211,ch03,"Characteristic motor symptoms include tremor, bradykinesia, a hurried shuffling gait, freezing episodes, rigidity and a bent posture.","Later, gait is affected, with difficulty starting off walking, small steps and shuffling. 'Festination' describes the typical hurrying gait, which may be interrupted by sudden stops as if the patient is nailed to the floor. Carers may nudge patients to start them moving again. These freezing episodes (paroxysmal akinesia) are often provoked by visual stimuli, such as an open doorway, or by anxiety. Many patients develop tricks to overcome the symptom, such as stepping over an inverted walking stick or marching to a rhythm. Eventually, some but not all patients require a wheelchair; however, in the early stages of disease, this is a red flag for an atypical parkinsonian syndrome and the diagnosis should be reappraised.",154,31,0.2012987012987013
9781910797211,ch03,"Non-motor symptoms include depression, dementia, sleep disorders, bowel and bladder problems, fatigue, apathy and pain; although common, these symptoms are often overlooked.","Non-motor-symptoms. A wide range of non-motor symptoms has been described in Parkinson's disease, all of which are likely to have a major effect on the health-related quality of life of patients. These symptoms include depression, dementia, sleep disorders, bowel and bladder problems, fatigue, apathy, pain and autonomic dysfunction (Table 3.3). Non-motor symptoms are common and can occur at all stages of the disease, even before diagnosis (prodromal phase) (Table 3.4). Before any drug treatment is started, more than 45% of patients may show a severe to very severe burden of non-motor symptoms regardless of motor impairment. Despite this, non-motor symptoms tend to be poorly recognized by health professionals, who tend to focus on motor symptoms.",167,34,0.20359281437125748
9781910797211,ch03,"There are no specific tests for the diagnosis of Parkinson's disease, but DaTSCAN with single-photon emission computed tomography (SPECT) is becoming widely available, and can help to support a clinical diagnosis.","The Movement Disorders Society has recently revised the clinical criteria for the diagnosis of Parkinson's disease, incorporating a range of non-motor symptoms as well as retaining the central core motor features. Recognizing that no diagnosis of Parkinson's disease can be made with 100% certainty and that the error rate can range from 75-95%, the new criteria suggest a two-way process: parkinsonism is first defined using central motor symptoms such as bradykinesia, tremor and rigidity; these are then considered with respect to ancillary and non-motor issues to determine whether the motor syndrome is likely to be specific to Parkinson's disease or not. Criteria for prodromal Parkinson's disease have also been suggested but only for use within a research framework. Confirmation of diagnosis. The diagnosis of Parkinson's disease remains primarily clinical; there are as yet no specific tests. Dopaminergic challenge tests (see below) are not routinely recommended for diagnostic purposes.",196,44,0.22448979591836735
9781910797211,ch03,Patients with idiopathic Parkinson's disease show a significant and sustained response to dopaminergic agents.,"Dopaminergic challenge. The response to levodopa, or to dopaminergic agents such as apomorphine, has been used as a potential diagnostic test for Parkinson's disease but it is fraught with pitfalls. Many Parkinson-plus syndromes such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) also respond initially to levodopa or dopaminergic therapy, so the use of challenge tests for diagnostic purposes is not recommended. There is also concern about the use of levodopa in untreated levodopa-naive patients, since a possible priming action of levodopa for the development of future dyskinesias has been demonstrated in animal models. The authors stress the importance of the points shown in bold. Typically, a patient with idiopathic Parkinson's disease will show a significant response to dopaminergic agents; about 50% of patients will go on to develop dyskinesia after 2-5 years of standard therapy with levodopa (at doses exceeding 600 mg/day), although this proportion is lower when smaller doses of levodopa (150-300 mg/day) are given.",239,22,0.09205020920502092
9781910797211,ch03,"Brain imaging is not typically used to diagnose Parkinson's disease, but may help to rule out tumors, vascular disease and normal-pressure hydrocephalus; transcranial ultrasound scanning reveals characteristic hyperechogenicity of the substantia nigra.","CT or MRI scans are usually not needed for diagnosis, but a brain scan should be performed if parkinsonism is purely unilateral or otherwise atypical, or if additional signs (exempli gratia pyramidal) are present. CT or MRI may also be used to rule out a space-occupying lesion, vascular disease and normal-pressure hydrocephalus. This last condition causes lower-body parkinsonism, cognitive decline and early bladder symptoms. The use of DWI and diffusion tensor (MR) imaging (DTI) has been explored and developed in an effort to differentiate idiopathic Parkinson's disease from parkinsonism due to other causes such as MSA. DWI reflects a quantifiable coefficient known as the apparent diffusion coefficient (ADC), and preliminary reports suggest that idiopathic Parkinson's disease produces substantially higher regional ADC values than does MSA. DWI is also thought to differentiate between MSA and PSP. Further studies using this potentially widely available technique are under way.",206,49,0.23786407766990292
9781910797211,ch03,"All patients with a 'suspected' diagnosis of Parkinson's disease should be referred untreated to a specialist who can reliably differentiate between Parkinson's disease and other parkinsonian syndromes. A shared care strategy can then be implemented, with ongoing care by the primary care team.","chromosome testing for fragile X syndrome, which can present with tremor and ataxia that may mimic Parkinson's disease and MSA. In some countries such as Japan, MIBG cardiac scanning may be useful in the differential diagnosis of Parkinsonian disorders, particularly in the early distinction between idiopathic Parkinson's disease and atypical synucleinopathies such as MSA. Cardiac uptake measured with a MIBG scan suggests a diagnosis of atypical Parkinson's disease such as MSA, while no cardiac uptake is more suggestive of idiopathic Parkinson's disease (Figure 3.9). Referral and 'shared care'. Current opinion and guidelines recommend that all patients with a 'suspected' diagnosis of Parkinson's disease must be referred untreated to a specialist who can reliably differentiate between Parkinson's disease and other parkinsonian syndromes. Initiation of treatment in primary care is discouraged. Referral to a specialist is important to ensure that diagnosis is as accurate as possible (approximately 96% certainty in specialist centers) and multidisciplinary team care is started promptly. Differential diagnoses. The key differential diagnoses include essential tremor, drug-induced parkinsonism, vascular pseudoparkinsonism and the Parkinson-plus syndromes such as MSA, PSP, dementia with Lewy bodies and corticobasal ganglionic degeneration (see Chapter 8).",284,56,0.19718309859154928
9781910797211,ch04,Levodopa restores the dopamine lost due to degeneration of striatonigral cells; patients with typical Parkinson's disease respond to levodopa almost immediately.,"Levodopa is a precursor of dopamine and restores the dopamine lost due to degeneration of striatonigral cells. It has improved the quality of patients' lives substantially, and appears to have led to a reduction in mortality. Levodopa is converted to dopamine by dopa decarboxylation in the brain (Figure 4.1), but this can also occur outside the blood-brain barrier, leading to side effects such as nausea and postural hypotension. The addition of a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier, such as carbidopa or benserazide, inhibits dopa decarboxylase in the rest of the body and reduces side effects. The bioavailability of levodopa has been enhanced further by the emergence of drugs such as tolcapone and entacapone, which inhibit catechol- O -methyl transferase (COMT), the enzyme principally responsible for the breakdown of dopamine.",199,32,0.16080402010050251
9781910797211,ch04,"Fear over the toxicity of levodopa has resulted in levodopa phobia in some patients; however, there is no robust evidence to suggest that levodopa is toxic to the human nigrostriatal pathway and these fears have mostly been discredited.","However, there is no robust evidence to suggest that levodopa is toxic to the human nigrostriatal pathway and these fears have mostly been discredited. A postmortem study of 5 patients with essential tremor, who were mistakenly given sustained levodopa therapy, found no evidence of damage to nigral cells. In addition, patients who receive long-term levodopa for restless legs syndrome show no evidence of damage to the substantia nigra at autopsy. These findings should reassure patients receiving long-term levodopa. Levodopa dyskinesia. Chronic therapy with levodopa, however, results in motor fluctuations and dyskinesias due to Parkinson's disease progression coupled with the short half-life of levodopa. The ELLDOPA study (see below) in patients with early Parkinson's disease suggests that a higher dosage of levodopa leads to a higher frequency of dyskinesia. The development of dyskinesias has been shown to adversely affect patients' and carers' quality of life, and to at least double the cost of care. In order to prevent/delay dyskinesia, several trials have examined initiating treatment with a dopamine agonist such as ropinirole, pramipexole, cabergoline or pergolide. Many trials have compared these dopamine agonists with levodopa in previously untreated patients over a 4-5 year period.",288,51,0.17708333333333334
9781910797211,ch04,"Dopamine agonists are useful for smoothing the 'on/off' fluctuations secondary to levodopa therapy; some, such as rotigotine, may offer continuous dopaminergic stimulation in practice and specifically offer night-time and early morning benefit.","CDS may prevent or reverse motor complications because it does not prime the basal ganglia for involuntary movements as much as agents that produce pulsatile stimulation. CDS may also improve some aspects of sleep in patients with Parkinson's disease. However, Nutt reinforced the idea that CDS remains a theoretical concept, and the effect of CDS on dyskinesias, to date, has never been tested in a robust randomized clinical trial. The STRIDE-PD study (see pages 66 -) with the drugs given orally every 3.5 hours probably failed to provide CDS. In practice, dopamine agonists are also useful for smoothing the 'on/off' fluctuations secondary to levodopa, as well as the many theoretical advantages listed in Table 4.4. Ropinirole and pramipexole are well-established non-ergot dopamine agonists in widespread clinical use in early and advanced Parkinson's disease. Both are effective in early and late disease as monotherapy and adjunctive therapy. In addition, pramipexole has been investigated for its anti-anxiety and antidepressant effects in Parkinson's disease. A direct beneficial effect of pramipexole on depressive symptoms, accounting for 80% of total treatment effect, was found in a 12-week randomized double-blind placebo-controlled trial of the drug in 287 mild-to-moderate Parkinson's disease patients with depressive symptoms.",286,52,0.18181818181818182
9781910797211,ch04,"Impuse control disorders have emerged as a major complication of mostly dopamine agonist treatment, and monitoring is a must.","Impulse-control disorders. The American Psychiatric Association's DSM5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) defines impulse control disorders (ICDs) as the failure to resist an impulse, drive or temptation to perform an act that is harmful to the person or to others. These are increasingly reported in Parkinson's disease and include a range of compulsive disorders (Table 4.5). Typically, the syndrome is characterized by a combination of impulsivity, compulsivity and preoccupation with a behavior or mood state. Unrecognized, ICDs can have serious consequences, such as breakdowns in interpersonal relationships and financial distress. The lifetime prevalence of ICDs, as reported by patients attending specialized clinics, is between 3 and 8%, although the DOMINION study reported a higher rate of 13.7% with ICDs, including problem/pathological gambling (5%), compulsive sexual behavior (3.5%), compulsive buying (5.7%) and binge-eating disorder (4.3%).",210,23,0.10952380952380952
9781910797211,ch04,"Treatment decisions should be based on the degree of disability, occupational needs, age, patient/clinician preference and adherence issues; neuroprotection remains a theoretical argument, while dyskinesias and wearing off are an important consideration in younger patients.","Current guidelines. Different international guidelines (NICE, AAN, EFNS/MDS-ES) all agree that there is no single universal first choice of drug for people with Parkinson's disease, particularly in the early stages of the condition. Individual choice of drug will be influenced, for example, by the degree of motor disability (if severe, the first choice is likely to be levodopa), occupational needs, the risk of motor complications (more common in younger patients, which would be delayed by agonists), neuropsychiatric complications (more common in older and cognitively impaired patients, so agonists should be avoided), patient/clinician preferences and adherence issues. For these reasons, many younger patients will choose a levodopa-sparing strategy, while older patients may prefer levodopa therapy (see below). Guidelines for the management of Parkinson's disease published in the UK by NICE in June 2006 offer evidence-based advice drawn up by a multidisciplinary panel. Key recommendations are that patients and their carers should be involved in deciding their treatment and care, and that the choice of treatment should suit the patient's needs and preferences. This guideline is currently being updated. The following key points were identified as priorities for implementation.",252,50,0.1984126984126984
9781910797211,ch04,The findings of the PDLIFE study suggest that early initiation of treatment may be beneficial in terms of health-related quality of life.,"Dopamine agonist versus levodopa. In younger patients, the issues of neuroprotection and dyskinesias should be considered. The results of four controlled dopamine-agonist monotherapy trials have been published and suggest that initiation of treatment with an agonist is beneficial in the early stages of Parkinson's disease. However, the results of the PD Med study, a multicenter real-life pragmatic study, reporting on quality of life-related outcomes in both young and old patients with Parkinson's disease, is likely to generate considerable controversy regarding the use of dopamine agonists and the choice of initial therapy. In total, 1620 patients with early Parkinson's disease were recruited and given one of three initial treatment regimens.",144,27,0.1875
9781910797211,ch04,The treatment of non-motor symptoms is important at all stages of Parkinson's disease. The results of the PANDA study may help people with Parkinson's-associated pain.,"Dopamine agonist versus levodopa. In younger patients, the issues of neuroprotection and dyskinesias should be considered. The results of four controlled dopamine-agonist monotherapy trials have been published and suggest that initiation of treatment with an agonist is beneficial in the early stages of Parkinson's disease. However, the results of the PD Med study, a multicenter real-life pragmatic study, reporting on quality of life-related outcomes in both young and old patients with Parkinson's disease, is likely to generate considerable controversy regarding the use of dopamine agonists and the choice of initial therapy. In total, 1620 patients with early Parkinson's disease were recruited and given one of three initial treatment regimens.",144,35,0.24305555555555555
9781910797211,ch04,"Trial data indicate that treatment of Parkinson's disease could be initiated with levodopa, oral dopamine agonists or a monoamine oxidase B (MAOB) inhibitor. The PD MED study seems to suggest that initial therapy with levodopa offers a small but persistent benefit compared with the alternatives, and initial MAOB inhibitor treatment is at least as effective as a dopamine agonist.","The study started in 2000 with a median follow-up of 3 years and maximum of 7 years. During this time the dopamine agonists varied, including ergot agonists that are no longer in widespread use. The randomization to levodopa or alternative regimens was at the discretion of the clinician and a large part of the study was conducted in centers for the care of the elderly. The findings suggest relatively small but persistent benefits of starting therapy with levodopa rather than the listed alternatives. Interestingly, initial treatment with a MAOB inhibitor appeared to be at least as effective as treatment with a dopamine agonist. Patients assigned to the levodopa arm scored, on average, 1.8 points (95% CI 0.5-3.0) higher on the Parkinson's Disease Questionnaire-39 (PDQ-39) mobility subscale than those assigned to levodopa-sparing therapies; however, the effects on non-motor aspects of the scale are unclear. A cost-utility analysis of the study will be reported separately. If levodopa is used and the dose is titrated to the response, most patients initially need 50-100 mg three times daily to produce a consistent effect without fluctuations. Within 2-3 years, most will need a more frequent dosage to avoid fluctuations; smaller, more frequent doses (every 2-3 hours) often lead to an overall increase in dose. COMT inhibitors or dopamine agonists can, however, be introduced instead of increasing the frequency of levodopa.",311,77,0.24758842443729903
9781910797211,ch05,Neurosurgery is an unpleasant experience for the patient; the main complications are stroke and infection.,"Irving Cooper's remarkable serendipity is worth recounting: he was attempting pedunculotomy for parkinsonism, when bleeding occurred. The operation was abandoned but the patient improved substantially. Cooper had clipped the anterior choroidal artery, the main blood supply to the globus pallidus. Following this, he embarked on a series of operations creating lesions within the globus pallidus and thalamus.",86,20,0.23255813953488372
9781910797211,ch05,Surgery is recommended when optimal drug treatment options have failed to control symptoms.,"Surgery is usually employed in patients when manipulations of drug therapy have failed to control 'off' symptoms, tremor, motor fluctuations and dyskinesias. It has a morbidity of approximately 2% from strokes and infection, and a mortality of about 0.5%, and may be an unpleasant experience. However, in carefully selected patients surgery leads to control of 'off' symptoms, motor fluctuations and dyskinesias.",87,15,0.1724137931034483
9781910797211,ch05,"For patients with young-onset Parkinson's disease who have had 'on/off' symptoms for many years, the procedure of choice is deep brain stimulation of the subthalamic nucleus to reduce dopaminergic therapy and control dyskinesias.","Surgery is usually employed in patients when manipulations of drug therapy have failed to control 'off' symptoms, tremor, motor fluctuations and dyskinesias. It has a morbidity of approximately 2% from strokes and infection, and a mortality of about 0.5%, and may be an unpleasant experience. However, in carefully selected patients surgery leads to control of 'off' symptoms, motor fluctuations and dyskinesias. Patients, their relatives and carers need to understand the limit of any benefits from an operation, and that surgery is not a cure. Sometimes patients are inclined to concentrate on an 'apparent' cure, such as surgery, when actually psychosocial concerns and dysfunctional family relationships are the main issues affecting their quality of life. Surgery will benefit a select number of patients, mostly those with young-onset Parkinson's disease who have had the disease for many years and who have 'on/off' syndromes. For these patients, the operation of choice is deep brain stimulation of the subthalamus to enable a reduction in dopaminergic therapy and control of dyskinesias.",226,50,0.22123893805309736
9781910797211,ch05,"Lesional surgery is an alternative to deep brain stimulation for patients unlikely to attend regular follow-up or who have to travel long distances, or in instances where the cost of a stimulator is prohibitive.","Lesional surgery may be preferred to deep brain stimulation when a simpler procedure without complex follow-up is required, especially when it is suspected that a patient will not attend the necessary follow-up after insertion of a stimulator, or if patients have to travel long distances. In some parts of the world, the prohibitive cost of the stimulator (about US$32 000/20 000 for hardware and follow-up) may lead to a preference for lesional surgery. Lesional surgery is performed by stereotaxy (Figure 5.1). MRI and other neuroimaging methods are insufficient to place a lesion accurately and should be combined with physiological assessment. The patient is therefore woken at the time of lesional placement for physiological stimulation and microelectrode recording. Usually the lesion is created by thermocoagulation; however, cryosurgery is an alternative.",179,41,0.22905027932960895
9781910797211,ch05,Pallidotomy is appropriate for severe dyskinesia.,"Pallidotomy, a procedure that involves destruction of part of the globus pallidus, is appropriate when there is severe dyskinesia (Table 5.2). Dyskinesias contralateral to the lesion may be greatly alleviated. Pharmacological adjustments are made postoperatively so that 'on' time can be increased. There is a 70% reduction in contralateral tremor and a 30% reduction in activities of daily living score, which allows some patients to return to functional independence.",105,13,0.12380952380952381
9781910797211,ch05,Thalamic deep brain surgery (VIM nucleus) is the most effective procedure for controlling parkinsonian tremor.,"Thalamotomy, surgery on the VIM nucleus of the thalamus, is the most effective way of controlling tremor. It can be used when tremor is the major disabling feature of Parkinson's disease, and also for essential or ataxic (Holmes') tremor. Deep brain stimulation is the best method of delivery, particularly if a bilateral operation is required. The complication rate is the same as for pallidotomy. Thalamotomy can effectively relieve tremor in 90% of cases, but it should be remembered that tremor is not usually a disabling feature of Parkinson's disease, and thalamotomy has no effect on bradykinesia.",135,24,0.17777777777777778
9781910797211,ch05,"In the future, nerve-cell transplantation could replace dopaminergic treatment if sources of dopamine cells other than 6-10-week-old fetuses can be found; trials using porcine fetal cells, stem cells that generate dopamine and other such cells (exempli gratia retinal cells) are under way.","Patients are given immunosuppressive therapy with ciclosporin and prednisolone (prednisone) for up to 6 months, although whether this is necessary has not been established. The aim is to restore lost dopamine cells. So far, results indicate that implanted cells can survive, grow and form dendritic connections with host neurons. Autopsy has revealed dopaminergic differentiation of these cells and clinically there have been individual successes, with reversal of motor signs and cessation of dopa drugs. However, in the first controlled trial by Freed et al. in 2001, involving 40 patients randomized to fetal neural transplant or sham surgery, primary outcome measures failed to show any significant differences between the two groups. Furthermore, about 15% of the transplant patients developed severe facial dystonia and disabling 'runaway' dyskinesias. In a controlled double-blind study reported by Olanow et al. in 2003, 34 patients were randomized to either fetal neural transplant with two volumes of donor tissue or sham surgery. Primary outcome measures again failed to show any significant differences between the two groups, and 56% of transplant patients developed dyskinesias. The authors commented that fetal nigral transplantation cannot be recommended as treatment for Parkinson's disease. There is hope that cell implantation may replace dopa therapy, but this has not yet been realized. Other sources of cells will need to be found if the technique is to become generalized. Immortalized neural stem-cell lines are in development, and porcine fetal cells are undergoing trials but may carry the additional risk of introducing porcine viruses into humans.",326,66,0.20245398773006135
9781910797211,ch06,"Early in the course of the disease, patients most need clear information, advice and counseling.","A multidisciplinary approach is an absolute requirement for optimal care of the parkinsonian patient. Early on, the main requirement is for information and counseling. In the later stages of the disease, coordination of the various agencies involved in care is often difficult and, as time passes, additional agencies will have to be accessed by the treating physician (Table 6.1). Many patients find the support offered by organizations such as Parkinson's UK helpful (see Useful resources, (pages 161 -). A Parkinson's disease nurse specialist (PDNS) can spend more time with the patient and can offer telephone support. Some patients may need specialist counseling to help them to come to terms with the diagnosis.",137,18,0.13138686131386862
9781910797211,ch06,"Multidisciplinary therapy and input from a Parkinson's disease nurse specialist (PDNS) should be available to all patients at all stages of the disease. The PDNS is ideally placed to recognize when palliative care is needed, and to initiate and support the appropriate care.","A multidisciplinary approach is an absolute requirement for optimal care of the parkinsonian patient. Early on, the main requirement is for information and counseling. In the later stages of the disease, coordination of the various agencies involved in care is often difficult and, as time passes, additional agencies will have to be accessed by the treating physician (Table 6.1). Many patients find the support offered by organizations such as Parkinson's UK helpful (see Useful resources, (pages 161 -). A Parkinson's disease nurse specialist (PDNS) can spend more time with the patient and can offer telephone support. Some patients may need specialist counseling to help them to come to terms with the diagnosis. Parkinson's disease nurse specialist. The PDNS is a key and essential member of the Parkinson's disease care team; they are usually the first point of contact for the patient, both within the hospital and at home. The PDNS is skilled in patient and carer assessment, differential diagnosis of Parkinson's disease and appropriate drug treatment, medicines management and communication. The role of the PDNS in the care of patients with Parkinson's disease has been reported in three randomized controlled trials (RCTs), although the methods used in these studies have varied widely. The studies reported that PDNS care allowed a swift implementation of good clinical practice for Parkinson's disease, including home visits, and a high rate of patient satisfaction.",280,55,0.19642857142857142
9781910797211,ch06,Physiotherapy is particularly useful at a stage when balance problems become obvious.,"Physiotherapy in Parkinson's disease is currently recommended to educate patients about gait, initiation of movement and balance, as well as providing advice on safety within the home environment. As such, these interventions are very useful as the condition advances and balance problems, along with fear of falling, become apparent.",60,15,0.25
9781910797211,ch06,"Hallucinations often presage cognitive decline with memory difficulties and disorientation, the most difficult problems for both patients and carers; drugs that are most likely to cause hallucinosis should be withdrawn immediately.","Patients who hallucinate or have dementia often provoke social crises and cries for help from carers. Hallucinations may be temporary and related to excessive drug treatment, but often presage cognitive decline with memory difficulties and disorientation. These are the most difficult problems for patients with Parkinson's disease and their carers, and occur in at least 30% of cases. Swift action is required, and the availability of a PDNS is often invaluable. The first step is to rationalize drug treatment, removing those drugs that are least effective or most likely to cause hallucinosis. Therapy with levodopa plus a decarboxylase inhibitor is often the best policy. Neuroleptics that may aggravate parkinsonism should be avoided. Support from nurses and social services is vital in keeping patients at home as long as possible, because admission to hospital in this situation may further aggravate decline. Despite this, patients with dementia frequently cannot be managed at home and will need to be admitted to a nursing home, either for respite care or on a permanent basis. The PDNS can advise nursing homes on effective management of patients with Parkinson's disease who have dementia, and the importance of regulating their medication. Demented patients who are prone to wander may need a locked facility.",258,42,0.16279069767441862
9781910797211,ch06,"In early Parkinson's disease, patients should be encouraged to eat plenty of fruit and vegetables to stimulate a sluggish bowel.","A healthy diet is recommended, with attention to overall nutrition and roughage. In the early stages of the disease, eating plenty of fruit and vegetables should be encouraged to stimulate a sluggish bowel. Advice from a dietitian may be needed if a patient's nutritional intake is thought to be poor. An early warning sign is when the patient does not finish meals. It may be necessary to liquidize food and to provide dietary supplements, althought these are a last resort.",94,23,0.24468085106382978
9781910797211,ch06,"Although a large protein intake may compete with levodopa absorption, patients should not restrict their total protein intake.","Interaction of food with drugs. Patients often ask how food interferes with drug treatment. In theory, a large protein intake competes with levodopa absorption and thereby prevents the drug's action, but significant dietary changes are not usually required. Even without drug treatment patients often feel worse in the afternoon, which may be due, in part, to a fall in blood pressure after a large meal at lunchtime. If there appears to be a clear-cut relationship between eating large meals and patient deterioration, then changes such as moving the main meal to the evening or eating more frequent smaller meals may help.",122,22,0.18032786885245902
9781910797211,ch06,"Skin problems are common, but patients rarely complain of them; drug rashes may necessitate withdrawal of the offending agent.","Although skin problems related to parkinsonism are common, patients rarely complain about them. Seborrheic dermatitis may cause crusting of the scalp and can be treated with antifungal preparations. Skin lesions may be treated with combination creams that contain antifungals and hydrocortisone. Episodic sweating can be troublesome and is not easily treated, though anticholinergics such as benzhexol may be tried. Drug rashes are not uncommon, particularly with the use of dopamine agonists, and may necessitate withdrawal of the offending drug.",118,24,0.2033898305084746
9781910797211,ch06,"Bladder symptoms, sleep problems and sexual problems are common, and need to be addressed.","Sexual problems are not uncommon and are usually the concern of male patients; these issues need to be addressed with the patient as they are often important in terms of overall quality of life. Early-onset erectile dysfunction may indicate an alternative diagnosis, such as multiple system atrophy (MSA), but also occurs in parkinsonism. Sexual problems can also result from relationship dysfunction (exempli gratia caused by fear of illness), apathy as part of cognitive decline or inappropriate sexual arousal as a result of drug treatment (particularly dopamine agonists and apomorphine).",114,18,0.15789473684210525
9781910797211,ch06,Patients and carers should be given the chance to discuss end-of-life issues at the appropriate time with suitably trained professionals.,"A randomized fast-track trial to evaluate the clinical- and cost-effectiveness of short-term integrated palliative care services for people with advanced long-term neurological conditions, including Parkinson's disease, is running in the UK. It aims to develop a palliative care outcome scale (IPOS Neuro-S8) that is specific to Parkinson's disease. 'End of Life' initiatives such as the one set up by the UK Department of Health train health professionals in the palliative needs and care of patients. However, it should be stressed that while early palliative intervention can be highly beneficial to patients' quality of life, the need for palliative care in Parkinson's disease does not mean an imminent end of life.",150,28,0.18666666666666668
9781910797211,ch07,Virtually all patients taking prolonged levodopa experience long-term complications within 2-3 years of treatment.,"Long-term complications. Long-term complications develop in virtually all patients taking continued levodopa therapy. Although levodopa is the most effective drug for the treatment of Parkinson's disease, the initial benefit begins to diminish over time with dyskinesias and fluctuations in motor response (Figure 7.1). It is likely that two factors determine the development of fluctuations and dyskinesias. disease severity. chronic pulsatile stimulation of postsynaptic dopamine receptors by the use of dopaminergic drugs with a short half-life.",110,23,0.20909090909090908
9781910797211,ch07,"Most dyskinesias progress; smaller, more frequent doses of levodopa, or a combination of the drug with a dopamine agonist, may help but problems are likely to reappear.","Dyskinesias may be related to 'off' or 'on' periods, but as the disease advances they become a continuum and difficult to classify. 'Peak-dose' dyskinesias are the most common. They involve choreic or ballistic movements, and may be associated with a variety of non-motor symptoms such as pain, mood alterations and cognitive changes. Dyskinesias may be socially unacceptable to carers, while patients may prefer to be dyskinetic when 'on'. Most dyskinesias progress and may lead to a reduced quality of life and weight loss. Reducing dopaminergic drugs will diminish dyskinesia, but may lead to a return of Parkinson's disease symptoms. Smaller doses of dopa given more frequently, or a combination of the drug with a dopamine agonist, may help, but problems are likely to reappear (see Table 7.4). The findings of a large number of preclinical and clinical studies indicate that continuous dopaminergic stimulation (CDS) may be the most desirable way to combat dyskinesias.",223,39,0.17488789237668162
9781910797211,ch07,Patients who are confused and hallucinating become difficult to manage at home and life expectancy may diminish to 1-2 years.,"Dyskinesias may be socially unacceptable to carers, while patients may prefer to be dyskinetic when 'on'. Most dyskinesias progress and may lead to a reduced quality of life and weight loss. Reducing dopaminergic drugs will diminish dyskinesia, but may lead to a return of Parkinson's disease symptoms. Smaller doses of dopa given more frequently, or a combination of the drug with a dopamine agonist, may help, but problems are likely to reappear (see Table 7.4). The findings of a large number of preclinical and clinical studies indicate that continuous dopaminergic stimulation (CDS) may be the most desirable way to combat dyskinesias. Dementia is an important cause of comorbidity in parkinsonism; when cognition declines, mortality increases. Dementia is a bad sign and will often lead to the breakdown of support networks. Patients who are confused and hallucinating become difficult to manage at home and are frequently admitted to nursing homes. At this stage, life expectancy may be only 1-2 years.",222,25,0.11261261261261261
9781910797211,ch07,Depression should be treated with antidepressants; depression/anxiety is a marker for dementia in older patients.,"Depression/anxiety is a marker for dementia in older patients. However, depression must not be mistaken for dementia. Pseudo-dementia can be mistaken for Parkinson's disease dementia. It is important to seek out depressive features and treat with antidepressants (tricyclic drugs or serotonin-reuptake inhibitors) if there is any suspicion of depression. The debate as to the advantages of the various antidepressants is ongoing (see Fast Facts: Depression).",93,21,0.22580645161290322
9781910797211,ch07,Sleep disorders may affect 60-98% of patients with Parkinson's disease; the presence of rapid eye movement (REM) behavior disorder may precede the motor diagnosis by years.,"Sleep problems in Parkinson's disease are common and may affect 60-98% of individuals at both early and late stages of the disease. Problems range from disease-related difficulties, such as rapid eye movement (REM) behavior disorder, sleep-maintenance insomnia, excessive daytime sleepiness and nocturia, to possibly drug-related problems, such as early-morning dystonia and night-time akinesia. The cause of restless legs syndrome in Parkinson's disease remains unclear, although it occurs around twice as commonly as in the general population. Sleep problems are a key determinant of quality of life in Parkinson's disease, and sleep scales specific to the disease such as the Parkinson's Disease Sleep Scale (PDSS) or the SCale for Outcomes in PArkinson's disease (SCOPA) are important for regular clinical assessments.",170,35,0.20588235294117646
9781910797211,ch07,The cause of death in Parkinson's disease is most commonly a secondary comorbid disorder.,"Sleep problems in Parkinson's disease are common and may affect 60-98% of individuals at both early and late stages of the disease. Problems range from disease-related difficulties, such as rapid eye movement (REM) behavior disorder, sleep-maintenance insomnia, excessive daytime sleepiness and nocturia, to possibly drug-related problems, such as early-morning dystonia and night-time akinesia. The cause of restless legs syndrome in Parkinson's disease remains unclear, although it occurs around twice as commonly as in the general population.",110,18,0.16363636363636364
9781910797211,ch08,It may be impossible to distinguish Parkinson's disease from other parkinsonian syndromes by clinial features alone.,"A variety of etiologies that are not secondary to the idiopathic loss of neurons in the substantia nigra may cause parkinsonian syndromes; they include infections, drugs, toxins and structural lesions. In addition, there are a number of degenerative diseases that have a more complex clinical picture than Parkinson's disease and a poorer response to therapy (Table 8.1). It may be impossible to distinguish idiopathic Parkinson's disease from other parkinsonian syndromes by clinical features alone.",105,23,0.21904761904761905
9781910797211,ch08,Drug-induced parkinsonism is the most common cause of secondary parkinsonism.,"This is the most common cause of secondary parkinsonism and it is often misdiagnosed as Parkinson's disease, because clinical features may be indistinguishable. It causes rigidity, bradykinesia, tremor and gait disturbance, and may be asymmetric. Although several medications are associated with secondary parkinsonism (Table 8.2), dopamine-blocking agents (neuroleptics) such as prochlorperazine or chlorpromazine are the most common offending agents, and are often prescribed to the elderly for non-specific complaints such as dizziness. The incidence of drug-induced parkinsonism is estimated to be 15-40% in patients receiving neuroleptics, and its prevalence increases with age.",147,17,0.11564625850340136
9781910797211,ch08,Progressive supranuclear palsy presents with gait disturbance and falls in later life; asymmetric signs (exempli gratia rest-tremor) favor a diagnosis of Parkinson's disease.,"Progressive supranuclear palsy. Progressive supranuclear palsy (PSP; Steele-Richardson-Olszewski syndrome) presents with gait disturbance and falls (predominantly backward) in over 50% of cases, and is a disease of later life. The pathological hallmark is tau protein-positive filamentous inclusions, known as neurofibrillary tangles, in the glia and neurons. The clinical picture consists of supranuclear gaze palsy, particularly down-gaze with nuchal extension, and predominant truncal extensor rigidity. Varying degrees of bradykinesia, dysphagia, personality changes and other behavioral disturbances, such as a subcortical frontal dementia, coexist. Eye-movement abnormalities (external ocular movements) are very characteristic but may not be present at disease onset. However, patients rarely die without developing these abnormalities. The external ocular movements consist of square-wave jerks, instability of fixation, slow or hypometric saccades and predominantly down-gaze supranuclear palsy. Most simply, patients are unable to look up or down to command, but vertical eye movements following a target are preserved early on, and vestibulo-ocular reflex is retained until very late.",269,42,0.15613382899628253
9781910797211,ch08,"Patients with parkinsonian dementia with Lewy bodies have early-onset dementia, and may have hallucinations or psychosis in the absence of dopaminergic therapy.","In dementia with Lewy bodies (DLB), widespread areas of neocortex as well as brainstem and diencephalic neurons have Lewy bodies. Some patients may have associated neurofibrillary tangles consistent with coincidental Alzheimer's disease. Parkinsonian DLB may be indistinguishable from Parkinson's disease, but patients with the former have early-onset dementia (progressive cognitive decline interfering with normal social and occupational function) and may have hallucinations, delusions and even psychosis in the absence of dopaminergic therapy. Clinical criteria for diagnosis were developed in 1996 and updated in 1999. Core features of DLB include fluctuations in cognition and attention, recurrent and persistent visual hallucinations and parkinsonian motor signs. Repeated and early falls and neuroleptic sensitivity can be seen. Rarely, patients develop supranuclear gaze palsy; this may lead to the condition being mistaken for PSP.",181,33,0.18232044198895028
9781910797211,ch08,Parkinsonism that presents before the age of 20 is more likely to be the result of a widespread degenerative or genetic disorder.,"The onset of parkinsonism before the age of 40 years is usually called young-onset parkinsonism. Onset of Parkinson's disease at this age is not rare. When symptoms begin before the age of 20, the term juvenile parkinsonism may be used. Parkinsonism at this early age typically occurs as a component of a more widespread degenerative disorder or a genetic disorder. Disorders such as Wilson's disease, Huntington's disease and dentatorubral-pallidoluysian atrophy should be ruled out by appropriate copper measurements and genetic testing. Often, young-onset Parkinson's disease can remain exquisitely sensitive to levodopa for many years, with concurrent development of increasing dyskinesia. The earlier the onset of Parkinson's disease, the more likely that genetic factors are important, and the greater the need for enquiry into family history.",179,26,0.1452513966480447
9781910797273,chp1,"MS has a heritable component, but the condition is not related to a single gene (multiple gene interactions are likely to be involved); the human leukocyte antigen (HLA) allele DRB1*1501 has a strong association with MS in Caucasians.","Incidence. The number of new cases per 100 000 population per year can indicate changes in the risk of a disease within a population, and can signify whether the disease frequency is increasing in a population. It is not affected by changes in survival. The incidence of MS, which peaks at age 30, appears to be rising in both the northern and southern hemispheres, particularly in women. The median estimated global incidence of MS is 2.5 per 100 000 per year, but in some countries the incidence may exceed 10 per 100 000 per year. Geo-epidemiology of MS. The prevalence of MS is significantly associated with latitude, particularly in populations of European descent (Figure 1.1). The 'latitudinal gradient' in MS has been confirmed by independent studies in Australia, New Zealand and the USA, with exceptions in Sardinia and northern Scandinavia. In Australia, the prevalence in Tasmania is six times greater than that in northern Queensland. Genetic variation between geographically discrete populations has been invoked as one explanation for this observation, particularly within the human leukocyte antigen (HLA). However, a statistically significant relationship between MS prevalence and latitude persists in some European populations even after adjustment for HLA-DRB1 allele frequency, supporting a role for environmental factors that vary with latitude (exempli gratia ultraviolet [UV] light exposure, viral infections and vitamin D levels).",278,54,0.19424460431654678
9781910797273,chp1,"The prevalence of MS is increasing worldwide, with a greater prevalence in populations of northern European descent.","Geo-epidemiology of MS. The prevalence of MS is significantly associated with latitude, particularly in populations of European descent (Figure 1.1). The 'latitudinal gradient' in MS has been confirmed by independent studies in Australia, New Zealand and the USA, with exceptions in Sardinia and northern Scandinavia. In Australia, the prevalence in Tasmania is six times greater than that in northern Queensland. Genetic variation between geographically discrete populations has been invoked as one explanation for this observation, particularly within the human leukocyte antigen (HLA). However, a statistically significant relationship between MS prevalence and latitude persists in some European populations even after adjustment for HLA-DRB1 allele frequency, supporting a role for environmental factors that vary with latitude (exempli gratia ultraviolet [UV] light exposure, viral infections and vitamin D levels).",168,19,0.1130952380952381
9781910797273,chp1,At least 2.3 million people worldwide have been diagnosed with multiple sclerosis (MS).,"Sex. MS is more common in women than men, at a ratio of 2-3:1. In Denmark, where an MS registry has been ongoing since 1948, there appears to be an increase in the incidence of MS in women, with a stable rate in the male population. An increasing incidence in females only has also been observed in Canada, Finland, Japan and southern hemisphere populations such as Australia. The pediatric MS population has a prepubertal sex ratio of 1:1, pointing to a likely association between sex hormones and disease onset.",110,17,0.15454545454545454
9781910797273,chp1,"MS is more common in women than men (2-3:1), and the incidence of MS in females is rising.","Sex. MS is more common in women than men, at a ratio of 2-3:1. In Denmark, where an MS registry has been ongoing since 1948, there appears to be an increase in the incidence of MS in women, with a stable rate in the male population. An increasing incidence in females only has also been observed in Canada, Finland, Japan and southern hemisphere populations such as Australia. The pediatric MS population has a prepubertal sex ratio of 1:1, pointing to a likely association between sex hormones and disease onset.",110,25,0.22727272727272727
9781910797273,chp1,"There is a 'latitudinal gradient' of MS, that is, a higher prevalence and incidence of MS in areas of higher latitude (remote from the equator).","Dietary vitamin D. There is an association between low levels of vitamin D and a number of diseases, including MS. Diet, dietary supplements and ambient UV exposure are all sources of vitamin D. Populations exposed to limited sunlight but who consume diets rich in fatty fish, a good source of vitamin D, have lower MS prevalence rates than expected for their latitude. Prospective studies have shown that MS risk is lower in groups who take vitamin D supplements regularly. Higher vitamin D levels are associated with lower risk of relapse and slower rates of progression in MS. Studies in clinically isolated syndromes have reported a delay before the second inflammatory episode in people with higher vitamin D levels.",135,33,0.24444444444444444
9781910797273,chp1,There is an association between low levels of vitamin D and prevalence (and possibly severity) of MS.,"Dietary vitamin D. There is an association between low levels of vitamin D and a number of diseases, including MS. Diet, dietary supplements and ambient UV exposure are all sources of vitamin D. Populations exposed to limited sunlight but who consume diets rich in fatty fish, a good source of vitamin D, have lower MS prevalence rates than expected for their latitude. Prospective studies have shown that MS risk is lower in groups who take vitamin D supplements regularly. Higher vitamin D levels are associated with lower risk of relapse and slower rates of progression in MS. Studies in clinically isolated syndromes have reported a delay before the second inflammatory episode in people with higher vitamin D levels.",135,20,0.14814814814814814
9781910797273,chp1,Most people with MS have been exposed to Epstein-Barr virus (EBV). People who have had infectious mononucleosis have a twofold higher risk of developing MS.,"Epstein-Barr virus is a double-stranded DNA virus that is transmitted via saliva. EBV does not always cause illness, and early childhood infection with the virus is usually asymptomatic. The acute illness caused by EBV, infectious mononucleosis, often accompanies primary infection in adolescence or young adulthood. Individuals with MS are rarely seronegative for EBV, and there is a strong association between previous history of infectious mononucleosis and MS, with a twofold greater risk of MS in this group. There also appears to be a relationship between the titers of EBV immunoglobulin G (IgG) and the risk of MS. The nature of the association between EBV and MS is yet to be established, but the infection may trigger or potentiate autoimmunity.",168,36,0.21428571428571427
9781910797273,chp1,The rate of MS is higher in smokers and in those with exposure to passive smoking than in those who have never smoked.,Smoking. The risk of MS is higher in 'ever smokers' than 'never smokers' and there is a direct link between duration and intensity of smoking. The risk appears to be greater in male (threefold) than female (twofold) smokers. Cultural trends that have led to an increase in the number of female smokers may be contributing to the rising incidence of MS in females. The risk of developing secondary progressive MS is higher in 'ever smokers' than 'never smokers'.,98,24,0.24489795918367346
9781910797273,chp2,Early relapsing MS is a multifocal inflammatory demyelinating and degenerative disease that affects both the white and gray matter.,"The neuropathological examination of affected brain and spinal cord tissue has driven multiple sclerosis (MS) research for more than 170 years, and in large part has shaped concepts of pathogenesis, tissue injury and repair. In contrast to gray matter, which contains neural cell bodies, white matter predominantly contains myelinated axon tracts. MS is characterized by the presence of multifocal lesions or 'plaques', predominantly in the white matter, which exhibit myelin destruction, perivascular inflammation and relative preservation of axons. It is now recognized that there is considerable gray matter involvement in MS as well as diffuse white matter pathology that contributes to long-standing disability.",131,27,0.20610687022900764
9781910797273,chp2,"Molecular reorganization of demyelinated axon membranes, characterized by a greater than normal sodium channel density, permits the restoration of continuous impulse propagation in non-remyelinated fibers.","The neuropathological examination of affected brain and spinal cord tissue has driven multiple sclerosis (MS) research for more than 170 years, and in large part has shaped concepts of pathogenesis, tissue injury and repair. In contrast to gray matter, which contains neural cell bodies, white matter predominantly contains myelinated axon tracts. MS is characterized by the presence of multifocal lesions or 'plaques', predominantly in the white matter, which exhibit myelin destruction, perivascular inflammation and relative preservation of axons. It is now recognized that there is considerable gray matter involvement in MS as well as diffuse white matter pathology that contributes to long-standing disability. The condition is traditionally regarded as a T-cell-mediated inflammatory demyelinating disease, initiated outside the central nervous system (CNS) by loss of tolerance to one, or a number of, CNS antigen(s). This hypothesis is now regarded as an oversimplification, and neuropathological, biomarker and treatment studies have implicated B cells, regulatory T cells and factors within the CNS as critical pathophysiological determinants.",219,40,0.182648401826484
9781910797273,chp2,"MS leads to a diffuse change in the white matter, which explains the brain atrophy that occurs early in the disease course.","The number, size and distribution of lesions vary widely amongst individuals with MS. In early disease most patients have small circumscribed lesions that typically occur in the periventricular and subcortical white matter, corpus callosum, optic nerves, cerebellum and spinal cord (Figure 2.1). Nowadays, more diffuse white matter pathology and early gray matter lesions are being seen using new MRI techniques, as well as in pathological studies. The whole brain volume loss seen early in the course of MS is likely to be associated with these diffuse as well as discrete changes of MS that lead to brain atrophy.",124,25,0.20161290322580644
9781910797273,chp2,"As the disease advances, the pathological complexity of MS increases. Multifocal adaptive inflammation is progressively replaced by a diffuse 'degenerative' phase, although these two facets of MS neuropathology are probably inextricably linked.","The number, size and distribution of lesions vary widely amongst individuals with MS. In early disease most patients have small circumscribed lesions that typically occur in the periventricular and subcortical white matter, corpus callosum, optic nerves, cerebellum and spinal cord (Figure 2.1). Nowadays, more diffuse white matter pathology and early gray matter lesions are being seen using new MRI techniques, as well as in pathological studies. The whole brain volume loss seen early in the course of MS is likely to be associated with these diffuse as well as discrete changes of MS that lead to brain atrophy. Although disease may be macroscopically confined to the white matter, careful neuropathological evaluation reveals focal cortical and deep gray matter lesions in almost all patients with MS (Figure 2.2). Rarely, patients present with massive ('tumefactive') hemispheric lesions that are mistaken for primary brain neoplasms until typical pathological changes of MS are identified on biopsy tissue.",202,47,0.23267326732673269
9781910797273,chp2,"Although still considered to be an organ-specific autoimmune disease, loss of myelin-forming oligodendrocytes in newly forming MS lesions is a critical event that may trigger or amplify the inflammatory cascade that characterizes active demyelination.","The hallmark of the acute MS lesion is the abrupt appearance of large numbers of activated microglia and macrophages, outnumbering lymphocytes by at least 10-20 times, in concert with the start of myelin breakdown and focal disruption of the blood-brain barrier. Active lesions, which predominate in early relapsing MS, are defined pathologically by the presence of partially myelinated axons in tissue infiltrated by macrophages. When stained with Luxol fast-blue (a stain for myelin), these macrophages are found to contain myelin particles that are immunoreactive for myelin proteins (Figure 2.4). Most such macrophages, which display enhanced expression of CD45 and major histocompatibility complex (MHC) class II antigens, appear in sheets and are thought to derive primarily from resident microglia, rather than circulating monocytes. The nature of the macrophage 'attack' on apparently normal myelin is unclear. In the most widely accepted paradigm, phagocytic activity is directed by myelin-specific T cells in perivascular cuffs and, in lesser numbers, diffusely infiltrating the parenchyma within such lesions. The process is facilitated by the secretion of injurious toxins, including tumor necrosis factor (TNF)alpha, reactive oxygen species and proteolytic enzymes. This hypothesis has been challenged by the neuropathological interrogation of ultra-acute (newly forming) MS lesions, which are characterized by extensive loss of oligodendrocytes without significant T-cell infiltrates. Whatever the cause, myelin loss from axons proceeds rapidly and is usually complete within 2 weeks of symptom onset. Lesions examined during this time show a variable reduction in oligodendrocyte numbers and evidence of at least modest axonal injury.",377,50,0.13262599469496023
9781910797273,chp2,"Current therapies effectively target the inflammatory pathology that peaks in early disease but, until recently, have failed to arrest the progression of established 'neurodegeneration' or promote endogenous repair mechanisms such as remyelination; we are on the cusp of a new era in MS therapies, with the first remyelination study showing positive effects.","Recovery from relapses is in part mediated by remyelination, the process by which denuded axons are enveloped by new myelin sheaths (Figures 2.6 and 2.7). New myelin is laid down by a population of oligodendrocytes that appears within lesions only days after an episode of acute inflammatory demyelination. These myelinating cells are derived from oligodendrocyte progenitor cells, which must migrate from the periplaque white matter and mature before commencing the process of axon ensheathment. Although remyelination is the default response to demyelination in early relapsing disease, the process progressively fails with advancing disease and age in many patients. The subsequent loss of myelin-associated trophic signals contributes to axonal degeneration and the accrual of irreversible disability. The molecular mechanisms that underpin remyelination failure are yet to be fully elucidated, and current MS therapies, which effectively target inflammatory pathology in early disease, do not promote endogenous repair mechanisms or arrest disease progression. A Phase II randomized controlled trial of anti-LINGO1, a humanized monoclonal antibody designed to promote remyelination and restore function, has shown enhanced remyelination following acute optic neuritis. Anti-LINGO1 is now being studied in relapsing forms of MS in a concurrent Phase II study.",294,70,0.23809523809523808
9781910797273,chp2,"Resolution of inflammation, restoration of axonal impulse propagation and remyelination mediate recovery from discrete clinical relapses in early disease.","Although remyelination is the default response to demyelination in early relapsing disease, the process progressively fails with advancing disease and age in many patients. The subsequent loss of myelin-associated trophic signals contributes to axonal degeneration and the accrual of irreversible disability. The molecular mechanisms that underpin remyelination failure are yet to be fully elucidated, and current MS therapies, which effectively target inflammatory pathology in early disease, do not promote endogenous repair mechanisms or arrest disease progression. A Phase II randomized controlled trial of anti-LINGO1, a humanized monoclonal antibody designed to promote remyelination and restore function, has shown enhanced remyelination following acute optic neuritis. Anti-LINGO1 is now being studied in relapsing forms of MS in a concurrent Phase II study.",174,28,0.16091954022988506
9781910797273,chp3,"The clinical presentation of MS depends on the location of inflammatory lesions in the CNS. Pathology in the optic nerve, spinal cord and brainstem can result in a broad range of signs and symptoms. However, the majority of deep white matter lesions in the hemispheres are clinically silent.","Historically, the earliest personal account of multiple sclerosis (MS) was recorded in the diaries of Frederick D'Este, grandson of King George III. Although his condition was not diagnosed in his lifetime, from 1822 to 1846 he kept a detailed log of his symptoms, which included transient loss of vision, clumsiness of the hands, weakness of the legs, incontinence and dizziness. MS became recognized as a clinicopathological entity around 1870, when Charcot noted a link between the symptoms of MS and nerve damage. Over the next 50 years various hypotheses were promulgated, including an infectious cause, and oligoclonal bands were discovered in the cerebrospinal fluid. By 1950, it was clear that MS was a disease of the central nervous system (CNS) and by 1960 the beneficial effect of steroids in the management of acute relapses had been identified. By the 1990s the first injectable disease-modifying drugs were in use, and in 2001 criteria for the diagnosis of MS were revolutionized by the incorporation of magnetic resonance imaging (MRI) to demonstrate dissemination of lesions in space and time. We now know that MS is an inflammatory demyelinating and neurodegenerative disease that affects multiple sites across the CNS. The clinical phenotype of MS depends largely on the location of inflammatory lesions, resulting in a broad spectrum of symptoms and signs. While the majority of individual lesions, particularly within the cerebral hemispheres, are asymptomatic, pathology in 'eloquent' areas such as the optic nerve, spinal cord and brainstem is usually accompanied by a relevant clinical syndrome.",329,57,0.17325227963525835
9781910797273,chp3,"Depending on MRI findings, MS can be diagnosed at the first presentation because of demyelination within the CNS; this is termed clinically isolated syndrome (CIS).","We now know that MS is an inflammatory demyelinating and neurodegenerative disease that affects multiple sites across the CNS. The clinical phenotype of MS depends largely on the location of inflammatory lesions, resulting in a broad spectrum of symptoms and signs. While the majority of individual lesions, particularly within the cerebral hemispheres, are asymptomatic, pathology in 'eloquent' areas such as the optic nerve, spinal cord and brainstem is usually accompanied by a relevant clinical syndrome. Clinically isolated syndrome. The term clinically isolated syndrome (CIS) has previously been used to describe the first presentation of demyelination. However, according to the revised 2010 McDonald criteria, a diagnosis of MS can be made following the very first attack where the initial MRI shows evidence of dissemination in time (both enhancing and non-enhancing lesions) and space. The term 'clinically isolated syndrome' is no longer in favor as it suggests diagnostic uncertainty for the patient and the physician.",200,33,0.165
9781910797273,chp3,"The pattern of MS - relapsing remitting, secondary progressive, primary progressive or progressive relapsing - will guide prognosis and choice of disease-modifying therapy. These definitions are in flux; one study suggested the term 'active' to indicate ongoing inflammation on brain MRI independent of the clinical course.","It is important to define the subtype of MS, as this will guide prognosis and choice of disease-modifying therapy. For example, therapies that reduce the frequency and severity of relapses may not be helpful to people with progressive disease. As all of the available treatments have potential side effects, all patients should be provided with a risk-benefit analysis appropriate to their MS subtype. The recognized patterns of MS are. relapsing remitting. secondary progressive. primary progressive. progressive relapsing. Relapsing remitting disease is the most common form of MS, accounting for 65-70% of patients. Relapsing remitting MS is characterized by periods of acute neurological disturbance (relapses), which last for at least 24 hours and are not attributable to other causes such as infection or changes in core temperature. These relapses must occur after more than 30 days of clinical stability, and the neurological deficit must be established objectively by clinical evaluation (history and/or examination). In early disease, recovery after a relapse (remission) is often near complete, but incomplete recovery is common in established disease and in these instances patients with MS often accrue disability with each successive relapse (Figure 3.1). Secondary progressive disease. In most cases (up to 75% of people with relapsing remitting disease) there is an eventual progression to the secondary progressive phase of MS. This is defined as an initial relapsing remitting disease course followed by progression with or without occasional relapses, minor remissions and plateaus (Figure 3.2). Risk factors for progression to secondary progressive MS are shown in Table 3.1. The progression of disease from relapsing remitting to the secondary progressive stage is usually noted retrospectively, for example when a patient with MS has accumulated disability over 6-12 months without any discrete episodes of relapse. Neuroaxonal loss without any 'overt' features of inflammation (clinical or radiological) is thought to underlie this phase of MS (Figure 3.3).",409,62,0.15158924205378974
9781910797273,chp3,People with MS do not always present with the first episode of demyelination. It is therefore important to determine whether the patient has experienced a prior neurological disturbance of any sort (exempli gratia mild or temporary visual blurring).,"Medical history. People with MS do not always seek medical attention in the early phase of the disease, especially when the sensory pathways are affected in isolation or if symptoms such as visual blurring are mild and temporary. However, it is important at presentation to determine whether a patient presenting with an apparent CIS has experienced a prior remitting neurological disturbance of any sort (Table 3.2). L'hermitte's sign is an unpleasant paroxysmal sensation, often described as an electric shock radiating along the spine and into the limbs when the neck is flexed. This indicates that there is an 'irritative' lesion at the level of the cervical cord and is thought to be due to stretching of hyperexcitable neurons in the dorsal column. It is common in MS, but can be associated with other causes of cervical spinal cord disease (exempli gratia cord compression, vitamin B deficiency, radiation myelopathy). Uhthoff's phenomenon is the worsening of neurological symptoms as the patient's core body temperature increases; for example, increased visual blurring after a hot shower or a worsening of pre-existing limb weakness in high ambient temperatures.",234,48,0.20512820512820512
9781910797273,chp3,MRI is the most important investigation in the diagnosis and monitoring of MS.,"Magnetic resonance imaging remains the most important investigation in the diagnosis and monitoring of MS. White matter lesions are best visualized on T2-weighted and fluid attenuated inversion recovery (FLAIR) sequences. Active inflammation is best seen on enhanced T1-weighted images. Although the abnormalities found on MRI scans - particularly those seen on a single examination - are not specific for the disease, certain combinations of findings on cerebral MRI have a high specificity for MS (Figure 3.8).",99,14,0.1414141414141414
9781910797273,chp3,"To diagnose MS, lesions must be shown to be present, separated by space and time.","The diagnosis of MS rests on the principle that CNS lesions must be disseminated in space (DIS), id est in different areas of the CNS; and disseminated in time (DIT), id est at intervals separated by at least 1 month of recovery or an interval in which the dysfunction from a previous attack clearly stabilizes. As the sophistication of MRI has increased, the diagnostic criteria for MS have been repeatedly reviewed and revised. The 'McDonald' diagnostic criteria in use today are named after Professor Ian McDonald, formerly neurologist at the National Hospital for Neurology and Neurosurgery, London, who initially described the criteria in 2001; they have since been revised in 2005 and 2010. The aims of the 2010 revisions were to simplify the MRI criteria for DIS and DIT, and to more clearly define the diagnostic criteria for primary progressive MS (Table 3.5).",172,18,0.10465116279069768
9781910797273,chp3,The number of asymptomatic demyelinating lesions on MRI at the time of CIS strongly predicts the likelihood of the patient developing clinically definite MS.,"The diagnosis of MS rests on the principle that CNS lesions must be disseminated in space (DIS), id est in different areas of the CNS; and disseminated in time (DIT), id est at intervals separated by at least 1 month of recovery or an interval in which the dysfunction from a previous attack clearly stabilizes. As the sophistication of MRI has increased, the diagnostic criteria for MS have been repeatedly reviewed and revised. The 'McDonald' diagnostic criteria in use today are named after Professor Ian McDonald, formerly neurologist at the National Hospital for Neurology and Neurosurgery, London, who initially described the criteria in 2001; they have since been revised in 2005 and 2010. The aims of the 2010 revisions were to simplify the MRI criteria for DIS and DIT, and to more clearly define the diagnostic criteria for primary progressive MS (Table 3.5).",172,31,0.18023255813953487
9781910797273,chp3,Rarer alternative causes of inflammatory demyelination within the CNS such as neuromyelitis optica (NMO) and acute disseminated encephalomyelitis (ADEM) should be considered and excluded in the diagnostic work-up of MS.,"It is important to consider and exclude the much rarer alternative causes of inflammatory demyelination within the CNS, such as NMO and ADEM, similar yet distinct conditions (Table 3.6). Red flag features that suggest an alternative diagnosis are listed in Table 3.7. Neuromyelitis optica is a predominantly relapsing inflammatory demyelinating disorder of the CNS that manifests with optic neuritis and longitudinally extensive (spanning three or more vertebral segments) transverse myelitis (LETM), although these index events may be separated by years and, in some cases, decades. Distinct clinical imaging (Figures 3.12 and 3.13) and laboratory and pathological features help to distinguish NMO from MS, although the diagnostic criteria remain in a state of flux. The seminal discovery of serum antibodies ('NMO IgG') to the water channel aquaporin 4 (AQP-4) in more than 70% of NMO cases suggests a discrete pathogenesis. AQP-4 is primarily expressed on astrocyte foot processes, and recent pathological findings have confirmed that widespread astrocyte destruction precedes inflammatory demyelination in NMO.",246,52,0.21138211382113822
9781910797273,chp3,"Red flag features that suggest an alternative diagnosis include involvement of the peripheral nervous system, atypical MRI findings or systemic features of disease.","Red flag features that suggest an alternative diagnosis are listed in Table 3.7. Neuromyelitis optica is a predominantly relapsing inflammatory demyelinating disorder of the CNS that manifests with optic neuritis and longitudinally extensive (spanning three or more vertebral segments) transverse myelitis (LETM), although these index events may be separated by years and, in some cases, decades. Distinct clinical imaging (Figures 3.12 and 3.13) and laboratory and pathological features help to distinguish NMO from MS, although the diagnostic criteria remain in a state of flux. The seminal discovery of serum antibodies ('NMO IgG') to the water channel aquaporin 4 (AQP-4) in more than 70% of NMO cases suggests a discrete pathogenesis. AQP-4 is primarily expressed on astrocyte foot processes, and recent pathological findings have confirmed that widespread astrocyte destruction precedes inflammatory demyelination in NMO.",205,27,0.13170731707317074
9781910797273,chp3,MS progression can be measured using the Expanded Disability Status Scale (EDSS) and with MRI.,"Whilst it is not always possible to predict the clinical outcome in individual patients, there are some features that may confer either a good or poor prognosis (Table 3.8). Natural history studies have suggested that 10 years from diagnosis, up to 10% of patients have an Expanded Disability Status Scale (EDSS; see below) score greater than 6.5, and up to 40% are unable to work full time. Much of the employment compromise in these patients is due to non-motor symptoms such as cognitive disability, bladder dysfunction and fatigue.",112,20,0.17857142857142858
9781910797273,chp4,Disabling multiple sclerosis (MS) relapses should be treated with high-dose (500-1000 mg/day) short-course (3-5 days) intravenous or oral methylprednisolone.,"Corticosteroids are the mainstay of acute treatment for multiple sclerosis (MS) relapses. There are conflicts in the data regarding effectiveness of steroids, with some studies suggesting steroids improve overall outcome after relapse and others showing transient worsening after steroids. Corticosteroid therapy is therefore reserved either for patients with disabling relapses or for those with an occupational (or other) need to recover function faster than the natural history of the condition allows. Studies showing an improvement in patient-reported outcomes after steroid treatment may also contribute to the decision to prescribe these agents in order to help lessen symptomatology and improve quality of life. As poor recovery from relapse indicates an increased risk of long-term disability, there is a need to focus on adequate disease-modifying therapy aimed at reducing relapse frequency and the long-term consequences of such relapses. Reassessment after relapse comprises a full evaluation using the Expanded Disability Status Scale (EDSS) and/or Multiple Sclerosis Functional Composite (MSFC) to determine if the patient has improved. In some studies, nearly 80% of EDSS and MSFC scores are near baseline 4 weeks after relapse, although the results are conflicting.",238,43,0.18067226890756302
9781910797273,chp4,Corticosteroid therapy hastens recovery from acute relapse but may not affect ultimate function. There is no indication for prolonged oral steroid therapy following MS relapse.,"Prednisolone/prednisone is available in a number of oral dosing regimens, starting at 40-60 mg/day, followed by a variable weaning period. However, evidence supporting the use of oral prednisolone/prednisone is limited and there is no indication for prolonged oral steroid therapy following MS relapse. The results of the Optic Neuritis Treatment Trial indicate that administration of moderate-dose oral prednisone, 60 mg/day, to patients with acute optic neuritis actually increases the risk of recurrence. For this reason, high-dose oral or intravenous methylprednisolone is the preferred treatment choice for acute relapse.",137,32,0.23357664233576642
9781910797273,chp4,Moderate dose (60 mg/day) oral corticosteroid therapy for optic neuritis may increase the risk of recurrence and should be avoided.,"Prednisolone/prednisone is available in a number of oral dosing regimens, starting at 40-60 mg/day, followed by a variable weaning period. However, evidence supporting the use of oral prednisolone/prednisone is limited and there is no indication for prolonged oral steroid therapy following MS relapse. The results of the Optic Neuritis Treatment Trial indicate that administration of moderate-dose oral prednisone, 60 mg/day, to patients with acute optic neuritis actually increases the risk of recurrence. For this reason, high-dose oral or intravenous methylprednisolone is the preferred treatment choice for acute relapse.",137,31,0.22627737226277372
9781910797273,chp4,"Bladder dysfunction commonly manifests with urinary frequency, urgency and urge incontinence and is ameliorated with anticholinergic therapy in most patients with low urinary residual volumes (< 100 mL).","Vitamin D. Low vitamin D levels are epidemiologically associated with an increased risk of developing MS (see Chapter 1). Several small studies have examined the potential of dietary vitamin D supplementation, 1000-4000 IU/day, to ameliorate relapse frequency in MS, but the results have been inconsistent. Larger studies, in particular the placebo-controlled PrevANZ study of vitamin D supplementation in patients with clinically isolated syndrome, are awaited with interest. In the interim, many patients with MS with low or low-normal vitamin D levels are empirically treated with dietary vitamin D supplementation. Studies of vitamin D supplementation in individuals predisposed to MS (exempli gratia those with a family history of MS) are also forthcoming. At present, standard use of vitamin D is variable; the general recommendation is to ensure that the patient has sufficient vitamin D by achieving levels of at least 30 ng/mL.",184,39,0.21195652173913043
9781910797273,chp4,"MS symptoms including pain, spasticity and sphincter dysfunction are a source of significant disability and should be treated proactively.","Changes in 'homeostatic' (normal physiological) function can exacerbate existing MS symptoms. Travel to areas of warm climate, exercise or pyrexia can result in overheating and transient deterioration in neurological function (Uhthoff's phenomenon). Intercurrent infection (bacterial or otherwise) activates inflammatory cytokines, which can result in a 'pseudo-relapse'. It is therefore important to exclude these types of exacerbation, particularly by checking for urinary sepsis, as they can be quickly and completely alleviated with appropriate antimicrobial and antipyretic therapies. Spasticity is a source of significant discomfort and disability in people with MS. Proactive management in a multidisciplinary setting is needed, with input from neurologists, rehabilitation physicians, physiotherapists and occupational therapists (see Chapter 8).",164,27,0.16463414634146342
9781910797273,chp4,"Spasticity may be severe and is managed in most patients with a combination of physical therapy and oral medication. In severe focal spasticity, botulinum toxin injections have a role.","Cannabinoids. Trials have suggested that cannabinoid-derived compounds may also have a role in this area. These include the oro-mucosally administered nabiximols (Sativex) and the oral medication nabilone. In a proportion of patients with MS, nabiximols, which contain -9-tetrahydro-cannabinol (THC) and cannabidiol (CBD) at a 1:1 fixed ratio, has been shown to improve self-reported spasticity scores, sleep disruption and the Barthel Activities of Daily Living Index when added to baseline stable therapies such as baclofen or tizanidine. Nabiximols is well tolerated and appears to have minimal psychotropic effects at standard doses (a maximum of 12 sprays in any 24-hour period). These products are not consistently available globally; their availability will relate to local regulations.",189,38,0.20105820105820105
9781910797273,chp4,"Intermittent self-catheterization should be considered in patients with significant urinary retention (urinary residual volume > 100 mL), and formal urodynamic studies may be indicated to exclude complex bladder dysfunction.","The use of these drugs is limited by anticholinergic side effects (exempli gratia dry mouth and constipation); if they lead to an increase in the urinary residual volume, their use should be reconsidered. However, they may be used in combination with intermittent self-catheterization in patients with high urinary residual volumes and symptomatic detrusor overactivity. They may also be used as required in patients with mild urinary frequency and urgency. Desmopressin, 10-20 g at night, is helpful in younger patients with nocturnal frequency and incontinence. Care should be taken to avoid fluid overload. A specialist urologic review should be sought for all patients who do not respond to anticholinergic therapies. Formal urodynamic studies may indicate more complex bladder dysfunction. If urgency and frequency are refractory to treatment, with a low residual volume of urine, then botulinum toxin A injections into the detrusor muscle via a cystoscope can be very successful (Figure 4.2). Botulinum toxin inhibits neurotransmitter release and reversibly decreases muscle contractility. Regeneration takes place within 5-9 months, so repeated injections may be necessary. The most important potential adverse effects are detrusor hypotonia and urinary retention.",260,42,0.16153846153846155
9781910797273,chp4,Pain in MS most commonly has a neuropathic origin and responds to anticonvulsant therapy or antidepressant (tricyclic or serotonin-norepinephrine reuptake inhibitor) therapy.,"Other neuropathic pain syndromes. Acute burning/dysesthetic (spinothalamic) pain occasionally accompanies MS relapse. This pain may have a radicular distribution, but is commonly more diffuse and usually involves the lower limbs. Both anticonvulsant and tricyclic antidepressant therapies may be efficacious in this setting. The serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine may be particularly helpful for this indication. All these drugs reduce 'central' transmission of pain impulses either by blocking ion channels (lamotrigine, carbamazepine), increasing inhibitory effects on pain pathways (gabapentin, pregabalin) or altering neurotransmitter balance in favor of pain suppression (amitryptiline, nortryptiline, duloxetine).",169,41,0.24260355029585798
9781910797273,chp4,"Impaired mobility is a dominant feature of progressive MS, and function should be optimized through multidisciplinary care, provision of appropriate walking aids and, in selected cases, symptomatic treatment with fampridine.","Multidisciplinary management with pain specialists who use non-pharmacological techniques can be very helpful. These include psychological therapies, acupuncture and transcutaneous electrical nerve stimulation (TENS). Rare use of stereotactic neurosurgical techniques, whereby stimulating electrodes are placed in strategic areas in the pain pathway (thalamus, periaqueductal gray matter, etc.), are being trialed with some success. These techniques are promising but await formal approvals. Mobility. Gait disturbance affects 80% of people with MS within 10-15 years of diagnosis, and many will need assistance to maintain their mobility. Losing the ability to walk is distressing, and an important aspect of management is the provision of walking aids and appropriate physical therapy to maintain independent mobility. It may be difficult to predict the degree of recovery from acute spinal relapses that impair mobility. Gait disturbance is a dominant feature in progressive forms of MS, reflected in the Kurtzke EDSS rating scale in which limitation of mobility becomes the defining characteristic from EDSS 4.0-7.5 (see Table 3.9).",224,42,0.1875
9781910797273,chp4,"Depression complicates the course of MS in up to 40% of patients and should be proactively managed with a program of physical exercise, behavioral therapy and pharmacotherapy as indicated.","Seizures must be differentiated from paroxysmal movement disorders such as tonic spasms, kinesogenic choreoathetosis and some dystonias. The pathophysiology of these conditions is distinct from seizures; for example, aberrant (ephaptic) transmission of nerve impulses has been implicated in tonic spasms. Unlike seizures, they do not impair consciousness, may be painful and often have clear triggers such as changes in position. Careful history taking and, in more complex cases, electrophysiological studies, will help to clarify the diagnosis. Both seizures and paroxysmal symptoms may respond rapidly to anticonvulsant therapy, but a diagnosis of epilepsy can have profound effects on the social/employment status of the patient. The patient will be prohibited from driving for 6-12 months after a single seizure, depending on geographic location. Mood disorders, particularly depression, are extremely common in MS. Some studies estimate rates to be as high as 40%. In an age-matched population-based study, the incidence and prevalence of anxiety, bipolar disorder, depression and schizophrenia were all higher in the MS population than in the matched population. A concurrent mood disorder may have a profound effect on both physical and cognitive functioning in patients with MS and must be sought and treated aggressively with a program of behavioral therapy, pharmacotherapy and physical exercise. Also see Fast Facts: Depression.",280,36,0.12857142857142856
9781910797273,chp5,"Disease-modifying therapies (DMTs) ameliorate CNS inflammation in relapsing multiple sclerosis (MS), effectively reducing the relapse rate and the accumulation of new brain lesions identified on MRI.","In general, disease-modifying therapies (DMTs) are used in ambulatory patients with relapsing remitting multiple sclerosis (MS). There is less evidence of benefit in patients with progressive forms of the disease but this is rapidly changing. In patients with relapsing disease, existing therapies reduce the rate of relapse and slow the rate of lesion accumulation on MRI, but neither of these endpoints has a clear correlation with disability. Progression of disability may occur over decades, and in this respect the true efficacy of existing and newer-generation treatments is slowly becoming apparent. While no treatments have been shown to reverse or slow the progression of MS over the longer term, new studies are showing short-term benefits. It is important to consider this when initiating treatment, and to be realistic about what each treatment can offer. Several DMTs are now available in injectable, oral and intravenous form (Table 5.1).",188,43,0.22872340425531915
9781910797273,chp5,"DMTs can be given in injectable, oral or intravenous form.","In patients with relapsing disease, existing therapies reduce the rate of relapse and slow the rate of lesion accumulation on MRI, but neither of these endpoints has a clear correlation with disability. Progression of disability may occur over decades, and in this respect the true efficacy of existing and newer-generation treatments is slowly becoming apparent. While no treatments have been shown to reverse or slow the progression of MS over the longer term, new studies are showing short-term benefits. It is important to consider this when initiating treatment, and to be realistic about what each treatment can offer. Several DMTs are now available in injectable, oral and intravenous form (Table 5.1).",138,16,0.11594202898550725
9781910797273,chp5,Cytotoxic immunosuppression and hematopoietic stem cell transplantation are reserved for patients with MS that is refractory to available DMT.,"Both treatments have been shown, in multiple clinical trials, to reduce relapse rates by 33-38% over a 2-year period, and in most countries are licensed for the treatment of patients with relapsing MS who have experienced two or more clinically significant relapses over the last 2 years. Early initiation of treatment. In patients with the first relapse, there is evidence that these treatments delay the second clinical attack which can be the defining event to confirm MS. Patients with the first clinical relapse and abnormal imaging that is consistent with MS, as per the updated McDonald criteria (see Table 3.5), should commence MS medication rather than waiting and potentially increasing the risk of long-term disability. Early initiation of DMTs in this cohort can delay a second relapse by up to 12 months and reduce disability progression by more than 2-3 years. However, longer-term studies suggest that DMTs may not significantly alter the patient's ultimate disability. The decision must be tailored to the individual on the basis of a risk-benefit discussion.",208,35,0.16826923076923078
9781910797273,chp5,"Early introduction of DMT, even at the clinically isolated syndrome stage, may be advantageous. Conversely, immune-directed DMT is not effective in patients with established secondary progressive MS.","Side effects. Common side effects include nausea, diarrhea within the first few months of treatment, hair thinning and predominantly asymptomatic and transient elevation of alanine aminotransferase levels (bi-monthly LFTs are required for the first 6 months of treatment). Rarely, treatment may be complicated by peripheral nerve toxicity requiring drug discontinuation. No new or unexpected safety concerns were identified in pooled data analysis from one Phase II and three Phase III clinical trials, with treatment duration exceeding 12 years and cumulative exposure exceeding 6800 patient years. Teriflunomide is a potential teratogen and is contraindicated in pregnancy and in men and women of child-bearing potential not using reliable contraception. The drug has a long half-life (approximately 19 days), and in the case of inadvertent pregnancy (or plans to fall pregnant) on therapy, the drug must be rapidly 'washed out' with cholestyramine or activated charcoal.",198,36,0.18181818181818182
9781910797273,chp5,"Newer DMTs, such as natalizumab, alemtuzumab and fingolimod, are significantly more effective than injectable agents, but carry modest risks that must be considered when making treatment choices in individual patients.","For patients with mild to moderate disease, a treatment escalation strategy has been advocated, starting with first-line injectable or oral DMTs. A suboptimal clinical or radiological response to treatment should trigger consideration of second- and third-line treatments with greater expected efficacy. The simplified paradigm shown in Figure 5.10 represents the authors' views on how treatment might be escalated. In mild MS, most neurologists commence therapy with an injectable DMT such as IFNbeta or glatiramer acetate, or oral therapy such as teriflunomide or dimethyl fumarate, and escalate therapy to more efficacious treatment in patients who continue to exhibit significant clinical or MRI disease activity. In patients with severe, or 'highly active' MS, natalizumab or alemtuzumab may be an appropriate choice, particularly when other therapies have failed. Some neurologists consider an induction approach, using one of the more efficacious DMTs such as alemtuzumab to 'reset' the disease course. There is, at present, no evidence to suggest whether escalation or induction have better outcomes. In particular, alemtuzumab should be considered in patients with highly active disease who have a higher risk of PML with natalizumab (exempli gratia those with positive JC virus antibodies; see Figures 5.8 and 5.9). Patients who have failed other therapeutic avenues may, in selected cases and preferably within the context of a clinical trial, warrant high-dose immunosuppression (high-dose cyclophosphamide) with or without autologous hematopoietic stem cell transplantation, an experimental therapy with a mortality rate of 1-2% and significant associated morbidity.",362,51,0.1408839779005525
9781910797273,chp5,A treatment escalation strategy is appropriate for most patients with mild to moderate disease. Clinical and radiological parameters should be carefully monitored for evidence of disease activity in this paradigm.,"For patients with mild to moderate disease, a treatment escalation strategy has been advocated, starting with first-line injectable or oral DMTs. A suboptimal clinical or radiological response to treatment should trigger consideration of second- and third-line treatments with greater expected efficacy. The simplified paradigm shown in Figure 5.10 represents the authors' views on how treatment might be escalated. In mild MS, most neurologists commence therapy with an injectable DMT such as IFNbeta or glatiramer acetate, or oral therapy such as teriflunomide or dimethyl fumarate, and escalate therapy to more efficacious treatment in patients who continue to exhibit significant clinical or MRI disease activity. In patients with severe, or 'highly active' MS, natalizumab or alemtuzumab may be an appropriate choice, particularly when other therapies have failed. Some neurologists consider an induction approach, using one of the more efficacious DMTs such as alemtuzumab to 'reset' the disease course. There is, at present, no evidence to suggest whether escalation or induction have better outcomes. In particular, alemtuzumab should be considered in patients with highly active disease who have a higher risk of PML with natalizumab (exempli gratia those with positive JC virus antibodies; see Figures 5.8 and 5.9). Patients who have failed other therapeutic avenues may, in selected cases and preferably within the context of a clinical trial, warrant high-dose immunosuppression (high-dose cyclophosphamide) with or without autologous hematopoietic stem cell transplantation, an experimental therapy with a mortality rate of 1-2% and significant associated morbidity.",362,33,0.09116022099447514
9781910797273,chp5,"Induction therapy for MS is a new concept, using one of the 'stronger' MS medications, to 'reset' the disease course.","For patients with mild to moderate disease, a treatment escalation strategy has been advocated, starting with first-line injectable or oral DMTs. A suboptimal clinical or radiological response to treatment should trigger consideration of second- and third-line treatments with greater expected efficacy. The simplified paradigm shown in Figure 5.10 represents the authors' views on how treatment might be escalated. In mild MS, most neurologists commence therapy with an injectable DMT such as IFNbeta or glatiramer acetate, or oral therapy such as teriflunomide or dimethyl fumarate, and escalate therapy to more efficacious treatment in patients who continue to exhibit significant clinical or MRI disease activity. In patients with severe, or 'highly active' MS, natalizumab or alemtuzumab may be an appropriate choice, particularly when other therapies have failed. Some neurologists consider an induction approach, using one of the more efficacious DMTs such as alemtuzumab to 'reset' the disease course. There is, at present, no evidence to suggest whether escalation or induction have better outcomes. In particular, alemtuzumab should be considered in patients with highly active disease who have a higher risk of PML with natalizumab (exempli gratia those with positive JC virus antibodies; see Figures 5.8 and 5.9). Patients who have failed other therapeutic avenues may, in selected cases and preferably within the context of a clinical trial, warrant high-dose immunosuppression (high-dose cyclophosphamide) with or without autologous hematopoietic stem cell transplantation, an experimental therapy with a mortality rate of 1-2% and significant associated morbidity.",362,29,0.08011049723756906
9781910797273,chp5,Early institution of efficacious newer-generation therapies should be strongly considered in patients with rapidly evolving MS.,"For patients with mild to moderate disease, a treatment escalation strategy has been advocated, starting with first-line injectable or oral DMTs. A suboptimal clinical or radiological response to treatment should trigger consideration of second- and third-line treatments with greater expected efficacy. The simplified paradigm shown in Figure 5.10 represents the authors' views on how treatment might be escalated. In mild MS, most neurologists commence therapy with an injectable DMT such as IFNbeta or glatiramer acetate, or oral therapy such as teriflunomide or dimethyl fumarate, and escalate therapy to more efficacious treatment in patients who continue to exhibit significant clinical or MRI disease activity. In patients with severe, or 'highly active' MS, natalizumab or alemtuzumab may be an appropriate choice, particularly when other therapies have failed. Some neurologists consider an induction approach, using one of the more efficacious DMTs such as alemtuzumab to 'reset' the disease course. There is, at present, no evidence to suggest whether escalation or induction have better outcomes. In particular, alemtuzumab should be considered in patients with highly active disease who have a higher risk of PML with natalizumab (exempli gratia those with positive JC virus antibodies; see Figures 5.8 and 5.9). Patients who have failed other therapeutic avenues may, in selected cases and preferably within the context of a clinical trial, warrant high-dose immunosuppression (high-dose cyclophosphamide) with or without autologous hematopoietic stem cell transplantation, an experimental therapy with a mortality rate of 1-2% and significant associated morbidity.",362,20,0.055248618784530384
9781910797273,chp6,Laquinimod may have a novel mechanism of action that targets innate immune cells; it appears to affect disability progression and brain volume loss more than relapse rate.,"Laquinimod, a novel synthetic derivative of quinoline-3-carboxamide, is given once daily as oral therapy. Following successful preclinical studies in animal models of neuroinflammation, it has been studied in two Phase III trials, where it exerted a modest (23%) non-significant reduction in annualized relapse rate, but a significant improvement in the progression of disability and whole brain volume loss compared with placebo. Laquinimod has exhibited some concerning side effects in the clinical trial program to date: elevation of liver enzymes and an increase in cardiovascular events. The apparent disjunct between an effect on relapses and disability progression/brain volume loss suggests that laquinimod may have a unique mechanism of action, possibly mediated through a direct effect on innate immune cells in the CNS. Additional Phase III trials are under way to establish the efficacy of laquinimod and define a potential place for this agent in MS treatment.",190,32,0.16842105263157894
9781910797273,chp6,Ocrelizumab may soon receive FDA approval as the first DMT for progressive MS.,"Laquinimod has exhibited some concerning side effects in the clinical trial program to date: elevation of liver enzymes and an increase in cardiovascular events. The apparent disjunct between an effect on relapses and disability progression/brain volume loss suggests that laquinimod may have a unique mechanism of action, possibly mediated through a direct effect on innate immune cells in the CNS. Additional Phase III trials are under way to establish the efficacy of laquinimod and define a potential place for this agent in MS treatment.",103,20,0.1941747572815534
9781910797273,chp6,The spectrum of disease-modifying therapies (DMTs) available to the MS clinician is expected to significantly expand over the next 5-10 years.,"The application of stem cell therapies to MS is perhaps more frequently raised by patients with the condition than their neurologists. However, both conventional (hematopoietic) and novel stem cell approaches (Table 6.1) offer potential new therapeutic avenues for MS, especially in patients whose disease is refractory to current disease-modifying treatments. Autologous hematopoietic stem cell transplantation (AHSCT) is in effect a means of 'rebooting' the immune system by ablating bone marrow and repopulating it with the patient's own hematopoietic (bone marrow) stem cells. The Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) study has shown the highest rate of NEDA (no evidence of disease activity) - 76% - in any trial to date, opening up the possibilities of changing the clinical course of MS. In Phase III randomized controlled trials of AHSCT, early studies in MS indicate a reduction in relapse rate of more than 90% compared with pretreatment levels of disease activity. Dramatic MRI responses to AHSCT have also been reported.",243,32,0.13168724279835392
9781910797273,chp6,"Treatments such as autologous hematopoietic stem cell transplant may be appropriate for the treatment of patients with highly active relapsing disease that has not responded to other DMTs, or as an inducing agent to 'reset' the course of MS.","Autologous hematopoietic stem cell transplantation (AHSCT) is in effect a means of 'rebooting' the immune system by ablating bone marrow and repopulating it with the patient's own hematopoietic (bone marrow) stem cells. The Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) study has shown the highest rate of NEDA (no evidence of disease activity) - 76% - in any trial to date, opening up the possibilities of changing the clinical course of MS. In Phase III randomized controlled trials of AHSCT, early studies in MS indicate a reduction in relapse rate of more than 90% compared with pretreatment levels of disease activity. Dramatic MRI responses to AHSCT have also been reported. Impressive clinical and radiological efficacy in patients with severe active disease comes at the cost of significant morbidity/mortality, associated in large part with the intensity of the chemotherapeutic conditioning regimen (2-4% in specialized units). The technique was reserved for patients with aggressive disease who had failed to respond to other treatments, and recent trials showed higher efficacy in patients earlier in their disease course. There is no evidence that immunoablative therapy will be efficacious in gradually progressive forms of MS. International multicenter clinical trials are ongoing, which should help to define a population of patients in whom the risk-benefit analysis weighs in favor of this treatment approach.",307,56,0.18241042345276873
9781910797273,chp6,"Therapies being investigated include novel small-molecule immunomodulators, targeted immune-directed monoclonal antibodies, hematopoietic and mesenchymal stem-cell therapies, re-engineering of previous MS medications and molecules that promote remyelination and repair.","Mesenchymal stem cell transplantation. The concept of self-renewing multipotent stem cells (id est cells that can differentiate into any cell type) as the basis for tissue repair in the nervous system, which has a physiologically limited regenerative capacity in adults, is extremely attractive. Mesenchymal tissue can be harvested from bone marrow, placental or adipose tissue, and multipotent mesenchymal stem cells expanded and purified in vitro. From only a few stem cells, billions/trillions of self-regenerating stem cells can be grown using specific nutrients (growth factors) and then readministered to the patient (intravenously or intrathecally) without the need for toxic conditioning regimens. Evidence from preclinical studies in experimental autoimmune encephalomyelitis (EAE) models supports both an immunomodulatory and neuroprotective role for mesenchymal stem cells. Experimental (Phase I/II) studies have demonstrated the feasibility of this approach in humans, with no serious adverse reactions reported to date. Although there have been only a few dozen patients in open-label studies so far, early data suggest that these cells may have an ameliorating effect on inflammation in patients with MS. The capacity of these cells to differentiate into physiologically functional neural tissue (remyelination/regeneration) is yet to be determined. Anti-LINGO-1. Promoting repair has been an unexplored sphere of MS therapy. Recently, in animal models of demyelination, LINGO antagonists have been shown to promote oligodendrocyte differentiation and myelination in vitro. Initiated in 2013, the first multinational Phase II trial of anti-LINGO-1 antibodies in patients with acute optic neuritis has shown an effect on promoting nerve repair following optic neuritis. Ultimately, therapies that successfully promote remyelination and repair may be applicable across the spectrum of MS subtypes, including progressive forms of the disease.",410,61,0.14878048780487804
9781910797273,chp6,"A greater understanding of MS pathogenesis, from genetic susceptibilities and mechanisms of immune-mediated tissue injury through to the molecular basis of impaired tissue repair, has facilitated the development of new treatments for the disease.","Experimental (Phase I/II) studies have demonstrated the feasibility of this approach in humans, with no serious adverse reactions reported to date. Although there have been only a few dozen patients in open-label studies so far, early data suggest that these cells may have an ameliorating effect on inflammation in patients with MS. The capacity of these cells to differentiate into physiologically functional neural tissue (remyelination/regeneration) is yet to be determined. Anti-LINGO-1. Promoting repair has been an unexplored sphere of MS therapy. Recently, in animal models of demyelination, LINGO antagonists have been shown to promote oligodendrocyte differentiation and myelination in vitro. Initiated in 2013, the first multinational Phase II trial of anti-LINGO-1 antibodies in patients with acute optic neuritis has shown an effect on promoting nerve repair following optic neuritis. Ultimately, therapies that successfully promote remyelination and repair may be applicable across the spectrum of MS subtypes, including progressive forms of the disease.",220,41,0.18636363636363637
9781910797273,chp6,Anti-LINGO antibody is the first remyelination-promoting therapy to reach Phase II clinical trials in optic neuritis. Treatments that overcome molecular obstacles to remyelination may complement immune-directed therapies for MS in the future.,"Experimental (Phase I/II) studies have demonstrated the feasibility of this approach in humans, with no serious adverse reactions reported to date. Although there have been only a few dozen patients in open-label studies so far, early data suggest that these cells may have an ameliorating effect on inflammation in patients with MS. The capacity of these cells to differentiate into physiologically functional neural tissue (remyelination/regeneration) is yet to be determined. Anti-LINGO-1. Promoting repair has been an unexplored sphere of MS therapy. Recently, in animal models of demyelination, LINGO antagonists have been shown to promote oligodendrocyte differentiation and myelination in vitro. Initiated in 2013, the first multinational Phase II trial of anti-LINGO-1 antibodies in patients with acute optic neuritis has shown an effect on promoting nerve repair following optic neuritis. Ultimately, therapies that successfully promote remyelination and repair may be applicable across the spectrum of MS subtypes, including progressive forms of the disease.",220,51,0.2318181818181818
9781910797273,chp6,Progressive MS may soon have a number of therapeutic options; the first is likely to be ocrelizumab.,"Mastinib has completed a positive Phase IIb study in patients with primary and secondary progressive MS, the results of which are reported to include improvement in the Multiple Sclerosis Functional Composite (see pages 54 -). A Phase III trial in this population is now in progress, and it may prove to be an oral treatment option for this more rare type of MS. Mastinib targets mast cells and inhibits several biochemical processes. It is used in the treatment of canine diseases and is also being evaluated in stroke, amyotrophic lateral sclerosis and Alzheimer's disease.",112,25,0.22321428571428573
9781910797273,chp7,Multiple sclerosis does not affect fertility.,"Effects of multiple sclerosis on pregnancy. It is important to note that while a diagnosis of MS may influence pregnancy planning, it does not affect fertility. However, sexual function may be adversely affected by multiple factors including psychological perceptions regarding body image and physical factors including genitourinary dysfunction and altered sensation.",59,7,0.11864406779661017
9781910797273,chp7,"Pregnancy may result in reduced relapse risk, especially in the third trimester, but does not affect the overall progression of MS.","Effects of pregnancy on multiple sclerosis. Pregnancy is a physiological state that involves relative immunologic modulation. Pregnancy appears to have a favorable effect on MS, with reduced rates of relapse, especially in the third trimester. This is usually accompanied by a compensatory rise in relapse rates in the postpartum period (the 3 months after delivery), so that overall pregnancy is largely neutral in terms of its effect on relapse rate. Previous reports of postpartum deterioration in MS have not been seen in robust studies, and pregnancy does not appear to affect disease progression.",112,26,0.23214285714285715
9781910797273,chp7,Relapses during pregnancy should be treated on a case-by-case basis with specialist input.,"Treating relapses in pregnancy. There are no guidelines on the treatment of relapse in pregnancy. All treatment options should be discussed on a case-by-case basis. Although there is limited information on the effect of steroid therapy in pregnancy, steroids are generally considered to be relatively safe. The placenta is responsible for the metabolism of methylprednisolone, thus minimizing fetal exposure.",78,19,0.24358974358974358
9781910797273,chp7,"Ideally, pregnancy in patients with MS should be planned and managed with both obstetric and neurological input.","Interferon beta. While there are limited data, pregnancy registers do not suggest a teratogenic effect or increased rate of spontaneous abortion with interferon beta (IFNbeta) in humans. Patients who become pregnant while taking IFNbeta therapy are advised to stop treatment for at least the remainder of the first trimester, as the effects on development of the fetal immune system are unknown. Pregnancy should be planned and the potential risks and benefits of therapy discussed in advance. Whilst cessation of IFNbeta before conception is recommended, the practice varies, with some centers discontinuing treatment before conception, some discontinuing it at the point when pregnancy is confirmed, and some continuing throughout pregnancy.",138,21,0.15217391304347827
9781910797273,chp7,"Although data are limited, there is no evidence of teratogenicity with interferon beta (IFNbeta), glatiramer acetate or natalizumab therapy.","Interferon beta. While there are limited data, pregnancy registers do not suggest a teratogenic effect or increased rate of spontaneous abortion with interferon beta (IFNbeta) in humans. Patients who become pregnant while taking IFNbeta therapy are advised to stop treatment for at least the remainder of the first trimester, as the effects on development of the fetal immune system are unknown. Pregnancy should be planned and the potential risks and benefits of therapy discussed in advance. Whilst cessation of IFNbeta before conception is recommended, the practice varies, with some centers discontinuing treatment before conception, some discontinuing it at the point when pregnancy is confirmed, and some continuing throughout pregnancy. Glatiramer acetate. Similarly, limited data suggest neither an increased risk of spontaneous abortion nor a teratogenic effect of glatiramer acetate. In patients with active relapsing MS, maintenance of glatiramer acetate through pregnancy has been advocated by some groups; the risk-benefit analysis should be assessed and discussed with the individual patient.",212,38,0.1792452830188679
9781910797273,chp7,"There are insufficient data regarding fingolimod and dimethyl fumarate in pregnancy; however, cessation of these therapies before conception is recommended.","Other disease-modifying therapies. There are limited data regarding fingolimod and dimethyl fumarate in pregnancy; however, recommendations mandate cessation of treatment before conception. Teriflunomide is a potential teratogen and must not be used in pregnancy or by men or women of childbearing potential who are not using reliable contraception. The drug has a long half-life, and in the case of inadvertent pregnancy (or plans to fall pregnant) on therapy, rapid 'wash out' with cholestyramine or activated charcoal is required. Azathioprine is considered relatively safe in pregnancy, but methotrexate is associated with an increased risk of congenital malformations and spontaneous abortion and should be avoided. These therapies were once widely adopted as MS treatments in Europe, but are now only rarely used following the introduction of natalizumab and fingolimod.",183,29,0.15846994535519127
9781910797273,chp7,Methotrexate and teriflunomide must not be used before conception in male or female patients. Teriflunomide has a long half-life and must be appropriately 'washed out' before conception.,"Teriflunomide is a potential teratogen and must not be used in pregnancy or by men or women of childbearing potential who are not using reliable contraception. The drug has a long half-life, and in the case of inadvertent pregnancy (or plans to fall pregnant) on therapy, rapid 'wash out' with cholestyramine or activated charcoal is required. Azathioprine is considered relatively safe in pregnancy, but methotrexate is associated with an increased risk of congenital malformations and spontaneous abortion and should be avoided. These therapies were once widely adopted as MS treatments in Europe, but are now only rarely used following the introduction of natalizumab and fingolimod. Breast-feeding. The ability to breast-feed is typically not affected in patients with MS and does not affect the risk of relapse in the postpartum period. The relative concentrations of DMTs within breast milk are not known, but it is generally recommended not to use these drugs whilst breast-feeding. Short courses of corticosteroids are not contraindicated during breast-feeding. In patients with clinically or radiologically active disease in the postpartum period, consideration should be given to cessation of breast-feeding and re-institution of DMT.",264,47,0.17803030303030304
9781910797273,chp7,The ability to breast-feed is not affected unless the patient has significant motor impairment. Disease-modifying therapies should in general not be used when breast-feeding.,"Azathioprine is considered relatively safe in pregnancy, but methotrexate is associated with an increased risk of congenital malformations and spontaneous abortion and should be avoided. These therapies were once widely adopted as MS treatments in Europe, but are now only rarely used following the introduction of natalizumab and fingolimod. Breast-feeding. The ability to breast-feed is typically not affected in patients with MS and does not affect the risk of relapse in the postpartum period. The relative concentrations of DMTs within breast milk are not known, but it is generally recommended not to use these drugs whilst breast-feeding. Short courses of corticosteroids are not contraindicated during breast-feeding. In patients with clinically or radiologically active disease in the postpartum period, consideration should be given to cessation of breast-feeding and re-institution of DMT.",185,33,0.1783783783783784
9781910797273,chp7,"The oral contraceptive pill (OCP) does not affect MS, and MS does not affect the efficacy of the OCP.","Breast-feeding. The ability to breast-feed is typically not affected in patients with MS and does not affect the risk of relapse in the postpartum period. The relative concentrations of DMTs within breast milk are not known, but it is generally recommended not to use these drugs whilst breast-feeding. Short courses of corticosteroids are not contraindicated during breast-feeding. In patients with clinically or radiologically active disease in the postpartum period, consideration should be given to cessation of breast-feeding and re-institution of DMT.",116,25,0.21551724137931033
9781910797273,chp7,Thromboprophylaxis should be considered in patients with MS who have significant immobility.,"Breast-feeding. The ability to breast-feed is typically not affected in patients with MS and does not affect the risk of relapse in the postpartum period. The relative concentrations of DMTs within breast milk are not known, but it is generally recommended not to use these drugs whilst breast-feeding. Short courses of corticosteroids are not contraindicated during breast-feeding. In patients with clinically or radiologically active disease in the postpartum period, consideration should be given to cessation of breast-feeding and re-institution of DMT. Other comorbidities associated with pregnancy. As pregnancy is a prothrombotic state, appropriate thromboprophylaxis should be considered in patients with significant immobility.",155,21,0.13548387096774195
9781910797273,chp7,"In general, IFNbeta and glatiramer acetate therapy should be stopped before pregnancy is confirmed. In patients with highly active MS, an argument can be made to maintain glatiramer acetate provided the patient is cognizant of the potential risks.","Relapse therapy. Corticosteroid therapy is used for treatment of disabling relapses. Although no trial data support the use of steroids in children, intravenous or oral methylprednisolone is used empirically up to a maximum of 1 g per dose for 3-5 days. Intravenous immunoglobulin (Ig) has been used, with case series stating benefit from doses of 2 g/kg administered over 2-5 days. Anecdotal reports suggest that, as in adults, plasma exchange can be useful in severe steroid-refractory relapses. Disease-modifying therapies. Conventional DMTs (IFNbeta and glatiramer acetate) are reported, in small open-label studies, to confer a similar benefit on relapse rate to that observed in adults (see pages 80 -). Similar side effects are also observed in many of the DMTs as compared with adult-onset MS, although liver dysfunction related to the use of IFNbeta may be more common in children. As in adults, glatiramer acetate can cause self-limiting episodes of flushing and tachycardia in some children, and the patient and their family should be aware of this benign though often frightening side effect.",261,54,0.20689655172413793
9781910797273,chp8,"Counseling can be helpful for all people with multiple sclerosis (MS): it will involve explaining the nature of the disease, the risks and benefits of therapy and the effect MS will have on all aspects of life, including career, family, travel and insurance.","Lifestyle considerations and the multidisciplinary team. Multiple sclerosis (MS) is a clinically heterogeneous condition, and the advice given must be tailored to the individual patient's disease phenotype, medical history and social circumstance. Counseling should not only involve what we know about the disease but also what effect MS will have on all aspects of life, including career, family, travel, insurance and the concerns raised by having a new diagnosis of MS. Patients are keen to know whether their life expectancy will be affected and whether the disease is transmissible to their children (Table 8.1). The diagnosis may affect their employment status, whether they decide to have children and where they decide to live. Patients often ask if they could have avoided the disease by changing their behavior in any way. The multidisciplinary team. Neurologist. The medical team is important in coordinating multidisciplinary patient care. It is the neurologist's role to make a firm diagnosis as early as possible in the course of the disease. Once the diagnosis has been established, the neurologist must ensure that the patient is fully informed of all approved treatment options and understands both their benefits and risks. Neurologists are also well-positioned to provide patients with the opportunity to participate in local clinical trials of emerging disease-modifying and symptomatic therapies. Neurologists strive to understand more about the pathophysiology and evolution of MS, and translate this information to the clinical care of their patients. Studies show that patients with MS do not always seek specialty care; this results in lower use of disease-modifying therapies (DMTs) and higher disability.",325,52,0.16
9781910797273,chp8,"Common concerns raised by patients include life expectancy, heritability of the disease, long-term planning and effect of pregnancy.","Multiple sclerosis (MS) is a clinically heterogeneous condition, and the advice given must be tailored to the individual patient's disease phenotype, medical history and social circumstance. Counseling should not only involve what we know about the disease but also what effect MS will have on all aspects of life, including career, family, travel, insurance and the concerns raised by having a new diagnosis of MS. Patients are keen to know whether their life expectancy will be affected and whether the disease is transmissible to their children (Table 8.1). The diagnosis may affect their employment status, whether they decide to have children and where they decide to live. Patients often ask if they could have avoided the disease by changing their behavior in any way.",145,24,0.16551724137931034
9781910797273,chp8,Healthcare teams need to stress the importance of overall health and wellness in MS given the known consequences of comorbidities in patients.,"Neurologist. The medical team is important in coordinating multidisciplinary patient care. It is the neurologist's role to make a firm diagnosis as early as possible in the course of the disease. Once the diagnosis has been established, the neurologist must ensure that the patient is fully informed of all approved treatment options and understands both their benefits and risks. Neurologists are also well-positioned to provide patients with the opportunity to participate in local clinical trials of emerging disease-modifying and symptomatic therapies. Neurologists strive to understand more about the pathophysiology and evolution of MS, and translate this information to the clinical care of their patients. Studies show that patients with MS do not always seek specialty care; this results in lower use of disease-modifying therapies (DMTs) and higher disability.",164,27,0.16463414634146342
9781910797273,chp8,"A multidisciplinary team is important for the coordination of patient care, and comprises neurologists, primary care providers, specialist nurses, physician assistants, physiotherapists, speech and language therapists, occupational therapists, dietitians, social workers, psychologists and continence nurses.","Neurologist. The medical team is important in coordinating multidisciplinary patient care. It is the neurologist's role to make a firm diagnosis as early as possible in the course of the disease. Once the diagnosis has been established, the neurologist must ensure that the patient is fully informed of all approved treatment options and understands both their benefits and risks. Neurologists are also well-positioned to provide patients with the opportunity to participate in local clinical trials of emerging disease-modifying and symptomatic therapies. Neurologists strive to understand more about the pathophysiology and evolution of MS, and translate this information to the clinical care of their patients. Studies show that patients with MS do not always seek specialty care; this results in lower use of disease-modifying therapies (DMTs) and higher disability. General practitioner/family doctor. The primary care provider will be able to coordinate all the threads of care for a patient with MS throughout their life. They will have access to allied healthcare professionals, and will be able to refer to specialists (neurologist, urologist, obstetrician, psychiatrist, rehabilitation therapist) for the wide range of symptoms and concerns that patients may have at different stages of the disease. As care providers over a lifetime, they have a unique insight into the needs of the individual. Good communication within the healthcare support team will ensure a well-integrated approach to the management of MS and its resulting morbidity. It is vital patients are provided with consistent messages, including guidance on preventative care, smoking cessation, stress management, regular exercise and healthy nutrition.",322,55,0.17080745341614906
9781910797273,chp8,"Advanced practice clinicians (APCs) are a reliable source of information about all aspects of the condition. They have an important role in helping patients recognize the signs and symptoms of relapse, providing practical advice on living with MS and providing a link with other services.","Advanced practice clinician. In large centers, the advanced practice clinician (APC), who could be a specialist nurse or physician's assistant, has become an integral and invaluable member of the multidisciplinary team. APCs are a reliable source of information about all aspects of MS, and can provide patients with practical advice on living with the condition. The APC can counsel people who have recently received a diagnosis of MS, and they are usually easy to contact when questions arise outside the consultation. After diagnosis, APCs are often the first port of call when a patient is concerned that they may be having a relapse. They can provide prompt clinical assessment and, where necessary, review. The MS specialist APC is well placed to explain the practical aspects associated with all DMTs. Traditionally, training in the use of injectable therapies has been a principal role for the MS nurse. In the modern therapeutic era, the APC also supervises patients who receive infusions, and coordinates and runs first-dose clinics for fingolimod. They can be called upon if adverse effects occur, or if patients are having difficulty adhering to a particular therapy. Finally, the APC helps patients deal with the social impact of MS and can provide a link to other services such as social workers and clinical psychologists.",264,51,0.19318181818181818
9781910797273,chp8,Concerns about employment can become a great source of stress. Employers have an obligation to aid people with MS as much as possible to remain in employment. Functional capacity evaluation and neuropsychological testing can help determine a person's employability.,"Maintaining a place in education and the workforce has numerous financial, physical and psychological benefits. It is therefore important that people with MS receive appropriate information and support to assist them to stay in education and employment for as long as possible. It is important to highlight to patients that they are not obliged to disclose their illness to everyone at work, according to local laws, but as MS can affect physical, cognitive and emotional functioning, they are likely to need support in the workplace as the disease progresses. The specific diagnosis does not need to be disclosed to employers at interview (although disability will usually need to be). In the UK, for example, employers must be informed of the diagnosis if employment is in the armed forces, on a plane or on a ship. Some employment contracts specifically request disclosure of diagnoses like MS, as most employers need to know about specific disabilities in order to adhere to the relevant laws in their country. Employers have an obligation to aid employees as much as possible to remain in employment. Functional capacity evaluation and neuropsychological testing can help determine the patient's limitations and strengths in relation to their condition to help plan for periods of disability. Even if there is little disability at the time of employment, employers will need to allow time off to recover from relapses or to attend hospital appointments. If 'reasonable adjustments' can be made to the workplace setting to enable the employee to continue working, in many countries the employer is required by law to make these. The nature of these adjustments will depend on the individual circumstances and what is considered 'reasonable' by both the employee and the employer. Such adjustments could include.",324,49,0.15123456790123457
9781910797273,chp9,"Natural history studies suggest that life expectancy of people with multiple sclerosis (MS) is reduced by 6-7 years compared with unaffected individuals, and comorbidities further increase the risk of mortality in people with MS.","Multiple sclerosis (MS) can almost span a lifetime: average time from disease onset to death is 48 years. Natural history studies suggest that people with MS have a reduced life expectancy of approximately 6-7 years, and the mortality rate is three times higher than that of the general population. Women tend to survive longer than men, unless they have the primary progressive subtype, in which case they do less well than men. Disease onset at a younger age is also associated with longer survival. Comorbidities increase the risk of mortality from MS. Use of disease-modifying therapies (DMTs; see Chapter 5) may reduce time to secondary progression, and there is soft evidence of a positive effect on all-cause mortality from the long-term (21-year) follow up of patients randomized to interferon beta (IFNbeta)-1b in the pivotal Phase III trial of that therapy.",183,43,0.23497267759562843
9781910797273,chp9,The average time from disease onset to mortality is 48 years.,"Multiple sclerosis (MS) can almost span a lifetime: average time from disease onset to death is 48 years. Natural history studies suggest that people with MS have a reduced life expectancy of approximately 6-7 years, and the mortality rate is three times higher than that of the general population. Women tend to survive longer than men, unless they have the primary progressive subtype, in which case they do less well than men. Disease onset at a younger age is also associated with longer survival. Comorbidities increase the risk of mortality from MS.",109,12,0.11009174311926606
9781910797273,chp9,Advance planning can help people with MS achieve the control they need in late disease.,"Multiple sclerosis (MS) can almost span a lifetime: average time from disease onset to death is 48 years. Natural history studies suggest that people with MS have a reduced life expectancy of approximately 6-7 years, and the mortality rate is three times higher than that of the general population. Women tend to survive longer than men, unless they have the primary progressive subtype, in which case they do less well than men. Disease onset at a younger age is also associated with longer survival. Comorbidities increase the risk of mortality from MS.",109,17,0.1559633027522936
9781910797273,chp9,Early introduction of disease-modifying therapy may positively affect long-term mortality.,"The course of MS is highly variable and often unpredictable in the early relapsing phase of the disease. However, secondary progression ensues in up to 75% of patients with relapsing remitting disease and is marked by inexorable decline that is unaffected by current approved treatments. Some medications under review may decrease disease progression, potentially reducing long-term disability and mortality risk.",75,16,0.21333333333333335
9781910797273,chp9,Palliative care offers patients improved quality of life in the later stages of the disease.,"Early intervention from the palliative care team can be highly beneficial to the patient's quality of life. As far as possible, control over the effects of the disease process should remain with the patient. The World Health Organization states that palliative care is an approach that improves the quality of life of patients and families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems - physical, psychosocial and spiritual. Spiritual beliefs are not necessarily related to religion, although for many people their faiths, beliefs and practices will be important. Spirituality has many facets; for example, questions concerning identity, the meaning of life, suffering and death, and reconciliation and forgiveness. While it is important that any needs in this respect are identified and provided for, it is not always appropriate within the healthcare setting. There may be a role for local chaplaincy services (for any religion) or support from psychological services.",203,18,0.08866995073891626
9781910797297,chp1,"Mycosis fungoides (MF) and Szary syndrome (SS) account for approximately 65% of cutaneous T-cell lymphomas (CTCLs); lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL) make-up 25%, and the remaining 10% are rare diseases.","Over the past few years much work has been done in the field of cutaneous T-cell lymphoma (CTCL) in terms of the clinical, pathological, biological and etiologic understanding of this diverse group of diseases. Nevertheless, controversy still exists with respect to the classification, biology and behavior of these neoplasms. Further advances in research, technology and treatment will inevitably increase our understanding. WHO classification by type. The term cutaneous T-cell lymphoma (CTCL) encompasses a wide range of disorders. The most common are mycosis fungoides (MF) and Szary syndrome (SS), which account for approximately 65% of all CTCLs (Figure 1.1). CD30+ lymphoproliferative disorders, such as lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL), make up around 25% of all CTCLs. The remaining 10% are the rarest of the CTCLs, and are listed in Table 1.1. The atypical cells in CTCL are usually CD4+ T cells, but may be CD8+; the latter is more common in children but is also seen in some adults. When the malignant cells are CD8+, the clinical presentation may be of hypopigmented patches rather than scaly red patches. In 2005 and 2008, an extensive classification of CTCL was published by the World Health Organization (WHO). However, following research advances in biological and clinical behavior, the advisory committee recently released the initial 2016 Revision of the WHO Classification of Lymphoid Neoplasms; the final version of this classification is expected later in 2016. Although this revision contains minimal alterations to the 2008 classification (see Table 1.1), it helps to further define this group of diseases.",380,78,0.20526315789473684
9781910797297,chp1,"Clinicopathological correlation is crucial in the diagnosis of CTCLs, as the histological findings do not always correspond with the clinical behavior, and many benign dermatoses can mimic the histopathology of MF and other CTCLs.","The atypical cells in CTCL are usually CD4+ T cells, but may be CD8+; the latter is more common in children but is also seen in some adults. When the malignant cells are CD8+, the clinical presentation may be of hypopigmented patches rather than scaly red patches. In 2005 and 2008, an extensive classification of CTCL was published by the World Health Organization (WHO). However, following research advances in biological and clinical behavior, the advisory committee recently released the initial 2016 Revision of the WHO Classification of Lymphoid Neoplasms; the final version of this classification is expected later in 2016. Although this revision contains minimal alterations to the 2008 classification (see Table 1.1), it helps to further define this group of diseases. Classification by clinical behavior. Clinicopathological correlation is crucial to the correct diagnosis of CTCL. However, the cytomorphology of T cells often does not correlate with the clinical behavior of the lymphoma, except in rare instances. Clear communication between pathologists and clinicians is needed to combine their knowledge of the clinical behavior with their awareness of the histological and clinical mimics of CTCL, all of which must be carefully reviewed before a definitive diagnosis is established.",254,50,0.1968503937007874
9781910797297,chp1,"CTCL is generally subdivided into neoplasms with indolent and those with aggressive clinical behavior. Indolent forms have a good prognosis and prolonged course, and often lack systemic symptoms. They are usually treated with skin-directed therapies. Aggressive forms have a poor prognosis, and are associated with systemic symptoms that warrant systemic treatment. They generally display a cytotoxic immunophenotype.","Indolent CTCLs generally have a good prognosis and prolonged course, and often lack systemic symptoms. They are usually treated with skin-directed therapies. A number of these patients will progress to advanced/aggressive disease (around 25% of patients with MF) with a higher risk of secondary malignancies, particularly in those with LyP who may develop a systemic lymphoma. As such, all patients with indolent CTCL should be followed up closely for development of lymphadenopathy or systemic symptoms such as fever, weight loss or night sweats suggestive of systemic lymphoma or another cancer type. CTCLs with intermediate/indeterminate clinical behavior include advanced stages of MF (stages IIB-IV), Epstein-Barr virus (EBV)-associated T- and natural killer (NK)-cell lymphoproliferative disorders and a subset of other NK/T-cell disorders that are rare and less well understood at this time. For example, hydroa vacciniforme-like lymphoproliferative disorder has been found to be associated with chronic active EBV infection in pediatric patients. Although it tends to have an indolent course, the disease does progress in some patients, who have an aggressive projection with fevers, hepatosplenomegaly and systemic involvement., Prospective and retrospective studies are continuing to evaluate and further categorize these conditions. Aggressive CTCLs often progress rapidly with extracutaneous involvement, have a poor prognosis and are associated with systemic symptoms. These CTCLs warrant systemic treatment and generally display a cytotoxic immunophenotype. However, both CTCLs with indolent behavior and benign dermatoses (id est vitiligo, lichen planus) can also display a cytotoxic immunohistochemical profile. Therefore, diagnosis cannot be based on a cytotoxic profile alone, again illustrating the need for clinicopathological correlation for these diseases.",397,81,0.2040302267002519
9781910797297,chp1,Patients with CTCL have an increased risk of secondary malignancies.,"Indolent CTCLs generally have a good prognosis and prolonged course, and often lack systemic symptoms. They are usually treated with skin-directed therapies. A number of these patients will progress to advanced/aggressive disease (around 25% of patients with MF) with a higher risk of secondary malignancies, particularly in those with LyP who may develop a systemic lymphoma. As such, all patients with indolent CTCL should be followed up closely for development of lymphadenopathy or systemic symptoms such as fever, weight loss or night sweats suggestive of systemic lymphoma or another cancer type.",123,16,0.13008130081300814
9781910797297,chp1,CTCL is a relatively rare group of diseases with an estimated incidence of 6.4 per million persons.,"Incidence. CTCLs are relatively rare diseases, with an annual age-adjusted incidence of 6.4 per million persons in the USA and similar worldwide. In the USA, the incidence of MF and non-MF has been reported to be 4.5 and 4.0 per million persons, respectively. One study reported a general increase in incidence of 2.9 x 10 -6 per decade between 1973 and 2002, while another reported a relatively stable incidence between 1998 and 2009. Several studies have shown geographic clustering of incidence within the USA, suggesting that environmental or other external etiologic factors have a role in the cause of the disease.",131,21,0.16030534351145037
9781910797297,chp1,"Onset most often occurs around the sixth decade of life in white people, with earlier onset in African-Americans.","Age, sex and ethnicity. In recent years, the Surveillance, Epidemiology and End Results (SEER) databases in the USA have been used to analyze the age-adjusted incidence and survival rates in individuals with CTCL by sex and ethnicity. CTCL primarily presents in white individuals in the sixth decade of life, although the highest incidence in this population is seen in 70-79 year-olds., African-American patients present with CTCL at a younger age than white patients (mean age of 51.5 vs 59.2 years). While the incidence of CTCL rises sharply with age, it also occurs in pediatric and young adult populations.",133,23,0.17293233082706766
9781910797297,chp1,"African-Americans have statistically significant higher incidence of both MF and non-MF CTCL, and often present with more advanced disease.","Age, sex and ethnicity. In recent years, the Surveillance, Epidemiology and End Results (SEER) databases in the USA have been used to analyze the age-adjusted incidence and survival rates in individuals with CTCL by sex and ethnicity. CTCL primarily presents in white individuals in the sixth decade of life, although the highest incidence in this population is seen in 70-79 year-olds., African-American patients present with CTCL at a younger age than white patients (mean age of 51.5 vs 59.2 years). While the incidence of CTCL rises sharply with age, it also occurs in pediatric and young adult populations. The overall incidence of both MF and non-MF CTCL is higher in men than women (Figure 1.2a), with a ratio of 2.2 to 1. African-Americans have a higher incidence of both MF and non-MF than whites, Asian/Pacific islanders and Native Americans (Figure 1.2b). Furthermore, African-Americans and hispanics have a statistically significant greater incidence of presenting at a more advanced stage of both MF and non-MF.",231,27,0.11688311688311688
9781910797297,chp1,No familial link in CTCL has been identified.,"Epidemiological studies have found an increased incidence of secondary internal malignancies in patients with CTCL, particularly lung carcinoma, colonic adenocarcinoma and non-Hodgkin's lymphoma, which do not appear to be related to therapy. MF is also associated with other lymphomas of both T-cell (LyP, nodal CD30+ anaplastic large cell lymphoma) and B-cell (Hodgkin's disease, chronic lymphocytic leukemia) origins. Furthermore, in some patients with a secondary T-cell neoplasm, the same T-cell clone has been identified in both lymphomas, indicating that they are derived from the same neoplastic clone.",148,11,0.07432432432432433
9781910797297,chp2,Cutaneous T-cell lymphomas (CTCL) are a rare group of lymphomas that affect the skin.,"The skin is the second most frequent extranodal site, after the gastrointestinal tract, for lymphoma, with an annual incidence of 0.5-1 cases per 100 000 people. - Primary cutaneous lymphomas are defined as lymphomas without evidence of extracutaneous spread. They can be divided into primary cutaneous T-cell lymphoma (CTCL) and B-cell cutaneous lymphoma. CTCL are a rare group of T-cell malignancies primarily involving the skin.",103,23,0.22330097087378642
9781910797297,chp2,Mycosis fungoides (MF) is the commonest type of CTCL and typically presents in the early stages with patches and plaques.,"Early disease. About 70% of patients with classic mycosis fungoides (MF) present with erythematous scaly patches (Figures 2.1 - 2.3) or plaques (Figures 2.4 and 2.5) in a 'sun bathing suit' distribution on non-sun-exposed sites (id est hips, buttocks, groin, lower trunk, axillae and breasts). Early lesions may resolve when exposed to sunlight. Because of the difficulty in diagnosing MF, patients are often treated for eczema or psoriasis for months to years before the correct diagnosis is made. Hypopigmented MF is more common in children and black skin, and the malignant T cells are more frequently CD8+. These early-stage lesions consist of atypical T lymphocytes that infiltrate the skin and show affinity for the epidermis (epidermotropism) (see Chapter 3). Some patches may become infiltrative and evolve into raised well-demarcated plaques.",210,31,0.14761904761904762
9781910797297,chp2,"Early-stage MF has an excellent prognosis and long survival (10+ years), whilst the advanced stages are rapidly progressive in 1-4 years.","In addition to the physical disfiguration associated with these skin lesions, patients with MF experience itching (pruritus) and pain, which generally worsens in more advanced disease, all of which has a negative effect on quality of life. Patients with limited patches and plaques (covering less than 10% of the body surface area) may have near-normal survival. About 25% of patients will progress to advanced disease, with survival of 10-25 years. Advanced disease. About 30% of patients with MF develop tumors (Figures 2.6 - 2.11) or erythroderma (Figures 2.12 and 2.13). Patients with these late-stage lesions tend to have rapidly progressive disease and a poor survival of 1-4 years, with spread to lymph nodes or internal organs (viscera).",170,30,0.17647058823529413
9781910797297,chp2,"Early-stage MF may progress to advanced disease with skin tumors and blood involvement, with lymph node or visceral spread. Some patients (30%) present with advanced disease.","Folliculotropic mycosis fungoides (FMF) is the term used when the patient presents with follicular lesions, id est patches, plaques or tumors with follicular accentuation (Figures 2.14 and 2.15). These folliculotropic lesions may present with cysts, comedones (Figure 2.16) or milia (Figure 2.17), often with a predilection for the head and neck. The histology of these lesions shows atypical lymphocytes infiltrating the hair follicles (see Chapter 3). Alopecia may occur; in fact, the combination of facial plaques and eyebrow alopecia is pathognomonic of FMF (Figure 2.18). Folliculotropic MF may present with lesions limited to patches of MF showing follicular accentuation +/ alopecia, +/ cysts, or with thick plaques and/or tumors with follicular accentuation often showing a predilection to the head and neck. Patients with lesions limited to follicular patches may have a similar prognosis to classical MF whilst those with dense follicular plaques have a poorer prognosis similar to those with advanced tumor stage classical MF.",252,33,0.13095238095238096
9781910797297,chp2,"Cutaneous lymphomas may be CD30+, and this group forms a spectrum from lymphomatoid papulosis with relapsing and remitting lesions to large cell anaplastic lymphomas that may grow rapidly. These types of CTCL have an excellent prognosis and should be differentiated from transformed MF, which also has large atypical CD30+ cells.","Folliculotropic mycosis fungoides (FMF) is the term used when the patient presents with follicular lesions, id est patches, plaques or tumors with follicular accentuation (Figures 2.14 and 2.15). These folliculotropic lesions may present with cysts, comedones (Figure 2.16) or milia (Figure 2.17), often with a predilection for the head and neck. The histology of these lesions shows atypical lymphocytes infiltrating the hair follicles (see Chapter 3). Alopecia may occur; in fact, the combination of facial plaques and eyebrow alopecia is pathognomonic of FMF (Figure 2.18). Folliculotropic MF may present with lesions limited to patches of MF showing follicular accentuation +/ alopecia, +/ cysts, or with thick plaques and/or tumors with follicular accentuation often showing a predilection to the head and neck. Patients with lesions limited to follicular patches may have a similar prognosis to classical MF whilst those with dense follicular plaques have a poorer prognosis similar to those with advanced tumor stage classical MF. Pagetoid reticulosis is a variant of MF that presents as a solitary patch or plaque, usually located on the extremities and acral sites. It rarely progresses and has a good prognosis. Granulomatous slack skin is a subtype of MF that presents with redundant folds of skin, typically in the flexor sites.",324,75,0.23148148148148148
9781910797297,chp2,Szary syndrome is the erythrodermic form of CTCL that presents in advanced disease with leukemic blood involvement.,"Szary syndrome (SS) is a form of CTCL that presents as advanced disease with erythroderma (Figure 2.19), lymphadenopathy and peripheral blood involvement. This leukemic form of CTCL is typically aggressive with a median survival of just 3 years. Patients experience extreme pruritus and often succumb to infection. The face may become infiltrated with atypical lymphocytes, resulting in thickening of the facial skin folds, the characteristic leonine facies (Figure 2.20). Nail dystrophy is often striking (Figure 2.21) and can affect both the hands and feet, as can hyperkeratosis. Ectropion is a common finding in these patients as well.",152,29,0.19078947368421054
9781910797297,chp2,"Other forms of CTCL are rare and include subcutaneous panniculitis-like lymphoma, extranodal natural killer/T-cell lymphoma and primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.","Lymphomatoid papulosis (LyP) is a self-resolving form of primary CD30+ CTCL that usually occurs in early adulthood. It presents with recurrent nodules and papules, typically less than 1 cm in diameter, at distant sites that become necrotic before resolving to form an atrophic scar (Figure 2.23). All subtypes of LyP have an almost identical clinical presentation, but the histology is varied (see Chapter 4). Adult T-cell leukemia/lymphoma (ATLL) is a T-cell neoplasm associated with the human T-cell leukemia virus 1 (HTLV-1). It most commonly presents as erythroderma, widespread papules and plaques and papular erythroderma. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is divided into those derived from alphabeta T cells and those from gamma T cells. Given their clinical, prognostic and immunophenotypic differences these are now considered two separate entities: SPTCL and primary cutaneous gamma T-cell lymphoma.",236,55,0.2330508474576271
9781910797297,chp3,"Malignant T cells in mycosis fungoides (MF) are derived from skin-homing resident effector memory T cells, while in Szary syndrome (SS), the malignant cells are derived from central memory T cells.","Pathophysiology. MF lacks the lymph-node homing molecules chemokine (C-C motif) receptor type 7 (CCR7) and L-selectin, and the differentiation marker CD27. Conversely, CCR4 and cutaneous lymphocyte antigen (CLA) are strongly expressed, which is a phenotype of skin-homing resident effector memory T cells. CLA, the ligand for E-selectin, is expressed on endothelial cells, and chemokine (C-C motif) ligands 17 and 22 (CCL-17 and CCL-22) assist in cutaneous trafficking. The subsequent CCL-17/CCR4 ligand/receptor interaction signals the recruitment of epidermotropic lymphocytes. Histopathology. Given the significant number of clinical and histological mimics of MF, good clinicopathological correlation is essential for accurate diagnosis in this disease. However, the histopathology of MF can vary greatly, especially with the differing clinical presentations of patches, plaques and tumors (see Chapter 2). In general, MF is characterized by small- to medium-sized T lymphocytes with cerebriform/pleomorphic nuclei within the epidermis, known as epidermotropism (Figure 3.2). The most specific finding tends to be intraepidermal collections of lymphocytes known as Pautrier's microabscesses (Figure 3.3). These are rare in early-stage MF, but common in plaque-stage disease.",309,50,0.16181229773462782
9781910797297,chp3,"Histopathology of MF is characterized by small- to medium-sized T lymphocytes with epidermotropic cerebriform/pleomorphic nuclei, Pautrier's microabscesses, haloed lymphocytes along the dermal-epidermal junction and papillary dermal fibrosis.","Histopathology. Given the significant number of clinical and histological mimics of MF, good clinicopathological correlation is essential for accurate diagnosis in this disease. However, the histopathology of MF can vary greatly, especially with the differing clinical presentations of patches, plaques and tumors (see Chapter 2). In general, MF is characterized by small- to medium-sized T lymphocytes with cerebriform/pleomorphic nuclei within the epidermis, known as epidermotropism (Figure 3.2). The most specific finding tends to be intraepidermal collections of lymphocytes known as Pautrier's microabscesses (Figure 3.3). These are rare in early-stage MF, but common in plaque-stage disease. Early patch-stage disease is most often composed of a patchy lichenoid dermal infiltrate, lymphocytes tagging along the dermal-epidermal junction, basal layer lymphocytes with perinuclear halos and fibrosis of the papillary dermis (Figures 3.4 - 3.6). Epidermotropic lymphocytes, especially those larger than dermal lymphocytes, are a helpful diagnostic clue. However, these may be absent if recent topical treatments have been initiated (Figure 3.7). Caution must be taken to avoid overcalling epidermotropic lymphocytes in areas of spongiosis, which is a common finding in inflammatory diseases. In inflammatory processes, this is best described as exocytosis of lymphocytes rather than epidermotropism, given the 'buzz word' association of the latter with MF. Haloed lymphocytes are also helpful in differentiating inflammatory diseases from MF. Furthermore, Langerhans cells and eosinophils are not an uncommon histological finding in MF.",367,63,0.17166212534059946
9781910797297,chp3,"Large cell transformation can occur in plaque- and tumor-stage disease. These cells are more than 4 times the size of a normal lymphocyte and must account for more than 25% of the atypical infiltrate. They can be either CD30+ or CD30-, with the latter leading to a poorer prognosis.","Plaque-stage disease. The lichenoid infiltrate is more dense and continuous in this later stage of disease (Figures 3.8 and 3.9) compared with the patchy infiltrate seen in earlier stages of MF. Pautrier's microabscesses are usually more readily identified (see Figure 3.3). Tumor-stage disease is characterized by a dense, nodular to diffuse, dermal lymphocytic infiltrate that can extend into the subcutis (Figure 3.10). Epidermotropism may be lost, and the lymphocytes can be much more varied in size and shape (Figure 3.11). Large cell transformation (id est cells that are more than 4 times the size of a normal lymphocyte) has been detected in up to 50% of patients with advanced-stage tumors. By definition, large cell transformation is present if more than 25% of the dermal infiltrate is composed of large pleomorphic, anaplastic or immunoblastic cells (Figure 3.12). Large cell transformation may be either CD30+ or CD30-, with the latter portending a poorer prognosis (Figure 3.13). The differential diagnosis would also include primary cutaneous anaplastic large cell lymphoma (PC-ALCL), therefore clinical history is needed in order to establish this diagnosis. However, PC-ALCL is defined by the presence of 75% or more CD30+ anaplastic cells, and IRF4 translocations occur in PC-ALCL.",306,64,0.20915032679738563
9781910797297,chp3,"Tumor-stage MF has a more dense, diffuse and nodular infiltrate of atypical lymphocytes and can lack epidermotropism.","Tumor-stage disease is characterized by a dense, nodular to diffuse, dermal lymphocytic infiltrate that can extend into the subcutis (Figure 3.10). Epidermotropism may be lost, and the lymphocytes can be much more varied in size and shape (Figure 3.11). Large cell transformation (id est cells that are more than 4 times the size of a normal lymphocyte) has been detected in up to 50% of patients with advanced-stage tumors. By definition, large cell transformation is present if more than 25% of the dermal infiltrate is composed of large pleomorphic, anaplastic or immunoblastic cells (Figure 3.12). Large cell transformation may be either CD30+ or CD30-, with the latter portending a poorer prognosis (Figure 3.13). The differential diagnosis would also include primary cutaneous anaplastic large cell lymphoma (PC-ALCL), therefore clinical history is needed in order to establish this diagnosis. However, PC-ALCL is defined by the presence of 75% or more CD30+ anaplastic cells, and IRF4 translocations occur in PC-ALCL.",240,31,0.12916666666666668
9781910797297,chp3,"With all cutaneous T-cell lymphomas (CTCLs), histopathology and clinical correlation is crucial in reaching the diagnosis.","CD8+ predominant cytotoxic cases also exist (Figure 3.20). These include CD8+ MF with a cytotoxic phenotype as well as the somewhat controversial entity of hypopigmented MF. Early-stage MF can present with CD8+ predominance in up to 20% of cases. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, and gamma/ T-cell lymphoma are also CD8+ predominant conditions. Furthermore, the cytotoxic markers T-cell intracellular antigen (TIA)-1, granzyme-B and perforin are positive in these cases. However, these markers can also be positive in indolent diseases such as MF, LyP, PC-ALCL and SPTCL. Clinical correlation is necessary to rule out the clinically aggressive cytotoxic lymphomas.",199,27,0.135678391959799
9781910797297,chp3,"Patients with early patch-stage MF generally do not need full systemic work-up; however, patients with plaque- and tumor-stage MF and SS need complete systemic work-up performed for staging.","In early patch-stage disease, a clinical assessment of body surface area and lymph node examination is generally all that is needed for staging (see Chapter 5). Some authorities perform flow cytometry even in patients with patch-stage disease, though others feel this is not necessary. If lymph nodes are fixed, clustered and/or greater than 1.5 cm, a nodal biopsy is warranted. In early patch-stage disease, the histology results and clinical presentation will determine whether a subsequent systemic work-up should be performed. On the other hand, patients with plaques, tumors and erythroderma should undergo a full systemic work-up, including CBC, LDH, ultrasonography of suspected enlarged lymph nodes, CT or positron emission tomography (PET-CT) of the chest, abdomen and pelvis, and flow cytometry (discussed in further detail below). A bone marrow biopsy should also be considered.",190,41,0.21578947368421053
9781910797297,chp3,"Both MF and SS usually display a CD3+, CD4+, CD7-, CD8- immunophenotype; however, CD8+ predominant cases of MF do exist.","Immunophenotype. As mentioned previously, unlike MF, SS cells have a central memory T-cell phenotype associated with CCR7/L-selectin and CD27, and a Th2 cytokine profile with expression of IL-4, IL-5 and IL-10. Although SS has a similar T-helper immunoprofile to MF (id est CD3+, CD4+, CD7-, CD8- on formalin fixed paraffin embedded tissues), in contrast to MF, SS is also associated with a T-follicular helper phenotype (PD-1+, BCL-6+, CXCL-13+). Interestingly, T-follicular helper phenotypes are also associated with other systemic T-cell processes such as angioimmunoblastic T-cell lymphoma and some peripheral T-cell lymphomas.",175,35,0.2
9781910797297,chp3,"T-cell receptor polymerase chain reacton (TCR PCR) is a useful ancillary test in the diagnosis of MF, SS and other CTCLs. It is not 100% specific; however, in the correct clinical and histopathological setting it can be useful in determining monoclonality of the malignant lymphocytes. Matching clones identified from different samples are more useful in the diagnosis.","T-cell receptor polymerase chain reaction. To date, the use of TCR PCR to identify monoclonal rearrangements of lymphocytes has been a mainstay of practice (although some authors feel it should not be used in early disease). Up to 80-90% of cases of MF are shown to have clonal populations for beta and/or gamma genes (Figure 3.24), although this may only be 50-60% in early disease. However, T-cell clonality is not specific to MF. Autoimmune disorders and other inflammatory processes can also have clonal T-cell populations. Distinguishing between CTCL and inflammatory disorders has a sensitivity of 78% and specificity of 74%. Other pitfalls of TCR PCR include difficulty in interpreting oligoclonal peaks and clonal heterogeneity, false negative results due to primer annealing and other technical issues, and false positive results due to preferential amplification with limited lymphoid populations. For these reasons, duplicate analyses are recommended to identify definitive clonality. TCR PCR can be particularly helpful if the histopathology is non-diagnostic or if there is a clinicopathological mismatch. Finding matching clones in separate cutaneous biopsies and/or blood samples is very beneficial in diagnosing the more clinically and histologically challenging cases. Finding clonality on TCR PCR is particularly crucial to diagnosis and prognosis when determining if a lymph node has tumor involvement or whether it is dermatographic/reactive in nature. It is also crucial in the diagnosis of SS, although clonal studies may be negative in early SS and the presence of a 'benign' positive TCR clone in the peripheral blood of an elderly individual can occur. With this in mind, the presence of matching clones in the blood and skin are more diagnostically informative and specific for a diagnosis of SS. Next generation sequencing/high throughput sequencing (NGS/HTS) may eventually replace TCR PCR, although it is too early to know for certain. A recent study showed that this platform more accurately diagnosed all stages of CTCL and, perhaps more importantly, helped to distinguish CTCL from benign inflammatory conditions. The decrease and eradication of clonal populations seen on NGS/HTS has also been used to identify treatment response. Multiple centers are studying this platform for use in earlier diagnosis, and to enhance understanding of the pathophysiology of CTCLs and the role of targeted therapeutics in these malignancies.",504,84,0.16666666666666666
9781910797297,chp4,"The clinically aggressive cytotoxic CTCLs are: primary cutaneous gamma/ lymphoma, primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (Berti's lymphoma) and extranodal NK-T cell lymphoma, nasal type. These diseases have a CD8+ or CD56+ immunophenotype and display T-cell intracellular antigen-1+, granzyme-B+ and perforin+ cytotoxic markers. Full systemic work-up is necessary.","Type B (mycosis fungoides-like). As suggested by the 'MF-like' pattern, LyP type B biopsies show either a wedge-shaped or lichenoid infiltrate of CD3+, CD4+, CD8-, CD30-, small- to medium-sized cerebriform lymphocytes. Epidermotropism is also usually present. Clinical correlation is needed to distinguish LyP type B from MF (Figure 4.2). Type C (ALCL-like), like type A, is characterized by large, atypical, anaplastic CD30+ T cells with a mixed inflammatory infiltrate. However, rather than a wedge-shaped infiltrate, this subtype demonstrates nodules and sheets of anaplastic cells, as seen in PC-ALCL. Clinical correlation is necessary for a definitive diagnosis (Figure 4.3). Type D (cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma-like) is characterized by CD3+, CD4-, CD8+, CD30+ markedly epidermotropic cerebriform T cells with a lichenoid or wedge-shaped dermal infiltrate (Figure 4.4). This histological pattern can be seen in both pagetoid reticulosis and cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. However, CD30+ is generally not seen in either of these differential diagnoses, so demonstration of CD30+ T cells with clinical correlation is crucial for diagnosis of this histological mimic. CD45RO can also be a helpful marker, as this is generally negative in cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Type E (angiotropic/angiodestructive) is characterized by large, anaplastic CD4+/-, CD8+/-, CD30+ and, rarely, CD56+ T cells in a wedge-shaped, lichenoid or diffuse pattern with notable angiotropism. Extravasated erythrocytes and vascular necrosis are prominent features. This pattern can mimic natural killer (NK)/T cell lymphoma, nasal type, and other cytotoxic lymphomas, but LyP type E always demonstrates in situ hybridization negativity for Epstein-Barr virus-encoded RNA-1 (EBER-1).",489,111,0.22699386503067484
9781910797297,chp4,"Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a subcutaneous indolent disorder composed of CD3+, CD8+, betaF-1+ T cells with notable rimming of adipocytes, in contrast to gamma/ lymphoma which is clinically aggressive and comprised of dermal and subcutaneous CD4-/CD8- or rarely CD4+, CD8+ T cells with a gamma/ (TCR-gamma+) phenotype.","Type C (ALCL-like), like type A, is characterized by large, atypical, anaplastic CD30+ T cells with a mixed inflammatory infiltrate. However, rather than a wedge-shaped infiltrate, this subtype demonstrates nodules and sheets of anaplastic cells, as seen in PC-ALCL. Clinical correlation is necessary for a definitive diagnosis (Figure 4.3). Type D (cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma-like) is characterized by CD3+, CD4-, CD8+, CD30+ markedly epidermotropic cerebriform T cells with a lichenoid or wedge-shaped dermal infiltrate (Figure 4.4). This histological pattern can be seen in both pagetoid reticulosis and cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. However, CD30+ is generally not seen in either of these differential diagnoses, so demonstration of CD30+ T cells with clinical correlation is crucial for diagnosis of this histological mimic. CD45RO can also be a helpful marker, as this is generally negative in cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Type E (angiotropic/angiodestructive) is characterized by large, anaplastic CD4+/-, CD8+/-, CD30+ and, rarely, CD56+ T cells in a wedge-shaped, lichenoid or diffuse pattern with notable angiotropism. Extravasated erythrocytes and vascular necrosis are prominent features. This pattern can mimic natural killer (NK)/T cell lymphoma, nasal type, and other cytotoxic lymphomas, but LyP type E always demonstrates in situ hybridization negativity for Epstein-Barr virus-encoded RNA-1 (EBER-1). Lymphomatoid papulosis with rearrangement of 6p25. Although monoclonality has been identified in lesions of LyP, recurrent mutations are rare. However, a variant of LyP has recently shown recurrent rearrangements of the DUSP22-IRF4 locus on 6p25. This has led to recognition of a separate subtype in the revised 2016 WHO classification. The histopathology shows small, cerebriform T cells in the epidermis with larger, atypical, anaplastic CD30+/- T cells in the dermis. Although the histological pattern overlaps with transformed MF, all lesions regress spontaneously.",533,106,0.19887429643527205
9781910797297,chp4,"Other rare secondary cutaneous T-cell processes occur from systemic T-cell lymphomas, and correlation with nodal histopathology is helpful in diagnosis.","Type D (cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma-like) is characterized by CD3+, CD4-, CD8+, CD30+ markedly epidermotropic cerebriform T cells with a lichenoid or wedge-shaped dermal infiltrate (Figure 4.4). This histological pattern can be seen in both pagetoid reticulosis and cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. However, CD30+ is generally not seen in either of these differential diagnoses, so demonstration of CD30+ T cells with clinical correlation is crucial for diagnosis of this histological mimic. CD45RO can also be a helpful marker, as this is generally negative in cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.",179,31,0.17318435754189945
9781910797297,chp4,"Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is composed of sheets of CD30+ activated T cells that comprise more than 75% of the neoplastic cells. Anaplastic lymphoma kinase-1, epithelial membrane antigen and full staging work-up are used to distinguish between a primary cutaneous tumor and cutaneous involvement from nodal ALCL.","Primary cutaneous anaplastic large cell lymphoma is recognized as a separate entity to nodal ALCL, because of the good response PC-ALCL has to treatment and good prognosis. Microscopically, PC-ALCL is composed of dense, diffuse sheets of CD30+ anaplastic T lymphocytes that make up 75% or more of the neoplastic infiltrate (Table 4.2; Figures 4.5 - 4.7). Because lesions are commonly ulcerated, a mixed inflammatory infiltrate of neutrophils, eosinophils and histiocytes may be present as well. Like LyP, the immunophenotype of PC-ALCL is generally CD3+/-, CD4+, CD8-, CD30+, with loss of CD5 and CD7. MF with CD30+ large cell transformation is also composed of CD30+ T cells (see Table 4.2). Clinical correlation is therefore crucial for the accurate diagnosis of PC-ALCL. Other differential diagnoses include LyP type C and nodal ALCL. Histologically, PC-ALCL is generally EMA and ALK-1 negative compared with systemic disease. However, ALK-1 negativity does not rule out nodal disease, and ALK-1+ and EMA+ PC-ALCL have been reported. Unlike patients with LyP, patients with clinical and histological findings for PC-ALCL must undergo full systemic work-up consisting of CBC, LDH, metabolic panel, HIV test and full body CT or PET-CT. Though not specific, molecular rearrangements in DUSP22-IRF4 are more common in PC-ALCL than in MF with large cell transformation. This translocation has also been identified in ALK-1-negative ALCL and LyP with 6p25 rearrangement., The WHO also recognizes ALK-1-positive and ALK-1-negative nodal ALCL as separate entities, given the differing prognostic significance - this is another reason for ensuring full systemic work-up in patients with suspected PC-ALCL.",429,80,0.1864801864801865
9781910797297,chp4,Primary cutaneous small/medium CD4+ T cell lymphoproliferative disorder is an indolent process comprised of diffuse to nodular collections of CD4+ cells that generally present as single papules on the head and neck.,"Primary cutaneous anaplastic large cell lymphoma is recognized as a separate entity to nodal ALCL, because of the good response PC-ALCL has to treatment and good prognosis. Microscopically, PC-ALCL is composed of dense, diffuse sheets of CD30+ anaplastic T lymphocytes that make up 75% or more of the neoplastic infiltrate (Table 4.2; Figures 4.5 - 4.7). Because lesions are commonly ulcerated, a mixed inflammatory infiltrate of neutrophils, eosinophils and histiocytes may be present as well. Like LyP, the immunophenotype of PC-ALCL is generally CD3+/-, CD4+, CD8-, CD30+, with loss of CD5 and CD7. MF with CD30+ large cell transformation is also composed of CD30+ T cells (see Table 4.2). Clinical correlation is therefore crucial for the accurate diagnosis of PC-ALCL. Other differential diagnoses include LyP type C and nodal ALCL. Histologically, PC-ALCL is generally EMA and ALK-1 negative compared with systemic disease. However, ALK-1 negativity does not rule out nodal disease, and ALK-1+ and EMA+ PC-ALCL have been reported.",271,48,0.17712177121771217
9781910797297,chp4,"Multiple histological variants of lymphomatoid papulosis (LyP) exist, although there is no prognostic significance between the subtypes. However, some of the subtypes histologically overlap with other forms of cutaneous T-cell lymphoma (CTCL) and clinical correlation is needed to distinguish these.","This cytotoxic T-cell lymphoma is characterized by marked epidermotropism of atypical CD8+ T cells (Figure 4.15). A nodular to diffuse dermal infiltrate of small- to large-sized pleomorphic T cells and immunoblasts may be present. The striking epidermotropism that is the most prominent feature of this malignancy may be absent in the late stages of the disease (Figure 4.16). The immunophenotype is CD3+, CD4-, CD7+, CD8+, TIA-1+, CD45RA+, CD45RO-, CD56-, EBER-, betaF1+ (Figure 4.17). The main histological differential diagnoses include CD8+ predominant MF, pagetoid reticulosis, and LyP type D. Clinical history is needed in order to distinguish all these entities. The previously recognized entity of generalized pagetoid reticulosis (also known as Ketron-Goodman disease) is now better categorized as primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. There can be a striking overlap with the features of primary cutaneous gamma/ lymphoma. Helpful features to distinguish primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma include lack of interface dermatitis, minimal subcutaneous involvement and an alpha/beta rather than gamma/ phenotype.",292,64,0.2191780821917808
9781910797297,chp5,Advanced-stage skin lesions include tumors and erythroderma.,"Cutaneous T-cell lymphomas (CTCLs) become more frequent with increasing age and have a male predominance (male:female ratio of 2.1:1). - Survival may also be worse with increasing age, which may reflect reduced innate immunity. Incidence also increases with age. Most patients with MF present with early-stage disease characterized by a long disease course but substantial morbidity (pain, pruritus, scaling), and cosmetic disfigurement may be considerable. Thirty percent of patients with MF and all those with Szary syndrome (SS) present with advanced-stage disease, and in addition 25% with early MF will progress to advanced disease.",137,14,0.10218978102189781
9781910797297,chp5,"Some patients with early-stage disease will have near-normal life expectancy, while advanced-stage survival is 1-4 years.","Cutaneous T-cell lymphomas (CTCLs) become more frequent with increasing age and have a male predominance (male:female ratio of 2.1:1). - Survival may also be worse with increasing age, which may reflect reduced innate immunity. Incidence also increases with age. Most patients with MF present with early-stage disease characterized by a long disease course but substantial morbidity (pain, pruritus, scaling), and cosmetic disfigurement may be considerable. Thirty percent of patients with MF and all those with Szary syndrome (SS) present with advanced-stage disease, and in addition 25% with early MF will progress to advanced disease.",137,26,0.1897810218978102
9781910797297,chp5,"Mycosis fungoides (MF) can be categorized according to nine stages, from IA to IVB.","A revised system (Table 5.1) was proposed by the International Society for Cutaneous Lymphoma (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC). This revised staging introduced a blood classification (B0-2) alongside the conventional tumor-node-metastasis (TNM) categories. The TNMB system uses tumor (T1-4), nodal (N0-3), metastasis (M0-1) and blood (B0-2) classification to produce nine stages from IA-IVB and provides prognostic information (see Table 5.1). Stages IA-IIA are considered early-stage disease and IIB-IVB advanced stage.",158,23,0.14556962025316456
9781910797297,chp5,"Stages IA-IIA are considered early-stage disease and have a good prognosis, while stages IIB-IVB are advanced stage disease and progress rapidly.","A revised system (Table 5.1) was proposed by the International Society for Cutaneous Lymphoma (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC). This revised staging introduced a blood classification (B0-2) alongside the conventional tumor-node-metastasis (TNM) categories. The TNMB system uses tumor (T1-4), nodal (N0-3), metastasis (M0-1) and blood (B0-2) classification to produce nine stages from IA-IVB and provides prognostic information (see Table 5.1). Stages IA-IIA are considered early-stage disease and IIB-IVB advanced stage.",158,34,0.21518987341772153
9781910797297,chp5,Early-stage lesions of the skin include patches and plaques.,Patients with early-stage disease tend to have a favorable prognosis of more than a decade and are managed with skin-directed therapy or a 'wait and see'/'expectant' approach. Patients with late-stage disease tend to have an aggressive clinical course and typically need systemic therapy.,60,13,0.21666666666666667
9781910797297,chp5,"Poor prognostic indicators for survival in MF include increasing age, raised lactate dehydrogenase, lymph node involvement and large cell transformation in the skin.","This study tested ten candidate prognostic markers (stage, age, sex, cutaneous histological features of folliculotropism, CD30 positivity, proliferation index, large cell transformation, white blood cell/lymphocyte count, serum lactate dehydrogenase, and presence of identical T-cell clone in blood and skin) with the aim of developing a prognostic index that would identify advanced-stage patients at risk of progression. Each parameter was recorded at diagnosis and tested against overall survival. Four independent prognostic markers were found for worse survival: stage IV disease, age greater than 60 years, large cell transformation and increased LDH. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%) and high risk (28%). This prognostic model may be used to stratify patients with advanced-stage disease who require more aggressive treatments.",196,30,0.15306122448979592
9781910797310,chp1,Tobacco smoke exposure accounts for 90% of all lung cancers. Smoking prevention and cessation represents the major target for prevention of non-small-cell lung cancer (NSCLC).,"Tobacco smoke is the most important cause of lung cancer. Close to 90% of all lung cancers are attributable to cigarette smoke, of which a small proportion are due to second-hand smoke. The number of cigarettes smoked, but more importantly the length of time that patients have smoked for, is proportional to the risk of developing lung cancer. Evidence from the landmark 1964 Surgeon General's report estimated that an average male smoker had a nine- to tenfold increased risk of developing lung cancer compared with a 'never smoker'. For heavy smokers (more than 25 cigarettes per day) the risk is at least 20-fold. Ex-smokers who have quit for more than 15 years show an 80-90% reduction in their risk of lung cancer compared with persistent smokers. The risk reduces by 50% in the first decade and continues to decrease the longer the duration of abstinence. Approximately 1 in 9 smokers develop lung cancer. Individual susceptibility to developing lung cancer is affected by genetic predisposition and other environmental factors.",202,37,0.18316831683168316
9781910797310,chp1,"The management of solitary pulmonary nodules is dependent on their risk stratification, evidence of growth on interval imaging (ideally using volumetric measurement) and patient comorbidities and choices.","Tobacco smoke is the most important cause of lung cancer. Close to 90% of all lung cancers are attributable to cigarette smoke, of which a small proportion are due to second-hand smoke. The number of cigarettes smoked, but more importantly the length of time that patients have smoked for, is proportional to the risk of developing lung cancer. Evidence from the landmark 1964 Surgeon General's report estimated that an average male smoker had a nine- to tenfold increased risk of developing lung cancer compared with a 'never smoker'. For heavy smokers (more than 25 cigarettes per day) the risk is at least 20-fold. Ex-smokers who have quit for more than 15 years show an 80-90% reduction in their risk of lung cancer compared with persistent smokers. The risk reduces by 50% in the first decade and continues to decrease the longer the duration of abstinence. Approximately 1 in 9 smokers develop lung cancer. Individual susceptibility to developing lung cancer is affected by genetic predisposition and other environmental factors.",202,39,0.19306930693069307
9781910797310,chp1,The National Lung Screening Trial showed that low-dose CT screening of high-risk individuals reduced the risk of lung cancer-related mortality by 20%.,"In around 70% of cases, patients with lung cancer present to secondary care with symptomatic, advanced, incurable disease. Although mass screening of high-risk asymptomatic patients has the potential to detect disease at an earlier stage, randomized trials using chest X-ray (CXR) have not shown a reduction in lung-cancer mortality. More recently, trials have focused on the use of low-dose computed tomography (LDCT). The largest of these, the US-based National Lung Screening Trial (NLST), in which 53 454 current and former smokers (> 30 pack-years) aged 55-74 years were randomized to LDCT or CXR, showed a 20% relative reduction in lung cancer-related mortality and a 6.7% reduction in all-cause mortality in patients screened by LDCT.",170,30,0.17647058823529413
9781910797310,chp2,Classification of NSCLC further into specific pathological subtypes (exempli gratia adenocarcinoma versus squamous cell carcinoma) will determine eligibility for certain types of molecular testing and aid therapeutic decisions based on the specific histological and genetic characteristics of the tumor.,"The most common symptoms of advanced intrathoracic disease are cough, hemoptysis, dyspnea, chest pain, bronchial obstruction and dysphagia. These symptoms usually trigger a chest X-ray (CXR). Some lung cancers are identified by an abnormality found on imaging that is carried out for reasons other than chest symptoms (exempli gratia for employment reasons or before elective surgery). Initial evaluation of a patient after imaging should involve tissue biopsy by bronchoscopy, endobronchial ultrasound, or guided ultrasonography or CT. This information, together with radiological staging and a multidisciplinary meeting discussion usually results in a treatment plan. This plan must then be considered in terms of the patient's comorbidities (cardiac and respiratory function) and individual wishes. Every patient with suspected lung cancer should undergo a thorough history and physical examination, which, together with laboratory testing can assess comorbid conditions and the likelihood of metastases. CT, and in some cases positron emission tomography (PET), provides a non-invasive assessment of tumor size (T), mediastinal node enlargement (N) and potential metastases (M) (see Staging, Chapter 3).",254,57,0.22440944881889763
9781910797310,chp2,The 2015 World Health Organization Classification of Lung Tumors recommends the use of immunohistochemistry for the classification of non-small-cell lung cancer (NSCLC).,"About 70% of patients present with advanced stage lung cancer. Diagnosis is usually made from small biopsy and cytology specimens. Historically, pathologists only needed to distinguish between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), but in recent years therapeutic and genetic advances have driven the need for larger quantities of tissue for histological subclassification, immunohistochemistry and molecular and immune pathology. The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus and Heart includes a new classification for small biopsies and cytology similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.",153,35,0.22875816993464052
9781910797310,chp2,An epidermal growth factor receptor ( EGFR ) mutation is a validated predictive marker for response to EGFR tyrosine kinase inhibitor treatments.,"The discovery of specific gene mutations in NSCLC (Table 2.1) has led to the development of targeted therapies. In particular, the presence of epidermal growth factor receptor (EGFR) gene mutations, found primarily in adenocarcinomas, is predictive of responsiveness to EGFR tyrosine kinase inhibitors. Furthermore, adenocarcinomas with ALK - MET rearrangements are responsive to crizotinib, and patients with adenocarcinoma or NSCLC-NOS are more responsive to pemetrexed than are those with squamous cell carcinoma. In the initial randomized phase 2 study of bevacizumab and chemotherapy in advanced NSCLC, bevacizumab was associated with life-threatening hemorrhage in patients with squamous cell carcinoma; therefore, it is contraindicated in patients with this NSCLC histology.",189,30,0.15873015873015872
9781910797310,chp3,Better subclassification of early-stage NSCLC according to the size of the tumor will allow trials to compare wedge resection and segmentectomy.,"Tumor size (T) is the primary descriptive and most significant prognostic factor for operable lung cancer. Table 3.1 shows the proposed changes to the current T classification. Subclassification of early-stage NSCLC according to the size of the tumor will allow trials to compare the survival benefit of sublobar resections (id est wedge resection or segmentectomy) and lobectomy (see pages 24 -). Surgical advances have enabled 'distance from the carina' to be removed from the new TNM classification. However, the poor prognosis associated with pleural invasion has been confirmed, and therefore it remains a contraindication to surgery.",136,29,0.21323529411764705
9781910797310,chp3,"Some locally advanced lung cancers benefit from multimodality therapy, which can include surgery.","Tumor size (T) is the primary descriptive and most significant prognostic factor for operable lung cancer. Table 3.1 shows the proposed changes to the current T classification. Subclassification of early-stage NSCLC according to the size of the tumor will allow trials to compare the survival benefit of sublobar resections (id est wedge resection or segmentectomy) and lobectomy (see pages 24 -). Surgical advances have enabled 'distance from the carina' to be removed from the new TNM classification. However, the poor prognosis associated with pleural invasion has been confirmed, and therefore it remains a contraindication to surgery.",136,17,0.125
9781910797310,chp3,New M1c staging for multiple metastases in one or several organs and the use of the term M1b for oligometastatic disease has the potential to provide rational selection criteria for clinical treatment trials.,"Nodal status (N). A fundamental prerequisite in selecting patients for surgical treatment is reliable nodal staging (Table 3.2). The current N classification of nodal staging adequately predicts prognosis, so no change to the N descriptors has been recommended in the eighth edition. Division of the N1 stage into N1a (N1 at a single station) and N1b (N1 at multiple stations), and division of the N2 stage into N2a1 (N2 at a single station without N1 involvement; 'skip' metastasis), N2a2 (N2 at a single station with N1 involvement) and N2b (N2 at multiple stations) is descriptive only, as the survival curves for N1b and N2a2 overlap. Although N2a1 was associated with a better prognosis than N1b, the difference was not significant. Metastasis (M). When patients were assessed according to the number of metastases, there were no significant differences in prognosis in patients with M1a staging (metastases within the chest cavity); however, patients with M1b tumors (distant metastases outside the chest cavity) with a single metastasis in a single organ had a significantly better prognosis than those with multiple metastases in one or several organs. This will now be the definition of M1b and will serve as a first step in providing rational selection criteria for surgical treatment of oligometastatic disease in clinical trials. There will also be a new M1c classification (Table 3.3) - multiple metastases in a single organ or in multiple organs.",335,42,0.1253731343283582
9781910797310,chp3,Ground glass opacity (GGO) visualized on high-resolution computed tomography should trigger careful evaluation for pulmonary malignancy.,"Ground glass opacity (GGO) is a pulmonary shadow visualized using high-resolution computed tomography (HRCT), comprised of hazy increased attenuation with preservation of the bronchial and vascular margins. Adenocarcinoma is the most common cause of GGO, therefore careful evaluation for pulmonary malignancy must be considered when GGO is identified. Patients with multiple tumors and a prominent ground glass component on imaging or lepidic component on microscopy are being seen with increasing frequency. These tumors are associated with good survival after resection and have a lower propensity for nodal and extrathoracic spread than other types of NSCLC; however, they frequently relapse. Sublobar resection with the goal of sparing lung parenchyma is the gold standard for treatment of small GGO. The main difficulty is localizing the tumor within the lung during minimally invasive surgery. Different means of tracking the GGO and guiding the resection have been studied, including ink injection, coil insertion, and indocianide green injection.",214,26,0.12149532710280374
9781910797310,chp4,"Surgery is the preferred treatment for all patients with early-stage (I-II) NSCLC, with radiotherapy reserved for those unsuitable for surgery.","Paul Kabuubi MBChB MRCP FRCR and Merina Ahmed BSc MBBS MRCP FRCR MD(Res), The Royal Marsden NHS Foundation Trust, London, UK. Radiotherapy has a role in the management of most patients with non-small-cell lung cancer (NSCLC). While it can be used as sole treatment, it is often integrated in a multimodal strategy with surgery and chemotherapy. Overall, treatment options vary according to the stage of the tumor (see Chapter 3) but also depend on the individual patient's lung function, volume of disease and performance status. Patient selection. To be eligible for radical radiotherapy, patients must have adequate lung function (forced expiratory volume in 1 second [FEV ] >= 1 liter or >= 40% predicted; transfer factor >= 40%), good performance status (Eastern Cooperative Oncology Group [ECOG] score 0-1) and disease that can be encompassed in a radiotherapy treatment volume without undue risk of damaging normal tissue. Patients with interstitial lung disease are rarely suitable. Patients with poor lung function may still be eligible provided they have been adequately counseled about the long-term risks of breathlessness. Unsuitable candidates for radical radiotherapy should be offered other palliative options.",265,33,0.12452830188679245
9781910797310,chp4,Postoperative radiotherapy is recommended when residual disease is present; it can also be discussed in patients with complete resections with pN2 disease.,"To be eligible for radical radiotherapy, patients must have adequate lung function (forced expiratory volume in 1 second [FEV ] >= 1 liter or >= 40% predicted; transfer factor >= 40%), good performance status (Eastern Cooperative Oncology Group [ECOG] score 0-1) and disease that can be encompassed in a radiotherapy treatment volume without undue risk of damaging normal tissue. Patients with interstitial lung disease are rarely suitable. Patients with poor lung function may still be eligible provided they have been adequately counseled about the long-term risks of breathlessness. Unsuitable candidates for radical radiotherapy should be offered other palliative options.",134,29,0.21641791044776118
9781910797310,chp4,Stereotactic body radiotherapy is an alternative to surgery in peripheral stage I-II tumors less than 5 cm.,"Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy is the delivery of an extremely high dose of radiotherapy to a small target using hypofractionation. The fraction sizes are typically greater than 8 Gy per fraction. It is used for the treatment of stage I disease, and more recently for the treatment of oligometastatic disease. Methods of delivery are shown in Table 4.2. Image-guided radiotherapy (IGRT) refers to the use of imaging to reduce the uncertainty of tumor position during treatment.",113,24,0.21238938053097345
9781910797310,chp4,Concurrent chemoradiotherapy is preferred to sequential chemoradiotherapy in stage IIB-IIIB disease.,"Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy is the delivery of an extremely high dose of radiotherapy to a small target using hypofractionation. The fraction sizes are typically greater than 8 Gy per fraction. It is used for the treatment of stage I disease, and more recently for the treatment of oligometastatic disease. Methods of delivery are shown in Table 4.2. Image-guided radiotherapy (IGRT) refers to the use of imaging to reduce the uncertainty of tumor position during treatment. It has been estimated that a dose greater than 84 Gy is needed to provide 50% tumor control at 3 years. A meta-analysis in stage I patients has confirmed equivalent survival to surgery at 2 years. Local failures occur in less than 10% of patients but these failure rates can increase as tumor volume increases, with T2 disease or as the dose falls.",185,23,0.12432432432432433
9781910797310,chp4,Patients with advanced disease and poor performance status should receive 10 Gy in 1 fraction for palliation of intrathoracic disease.,"Radiotherapy provides effective palliation of symptomatic advanced intrathoracic disease and metastases. Three randomized trials conducted by the UK's Medical Research Council (MRC) have assessed fractionation for palliation of intrathoracic symptoms. - Even when a single fraction is used, radiotherapy can produce complete resolution of symptoms in around 50% of cases. When considering palliation of cough, chest pain and hemoptysis in those with moderate or poor performance status, 17 Gy in 2 fractions is equivalent to longer schedules (exempli gratia 30 Gy in 10 or 27 Gy in 6 fractions) with no difference in survival. One of the MRC trials established that 10 Gy in 1 fraction was equally effective as the 2-fraction schedule with substantially less dysphagia and no risk to the spinal cord.",168,27,0.16071428571428573
9781910797310,chp5,"Combination strategies with both cytotoxic T-lymphoma-associated protein 4 (CTLA-4) antagonism and first-line chemotherapy offer better response rates; however, caution needs to be exercised with the inherent risk of increased toxicity.","Rajiv Kumar FRACP MBChB BMedSc, The Royal Marsden NHS Foundation Trust, London, UK; and Jordi Remon MD, Medical Oncology Department, Gustave Roussy, Villejuif, France. In general, non-small-cell lung cancer (NSCLC) is associated with tumor DNA damage and mutations induced by carcinogens in tobacco smoke. In the mid-1990s an antibody to one of the murine immune checkpoints was found to cure tumors in vivo. The first antibody to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was licensed 15 years later for the treatment of melanoma. This reignited the pursuit of immunotherapies in the management of cancer, including NSCLC. Known as immune checkpoint inhibitors, these therapies target the programmed cell death 1 (PD-1) receptor, programmed cell death ligand-1 (PD-L1) and the CTLA-4 receptor.",203,50,0.24630541871921183
9781910797310,chp5,"Generally, programmed cell death protein-1 (PD-1) and PD-L1 inhibitors have a similar side-effect profile and efficacy.","In general, non-small-cell lung cancer (NSCLC) is associated with tumor DNA damage and mutations induced by carcinogens in tobacco smoke. In the mid-1990s an antibody to one of the murine immune checkpoints was found to cure tumors in vivo. The first antibody to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was licensed 15 years later for the treatment of melanoma. This reignited the pursuit of immunotherapies in the management of cancer, including NSCLC. Known as immune checkpoint inhibitors, these therapies target the programmed cell death 1 (PD-1) receptor, programmed cell death ligand-1 (PD-L1) and the CTLA-4 receptor.",152,29,0.19078947368421054
9781910797310,chp5,Strong PD-L1 staining is a biomarker for response to PD-1/PD-L1 inhibition.,"PD-1 is an inhibitory cell-surface receptor that is expressed on activated T cells, B cells, natural killer cells, monocytes and dendritic cells. The effector function of T cells that express PD-1 in the tumor microenvironment can be suppressed when PD-1 is coupled to the ligand PD-L1 (B7-H1) or PD-L2 (B7-DC) on tumor cells, thus preventing an immune attack on the cancer. The PD-L1 and PD-L2 ligands cross-compete for PD-1 binding; although PD-L2 has a sixfold higher binding affinity for PD-1, it has lower levels of expression, so that PD-L1 is the best ligand to target. Inhibition of the PD-1/PD-L1 immune checkpoint using monoclonal antibodies (mAbs) prevents the inhibition of the effector T-cell function, allowing T cells to maintain their tumor cell killing function (Figure 5.1).",211,24,0.11374407582938388
9781910797310,chp5,Nivolumab should be considered as a second-line treatment option for patients with non-squamous cell histology whose tumors are positive for programmed cell death ligand-1 (PD-L1) and all patients with squamous cell histology.,"Nivolumab, a fully humanized IgG4 PD-1 mAb, is licensed as second-line monotherapy for NSCLC of squamous cell histology; the approval for non-squamous histological subtypes will follow soon on the basis of the CHECKMATE-017 and CHECKMATE-057 trials., In 272 patients with pretreated advanced squamous NSCLC, nivolumab demonstrated a significant improvement in overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) compared with docetaxel, with a 1-year OS of 42% versus 24%, respectively (Table 5.2). The benefits of nivolumab were independent of clinical and tumor characteristics, including PD-L1 expression. In 582 patients with non-squamous NSCLC, nivolumab improved OS and ORR but not PFS (see Table 5.2). The treatment effect was consistent in all patient subgroups, especially in PD-L1-positive tumors, except for never-smokers and those with epidermal growth factor receptor (EGFR)-mutant tumors.",243,53,0.21810699588477367
9781910797310,chp5,Pembrolizumab should be considered as a treatment option for all patients whose tumors are PD-L1 positive.,"Pembrolizumab, a highly selective, humanized IgG4 PD-1 mAb, is also licensed as second-line monotherapy for all pathological subtypes of NSCLC that express PD-L1, following the results of the KEYNOTE-001 and KEYNOTE-010 trials., In 1034 patients with previously treated NSCLC, OS and ORR were significantly greater for pembrolizumab independent of the dose compared with docetaxel (see Table 5.2). Pembrolizumab benefited all patient subgroups except those with EGFR -mutant tumors and squamous histology, probably partly because of the small population size. Among the patients with at least 50% of tumor cells expressing PD-L1, pembrolizumab resulted in significantly longer PFS and OS than docetaxel, suggesting PD-L1 has value as a predictive biomarker.",190,25,0.13157894736842105
9781910797310,chp6,"Treatment for patients with metastatic NSCLC without an actional somatic gene mutation consists of systemic chemotherapy; regimen selection is based on histology, comorbidities and performance status (PS).","First and second-line chemotherapy in advanced NSCLC. Maria-Virginia Bluthgen MD, Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Chemotherapy is still the mainstay of systemic treatment for patients with metastatic non-small-cell lung cancer (NSCLC). The main factors influencing chemotherapy regimen selection are histology of the tumor, comorbidities and performance status (PS). Since 2004, patients with tumors harboring sensitizing mutations in the epidermal growth factor receptor (EGFR) gene, may receive an EGFR tyrosine kinase inhibitor (TKI) as an alternative to chemotherapy (see Chapter 8). This chapter describes treatment for patients without such actionable mutations. First-line chemotherapy. A systematic review showed that platinum-based therapy was associated with greater 1-year survival (RR 1.08, 95% CI 1.01-1.16) and increased response rate (RR 1.11, 95% CI 1.02-1.21) than non-platinum-based therapy. The use of a platinum-based combination is the backbone of first-line treatment in patients with advanced NSCLC.",244,41,0.1680327868852459
9781910797310,chp6,Platinum-based combinations are the backbone of first-line treatment for patients with advanced NSCLC.,"A systematic review showed that platinum-based therapy was associated with greater 1-year survival (RR 1.08, 95% CI 1.01-1.16) and increased response rate (RR 1.11, 95% CI 1.02-1.21) than non-platinum-based therapy. The use of a platinum-based combination is the backbone of first-line treatment in patients with advanced NSCLC.",88,21,0.23863636363636365
9781910797310,chp6,Pemetrexed regimens are restricted to non-squamous histology.,"Two-drug combinations comprised of a platinum and a cytotoxic agent, such as gemcitabine, vinorelbine, docetaxel or paclitaxel, have all resulted in similar survival. - However, toxicity profiles may differ. Differences in survival outcomes have been reported depending on the histology of NSCLC. For example, the benefit of pemetrexed appears to be restricted to non-squamous tumors.",91,16,0.17582417582417584
9781910797310,chp6,"Platinum re-challenge could represent a potential option for fit, relapsed patients with a platinum-free interval treatment of more than 6 months.","Combinations with targeted therapy are an alternative option for first-line systemic treatment in selected patients. Two randomized trials have evaluated the efficacy of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), added to standard first-line platinum-based combination chemotherapy., Both trials showed benefit in terms of progression-free survival (PFS) in patients who received the antiangiogenic therapy, but a significant difference in overall survival (OS) was only seen in those who received carboplatin-paclitaxel (12.3 vs 10.3 months; HR: 0.79 p =0.003 favoring bevacizumab). A significant bleeding rate of 4.4% was seen in the chemotherapy plus bevacizumab group compared with 0.7% in the chemotherapy only group.",175,30,0.17142857142857143
9781910797310,chp6,Bevacizumab combined with a paclitaxel regimen can provide a survival benefit over a paclitaxel regimen alone in patients with non-squamous subgroups.,"The two strategies for maintenance therapy following disease control after first-line treatment are continuous and switch maintenance. Continuous maintenance with pemetrexed has demonstrated statistical improvement in OS in patients with NSCLC compared with placebo (HR 0.78, 95% CI 0.64-0.96, p =0.0195; median OS 13.9 vs 11 months). A benefit in PFS only was seen with the same strategy in combination with gemcitabine. Switch maintenance with pemetrexed after non-progression following a non-pemetrexed combination regimen, has also shown a benefit in terms of PFS and OS in one randomized trial. Collectively, these data suggest that survival could be improved with maintenance pemetrexed for patients with non-squamous histology.",163,37,0.22699386503067484
9781910797310,chp6,"Pemetrexed as continuous or switch maintenance prolongs survival over no maintenance in patients with non-squamous histologies and PS 0,1.","Continuous maintenance with pemetrexed has demonstrated statistical improvement in OS in patients with NSCLC compared with placebo (HR 0.78, 95% CI 0.64-0.96, p =0.0195; median OS 13.9 vs 11 months). A benefit in PFS only was seen with the same strategy in combination with gemcitabine. Switch maintenance with pemetrexed after non-progression following a non-pemetrexed combination regimen, has also shown a benefit in terms of PFS and OS in one randomized trial. Collectively, these data suggest that survival could be improved with maintenance pemetrexed for patients with non-squamous histology.",143,30,0.2097902097902098
9781910797310,chp6,Advanced age alone should not preclude appropriate NSCLC treatment.,"Two chemotherapy drugs are currently approved for second-line treatment of advanced NSCLC: docetaxel and pemetrexed. In 1999, a significant survival benefit (37% vs 11%) and improvement in disease-related symptoms was demonstrated with second-line docetaxel compared with BSC in patients with advanced NSCLC and good PS who had relapsed following a first-line platinum-based treatment. In 2004, second-line pemetrexed showed equivalent efficacy with fewer side effects to docetaxel.",108,12,0.1111111111111111
9781910797310,chp6,Two chemotherapy drugs have been approved for the treatment of advanced NSCLC in the second-line setting: docetaxel and pemetrexed.,"Two chemotherapy drugs are currently approved for second-line treatment of advanced NSCLC: docetaxel and pemetrexed. In 1999, a significant survival benefit (37% vs 11%) and improvement in disease-related symptoms was demonstrated with second-line docetaxel compared with BSC in patients with advanced NSCLC and good PS who had relapsed following a first-line platinum-based treatment. In 2004, second-line pemetrexed showed equivalent efficacy with fewer side effects to docetaxel. While combinations of cytotoxic drugs have been successful in improving efficacy compared with single agents in the first-line setting, the role of second-line combination therapy is less clear. Several randomized studies have been performed in patients with NSCLC comparing second-line docetaxel-based combination chemotherapy with docetaxel single agent: no significant differences in response rate, median survival or PFS were reported. - In two randomized phase II trials, pemetrexed-based combination therapy produced a higher response rate than the single agent but showed no benefit in terms of survival. Two meta-analyses addressing the efficacy of combined therapy found no difference in OS between the two strategies, but a statistically significant increase in PFS (14 vs 11 weeks; HR=0.79, p =0.0009) and response rate (15.1% vs 7.3%, p =0.0004) in favor of the combination therapy, albeit with a much higher incidence of adverse events.",310,31,0.1
9781910797310,chp7,"The Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score, which is based on age, Karnofsky performance score, the presence of extracranial metastases and the number of BM, can guide clinicians' decisions.","Gokoulakrichenane Loganadane MD and Antonin Levy MD, Department of Radiation Oncology, Thoracic Oncology Institute, Gustave Roussy Cancer Campus, Villejuif, France. Brain metastases (BM) are common in the natural history of non-small-cell lung cancer (NSCLC) and, with advances in imaging modalities and improvements in systemic disease control, both the incidence and prevalence of BM are rising. BM have deleterious effects on many critical neurological functions. Survival ranges from 3 to 14.8 months, depending on the lung diagnosis-specific graded prognostic assessment (DS-GPA): age, Karnofsky Performance Score (KPS), presence of extracranial metastases (ECM) and number of BM (Table 7.1)., The DS-GPA score has a central role in the management of patients; focal interventions should preferentially be delivered to patients with a good prognosis. Radiation therapy, surgery and systemic therapies are options for the management of metastatic lesions in the brain.",222,52,0.23423423423423423
9781910797310,chp7,Brain metastases (BM) are common in the natural history of patients with NSCLC.,"Brain metastases (BM) are common in the natural history of non-small-cell lung cancer (NSCLC) and, with advances in imaging modalities and improvements in systemic disease control, both the incidence and prevalence of BM are rising. BM have deleterious effects on many critical neurological functions. Survival ranges from 3 to 14.8 months, depending on the lung diagnosis-specific graded prognostic assessment (DS-GPA): age, Karnofsky Performance Score (KPS), presence of extracranial metastases (ECM) and number of BM (Table 7.1)., The DS-GPA score has a central role in the management of patients; focal interventions should preferentially be delivered to patients with a good prognosis. Radiation therapy, surgery and systemic therapies are options for the management of metastatic lesions in the brain.",175,19,0.10857142857142857
9781910797310,chp7,Surgical resection may be required for patients presenting with neurological symptoms or a large single lesion.,"Whole brain radiation therapy continues to be the standard of care for patients with a poor prognosis according to the DS-GPA (id est patients who are not candidates for surgery or SRS) with multiple (more than 3-5) BM. The most widely used schedule is 30 Gy over 2 weeks (10 daily fractions). WBRT does not increase survival or quality of life compared with best supportive care (BSC), as reported in the large prospective randomized Quartz trial.",97,20,0.20618556701030927
9781910797310,chp7,"Whole brain radiotherapy was the standard treatment for patients with a poor prognosis, but this has recently been challenged.","Whole brain radiation therapy continues to be the standard of care for patients with a poor prognosis according to the DS-GPA (id est patients who are not candidates for surgery or SRS) with multiple (more than 3-5) BM. The most widely used schedule is 30 Gy over 2 weeks (10 daily fractions). WBRT does not increase survival or quality of life compared with best supportive care (BSC), as reported in the large prospective randomized Quartz trial.",97,24,0.24742268041237114
9781910797310,chp7,"Stereotactic radiosurgery could be given to patients with a limited number of small well-defined BM, as it provides excellent local control with limited toxicities.","Stereotactic radiosurgery concentrates high-dose ablative radiation within a tumor while avoiding radiation of the surrounding healthy tissue. It is suitable for small well-defined metastases (< 4 cm). Focal high-dose irradiation, compared with neurosurgery, has the ability to treat surgically inaccessible areas and several lesions at a time; furthermore, it is non-invasive and cost-effective. In a large randomized trial (RTOG 9508), an SRS boost increased survival in patients with a good prognostic score and a single lesion., Although no randomized trials have directly compared surgery to SRS, SRS seems to provide a similar local control rate (80-90%), especially when SRS is combined with WBRT.",153,34,0.2222222222222222
9781910797310,chp7,Systemic treatment (chemotherapy or targeted compounds) is a reasonable treatment option for asymptomatic patients.,"The order of chemotherapy and radiotherapy is often dictated by how symptomatic a patient is and their performance status (PS). Radiotherapy is often used for very symptomatic patients with poor PS. Systemic treatment is usually the first choice for asymptomatic or minimally symptomatic BM, particularly if a sensitizing driver mutation is present in the tumor. Concurrent WBRT and chemotherapy resulted in higher neurocognitive deficit without clear benefit in response rate or survival., European Society Medical Oncology (ESMO) guidelines and data from randomized trials support chemotherapy as a reasonable first-line treatment option for patients with stage IV NSCLC and asymptomatic BM. - Chemotherapy may also be proposed as a salvage treatment.",148,23,0.1554054054054054
9781910797310,chp8,Second-generation drugs are becoming available.,"To date, nine randomized phase III trials have established reversible EGFR-TKI (erlotinib and gefitinib) and irreversible EGFR-TKI (afatinib) as standard first-line treatment in patients with NSCLC EGFR mutations. These agents have demonstrated improved response rates (RR) (56-84.6% vs 15-47.3%) and progression-free survival (PFS) (9.2-13.1 vs 4.6-6.9 months) compared with standard first-line platinum two-drug chemotherapy. To date, no differences in overall survival (OS) have been reported, possibly because of the high crossover rate. Prospective data on afatinib use in uncommon EGFR mutations are available.",158,8,0.05063291139240506
9781910797310,chp8,All patients with adenocarcinoma should have mutation testing for EGFR and ALK-MET at diagnosis.,"The gatekeeper T790M mutation in exon 20 of the EGFR gene is the most common type of AR mechanism observed in 49-63% of resistant biopsies. - Third-generation EGFR-TKIs osimertinib and rociletinib, which target both T790M and EGFR -sensitive mutations have been tested in phase I trials. Osimertinib has reported an RR of 61% and median PFS of 9.6 months in patients with T790M-positive NSCLC with AR to EGFR-TKI, and has been approved by the FDA. Rociletinib has also reported an RR of 53% and PFS of 8 months in this population. For those patients without T790M who develop AR, platinum-based chemotherapy seems to be a reasonable option beyond participating in clinical trials. The randomized phase III IMPRESS trial suggests that EGFR-TKI should be discontinued in patients with AR when commenced on two-drug second-line chemotherapy based on lack of PFS benefit and probable deleterious effect on OS. For those patients with slow progressive disease, continuation of first-line EGFR-TKI beyond RECIST (response evaluation criteria in solid tumors) progression was possible for about another 3.9 months. In cases of local progression, local therapies in conjunction with continued EGFR-TKI prolong survival.",283,24,0.08480565371024736
9781910797310,chp8,EGFR mutations at any stage should have treatment with a tyrosine kinase inhibitor until symptomatic progression.,"The gatekeeper T790M mutation in exon 20 of the EGFR gene is the most common type of AR mechanism observed in 49-63% of resistant biopsies. - Third-generation EGFR-TKIs osimertinib and rociletinib, which target both T790M and EGFR -sensitive mutations have been tested in phase I trials. Osimertinib has reported an RR of 61% and median PFS of 9.6 months in patients with T790M-positive NSCLC with AR to EGFR-TKI, and has been approved by the FDA. Rociletinib has also reported an RR of 53% and PFS of 8 months in this population. For those patients without T790M who develop AR, platinum-based chemotherapy seems to be a reasonable option beyond participating in clinical trials. The randomized phase III IMPRESS trial suggests that EGFR-TKI should be discontinued in patients with AR when commenced on two-drug second-line chemotherapy based on lack of PFS benefit and probable deleterious effect on OS. For those patients with slow progressive disease, continuation of first-line EGFR-TKI beyond RECIST (response evaluation criteria in solid tumors) progression was possible for about another 3.9 months. In cases of local progression, local therapies in conjunction with continued EGFR-TKI prolong survival.",283,22,0.07773851590106007
9781910797310,chp8,Other driver mutations and targeted therapies need acceleration into the clinic for patient benefit.,"The gatekeeper T790M mutation in exon 20 of the EGFR gene is the most common type of AR mechanism observed in 49-63% of resistant biopsies. - Third-generation EGFR-TKIs osimertinib and rociletinib, which target both T790M and EGFR -sensitive mutations have been tested in phase I trials. Osimertinib has reported an RR of 61% and median PFS of 9.6 months in patients with T790M-positive NSCLC with AR to EGFR-TKI, and has been approved by the FDA. Rociletinib has also reported an RR of 53% and PFS of 8 months in this population. For those patients without T790M who develop AR, platinum-based chemotherapy seems to be a reasonable option beyond participating in clinical trials. The randomized phase III IMPRESS trial suggests that EGFR-TKI should be discontinued in patients with AR when commenced on two-drug second-line chemotherapy based on lack of PFS benefit and probable deleterious effect on OS. For those patients with slow progressive disease, continuation of first-line EGFR-TKI beyond RECIST (response evaluation criteria in solid tumors) progression was possible for about another 3.9 months. In cases of local progression, local therapies in conjunction with continued EGFR-TKI prolong survival.",283,15,0.053003533568904596
9781910797310,chp8,Patients with ALK-MET or ROS1 translocations respond well to crizotinib.,"Clinical data from a phase I/II trial investigating brigatinib (AP26113) in 78 patients with ALK+ NSCLC pretreated with crizotinib, reported a RR of 71%, PFS of 13.4 months and 1-year OS of 100%. On the basis of these results, the FDA has granted brigatinib a breakthrough-therapy designation for advanced ALK + NSCLC that has progressed to crizotinib. The ALTA-1L trial will compare brigatinib with crizotinib as first-line treatment.",118,20,0.1694915254237288
9781910797426,ch01,"The pancreas is 6-8 inches long and lies behind the stomach between the duodenum on the right and the center of the spleen on the left. It produces digestive enzymes, bicarbonate and insulin.","Anatomy, physiology and epidemiology. The pancreas. Anatomy. The pancreas is the shape of a small flat fish, 6-8 inches long and salmon pink in color. It lies behind the stomach, stretching between the duodenum on the right, to the center of the spleen (hilum) on the left (Figure 1.1). It is conventionally divided into the head, uncinate process, neck, body and tail. Physiology. The pancreas is important for the production of. digestive enzymes - from the acinar cells. bicarbonate - from the duct cells (to neutralize gastric acid). insulin - from the cells of the islets of Langerhans (essential for glucose control). Epidemiology of pancreatic disease. In the year 2000 there were 1.15 million patients with non-malignant pancreatic disease in the USA. Each year 125 000 North Americans present with acute pancreatitis, 100 000 present with chronic pancreatitis and at least 45 000 die from diseases of the pancreas. Pancreatic cancer is a highly lethal cancer and ranks fourth among cancer-related deaths in the USA. It is estimated that about 48 960 people will be diagnosed with pancreatic cancer and about 40 560 people will die of pancreatic cancer in 2015 in the USA.",278,46,0.16546762589928057
9781910797426,ch01,Pancreatic cancer is the fourth highest cause of cancer-related deaths in the USA.,"Epidemiology of pancreatic disease. In the year 2000 there were 1.15 million patients with non-malignant pancreatic disease in the USA. Each year 125 000 North Americans present with acute pancreatitis, 100 000 present with chronic pancreatitis and at least 45 000 die from diseases of the pancreas. Pancreatic cancer is a highly lethal cancer and ranks fourth among cancer-related deaths in the USA. It is estimated that about 48 960 people will be diagnosed with pancreatic cancer and about 40 560 people will die of pancreatic cancer in 2015 in the USA.",117,19,0.1623931623931624
9781910797426,ch01,The biliary system comprises the organs and ducts that store bile and release it into the duodenum.,"Anatomy. The main pancreatic duct joins the bile duct to form the common channel or ampulla of Vater (also known as the major papilla). In 90% of people, the embryonic dorsal and ventral pancreatic ducts are fused to form this pancreatic duct, meeting in the head of the pancreas. In the other 10%, the ducts drain separately into the duodenum (pancreas divisum) and the dorsal duct (known as the accessory duct) drains through the minor papilla. Small sphincters around the ends of the main bile and pancreatic ducts control the flow of bile and pancreatic juice, respectively; the sphincter of Oddi controls the outflow from the ampulla of Vater.",162,23,0.1419753086419753
9781910797426,ch01,Gallstones are prevalent worldwide and a considerable cause of morbidity and mortality.,"Epidemiology of biliary tract disease. Gallstones are prevalent worldwide and are a considerable cause of morbidity and mortality. They may cause acute biliary colic, acute cholecystitis or chronic cholecystitis, acute pancreatitis or cholangitis. Gallbladder carcinoma is the fifth most common gastrointestinal (GI) cancer in the USA and the most common GI cancer in Native Americans. Incidence and mortality are very high in certain Latin American countries, especially Chile. Of the most commonly seen GI cancers in the USA, Europe and Australia, gallbladder cancer is the least common compared with other parts of the world. In most EU countries (with similar trends in the USA and Australia), mortality rates for gallbladder cancer have declined by approximately 30% among women and 10% among men, but mortality is still high in central and eastern Europe.",178,15,0.08426966292134831
9781910797426,ch02,The symptoms and signs of pancreaticobiliary diseases are usually non-specific.,"The signs and symptoms of pancreaticobiliary diseases are usually non-specific. Patients typically present with variable symptoms related to the specific disease, ranging from chronic or intermittent abdominal pain (either biliary or pancreatic type), jaundice and/or pruritus due to obstruction of the biliary tract, nausea, vomiting, diarrhea or constipation, new-onset diabetes, fatigue, back pain and/or weight loss.",87,16,0.1839080459770115
9781910797426,ch02,"Imaging tests with varied diagnostic performance, technical success, complications and cost efficacy are used to confirm the presence, location and possible cause of pancreaticobiliary diseases.","Multiple tests with variable sensitivity and specificity are used for the differential diagnosis of pancreaticobiliary diseases. Usual laboratory tests include serum bilirubin, aminotransferases (transaminases), alkaline phosphatase, gamma-glutamyltransferase, coagulation factors, amylase, lipase and, if pancreatic disease is suspected, blood glucose. These can highlight a possible cause for suspected biliary or pancreatic diseases. As the signs and symptoms of pancreaticobiliary diseases are non-specific, imaging is key to the diagnosis and management of patients. Imaging can clarify the presence and site of obstruction, as well as a possible cause in patients with cholestasis. Imaging modalities vary in diagnostic performance, technical success, complications and cost efficacy (Table 2.1).",167,33,0.19760479041916168
9781910797426,ch03,"The prevalence of gallstones is greater in people over 40 years of age, and women are at higher risk than men.","Epidemiology and risk factors. Gallstones are a significant cause of morbidity and mortality worldwide. The prevalence of gallstones is greater in people over 40 years of age; women are at higher risk than men. In the USA, 5-8% of men and 13-26% of women have gallstones. Native Americans have the highest prevalence in North America, with more than 70% of Pima Indian women having gallstones; African-Americans have the lowest prevalence. European studies have reported the prevalence of gallstones to be about 10% in men and 20% in women, figures that increase to 30% and 40% respectively in older patients. Other risk factors for gallstones are given in Table 3.1.",146,24,0.1643835616438356
9781910797426,ch03,Patients with gallbladder polyps more than 1 cm in size should be considered for cholecystectomy owing to the increased risk of malignancy.,"There are relatively few contraindications to this procedure. They include severe coagulopathy, severe congestive heart failure and chronic obstructive pulmonary disease; patients with either of the last two conditions may not tolerate the pneumoperitoneum needed for a laparoscopic cholecystectomy. Previous upper abdominal surgery may make the procedure difficult. Laparoscopic cholecystectomy can be performed in patients with well-compensated liver cirrhosis, although there is an increased risk of bleeding in some patients. Conversion to an open operation is needed in about 5% of elective laparoscopic cholecystectomies, usually because anatomic landmarks cannot be seen clearly enough.",142,33,0.2323943661971831
9781910797426,ch03,"Transabdominal ultrasound is the imaging test of choice, with an accuracy of over 95%, for the diagnosis of gallstones in either acute or chronic cholecystitis. A Tc-HIDA (hepatobiliary iminodiacetic acid) scan is 95% accurate for the diagnosis of acute cholecystitis.","Symptoms and signs include pain or tenderness and guarding in the right upper quadrant, nausea and vomiting, fever, fast pulse (tachycardia) and a positive Murphy's sign (transient cessation of breathing due to pain during inspiration while the right upper quadrant is palpated, but not the left upper quadrant). Complications include empyema, perforation of the gallbladder, liver abscess and emphysematous cholecystitis. An inflamed and distended gallbladder may obstruct the main bile duct by pressure from a gallstone causing obstructive jaundice (Mirizzi's syndrome). Laboratory tests. Leukocytosis and mild elevation in serum bilirubin and transaminases may be present. Transabdominal ultrasonography is the most useful test for acute cholecystitis as it establishes the presence of gallstones (Figure 3.5). A thickened gallbladder wall (> 4 mm) and pericholecystic fluid are highly suggestive of acute cholecystitis (Figure 3.6). Sonographic Murphy's sign (tenderness over the gallbladder from the ultrasound transducer during imaging) is also diagnostic. Radionuclide scanning is a useful test if ultrasound is non-diagnostic or inconclusive but there is clinical suspicion of acute cholecystitis. A Tc-HIDA (hepatobiliary iminodiacetic acid) scan uses a technetium-labeled analog of iminodiacetic acid. Non-visualization of the gallbladder with visualization of the tracer in the CBD and the small intestine is consistent with cystic duct obstruction. This test is about 95% accurate for the diagnosis of acute cholecystitis. Computed tomography is useful for identifying local complications of acute cholecystitis (Figure 3.7). Medical treatment of acute cholecystitis involves.",401,69,0.17206982543640897
9781910797426,ch03,Acalculous cholecystitis may occur in critically ill patients; the diagnosis requires a high index of suspicion.,"Epidemiology and risk factors. Acalculous cholecystitis is associated with a myriad of clinical conditions and frequently occurs in critically ill patients, with the incidence in this group ranging from 0.5 to 18%. There are many predisposing risk factors (Table 3.2). Symptoms and signs. The usual scenario consists of abdominal pain, fever and leukocytosis in a patient with one of the above predisposing conditions. Diagnosis requires a high index of suspicion. Right upper quadrant tenderness and Murphy's sign may be present, and a palpable mass may be detected in a minority of patients. Jaundice is not uncommon.",134,25,0.1865671641791045
9781910797426,ch03,"Gallbladder cancer is the most common gastrointestinal cancer in Native Americans in the USA and also has a very high incidence in certain Latin American countries, particularly Chile.","Etiology and pathogenesis. Chronic gallbladder inflammation is attributed as an etiologic factor in gallbladder cancer along with molecular alterations in p53 and K-ras. Inflammation may occur as a result of gallstones, gallbladder polyps, chronic Salmonella infection, congenital biliary cysts, abnormal pancreaticobiliary duct junction, carcinogen exposure and certain drugs. There are molecular differences between gallbladder cancers associated with gallstones and those with an abnormal pancreaticobiliary junction. Epidemiology and risk factors. Gallbladder carcinoma is the fifth most common gastrointestinal (GI) cancer in the USA and is the most common GI cancer in Native Americans. Incidence and mortality are very high in certain Latin American countries, especially Chile.",159,32,0.20125786163522014
9781910797426,ch04,Around 10-20% of patients with stones in the gallbladder have common bile duct (CBD) stones at the time of cholecystectomy (the prevalence rises with age).,"Around 10% of younger patients with stones in the gallbladder have CBD stones at the time of cholecystectomy, rising with age to around 20%. The exact prevalence and incidence of bile duct stones is not known. Symptoms and signs include right upper quadrant pain/tenderness, jaundice, fever, clay-colored stools and dark urine. Symptoms and signs of concomitant acute cholangitis include pain and tenderness in the right upper quadrant, jaundice and fever spikes (> 38C) with chills (Charcot's triad). Patients with severe or suppurative cholangitis are severely ill, with septicemia, shock and mental confusion. Laboratory tests may reveal elevated serum levels of bilirubin, alkaline phosphatase, gamma-glutamyltransferase, aspartate aminotransferase and alanine aminotransferase, although these tests may occasionally be normal in patients with CBD stones. Leukocytosis is seen in patients with cholangitis. Increased amylase or lipase are present in patients with acute biliary pancreatitis.",243,40,0.1646090534979424
9781910797426,ch04,"Transabdominal ultrasound is 25-80% accurate for detection of CBD stones, depending on the experience of the examiner.","Transabdominal ultrasound is non-invasive and is generally the first imaging modality used when a stone in the CBD is suspected. Its sensitivity for detection of a dilated bile duct is up to 90%, and even higher in jaundiced patients. However, its sensitivity for detection of stones in the CBD is lower, about 25-80%, depending on the examiner's experience and the size of the bile duct (Figure 4.1). Endoscopic ultrasonography (EUS) is a minimally invasive endoscopic imaging modality for CBD stones with an accuracy of around 98% (Figure 4.2). It can be performed in a combined session with therapeutic endoscopic retrograde cholangiopancreatography (ERCP) to achieve diagnosis and stone removal.",159,25,0.15723270440251572
9781910797426,ch04,"Endoscopic ultrasonography and magnetic resonance cholangiopancreatography are accurate tests for detection of CBD stones and should generally precede endoscopic retrograde cholangiopancreatography (ERCP), unless the clinical signs and symptoms and transabdominal ultrasound findings make therapeutic ERCP inevitable.","Transabdominal ultrasound is non-invasive and is generally the first imaging modality used when a stone in the CBD is suspected. Its sensitivity for detection of a dilated bile duct is up to 90%, and even higher in jaundiced patients. However, its sensitivity for detection of stones in the CBD is lower, about 25-80%, depending on the examiner's experience and the size of the bile duct (Figure 4.1). Endoscopic ultrasonography (EUS) is a minimally invasive endoscopic imaging modality for CBD stones with an accuracy of around 98% (Figure 4.2). It can be performed in a combined session with therapeutic endoscopic retrograde cholangiopancreatography (ERCP) to achieve diagnosis and stone removal. Magnetic resonance cholangiopancreatography (MRCP) is a non-invasive technique for imaging the extra- and intrahepatic biliary system with a sensitivity of 93% and specificity of 94% (Figure 4.3). Contraindications include claustrophobia and implanted metal devices and fragments. MRCP is a useful, non-invasive and reliable test for CBD stones. MRCP and EUS generally have comparable high accuracy; however, for small stones less than 6 mm in diameter, EUS may be more accurate.",276,63,0.22826086956521738
9781910797426,ch04,Clearance of all stones from the CBD via ERCP is possible in more than 95% of patients.,"Endoscopic biliary decompression by ERCP with sphincterotomy allows endoscopic extraction of stones from the CBD. If ERCP clears all stones from the CBD, the patient can then undergo laparoscopic cholecystectomy. Some patients may require more than one attempt by ERCP to clear all stones from the CBD. A plastic stent is sometimes placed in the bile duct during ERCP to achieve biliary drainage if it is not possible to remove all the stones and further attempts should be planned. Large stones may require endoscopic lithotripsy during ERCP with or without cholangioscopy or extracorporeal shock wave lithotripsy in combination with ERCP. Clearance of all stones from the CBD through ERCP is possible in more than 95% of patients. ERCP with sphincterotomy is also useful for patients who have recently undergone a cholecystectomy and present with retained CBD stones.",202,22,0.10891089108910891
9781910797426,ch04,"Biliary decompression, preferably by endoscopic or radiologic means, is critical in severe suppurative cholangitis with choledocholithiasis.","Endoscopic biliary decompression by ERCP with sphincterotomy allows endoscopic extraction of stones from the CBD. If ERCP clears all stones from the CBD, the patient can then undergo laparoscopic cholecystectomy. Some patients may require more than one attempt by ERCP to clear all stones from the CBD. A plastic stent is sometimes placed in the bile duct during ERCP to achieve biliary drainage if it is not possible to remove all the stones and further attempts should be planned. Large stones may require endoscopic lithotripsy during ERCP with or without cholangioscopy or extracorporeal shock wave lithotripsy in combination with ERCP.",149,32,0.21476510067114093
9781910797426,ch05,Bifurcation of the hepatic duct is the most common site for cholangiocarcinoma.,Etiology and pathogenesis. Bile duct cancer or cholangiocarcinoma may arise in the intra- or extrahepatic biliary system. The bifurcation of the hepatic duct (hilum) is the most common site for cholangiocarcinomas (Klatskin tumor). Adenocarcinoma is the most common histological type; molecular changes include the expression of mutant p53 and K-ras.,98,24,0.24489795918367346
9781910797426,ch05,Primary sclerosing cholangitis is the major risk factor for the development of cholangiocarcinoma.,"Etiology and pathogenesis. Bile duct cancer or cholangiocarcinoma may arise in the intra- or extrahepatic biliary system. The bifurcation of the hepatic duct (hilum) is the most common site for cholangiocarcinomas (Klatskin tumor). Adenocarcinoma is the most common histological type; molecular changes include the expression of mutant p53 and K-ras. The overall pathophysiology of cholangiocarcinoma is poorly understood. Mutations leading to cholangiocarcinoma occur in a background of chronic inflammation, leading to proliferation of mutated cells and angiogenesis.",147,26,0.17687074829931973
9781910797426,ch05,Benign biliary obstruction may increase cancer antigen 19.9 levels.,"Laboratory tests may show increased levels of bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and gamma-glutamyltransferase. The serum tumor markers carcinoembryonic antigen and cancer antigen 19.9 are usually elevated; however, they may also indicate other types of tumor, and can be mildly or moderately elevated in benign biliary obstruction.",92,14,0.15217391304347827
9781910797426,ch05,"Biliary papillomatosis lesions are diffuse and multiple, with the abnormal biliary epithelium producing a large amount of mucus.","Biliary papillomatosis presents as tumorous papillary growths of the bile duct epithelium, which are usually diffuse and multiple. A large amount of mucus is produced by the abnormal biliary epithelium, causing biliary obstruction with resultant cholestatic jaundice and cholangitis. A possible association between Caroli's disease and biliary papillomatosis has been reported. Biliary cystadenoma is a rare tumor. Malignant degeneration does occur, but very little is known of the risk for this. Because of the risk for malignancy and recurrence, surgical treatment encompassing resection or complete enucleation is recommended.",142,29,0.20422535211267606
9781910797426,ch05,Rare tumors include biliary cystadenoma and primary non-Hodgkin's lymphoma.,"Lymphoma of the bile duct. Primary non-Hodgkin's lymphoma may arise from the bile duct. Jaundice may occur due to a variety of causes, including direct hepatic involvement or compression of the bile ducts by lymph nodes, as well as tumor-related hemolysis. This tumor can occur between the first and seventh decades of life. The most common lymphoma subtype pattern is large-cell lymphoma. Treatment is variable and includes a combination of chemotherapy, radiation and surgery.",108,21,0.19444444444444445
9781910797426,ch06,More than 70% of patients with choledochal cysts have an abnormal pancreaticobiliary junction.,"Cysts of the biliary tree can be congenital or acquired. Congenital cysts may be diagnosed in the prenatal period and there may be a familial occurrence. Cysts involving the biliary tree may be isolated or multiple, and dilation of the biliary tree can be intrahepatic or extrahepatic. More than 70% of patients with choledochal cysts have an abnormal pancreaticobiliary junction, with a long common channel.",95,22,0.23157894736842105
9781910797426,ch06,Caroli's disease is a congenital condition resulting in multiple segmental dilations of intrahepatic ducts.,"Treatment. Type I/II choledochal cysts are treated with cholecystectomy, resection of the extrahepatic biliary duct and hepaticojejunostomy. Type III cysts may be treated endoscopically. Type IV cysts should be resected. Hepatic lobectomy may be considered for intrahepatic cysts limited to one lobe (type V). Stenosis of the hepaticojejunostomy with its sequelae is the most common long-term complication of surgery. Surgery decreases but does not eliminate the risk of cancer. Caroli's disease. Etiology and pathogenesis. Caroli's disease is a congenital condition characterized by multiple segmental dilations of the intrahepatic bile duct. Stagnation of bile leads to cholelithiasis, and patients have an increased risk for cholangiocarcinoma.",192,24,0.125
9781910797426,ch06,Liver flukes and roundworms may cause Oriental cholangiohepatitis.,"Etiology and pathogenesis. Oriental cholangiohepatitis, also called recurrent pyogenic cholangitis, is a disease of the biliary tree with multiple pigmented stones, biliary strictures and multiple bouts of cholangitis. Biliary parasites are implicated in the etiology of Oriental cholangiohepatitis. Liver flukes (Clonorchis sinensis, Opisthorchis felineus, O. viverrini, Fasciola hepatica, F. giganta) and roundworms (Ascaris lumbricoides) are the parasites most commonly involved in this disease. Bacterial infection and stasis further contribute to stone formation, stricturing and infection.",152,18,0.11842105263157894
9781910797426,ch06,"AIDS cholangiopathy may result in right upper quadrant abdominal pain, biliary strictures and papillary stenosis.","Medical treatment for infection (if the causative agent is identified) does not usually affect progression of this disease. In addition, AIDS cholangiopathy usually occurs in patients with advanced AIDS, and as such their survival is not likely to be determined by this condition. Ursodeoxycholic acid may help a small percentage of patients. Endoscopic treatment. Sphincterotomy may be performed in patients with papillary stenosis and abdominal pain or jaundice. It provides pain relief for 23-70% of patients, but does not change strictures in the biliary tree. It is not helpful in the absence of papillary stenosis.",131,26,0.1984732824427481
9781910797426,ch06,Up to 70% of patients with primary sclerosing cholangitis (PSC) may have ulcerative colitis.,"Etiology and pathogenesis. In primary sclerosing cholangitis (PSC), fibrotic strictures occur in the intra- and extrahepatic biliary system with no obvious cause. Genetic and immunologic factors are important in the pathogenesis of PSC. Up to 70% of patients with PSC may also have ulcerative colitis. Patients with PSC have an increased risk for cholangiocarcinoma, estimated at 1% per year. Biliary obstruction may cause secondary biliary cirrhosis and hepatic failure. The natural history of PSC is variable.",126,27,0.21428571428571427
9781910797426,ch06,Liver transplantation is the treatment of choice for PSC with end-stage liver disease.,Liver biopsy may be required in selected patients to assess the degree of liver fibrosis or to document the presence of cirrhosis in order to select appropriate therapy. Treatment. Surgical resection may be an option in patients with significant hepatic fibrosis without cirrhosis; it may involve resection of the extrahepatic biliary tree and hepaticojejunostomy. Liver transplantation is the treatment of choice for patients with PSC and end-stage liver disease.,101,19,0.18811881188118812
9781910797426,ch07,"Sphincter of Oddi dysfunction may be due to anatomic stenosis or a spastic functional disorder, and is most common after cholecystectomy. A lot of controversy surrounds this topic.","Etiology and pathogenesis. The sphincter of Oddi is a complex of circular and longitudinal muscle fibers that surrounds the biliary and pancreatic sphincters where they open into the duodenum (Figure 7.1). Disorders of the sphincter of Oddi may present as sphincter stenosis or dyskinesia. Sphincter of Oddi stenosis is an actual anatomic narrowing of the sphincter, caused by inflammation, pancreatitis, gallstone passage or other unusual causes. Sphincter dyskinesia on the other hand is a spastic functional disorder of the sphincter, the cause of which is poorly understood. Epidemiology and risk factors. Dysfunction mostly occurs after cholecystectomy, but it may occur in a patient with an intact gallbladder; this occurs more often in young women.",183,42,0.22950819672131148
9781910797426,ch07,"Sphincter of Oddi manometry is the diagnostic gold standard for the dysfunction. Biliary or pancreatic duct pressure of more than 40 mmHg is diagnostic of biliary or pancreatic sphincter dysfunction, respectively.","Cross-sectional imaging. Dilation of the common bile duct is seen on transabdominal ultrasound or endoscopic ultrasonography (EUS). Endoscopic retrograde cholangiopancreatography (ERCP) reveals dilation of the bile or pancreatic duct when drainage of contrast medium from the biliary or pancreatic ductal systems is delayed. Sphincter of Oddi manometry is the diagnostic gold standard. The biliary and pancreatic duct pressures are measured; an elevated basal pressure above 40 mmHg is diagnostic. A decrease in basal pressure after administration of a smooth muscle relaxant may help to differentiate between stenosis and spasm. Sphincter of Oddi manometry could be considered to confirm a diagnosis of type II biliary dysfunction. The limitations of this test include its invasiveness, lack of availability and an increased risk of pancreatitis (up to 20-30% in some series). Provocation tests. An increase in the size of the bile duct (> 2 mm) after injection of cholecystokinin, or an increase in the size of the pancreatic duct (> 1.5 mm) after injection of secretin supports the diagnosis of biliary or pancreatic sphincter dysfunction, respectively.",258,48,0.18604651162790697
9781910797426,ch07,"Data suggest that sphincterotomy is not more effective than a sham procedure in patients with type III dysfunction, leading some to suggest type III dysfunction may not be a real disease.","Pancreatic sphincterotomy may be undertaken if recurrent pancreatitis is considered to be related to pancreatic sphincter hypertension. Underlying chronic pancreatitis may adversely affect the outcome of pancreatic sphincterotomy via surgical or endoscopic methods. A randomized sham-controlled trial of sphincterotomy in patients with pain after cholecystectomy, without significant imaging findings (dilated bile duct) or laboratory abnormalities, showed that sphincterotomy was not more effective than a sham procedure. Manometeric pressure abnormalities were not associated with the sphincterotomy outcome. This study mostly involved patients in the type III sphincter of Oddi dysfunction group. Based on this evidence-based study, some have suggested that sphincter of Oddi dysfunction type III is not a real disease and one should not pursue manometry or ERCP in these patients.",187,37,0.19786096256684493
9781910797426,ch07,"A low gallbladder ejection fraction of less than 35-40% on Tc-HIDA (hepatobiliary iminodiacetic acid) scan with gallbladder stimulation may be diagnostic of gallbladder dyskinesia (functional gallbladder disorder), and is the best predictor of response to cholecystectomy.","Diagnosis. Liver function tests and white cell count are normal. Transabdominal ultrasonography shows a normal-sized common bile duct and no stones in the gallbladder. Other investigations (exempli gratia endoscopy, EUS and CT) may be needed to rule out other causes of right upper quadrant pain. Symptoms and signs include intermittent right upper quadrant pain, often postprandially. Nausea and vomiting also occur, possibly related to intake of fatty food. Cholecystokinin-stimulated scintigraphy. A Tc-HIDA (technetium-labeled hepatobiliary iminodiacetic acid) scan with gallbladder stimulation by intravenous administration of cholecystokinin (CCK) can be used to calculate the gallbladder ejection fraction. An ejection fraction below 35-40% is considered abnormal and these patients are more likely to respond to cholecystectomy. In some patients the pain of gallbladder dyskinesia is reproduced when CCK is administered. Treatment is by cholecystectomy, usually laparoscopic. In patients whose gallbladder ejection fraction by CCK-stimulated scintigraphy is less than 35-40%, a significant number will experience improvement or resolution of pain following cholecystectomy. Before attempting cholecystectomy other diagnoses need to be eliminated as a cause for the patient's abdominal pain. Careful selection of appropriate patients for cholecystectomy must be undertaken. Treatment by cholecystectomy for this condition is controversial.",333,70,0.21021021021021022
9781910797426,ch07,The pain of gallbladder dyskinesia is reproduced in some patients when cholecystokinin is administered.,Cholecystokinin-stimulated scintigraphy. A Tc-HIDA (technetium-labeled hepatobiliary iminodiacetic acid) scan with gallbladder stimulation by intravenous administration of cholecystokinin (CCK) can be used to calculate the gallbladder ejection fraction. An ejection fraction below 35-40% is considered abnormal and these patients are more likely to respond to cholecystectomy. In some patients the pain of gallbladder dyskinesia is reproduced when CCK is administered.,118,25,0.211864406779661
9781910797426,ch08,"If the etiology is uncertain, endoscopic ultrasonography should be performed following resolution of the attack to exclude unusual causes of obstruction such as small stones or tumors.","Laboratory tests. The diagnosis is based on a typical clinical presentation (abdominal pain with acute onset of persistent severe epigastric pain radiating to the back), plus a serum lipase (or amylase) that is three times the normal upper limit within 2-3 days of the onset of symptoms. The serum amylase peaks at about 24 hours after the onset of the attack and then declines exponentially over the next 5-7 days. Thus, if the amylase is measured at day 4 or 5 after the onset of the attack, it may be only marginally raised or within normal limits. Urinary amylase may be cleared more slowly, but the diagnostic threshold is much higher (tenfold). An elevated serum alanine transaminase level (> 60 IU/L) within 48 hours of an attack is highly indicative of a possible biliary cause. Imaging. Absence of gas on an erect plain abdominal and chest radiograph will eliminate most large gastrointestinal perforations. The presence of gallbladder stones is often missed by abdominal ultrasound during an acute attack, but endoscopic ultrasonography (EUS) has high sensitivity and specificity for the diagnosis of gallstones, especially small stones (< 3 mm; microlithiasis). MRI or transabdominal ultrasound are used less commonly for the initial diagnosis.",272,33,0.1213235294117647
9781910797426,ch08,Prognostic evaluation for the severity of the disease should be completed within the first 3 days of symptom onset.,"The majority of patients have diffuse enlargement of the pancreas due to edema, with symptoms that usually resolve rapidly. Up to 10% of patients have necrosis of the pancreatic and peripancreatic tissues, which continues for several days, with variable evolution towards persistence or disappearance, remaining sterile or becoming infected. Based on the revised Atlanta classification, the presence of fluid alone and the presence of necrosis with variable amounts of fluid about the pancreas are important distinctions in the definition of acute pancreatitis type. Predicting severity. It is important to determine as early as possible (within the first 3 days of symptom onset) whether the attack of pancreatitis is likely to be mild or severe.",144,22,0.1527777777777778
9781910797426,ch08,An urgent CT scan of the abdomen should be performed if there is any doubt about the diagnosis of acute pancreatitis.,"Endoscopic treatment. Urgent endoscopic retrograde cholangiopancreatography (ERCP), undertaken less than 24 hours from onset with an intention to complete endoscopic sphincterotomy, should be performed in patients with acute pancreatitis and concurrent acute cholangitis due to retained common bile duct (CBD) stones. ERCP is usually not indicated in mild or moderately severe acute biliary pancreatitis without cholangitis or CBD obstruction. However, in patients with predicted severe acute pancreatitis secondary to gallstones, when imaging and biochemical tests highly predict an obstructed CBD (even without cholangitis), ERCP will possibly reduce morbidity and mortality from acute pancreatitis. EUS and magnetic resonance cholangiopancreatography are needed to prove the presence of suspected CBD stones, and will prevent unnecessary ERCP in patients with acute biliary pancreatitis without cholangitis and/or jaundice.",195,23,0.11794871794871795
9781910797426,ch08,"It should be determined whether gallstones are the cause of the attack; if so, urgent endoscopic sphincterotomy should be performed in severe cases; all cases of acute biliary pancreatitis usually require cholecystectomy.","Endoscopic treatment. Urgent endoscopic retrograde cholangiopancreatography (ERCP), undertaken less than 24 hours from onset with an intention to complete endoscopic sphincterotomy, should be performed in patients with acute pancreatitis and concurrent acute cholangitis due to retained common bile duct (CBD) stones. ERCP is usually not indicated in mild or moderately severe acute biliary pancreatitis without cholangitis or CBD obstruction. However, in patients with predicted severe acute pancreatitis secondary to gallstones, when imaging and biochemical tests highly predict an obstructed CBD (even without cholangitis), ERCP will possibly reduce morbidity and mortality from acute pancreatitis. EUS and magnetic resonance cholangiopancreatography are needed to prove the presence of suspected CBD stones, and will prevent unnecessary ERCP in patients with acute biliary pancreatitis without cholangitis and/or jaundice.",195,48,0.24615384615384617
9781910797426,ch08,"If severe acute pancreatitis with extensive necrosis is found beyond the first week, fine needle aspiration for bacteriology and fungi should be performed; if there is proven infected necrosis, pancreatic necrosectomy might be required.","Surgical treatment may be required in necrotizing acute pancreatitis if infected necrosis is present or suspected (based on clinical deterioration or prolonged organ failure). It should, however, be postponed as much as possible in favor of minimally invasive radiological or endoscopic drainage options. The principal purpose of surgery in severe acute pancreatitis is the removal of necrotic pancreatic tissue (necrosectomy). Surgery is indicated (relatively) in extensive sterile pancreatic necrosis where there is no improvement of symptoms following at least 2 weeks of optimal care from the detection of extensive necrosis. Drainage is indicated in cases with symptoms of obstruction (gastrointestinal or biliary), although it should be postponed for at least 4 weeks to allow liquefaction of the contents and development of a fibrous wall (walled-off necrosis). Minimally invasive methods include percutaneous (CT or ultrasound guided) or endoscopic methods (EUS-guided drainage and necrosectomy), as well as minimally invasive retroperitoneal necrosectomy. Most tertiary referral centers prefer these methods to open necrosectomy.",232,46,0.19827586206896552
9781910797426,ch09,"Chronic pancreatitis is a risk factor for pancreatic cancer, which may develop within the chronic pancreatitis.","Chronic pancreatitis is a progressive inflammatory process of the pancreas that leads to irreversible functional and morphological destruction of the pancreas. The pathological features of chronic pancreatitis are. disruption of the lobular parenchymal architecture, with extensive destruction of pancreatic acini (and subsequently islets of Langerhans) and replacement by fibrous or fatty tissue. chronic inflammatory infiltrate. pancreatic ductal and parenchymal calcification.",99,22,0.2222222222222222
9781910797426,ch09,"Beside medical treatment, severe pain may need endoscopic or surgical intervention.",Inflammatory cells interact with the damaged nerves (neuroimmune interactions). Expression of nerve growth factor and tyrosine kinase receptor A is increased and has a significant relationship with pain intensity. Pain may be increased as a consequence of local complications such as pseudocysts and biliary tract or duodenal obstruction.,65,16,0.24615384615384617
9781910797426,ch09,"The diagnosis must be clearly established by radiological, endoscopic and/or functional tests.","Tissue diagnosis by endoscopic ultrasonography. EUS-guided fine needle aspiration and EUS-guided core biopsy techniques appear to be attractive options for cytological or tissue diagnosis of chronic pancreatitis. However, the application of these techniques for chronic pancreatitis is still developing (along with concern about complications, especially with EUS-guided core biopsy) and they are not yet used routinely, except for the differentiation of pancreatic adenocarcinoma from pseudotumoral chronic pancreatitis (Figure 9.6).",108,18,0.16666666666666666
9781910797426,ch09,Risk factors such as smoking and alcohol should be discouraged.,"Elimination of environmental risk factors such as alcohol consumption and tobacco smoking may modify symptoms and, to some extent, the long-term outcome. Before any type of interventional treatment is considered, medical management must be optimized. The factors governing appropriate fat digestion are complex (Figure 9.7). Fat intake should not be restricted but the patient must take sufficient pancreatic enzyme supplementation with each meal. Replacement of lipase is the key factor; at least 40 to 80 000 lipase units should be divided between meals every day. The addition of a proton pump inhibitor is of particular importance, as this will increase duodenal pH and improve lipase activity. Some pancreatic enzyme products are microencapsulated enteric-coated preparations which prevent acid denaturation of lipase through delayed release.",161,12,0.07453416149068323
9781910797426,ch09,Medical measures must be optimized.,"Elimination of environmental risk factors such as alcohol consumption and tobacco smoking may modify symptoms and, to some extent, the long-term outcome. Before any type of interventional treatment is considered, medical management must be optimized.",45,6,0.13333333333333333
9781910797426,ch10,Patients with idiopathic chronic pancreatitis are likely to carry cystic fibrosis transmembrane conductance regulator ( CFTR ) mutations in one or both alleles of the gene (compound heterozygotes).,"Hereditary pancreatitis represents a rare cause of chronic pancreatitis and is associated mostly with mutations in the protease serine 1 (PRSS1) gene. These mutations often afflict individuals from a very young age (< 10 years), inducing recurrent acute abdominal pain (acute pancreatitis) in over 70%. In addition to PRSS1 mutations, other mutations, primarily mutations in the serine protease inhibitor Kazal type 1 (SPINK1) and cystic fibrosis transmembrane conductance regulator (CFTR) genes, are involved in the etiopathogenesis of hereditary pancreatitis. Patients can have severe episodes of acute recurrent pancreatitis, which lead to chronic pancreatitis with calcifications, and possibly exocrine and endocrine insufficiency. The risk of pancreatic cancer in these patients is higher compared with the general population. By the age of 70 years, 60% of patients with hereditary pancreatitis will develop exocrine insufficiency, including all of the expected symptoms of steatorrhea and weight loss. By this age, 70% will also develop diabetes mellitus, almost all of whom will require insulin. Exocrine and endocrine failure develop in a much higher proportion of patients with hereditary pancreatitis than those with either idiopathic or alcoholic pancreatitis, but the time until failure is longer. About 35% of 70-year-old patients are at risk of pancreatic cancer. This incidence is much higher than with other forms of chronic pancreatitis (around 5%) and compares with an incidence of 1% in the general population.",319,46,0.14420062695924765
9781910797426,ch10,"There is a lifetime risk of pancreatic cancer (35%), as well as a high risk of diabetes mellitus and exocrine insufficiency.","Patients can have severe episodes of acute recurrent pancreatitis, which lead to chronic pancreatitis with calcifications, and possibly exocrine and endocrine insufficiency. The risk of pancreatic cancer in these patients is higher compared with the general population. By the age of 70 years, 60% of patients with hereditary pancreatitis will develop exocrine insufficiency, including all of the expected symptoms of steatorrhea and weight loss. By this age, 70% will also develop diabetes mellitus, almost all of whom will require insulin. Exocrine and endocrine failure develop in a much higher proportion of patients with hereditary pancreatitis than those with either idiopathic or alcoholic pancreatitis, but the time until failure is longer. About 35% of 70-year-old patients are at risk of pancreatic cancer. This incidence is much higher than with other forms of chronic pancreatitis (around 5%) and compares with an incidence of 1% in the general population.",196,29,0.14795918367346939
9781910797426,ch10,Children and young adults are often misdiagnosed with other gastrointestinal diseases.,"The nature of the abdominal pain seen in hereditary pancreatitis is commonly misdiagnosed in children and young adults; this fact, coupled with the reduced penetrance, often leads to clinical confusion and a failure to identify the existence of close relatives with pancreatitis. It is vital that patients undergo appropriate genetic counseling before any genetic tests are undertaken. A positive genetic test may help in the future management of any symptomatic children. Patients with idiopathic chronic pancreatitis are at high risk of having a CFTR mutation; this may have significant implications for people planning to have children, particularly in areas where there are many carriers of the mutated CFTR gene in the general population. This is because there will be an increased risk of parenting a child with cystic fibrosis (an autosomal-recessive condition) caused by the inheritance of two mutated CFTR genes, one from each parent.",177,14,0.07909604519774012
9781910797426,ch10,"Patients should undergo genetic counseling prior to genetic testing, and from the age of 40 years patients should be offered secondary screening for cancer in a regional pancreas cancer center.","The treatment of hereditary pancreatitis is at first identical to that of other forms of chronic pancreatitis. Alcohol consumption and tobacco smoking are both independent risk factors for chronic pancreatitis and pancreatic cancer, and should therefore be strongly discouraged. As with other forms of chronic pancreatitis, about 30% of patients will require active intervention by endoscopy and/or surgery because of local pancreatic complications or intractable pain. From the age of 40 years, patients with hereditary pancreatitis should be counseled regarding regular secondary screening for the detection of pancreatic cancer. Screening is an evolving field and international guidelines state that it should only take place at major regional pancreas centers using both MRI and endoscopic ultrasonography.",145,35,0.2413793103448276
9781910797426,ch10,Alcohol and tobacco consumption should be strongly discouraged.,"The treatment of hereditary pancreatitis is at first identical to that of other forms of chronic pancreatitis. Alcohol consumption and tobacco smoking are both independent risk factors for chronic pancreatitis and pancreatic cancer, and should therefore be strongly discouraged.",46,10,0.21739130434782608
9781910797426,ch11,Pancreatic cancer should be suspected in any patient (over 40 years of age) with unresolving epigastric symptoms.,"Symptoms and signs of pancreatic cancer are shown in Table 11.2. In the case of tumors of the head of the pancreas, painless obstructive jaundice (jaundice with dark urine and pale stools) commonly occurs but the presentation is usually insidious. Weight loss, nausea, vomiting, and abdominal and back pain can also be suggestive of pancreatic head cancer, although they are more frequently encountered in body and tail tumors. As a result of the location, symptoms appear earlier in the head of the pancreas, while the evolution is often insidious until late stages in body and tail lesions. Pancreatic cancer should be suspected in any patient (over 40 years of age) with unresolving epigastric symptoms.",153,27,0.17647058823529413
9781910797426,ch11,"Accurate detection and staging are based on CT and may be supplemented by endoscopic ultrasonography (EUS), MRI and laparoscopy.","Contrast-enhanced computed tomography is the examination of choice for diagnosis and staging for resectability, provided that dedicated pancreatic protocols and latest state-of-the-art multidetector scanners are used (Figure 11.2). Enlargement of lymph nodes per se is a poor prognostic indicator. Portal or splenic venous involvement has become less relevant for surgical resection, while arterial encasement or involvement of the celiac artery and/or superior mesenteric artery is a very important factor in determining resectability. Although dynamic contrast-enhanced CT has less accuracy than endoscopic ultrasonography (EUS) for detecting small tumors (less than 2 cm), for staging purposes CT is still recommended. CT may be supplemented by EUS, MRI and laparoscopy.",166,30,0.18072289156626506
9781910797426,ch11,Adjuvant chemotherapy is used systematically following resection.,"Contrast-enhanced computed tomography is the examination of choice for diagnosis and staging for resectability, provided that dedicated pancreatic protocols and latest state-of-the-art multidetector scanners are used (Figure 11.2). Enlargement of lymph nodes per se is a poor prognostic indicator. Portal or splenic venous involvement has become less relevant for surgical resection, while arterial encasement or involvement of the celiac artery and/or superior mesenteric artery is a very important factor in determining resectability. Although dynamic contrast-enhanced CT has less accuracy than endoscopic ultrasonography (EUS) for detecting small tumors (less than 2 cm), for staging purposes CT is still recommended. CT may be supplemented by EUS, MRI and laparoscopy.",166,11,0.06626506024096386
9781910797426,ch11,"If the cancer is not resectable, symptoms may be relieved with EUS-guided celiac plexus neurolysis and non-surgical treatment consisting of chemotherapy (exempli gratia gemcitabine or fluoropyrimidine combinations) and pain management.","Positron-emission tomography (PET) is not routinely used in the diagnosis and staging of pancreatic cancer. However, PET in combination with CT or MRI may play an important role in the future for the staging of pancreatic cancer and patient stratification. Tissue diagnosis may be obtained by brushings during ERCP or fine needle aspirations (FNA) obtained percutaneously or by EUS. However, EUS-guided FNA is the preferred method for tissue diagnosis and has a higher accuracy than ERCP with brush cytology. Preoperative tissue diagnosis may not always be needed in a resectable pancreatic mass if the symptoms, signs, laboratory data and imaging are classic for pancreatic cancer in an otherwise surgically fit patient. However, when a preoperative tissue diagnosis is required in a potentially resectable pancreatic mass, EUS-guided FNA should be the preferred route on account of the lower potential risk of peritoneal seeding, the shorter needle tract and the inclusion of the needle track in the resection specimen (in pancreatic head tumors). Tissue diagnosis may be needed in borderline resectable pancreatic tumors if the patient is to undergo preoperative neoadjuvant chemotherapy or chemoradiation therapy before surgery.",258,56,0.21705426356589147
9781910797426,ch11,"In borderline resectable patients, preoperative neoadjuvant chemotherapy and radiation can be considered.","Tissue diagnosis may be obtained by brushings during ERCP or fine needle aspirations (FNA) obtained percutaneously or by EUS. However, EUS-guided FNA is the preferred method for tissue diagnosis and has a higher accuracy than ERCP with brush cytology. Preoperative tissue diagnosis may not always be needed in a resectable pancreatic mass if the symptoms, signs, laboratory data and imaging are classic for pancreatic cancer in an otherwise surgically fit patient. However, when a preoperative tissue diagnosis is required in a potentially resectable pancreatic mass, EUS-guided FNA should be the preferred route on account of the lower potential risk of peritoneal seeding, the shorter needle tract and the inclusion of the needle track in the resection specimen (in pancreatic head tumors). Tissue diagnosis may be needed in borderline resectable pancreatic tumors if the patient is to undergo preoperative neoadjuvant chemotherapy or chemoradiation therapy before surgery.",204,20,0.09803921568627451
9781910797426,ch11,Patients with pancreatic adenocarcinoma must be managed by a multidisciplinary team in a high-volume regional pancreas cancer center.,"The majority of patients present with advanced disease and have an overall median survival of less than 6 months, and a 5-year survival rate of up to 5%. Up to 10-20% of patients undergo pancreatic resection, with an overall median survival of 11-20 months, and a 5-year survival rate of 7-25%; virtually all patients die within 7 years of surgery. According to published guidelines, all patients with pancreatic cancer must be treated in a specialist high-volume center by a multidisciplinary team (Figure 11.5). Once the diagnosis is made or strongly suspected, the next objective is to stage the disease. If the tumor is resectable and there are no metastases then resection should be undertaken. If resection is not possible then non-surgical treatment should be undertaken.",166,32,0.1927710843373494
9781910797426,ch12,Solitary metastases to the pancreas may be worth resecting.,"Unusual tumors of the pancreas and ampulla of Vater. A variety of tumors arise in close proximity to or within the pancreas that require special consideration and need to be differentiated from pancreatic ductal adenocarcinoma (Table 12.1). Ampullary, bile duct and duodenal tumors.",71,17,0.23943661971830985
9781910797426,ch12,Tumor types that occur in the ampullary and periampullary regions may have a much better prognosis than pancreatic adenocarcinoma.,"Etiology and pathogenesis. Cancers of the ampulla of Vater, the intrapancreatic bile duct and duodenum are all adenocarcinomas and often present in a manner similar to pancreatic cancer. Bile duct cancers are also called cholangiocarcinomas, although this term is usually reserved for more proximal bile duct tumors. All of these tumors progress from a small benign adenoma through to invasive adenocarcinoma, although most are only detected at the cancerous stage. Ampullary tumors arise from the common channel of the ampulla of Vater as benign adenomas and progress as tubulovillous adenomas before becoming adenocarcinomas. Two pathological types of ampullary cancer have been described (intestinal versus pancreaticobiliary), with important consequences for patients' prognosis. Duodenal tumors also commence as adenomas before progressing to invasive adenocarcinoma. The long-term survival of patients with these cancers is better than that for pancreatic ductal adenocarcinoma (Figure 12.1).",236,35,0.1483050847457627
9781910797426,ch12,Patients with inherited neuroendocrine tumors require genetic counseling and long-term follow-up for pancreatic and other tumor types.,"Etiology and pathogenesis. Cancers of the ampulla of Vater, the intrapancreatic bile duct and duodenum are all adenocarcinomas and often present in a manner similar to pancreatic cancer. Bile duct cancers are also called cholangiocarcinomas, although this term is usually reserved for more proximal bile duct tumors. All of these tumors progress from a small benign adenoma through to invasive adenocarcinoma, although most are only detected at the cancerous stage. Ampullary tumors arise from the common channel of the ampulla of Vater as benign adenomas and progress as tubulovillous adenomas before becoming adenocarcinomas. Two pathological types of ampullary cancer have been described (intestinal versus pancreaticobiliary), with important consequences for patients' prognosis. Duodenal tumors also commence as adenomas before progressing to invasive adenocarcinoma. The long-term survival of patients with these cancers is better than that for pancreatic ductal adenocarcinoma (Figure 12.1).",236,26,0.11016949152542373
9781910797426,ch12,Neuroendocrine tumors should usually be removed surgically.,"Imaging and biopsy. Ampullary and duodenal tumors may be visualized by endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasonography (EUS). Brush cytology of the bile duct may also be undertaken for bile duct strictures using ERCP. Invasive adenocarcinomas usually arise deep within an ampullary tumor. For this reason, endoscopic sphincterotomy through the ampullary tumor needs to be performed and biopsies taken from deep within the tumor.",118,12,0.1016949152542373
9781910797426,ch12,Patients with pancreatic neuroendocrine tumors need to be managed by a multidisciplinary team.,"Management. Patients with pNETs need to be managed by a multidisciplinary team that includes specialist endocrinologists, gastroenterologists, radiologists and pancreatic surgeons. Medical treatment. The syndromes associated with all of these tumors, except for insulinoma, can be managed medically during the wait for surgery or, if there is metastatic disease, with a long-acting somatostatin receptor antagonist (octreotide long-acting release or lanreotide slow release). Although antitumor efficacy of somatostatin analogs is rather weak, there is disease stabilization in more than 50% of patients. Surgical tumor debulking is commonly undertaken, since the symptoms may still be difficult to control with somatostatin receptor antagonists.",153,20,0.13071895424836602
9781910797426,ch12,"Cystic pancreatic tumors need to be differentiated from pancreatic pseudocysts, but only a minority need resection at the time of diagnosis.","Cystic pancreatic tumors. Cystic neoplasms need to be distinguished from pseudocysts secondary to acute or chronic pancreatitis. These tumors include serous cystadenomas, mucinous cystadenomas, mucinous cystadenocarcinomas, intraductal papillary mucinous neoplasms and other rare cystic lesions (cystic neuroendocrine tumors, etc.). Diagnosis is made by CT (Figure 12.4) or MRI with magnetic resonance cholangiopancreatography sequences (Figure 12.5), usually followed by EUS-guided FNA and analysis of the cystic fluid (Figure 12.6).",134,29,0.21641791044776118
9781910797433,ch01,"Ovarian cancer is the seventh most common cancer in women worldwide, and a leading cause of cancer death among women.","Epithelial ovarian cancer is the seventh most common cancer among women worldwide, with nearly 239 000 new cases reported in 2012. It has the highest mortality of all gynecologic cancers, largely due to the fact that the majority of cases are not diagnosed until the disease has reached an advanced stage. Ovarian cancer often presents with a vague clinical picture, with gradual onset of non-specific symptoms that may be mistaken for those of other, benign, conditions such as the menopause or irritable bowel syndrome. A high index of suspicion is needed for prompt diagnosis, but even so, most cases will still present at advanced stages when the disease has already spread into the upper abdomen.",136,24,0.17647058823529413
9781910797433,ch01,"The highest incidence rates are seen in non-Hispanic white women, and the lowest in African or Asian women.","Epithelial ovarian cancer is the seventh most common cancer among women worldwide, with nearly 239 000 new cases reported in 2012. It has the highest mortality of all gynecologic cancers, largely due to the fact that the majority of cases are not diagnosed until the disease has reached an advanced stage. Ovarian cancer often presents with a vague clinical picture, with gradual onset of non-specific symptoms that may be mistaken for those of other, benign, conditions such as the menopause or irritable bowel syndrome. A high index of suspicion is needed for prompt diagnosis, but even so, most cases will still present at advanced stages when the disease has already spread into the upper abdomen. The incidence of ovarian cancer varies markedly around the world: typically, the highest rates are seen in non-Hispanic white women, followed by Hispanic, African and Asian women (Figure 1.1).",175,22,0.12571428571428572
9781910797433,ch01,"Survival rates in ovarian cancer are the lowest of any gynecologic malignancy, largely because the majority of cases are diagnosed at an advanced stage.","Ovarian cancer accounted for an estimated 152 000 deaths worldwide in 2012. In the UK, approximately 4100 women died as a result of ovarian cancer in 2014, making it the fifth most common cause of cancer death among women. Across the UK, the age-standardized mortality rate in 2014 was 12.9 per 100 000 population, with the highest rates in Northern Ireland and Wales (15.8 and 14.5 per 100 000, respectively) and the lowest in England (12.7 per 100 000). In the USA, it is anticipated that ovarian cancer will account for approximately 14 080 deaths in 2017. Mortality rates are disproportionately higher among women of African-American descent. Survival rates in ovarian cancer are the lowest of any gynecologic malignancy. Typically, 5-year survival rates are less than 50%, largely because three-quarters of cases are diagnosed at advanced stages (III/IV). Although age-standardized mortality rates are falling in many high-income countries, they are increasing in many low- and middle-income countries.",215,31,0.14418604651162792
9781910797433,ch01,"Mutations in the BRCA1 or BRCA2 genes are the most important genetic factors contributing to an increased risk of ovarian cancer. However, the genetic risk factors known at present account for less than half of the excess risk of the disease.","Genetics. The risk of ovarian cancer is approximately threefold higher in women with a first-degree relative (id est mother or sister) affected by ovarian cancer: indeed, a positive family history is the strongest known risk factor for ovarian cancer, even though 40% of patients with BRCA1- or BRCA2- related ovarian cancer have a negative family history. Furthermore, as noted above, the incidence of ovarian cancer varies markedly between ethnic groups. These findings clearly demonstrate the importance of genetic factors in ovarian cancer. However, the role of genetics is complex: specific genes have been implicated in both the development and progression of the disease, and in the response to therapy (Figure 1.3), while the effect of individual genes may be modulated by environmental factors. Numerous genes have been implicated in the development of ovarian cancer (Table 1.2), of which the most common are BRCA1 and BRCA2 and the mismatch repair genes MSH6, MSH2 and MLH1, which are also associated with colorectal and endometrial cancers. However, it is estimated that the genetic risk factors known at present account for less than half of the excess familial risk of ovarian cancer.",248,51,0.2056451612903226
9781910797433,ch01,Oral contraceptive use is strongly protective against ovarian cancer.,"Oral contraceptive use. In a landmark analysis of 45 epidemiological studies, the use of oral contraceptives was associated with proportional reductions in the risk of ovarian cancer of 15-29% over 5 years. The protective effect of oral contraceptives increased with duration of use, and persisted for more than 30 years after discontinuation (Figure 1.4). On the basis of these results, the authors concluded that, at the date of publication (2008), oral contraceptives had prevented about 200 000 ovarian cancers, and 100 000 deaths from the disease and that the number of cancers prevented would rise to at least 30 000 per year over coming decades. Similarly, a meta-analysis of six studies in women with BRCA1 and BRCA2 mutations showed that oral contraceptive use reduced the risk for ovarian cancer by more than 40% (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.46-0.73) in this high-risk population.",196,11,0.05612244897959184
9781910797433,ch01,Risk-reducing surgery (salpingo-oophorectomy) is recommended for high-risk women up to the age of 45 years.,"Recognition of the importance of genetic and hormonal factors in the development of ovarian cancer has led to potential strategies for prevention of the disease. In particular, salpingo-oophorectomy is now widely recommended for high-risk (BRCA1/2- positive) women aged 40-45 years, once child-bearing is complete. A recent meta-analysis showed that prophylactic salpingo-oophorectomy reduced the risk of ovarian cancer by more than 80% (hazard ratio [HR] 0.19, 95% CI 0.13-0.27, p < 0.00001) in women with BRCA1 or BRCA2 mutations. It was also associated with a significant decrease in all-cause mortality (HR 0.32, 95% CI 0.27-0.38, p < 0.00001). Iatrogenic menopause and its effects must be fully discussed with the patient.",200,32,0.16
9781910797433,ch01,"To date, large screening trials based on CA125 measurement and transvaginal ultrasound have failed to show any significant benefits in terms of reducing deaths from ovarian cancer.","The US Prostate, Lung, Colorectal and Ovarian (PLCO) study included 78 216 women, aged 55-74 years, randomized to receive annual screening with CA125 for 6 years and transvaginal ultrasound for 4 years, or no screening. Participants were followed for up to 13 years. Screening had no significant effect on the incidence of deaths from ovarian cancer (RR 1.18, 95% CI 0.82-1.71), but surgery following false-positive diagnoses was associated with serious complications in 15% of patients. On the basis of these results, the US Preventative Services Task Force concluded that ovarian cancer screening should not be offered to women at low risk of the disease.",145,32,0.2206896551724138
9781910797433,ch02,"Increasing evidence suggests that serous tubal intraepithelial carcinomas (STICs) in the fallopian tube are the most common precursor lesions of high-grade serous ovarian cancer, the most common type of epithelial ovarian cancer.","Traditionally, it was believed that ovarian cancers usually originated in the surface epithelium of the ovaries. Although this theory supports the genesis of low-grade serous carcinoma, recent studies indicate that high-grade serous carcinoma (HGSC), the most common histological subtype of ovarian cancer, originates in the fimbria of the fallopian tubes (Figure 2.1). Precancerous lesions, called serous tubal intraepithelial carcinomas (STICs) have been found on the fimbria in 5-10% of women with BRCA1 or BRCA2 mutations undergoing risk-reducing surgery and in up to 60% of unselected women with pelvic HGSC. For this reason, the term 'ovarian cancer' should be considered a collective term that covers all ovarian-fallopial tube and primary peritoneal cancers. Ovarian cancer cells tend to exfoliate into the peritoneum, where circulation of peritoneal fluid distributes them to the peritoneal surfaces and omentum. Indeed, intraperitoneal dissemination is the most characteristic feature of ovarian cancer; malignant cells can implant anywhere in the peritoneal cavity, particularly at sites of stasis within the peritoneal fluid circulation system. The disease can spread via a number of mechanisms, including.",277,50,0.18050541516245489
9781910797433,ch02,Intraperitoneal dissemination is the most characteristic feature of ovarian cancer.,"Ovarian cancer cells tend to exfoliate into the peritoneum, where circulation of peritoneal fluid distributes them to the peritoneal surfaces and omentum. Indeed, intraperitoneal dissemination is the most characteristic feature of ovarian cancer; malignant cells can implant anywhere in the peritoneal cavity, particularly at sites of stasis within the peritoneal fluid circulation system. The disease can spread via a number of mechanisms, including.",93,14,0.15053763440860216
9781910797433,ch02,Borderline ovarian tumors constitute a separate tumor entity and can present with the same histological subgroups as the invasive form of the disease.,"The World Health Organization (WHO) histological classification of epithelial ovarian cancer is summarized in Figure 2.2. Epithelial tumors are the most common form of ovarian cancer, and the main focus of this book. The WHO classification for other forms of ovarian cancer are summarized in Table 2.1 and discussed in Chapter 9. Epithelial tumors include benign, borderline and malignant histologies. Borderline tumors are a separate tumor entity characterized by complex papillary architecture, stratified epithelium with tufting (apparent detachment of cell clusters from their sites of origin), moderate nuclear abnormalities and moderately increased mitotic activity; in contrast to malignant tumors, they do not show stromal invasion. The pathological characteristics of borderline tumors are.",151,27,0.17880794701986755
9781910797433,ch03,"Inherited genetic mutations are associated with about 15% of ovarian cancers, depending on the histological subtype.","As described in Chapter 1, genetic factors are an important determinant of ovarian cancer risk. Indeed, inherited genetic mutations are associated with about 15% of ovarian cancers, depending on the cancer subtype. Furthermore, some epithelial ovarian cancers result from somatic mutations, as well as mutations in other genes that are critical in DNA repair pathways. Importantly, the absence of a family history of ovarian cancer may not preclude a genetic predisposition: inherited mutations may be present in up to 25% of women with high-grade serous carcinoma (HGSC), but up to half of these women may not have a family history of ovarian or breast cancer., For these reasons, genetic testing has a valuable role to play in identifying women at risk of ovarian cancer.",153,23,0.1503267973856209
9781910797433,ch03,"Most guidelines recommend that all women diagnosed with ovarian cancer should be referred for genetic counseling and testing, irrespective of their family history.","Guidelines for genetic testing. A number of organizations have published recommendations and guidelines for genetic counseling and testing (also see Further reading, page 31). -, Most of these recommend that all women diagnosed with epithelial ovarian cancer should undergo genetic testing, irrespective of their family history or age at diagnosis. The majority of guidelines recommend that genetic testing should include both pre- and post-test counseling with a genetic counselor or other appropriate healthcare professional with expertise in cancer genetics. The benefits of genetic testing in patients with ovarian cancer include.",104,25,0.2403846153846154
9781910797433,ch03,"Cascade screening of close blood relatives of individuals found to carry specific genetic mutations can markedly reduce testing costs, because it is only necessary to test for the specific mutation.","enabling amendments to screening recommendations and patient counseling, including consideration of surgical or non-surgical risk reduction strategies. the opportunity for cascade testing of relatives (see below). Cascade testing. Cascade testing is the testing of close blood relatives of individuals known to be at high risk of genetic conditions. If a genetic mutation (exempli gratia a BRCA1 mutation) is identified through initial genetic testing of the patient, further testing for this mutation can then be offered to close blood relatives of the affected individual (Figure 3.1). Using this strategy, it is only necessary to test for the specific mutation, rather than performing multigene testing; as a result, the cost of testing can be significantly reduced.",146,33,0.22602739726027396
9781910797433,ch03,"Referral rates to genetic counseling services are low, despite numerous guideline recommendations, because there are still significant funding issues.","Despite the potential benefits of genetic testing in terms of identifying women at high risk of ovarian cancer, referral rates for genetic counseling services are low. In one study, only 14.5% of women with ovarian cancer who should have been referred according to the US National Comprehensive Cancer Network guidelines received a referral for genetic counseling, and of those only 59.5% opted for counseling (although it should be noted that about 95% of women who received counseling subsequently underwent genetic testing). Significant predictors for referral included.",101,23,0.22772277227722773
9781910797433,ch04,The majority (> 80%) of women with epithelial ovarian cancer will become apparent and diagnosed at an advanced stage of the disease.,"As outlined in Chapter 1, the majority of women with ovarian cancer (> 80%) are not diagnosed until the disease has reached an advanced stage. The initial diagnostic pathway of epithelial ovarian cancer is based on the assessment of symptoms and overall clinical picture, biomarkers (particularly CA125), family history and imaging. Symptoms. Although ovarian cancer has previously been considered a 'silent killer', it is now recognized that a high proportion of women have symptoms before diagnosis., The most common symptoms are vague and non-specific, resembling irritable bowel syndrome, and hence a diagnosis of ovarian cancer may be missed (Table 4.1). In general, further evaluation may be appropriate in a patient with severe or frequent symptoms of recent onset.",145,25,0.1724137931034483
9781910797433,ch04,"There are no reliable imaging tools to accurately describe the stage of the disease or tumor dissemination patterns, especially in fine nodular peritoneal carcinomatosis and microscopically involved lymph nodes.","Imaging. The ability of current imaging techniques to accurately depict lesions in the peritoneum is limited, especially in fine nodular disease. This represents a significant challenge in diagnosing low-volume disease and accurately describing intra-abdominal tumor dissemination patterns. Nevertheless, CT has a well-established role in diagnosing bulky (> 1 cm) lymphadenopathy, distant intraparenchymatous metastatic lesions and additional lesions such as secondary cancers and thromboembolic events that have a significant effect on patient management. Diffusion-weighted MRI may have a future role in the description of tumor dissemination patterns and assessment of operability, but prospective evidence data are needed. There is also no evidence to support the routine use of positron emission tomography (PET)-CT, although this technique may be useful in highly specialized situations; for example, in the evaluation of thoracic or mediastinal lymph nodes before secondary or tertiary debulking.",195,39,0.2
9781910797433,ch04,"Comprehensive surgical staging accurately defines the disease stage, resulting in more reliable prediction of prognosis and more appropriate management strategies and systemic treatment.","Complete surgical staging of ovarian cancer is essential to accurately define the stage of the disease and determine appropriate adjuvant treatment. This is a multistage process involving cytology, multiple peritoneal biopsies, omentectomy and, in cases of early disease, pelvic/para-aortic lymph node dissection (Figure 4.1). Up to 30% of patients with apparent early disease will be upstaged after comprehensive staging. The staging system of the International Federation of Gynecological Oncology (FIGO) is shown in Figure 4.2. Having an accurate FIGO stage will influence the treatment strategies that are most appropriate for the individual patient.",137,27,0.19708029197080293
9781910797433,ch05,Surgery is one of the cornerstones of treatment for ovarian cancer.,"Surgery is the cornerstone of management for both early and advanced ovarian cancer, although the aims are different in each case. In patients with presumed early disease, the aim of surgery is to remove the primary tumor, along with adequate peritoneal and lymphogenic staging. In advanced disease, the aim is to achieve maximal cytoreduction and tumor reduction.",70,14,0.2
9781910797433,ch05,The key aims of surgery are tumor removal and accurate staging.,"Surgery is the cornerstone of management for both early and advanced ovarian cancer, although the aims are different in each case. In patients with presumed early disease, the aim of surgery is to remove the primary tumor, along with adequate peritoneal and lymphogenic staging.",53,12,0.22641509433962265
9781910797433,ch05,Multivisceral surgery is needed to achieve complete tumor resection.,"Tertiary cytoreduction. The largest multicenter analysis of tertiary cytoreductive surgery evaluated 406 patients (median age 55 years; range 16-80) who underwent surgery between 1997 and 2011 in 12 centers across Europe, the USA and Asia. Most of the patients had initial FIGO stage III/IV disease (69%), peritoneal carcinomatosis (51.7%) and absence of ascites (72.2%). The most frequent tumor dissemination site was the pelvis (73%). In total, 224 patients (54.1%) underwent complete tumor resection. This study confirmed that - even in the tertiary setting - complete macroscopic tumor clearance is a significant predictor of both overall and progression-free survival. Median overall survival for patients without residual tumor was 49 months (95% CI 42.5-56.4) compared with 12 months (95% CI 9.3-14.7) in patients with residual tumor (p < 0.001). By contrast, peritoneal carcinomatosis was not prognostic for survival after controlling for residual tumor status. Importantly, common clinicopathological characteristics such as tumor stage, age and histological subtype, which have been shown to be significant predictors of survival at initial presentation, did not appear to be of any prognostic significance at the tertiary stage. Multivariate analysis identified platinum resistance, residual tumor at secondary surgery and peritoneal carcinomatosis to be of predictive significance for complete tumor resection, while residual tumor at secondary and tertiary surgery, decreasing time to second relapse, ascites, upper abdominal tumor involvement and non-platinum third-line chemotherapy significantly affected overall survival.",344,14,0.040697674418604654
9781910797433,ch05,"Surgery for relapsed disease is associated with significant prolongation of progression-free survival in prospective studies; data for overall survival are not yet mature, but in retrospective series patients who are tumor free after surgery at relapse have significantly longer overall survival than those with residual tumor.","Tertiary cytoreduction. The largest multicenter analysis of tertiary cytoreductive surgery evaluated 406 patients (median age 55 years; range 16-80) who underwent surgery between 1997 and 2011 in 12 centers across Europe, the USA and Asia. Most of the patients had initial FIGO stage III/IV disease (69%), peritoneal carcinomatosis (51.7%) and absence of ascites (72.2%). The most frequent tumor dissemination site was the pelvis (73%). In total, 224 patients (54.1%) underwent complete tumor resection. This study confirmed that - even in the tertiary setting - complete macroscopic tumor clearance is a significant predictor of both overall and progression-free survival. Median overall survival for patients without residual tumor was 49 months (95% CI 42.5-56.4) compared with 12 months (95% CI 9.3-14.7) in patients with residual tumor (p < 0.001). By contrast, peritoneal carcinomatosis was not prognostic for survival after controlling for residual tumor status. Importantly, common clinicopathological characteristics such as tumor stage, age and histological subtype, which have been shown to be significant predictors of survival at initial presentation, did not appear to be of any prognostic significance at the tertiary stage. Multivariate analysis identified platinum resistance, residual tumor at secondary surgery and peritoneal carcinomatosis to be of predictive significance for complete tumor resection, while residual tumor at secondary and tertiary surgery, decreasing time to second relapse, ascites, upper abdominal tumor involvement and non-platinum third-line chemotherapy significantly affected overall survival.",344,54,0.1569767441860465
9781910797433,ch05,"Peritoneal carcinomatosis is associated with lower complete debulking rates at relapse, but not with inferior overall survival in tumor-free patients who undergo surgery.","Tertiary cytoreduction. The largest multicenter analysis of tertiary cytoreductive surgery evaluated 406 patients (median age 55 years; range 16-80) who underwent surgery between 1997 and 2011 in 12 centers across Europe, the USA and Asia. Most of the patients had initial FIGO stage III/IV disease (69%), peritoneal carcinomatosis (51.7%) and absence of ascites (72.2%). The most frequent tumor dissemination site was the pelvis (73%). In total, 224 patients (54.1%) underwent complete tumor resection. This study confirmed that - even in the tertiary setting - complete macroscopic tumor clearance is a significant predictor of both overall and progression-free survival. Median overall survival for patients without residual tumor was 49 months (95% CI 42.5-56.4) compared with 12 months (95% CI 9.3-14.7) in patients with residual tumor (p < 0.001). By contrast, peritoneal carcinomatosis was not prognostic for survival after controlling for residual tumor status. Importantly, common clinicopathological characteristics such as tumor stage, age and histological subtype, which have been shown to be significant predictors of survival at initial presentation, did not appear to be of any prognostic significance at the tertiary stage. Multivariate analysis identified platinum resistance, residual tumor at secondary surgery and peritoneal carcinomatosis to be of predictive significance for complete tumor resection, while residual tumor at secondary and tertiary surgery, decreasing time to second relapse, ascites, upper abdominal tumor involvement and non-platinum third-line chemotherapy significantly affected overall survival.",344,34,0.09883720930232558
9781910797433,ch06,"Most patients with ovarian cancer present at advanced stages of disease, and thus require chemotherapy.","Most patients with ovarian cancer present at advanced stages of disease, and thus require chemotherapy. Only those found to have stage I grade 1 disease after comprehensive staging are not considered for any adjuvant therapy. Patients with stage I grade 2 disease are sometimes excluded from adjuvant treatment, and the number of cycles prescribed is sometimes reduced in such cases. At least 6 cycles of chemotherapy are routinely recommended in patients with stage II disease and beyond (Figure 6.1).",92,17,0.18478260869565216
9781910797433,ch06,"Options for adjuvant therapy include standard chemotherapy, dose-dense chemotherapy and intraperitoneal treatment.","Most patients with ovarian cancer present at advanced stages of disease, and thus require chemotherapy. Only those found to have stage I grade 1 disease after comprehensive staging are not considered for any adjuvant therapy. Patients with stage I grade 2 disease are sometimes excluded from adjuvant treatment, and the number of cycles prescribed is sometimes reduced in such cases. At least 6 cycles of chemotherapy are routinely recommended in patients with stage II disease and beyond (Figure 6.1).",92,22,0.2391304347826087
9781910797433,ch06,The combination of carboplatin and paclitaxel is the standard of care for the front-line treatment of ovarian cancer.,"The choice of therapy depends on the physician, and is often tailored to the characteristics of the patient. The combination of carboplatin and paclitaxel is the current standard of care for first-line chemotherapy in ovarian cancer. A number of key clinical trials have shown that a combination of paclitaxel and cisplatin is superior in efficacy to cisplatin plus cyclophosphamide,, and that carboplatin/paclitaxel is at least comparable in efficacy to cisplatin/paclitaxel but better tolerated (Table 6.1).",114,26,0.22807017543859648
9781910797433,ch06,Women who have a high perioperative risk profile or a low likelihood of achieving cytoreduction to less than 1 cm (ideally to no visible disease) should receive neoadjuvant chemotherapy.,"Two landmark Phase III trials have shown that interval cytoreduction after initial chemotherapy is a viable option in patients with advanced stage ovarian cancer., The first involved 670 women with stage IIIC/IV epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer and an extrapelvic tumor 2 cm or more in diameter. The experimental group received platinum-based neoadjuvant therapy, followed by interval debulking surgery and subsequent adjuvant chemotherapy; the control group received primary debulking surgery followed by at least 6 cycles of platinum-based chemotherapy. There were no significant differences between the study groups with regard to overall survival (OS) (hazard ratio [HR] 0.98; 90% CI 0.84-1.13, p = 0.01 for non-inferiority) or progression-free survival (PFS) (HR 1.01; 90% CI 0.89-1.15). However, there were significant differences between the study groups in the incidence of surgery-related serious (grade 3/4) adverse events, including hemorrhage (12 versus 23, respectively; relative risk [RR] 0.50; 95% CI 0.25-0.99), venous thromboembolism (0 versus 8; RR 0.06; 95% CI 0-0.98) and infection (5 versus 25; RR 0.19; 95% CI 0.07-0.50).",298,40,0.1342281879194631
9781910797433,ch06,"A key component in the choice of adjuvant or neoadjuvant therapy is the ability to cytoreduce, ideally to 'no gross residual tumor'.","As a result of these studies, the Society of Gynecologic Oncology (SGO) and the American Society of Clinical Oncology (ASCO) issued a joint guidance statement on the use of neoadjuvant chemotherapy in patients with advanced ovarian cancer. Key recommendations from these guidelines are summarized in Table 6.2. According to these guidelines, a key component in the choice of adjuvant or neoadjuvant therapy (in addition to patient comorbidities) is the ability to cytoreduce, based upon tumor distribution. The goal is to cytoreduce to no gross residual tumor, as this R-0 status yields the highest survival rates.",138,33,0.2391304347826087
9781910797433,ch06,"Among the current standards of care, the choice of therapy is generally based on a number of considerations, including patient characteristics, physician preference and regulatory status.","Intraperitoneal chemotherapy. The use of IP chemotherapy has been advocated for small-volume residual disease, given that an extremely high peritoneal to serum drug concentration ratio can potentially be achieved by this approach. Several randomized studies have shown that IP therapy can produce improvements of 20-30% in PFS, OS, or both (Table 6.3). - However, to date the GOG252 trial has not shown an advantage for IP therapy in terms of the primary endpoint, PFS; it has been suggested that the lower doses of drug used in this study, and the use of bevacizumab in all three arms of the trial, may have confounded the efficacy results. Increased toxicity is an important concern in patients receiving IP chemotherapy. For example, in the GOG172 trial, which compared intravenous and IP paclitaxel and cisplatin, grade 3/4 fatigue, pain or hematologic, gastrointestinal, metabolic or neurological toxicities were significantly more common with IP than with intravenous therapy (Table 6.4). Among the current standards of care, the choice of therapy is generally based on a number of considerations, including. patient characteristics (age, performance status, comorbidities, etc.).",251,30,0.11952191235059761
9781910797433,ch07,Ovarian cancer will recur in approximately two-thirds of patients with advanced ovarian cancer after primary treatment.,"Recurrent ovarian cancer. Despite initial treatment, ovarian cancer will recur in nearly two-thirds of women who originally presented with advanced disease. In this situation, the aims of treatment change from achieving cure to. extending survival. preserving quality of life by mitigating treatment-related adverse effects and ameliorating symptoms of the recurrent disease. Recurrent ovarian cancer may present in a number of ways, and may be asymptomatic or symptomatic. With asymptomatic (chemical) recurrence, disease may be minimal and the value of treatment in this situation has been challenged. The use of routine CA125 monitoring after front-line therapy varies globally, and is still common in the USA despite data questioning the value of such monitoring.",150,22,0.14666666666666667
9781910797433,ch07,"The choice of treatment in patients with recurrent ovarian cancer will depend on a number of patient-, drug- and tumor-related factors.","The choice of treatment in patients with recurrent ovarian cancer will depend on a number of patient-, drug- and tumor-related factors (Figure 7.1). Traditionally, the choice of treatment has been determined by the time that has elapsed since the last platinum-based chemotherapy: in practice, however, the treatment-free interval, irrespective of last platinum dose, may be even more valuable. In the near future, these somewhat restrictive determinants of treatment will be supplemented with more predictive factors such as BRCA status or tumor histology, and by gene- or pathway-based assessments that facilitate individualized therapy. Nevertheless, the traditional definitions of platinum resistance or sensitivity remain relevant in guiding treatment (Figure 7.2).",144,26,0.18055555555555555
9781910797433,ch07,Platinum-sensitive patients are generally treated with platinum-containing regimens. Platinum-resistant patients are generally treated with non-platinum single agent chemotherapies with or without bevacizumab.,"Patients in whom recurrence occurs more than 6 months after primary platinum treatment are often subdivided into two groups. highly platinum-sensitive patients, in whom recurrence occurs more than 12 months after primary platinum treatment. intermediately sensitive patients, in whom recurrence occurs 6-12 months after primary treatment. Platinum-resistant patients, in whom recurrence occurs within 6 months of primary platinum treatment, are generally treated with non-platinum options; these usually include single agent chemotherapies with or without bevacizumab. Some clinicians define patients who actually progress on front-line treatment as platinum-refractory. They are often treated similarly to platinum-resistant patients, although some clinicians recommend continuing the platinum backbone while substituting the taxane with an alternative chemotherapeutic. The prognosis and probability of response to subsequent treatment correlate directly with the time from the previous platinum or other treatment (Figure 7.3).",189,43,0.2275132275132275
9781910797433,ch07,Survival data and response rates are suboptimal with all single-agent therapies used in platinum-resistant recurrent disease: new therapies are needed in this setting.,"Chemotherapy for platinum-resistant disease. Patients with disease that recurs within 6 months of primary platinum treatment are generally treated with single agents, with or without bevacizumab. The most commonly used agents for retreatment include (usually weekly) paclitaxel, docetaxel, PLD, gemcitabine, topotecan and pemetrexed. Key clinical trials with these agents are summarized in Table 7.2. Unfortunately, the survival data and the objective response rates (less than 15%) are not impressive for any of the available single agents in the platinum-resistant setting; novel compounds and approaches are needed.",132,32,0.24242424242424243
9781910797433,ch08,Precision medicine has become a key strategy in ovarian cancer.,"Precision medicine has become a key strategy in ovarian cancer as a result of advances in a number of areas, including pharmacogenomics, bioinformatics and molecular biology (Figure 8.1). It is hoped that precision medicine will allow the identification of patients who could maximally benefit from a particular drug or combination of drugs, and that this more precise targeted strategy will result in improved efficacy while minimizing toxicity.",82,12,0.14634146341463414
9781910797433,ch08,There is great hope that targeted therapies will offer improved outcomes.,"Precision medicine has become a key strategy in ovarian cancer as a result of advances in a number of areas, including pharmacogenomics, bioinformatics and molecular biology (Figure 8.1). It is hoped that precision medicine will allow the identification of patients who could maximally benefit from a particular drug or combination of drugs, and that this more precise targeted strategy will result in improved efficacy while minimizing toxicity. Ultimately, it is hoped that targeted therapies will offer improved outcomes.",95,12,0.12631578947368421
9781910797433,ch08,Targeted therapy generally involves identifying a gene or protein that is overexpressed in cancer and can be reasonably targeted with acceptable toxicity.,"The first attempts at developing targeted therapies in ovarian cancer have revolved around the recognition that epithelial ovarian cancers have different prognoses and distinct molecular changes associated with different histological subtypes. Among the tumors with a better prognostic histology, high-grade serous carcinomas (HGSC) commonly present with p53 mutations and overall genomic instability, while endometrioid tumors often exhibit PTEN and PI3K mutations. By contrast, mucinous and clear cell tumors confer a significantly worse prognosis, and are more usually associated with KRAS and ARID1A mutations. These findings, particularly in tumors with poor prognostic histologies, offer opportunities to design clinical trials targeting these molecular pathways. Several different strategies have been advocated for targeted approaches to ovarian cancer, generally involving identification of a gene or protein that is overexpressed and can be reasonably targeted with acceptable toxicity (Figure 8.2). Clinically relevant approaches, or those that are likely to become so in the near future, are discussed in this chapter.",207,26,0.12560386473429952
9781910797433,ch08,"Poly (ADP-ribose) polymerase (PARP) inhibitors - olaparib, rucaparib, niraparib and veliparib - appear to be comparable in efficacy, but have differing toxicity profiles.","Strategies to increase the number of patients who would benefit from PARP inhibition have led investigators to examine the role of other genes that influence DNA repair in the homologous recombination pathway. In addition to BRCA1 and BRCA2, a number of other genes such as RAD51 and PALB2 have been shown to play a significant role in the development of ovarian cancer, as described in Chapter 3. Mutations or epigenetic alterations in these genes result in homologous recombination deficiency (HRD). Up to 50% of epithelial ovarian cancers show defective DNA repair, making this process an important therapeutic target. PARP inhibitors. Four PARP inhibitors have been developed for use in ovarian cancer: olaparib, rucaparib, niraparib and veliparib. They appear to have similar efficacy, although further data are needed to confirm this initial impression. Preclinical data have shown some differences such as the higher tumor penetration observed with niraparib versus olaparib, but the clinical implications of these data remain unclear. The PARP inhibitors have distinct toxicity profiles, including an increased incidence of liver enzyme elevations with rucaparib, higher rates of grade 3/4 thrombocytopenia with niraparib, and diarrhea with olaparib. All agents are associated with fatigue, and there has been concern about myelodysplastic syndrome; however, to date, the incidence of the latter does not appear to exceed the background rate for ovarian cancer.",319,51,0.15987460815047022
9781910797433,ch08,Inhibition of tumor angiogenesis is the most successful targeted therapy strategy in ovarian cancer.,"Therapies that target angiogenesis and associated growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), have been shown to inhibit new blood vessel growth, which in turn leads to tumor regression. There are a number of angiogenesis pathways that represent promising therapeutic targets; indeed, to date, inhibition of angiogenesis has been the most successful targeted strategy in ovarian cancer.",98,18,0.1836734693877551
9781910797433,ch08,Bevacizumab has shown activity as a single agent in recurrent ovarian cancer in both platinum-sensitive and -resistant disease.,"Bevacizumab, a monoclonal antibody directed against VEGF, has been the most widely studied anti-angiogenic agent in ovarian cancer. Initial single-agent activity has been demonstrated in recurrent ovarian cancer in both platinum-sensitive and -resistant disease: Table 8.1 details the various trials by line of therapy. In addition, results from the ENGOT-ov15/AGO OVAR 17 study are pending. However, regulatory approval has lacked harmonization globally: some countries have limited approval to use in recurrent disease, whereas others have permitted use in front-line treatment. Major adverse effects of bevacizumab include hypertension, proteinuria, gastrointestinal perforation or fistula and thromboembolic disease.",155,27,0.17419354838709677
9781910797433,ch08,"A number of immuno-oncologic therapies, including inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1), have shown efficacy in various solid tumors and are under active development in ovarian cancer.","Interest in manipulating the immune system to combat cancers has expanded dramatically in recent years. The concept is that if the immune system can learn to recognize malignant cells as foreign antigens, a robust T-cell mediated response, among other pathways, could be induced. Cancer cells evade these tumor-directed T cells by subverting immune checkpoint pathways and other immune-regulatory mechanisms. This observation has led to the identification of numerous targets and therapeutic strategies with checkpoint inhibitors and other agents (Figure 8.4). Checkpoint proteins, such as programmed cell death (PD)-1, prevent the immune system from activating a response, and some tumor cells are able to express the ligand that binds to this protein (PD-L1), thereby suppressing an immune response. Antibodies that target the PD-1 protein or its ligand can block this suppression and thereby activate an immune response. Another important protein on the T cell, which if bound and activated can suppress an immune response, is cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).",215,50,0.23255813953488372
9781910797433,ch09,Non-epithelial malignant neoplasms account for 10-15% of ovarian cancers.,"Non-epithelial tumors are rare, accounting for 10-15% of all ovarian malignant neoplasms., The most common types are germ cell tumors (GCTs) and sex cord-stromal tumors (SCSTs) (Table 9.1). The prognosis of non-epithelial ovarian neoplasms tends to be better than for epithelial cancers, largely because most tend to present at an earlier stage: 60-70% of GCTs and 60-95% of SCSTs are detected at an early stage., They will commonly present at younger ages, compared with the more common epithelial ovarian cancer.",131,20,0.15267175572519084
9781910797433,ch09,They occur at younger ages than the more common epithelial ovarian cancer.,"Non-epithelial tumors are rare, accounting for 10-15% of all ovarian malignant neoplasms., The most common types are germ cell tumors (GCTs) and sex cord-stromal tumors (SCSTs) (Table 9.1). The prognosis of non-epithelial ovarian neoplasms tends to be better than for epithelial cancers, largely because most tend to present at an earlier stage: 60-70% of GCTs and 60-95% of SCSTs are detected at an early stage., They will commonly present at younger ages, compared with the more common epithelial ovarian cancer.",131,14,0.10687022900763359
9781910797433,ch09,"Adequate surgical staging is essential, and should be performed even when fertility-sparing surgery is planned.","Treatment. Unilateral salpingo-oophorectomy (see Figure 5.1) with adequate peritoneal staging should be considered as a fertility-preserving option for patients with stage I disease. If the uterus is preserved, an evaluation of the endometrium, for example through dilatation and curettage, should be performed to exclude an estrogen-induced endometrial cancerous or precancerous state. Systematic lymph node dissection or sampling has no value in the absence of bulky nodes. Similarly, there is no value in blind biopsies of a normal contralateral ovary.",127,22,0.1732283464566929
9781910797433,ch09,"There is inconclusive evidence for the use of systemic chemotherapy, rather than antihormonal treatment, in malignant non-epithelial ovarian tumors. In completely resected disease, there is little evidence to support a survival benefit with additional systemic treatment.","Treatment. Unilateral salpingo-oophorectomy (see Figure 5.1) with adequate peritoneal staging should be considered as a fertility-preserving option for patients with stage I disease. If the uterus is preserved, an evaluation of the endometrium, for example through dilatation and curettage, should be performed to exclude an estrogen-induced endometrial cancerous or precancerous state. Systematic lymph node dissection or sampling has no value in the absence of bulky nodes. Similarly, there is no value in blind biopsies of a normal contralateral ovary. Maximal effort debulking surgery, aiming at complete cytoreduction, is the most effective treatment for patients with metastatic or recurrent granulosa cell tumors., There are no data to support a survival benefit with postoperative chemotherapy for women with resected disease. However, the BEP regimen (bleomycin, etoposide, cisplatin) is usually recommended for women with advanced disease, although the less toxic carboplatin and paclitaxel combination is increasingly being used. In patients with hormone receptor-positive disease, antihormonal treatment has also been shown to be effective.",249,51,0.20481927710843373
9781910797433,ch09,Complete cytoreduction is the cornerstone of treatment in advanced and relapsed disease.,"Maximal effort debulking surgery, aiming at complete cytoreduction, is the most effective treatment for patients with metastatic or recurrent granulosa cell tumors., There are no data to support a survival benefit with postoperative chemotherapy for women with resected disease. However, the BEP regimen (bleomycin, etoposide, cisplatin) is usually recommended for women with advanced disease, although the less toxic carboplatin and paclitaxel combination is increasingly being used. In patients with hormone receptor-positive disease, antihormonal treatment has also been shown to be effective.",122,16,0.13114754098360656
9781910797433,ch10,Follow-up should involve holistic aspects and psycho-oncologic support.,"Follow-up and palliative surgery. As in all cancer care, the follow-up of patients with ovarian cancer mostly lacks any prospective randomized evidence basis: guidelines are largely based on tradition, the wishes and experiences of patients and physicians, and rather arbitrary timelines depending on the type of examinations performed. In general, follow-up aims not only to diagnose relapse, but also to holistically assess and manage ongoing physical, psychological, emotional, financial and sexual survivorship issues.",95,15,0.15789473684210525
9781910797433,ch10,"The value, type and role of follow-up in cancer care is not well defined and prospective randomized trials are scarce.","Serial measurement of CA125 often forms part of follow-up, because elevations of CA125 precede symptomatic relapse by a median of 4.5 months (range 0.5-29.5 months). However, this approach failed to demonstrate any significant effect on patients' survival in the UK-based prospective randomized MRC/EORTC trial, in which there was no difference in overall survival between patients who received chemotherapy based on a rising CA125 level and those who did not receive chemotherapy until they were symptomatic (Figure 10.1). In this study, however, only 6% of the patients underwent surgery for relapsed disease. Depending on the final analysis of the DESKTOP III survival data, follow-up for ovarian cancer may need to be reshaped and redefined, as it may be worthwhile detecting the disease while it is apparently operable and when the patient has a good performance status.",184,24,0.13043478260869565
9781910797433,ch10,The type of follow-up depends on whether the patient has undergone fertility-sparing surgery.,"Serial measurement of CA125 often forms part of follow-up, because elevations of CA125 precede symptomatic relapse by a median of 4.5 months (range 0.5-29.5 months). However, this approach failed to demonstrate any significant effect on patients' survival in the UK-based prospective randomized MRC/EORTC trial, in which there was no difference in overall survival between patients who received chemotherapy based on a rising CA125 level and those who did not receive chemotherapy until they were symptomatic (Figure 10.1). In this study, however, only 6% of the patients underwent surgery for relapsed disease. Depending on the final analysis of the DESKTOP III survival data, follow-up for ovarian cancer may need to be reshaped and redefined, as it may be worthwhile detecting the disease while it is apparently operable and when the patient has a good performance status.",184,19,0.10326086956521739
9781910797433,ch10,Serial CA125 measurements have failed to show any survival benefit over observation alone.,"Serial measurement of CA125 often forms part of follow-up, because elevations of CA125 precede symptomatic relapse by a median of 4.5 months (range 0.5-29.5 months). However, this approach failed to demonstrate any significant effect on patients' survival in the UK-based prospective randomized MRC/EORTC trial, in which there was no difference in overall survival between patients who received chemotherapy based on a rising CA125 level and those who did not receive chemotherapy until they were symptomatic (Figure 10.1). In this study, however, only 6% of the patients underwent surgery for relapsed disease. Depending on the final analysis of the DESKTOP III survival data, follow-up for ovarian cancer may need to be reshaped and redefined, as it may be worthwhile detecting the disease while it is apparently operable and when the patient has a good performance status.",184,15,0.08152173913043478
9781910797433,ch10,Palliative surgery should be performed only after all conservative management options have been exhausted.,"Patients undergoing fertility-sparing treatment should receive regular ultrasonographic examination of the contralateral ovary and the endometrial cavity to diagnose relapse in the remaining Mllerian organs. Depending on the initial stage, the patient's wishes and reproductive history and her overall response to cancer treatment, removal of the uterus and contralateral ovary may be discussed after completion of childbearing.",79,17,0.21518987341772153
9781910797433,ch10,Short bowel syndrome is a common complication after palliative surgery for bowel obstruction in relapsed disease.,"Patients with epithelial ovarian cancer often present with symptoms of impaired intestinal transit or clinical bowel obstruction at relapse, which is attributable to the diffuse peritoneal dissemination of recurrent tumor. The use of novel targeted therapies with anti-angiogenic potential may favor fistula formation or intestinal perforation, and so recurrent epithelial ovarian cancer with the potential for such severe acute complications constitutes a therapeutic dilemma. Palliative surgery in patients with gastrointestinal and other symptoms of ovarian cancer recurrence therefore requires a multidisciplinary approach.",104,20,0.19230769230769232
9781910797457,chp1,"Prostate cancer is soon likely to supersede lung cancer as the most common cause of cancer death in men in western countries, as fewer men smoke and the population is aging.","Prostate cancer is the most common malignancy to affect men of middle age and beyond in most developed countries and, increasingly in developing countries, it is second only to lung cancer as a cause of cancer deaths in men. The lifetime risk of developing clinical prostate cancer in western countries is about 1 in 8. Approximately 80% of men aged 80 years have prostate cancer at autopsy. However, many of these cancers grow slowly and the risk of developing clinically detectable cancer is about 13%; the lifetime risk of actually dying from prostate cancer is approximately 3%. Worldwide, there has been a steady increase in the incidence of clinically significant prostate cancer, although in the USA the number of incidental diagnoses of prostate cancer has fallen by 28% since the US Preventive Task Force issued a draft guideline in 2011 (which became a final recommendation 2012) discouraging prostate-specific antigen (PSA)-based screening in all men (Figure 1.1).",185,35,0.1891891891891892
9781910797457,chp1,"Age is the greatest risk factor but race, family history, western-style diet and obesity also have an effect.","Race. Marked geographic and racial variations are seen in the incidence of clinical prostate cancer (Table 1.2). The risk is highest in North America and northern European countries, and lowest in the Far East. In the USA, the risk is higher in black men than in white men, and black men also appear to develop more aggressive disease earlier. The incidence of prostate cancer is lowest in Chinese and Japanese races, although the prevalence is now increasing in both. The incidence of latent (clinically insignificant) disease is similar in all populations studied. The incidence of prostate cancer in men who emigrate from a low- to a high-risk area increases to that of the local population within two generations. This suggests that environmental influences such as diet and lifestyle factors may have a profound effect on the development of prostate cancer and on the progression of latent to clinically detectable cancer.",174,23,0.13218390804597702
9781910797457,chp1,Most prostate cancers are adenocarcinomas arising in the peripheral zone of the gland.,"Most prostate cancers are adenocarcinomas. The majority (> 70%) appear to arise in the peripheral zone of the gland (Figure 1.3); 5-15% arise in the central zone and the remainder from the transition zone, which is where benign prostatic hyperplasia (BPH) also develops. Microscopic foci of 'latent' prostate cancer are a common autopsy finding and may appear very early in life: approximately 30% of men over 50 years of age have evidence of latent disease. However, these microscopic tumors often grow very slowly, and many never progress to clinical disease. Beyond a certain size, however, these lesions progressively de-differentiate, probably as a result of clonal selection, and become increasingly invasive. A tumor with a volume greater than 0.5 cm or that is anything other than well differentiated is generally regarded as clinically significant.",179,19,0.10614525139664804
9781910797457,chp1,"Prostate cancers are graded according to the Gleason system, which carries prognostic significance.","Because prostate cancers are often heterogeneous, the numbers of the two most widely represented grades are added to produce the Gleason score (exempli gratia 3 + 4), which provides useful prognostic information. Occasionally, more than two grades are observed in prostatectomy or biopsy specimens, the least common being known as the tertiary grade. If the tertiary grade has a high score (4 or 5), the patient has increased risk of disease progression even if the primary and secondary grades are lower, and the tertiary rather than the secondary grade informs the score.",115,18,0.1565217391304348
9781910797457,chp2,"In one trial, the 5alpha-reductase inhibitor, dutasteride, reduced the incidence of prostate cancer by about one-quarter over 4 years and also relieved symptoms of benign prostatic hyperplasia (BPH), but slightly increased the incidence of high-grade cancer. Finasteride produced similar results.","Chemoprevention refers to the use of drugs to reduce the risk of cancer. The 5alpha-reductase inhibitor finasteride has been shown to reduce the incidence of prostate cancer by 24.8% compared with placebo over a 7-year period, although at the cost of a small but significant increase in sexual side effects. However, this is counterbalanced by the finding that a small proportion of cancers in the finasteride group tended to be more aggressive than those in the placebo group, although this may have been an artifact of taking biopsies from the smaller prostates in the active treatment arm resulting from the shrinkage effect of finasteride. A 2013 study reported that there was no difference in the overall survival (OS) rate, or survival after a diagnosis of prostate cancer, between the placebo-treated and finasteride-treated patients after 18 years of follow-up. Another 5alpha-reductase inhibitor, dutasteride, has been evaluated for its effect on the occurrence of prostate cancer in the REDUCE study (Reduction by Dutasteride of Prostate Cancer Events). Dutasteride resulted in a 23% reduction in the development of prostate cancer, mainly by suppressing the well-differentiated cancers, with only a slight (statistically insignificant) increase in Gleason pattern 7 or 8-10 poorly differentiated tumors. It also effectively treated the symptoms arising from benign prostatic hyperplasia (BPH). Neither of these compounds were approved by the regulatory authorities for chemoprevention.",311,65,0.2090032154340836
9781910797457,chp2,"Men should be advised / supported to lower lipid profiles, address obesity and increase exercise and fitness as part of a strategy to cut the risk of cardiovascular disease and associated death, and, possibly, prostate cancer.","Very few trials have investigated the effect of diet and lifestyle change on prostate cancer progression. Table 2.2 outlines the current body of evidence. In addition, a large number of compounds - many of them herbal - have been tested in the laboratory and show potential; these include green tea and other polyphenols, resveratrol from red wine, vitamin D, epilobium and Serenoa repens (saw palmetto). It must be remembered that cardiovascular disease is still the primary cause of death in men, with or without prostate cancer, and heart-healthy lifestyle choices will reduce mortality in men with prostate cancer. These include improving lipid profiles, decreasing obesity and increasing physical fitness. A healthy diet and regular vigorous exercise may help protect the individual against various forms of cancer, in addition to decreasing the risk of death from cardiovascular causes.",170,41,0.2411764705882353
9781910797457,chp3,"Increasingly, prostate cancer is being diagnosed on the basis of a raised prostate-specific antigen (PSA) level and subsequent investigation.","The past decade has seen a significant downward shift in the stage at presentation of prostate cancer in most countries. Historically, most men with clinically significant disease presented with a combination of weight loss, bone pain, lethargy and bladder outflow obstruction, attributable to locally advanced or metastatic disease. More commonly today, early disease is detected incidentally from measurement of prostate-specific antigen (PSA) in younger, asymptomatic men; occasionally it is an incidental histological finding following transurethral resection of the prostate (TURP) for benign obstructive symptoms. This earlier presentation has posed dilemmas concerning management, and the increasing life expectancy of patients (Figure 3.1) underscores the urgent need for effective evidence-based diagnosis and treatment regimens.",155,28,0.18064516129032257
9781910797457,chp3,"More advanced disease can present with symptoms of bladder outflow obstruction, hematuria or ureteric obstruction.","The past decade has seen a significant downward shift in the stage at presentation of prostate cancer in most countries. Historically, most men with clinically significant disease presented with a combination of weight loss, bone pain, lethargy and bladder outflow obstruction, attributable to locally advanced or metastatic disease. More commonly today, early disease is detected incidentally from measurement of prostate-specific antigen (PSA) in younger, asymptomatic men; occasionally it is an incidental histological finding following transurethral resection of the prostate (TURP) for benign obstructive symptoms. This earlier presentation has posed dilemmas concerning management, and the increasing life expectancy of patients (Figure 3.1) underscores the urgent need for effective evidence-based diagnosis and treatment regimens.",155,23,0.14838709677419354
9781910797457,chp3,PSA-based screening of asymptomatic men is controversial.,"PSA velocity refers to the rate of PSA change, usually over 1 or 2 years, based on a minimum of three readings. A velocity above 0.75 ng/mL/year has been used to predict the presence of prostate cancer. However, recent studies have shown that the average PSA velocity in men without prostate cancer is 0.03 ng/mL/year, compared with 0.4 ng/mL/year in men ultimately diagnosed with prostate cancer. A PSA velocity of 0.35-0.4 ng/mL/year is largely recommended as the threshold at which biopsy is recommended, even if the actual PSA level is within the normal range. Problems associated with PSA velocity include inaccuracy of velocity calculation over short time periods, and too few measurements being made (PSA levels show natural fluctuation, such as after ejaculation).",175,14,0.08
9781910797457,chp3,A baseline PSA at age 40-55 years may assess a man's future risk of developing prostate cancer.,Measurement of PSA in early midlife (40-55 years) can identify a small group of men at risk of prostate cancer metastasis several decades later: men who have a PSA in the highest 10th percentile for their age group have a 3-10-fold higher risk of metastasis 15 years later. Men with a PSA above 1.0 ng/mL in this age group have also been found to be at higher risk of developing metastatic prostate cancer and it has been suggested that they should be invited for regular PSA tests.,112,22,0.19642857142857142
9781910797457,chp3,Bone metastases may cause bone pain or pathological fracture.,"Metastasis into the lymph nodes may cause their enlargement. Intra-abdominal lymph node metastasis usually begins in the obturator and internal iliac nodes, spreads to the common iliac nodes and beyond and may, with local tumors, obstruct the ureters. In advanced disease, lymphatic involvement may extend to the thoracic, cervical, inguinal and axillary nodes. Lymph node metastases may produce a number of symptoms, including palpable swellings, loin pain or anuria due to obstruction of the ureters, and swelling of the legs due to lymphedema.",129,11,0.08527131782945736
9781910797457,chp4,Multiparametric MRI is increasingly used to target biopsies and can provide information about local staging.,"Once a man has undergone a prostate-specific antigen (PSA) test and digital rectal exam (DRE), a reasonable level of suspicion for the presence of prostate cancer may arise. The next step is to make the definitive diagnosis. This requires a prostate biopsy which will give definitive histological evidence of prostate cancer and also the cancer grade (Gleason grade group; see pages 14 -). Multiparametric MRI is increasingly used before biopsy to identify suspicious lesions within the prostate that would allow targeted biopsy, and may also mean that biopsy can be avoided in some men with normal MRI findings and lower levels of suspicion.",129,21,0.16279069767441862
9781910797457,chp4,Prostate cancer is usually diagnosed on the basis of transrectal or transperineal biopsy.,"Accuracy. The combination of MRI methods is claimed to significantly improve the detection and local staging of prostate cancer by MRI, and is now widely used before prostate biopsy to target suspicious areas, and to follow up patients managed by active surveillance. Indeed, some are now arguing that prior MRI is a prerequisite to improve the accuracy of biopsy and to avoid false-negative findings. Furthermore, in cases where a biopsy is warranted, a negative finding on MRI can provide reassurance to the patient, id est that they don't have prostate cancer. The recently completed PROMIS study evaluated the diagnostic accuracy of an mpMRI scan followed by both template prostate mapping (TPM) biopsy and standard transrectal ultrasonography (TRUS)-guided biopsy in 576 men with suspected prostate cancer. Fewer than half (40%) of those who underwent TPM were diagnosed with aggressive cancer, and mpMRI identified 93% of the clinically significant cancers, whereas the TRUS biopsy only correctly identified 48%. Furthermore, nine out of 10 men (89%) who had a negative mpMRI scan did not have a cancer, or had a harmless cancer. The authors concluded that prior MRI avoids unnecessary TRUS biopsy in 27% of men whilst reducing the number of men who are 'over diagnosed' by 5%. If subsequent TRUS biopsy is directed by mpMRI findings, up to 18% more cases of clinically significant cancer might be detected compared with using TRUS biopsy in all patients.",301,21,0.06976744186046512
9781910797457,chp4,Ultrasound-guided biopsy is needed to confirm the diagnosis.,"Transrectal ultrasonography-guided biopsy (Figure 4.2) has been the standard method for performing prostate biopsy for decades and it is now routinely performed on an outpatient basis, after infiltration with local anesthesia. Usually 12-18 TRUS-guided biopsies are taken from different regions of the prostate using an 18-gauge needle. Antibiotics are obligatory before and after the procedure to reduce the risk of infection, currently estimated at 2-5%, although this may be rising because of increases in the antibiotic resistance of bacteria, particularly Escherichia coli. A quinolone is the usual choice, sometimes in combination with gentamicin or amikacin, depending on prostate size, personal preference and previous biopsy results. Patients should be warned about the risk of post-biopsy sepsis and the need for treatment if it occurs.",179,15,0.08379888268156424
9781910797457,chp4,"Bone scanning identifies bone metastases, although the probability of these in patients with PSA below 10 ng/mL is low.","Although the serum PSA level alone may not be a precise indicator of stage on an individual basis, it can sometimes be used to eliminate some staging investigations. Men who present with newly diagnosed, well- or moderately well-differentiated prostate cancer, no skeletal symptoms and a serum PSA value of 10 ng/mL or less may not need a staging radionuclide bone scan because the probability of skeletal metastases approaches zero. However, many clinicians still like to use this test as a baseline investigation, because it may identify 'hot spots' due to conditions such as degenerative osteoarthritis that may cause confusion later, if the PSA level starts to rise. A negative scan also serves to reassure a patient that his skeleton is not involved.",151,25,0.16556291390728478
9781910797457,chp4,PET/CT is useful to detect soft-tissue and bone metastases.,"CT of the abdomen and pelvis may be used to inform treatment decisions that depend on the presence and degree of lymph node or other soft tissue involvement. Small-volume and microscopic metastases (< 1 cm) are not usually detected by this technique, however, and the accuracy of CT scanning is only 40-50%. CT scanning may also be used occasionally to guide fine-needle aspiration of enlarged lymph nodes for cytological analysis to aid diagnosis.",89,16,0.1797752808988764
9781910797457,chp4,"The Gleason score of these biopsies, clinical stage on digital rectal exam (DRE) and presenting prostate-specific antigen (PSA) value provide an estimate of the risk of extraprostatic extension.","While cancer characteristics such as PSA, Gleason score, clinical stage, number of biopsy cores involved and percentage of each core involved provide valuable prognostic information, combining all these variables in a nomogram provides a much more accurate prediction of the outcome. Many of these nomograms are available on the web or as an app, such as the Memorial Sloan-Kettering Cancer Center's pretreatment nomogram (). Nomograms are based on data from thousands of patients and are used to predict the pathological likelihood of seminal vesicle invasion, lymph node metastasis and extracapsular extension on each side, or the presence of a small, insignificant cancer. Other nomograms have been developed to predict the likelihood of recurrence of cancer after radical prostatectomy, external-beam radiotherapy or brachytherapy. Simpler prediction tools, such as Partin's tables, predict the likely pathology from PSA values, Gleason score and clinical stage. These readily available clinical predictors are useful for patient counseling and planning treatment such as surgery or radiotherapy.",213,44,0.20657276995305165
9781910797457,chp5,Active surveillance is increasingly used for very-low- and low-risk disease.,"Active surveillance is increasingly popular, particularly for men with small-volume and low-to-moderate-grade prostate cancer (very-low- or low-risk category), who have a low risk of death from prostate cancer (Table 5.3). These men are eligible for curative therapy but this option is often deferred until objective signs of disease progression are observed. This approach means that the majority of men (60-70%) are spared the side effects of curative therapy that they do not require. Recent studies have shown that men with low-risk prostate cancer have a low risk of developing metastases, although the risk is reasonably high for men with intermediate-risk cancers. Therefore, younger men with intermediate risk cancers should usually be encouraged to choose treatment rather than active surveillance.",156,16,0.10256410256410256
9781910797457,chp5,Only about one-third of men managed with active surveillance will go on to require curative treatment.,"Active surveillance involves PSA measurement and a digital rectal exam (DRE) every 3-6 months. MRI and repeat biopsies are usually organized 6-12 months after diagnosis or if cancer progression is suspected. Increasingly, multiparametric MRI (see page 45) is also being used to select patients for entry or follow-up in active surveillance protocols. Curative-intent therapy is initiated if the cancer shows signs of progression and before it becomes incurable. Cancer-specific survival in men who fit the criteria for active surveillance is 99% at 8 years' follow-up. While men avoid the physical side effects of treatment, they do have to live with the psychological effects of having an untreated cancer, although these do not seem to be troublesome for most men. In most untreated series, only about one-third of men managed by active surveillance progressed to active treatment, and those who did were usually cured.",185,20,0.10810810810810811
9781910797457,chp5,Radical prostatectomy probably offers the best prospect of long-term cure but carries the disadvantages of possible sexual dysfunction and incontinence.,"The major advantage of radical prostatectomy is that all prostatic tissue is excised and it provides precise histological information and definitive cure in patients in whom the tumor is confined to the prostate, relieving the patient's anxiety. Given that prostate cancer has a long natural history, this is an important consideration in terms of the patient's quality of life. Long-term studies have shown normal life expectancy in patients with complete excision of specimen-confined disease. Ten-year survival for men with clinically localized disease treated with radical prostatectomy is 98% for Gleason grade group 1, and 91% and 76% for groups 2-3 and 4-5, respectively. Moreover, the procedure also offers definitive treatment of concomitant benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms and reliably results in undetectable PSA, which patients find reassuring.",180,28,0.15555555555555556
9781910797457,chp5,Treatment with EBRT and hormonal therapy is more effective than radiotherapy alone in men with intermediate- and high-risk cancer.,"The most recent study, ProtecT, randomized men with predominantly low- and intermediate-risk cancers to active surveillance, radical prostatectomy or radiotherapy. The outcomes at 10 years showed no difference in mortality between surgery and radiotherapy, while those on active surveillance had a substantially greater risk (almost double) of developing metastases than those who underwent active treatment. This study has been criticized on the basis of the allocation of intermediate-risk patients to active surveillance, and because a difference in mortality between surgery and radiotherapy would not be expected as early as 10 years in men with predominantly low/intermediate-risk disease.",125,27,0.216
9781910797457,chp5,"In the case of high-risk cancer, surgery may be considered as part of a multimodal therapeutic approach.","Surgery can also be effective for high-risk prostate cancer, particularly if the disease appears to be localized to the prostate gland. In cases of T3 prostate cancer, surgery may be appropriate if it is considered that the cancer can be fully excised. A multimodal approach that includes adjuvant radiotherapy should be considered. Following surgery, patients who have adverse pathological features such as extracapsular extension, seminal vesicle extension or positive margins can be treated with adjuvant radiotherapy to the prostatic bed, often with concomitant androgen ablation (see pages 86 -). Three randomized trials have shown that this decreases the risk of PSA recurrence by 52% compared with no treatment, and improves survival. Whether early salvage radiation is equivalent to adjuvant radiation is not yet known, and salvage radiotherapy remains an option in these patients (see Chapter 6).",180,23,0.12777777777777777
9781910797457,chp5,Brachytherapy can be combined with EBRT in higher-risk individuals.,"Surgery can also be effective for high-risk prostate cancer, particularly if the disease appears to be localized to the prostate gland. In cases of T3 prostate cancer, surgery may be appropriate if it is considered that the cancer can be fully excised. A multimodal approach that includes adjuvant radiotherapy should be considered. Following surgery, patients who have adverse pathological features such as extracapsular extension, seminal vesicle extension or positive margins can be treated with adjuvant radiotherapy to the prostatic bed, often with concomitant androgen ablation (see pages 86 -). Three randomized trials have shown that this decreases the risk of PSA recurrence by 52% compared with no treatment, and improves survival. Whether early salvage radiation is equivalent to adjuvant radiation is not yet known, and salvage radiotherapy remains an option in these patients (see Chapter 6).",180,17,0.09444444444444444
9781910797457,chp5,External-beam radiotherapy (EBRT) can be curative but may be associated with rectal or bladder complications.,"External-beam radiotherapy (EBRT) is widely used in the treatment of localized and locally advanced prostate cancer, offering a particular advantage in patients who are unsuitable for surgery because of comorbidity or evidence of extraprostatic spread of the cancer. The eligibility criteria for radiotherapy are shown in Table 5.6. Standard treatment generally involves an 8-week course of three-dimensional conformal radiotherapy, or intensity-modulated radiotherapy (IMRT) delivering at at least 78 Gy. The recently completed CHHiP trial (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer) showed that hypofractionation can decrease the duration of radiotherapy delivery to 4 weeks but with no difference in cancer recurrence rates or side effects; however, this study has been criticized for undertreating the control arm with only 74 Gy.",181,25,0.13812154696132597
9781910797457,chp5,The treatment of localized prostate cancer is controversial.,"High-intensity focused ultrasonography (HIFU) has been developed for the treatment of localized prostate cancer. A probe delivers HIFU transrectally to the prostate and achieves focal tissue destruction. Early results are promising, with some series reporting that about three-quarters of men with low-risk disease are disease free at 5 years' follow-up. HIFU can also be used for the treatment of cancer recurrence after radiotherapy. This technique should currently be regarded as experimental, particularly as the side effects of incontinence and the development of a urinary fistula may be troublesome and are often difficult to resolve. The reliability and durability of this treatment is still uncertain.",138,9,0.06521739130434782
9781910797457,chp5,"In a large international trial, the antiandrogen bicalutamide, 150 mg/day, reduced objective progression by 31% but gynecomastia was common.","Hormonal therapy is discussed in full in Chapter 7. Conventional hormone ablation therapy for locally advanced prostate cancer (T3 or T4) involves the use of depot LHRH analogs, preceded and accompanied by an antiandrogen for at least 2-6 weeks and sometimes continued thereafter for up to 3 years. Randomized trials have shown that monotherapy with the antiandrogen bicalutamide, 150 mg/day, is as effective in the control of locally advanced disease as castration by either orchidectomy or an LHRH analog. In addition, a very large international randomized trial, with median follow-up of 7.4 years, showed that adjuvant treatment with bicalutamide, 150 mg/day, plus standard therapy for locally advanced prostate cancer (id est surgery, radiotherapy or watchful waiting) significantly reduced objective progression by 31% when compared with standard therapy. A survival benefit of 35% was also observed in men receiving radiation with adjuvant bicalutamide.",206,35,0.16990291262135923
9781910797457,chp6,"Following radiotherapy, patients who have recurrence in the prostate only may be offered a salvage treatment such as radical prostatectomy, High-intensity focused ultrasonography (HIFU) or cryotherapy, but all of these carry the risk of side effects.","Managing recurrence after initial therapy. Recurrence after initial surgery or radiotherapy usually manifests as a rise in serum prostate-specific antigen (PSA). Digital rectal exam (DRE), CT or MRI, and bone scan are the next steps but may not reveal a specific site unless the PSA level is significantly raised. A prostate-specific membrane antigen (PSMA) PET scan (see page 52) may reveal sites of cancer recurrence at very low PSA levels, typically in the prostate bed (after prostatectomy), within the prostate (after radiotherapy) or in more distant lymph nodes or bone sites. Less commonly, pulmonary metastases may be detected. The likelihood of having a positive PSMA PET scan at various PSA levels is shown in Figure 6.1. If the site of recurrence can be identified, appropriate therapy can then be delivered. Recurrence after prostatectomy. Prostate cancer recurs in 15-46% of men who undergo radical prostatectomy. Risk factors for recurrence include. positive surgical margins.",213,53,0.24882629107981222
9781910797457,chp6,Prostate-specific antigen (PSA) level should reliably fall to below 0.1 ng/mL following radical prostatectomy.,"The PSA level should reliably fall to below 0.1 ng/mL after prostatectomy. The recommendations for cut-off values that indicate cancer recurrence range from 0.2 to 0.5 ng/mL. If the PSA level does not fall below this level within 6 weeks of surgery, systemic disease should be suspected. Cancer recurrence is confirmed if the PSA level is above the cut-off and rising with sequential measurements, but time to metastasis and death is variable and is often quite prolonged. On average, a patient with recurrence of raised PSA will develop metastases over a median of 8 years, with death 5 years after the development of metastases. A number of factors determine how fast the cancer recurrence actually progresses.",154,27,0.17532467532467533
9781910797457,chp6,"For the average patient, metastases do not develop until 8 years after a PSA rise is detected, with death some 5 years later, so watchful waiting is an appropriate option for some men with recurrence.","Watchful waiting is ideal for a man with a limited life expectancy and/or lower probability of disease progression based on the earlier criteria. It should be remembered that, in the average patient, metastases do not develop until 8 years after a PSA rise is detected, with death 5 years later. This treatment can be offered to men who have recurrence in the prostate bed or at distant metastatic sites confirmed by PSMA PET. Salvage radiotherapy is a potentially curative treatment for men with a high likelihood of residual cancer in the prostatic bed. The best results are in men who have a Gleason grade group of 3 or lower, pre-radiotherapy PSA below 1.0 ng/mL, positive surgical margins, and a PSA doubling time of more than 10 months. It is also more effective if PSMA PET confirms that the prostate bed is the only site of recurrence. The effectiveness of salvage radiation is improving, with 60-90% of men achieving undetectable PSA levels, especially if concomitant androgen ablation is used (see page 86-90).",225,43,0.19111111111111112
9781910797457,chp6,"Following prostatectomy, patients who have a high likelihood of local disease can be offered salvage radiotherapy.","Watchful waiting is ideal for a man with a limited life expectancy and/or lower probability of disease progression based on the earlier criteria. It should be remembered that, in the average patient, metastases do not develop until 8 years after a PSA rise is detected, with death 5 years later. This treatment can be offered to men who have recurrence in the prostate bed or at distant metastatic sites confirmed by PSMA PET.",87,21,0.2413793103448276
9781910797457,chp6,"Progressive PSA rises following initial therapy suggest micrometastatic disease, which should be treated with hormone therapy; however, the timing of this treatment is controversial.","Side effects include possible loss of erectile function, bladder neck contracture and radiation proctitis. Androgen ablation with an antiandrogen or luteinizing hormone-releasing hormone (LHRH) analog/antagonist is increasingly used to enhance the effectiveness of the radiation treatment and can continue for 12-24 months. Hormonal therapy is reserved for men who have progressive PSA rises and are unlikely to harbor isolated local recurrence, or have confirmed widespread metastatic disease. The timing for initiation of hormonal therapy in these men is controversial, however. A recent randomized trial has shown that immediate hormonal therapy for PSA recurrence resulted in better overall survival (OS) than delayed treatment. Hormone therapy is described in greater detail in Chapter 7.",154,34,0.22077922077922077
9781910797457,chp6,Recurrence after prostatectomy is generally defined as PSA above 0.2 ng/mL and rising.,"The definition of recurrence is less straightforward after radiation treatment than after surgery, and the natural history of PSA recurrence is less clear after radiation than surgery. Following radiation, the PSA level falls slowly over 12-24 months to a nadir at detectable levels, usually below 1.0 ng/mL. However, approximately 30% of men have a transient rise (a 'bounce') in the first 2 years, and, complicating matters further, adjuvant hormonal therapy is often used, which suppresses PSA, although once this is stopped, the PSA slowly rises as the testosterone levels rise. Currently, recurrence after radiation therapy is defined as a PSA level that is 2 ng/mL or more above the nadir level. PSA doubling time (see page 80) is usually the best predictor of metastatic disease; a PSA doubling time of less than 3 months is associated with a higher risk of death.",193,22,0.11398963730569948
9781910797457,chp6,Recurrence after radiation therapy is usually defined as PSA that is at least 2 ng/mL above the nadir.,"The definition of recurrence is less straightforward after radiation treatment than after surgery, and the natural history of PSA recurrence is less clear after radiation than surgery. Following radiation, the PSA level falls slowly over 12-24 months to a nadir at detectable levels, usually below 1.0 ng/mL. However, approximately 30% of men have a transient rise (a 'bounce') in the first 2 years, and, complicating matters further, adjuvant hormonal therapy is often used, which suppresses PSA, although once this is stopped, the PSA slowly rises as the testosterone levels rise. Currently, recurrence after radiation therapy is defined as a PSA level that is 2 ng/mL or more above the nadir level. PSA doubling time (see page 80) is usually the best predictor of metastatic disease; a PSA doubling time of less than 3 months is associated with a higher risk of death.",193,25,0.12953367875647667
9781910797457,chp6,Prostate-specific membrane antigen (PSMA) PET/CT can be used to evaluate men who have a PSA rise after local treatment.,"Once PSA recurrence has been identified, further investigations depend on the individual's circumstances and expectations, and involve determining whether the cancer is in the prostate, systemic or both. PSMA PET can be used in addition to staging CT/MRI and bone scan. A prostate re-biopsy can be performed if salvage treatment for local disease is being considered, although tissue sampling is often more difficult because of post-radiation fibrosis, and the result is often negative. There are several options for treatment. Watchful waiting can be offered to men who have limited life expectancy, and/or progression of the cancer is slow.",125,29,0.232
9781910797457,chp6,More evidence is needed from clinical trials to inform us of the most effective treatment options in these situations.,"Oligometastatic disease. The advent of PSMA and choline PET scans has allowed earlier and more precise identification of metastases. Disease is described as oligometastatic when metastases are limited (3-5). This disease probably incorporates a spectrum of biologies, ranging from cancers that will soon become widespread metastases to those that will remain relatively indolent. A number of studies have reported on the treatment of oligometastatic lesions by surgical removal (salvage lymph node dissection) or, more often, stereotactic radiotherapy. While the results have been somewhat conflicting, only a small proportion of men gain long-term freedom from progression with these salvage therapies.",140,20,0.14285714285714285
9781910797457,chp7,Treatment of metastatic prostate cancer is usually by androgen ablation.,"Although there is a trend towards earlier detection of prostate cancer, many men worldwide still present with widespread metastatic disease. In countries where prostate-specific antigen (PSA) testing is not widely used, about 30% of patients present with localized disease, 40% with locally advanced disease and the remaining 30% with metastases. In contrast to localized or locally advanced disease, metastatic prostate cancer is associated with high mortality - approximately 70% within 5 years. Androgen deprivation, which has become the mainstay of treatment, effectively reduces the intratumoral dihydrotestosterone (DHT) concentration by 70-80%, reducing stimulation of androgen receptors and increasing apoptosis of prostate cancer cells (Table 7.1). Androgen deprivation can be achieved by orchidectomy (surgical removal of the testes) or treatment with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists; the value of adding an antiandrogen (maximal androgen blockade; see page 90) is still debated.",210,15,0.07142857142857142
9781910797457,chp7,A luteinizing hormone-releasing hormone (LHRH) analog preceded and then accompanied by an antiandrogen is the most frequent treatment strategy.,"Although there is a trend towards earlier detection of prostate cancer, many men worldwide still present with widespread metastatic disease. In countries where prostate-specific antigen (PSA) testing is not widely used, about 30% of patients present with localized disease, 40% with locally advanced disease and the remaining 30% with metastases. In contrast to localized or locally advanced disease, metastatic prostate cancer is associated with high mortality - approximately 70% within 5 years. Androgen deprivation, which has become the mainstay of treatment, effectively reduces the intratumoral dihydrotestosterone (DHT) concentration by 70-80%, reducing stimulation of androgen receptors and increasing apoptosis of prostate cancer cells (Table 7.1). Androgen deprivation can be achieved by orchidectomy (surgical removal of the testes) or treatment with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists; the value of adding an antiandrogen (maximal androgen blockade; see page 90) is still debated.",210,32,0.1523809523809524
9781910797457,chp7,"Treatment with a pure LHRH antagonist is another option, which avoids the need for an antiandrogen.","Although there is a trend towards earlier detection of prostate cancer, many men worldwide still present with widespread metastatic disease. In countries where prostate-specific antigen (PSA) testing is not widely used, about 30% of patients present with localized disease, 40% with locally advanced disease and the remaining 30% with metastases. In contrast to localized or locally advanced disease, metastatic prostate cancer is associated with high mortality - approximately 70% within 5 years. Androgen deprivation, which has become the mainstay of treatment, effectively reduces the intratumoral dihydrotestosterone (DHT) concentration by 70-80%, reducing stimulation of androgen receptors and increasing apoptosis of prostate cancer cells (Table 7.1). Androgen deprivation can be achieved by orchidectomy (surgical removal of the testes) or treatment with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists; the value of adding an antiandrogen (maximal androgen blockade; see page 90) is still debated.",210,23,0.10952380952380952
9781910797457,chp7,Responses in terms of prostate-specific antigen (PSA) reduction and clinical improvement are seen in more than 80% of patients.,"Although there is a trend towards earlier detection of prostate cancer, many men worldwide still present with widespread metastatic disease. In countries where prostate-specific antigen (PSA) testing is not widely used, about 30% of patients present with localized disease, 40% with locally advanced disease and the remaining 30% with metastases. In contrast to localized or locally advanced disease, metastatic prostate cancer is associated with high mortality - approximately 70% within 5 years. Androgen deprivation, which has become the mainstay of treatment, effectively reduces the intratumoral dihydrotestosterone (DHT) concentration by 70-80%, reducing stimulation of androgen receptors and increasing apoptosis of prostate cancer cells (Table 7.1). Androgen deprivation can be achieved by orchidectomy (surgical removal of the testes) or treatment with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists; the value of adding an antiandrogen (maximal androgen blockade; see page 90) is still debated.",210,28,0.13333333333333333
9781910797457,chp7,"The side effects of medical castration include hot flashes, loss of libido and erectile dysfunction, and the reduced testosterone level may also be associated with features of the metabolic syndrome.","Bilateral orchidectomy or bilateral subcapsular orchidectomy is performed through a midline scrotal incision (Figure 7.1) under local, regional or light general anesthesia. The procedure is simple and is associated with little morbidity. The principal adverse events are local complications such as hematoma and wound infections, together with the usual effects of androgen deprivation such as loss of libido, erectile dysfunction and hot flashes (Table 7.2). Clinical responses (decreased bone pain and reduced PSA concentration) are obtained in more than 75% of patients. Because of the psychological/cosmetic impact of orchidectomy and its irreversibility, however, most patients and their partners prefer non-surgical treatment with LHRH analogs/antagonists.",160,36,0.225
9781910797457,chp7,"Eventually, androgen-insensitive cell clones develop and the PSA level begins to rise (castrate resistance).","Although both orchidectomy and LHRH treatment produce dramatic initial responses in 70-80% of men, remission is not usually maintained in the long term. Androgen-independent cancer cell clones are selected out, and the mean time to tumor progression is less than 18 months and mean overall survival (OS) is 28-36 months. Persistent adrenal androgen secretion may contribute to this poor prognosis; there is evidence that adrenal androgens account for up to 15-20% of total androgen concentrations within the prostate. This has led to the concept of 'maximal androgen blockade', in which androgen deprivation by orchidectomy or LHRH treatment is accompanied by treatment with an antiandrogen to block the effects of adrenal androgens in the prostate.",158,23,0.14556962025316456
9781910797457,chp7,Men with a high volume of metastases should be treated with a combination of androgen deprivation therapy and docetaxel chemotherapy.,"The appropriate timing of hormonal therapy has been the subject of vigorous debate and the evidence now favors earlier therapy rather than waiting for symptoms. This evidence includes a re-analysis of the cooperative studies (USA) in which men receiving diethylstilbestrol (DES), 1 mg, had a survival advantage. The Medical Research Council (UK) study showed that men with locally advanced or metastatic disease treated with castration at diagnosis had better outcomes than those in whom therapy was deferred (Table 7.3), and a US trial reported by Messing et al. in 2006 found that delayed hormonal treatment in men with pelvic lymph node metastases was associated with a sevenfold increase in deaths from prostate cancer compared with those who had immediate androgen ablation therapy. A study that explored the timing of androgen deprivation therapy (ADT) in men who experienced a rising PSA after primary treatment of prostate cancer reported a 45% decrease in OS in those who delayed therapy (by >= 2 years) compared with those who had immediate treatment.",207,26,0.12560386473429952
9781910797457,chp8,"After an initial response to androgen ablation, the serum prostate-specific antigen (PSA) value starts to rise as a result of androgen-insensitive cell clones.","Antiandrogens. When the serum PSA level rises after a period of ADT alone, an initial step may be to add an antiandrogen to the treatment. This may transiently reduce PSA, but the PSA will usually start to rise again relatively soon. Withdrawal of the antiandrogen at this time produces a favorable PSA response in approximately 40% of men for 4-6 months. This phenomenon has been ascribed to a mutation affecting androgen receptors in malignant tissue which means that the antiandrogen acts as an agonist (stimulatory) rather than an antagonist (blocker), so when the antiandrogen is withdrawn the stimulation is reduced; a similar phenomenon occurs in breast cancer treated with antiestrogens. As long as the patient is asymptomatic, the addition and withdrawal of different antiandrogens can be continued for 2-3 cycles, as previous antiandrogen administration does not appear to diminish the response to different antiandrogens.",199,36,0.18090452261306533
9781910797457,chp8,"As an initial step, withdraw any antiandrogen, then consider trying another antiandrogen.","Antiandrogens. When the serum PSA level rises after a period of ADT alone, an initial step may be to add an antiandrogen to the treatment. This may transiently reduce PSA, but the PSA will usually start to rise again relatively soon. Withdrawal of the antiandrogen at this time produces a favorable PSA response in approximately 40% of men for 4-6 months. This phenomenon has been ascribed to a mutation affecting androgen receptors in malignant tissue which means that the antiandrogen acts as an agonist (stimulatory) rather than an antagonist (blocker), so when the antiandrogen is withdrawn the stimulation is reduced; a similar phenomenon occurs in breast cancer treated with antiestrogens. As long as the patient is asymptomatic, the addition and withdrawal of different antiandrogens can be continued for 2-3 cycles, as previous antiandrogen administration does not appear to diminish the response to different antiandrogens.",199,19,0.09547738693467336
9781910797457,chp8,"The mainstay of management for metastatic CRPC is docetaxel chemotherapy. The CYP17 inhibitor abiraterone is now also licensed for use before chemotherapy, and trials of other antiandrogens prior to chemotherapy are under way.","Antiandrogens. When the serum PSA level rises after a period of ADT alone, an initial step may be to add an antiandrogen to the treatment. This may transiently reduce PSA, but the PSA will usually start to rise again relatively soon. Withdrawal of the antiandrogen at this time produces a favorable PSA response in approximately 40% of men for 4-6 months. This phenomenon has been ascribed to a mutation affecting androgen receptors in malignant tissue which means that the antiandrogen acts as an agonist (stimulatory) rather than an antagonist (blocker), so when the antiandrogen is withdrawn the stimulation is reduced; a similar phenomenon occurs in breast cancer treated with antiestrogens. As long as the patient is asymptomatic, the addition and withdrawal of different antiandrogens can be continued for 2-3 cycles, as previous antiandrogen administration does not appear to diminish the response to different antiandrogens.",199,49,0.24623115577889448
9781910797457,chp8,Immunotherapy for CRPC may be best implemented before significant symptoms appear.,"Antiandrogens. When the serum PSA level rises after a period of ADT alone, an initial step may be to add an antiandrogen to the treatment. This may transiently reduce PSA, but the PSA will usually start to rise again relatively soon. Withdrawal of the antiandrogen at this time produces a favorable PSA response in approximately 40% of men for 4-6 months. This phenomenon has been ascribed to a mutation affecting androgen receptors in malignant tissue which means that the antiandrogen acts as an agonist (stimulatory) rather than an antagonist (blocker), so when the antiandrogen is withdrawn the stimulation is reduced; a similar phenomenon occurs in breast cancer treated with antiestrogens. As long as the patient is asymptomatic, the addition and withdrawal of different antiandrogens can be continued for 2-3 cycles, as previous antiandrogen administration does not appear to diminish the response to different antiandrogens.",199,15,0.07537688442211055
9781910797457,chp8,"When docetaxel chemotherapy has failed, second-line therapies such as cabazitaxel chemotherapy, abiraterone (a selective inhibitor of androgen biosynthesis), enzalutamide (an androgen-receptor-signaling inhibitor) and radium-223 (targeted alpha therapy) have been shown to improve survival and quality of life.","Cabazitaxel. This taxane chemotherapy was developed to overcome the resistance that can develop as a result of docetaxel treatment. In the TROPIC study, men with CRPC that had progressed after docetaxel treatment were randomized to cabazitaxel or mitoxantrone. Those who received cabazitaxel demonstrated a 30% improvement in survival compared with those receiving mitoxantrone (15.1 versus 12.7 months; Figure 8.6 and see Table 8.1). Side effects were similar to those seen with docetaxel. Mitoxantrone and prednisone was the first chemotherapy combination to be tested in a randomized trial in advanced prostate cancer. The combination was very well tolerated and more than doubled the time of palliation response compared with prednisone alone. It also improved the quality of life of men with CRPC. It has now been replaced by docetaxel as first-line chemotherapy and by cabazitaxel as second-line chemotherapy, which have better efficacy; however, the combination still has a place in second-line therapy when resistance to docetaxel has developed and cabazitaxel is not an option. Abiraterone. In a study in men with metastatic CRPC for whom docetaxel chemotherapy had failed, abiraterone plus prednisone resulted in a 35% improvement in survival compared with prednisone alone (see Table 8.1). Mineralocorticoid-related adverse events, including fluid retention, hypertension and hypokalemia, were more frequent in the abiraterone group, highlighting the continuing dependency of CRPC on androgen-receptor signaling even after it has become castrate resistant (see Table 8.1).",363,74,0.20385674931129477
9781910797457,chp8,External-beam radiotherapy may provide useful control of pain from bone metastases.,"Palliative radiotherapy. Hormone-nave disease is initially managed with ADT. However, some men do not get full resolution of pain, or may have painful bone metastases in the setting of CRPC. Focal external-beam radiotherapy is a well-established treatment, providing rapid improvement in pain in up to 80% of men. Treatment can be given as either a single fraction or as multiple fractions over 2-3 weeks. This type of irradiation is associated with very few side effects.",105,16,0.1523809523809524
9781910797457,chp8,The monoclonal antibody denosumab and the bisphosphonate zoledronic acid have been reported to significantly delay bone-related events in men with metastatic prostate cancer.,"Bisphosphonates suppress bone resorption and demineralization, providing symptomatic benefit in some patients. A study involving over 600 men with CRPC demonstrated a significant reduction in the number of patients with bone-related events among those receiving zoledronic acid (zoledronate), given as an intravenous infusion every 3 weeks, compared with placebo. Zoledronic acid also significantly delayed the onset of first skeletal-related event (see Table 8.1); however, the number needed to treat (NNT) to save one death is 10. Side effects with bisphosphonates include renal deterioration and, rarely, osteonecrosis of the jaw. Denosumab is a human monoclonal antibody directed against RANKL (receptor activator of nuclear factor B ligand); it inhibits osteoclast function and bone turnover. A randomized trial involving 1904 men with CRPC supported denosumab as the optimal medication to reduce bone-related events in men with CRPC (see Table 8.1).",215,39,0.1813953488372093
9781910797457,chp9,"Erectile dysfunction can often be improved with phosphodiesterase-5 (PDE5) inhibitors, prostaglandin suppositories or injections, or mechanical vacuum devices.","Intracorporeal fibrosis results from the release of transforming growth factor alpha (TGFalpha) in response to anoxia; thus, therapies that bring oxygenated arterial blood into the corpora and induce erection may inhibit the release of TGFalpha and help maintain smooth muscle function. Early administration of pharmaceutical treatments for erectile dysfunction soon after surgery has been shown to improve the time and quality of subsequent erections. Montorsi et al. have shown in a randomized trial that early intracavernosal injection of alprostadil (prostaglandin E), once or twice a week, results in early recovery of spontaneous erections after nerve-sparing radical prostatectomy. Early administration of phosphodiesterase type 5 (PDE5) inhibitors, such as tadalafil, 5 mg daily, has also been shown to improve the time and quality of spontaneous erections after bilateral nerve-sparing surgery. Patients refractory to intracavernosal and oral PDE5 inhibitor treatment have the option of using a vacuum constriction device to obtain erections, or surgery to insert an inflatable penile prosthesis (Figure 9.2).",237,36,0.1518987341772152
9781910797457,chp9,Loss of libido can be reduced by using antiandrogens to treat prostate cancer in preference to bilateral orchidectomy or a luteinizing hormone-releasing hormone (LHRH) analog/antagonist.,"Ejaculatory problems. Men who undergo radical prostatectomy or transurethral resection of the prostate (TURP) for localized prostate cancer may also experience ejaculatory problems, although the sensation of orgasm is usually preserved. In the case of TURP, semen is still produced but passes retrogradely into the bladder. After radical prostatectomy, in which the entire prostate and seminal vesicles are removed, semen is not produced but most patients are still able to achieve orgasm. Patients must be informed about these consequences before surgery. Drugs such as the alpha -blocker tamsulosin, used to treat bladder outflow obstruction, may also cause loss of, or reduced, ejaculation, but this is reversible on cessation of treatment. Loss of libido is a common complaint in patients with prostate cancer. It may result from the disease itself causing debilitation or depression but, more commonly, it is a side effect of hormone ablation therapy. Bilateral orchidectomy or therapy with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists is almost invariably associated with loss of libido, as well as erectile dysfunction. Therapy with an antiandrogen can effectively deprive prostate cancer cells of androgen stimulation without such a profound effect on libido or erectile function. Preservation of sexual function. If this is an important factor in terms of the quality of life, treatment with an antiandrogen as monotherapy may well be considered as an alternative to bilateral orchidectomy or an LHRH analog.",318,45,0.14150943396226415
9781910797457,chp9,Sexual dysfunction is a common sequela of prostate cancer treatment. An open and informed discussion with the patient and his partner will do much to counter anxiety and loss of self-esteem.,"Loss of libido is a common complaint in patients with prostate cancer. It may result from the disease itself causing debilitation or depression but, more commonly, it is a side effect of hormone ablation therapy. Bilateral orchidectomy or therapy with luteinizing hormone-releasing hormone (LHRH) analogs/antagonists is almost invariably associated with loss of libido, as well as erectile dysfunction. Therapy with an antiandrogen can effectively deprive prostate cancer cells of androgen stimulation without such a profound effect on libido or erectile function. Preservation of sexual function. If this is an important factor in terms of the quality of life, treatment with an antiandrogen as monotherapy may well be considered as an alternative to bilateral orchidectomy or an LHRH analog. Counseling. Men with prostate cancer, and their partners, should be counseled not only about probable outcomes, but also about the likely effect of the disease and its therapy on sexual activity. An open and informed approach to this important aspect of prostate cancer will do much to counter the anxiety and loss of self-esteem that often accompany the diagnosis of this prevalent malignancy, and to restore effective sexual function after treatment and thereby maintain an important aspect of quality of life.",259,36,0.138996138996139
9781910797457,chp9,Men with prostate cancer require emotional support as well as information on probable outcomes and the effects of the disease and its treatment.,"Preservation of sexual function. If this is an important factor in terms of the quality of life, treatment with an antiandrogen as monotherapy may well be considered as an alternative to bilateral orchidectomy or an LHRH analog. Counseling. Men with prostate cancer, and their partners, should be counseled not only about probable outcomes, but also about the likely effect of the disease and its therapy on sexual activity. An open and informed approach to this important aspect of prostate cancer will do much to counter the anxiety and loss of self-esteem that often accompany the diagnosis of this prevalent malignancy, and to restore effective sexual function after treatment and thereby maintain an important aspect of quality of life.",143,24,0.16783216783216784
9781910797457,chp9,"Osteoporosis and fractures are side effects of long-term androgen deprivation therapy (ADT): vitamin D status should be evaluated before starting ADT, and calcium and vitamin D supplementation, as well as isometric exercises, encouraged during treatment.","Bisphosphonates and the anti-RANKL monoclonal antibody denosumab (see pages 113 -) have also been shown to reduce the incidence of skeletal-related events in men with prostate cancer. Further prospective trials are required to assess the efficacy and cost-effectiveness of bisphosphonates in men with prostate cancer who require ADT. Until the results from these trials become available, suggestions for the management of bone effects in men receiving ADT include baseline and yearly measurements of BMD. Baseline calcium, phosphate, liver function, thyroid function, 25-hydroxy vitamin D and parathyroid hormone should be measured, and calcium and vitamin D supplementation as well as isometric exercises, should be encouraged. Osteonecrosis of the jaw is a rare complication of bisphosphonate therapy. Metabolic syndrome and cardiovascular risk. Metabolic syndrome is a constellation of cardiovascular risk factors (exempli gratia fasting hyperglycemia, hypertriglyceridemia, decreased serum high-density lipoprotein [HDL] cholesterol, increases in waist circumference and waist to hip ratio, and hypertension) that have been reported to be increased in men receiving ADT.",247,51,0.20647773279352227
9781910797457,chp9,"It is prudent to weigh the risks and benefits of ADT in men with cardiovascular risk factors and to monitor all risk factors during therapy. At-risk patients should be advised to make lifestyle changes as appropriate (exempli gratia stop smoking, lose weight, increase physical activity, improve diet).","Metabolic syndrome and cardiovascular risk. Metabolic syndrome is a constellation of cardiovascular risk factors (exempli gratia fasting hyperglycemia, hypertriglyceridemia, decreased serum high-density lipoprotein [HDL] cholesterol, increases in waist circumference and waist to hip ratio, and hypertension) that have been reported to be increased in men receiving ADT. The first study to report an increase in cardiovascular risk in men treated with ADT was a retrospective study of 79 196 men in whom an increased risk of coronary disease, myocardial infarction and ventricular arrhythmia was identified. Another large retrospective study also suggested a 20% increase in cardiovascular morbidity with 1 year of ADT. A study by D'Amico et al. reported that, in men over 65 years, treatment with ADT decreased the time to fatal myocardial infarction compared with men not receiving this therapy. However, a large number of other studies have not shown any major differences in cardiovascular morbidity. As this area is controversial, it is prudent to critically weigh the risks and benefits of ADT in men with cardiovascular risk factors. It is also important to monitor all the risk factors in all men undergoing ADT, and to treat these risk factors where appropriate.",259,59,0.2277992277992278
9781910797471,ch01,"The European Society of Cardiology has defined a new category of heart failure with mid-range ejection fraction (HFmrEF), characterized by an EF of 40-49%.","An EF over 50% is generally regarded as normal, although there remains some debate regarding the specific cut-off point. The latest (2016) ESC guidelines divide patients into three groups according to their left ventricular ejection fraction (LVEF). heart failure with reduced EF (HFrEF) when EF is less than 40%. heart failure with mid-range EF (HFmrEF) when EF is 40-49%. heart failure with preserved (or normal) EF (HFpEF/HFnEF) when EF is 50% or more. Systolic heart failure or heart failure with reduced ejection fraction results from myocardial injury, which leads to impaired pumping function of the left ventricle (LV) and significantly reduced LVEF (< 40%). This is the typical manifestation of patients with ischemic heart disease and multiple infarcts.",176,35,0.19886363636363635
9781910797471,ch01,Heart failure (HF) with reduced ejection fraction (HFrEF) is characterized by an ejection fraction (EF) of less than 40%.,"heart failure with reduced EF (HFrEF) when EF is less than 40%. heart failure with mid-range EF (HFmrEF) when EF is 40-49%. heart failure with preserved (or normal) EF (HFpEF/HFnEF) when EF is 50% or more. Systolic heart failure or heart failure with reduced ejection fraction results from myocardial injury, which leads to impaired pumping function of the left ventricle (LV) and significantly reduced LVEF (< 40%). This is the typical manifestation of patients with ischemic heart disease and multiple infarcts.",126,30,0.23809523809523808
9781910797471,ch01,Left ventricular HF is the most common type of HF.,"Right, left and biventricular failure. Left ventricular HF is the most common type of HF. It is associated with exertional dyspnea, orthopnea and paroxysmal nocturnal dyspnea. Right ventricular HF, most commonly caused by left ventricular HF, is characterized by peripheral edema, abdominal distension (due to ascites), right upper quadrant discomfort (due to liver congestion) and elevated jugular venous pressure, often with prominent v waves due to tricuspid regurgitation (see Chapter 5). Either left- or right-sided HF may occur in the context of low output (fatigue, syncope and hypotension).",141,12,0.0851063829787234
9781910797471,ch01,Symptomatic HF affects 2-3% of the global population.,"HF affects an estimated 26 million people worldwide. Although advances in the treatment of acute coronary syndromes have reduced deaths from coronary artery disease (CAD), in the USA in 2014 non-cardiovascular disease was the underlying cause of death for more than one-third of HF-related deaths of adults aged 45 or over. This shift toward less ischemic heart disease is important for HF management approaches.",81,14,0.1728395061728395
9781910797471,ch01,The financial burden associated with HF is likely to rise over the next 20 years.,"HF affects an estimated 26 million people worldwide. Although advances in the treatment of acute coronary syndromes have reduced deaths from coronary artery disease (CAD), in the USA in 2014 non-cardiovascular disease was the underlying cause of death for more than one-third of HF-related deaths of adults aged 45 or over. This shift toward less ischemic heart disease is important for HF management approaches. The enormous impact of HF on individuals and their families is compounded by the huge costs to healthcare budgets around the world. The burden associated with HF is expected to keep rising over the next 20 years due to a number of factors.",126,16,0.12698412698412698
9781910797471,ch01,"Coronary artery disease, arterial hypertension, valvular heart disease and diabetes mellitus are the four most important predisposing conditions for the development of HF.","Predisposing conditions. CAD, arterial hypertension, valvular heart disease and diabetes mellitus are the four most important predisposing conditions for the development of HF (see Chapter 3). Over the past 50 years, the prevalence of CAD and diabetes mellitus has increased, while rates of valvular heart disease and hypertension have fallen. Nevertheless, aortic valve disease and arterial hypertension remain the commonest causes of HFpEF in elderly people. Population attributable risk estimates the proportion of HF in the population that is attributable to each predisposing condition. Data suggest that for individuals over 65 years of age CAD (13.1% annual risk), uncontrolled arterial hypertension (12.8%), C-reactive protein as a marker of vascular inflammation (9.7%) and low ankle-brachial index (the ratio of blood pressure in the ankle to that in the upper arm; 9.2%) have the largest effects, while low LVEF (4.1%) and atrial fibrillation (2.2%) have less effect than expected. Table 1.2 shows the risks for some of the most common predisposing conditions.",233,33,0.14163090128755365
9781910797471,ch02,"Inappropriate non-cardiac responses include activation of a variety of hormonal reflexes (vasoconstriction, and sodium and water retention). Reversal of these inappropriate responses is critical to the management of HF.","Advances in the management of heart failure (HF) over the past 20 years have been informed by a better understanding of its pathophysiology. There are few situations in cardiology where treatment has been as closely linked to an appreciation of the underlying science. Vicious cycle of heart failure. HF is a disease of inappropriate adaptation to injury. The body has a limited range of compensatory responses to circulatory impairment, mainly vasoconstriction and sodium and water retention (see below). In general, however, these adjustments to hypovolemia are poorly suited to pump failure, and increases in the preload and afterload of the failing heart lead to worsening HF (Figure 2.1). Neurohormonal pathways activated in HF include the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide (NP) system. They play a significant role in the pathophysiology of HF, and pharmacological interventions have been developed accordingly (see Chapter 7).",211,43,0.2037914691943128
9781910797471,ch02,"Heart failure (HF) is a disease of response to injury, which is initially appropriate and becomes inappropriate.","Vicious cycle of heart failure. HF is a disease of inappropriate adaptation to injury. The body has a limited range of compensatory responses to circulatory impairment, mainly vasoconstriction and sodium and water retention (see below). In general, however, these adjustments to hypovolemia are poorly suited to pump failure, and increases in the preload and afterload of the failing heart lead to worsening HF (Figure 2.1).",88,21,0.23863636363636365
9781910797471,ch02,Remodeling is a cardiac response that is initially appropriate and becomes inappropriate as the heart enlarges excessively and hypertrophies.,"Natriuretic peptide system. The natriuretic peptide family consists of A (atrial) and B (brain) type natriuretic peptides (ANP and BNP), which are produced by cardiomyocytes in response to atrial and ventricular stretch, and C type natriuretic peptide, which is secreted by endothelial and renal cells. NPs, mainly BNP, lead to increased sodium excretion and vasodilation, especially in the early phases of HF. BNP also has anti-remodeling properties. The biological action of BNP is mediated through membrane-bound natriuretic peptide receptors (NPRs) and the peptide is degraded by neutral endopeptidase (including neprilysin). It is postulated that HF is a state of relative BNP deficiency caused by both lack of biologically active peptide and resistance at a receptor level. In end-stage HF, the peptides may not be released because of myocyte loss.",210,25,0.11904761904761904
9781910797471,ch02,"Symptoms develop in HF as a result of a complex web of interactions, involving not only the heart, hormonal changes and skeletal muscle, but also the vasculature (especially the endothelium), lungs and other organs.","Peripheral vasoconstriction, as described above, symptomatically may contribute to cold sensitivity. Loss of skeletal muscle is an important manifestation of HF, reflecting inactivity, consequences of circulating substances such as tumor growth factor (TGF)-beta and reduced cardiac output. In its most advanced manifestation, loss of skeletal muscle may lead to cachexia. The consequences of this process include contributions to insulin resistance as well as loss of the skeletal muscle circulatory bed. The loss of this vasculature represents an additional decrement in the amount of vasculature that can undergo vasodilation (and therefore unload the LV). Cardiorenal interactions. Reduced renal perfusion in HF (due to reduced stroke volume and vasoconstriction) is an important contributor to sodium and fluid overload. The exact links between cardiac and renal function have yet to be resolved. More marked disturbances of renal function, leading to coexisting renal failure, may also occur and pose problems for volume control.",198,45,0.22727272727272727
9781910797471,ch02,"In addition to the classification of HF by clinical manifestation (acute vs chronic, systolic vs diastolic), etiology and precipitants (addressed in other chapters), HF can be classified by clinical stage (the course of the disease) and functional class (functional status based on symptom severity and exercise capacity).","Cardiorenal interactions. Reduced renal perfusion in HF (due to reduced stroke volume and vasoconstriction) is an important contributor to sodium and fluid overload. The exact links between cardiac and renal function have yet to be resolved. More marked disturbances of renal function, leading to coexisting renal failure, may also occur and pose problems for volume control. Clinical stages and functional classes. The clinical syndrome of HF represents the final manifestation of advanced disease. Although progress has been made in the management of this entity, the greatest hope of avoiding the adverse outcome of HF is to intervene at an earlier subclinical stage, when there is more likelihood of reversing the process. The American Cardiology Association (ACC)/American Heart Association (AHA) guidelines divide progression of the disease into four preclinical and clinical stages (Table 2.1). It is important to distinguish these from functional classes, as described in the New York Heart Association (NYHA) classification system, which is based on severity of symptoms and exercise capacity and can be used to assess response to treatment (see Table 2.1). ACC/AHA stages A and B are preclinical; these patients fall into NYHA functional class I. ACC/AHA stage C reflects patients with symptoms or signs of HF, so these patients may be classified functionally in any of the NYHA classes I to III. The functional status of patients in ACC/AHA class D (with marked symptoms and signs of HF) is usually limited (NYHA class II to IV). The association between functional class, cardiac function (LVEF) and prognosis is discussed in more detail in Chapter 9.",331,65,0.19637462235649547
9781910797471,ch03,Ischemic heart disease is the commonest cause of left ventricular dysfunction and heart failure (HF).,"Ischemic heart disease is the commonest cause of left ventricular (LV) dysfunction and HF. It is characterized by a constant or intermittent decrease in coronary perfusion, caused by significant narrowing of the lumen of coronary arteries. This leads to a mismatch between the rate of oxygen delivery and the rate of its utilization by the cardiac muscle. Coronary ischemia is usually due to coronary artery disease (CAD), in which an atherosclerotic lesion (plaque) develops within the wall of the coronary artery; when unstable, the plaque ruptures causing acute coronary occlusion and subsequent MI (Figure 3.1). Predisposing factors for the development of CAD are shown in Table 3.2.",148,22,0.14864864864864866
9781910797471,ch03,"Aortic valve disease is an important cause of HF. Surgery is the best therapy for suitable candidates; assessment of severity in the context of existing cardiac dysfunction can be challenging, but helps to define individuals who would benefit most from surgery.","Ischemic heart disease is the commonest cause of left ventricular (LV) dysfunction and HF. It is characterized by a constant or intermittent decrease in coronary perfusion, caused by significant narrowing of the lumen of coronary arteries. This leads to a mismatch between the rate of oxygen delivery and the rate of its utilization by the cardiac muscle. Coronary ischemia is usually due to coronary artery disease (CAD), in which an atherosclerotic lesion (plaque) develops within the wall of the coronary artery; when unstable, the plaque ruptures causing acute coronary occlusion and subsequent MI (Figure 3.1). Predisposing factors for the development of CAD are shown in Table 3.2. Ischemic and non-ischemic cardiomyopathy. Ischemic cardiomyopathy is the term widely used to encompass coronary ischemia and MI with resulting myocardial scarring. In some patients, however, the degree of LV dysfunction is out of proportion to the magnitude of CAD. Such patients require further testing (invasive or non-invasive), as those with non-ischemic cardiomyopathy (id est not related to CAD) often present with typical angina, while those with CAD may have silent (asymptomatic) ischemia.",270,47,0.17407407407407408
9781910797471,ch03,"Surgery is always required for organic mitral valve regurgitation, but if the cause is functional then surgery may not help and may even be deleterious.","Aortic valve stenosis. The most common cause of aortic valve stenosis is age-related valve degeneration, a result of ongoing inflammation with lipid deposition and progressive calcification. Congenital bicuspid aortic valve stenosis may be found in middle-aged populations. Rheumatic fever remains an important cause of aortic valve stenosis in areas of lower socioeconomic status. Progressive aortic stenosis leads to exertional symptoms, such as dyspnea, chest pain and syncope, and the development of congestive HF. The emergence of symptoms heralds a worse prognosis (50% survival for 2-3 years) and dictates the need for aortic valve replacement. Historically, poor surgical candidates were managed medically or palliated with balloon valvuloplasty. However, the emergence of transcatheter aortic valve implantation (TAVI) with acceptable initial results provides an alternative for patients for whom corrective surgery is not appropriate.",201,33,0.16417910447761194
9781910797471,ch03,All patients with a new diagnosis of cardiomyopathy require cardiologic referral.,"In pregnancy, there is no convincing evidence that HCM increases risk, but all patients should be offered obstetric and cardiologic care at specialized centers experienced in treating such conditions. Normal delivery is possible, but patients with severe outflow obstruction require special care and possibly Cesarean section. All patients with HCM require cardiologic referral, and syncope requires urgent investigation. Family members should be screened.",82,17,0.2073170731707317
9781910797471,ch03,Arterial hypertension is an important cause of new presentation but also a powerful precipitant of acute worsening of existing HF.,"Arrhythmogenic right ventricular cardiomyopathy (ARVC)/dysplasia is an uncommon genetic condition characterized by fibrofatty infiltration of the right ventricle. Both autosomal dominant and recessive inheritance have been described and a number of genes that encode desmosomal proteins have been implicated. It is an important cause of sudden cardiac death, particularly in the young, and is usually due to a ventricular arrhythmia, or patients may manifest signs of right-sided HF and eventually biventricular failure.",110,24,0.21818181818181817
9781910797471,ch03,Cardiotoxicity is one of the most serious side effects of cancer therapy; cardiac function must be assessed at baseline and during therapy.,"Cardiotoxicity is one of the most serious side effects of cancer therapy (chemotherapy, and mediastinal and neck radiation). It may manifest as cardiomyopathy, pericarditis, congestive HF, valvular heart disease or premature CAD. Causes. Anthracycline chemotherapy (exempli gratia doxorubicin) is by far the most common cause of type 1 myocardial damage (Table 3.6). Acute toxicity is unlikely with current regimens. Chronic toxicity (development of cardiomyopathy within 1 year of therapy) and late onset (development of cardiomyopathy from years to decades after therapy) are all dose dependent. Other agents that have been associated with cardiotoxicity include cyclophosphamide, ifosfamide, cisplatin, carmustine, busulfan, mechlorethamine and mitomycin.",185,26,0.14054054054054055
9781910797471,ch03,"Timely detection and treatment of cardiac and non-cardiac factors that may worsen HF, and in some cases preventative measures, constitute an inherent part of modern HF management.","Management. If LVEF decreases by more than 10% to a value below the lower limit of normal (an LVEF of 50%), angiotensin-converting enzyme (ACE) inhibitors (or angiotensin-receptor blockers [ARBs]) in combination with beta-blockers are recommended to prevent further LV dysfunction or the development of symptomatic HF, unless contraindicated. ACE inhibitors (or ARBs) and beta-blockers are also recommended in patients with symptomatic HF or asymptomatic cardiac dysfunction unless contraindicated. Common causes of worsened heart failure. There are a number of cardiac and non-cardiac factors not directly related to the biology of HF that may worsen the symptoms of HF and lead to acute hospitalization (Table 3.9). Identification, prevention and early treatment of these form the target for disease management programs.",179,35,0.19553072625698323
9781910797471,ch04,"Patients with heart failure (HF) should undergo regular monitoring for early diagnosis of anemia and appropriate investigation to determine the cause. Therapeutic intervention should be tailored to the individual, taking into account the velocity of hemoglobin fall, the presence or absence of concomitant renal dysfunction and the cause of the anemia.","Dysfunction of erythropoietin production. Renal dysfunction leads to a decline in erythropoietin production through the loss of erythropoietin-producing cells in the kidney. However, it is unusual to see significant anemia due to renal failure until the glomerular filtration rate (GFR) drops below 20 mL/minute. Activation of the renin-angiotensin system, and the consequent angiotensin-converting enzyme (ACE) inhibition and angiotensin-receptor blockade, also reduces erythropoietin production and causes a modest reduction in hemoglobin. Investigation. It is still unclear whether anemia in HF represents a marker of disease severity and is therefore a prognostic tool, or whether it is a mediator of poorer outcomes and therefore represents a therapeutic target. However, there is evidence that it can worsen cardiac function and symptoms and that correction improves outcome (although further studies are required). Therefore, anemia should be regarded as an easily identifiable and potentially remediable aspect of the disease (Figure 4.1). Common and reversible causes of anemia such as hematinic deficiencies require exclusion, although the underlying etiology is often multifactorial, with the pentad of chronic renal failure, neurohormonal activation, a proinflammatory cytokine milieu, defective erythropoietin production and defective bone marrow function contributing in varying proportions. Blood transfusion may be appropriate in an acute setting for selected patients with severe anemia. The benefit is rapid correction of anemia, although this must be weighed against the risks of circulatory overload, transfusion-transmitted infection, hemolytic transfusion reactions and the longer-term issues of alloimmunization and iron overload.",364,65,0.17857142857142858
9781910797471,ch04,Early diagnosis of sleep-disordered breathing is important as treatment with continuous positive airway pressure in symptomatic patients is effective.,Prognosis. Untreated sleep-disordered breathing is associated with higher cardiovascular mortality. Moderate-to-severe OSA (apnea-hypopnea index [AHI] > 15) in patients with ischemic cardiomyopathy has been shown to be independently associated with increased mortality (mainly due to sudden cardiac death). A similar association has not been observed in patients without cardiac ischemia. Higher mortality (median survival reduced by 50%) has also been reported in patients with severe LV dysfunction (LVEF < 40%) and CSA.,115,25,0.21739130434782608
9781910797471,ch04,Despite inherent diagnostic limitations it is important for clinicians to establish the presence of pulmonary disease and to introduce early therapy for both chronic obstructive pulmonary disease and HF in order to limit their negative impact on morbidity and mortality.,"servo-adaptive ventilation (in patients with predominant CSA). Treatment with CPAP alleviates episodes of OSA and associated physiological consequences that may lead to a reduction in LV afterload and ongoing oxidative stress. However, up to 30% of patients may not be able to tolerate it. Evidence that CPAP has a positive effect on cardiovascular morbidity and mortality in patients with HF is lacking, despite observational studies reporting a decrease in sympathetic nervous activity, and blood pressure and improvement in cardiac performance (LVEF). Hence, the current indications for CPAP in patients with HF and sleep-disordered breathing are limited to management of diurnal hypersomnolence. Disappointingly, a recent study of CPAP in patients with predominant CSA showed an increase in mortality in the treatment group. Renal disease. Renal dysfunction is frequently found in patients hospitalized with HF and is strongly associated with increased morbidity and mortality. Up to 50% of ambulatory patients with stable HF have some degree of renal dysfunction. Moderate-to-severe renal dysfunction in patients with HF increases the relative mortality risk by 100% (absolute risk > 50% at 5 years). In patients with baseline estimated GFR < 50 mL/min/m a further drop of 10 mL/min/m increases mortality by 7%.",264,43,0.16287878787878787
9781910797471,ch04,Clinical depression is not uncommon in patients with HF and is associated with a marked increase in HF morbidity and mortality. Initial screening for depression is therefore important.,"Renal dysfunction is frequently found in patients hospitalized with HF and is strongly associated with increased morbidity and mortality. Up to 50% of ambulatory patients with stable HF have some degree of renal dysfunction. Moderate-to-severe renal dysfunction in patients with HF increases the relative mortality risk by 100% (absolute risk > 50% at 5 years). In patients with baseline estimated GFR < 50 mL/min/m a further drop of 10 mL/min/m increases mortality by 7%. It is generally accepted that renal dysfunction is a marker of progressive HF. However, it has also been postulated that renal dysfunction may directly affect the biology of HF by upregulating the renin-angiotensin-aldosterone and sympathetic nervous systems, increasing production of proinflammatory factors and worsening anemia, leading to LV hypertrophy (LVH) and impaired myocardial contractility.",179,32,0.1787709497206704
9781910797471,ch04,"HF therapy is challenging in the context of comorbid renal disease, as vasodilators may precipitate an increase in serum creatinine and potassium levels; however, current evidence supports the use of these drugs in patients with CRS type 1 providing the initial increase in serum creatinine and potassium are less than 30% and 5.6 mmol/L, respectively.","CRS type 5 (secondary CRS) - combined heart and kidney dysfunction due to an acute (exempli gratia sepsis) or chronic (exempli gratia diabetes mellitus) systemic disorder. Treatment differs for the types. In general, careful patient selection and monitoring are crucial. ACE inhibitors or angiotensin-receptor blockers (ARBs) are safe to introduce in patients with CRS type 1 provided the initial rises in serum creatinine and potassium are less than 30% and 5.6 mmol/L, respectively. These drugs should not be initiated in patients with CRS type 3 or known bilateral renal artery stenosis. Chronic therapy with ACE inhibitors or ARBs should be continued (in CRS types 1, 2, 3 and 4), but with close monitoring of serum creatinine and potassium levels. Beta-blockers should not be initiated in CRS type 1 as they may precipitate an acute drop in cardiac output and a worsening of both AKI and HF, but their continuous use in CRS types 2, 3 and 4 should not be interrupted. In CRS type 5, the source of infection should be treated (antibiotics, surgery) and supportive cardiac therapy given, including judicious use of intravenous fluids, vasopressors and inotropic agents. If required, hemofiltration may be preferable to hemodialysis, as the latter may cause shifts in intravascular volume, hypotension, arrhythmia and worsening cardiac function.",307,76,0.247557003257329
9781910797471,ch04,Acute ischemic hepatitis may develop in HF with low-output state and is generally reversible.,"Acute ischemic hepatitis has been reported in patients with acute cardiac dysfunction (either new or decompensated chronic HF). It develops in response to a sudden drop in hepatic perfusion resulting from a combination of poor cardiac output and venous congestion. The condition is characterized by acute hepatocellular necrosis with an increase in serum AST and ALT levels (frequently in the thousands) with accompanying signs (cold periphery, poor urine output, pulmonary congestion) and symptoms (dyspnea, fatigue, nausea, poor appetite) of a low-output state.",116,20,0.1724137931034483
9781910797471,ch05,"Investigations in patients with HF include blood tests, ECG, chest X-ray, echocardiography and other imaging techniques.","A 67-year-old man with diabetes mellitus, hypertension and renal impairment is referred to the cardiology outpatient department because of fatigue. He is overweight and relatively inactive, but still able to visit his country property and went hunting as recently as last year. He has experienced shortness of breath when climbing two flights of stairs at home and has difficulty in walking uphill to his house. He has no history of ischemic heart disease or other cardiac symptoms. His blood pressure is 164/96 mmHg and he has an irregular pulse of 102 beats per minute. He has no jugular venous distension or edema, and his chest is clear to auscultation; the apex beat is impalpable but there is a blowing pansystolic murmur at the apex. The chest X-ray shows cardiomegaly and the ECG shows atrial fibrillation with left bundle branch block.",188,29,0.15425531914893617
9781910797471,ch05,"Assessment of functional class, based on exercise capacity, is important in chronic heart failure (HF) as it is linked to outcome.","The onset of HF symptoms (Table 5.2) may be acute (typically with pulmonary edema, even with cardiogenic shock) or subacute. Both right and left HF may occur in the context of low output (fatigue, syncope and hypotension), and both right- and left-sided HF usually occur together. Assessment of functional class (see Table 2.1), based on exercise capacity, is important in chronic HF because it is linked to outcome - the annualized mortality in NYHA class IV HF is about 50%, which is four to five times that of class II and twice that of class III.",128,27,0.2109375
9781910797471,ch05,The hemodynamic profile of acute HF varies according to the degree of pulmonary congestion (wet versus dry) and the state of tissue perfusion (warm versus cold).,"The initial clinical picture of acute HF reflects the varying degree of impairment of cardiac output and elevation in left ventricular (LV) diastolic pressure or pulmonary artery wedge pressure (obtained at left and right heart catheterization, respectively). Patients with acute HF can present with one of several distinct hemodynamic profiles, based on the degree of pulmonary congestion (wet versus dry) and the state of tissue perfusion (warm versus cold) (Figure 5.3). More specific for acute HF is Gheorgiade's classification in which the therapeutic target - cardiac output, blood pressure or intravascular volume - dictates the intervention. Arrhythmias may play a part in both acute and chronic HF. Atrial fibrillation is an important precipitant of acute deterioration and is itself engendered by persistent elevation of filling pressure leading to left atrial enlargement. Atrial arrhythmias contribute to reduced functional capacity, as atrial systole makes an important contribution to stroke volume, especially in the context of LV filling problems and particularly with exercise. Although some patients die from progressive HF, ventricular arrhythmias are an important cause of death in patients with HF. The risk of fatal arrhythmias is greatest in the presence of low ejection fraction, but because of the higher number of patients with less severe reduction of ejection fraction, this group has the highest absolute number of sudden deaths.",287,33,0.11498257839721254
9781910797471,ch05,"Also key to the diagnosis of HF is the assessment of ejection fraction, underlying etiology and precipitating factors, and the role of coronary artery disease.","Arrhythmias may play a part in both acute and chronic HF. Atrial fibrillation is an important precipitant of acute deterioration and is itself engendered by persistent elevation of filling pressure leading to left atrial enlargement. Atrial arrhythmias contribute to reduced functional capacity, as atrial systole makes an important contribution to stroke volume, especially in the context of LV filling problems and particularly with exercise. Although some patients die from progressive HF, ventricular arrhythmias are an important cause of death in patients with HF. The risk of fatal arrhythmias is greatest in the presence of low ejection fraction, but because of the higher number of patients with less severe reduction of ejection fraction, this group has the highest absolute number of sudden deaths.",158,31,0.1962025316455696
9781910797471,ch05,"Atrial arrhythmias contribute to a reduction in functional capacity, while ventricular arrhythmias are an important cause of death in patients with HF.","Arrhythmias may play a part in both acute and chronic HF. Atrial fibrillation is an important precipitant of acute deterioration and is itself engendered by persistent elevation of filling pressure leading to left atrial enlargement. Atrial arrhythmias contribute to reduced functional capacity, as atrial systole makes an important contribution to stroke volume, especially in the context of LV filling problems and particularly with exercise. Although some patients die from progressive HF, ventricular arrhythmias are an important cause of death in patients with HF. The risk of fatal arrhythmias is greatest in the presence of low ejection fraction, but because of the higher number of patients with less severe reduction of ejection fraction, this group has the highest absolute number of sudden deaths.",158,32,0.20253164556962025
9781910797471,ch05,Functional testing is of particular value in patients deemed suitable candidates for devices or transplantation.,"Once coronary disease has been identified, the next question is whether this is an 'innocent bystander'. A variety of tests have been reported for the detection of viable myocardium, ranging from the simple (single-photon-emission CT, dobutamine echo) to the complex (MRI, positron emission tomography). Although the STICH trial found no relationship between the results of viability imaging and outcome, it is important to consider not only the presence of dysfunctional but viable tissue, but also its extent, id est the total burden of compromised myocardium, including ischemia. Functional testing involves exercise testing using either a treadmill or ergometer, with or without analysis of expired gases to obtain peak oxygen consumption or carbon dioxide generation. Functional testing is of value for objective quantification of exercise capacity at any stage, but especially in patients who are being evaluated for advanced therapies, including devices and transplantation.",186,18,0.0967741935483871
9781910797471,ch06,"General non-pharmacological strategies, including self-care education, treatment adherence, symptom recognition, weight control, sodium and fluid management and healthy lifestyle choices are as important as heart failure (HF)-specific medications.","General non-pharmacological management may be as important as the prescription of HF-specific medications. The majority of HF care is conducted in the home by either the patient and/or the caregiver. It is therefore essential that all patients with HF and those who care for them receive comprehensive education and counseling to develop the knowledge, skills, strategies, problem-solving approaches and motivation required to adhere to a complex treatment plan and effectively participate in HF self-care. It is important to include carers and family members in this education as patients with HF often experience difficulties with cognition, functional ability and other conditions that may limit their understanding of what is required. Non-adherence to HF management plans can be related to patient and/or caregiver misconceptions and lack of knowledge. Self-care involves active participation in the maintenance and management of HF. Included within self-care maintenance are healthy lifestyle choices, treatment adherence and monitoring of behaviors. Self-care management is a cognitive process that involves the recognition of signs and symptoms of worsening HF, evaluation of the importance of a change in symptoms, implementation of a self-care strategy (such as increasing diuretic medication) and evaluating the effectiveness of any changes.",242,43,0.17768595041322313
9781910797471,ch06,"Patients with HF appear to benefit from exercise as much as others, with a documented improvement in quality of life and a tendency towards reductions in morbidity and mortality.","Sexual activity. It is common for patients with HF to experience sexual problems related to cardiovascular disease, medical treatment (beta-blockers, digoxin, spironolactone, thiazide diuretic) or physiological factors such as fatigue and depression. Such problems adversely affect the quality of life of the patient and their partner. There is, however, little evidence related to sexual activity in patients with HF and it has been suggested that sexual activity is likely to be safe. Patients who are able to achieve approximately 6 METs (metabolic equivalents of task [see Table 6.2 ]) of exercise (id est able to climb two flights of stairs without stopping due to angina, breathlessness or fatigue) should be able to undertake regular sexual activity.",152,33,0.21710526315789475
9781910797471,ch06,Patients with a private driving license are generally restricted from driving only if they have advanced or uncontrolled HF; those with a commercial driving license are banned from driving until further testing.,"Travel for patients with HF is possible but complex, and preparation is the key. Any intention to travel should be discussed with a healthcare practitioner before arrangements are made. Patients wishing to travel to hot and humid destinations should be counseled about the risk of dehydration and adjustments to their fluid-management regimen, while patients with ischemic cardiomyopathy should be warned that colder climates can precipitate angina because of the increase in peripheral vascular resistance. Prophylaxis for deep vein thrombosis (DVT) should be considered in patients preparing for long flights. Driving. The driving rules for patients with HF vary between countries and clinicians should refer to national guidelines (see Further reading, page 147). In general, patients with a commercial driving license and symptomatic HF are banned from driving. In the UK relicensing may be permitted provided.",170,35,0.20588235294117646
9781910797471,ch06,"In general, there is no convincing evidence that electromagnetic interference, cosmic radiation or vibration have an important effect on the function of pacemakers or implantable cardiac defibrillators.","Air travel may have a negative effect on HF either directly through hypoxia or immobilization, or indirectly and very rarely because of interference of an electromagnetic field, cosmic radiation or vibration with implanted devices such as pacemakers or implantable cardiac defibrillators (ICDs). During flights, the changes in ambient partial pressure of oxygen (p O) due to the changing altitude cause a drop in arterial p O in healthy subjects by about 30% to 62-67 mmHg (8.2-9 kPa). The resulting hypoxia could have negative cardiovascular consequences in patients with HF. Effects of hypoxia in heart failure. Significant hypoxia may have a deleterious effect on patients suffering from LV dysfunction. It can lead to tachycardia or an elevation in systemic and pulmonary blood pressure, and can even trigger arrhythmia or coronary ischemia in patients with underlying coronary artery disease (CAD). However, in patients with HF, pulmonary vasoconstriction may help protect the pulmonary microvasculature from increased pressure. It appears that the systemic vascular resistance falls in response to hypoxia (thought to be mediated by nitric oxide), which may limit rises in pulmonary venous and LV filling pressures.",253,36,0.1422924901185771
9781910797471,ch06,"Most patients who have had an episode of acute HF should be able to fly, if stable, in 6 weeks. There should be no restriction for patients with chronic HF, although those with NYHA class III or IV should consider airport assistance and request the availability of in-flight oxygen.","Acute left ventricular failure. The risk of hospitalization for HF following acute myocardial infarction (MI) is highest in the few weeks after the infarction but stabilizes after 45 days. Once any precipitant has been identified and treated, most patients should be stabilized within 6 weeks and are considered safe to fly. Chronic heart failure. Passengers with stable chronic HF without recent changes in symptoms or medication are likely to be able to tolerate the mild hypoxia of the aircraft cabin environment even if they have severe HF. However, they should avoid physical exertion at the airport and make sure that they take their regular medication. It is probably prudent for passengers who are severely limited with NYHA class IV symptoms not to fly without special consideration and the availability of in-flight oxygen. Deep vein thrombosis/venous thromboembolism risk. Patients with HF are at moderate risk of DVT/venous thromboembolism (VTE) while travelling by air. In general, patients should keep mobile, practice regular flexion and extension exercises of the lower limbs, and avoid dehydration. Alcohol and sedatives should be avoided. Compression stockings have been shown to reduce risk in the non-HF population. Prophylactic low-molecular-weight heparin may be considered in patients with severe HF on long intercontinental flights.",284,57,0.2007042253521127
9781910797471,ch07,"Diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta-blockers and aldosterone antagonists are the mainstay of therapy for symptomatic left ventricular systolic dysfunction.","The different forms of heart failure (HF) (systolic and diastolic, left and right ventricular ([LV/RV] dysfunction, acute and chronic - see Chapter 1) require somewhat different treatment approaches. While successful evidence-based therapy now exists for HF due to LV systolic dysfunction, the search for the 'holy grail' in diastolic HF (heart failure with preserved ejection fraction [HFpEF]) continues. Several large studies of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have not been successful. In general, the management of HFpEF should be directed towards the underlying cause (exempli gratia lowering blood pressure in patients with hypertension, revascularization in patients with coronary ischemia). Symptoms of congestion should be managed with diuretics (see pages 95 -). The recent TOPCAT trial of the mineraloreceptor antagonist spironolactone in patients with HFpEF showed an overall neutral effect on primary composite endpoints (mortality and HF hospitalization). Interestingly, a post hoc analysis showed regional differences in outcome, and patients from American centers had a significant reduction in cardiac events.",254,55,0.21653543307086615
9781910797471,ch07,"Medical management of heart failure (HF) with preserved systolic function remains challenging, but in principle should target the underlying cause (exempli gratia blood pressure, coronary ischemia).","While successful evidence-based therapy now exists for HF due to LV systolic dysfunction, the search for the 'holy grail' in diastolic HF (heart failure with preserved ejection fraction [HFpEF]) continues. Several large studies of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have not been successful. In general, the management of HFpEF should be directed towards the underlying cause (exempli gratia lowering blood pressure in patients with hypertension, revascularization in patients with coronary ischemia). Symptoms of congestion should be managed with diuretics (see pages 95 -). The recent TOPCAT trial of the mineraloreceptor antagonist spironolactone in patients with HFpEF showed an overall neutral effect on primary composite endpoints (mortality and HF hospitalization). Interestingly, a post hoc analysis showed regional differences in outcome, and patients from American centers had a significant reduction in cardiac events.",209,39,0.18660287081339713
9781910797471,ch07,"Acute HF is a medical emergency and the treatment has to be tailored to the underlying clinical problem (lowering blood pressure in severe hypertension, revascularization in acute myocardial infarction).","While successful evidence-based therapy now exists for HF due to LV systolic dysfunction, the search for the 'holy grail' in diastolic HF (heart failure with preserved ejection fraction [HFpEF]) continues. Several large studies of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have not been successful. In general, the management of HFpEF should be directed towards the underlying cause (exempli gratia lowering blood pressure in patients with hypertension, revascularization in patients with coronary ischemia). Symptoms of congestion should be managed with diuretics (see pages 95 -). The recent TOPCAT trial of the mineraloreceptor antagonist spironolactone in patients with HFpEF showed an overall neutral effect on primary composite endpoints (mortality and HF hospitalization). Interestingly, a post hoc analysis showed regional differences in outcome, and patients from American centers had a significant reduction in cardiac events.",209,40,0.19138755980861244
9781910797471,ch07,The new angiotensive receptor neprilysin inhibitor sacubitril/valsartan and the selective sodium-potassium channel inhibitor ivabradine should be considered in patients who remain symptomatic despite therapy with an ACE inhibitor or ARB and beta-blocker.,"Angiotensin receptor neprilysin inhibitor (ARNI). A combination of the neprilysin (endopeptidase) inhibitor prodrug sacubitril and the ARB valsartan has been shown to inhibit neprilysin while blocking the adverse effects of the renin-angiotensin-aldosterone system (RAAS) and reducing bradykinin potentiation. It increases the concentration of vasodilatory peptides, augments sodium loss and retards hypertrophy and remodeling. Combination with an ARB (valsartan) is necessary, as inhibition of neprilysin leads to activation of the RAAS. Changing from ACE inhibitor/ARB therapy to ARNI should be considered in symptomatic patients (NYHA class II and III) with chronic HFrEF and low LVEF (< 35%) despite initial therapy with a beta-blocker and ACE inhibitor or ARB. The PARADIGM-HF study demonstrated a 20% reduction in the incidence of cardiovascular death and HF hospitalization with sacubitril/valsartan compared with enalapril, a benefit that was above and beyond that already shown with ACE inhibitors.",246,56,0.22764227642276422
9781910797471,ch07,"Inotropic agents are used short term in acute cases with severe cardiac dysfunction (cardiogenic shock) and can be supplemented by mechanical circulatory support (exempli gratia intra-aortic balloon pump, left ventricular assist device).","Intravenous inotropic agents (drugs that increase the strength of heart muscle contraction) such as dopamine, dobutamine and milrinone are used in patients with acute decompensated HF, as they stabilize cardiac output and blood pressure and support adequate blood supply to vital organs (kidneys, heart) until more definitive therapy is introduced (exempli gratia revascularization, LV assist device). Long-term use of moderate to high doses of inotropic agents is associated with excessive mortality (due to the increase in oxygen debt of the working myocardium) and should be avoided. The effects of low-dose or intermittent infusion are not yet known; the results of a study of low-dose dopamine infusion (< 5 g/kg/minute) in patients with cardiorenal syndrome are awaited. Some HF centers use intravenous inotropic agents in ambulatory patients with severe intractable HF ('pulsed therapy'). Although this intermittent therapy provides some patients with hemodynamic and clinical improvement, the potential for life-threatening arrhythmia and rebound HF in between treatments is a concern.",224,49,0.21875
9781910797471,ch08,"Patients with poor left ventricular systolic function (ejection fraction < 35%), who are symptomatic on optimal medical treatment, with broad QRS complexes (> 120 ms) and left bundle branch block should be referred for cardiac resynchronization therapy.","Cardiac contractility modulation via a pacemaker-like device is a relatively new development for the treatment of HF. A high-voltage biphasic signal is delivered through one of three intracardiac pacing leads to the RV septum (a newer device has only two leads). The signal is timed to coincide with the absolute refractory period of the ventricle. Although it does not result in cardiac contraction, it enhances myocardial function by improving myocyte calcium handling and mitochondrial function. It also has a positive effect on cardiac protein modification, including enhancing myocardial gene expression. In general, clinical studies have indicated a sustained improvement in quality of life, exercise capacity and LVEF. There are few randomized studies, but recent evidence suggests that the patients who benefit the most are those with an ejection fraction of 25-40% and a narrow QRS duration, who remain symptomatic on optimal medical treatment and whose LV function does not require a prophylactic defibrillator. These patients are not eligible for CRT and therefore represent an additional group who do not respond to medical therapy alone.",228,51,0.2236842105263158
9781910797471,ch08,"With evolving technology, the complication rate of left ventricle assist devices and total artificial hearts will decline and their use will significantly increase as a bridge to transplantation and as destination therapy.","The total artificial heart is a mechanical device that entirely replaces the heart's function. It is currently used as a bridge to transplantation, but work continues to make it ready for potential destination therapy. A synthetic fully functional mechanical heart is one of the holy grails of medicine. While transplant recipients outnumber organ donors there will be a drive to develop this technology. The first mechanical heart was used as a bridge to transplant in 1969. A number of versions of the device have been made since. Studies show that up to 80% of patients survive to transplant. Newer prototypes using electronic sensors and 'biomaterials' such as chemically treated animal tissues are in the advanced stages of development, and it is projected that in the long term totally implantable hearts will be available within the next 5-10 years.",162,37,0.22839506172839505
9781910797471,ch08,"Assuming that the candidate pool (patients with end-stage heart failure [HF]) continues to grow, the burden on healthcare systems worldwide could become significant.","Currently in use, the SynCardia TAH is a biventricular, pneumatic pulsatile blood pump that completely replaces the patient's native ventricles. It is lined with polyurethane and has a pneumatically driven diaphragm (Figure 8.9). The device is used as a bridge to transplantation in patients for whom LV assist and CRT devices are contraindicated, including those with aortic regurgitation, cardiac arrhythmias, an LV thrombus, an aortic prosthesis, an acquired ventricular septal defect, or irreversible biventricular failure requiring high pump outputs. The device is powered by a large console that limits the patient's movement. Portable drivers that will enable patients to return home are in the testing phase. Over 1500 such devices have been implanted worldwide, although there are still significant technical and patient-related challenges; a fully functioning chronically implanted device is still some years away.",198,31,0.15656565656565657
9781910797471,ch08,Cardiac transplantation remains a viable option in selected individuals with end-stage HF despite the shortage of donor organs; steady improvement in survival after cardiac transplantation has been observed.,"Complications. As with all mechanical devices the two major complications are thromboembolism and infection. Infection is common (up to 20% of cases are device related) but treatable and does not necessarily mandate device removal. Pulmonary infection is also common (up to 20%), as are neurological events (15%). Despite these complications, overall success has been increasing and these devices are becoming increasingly acceptable. Cardiac transplantation outcomes have been steadily improving over the last 30 years. Currently, over 85% of patients will survive 12 months and 50% of transplant recipients are still alive at 10 years. Although highly successful, the major limitation is the availability of donor hearts. In the USA there are approximately 2500 transplants per year, 3500 worldwide, against an estimated 800 000 eligible people with end-stage HF. This mismatch in demand has spurred the development of other approaches to support a failing heart (see above). A new technique acquiring donor hearts shortly after death has been pioneered in Australia and, if viable, may help to increase donor availability.",211,35,0.16587677725118483
9781910797471,ch09,Heart failure (HF) has a poor prognosis with an annual mortality of 25-50% depending on severity of symptoms and left ventricular (LV) systolic dysfunction.,"Diagnosis of heart failure (HF) carries a poor prognosis, often comparable with that of cancer. The annual mortality for mild-to-moderate HF (NYHA class II or III) is 24-28%, and increases to 50% in patients with severe NYHA class IV symptoms. Hospital admission with acute HF is a strong and independent predictor of worse prognosis, and is associated with 2-4% in-hospital and 5-15% 90-day mortality. Between 30% and 50% of patients with acute HF are readmitted within 6 months, although 50% of these readmissions are due to comorbidities, often associated with advanced age, rather than existing HF. Prognosis of HF in individual patients is challenging as a number of independent variables must be considered, including symptoms, severity, etiology and type of HF. The fact that sudden death can occur at any stage of the disease makes the prognostic process even less predictable. In general, patients with NYHA class IV symptoms, and HF caused by infiltrative heart disease, HIV infection or anthracycline toxicity, with systolic left ventricular (LV) or biventricular dysfunction, have the worse prognosis.",248,36,0.14516129032258066
9781910797471,ch09,"Poor prognostic signs include impaired renal function, marked prolongation of QRS, hypotension and hyponatremia.","Several clinical and laboratory markers of poor prognosis have been validated (Table 9.1). Other identified factors of reduced survival in patients with HF include attenuated response to diuretics, low peak oxygen consumption (VO max) or short distance in the 6-Minute Walk Test (6MWT), a large burden of ventricular ectopy and complex ventricular arrhythmia, significant pulmonary hypertension, new-onset atrial fibrillation and specific echocardiographic features (significant LV dyssynchrony, evidence of ongoing remodeling and a marked increase in left atrial volume).",122,25,0.20491803278688525
9781910797471,ch09,The search for reversible factors is always indicated.,"Initial assessment in patients with HF should include a review of the prognosis but, importantly, a search for reversible factors contributing to disease progression (Table 9.2). If any of these problems are identified, prompt and comprehensive treatment should improve HF symptoms, in many cases arrest disease progression and improve prognosis.",61,9,0.14754098360655737
9781910797471,ch09,"The model of palliative care for advanced HF needs to be very flexible, individualized to the needs of the patient and their family.","If the patient assessment indicates the need for palliative care, management should shift to symptom control (Table 9.5). Patients and their families or carers may require assistance in negotiating the change in goals of care from prolongation of life to improvement of quality of life by maximizing comfort and dignity. Time should be set aside to discuss the prognosis, course of the illness and palliative-care strategies in detail with the patient and carer. A program of care individualized to the needs of the patient and their family is extremely important. Palliative-care strategies should build on, rather than replace, multidisciplinary programs of care that optimize advanced HF management. Properly applied, they can cut the overall cost of care by reducing the amount of time patients spend in acute-care settings.",162,28,0.1728395061728395
9781910797471,ch09,Good communication skills are the key to effective palliative care delivery.,"If the patient assessment indicates the need for palliative care, management should shift to symptom control (Table 9.5). Patients and their families or carers may require assistance in negotiating the change in goals of care from prolongation of life to improvement of quality of life by maximizing comfort and dignity. Time should be set aside to discuss the prognosis, course of the illness and palliative-care strategies in detail with the patient and carer. A program of care individualized to the needs of the patient and their family is extremely important. Palliative-care strategies should build on, rather than replace, multidisciplinary programs of care that optimize advanced HF management. Properly applied, they can cut the overall cost of care by reducing the amount of time patients spend in acute-care settings.",162,14,0.08641975308641975
9781910797471,ch09,"Primary care, cardiology and palliative care teams should work in collaboration to deliver an effective phase-specific treatment in advanced HF.","If the patient assessment indicates the need for palliative care, management should shift to symptom control (Table 9.5). Patients and their families or carers may require assistance in negotiating the change in goals of care from prolongation of life to improvement of quality of life by maximizing comfort and dignity. Time should be set aside to discuss the prognosis, course of the illness and palliative-care strategies in detail with the patient and carer. A program of care individualized to the needs of the patient and their family is extremely important. Palliative-care strategies should build on, rather than replace, multidisciplinary programs of care that optimize advanced HF management. Properly applied, they can cut the overall cost of care by reducing the amount of time patients spend in acute-care settings.",162,27,0.16666666666666666
9781910797471,ch09,End-of-life planning and decision making are essential and should be discussed early in the process.,"Clear communication with community-care providers and family members should always precede any changes in direction or content of care provided by the treating team. An advance care plan is often documented and the ways of managing future clinical deterioration discussed with the patient. Carers should be included in the management plans. Advanced health directive. Recognizing that the outcomes of resuscitation in patients with advanced HF are dismal, individuals should be empowered to express their treatment preferences even when unable to speak for themselves. The existence and process of obtaining such a legal document should be discussed with the patient and their carers early in the course of advanced HF.",123,20,0.16260162601626016
9781910797471,ch10,"Stem cell therapy has demonstrated a modest improvement in cardiac performance in some studies, but the clinical effect of such therapies has not yet been proven.","Stem cell therapy remains a promising treatment for patients with left ventricular (LV) dysfunction caused by coronary ischemia/infarction. Intracoronary or intramyocardial injections of skeletal myoblasts or bone-marrow-derived mononuclear cells (BMSCs) have led to a modest improvement in cardiac performance in some studies, including improvement in the LVEF and reduction in the size of scar tissue and cardiac volume. However, the clinical effect of such therapies has not yet been proven. The therapy appears to be well tolerated in patients after recent myocardial infarction (MI), but a proarrhythmic effect of cell therapy has been observed in patients with chronic heart failure (HF).",151,29,0.19205298013245034
9781910797471,ch10,"A fully implantable, automated, phrenic nerve stimulation system is an alternative approach to the treatment of patients with central sleep apnea. Early findings are promising, and the results of ongoing trials in patients with HF are awaited.","In addition, intracoronary administration of BMSCs seems to be associated with improvements in cardiac contractile and microvascular function in patients with dilated cardiomyopathy. Intensive work in this and other areas (including the type of cell used, and the method and time of delivery) continues. However, stem cell therapy is not yet ready to become a mainstay of clinical practice. Phrenic nerve stimulation in patients with central sleep apnea. This is an alternative approach to the treatment of patients with central sleep apnea (CSA), designed to restore a physiological breathing pattern throughout sleep. It uses a fully implantable system with transvenous leads designed for the long-term application of transvenous phrenic nerve stimulation (The Remed System, Respicardia). The system is fully automated, thereby eliminating patient non-adherence. It works by stimulating the diaphragm during sleep to stabilize gas exchange and maintain normal breathing. It has recently been shown to stabilize the breathing pattern, reduce the number of apneic events, improve oxygen saturation and increase end-tidal carbon dioxide without suppressing the intrinsic drive to breathe. Future large studies in patients with HF and CSA are awaited.",250,46,0.184
9781910797471,ch10,"In short-term studies, patiromer, a non-absorbable compound that predominantly binds to potassium in the colon and exchanges it for calcium, has demonstrated efficacy in managing hyperkalemia in patients treated with HF medications.","Hyperkalemia is common in patients receiving HF medications such as angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blockers (ARBs), spironolactone or eplerenone, and often limits their use. Management of hyperkalemia in these patients is often challenging and comprises dietary restriction and dose reduction or withdrawal of the offending agent. Potassium-binding resins, such as resonium A (sodium polystyrene sulfonate) and calcium resonium (calcium polystyrene sulfonate) are commonly used in the management of chronic hyperkalemia. However, high quality evidence of the effectiveness of these agents is lacking. Furthermore, they can cause serious or intolerable gastrointestinal adverse events ranging from gastric irritation to (rarely) ischemic colitis, gastrointestinal obstruction, ulceration, perforation or necrosis. Patiromer is a non-absorbable compound that predominantly binds to potassium in the colon and exchanges it for calcium. The most common adverse effects are constipation (11%) and hypokalemia (3%). Short-term studies have confirmed its efficacy in maintaining normokalemia in patients treated with HF medications.",250,47,0.188
9781910797471,ch10,A new formulation of subcutaneous furosemide delivered via a dedicated device has been developed.,"Furosemide, the loop diuretic used to treat congestive HF, is licensed for use in oral and intravenous forms (see pages 96 -). For patients with recurrent fluid overload, intravenous administration in a hospital setting is the only licensed choice, although in some countries off-label subcutaneous furosemide has been used for several years in the palliative care setting. A new formulation of subcutaneous furosemide that uses a dedicated sc2Wear infusor pump has been developed. The drug pH has been reduced to a neutral level to minimize the risk of local irritation or discomfort.",129,20,0.15503875968992248
9781910797495,chp1,The nervous system is dynamic and plastic; noxious stimuli trigger biological processes that lead to amplification or inhibition of the noxious signal.,"The PNS and CNS do not passively transduce stimuli and convey sensory information. Instead, noxious stimuli trigger biological processes that then amplify or inhibit the noxious signal. Potentiation. After tissue or nerve damage, peripheral nociceptors become sensitized to noxious stimuli owing to the formation and accumulation of algogenic and inflammatory mediators in the periphery, such as prostanoids, interleukins, bradykinin and histamine. Peripheral sensitization and heightened afferent activity in pain fibers elicit functional, chemical and anatomic reorganization in spinal cord neurons. These changes lead to long-term central potentiation, a form of pain memory characterized by progressively enhanced and prolonged spinal neuronal responses to afferent impulses.",152,26,0.17105263157894737
9781910797495,chp1,Nociceptive input activates descending pathways that inhibit spinal noxious transmission. These descending pathways are potential targets for analgesic drugs.,"Inhibition. Pain also triggers processes that dampen the perception of nociceptive stimuli. Nociceptive afferent traffic ascends to the midbrain and brainstem, where it activates descending pathways that inhibit spinal pain transmission (see Figure 1.2). These descending inhibitory systems are stimulated by endogenous opioids, as well as monoamines such as norepinephrine (noradrenaline) and serotonin. They inhibit spinal nociceptive transmission through the local release of inhibitory transmitters such as gamma-aminobutyric acid (GABA), glycine, adenosine and endogenous opioids at the spinal level.",128,26,0.203125
9781910797495,chp1,Neuropathic pain is produced by a lesion of the peripheral or central nervous system (CNS).,"Because it is an experience, pain itself cannot be measured directly. Pain, like consciousness itself, is constructed by complex brain processes that are strongly affected by a person's attitudes, beliefs, personality and interpretation of the significance of nociceptive stimuli. Central to the understanding of clinical pain is the concept that pain may be present without an obvious peripheral source or cause. Mechanisms of neuropathic pain. Definition. Neuropathic pain is initiated or caused by a primary lesion of the PNS or CNS. Patients often complain not only of spontaneous pain, but also of pain from stimuli that are not normally painful (allodynia). For example, a light touch may be described as painful.",139,21,0.1510791366906475
9781910797495,chp1,Nerve injury produces hyperexcitability and spontaneous generation of ectopic impulses in axons and neurons.,"Peripheral nerve injury produces axonal membrane hyper-excitability that leads to spontaneous generation of ectopic impulses. In addition, changes in the chemical environment surrounding the damaged axon trigger ectopic nerve action potentials, which lead to further impulses (Figure 1.4). Abnormal repetitive firing of injured axons occurs because sodium channels accumulate at the site of injury, creating a lower threshold for the initiation of action potentials (Figure 1.5). Abeta fibers rather than C fibers show the greatest degree of spontaneous ectopic discharge after peripheral nerve injury. Abeta fibers are specialized for light touch and are therefore likely to mediate the allodynia experienced after nerve injury. Nerve injury also triggers the production of a series of inflammatory mediators that promote ectopic activity in primary afferent fibers. These mediators are produced by macrophages that migrate to sites of nerve injury and contribute to chronic inflammation in their immediate environment.",187,21,0.11229946524064172
9781910797495,chp1,Ectopic peripheral nerve activity contributes to the central hyperexcitable state and enlargement of neuronal receptive fields.,The sensitization (increased excitability) and increased synaptic efficacy of second-order neurons termed 'wide dynamic range neurons' (id est neurons that respond to a range of noxious and non-noxious stimuli) could explain the allodynia that patients experience after nerve injury. The central hyperexcitable state and enlargement of the area in the periphery where stimulation evokes a neuronal response are sustained by ectopic peripheral nerve activity that causes ongoing release of neurotransmitters in the spinal cord (see Figure 1.3).,106,23,0.2169811320754717
9781910797495,chp1,After nerve injury there may be a loss of spinal inhibition control resulting from loss of neuronal inhibitory processes and persistence of glia-induced neuronal hypersensitivity. The connectivity of sympathic fibers to injured neurons contributes to the activation of pain by stress. All three of these maladaptions may play a major role in chronic neuropathic pain.,"The processes shown in Figure 1.8 can become prolonged, lasting past the time of healing and resulting in chronic neuronal hypersensitivity and persisting (chronic) neuropathic pain. Thus, new treatments for chronic neuropathic pain could focus on the cause of the ongoing pain - overactive glia. At least nine anti-glial drugs are being evaluated. AV411 (or MN-166, ibudilast) inhibits astrocytes. In 2016, it received 'fast track' designation by the FDA for its potential use in multiple sclerosis (MS). Etanercept and the antibiotic minocycline, which both inhibit microglia activation, have shown promise in animal studies but have not proven successful in human studies of pain. The cannabinoid Sativex, which inhibits CB2 cannabinoid spinal receptors on glia, is being studied for neuropathic pain due to MS and in trials of tetrahydrocannabinol:cannabidiol (THC:CBD) extract in patients with intractable cancer-related pain. It has been successful in two of three clinical trials for neuropathic pain in humans. Sativex is approved in many countries for the treatment of spasticity in people with MS. As glia appear to play a key role in opioid tolerance and withdrawal, these drugs may also slow the development of tolerance to opioids. Increased glial cell activity normally subsides gradually after injury; its continuation in some patients may be one of the keys to 'what goes wrong in chronic pain'. Chronic use of opioid drugs seems to play a role in glial cell activation, thus increasing pain and decreasing opioid analgesia in a vicious circle (see Figure 1.8). Loss of inhibition. Moreover, after nerve injury there is also a loss of spinal inhibitory control. Mitochondrial superoxide is produced after the influx of calcium associated with nerve injury, and leads to cell dysfunction and the death of interneurons with inhibitory control. The death of these neurons could explain the decrease in GABA, an inhibitory transmitter, in the dorsal horn of the spinal cord after nerve damage, as shown by immunoreactivity experiments (Figure 1.9). Finally, the persistent afferent input after peripheral nerve injury provokes changes in the nerve structure of the rostroventromedial medulla. These changes in turn encourage tonic discharge (firing at regular intervals) of the descending pathways that facilitate nociceptive transmission, further perpetuating the hyperexcitable state observed after nerve injury.",512,67,0.130859375
9781910797495,chp1,"Increased understanding of the causal pathway from acute to chronic pain (chronification), provides targets for early preventive interventions following onset of pain-causing injury or disease.","There is strong evidence that learning and memory processes play a key role in determining which patients progress from acute to chronic pain, and continue to experience chronic pain. Such learning processes are accompanied by neuroplasticity changes at multiple levels of the nervous system. Encoding of pain memory is enhanced by circumstantial fear; for example, when injury occurs in highly stressful circumstances such as that associated with post-traumatic stress disorder (PTSD). Extinction (unlearning) plays a key role in keeping neuroplasticity changes in check after nerve injury. However, in patients with chronic neuropathic pain, extinction processes may be impaired. Training the patient to extinguish pain-related memory processes may be a crucial but difficult key to treatment. Such treatment may be via behavioral, pharmacological or neurostimulation techniques, or a combination of these. Innovations in all three of these treatment areas already show promise.",182,32,0.17582417582417584
9781910797495,chp1,Increased understanding of chronic pain pathophysiology is leading to new pharmacological targets for treatment.,"Novel analgesics. Increased understanding of nociceptive transmission and pain pathophysiology, recognition of heterogeneity among C fibers extending to their production of different molecular transducers, discovery of new receptors such as those for vanilloids or growth factors, and identification of new receptor subtypes have already resulted in preclinical and early clinical testing of novel analgesics. These agents will more specifically target receptor subtypes or ion channels, and promise to be more effective and better tolerated than present therapies. Other novel molecules are designed to interact with multiple receptors simultaneously.",110,18,0.16363636363636364
9781910797495,chp1,New imaging (especially of the brain) is increasing knowledge of pathophysiological CNS neuroplasticity changes and showing the effects of biobehavioral training to reverse these changes.,"Iontophoretic or inhalational technology now permits the delivery of lipophilic opioids into the systemic circulation through the skin or lungs. Likewise, intranasal delivery of novel agents (or established agents coadministered with novel excipients) permits more rapid control of breakthrough pain than oral or transbuccal drug delivery. Advances in imaging technology have taken us beyond a static detailed image of the CNS: we can now see the brain at work. Functional MRI allows real-time clinical observation of the brain's pain excitatory and inhibitory circuitry, which helps us to understand how nociceptive input is processed and translated into pain and suffering. Functional imaging has advanced our knowledge of placebo and analgesic responses, and has even been applied as a novel form of biofeedback to allow patients to control their otherwise refractory chronic pain.",174,37,0.21264367816091953
9781910797495,chp2,A thorough evaluation of pain history and a detailed examination are the foundations for a rational treatment plan.,"Assessment of pain. The initial evaluation of a patient's pain forms the foundation for a rational treatment plan and so it must be as thorough as possible. For patients with chronic pain, this evaluation should include. a general medical history, including a detailed pain history. a physical examination (paying particular attention to neurological and musculoskeletal function). a psychosocial assessment.",76,19,0.25
9781910797495,chp2,"Assessment of patients with chronic pain should include a physical examination with particular attention to neurological and musculoskeletal function, a psychosocial assessment and, when appropriate, diagnostic testing such as imaging.","Assessment of pain. The initial evaluation of a patient's pain forms the foundation for a rational treatment plan and so it must be as thorough as possible. For patients with chronic pain, this evaluation should include. a general medical history, including a detailed pain history. a physical examination (paying particular attention to neurological and musculoskeletal function). a psychosocial assessment. diagnostic testing (exempli gratia imaging), when appropriate. For the busy clinician, a handy mnemonic for assessing the patient's pain history and pattern is PQRSTU (Table 2.1). Clearly, the history, physical examination and any laboratory evaluation performed to assess chronic pain may overlap with those carried out for general medical diagnosis and therapy. Many patients with pain due to cancer (see Table 9.1) or other serious illnesses such as HIV/AIDS experience pain from multiple mechanisms, locations and etiologies. These patients may simultaneously experience: acute and chronic pain; somatic and neuropathic pain related to the primary diagnosis or its treatment; the effects of mood state on pain; or pain from unrelated, possibly pre-existing, common medical conditions affecting the nervous and/or musculoskeletal systems (exempli gratia neuropathies, spinal pain, arthritis).",260,41,0.1576923076923077
9781910797495,chp2,"The patient's pain history should document the onset, location, radiation, duration, type (character) and intensity of pain, exacerbating or alleviating factors, previous treatments and response to them, and the meaning of the pain to the patient and their family.","Many patients with pain due to cancer (see Table 9.1) or other serious illnesses such as HIV/AIDS experience pain from multiple mechanisms, locations and etiologies. These patients may simultaneously experience: acute and chronic pain; somatic and neuropathic pain related to the primary diagnosis or its treatment; the effects of mood state on pain; or pain from unrelated, possibly pre-existing, common medical conditions affecting the nervous and/or musculoskeletal systems (exempli gratia neuropathies, spinal pain, arthritis). Because of the multiple and evolving etiologies of pain, each time a clinician assesses any patient at risk of undertreated pain there must be a fresh evaluation of the pain. Unless pain is assessed systematically and classified according to its likely origin as well as its temporal pattern, aggravating and ameliorating factors and perpetuating factors and comorbidities, then the patient is at risk of receiving suboptimal treatment. Even after an initial pain treatment plan is put in place, the source and severity of a person's pain and the effectiveness of treatment may fluctuate, and therefore their pain should be reviewed and documented at regular intervals. The patient is a key partner in this. When taking the patient's pain history, aspects that should be obtained and recorded in detail include: location, duration, type and intensity of the pain; exacerbating or alleviating factors; previous treatments and response to them; and the meaning of the pain to the patient and their family (Table 2.2).",310,52,0.16774193548387098
9781910797495,chp2,Persistent pain is a disease entity per se that can undermine many dimensions of health-related quality of life.,"Persistent pain commonly undermines mood, sleep, vitality, function and other dimensions of health-related quality of life (HRQoL). Thus, it is important to monitor how pain and its treatment affect function, daily activities, mood, sleep patterns and other aspects of HRQoL. Scales such as the Brief Pain Inventory, which evaluates pain intensity and the effect of pain on mood, sleep, social function and activities, are commonly used to monitor the effects of treatment from visit to visit.",101,22,0.21782178217821782
9781910797495,chp2,"Particular attention must be paid to risks for addiction and/or overdose before prescribing, and during a course of, opioid analgesics.","A number of instruments are now available to assess the level of risk for aberrant medication-related behavior, such as the Screener and Opioid Assessment for Patients in Pain (SOAPP) and the Current Opioid Misuse Measure (COMM); they are available for free online at www.painedu.org. Critical to outcomes is the balance between caution by eliminating or managing risks such as co-prescribed benzodiazepines, depression or substance abuse, and effective management of pain to prevent chronification and its associated pathologies, including overdose by suicide in patients with chronic pain and depression who see no hope for the future. The stratification tool for opioid risk mitigation (STORM) is a new approach to risk assessment for opioid overdose. Statistically derived from a large population sample, STORM is a predictive tool for risk assessment of any individual patient.",178,27,0.15168539325842698
9781910797495,chp3,"As chronic pain is a multidimensional interdisciplinary biopsychosocial condition, expert consensus and some research recommends a selective, interdisciplinary, mechanism-based approach as the method of choice to restore quality of life and functionality.","The International Association for the Study of Pain (IASP), the American Academy of Pain Medicine, the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists and the American College of Rheumatology, among many other professional organizations, have long advocated a multidisciplinary stepped care approach that addresses the multidimensional phenomenology of pain chronification (see page 25) as the preferred method of restoring health-related quality of life and functionality to patients with chronic pain. The high prevalence of chronic pain in the general population and the relatively small number of pain specialists dictates that prevention of chronification largely rests with primary care physicians and clinical specialty teams who are most often present after the onset of pain. Others in the health system, such as surgeons and acute pain subspecialists/anesthesiologists, may intervene effectively with surgical and anesthetic techniques to reduce the incidence or severity of pain chronification after injury or surgery and to identify factors that may influence progression to chronification. Regardless of the setting, patients should be aligned with a healthcare team that has the requisite competencies to evaluate and treat their pain successfully. Partnership between the primary care clinical team and patient, supported by ready access to consultation, and collaborative care with pain medicine and other specialists, enables cost-effective selective use of healthcare resources.",264,46,0.17424242424242425
9781910797495,chp3,"The education of patients about their pain conditions, enabling their participation in shared decision-making and the development of self-management skills, is now considered a cornerstone of successful pain management, whether it is delivered at home, in primary care or specialty care settings.","The high prevalence of chronic pain in the general population and the relatively small number of pain specialists dictates that prevention of chronification largely rests with primary care physicians and clinical specialty teams who are most often present after the onset of pain. Others in the health system, such as surgeons and acute pain subspecialists/anesthesiologists, may intervene effectively with surgical and anesthetic techniques to reduce the incidence or severity of pain chronification after injury or surgery and to identify factors that may influence progression to chronification. Regardless of the setting, patients should be aligned with a healthcare team that has the requisite competencies to evaluate and treat their pain successfully. Partnership between the primary care clinical team and patient, supported by ready access to consultation, and collaborative care with pain medicine and other specialists, enables cost-effective selective use of healthcare resources. The stepped care model. Using the stepped care model, pain treatment modalities can be added and intensity of treatment increased according to the need to manage factors such as complexity, risks, comorbidities and treatment refractoriness (Figure 3.1). For most patients, attention to all the potential physical, psychosocial, medical, vocational and social aspects of their chronic pain is not necessary, but rather selective attention is given to the most salient features of their pain condition. Thus, several large health systems in the USA, Australia and Europe have instituted the stepped care model of pain management that begins with patient education and training in self-management and provides additional pain treatments in a step-wise fashion. The foundation of the stepped care model is an informed patient who understands the nature of their chronic pain and can participate fully with their treatment team in planning and instituting appropriate self-management and biopsychosocial treatment.",350,51,0.1457142857142857
9781910797495,chp3,"Pharmacotherapy of chronic and cancer pain is mostly multimodal, combining several different drugs that act on different targets. Pharmacotherapy is often combined with other treatment options.","The stepped care model. Using the stepped care model, pain treatment modalities can be added and intensity of treatment increased according to the need to manage factors such as complexity, risks, comorbidities and treatment refractoriness (Figure 3.1). For most patients, attention to all the potential physical, psychosocial, medical, vocational and social aspects of their chronic pain is not necessary, but rather selective attention is given to the most salient features of their pain condition. Thus, several large health systems in the USA, Australia and Europe have instituted the stepped care model of pain management that begins with patient education and training in self-management and provides additional pain treatments in a step-wise fashion. The foundation of the stepped care model is an informed patient who understands the nature of their chronic pain and can participate fully with their treatment team in planning and instituting appropriate self-management and biopsychosocial treatment.",185,34,0.1837837837837838
9781910797495,chp3,"The specific disciplines of healthcare providers required to offer a multidisciplinary approach depend on the variety and complexity of patients seen and the available resources, as outlined in the stepped care model. Most pain care will occur in primary care settings, but ideally with close support from interdisciplinary teams of relevant health practitioners (exempli gratia psychology, physical therapy, complementary and integrative medicine) including pain medicine and other relevant specialists.","Many patients do well with minimal resources; for example, instructions in self-management of an uncomplicated episode of low back pain with simple medical and non-medical interventions such as over-the-counter medications, relaxation training/stress management and physical exercises. Other patients with more complexity or risk such as injuries or comorbid conditions (exempli gratia anxiety, depression, neuropathic condition) who are refractory to self-management alone, will require additional and more focused care such as condition-focused prescription medication and more formal behavioral and physical therapies. A still smaller group will require formal consultation and collaborative treatment with pain specialists, including procedures, complex pharmacology and more intensive psychological interventions such as cognitive behavioral treatment (CBT). The most complex and treatment-refractory cases may require advanced pain medicine procedures and intensive pain rehabilitation programs to optimize pain control, function and quality of life. Of course, 'two-way' movement of patients to appropriate levels of care may also be carried out. The critical factor is obtaining an early treatment response to prevent chronification (see Chapter 2) by establishing functional networks that quickly move patients to the right level of care for their needs. Too often patients are inadequately evaluated for risk factors for chronicity and treated with escalating doses of medication that only suppress symptoms, such that they begin to develop psychobiological (exempli gratia depression, anxiety, sleep), physical (exempli gratia weakness, gait/posture change) and social (exempli gratia job/family stress and loss) consequences. Interdisciplinary care. The specific disciplines of healthcare providers needed to offer multidisciplinary care are a function of the variety of patients seen, their complexity and the available resources. The team may include physicians, nurses, psychologists, physical therapists, occupational therapists, vocational counselors, social workers, pharmacists and any other health professional able to contribute to diagnosis and/or treatment.",391,84,0.21483375959079284
9781910797495,chp3,"Research evidence to support the effectiveness of the selective, interdisciplinary stepped approach to chronic pain treatment is not yet conclusive; more research is needed to prove its cost-effectiveness in specific pain phenotypes.","Research evidence to support the effectiveness of this approach to chronic pain treatment is just emerging. Meta-analyses of case-controlled cohort studies suggest that, in the case of disability from low back pain, interdisciplinary care increases the rate at which patients return to work and stay at work compared with controls. However, researchers consistently stress the need to improve the number and quality of trials to evaluate the effectiveness of chronic pain treatment programs, particularly the selective integration of two or more treatments to address different pathophysiological pain mechanisms or salient perpetuating factors (exempli gratia depression). For example, much like the treatment of major depression, a combination of medication and cognitive therapy is superior to either therapy alone, and combining CBT and/or physical therapy with medication and/or injections should be superior to any one treatment; indeed, most clinical experts recommend this approach.",172,40,0.23255813953488372
9781910797495,chp3,Opioids play a major role in cancer pain but data for their long-term effectiveness in chronic non-cancer pain are limited.,"Regrettably, some pain management professionals do continue to seek 'the cause' and 'the treatment', while some, who strongly support the use of a broad range of self-help strategies, fail to keep up to date with the risks and benefits of evidence-based 'passive treatments'. Commonsense suggests that a multimodal approach should be used, with a combination of appropriate treatments following a step-wise approach, with the least invasive options given a reasonable trial before the introduction of more invasive treatments, in addition to active self-management. For patients with cancer, major emphasis should be on the cancer itself, as well as some of its treatments (exempli gratia chemotherapy, radiation, surgery), as a cause of the pain (see Tables 9.1 - 9.5). The pharmacological options for chronic non-cancer pain and cancer pain overlap substantially. However, there are also particular separate issues for chronic cancer pain (as discussed in Chapter 9). Major issues concerning the use of opioids in chronic non-cancer pain overlap, for example, into the 'cancer survivors' group, some of whom may be prescribed opioids over a very long period of time, as can be the case for chronic non-cancer pain.",248,27,0.10887096774193548
9781910797495,chp3,"There is substantial variation among patients in dose-response and side effects for individual drugs within a drug category. Thus, careful drug titration is required for each individual patient.","Drugs used for the treatment of neuropathic non-cancer pain. As discussed in Chapter 6, different drugs in each drug class have been investigated for the treatment of different subtypes of neuropathic pain. Thus, it should not be assumed that a drug that is, for example, effective for diabetic neuropathy will be effective for neuropathic post-spinal cord injury. Nevertheless, there is some evidence of carry-over from one neuropathic pain type to another. This is why each chapter refers to studies of pharmacological management of specific pain types (exempli gratia post-herpetic neuralgia, diabetic neuropathy, spinal cord injury pain). Antiepileptics, antidepressants and other drugs useful in the treatment of neuropathic pain are outlined in Tables 3.2 and 3.3. Antidepressants act as analgesics via a wide range of mechanisms. TCAs and SNRIs are superior to SSRIs. In future, it is likely there will be individualized pharmacotherapy for each patient and for each neuropathic (and other) pain condition. For the time being, success with particular drug types in some but not other pain conditions gives us clues to improving treatment. For example, it is known that trigeminal neuralgia is a unique neuropathic pain condition with paroxysms (or 'lightning bolts') of pain. The paroxysms are directly related to spontaneous action potentials (APs) in trigeminal system neurons (see Chapter 1). As these APs involve the sodium channels, treatment should include sodium channel-blocking drugs of which carbamazepine is one example. Basic studies reveal that there are nine subtypes of sodium channel and it appears that the Na V 1.8 channel is the most effective for neuropathic pain, while having a wide margin of safety before CNS (brain/convulsions) and cardiovascular system (arrhythmogenic or hypotension) adverse effects. Attempts are therefore being made to develop Na V 1.8 and other sodium channel subtype blockers.",418,34,0.08133971291866028
9781910797495,chp4,Failed medical treatment is an indication for consideration of microvascular decompression or alternative techniques.,"Trigeminal neuralgia is an idiopathic paroxysmal recurrent pain in the distribution of one or more branches of the trigeminal (fifth cranial) nerve (Figure 4.1). Pain is usually caused by vascular compression of the trigeminal ganglion or its branches (Figure 4.2), but bony abnormalities or otherwise inapparent multiple sclerosis (MS) can also be associated with trigeminal neuralgia. Although up to 15% of people with MS have trigeminal neuralgia, it is only rarely (0.2%) diagnosed before MS. Rarely, a space-occupying lesion (exempli gratia tumor) in the cerebellopontine angle can be a cause of trigeminal neuralgia, particularly if there is loss of sensation in trigeminal territory - sometimes called atypical trigeminal neuralgia. Compression of the peripheral branches of the trigeminal nerve can also occur intraorally or in the region of the chin as the result of trauma, metastatic tumor or injury during alveolar or mandibular bone excision during tooth extraction.",238,19,0.07983193277310924
9781910797495,chp4,Pain is usually caused by compression of the trigeminal ganglion or its branches.,"Pain is usually caused by vascular compression of the trigeminal ganglion or its branches (Figure 4.2), but bony abnormalities or otherwise inapparent multiple sclerosis (MS) can also be associated with trigeminal neuralgia. Although up to 15% of people with MS have trigeminal neuralgia, it is only rarely (0.2%) diagnosed before MS. Rarely, a space-occupying lesion (exempli gratia tumor) in the cerebellopontine angle can be a cause of trigeminal neuralgia, particularly if there is loss of sensation in trigeminal territory - sometimes called atypical trigeminal neuralgia. Compression of the peripheral branches of the trigeminal nerve can also occur intraorally or in the region of the chin as the result of trauma, metastatic tumor or injury during alveolar or mandibular bone excision during tooth extraction.",194,18,0.09278350515463918
9781910797495,chp4,"Trigeminal neuralgia is characterized by paroxysmal and recurrent attacks of facial pain that are sudden and unilateral, and follow the distribution of one or more divisions of the trigeminal nerve.","Because there are no objective tests for trigeminal neuralgia, clinical manifestations are the mainstay of diagnosis. Trigeminal neuralgia is more prevalent in women than men by a ratio of 3:2. It can occur at any age, but usually has its onset in individuals over 50 years old. Clinical features. Trigeminal neuralgia is characterized by paroxysmal and recurrent attacks of facial pain that are sudden and unilateral, and that follow the distribution of one or more divisions of the trigeminal nerve. Pain is precipitated from trigger areas or by innocuous daily activities such as eating, talking, washing the face or brushing the teeth. Patients describe the severe, often excruciating, pain as sharp, stabbing or burning in quality, usually lasting between seconds and less than 2 minutes. A few progress to less intense persistent pain between paroxysms. Remission can be months and even many years, but generally the attacks become shorter over time. Attacks can occur up to 70 times daily, terrifying patients because of their severity and unpredictability despite their brief duration.",221,42,0.19004524886877827
9781910797495,chp4,"Medical management remains the first line of treatment. Carbamazepine, traditionally the drug of choice, is often replaced by gabapentin and pregabalin because of fewer side effects. Patients hospitalized because of the severity of pain may be effectively controlled by use of a subcutaneous infusion of lidocaine (lignocaine).","If medical management has failed and the patient can tolerate surgery, microvascular decompression of the trigeminal neural complex (also known as the Jannetta procedure) is the preferred treatment. This procedure directly treats the cause of the problem without destroying any neural tissue. Morbidity and mortality are low. Pain relief persists in more than 85% of patients at 5-year follow-up, with no risk of sensory loss. Many patients have complete abolition of pain - a result that is attainable for very few chronic pain conditions. In older patients, percutaneous radiofrequency lesioning of the affected components of the trigeminal complex is the method of choice. This is a rapid and highly controllable procedure that aims to minimize risk of sensory loss. However, pain tends to recur after about 3 years and about 5% of patients have painful sensory loss (anesthesia dolorosa). Balloon compression and retro-Gasserian glycerol injection are alternative lesioning procedures. Unfortunately, there are no comparative studies among invasive procedures, so the choice is often guided by operator expertise in a particular technique. For non-responders and those in whom the pain relief is only temporary, a new or repeat procedure is sometimes performed. The long-term effectiveness of this strategy is unknown, and the risk of producing new neurological deficits is higher. Patients who elect to undergo repeat procedures should be informed of the increased risks.",290,69,0.23793103448275862
9781910797495,chp5,"Complex regional pain syndrome (CRPS) involves abnormalities in sensation, motor and sympathetic function, as well as edema and abnormal sweating, with possible trophic changes.","The term 'complex regional pain syndrome' (CRPS) was coined in 1995 by the International Association for the Study of Pain (IASP) to replace terms previously used to describe the condition. The diagnosis of CRPS requires the presence of several factors, which may include sensory, vascular and motor abnormalities as well as edema and sweating abnormalities. The syndrome encompasses an array of painful conditions characterized by continuing (spontaneous and/or evoked) regional pain that is seemingly disproportionate in time or degree to the usual course of any known trauma or other lesion. The pain is regional (that is, not in a specific nerve territory or dermatome) and usually has a distal predominance of abnormal sensory, motor, sudomotor, vasomotor and/or trophic findings. The syndrome shows variable progression over time. Harden et al. have published statistically derived criteria (the 'Budapest criteria') for clinical diagnosis (Table 5.1). More information on diagnosis is also available from the IASP (Table 5.2).",212,35,0.1650943396226415
9781910797495,chp5,"Diagnosis requires the presence of a number of symptoms and signs in the areas of sensory, motor and sympathetic function in the absence of any other condition that might account for the symptoms.","The term 'complex regional pain syndrome' (CRPS) was coined in 1995 by the International Association for the Study of Pain (IASP) to replace terms previously used to describe the condition. The diagnosis of CRPS requires the presence of several factors, which may include sensory, vascular and motor abnormalities as well as edema and sweating abnormalities. The syndrome encompasses an array of painful conditions characterized by continuing (spontaneous and/or evoked) regional pain that is seemingly disproportionate in time or degree to the usual course of any known trauma or other lesion. The pain is regional (that is, not in a specific nerve territory or dermatome) and usually has a distal predominance of abnormal sensory, motor, sudomotor, vasomotor and/or trophic findings. The syndrome shows variable progression over time. Harden et al. have published statistically derived criteria (the 'Budapest criteria') for clinical diagnosis (Table 5.1). More information on diagnosis is also available from the IASP (Table 5.2).",212,37,0.17452830188679244
9781910797495,chp5,"The involvement of the sympathetic nervous system in CRPS is likely, but detailed mechanisms differ among patients and remain unclear.","In humans, the nature and extent of involvement of the sympathetic nervous system is less clear (see below). Pain alleviation after sympathetic nerve blockade or sympatholytic drug therapy is not consistent, and relapses are common. Motor abnormalities, found in 50% of patients with CRPS, are most probably generated by changes in brain motor neurons. Baron's group in Germany has reported disturbed integration of visual and proprioceptive inputs in the posterior parietal cortices of patients with CRPS. Also, functional MRI during finger tapping of the affected limb in patients with CRPS showed reorganization of central motor circuits. The degree of reorganization correlated with the extent of motor dysfunction detected by clinical examination. Thus, it seems clear that maladaptive changes in the brain motor system contribute to motor symptoms in patients with CRPS. This is further evidence of chronic pain as a 'disease entity'. Behavioral/physical treatments aimed at motor components of CRPS in the brain have been described as 'reprogramming the brain'.",203,23,0.11330049261083744
9781910797495,chp5,CRPS warrants a cognitive behavioral and rehabilitation treatment program to improve coping and function.,"The pain-relieving effects of sympathetic blocks in patients with SMP outlast the conduction block of sympathetic neurons - in a small number of cases producing permanent relief if applied early in the course of CRPS. It appears that, in SMP, spinal cord sympathetic neurons maintain a positive feedback via sympathetic efferents and then primary afferent nociceptors. Sympathetic block switches off the sympathetic chain, decreases sensitization of afferent nociceptors which, in turn, decreases input to spinal afferents and then to spinal sympathetic neurons. Unfortunately, in most patients, spinal hyperactivity resumes when the block wears off.",131,16,0.12213740458015267
9781910797495,chp5,Pharmacotherapy largely relies on studies of treatment of other types of neuropathic pain.,"A lack of understanding of pathophysiological abnormalities, and differing views on diagnostic criteria, has hampered the selection of well-defined populations of patients with CRPS to participate in controlled trials of potential treatments. Three literature reviews found little consistent information, and consequently the treatment for CRPS is often based on studies of outcomes from treatment of other neuropathic pain syndromes.",73,17,0.2328767123287671
9781910797495,chp5,New strategies in 'reprogramming the brain' may be able to address the neuroplastic changes that occur with CRPS.,"Physical therapy, particularly weight bearing, is one of the keys to recovery of function. Particularly in children, physical therapy combined with behavioral strategies can be highly successful. Development of motor imagery using a mirror box and other techniques has proven to be helpful. Such techniques can be described as 'reprogramming the brain', and are aimed particularly at the motor cortex changes now known to occur. Physical therapy and, to a lesser extent, occupational therapy can reduce pain and improve active mobility in CRPS I. The order of physical therapy strategies appears to be important: laterality recognition, followed by imagining movement, followed by mirror movements.",124,26,0.20967741935483872
9781910797495,chp5,Intravenous regional sympathetic blockade with guanethidine or systemic phentolamine lack efficacy.,"Modulation of the sympathetic nervous system. The efficacy of phentolamine and of intravenous regional sympathetic block with guanethidine has not been confirmed in RCTs. Local anesthetic blockade of the sympathetic chain is a standard clinical therapy for CRPS, but the scarcity of RCTs precludes any conclusion concerning its effectiveness. A qualitative systematic review of observational studies of this therapy suggests that less than one-third of patients treated by local anesthetic sympathetic blockade obtain full pain relief. This rate of success is acceptable to many patients and clinicians, yet its magnitude could be attributed to placebo response, natural history or regression to the mean. Treatment early in the course of CRPS appears to be more effective than in well-established CRPS.",150,21,0.14
9781910797495,chp5,"Local anesthetic blockade of the sympathetic chain is a default clinical treatment for acute CRPS, but the scarcity of data from randomized controlled trials precludes any firm conclusion regarding its effectiveness.","Modulation of the sympathetic nervous system. The efficacy of phentolamine and of intravenous regional sympathetic block with guanethidine has not been confirmed in RCTs. Local anesthetic blockade of the sympathetic chain is a standard clinical therapy for CRPS, but the scarcity of RCTs precludes any conclusion concerning its effectiveness. A qualitative systematic review of observational studies of this therapy suggests that less than one-third of patients treated by local anesthetic sympathetic blockade obtain full pain relief. This rate of success is acceptable to many patients and clinicians, yet its magnitude could be attributed to placebo response, natural history or regression to the mean. Treatment early in the course of CRPS appears to be more effective than in well-established CRPS.",150,36,0.24
9781910797495,chp5,"Sympathectomy by surgical division, chemical neurolysis or radiofrequency lesioning should be avoided.","Invasive procedures should not be considered in the early treatment of CRPS. Evidence supporting their use is scarce and, to date, only short follow-up periods have been reported. These therapies should, therefore, be offered only in the context of multidisciplinary treatment and after careful screening and patient selection. Nevertheless, the dilemma associated with the use of invasive techniques is that they seem to be more successful when applied early in the course of the condition. Thus, a stepwise approach to non-invasive treatment should be pursued with deliberate speed. Surgical sympathectomy. Definitive sympathectomy by surgical division, neurolytic nerve blocks or radiofrequency lesioning is not recommended as none provides long-lasting pain relief. In fact, surgical sympathectomy frequently leads to new or worsened chronic pain.",165,23,0.1393939393939394
9781910797495,chp5,Severe CRPS may benefit from a trial of spinal cord stimulation or lidocaine (lignocaine) infusions and/or dorsal rate ganglion stimulation.,"Patients known to have had a previous episode of CRPS, or who are currently suffering from CRPS, are at risk of triggering or exacerbating CRPS if they undergo surgery of the affected limb or suffer trauma to the limb. There are reports that contralateral injuries may also trigger or exacerbate CRPS. Preventive measures should be initiated as soon as possible. Stellate ganglion block before upper limb surgery in patients with a prior history of CRPS reduced the recurrence rate in one study. In a second study, intravenous regional anesthesia with lidocaine (lignocaine) and clonidine was also effective. On theoretical grounds a number of the pharmacotherapeutic options described above may be effective but have not been studied. In the authors' experience, perioperative low-dose ketamine infusion, combined with gabapentin or pregabalin, has proven valuable. Rarely, epidural clonidine is used where there is severe risk of CRPS exacerbation.",206,35,0.16990291262135923
9781910797495,chp6,"Combining medications that address different mechanisms (exempli gratia SNRIs or TCAs with gabapentinoids), while being mindful of drug interactions, can be helpful for treatment-resistant cases, and may enable smaller doses of one or both drugs to be given, which may reduce the total side-effect burden.","Diabetic neuropathy (DN) refers to a group of heterogeneous disorders that affect the autonomic and peripheral nervous systems of approximately 20% of patients with diabetes mellitus. The neuropathy may or may not be painful, though over 45% of individuals who have had diabetes for 25 years will experience painful DN. Patients report a spectrum of symptoms ranging from mildly disturbing tingling to severe pain that can interfere with sleep and normal activities. Pain may be burning and constant and there may be intermittent electric-shock-like symptoms. Allodynia may be present as well as dysesthesias. The degree of nerve damage does not correlate with pain intensity, and patients can develop insensitive feet without preceding pain or paresthesias. Table 6.1 lists the major types of painful diabetic neuropathy. Small-fiber neuropathy results in loss of ability to feel pressure on the skin of the feet leading to the development of pressure sores, which commonly become infected and painful. All of the other types of neuropathy can be painful. Pathophysiology. Persistent hyperglycemia is the primary factor responsible for nerve damage. Hyperglycemia increases oxidative stress in nerve cells because of an excess of polyol (sugar alcohol) in the aldose reductase pathway and increases production of diacylglycerol, which subsequently activates protein kinase C.",278,66,0.23741007194244604
9781910797495,chp6,Persistent hyperglycemia is the primary factor responsible for nerve damage in diabetes mellitus. Diabetic neuropathy (DN) affects the autonomic and peripheral nervous systems.,"Patients report a spectrum of symptoms ranging from mildly disturbing tingling to severe pain that can interfere with sleep and normal activities. Pain may be burning and constant and there may be intermittent electric-shock-like symptoms. Allodynia may be present as well as dysesthesias. The degree of nerve damage does not correlate with pain intensity, and patients can develop insensitive feet without preceding pain or paresthesias. Table 6.1 lists the major types of painful diabetic neuropathy. Small-fiber neuropathy results in loss of ability to feel pressure on the skin of the feet leading to the development of pressure sores, which commonly become infected and painful. All of the other types of neuropathy can be painful. Pathophysiology. Persistent hyperglycemia is the primary factor responsible for nerve damage. Hyperglycemia increases oxidative stress in nerve cells because of an excess of polyol (sugar alcohol) in the aldose reductase pathway and increases production of diacylglycerol, which subsequently activates protein kinase C.",215,35,0.16279069767441862
9781910797495,chp6,Maintenance of near-normal blood glucose levels is the best approach to primary and secondary prevention of DN.,"During the physical examination, clinicians can simply, rapidly and reliably screen patients for polyneuropathy using the vibration test. This test comprises the application of a 128-Hz tuning fork to the bony prominence bilaterally situated at the dorsum of the toe just proximal to the nail bed. The patient is then asked to report the perception of both the onset and the subsiding of the sensation of vibration. Testing should be conducted twice on each toe. Peripheral neuropathy is diagnosed if more than half of the responses are incorrect (five incorrect responses or more out of ten tests). Prevention. Complications of diabetes mellitus (including infections) are more common with poor glycemic control. Randomized controlled trials (RCTs) have shown that maintenance of near-normal blood glucose levels with intensive insulin treatment is the best approach to primary and secondary prevention of late diabetic complications such as DN, the prevalence of which may be reduced by 64%.",191,21,0.1099476439790576
9781910797495,chp6,"Tricyclic antidepressants (TCAs), serotonin-norepinephrine-reuptake inhibitors (SNRIs) and anticonvulsants are the medications of choice for neuropathic pain, but side effects are common. Pregabalin is specifically approved for DN. Duloxetine has also gained approval for DN in some countries.","During the physical examination, clinicians can simply, rapidly and reliably screen patients for polyneuropathy using the vibration test. This test comprises the application of a 128-Hz tuning fork to the bony prominence bilaterally situated at the dorsum of the toe just proximal to the nail bed. The patient is then asked to report the perception of both the onset and the subsiding of the sensation of vibration. Testing should be conducted twice on each toe. Peripheral neuropathy is diagnosed if more than half of the responses are incorrect (five incorrect responses or more out of ten tests). Prevention. Complications of diabetes mellitus (including infections) are more common with poor glycemic control. Randomized controlled trials (RCTs) have shown that maintenance of near-normal blood glucose levels with intensive insulin treatment is the best approach to primary and secondary prevention of late diabetic complications such as DN, the prevalence of which may be reduced by 64%. Metabolic treatment seems to be a promising approach. Aldose reductase inhibitors suppress the accumulation of alcohol sugars in nerve cells and thus improve conduction velocity; however, the clinical importance of these surrogates is inconclusive. Pharmacological management. Antidepressants and anticonvulsants are the medications of choice for neuropathic pain, but side effects are common, and particularly troublesome with tricyclic antidepressants (TCAs). Clinical guidelines recommend serotonin-norepinephrine-reuptake inhibitors (SNRIs; duloxetine, venlafaxine, milnacipran), gabapentinoids (gabapentin, pregabalin) or a TCA as a first-line treatment, as medications with these mechanisms are all supported by findings from more than two RCTs.",361,72,0.1994459833795014
9781910797495,chp6,"Although efficacy in clinical trials is established, the use of opioids for the treatment of neuropathic pain remains controversial because of safety and overdose concerns, particularly in at-risk individuals, such as those with substance use disorder or psychiatric comorbidities, or those using benzodiazepines or other sedatives.","Efficacy. The effectiveness of TCAs for DN has been confirmed in meta-analyses of RCTs. Trial findings have indicated that 1 in 4 individuals given a TCA experiences substantial pain relief (at least 50% relief). However, 1 in 3 individuals develops minor side effects and 1 in 17 stops the medication because of the severity of side effects. The best-studied TCAs are amitriptyline (25-150 mg/day), imipramine and desipramine (desipramine is not licensed in the UK). With fewer side effects, nortriptylene and desipramine are generally preferred, in lower doses than for depression. In older adults, TCAs are used (if at all) with extreme caution, starting at very low doses, because of the increased risk of side effects and toxicity. Newer antidepressants such as selective serotonin-reuptake inhibitors (SSRIs) are preferable to TCAs for the treatment of depression, but SSRIs do not inhibit the reuptake of both serotonin and norepinephrine, which appears to be necessary for effect against DN. The 'balanced' SNRI class of antidepressants, such as duloxetine, venlafaxine and milnacipran, are generally efficacious in neuropathic pain conditions.",271,61,0.22509225092250923
9781910797495,chp6,"TCAs and anticonvulsants are useful therapies for PHN; the physical, psychological and social consequences of PHN should also receive attention.","Side effects. The main side effects of TCAs are dry mouth and sedation, both of which are the result of the antimuscarinic activity of the drugs. Low starting doses and careful titration may help to minimize these effects. Orthostatic hypotension, tachycardia, urinary retention and constipation, sometimes associated with TCAs, often pose a problem in the elderly. Because disturbances of cardiac rhythm may be potentiated by TCAs, a baseline electrocardiogram should be taken before therapy is started. For all these reasons, in general, TCAs should be prescribed cautiously in older patients, and started at very low doses. The main side effects of SNRI antidepressants, which are better tolerated than TCAs, are nausea and vomiting and sexual dysfunction; venlafaxine is associated with an increase in blood pressure at higher doses.",173,30,0.17341040462427745
9781910797495,chp6,Postherpetic neuralgia (PHN) is pain that persists after the vesicular rash of herpes zoster has resolved.,"Postherpetic neuralgia (PHN) is pain that persists after the vesicular rash of acute herpes zoster (shingles) has resolved. Rarely, the condition occurs despite the absence of an obvious rash. The associated pain is usually mild or moderate in intensity, but it may be excruciating. Typically, a single dermatome is involved, but occasionally more than one is affected. Acute herpes zoster is common, developing in up to 20% of people, though PHN is predominantly a disease of older people (see below).",113,28,0.24778761061946902
9781910797495,chp6,"During an attack of acute herpes zoster (shingles), reactivation of the varicella zoster virus (VZV), previously dormant in the dorsal root ganglia, induces inflammation and neuronal destruction.","Postherpetic neuralgia (PHN) is pain that persists after the vesicular rash of acute herpes zoster (shingles) has resolved. Rarely, the condition occurs despite the absence of an obvious rash. The associated pain is usually mild or moderate in intensity, but it may be excruciating. Typically, a single dermatome is involved, but occasionally more than one is affected. Acute herpes zoster is common, developing in up to 20% of people, though PHN is predominantly a disease of older people (see below). Pathophysiology. Acute herpes zoster results from reactivation of varicella zoster virus (VZV) that has remained latent in neurons of the spinal dorsal root ganglia since an earlier infection, usually childhood chickenpox (in more than 90% of cases). Risk factors for virus activation include older age, malignant disease including lymphoma, stress, and immunosuppression due to drugs or disease.",198,43,0.21717171717171718
9781910797495,chp6,"Once developed, PHN is difficult to manage and thus efforts to prevent PHN are crucial via: prevention of VZV infection, boosting VZV immunity, treating at the time of acute herpes zoster infection, and effective treatment of the acute pain.","Natural history. Advancing age is an important risk factor for developing PHN. After acute herpes zoster infection, 2% of patients under 60 years old develop PHN, but this figure progressively increases to about 50% with advancing age. The apparent severity of PHN reported in RCTs is higher, perhaps reflecting a referral bias. Other risk factors are the severity of the acute zoster lesions and the intensity of the acute pain. The duration of PHN is highly variable: at least 30% of all individuals with this type of pain will continue to have severe pain 1 year after the onset of herpes zoster. Diagnosis. PHN is diagnosed on the basis of a history of shingles and the presence of persistent neuropathic pain in the affected dermatome. Symptoms are experienced around the area of skin where the shingles outbreak first occurred. Patients describe a sharp jabbing burning pain or a deep aching pain, with extreme sensitivity to touch and temperature change. They sometimes describe an itching sensation or numbness and, in instances of cranial nerve involvement, their complaint may be considered simply as a headache. PHN often has three distinct types of pain (Table 6.2). Allodynia may result in extreme difficulty wearing clothes and carrying out self-care.",259,52,0.20077220077220076
9781910797495,chp7,"Pharmacotherapy, based on only a small number of controlled studies, have demonstrated efficacy of amitriptyline for CPSP (although not yet studied, a trial of serotonin-norepinephrine-reuptake inhibitors [SNRIs] may be preferable because of their lower toxicity) and pregabalin in both SCI and CPSP. Short-term efficacy has been reported for systemic (intravenous infusion) lidocaine (lignocaine), propofol and ketamine, but there is no evidence of long-term efficacy.","Central pain is defined by the International Association for the Study of Pain (IASP) as 'pain initiated or caused by a primary lesion (or dysfunction) of the central nervous system (CNS)'. It has been suggested that 'or dysfunction' be deleted, as peripheral nerve lesions can eventually lead to dysfunction in the CNS. Spinal cord injury (SCI; trauma or disease) (Figure 7.1) and stroke are the most common causes of lesions in the spinal cord or brain and brainstem that cause central pain, but there are many others (Table 7.1). It has now been recognized that epilepsy can be painful as can Parkinson's disease. Multiple sclerosis causes central pain in about 60% of patients. Post-stroke pain. Conditions sufficient for the generation of central pain were previously thought to be an imbalance between the spinothalamic system (caused by a lesion in that system) and medial lemniscal pathways. This is now known to be untrue. However, Craig et al. have provided evidence of a key role of ventromedial posterior thalamic lesions that allow disinhibition of a medial spinothalamic tract projecting via the medial dorsal nucleus of the thalamus to the anterior cingulate cortex (limbic system) - this appears to be associated with the burning nature of central post-stroke pain and also generates cold hypesthesia. In 2007, Kim et al. reported that lesions limited to the ventral caudal thalamic nucleus may produce a similar presentation of central post-stroke pain. Thus, there are several sites of lesion associated with post-stroke pain; unfortunately, this does not yet provide insight into the precise mechanisms of such pain. Pain following spinal cord injury. The study of central pain arising from SCI has been more productive than that of post-stroke pain. Key insight was provided from a 5-year follow-up study of SCI pain by Siddall et al., which reported that at-level SCI pain often progressed to below-level pain - suggesting spinal and supraspinal mechanisms triggered by at-level SCI pain predispose to below-level 'central' pain. A number of putative mechanisms have emerged from basic, clinical, epidemiological and brain-imaging research. loss of balance between different sensory channels.",471,116,0.24628450106157113
9781910797495,chp7,"Central pain results from lesions in the brain and brainstem or spinal cord. The most common causes are stroke and traumatic spinal cord injury (SCI), though there are many other causes.","Spinal cord injury (SCI; trauma or disease) (Figure 7.1) and stroke are the most common causes of lesions in the spinal cord or brain and brainstem that cause central pain, but there are many others (Table 7.1). It has now been recognized that epilepsy can be painful as can Parkinson's disease. Multiple sclerosis causes central pain in about 60% of patients. Post-stroke pain. Conditions sufficient for the generation of central pain were previously thought to be an imbalance between the spinothalamic system (caused by a lesion in that system) and medial lemniscal pathways. This is now known to be untrue. However, Craig et al. have provided evidence of a key role of ventromedial posterior thalamic lesions that allow disinhibition of a medial spinothalamic tract projecting via the medial dorsal nucleus of the thalamus to the anterior cingulate cortex (limbic system) - this appears to be associated with the burning nature of central post-stroke pain and also generates cold hypesthesia. In 2007, Kim et al. reported that lesions limited to the ventral caudal thalamic nucleus may produce a similar presentation of central post-stroke pain. Thus, there are several sites of lesion associated with post-stroke pain; unfortunately, this does not yet provide insight into the precise mechanisms of such pain.",280,37,0.13214285714285715
9781910797495,chp7,"The pathophysiology of central post-stroke pain (CPSP) involves a key role for lesions in diverse areas of the brain, including several different thalamic nuclei. One such lesion results in disinhibition of a nociceptive pathway that projects to the anterior cingulate cortex (limbic system) - this pathophysiology is associated with the burning quality of CPSP.","Spinal cord injury (SCI; trauma or disease) (Figure 7.1) and stroke are the most common causes of lesions in the spinal cord or brain and brainstem that cause central pain, but there are many others (Table 7.1). It has now been recognized that epilepsy can be painful as can Parkinson's disease. Multiple sclerosis causes central pain in about 60% of patients. Post-stroke pain. Conditions sufficient for the generation of central pain were previously thought to be an imbalance between the spinothalamic system (caused by a lesion in that system) and medial lemniscal pathways. This is now known to be untrue. However, Craig et al. have provided evidence of a key role of ventromedial posterior thalamic lesions that allow disinhibition of a medial spinothalamic tract projecting via the medial dorsal nucleus of the thalamus to the anterior cingulate cortex (limbic system) - this appears to be associated with the burning nature of central post-stroke pain and also generates cold hypesthesia. In 2007, Kim et al. reported that lesions limited to the ventral caudal thalamic nucleus may produce a similar presentation of central post-stroke pain. Thus, there are several sites of lesion associated with post-stroke pain; unfortunately, this does not yet provide insight into the precise mechanisms of such pain. Pain following spinal cord injury. The study of central pain arising from SCI has been more productive than that of post-stroke pain. Key insight was provided from a 5-year follow-up study of SCI pain by Siddall et al., which reported that at-level SCI pain often progressed to below-level pain - suggesting spinal and supraspinal mechanisms triggered by at-level SCI pain predispose to below-level 'central' pain.",374,83,0.22192513368983957
9781910797495,chp7,The pathophysiology of SCI pain involves a 'spinal generator' and a 'supraspinal generator/amplifier'.,"Overall, complex processes appear to operate at the level of a 'spinal generator' and a 'supraspinal generator/amplifier'. The relative roles of each level in at-level and below-level SCI pain remain to be clarified. An important aspect is the relationship of post-SCI neuropathic pain and hyperreflexic responses (autonomic hyperreflexia). It has long been known that complete SCI lesions remove descending inhibitory control and allow severe autonomic mass reflexes. An example is severe vasoconstriction in response to a noxious stimulus - the vasoconstriction increases blood pressure which, in turn, activates vasomotor and other brainstem and brain structures, resulting in exacerbation of neuropathic pain (Figure 7.2).",159,28,0.1761006289308176
9781910797495,chp7,More than 8% of patients who have had a stroke develop central pain. This is probably an underestimate because communication problems may impede diagnosis of pain.,"Lesions in the brain. Stroke is the most common cause of neuropathic pain related to brain lesions. More than 8% of all patients who have had a stroke suffer with central pain. In view of the high incidence of stroke, about 90% of all central pain is associated with stroke. Because stroke is associated with communication difficulties, the high prevalence of central pain was not recognized until quite recently. Previously, it was erroneously believed that only thalamic lesions resulted in central pain. Now the diagnosis of 'thalamic syndrome' is reserved for thalamic lesions and otherwise the diagnosis of 'post-stroke pain' is used.",129,29,0.2248062015503876
9781910797495,chp7,"Within 2 weeks of SCI, 12% of patients have below-level neuropathic pain which is 'central'; by 6 months, 20% have central pain. Mean onset time is 1.8 +- 1.7 years (wide variation).","An IASP taxonomy of post-SCI pain types has been promulgated (see Table 7.2), based on an earlier proposal by Siddall et al. in 1997. This has facilitated comparison of studies using the same terminology. It is important to differentiate non-neuropathic pain, which is present in 60% of SCI patients at 5 years, and includes mechanical spinal instability, painful muscle spasms and secondary overuse syndromes (exempli gratia of the shoulder joint in paraplegics). Visceral pain may be associated with nociceptive visceral pathology, though in many cases no pathology is found and the pain is presumed to be below-level neuropathic pain (exempli gratia bladder and rectal pain). Onset of central pain. Time of pain onset after the initial lesion is extremely variable. In one study of SCI from trauma, 12% of patients had below-level neuropathic pain by 2 weeks after injury, and this had risen to 20% by 6 months. However, the mean onset time (+- implied standard deviation) was 1.8 +- 1.7 years (note the large variance). With stroke, 63% reported onset of central pain within 1 month, 19% between 1 and 6 months and another 19% between 6 and 12 months. Sometimes onset of central pain occurs several years after injury.",281,50,0.17793594306049823
9781910797495,chp7,Onset of post-stroke pain may occur up to several years after the injury.,"Time of pain onset after the initial lesion is extremely variable. In one study of SCI from trauma, 12% of patients had below-level neuropathic pain by 2 weeks after injury, and this had risen to 20% by 6 months. However, the mean onset time (+- implied standard deviation) was 1.8 +- 1.7 years (note the large variance). With stroke, 63% reported onset of central pain within 1 month, 19% between 1 and 6 months and another 19% between 6 and 12 months. Sometimes onset of central pain occurs several years after injury.",120,17,0.14166666666666666
9781910797495,chp7,Treatment of central pain is extremely challenging and requires a multimodal approach based on a biopsychosocial model. Differential diagnosis of pain type is crucial. New innovative physical/psychological treatments show promise of addressing maladaptive brain neuroplasticity changes.,"Central pain is one of the most challenging of all chronic pain conditions. Except for a few exceptions, the underlying condition cannot be successfully treated. However, differential diagnosis of the type of pain is crucial to distinguish nociceptive pain and peripheral neuropathic pain from central pain (see Table 7.2). The impact of central pain on the individual is usually severe, so a multidisciplinary assessment in a biopsychosocial framework is essential. In many cases a multimodal approach to treatment needs to incorporate pharmacological, psychological and physical therapy strategies. Invasive procedures may be needed in extreme cases. Psychological, physical and other treatments. Physical therapy has a wide range of roles in patients with post-stroke and SCI pain because of complications related to immobility, postural changes and/or overuse syndromes, or to help relieve symptoms related to neurological disease, such as multiple sclerosis. Mirror visual feedback with 'virtual walking' was effective in 4 patients, but in another study imaginary ankle movement increased neuropathic pain in patients with SCI. Further research into such techniques is needed.",223,55,0.24663677130044842
9781910797495,chp7,Dorsal root entry zone lesioning can provide long-term relief of central pain after brachial plexus avulsion.,"Dorsal root entry zone (DREZ) lesioning involves a laminectomy to allow multiple radiofrequency lesions to be made in spinal cord dorsal horn substantia gelatinosa. This technique can provide complete pain relief for many years in patients with avulsion of the roots of the brachial plexus from the spinal cord. Strictly speaking this is a 'peripheral lesion'; however, often there is extensive damage to the spinal cord and the pain is similar to central pain. Patients of this type in whom pharmacotherapy fails should be considered for DREZ lesioning. To reduce the risk of serious complications, including paraplegia and/or extension of the neurological deficit into the neck region, DREZ lesioning should be performed by a neurosurgeon with special training and experience.",168,28,0.16666666666666666
9781910797495,chp8,"Nerve injury plays an important role in pathogenesis, but genetics, pre-existing pain and severity of postoperative pain are also risk factors, in addition to cancer treatment and possible psychosocial factors.","Although there is evidence that nerve damage plays a key role, there are other factors that probably determine which patients with nerve damage progress from acute to persistent pain as, in many operations (exempli gratia amputation), all patients have nerve damage but only a percentage (10-50%) progress to chronic pain (Table 8.1). The only reliable data currently available derive from postsurgery patients and thus this discussion will be limited to these patients. It is possible, but not studied, that similar factors may occur in post-trauma patients (many of whom also undergo surgery). A major review of this subject by Kehlet et al. was published in 2006. The factors in Table 8.2 are associated with increased risk of PPSP, but no comprehensive study has been carried out to evaluate their relative importance. Although evidence of genetic factors is not available for PPSP, Tegeder et al. (2006) have identified a genetic influence on the development of chronic pain following an acute episode of sciatica. More attention is now being focused on the influence of other patient factors, such as catastrophizing and depression, which influence perioperative and postoperative pain and analgesic use.",244,41,0.1680327868852459
9781910797495,chp8,"Patients who catastrophize, which increases postoperative pain and opioid analgesic use, may benefit from psychological services such as cognitive behavioral therapy.","The factors in Table 8.2 are associated with increased risk of PPSP, but no comprehensive study has been carried out to evaluate their relative importance. Although evidence of genetic factors is not available for PPSP, Tegeder et al. (2006) have identified a genetic influence on the development of chronic pain following an acute episode of sciatica. More attention is now being focused on the influence of other patient factors, such as catastrophizing and depression, which influence perioperative and postoperative pain and analgesic use. Preoperative pain intensity has been correlated with postoperative pain intensity in a prospective study of 346 patients undergoing abdominal surgery. The intensity of postoperative pain has been linked to the prevalence of chronic pain. Thus, improved acute pain control pre- and postoperatively may help to prevent PPSP. There is also evidence that intra- and postoperative use of epidural or regional neural blockade may be helpful.",189,29,0.15343915343915343
9781910797495,chp8,"Effective acute pain control may be preventive for PPSP - for example, intra- and postoperative use of epidural analgesia can prevent PPSP following some operations.","The factors in Table 8.2 are associated with increased risk of PPSP, but no comprehensive study has been carried out to evaluate their relative importance. Although evidence of genetic factors is not available for PPSP, Tegeder et al. (2006) have identified a genetic influence on the development of chronic pain following an acute episode of sciatica. More attention is now being focused on the influence of other patient factors, such as catastrophizing and depression, which influence perioperative and postoperative pain and analgesic use. Preoperative pain intensity has been correlated with postoperative pain intensity in a prospective study of 346 patients undergoing abdominal surgery. The intensity of postoperative pain has been linked to the prevalence of chronic pain. Thus, improved acute pain control pre- and postoperatively may help to prevent PPSP. There is also evidence that intra- and postoperative use of epidural or regional neural blockade may be helpful.",189,35,0.18518518518518517
9781910797495,chp8,"The incidence of PPSP varies from about 10% for very limited peripheral surgery, such as inguinal hernia repair or joint replacement, to 10-30% for mastectomy and up to 50% for thoracotomy and amputation.","Patient education. As the majority of PPSP is caused by nerve damage, the treatment options are similar to those for other neuropathic pain syndromes. Pharmacotherapy alone will rarely be sufficient. A biopsychosocial assessment should be made and treatment plans should aim to rectify maladaptive changes in physical, psychological and environmental domains. For example, patients are rarely told that PPSP is a possible complication of surgery. Thus, patients often feel angry and let down and find it difficult to move on unless the anger is addressed with careful explanation and reassurance. Patients may have been stigmatized at work because of a perceived unnecessarily long recovery, requiring input to the workplace. Preoperative patient education about the possibility of PPSP, during the informed consent procedure, may reduce the negative postoperative psychosocial consequences that can complicate treatment. In the authors' experience of patients with PPSP, and supported by several studies, psychosocial factors such as catastrophizing and the pain itself often activate stress and mood disorders, thus worsening pain and interfering with adaptive coping.",219,50,0.228310502283105
9781910797495,chp8,Pharmacotherapy is based on the study results of neuropathic drugs used to treat pain caused by other types of nerve injury. Tricyclic antidepressants and anticonvulsants are first-line drugs.,"Patient education. As the majority of PPSP is caused by nerve damage, the treatment options are similar to those for other neuropathic pain syndromes. Pharmacotherapy alone will rarely be sufficient. A biopsychosocial assessment should be made and treatment plans should aim to rectify maladaptive changes in physical, psychological and environmental domains. For example, patients are rarely told that PPSP is a possible complication of surgery. Thus, patients often feel angry and let down and find it difficult to move on unless the anger is addressed with careful explanation and reassurance. Patients may have been stigmatized at work because of a perceived unnecessarily long recovery, requiring input to the workplace. Preoperative patient education about the possibility of PPSP, during the informed consent procedure, may reduce the negative postoperative psychosocial consequences that can complicate treatment. In the authors' experience of patients with PPSP, and supported by several studies, psychosocial factors such as catastrophizing and the pain itself often activate stress and mood disorders, thus worsening pain and interfering with adaptive coping.",219,42,0.1917808219178082
9781910797495,chp8,Peripheral nerve stimulation is emerging as a possible treatment option for severe PPSP.,"Pharmacotherapy relies on tricyclic antidepressants (TCAs), serotonin-norepinephrine-reuptake inhibitors (SNRIs), anticonvulsants and sometimes membrane stabilizers. In severe cases a trial of subcutaneous peripheral nerve stimulation (PNS) may be necessary. PNS is emerging as a valuable option for postinguinal hernia repair PPSP. In a trial stimulation, electrodes are placed across the path of ilio-inguinal, iliohypogastric and genitofemoral nerves; if the trial stimulation is successful patients proceed at a later date to implantation of electrodes and a pulse generator.",134,18,0.13432835820895522
9781910797495,chp8,Persistent postsurgical pain (PPSP) is defined as pain at or close to the site of surgical incision that persists beyond the expected healing period.,"Postincisional syndrome is defined as pain at or close to the site of a surgical incision that persists beyond the usual healing period. As with other neuropathic pain syndromes, patients exhibit allodynia and sometimes also edema in the vicinity of the surgical wound, which is typical of temporary peripheral sensitization. Postamputation persistent pain. Postamputation persistent pain is a special case of PPSP because large nerves are deliberately cut in all patients. It is interesting, then, that only 30-50% develop PPSP, whereas 100% have nerve injury (see Table 8.1). This emphasizes the multifactorial basis of PPSP. A surprising omission in studies of amputation pain is information about how the nerves amputated are managed (id est clean cut or ligature tied). Use of a ligature tie in animal studies is known to generate neuropathic pain.",182,32,0.17582417582417584
9781910797495,chp8,"Although spinal cord stimulation (SCS) has not been found to be successful for amputation pain, early data indicate positive outcomes for dorsal root (DRG) stimulation.","Antidepressants and anticonvulsants. There is a scarcity of controlled trial results to guide clinicians in the treatment of phantom pain, and clinicians must rely on favorable results from clinical research in which these agents have been given to treat other neuropathic pain syndromes. Mirror therapy, which is based on manipulating neuroplastic changes in the brain associated with phantom pain, has been reported to reduce phantom limb pain in clinical reports and in a small RCT in which it was significantly more effective (p = 0.008) for reducing pain than guided imagery and sham mirror therapy. Neurostimulation of various types (low- and high-intensity transcutaneous electrical nerve stimulation [TENS], transcranial magnetic stimulation of the motor cortex, epidural cervical spinal cord stimulation and epidural motor cortex stimulation) has been reported to be effective for phantom pain in case series, though carefully controlled trials have yet to be performed.",188,34,0.18085106382978725
9781910797495,chp9,"Opioids are the foundation for management of cancer pain of moderate to severe intensity, but other drugs should also be considered depending on the pain conditions and mechanisms involved (exempli gratia neuropathic, myofascial, arthritic); however, treatment of cancer pain should not rely on drugs alone, since there are many other options that will produce good results.","Pain in patients with cancer may present as various types of pain at different stages of the patient's journey with cancer. Thus, the pain may comprise acute, recurrent or chronic presentations due to the cancer and/or its treatment. Assessment of pain in patients with cancer should be the same as in other patients with pain (see Chapter 2), so that the widest possible range of treatments can be considered, with the aim of optimal treatment. Other additional symptoms such as fatigue, nausea, anxiety, depression, breathlessness and insomnia are common and also require treatment. Also, patients with cancer may have pre-existing chronic pain that continues, in addition to cancer pain (Table 9.1). Some patients with aggressive tumors may have escalating (or 'crescendo') pain requiring optimum pain management options, and the needs of cancer 'survivors' - who live for many years with chronic pain and who are increasing in numbers - also need to be addressed. Finally, patients with cancer require particular strategies during the end-of-life stage. The choice of treatment options is based on similar considerations to those for patients with chronic non-cancer pain. Unfortunately, the prevalence of pain is high in patients with cancer: 20-50% at the time of diagnosis; 50% during the treatment phase; 75-90% during the advanced cancer phase. At all of these stages, still less than 50% of patients receive effective pain relief according to studies in the USA, France and China - despite the fact that use of the full range of currently available options could provide relief for over 90% of patients. Sadly, this lamentable situation is no better for children: a study in Australia in 2010 reported that treatment was successful in only 47% of children.",350,75,0.21428571428571427
9781910797495,chp9,"Psychological therapies that promote 'self-help' strategies, such as cognitive behavioral therapy (CBT) and meditation/relaxation, as well as integrative treatments such as massage and acupuncture, are often useful as part of a multimodal treatment approach to support patients with cancer pain and related symptoms.","Pain in patients with cancer may present as various types of pain at different stages of the patient's journey with cancer. Thus, the pain may comprise acute, recurrent or chronic presentations due to the cancer and/or its treatment. Assessment of pain in patients with cancer should be the same as in other patients with pain (see Chapter 2), so that the widest possible range of treatments can be considered, with the aim of optimal treatment. Other additional symptoms such as fatigue, nausea, anxiety, depression, breathlessness and insomnia are common and also require treatment. Also, patients with cancer may have pre-existing chronic pain that continues, in addition to cancer pain (Table 9.1). Some patients with aggressive tumors may have escalating (or 'crescendo') pain requiring optimum pain management options, and the needs of cancer 'survivors' - who live for many years with chronic pain and who are increasing in numbers - also need to be addressed. Finally, patients with cancer require particular strategies during the end-of-life stage. The choice of treatment options is based on similar considerations to those for patients with chronic non-cancer pain. Unfortunately, the prevalence of pain is high in patients with cancer: 20-50% at the time of diagnosis; 50% during the treatment phase; 75-90% during the advanced cancer phase. At all of these stages, still less than 50% of patients receive effective pain relief according to studies in the USA, France and China - despite the fact that use of the full range of currently available options could provide relief for over 90% of patients. Sadly, this lamentable situation is no better for children: a study in Australia in 2010 reported that treatment was successful in only 47% of children.",350,62,0.17714285714285713
9781910797495,chp9,Neural blockade can be used for isolated pain-causing lesions.,"Pain in patients with cancer may present as various types of pain at different stages of the patient's journey with cancer. Thus, the pain may comprise acute, recurrent or chronic presentations due to the cancer and/or its treatment. Assessment of pain in patients with cancer should be the same as in other patients with pain (see Chapter 2), so that the widest possible range of treatments can be considered, with the aim of optimal treatment. Other additional symptoms such as fatigue, nausea, anxiety, depression, breathlessness and insomnia are common and also require treatment. Also, patients with cancer may have pre-existing chronic pain that continues, in addition to cancer pain (Table 9.1). Some patients with aggressive tumors may have escalating (or 'crescendo') pain requiring optimum pain management options, and the needs of cancer 'survivors' - who live for many years with chronic pain and who are increasing in numbers - also need to be addressed. Finally, patients with cancer require particular strategies during the end-of-life stage. The choice of treatment options is based on similar considerations to those for patients with chronic non-cancer pain.",229,14,0.0611353711790393
9781910797495,chp9,"Cancer pain is a nociceptive mosaic in which pain may arise from inflammation, tumor infiltration of nerves (neuropathic pain) or other tissues (visceral or somatic pain), treatment, diagnostic and therapeutic procedures, and from other psychological and environmental factors.","Metastatic spread of cancer to bone is the most common cause of cancer pain (Figure 9.1). Animal models using mice that had sarcoma cells implanted into the femur showed pain behavior related both to bone destruction and to the release of inflammatory mediators derived from the tumor (exempli gratia prostaglandins, cytokines, endothelins). Macrophages, which are often present in large numbers in some tumor masses, also produce mediators such as tumor necrosis factor and interleukins capable of activating nociceptors (see Chapter 1). Yet chronic cancer pain is a nociceptive mosaic; pain may be due to tumor infiltration of nerves (neuropathic pain) or other tissues (somatic or visceral pain), or may be related to the treatment or procedure that the patient receives. Given the spectrum of potential pain sources and mechanisms, it is clear that several elements may be active in a single patient with cancer pain and that treatment should address all the pain mechanisms at play (Tables 9.2 - 9.5). Thus, regardless of the initial cause of pain, central sensitization can play a key role in cancer pain (see Chapter 1). Also neuroplastic changes may occur in the brain (see Chapter 1).",259,55,0.21235521235521235
9781910797495,chp9,"Treatment of the cancer itself (by chemotherapy, radiotherapy, surgery etc.) is a primary option in cancer pain management; however, such treatment may be the cause of pain (especially neuropathic pain).","Treatment of the cancer itself. In addition, if feasible, treatment of the cancer itself, with chemotherapy, surgery, external radiotherapy and/or radionuclide therapy is potentially a primary option for reducing pain. Conversely, each of these treatment options can be the cause of further pain - usually neuropathic (see Table 9.3). Thus, there needs to be a detailed discussion about the risks and benefits of treatment. External radiotherapy employs ionizing radiation to destroy cancer cells. A systematic review of randomized controlled trials (RCTs) found that radiation is efficacious to treat pain from bone metastasis. The trial data indicate that 1 of every 4 individuals treated with external radiotherapy experiences 50% pain relief within 1 month. Radiation therapy produces pain relief by inducing apoptotic death, not only of tumor cells, thereby reducing pressure in the bone marrow, but also of highly radiosensitive inflammatory cells. The multifraction regimen is the most widely used (id est 30 Gy delivered in ten treatment fractions over 2 weeks). However, no particular fractionation schedule has been found to be superior.",220,41,0.18636363636363637
9781910797495,chp9,Radiotherapy is effective for pain from bone metastases.,External radiotherapy employs ionizing radiation to destroy cancer cells. A systematic review of randomized controlled trials (RCTs) found that radiation is efficacious to treat pain from bone metastasis. The trial data indicate that 1 of every 4 individuals treated with external radiotherapy experiences 50% pain relief within 1 month.,62,12,0.1935483870967742
9781910797495,chp10,"There is insufficient evidence to support the long-term use of non-steroidal anti-inflammatory drugs for the treatment of chronic low back pain, particularly in light of the increased risks for gastrointestinal bleeding and cardiovascular events.","Given this variety of definitions, estimates of prevalence vary (Table 10.1). In contrast to the prevalence of osteoarthritis (see page 154), that of back pain decreases with age (see Table 10.1). One epidemiological study in the Netherlands found that as many as 25% of individuals with new-onset low back pain were symptomatic at 12 months, though in most cases pain resolved within 2 months. Symptoms of pain in the lower back are more prevalent than those in the mid or upper back. Pathophysiology. Chronic low back pain is a complex biopsychosocial process that cannot be explained on purely anatomic, biomechanical, neurophysiological, immunologic, inflammatory or neurochemical grounds. For example, job dissatisfaction and fear of re-injury are strong risk factors for the development of chronic pain in individuals with acute back pain. Low income and poor education are also risk factors for chronic back pain and disability, possibly related to physical and psychological stressors of lower income jobs associated with low education. For these reasons some researchers argue that chronic disability from back pain is primarily related to a psychosocial dysfunction, but the validity and reliability of this statement is uncertain.",243,43,0.17695473251028807
9781910797495,chp10,"When the etiology of low back pain is apparent, it is most often a musculoskeletal abnormality of the lumbar spine; however, low back pain may also be referred from visceral pathology.","Pathophysiology. Chronic low back pain is a complex biopsychosocial process that cannot be explained on purely anatomic, biomechanical, neurophysiological, immunologic, inflammatory or neurochemical grounds. For example, job dissatisfaction and fear of re-injury are strong risk factors for the development of chronic pain in individuals with acute back pain. Low income and poor education are also risk factors for chronic back pain and disability, possibly related to physical and psychological stressors of lower income jobs associated with low education. For these reasons some researchers argue that chronic disability from back pain is primarily related to a psychosocial dysfunction, but the validity and reliability of this statement is uncertain. Models of low back pain indicate that mechanical and neurochemical factors interact closely. Mechanical trauma could lead to the production of metalloproteinases and cytokines; the actions of these substances on the extracellular matrix of the intervertebral disk produce disk degeneration and pain. When the etiology of low back pain is apparent, there is most often a musculoskeletal abnormality of the lumbar spine, such as muscle strain, arthritis or disk degeneration or facet joint arthropathy. Back pain may also be accompanied by radiating pain in a radicular pattern into the lower limb due to nerve root irritation or compression (often called 'sciatica'). Low back pain may also be referred from visceral pathology, including vascular problems such as abdominal aortic aneurysm and cancer.",304,43,0.14144736842105263
9781910797495,chp10,"Chronic low back pain is a complex biopsychosocial process that cannot be explained on purely anatomic, biomechanical, neurophysiological, immunologic, inflammatory or neurochemical grounds.","Pathophysiology. Chronic low back pain is a complex biopsychosocial process that cannot be explained on purely anatomic, biomechanical, neurophysiological, immunologic, inflammatory or neurochemical grounds. For example, job dissatisfaction and fear of re-injury are strong risk factors for the development of chronic pain in individuals with acute back pain. Low income and poor education are also risk factors for chronic back pain and disability, possibly related to physical and psychological stressors of lower income jobs associated with low education. For these reasons some researchers argue that chronic disability from back pain is primarily related to a psychosocial dysfunction, but the validity and reliability of this statement is uncertain. Models of low back pain indicate that mechanical and neurochemical factors interact closely. Mechanical trauma could lead to the production of metalloproteinases and cytokines; the actions of these substances on the extracellular matrix of the intervertebral disk produce disk degeneration and pain.",196,40,0.20408163265306123
9781910797495,chp10,"Symptomatic therapy can be initiated without imaging tests in adults under 50 who lack 'red flags' - history of major trauma, cancer, or signs or symptoms of systemic disease, tumor, immunocompromise, fracture, abscess, progressive and severe neurological loss, or cauda equina syndrome.","Like other chronic pain syndromes, chronic back pain may also involve central neuroplastic changes such as neuronal hyperactivity, changes in membrane excitability and expression of new genes that perpetuate pain even in the absence of new tissue injury. Diagnosis of chronic back pain is a clinical one. Although anatomic abnormalities can be readily identified by imaging studies, there is no causal relationship between radiographic findings and non-specific low back pain, because most radiological abnormalities are common in asymptomatic people. Careful physical examination may help isolate anatomic contributions to low back pain, but often it is difficult to reach a specific diagnostic formulation. The diagnostic strategy recommended by the US Agency for Healthcare Policy and Research in 1994 (now the Agency for Healthcare Research and Quality) remains valid today. It is appropriate to start symptomatic therapy without imaging in adults under 50 years of age who lack so-called 'red flags' - signs or symptoms of systemic disease or progressive neurological dysfunction indicating tumor, abscess, fracture or cauda equina syndrome. For patients over 50 years of age, or for those whose history or physical findings raise the possibility of 'red flags', plain radiography and simple laboratory tests can almost completely rule out any serious underlying conditions such as fracture, cancer or abscess.",258,62,0.24031007751937986
9781910797495,chp10,"For patients over 50 and those whose findings suggest systemic disease, plain radiography and simple laboratory tests can almost completely rule out underlying systemic disease.","The diagnostic strategy recommended by the US Agency for Healthcare Policy and Research in 1994 (now the Agency for Healthcare Research and Quality) remains valid today. It is appropriate to start symptomatic therapy without imaging in adults under 50 years of age who lack so-called 'red flags' - signs or symptoms of systemic disease or progressive neurological dysfunction indicating tumor, abscess, fracture or cauda equina syndrome. For patients over 50 years of age, or for those whose history or physical findings raise the possibility of 'red flags', plain radiography and simple laboratory tests can almost completely rule out any serious underlying conditions such as fracture, cancer or abscess.",129,28,0.21705426356589147
9781910797495,chp10,CT or MRI should be reserved for patients over 50 and those with 'red flags' (see above).,"The diagnostic strategy recommended by the US Agency for Healthcare Policy and Research in 1994 (now the Agency for Healthcare Research and Quality) remains valid today. It is appropriate to start symptomatic therapy without imaging in adults under 50 years of age who lack so-called 'red flags' - signs or symptoms of systemic disease or progressive neurological dysfunction indicating tumor, abscess, fracture or cauda equina syndrome. For patients over 50 years of age, or for those whose history or physical findings raise the possibility of 'red flags', plain radiography and simple laboratory tests can almost completely rule out any serious underlying conditions such as fracture, cancer or abscess.",129,21,0.16279069767441862
9781910797495,chp10,Exercise has moderate utility in the prevention or treatment of chronic back pain.,"Exercise. A systematic review of randomized controlled trials (RCTs) has found that exercise and physical activity are of moderate utility for the prevention of chronic back pain. Lumbar supports and back schools. There is strong evidence from RCTs that lumbar supports and back schools are not effective pre-emptive interventions. A back school is a structured educational program, usually in a group setting, designed to inform patients about low back problems.",91,15,0.16483516483516483
9781910797495,chp10,"Massage, spinal manipulation and acupuncture provide small-to-moderate short-term benefits.","Massage and spinal manipulation. A meta-analysis of trials that evaluated massage has concluded that the technique is beneficial for subacute and chronic back pain. Methodological flaws in the analysed trials (lack of randomization or blinding) weaken the findings. Systematic reviews and a large RCT of 1334 participants have concluded that spinal manipulation produces a small to moderate benefit at 3 months; however, its effectiveness decreases over time and at 12 months the benefit is only small.",95,18,0.18947368421052632
9781910797495,chp10,Antidepressants reduce pain severity but do not improve function.,"Antidepressants. A systematic review of RCTs suggests that while antidepressants reduce the severity of chronic back pain, they do not improve functional status. As the comorbidity of depression may be quite high (15-80%) in those with chronic low back pain, particularly those treated at referral centers such as pain clinics, diagnosing depression and treating it appropriately is key to the successful treatment of back pain itself. Untreated depression reduces the positive effect of all back pain treatments.",97,12,0.12371134020618557
9781910797495,chp10,Epidural steroid injections produce small-to-moderate short-term pain relief.,"Epidural steroid injections should not be used for non-specific low back pain; rather, their role is in the treatment of back pain that is accompanied by radicular pain. Injections can be made either translaminar via a posterior approach via the ligamentum flavum, or transforaminal via an oblique approach. Both techniques are best carried out with an image intensifier or CT control. In the acute phase of spinal nerve root irritation, early evidence points to the potential of transforaminal injection to prevent progression to chronic sciatica. However, rigorous controlled studies are not available. Of 8 patients who receive epidural steroid injections, 1 will experience at least 75% pain relief in the short term, but this benefit fades over time as only 1 out of 13 patients has 50% pain relief in the long term (12 weeks to 1 year).",177,17,0.096045197740113
9781910797495,chp10,Integrated treatments that address the salient biopsychosocial factors perpetuating disability appear to have the best chance of returning disabled persons to a functional quality of life.,"There is no evidence that spinal fusion, one of the most common operations for low back problems, is superior to other surgical procedures such as laminectomy for common degenerative conditions of the spine. Interestingly, the outcome of spinal stenosis surgery does not seem to correlate with the degree of postsurgical spinal canal narrowing. Interdisciplinary rehabilitation. Treatment designed to integrate several modalities that address the biopsychosocial factors perpetuating functional loss in chronic back pain, rather than attempting to find and treat a single cause (id est the 'pain generator'), is more effective for enabling patients disabled by low back pain to return to work and stay at work than are conventional or surgical treatments. Selectively combining treatments that, based on a biopsychosocial formulation, specifically address the perpetuating factor influencing recovery, appears to have the best chance of returning disabled patients to a functional quality of life.",178,33,0.1853932584269663
9781910797495,chp10,Pregabalin has small to modest analgesic efficacy.,"Anticonvulsants. The gabapentinoid pregabalin has been shown to produce small to modest benefits in patients with fibromyalgia. The results of an RCT have suggested that pregabalin reduces pain, improves sleep and reduces fatigue in patients with fibromyalgia. Pregabalin provides pain relief in 1 in every 6 individuals, but minor adverse events also occur with the same prevalence.",85,12,0.1411764705882353
9781910797495,chp11,"Visceral pain results from activation of sensory afferent nerves that innervate the stomach, kidney, gallbladder, urinary bladder, intestines, pancreas and other visceral organs.","In the past, viscera were considered insensitive to pain. It is now clear that visceral pain results from the activation of sensory afferent nerves that innervate internal organs such as the stomach, kidney, gallbladder, urinary bladder, intestines or pancreas. Disorders that could trigger visceral pain include distension from impaction, tumors, ischemia, inflammation and traction on the mesentery. There are a variety of pain syndromes thought to be maintained by the persistent activation of visceral nociceptive fibers. However, there is a common pathophysiology and symptomatic management approach to all of these syndromes. Nociceptive input from the body surface travels along somatic nerves that enter spinal roots, accounting for the clear dermatomal organization of somatic pain sensations. Nociceptive information from internal organs, which are exclusively innervated by A and unmyelinated C fibers, travels via more diffusely organized sympathetic and parasympathetic afferent pathways that enter the spinal cord at the thoracic and lumbar levels. In addition, visceral afferent fibers contain a greater percentage of neuroexcitatory transmitters such as substance P than do somatic afferent fibers. These differences between somatic and visceral innervation explain why sensations arising from visceral stimulation are generally more diffuse, more difficult to localize and more unpleasant than somatic sensations, and also why they are referred to poorly localized regions of the body surface (Figure 11.1). Visceral sensations are often accompanied by autonomic reflexes and symptoms such as nausea, sweating and malaise.",329,39,0.11854103343465046
9781910797495,chp11,"Pain syndromes such as male chronic pelvic pain syndrome, interstitial cystitis, endometriosis and irritable bowel syndrome are thought to be maintained by the persistent activation of visceral fibers, and central sensitization.","In the past, viscera were considered insensitive to pain. It is now clear that visceral pain results from the activation of sensory afferent nerves that innervate internal organs such as the stomach, kidney, gallbladder, urinary bladder, intestines or pancreas. Disorders that could trigger visceral pain include distension from impaction, tumors, ischemia, inflammation and traction on the mesentery. There are a variety of pain syndromes thought to be maintained by the persistent activation of visceral nociceptive fibers. However, there is a common pathophysiology and symptomatic management approach to all of these syndromes. Nociceptive input from the body surface travels along somatic nerves that enter spinal roots, accounting for the clear dermatomal organization of somatic pain sensations. Nociceptive information from internal organs, which are exclusively innervated by A and unmyelinated C fibers, travels via more diffusely organized sympathetic and parasympathetic afferent pathways that enter the spinal cord at the thoracic and lumbar levels. In addition, visceral afferent fibers contain a greater percentage of neuroexcitatory transmitters such as substance P than do somatic afferent fibers. These differences between somatic and visceral innervation explain why sensations arising from visceral stimulation are generally more diffuse, more difficult to localize and more unpleasant than somatic sensations, and also why they are referred to poorly localized regions of the body surface (Figure 11.1). Visceral sensations are often accompanied by autonomic reflexes and symptoms such as nausea, sweating and malaise.",329,45,0.13677811550151975
9781910797495,chp11,"Sensations arising from visceral stimulation are generally more diffuse, more difficult to localize and more unpleasant than those associated with somatic pain.","Nociceptive input from the body surface travels along somatic nerves that enter spinal roots, accounting for the clear dermatomal organization of somatic pain sensations. Nociceptive information from internal organs, which are exclusively innervated by A and unmyelinated C fibers, travels via more diffusely organized sympathetic and parasympathetic afferent pathways that enter the spinal cord at the thoracic and lumbar levels. In addition, visceral afferent fibers contain a greater percentage of neuroexcitatory transmitters such as substance P than do somatic afferent fibers. These differences between somatic and visceral innervation explain why sensations arising from visceral stimulation are generally more diffuse, more difficult to localize and more unpleasant than somatic sensations, and also why they are referred to poorly localized regions of the body surface (Figure 11.1). Visceral sensations are often accompanied by autonomic reflexes and symptoms such as nausea, sweating and malaise.",198,28,0.1414141414141414
9781910797495,chp11,"Visceral pain is more likely than somatic pain to be associated with autonomic signs such as pallor and sweating, or symptoms such as nausea.","Nociceptive input from the body surface travels along somatic nerves that enter spinal roots, accounting for the clear dermatomal organization of somatic pain sensations. Nociceptive information from internal organs, which are exclusively innervated by A and unmyelinated C fibers, travels via more diffusely organized sympathetic and parasympathetic afferent pathways that enter the spinal cord at the thoracic and lumbar levels. In addition, visceral afferent fibers contain a greater percentage of neuroexcitatory transmitters such as substance P than do somatic afferent fibers. These differences between somatic and visceral innervation explain why sensations arising from visceral stimulation are generally more diffuse, more difficult to localize and more unpleasant than somatic sensations, and also why they are referred to poorly localized regions of the body surface (Figure 11.1). Visceral sensations are often accompanied by autonomic reflexes and symptoms such as nausea, sweating and malaise.",198,31,0.15656565656565657
9781910797495,chp11,Management includes identifying and avoiding factors that aggravate the underlying condition and individual clinical trials of medication. Neuromodulatory techniques have been reported as helpful in selected cases.,"Treatment of visceral chronic pain syndromes is aimed at symptomatic pain management. Today, visceral pain management focuses on both pharmacological and interventional techniques. Combinations of non-steroidal anti-inflammatory drugs (NSAIDs), adjuvant medications and opioids, in that sequence, form the mainstay of therapy. As stress can activate or worsen visceral pain syndromes, stress reduction techniques such as cognitive behavioral therapy (CBT) and integrative therapies can be helpful adjuncts. When pharmacological therapies prove ineffective or are limited by side effects, regional anesthesia techniques, neurostimulation (peripheral or spinal cord) or neurosurgical techniques are considered. However, the effectiveness of these last therapies has not been evaluated rigorously, and therefore they should only be used as a last resort.",162,34,0.20987654320987653
9781910797495,chp12,"In patients without history of chronic headaches, determine whether an acute new headache is a serious, potentially life-threatening condition.","Acute headache. The immediate, important first step in assessing a new headache is determining whether the headache is a serious, potentially life-threatening medical event requiring emergency evaluation and management. All the possibilities highlighted in Table 12.1 must be entertained and discarded before considering the headache to be caused by a chronic headache condition. Brain imaging, including neurovascular studies, may be needed as well as cerebrospinal fluid (CSF) pressure measurement and analysis and further evaluation by a neurologist.",99,24,0.24242424242424243
9781910797495,chp12,"In chronic headache:- use a headache diary to differentiate headache type and establish pattern of triggers to enable self-management strategies- institute preventive measures such as trigger avoidance, stress control and medication- institute abortive regimen appropriate for headache type- migraine: non-steroidal anti-inflammatory drugs (NSAIDs), stress control, triptans- tension/myofascial: NSAIDs, stress control, icing, stretching- avoid regular frequent analgesic use to reduce incidence of transform (rebound) headache physical dependency.","For most chronic headaches, diagnostic tests are unnecessary except when a 'red flag' on history or physical examination indicates concern for an intracerebral mass and the need for imaging, or history and physical examination indicate a need for spinal evaluation and related imaging. In occipital neuralgia, sometimes neural blockade of the occipital nerves can help with diagnosis. Administration of indometacin (indomethacin) results in complete relief of chronic paroxysmal hemicrania (CPH) and this effect continues with long-term treatment. Cluster headache diagnosis may be aided by the autonomic features and at least partial response to inhaled oxygen. Migraine. The treatment approach for migraine is best conceptualized as longitudinal chronic disease management in three parts: preventive measures, abortive treatment and symptom management. This approach is based on understanding the phenomenological pattern of each individual's headache, as in Figure 12.1. First, preventive treatments aim to reduce the frequency, severity and duration of attacks and include daily use of medications such as antidepressants, anticonvulsants, alpha -agonists, and beta-blockers (Table 12.4). Second, once prodromal or actual migraine symptoms occur, a stepped-care approach should be taken (Table 12.5). It is important to avoid frequent regular dosing (more than twice weekly) of short-acting analgesics or sedatives such as compounds containing butalbital (a short-acting barbiturate often compounded with non-steroidal anti-inflammatory drugs [NSAIDs] or paracetamol [acetaminophen]), to reduce the incidence of transform (rebound) daily headaches. Psychotherapies, such as support/directive and cognitive behavioral therapies (CBT), may help patients manage a complex interaction of factors that perpetuate headache. Botulinum toxin injections have been reported to be successful in some case series, but the clinical trials are equivocal; a trial should be reserved for treatment-resistant patients. For intractable migraine and occipital neuralgia, non-invasive methods of vagal neurostimulation and transcranial magnetic neurostimulation may serve as useful adjuncts to more conventional therapies. Trials of more invasive forms of neuromodulation in the form of temporary insertion of suboccipital electrodes result in about 50% of these patients proceeding to permanent implantation of electrodes with a pulse generator.",493,103,0.20892494929006086
9781910797556,chp1,"Treatment-refractory MG is defined as disease that inadequately responds, or results in unacceptable adverse reactions, to conventional immunosuppressive treatments, or requires excessive amounts of potentially harmful agents or repeated rescue therapy.","When adequately treated, most patients with MG are able to live productive lives with few or no symptoms. A distinct subset of patients, however, have very aggressive and difficult-to-control disease. These patients, who continue to have symptoms and are at continuing risk of crisis and exacerbation because of an inadequate response to appropriate immunosuppressive therapy, are often referred to as having treatment-refractory MG. The exact prevalence of refractory myasthenia is unknown, but it is estimated to occur in approximately 10-15% of patients with generalized disease. In a large retrospective study by Suh et al. of 128 sequential patients seen in a large tertiary referral center, 19 (14.8%) patients were found to be treatment-refractory. The definition of refractory included those patients who could not lower their immunotherapy without clinical relapse, were not clinically controlled on their immunotherapy regimen, or experienced severe side effects from immunotherapy. This study may have overestimated the true incidence of refractory MG as it was conducted at a large tertiary clinic, where the referral population comprised patients with more active disease.",231,44,0.19047619047619047
9781910797556,chp1,Patients with comorbidities that preclude the use of conventional treatments and/or who have frequent myasthenic crises are also considered to have refractory MG.,"When adequately treated, most patients with MG are able to live productive lives with few or no symptoms. A distinct subset of patients, however, have very aggressive and difficult-to-control disease. These patients, who continue to have symptoms and are at continuing risk of crisis and exacerbation because of an inadequate response to appropriate immunosuppressive therapy, are often referred to as having treatment-refractory MG. The exact prevalence of refractory myasthenia is unknown, but it is estimated to occur in approximately 10-15% of patients with generalized disease. In a large retrospective study by Suh et al. of 128 sequential patients seen in a large tertiary referral center, 19 (14.8%) patients were found to be treatment-refractory. The definition of refractory included those patients who could not lower their immunotherapy without clinical relapse, were not clinically controlled on their immunotherapy regimen, or experienced severe side effects from immunotherapy. This study may have overestimated the true incidence of refractory MG as it was conducted at a large tertiary clinic, where the referral population comprised patients with more active disease.",231,35,0.15151515151515152
9781910797556,chp1,Treatment-refractory myasthenia gravis (MG) is estimated to occur in approximately 10-15% of patients with generalized MG.,"When adequately treated, most patients with MG are able to live productive lives with few or no symptoms. A distinct subset of patients, however, have very aggressive and difficult-to-control disease. These patients, who continue to have symptoms and are at continuing risk of crisis and exacerbation because of an inadequate response to appropriate immunosuppressive therapy, are often referred to as having treatment-refractory MG. The exact prevalence of refractory myasthenia is unknown, but it is estimated to occur in approximately 10-15% of patients with generalized disease. In a large retrospective study by Suh et al. of 128 sequential patients seen in a large tertiary referral center, 19 (14.8%) patients were found to be treatment-refractory. The definition of refractory included those patients who could not lower their immunotherapy without clinical relapse, were not clinically controlled on their immunotherapy regimen, or experienced severe side effects from immunotherapy. This study may have overestimated the true incidence of refractory MG as it was conducted at a large tertiary clinic, where the referral population comprised patients with more active disease.",231,31,0.1341991341991342
9781910797556,chp1,"Compared with non-refractory patients, treatment-refractory patients are more likely to be younger at disease onset, female, thymomatous and muscle receptor tyrosine kinase (MuSK)-antibody positive.","The incidence of generalized MG has been found to have a bimodal age distribution, with a peak around 30 years of age and again at 50 years, with a steady rise in incidence thereafter. Female cases predominate in the younger age group and males in the older (Figure 1.1)., Juvenile MG is defined as disease with onset before the age of 18 years and accounts for roughly 10% of all cases of MG. In the Suh et al. study discussed above, the median age of the refractory group was 36 years versus 60 years in the non-refractory group. Refractory patients were more likely to be female (14 of 19). In the Sudulagunta et al. study, the age of disease onset in the refractory MG group was significantly lower than in the non-refractory group (median age of 36 years versus 61 years). The refractory group also had a higher percentage of females.",198,49,0.2474747474747475
9781910797556,chp2,"In myasthenia gravis (MG), pathogenic antibodies against acetylcholine receptors (AChRs) or muscle-specific receptor tyrosine kinase (MuSK) are responsible for the abnormal neuromuscular junction transmission leading to muscle weakness.","At the normal neuromuscular junction (NMJ), acetylcholine (ACh) is released from the motor neuron terminal, diffuses across the synaptic space and binds to ACh receptors (AChR), which are densely clustered on the folded endplate membrane of the muscle fiber. The high concentration of AChRs is crucial for efficient neuromuscular transmission. The ACh depolarizes the muscle endplate region, ultimately causing the muscle to contract (Figure 2.1). Myasthenia gravis (MG) is the best characterized autoimmune disorder of the nervous system. The immune-mediated nature of MG was suspected as early as the 1960s when it was speculated to be caused by a dysregulated immune response, with antibodies directed against skeletal muscle. Acetylcholine receptor antibodies. A series of animal and human experiments in the 1970s confirmed the above hypothesis, and elevated titers of antibodies against the acetylcholine receptor (AChR) were ultimately discovered in the serum of patients with MG. Loss of AChRs results in impaired neuromuscular transmission and muscle weakness.",227,54,0.23788546255506607
9781910797556,chp2,"Antibodies to AChRs reduce the number of AChRs by several pathological mechanisms including complement-activated damage, antigenic modulation leading to accelerated endocytosis and degradation of the AChR, and direct blockade of the receptor.","Complement-mediated lysis is thought to be the most important mode of loss of AChR, but the actual process that initiates the aberrant immune attack on the AChR is unknown. Both the immunoglobulin (Ig) G antibody and complement have been localized to the motor endplate in myasthenia models, indicating that circulating IgG antibodies directed against the AChR bind to the postsynaptic membrane and activate the terminal complement sequence (C5b-9), or membrane attack complex (MAC). This results in lysis of the postsynaptic membrane, causing loss of the AChR (Figure 2.2). In fact, elevated MAC levels have been demonstrated in the plasma of patients with MG. 'Binding' antibodies are the most common type found in patients with MG. Accelerated internalization and degradation of acetylcholine receptors. A key mechanism of disease pathology in MG is the modulation, internalization and eventual destruction of AChRs at the NMJ by the crosslinking of AChR-specific autoantibodies (Figure 2.3). This process is known as antigenic modulation.",236,49,0.2076271186440678
9781910797556,chp2,"About 7% of cases of generalized MG have antibodies to MuSK. This is a distinct clinical subset of the disease, which is generally more severe than AChR-antibody-positive MG, not associated with thymic pathology and more likely to be refractory to treatment.","Antibodies to AChR. As noted above, MG is most often caused by antibodies to the AChR. This is the case for 85% of cases of generalized disease and approximately 50% of cases of purely ocular MG. Antibodies to AChR may be of the binding, blocking or modulating type, with binding being the most common. AChR antibodies are highly specific for the diagnosis of MG, although the degree of elevation in titers has never been found to correlate with the severity of disease. Antibody titers may decline with immunosuppressive treatment within an individual, although the reliability of determining treatment effect is less robust. Antibodies to muscle receptor tyrosine kinase (MuSK) occur in about 7% of cases of generalized MG but are rarely reported in isolated ocular disease. MuSK-antibody-positive MG is a distinct clinical subset of the disease, almost always seen in adults, more frequently in women, and never in conjunction with thymic disease. There is predominant involvement of the bulbar muscles, often with concurrent neck and respiratory muscle weakness. Ocular and limb muscle weakness is less common than in AChR-antibody-related disease but is certainly seen in this population. Most patients can actually worsen on treatment with acetylcholinesterase inhibitors such as pyridostigmine.",283,59,0.20848056537102475
9781910797556,chp2,"Abnormal thymic pathology is associated with AChR-antibody-positive MG, particularly late-onset disease.","Antibodies to muscle receptor tyrosine kinase (MuSK) occur in about 7% of cases of generalized MG but are rarely reported in isolated ocular disease. MuSK-antibody-positive MG is a distinct clinical subset of the disease, almost always seen in adults, more frequently in women, and never in conjunction with thymic disease. There is predominant involvement of the bulbar muscles, often with concurrent neck and respiratory muscle weakness. Ocular and limb muscle weakness is less common than in AChR-antibody-related disease but is certainly seen in this population. Most patients can actually worsen on treatment with acetylcholinesterase inhibitors such as pyridostigmine.",147,27,0.1836734693877551
9781910797556,chp3,"Myasthenia gravis (MG) is characterized by skeletal muscle weakness and fatigability. It can affect the ocular, bulbar, facial, neck, respiratory and limb muscles.","Myasthenia gravis (MG) is characterized by skeletal muscle weakness (Table 3.1). As with any disorder of neuromuscular transmission, the distinctive clinical feature of MG is the fluctuating nature of weakness that patients report - a phenomenon known as 'fatigability'. Symptoms of MG tend to worsen with concurrent illness, over-exertion of the muscle (exempli gratia fatigue from speaking or eating), the use of certain medications, and as the day progresses. The presentation of MG in any given patient is variable; not all patients will experience all of the symptoms described below. Ocular symptoms. Approximately two-thirds of patients initially present with ocular symptoms., Neurological examination often discloses evidence of ptosis or dysconjugate gaze on testing of extraocular movements, which may demonstrate fatigability with sustained upward or lateral gaze. Weakness of the eye muscles is often asymmetric and variable - a combination of alternating ptosis and diplopia in any direction.",202,38,0.18811881188118812
9781910797556,chp3,"The symptoms of MG may be exacerbated by concurrent illness, over-exertion of the muscle, the use of certain medications, and as the day progresses.","Myasthenia gravis (MG) is characterized by skeletal muscle weakness (Table 3.1). As with any disorder of neuromuscular transmission, the distinctive clinical feature of MG is the fluctuating nature of weakness that patients report - a phenomenon known as 'fatigability'. Symptoms of MG tend to worsen with concurrent illness, over-exertion of the muscle (exempli gratia fatigue from speaking or eating), the use of certain medications, and as the day progresses. The presentation of MG in any given patient is variable; not all patients will experience all of the symptoms described below. Ocular symptoms. Approximately two-thirds of patients initially present with ocular symptoms., Neurological examination often discloses evidence of ptosis or dysconjugate gaze on testing of extraocular movements, which may demonstrate fatigability with sustained upward or lateral gaze. Weakness of the eye muscles is often asymmetric and variable - a combination of alternating ptosis and diplopia in any direction.",202,32,0.15841584158415842
9781910797556,chp3,"All patients suspected of having MG should be tested for acetylcholine receptor (AChR) antibodies. If these antibodies are present, no further diagnostic testing is usually required other than the use of imaging to determine if a thymoma is present.","In most instances, the clinician can be confident about the diagnosis of MG based on a characteristic history and physical examination. However, one or more tests are routinely performed to confirm the clinical diagnosis. Antibody testing. Testing for acetylcholine receptor (AChR) antibodies is always performed in patients suspected of having MG. If these antibodies are present, no further diagnostic testing is usually required other than to evaluate for the presence of a thymoma with either CT or MRI of the thorax. AChR-antibody-negative patients with predominant bulbar involvement are often tested for muscle-specific receptor tyrosine kinase (MuSK) antibodies. Testing for antibodies to the P/Q type voltage-gated calcium channel is also often performed in cases of AChR antibody negativity to rule out Lambert Eaton myasthenic syndrome. In children with myasthenic features but with AChR-, clustered AChR- and MuSK-antibody negativity, congenital (genetic) myasthenic syndromes should be considered.",219,51,0.2328767123287671
9781910797556,chp3,"AChR-antibody-negative patients with predominant bulbar involvement are often tested for muscle-specific receptor tyrosine kinase (MuSK) antibodies and, where available, antibodies to clustered AChR. (It should be noted, however, that clustered AChR antibody testing is available only at a few specialist centers, and is not routinely performed in general laboratories.)","In most instances, the clinician can be confident about the diagnosis of MG based on a characteristic history and physical examination. However, one or more tests are routinely performed to confirm the clinical diagnosis. Antibody testing. Testing for acetylcholine receptor (AChR) antibodies is always performed in patients suspected of having MG. If these antibodies are present, no further diagnostic testing is usually required other than to evaluate for the presence of a thymoma with either CT or MRI of the thorax. AChR-antibody-negative patients with predominant bulbar involvement are often tested for muscle-specific receptor tyrosine kinase (MuSK) antibodies. Testing for antibodies to the P/Q type voltage-gated calcium channel is also often performed in cases of AChR antibody negativity to rule out Lambert Eaton myasthenic syndrome. In children with myasthenic features but with AChR-, clustered AChR- and MuSK-antibody negativity, congenital (genetic) myasthenic syndromes should be considered. Electrophysiological tests. In cases of antibody negativity, a decrementing response on slow (3 Hz) repetitive nerve stimulation (Figure 3.1) or elevated jitter values on single fiber electromyography (Figure 3.2) may be necessary to confirm the diagnosis of MG. It is worth noting that, while increased jitter on single fiber electromyography is very sensitive in patients with MG, it is not specific for the disease, therefore other causes of weakness should be ruled out. In addition, a decremental response on repetitive nerve stimuation may disappear in patients with MG in a muscle that is no longer clinically weak. In other words, lack of decrement in a muscle that is reported to be weak may indicate a cause other than MG.",373,78,0.20911528150134048
9781910797556,chp3,"Patients who are antibody negative should be tested for a decrementing response on repetitive nerve stimulation, elevated jitter values on single fiber electromyography or a positive edrophonium test.","Electrophysiological tests. In cases of antibody negativity, a decrementing response on slow (3 Hz) repetitive nerve stimulation (Figure 3.1) or elevated jitter values on single fiber electromyography (Figure 3.2) may be necessary to confirm the diagnosis of MG. It is worth noting that, while increased jitter on single fiber electromyography is very sensitive in patients with MG, it is not specific for the disease, therefore other causes of weakness should be ruled out. In addition, a decremental response on repetitive nerve stimuation may disappear in patients with MG in a muscle that is no longer clinically weak. In other words, lack of decrement in a muscle that is reported to be weak may indicate a cause other than MG. Edrophonium test. A positive edrophonium test ('Tensilon test') can also be used to confirm the diagnosis. Patients with MG should show an improvement in muscular strength following administration of edrophonium, a very short-acting anticholinesterase, which therefore increases the effective amount of acetylcholine at the neuromuscular junction (NMJ).",234,39,0.16666666666666666
9781910797556,chp3,Acetylcholinesterase inhibitors are often the initial therapeutic intervention in patients with MG.,"Acetylcholinesterase inhibitors have been used in the treatment of MG since 1934 when Walker successfully treated a patient with physostigmine for generalized disease. These agents are often the initial therapeutic intervention in MG. They work by inhibiting the enzymatic hydrolysis of acetylcholine (ACh) at the synapse, allowing the neurotransmitter to accumulate at the NMJ, prolonging its activity and increasing the number of neurotransmitter and AChR interactions.",99,20,0.20202020202020202
9781910797556,chp3,Most patients with MG require additional treatment with either thymectomy or immunosuppressive or immunomodulatory therapy.,"Pyridostigmine bromide is the preferred acetylcholinesterase inhibitor as it has a longer half-life and a more favorable side-effect profile than other available agents. Unfortunately, most patients with MG cannot be controlled on anticholinesterase medications alone and require treatment with either thymectomy or immunosuppressive or immunomodulatory therapy (Figure 3.3). Corticosteroids were the first immunosuppressant drugs to be widely used in the treatment of MG. They produce significant clinical improvement in the vast majority of patients. The response to treatment with corticosteroids begins relatively rapidly and is typically observed within the first 2-4 weeks at a dose of approximately 1-1.5 mg/kg/day, although it is recommended that the dose is gradually increased under close medical supervision because of the temporary worsening that corticosteroids can cause.",186,24,0.12903225806451613
9781910797556,chp3,Consideration of additional therapeutic options is warranted for patients who are identified as being refractory to conventional treatment.,"When patients with MG are deemed to be refractory to conventional treatment (see page 8), consideration of additional therapeutic options is warranted in order to improve quality of life, reduce morbidity and prevent life-threatening crises and death. While there are no evidence-based guidelines, recently published international consensus guidelines for the management of MG recommend referral to a physician or center with expertise in the management of the disorder, and that treatment with chronic intravenous immunoglobulin or plasma exchange, cyclophosphamide or rituximab should be considered. Other treatment options are emerging.",116,22,0.1896551724137931
9781910797556,chp4,"Electrophysiological studies, disease severity rating scales and patient-reported outcome measures are all tools with which disease activity and response to treatment can be measured in myasthenia gravis (MG).","4 Assessment of disease severity and treatment response. Although myasthenia gravis (MG) is a very treatable disease in most patients, approximately 10-15% have very difficult-to-control disease. These patients often experience disabling symptoms that lead to poor quality of life and are prone to life-threatening crises. Given the fluctuations in severity of symptoms in patients with MG, there are inherent difficulties in assessing baseline disease severity and response to treatment. Electrophysiological studies, disease severity rating scales and patient-reported outcome measures are all tools with which disease activity and response to treatment have been measured in MG. Measuring antibodies. Intuitively, the measurement of acetylcholine receptor (AChR) antibody titers serves as an attractive biomarker to discern disease activity and response to treatment in patients with MG. However, it is generally accepted that there is no reliable correlation between serum AChR antibody titers and clinical severity in generalized MG. A recent study using a commercial assay noted a high positive predictive value but a low negative predictive value when correlating titers with several validated outcome measures in MG. The measurement of AChR antibody levels is therefore likely to be of limited benefit when attempting to discern the level of disease activity.",252,40,0.15873015873015872
9781910797556,chp4,There is no reliable correlation between serum acetylcholine receptor (AChR) antibody titers and clinical severity in generalized MG; better prognostic biomarkers for MG are needed to better assess response to treatment over time.,"Given the fluctuations in severity of symptoms in patients with MG, there are inherent difficulties in assessing baseline disease severity and response to treatment. Electrophysiological studies, disease severity rating scales and patient-reported outcome measures are all tools with which disease activity and response to treatment have been measured in MG. Measuring antibodies. Intuitively, the measurement of acetylcholine receptor (AChR) antibody titers serves as an attractive biomarker to discern disease activity and response to treatment in patients with MG. However, it is generally accepted that there is no reliable correlation between serum AChR antibody titers and clinical severity in generalized MG. A recent study using a commercial assay noted a high positive predictive value but a low negative predictive value when correlating titers with several validated outcome measures in MG. The measurement of AChR antibody levels is therefore likely to be of limited benefit when attempting to discern the level of disease activity. Research need. Better prognostic biomarkers for MG are needed to more sensitively determine which treatments might work better for specific patients, to better assess the response to treatment over time and for use in clinical trial design in studies of MG.",234,45,0.19230769230769232
9781910797556,chp4,"Measurement of jitter on single fiber electromyography (SFEMG) may be a useful biomarker of disease activity in MG. Absolute or percentage change in mean jitter from one electrophysiological study to another has a potential role as a biomarker provided the parameters of the study, such as time of day and time after medication, are kept the same.","Intuitively, the measurement of acetylcholine receptor (AChR) antibody titers serves as an attractive biomarker to discern disease activity and response to treatment in patients with MG. However, it is generally accepted that there is no reliable correlation between serum AChR antibody titers and clinical severity in generalized MG. A recent study using a commercial assay noted a high positive predictive value but a low negative predictive value when correlating titers with several validated outcome measures in MG. The measurement of AChR antibody levels is therefore likely to be of limited benefit when attempting to discern the level of disease activity. Research need. Better prognostic biomarkers for MG are needed to more sensitively determine which treatments might work better for specific patients, to better assess the response to treatment over time and for use in clinical trial design in studies of MG. Electrophysiological tests. Measurement of jitter on single fiber electromyography (SFEMG) has shown promise as a useful biomarker of disease activity in MG (see page 25 -). One recent study found that jitter is a sensitive measure of disease severity in MG; absolute or percentage change in mean jitter from one electrophysiological study to another in a given patient has a potential role as a biomarker. Another study showed that high jitter values on SFEMG and decrement values on repetitive nerve stimulation were associated with more severe disease, as determined by more frequent subjective and objective measures of muscle strength and worse quantitative MG score (see below).",307,75,0.24429967426710097
9781910797556,chp4,"The quantitative MG score, which can be completed in 20-30 minutes and requires no specialized equipment, is the best studied objective outcome measure in MG. It is recommended for use in all prospective studies of therapy for MG.","The quantitative MG score (QMG) is the best studied objective outcome measure in MG, and it has been used in many drug trials in MG. It is a severity score, determined from measurement of 13 objective items (Table 4.1), with measures varying between 0 (normal) to 39 (maximum severity). The QMG can be completed in 20-30 minutes, and the only specialized equipment required is a spirometer and handheld dynamometer. Spirometry, dynamometry and quantitative timed tests can also be useful longitudinally in individual patients even when the total QMG does not change. The Myasthenia Gravis Foundation of America (MGFA) task force recommended that the QMG be used in all prospective studies of therapy for MG. The MG activities of daily living score (MG-ADL) is a simple eight-point questionnaire, designed to complement the QMG, which enquires about common symptoms reported by patients with MG (Table 4.2). Widely used in many studies, the MG-ADL correlates well with the QMG and can serve as a measure of efficacy in clinical trials. No specialized training is required to administer the scale, which can be completed in less than 10 minutes.",246,44,0.17886178861788618
9781910797556,chp4,"Other useful tools for assessing response to treatment include the MG activities of daily living score (MG-ADL), MG composite scale (MGC), revised MG quality of life 15 scale (MG-QOL15R), MG impairment index (MGII) and MGFA assessment of post-intervention status (PIS).","The MG quality of life 15 scale (MG-QOL15). Measures of health-related quality of life attempt to ascertain a patient's subjective determination of the extent of dysfunction caused by disease and their degree of satisfaction or dissatisfaction with that dysfunction. MG-QOL15 is a 15-item MG-specific self-administered scale, the test items of which address MG-specific psychological well-being and social functioning. It is meant to inform the treating physician about a particular patient's perception of the extent of dysfunction specifically due to MG, and the degree of satisfaction or dissatisfaction with that dysfunction, which can then be used to help guide treatment decisions. It can also be used to follow an individual patient's response over time to assist in assessing the degree of disease severity and to determine the efficacy of treatment, controlling for other potential confounding factors. In addition, like the other scales discussed, the MG-QOL15 has served to assist in following groups of patients with MG over time in clinical trials. The scale has been revised using Rasch analysis (MG-QOL15R), which has slightly improved clinimetric properties and improved face and content validity (Table 4.4). Both scales are validated; however, the MG-QOL15R is preferred given the better content validity and because it is somewhat easier to interpret in the clinical setting. Both scales take less than 5 minutes to administer.",282,65,0.23049645390070922
9781910797587,chp01,The complex joint structure provides frictionless articulation and load-bearing abilities.,"An understanding of the key structures in normal synovial joints (Figure 1.1), including their composition and function, is a prerequisite for understanding any arthritic process. Synovial joints (diarthroses) are the only joints that have a space, namely the synovial cavity filled with fluid, between the adjoining bones. They are surrounded by an articular capsule composed of fibrous connective tissue that is attached just outside the area of each bone's articulating surface. The complex joint structure provides frictionless articulation and load-bearing abilities. Synovial joints mainly comprise.",121,15,0.12396694214876033
9781910797587,chp01,"Articular hyaline cartilage lines the end of each bone within a joint; it allows an efficient gliding motion when the joint moves, and absorbs and dissipates mechanical load.","articular cartilage. subchondral bone. synovial membrane. synovial fluid. fibrocartilaginous menisci (in some joints, exempli gratia the knee). Articular cartilage. The end of each bone within a joint is lined with articular hyaline cartilage, which has a low coefficient of friction that enables an efficient gliding motion when the joint moves. Normal articular hyaline cartilage varies in thickness at different joint sites, and is different between men and women. Histologically, the cartilage is seen as an upper non-calcified layer divided into the following zones. superficial, with few cells and tangential collagen fibers (zone I).",147,36,0.24489795918367346
9781910797587,chp01,The synovial joint should be seen as a single dynamic structure with inter-relating components.,"Subchondral bone comprises a subchondral plate and underlying trabecular bone. As described above, the subchondral bone is intimately associated with the overlying cartilage and together probably act as a single structure for load transmission. Like cartilage, the thickness of the subchondral bone may vary with location within a joint; it may be thicker in the central weight-bearing areas of joints. The calcified cartilage layer is of intermediate stiffness between overlying cartilage and subchondral bone. The subchondral bone has a density similar to cortical bone but the trabeculae are aligned in different directions, resulting in different mechanical properties depending on the plane of loading.",146,20,0.136986301369863
9781910797587,chp01,"Subchondral bone is intimately associated with the overlying cartilage, which together probably act as a single structure for load transmission.","Subchondral bone comprises a subchondral plate and underlying trabecular bone. As described above, the subchondral bone is intimately associated with the overlying cartilage and together probably act as a single structure for load transmission. Like cartilage, the thickness of the subchondral bone may vary with location within a joint; it may be thicker in the central weight-bearing areas of joints. The calcified cartilage layer is of intermediate stiffness between overlying cartilage and subchondral bone. The subchondral bone has a density similar to cortical bone but the trabeculae are aligned in different directions, resulting in different mechanical properties depending on the plane of loading.",146,27,0.18493150684931506
9781910797587,chp01,"Healthy synovial joints contain a small amount of synovial fluid, a lubricating liquid that supplies nutrients and oxygen to the cartilage.","The subintimal layer comprises a loose connective tissue, which may be areolar, fibrous or adipose, and allows the membrane to move freely. In humans, the thickness of the subintimal layer varies in depth, from 100 m to 5 mm, at given sites within an individual. It comprises blood and lymphatic vessels, and a range of cells. Synovial fluid. Within the synovial cavity, healthy joints contain a small amount of synovial fluid, a lubricating liquid that supplies nutrients and oxygen to the cartilage. Molecules and cells pass in and out of the synovial fluid passage via the synovial intima and its underlying microcirculation. The intimal matrix has a sieve-like role, allowing diffusion of water and other small molecules while preventing the rapid movement of large molecules such as albumin and HA.",178,30,0.16853932584269662
9781910797587,chp02,"All tissues of the joint may show pathology, including cartilage, subchondral bone, the menisci and the synovium.","Osteoarthritis (OA), although often incorrectly referred to as a 'degenerative joint disease', is not only a process of wear and tear, but rather an active response to injury that involves abnormal remodeling of all the tissues within a synovial joint. This includes degradation of the articular cartilage, first at the joint surface but progressing to full thickness loss; thickening of the subchondral bone; osteophyte formation at the margins of the joint surfaces; variable degrees of synovial inflammation; and in the knee, damage to the cruciate ligaments and the menisci. In the periarticular region, there may be evidence of enthesitis, tendinitis and muscle loss.",150,29,0.19333333333333333
9781910797587,chp02,"Modern imaging has highlighted the extensive nature of the pathology, even in joints with limited radiographic evidence of damage.","The early changes in cartilage degradation are those of increased hydration along with progressive breakdown of the collagen fibrillar network, especially due to denaturation of type II collagen, at the joint surface in areas where mechanical forces are greatest. Later, there are areas in which chondrocytes both replicate and die, resulting in disruption to the cartilage surface with the formation of fibrillated areas and clefts, and evidence of vascular invasion into the calcified cartilage zone (Figure 2.1).",104,22,0.21153846153846154
9781910797587,chp02,"The joint should be considered a functional organ, with gait, periarticular muscles and related mechanical forces all playing a role in pathology.","It is not sufficient to merely describe the pathological features of individual tissues in the OA joint without considering the pathology of the joint as a functional unit, where a complex interplay of periarticular muscles, joint alignment, ligamentous strength and intra-articular pathology occurs. Joint stability. Malalignment of the knee increases load through the medial compartment in the varus knee. Associations with both increased medial bone mineral density and bone-marrow lesions on MRI have been described. Knee alignment influences structural progression at both the tibiofemoral and patellofemoral joints. Gait analyses suggest that the most important force through the knee is the external adduction moment, which produces medial joint force in knees with a varus deformity (Figure 2.4). This adduction moment is negatively correlated with the width of the medial joint space. Differences in gait have been demonstrated between normal subjects and those with mild or severe (radiographic) OA. Patterns of varus and valgus thrust (dynamic malalignment) may specifically predispose to medial and lateral knee OA, respectively.",231,29,0.12554112554112554
9781910797587,chp03,OA has a large impact on the individual and society.,"Osteoarthritis (OA) is the most common joint disorder and represents a major cause of pain and disability for the individual, as well as resulting in enormous health expenditure in Western countries. In the USA, an estimated 30 million people are affected by the disorder, while in the UK some 8.75 million people aged 45 years or older sought treatment for OA between 2004 and 2010.",79,11,0.13924050632911392
9781910797587,chp03,"For most people and clinicians, osteoarthritis (OA) refers to a clinical syndrome of joint pain, functional impairment and impaired quality of life.","OA is not an acquired disease in the traditional medical model, and definitions have not always been clear. OA is a syndrome of joint pain and stiffness with associated functional problems, which can have a substantial effect on quality of life. In terms of structural abnormalities, OA encompasses a number of problems that result in common pathological and radiological features. The OA disease process in synovial joints is classically characterized in its later stages by focal cartilage degradation, involvement of the subchondral bone and synovium, and the formation of marginal osteophytes; in reality, all components of the joint are affected (see Chapter 2). Importantly, periarticular tissue, especially muscle, is often affected as well.",148,30,0.20270270270270271
9781910797587,chp03,"Although radiographic OA is common, it is not always symptomatic.","Radiographic OA is more common than symptomatic OA, and detection rates in a given joint may increase when more radiographic views are obtained. Studies on the distribution of radiographic OA have suggested that right-sided hand and knee OA is more common than left-sided disease (consistent with a biomechanical cause). Even within a specific joint, the distribution of osteophytes or joint-space narrowing differs in prevalence, as well as by sex and ethnicity, again reflecting biomechanical and genetic factors (Table 3.1).",112,15,0.13392857142857142
9781910797587,chp03,"Joint pain is common, increasingly so with age; individuals frequently have multiple joint pains.","Symptomatic OA. Joint pain is common, but not all joint pain is attributable to OA (depending on the definition of OA and extra-articular causes of pain such as tendonitis); indeed, about half of those with radiographic OA report no symptoms. Women report more pain than men: worldwide estimates suggest that 9.6% of men and 18.0% of women over 60 years of age have symptomatic OA. African-Americans tend to report greater pain and disability than Caucasians.",106,18,0.16981132075471697
9781910797587,chp03,People with OA are more likely to have comorbid conditions than the general population and comorbidities can exacerbate the impact of OA on an individual.,"Studies have suggested that even after adjustment for age, sex and social class, people with OA are at least twice as likely to have comorbid conditions as the general population. Between 59% and 87% of adults with OA are estimated to have at least one additional significant chronic condition; indeed, people with OA have an average of 2.6 moderate-to-severe comorbidities. Cardiovascular disease, diabetes mellitus and hypertension are the most common comorbid conditions. Studies suggest that the presence of such comorbidities magnifies the impact of OA on the individual; conversely, having OA may affect an individual's ability to manage some comorbid conditions. Comorbid conditions may also reduce the effectiveness of therapies.",154,33,0.21428571428571427
9781910797587,chp04,The osteoarthritis (OA) phenotype represents a common endpoint of multiple insults that result in failure of the joint.,"It is likely that the clinical osteoarthritis (OA) in a given joint represents a common endpoint of multiple insults that result in failure of the joint. Trying to define what causes OA is complicated by factors already alluded to, including the lack of a uniform definition for OA and, in particular, the difficulty of detecting early asymptomatic OA. As discussed in Chapter 3, joints most commonly affected in humans are the hips, knees, cervical and lumbar spine, the small joints of the hands, base of thumb and base of the great toe. This pattern, together with other observations in humans and animals, has led to one concept of OA as an evolution-related problem, associated with changes in use of joints and grip, walking upright and our relative longevity.",160,24,0.15
9781910797587,chp04,The risk factors differ for incidence and progression.,"Risk factors for OA can be summarized as those resulting in a generalized predisposition for the disease together with localized biomechanical factors; the importance of each risk factor (and the interplay between factors) differs depending on the anatomic site of OA. Although there is some overlap between risk factor profiles for OA incidence and OA progression, these profiles are not identical.",77,9,0.11688311688311688
9781910797587,chp04,"The findings of genome-wide association studies and research into the epigenetics of OA have the potential to identify new etiologic pathways and OA phenotypes, diagnostic and prognostic biomarkers and therapeutic targets.","Future directions. Having identified the genetic locations of interest for OA, further identification of the causal SNP within each locus, their target genes and the mechanisms by which SNPs predispose to OA are needed. This will provide a solid basis for future replication analyses and functional studies. Epigenetics has also developed as a new and important area of OA research over the past decade, with studies mainly focusing on microRNAs and DNA methylation levels for genes implicated in OA in articular cartilage, primary chondrocytes and transformed chondrogenic cell lines. Over the next few years there are likely to be more genome-wide methylation studies on cartilage and other joint tissues. Together, these studies have the potential to identify new etiologic pathways and OA phenotypes, diagnostic and prognostic biomarkers and therapeutic targets.",173,43,0.24855491329479767
9781910797587,chp04,"There are multiple potential peripheral sources of pain in the pathological OA joint, but the role of spinal and central pain pathways has not been well explored.","Female sex/hormones. As mentioned above, the prevalence of OA increases in women after the menopause. This has led to many studies (most cross-sectional) examining the relationship between hormonal status and OA, with conflicting results. Whether estrogen replacement therapy is protective has also not been fully elucidated. Nutrition. The mechanisms by which nutrients may affect the development of OA are multiple and may include protection from oxidants such as reactive oxygen species and complex modulation of inflammatory responses. Lower levels of vitamin D (an essential component of normal bone biology) have been associated with a greater risk of knee OA progression in some studies, but the association remains controversial. Some preliminary studies have suggested a relationship between serum lipids and MRI bone-marrow lesions, though the mechanism of the relationship is not clear.",166,30,0.18072289156626506
9781910797587,chp05,Differential diagnosis from other rheumatologic conditions and inflammatory arthritides is part of the diagnostic process.,"Osteoarthritis (OA) is usually diagnosed clinically but may require investigations to aid in differential diagnosis or in assessing the degree of structural severity. Like most rheumatologic conditions, composite diagnostic criteria have been established by experts. Formal consensus-agreed criteria for OA of different joints have been developed by the American College of Rheumatology (Figures 5.1 - 5.3). Such criteria involve clinical, laboratory and radiographic elements, but most population-based studies have not employed such strict criteria. It is important to note that these criteria are good for diagnosis of moderate-to-severe disease but have not been used to identify early OA, something that may well be more important for future intervention.",148,23,0.1554054054054054
9781910797587,chp05,Careful history taken together with clinical examination of joints establishes most diagnoses.,Table 5.1 compares the characteristic presenting features of OA with those suggestive of inflammatory arthritis; these form the basis of useful questions to aid diagnosis. The occupational and social history is often useful in determining the 'lifetime load' to which a patient's joints have been exposed. Issues related to diagnoses of the specific joint region are discussed later in this chapter.,72,14,0.19444444444444445
9781910797587,chp05,Imaging and laboratory investigations may occasionally aid the assessment process.,"Modern imaging modalities. To help with additional diagnoses in patients with OA, the EULAR task force recommends the use of ultrasonography and MRI to image soft tissues, and CT and MRI to image bone. MRI and ultrasonography are more sensitive than clinical examination in detecting synovitis and effusions (and in distinguishing between the two), but the presence of either pathology does not usually differentiate mechanical from inflammatory arthritides. Although MRI has improved our understanding of the pathology and causes of pain in OA, it has no role in the routine assessment of the OA joint. MRI-detected meniscal tears are not an indication for surgical intervention in the OA knee unless clear locking symptoms are present.",146,12,0.0821917808219178
9781910797587,chp06,Prevention currently means advice to avoid trauma and high-impact repetitive loading of joints.,"Current therapy of osteoarthritis (OA) largely aims to treat existing disease by controlling its major symptom - pain - and maintain or improve joint and limb function and improve quality of life. While there are numerous therapies targeted against symptoms, at present no treatments have been definitively shown to modify the structural progression of OA. Currently, the best advice we can give on preventing OA relates to the following lifestyle modifications. avoid joint trauma. avoid high-impact loading of joints (through sport or occupation).",100,17,0.17
9781910797587,chp06,Essential management requires involving and educating the person and choosing a range of non-pharmacological and pharmacological therapies.,"A healthy diet is important to aid weight control, but no diets or dietary supplements have been shown to prevent, or to modify the progression of, OA. Management of OA. There are many evidence-based guidelines from a variety of specialty societies for managing OA (see Key references, page 72). These guidelines agree on several main principles for the treatment of the disease. People with OA should be involved in their own management, and should receive education about their condition and the range and safety of treatment options available. Optimum treatment involves a combination of non-pharmacological and pharmacological approaches.",122,24,0.19672131147540983
9781910797587,chp06,"Muscle strengthening, aerobic exercise and weight loss are a good starting point for management.","People with OA should be involved in their own management, and should receive education about their condition and the range and safety of treatment options available. Optimum treatment involves a combination of non-pharmacological and pharmacological approaches. Therapies, particularly pharmacological ones, need to be tailored according to an individual person's comorbidities and risk factors. Exercise and weight management should be recommended to all patients.",85,17,0.2
9781910797587,chp07,"Education, self-management and exercise are important components of treatment.","Education and exercise are components of a self-management program, but other issues such as spousal/partner support, emotional aspects and coping skills, such as relaxation and distraction methods, can also be addressed. It is important to review a patient's work and social life to identify any activities that may aggravate pain and/or place them at risk of injury. For example, patients who present with knee pain who have difficulty putting on shoes and socks, may have referred pain from the hip, and hip pathology should be considered.",107,13,0.12149532710280374
9781910797587,chp07,Use of aids such as a walking stick or devices to aid everyday activities (exempli gratia for opening jars) can also help symptoms and improve participation.,"Education and exercise are components of a self-management program, but other issues such as spousal/partner support, emotional aspects and coping skills, such as relaxation and distraction methods, can also be addressed. It is important to review a patient's work and social life to identify any activities that may aggravate pain and/or place them at risk of injury. For example, patients who present with knee pain who have difficulty putting on shoes and socks, may have referred pain from the hip, and hip pathology should be considered. An understanding of appropriate activity and rest cycles may improve adherence to exercise programs, while dietary modifications can encourage weight loss, contributing to the overall success of a program. As might be expected, these programs have small effect sizes on physical outcomes, but moderate effects on psychosocial outcomes in OA.",166,32,0.1927710843373494
9781910797587,chp07,"Use of proper footwear, and weight reduction in overweight individuals, will reduce biomechanical loading of joints and improve symptoms.","The benefits of exercise may be mediated through different routes, including increased strength and endurance, weight reduction, more accurate proprioception and joint position sense, improvement in comorbidities and reduction in anxiety or depression. Numerous studies have examined the benefits of exercise for OA of the knee and a few studies have assessed the benefits of exercise for OA of the hip. On balance, these studies show that therapeutic exercise brings about a moderate reduction in pain and some improvement in function, although the nature of the exercise differs between studies. It appears that benefits arise from individual programs and group classes and from exercises performed at home. Not surprisingly, the benefits of exercise may not be sustained for more than a few months if the exercises are not continued; it is therefore important to consider not only patient adherence but also the longer-term use of strategies such as an intermittent overview by a physical therapist to encourage ongoing exercise. Organizations such as the Arthritis Foundation in the USA and Arthritis Care in the UK provide a range of individual and group programs geared toward people with OA. Several evidence-based physical activity programs are available, such as Walk With Ease, Active Living Every Day, People with Arthritis Can Exercise, and EnhanceFitness, among others (see Useful resources).",254,24,0.09448818897637795
9781910797587,chp07,The effects of many non-pharmacological therapies are difficult to discern because of differences in study designs and heterogeneous outcomes.,"The benefits of exercise may be mediated through different routes, including increased strength and endurance, weight reduction, more accurate proprioception and joint position sense, improvement in comorbidities and reduction in anxiety or depression. Numerous studies have examined the benefits of exercise for OA of the knee and a few studies have assessed the benefits of exercise for OA of the hip. On balance, these studies show that therapeutic exercise brings about a moderate reduction in pain and some improvement in function, although the nature of the exercise differs between studies. It appears that benefits arise from individual programs and group classes and from exercises performed at home. Not surprisingly, the benefits of exercise may not be sustained for more than a few months if the exercises are not continued; it is therefore important to consider not only patient adherence but also the longer-term use of strategies such as an intermittent overview by a physical therapist to encourage ongoing exercise. Organizations such as the Arthritis Foundation in the USA and Arthritis Care in the UK provide a range of individual and group programs geared toward people with OA. Several evidence-based physical activity programs are available, such as Walk With Ease, Active Living Every Day, People with Arthritis Can Exercise, and EnhanceFitness, among others (see Useful resources).",254,25,0.0984251968503937
9781910797587,chp07,Muscle strengthening if weak and then aerobic exercises are the key to good management.,"One simple exercise for quadriceps strengthening is demonstrated in Figure 7.1. The patient lies on a flat surface and bends up the non-exercising leg (to take some strain off the lower back and hips). The knee to be exercised is extended fully and pushed down toward the bed or supporting surface. The patient can be asked to pull their toes back at the same time, which adds a hamstring stretch to this exercise. With the knee fully extended the patient then lifts the leg for a count of 10-20 seconds. Multiple repetitions on both sides are encouraged. However, not uncommonly, a patient may not be able to do this straight-leg raise off the bed, in which case it may be useful to start with an 'inner-range' quadriceps exercise using a rolled-up towel placed directly under the affected knee. Pushing down with the knee to fully extend it into the towel and simultaneously lifting the heel off the bed provides an easier way of doing the straight-leg raise exercise.",206,16,0.07766990291262135
9781910797587,chp08,Optimal timing of analgesia should be considered in relation to when the patient has most symptoms and the likely duration of effect of the pharmacological intervention.,"This chapter provides an overview of the pharmacological therapies introduced in Chapter 6 (see Table 6.1) and their potential side effects. As mentioned previously, these therapies are aimed at managing the pain of osteoarthritis (OA). It is worth considering the optimal timing of analgesia - that is, when the patient has most symptoms (see pages 87 -). For example, small joint OA (distal and proximal interphalangeal) is often painful for months while clinical deformity is first developing, after which the joint may be stiff but less painful. Furthermore, the management of any chronic musculoskeletal pain should include consideration of comorbid medical conditions and prompt evaluation, and occasionally pharmacological management, of associated sleep and mood disorders.",154,30,0.19480519480519481
9781910797587,chp08,"Paracetamol (acetaminophen), topical non-steroidal anti-inflammatory drugs (NSAIDs) and capsaicin are well-tolerated early pharmacological interventions in osteoarthritis (OA).","Paracetamol (acetaminophen) is generally well-tolerated and has long been considered a first-line analgesic for OA. However, recent studies have called into question the true benefit of paracetamol in OA. The site of action of the drug, which has some weak anti-inflammatory action, seems to be in the central nervous system (CNS). Safety concerns have resulted in the recommended dose being reduced to 3 g/day or less; many people do not take adequate regular doses, probably because they are concerned about the number of tablets required. Paracetamol can be used in combination with oral agents such as non-steroidal anti-inflammatory drugs (NSAIDs) or in formulations with mild opioids. Side effects. Paracetamol is metabolized by the liver and can accumulate in patients with chronic liver disease. The major concern lies in overdose, which can lead to acute hepatic toxicity that may be enhanced by alcohol. Despite its relative safety, recent data suggest that higher-dose paracetamol (more than 3 g/day) may still lead to upper gastrointestinal side effects, including bleeding, and may negatively affect renal function and blood pressure with daily use.",246,44,0.17886178861788618
9781910797587,chp08,"Traditional NSAIDs and cyclooxygenase (COX)-2 inhibitors are effective but have a range of important side effects that must be taken into consideration, including gastrointestinal and cardiovascular risks.","How should NSAIDs and COX-2 inhibitors be prescribed? It is difficult to be didactic, as prescribers must evaluate individual patient risk factors, especially the balance of GI and CV risks, and also relevant national guidelines. It is important to remember that older patients with significant comorbidities, who use multiple medications, will often use these drugs. In general, extra caution should be exercised when using these drugs in elderly patients, as there are higher incidences of important side effects, including confusion. Certainly, patients should be fully informed of the potential risks associated with these agents. Table 8.2 provides a summary of prescribing advice with respect to GI and CV risk. A safe rule is to use the lowest possible dose of drug for the shortest period of time. In the USA, certain insurers/reimbursers require evidence of prior use of the less expensive non-selective NSAIDs before providing prescription coverage for the COX-2-selective NSAIDs. In the UK, the National Institute for Health and Care Excellence (NICE) has recommended the routine addition of a proton pump inhibitor (PPI) to either a traditional NSAID or COX-2 inhibitor to reduce the risk of GI side effects. However, such recommendations were made on the basis of cost-effectiveness for generic, not brand-name, PPIs.",275,38,0.13818181818181818
9781910797587,chp08,Care should be taken with the use of opioids for chronic OA pain.,"How should opioids be prescribed? As with all analgesic therapies, it is sensible to start with a low dose and increase as dictated by analgesic efficacy and side effects. Opioids are recommended in all modern evidence-based OA guidelines. However, guidance varies by country; because of increases in overdose and other adverse events, in the USA, the Centers for Disease Control and Prevention recently recommended that opioids should not be used as first-line pharmacological therapy for chronic pain. Opioids are only appropriate for carefully selected patients with moderate-to-severe chronic non-cancer pain with impaired physical functioning and quality of life who have not responded to non-pharmacotherapies and non-opioid analgesics.",146,15,0.10273972602739725
9781910797587,chp09,Injections should always be used in conjunction with muscle-strengthening exercises to take full advantage of the steroid-induced reduction in pain.,"As most readers will be aware, there are a number of different corticosteroid preparations but experts have not reached consensus on what dose or which particular agent should be used for a given OA joint. Methylprednisolone and triamcinolone are commonly used, the latter being a more potent steroid, although few data exist on whether this provides any clinically significant differences in outcome. In general, a greater dose of drug is given into a large joint (exempli gratia methylprednisolone, 80 mg for the knee versus 10 mg in the base of the thumb).",121,29,0.2396694214876033
9781910797587,chp09,Corticosteroid joint injections provide moderate short-term pain relief in a number of joints.,"Platelet-rich plasma (PRP) injections for hip and knee OA have increased in popularity over the last few years. PRP is an autologous blood product with concentrated platelets that contains various growth factors and cytokines. A recent review including 15 randomized controlled trials found that these injections appear to be safe, and may provide some short-term symptomatic benefit. However, the trials were all of low to moderate quality, used a variety of different protocols and preparations of PRP, and did not assess structural benefit or harms or longer-term outcomes. To date, given the lack of high-quality evidence to support its use, PRP is not recommended in any clinical guideline.",141,20,0.14184397163120568
9781910797587,chp10,"Appropriate education, advice and rehabilitation should be provided, both preoperatively and postoperatively, for people undergoing surgery.","Patient selection. The decision to consider surgical intervention should be made after conservative treatment approaches - adequate analgesia, muscle strengthening and weight loss if appropriate - have been exhausted. There is little evidence on which to base the selection of suitable candidates for surgery, and ultimately the decision for surgical referral should be made by the patient in conjunction with a relevant musculoskeletal specialist who will provide information on the benefits and risks of the particular surgical intervention. Each case must be assessed individually, and should include an analysis of the patient's.",106,26,0.24528301886792453
9781910797587,chp10,Surgery should be considered only when appropriate non-surgical treatment approaches have been exhausted.,"The decision to consider surgical intervention should be made after conservative treatment approaches - adequate analgesia, muscle strengthening and weight loss if appropriate - have been exhausted. There is little evidence on which to base the selection of suitable candidates for surgery, and ultimately the decision for surgical referral should be made by the patient in conjunction with a relevant musculoskeletal specialist who will provide information on the benefits and risks of the particular surgical intervention.",85,18,0.21176470588235294
9781910797587,chp10,Hip and knee replacement surgery is well established and may be one of the most effective therapies for these joints.,"Joint replacement is arguably one of the most effective therapies for OA of the knee or hip, although the evidence for this benefit is drawn mostly from observational studies. The indications for joint replacement usually include moderate-to-severe pain that is unresponsive to non-surgical measures and radiographic evidence of severe OA structural damage. With modern techniques, 90% or more of hip and knee replacements function 10-20 years after surgery (risk of revision surgery of 1% per year), and approximately 90% of patients will get a good reduction in pain after joint replacement.",115,22,0.19130434782608696
9781910797587,chp10,Other surgical techniques include joint preservation and joint fusion but currently are not widely adopted in the setting of severe hip or knee osteoarthritis.,"Femoral head resurfacing involves replacement of the surface of the femoral head without removal of the neck of the femur. The potential advantages over total hip replacement include femoral bone preservation and a potentially lower incidence of hip dislocation, although disadvantages include possible femoral neck fracture and high revision rates. This procedure is generally used in younger people, but anatomic factors of the hip joint are also relevant in selection of appropriate candidates. Modern femoral head resurfacing implants involving a metal-on-metal articulation have led to poor results in a significant number of patients. Although this procedure is still being performed, the incidence of resurfacing arthroplasty of the hip has fallen to a small percentage of what it was just 10 years ago.",150,28,0.18666666666666668
9781910797617,chp1,"Acute myeloid leukemia (AML) is a relatively rare cancer. It is due to proliferation of immature myeloid cells, which interfere with the production of normal red blood cells, white blood cells and platelets. Patients typically require transfusion support and are at risk for potentially fatal infection. AML is uniformly fatal without treatment.","Acute myeloid leukemia (AML) is a hematologic malignancy that affects the blood and bone marrow. The build up of abnormal white blood cells interferes with the production of red blood cells, platelets and white blood cells, and indirectly leads to leukemic complications of infection, fatigue and hemorrhage. Complications also arise directly from the proliferation and accumulation of immature leukemia cells, which can affect blood flow or infiltrate other organs. The pathogenesis is described in more detail on page 9. Incidence data specific for AML worldwide are limited, as AML is usually included within the broader category of leukemia in epidemiology registries such as GLOBOCAN. The incidence of AML in the USA is 4.2 per 100 000 per year, with an estimated 21 380 new cases in 2017. AML accounts for about 1.3% of all new cancer cases and 31% of all new leukemia cases. In the UK in 2014, there were 3072 new cases of AML (fewer than 1% of all new cancer cases); there the incidence has risen by 28% since the early 1990s. Annual incidence rates differ little between large datasets from the USA (Surveillance, Epidemiology, and End Results), the UK (Cancer Research UK), and Sweden (Swedish Acute Leukemia Registry). Data from developing countries are sparse. AML is rare compared with other cancers, but is the most common acute leukemia in adults.",301,69,0.2292358803986711
9781910797617,chp1,"AML is the most common acute leukemia in older adults, with median age at diagnosis of 67-69 years.","Incidence data specific for AML worldwide are limited, as AML is usually included within the broader category of leukemia in epidemiology registries such as GLOBOCAN. The incidence of AML in the USA is 4.2 per 100 000 per year, with an estimated 21 380 new cases in 2017. AML accounts for about 1.3% of all new cancer cases and 31% of all new leukemia cases. In the UK in 2014, there were 3072 new cases of AML (fewer than 1% of all new cancer cases); there the incidence has risen by 28% since the early 1990s. Annual incidence rates differ little between large datasets from the USA (Surveillance, Epidemiology, and End Results), the UK (Cancer Research UK), and Sweden (Swedish Acute Leukemia Registry). Data from developing countries are sparse. AML is rare compared with other cancers, but is the most common acute leukemia in adults.",196,23,0.11734693877551021
9781910797617,chp1,Long-term survival of patients with AML is poor: about a quarter of patients survive 5 years but only 10% of older patients.,"Survival. AML is universally fatal if untreated. Even with treatment, patients seldom survive long term: according to US registry data, only 27% of patients survive 5 years from diagnosis. Survival is particularly poor in older patients, with fewer than 10% surviving 5 years. This is attributed to a marked increase in intrinsic chemoresistance with age and a greater number of comorbidities that compromise tolerance to chemotherapy. Some older patients do not receive treatment for AML because of these concerns, although data from the Swedish Acute Leukemia Registry demonstrate that this population benefits from treatment instead of purely palliative care., Figure 1.2 shows overall survival estimates by age group for patients in the Swedish registry.",142,28,0.19718309859154928
9781910797617,chp1,Our understanding of the genetic basis for AML is improving. A small number of mutations are seen in the typical AML patient; the mutation profile of an individual patient may change over time.,"Advances in genetics have dramatically improved our understanding of the pathophysiology of AML. Although in-depth understanding of the relationship between a specific genetic mutation and a specific pathophysiological or clinical feature is clear in only a few cases, this is slowly changing. One such example is the association of the PML-RARA fusion gene with acute promyelocytic leukemia (APL), which is a subtype of AML (see Tables 2.2 and 2.3). The PML-RARA fusion gene is typically detected as a chromosomal rearrangement: t(15;17)(q22;q21). Patients with APL have a high risk for fatal hemorrhage due to disseminated intravascular coagulation (DIC), the consequence of a halt in myeloid differentiation that is mediated by the PML-RARA fusion gene. The PML-RARA fusion gene encodes a chimeric protein that disrupts various cellular processes, including nuclear body formation and apoptosis, adversely affecting normal myeloid development. In normal cells, RARA encodes a member of the nuclear hormone receptor family of transcription factors; PML is important in controlling proliferation and apoptosis, among other processes. The PML-RARA fusion protein suppresses gene transcription and blocks differentiation beyond the promyelocyte stage, resulting in the accumulation of malignant promyelocytes seen in APL. Degranulation of promyelocytes contributes to the development of DIC in patients with APL, putting them at risk for hemorrhage. The complex role of the PML-RARA fusion protein in modulating cellular functions is largely, and remarkably, understood. Treatment of APL is unique and ultimately capitalizes on these unique pathophysiological findings (though clinical advances preceded genetic understanding in this case; see pages 49-50 for the treatment of APL).",385,38,0.0987012987012987
9781910797617,chp1,Inherited risk is uncommon but is likely to be more frequent than is currently understood.,"Patients with APL have a high risk for fatal hemorrhage due to disseminated intravascular coagulation (DIC), the consequence of a halt in myeloid differentiation that is mediated by the PML-RARA fusion gene. The PML-RARA fusion gene encodes a chimeric protein that disrupts various cellular processes, including nuclear body formation and apoptosis, adversely affecting normal myeloid development. In normal cells, RARA encodes a member of the nuclear hormone receptor family of transcription factors; PML is important in controlling proliferation and apoptosis, among other processes. The PML-RARA fusion protein suppresses gene transcription and blocks differentiation beyond the promyelocyte stage, resulting in the accumulation of malignant promyelocytes seen in APL. Degranulation of promyelocytes contributes to the development of DIC in patients with APL, putting them at risk for hemorrhage. The complex role of the PML-RARA fusion protein in modulating cellular functions is largely, and remarkably, understood. Treatment of APL is unique and ultimately capitalizes on these unique pathophysiological findings (though clinical advances preceded genetic understanding in this case; see pages 49-50 for the treatment of APL).",255,18,0.07058823529411765
9781910797617,chp1,"Most cases of AML are idiopathic; however, prior exposure to topoisomerase II inhibitors and alkylating agents increases the risk of AML.","Most cases of AML are idiopathic, arising in previously healthy individuals with no (or unknown) genetic predisposition. Advancing age is the main risk factor for AML, as noted above and described by TCGA, but a number of other risk factors contribute to the development of AML in some patients. These include familial risk, environmental exposure to chemicals, drugs or ionizing radiation, and antecedent hematologic disorders such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN). Familial risk. Although most cases of AML are not familial, it is now clear that myeloid neoplasms with germline predisposition (exempli gratia an inherited risk) are more frequent than has been recognized previously. Myeloid neoplasms with germline predisposition - that is, AML and related disorders that arise in the setting of an inherited genetic mutation which puts the patient at increased risk for developing the disease - are an important component of the forthcoming revision to the World Health Organization classification of AML (see Table 2.3). Germline mutations associated with an increased risk of developing a myeloid neoplasm occur in the CEBPA, DDX41, RUNX1, ANKRD26, ETV6 and GATA2 genes, among others.",283,35,0.12367491166077739
9781910797617,chp2,"Patients with acute myeloid leukemia (AML) typically present with vague symptoms resulting from pancytopenia. Fatigue, anorexia, weight loss and vague bone pain in the back or pelvis are common. Fever, infection or abnormal hemostasis may be the presenting symptom in some patients.","Symptoms. Patients with acute myeloid leukemia (AML) usually present with vague symptoms that are consequences of pancytopenia. Typically, the onset of symptoms is no more than 3 months before diagnosis. Fatigue is a common first symptom (Table 2.1), often accompanied by anorexia and weight loss. Fever or infection is the initial symptom in approximately 10% of patients, and 5% have signs of abnormal hemostasis (beyond minor bleeding and easy bruising). Bone pain, lymphadenopathy, non-specific cough, headache and diaphoresis (excessive sweating) may also occur. Bone pain, typically vaguely localized to the pelvis or back, is also a frequent symptom. Rarely, patients present with symptoms due to extramedullary leukemia (id est outside the blood and marrow), such as myeloid sarcoma (a tumor mass consisting of myeloid blasts); AML may infiltrate skin, lymph nodes, the gastrointestinal tract, soft tissue or testes. Patients who present with isolated myeloid sarcoma typically develop blood and/or marrow involvement quickly thereafter. Central nervous system (CNS) involvement is uncommon in AML (approximately 5% of cases, in contrast to acute lymphoblastic leukemia where CNS involvement is common).",264,64,0.24242424242424243
9781910797617,chp2,"Typical hematologic findings include normochromic, normocytic anemia, elevated white blood cell count and mild thrombocytopenia; the presence of Auer rods on light microscopy distinguishes acute myeloid from lymphoblastic leukemia.","On peripheral blood smears, the cytoplasm of the myeloid blast often contains primary (non-specific) granules, and the nucleus shows fine, lacy chromatin, with one or more nucleoli characteristic of immature cells. The presence of abnormal rod-shaped granules called Auer rods (Figure 2.1) on light microscopy of a blood smear or bone aspirate indicates a diagnosis of AML. Additionally, the morphology in some AML subsets is distinctly different and strongly suggests diagnosis of a particular subtype; however, this will need to be confirmed by a combination of additional diagnostic tests, such as cytochemistry, immunophenotyping, karyotype and molecular methods. For example, the myeloblasts in APL are classically hypergranular with clusters of Auer rods (called faggot cells) with a bi-lobed or reniform nucleus. While these features strongly suggest a diagnosis of APL, the final diagnosis will require demonstration of the appropriate molecular abnormality by either karyotyping or other molecular methods.",220,54,0.24545454545454545
9781910797617,chp2,"Cytogenetic and genetic tests are key aspects of the diagnostic work-up, required to aid rapid diagnosis, assess prognosis and inform treatment. Current genetic testing should include at least FLT3 (with allelic ratio), NPM1, CEBPA (bi-allelic), IDH1, IDH2 and TP53.","Once a diagnosis of AML is suspected, cytogenetic and genetic tests are required to aid rapid diagnosis, assess prognosis and to inform the best approach to treatment. Initial assessments should evaluate the functional integrity of the cardiovascular, pulmonary, hepatic and renal systems, and patients should also be evaluated for infection and DIC. Preparation for transfusion of blood or platelets requires blood type and crossmatch to be determined, and human leukocyte antigen (HLA) testing is required early in the treatment course (before chemotherapy) in consideration of future allogeneic hematopoietic cell transplantation. Cytogenetics has been a part of AML diagnosis for several decades, and typically requires bone marrow for successful testing (the increased number of proliferating cells in marrow yields better results than blood for karyotype analysis). Genetic testing (from blood or marrow) continues to evolve in both complexity and number of tests, and should include at least FLT3 (with allelic ratio), NPM1, CEBPA (bi-allelic), IDH1, IDH2 and TP53. Note that the European LeukemiaNet (ELN) recommendations do not include IDH1 and IDH2 (although this might be expected to change given the advent of treatments targeted at the encoded proteins); the World Health Organization (WHO) classification also recognizes RUNX1 - and ASXL1 -mutated AML as distinct entities.",295,70,0.23728813559322035
9781910797617,chp2,"The diagnosis of AML is based on a finding of 20% or more myeloblasts although this is not a requirement in the presence of t(15;17), t(8;21), inv(16) or t(16;16) cytogenetic abnormalities.","Histology. The diagnosis of AML is based on a finding of 20% or more myeloid blasts by histology, cytochemistry or (more commonly) flow cytometry. However, this criterion is not required for diagnosis if any of the following recurrent cytogenetic abnormalities is present: t(15;17), t(8;21), inv(16) or t(16;16). Historically, the diagnosis and classification of AML was based on the French-American-British (FAB) criteria, which assigned patients to one of eight groups, designated M0-M7, based on morphologic and cytochemical features (Table 2.2). Essentially, M0-M5 describe stages of myeloid maturation; M6 and M7 describe erythroid leukemia and megakaryocytic leukemia, respectively. The FAB classification has been superseded by the WHO classification (Table 2.3) and the ELN risk stratification (Table 2.4), which include highly relevant cytogenetic and genetic aberrations. However, morphologic description using the FAB terminology is still a common feature of clinical discussion among clinicians and with patients.",242,57,0.23553719008264462
9781910797617,chp2,"The French-American-British morphologic classification of AML has been superseded by the World Health Organization classification and European LeukemiaNet stratification, which provide prognostic categories of 'favorable', 'intermediate' and 'adverse risk' based on cytogenetic and genetic findings.","Historically, the diagnosis and classification of AML was based on the French-American-British (FAB) criteria, which assigned patients to one of eight groups, designated M0-M7, based on morphologic and cytochemical features (Table 2.2). Essentially, M0-M5 describe stages of myeloid maturation; M6 and M7 describe erythroid leukemia and megakaryocytic leukemia, respectively. The FAB classification has been superseded by the WHO classification (Table 2.3) and the ELN risk stratification (Table 2.4), which include highly relevant cytogenetic and genetic aberrations. However, morphologic description using the FAB terminology is still a common feature of clinical discussion among clinicians and with patients. Cytogenetic analysis of leukemic cells provides important independent prognostic information and is a feature of both the WHO and ELN systems. The prognostic categories using cytogenetics are 'favorable', 'intermediate' and 'adverse' risk, based on the presence of structural and/or numeric chromosomal abnormalities. Patients with t(15;17), for example, have an excellent prognosis ( around 85% cured), and those with t(8;21) or inv(16) (inversion of chromosome 16) also have a favorable prognosis ( around 55% cured), at least when treated appropriately (see 'Treatment' chapter). Patients with no cytogenetic abnormalities (cytogenetically normal AML; CN-AML) have an intermediate risk ( around 40% cured). Patients with a complex karyotype such as t(6;9), inv(3) or -7 (absence of chromosome 7) have an adverse prognosis, with few cures, particularly for older patients.",370,59,0.15945945945945947
9781910797617,chp3,"Historically, treatment of acute myeloid leukemia (AML) adopted a 'one way fits all' approach, using induction chemotherapy to kill large numbers of leukemic cells. In individualized consolidation therapy, the same effect is achieved with either repeated intensive non-myeloablative chemotherapy or, for eligible patients, allogeneic or autologous hematopoietic cell transplantation.","Until relatively recently, a 'one way fits all' approach was used in the treatment of acute myeloid leukemia (AML). This chapter provides an overview of this standard therapeutic approach and illustrates the complexity of treatment decisions in weighing benefit versus risk in patients with different risk status. It also discusses novel approaches, including new targeted therapies that are emerging as our understanding of the genetic pathology of AML improves and the heterogeneity of the disease is recognized. Outcomes remain poor, highlighting the reality for AML patients that, when feasible, treatment on clinical trials remains the best option. The unique treatment of acute promyelocytic leukemia (APL) is considered separately at the end of this chapter. Standard treatment. The standard treatment course for patients with newly diagnosed AML is. induction chemotherapy to remove the majority of malignant cells and restore normal hematopoiesis, followed, once remission is achieved, by. consolidation therapy with either high-dose non-myeloablative chemotherapy or allogeneic hematopoietic cell transplantation (alloHCT) to effectively eliminate residual disease. Standard induction chemotherapy. The regimen for standard induction chemotherapy was established from a series of studies conducted by the Cancer and Leukemia Group B in the 1970s and 1980s. It consists of daunorubicin for 3 days and cytosine arabinoside (cytarabine; AraC), 100-200 mg/m per day, administered as a continuous infusion for 7 days, commonly known as the 3 + 7 schedule. It is recognized today that previously used doses of daunorubicin 45 mg/m /day were suboptimal; a dose intensity of daunorubicin 60-90 mg/m is now the norm.",363,82,0.22589531680440772
9781910797617,chp3,"Midostaurin inhibits several tyrosine kinases, including FLT3, which is constitutively activated in about 30% of patients with AML, usually because of an internal tandem duplication ( FLT3 -ITD). It is indicated for use in combination with standard induction chemotherapy for the first-line treatment of adults with FLT3 -ITD.","Midostaurin is an oral multiple tyrosine kinase inhibitor (TKI) that mainly inhibits FLT3 but also PDGFR, KIT and other tyrosine kinases. Midostaurin was approved by the US Food and Drug Administration (FDA) in April 2017 for use in combination with standard intensive chemotherapy in the first-line treatment of adults with FLT3 -mutated AML; the US label specifies use of the LeukoStrat CDx FLT3 Mutation Assay to detect the FLT3 mutation. Early clinical trials with midostaurin as monotherapy showed only modest clinical benefit, but this was considered worthy of future research given the poor prognosis of patients with FLT3 -mutated AML. Laboratory studies of midostaurin in combination with chemotherapy demonstrated a synergistic effect, and clinical studies demonstrated that the combination was safe and promising. The RATIFY trial was an international, randomized, placebo-controlled trial of midostaurin, 50 mg twice daily for 2 weeks, starting after completion of chemotherapy, in adults (aged 18-60 years) with newly diagnosed AML. Chemotherapy was daunorubicin (60 g/m) and AraC in a standard 3 + 7 schedule. A total of 717 patients were randomized, 77% of whom had a FLT3 internal tandem duplication (FLT3 -ITD); patients with a FLT3 tyrosine kinase domain (FLT3 -TKD) were also eligible. Overall survival (OS) was longer in the midostaurin-treated patients (hazard ratio [HR] 0.78, p = 0.009), as was event-free survival (HR 0.78, p = 0.002) (Figure 3.1). Notably, these survival data held up after censoring for transplant, and the benefit of midostaurin was seen across all FLT3 mutation groups (ITD allelic ratio high or low, and FLT3 -TKD mutation).",422,75,0.17772511848341233
9781910797617,chp3,"The anti-CD33 monoclonal antibody-drug conjugate gemtuzumab ozogamicin has been approved for first-line treatment of AML, following modifications to the dosage and schedule in order to address the safety concerns that arose following its initial approval. It is also approved for relapsed AML (including in pediatric patients); both indications are with a reduced fractionated dose schedule.","Midostaurin is an oral multiple tyrosine kinase inhibitor (TKI) that mainly inhibits FLT3 but also PDGFR, KIT and other tyrosine kinases. Midostaurin was approved by the US Food and Drug Administration (FDA) in April 2017 for use in combination with standard intensive chemotherapy in the first-line treatment of adults with FLT3 -mutated AML; the US label specifies use of the LeukoStrat CDx FLT3 Mutation Assay to detect the FLT3 mutation. Early clinical trials with midostaurin as monotherapy showed only modest clinical benefit, but this was considered worthy of future research given the poor prognosis of patients with FLT3 -mutated AML. Laboratory studies of midostaurin in combination with chemotherapy demonstrated a synergistic effect, and clinical studies demonstrated that the combination was safe and promising. The RATIFY trial was an international, randomized, placebo-controlled trial of midostaurin, 50 mg twice daily for 2 weeks, starting after completion of chemotherapy, in adults (aged 18-60 years) with newly diagnosed AML. Chemotherapy was daunorubicin (60 g/m) and AraC in a standard 3 + 7 schedule. A total of 717 patients were randomized, 77% of whom had a FLT3 internal tandem duplication (FLT3 -ITD); patients with a FLT3 tyrosine kinase domain (FLT3 -TKD) were also eligible. Overall survival (OS) was longer in the midostaurin-treated patients (hazard ratio [HR] 0.78, p = 0.009), as was event-free survival (HR 0.78, p = 0.002) (Figure 3.1). Notably, these survival data held up after censoring for transplant, and the benefit of midostaurin was seen across all FLT3 mutation groups (ITD allelic ratio high or low, and FLT3 -TKD mutation).",422,83,0.1966824644549763
9781910797617,chp3,"Clinical trials focusing on small, genetically similar subsets are becoming the norm; success with molecular targeted therapies approved in 2017 is likely to herald a shift towards a more targeted, individualized approach.","Gemtuzumab ozogamicin (GO) is an antibody-toxin (chalicheamicin) conjugate that targets CD33+ myeloblasts. It was first approved by the FDA in 2000 but was later withdrawn from the market because of safety concerns (particularly hepatotoxicity/veno-occlusive disease). However, clinical trials continued and the safety concerns were overcome. Further studies explored GO at a lower dose and with fractionated administration, alone and in combination with chemotherapy. GO was approved by the FDA in 2017 for use in combination with chemotherapy for the first-line treatment of adults with AML, based primarily on the results of the ALFA-0701 trial, the results of which were published in 2012 and then updated in 2014., In ALFA-0701, low-dose fractionated GO (3 mg/m on days 1, 4 and 7) was administered in combination with daunorubicin (60 mg/m) and AraC given in a typical 3 + 7 schedule. (The previously approved dosage of GO in 2000 was 9 mg/m on days 1 and 14, as monotherapy, or 6 mg/m as a single dose in combination with chemotherapy [SWOG 0106], which proved too toxic.) Long-term follow-up results of the ALFA trial demonstrated a marked event-free survival benefit with GO: 3-year event-free survival was 31%, compared with 19% in the control group (HR 0.66, p = 0.0026), although OS was not significantly improved (3-year OS 44% vs 36%). The treatment effect appears to be seen in patients with more favorable risk. Additional evidence of efficacy with low-dose GO plus chemotherapy had also been observed in mostly younger, favorable-risk patients, as previously reported by the Medical Research Council AML15 study (GO at 3 mg/m given during courses 1 and 3).",395,39,0.09873417721518987
9781910797617,chp3,"Whilst the outlook for younger adults (< 60 years) has gradually improved over recent years, the outlook for older patients remains dismal.","It is important to recognize from the outset that outcomes after remission is achieved (termed DFS) in young adults (< 60 years) have improved steadily over the last three decades: 5-year DFS has improved from 11% to 37%. However, the prognosis for older patients (> 60 years) remains dismal (5-year DFS has improved from 6% to 12%). Consolidation therapy is required once CR is achieved with induction chemotherapy, in order to eliminate all residual disease; disease recurrence is inevitable without this treatment (Table 3.2). For patients who achieve first CR (CR1) following intensive induction chemotherapy, the options for consolidation therapy are.",135,26,0.1925925925925926
9781910797617,chp3,"Treatment is strongly influenced by a patient's cytogenetic/molecular risk profile, and is informed by other factors, such as age, fitness and the response to induction chemotherapy; it is therefore highly individualized.","Decisions about the treatment course for individual patients are strongly influenced by cytogenetic risk, together with additional parameters such as age, comorbidities at diagnosis, white blood cell count at diagnosis, response to induction chemotherapy, and type of consolidation therapy. In the favorable-risk group, alloHCT is generally not considered in view of a TRM of 10-20%, whereas repeated cycles of high-dose non-myeloablative consolidation chemotherapy can achieve long-term DFS rates above 60%, with TRM rates below 5% (at least in younger patients). In the adverse-risk group, the choice would be to proceed with alloHCT in CR1 where possible, given the well-recognized dismal outcome with chemotherapy (Figure 3.2). In the intermediate-risk group, which constitutes 40-50% of patients with AML, the options in CR1 are less clearly defined. This group is heterogeneous in their response to therapy and most have a normal karyotype. New markers and MRD assessment could help identify subsets at high risk of relapse and therefore candidates for HCT. There is no clear indication for autoHCT in CR1, although it may be beneficial for patients who are ineligible for repeated consolidation chemotherapy or alloHCT.",261,45,0.1724137931034483
9781910797617,chp3,All patients with relapsed or refractory disease should be considered for allogeneic hematopoietic cell transplantation.,"Induction chemotherapy fails to induce remission in a proportion of patients. By convention, a patient is stated to have primary refractory AML if hematologic remission has not been achieved despite at least two cycles of induction chemotherapy. The prognosis of these patients remains poor despite salvage chemotherapy and alloHCT. AlloHCT for patients not in remission may be considered for younger, fit patients with primary refractory AML. Intensive salvage chemotherapy and allogeneic hematopoietic cell transplantation. Overall consensus is that patients with relapsed or refractory disease should receive alloHCT as part of consolidation following successful re-induction with salvage chemotherapy. Unfortunately, the proportion of patients with relapsed and refractory disease who achieve CR is less than 50%, and fewer than 30% actually proceed to alloHCT.",174,27,0.15517241379310345
9781910797617,chp3,"Enasidenib inhibits aberrant isocitrate dehydrogenase 2 (IDH2) which catalyzes formation of the oncometabolite 2-hydroxyglutarate. IDH2 mutations occur in approximately 12% of AML patients, particularly in older adults with normal karyotype. Enasidenib is approved for the treatment of relapsed or refractory AML with the IDH2 mutation.","Enasidenib is an oral inhibitor of isocitrate dehydrogenase 2 (IDH2) recently approved by FDA for relapsed or refractory AML with IDH2 mutation. IDH2 is an enzyme that catalyzes the conversion of isocitrate to a -ketoglutarate in the Krebs cycle (Figure 3.3). Mutations in the genes that encode mitochondrial IDH2 (and cytosolic IDH1) ultimately lead to aberrations in the Krebs cycle that result in the production of 2-hydroxyglutarate (2HG), which has been shown to act as a so-called 'oncometabolite'. Increased levels of 2HG result in increased DNA methylation and chromatin modifications that affect gene expression and contribute to oncogenesis in several different cancers, including AML. - In early studies in AML, enasidenib reduced 2HG levels by more than 90% and reversed these aberrant epigenetic changes, resulting in myeloid cell differentiation. - IDH2 mutations occur in approximately 12% of patients with AML, particularly in older adults with a normal karyotype. Enasidenib was evaluated in a Phase I/II first-in-human trial involving 199 patients with relapsed or refractory AML and the IDH2 mutation. The drug, given once daily, was well tolerated, allowing it to be administered largely in the outpatient setting. The FDA press release noted that 19% of patients treated for at least 6 months achieved a CR that lasted a median of 8.2 months. Moreover, patients who did not achieve objective CR also benefited, with reduced transfusion needs and stable disease for a median of 9.6 months. Furthermore, 34 of 157 patients who required blood or platelet transfusions at the start of the study no longer required transfusions after treatment., The overall response rate was 40% (including 19% CR), with a median response duration of 5.8 months and a median OS of 9.3 months. Median OS was 19.7 months in patients who achieved CR. These results supported rapid approval of enasidenib by the FDA, for the treatment of adults with relapsed or refractory IDH2 -mutated AML. Ongoing studies are combining enasidenib with chemotherapy in the first-line treatment of AML.",490,88,0.17959183673469387
9781910797617,chp3,Acute promyelocytic leukemia (APL) therapy has high cure rates but early death rates remain an issue for patients presenting with a high white blood cell count.,"Patients with APL have an excellent prognosis; greater than 85% of patients are cured. With initial therapy, nearly all patients with APL who survive induction go on to achieve remission. However, the frequency of early death is higher in APL than in other AML subtypes due to the risk of fatal hemorrhage, especially in patients presenting with a high leukocyte count (> 10 000/uL). Available treatments for APL include all- trans -retinoic acid (ATRA) with either chemotherapy or arsenic trioxide (ATO). An important component of APL therapy is the use of oral ATRA therapy; ATRA induces differentiation of malignant promyelocytes, thus reducing disseminated intravascular coagulation (DIC) very effectively over 3-4 days. Initiation of ATRA at suspicion of APL based on morphologic and clinical grounds, before molecular or cytogenetic confirmation of the PML-RARA fusion, reduces early fatal hemorrhage in these patients.",207,35,0.16908212560386474
9781910797617,chp4,"The standard treatment of acute myeloid leukaemia (AML) involves repeated cycles of myelotoxic chemotherapy, resulting in prolonged cytopenia that requires intensive supportive care.","Treatment of acute myeloid leukaemia (AML) involves repeated cycles of myelotoxic chemotherapy, resulting in prolonged cytopenia that requires intensive supportive care. Despite significant advances in supportive care over the last few decades, the treatment of AML is still associated with considerable morbidity and mortality, mostly related to infection. In the case of infection-related mortality, the emergence of multidrug resistant (MDR) organisms is a growing concern, particularly in developing economies, although increasingly this is now being recognized as a global phenomenon. The presence of MDR bacteria adds significantly to morbidity and mortality in AML, and also contributes significantly to the cost of supportive care. In addition, proven (and suspected) invasive fungal infections occur in 14-28% of patients following induction chemotherapy, , and are associated with early mortality.",172,38,0.22093023255813954
9781910797617,chp4,"Treatment of AML is still associated with considerable morbidity and mortality, mostly related to infection; this risk is compounded by the emergence of bacteria with multidrug resistance.","Treatment of acute myeloid leukaemia (AML) involves repeated cycles of myelotoxic chemotherapy, resulting in prolonged cytopenia that requires intensive supportive care. Despite significant advances in supportive care over the last few decades, the treatment of AML is still associated with considerable morbidity and mortality, mostly related to infection. In the case of infection-related mortality, the emergence of multidrug resistant (MDR) organisms is a growing concern, particularly in developing economies, although increasingly this is now being recognized as a global phenomenon. The presence of MDR bacteria adds significantly to morbidity and mortality in AML, and also contributes significantly to the cost of supportive care. In addition, proven (and suspected) invasive fungal infections occur in 14-28% of patients following induction chemotherapy, , and are associated with early mortality.",172,35,0.20348837209302326
9781910797617,chp4,Standard practice is for patients to be hospitalized for induction chemotherapy until neutrophil recovery is achieved (3-4 weeks).,"Mandatory hospitalization. During initial induction therapy, it is common practice to admit patients, typically for 3-4 weeks, until neutrophil levels recover, although data to support this approach are limited. In a pediatric population, a retrospective study by the Children's Oncology Group found no evidence that mandatory hospitalization reduced either systemic infections or treatment-related mortality. Similar studies in adults have not been reported, but until more data become available, it seems reasonable to admit patients for at least the first 3-4 weeks of induction chemotherapy, unless easily accessible 24-hour supportive care is available. Limited data suggest that using a high-efficiency particulate-air-filtered facility is beneficial, and although this cannot be considered a standard recommendation, some indirect evidence suggests that this could reduce the rate of fungal infection.",165,24,0.14545454545454545
9781910797617,chp4,"Following chemotherapy, prophylactic antibiotics to prevent infection and reduce mortality rates is a standard recommendation; the choice of antibiotic should be informed by the local antibiogram. Prophylaxis with antifungals with both anti-mold and anticandida activity is beneficial.","Use of granulocyte colony-stimulating factor after chemotherapy. Numerous studies, including meta-analyses, have consistently shown that the administration of G-CSF after completion of chemotherapy reduces the duration of neutropenia (typically 2-3 weeks) by 2-5 days. These studies have also shown that use of G-CSF reduces the duration of hospitalization, duration of fever and antibiotic use, and does not retard platelet recovery., However, none of these beneficial effects has translated into improvements in overall survival. Based on current data, G-CSF is not recommended for all patients; however, its use can be considered in order to accelerate neutrophil recovery in patients with active or persistent infection, and those who are hemodynamically unstable secondary to infection. Prophylactic antibiotics. Prophylactic use of quinolone antibiotics has been shown to reduce infection and mortality rates after chemotherapy., Based on the available evidence, antibiotic prophylaxis after chemotherapy can be considered as standard care, and is a component of most international recommendations. While quinolones are recommended on the basis of the available data, it is reasonable to review the treatment center's antibiogram to inform the choice of antibiotic. Prophylactic antifungal therapy. The overall consensus, based on the available data, is that antifungal prophylaxis with posaconazole following chemotherapy is beneficial, Micafungin is an alternative if azoles are contraindicated. Fungal prophylaxis typically consists of an anti-mold agent (exempli gratia posaconazole, micafungin or amphotericin) and should not be limited to anticandida cover, as would be achieved with fluconazole.",363,57,0.15702479338842976
9781910797617,chp4,"Attention to good hygiene, particularly dental and perianal care, is important.","Granulocyte infusion. There is no evidence to support routine use of granulocyte infusion to reduce treatment-related infection and mortality. General hygiene. Good personal hygiene is important, and particular attention should be paid to dental and perianal care during the post-chemotherapy neutropenic state. While patients are often advised not to eat uncooked food such as salads and fruits (neutropenic diet), there is no evidence to support this.",93,17,0.1827956989247312
9781910797617,chp5,Accurate prognostication is important when considering the risk versus benefit associated with different approaches to treatment.,"Acute myeloid leukemia (AML) is a heterogeneous disorder; the current World Health Organization (WHO) classification (see Table 2.3) classifies the patient's 'risk' according to the molecular pathology (where this is known), which in turn informs the prognosis. Accurate prognostication is important when considering the risk versus benefit associated with different approaches to treatment (chemotherapy, novel targeted therapies, allogeneic hematopoetic cell transplant [alloHCT]), which are associated with different levels of early treatment-related mortality and risk of relapse. Prognostication requires evaluation of the following.",130,21,0.16153846153846155
9781910797617,chp5,The World Health Organization system classifies patients' 'risk' based on molecular pathology.,"Acute myeloid leukemia (AML) is a heterogeneous disorder; the current World Health Organization (WHO) classification (see Table 2.3) classifies the patient's 'risk' according to the molecular pathology (where this is known), which in turn informs the prognosis. Accurate prognostication is important when considering the risk versus benefit associated with different approaches to treatment (chemotherapy, novel targeted therapies, allogeneic hematopoetic cell transplant [alloHCT]), which are associated with different levels of early treatment-related mortality and risk of relapse. Prognostication requires evaluation of the following.",130,17,0.13076923076923078
9781910797617,chp5,"Age is an important and independent adverse risk factor, and older patients (> 60 years) have particularly dismal outcomes with conventional treatment. Age and certain cytogenetic or molecular abnormalities increase the risk of multidrug resistance to chemotherapy.","Multiple studies have established age as an important and independent adverse risk factor; in particular, older patients (> 60 years) have dismal outcomes with conventional treatment. Table 5.1 summarizes data from a retrospective analysis of the combined adverse effects of older age and poor performance status on mortality risk. This and other studies have also identified a positive correlation between increasing age and adverse cytogenetic and molecular markers, and with increased incidence of multidrug resistance to chemotherapy., Performance status and comorbidities should also be considered alongside age when deciding on the intensity of treatment to offer older patients with AML. Comorbidities affect the morbidity and mortality risks of treatments and therefore inform treatment choices. For example, conventional anthracycline-based induction chemotherapy would not be suitable for a patient with a history of ischemic or congestive heart disease. Patients may also develop consequences of AML that influence the treatment strategy, such as severe sepsis.",191,45,0.2356020942408377
9781910797617,chp5,"Understanding of the molecular genetics of acute myeloid leukemia has increased in the last decade, and several mutations, either alone or in combination, have been shown to have a significant bearing on prognosis. European LeukemiaNet includes these genetic abnormalities in its risk stratification.","Cytogenetics and the molecular signature have become the cornerstone of risk stratification in AML., The risk groups based on karyotyping used by the cooperative groups (Cancer and Leukemia Group B, SWOG and the Eastern Cooperative Oncology Group) are illustrated in Table 5.2. Prognostic assignment differs slightly among North American and European groups but the basic premise is shared. Additional parameters such as age, white blood cell count at diagnosis, presence of certain gene mutations and response to induction chemotherapy can influence prognosis, while the type of consolidation therapy could potentially alter the predicted outcomes, as discussed in Chapter 4. The last decade has seen an explosion in our understanding of the molecular genetics of AML, and the recognition that several of these abnormalities (not previously recognized on a conventional karyotype), either alone or in combination, have a significant bearing on prognosis. The numerous genetic abnormalities seen in AML are summarized in the recent European LeukemiaNet (ELN) guidelines. The ELN has recently revised the risk stratification groups for AML on the basis of the genetic abnormalities detected by conventional karyotyping and molecular techniques (see Table 2.4). Many of these mutations are context specific in both their occurrence and impact on clinical outcomes. For example.",260,54,0.2076923076923077
9781910797617,chp5,Molecular markers can be used within the cytogenetically defined risk groups to further refine the prognostic risk and may influence the choice of consolidation therapy.,"Molecular markers can be used within the cytogenetically defined risk groups to further refine the prognostic risk, and may even be useful in deciding the optimal consolidation therapy, as illustrated in the following two scenarios. In the large cohort of patient with cytogenetically normal karyotype, mutation analysis in NPM1 and FLT3 can help distinguish three subsets. NPM1+ / FLT3 -ITD (without adverse-risk genetic lesions) is associated with good prognosis; consolidation with chemotherapy alone may be considered, as for a cytogenetic favorable-risk group (note that the ELN 2017 update includes FLT3 -ITD with a 'low' mutated to wild-type ratio [< 0.5] in this group).",156,31,0.1987179487179487
9781910797617,chp5,The presence of measurable residual disease after induction chemotherapy indicates a high risk of relapse.,"Patients who do not achieve CR after the first cycle of induction chemotherapy are considered to be at high risk for relapse. The presence of MRD after completion of induction and consolidation chemotherapy despite morphological remission has significant prognostic implication. MRD can be measured using multiparameter flow cytometry (MFC; successful in > 90% of cases) or real-time quantitative polymerase chain reaction (RT-qPCR) assays where a molecular lesion has been identified. MFC requires substantial technical expertise, and interpretation is partially subjective so it has been difficult to establish inter-laboratory standardization. RT-qPCR can only be used if a molecular marker has been identified (< 60% of cases) and also has challenges in standardization; more importantly, the oligoclonal nature of AML at diagnosis (see pages 14-15) means that a negative reading must be interpreted with caution. Despite these challenges, several studies have established the role of MRD in the accurate prognosis of outcomes when performed after induction and consolidation therapy and before alloHCT. MRD monitoring is uniquely beneficial for high-risk APL patients in CR1.",237,16,0.06751054852320675
9781910797617,chp6,"A wide range of targeted agencies for the treatment of acute myeloid leukemia (AML) are currently in the late stages of development, including FLT3 inhibitors (crenolanib, quizartinib, giltertinib, sorafenib), hypomethylating agents (guadecitabine, oral azacitidine), the histone deacetylase inhibitor pracinostat, the blc-2 inhibitor venetoclax and the E-selectin inhibitor GM-1271.","The expanded genetic characterization of acute myeloid leukemia (AML) at diagnosis is a critical advance in the last 5 years and is influencing both treatment and patient selection for standard therapy and clinical trials in AML. While the karyotype remains key in prognostication, molecular profiling represents a paradigm shift for both research and the clinical management of AML. Molecular testing is destined to become an essential part of the initial characterization of patients with AML. Drugs in late-stage development. As described in Chapter 3, four new treatments for AML were recently approved, three of which are molecularly targeted products, marking a turning point in the treatment of AML. Several targeted agents are currently in the late stages of clinical development, as described below, and many more approaches are being explored (see Table 6.1). Many of these products in development have been awarded breakthrough status by the US Food and Drug Administration (FDA), recognizing the lack of effective treatments for patients who are not eligible for intensive chemotherapy and hematopoietic cell transplantation (HCT), and those with relapsed or refractory disease, for whom the prognosis is poor. FLT3 inhibitors. In addition to midostaurin, several other FLT3 inhibitors are currently in trials. Crenolanib inhibits FLT3 internal tandem repeat (FLT3 -ITD) and FLT3 tyrosine kinase domain (FLT3 -TKD) mutations in the active conformation but has little activity against cKIT; this is expected to avoid the myelosuppression seen with other FLT3 inhibitors that have been shown to inhibit KIT. The addition of crenolanib to standard 3 + 7 induction therapy in patients with newly diagnosed AML resulted in 88% complete response rate (CR), with no unexpected toxicities. Quizartinib (AC220). A non-randomized Phase II study reported a remission rate of 44% and median overall survival (OS) of 23 weeks in patients with FLT3 -ITD-mutated AML that had relapsed or was refractory to second-line treatment or relapsed following HCT in a non-randomized Phase II study. Quizartinib is being investigated across multiple lines of treatment, including induction and consolidation chemotherapy, as a maintenance therapy for patients in first remission after chemotherapy, and for salvage therapy.",493,110,0.2231237322515213
9781910797617,chp6,"Immunologic therapies, antibody-drug conjugates and antibody-based approaches are also being explored in AML.","Nevertheless, studies of cellular therapies, including CAR-T and natural killer (NK) cells, and antibody products targeting CD123, CD33 and other markers, are of interest. New approaches to treatment include antibody-drug conjugates (ADC) and novel antibody-based approaches using bispecific T-cell engagers (BiTEs) and dual-affinity re-targeting (DART) molecules, which bind to CD3 on T-lymphocytes and CD33 on myeloid blasts, thereby directing activated immune cells to malignant cells. Studies with cellular therapies and other antibody-based therapies are of great interest and promise in AML, including with CAR-T or NK cells, and likewise with antibody products targeting CD123, CD33 or other markers of interest. Included among these are new ADCs and novel antibody-based approaches using BiTEs or DARTs designed to direct activated immune cells to malignant cells (id est dual affinity for CD3 on T-lymphocytes and CD33 on myeloid blasts).",216,24,0.1111111111111111
9781910797617,chp6,"The approval of enasidenib based on single-arm Phase I/II data is challenging the dogma that large randomized controlled trials in a general AML population are required. Trials of new targeted agents are likely to be in small, clearly defined patients with subtypes of AML.","Recent experience with enasidenib, approved on the basis of data from patients specifically with IDH2 mutations, challenges the dogma that large randomized controlled trials showing survival benefit in a general AML population are required for approval. The approval of enasidenib was based on data from a single-arm phase 1/2 monotherapy trial involving only 199 patients; historical data were used for the control. This approval reflects the regulatory agencies' recognition of the challenges of evaluating new treatments in relatively rare subtypes of a disease; similar approvals have been seen across a range of oncology (hematologic and solid tumors) in recent years. Trials of new targeted agents are also likely to be in small, clearly identified patient populations. Beat AML is a new approach to clinical trials, begun in late 2016 and sponsored by the Leukemia and Lymphoma Society. The aim is to quickly and comprehensively genetically characterize older patients (> 60 years) with previously untreated AML and to treat with novel targeted therapy on the basis of the genetic result. Within a week of diagnosis, patients will be assigned to one of nine groups with targetable molecular aberrations (Table 6.2). Each group is treated with unique therapy designed for that molecular aberration. Patients who have more favorable clinical outcomes with conventional chemotherapy (such as those with core binding factor rearrangements or an NPM1 mutation without an FLT3 mutation) are assigned 3 + 7-based treatment in combination with an investigational agent. Patients with poor long-term outcomes and lower remission rates with conventional chemotherapy (such as those with a p53 mutation) receive less intensive therapy. Two examples of treatments in these poor-risk subsets are hypomethylating agent in combination with novel therapy, and monotherapy with an investigational agent followed by lower-intensity treatment (if no response is observed during the monotherapy window). Hopefully, such an approach will quickly identify promising agents and speed up drug approvals in AML. Subsequent iterations of the trial (exempli gratia 'version 2.0' and beyond) will include agents for other targets and possibly combinations of novel drugs.",433,57,0.13163972286374134
9781910797617,chp6,"The Beat AML trial is using early and comprehensive genetic characterization to assign patients to one of nine groups with targetable molecular aberrations, each receiving a tailored treatment. This approach will hopefully speed up the development of promising agents.","Beat AML is a new approach to clinical trials, begun in late 2016 and sponsored by the Leukemia and Lymphoma Society. The aim is to quickly and comprehensively genetically characterize older patients (> 60 years) with previously untreated AML and to treat with novel targeted therapy on the basis of the genetic result. Within a week of diagnosis, patients will be assigned to one of nine groups with targetable molecular aberrations (Table 6.2). Each group is treated with unique therapy designed for that molecular aberration. Patients who have more favorable clinical outcomes with conventional chemotherapy (such as those with core binding factor rearrangements or an NPM1 mutation without an FLT3 mutation) are assigned 3 + 7-based treatment in combination with an investigational agent. Patients with poor long-term outcomes and lower remission rates with conventional chemotherapy (such as those with a p53 mutation) receive less intensive therapy. Two examples of treatments in these poor-risk subsets are hypomethylating agent in combination with novel therapy, and monotherapy with an investigational agent followed by lower-intensity treatment (if no response is observed during the monotherapy window). Hopefully, such an approach will quickly identify promising agents and speed up drug approvals in AML. Subsequent iterations of the trial (exempli gratia 'version 2.0' and beyond) will include agents for other targets and possibly combinations of novel drugs.",287,46,0.1602787456445993
9781910797617,chp6,"Key to all approaches to the treatment of AML is the need to achieve disease control, and continued consideration of allogeneic hematopoietic cell transplantation when feasible.","Beat AML is a new approach to clinical trials, begun in late 2016 and sponsored by the Leukemia and Lymphoma Society. The aim is to quickly and comprehensively genetically characterize older patients (> 60 years) with previously untreated AML and to treat with novel targeted therapy on the basis of the genetic result. Within a week of diagnosis, patients will be assigned to one of nine groups with targetable molecular aberrations (Table 6.2). Each group is treated with unique therapy designed for that molecular aberration. Patients who have more favorable clinical outcomes with conventional chemotherapy (such as those with core binding factor rearrangements or an NPM1 mutation without an FLT3 mutation) are assigned 3 + 7-based treatment in combination with an investigational agent. Patients with poor long-term outcomes and lower remission rates with conventional chemotherapy (such as those with a p53 mutation) receive less intensive therapy. Two examples of treatments in these poor-risk subsets are hypomethylating agent in combination with novel therapy, and monotherapy with an investigational agent followed by lower-intensity treatment (if no response is observed during the monotherapy window). Hopefully, such an approach will quickly identify promising agents and speed up drug approvals in AML. Subsequent iterations of the trial (exempli gratia 'version 2.0' and beyond) will include agents for other targets and possibly combinations of novel drugs. Of critical importance to the Beat AML trial, as well as for trials of treatments, is the need to achieve disease control in order to facilitate the opportunity for alloHCT for eligible patients. Even in the era of molecular targeted treatment, alloHCT remains the best tool available for the prevention of relapse.",351,37,0.10541310541310542
9781910797631,chp1,"Depression has been evident as a problem for individuals and societies since antiquity, but public and professional awareness has markedly increased over the past half-century.","A distinct condition characterized by a dejected mood has been evident in writings since antiquity, with key features alluded to in the Christian Bible (exempli gratia Psalms 32, 38, 143; 1Kings 19, 1-5; Job 17), and a long tradition systematized in the medical writings of Hippocrates and Galen, who theorized about bodily fluids called humors, the imbalance of which was seen as being responsible for disease (Figure 1.1). A tendency toward melancholy was understood to be related to an excess of the humor associated with coldness and dryness - black bile; indeed, the term melancholia is derived from the Greek word for 'black bile'. Grief and fear were regarded as both characteristic features and provoking influences for melancholia, and this concept encompassed both depression and anxiety - which were not considered or classified as separate conditions until the mid-19th century.",185,30,0.16216216216216217
9781910797631,chp1,"Although much progress has been made in clarifying the clinical features and distribution of depression within populations, significant debate remains and there are ongoing difficulties about how to best understand and manage depression, particularly in its milder forms.","A distinct condition characterized by a dejected mood has been evident in writings since antiquity, with key features alluded to in the Christian Bible (exempli gratia Psalms 32, 38, 143; 1Kings 19, 1-5; Job 17), and a long tradition systematized in the medical writings of Hippocrates and Galen, who theorized about bodily fluids called humors, the imbalance of which was seen as being responsible for disease (Figure 1.1). A tendency toward melancholy was understood to be related to an excess of the humor associated with coldness and dryness - black bile; indeed, the term melancholia is derived from the Greek word for 'black bile'. Grief and fear were regarded as both characteristic features and provoking influences for melancholia, and this concept encompassed both depression and anxiety - which were not considered or classified as separate conditions until the mid-19th century.",185,43,0.23243243243243245
9781910797631,chp1,"Improved knowledge about the features, course and management of depression has enabled more prompt recognition, evidence-based treatment decisions and improved outcomes. However, depression is still both under- and over-diagnosed, and therapies are not always targeted appropriately: many depressed people do not receive treatment that could help them whilst prescribing for patients with mild or uncertain symptoms remains evident.","The stigma of mental health. However, there are well-justified contrary concerns too. Even though depression is one of the leading causes of disability worldwide, many people need, but do not receive, treatment. In general, people with depression and other mental health problems face stereotyped views and discrimination. This public stigma in tandem with self-stigma hinders individuals from disclosing their problems, seeking help and, ultimately, recovering. Considerable work has been done over the past two decades to challenge negative stereotypes and help overcome this stigma, with concerted public health campaigns to inform the community about depression, improve understanding of the disorder and encourage people to seek help. Actions have included education via the mass media and social marketing, the involvement of prominent people as opinion leaders, and initiatives to increase personal contact between people with and without mental health problems. Missed diagnoses. There is good evidence that depression is often not recognized by clinicians and that even when it is identified, it is frequently inadequately managed by health services in the USA, UK and other countries. Research indicates that 30-50% of depression cases are missed in primary care, and it appears that recognition problems are amplified by the presence of comorbid medical conditions, which complicate the help-seeking and assessment processes. Classification. At a fundamental level, important questions and uncertainties remain about the best way to understand and classify depression. A central debate about the relative merits of categorical (case or non-case based on a specific pattern of symptoms) or dimensional (based on measures of symptom severity or prior illness course) approaches to classification is particularly relevant to this disorder. A continuity between milder forms of depression and a fully symptomatic disorder appears in community studies that have examined course and correlates for a range of presentations. Depression that does not meet the full criteria for a formal diagnosis is increasingly recognized to cause considerable suffering and places a significant burden on the healthcare system; it is also related to increased mortality and is a risk factor for future major depression.",400,71,0.1775
9781910797631,chp2,"Depression may involve single or recurrent episodes or it may be persistent; it may also be characterized by particular features (psychotic, melancholic) or patterns of onset (seasonal, postnatal).","'Depression', or 'clinical depression', refers to a mood disorder that ranges in severity from mild to severe, in duration from brief to enduring, and in pattern of illness from single to recurrent episodes. Diagnosis is based on the symptom profile and the severity, duration and course of the disorder. It is characterized by low mood and the absence of positive affect (id est loss of interest and enjoyment in everyday activities), together with a range of emotional, cognitive, physical and behavioral features. Clinical depression is a heterogeneous disorder, with some forms having clear biological underpinnings whereas others arise from psychosocial adversity. While classification systems have specified diagnostic criteria, uncertainties remain about the validity of the threshold that differentiates clinical depression from 'normal' unhappiness. Some investigators and commentators have questioned the validity of depression on the basis of variations that are purported to exist in its presentation, prevalence, prognosis and meaning within different cultures. Some commentators identify psychiatric diagnoses such as depression as 'Western' categories that can be imposed on non-Western peoples - a form of medical imperialism.",216,40,0.18518518518518517
9781910797631,chp2,The diagnosis of depression is problematic - primarily in relation to the validity of distinguishing this state from normal human responses to loss and trauma.,"Alongside the lack of clear biological characteristics for depression (as well as for a large number of other psychiatric conditions), there is a problem of where to draw the boundary between normal and pathological depression. The distinction between depression and the distress and angst that are part of normal human experience requires a dichotomization of this continuum of symptoms. Rather than being based on 'hard' criteria related to a clear causal mechanism, with associated biological markers, this differentiation is based on clinical characteristics. Although this is problematic, it is useful to bear in mind that this also applies to other common medical conditions such as diabetes, hypertension and irritable bowel syndrome, where the variation between extensive and disabling symptoms and few and insignificant symptoms are on a continuum.",145,26,0.1793103448275862
9781910797631,chp2,"Depression severity is an important part of its clinical description (informing treatment decisions), and is based on the number of symptoms and their severity and effect on function.","Alongside the lack of clear biological characteristics for depression (as well as for a large number of other psychiatric conditions), there is a problem of where to draw the boundary between normal and pathological depression. The distinction between depression and the distress and angst that are part of normal human experience requires a dichotomization of this continuum of symptoms. Rather than being based on 'hard' criteria related to a clear causal mechanism, with associated biological markers, this differentiation is based on clinical characteristics. Although this is problematic, it is useful to bear in mind that this also applies to other common medical conditions such as diabetes, hypertension and irritable bowel syndrome, where the variation between extensive and disabling symptoms and few and insignificant symptoms are on a continuum.",145,33,0.22758620689655173
9781910797631,chp2,Depression occurs at a range of severities and may often be experienced in combination with other mental disorders such as anxiety; this can be an additional source of difficulty in diagnosis.,"Delineating depression from other mental disorders. In the community, as well as in primary care settings, the most prevalent mood disorder is a combination of depression and anxiety. The overlap between symptoms such as low mood, lack of energy, insomnia, worry and irritability is considerable; for example, in 2014, nearly 8% of the UK household population demonstrated this combination of symptoms to a clinically significant extent, although smaller proportions have sufficient symptoms to be diagnosed with depression or anxiety disorders. Among people who meet the diagnostic thresholds for depression or anxiety disorders there is also a high degree of concurrence of these conditions, raising questions about the specificity of these diagnostic categories. While there is no distinct etiology for depression - it is best conceptualized as having a mix of biopsychosocial and lifestyle factors that contribute to its onset - a common genetic factor for anxiety and depressive conditions is apparent, and similarities in the types of environmental adversities that seem to provoke depression and anxiety, such as childhood adversity, have been reported. Moreover, the pharmacological treatments principally classified as antidepressants are also effective in anxiety disorders, and similar types of individual, group and internet-based psychological treatments appear to be effective for both conditions.",241,35,0.14522821576763487
9781910797631,chp2,Widely used diagnostic criteria enable agreement about the types of symptoms and the level of severity and persistence that comprise depressive disorder.,"The cluster of symptoms experienced in depression is central to its classification as a mental health disorder. The number, intensity and effects of these symptoms are central to differentiating depression from normal experiences and from other disorders. There is a consensus concerning the symptoms of depression. The two most widely used diagnostic systems are the World Health Organization's International Classification of Diseases and Related Health Problems, currently in its tenth revision (ICD-10), and the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, currently in its fifth edition (DSM-5). The criteria used by these classification systems are broadly similar, although the symptom thresholds differ. The DSM-5 criteria are used as the basis for clinical descriptions of depression and the related disorders considered in this book, as the majority of research and the most recent clinical guidelines that inform knowledge about depression and its management use the DSM criteria.",175,24,0.13714285714285715
9781910797631,chp2,"The diagnosis of depression involves the presence of at least one core symptom together with other associated symptoms that are experienced most of the day, for most days, for a period of at least 2 weeks.","The cardinal features of low mood and diminished interest are central to the condition; at least one of these has to be present for a diagnosis to be made. A minimum number of additional depressive symptoms must also be present, such that at least five of the group of nine symptoms are present in total (Table 2.1). Major depression needs to be distinguished from normal bereavement where similar symptoms may occur; however, a major depressive episode in addition to the normal response to a significant loss may be considered. A diagnosis of depression is excluded if the symptoms are judged to be due to the direct physiological effects of a medical illness or prescribed or illicit medications. Single episode or recurrent. A generation ago, standard psychiatry texts typically considered depression as an acute illness best managed by specialist treatment. The findings of longitudinal observational studies have increasingly revealed the variability of illness course and show that, for many people, depression has a lifelong episodic course, characterized by relapses. There is consistent evidence from population-based studies (as well as primary and specialist care samples) that around 50% of people who have an initial depressive episode will have further episodes.",225,39,0.17333333333333334
9781910797631,chp3,"Depression is related to a range of biological, sociocultural and psychological factors, and although there are strong links between adversity and its onset, these factors are not necessarily predictive of depression for individuals.","Depression, like practically all health states and indicators, is inversely related to socioeconomic position. Cross-national comparisons of data from the Americas and Europe indicate that poverty, unemployment and low educational attainment are associated with a near doubling of risk for common mental disorders when the lowest and highest socioeconomic categories are compared. Socioeconomic adversity appears to predict the persistence of depression, with community epidemiology studies and examinations of depression management in primary care identifying this risk association. A systematic review and meta-analysis incorporating 60 prevalence, incidence and persistence studies revealed compelling evidence for the relationship between socioeconomic inequality and depression, although constituent variables such as education, occupation, employment and income exerted differing influences. Whilst low socioeconomic status plays a causal role in depression development and persistence, it also appears that the experience of depression may lead to social and economic adversity.",164,41,0.25
9781910797631,chp3,"At least half of all people affected by depression experience more than a single episode, and the risk of recurrence increases with each successive episode.","Relapse, recovery and recurrence. At least half of all people affected by depression experience more than one episode. Relapse is defined as an episode of depression that occurs within 6 months of response to treatment or remission; recurrence is defined as another depressive episode that occurs after 6 months have elapsed. Recovery from depression is usually understood to be a period of full remission lasting at least 8 weeks. A pattern of repeated episodes - including recurrence or relapse - may be the commonest expression of depressive disorder. Several studies indicate that depression recurrence may be a typical feature: the NCS-R found that for more than 90% of people identified with depression, this was a recurrence rather than an initial episode. The length of time between episodes appears to be variable: once a first episode has occurred, recurrent episodes will usually begin within 5 years of the initial episode, and around 35% of people experience a further episode within 2 years of their first episode. On average, individuals with a history of depression will have five to nine separate depressive episodes in their lifetime. Risk factors for recurrence are listed in Table 3.2.",227,28,0.12334801762114538
9781910797631,chp3,"Depression is a common mental disorder, affecting around 5% of the population over a 12-month period, with 10-15% of people likely to experience depression over the course of their lifetime.","Several studies indicate that depression recurrence may be a typical feature: the NCS-R found that for more than 90% of people identified with depression, this was a recurrence rather than an initial episode. The length of time between episodes appears to be variable: once a first episode has occurred, recurrent episodes will usually begin within 5 years of the initial episode, and around 35% of people experience a further episode within 2 years of their first episode. On average, individuals with a history of depression will have five to nine separate depressive episodes in their lifetime. Risk factors for recurrence are listed in Table 3.2. Duration. There is evidence that few episodes of depression persist beyond 1 year, with several community studies noting that 80% of individuals experiencing an episode had recovered by this time. It is likely that typical episodes of depression experienced in the general population are considerably shorter than has been identified in patients who are treated by health services, as shorter episodes are obviously less likely to prompt help-seeking. Community studies in the USA indicate mean durations of 13-30 weeks, and median duration of around 12 weeks; studies in primary care populations in the USA and France found a mean duration of episode of 12 weeks. For about 20% of people with depression, the illness follows a chronic course with persistence of symptoms at diagnostic threshold level for at least 2 years.",273,40,0.14652014652014653
9781910797631,chp3,"Women are nearly twice as likely to experience depression as men, and depression more commonly affects people who are divorced or separated, or who have experienced violence or abuse, as well as those experiencing socioeconomic adversity.","In older people. Although older people are less likely to experience depression, those who do are more likely to exhibit a chronic disease course, with longer duration of episodes and shorter times to relapse than younger individuals, and around 30% are likely to remain chronically depressed. A meta-analysis of data from 12 primary care and community secondary care studies of depressed patients aged 60 years and over showed that, after 2 years, nearly half of those still living remained depressed. Subthreshold depression as well as major depression is associated with functional impairment and increased mortality, and together with the risk of suicide - which is highest among older people - underlines the fact that mood disorders are potentially fatal diseases. This more adverse longitudinal trajectory seems to be accounted for by factors such as previous episodes and medical comorbidity (which is explored in Chapter 7). As for other age groups, the number of previous episodes is one of the strongest predictors of relapse and recurrence. Other variables most clearly associated with longer durations of depression episode include poor self-rated health status, depression severity, inadequacy of social support, and adverse life events, as well as comorbidities.",232,40,0.1724137931034483
9781910797631,chp3,"In high- and middle-income countries, depression is the leading cause of disability and, primarily due to changes in demographic and disease distribution patterns, its contribution to global disability is projected to increase over future decades.","Disability. The frequency and severity of mental disorders was not fully appreciated until an international study initiated in the early 1990s by the World Bank and coordinated by the World Health Organization quantified the extent of disability attributable to particular diseases. This enterprise - the Global Burden of Disease (GBD) project - revealed that mental illness accounted for much of the total disability in economically developed and developing countries, with depression identified as the chief cause among this disorder group. Depression is ranked as a leading cause of burden among all diseases, accounting in 2010 for 3.5% of the total disability-adjusted life-years (DALYs); it is the leading cause of years lived with disability (YLDs) throughout the world (Table 3.3). (The DALY, developed in 1990 to quantify the burden of diseases, injuries and risk factors, is based on the years of life lost by premature death and YLD.).",187,42,0.22459893048128343
9781910797631,chp4,"Identifying depression is the necessary first stage to enable ongoing monitoring, risk assessment, support and clinical management; however, many people with depression are not identified in primary care or medical settings.","Recognizing depression is clearly the essential starting point for any effective management - whether this is active monitoring, support for self-help, or more active or health technology-oriented interventions. Most people with depression will have initial contact with primary care services and receive ongoing management from primary care practitioners. In settings where a well-developed primary care system with a gate-keeping function exists, such as the UK and Australia, this amounts to around 80% of people who receive treatment for depression. In the USA, primary care practitioners manage approximately one-half of adults and nearly two-thirds of older adults treated for depression. Clinician recognition. Studies conducted over several decades and in many countries have revealed that depression is missed in primary care consultations - particularly the initial presentation - relatively often. Although clinicians' problems in recognizing depression have been most commonly investigated in primary care settings, this under-recognition has also been noted in studies of inpatient medical and surgical settings, medical outpatient clinics, emergency departments and care homes. Clinician recognition is typically evaluated in these studies by comparing a diagnosis of depression reached using a validated rating scale with a specified cut-point or (less commonly) by a standardized diagnostic interview, with one of the following.",246,37,0.15040650406504066
9781910797631,chp4,"A combination of patient, clinician and contextual factors operate to hinder depression identification, but these factors can all be modified to improve the process of condition recognition.","The process of problem formulation and diagnostic reasoning comprises several stages that involve particular strategies on the part of the clinician, such as attention to initial complaints, identifying symptom patterns, eliciting elements of examination and history, and use of active monitoring, 'watchful waiting' or trials of treatments. The quality of practitioners' interviewing skills, particularly the appropriate use of open questions, awareness of non-verbal elements of communication, exploration of psychosocial issues and demonstration of empathy, are central to these processes and have, unsurprisingly, been found to be linked to accuracy of detection. Importantly, these aspects of clinical communication have been shown to be improved by training interventions.",132,31,0.23484848484848486
9781910797631,chp4,Interventions to improve recognition that do not incorporate changes to the context and organization of care are likely to have only weak effects on depression outcomes.,"The use of case-finding measures. Given the substantial proportion of cases of depression missed in primary care, the use of case-finding tools is an appealing approach to assist recognition. There are several measures that are brief, easy to administer and score, psychometrically robust and acceptable to patients (see below). However, published studies of the feedback of such standardized measures to primary care providers have given contradictory results, and systematic reviews of randomized controlled trials of the use of screening or case finding in general medical and primary care settings have failed to find evidence that routine feedback of instrument results increases the recognition rate for depression or is linked to clinical improvements. While the most recent (2016) US Preventive Services Task Force review supports routine screening using brief symptom scales, the analogous Canadian body does not recommend routine screening either for adults at average risk of depression or those judged to be at increased risk (2013). The National Institute for Health and Care Excellence (NICE) in England, Wales and Northern Ireland has eschewed routine screening and advocated the use of validated measures and case-finding instruments to assist in the assessment of people with suspected depression. The Australian and New Zealand Colleges of Psychiatrists and of GPs also advocate this opportunistic approach to depression identification.",249,28,0.11244979919678715
9781910797631,chp4,"The best evidence indicates the effectiveness of a combined approach involving education for clinicians and patients, systematic use of case-finding tools, and organizational changes to improve depression management capacity and sustain practice changes.","The use of case-finding measures. Given the substantial proportion of cases of depression missed in primary care, the use of case-finding tools is an appealing approach to assist recognition. There are several measures that are brief, easy to administer and score, psychometrically robust and acceptable to patients (see below). However, published studies of the feedback of such standardized measures to primary care providers have given contradictory results, and systematic reviews of randomized controlled trials of the use of screening or case finding in general medical and primary care settings have failed to find evidence that routine feedback of instrument results increases the recognition rate for depression or is linked to clinical improvements. While the most recent (2016) US Preventive Services Task Force review supports routine screening using brief symptom scales, the analogous Canadian body does not recommend routine screening either for adults at average risk of depression or those judged to be at increased risk (2013). The National Institute for Health and Care Excellence (NICE) in England, Wales and Northern Ireland has eschewed routine screening and advocated the use of validated measures and case-finding instruments to assist in the assessment of people with suspected depression. The Australian and New Zealand Colleges of Psychiatrists and of GPs also advocate this opportunistic approach to depression identification.",249,38,0.15261044176706828
9781910797631,chp5,"Depression is about twice as common among women as men as a result of sociocultural, psychological and biological factors.","Women and depression. As discussed in Chapter 3, depression is about twice as common among women than men, because of a combination of sociocultural, psychological and biological factors. Biological factors. The biological differences between women and men, particularly in regard to reproductive function, have often been considered to be the principal explanation for this higher rate of depression. Without doubt, some women will experience some mood changes in conjunction with the changing hormonal levels of the menstrual cycle (premenstrual dysphoric disorder) and the perimenopause (perimenopausal depression) but such mood changes do not explain the higher prevalence of depression among women; sociocultural and psychological factors are of more relevance in this regard.",143,25,0.17482517482517482
9781910797631,chp5,Women are at particular risk of developing depression during the perinatal period - the time from conception through to the end of the first postnatal year. Antenatal depression is a predictor of subsequent postnatal depression.,"The perinatal period is defined as the time from conception through to the end of the first postnatal year. It is a time when women are at particular risk of developing depression and also experience a high risk (30-40%) of having a postpartum relapse of bipolar disorder. A number of depressive disorders can arise over this period (Table 5.1); however, these are not given official status in classification systems. The fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) allows for a peripartum specifier, but this is restricted to an onset of depression during pregnancy or in the first 4 weeks following delivery. These restricted specifications lack the heuristic value of the broader types of depression, here labeled 'the blues', antenatal and postnatal depression (see Table 5.1).",173,43,0.24855491329479767
9781910797631,chp5,"There are risks associated with the use of selective serotonin-reuptake inhibitors (SSRIs) during pregnancy. Only small amounts of the SSRIs pass into breast milk, and breastfeeding is considered safe.","Pharmacological treatment can be considered for women with more severe postnatal depression. An important issue to consider is their safety for breastfeeding mothers, and many women may prefer not to take an antidepressant if breastfeeding. However, only small amounts of the common antidepressants (SSRIs) pass through breast milk, and breastfeeding is considered safe for the infants of women taking antidepressants. Other management considerations. Women with severe depression may require admission to a specialized mother and baby unit, especially when there are concerns about the safety of the mother and the infant. Suicide, although rare in the perinatal period, is one of the commonest causes of indirect maternal death over the perinatal period. Women may attempt suicide because they feel they are not being a 'good enough' mother, and that their infant will be better off without them. Suicidal ideation should be checked with new mothers, particularly those with severe depression. If there is a risk, admission to an appropriate mother and baby unit is indicated.",199,42,0.21105527638190955
9781910797631,chp5,Premenstrual dysphoric disorder affects up to 5% of women; its assessment requires the presence of symptoms over a number of menstrual cycles.,"Diagnosis. This form of depression has now been recognized in DSM-5 as premenstrual dysphoric disorder (PMDD). The diagnostic criteria require that women experience symptoms in the final week before the onset of menses in the majority of their menstrual cycles and that the symptoms improve within a few days of the onset of menses. They will need to have a minimum of five symptoms, including one of several specified core symptoms (Table 5.5). The assessment of PMDD requires confirmation of the presence of symptoms over a number of cycles. The use of a diary, charting mood changes in relation to the onset of menses, is helpful.",133,29,0.21804511278195488
9781910797631,chp5,"Some women do not respond to antidepressants during the perimenopause, and the addition of hormone replacement therapy to an antidepressant may help.","When women present with perimenopausal symptoms, it is worthwhile asking about their mood as well as reviewing the physical symptoms. Depressive symptoms can be distressing, even if they do not reach the criteria for major depression, and non-pharmacological interventions may be of benefit, especially if they also help women to cope with role transitions. The SSRIs and serotonin-norepinephrine-reuptake inhibitors have been demonstrated to benefit women with major depression, and are now considered to be the first-line intervention. Sometimes women do not respond to antidepressants during the perimenopausal years (when they may not be explicitly reporting menopausal symptoms), and an inadequate response warrants exploring whether such symptoms are present. The addition of hormone replacement therapy to the antidepressant may be sufficient to overcome the depressive episode.",161,27,0.16770186335403728
9781910797631,chp6,"The treatment rather than the prevention of depression has dominated agendas to date. However, better understanding of depression risk factors is enabling the emergence and evaluation of preventive approaches, and there are indications that incidence may be substantially reduced by these methods.","Universal versus selected prevention approaches. Although the science of depression prevention is at an early stage, the developing evidence base indicates promising findings, and a systematic review has identified good evidence for prevention among at-risk individuals and those with early features. In general, it seems that although universally directed services are a vital part of delivering health and social care, there are limits to broad-based community education programs. The most efficient and effective approaches for depression prevention may be those that target populations at risk rather than broader approaches. Selective prevention approaches that enhance protective factors using particular psychotherapy approaches appear able to delay the onset of depression in a range of at-risk groups. Current evidence indicates that interventions based on cognitive-behavior therapy (CBT) and interpersonal psychotherapy (IPT) are useful approaches. For instance, a Cochrane review () provides promising evidence for the effectiveness of individually delivered support for postnatal women. Intensive home visits by nurses and health visitors and telephone peer support were both found to reduce depression onset when targeted to those at risk. Preventing depression onset in patients with stroke has also been evaluated, and both antidepressant medication and problem-solving approaches have been found to be effective.",238,46,0.19327731092436976
9781910797631,chp6,"For milder forms of depression, self-help, relaxation, sleep hygiene, exercise and problem-solving therapy are likely to be effective; for moderate to severe depression, antidepressants or a structured psychological treatment (cognitive-behavior therapy) is indicated; combined antidepressants and psychological therapy may be most appropriate for severe depression.","Overall, findings from trials conducted in a range of settings indicate that preventive interventions may reduce the incidence of depressive disorders by around 20% compared with treatment-as-usual control groups. The extent of effect means that prevention should play a larger role in the further reduction of the disease burden of depressive disorders. Low participation rates in depression prevention programs have been noted as a problem, but it seems likely that the increased use of communications technologies such as mobile phones and the internet, together with appropriate marketing approaches, will enhance involvement. The attention given to improving recognition of depression in primary care explored in Chapter 4 is encouraging. However, a central problem with innovations to improve detection is that they have not necessarily led to more effective depression management. It appears that many people who are recognized as being depressed are not provided with appropriate treatment, and many of those prescribed antidepressants discontinue them too soon. These management problems relate to the availability, acceptability and effectiveness of current treatments for depression: although considerable progress has been made over recent decades, difficulties and limitations remain in all these areas. A central issue in relation to depression management is the heterogeneity of this condition. As discussed earlier, depression covers a spectrum of symptoms, and different approaches are appropriate for differing levels and types of presentation. As well as matching different approaches according to severity, a number of different treatments appear to be equally effective for managing depression. People receiving the same treatments show a range of differing responses, with 25-30% of people treated showing no improvement with initial treatment. The clinical benefits of treatment are likely to be incomplete for a substantial proportion of people, with many requiring changes and combinations of treatments. At present around one-third of people achieve only partial remission from symptoms despite treatment.",344,64,0.18604651162790697
9781910797631,chp6,"There are a range of treatments that may be effective for depression, and matching management intensity to the level of depression severity - termed 'stepped care' - is a widely adopted framework for care.","The attention given to improving recognition of depression in primary care explored in Chapter 4 is encouraging. However, a central problem with innovations to improve detection is that they have not necessarily led to more effective depression management. It appears that many people who are recognized as being depressed are not provided with appropriate treatment, and many of those prescribed antidepressants discontinue them too soon. These management problems relate to the availability, acceptability and effectiveness of current treatments for depression: although considerable progress has been made over recent decades, difficulties and limitations remain in all these areas. A central issue in relation to depression management is the heterogeneity of this condition. As discussed earlier, depression covers a spectrum of symptoms, and different approaches are appropriate for differing levels and types of presentation. As well as matching different approaches according to severity, a number of different treatments appear to be equally effective for managing depression. People receiving the same treatments show a range of differing responses, with 25-30% of people treated showing no improvement with initial treatment. The clinical benefits of treatment are likely to be incomplete for a substantial proportion of people, with many requiring changes and combinations of treatments. At present around one-third of people achieve only partial remission from symptoms despite treatment.",241,39,0.16182572614107885
9781910797631,chp6,"Depression is complex, and understanding and helping requires a sensitive weighing up of the many factors that are relevant to the individuals and families affected.","Psychological approaches using the computer and internet. One of the main barriers to patients receiving appropriate psychological treatments, such as CBT or PST, is a shortage of clinicians who can deliver them. Additionally, there may be problems for individuals scheduling appointments with family, work or carer commitments. Internet-based CBT programs, such as MoodGym and the Sadness Program in Australia, make use of the same techniques as face-to-face therapy but these are delivered in a more accessible and cost-effective way via a website. Evaluations of a range of computer- and internet-based CBT programs indicate significant improvements in the symptoms of depression compared with control patients. There is some indication that improvements in symptoms are maintained over time (up to 12 months). The use of such innovations in delivery may be particularly useful in rural and remote settings where access to clinicians may be limited.",177,28,0.15819209039548024
9781910797631,chp6,"Selective serotonin-reuptake inhibitor antidepressants are the first-choice medication but prior treatment history, medical history and drug interactions are key considerations in treatment selection.","Regimen changes. Increasing the dose may be beneficial, but there is limited evidence that exceeding the recommended dose has additional benefit. Alternatively, switching to another medication, either within class when side effects may be the problem, or to another class of antidepressants when the response is limited, can be considered, with choice guided by factors such as previous treatment history and the potential of the drug to cause side effects. Switching between antidepressants because of poor response to initial treatment is more likely to be needed for people with more chronic depression and more coexisting health problems. If there is poor response to these strategies, augmentation with another psychotropic drug such as lithium, a second-generation antipsychotic or another antidepressant may be considered. This is usually undertaken in consultation with a consultant psychiatrist or within a specialist mental health service.",162,32,0.19753086419753085
9781910797631,chp7,"Depression is two to three times more common among people experiencing medical conditions, as physical illness increases the risks for depression and, vice versa, depression makes physical illness more likely.","Mental and physical health are closely connected: there is consistent evidence from cross-sectional studies that depression and other mental health problems, such as anxiety or substance misuse, are more common in people with communicable and non-communicable diseases. Large-scale community studies in Canada and elsewhere show that this association remains after controlling for factors such as age, sex and social support. The relationship between depression and medical illness appears strongest for conditions that are painful and disabling, prompting the possibility that these attributes of medical illness are the influential factors for the association. The prevalence of depression among a range of medically ill populations has been widely investigated, and this research shows rates of depression two- to threefold higher than among comparable groups of people not experiencing such diseases (Table 7.1). Alternatively, studies that have examined the existence of medical conditions among people with depression have found this to be common: one study in 14 regional centers in the USA involving more than 2500 outpatients with depression found that 50% had disabling general medical conditions.",204,35,0.1715686274509804
9781910797631,chp7,"Recognizing depression in people with physical health problems can be challenging, but being alert to the increased risk and using validated case-finding measures assist this process.","The presence of depression together with medical illness has important implications for the individual, their carers and for health services and society. This combination has complex and extensive effects, involving negative impact on illness course and disability, the uptake of treatments, risk of complications and death rates. It also complicates the way in which people seek help for their problems, and it can interfere with the recognition of their problems by clinicians, especially when the focus of the consultation is on the very real physical problem and mental health issues are not prioritized. The extent of these adverse effects is particularly clear for cardiovascular disease: depression is a well-recognized risk factor for new onset and for recurrences of established disease, and among patients with heart disease the relative risk of subsequent cardiac mortality is increased threefold in those with depression compared with those who are not depressed. This increased risk remains after adjusting for confounding factors.",178,32,0.1797752808988764
9781910797631,chp7,"When depression and physical illnesses are combined, the course and outcome of both conditions are worsened, with increased disability, higher medical costs and greater likelihood of adverse outcomes (including death).","Depression combined with medical illness causes greater disability than these conditions in isolation, and the extent of lost productivity and healthcare use is greatly increased when these conditions exist together. A World Health Organization (WHO) survey of nearly a quarter of a million adults from 60 countries showed that people with depression comorbid with a chronic medical condition reported much worse overall health than those with the medical condition alone. This led the WHO to highlight the negative effects of depression on physical illnesses among one of its ten most important global public health statistics for 2007, and to develop policy and practice guidance for greater integration of care between primary and specialist services and physical and mental health services such as outlined by NHS England in its Five Year Forward View policy document (2014) and in reviews by the Australian Health Policy Collaboration.",157,35,0.2229299363057325
9781910797631,chp7,People with depression are less likely to adhere to treatments for medical conditions or to adopt healthy behaviors and self-management for these health problems.,"Shared genetic factors that increase the risk for both depression and particular physical conditions such as diabetes or heart disease may play a part in the relationship between medical conditions and depression. Research evidence indicates that genetically influenced pathways linking these conditions are highly likely, and that - as for many other health problems - there is an interaction between multiple genetic factors and environmental factors. There is clear evidence that social and economic adversity and traumatic early childhood experiences such as physical, psychological or sexual abuse and emotional neglect are linked to a heightened risk of both medical illness and depression. Patterns of coping and ways of responding to stressors that develop in the first years of life and are powerfully influenced by early environment appear to act as further predisposing and perpetuating factors for these health problems.",149,27,0.18120805369127516
9781910797631,chp7,"There is a good evidence base for managing depression combined with medical conditions: selective serotonin-reuptake inhibitors are an appropriate first line drug treatment, and psychological therapies are effective.","Management. There are well-founded concerns that standard guidance for the management of depression is inappropriate for people who experience depression together with medical conditions, because of uncertainty about the effectiveness of routine treatments for these people, and the risks of side effects and drug interactions related to these conditions and their treatments. Although the presence of comorbid medical illness complicates treatment decisions, there is a strong evidence base to guide practice, with antidepressant and psychological treatments shown to be effective for depression and improving quality of life across many disorders - from diabetes and heart disease to cancer and COPD. Recent guidance from the National Institute for Health and Care Excellence notes that selective serotonin-reuptake inhibitors are an appropriate first line drug treatment. Sertraline and citalopram are the probable drugs of first choice on the basis of lower interaction potential and safety in relation to cardiac events.",172,35,0.20348837209302326
9781910797631,chp8,"Suicide is strongly associated with depression, but despite depression being more common among adult women, men are around twice as likely to kill themselves in most countries, and three to four times more likely in many high-income nations.","Suicide is a major public health problem, and each suicide act is tragic and preventable. In 2015, suicide accounted for 780 000 or 1.4% of deaths in the world, making it the 17th leading cause of death; for 15-29 year-olds it was the second leading cause of death. Globally, more than half of all violent deaths are due to suicide, and in the USA twice as many people die by suicide as by homicide. There are wide variations in the suicide rates for different countries and regions, with the highest rates in the Baltic States and sub-Saharan Africa, and the lowest in Latin America. Similarly, although suicide is most common among people aged over 70 years in nearly all world regions, there are marked differences in age and sex patterns across countries and regions. Suicide rates are much higher among men than women in most regions of the world, the ratio of male to female suicides is lower in low- and middle-income countries.",196,45,0.22959183673469388
9781910797631,chp8,"Assessment practice following self-harm needs to be sensitive and skilled, focusing on the presence of risk factors for suicide and basing care plans on clearly defined risks and the capacity of the individual and their support network to manage problems and take responsibility for safety.","Suicide is a major public health problem, and each suicide act is tragic and preventable. In 2015, suicide accounted for 780 000 or 1.4% of deaths in the world, making it the 17th leading cause of death; for 15-29 year-olds it was the second leading cause of death. Globally, more than half of all violent deaths are due to suicide, and in the USA twice as many people die by suicide as by homicide. There are wide variations in the suicide rates for different countries and regions, with the highest rates in the Baltic States and sub-Saharan Africa, and the lowest in Latin America. Similarly, although suicide is most common among people aged over 70 years in nearly all world regions, there are marked differences in age and sex patterns across countries and regions. Suicide rates are much higher among men than women in most regions of the world, the ratio of male to female suicides is lower in low- and middle-income countries. Many more people make suicide attempts or self-harming acts than kill themselves: self-harm is estimated to be 20 times more common than suicide, and a history of self-harm is an important risk factor for completed suicide. The reasons for suicide are complex and vary with age, sex, culture and ethnicity. Many of these factors are best understood in the context of each person's individual life and life circumstances.",279,51,0.1827956989247312
9781910797631,chp8,"In addition to previous self-harm, risk factors for suicide include depression, substance misuse, a family history of suicide, male sex, being separated or divorced, and being in custody.","There are wide variations in the suicide rates for different countries and regions, with the highest rates in the Baltic States and sub-Saharan Africa, and the lowest in Latin America. Similarly, although suicide is most common among people aged over 70 years in nearly all world regions, there are marked differences in age and sex patterns across countries and regions. Suicide rates are much higher among men than women in most regions of the world, the ratio of male to female suicides is lower in low- and middle-income countries. Many more people make suicide attempts or self-harming acts than kill themselves: self-harm is estimated to be 20 times more common than suicide, and a history of self-harm is an important risk factor for completed suicide. The reasons for suicide are complex and vary with age, sex, culture and ethnicity. Many of these factors are best understood in the context of each person's individual life and life circumstances.",185,37,0.2
9781910797631,chp8,"Self-harm is most common in adolescent girls and young women and usually does not involve an intention to endanger life. Nonetheless, a history of self-harm is an important predictor of future suicide, increasing the risk by 50-100-fold compared with people who have not self-harmed.","Epidemiology. Self-harm is far more common among adolescents than any other age group: an anonymized questionnaire survey of young people from seven European countries (2008) indicated a combined lifetime prevalence of 13.5% among females and 4.3% among males. In a more recent (2017) survey of young people in England, 15.5% reported ever having self-harmed, and rates were around three times higher for females than males. Rates of self-harm peak around the age of 14-17 years, with this appearing consistent in cross-national studies. A higher frequency of self-harm in adolescence is correlated with the consumption of cigarettes or alcohol and the frequency of being intoxicated (particularly in women), and all categories of drug misuse. It is also associated with being bullied, including cyber bullying on social media, or 'trolling', and with physical and sexual abuse. Many young people report repeated self-harm, and such repetition has been found most commonly in the presence of mental health problems or significant psychosocial disadvantages. A history of self-harm is the strongest predictor of future suicide, increasing the risk by 50-100-fold compared with people who have not self-harmed. A systematic review found that 16% of patients who attended an emergency department because of self-harm repeated this behavior, and 1.8% died by suicide. A recent review () that examined risk factors associated with suicide following an episode of self-harm identified key predictors as previous episodes of self-harm, suicidal intent, male sex and physical health problems.",317,59,0.1861198738170347
9781910797662,ch01,"Bladder cancer incidence has a male-to-female ratio of 4:1. The incidence increases with age, with a median age at presentation of 60-65 years.","Bladder cancer is more common in men than women, with a male-to-female incidence ratio of 4:1, although the incidence among women appears to be rising. The global age-standardized incidence is 14.1 per 100 000 person-years for men and 3.6 for women. Bladder cancer is the fourth most common cancer in men in the USA. Incidence increases with age, with a median age at presentation of over 75 years in the UK. Most cases of bladder cancer are non-muscle-invasive urothelial cancers, which can usually be cured; the 5-year survival rate for these cancers is more than 95%. However, invasive or metastatic bladder cancer is a frequent cause of cancer death, accounting for approximately 17 000 deaths annually in the USA and 188 000 globally. Age-standardized death rates for bladder cancer are 5.1 per 100 000 person-years in men and 1.5 per 100 000 person-years in women. Survival rates at different stages of the disease are reported on page 25. Globally, bladder cancer is responsible for over 3 million disability-adjusted life-years, mainly years of life lost due to advanced disease.",242,35,0.1446280991735537
9781910797662,ch01,"Bladder cancer is a common tumor; each year approximately 17 000 people in the USA die from the disease, and 188 000 globally.","Most cases of bladder cancer are non-muscle-invasive urothelial cancers, which can usually be cured; the 5-year survival rate for these cancers is more than 95%. However, invasive or metastatic bladder cancer is a frequent cause of cancer death, accounting for approximately 17 000 deaths annually in the USA and 188 000 globally. Age-standardized death rates for bladder cancer are 5.1 per 100 000 person-years in men and 1.5 per 100 000 person-years in women. Survival rates at different stages of the disease are reported on page 25. Globally, bladder cancer is responsible for over 3 million disability-adjusted life-years, mainly years of life lost due to advanced disease.",146,27,0.18493150684931506
9781910797662,ch01,"Bladder cancer has many etiological risk factors, most of which are avoidable; the most common cause is cigarette smoking.","All stages of presentation are more common in Africa, the Middle East, Central America, and Asia, and less common in affluent countries. The lifetime risk of developing bladder cancer before 79 years of age is 1/36 for men and 1/165 for women in high sociodemographic index countries, and 1/122 and 1/310, respectively, in low sociodemographic index countries. Numerous factors are implicated in bladder carcinogenesis, as shown in Table 1.1. These include host factors (exempli gratia age, sex, comorbidities, familial cancer syndromes), social and economic influences and exposure to carcinogens. Many of these are avoidable, and as a result, many cases of bladder cancer could be prevented. The importance of genetic factors is discussed in more detail on page 21.",168,25,0.1488095238095238
9781910797662,ch01,Some familial syndromes and genetic predispositions increase the risk of bladder cancer.,"Cyclophosphamide, used in the treatment of various malignancies and autoimmune conditions, sometimes at very high doses, has known bladder carcinogenic effects. A dose-response relationship is evident: cumulative doses above 20 g increase the risk 6-fold, and doses of 50 g or more increase the risk by 14.5-fold. Latency is relatively short - the time between exposure and subsequent bladder cancer diagnosis is 6-13 years. The risk of subsequent bladder cancer can be reduced in the oncology setting by minimizing the cumulative dose, although this is not always feasible. Co-administration of the chemoprotectant 2-mercaptoethanesulfonic acid (MESNA) reduces the rate of cyclophosphamide-related cystitis and may reduce the risk of subsequent bladder cancer.",167,17,0.10179640718562874
9781910797662,ch02,Urothelial carcinoma is the predominant histology of bladder cancer.,"Urothelial cancer (UC; Figure 2.1) is derived from the transitional epithelium. It accounts for almost 90% of the bladder cancers that occur in industrialized countries such as the USA and the UK, and most discussion of bladder cancer relates to this type. Such tumors may be papillary (confined to the urothelium or lamina propria) (70-75%) or solid and invasive (20-25%).",91,15,0.16483516483516483
9781910797662,ch02,Variant histology is common and is usually seen as a mixed pattern with conventional urothelial cancer.,"Carcinoma in situ (CIS) is an additional and important type seen in about 10% of cases (sometimes as secondary CIS associated with papillary UC). CIS is a flat, intraepithelial, high-grade carcinoma, often with increased numbers of mitotic structures. In approximately half of all cases, CIS occurs as one or more de novo lesions (primary CIS), while in the remainder it occurs in association with either papillary or solid tumors (secondary CIS). Coexistent CIS and papillary non-muscle-invasive bladder cancer confers a worse prognosis than papillary disease alone.",126,22,0.1746031746031746
9781910797662,ch02,"Carcinoma in situ, whether primary or associated with Ta or T1 papillary tumor, is a high-risk cancer.","Carcinoma in situ (CIS) is an additional and important type seen in about 10% of cases (sometimes as secondary CIS associated with papillary UC). CIS is a flat, intraepithelial, high-grade carcinoma, often with increased numbers of mitotic structures. In approximately half of all cases, CIS occurs as one or more de novo lesions (primary CIS), while in the remainder it occurs in association with either papillary or solid tumors (secondary CIS). Coexistent CIS and papillary non-muscle-invasive bladder cancer confers a worse prognosis than papillary disease alone.",126,27,0.21428571428571427
9781910797662,ch02,Up to 30% of patients with high-grade non-muscle-invasive tumors and up to 70% with muscle-invasive disease may die of bladder cancer.,"Adenocarcinomas are usually solitary, high grade and ulcerative. They can be difficult to distinguish histologically from adenocarcinomas of the colon or rectum, and clinical determination of the source is often difficult. Any bladder adenocarcinoma may be mucin-producing. Many patients with adenocarcinoma have poor prognosis because the tumor is already at an advanced stage at diagnosis. Urachal adenocarcinomas present as invasive tumors often visible on the dome of the bladder and tend to be asymptomatic until late in the disease course, since they arise in a minimally functional part of the bladder. Surgical therapy is closed partial cystectomy.",148,35,0.23648648648648649
9781910797662,ch02,High-grade non-muscle-invasive bladder cancer will progress if not adequately treated with resection and intravesical therapy.,"CIS has a high rate of progression to muscle-invasive disease if it is not eradicated with intravesical therapy, usually bacillus Calmette-Gurin (BCG). On average, muscle-invasive disease is associated with regional lymph node metastases in 25% of patients. Hematogenous spread is most common to the lungs, liver and bones, and these are the most common sites of progression in patients who experience recurrence after definitive loco-regional therapy with radical cystectomy or chemoradiation. Distant metastases are present at initial diagnosis in 5% of patients.",127,27,0.2125984251968504
9781910797662,ch02,Low-grade non-muscle-invasive bladder tumors may recur but progression to muscle invasion occurs in < 5% of cases.,"Mortality due to UC is directly related to the pathological stage and grade of bladder cancer (Table 2.2). For those with low-grade Ta and T1 tumors, 5-year disease-specific survival should exceed 95%, whereas reported 5-year survival may be as low as 50% for patients with high-grade T1 cancers or CIS without adjuvant therapy. Intravesical immunotherapy with BCG is associated with frequent complete response at 6 months following induction and initial maintenance, and 5-year survival should approach 80-85%. For patients with T2/T3aN0M0 disease, the 5-year survival rate is 60-70%, despite radical cystectomy. Progression is often due to subclinical 'micrometastases' that were present at the time of cystectomy but were not radiologically detectable. In patients who experience disease progression, this occurs within 2-3 years of cystectomy in about 80% of cases. Patients who are treated with peri-operative chemotherapy may experience late relapse (after 5 years), with metastases often occurring at unusual sites, including the central nervous system or intraperitoneally, presenting as bowel obstruction.",244,28,0.11475409836065574
9781910797662,ch03,Painless hematuria is the most common presentation of bladder cancer.,"The classic presenting sign or symptom of a bladder tumor is painless gross or microscopic hematuria; it is the sole presenting symptom in 60-80% of patients. Unfortunately, and despite the well-known sinister implications of this finding, many patients who present with hematuria are not evaluated further or referred to a urologist., Up to 20% of patients with bladder cancer will not have hematuria at presentation. Other patterns of presentation also occur (Table 3.1) and are sometimes similarly unrecognized as an indication of serious underlying pathology.",112,14,0.125
9781910797662,ch03,A single episode of hematuria should prompt urgent referral to a urologist.,"The classic presenting sign or symptom of a bladder tumor is painless gross or microscopic hematuria; it is the sole presenting symptom in 60-80% of patients. Unfortunately, and despite the well-known sinister implications of this finding, many patients who present with hematuria are not evaluated further or referred to a urologist., Up to 20% of patients with bladder cancer will not have hematuria at presentation. Other patterns of presentation also occur (Table 3.1) and are sometimes similarly unrecognized as an indication of serious underlying pathology.",112,17,0.15178571428571427
9781910797662,ch03,Hematuria clinics allow rapid diagnosis and reduce time to treatment.,"Painless hematuria may occur at the beginning, end or throughout the urine stream. It may be profuse (such that the patient describes passing pure blood) and contain clots or it may have only a slight pink discoloration. Clots that have been in the bladder for some time may impart a rusty color to the urine. Any patient with these symptoms should be referred to a urologist immediately.",84,14,0.16666666666666666
9781910797662,ch03,"Unexplained irritative symptoms may be due to bladder cancer, particularly carcinoma in situ.","Irritative symptoms such as dysuria, increased frequency and urgency are often dismissed because they are common, are usually due to urinary tract infection (UTI) and are typically not associated with serious disease. However, if infection is absent or symptoms persist after the UTI has been treated, the possibility of an underlying bladder malignancy must be considered and the patient referred to a urologist. Irritative symptoms are particularly common in patients with carcinoma in situ (CIS), and suprapubic pain when the bladder is full can also be caused by carcinoma of the bladder.",120,20,0.16666666666666666
9781910797662,ch03,Recurrent infections may indicate an underlying tumor.,"Anorexia, nausea, weight loss and malaise may result from renal failure due to bilateral ureteric obstruction, or from the systemic effects of the tumor itself. Bone pain or pathological fractures may result from skeletal metastases (Figure 3.3); the pain is unrelieved by rest and can be severe. Anemia and hypercalcemia may occur as metabolic complications of advanced disease; leukocytosis is occasionally associated with the elaboration of colony-stimulating factors by the tumor. Headache or disordered thought processes are uncommon as a presenting feature but may indicate underlying brain metastases or carcinomatous meningitis.",132,9,0.06818181818181818
9781910797662,ch03,Delay in treatment adversely affects prognosis.,"Although it is difficult to prove that delay in diagnosis affects prognosis, screening for asymptomatic microscopic hematuria is associated with a shift towards more favorable tumor characteristics of lower stage and grade at diagnosis, and better survival. Delays may occur for a variety of reasons.",56,9,0.16071428571428573
9781910797662,ch04,"The investigation of a patient with suspected bladder cancer should include urinalysis, cross-sectional upper-tract imaging and cystoscopy.","Imaging. The upper tracts (ureter and renal pelvis) should be imaged in all patients with symptoms suggestive of bladder cancer. In the investigation of hematuria (the most common presentation of bladder cancer), contemporary imaging can be performed by computed tomographic urography (CTU) (Figure 4.1),, which has replaced intravenous urography. Renal ultrasonography plus a plain radiograph of the kidneys, ureters and bladder is an option when CTU is not available and if the patient cannot receive intravenous contrast. Retrograde ureteropyelography should be used to resolve any abnormalities on non-contrast studies. Magnetic resonance urography is another option, particularly for patients with an allergy to iodinated intravenous contrast and for pregnant women. It has 69% sensitivity and 97% specificity for upper-tract tumors. As radiological imaging cannot sufficiently evaluate the bladder, cystoscopy is a required part of the evaluation for all patients.",206,29,0.1407766990291262
9781910797662,ch04,Cross-sectional imaging (computed tomography or magnetic resonance imaging) is used to stage invasive disease.,"If a patient is found to have low-grade bladder cancer on biopsy, no further imaging is required. High-risk NMIBC can be associated with occult lymph node metastases, and computed tomography (CT) or magnetic resonance imaging (MRI) may be considered in these patients. However, if muscle-invasive disease is present, staging with chest, abdominal and pelvic CT is necessary. This should identify any visceral metastatic disease within the limits of resolution of the scanner. Pelvic MRI scanning may give more accurate information about the local spread of an invasive tumor.",116,21,0.1810344827586207
9781910797662,ch04,Urinary markers are not yet sufficiently sensitive for diagnosis but may be useful in following up patients with superficial disease.,"Cytological examination of exfoliated cells is part of the hematuria evaluation for all patients. When a bladder tumor is diagnosed, cytology is useful to determine the grade as, by definition, positive cytology denotes high-grade malignant cells. A bladder wash for cytology should be obtained at the time of cystoscopy, as this is the most sensitive means for detection of bladder cancer particularly if areas that might be carcinoma in situ (CIS) or ulcers rather than obvious papillary or exophytic solid tumor are seen. Cytology may be helpful in following up such patients for signs of recurrence, as well as for ensuring that all disease present at initial diagnosis has been diagnosed and treated adequately.",149,22,0.1476510067114094
9781910797662,ch04,Expert pathological review of biopsy specimens is critical to determining appropriate treatment.,"Expert pathological interpretation of both histology and cytology specimens is critical. Recent reports indicate a rate of discordance of at least 30% among pathologists, including many who specialize in uropathology. Because many treatment and prognostic decisions are based on fine distinctions between grade (3 versus 1 or 2), depth of invasion (T1 versus T2) and field changes (CIS versus mild or moderate dysplasia), it is important that both understaging and overstaging of bladder cancers is minimized. Second-opinion pathology should be routine if the initial reporting pathologist sees only an occasional case of bladder cancer.",128,15,0.1171875
9781910797662,ch05,"Risk-adapted treatment is based on accurate determination of stage, grade, number of tumors and presence of carcinoma in situ, and stratified as primary versus recurrent disease.","Pathological diagnosis is established by transurethral resection of bladder tumor (TURBT) and biopsy of abnormal-appearing adjacent or remote bladder mucosa. The goal of this endoscopic surgery is to establish the histology, grade and depth of invasion of the tumor and the presence or absence of carcinoma in situ (CIS), which is often not detectable by white light. The standard of care for patients with T1 high-grade (HG) disease, uniformly supported by all the guidelines, is repeat resection, in order to determine the completeness of the resection and to rule out a more deeply invasive cancer prior to determination of treatment. Enhanced cystoscopic imaging with fluorescence cystoscopy using pre-operative instillation of 5-aminolevulinic acid or hexylaminolevulinate (Cysview ) improves the detection of papillary and CIS lesions and modestly reduces the recurrence rate., Narrow-band imaging is an alternative technique that does not require an imaging agent as it detects hypervascularity associated with bladder tumors. Initial reports suggested a similar association with reduction in recurrence risk but this was not confirmed by a large international trial, except in patients with low-risk disease.",256,36,0.140625
9781910797662,ch05,"Tumors can be classified into low-, intermediate- and high-risk based on these factors; these risk strata drive treatment decisions and surveillance recommendations.","Patients are stratified into risk groups for progression, based on low grade to high grade or non-invasive to invasive cancer. Most risk stratification schemes use three strata: low, intermediate and high risk, as illustrated by the American Urological Association system presented in Table 5.2. The European Association of Urology adds a highest-risk group which should be treated with radical cystectomy. This group includes HG T1 associated with concurrent CIS, multiple and/or large HG T1 and/or recurrent HG T1, HG T1 with CIS in the prostatic urethra, unusual histology of urothelial carcinoma and lymphovascular invasion.",139,31,0.22302158273381295
9781910797662,ch05,"Low-risk tumors may recur but are unlikely to progress. Peri-operative single-dose chemotherapy reduces recurrence, and patients may only need cystoscopic follow-up.","Low-risk tumors. Patients with a solitary low-grade Ta lesion are at low risk of recurrence or progression. Level-I evidence supports use of peri-operative single-dose chemotherapy, with an 11% absolute reduction in recurrence and a 39% relative risk reduction. Mitomycin is the most commonly used drug in this setting, and epirubicin is available in Europe. The recent report of the SWOG S-0337 trial provides additional level-I evidence for the use of gemcitabine. Induction chemotherapy (intravesical therapy weekly for 6 weeks) is not indicated for patients with low-risk disease. Furthermore, recent experience suggests that if the first surveillance cystoscopy is negative, the interval to the next cystoscopy can be extended to 9 months (rather than 3 months), with annual cystoscopy thereafter.",180,37,0.20555555555555555
9781910797662,ch05,Intermediate-risk tumors are more likely to recur and have a modest progression risk. A course of intravesical chemotherapy will reduce the risk of recurrence but not of progression. Optimized mitomycin treatment is associated with optimal outcomes. Induction with bacillus Calmette-Gurin (BCG) followed by maintenance for 1 year is also a standard of care.,"Intermediate-risk tumors. Patients with multiple or recurrent low-grade Ta tumors are at intermediate risk of recurrence or progression. Small-volume Ta HG cancers are included in this risk stratum in the American Urological Association scheme (Table 5.2). Patients with frequent recurrences of low-grade Ta tumors require cystoscopic resection for each recurrence: this interferes with the patient's life; however, this stage does not usually threaten life or bladder preservation. These patients should receive a course of intravesical therapy following resection (see below). Mitomycin is the most commonly used cytotoxic drug. BCG induction plus maintenance for 1 year is also an option. High-risk tumors. Patients who present with CIS and/or HG papillary tumors (Ta or T1) have an 80% risk of recurrence and progression rates of 40-70%. BCG is the standard of care; level-I evidence supports induction therapy weekly for 6 weeks, followed by maintenance treatment weekly for 3 weeks at months 3 and 6 and then at 6-month intervals to 3 years., Disease that recurs or persists after one course of BCG has a greater likelihood of progressing; however, approximately one-third of such patients respond to a second induction course. Recurrence with a HG tumor after two induction courses (6 weeks + 6 weeks) or induction plus first maintenance therapy (6 weeks + 3 weeks) are deemed BCG unresponsive and should not receive further BCG. Radical cystectomy is the standard of care, supported by multiple guidelines. The US Food and Drug Administration (FDA) has defined a registration pathway based on a single-arm trial that has led to multiple ongoing clinical trials in this disease stage. Valrubicin is currently the only FDA-approved drug for the treatment of BCG-unresponsive CIS in patients who refuse or are deemed medically unfit for cystectomy.",391,79,0.2020460358056266
9781910797662,ch05,"High-risk bladder cancer is likely to recur and, unless adequately treated, to progress. It is fatal in up to 30% of patients. Intravesical BCG induction plus maintenance for 3 years is standard of care.","High-risk tumors. Patients who present with CIS and/or HG papillary tumors (Ta or T1) have an 80% risk of recurrence and progression rates of 40-70%. BCG is the standard of care; level-I evidence supports induction therapy weekly for 6 weeks, followed by maintenance treatment weekly for 3 weeks at months 3 and 6 and then at 6-month intervals to 3 years., Disease that recurs or persists after one course of BCG has a greater likelihood of progressing; however, approximately one-third of such patients respond to a second induction course. Recurrence with a HG tumor after two induction courses (6 weeks + 6 weeks) or induction plus first maintenance therapy (6 weeks + 3 weeks) are deemed BCG unresponsive and should not receive further BCG. Radical cystectomy is the standard of care, supported by multiple guidelines. The US Food and Drug Administration (FDA) has defined a registration pathway based on a single-arm trial that has led to multiple ongoing clinical trials in this disease stage. Valrubicin is currently the only FDA-approved drug for the treatment of BCG-unresponsive CIS in patients who refuse or are deemed medically unfit for cystectomy.",248,47,0.18951612903225806
9781910797662,ch05,"Radical cystectomy is indicated for patients with high-risk disease that is unresponsive to BCG, if the patient is medically fit and accepts the risks.","A disadvantage of BCG is its toxicity, which is greater than that of intravesical chemotherapy (Table 5.3) and may be substantial during maintenance courses. For this reason, BCG immunotherapy is generally used only for first-line treatment in patients with high-risk disease, and as a second-line therapy for patients with intermediate-risk disease that continues to recur after adequate intravesical chemotherapy. Some of the side effects of BCG may be prevented or decreased in severity, without affecting effectiveness, through the concomitant administration of quinolones with each intravesical treatment., BCG is contraindicated in the presence of gross hematuria, traumatic catheterization or immune suppression, as these increase the risk of potentially life-threatening intravascular dissemination.",161,33,0.20496894409937888
9781910797662,ch06,Adequate node dissection should be performed at the time of cystectomy.,"A meticulous bilateral pelvic lymph node dissection that includes the external and internal iliac, obturator and hypogastric lymph nodes should be performed as part of radical or partial cystectomy. Removal of these lymph nodes is crucial for accurate staging and provides potentially curative treatment in patients with N1 or N2 disease., Further extended pelvic lymph node dissection, including the presacral, common iliac, paracaval and para-aortic lymph nodes up to or above the aortic bifurcation may provide additional survival benefit.",115,17,0.14782608695652175
9781910797662,ch06,"For patients being managed with curative intent, chemoradiotherapy should be considered as an alternative to surgery, with appropriate multidisciplinary input.","Urethrectomy. Indications for urethrectomy include diffuse carcinoma in situ (CIS), papillary tumor involving the prostatic urethra, prostatic stromal invasion (T4a), and positive apical margin with CIS or frank tumor involvement. Urethral preservation should be considered in women who desire orthotopic neobladder reconstruction, provided that the bladder neck and urethra are not involved. However, a posterior-based T3 tumor or anterior vaginal wall involvement (T4a) are contraindications, as these restrict the ability to obtain an adequate surgical margin. Second primary tumors of the retained urethra may be late events so long-term monitoring is required.",147,29,0.19727891156462585
9781910797662,ch06,Bacillus Calmette-Gurin treatment is not indicated for bladder cancer that is T2 or higher.,"Additional treatment approaches should be considered for the management of organ-confined cancer that is at high risk of local or distant recurrence. Adjuvant and neoadjuvant therapy are collectively referred to as perioperative systemic therapies. Adjuvant therapy refers to additional treatment given after definitive primary treatment, with the intention of destroying microscopic residual cancer cells in order to reduce the risk of local or distant relapse. Most patients who receive adjuvant therapy will not benefit from it: either the cancer has already been cured by primary therapy or micrometastatic disease exists that is already resistant to the planned adjuvant therapy. However, adjuvant therapy is curative in a subgroup of patients. Until these patients can be identified reliably, all eligible patients are treated and may experience the resultant side effects of treatment, even though only a minority will benefit.",173,24,0.13872832369942195
9781910797662,ch06,Surgical resection (radical or partial cystectomy) is the mainstay of treatment for patients suitable for surgery.,"Whilst radical cystectomy is the curative modality used for most patients with cancer that is clinically confined to the bladder, not all patients are medically suitable for this procedure, or choose not to undergo it. Medically unfit patients may derive better palliative benefit from more conservative therapy such as radiation therapy or best supportive care. Bladder-conserving definitive treatment can be considered for appropriate patients - generally those with smaller-volume cancers. This approach integrates systemic chemotherapy with radiation therapy, the former primarily acting as a radiosensitizer. Chemotherapy in combination with radiation therapy may also assist in eradicating micrometastatic disease; simpler regimens and lower doses are used compared with chemotherapy for overt metastatic disease. Finally, some patients may benefit from multimodality approaches combining two or more of surgery, radiation therapy and systemic treatment.",170,24,0.1411764705882353
9781910797662,ch06,Toxicity is greater with combined chemotherapy and radiation than with radiation therapy alone.,"Whilst radical cystectomy is the curative modality used for most patients with cancer that is clinically confined to the bladder, not all patients are medically suitable for this procedure, or choose not to undergo it. Medically unfit patients may derive better palliative benefit from more conservative therapy such as radiation therapy or best supportive care. Bladder-conserving definitive treatment can be considered for appropriate patients - generally those with smaller-volume cancers. This approach integrates systemic chemotherapy with radiation therapy, the former primarily acting as a radiosensitizer. Chemotherapy in combination with radiation therapy may also assist in eradicating micrometastatic disease; simpler regimens and lower doses are used compared with chemotherapy for overt metastatic disease. Finally, some patients may benefit from multimodality approaches combining two or more of surgery, radiation therapy and systemic treatment.",170,15,0.08823529411764706
9781910797662,ch06,Patients treated with palliative intent are probably best offered radiation therapy only if surgery is not appropriate.,"Whilst radical cystectomy is the curative modality used for most patients with cancer that is clinically confined to the bladder, not all patients are medically suitable for this procedure, or choose not to undergo it. Medically unfit patients may derive better palliative benefit from more conservative therapy such as radiation therapy or best supportive care. Bladder-conserving definitive treatment can be considered for appropriate patients - generally those with smaller-volume cancers. This approach integrates systemic chemotherapy with radiation therapy, the former primarily acting as a radiosensitizer. Chemotherapy in combination with radiation therapy may also assist in eradicating micrometastatic disease; simpler regimens and lower doses are used compared with chemotherapy for overt metastatic disease. Finally, some patients may benefit from multimodality approaches combining two or more of surgery, radiation therapy and systemic treatment.",170,21,0.12352941176470589
9781910797662,ch06,Cytotoxic drugs are used in the context of chemoradiotherapy with the intention of improving local disease control rather than achieving distant control.,"Unfortunately, there is no high-level evidence that compares bladder-preserving approaches and radical cystectomy. A large retrospective study of 348 patients with stage T2-T4a disease assessed outcomes after treatment with cisplatin and radiation therapy in the context of maximal transurethral resection of tumor, and neoadjuvant or adjuvant chemotherapy. Patients were monitored with repeat biopsy, and subsequent treatment was guided by the initial tumor response. Patients experiencing complete remission received additional chemotherapy and a boost of radiation. Complete remission was observed in 72% of patients. Disease-specific and overall survival rates were excellent and comparable to contemporary cystectomy data. Cystectomy was required in 144 patients with suboptimal response or recurrent disease; no patient required cystectomy for treatment-related toxicity.",163,29,0.17791411042944785
9781910797662,ch07,Management of both local and distant metastatic disease should be considered.,"Management of advanced and metastatic disease. A core principle in the management of solid tumors is to consider control of both the primary and metastatic disease. Several clinical scenarios occur in bladder cancer. Cancers that are clearly confined to the bladder can potentially be cured if the primary tumor can be removed or ablated, through surgery, radiation therapy or multimodality approaches, and there is no metastatic disease; 5-year survival rates are about 70%. Management of these cancers is discussed in chapter on 'Management of non-muscle-invasive disease'.",111,13,0.11711711711711711
9781910797662,ch07,Cisplatin-based chemotherapy can provide excellent outcomes for some patients with advanced or metastatic disease.,"Locally advanced cancers and tumors that have spread to loco-regional lymph nodes are associated with an increased risk of local relapse and a higher risk of micrometastatic disease at diagnosis. Five-year survival is about 35%. Lymph node involvement is identified through lymph node dissection or accurate imaging. The primary cancer may still be amenable to local therapy, and is potentially curable in the absence of distant metastases. Optimum systemic therapy with cisplatin-based chemotherapy is standard of care for patients with adequate renal function who are suitable for chemotherapy.",115,21,0.1826086956521739
9781910797662,ch07,Combination chemoradiotherapy to the bladder is best reserved for patients being treated with curative intent.,"Locally advanced cancers and tumors that have spread to loco-regional lymph nodes are associated with an increased risk of local relapse and a higher risk of micrometastatic disease at diagnosis. Five-year survival is about 35%. Lymph node involvement is identified through lymph node dissection or accurate imaging. The primary cancer may still be amenable to local therapy, and is potentially curable in the absence of distant metastases. Optimum systemic therapy with cisplatin-based chemotherapy is standard of care for patients with adequate renal function who are suitable for chemotherapy.",115,21,0.1826086956521739
9781910797662,ch07,The intent of treatment for patients with metastatic disease is optimal palliation (improved quality of life with or without prolonging survival). The benefits of any treatment must outweigh the risks.,"Cancers predominantly involving the bladder but where there is small-volume overt metastatic disease are unlikely to be cured with currently available modalities; treatment is therefore palliative in intent, which must be clearly understood from the outset. Five-year survival for patients with metastatic disease is approximately 5%, although this varies depending on the bulk of disease, response to therapy and patient factors, including comorbidities. The mainstay of therapy is systemic treatment to control the progression of metastatic disease although management of the primary cancer may be necessary to alleviate symptoms and to prevent future complications such as pain, intractable hematuria and upper urinary tract obstruction. Surgery or radiation therapy may therefore be necessary for management of the primary tumor, and sometimes for management of metastatic disease.",156,37,0.23717948717948717
9781910797662,ch07,"Perioperative chemotherapy should be considered for suitable patients with high-risk bladder-confined disease, but preoperative chemotherapy is preferred where possible.","Cancers predominantly involving the bladder but where there is small-volume overt metastatic disease are unlikely to be cured with currently available modalities; treatment is therefore palliative in intent, which must be clearly understood from the outset. Five-year survival for patients with metastatic disease is approximately 5%, although this varies depending on the bulk of disease, response to therapy and patient factors, including comorbidities. The mainstay of therapy is systemic treatment to control the progression of metastatic disease although management of the primary cancer may be necessary to alleviate symptoms and to prevent future complications such as pain, intractable hematuria and upper urinary tract obstruction. Surgery or radiation therapy may therefore be necessary for management of the primary tumor, and sometimes for management of metastatic disease.",156,29,0.1858974358974359
9781910797662,ch07,Combination chemoradiotherapy can be an alternative to cystectomy for the management of locally advanced disease.,"Cancers predominantly involving the bladder but where there is small-volume overt metastatic disease are unlikely to be cured with currently available modalities; treatment is therefore palliative in intent, which must be clearly understood from the outset. Five-year survival for patients with metastatic disease is approximately 5%, although this varies depending on the bulk of disease, response to therapy and patient factors, including comorbidities. The mainstay of therapy is systemic treatment to control the progression of metastatic disease although management of the primary cancer may be necessary to alleviate symptoms and to prevent future complications such as pain, intractable hematuria and upper urinary tract obstruction. Surgery or radiation therapy may therefore be necessary for management of the primary tumor, and sometimes for management of metastatic disease.",156,22,0.14102564102564102
9781910797662,ch07,Radiation therapy to the primary or appropriate metastatic sites can provide useful palliation.,"Cancers predominantly involving the bladder but where there is small-volume overt metastatic disease are unlikely to be cured with currently available modalities; treatment is therefore palliative in intent, which must be clearly understood from the outset. Five-year survival for patients with metastatic disease is approximately 5%, although this varies depending on the bulk of disease, response to therapy and patient factors, including comorbidities. The mainstay of therapy is systemic treatment to control the progression of metastatic disease although management of the primary cancer may be necessary to alleviate symptoms and to prevent future complications such as pain, intractable hematuria and upper urinary tract obstruction. Surgery or radiation therapy may therefore be necessary for management of the primary tumor, and sometimes for management of metastatic disease.",156,17,0.10897435897435898
9781910797662,ch07,Management of patients with advanced or metastatic disease is complex and requires a multidisciplinary approach.,"The treatment of metastatic bladder cancer was transformed following publication of a randomized Phase III trial comparing MVAC versus gemcitabine and cisplatin (GC)., The study was somewhat ambitiously designed to demonstrate a 33% improvement in OS with GC, rather than as an equivalence or non-inferiority study. The survival curves for the two regimens were similar, and the trial did not meet its primary endpoint. However, GC was found to be better tolerated than MVAC and was adopted as standard of care for the treatment of metastatic disease. GC has become the de facto standard for trials in other settings, even though this is not supported by high-level evidence. Modifications to the regimen are frequently made (often with little supporting evidence), such as splitting the dose of cisplatin, dropping treatment weeks or shortening treatment cycles, modifying the gemcitabine dosage, or substitution with drugs such as carboplatin. It is important to recognize when and how far we should go beyond high-level evidence when making treatment decisions with patients.",216,19,0.08796296296296297
9781910797662,ch08,"First-line treatment is also efficacious, particularly in patients less likely to tolerate cytotoxic chemotherapy.","Bladder cancer has long been considered responsive to immunological manipulation. Treatment of non-muscle-invasive urothelial bladder cancer with bacillus Calmette-Gurin is well established as standard of care, see pages 45-48. After decades with few clinical trials or advances in treatment, recent years have seen the advent of new and efficacious immunotherapeutic approaches, and several new treatments have been approved, across all stages of urothelial cancer. The field has suddenly become both crowded and exciting. This chapter provides a snapshot as at early 2018; however, substantial changes in practice are likely as new information continues to emerge.",134,21,0.15671641791044777
9781910797662,ch08,So far there is no strong evidence that immunotherapies targeted at the programmed cell death protein 1 (PD-1) axis differ substantially in terms of efficacy or toxicity.,"Blockade of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) was one of the first effective systemic immunotherapy approaches in the modern era. CTLA-4 mediates inhibitory signals to the T cell during its interaction with antigen-presenting cells such as dendritic cells, ensuring that the immune system does not become overactivated in an uncontrolled fashion. Monoclonal antibodies against CTLA-4, such as ipilimumab and tremelimumab, are approved or are being developed for a range of indications. The programmed cell death protein 1 (PD-1) axis has also been a key target, described in more detail below. Simultaneous blockade of both CTLA-4 and the PD-1 axis is a logical approach and in some settings improves clinical outcomes but increases the risk of significant autoimmune toxicities.",178,35,0.19662921348314608
9781910797662,ch08,"Five immunotherapies have recently been approved for the second-line treatment of advanced or metastatic bladder cancer, and two have also been approved in the first-line setting.","The first PD-1-targeted immunotherapy to be approved was atezolizumab, based on results from the Phase II IMvigor 210 trial, which showed an overall response rate of 15% and acceptable toxicity. At the time of writing, five monoclonal antibodies targeting either PD-1 or PD-L1 have been approved by the US Food and Drug Administration (FDA) for the management of advanced or metastatic urothelial cancer (Table 8.2). All received breakthrough therapy designation and were approved via priority review, based on data from Phase II single-arm studies, with the exception of pembrolizumab, which was compared with chemotherapy (investigators' choice). Note that the outcomes of further trials may affect approval and subsequent use of these agents.",164,36,0.21951219512195122
9781910797662,ch08,The management of advanced and metastatic bladder cancer will evolve as the results of further trials emerge.,"At the time of writing, five monoclonal antibodies targeting either PD-1 or PD-L1 have been approved by the US Food and Drug Administration (FDA) for the management of advanced or metastatic urothelial cancer (Table 8.2). All received breakthrough therapy designation and were approved via priority review, based on data from Phase II single-arm studies, with the exception of pembrolizumab, which was compared with chemotherapy (investigators' choice). Note that the outcomes of further trials may affect approval and subsequent use of these agents.",117,19,0.1623931623931624
9781910797662,ch08,"There is good evidence that second-line treatment after cisplatin-based chemotherapy is generally well tolerated, efficacious, and can confer a survival advantage.","The most convincing data so far relate to pembrolizumab, which is the first product for which Phase III results were reported. The Keynote-045 Phase III trial demonstrated that pembrolizumab was active in the second-line setting for patients whose cancers had progressed after cisplatin-based chemotherapy, and provided a significant overall survival (OS) benefit compared with standard chemotherapy: 10.3 versus 7.4 months (hazard ratio for death 0.73, 95% confidence interval [CI] 0.59-0.91; p = 0.002). Other drugs in this class are likely to have similar efficacy, as illustrated in Table 8.3. However, study design needs to be considered carefully when looking at trial results. For example, the IMvigor 211 trial, which compared atezolizumab versus chemotherapy following failure of platinum-based chemotherapy, did not meet its OS primary endpoint, although this was probably because of the way the statistical analysis was planned, and overconfidence in the PD-L1 tissue assay: the outcome was negative for the apparently PD-L1-expressing subset but positive when the entire study population was included.",242,31,0.128099173553719
9781910797662,ch08,"A survival benefit has been shown with pembrolizumab versus chemotherapy but not atezolizumab (likely a reflection of the study design); however, survival data from the trials of the other immunotherapies are not yet mature.","The identification of biomarkers, and therefore tests, that predict response to treatment has not been a priority in pharmaceutical drug development. This is changing with the development of immunotherapies and the pressure to be able to identify patients who are likely to benefit from treatment with particular monoclonal antibodies, such as trastuzumab in HER2-overexpressing breast cancer and BRAF mutations in melanoma. Availability of such validated tests would allow rational use of the drugs and avoid exposing patients to the adverse effects of drugs that might provide no clinical benefit. However, BRAF and HER2 are 'driver' molecules and their status can be accurately determined, whereas this is not the case with PD-L1. Expression of PD-L1 is often associated with poorer outcomes in bladder cancer, regardless of the treatment used. It is logical to expect that expression of PD-L1 by tumor, immune or other cells in the tumor deposit would predict response to therapies targeted at the PD-1 axis; however, this has not yet been reliably shown to be the case, mainly because of deficiencies and variability in the available tissue-based assays for PD-L1.",239,51,0.21338912133891214
9781910797662,ch08,Current tissue-based programmed cell death ligand 1 (PD-L1) assays do not reliably predict response or lack of response to PD-1-targeted therapy.,"Variation in PD-L1 expression. Importantly, PD-L1 expression is both dynamic and sporadic: it probably changes over short periods, and PD-L1 is not necessarily expressed by all cells. It is therefore not surprising that measurement of PD-L1 expression in a small sample of tissue, perhaps obtained many years previously and stored under suboptimal conditions, does not correlate well with the probability of response to PD-1 axis blockade. Tissue PD-L1 expression has reasonable positive predictive value, in that cancers that are positive for PD-L1 expression are generally more likely to respond to PD-1-targeted therapies. However, cancers that do not appear to express PD-L1 may still respond to therapies targeted at the PD-1 axis.",158,36,0.22784810126582278
9781910797662,ch08,Combination strategies are being explored; these may be more active than monotherapies but are likely to be more toxic and more costly.,"The main adverse effects of immunotherapy relate to autoimmunity, that is, unmasking of immune responses against normal tissues. The systems most commonly affected are the skin, gastrointestinal tract, liver, endocrine system (including hypophysitis) and respiratory tract. However, rarer effects can occur, such as neurological or myocardial autoimmunity. Patients need to be treated by teams experienced in the management of these effects, and should be fully informed so that subtle autoimmunity can be detected and treated before significant toxicity occurs. Examples include endocrine dysfunction (panhypopituitarism, hypothyroidism, hypogonadism, hypoadrenalism), which can be subtle in presentation and easily missed but which can become life-threatening. Similarly, mild diarrhea may result from autoimmune colitis but without treatment can deteriorate and become fatal. Immune-related adverse events can usually be managed according to algorithms for immunosuppression, although some patients may not recover and may need ongoing management such as hormone replacement therapy. Interestingly, autoimmunity is correlated with an increased probability of an anticancer benefit but treatment of autoimmunity does not abrogate the antitumor effect. The reasons for this discrepancy remain unclear.",257,28,0.10894941634241245
9781910797662,ch09,Earlier diagnosis will shift the pattern of disease towards more favorable stage and grade cancers.,"Most non-muscle-invasive bladder cancer is low or intermediate risk (low-grade Ta), can be managed endoscopically and requires only limited further assessment or treatment. High-risk disease (all Ta, T1, high-grade carcinoma in situ [CIS], or large volume Ta) is less common but accounts for the majority of health resources in this therapy area, in managing the initial disease and reducing the risk of recurrence or progression to more advanced or metastatic disease. Newer surgical and other ablative techniques, and enhanced endoscopic imaging with fluorescence cystoscopy, optical coherence tomography and confocal laser, may improve diagnostic risk stratification and the definitive treatment of early disease. Standardization of protocols for adjunctive therapies such as bacillus Calmette-Gurin (BCG) treatment will also reduce the number of non-muscle-invasive cancers that progress to fatal invasive cancers. Hayne and colleagues have summarized the current status of several relevant trials with BCG.",212,16,0.07547169811320754
9781910797662,ch09,"Outcomes in advanced disease are likely to improve through the uptake of new therapies, including immunotherapy, as well as better application of existing evidence and treatments.","Most non-muscle-invasive bladder cancer is low or intermediate risk (low-grade Ta), can be managed endoscopically and requires only limited further assessment or treatment. High-risk disease (all Ta, T1, high-grade carcinoma in situ [CIS], or large volume Ta) is less common but accounts for the majority of health resources in this therapy area, in managing the initial disease and reducing the risk of recurrence or progression to more advanced or metastatic disease. Newer surgical and other ablative techniques, and enhanced endoscopic imaging with fluorescence cystoscopy, optical coherence tomography and confocal laser, may improve diagnostic risk stratification and the definitive treatment of early disease. Standardization of protocols for adjunctive therapies such as bacillus Calmette-Gurin (BCG) treatment will also reduce the number of non-muscle-invasive cancers that progress to fatal invasive cancers. Hayne and colleagues have summarized the current status of several relevant trials with BCG.",212,31,0.14622641509433962
9781910797662,ch09,"Improved biological characterization of tumors may point towards more appropriate and patient-specific treatments, including those aimed at specific molecular targets.","Several relevant biomarkers for risk stratification and prediction of response to treatment of bladder cancer are being explored (exempli gratia FGFR, VEGFR, HER2, circulating tumor DNA) and some (exempli gratia PD-L1) are beginning to be used in clinical practice in the hope that this might increase the probability that patients receiving treatments aimed at such targets will respond to them; however, uptake of such assays remains limited on a global scale and it is not yet clear whether their use improves outcomes. Improvements in the specificity and sensitivity of assays are required before these approaches are used in routine practice.",128,24,0.1875
9781910797662,ch09,Public health preventative measures are likely to have the greatest influence on bladder cancer outcomes globally.,"Better technology in this arena, including tests that are less invasive than cystoscopy or biopsy and therefore more acceptable to patients, will lead to earlier diagnosis and treatment and reduction of costs. Future developments are likely to involve refinements based on rational assessment of the tumor biology based on genomic, proteomic or immunologic profiling. However, incorporation of these assays into clinical practice requires care, particularly if the tissue was not obtained recently (exempli gratia past cystectomy) or is not representative of the cancer (exempli gratia small endoscopic biopsy of a bladder tumor in a patient with widespread metastatic disease). We will do well to learn from experience with the PD-L1 assays and the effects that blind faith in an unproven biomarker can have on clinical trial outcomes and drug development, as seen in the IMvigor 211 trial of atezolizumab (see page 77).",188,18,0.09574468085106383
9781910797662,ch09,Multidisciplinary management and extended supportive and palliative care measures will increasingly be adopted and improve cancer outcomes and quality of life.,"Most of the progress in bladder cancer management in the last 20 years has been in supportive care. This relates to improvement in quality of life through better control of symptoms, reduction in treatment-related toxicity, improved management of comorbidities and involvement of other disciplines such as exercise physiology, where improvements in cancer-specific outcomes can also be shown. There is a risk that quality of life is sacrificed by favoring treatments that have good efficacy but might be toxic. Whilst this is understandable, our patients often tell us that quality of life is more important than extending survival. It is important to recognize this, and to remember when considering the choice of treatment in the setting of incurable cancer, that improvement, or at least maintenance, of quality of life and functioning is a paramount objective. It is heartening to see this growing emphasis on patient-reported outcomes. A further benefit from this approach is the focus on reducing and managing the toxicities of treatment, with consequent improvements in response (and potentially cure) rates as well.",204,26,0.12745098039215685
9781910797693,chp1,"Biologics are typically proteins, ranging in size from simple proteins to large, complex monoclonal antibodies. They are created in living systems.","Biologics are large macromolecules, typically proteins. They range in size and structural complexity from simple proteins such as insulin and growth hormone to complex molecules such as coagulation factors and monoclonal antibodies, as shown in Figure 1.1. Many biologics, particularly the monoclonal antibodies, are described as targeted therapies because they have been designed to interact with specific receptors on cells. Biologics are created in living systems, such as bacterial, animal or human cell cultures, or are extracted from whole organisms; they cannot be synthesized chemically. Most biologics are complex mixtures; whilst their primary and secondary structures are known, they are less easily characterized at the tertiary level. This stands in contrast to conventional 'small molecule' drugs, which usually have a unique structure that can be fully characterized and are typically produced by inexpensive chemical synthesis that is straightforward to replicate. The complex nature of the biologics, and their manufacturing processes, means that identical copies of these molecule cannot be created.",208,30,0.14423076923076922
9781910797693,chp1,"The slight differences between batches of biologics, or between biologics and biosimilars, are authorised and not expected to have any meaningful effect on clinical use.","Biologics are created in living systems, such as bacterial, animal or human cell cultures, or are extracted from whole organisms; they cannot be synthesized chemically. Most biologics are complex mixtures; whilst their primary and secondary structures are known, they are less easily characterized at the tertiary level. This stands in contrast to conventional 'small molecule' drugs, which usually have a unique structure that can be fully characterized and are typically produced by inexpensive chemical synthesis that is straightforward to replicate. The complex nature of the biologics, and their manufacturing processes, means that identical copies of these molecule cannot be created. Biosimilar medicines. A biosimilar, as its name suggests, is highly similar to the reference biologic product, but is not identical. The primary and secondary amino acid structure, dosing, and route of administration are the same; differences in formulation, presentation, and the administration device are permitted, provided that these differences do not affect safety or effectiveness. As with all biologic medicines, the challenge for manufacturers and regulators is to ensure that copies of biologics are close enough in structure and function to the reference product to have no clinically meaningful differences in practical use.",239,34,0.14225941422594143
9781910797693,chp1,"Biosimilars are highly similar, but not identical, to their reference (originator) biologic. Furthermore, biologics themselves show inherent variation between batches (microheterogeneity), such that no batch is identical to previous batches.","A biosimilar, as its name suggests, is highly similar to the reference biologic product, but is not identical. The primary and secondary amino acid structure, dosing, and route of administration are the same; differences in formulation, presentation, and the administration device are permitted, provided that these differences do not affect safety or effectiveness. As with all biologic medicines, the challenge for manufacturers and regulators is to ensure that copies of biologics are close enough in structure and function to the reference product to have no clinically meaningful differences in practical use. Inherent variation in biological products. There is inherent variability in the biologics themselves - an important point that is relevant to the discussion of biologics and biosimilars but is often overlooked. This variability has two main sources. Microheterogeneity. Molecules made in living systems have inherent variability, even between batches of the same product, which is known as microheterogeneity. Thus, over time, a reference drug can never be considered to be a generic copy of its version at launch, as illustrated in Figure 1.2. This inherent variation is known as 'product drift' (see Figure 1.3).",235,48,0.20425531914893616
9781910797693,chp1,Inherent variability exists for all biologics and creates batch-to-batch variability for all products.,"There is inherent variability in the biologics themselves - an important point that is relevant to the discussion of biologics and biosimilars but is often overlooked. This variability has two main sources. Microheterogeneity. Molecules made in living systems have inherent variability, even between batches of the same product, which is known as microheterogeneity. Thus, over time, a reference drug can never be considered to be a generic copy of its version at launch, as illustrated in Figure 1.2. This inherent variation is known as 'product drift' (see Figure 1.3).",118,21,0.17796610169491525
9781910797693,chp1,"Changes to manufacturing processes can introduce significant changes to the tertiary structure of a biologic; analytics tests (and, exceptionally, new clinical trials) are required to assure that safety and efficacy have not changed.","In addition, manufacturing processes change frequently over the life of a biologic, adding to the potential for variability. A 2016 study of all European-approved originator monoclonal antibodies identified a mean of 11 changes with moderate or high potential risk per drug. Process change can result from advances in technology, such as higher yielding host cell systems, improvements in bioreactor design, scaling up of production to meet demand or if production is moved to a new manufacturing site. Changes in manufacturing risks the introduction of more significant variation in the tertiary structure of a biologic, known as 'step changes' (see Figure 1.3). Comparability of the drug before and after a step change needs to be demonstrated to assure that safety and efficacy have not changed. This comparability is usually assessed using only analytic tests although, rarely, new regulatory trials have been required. One example, a step change resulting from a new process in the manufacture of darbepoetin-alfa required confirmation through additional phase I, II and III studies. For this reason, manufacturing changes are monitored closely under the 2014 International Council for Harmonisation Q5E.",230,41,0.1782608695652174
9781910797693,chp3,"The quality attributes - chemical, physical, and biological properties - of a biologic must be within a development corridor that defines the acceptable upper and lower limits of the marketed product.","Biosimilars have a development advantage in that they are built on the large body of evidence created by the originator medicine and available at the time of the biosimilar's development. This totality of experience available with the original reference product can highlight issues such as immunogenicity or multiple potential mechanisms of action that will be critical in developing follow-on products. Manufacturers and regulators define quality according to critical 'quality attributes': chemical, physical and biological properties that need to be within agreed tolerances. Advances in analytical technology have permitted detailed characterization of the active ingredients in biologics. Importantly, for biosimilarity with a reference protein product, it is necessary to demonstrate that the amino acid sequence (primary structure) and higher order structure is the same.",153,35,0.22875816993464052
9781910797693,chp3,"The regulations were originally developed to cover variation in batches of biologics resulting from manufacturing changes, including procedures to ensure that batches of originator biologics were within the development corridor.","Batches of biologics vary over time, and this is true for both the originator and biosimilar drug. Clinical studies of an originator drug to support different indications are likely to have been conducted with different batches. Indeed, it is possible that a biosimilar batch could more closely share critical attributes of that (originator) batch than the current batch. A change in the production process of a biological drug (originator or biosimilar) could affect outcomes. For this reason, manufacturing changes are regulated to ensure that new batches of product meet the defined critical attributes. The regulation of biosimilar production is based on the procedures developed to address changes to manufacturing of originator biologics. Biologic and biosimilar drug developers can determine the natural variation in the structure and biopotency of the reference drug from sequential batches of the drug. Variation in these attributes over time defines the limits of acceptable analytic differences that a regulator accepts between a reference drug and its biosimilar and so defines the development corridor for a biosimilar.",206,37,0.1796116504854369
9781910797693,chp4,The evidence required for approval of biosimilars is greater than that for generic versions of small molecule drugs.,"The development and characteristics of generic and biosimilar medicines is compared in Table 4.1. As can be seen, the evidence required for biosimilars is greater than that for generic versions of small molecule drugs. European regulation of biosimilars. The European Medicines Agency (EMA) pioneered the regulation of safe and effective copies of biologic drugs without having to recreate the full drug development steps of an original reference drug. The agency adapted the 'biosimilar pathway' from the existing regulatory pathway designed for reference drugs following a manufacturing change. This process recognizes that all biologic drugs vary in structure and potency over time, such that identical copies of a biologic drug can never be made (see page 11). The critical attributes of a biologic or biosimilar can be followed with high acuity analytics and must be maintained within a range which ensures that the product, whilst not identical, is similar enough to predict that the safety and efficacy would show no clinically meaningful differences.",194,21,0.10824742268041238
9781910797693,chp4,"The 'biosimilar pathway' developed by the European Medicines Agency follows the principles that apply following a change to manufacturing of a biologic. Central to the pathway is the demonstration that there are no significant clinical differences between a biosimilar and its reference biologic, based on analytical, preclinical and clinical data.","The only major difference between the biosimilar pathway and the protocol following a manufacturing change is that Phase I and III trials are required for all biosimilars in at least one indication (see next section); these studies must include evaluation of immunogenicity, which is difficult to predict without human studies. In contrast to originator drugs, which require pivotal clinical trials to gain new approved indications, biosimilars may gain approval by extrapolating the equivalence demonstrated in one approved indication to another. Clinical studies are required for additional indications if the approved indications have different mechanisms of action (MOA) or mechanisms of toxicity (MOT) that could suggest a potential risk to drug safety or efficacy. The biosimilar pathway. In Europe biologics are assessed centrally by the EMA. The 'biosimilar pathway' was established in 2003 and shows significant difference with the regulatory pathway for small molecule generic drugs, as shown in Figure 4.1. Central to this pathway is the demonstration that there are no significant clinical differences between the biosimilar and the reference biological product. However, it is not necessary to demonstrate safety and efficacy across all the indications of the originator brand: based on the expectation that the biosimilar and reference biological agent have the same safety and efficacy, they can be used to treat the same indications. This concept of extrapolation is explained in more detail on page 33. There is no single analytic test for a biosimilar, whether chemical or clinical. Approval is based on the totality of data built up in a stepwise fashion from initial chemical analytics, biopotency modelling, and toxicology, through to Phase I and, finally, comparative Phase III trials (see Figure 4.1). Key steps in the biosimilar approval pathway. Demonstration of the comparability of a biosimilar with its reference product follows a sequential process, as illustrated in Figure 4.1.",378,63,0.16666666666666666
9781910797693,chp4,'Intended copy' biologics manufactured in countries with less stringent regulation than the EU and USA may not be true biosimilars and clinical equivalence cannot be assumed.,"The manufacture of 'intended copy' biologics (defined on page 14) in countries where robust regulatory pathways have not been established may address an unmet health need but presents risks - such medicines, while clinically active, may not be close enough to the originator molecule to be judged biosimilar in analytical or clinical testing. Without either a 'biosimilarity exercise' or the security of a large-scale Phase 3 trial, the safety and efficacy of these copies cannot be predicted. Furthermore, the infrastructure to produce evidence relating to safety and efficacy may be poor. For less wealthy nations, abbreviated drug development and regulatory pathways for the approval of biosimilars can cut costs and deliver affordable medicines. This lack of regulation has resulted in the introduction of many copies of biologics. Early marketing in poorer nations is possible because intellectual property laws are not applied or are ignored. As a result, many versions of biologics will have been used in Asia, Africa and South America before biosimilar versions can be approved and launched in the highly regulated markets of Europe, the USA, and Japan. Prescribers therefore need to be aware that some products available outside of Europe, the USA and Japan are not true biosimilars and have not been subjected to the same robust regulatory scrutiny.",260,35,0.1346153846153846
9781910797693,chp4,"Based on this, and demonstration that the mechanism of action is the same in different conditions, the biosimilar will be approved for the same indications as the reference biologic - known as extrapolation.","Epoetin. In Thailand, more than a dozen different copies of epoetin-alfa were marketed but had not been approved through stringent regulatory procedures such as in the EU and USA. Simple analytics such as isoelectric gel chromatography showed that many of these copies were structurally different from the reference drug (epoetin-alfa Epogen ). Twelve such intended copy biologics were analyzed in a joint Thai-Dutch study. Some showed high aggregate levels and contained substantial levels of protein fragments - a critical attribute of these medicines that has been strongly associated with a rare but potentially fatal adverse drug reaction., Epoetin aggregates can promote the development of anti-drug immune reactions which can neutralize both the medicine and the erythropoietin produced by the kidneys, causing pure red cell aplasia (PRCA). Affected patients become profoundly anemic and transfusion dependent, and will die if the auto-immunity cannot be suppressed. It is therefore not surprising that an outbreak of PRCA was reported in Thailand in 2011, with 23 cases in 59 990 patient-years' exposure, equivalent to a risk of 1 in 2608 (0.00038). This is substantially higher than the risk reported by Mikhail and Farouk (2013), who estimated that the rate of PRCA with epoetin-alfa Eprex in its original formulation was 1 per 100,000 patient-years' exposure (0.00001), with only three cases reported in the first decade of use. Worryingly, Thai reporters misattributed the problem to 'biosimilar recombinant human erythropoietin', and the misinformation was continued by subsequent editorials and opinion pieces. For example, an editorial in the scientifically respected peer-reviewed journal Kidney International explained ' Biosimilar agents may not undergo the same quality control in their production, packaging, storage, and distribution as their patented competitors. The extensive use of biosimilar erythropoiesis-stimulating agents led to an epidemic of PRCA in Thailand '. Both these statements are incorrect, as both original reference drugs and WHO-compliant biosimilar drugs are assessed according to the same standard quality control, including packaging, storage, and distribution.",462,39,0.08441558441558442
9781910797693,chp4,"Safety monitoring in the EU over the 10 years since the introduction of biosimilars has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines.","Safety data for a biosimilar are likely to be limited at the time of launch; however, experience to date indicates that the adverse event profiles of biosimilars match those of their originators. Indeed, safety monitoring within the EU over the 10 years since the introduction of biosimilars has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines. The comparability studies performed on biosimilars mean that the risk of new or severe adverse events (type 2) is likely to be lower than with a novel biological agent. Pharmacovigilance. Clinical studies on a biosimilar prior to authorization are generally limited and, as for any new drug, post-marketing surveillance is required to enable identification of any rare adverse effects. Biosimilars are subject to the same degree of post-approval pharmacovigilance as the originator biologic. Crucial to this will be product naming - since biosimilars and originators will share the same International Non-propriety drug name (INN). In 2010, Europe updated its pharmacovigilance guidance requiring member states to encourage use of brand names in prescribing, health records and adverse event reporting. This appears to have been successful. For example product-specific attribution of epoetins is near 99%, and over all is 96%. However such success has not been universal: for example of 19 adverse event reports in the Australian Database of Adverse Event Notifications (DAEN) for filgrastim over 2011 to 2014, the full brand name was reported in only 11 (58%). This is an issue that affects originator medicines as well. For example, in the USA brand name reporting for different insulins was only 84% in the MedWatch system.",362,41,0.1132596685082873
9781910797693,chp4,"While the safety data for a biosimilar may be limited at launch, comparability studies mean that the range and severity of potential adverse events can be predicted from the experience with the originator reference biologic gained over many years of clinical use.","Safety data for a biosimilar are likely to be limited at the time of launch; however, experience to date indicates that the adverse event profiles of biosimilars match those of their originators. Indeed, safety monitoring within the EU over the 10 years since the introduction of biosimilars has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines. The comparability studies performed on biosimilars mean that the risk of new or severe adverse events (type 2) is likely to be lower than with a novel biological agent. Pharmacovigilance. Clinical studies on a biosimilar prior to authorization are generally limited and, as for any new drug, post-marketing surveillance is required to enable identification of any rare adverse effects. Biosimilars are subject to the same degree of post-approval pharmacovigilance as the originator biologic. Crucial to this will be product naming - since biosimilars and originators will share the same International Non-propriety drug name (INN). In 2010, Europe updated its pharmacovigilance guidance requiring member states to encourage use of brand names in prescribing, health records and adverse event reporting. This appears to have been successful. For example product-specific attribution of epoetins is near 99%, and over all is 96%. However such success has not been universal: for example of 19 adverse event reports in the Australian Database of Adverse Event Notifications (DAEN) for filgrastim over 2011 to 2014, the full brand name was reported in only 11 (58%). This is an issue that affects originator medicines as well. For example, in the USA brand name reporting for different insulins was only 84% in the MedWatch system.",362,48,0.13259668508287292
9781910797693,chp4,"Biosimilars are subject to the same pharmacovigilance as their reference biologic, including special report requirements (black triangle; risk minimization plan).","Pharmacovigilance. Clinical studies on a biosimilar prior to authorization are generally limited and, as for any new drug, post-marketing surveillance is required to enable identification of any rare adverse effects. Biosimilars are subject to the same degree of post-approval pharmacovigilance as the originator biologic. Crucial to this will be product naming - since biosimilars and originators will share the same International Non-propriety drug name (INN). In 2010, Europe updated its pharmacovigilance guidance requiring member states to encourage use of brand names in prescribing, health records and adverse event reporting. This appears to have been successful. For example product-specific attribution of epoetins is near 99%, and over all is 96%. However such success has not been universal: for example of 19 adverse event reports in the Australian Database of Adverse Event Notifications (DAEN) for filgrastim over 2011 to 2014, the full brand name was reported in only 11 (58%). This is an issue that affects originator medicines as well. For example, in the USA brand name reporting for different insulins was only 84% in the MedWatch system.",245,32,0.1306122448979592
9781910797693,chp5,"Four generations of biosimilar have been developed, from the simple hormone replacement molecules to complex monoclonal antibodies used for chronic inflammatory disorders and cancer, and more than 30 are now approved in the EU, but only six in the USA.","Biosimilars have been available in Europe for more than a decade, since the first biosimilar (human growth hormone, Omnitrope ) was approved in 2006; more than 30 biosimilars had been approved at the start of September 2017, listed in Table 5.2. Patient exposure to European-approved biosimilars over this period has been more than 700 million patient-days, with no signal that these less-costly biosimilars have any meaningful difference in safety or efficacy from their originator biologics. By contrast, only six biosimilars are currently approved in the USA (Table 5.3). While a biosimilar may have regulatory approval there may be a delay before sales can begin due to patent expiry dates. For example a biosimilar of adalimumab was approved by the European Medicines Agency (EMA) in March 2017; however, the European patent of adalimumab-Humira TM doesn't expire until the last quarter of 2018, indicating that the product may not be available until early in 2019.",215,48,0.22325581395348837
9781910797693,chp5,"There has been no indication that the biosimilars have any meaningful difference in safety or efficacy from their originator biologics, based on more than 700 million patient-days' exposure to European-approved biosimilars over the last 10 years.","Biosimilars have been available in Europe for more than a decade, since the first biosimilar (human growth hormone, Omnitrope ) was approved in 2006; more than 30 biosimilars had been approved at the start of September 2017, listed in Table 5.2. Patient exposure to European-approved biosimilars over this period has been more than 700 million patient-days, with no signal that these less-costly biosimilars have any meaningful difference in safety or efficacy from their originator biologics. By contrast, only six biosimilars are currently approved in the USA (Table 5.3). While a biosimilar may have regulatory approval there may be a delay before sales can begin due to patent expiry dates. For example a biosimilar of adalimumab was approved by the European Medicines Agency (EMA) in March 2017; however, the European patent of adalimumab-Humira TM doesn't expire until the last quarter of 2018, indicating that the product may not be available until early in 2019.",215,50,0.23255813953488372
9781910797693,chp5,Managed programs in which savings from switching could be reinvested in staffing have realized substantial savings.,"A managed program was used in the UK to encourage switching: the scheme was based on the concept of 'gain share', in which a portion of the anticipated savings from switching was reinvested in staffing. Such a program at a single hospital reported savings of 40 000-60 000 per month (45 000-68 000 [US$52 000-77 000]) realized from switching 143 patients with inflammatory bowel disease to biosimilar infliximab. Furthermore, the extra staffing enabled the collection of data, which showed no changes in inflammatory disease markers, patient-reported side effects, immunogenicity or persistence with prescriptions; in fact, switching was associated with a significant improvement in disease control (improvement in the mean IBD-control-8 score from 10.4 to 11.2; p = 0.041).",166,19,0.1144578313253012
9781910797693,chp5,"Uptake of biosimilars has varied by therapy area and geography, ranging from 1% to 90%; some surveys report persistent concerns among clinicians about the interchangeability and substitution of biosimilars.","Recognition that switching from biologics to biosimilars, whilst potentially problematic, is crucial to the economic benefit of biosimilars, prompted an unprecedented intervention in 2017 by some of Europe's national drug regulators. Pekka Kurki of the Finnish Medicines Evaluation Agency, together with colleagues (including the former and current chairs of the EMAs Biosimilar Working Party and regulators from Germany, Netherlands and Norway), explained that European biosimilars are to be considered 'interchangeable' and safe for switching brands under the control of a physician. This was based on three factors: the high analytic similarity of biosimilars to originator drugs; no evidence of a difference in drug immunogenicity; and the wealth of clinical trial data available from over a decade of biosimilar use. They further expanded on the explanation as an issue of proportionality of risk - in that patients remaining on one brand of drug would themselves be exposed to 'switching' between different versions of the drug through inherent product drift and step changes in manufacturing processes.",210,40,0.19047619047619047
9781910797693,chp5,The introduction of the biosimilar filgrastim led to a dramatic increase in use whilst realizing cost savings because fewer patients required treatment for neutropenia; it also drove down the price of a long-acting version of filgrastim that was still patent protected.,"Even though biosimilars have relatively high prices compared with small molecule drugs, their introduction has served to improve patient access through the resultant cost savings that can be realized. For example, when the London Medicines Procurement Programme introduced biosimilar versions of filgrastim (recombinant human granulocyte colony-stimulating factor [G-CSF], a white cell growth factor used to minimize the risk of neutropenia [low neutrophil cell count], and therefore infection, during cancer chemotherapy), the number of patients treated increased five-fold, driven by the lower price compared with the original brand. Despite this dramatic increase in drug volume, however, cost savings were realized through the prevention of neutropenia and the high associated cost of treatment. A similar pattern was seen in Sweden, where a five-fold increase in daily G-CSF usage was matched by 4-5% saving in the total drug budget. When biosimilar filgrastim was introduced in New Zealand in 2012, national audits confirmed both increased patient access and improved outcomes for the overall patient population. While filgrastim was only given to women who had already experienced one episode of neutropenia, filgrastim-Zarzio was also given to women at risk of neutropenia. As a result, the proportion of women receiving docetaxel-based chemotherapy for breast cancer who experienced neutropenic fever decreased from one-third prior to biosimilars to fewer than 7% with biosimilars. Furthermore, the introduction of filgrastim-Zarzio also drove down the price of pegfilgrastim, a long-acting version of filgrastim that was still on patent. This is illustrated in Figure 5.2.",362,55,0.15193370165745856
9781910797693,chp5,Competitive pricing has also reversed health technology assessments for erythropoietins by improving the cost-effectiveness of treatment.,"Biosimilars have also reversed negative decisions in heath technology assessments. For example, the UK National Institute for Health and Care Excellence (NICE) appraised epoetins (recombinant red cell growth factors) in the treatment of anemia due to cancer chemotherapy for the first time in 2008 (technology appraisal [TA] 142). Whilst epoetin alfa, epoetin beta, and darbepoetin alfa were considered clinically effective in this indication, they were not cost-effective and NICE did not recommend their use in the National Health Service (NHS). However, in a subsequent appraisal in 2014 (TA323), prices were taken from the tender bids placed for contracts to supply epoetins to the London Medicines Procurement Programme; as a result of the competition created by biosimilars, NICE approved use of these drugs in the NHS. This demonstrates the potential effect of biosimilars on the prices of all drugs within the same class: epoetin alfa, epoetin beta and darbepoetin alfa are all epoetins (erythropoiesis stimulating agents) but only biosimilars of epoetin-alfa were available at the time of the second NICE appraisal.",267,26,0.09737827715355805
9781910797693,chp6,"The next wave of biosimilars will be therapeutic oncology drugs, such as rituximab, bevacizumab, and trastuzumab, and recombinant insulins.","Based on patent expiry dates, the next wave of biosimilars will be therapeutic oncology drugs and recombinant insulins. Two rituximab biosimilars have been approved in Europe, two biosimilars of trastuzumab have been approved by the Oncology Drugs Advisory Committee (ODAC) of the Food and Drug Administration, a further trastuzumab biosimilar (Ontruzant ; Samsung Bioepis) has received a postitive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and a biosimilar of bevacizumab has recently been reviewed by the ODAC. Trial endpoints. Biosimilar oncologics face a challenge of confidence given that the aim of curative treatment is the absence of disease. For originator drugs, the pivotal trial endpoints were disease-free survival and overall survival rates 5 years after treatment. The regulatory's aim for a biosimilar is to show no clinically meaningful difference in efficacy, as determined by the totality of evidence from structural analytics and functional assays of biopotency, and phase I and III trials to show comparable safety, immunogenicity, pharmacokinetic and pharmacodynamic (PD) endpoints. Critically, the PD endpoints for biosimilars are usually surrogate rather than clinical results.",276,44,0.15942028985507245
9781910797693,chp6,"The equivalence of oncology biosimilars will be based on surrogate pharmacodynamic endpoints, rather than survival, and extrapolation from non-oncology indications, with regulators considering the totality of evidence.","Confusion, stemming from differences in trial design, is compounded by the desire of competing manufacturers to create differentiation between biosimilars of the same drug. With the originator cancer drugs, claims of superiority were based on differences in trial outcomes, such as a longer time without tumor or disease progression, higher 5-year overall survival rates, or lower drug toxicity. In contrast, biologics and biosimilars are deemed by regulators to be either equivalent or not equivalent - a binary decision, with analytics being the dominant driver of the decision. Since phase III clinial trials for biosimilars are tailored for each drug, and trial endpoints may be different from the originator pivotal study, it may be impossible to directly compare a biosimilar with the originator, or indeed, other biosimilars. Formulary decisions about the choice of biosimilar would then be driven by price and convenience, as is the case for generic drugs. This offers little opportunity to claim technical superiority of one biosimilar over another, as all versions of a drug will have been determined comparable.",215,43,0.2
9781910797693,chp6,"Marketing pressure to differentiate between medicines is usually based on clinical differences in phase III trials. However, biosimilars do not fit this commercial model, as by definition, they offer no difference in efficacy or safety with which to differentiate brands.","Confusion, stemming from differences in trial design, is compounded by the desire of competing manufacturers to create differentiation between biosimilars of the same drug. With the originator cancer drugs, claims of superiority were based on differences in trial outcomes, such as a longer time without tumor or disease progression, higher 5-year overall survival rates, or lower drug toxicity. In contrast, biologics and biosimilars are deemed by regulators to be either equivalent or not equivalent - a binary decision, with analytics being the dominant driver of the decision. Since phase III clinial trials for biosimilars are tailored for each drug, and trial endpoints may be different from the originator pivotal study, it may be impossible to directly compare a biosimilar with the originator, or indeed, other biosimilars. Formulary decisions about the choice of biosimilar would then be driven by price and convenience, as is the case for generic drugs. This offers little opportunity to claim technical superiority of one biosimilar over another, as all versions of a drug will have been determined comparable.",215,48,0.22325581395348837
9781910797693,chp7,"The decision to prescribe a biosimilar in place of a biologic is a clinical one, and has long been practiced with the epoetins and recombinant growth hormone. The demonstration of compatibility with the originator biological provides clinicians with the confidence to switch to a biosimilar.","The term switching is used in this context to mean changing a patient's treatment at the clinical level, so the decision by the clinician - in discussion with the patient- to prescribe a biosimilar in place of the originator biologic. (This contrasts with substitution, which occurs at pharmacy level; see page 65 .). The concept of switching a patient from one brand of a drug on which they have been established to another brand of the same drug is crucial to biosimilar usage. Switching between different originator brands has already been a feature of medical practice in the case of epoetins and recombinant growth hormone. The demonstration of comparability with the originator biological provides clinicians with the confidence to switch a patient to a biosimilar. Experience with switching from originator to biosimilar is increasing, although published data (especially long-term outcomes) have, until recently, been limited. In one published study of patients receiving growth hormone, 98 patients from a cohort of 130 were switched from an originator brand to a biosimilar; 15 reported non-serious adverse drug reactions (mainly injection site discomfort).",224,56,0.25
9781910797693,chp7,Patients may be started on a biosimilar or switched from an originator biologic.,"The concept of switching a patient from one brand of a drug on which they have been established to another brand of the same drug is crucial to biosimilar usage. Switching between different originator brands has already been a feature of medical practice in the case of epoetins and recombinant growth hormone. The demonstration of comparability with the originator biological provides clinicians with the confidence to switch a patient to a biosimilar. Experience with switching from originator to biosimilar is increasing, although published data (especially long-term outcomes) have, until recently, been limited. In one published study of patients receiving growth hormone, 98 patients from a cohort of 130 were switched from an originator brand to a biosimilar; 15 reported non-serious adverse drug reactions (mainly injection site discomfort).",159,18,0.11320754716981132
9781910797693,chp7,"Clinicians' concerns that switching risks problems with immunogenicity are unfounded; indeed, numerous medicines agencies have concluded that biosimilars licensed in the EU are interchangeable and that switching would not be expected to trigger or enhance immunogenicity. Furthermore, microheterogeneity in the originator biologic means that a patient is exposed to slightly different molecules over the course of treatment.","Concerns about immunogenicity. Product drift over time means that no biologic drug can ever be considered truly identical to itself over time. Switching from a reference drug to a biosimilar is argued to carry a risk to the patient in that introducing a new version of the drug that may have differences in tertiary structure could affect efficacy or safety, including concerns about immunogenicity. However, the counter-argument is that this will happen anyway: if the patient remains on the same brand, variation will occur. Furthermore, since the biosimilar has been developed to maintain critical analytic attributes within the release specification, the risks posed by new versions of either brand must be considered similar. This concept lies behind the statement on biosimilar interchangeability by leaders of the Finnish Medicines Agency, Netherlands' Medicines Evaluation Board, the Norwegian Medicines Agency, Germany's Paul-Ehrlich-Institute and others, which concluded that biosimilars licensed in the EU are interchangeable. A switch between comparable versions of the same active substance approved in accordance with EU legislation is not expected to trigger or enhance immunogenicity and, on the basis of current knowledge, it is considered unlikely - and difficult to substantiate - that two products that are comparable at a population level would have different safety or efficacy in individual patients following a switch. A systematic literature review of the evidence relating to the consequences of switching from original biologics to biosimilars concluded that concern over switching to biosimilars was 'overhyped', and that preventing switching because of anticipated risks was disproportional compared with the expected cost savings and improved patient access.",325,75,0.23076923076923078
9781910797693,chp7,"The prescription should state the brand name and international non-proprietary name of the biologic or biosimilar, and in some countries the prescriber must indicate that substitution is not permitted. Substitution of a biologic with a biosimilar at pharmacy level is not permitted in the EU. The batch number must also be recorded.","Biosimilars, like small molecule generic drugs, share the same international non-proprietary name (INN) as the reference drug. This is because, as the EMA says, a biosimilar is a biological medicinal product that contains a version of the same active substance. Promoting INN use has been a priority for the World Health Assembly (Resolution WHA46.19 on non-proprietary names for pharmaceutical substances). However since biosimilars are not yet approved as suitable for automatic substitution at a pharmacy level, using the INN alone for prescribing will be insufficient. Confusingly, Europe and the USA have adopted different naming conventions - illustrated in Table 6.1. Clear product naming in prescriptions ensures correct dispensing and also enables retrospective identification for pharmacovigilance (see page 38). In some countries, the prescriber may have to specify that the drug may not be substituted at pharmacy level. Rules on counterfeit drugs also require the batch number to be recorded. Note that epoetin-zeta is an anomaly in the naming convention: at the time it was approved, the World Health Organization had proposed that erythropoetins should be named 'epoetin' together with a Greek letter to differentiate between compounds with the same amino acid sequence as human erythropoietin but that might vary in the glycosylation pattern; starting with epoetin-alfa (Eprex ), then epoetin-beta (Neorecormon ) and so on. Confusingly, epoetin-zeta (Retacrit ) is a biosimilar of epoetin-alfa (Eprex).",349,66,0.18911174785100288
9781910797693,chp7,"Switching does not require any dosage modification, although patients may need to be taught how to use a new injection device.","Given that for EMA approval, the dosing and route of administration of the biosimilar must be the same as for the reference medicinal product, changes to the dosage, dosing frequency or route of administration should not be necessary. However, the method of administration may be different in the case of an injectable; for example, the specific injection pen or device used for growth hormone preparations. Thus, if patients are switched to a new injection device, the potential for patient error or poor adherence should be managed.",102,24,0.23529411764705882
9781910797723,chp1,"The immune system has two components: innate immunity, involving mechanisms present throughout life, and adaptive (acquired) immunity, which is conferred by immune responses following exposure to an antigen, and is specific to that antigen.","The immune system has evolved to protect the host against infectious agents such as bacteria, viruses and fungi, and to detect and eliminate potentially harmful foreign material. A hallmark of cancer is that tumor cells - which would normally be recognized by the immune system as abnormal - acquire the ability to evade the immune system. Immuno-oncology is a new, multi-faceted and rapidly evolving collection of treatment strategies aimed at harnessing immune processes to target and destroy tumor cells and prolong survival. An understanding of the basic elements of the normal and tumor-altered immune system is therefore key to understanding potential immuno-oncology therapies. The immune system consists of two components: innate immunity and adaptive immunity. Innate immunity is conferred by mechanisms that are present throughout life, such as the physical barriers to infection provided by the skin and mucous membranes, white blood cells that remove foreign material, and serum proteins such as lysozymes and kinins. Adaptive (acquired) immunity is conferred by the formation of antibodies following exposure to foreign material (antigens), and is specific to the particular antigen.",225,43,0.19111111111111112
9781910797723,chp1,"Innate immunity is primarily conferred by phagocytic cells derived from stem cells in the bone marrow, principally macrophages, monocytes and neutrophils.","In addition to the physical barrier of skin and membranes, innate immunity is primarily conferred by phagocytic cells derived from stem cells in the bone marrow. The most important of these include macrophages, monocytes and neutrophils, although other cell types, such as natural killer (NK) cells, also play important roles (Table 1.1). Phagocytosis. Phagocytes are attracted to foreign material, such as a pathogen, and engulf it in a process known as phagocytosis. The foreign material is then contained inside an endosome, and digested by enzymes and acids contained in organelles known as lysosomes.",138,34,0.2463768115942029
9781910797723,chp1,"In cellular immunity, T cells recognize their target antigens as protein sequences presented on the surface of antigen-presenting cells (APCs) in association with major histocompatibility complex (MHC) molecules.- Activation of CD4+ T cells leads to cytokine release that affects multiple immune cells, including APCs.- Activation of CD8+ cytotoxic T cells triggers clonal selection, during which the T cells proliferate to produce a population of effector T cells, which release enzymes and toxins that lyse the membrane of antigen-bearing cells and induce programmed cell death (apoptosis).","T reg cells mainly regulate and suppress the immune response of naive and effector T cells through a variety of cytokine and signaling mechanisms, including transforming growth factor (TGF)-beta and IL-10. T reg cells regulate the immune response to common environmental allergens and prevent the development of atopy or undesirable inflammation. However, their role in maintenance of peripheral tolerance is also used by cancers to evade the immune system. CD8+ cytotoxic T cells (also known as killer T cells) are activated by antigens from intracellular pathogens presented on MHC class I molecules. Activation of these cells triggers a process known as clonal selection, during which the T cells proliferate to produce a population of effector T cells (Teff). These cells recognize cells with a unique MHC class I-antigen complex, and release enzymes and toxins that lyse the cell membrane and induce programmed cell death (apoptosis). To prevent extensive tissue damage during an infection, activation of CD8+ cells requires three signals (Figure 1.4). binding of the antigen to the TCR. binding of the MHC class I or II molecules to accessory CD8 or CD4 molecules, respectively, on the T cell. co-regulatory (co-stimulatory and co-inhibitory) signals resulting from binding of CD80 (B7-1) and CD28 on the APC and T cell: binding of CD80 (B7-1) on the APC to T cell CD28 leads to a positive signal, causing the T cell to kill cells bearing the relevant antigen, whereas binding of CD80 (B7-1) on the APC to CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on the T cell results in a negative signal, preventing the T cell from killing antigen-bearing cells. Humoral immunity involves the production in B cells of antibodies (immunoglobulins) against specific antigens. In contrast to T cells, where the antigen is processed intracellularly before being expressed on the cell surface in association with MHC molecules, B cells recognize the native, unprocessed, form of the antigen. The B cell receptor (BCR) consists of an antibody that recognizes a specific antigen. Upon activation by binding of the antigen to the BCR, B cells differentiate into short-lived antibody-producing cells (plasma cells) (Figure 1.5). The antibodies bind to the antigen, rendering it more susceptible to phagocytosis and triggering the complement system. Once the antigen has been cleared, the plasma cells are eliminated via programmed cell death (apoptosis). However, approximately 10% of activated B cells differentiate into long-lived antigen-specific memory B cells (see Figure 1.5); this allows a rapid immune response to be mounted in the event of re-exposure to the antigen.",595,125,0.21008403361344538
9781910797723,chp1,Humoral immunity involves the production by B cells of antibodies against specific antigens.,"Humoral immunity involves the production in B cells of antibodies (immunoglobulins) against specific antigens. In contrast to T cells, where the antigen is processed intracellularly before being expressed on the cell surface in association with MHC molecules, B cells recognize the native, unprocessed, form of the antigen.",69,17,0.2463768115942029
9781910797723,chp1,"Immune tolerance is a state in which the immune system is unresponsive to a stimulus that would normally provoke an immune response. This may be central or peripheral, depending on where tolerance develops. Immune tolerance is an important mechanism by which tumor cells evade the immune system.","Immune tolerance is a state in which the immune system is unresponsive to a stimulus that would normally provoke an immune response. It is an important mechanism by which tumor cells evade the immune system. Immune tolerance may be central or peripheral, depending on where it is induced. central tolerance is induced in the thymus and bone marrow. peripheral tolerance is induced in lymph nodes or other tissues. Central tolerance is the principal mechanism by which the immune system learns to distinguish between 'self' and 'non-self'. Maturing T and B lymphocytes in the thymus and bone marrow, respectively, are presented with self-antigens; cells bearing receptors for these antigens are removed by apoptosis or by induction of an inactive state known as anergy. Some autoreactive B cells may be retained in a state in which they do not respond to stimulation of their receptors. Conversely, some weakly autoreactive T cells may differentiate into natural regulatory T cells (nT reg), which act in the periphery to diminish potential T cell autoreactivity (see below).",220,54,0.24545454545454545
9781910797723,chp1,"There are two forms of adaptive immunity: cellular immunity mediated by T cells originating in the thymus, and humoral immunity mediated by B cells originating in the bone marrow.","Central tolerance is the principal mechanism by which the immune system learns to distinguish between 'self' and 'non-self'. Maturing T and B lymphocytes in the thymus and bone marrow, respectively, are presented with self-antigens; cells bearing receptors for these antigens are removed by apoptosis or by induction of an inactive state known as anergy. Some autoreactive B cells may be retained in a state in which they do not respond to stimulation of their receptors. Conversely, some weakly autoreactive T cells may differentiate into natural regulatory T cells (nT reg), which act in the periphery to diminish potential T cell autoreactivity (see below). Peripheral tolerance plays a key role in preventing hyperreactivity of the immune system in response to environmental agents such as allergens or gut microbes. A number of mechanisms contribute to peripheral tolerance, primarily involving regulation of T-cell populations, particularly CD4+ T h cells.",195,35,0.1794871794871795
9781910797723,chp2,"The immune response to the presence of cancer cells is a cyclical process that is potentially self-propagating. However, the existence of numerous negative regulators allows tumor cells to evade the immune system.","The response of the immune system to cancer cells is a cyclical process (Figure 2.1) that may in principle be self-perpetuating, leading to a heightened immune response. Initially, cancer cells are detected by natural killer (NK) cells, which interact with specific ligands on the cancer cell surface, leading to the destruction of the cancer cells. This causes the release of cancer antigens that bind to dendritic cells or other antigen-presenting cells (APCs), leading to cytokine secretion by APCs and priming the activation of T cells in lymphoid tissue. These cytotoxic T cells are transported to the tumor, where they bind to major histocompatibility complex (MHC) class I proteins on the cancer cell surface and kill the target cancer cells. This in turn leads to further release of antigens, thereby amplifying the immune response. However, each step in the process has multiple regulators - both positive and negative. The negative regulators can set up feedback loops that diminish or block the immune response. In addition to allowing the tumor cell to evade immune attack, these mechanisms may actually facilitate tumor progression.",233,40,0.17167381974248927
9781910797723,chp2,"Tumor immunoediting has three components, known as the 'three Es': elimination, equilibrium and evasion:- during the initial elimination phase, some cancer cells are recognized as altered by the immune system and are destroyed- during the equilibrium phase, some cancer cells persist, but the immune response is sufficient to prevent proliferation- eventually, however, selective pressure leads to a predominance of cells that are able to avoid the immune response - escape.","The response of the immune system to cancer cells is a cyclical process (Figure 2.1) that may in principle be self-perpetuating, leading to a heightened immune response. Initially, cancer cells are detected by natural killer (NK) cells, which interact with specific ligands on the cancer cell surface, leading to the destruction of the cancer cells. This causes the release of cancer antigens that bind to dendritic cells or other antigen-presenting cells (APCs), leading to cytokine secretion by APCs and priming the activation of T cells in lymphoid tissue. These cytotoxic T cells are transported to the tumor, where they bind to major histocompatibility complex (MHC) class I proteins on the cancer cell surface and kill the target cancer cells. This in turn leads to further release of antigens, thereby amplifying the immune response. However, each step in the process has multiple regulators - both positive and negative. The negative regulators can set up feedback loops that diminish or block the immune response. In addition to allowing the tumor cell to evade immune attack, these mechanisms may actually facilitate tumor progression. Immunoediting of cancer cells: the 'three Es'. The recognition that the immune system may both suppress and promote tumor growth has led to a shift in attention away from immunosurveillance (with a focus on recognition and elimination of cancer cells) to immunoediting (which encompasses both immunosurveillance and pro-proliferative mechanisms). Depending on the type of cancer and the characteristics of the individual patient, tumor immunoediting can be governed by at least three aspects, known collectively as the 'three Es': E limination, E quilibrium and E scape (Table 2.1).",361,89,0.24653739612188366
9781910797723,chp2,Solid tumors consist of multiple cell types that together contribute to the development of a microenvironment that favors tumor growth and evasion of the immune system.,"The response of the immune system to cancer cells is a cyclical process (Figure 2.1) that may in principle be self-perpetuating, leading to a heightened immune response. Initially, cancer cells are detected by natural killer (NK) cells, which interact with specific ligands on the cancer cell surface, leading to the destruction of the cancer cells. This causes the release of cancer antigens that bind to dendritic cells or other antigen-presenting cells (APCs), leading to cytokine secretion by APCs and priming the activation of T cells in lymphoid tissue. These cytotoxic T cells are transported to the tumor, where they bind to major histocompatibility complex (MHC) class I proteins on the cancer cell surface and kill the target cancer cells. This in turn leads to further release of antigens, thereby amplifying the immune response. However, each step in the process has multiple regulators - both positive and negative. The negative regulators can set up feedback loops that diminish or block the immune response. In addition to allowing the tumor cell to evade immune attack, these mechanisms may actually facilitate tumor progression.",233,28,0.12017167381974249
9781910797723,chp2,"The immune checkpoint molecules PD-1 and CTLA-4 are key factors in the ability of tumor cells to evade the immune system. However, there are multiple other potential targets, some of which have inhibitory activity and others agonistic activity in T-cell activation.","Differences between the PD-1/PD-L1 and CTLA-4 pathways have implications for their use as therapeutic targets in immuno-oncology. In particular, the effects of PD-1 are largely confined to the tumor site: expression of PD-L1 is low in non-cancerous tissue. Furthermore, therapies acting on PD-1/PD-L1 have the potential to reset tumor-related alterations in the immune system while leaving normal peripheral tolerance to self-antigens unaffected. These differences between the two pathways suggest that combined PD-1/PD-L1 and CTLA-4 blockade might have synergistic anti-tumor effects: CTLA-4 blockade allows activation and proliferation of more T-cell populations while reducing T reg -mediated immunosuppression, and PD-1/PD-L1 blockade restores the activity of quiescent T cells (Figure 2.4). It has also been suggested that therapies directed against PD-1/PD-L1 should be termed tumor site immune modulation therapy, to distinguish this approach from CTLA-4 blockade.",227,54,0.23788546255506607
9781910797723,chp3,"The term immunotherapy encompasses a variety of approaches, targeting diverse immunologic targets.","In the context of cancer, the term immunotherapy encompasses a variety of approaches, targeting diverse immunologic targets. The history of immuno-oncology. The concept of immuno-oncology dates back more than 100 years, to 1893 (Figure 3.1). In that year, William Coley, an American surgeon and cancer researcher, observed remission of cancer in patients with postoperative bacterial infections, and suggested that activation of the immune system must play a role in combating cancer., Subsequently, in 1909, Paul Ehrlich suggested that the immune system must play an important role in preventing the development of cancer. However, it was not until the mid-20th century when Lewis Thomas and Frank MacFarlane Burnet hypothesized that the immune system is capable of eliminating cancerous cells through a process known as immune surveillance, and that this process depends on recognition of tumor-associated antigens by the immune system., Subsequently, through the laboratory work of Lloyd Old and Robert Schreiber, the concept of immune surveillance has evolved into 'immunoediting', reflecting the ability of tumor cells to evade the immune system. Increasing understanding of the underlying mechanisms of immunoediting has identified numerous potential therapeutic targets, some of which - notably immune checkpoint inhibition as first demonstrated by James Allison in the 1990s - are already yielding promising results in clinical practice., Indeed, in 2013, cancer immunotherapy was cited as the 'breakthrough of the year' by the journal Science.",300,16,0.05333333333333334
9781910797723,chp3,"The potential sensitivity of a given cancer to immunotherapy depends on the immunogenicity of the tumor, which is related to the somatic mutation rate within tumor cells.- The highest mutation rates are seen in cancers of the skin, lung, bladder and stomach, rendering these tumor types more sensitive to immunotherapy.","What types of tumor are potentially susceptible to immuno-oncology?. Clearly, the potential sensitivity of a given cancer to immuno-oncology therapies will depend on the ability of the tumor to trigger an immune response (immunogenicity). Cancer is characterized by an accumulation of genetic mutations, many of which result in the expression of cancer-specific antigens that can bind to major histocompatibility complex (MHC) class I molecules on the cancer cell surface. These antigen-MHC complexes can be recognized by cytotoxic CD8+ lymphocytes, that, if activated, could potentially mount an immune response against the tumor. As a result, tumors with high somatic mutation rates may be more susceptible to immuno-oncology therapies than those with lower mutation rates. Somatic mutation rates differ markedly, both between tumor types and within an individual tumor type: the rate may vary more than 1000-fold between tumors with the highest and lowest rates (Figure 3.2). The highest rates are seen in cancers of the skin, lung, bladder and stomach, while the lowest are seen in hematologic and pediatric cancers. It is noteworthy that the highest rates occur in tumors that are induced by carcinogens such as tobacco smoke or ultraviolet light.",258,61,0.2364341085271318
9781910797723,chp3,"Immunotherapies are conventionally classified as passive or active, depending on their ability to activate an immune response against tumor cells.- Passive immunotherapies include tumor-targeting monoclonal antibodies, adoptive cell transfer and oncolytic viruses.- Active immunotherapies include dendritic cell-based therapies, vaccines, immunomodulatory monoclonal antibodies (immune checkpoint inhibitors) and pattern recognition receptor agonists.","Clearly, the potential sensitivity of a given cancer to immuno-oncology therapies will depend on the ability of the tumor to trigger an immune response (immunogenicity). Cancer is characterized by an accumulation of genetic mutations, many of which result in the expression of cancer-specific antigens that can bind to major histocompatibility complex (MHC) class I molecules on the cancer cell surface. These antigen-MHC complexes can be recognized by cytotoxic CD8+ lymphocytes, that, if activated, could potentially mount an immune response against the tumor. As a result, tumors with high somatic mutation rates may be more susceptible to immuno-oncology therapies than those with lower mutation rates. Somatic mutation rates differ markedly, both between tumor types and within an individual tumor type: the rate may vary more than 1000-fold between tumors with the highest and lowest rates (Figure 3.2). The highest rates are seen in cancers of the skin, lung, bladder and stomach, while the lowest are seen in hematologic and pediatric cancers. It is noteworthy that the highest rates occur in tumors that are induced by carcinogens such as tobacco smoke or ultraviolet light. Potential targets for cancer immunotherapy. A variety of cancer immunotherapy strategies are currently being investigated, or have already entered clinical practice. These are conventionally classified as passive or active immunotherapies, according to their ability to activate an immune response against tumor cells (Table 3.1), although this classification does not adequately reflect the complexity of drug-host-tumor interactions. As a result, it has been suggested that immunotherapies should be classified according to their antigen specificity; however, even therapies initially directed against a single antigen may eventually become responsive to multiple antigens, a phenomenon known as epitope spreading. Passive immunotherapies. Tumor-targeting monoclonal antibodies. Monoclonal antibodies (mAbs) that specifically target malignant cells are among the best characterized forms of cancer immunotherapy.",415,90,0.21686746987951808
9781910797723,chp3,"Efficacy criteria used for conventional cancer therapies cannot readily be extrapolated to immunotherapies.- Survival may be increased in the absence of an objective response as assessed by conventional criteria, and hence immune-related response criteria are required.","Assessment of the benefits and risks of cancer immunotherapies can be challenging, as the criteria used for conventional therapies cannot generally be extrapolated to immunotherapies. Assessing efficacy. A key issue in immuno-oncology is that patients may show a survival benefit in the absence of an objective response as defined by conventional RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Response to immunotherapies may vary markedly between patients: while some patients may show an initial response or stable disease, in others the response may be delayed because of the need to restore T-cell responses - a process that requires the interaction of numerous other immune cells. Indeed, in some patients, there is an initial phase of pseudoprogression during which the tumor appears to enlarge due to infiltration of newly reactivated T cells and subsequent inflammation. For these reasons, a set of immune-related response criteria (irRC) have been proposed (Table 3.6), relating to four patterns of response.",205,47,0.22926829268292684
9781910797723,chp3,Immune-related adverse events are generally due to autoimmune inflammation through uncontrolled T-cell activation.- Such events should be treated promptly to prevent potentially harmful escalation: patient education is essential in this respect.,"Assessing safety and tolerability. Some immunotherapies, notably checkpoint inhibitors, are associated with immune-related adverse events such as fatigue, diarrhea, nausea and altered liver or kidney function (Figure 3.4). Many of these resemble the adverse events often seen with conventional chemotherapy but have different etiologies: while adverse events with conventional chemotherapy usually reflect cytotoxic effects on healthy tissue, adverse events with immunotherapies typically reflect actions on the immune system. For example, diarrhea associated with immunotherapy may be due to a reaction to gut-associated or self-antigens. Such adverse events require careful management, because although most are mild or moderate in severity, failure to recognize them as immune related could lead to suboptimal management, with potentially serious or life-threatening consequences. For example, if untreated, diarrhea from immune-related colitis may become self-perpetuating, potentially leading to gut perforation.",189,39,0.20634920634920634
9781910797723,chp4,"Immune checkpoints are cell surface receptors that are expressed on activated T cells and other immune cells, which normally serve a co-inhibitory role in keeping the adaptive immune system in check to prevent autoimmune diseases.","Immune checkpoint molecules are cell surface receptors that are expressed on activated T cells and other immune cells, which normally serve a co-inhibitory role in keeping the adaptive immune system in check to prevent autoimmune diseases. CTLA-4 is the first immune checkpoint found to be expressed by immune cells, especially T regulatory cells (T reg) and activated T cells that have been acutely exposed to antigens. When bound to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs), CTLA-4 acts as an off switch to down-regulate the immune response (Figure 4.1). PD-1 is another immune checkpoint expressed by activated T cells, B cells and macrophages. PD-1 signaling may inhibit T-cell activation by binding to either one of two ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). As described in Chapter 2, the PD-L1/2 ligands may be expressed on tumor cells and immune cells in the tumor microenvironment, thus inhibiting effector T cells (T eff) and preventing an adequate immune response on cancer (see Figure 4.1).",253,42,0.16600790513833993
9781910797723,chp4,"Immune checkpoint inhibitors have been approved by the US Food and Drug Administration for use in patients with melanoma, lung cancers, head and neck cancers, bladder cancers, kidney cancers, colorectal cancers, MSI-high solid tumors, Merkel cell cancers and Hodgkin's lymphoma. These include ipilimumab (CTLA-4 mAb), nivolumab, pembrolizumab (PD-1 mAbs), atezolizumab, avelumab and durvalumab (PD-L1 mAbs).","CTLA-4 is the first immune checkpoint found to be expressed by immune cells, especially T regulatory cells (T reg) and activated T cells that have been acutely exposed to antigens. When bound to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs), CTLA-4 acts as an off switch to down-regulate the immune response (Figure 4.1). PD-1 is another immune checkpoint expressed by activated T cells, B cells and macrophages. PD-1 signaling may inhibit T-cell activation by binding to either one of two ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). As described in Chapter 2, the PD-L1/2 ligands may be expressed on tumor cells and immune cells in the tumor microenvironment, thus inhibiting effector T cells (T eff) and preventing an adequate immune response on cancer (see Figure 4.1). Checkpoint inhibition. CTLA-4, PD-1 and PD-L1 therefore represent attractive therapeutic targets where checkpoint inhibition by monoclonal antibodies (mAbs) helps activate T-cell function to uncover and attack cancer cells. The analogy of releasing the brakes to accelerate a fast car has been widely used to explain this mechanism of action. Antibodies against PD-1/PD-L1. This is one of the most prolific areas of drug development at present, and many pharmaceutical companies have a PD-1 or PD-L1 mAb in late-stage clinical development. Those approved by the US Food and Drug Administration (FDA) are summarized in Table 4.1. As can be seen, the registration status of the various mAbs differs; pembrolizumab and nivolumab have the widest indications at present. Pembrolizumab and nivolumab are mAbs against PD-1, on the surface of T cells, while avelumab, durvalumab and atezolizumab block tumor-based PD-L1. While there have been modest differences in clinical outcomes in different tumors, there is currently little evidence of significant differences between these agents in terms of their clinical activity and toxicity profiles.",472,115,0.24364406779661016
9781910797723,chp4,"Immune checkpoints may be inhibited by monoclonal antibodies, resulting in T-cell activation and an immune response against cancer. This is analogous to releasing the brakes to accelerate a fast car.","PD-1 is another immune checkpoint expressed by activated T cells, B cells and macrophages. PD-1 signaling may inhibit T-cell activation by binding to either one of two ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). As described in Chapter 2, the PD-L1/2 ligands may be expressed on tumor cells and immune cells in the tumor microenvironment, thus inhibiting effector T cells (T eff) and preventing an adequate immune response on cancer (see Figure 4.1). Checkpoint inhibition. CTLA-4, PD-1 and PD-L1 therefore represent attractive therapeutic targets where checkpoint inhibition by monoclonal antibodies (mAbs) helps activate T-cell function to uncover and attack cancer cells. The analogy of releasing the brakes to accelerate a fast car has been widely used to explain this mechanism of action.",188,39,0.2074468085106383
9781910797723,chp4,"Immune checkpoint inhibitors against CTLA-4, PD-1 and PD-L1 have produced durable tumor shrinkage and prolonged survival in patients with a variety of solid tumors.","PD-1 is another immune checkpoint expressed by activated T cells, B cells and macrophages. PD-1 signaling may inhibit T-cell activation by binding to either one of two ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). As described in Chapter 2, the PD-L1/2 ligands may be expressed on tumor cells and immune cells in the tumor microenvironment, thus inhibiting effector T cells (T eff) and preventing an adequate immune response on cancer (see Figure 4.1). Checkpoint inhibition. CTLA-4, PD-1 and PD-L1 therefore represent attractive therapeutic targets where checkpoint inhibition by monoclonal antibodies (mAbs) helps activate T-cell function to uncover and attack cancer cells. The analogy of releasing the brakes to accelerate a fast car has been widely used to explain this mechanism of action.",188,36,0.19148936170212766
9781910797723,chp4,"Clinical trials are ongoing for additional indications, as well as various combination therapies.","This is one of the most prolific areas of drug development at present, and many pharmaceutical companies have a PD-1 or PD-L1 mAb in late-stage clinical development. Those approved by the US Food and Drug Administration (FDA) are summarized in Table 4.1. As can be seen, the registration status of the various mAbs differs; pembrolizumab and nivolumab have the widest indications at present. Pembrolizumab and nivolumab are mAbs against PD-1, on the surface of T cells, while avelumab, durvalumab and atezolizumab block tumor-based PD-L1. While there have been modest differences in clinical outcomes in different tumors, there is currently little evidence of significant differences between these agents in terms of their clinical activity and toxicity profiles.",179,16,0.0893854748603352
9781910797723,chp4,"Immune-related adverse events are due to autoimmune inflammation resulting from overactivation of T cells; they include colitis, dermatitis, hepatitis, thyroiditis and pneumonitis.","The biggest limitation to the use of checkpoint inhibitors has been toxicity, even though tolerability is generally superior to chemotherapy. Immune-related adverse events usually result from autoimmune inflammation of various organs due to over-activation of T cells. Severe toxicities can lead to interruption and/or cessation of therapy, substantial morbidity and occasional mortality. Sometimes expensive therapies may be needed to effectively manage adverse effects that do not respond to steroids. At present, there are no effective predictors of toxicities. Nevertheless, a number of general statements can be made regarding the toxicities of checkpoint inhibitors. Patients in clinical trials have been highly selected for performance status and good organ function and thus toxicities may be worse in non-trial patient populations. Patients with pre-existing autoimmune toxicities have been excluded from trials of immunotherapies and thus toxicities may be greater in this group.",176,36,0.20454545454545456
9781910797723,chp5,"Combinations of immune checkpoint inhibitors with targeted therapy, chemotherapy or radiotherapy are being explored to see whether responses may be augmented.","Despite these encouraging developments, the outcomes with immunotherapies have been less encouraging in other common malignancies such as microsatellite stable colorectal cancer and pancreatic cancer. As a result, combinations with other targeted immunotherapies or chemotherapy are now being extensively investigated. It is too early to gauge the place of immunotherapy in some other common malignancies, because pivotal clinical trials are still ongoing. Clearly, a number of important issues around the use of cancer immunotherapies remain to be resolved. Some of the most important of these are highlighted here.",117,25,0.21367521367521367
9781910797723,chp5,"Tumor mutation burden is a promising predictor of response to immune checkpoint inhibitors but requires further study, including the use of non-invasive tools such as plasma-circulating tumor DNA analysis.","The lack of reliable predictive biomarkers of efficacy or toxicity is perhaps the major current issue around the use of immunotherapies. At present, the best predictor of benefit from immune checkpoint inhibitors is mutational burden,, but this cannot be routinely assessed, particularly in a serial fashion in patients receiving treatment. Liquid biopsies with plasma-circulating tumor DNA may provide a non-invasive tool to explore this, but much more research is required in this area. While there is some correlation between levels of PD-L1 expression and response and survival in lung cancer, these relationships lack sensitivity and specificity, and this situation is further complicated by the availability of multiple separate testing platforms, with variable correlation between them. In other tumor types, especially melanoma, there appears to be no such correlation.",159,39,0.24528301886792453
9781910797723,chp5,Predictive biomarkers are urgently needed to direct precision immunotherapy.,"Immuno-oncology has made incredible advances in recent years. In order to harness the immune system for enhanced anti-tumor response and deliver optimal immunotherapy to every patient, predictive biomarkers and novel combination treatment strategies are urgently needed. In the future, the one size fits all model will become obsolete, and precision immunotherapy will be tailored to each individual to radically improve their outcomes.",80,14,0.175
9781910797723,chp5,Predictive biomarkers for immune-related toxicity are also needed.,"Immuno-oncology has made incredible advances in recent years. In order to harness the immune system for enhanced anti-tumor response and deliver optimal immunotherapy to every patient, predictive biomarkers and novel combination treatment strategies are urgently needed. In the future, the one size fits all model will become obsolete, and precision immunotherapy will be tailored to each individual to radically improve their outcomes.",80,14,0.175
9781910797815,chp1,"Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) are usually caused by driver mutations in the JAK2, MPL and CALR genes.","Driver mutations. The MPNs are caused by driver mutations in the Janus kinase 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL) or calreticulin (CALR) genes (Table 1.1). JAK2 and CALR mutations are most commonly involved, although the distribution of driver mutations differs in ET, PV and PMF (Figure 1.1). In general, these mutations are mutually exclusive (exempli gratia the presence of a JAK2 mutation largely precludes MPL or CALR mutations) and predominantly present only in MPNs (described as MPN restricted). Non-restricted mutations found in other myeloid disorders are also found in MPNs, such as mutations of ASXL1. JAK2 mutations. JAK2 is a tyrosine kinase that activates downstream signaling via erythropoietin, granulocyte colony-stimulating factor receptors and thrombopoietin receptors (the three principal myeloid cytokine receptors) (Figure 1.2). Activation of these receptors triggers increased signaling via the STAT (signal transducer and activator of transcription)-5, MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol 3-kinase) pathways.",277,51,0.18411552346570398
9781910797815,chp1,"The most common JAK2 mutation is V617F, which activates downstream signaling via erythropoietin, granulocyte colony-stimulating factor and thrombopoietin receptors. This mutation is associated with all three MPNs, whereas MPL and CALR mutations activate mainly the thrombopoietin receptor and hence are only associated with ET and PMF.","Driver mutations. The MPNs are caused by driver mutations in the Janus kinase 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL) or calreticulin (CALR) genes (Table 1.1). JAK2 and CALR mutations are most commonly involved, although the distribution of driver mutations differs in ET, PV and PMF (Figure 1.1). In general, these mutations are mutually exclusive (exempli gratia the presence of a JAK2 mutation largely precludes MPL or CALR mutations) and predominantly present only in MPNs (described as MPN restricted). Non-restricted mutations found in other myeloid disorders are also found in MPNs, such as mutations of ASXL1. JAK2 mutations. JAK2 is a tyrosine kinase that activates downstream signaling via erythropoietin, granulocyte colony-stimulating factor receptors and thrombopoietin receptors (the three principal myeloid cytokine receptors) (Figure 1.2). Activation of these receptors triggers increased signaling via the STAT (signal transducer and activator of transcription)-5, MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol 3-kinase) pathways. The most common JAK2 mutation, V617F, results in substitution of phenylalanine for valine at position 617, which appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin. The JAK2 V617F mutation is present in approximately 70% of MPNs, but 95% of cases of PV.",364,81,0.22252747252747251
9781910797815,chp1,"Numerous other somatic mutations have also been implicated in the initiation and progression of MPN, including mutations that affect intracellular signaling pathways, epigenetic regulators, transcription factors and RNA splicing.","CALR mutations. The CALR gene encodes calreticulin, a multifunctional protein that acts as a calcium storage protein in the endoplasmic reticulum and as a molecular chaperone, facilitating the folding and unfolding of proteins and other macromolecules. Frameshift mutations in the CALR gene are present in 50-60% of individuals with ET and 75% of those with PMF who do not have JAK2 or MPL mutations. More than 50 different mutations in the CALR gene have been reported, all located in exon 9, where they cause +1 frameshifts, resulting in MPL activation. The two most common mutations result in the deletion of 52 base pairs (type 1) or the insertion of five base pairs (type 2); all other mutations are classified as type 1-like or type 2-like, depending on their effect on the calreticulin C-terminus. Type 1 mutations are most common. Triple-negative MPN has features consistent with MPN (typically ET or PMF; rarely PV) but lacks one of the common driver mutations. It is a heterogeneous condition: some cases may be hereditary thrombocytosis, some have rarer mutations in JAK2, MPL or non-driver genes and some patients have no detectable mutations. Non-driver mutations have also been implicated in the initiation and progression of MPNs. These include mutations affecting.",298,40,0.1342281879194631
9781910797815,chp1,"Clonal hematopoiesis of indeterminate potential (CHIP) refers to the acquisition of somatic mutations that drive clonal expansion in the absence of cytopenia and dysplastic hematopoiesis. Rarely, CHIP can progress to acute myeloid leukemia, either directly or via myeloid neoplasia or myelodysplastic syndrome; it can therefore be considered a precursor of hematopoietic neoplasms.","CHIP describes the acquisition of somatic mutations that drive clonal expansion in the absence of cytopenia and dysplastic hematopoiesis. A variety of mutations may be involved, the most common of which are in DNMT3A, TET2, ASXL1, TP53 (which encodes p53), JAK2 and SF3B1. The prevalence of CHIP increases with age, reaching approximately 10% among individuals aged 70-80 years. The key features of this condition are summarized in Table 1.3. CHIP may progress to acute myeloid leukemia (AML), either directly or via myeloid neoplasia or myelodysplastic syndrome (Figure 1.3); however, the progression rate is low (0.5-1% per year) and progression does not occur in the majority of patients. Thus, CHIP can be considered a precursor of hematopoietic neoplasms, analogous to the relationship between monoclonal gammopathy of undetermined significance and multiple myeloma, or between monoclonal B cell lymphocytosis and chronic lymphocytic leukemia. A recent study has shown that the presence of CHIP in peripheral blood is associated with an approximately twofold increase in the risk of coronary heart disease, and with accelerated atherosclerosis in animal models. The greatest increase in risk is seen in carriers of the DNMT3A and TET2 mutations. Inflammation appears to play a key role in the development of PMF, and the other MPNs to a lesser extent. These conditions are marked by increased circulating concentrations of inflammatory cytokines such as interleukin-1beta and tumor necrosis factor, and symptoms of inflammation such as fatigue, fever and night sweats. Inflammatory cytokines are secreted by hematopoietic cells (with and without mutations) and by non-hematopoietic cells such as mesenchymal stem cells, and appear to create a favorable environment for the expression of JAK2 V617F.",427,100,0.234192037470726
9781910797815,chp1,"Inflammation appears to play a key role in the development of PMF and other MPNs. Other factors, particularly older age and genetic predisposition, may also influence the initiation and development of these conditions.","A recent study has shown that the presence of CHIP in peripheral blood is associated with an approximately twofold increase in the risk of coronary heart disease, and with accelerated atherosclerosis in animal models. The greatest increase in risk is seen in carriers of the DNMT3A and TET2 mutations. Inflammation appears to play a key role in the development of PMF, and the other MPNs to a lesser extent. These conditions are marked by increased circulating concentrations of inflammatory cytokines such as interleukin-1beta and tumor necrosis factor, and symptoms of inflammation such as fatigue, fever and night sweats. Inflammatory cytokines are secreted by hematopoietic cells (with and without mutations) and by non-hematopoietic cells such as mesenchymal stem cells, and appear to create a favorable environment for the expression of JAK2 V617F.",186,42,0.22580645161290322
9781910797815,chp2,The incidence of the myeloproliferative neoplasms (MPNs) is approximately 2.6 per 100 000.,"Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) are the most common MPNs and, together with acute myeloid leukemia (AML), account for about one-third of all newly diagnosed hematologic malignancies. The incidence and prevalence of these MPNs has been investigated in a systematic review and meta-analysis of 34 studies conducted worldwide. The crude annual incidence for the MPNs combined was 2.58 per 100 000 (95% confidence interval 1.90-3.50), with individual studies yielding rates of 1.15-4.99 per 100 000 (Table 2.1). ET had the highest incidence, followed by PV and PMF.",157,26,0.16560509554140126
9781910797815,chp2,"Essential thrombocythemia (ET) is the most common, with an incidence of approximately 1.0 per 100 000, followed by polycythemia vera (PV) (0.8) and primary myelofibrosis (PMF) (0.5).","Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) are the most common MPNs and, together with acute myeloid leukemia (AML), account for about one-third of all newly diagnosed hematologic malignancies. The incidence and prevalence of these MPNs has been investigated in a systematic review and meta-analysis of 34 studies conducted worldwide. The crude annual incidence for the MPNs combined was 2.58 per 100 000 (95% confidence interval 1.90-3.50), with individual studies yielding rates of 1.15-4.99 per 100 000 (Table 2.1). ET had the highest incidence, followed by PV and PMF. In general, incidence was similar in men and women in the systematic review, although the incidence of ET was numerically higher in women (Table 2.1). By contrast, real-world data from the UK population-based Haematological Malignancy Research Network (HMRN) show that age-standardized incidence is similar for ET, PV and MPN, unclassifiable, whereas myelofibrosis is approximately twice as common in men as in women.",254,61,0.24015748031496062
9781910797815,chp2,"Recent data from the UK suggest that the incidence of ET and PV is similar in men and women, whereas PMF is twice as common in men.","In general, incidence was similar in men and women in the systematic review, although the incidence of ET was numerically higher in women (Table 2.1). By contrast, real-world data from the UK population-based Haematological Malignancy Research Network (HMRN) show that age-standardized incidence is similar for ET, PV and MPN, unclassifiable, whereas myelofibrosis is approximately twice as common in men as in women. Most of the available epidemiology data are from Europe and North America; the incidence of the MPNs is similar in these two regions, as shown in Table 2.2.",132,30,0.22727272727272727
9781910797815,chp2,ET and PV are associated with near-normal life expectancy whereas PMF is associated with reduced survival.,"In general, patients with ET or PV have a near-normal life expectancy with current treatment strategies, whereas PMF is associated with reduced survival. The UK HMRN has reported 3-year relative survival rates of more than 90% in patients with the chronic MPNs (ET, PV, MPN, unclassifiable) compared with fewer than 70% in those with myelofibrosis (Figure 2.1). However, the emergence of new and improved treatments in recent years has markedly improved survival rates. For example, the introduction of phlebotomy as a routine treatment for PV increased median survival from less than 2 years to approximately 14 years.",133,20,0.15037593984962405
9781910797815,chp2,MPNs primarily affect older individuals: the median age at diagnosis is 70-74 years.,"Genetic predisposition. In addition to the presence of the driver mutations described in Chapter 1, age is a predominant risk factor for the MPNs. In the UK HMRN study, the median age at diagnosis in people with chronic MPNs was 70-74 years (Table 2.4). PV tended to be diagnosed at an earlier age in men than in women.",75,18,0.24
9781910797815,chp2,"Risk factors that may increase the risk of MPNs include higher body mass index, smoking and some occupational exposures.","An estimated 7-8% of individuals with apparently sporadic MPN have a family history with at least two cases of MPN, as illustrated in Figure 2.2. Such familial cases are presumed to be due to acquisition of the somatic driver mutation through a genetic predisposition. To date, familial MPN has been identified in only a small number of families; however, identification of such cases may facilitate early diagnosis and appropriate intervention. Other risk factors for the MPNs have been proposed (Table 2.5), although in many cases the supporting evidence is limited. Two major long-term epidemiology studies have reported strong evidence that increased body mass index and smoking have significant associations with some or all of the MPNs.",144,23,0.1597222222222222
9781910797815,chp3,The World Health Organization diagnostic criteria for the myeloproliferative neoplasms (MPNs) are based on abnormalities of peripheral blood counts and alterations in bone marrow morphology.,"The MPNs vary markedly in morphologic and clinical features (Table 3.1). Thrombocytosis and erythrocytosis are major diagnostic criteria for essential thrombocythemia (ET) and polycythemia vera (PV), respectively. Primary myelofibrosis (PMF) has a more variable presentation, which may include all the features of PV and ET; however, anemia is a common finding and work-up requires the differential diagnosis of anemia. Furthermore, PMF is generally associated with the most severe symptom burden among the MPNs, although patients with PV or ET often also have significant disease-related symptoms (see Table 3.1). The World Health Organization (WHO) diagnostic criteria for MPNs (Tables 3.2 - 3.4) are based on peripheral blood counts, molecular abnormalities and alterations in bone marrow morphology, reflecting the central role of erythrocytosis and thrombocytosis in the pathophysiology of these conditions. The 2016 updated WHO criteria differ from the 2008 criteria in the following ways.",225,36,0.16
9781910797815,chp3,The diagnostic approach to essential thrombocythemia (ET) generally involves the differential diagnosis of thrombocytosis.,"Thrombocytosis is a major criterion for the diagnosis of ET (Table 3.2) but can also be present in other MPNs; the diagnostic approach to ET therefore generally involves the differential diagnosis of thrombocytosis. As shown in Figure 3.1, a patient with elevated platelet count (>= 450 x 10 /L) should undergo further blood testing, including a complete blood count, blood film/smear and determination of iron and C-reactive protein status, together with testing for MPN driver mutations and BCR-ABL1. The presence of a driver mutation might suggest a diagnosis of ET but bone marrow biopsy is required to preclude other MPNs such as PV, PMF or myelodysplastic syndrome.",157,27,0.17197452229299362
9781910797815,chp3,"In contrast to ET, polycythemia vera (PV) is characterized by erythrocytosis, although some increase in hemoglobin levels may also be seen in JAK2 V617F ET and in primary myelofibrosis (PMF).","Thrombocytosis is a major criterion for the diagnosis of ET (Table 3.2) but can also be present in other MPNs; the diagnostic approach to ET therefore generally involves the differential diagnosis of thrombocytosis. As shown in Figure 3.1, a patient with elevated platelet count (>= 450 x 10 /L) should undergo further blood testing, including a complete blood count, blood film/smear and determination of iron and C-reactive protein status, together with testing for MPN driver mutations and BCR-ABL1. The presence of a driver mutation might suggest a diagnosis of ET but bone marrow biopsy is required to preclude other MPNs such as PV, PMF or myelodysplastic syndrome. Diagnosis of polycythemia vera. In contrast to ET, PV is characterized by erythrocytosis, although some increase in hemoglobin levels may also be seen in JAK2 V617F ET and PMF. The WHO criteria for the diagnosis of PV are shown in Table 3.3 and an algorithm for the differential diagnosis in Figure 3.2.",235,56,0.23829787234042554
9781910797815,chp3,"The presentation of PMF is more variable than that of ET or PV, and may include symptomatic splenomegaly, anemia, constitutional symptoms (exempli gratia fatigue, pruritus), thrombosis and bleeding.","Thrombocytosis is a major criterion for the diagnosis of ET (Table 3.2) but can also be present in other MPNs; the diagnostic approach to ET therefore generally involves the differential diagnosis of thrombocytosis. As shown in Figure 3.1, a patient with elevated platelet count (>= 450 x 10 /L) should undergo further blood testing, including a complete blood count, blood film/smear and determination of iron and C-reactive protein status, together with testing for MPN driver mutations and BCR-ABL1. The presence of a driver mutation might suggest a diagnosis of ET but bone marrow biopsy is required to preclude other MPNs such as PV, PMF or myelodysplastic syndrome. Diagnosis of polycythemia vera. In contrast to ET, PV is characterized by erythrocytosis, although some increase in hemoglobin levels may also be seen in JAK2 V617F ET and PMF. The WHO criteria for the diagnosis of PV are shown in Table 3.3 and an algorithm for the differential diagnosis in Figure 3.2. Diagnosis of primary myelofibrosis. As noted above, the presentation of PMF is more variable than that of ET or PV, and may include. symptomatic splenomegaly. constitutional symptoms such as fatigue and pruritus. thrombosis or bleeding.",295,50,0.1694915254237288
9781910797815,chp3,"In addition to the risk of thrombosis, hemorrhage and transformation to acute myeloid leukemia, MPNs impose a significant symptomatic burden that can markedly impair patients' quality of life.","In addition to the risks of thrombosis, hemorrhage and transformation to AML, the MPNs impose a significant symptomatic burden that can markedly impair patients' quality of life. For example, an internet-based survey found that almost all of 1179 patients with myeloproliferative disorders reported some constitutional symptoms (Figure 3.4). The most common was fatigue, reported by 81% of patients, followed by pruritus (52%) and night sweats (49%). Furthermore, many patients reported decreased functioning, and 14% reported being disabled. With the exception of spleen pain, each of these symptoms was significantly more common in patients with PV or PMF than in those with ET. Constitutional symptoms in patients with MPNs have a number of causes, including. cytopenias, which lead to fatigue and decreased physical activity (which may further worsen fatigue).",179,40,0.22346368715083798
9781910797815,chp3,"An individual patient's risk of vascular complications and disease progression depends on multiple clinical and molecular risk factors. Since the level of risk will influence treatment decisions, effective risk stratification is essential for effective management of MPNs. Risk stratification models have been developed for all three MPNs.","Importantly, novel therapies such as Janus kinase inhibitors and inhibitors of mTOR (mechanistic target of rapamycin) are effective in relieving the symptom burden in MPNs, in addition to reducing cytopenias and spleen size. Assessment of symptoms is therefore an essential aspect of treatment monitoring. Risk stratification. Patients with MPNs are at risk of vascular complications such as hemorrhage and venous or arterial thrombosis. Moreover, PV (and ET to a lesser extent) has a risk of progression to secondary myelofibrosis, while PMF may progress to an AML-like blast phase, which may be preceded by a myelodysplastic phase. The extent to which an individual patient is at risk of vascular complications and disease progression is determined by multiple clinical and molecular risk factors (Table 3.5). Since the level of risk influences treatment decisions, risk stratification is essential in the management of MPNs. ET is usually considered to have the best prognosis among the MPNs. Risk stratification focuses on the likelihood of thrombotic complications, and is based on the two main risk factors for thrombosis: age 60 years or older, and a previous thrombotic event. To date, two prognostic scoring systems have been developed for use in patients with ET.",276,56,0.2028985507246377
9781910797815,chp4,"The aim when treating essential thrombocythemia (ET) is to reduce the risk of thrombosis and bleeding, and to alleviate symptoms.","Essential thrombocythemia (ET) is characterized by vascular features, including both thrombosis and paradoxical bleeding. In addition to the risk of major vessel thrombosis, thrombosis in the microcirculation (most likely transient) can give rise to symptoms such as red and painful extremities (erythromelalgia; Figure 4.1), headache, paresthesia, loss of vision or hearing and transient ischemic attack. Given this risk of thrombosis and hemorrhage, a key aim in the treatment of ET is to prevent blood clotting and bleeding; however, it is also important to alleviate any problematic symptoms.",139,32,0.2302158273381295
9781910797815,chp4,Treatment is tailored according to the risk of thrombosis or bleeding in the individual patient.,"Essential thrombocythemia (ET) is characterized by vascular features, including both thrombosis and paradoxical bleeding. In addition to the risk of major vessel thrombosis, thrombosis in the microcirculation (most likely transient) can give rise to symptoms such as red and painful extremities (erythromelalgia; Figure 4.1), headache, paresthesia, loss of vision or hearing and transient ischemic attack. Given this risk of thrombosis and hemorrhage, a key aim in the treatment of ET is to prevent blood clotting and bleeding; however, it is also important to alleviate any problematic symptoms.",139,20,0.14388489208633093
9781910797815,chp4,"Patients at the lowest level of risk (age < 60 years, no history of thrombosis, JAK2 V617F-negative, no cardiovascular risk factors) can be managed by observation alone. Other low-risk patients should receive low-dose aspirin.","As described in Chapter 3, the risk of thrombosis in ET is assessed on the basis of age and previous history of thrombosis. Thus, a patient below the age of 60 years with no previous history of thrombosis would be considered at low risk of vascular complications, whereas an older patient or one with previous thrombosis is considered to be at high risk. Similarly, Janus kinase 2 (JAK2) mutations are associated with a higher risk of thrombosis than are calreticulin (CALR) mutations, and may therefore be considered an additional risk factor for thrombosis in patients with ET (Figure 4.2), although this has yet to be fully incorporated into clinical practice. The choice of treatment depends on the patient's risk level. In general, patients at the lowest level of risk defined by the International Prognostic Score for Essential Thrombocythemia (IPSET) scoring system (Table 3.6, page 38) - younger patients without JAK2 mutations, no cardiovascular risk factors and no history of thrombosis - can often be managed by observation only, and they may not require aspirin (yet to be validated in clinical practice). Low-risk patients with JAK2 mutations, or cardiovascular risk factors in the absence of JAK2 mutations, should perhaps be treated with aspirin. As a general principle, all high-risk patients should be treated with aspirin (unless contraindicated) and cytoreductive therapy to reduce the platelet count.",316,55,0.17405063291139242
9781910797815,chp4,"All patients should receive interventions to reduce cardiovascular risk factors, particularly smoking cessation advice.","Management of low-risk patients. Treatment to reduce cardiovascular risk factors, and promotion of a generally healthy lifestyle, may be sufficient intervention for very-low-risk patients. Smoking cessation should be actively promoted because cigarette smoking has been shown to be an independent risk factor for thrombosis in patients with ET. Low-dose aspirin has been shown to reduce both microvascular symptoms (exempli gratia erythromelalgia) and transient neurological and visual disturbances such as hemiparesis, scintillating scotomas, amaurosis fugax (transcient monocular blindness) and seizures. There is also evidence that antiplatelet therapy reduces the risk of venous thrombosis in patients with JAK2 V617F mutations and cardiovascular risk factors (arterial thrombosis). Higher doses of aspirin (up to 500 mg daily) may be required in patients with acute erythromelalgia.",191,16,0.08376963350785341
9781910797815,chp4,"High-risk patients should receive cytoreductive therapy in addition to aspirin. Hydroxyurea (hydroxycarbamide) should be considered as first-line therapy. Options for second-line therapy include anagrelide, interferon-alpha and busulfan.","Low-dose aspirin has been shown to reduce both microvascular symptoms (exempli gratia erythromelalgia) and transient neurological and visual disturbances such as hemiparesis, scintillating scotomas, amaurosis fugax (transcient monocular blindness) and seizures. There is also evidence that antiplatelet therapy reduces the risk of venous thrombosis in patients with JAK2 V617F mutations and cardiovascular risk factors (arterial thrombosis). Higher doses of aspirin (up to 500 mg daily) may be required in patients with acute erythromelalgia. Cytoreductive therapy does not reduce the risk of thrombosis compared with observation alone in low-risk patients with ET, and recent data from the PT-1 study have shown that early cytoreductive therapy does not reduce mortality from thrombotic events. Management of high-risk patients. The agents most commonly used for cytoreductive therapy in high-risk patients with ET are hydroxyurea (also known as hydroxycarbamide), interferon-(IFN)-alpha, which suppresses hematopoietic cells in the bone marrow, anagrelide and busulfan (Table 4.1).",263,57,0.21673003802281368
9781910797815,chp4,"Patients should be monitored for signs of treatment failure, which may include elevated platelet or white blood cell counts, burdensome symptoms and clinical events such as thrombosis or bleeding.","Typically, evaluation of treatment responses involves monitoring of blood cell counts and assessment of constitutional symptoms and their impact on the patient's quality of life and general wellbeing. Since the treatment of ET aims primarily to reduce the risk of thrombosis and bleeding, response criteria have traditionally focused on platelet count. Response criteria cannot be defined in low-risk patients treated with aspirin, whereas the aim of treatment in higher-risk patients receiving cytoreductive therapy is to reduce platelet counts to below 400-450 x 10 /L. However, the likelihood of thrombosis during cytoreductive treatment appears to be influenced more by the degree of leukocytosis (> 10 x 10 /L) than by the platelet count, which suggests that this is a more relevant response criterion. In clinical practice, an inadequate response to treatment in patients with ET (or indeed PV) may be identified by various criteria, including elevated platelet or white blood cell counts, burdensome symptoms and clinical events such as thrombosis or bleeding (Table 4.2). It is important to recognize developing resistance to standard therapy - hydroxyurea in particular - because of an increased risk of disease transformation.",242,38,0.15702479338842976
9781910797815,chp5,"The aims of treatment in polycythemia vera (PV) are to reduce the risk of primary or recurrent thrombosis and to control symptoms, but without increasing the risk of hemorrhage or disease transformation.","The principal complications of polycythemia vera (PV) relate to arterial and venous thrombosis, which are reported to occur in 16-27% and 7-12% of patients, respectively., The clinical features of PV include headache, visual disturbances, fatigue, pruritis (itching), weight loss, red face (plethora; Figure 5.1) and enlargement of the spleen. In addition to the risk of thrombosis, approximately 20% of patients experience hemorrhage and 4-8% experience severe bleeding before or at the time of diagnosis. Furthermore, the disease may progress to myelofibrosis (post-PV myelofibrosis) in a significant proportion of patients, or to an acute blast crisis (Figure 5.2). Because of the risk of thrombotic and hemorrhagic complications and disease progression, the principal aims of treatment in PV are to reduce the risk of primary or recurrent thrombosis and to control symptoms, but without increasing the risk of hemorrhage or disease transformation.",218,45,0.20642201834862386
9781910797815,chp5,"Current treatment strategies focus on reducing the elevated hematocrit resulting from excessive red blood cell production, and aspiring to decrease the risk of thrombosis.","In addition to the risk of thrombosis, approximately 20% of patients experience hemorrhage and 4-8% experience severe bleeding before or at the time of diagnosis. Furthermore, the disease may progress to myelofibrosis (post-PV myelofibrosis) in a significant proportion of patients, or to an acute blast crisis (Figure 5.2). Because of the risk of thrombotic and hemorrhagic complications and disease progression, the principal aims of treatment in PV are to reduce the risk of primary or recurrent thrombosis and to control symptoms, but without increasing the risk of hemorrhage or disease transformation. Current treatment options. Current treatment strategies in PV (Table 5.1) focus on reducing the risk of thrombosis by. controlling an elevated hematocrit resulting from excessive red blood cell production. decreasing the risk of thrombosis, using aspirin.",188,32,0.1702127659574468
9781910797815,chp5,"Treatment is stratified according to the level of risk. All patients should receive low-dose aspirin and undergo regular phlebotomy to reduce the hematocrit. These measures may be sufficient in low-risk patients whereas those at higher risk may require cytoreductive therapy with hydroxyurea, interferon-alpha or other agents.","The level of risk is also influenced by the JAK2 V617F allele burden, although stratification by genetic risk is not currently widely used in clinical practice. Accurate risk stratification is essential because the level of risk has a marked impact on survival: patients with the highest risk have a median survival of approximately 11 years, compared with almost 30 years in those at low risk (Figure 5.3). The National Comprehensive Cancer Network (NCCN) recommendations for the management of PV are summarized in Figure 5.4. Phlebotomy to reduce the red cell mass is central to the treatment of PV in all patients. Phlebotomy is performed at varying intervals, as needed to maintain hematocrit at the target level (usually < 45%, although lower targets may be appropriate in women and in patients with splanchnic vein thrombosis; during pregnancy, a target in the middle of the normal range for gestation is selected). The requirement for phlebotomy tends to decrease over time. Phlebotomy is generally well tolerated, but some patients may develop adverse reactions, most commonly immediate or delayed vasovagal episodes or asthenia related to iron deficiency. Cytoreductive therapy may be required in such patients and for patients with constitutive symptoms, symptomatic splenomegaly or uncontrolled myeloproliferation. Some patients become intolerant to repeated phlebotomy.",289,72,0.2491349480968858
9781910797815,chp5,"A significant proportion of patients develop resistance to hydroxyurea, necessitating repeated phlebotomy at increasingly shorter intervals to control the hematocrit, indicative of inadequate disease control.","Resistance to hydroxyurea, as defined according to the ELN criteria (Table 5.2), may occur in 10-15% of patients,, and is associated with a poor prognosis. In a study of 261 patients with PV who received hydroxyurea for a median of 4.4 years, resistance was associated with decreased survival (HR 5.6 [95% CI 2.7-11.9]; p < 0.001) and an increased risk of transformation to acute myeloid leukemia or myelofibrosis (HR 6.8 [95% CI 3.0-15.4]; p < 0.001). Patients with hydroxyurea-resistant PV may require repeated phlebotomy to maintain the hematocrit below 45% (Figure 5.5). An increasing need for phlebotomy may therefore indicate inadequate disease control and the need to change treatment.",188,38,0.20212765957446807
9781910797815,chp5,The Janus kinase inhibitor ruxolitinib may be useful in patients with hydroxyurea-refractory PV.,"A number of studies have investigated the efficacy of the JAK inhibitor ruxolitinib in patients with PV. In the RESPONSE trial, 222 phlebotomy-dependent patients with splenomegaly and either resistance to or intolerance of hydroxyurea were randomized to receive ruxolitinib or placebo for 32 weeks. The primary endpoint (a composite of hematocrit control [ineligibility for phlebotomy] and >= 35% reduction in spleen volume) was achieved in significantly more patients receiving ruxolitinib (Figure 5.6), and a significantly higher proportion of patients achieved a complete response (ELN criteria): 23.6%, versus 8.9% with placebo (p = 0.003). Furthermore, 49% of ruxolitinib-treated patients had a reduction in symptom scores of at least 50%, compared with 5% of placebo recipients. Ruxolitinib was also associated with improvements in quality of life scores and a reduction in JAK2 V617F allele burden.",214,27,0.1261682242990654
9781910797815,chp6,"Myelofibrosis has the most diverse presentation of the myeloproliferative neoplasms (MPNs), and carries the worst prognosis.","Myelofibrosis has the most diverse presentation of the myeloproliferative neoplasms (MPNs), and carries the worst prognosis. Although up to 30% of patients are initially asymptomatic, most present with constitutional symptoms or symptoms resulting from anemia or splenomegaly., All patients eventually become symptomatic as the disease progresses, due to bone marrow failure and increasing splenomegaly, which can lead to abdominal symptoms and early satiety. Extramedullary hematopoiesis and progression to acute myeloid leukemia may also occur. The clinical features of the myelofibrosis are essentially the same irrespective of whether it presents as primary myelofibrosis or is secondary to essential thrombocythemia (ET) or polycythemia vera (PV).",173,32,0.18497109826589594
9781910797815,chp6,Approximately 30% of patients are asymptomatic initially but all patients eventually develop symptoms of bone marrow failure and progressive splenomegaly.,"Myelofibrosis has the most diverse presentation of the myeloproliferative neoplasms (MPNs), and carries the worst prognosis. Although up to 30% of patients are initially asymptomatic, most present with constitutional symptoms or symptoms resulting from anemia or splenomegaly., All patients eventually become symptomatic as the disease progresses, due to bone marrow failure and increasing splenomegaly, which can lead to abdominal symptoms and early satiety. Extramedullary hematopoiesis and progression to acute myeloid leukemia may also occur. The clinical features of the myelofibrosis are essentially the same irrespective of whether it presents as primary myelofibrosis or is secondary to essential thrombocythemia (ET) or polycythemia vera (PV).",173,30,0.17341040462427745
9781910797815,chp6,The aims of treatment include reduction of anemia and splenomegaly and alleviation of constitutional symptoms.,"Myelofibrosis has the most diverse presentation of the myeloproliferative neoplasms (MPNs), and carries the worst prognosis. Although up to 30% of patients are initially asymptomatic, most present with constitutional symptoms or symptoms resulting from anemia or splenomegaly., All patients eventually become symptomatic as the disease progresses, due to bone marrow failure and increasing splenomegaly, which can lead to abdominal symptoms and early satiety. Extramedullary hematopoiesis and progression to acute myeloid leukemia may also occur. The clinical features of the myelofibrosis are essentially the same irrespective of whether it presents as primary myelofibrosis or is secondary to essential thrombocythemia (ET) or polycythemia vera (PV).",173,22,0.12716763005780346
9781910797815,chp6,"Risk stratification is currently based on the International Progression Scoring System (IPSS) or Dynamic IPSS but new systems that incorporate genetic and cytogenetic risk factors, such as the Mutation-Enhanced International Prognostic Score System (MIPSS70) and MIPSS70-Plus are being developed.","As with ET and PV, the choice of treatment for patients with myelofibrosis depends on the level of risk. This can be assessed using the International Prognostic Scoring System (IPSS) or Dynamic IPSS (DIPSS), as described in Chapter 3; these are based on age, constitutional symptoms, hemoglobin levels, and leukocyte and circulating blast counts. In addition, a modified version of the DIPSS (DIPSS-Plus) incorporates low platelet counts, a need for red blood cell transfusion and the presence of an unfavorable karyotype (Table 6.1). Further versions of the IPSS have been developed to incorporate genetic risk (Mutation-Enhanced International Prognostic Score System [MIPSS70]) and cytogenetic risk (MIPSS70-Plus). Risk stratification is essential in patients with myelofibrosis because the level of risk has a marked impact on the prognosis. Median survival in patients at the highest level of risk is approximately 2 years, compared with approximately 20 years in low-risk patients (Figure 6.1). Use of molecular markers in risk stratification. In addition to the clinical risk factors included in the International Scoring Systems, survival in patients with myelofibrosis is affected by the presence of driver mutations in Janus kinase (JAK) 2, myeloproliferative leukemia virus oncogene (MPL) or calreticulin (CALR) and other molecular factors, although stratification by genetic risk is not currently used in clinical practice. This risk stratification has been included in the MIPPS70, which includes the absence of CALR type-1 mutations, in addition to a number of high molecular risk mutations in ASXL1, EZH2, SRSF2 and IDH1/2.",381,66,0.1732283464566929
9781910797815,chp6,The JAK2 inhibitor ruxolitinib is indicated as first-line therapy in patients with splenomegaly or constitutional symptoms.,"The National Comprehensive Cancer Network (NCCN) guidelines for the management of myelofibrosis are summarized in Figure 6.3. In general, JAK inhibitors such as ruxolitinib are considered as first-line treatment for splenomegaly and symptoms in patients with intermediate- or high-risk myelofibrosis, and SCT is an option for high-risk patients with a poor prognosis. Other treatments, used as needed, include cytoreductive therapy with hydroxyurea or interferon (IFN), and treatment to improve anemia, splenomegaly and extramedullary hematopoiesis. With the exception of SCT, none of the currently available therapies is curative.",156,29,0.1858974358974359
9781910797815,chp6,"Allogeneic stem cell transplantation is potentially curative but is associated with substantial mortality and morbidity and is therefore reserved for high-risk patients, possibly those who are transfusion dependent or who have an unfavorable karyotype.","pacritinib inhibits both JAK2 and FMS-like tyrosine kinase-3 (FLT3), a tyrosine kinase involved in the development of the hematopoietic and immune systems. momelotinib inhibits JAK1 and JAK2. fedratinib is a JAK2 inhibitor. Stem cell transplantation. Allogeneic SCT is currently the only potentially curative therapy for myelofibrosis but is associated with significant mortality and morbidity: 1-year mortality rates with conventional conditioning regimens are 15-30%, and 10-30% of patients experience long-term complications such as toxicity from the conditioning regimens, graft-versus-host disease, infections or graft failure. There is therefore broad consensus that SCT should be reserved for intermediate-2 and high-risk patients (as determined by the IPSS) with expected survival of less than 5 years. Other potential indications include transfusion dependency and unfavorable karyotype, and this is likely to be expanded to include particular molecular signatures.",219,46,0.2100456621004566
9781910797815,chp6,- Splenectomy is associated with substantial mortality and morbidity but may be an option for patients with drug-resistant splenomegaly.,"Allogeneic SCT is currently the only potentially curative therapy for myelofibrosis but is associated with significant mortality and morbidity: 1-year mortality rates with conventional conditioning regimens are 15-30%, and 10-30% of patients experience long-term complications such as toxicity from the conditioning regimens, graft-versus-host disease, infections or graft failure. There is therefore broad consensus that SCT should be reserved for intermediate-2 and high-risk patients (as determined by the IPSS) with expected survival of less than 5 years. Other potential indications include transfusion dependency and unfavorable karyotype, and this is likely to be expanded to include particular molecular signatures.",141,29,0.20567375886524822
9781910797815,chp6,"Splenomegaly can be managed using cytoreductive agents, splenectomy, radiation therapy or Janus kinase (JAK) inhibitors. Approximately 80% of patients treated with hydroxyurea will require additional therapy within about 1 year.- Splenectomy is associated with substantial mortality and morbidity but may be an option for patients with drug-resistant splenomegaly.","Cytoreductive therapy. The JAK2 inhibitors such as ruxolitinib have largely superseded hydroxyurea as the treatment of choice for symptomatic splenomegaly. Reduction in spleen volume with hydroxyurea is seen in approximately 40% of patients, and hydroxyurea can also be used to treat symptomatic thrombocytosis or leukocytosis., However, about 80% of patients require an alternative treatment within approximately 1 year. Potential cytoreductive therapies for hydroxyurea-refractory disease include intravenous cladribine, oral melphalan and/or busulfan, although these agents are now rarely used. IFN-alpha, usually administered as pegylated IFN-alpha-2a, may be useful in lower-risk patients who do not have marked splenomegaly (<10 cm). Support for the use of pegylated IFN comes from a retrospective study of an international cohort of 118 patients with advanced MPN. Among the 17 patients with myelofibrosis, 12 (71%) showed partial remission, clinical improvement or stable disease, as assessed using the International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria. In the overall study cohort, only four patients (3%) experienced grade 3 adverse events and none experienced grade 4 events. An analysis of 75 patients (19 with myelofibrosis) treated in the real-world setting at a single center reported stable disease in 63% and a favorable safety profile: only one patient experienced grade 3 adverse events. Recent data from a French group are also broadly supportive but highlight that responses are mixed, and many patients discontinue IFN.",354,80,0.22598870056497175
9781910797815,chp6,"Anemia can be treated in the short term with androgens, erythropoiesis-stimulating agents and immunomodulators, but most patients eventually become transfusion-dependent.","IFN-alpha, usually administered as pegylated IFN-alpha-2a, may be useful in lower-risk patients who do not have marked splenomegaly (<10 cm). Support for the use of pegylated IFN comes from a retrospective study of an international cohort of 118 patients with advanced MPN. Among the 17 patients with myelofibrosis, 12 (71%) showed partial remission, clinical improvement or stable disease, as assessed using the International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria. In the overall study cohort, only four patients (3%) experienced grade 3 adverse events and none experienced grade 4 events. An analysis of 75 patients (19 with myelofibrosis) treated in the real-world setting at a single center reported stable disease in 63% and a favorable safety profile: only one patient experienced grade 3 adverse events. Recent data from a French group are also broadly supportive but highlight that responses are mixed, and many patients discontinue IFN.",210,39,0.18571428571428572
9781910797815,chp6,Low-dose fractionated radiotherapy is the current standard of care for extramedullary hematopoiesis.,"Radiation therapy. Fractionated splenic radiotherapy may be appropriate for patients with symptomatic hepatosplenomegaly that is resistant to JAK inhibitors and in patients who are not good candidates for surgery, and for the treatment of extramedullary hematopoiesis. However, responses are short-lived (median 3-6 months), and approximately one-third of patients develop severe and prolonged cytopenia due to effects on circulating progenitor cells. Management of anemia is usually warranted when the hemoglobin level is below 100 g/L. Treatable causes of anemia, such as iron, folate or vitamin B12 deficiency, should be excluded before starting treatment. The NCCN guidelines for the management of myelofibrosis-associated anemia recommend the following.",168,26,0.15476190476190477
9781910797815,chp6,"Treatment response should be monitored by blood counts, assessment of symptoms using the Myeloproliferative Neoplasm-Symptoms Assessment Form Total Symptom Score, and objective measurement of spleen volume.","Disease- and patient-related dimensions must be considered when monitoring response to treatment in patients with myelofibrosis. Symptoms can be assessed using the Myeloproliferative Neoplasm Symptoms Assessment Form Total Symptom Score (MPN-SAF-TSS or MPN10). This instrument assesses 10 symptoms (Table 6.4) which the patient rates on a scale ranging from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be). The MPN-SAF TSS is the total of the ten individual scores (maximum score 100). The MPN-SAF-TSS can be used at successive clinic visits to provide an indication of the effectiveness of treatment. Monitoring spleen size in response to therapy and over time is becoming increasingly important in routine practice; this can be done with manual palpation or by imaging, in which case the preferred modality is probably ultrasonography.",201,43,0.21393034825870647
9781910797815,chp7,The Janus kinase 2 inhibitor pacritinib was superior to best available therapy in patients with myelofibrosis in terms of spleen and symptom responses.,"Pacritinib is an inhibitor of both JAK2 and FLT3 (Fms-like tyrosine kinase 3), an enzyme that is important in the development of the hematopoietic and immune systems. The efficacy of this agent in patients with myelofibrosis has been evaluated in two randomized Phase III trials: PERSIST-1 and PERSIST-2. PERSIST-1 excluded patients who had previously received JAK2 inhibitors whereas such patients were eligible to enter PERSIST-2. In PERSIST-1, the primary endpoint was at least 35% reduction in spleen volume, and a secondary endpoint was at least 50% reduction in total symptom scores; these were co-primary endpoints in PERSIST-2. Both trials showed pacritinib to be superior to best available therapy in terms of spleen and symptom responses. The most common adverse events were gastrointestinal (diarrhea and vomiting) and hematologic (anemia and thrombocytopenia).",214,34,0.1588785046728972
9781910797815,chp7,A variety of new therapies directed against diverse molecular targets are currently being evaluated.,"Many therapies targeting diverse molecular targets are currently being investigated in myelofibrosis (Table 7.1). PI3K/Akt/mTOR pathway. The JAK2/STAT (signal transducer and activator of transcription) pathway is an indirect activator of the PI3K (phosphatidylinositol 3-kinase)/Akt (protein kinase B)/mTOR (mechanistic target of rapamycin) pathway, inhibitors of which have been shown to dose-dependently inhibit the proliferation of cell lines with JAK2 V617F mutations, and to reduce clonogenic activity in hematopoietic progenitor cells from patients with MPNs. Everolimus, which inhibits the mTOR kinase TORC1, has been shown to inhibit proliferation in JAK2 V617F-mutated cell lines when administered alone or in combination with JAK2 inhibitors, and produced a response rate of 23% in a Phase I/II study in patients with myelofibrosis. The PI3K inhibitor buparlisib (BKM120) was not effective in combination with ruxolitinib in patients with myelofibrosis.",252,15,0.05952380952380952
9781910797815,chp7,"Other potential therapeutic targets include signaling pathways, histone deacetylase, telomerase, DNA methyltransferase and blockade of erythropoietin inhibitors.","DNA methyltransferase inhibitors such as decitabine and azacitidine may be effective in patients with MPN with signs of leukemic transformation (see Chapter 9). - These agents have also been evaluated in combination with ruxolitinib in the treatment of myelofibrosis but to date there is no clear evidence that combination therapy improves efficacy. Hedgehog pathway inhibitors. Hedgehog is a signaling pathway required for cell differentiation. Abnormalities in hedgehog pathway signaling have been described in animal models of myelofibrosis but most trials with inhibitors of this pathway in patients with MPN have not shown any benefit. However, some efficacy was seen with glasdegib in a recent Phase Ib/II trial involving 21 patients with myelofibrosis previously treated with JAK inhibitors: five patients had reductions in spleen volume and one showed improvement in anemia and became transfusion-independent.",187,34,0.18181818181818182
9781910797815,chp7,The use of ruxolitinib in combination with new therapies may offer a further potential approach to treatment.,"BET inhibitors. Bromodomain and extra-terminal motif (BET) inhibitors bind to the bromodomain of the BET proteins, BRD2, BRD3, BRD4 and BRDT, blocking their interaction with acetylated histones and transcription factors. These proteins are examples of 'epigenetic readers' and have been implicated in various hematologic malignancies, prompting trials of BET inhibitors. Early studies also suggest that use of a BET inhibitor in combination with a targeted therapy may prevent resistance. However, the BET proteins have distinct transcriptional pathways, and selectivity may be a challenge in clinical development.",132,22,0.16666666666666666
9781910797815,chp8,Combined oral contraceptives are not recommended for women with myeloproliferative neoplasm (MPN) because of the risk of thrombosis.,"Contraception and family planning should be discussed with women of reproductive age at the initial consultation following the diagnosis of MPN. Combined oral contraceptives are associated with an increased risk of thrombosis, and are not recommended for women with any MPN. Potential alternatives include progestogen-only pills, implants or depot formulations, intrauterine devices or systems and barrier methods. Contraception should also be discussed when considering cytoreductive therapy, because of the risk of teratogenicity with some cytoreductive agents, notably hydroxyurea. Pregnancy. Table 8.1 presents the potential complications of pregnancy in women with MPNs. In a review of outcomes data from 564 pregnancies in women with essential thrombocythemia (ET) (the most common MPN in women of reproductive age), first-trimester loss occurred in 26% and late-pregnancy loss in 11%. The most common maternal complication was pre-eclampsia, which occurred in 3.4% of women. Similar findings have been reported in women with PV, while a study of eight women with primary myelofibrosis (PMF) reported a live birth rate of 50%.",244,33,0.13524590163934427
9781910797815,chp8,"MPN increases the risk of pregnancy complications, including early fetal loss and pre-eclampsia.","Pregnancy. Table 8.1 presents the potential complications of pregnancy in women with MPNs. In a review of outcomes data from 564 pregnancies in women with essential thrombocythemia (ET) (the most common MPN in women of reproductive age), first-trimester loss occurred in 26% and late-pregnancy loss in 11%. The most common maternal complication was pre-eclampsia, which occurred in 3.4% of women. Similar findings have been reported in women with PV, while a study of eight women with primary myelofibrosis (PMF) reported a live birth rate of 50%.",130,21,0.16153846153846155
9781910797815,chp8,"Antithrombotic therapy for pregnant women at risk of vascular complications consists of aspirin, possibly with phlebotomy in women with polycythemia vera. Low-molecular-weight heparin and cytoreductive therapy with interferon (IFN)-alpha may be considered in women at high risk of complications.","Potential risk factors for thrombosis and other adverse outcomes in pregnancy are listed in Table 8.2. While there are no validated predictors of outcome in pregnancy, previous thrombosis or hemorrhage and extreme thrombocytosis are considered to be risk factors for adverse outcomes in women with MPN. It is not clear whether the presence of the JAK2 V617F mutation predicts adverse pregnancy outcome. An algorithm for the management of pregnancy in women with MPNs is shown in Figure 8.1. Antithrombotic therapy for women at risk of vascular complications consists of aspirin 75 mg daily, possibly with phlebotomy in women with PV (the packed volume target is adjusted to middle of gestational range); low-molecular-weight heparin and cytoreductive therapy with interferon (IFN)-alpha may be considered in women at high risk of complications. Menopause. There are few data on the safety of hormone replacement therapy (HRT) in women with MPN. Although estrogens are associated with an increased risk of thrombosis, one retrospective study found that the use of estrogen-based HRT was not associated with an increased risk of major thrombotic events in women with MPN. Based on these limited data, it seems reasonable to recommend HRT at the lowest possible dose (exempli gratia patches or gel), and only in patients with no other risk factors for venous thromboembolism and no history of thrombosis.",315,70,0.2222222222222222
9781910797815,chp8,Hormone replacement therapy should only be used in perimenopausal women with no other risk factors for venous thromboembolism or a history of thrombosis.,"An algorithm for the management of pregnancy in women with MPNs is shown in Figure 8.1. Antithrombotic therapy for women at risk of vascular complications consists of aspirin 75 mg daily, possibly with phlebotomy in women with PV (the packed volume target is adjusted to middle of gestational range); low-molecular-weight heparin and cytoreductive therapy with interferon (IFN)-alpha may be considered in women at high risk of complications. Menopause. There are few data on the safety of hormone replacement therapy (HRT) in women with MPN. Although estrogens are associated with an increased risk of thrombosis, one retrospective study found that the use of estrogen-based HRT was not associated with an increased risk of major thrombotic events in women with MPN. Based on these limited data, it seems reasonable to recommend HRT at the lowest possible dose (exempli gratia patches or gel), and only in patients with no other risk factors for venous thromboembolism and no history of thrombosis.",228,37,0.16228070175438597
9781910797815,chp8,"There is currently no risk stratification specifically for children with MPN, although a history of life-threatening venous or arterial thrombosis should be considered high risk, warranting cytoreductive therapy (hydroxyurea or IFN-alpha)","MPNs are extremely rare in children, although diagnosis rates are increasing with the availability of rapid tests for JAK2 V617F and other driver mutations. Treatment recommendations are largely based on trials in adults. Before starting treatment, it is essential to exclude secondary or reactive polycythemia, which may result from infection, trauma, allergic reactions or other conditions. Congenital polycythemic conditions and hereditary thrombocythemias should also be excluded. ET and PV. There is currently no risk stratification system for children with MPNs because of a lack of long-term data. However, the consensus is that a child with a history of life-threatening venous or arterial thrombosis is at high risk, and cytoreductive therapy is warranted. Observation alone may be appropriate for children with asymptomatic ET. Phlebotomy is recommended for asymptomatic patients with PV, and low-dose aspirin may be considered for teenagers with PV who have outgrown the risk of Reye's syndrome., Cytoreductive therapy should be used only as a last resort in high-risk patients. Hydroxyurea or IFN-alpha may be considered as first-line therapy, although the adverse effects of IFN-alpha, such as flu-like symptoms and autoimmune effects, may be a particular concern in children.",278,54,0.19424460431654678
9781910797815,chp8,"The treatment of splanchnic vein thrombosis requires a multidisciplinary approach. All patients should receive long-term anticoagulant therapy, and patients with thrombocytosis require cytoreductive therapy; some patients may require invasive intervention.","MPN may not be readily clinically apparent in patients with splanchnic vein thrombosis because abnormal blood cell counts may be masked by concurrent splenomegaly, hemodilution, gastrointestinal bleeding and iron deficiency. In fact, splanchnic vein thrombosis may be the first clinical sign of MPN. In a 2012 meta-analysis, MPN was present in approximately 41% of patients with Budd-Chiari syndrome and 32% of those with portal vein thrombosis. The JAK2 V617F mutation was present in approximately 70% of cases, suggesting that screening for this mutation might be useful in the diagnostic process. Treatment of splanchnic vein thrombosis requires a multidisciplinary approach including hematologists, gastroenterologists or hepatologists, thrombosis experts, interventional radiologists and surgeons., All patients should receive anticoagulant therapy (exempli gratia low-molecular-weight heparin), followed by long-term oral anticoagulants to maintain an international normalized ratio of 2.0-3.0. In addition, patients ideally require cytoreductive therapy (exempli gratia hydroxyurea) to optimize blood counts (platelets <= 200 x 10 /L; hematocrit <= 40% [in PV]; white blood cell count < 5 x 10 /L). Some patients may require invasive procedures such as transjugular intrahepatic portosystemic shunting, angioplasty (alone or with stenting), surgical shunting or, in severe cases, liver transplantation.",337,56,0.1661721068249258
9781910797815,chp8,There are few data to inform treatment decisions in patients with MPN undergoing elective surgery. Best practice indicates optimizing blood counts and a clear plan for anticoagulants.,"Given the risks of thrombosis and bleeding associated with MPN, patients undergoing surgery require careful management; however, data to inform treatment decisions in this setting are limited. For example, a recent systematic review identified only three studies of surgery in patients with ET, and there are no evidence-based guidelines for the management of patients with ET undergoing elective surgery. Similarly, retrospective studies indicate that surgery is associated with increased mortality and morbidity in patients with PV (Figure 8.2), but prospective data are lacking. The following recommendations have been made for the management of surgical patients with PV and can be generalized to other MPNs. phlebotomy to maintain hematocrit at or below 45% for at least 3 months before elective surgery.",152,35,0.23026315789473684
9781910797815,chp9,Myeloproliferative neoplasm (MPN) may progress to acute leukemia (MPN-blast phase [MPN-BP]) in a minority of patients. This transformation most commonly occurs in patients with primary myelofibrosis but may also occur in those with essential thrombocythemia (ET) or polycythemia vera (PV) (usually only after first progressing to post-ET/PV myelofibrosis).,"Management of myeloproliferative neoplasm blast phase. Most myeloproliferative neoplasms (MPNs) are chronic conditions that remain clinically stable for many years; however, the condition may progress to acute leukemia in a minority of patients, referred to as MPN blast phase (MPN-BP). This transformation most commonly occurs in patients with myelofibrosis, in whom transformation rates of 15-30% have been reported, compared with 1-4% for patients with essential thrombocythemia (ET) and 4-9% for those with polycythemia vera (PV)., Typically, patients with ET or PV initially develop post-ET or post-PV myelofibrosis, which may subsequently undergo transformation to MPN-BP, although in rare cases these conditions may transform directly into MPN-BP without an intermediate myelofibrotic stage., Risk factors for the development of MPN-BP include leukocytosis, thrombocytopenia and unfavorable karyotype (Table 9.1). There are no specific diagnostic criteria for MPN-BP. The principal criterion is the same as for de novo acute myeloid leukemia (AML): more than 20% blasts in bone marrow or peripheral blood. Persistence is also important if only peripheral blood blasts are considered. Importantly, acceleration or progression of myelofibrosis is usually apparent before the development of overt leukemia. Signs of this include. worsening cytopenia or anemia. worsening of constitutional symptoms. progressive and resistant splenomegaly. increasing numbers of blasts in bone marrow and peripheral blood. rising lactate dehydrogenase. new cytogenetic or molecular marker. In addition, recent evidence suggests that progression during treatment with Janus kinase inhibitors is associated with a risk of MPN-BP.",391,97,0.24808184143222506
9781910797815,chp9,"Risk factors for MPN-BP include leukocytosis, thrombocytopenia and unfavorable karyotype.","Most myeloproliferative neoplasms (MPNs) are chronic conditions that remain clinically stable for many years; however, the condition may progress to acute leukemia in a minority of patients, referred to as MPN blast phase (MPN-BP). This transformation most commonly occurs in patients with myelofibrosis, in whom transformation rates of 15-30% have been reported, compared with 1-4% for patients with essential thrombocythemia (ET) and 4-9% for those with polycythemia vera (PV)., Typically, patients with ET or PV initially develop post-ET or post-PV myelofibrosis, which may subsequently undergo transformation to MPN-BP, although in rare cases these conditions may transform directly into MPN-BP without an intermediate myelofibrotic stage., Risk factors for the development of MPN-BP include leukocytosis, thrombocytopenia and unfavorable karyotype (Table 9.1).",212,28,0.1320754716981132
9781910797815,chp9,Signs of accelerating myelofibrosis may precede the development of overt leukemia.,"There are no specific diagnostic criteria for MPN-BP. The principal criterion is the same as for de novo acute myeloid leukemia (AML): more than 20% blasts in bone marrow or peripheral blood. Persistence is also important if only peripheral blood blasts are considered. Importantly, acceleration or progression of myelofibrosis is usually apparent before the development of overt leukemia. Signs of this include.",84,18,0.21428571428571427
9781910797815,chp9,"MPN-BP is associated with a poor prognosis: in the absence of active treatment, median survival is 2-6 months.","MPN-BP is associated with a poor prognosis: median survival is 2-6 months, although this may be prolonged by intensive treatment and prompt recourse to stem cell transplantation (SCT). There is no standard of care for MPN-BP, and many of the current treatment regimens (Table 9.2) are derived from experience in AML. Induction chemotherapy and SCT. In general, MPN-BP should only be treated with induction chemotherapy when allogeneic SCT is planned in eligible patients. The induction chemotherapy regimens are the same as those used in AML, and response rates are similar to those seen in poor-risk AML patients: typically, complete response (CR) and CR with incomplete count recovery (CRi) rates are 40-50%, although rates of approximately 70% have been reported with a combination of cytosine arabinoside and anthracycline., , However, these responses are not durable, having a median duration of approximately 5 months. Eligible patients should therefore undergo SCT as soon as possible. The importance of this is highlighted by a study in which median overall survival in patients who completed allogeneic SCT following CR/CRi with induction chemotherapy was 47 months, compared with 9.4 months in those who achieved a CR/CRi but did not go on to SCT. Two-year overall survival rates were 47% and 17%, respectively.",292,27,0.09246575342465753
9781910797815,chp9,"There is no standard of care for MPN-BP, and treatment regimens are derived from experience in acute myeloid leukemia. All eligible patients should receive induction chemotherapy, followed by allogeneic stem cell transplantation (SCT). Achieving a complete response during induction chemotherapy is essential for an optimal outcome after SCT.","MPN-BP is associated with a poor prognosis: median survival is 2-6 months, although this may be prolonged by intensive treatment and prompt recourse to stem cell transplantation (SCT). There is no standard of care for MPN-BP, and many of the current treatment regimens (Table 9.2) are derived from experience in AML. Induction chemotherapy and SCT. In general, MPN-BP should only be treated with induction chemotherapy when allogeneic SCT is planned in eligible patients. The induction chemotherapy regimens are the same as those used in AML, and response rates are similar to those seen in poor-risk AML patients: typically, complete response (CR) and CR with incomplete count recovery (CRi) rates are 40-50%, although rates of approximately 70% have been reported with a combination of cytosine arabinoside and anthracycline., , However, these responses are not durable, having a median duration of approximately 5 months. Eligible patients should therefore undergo SCT as soon as possible. The importance of this is highlighted by a study in which median overall survival in patients who completed allogeneic SCT following CR/CRi with induction chemotherapy was 47 months, compared with 9.4 months in those who achieved a CR/CRi but did not go on to SCT. Two-year overall survival rates were 47% and 17%, respectively.",292,67,0.22945205479452055
9781910797815,chp9,Patients with MPN-BP who are not eligible for induction chemotherapy or SCT may benefit from treatment with hypomethylating agents such as azacitidine (perhaps in combination).,"Achieving a CR is essential for successful SCT. In one study, 8 of 13 patients proceeded to SCT after induction chemotherapy and were followed for a median of 20 months. All five who achieved CR had returned to chronic MPN at the time of SCT but remained in remission, whereas 2 of 3 patients with persistent marrow or circulating blasts died. There is growing interest in post-transplant immunomodulation with donor lymphocyte infusion or drugs such as hypomethylating agents. Less-intensive chemotherapy. Patients with MPN-BP who are not eligible for induction chemotherapy or SCT may benefit from treatment with hypomethylating agents. In one study involving 54 patients with MPN-BP or a condition suggestive of myelodysplastic syndrome, treatment with azacitidine resulted in an overall response rate (CR + CRi + partial response) of 28% after a median of 20 months' follow-up, and median overall survival was 8 months in the MPN-BP group. However, support for this approach currently comes mainly from small case series.",222,39,0.17567567567567569
9781910797853,chp1,Hematopoietic stem cells (HSCs) develop into terminally differentiated myeloid and lymphoid cells through intermediate progenitor cells.,"Differentiation. HSCs in the bone marrow subsequently develop into other terminally differentiated cells such as erythrocytes, granulocytes and monocytes (Figure 1.1). HSCs give rise to both myeloid and lymphoid lineages of blood cells. The commitment of differentiated cells is irreversible: for example, monocytes cannot form erythrocytes. Self-renewal. The second fundamental attribute of HSCs is the ability to self-renew to provide a continuous source of blood cells throughout the human lifespan. The ability to self-renew is maintained through a number of tightly regulated mechanisms that are gradually being elucidated. The incidence of uncontrolled proliferation (as occurs in cancer) is rare compared with the number of times the hematopoietic system has to respond by controlled proliferation to injury or infection. One way in which this is regulated is through the loss of self-renewal properties in differentiated cells such as neutrophils and monocytes. For example, vast numbers of neutrophils are drawn to sites of infection, but they have a limited lifespan and have to be replaced by upstream progenitors. This requires the HSCs to exit dormancy and generate intermediate progenitors (see Figure 1.1), which are able to divide rapidly and replenish these peripheral cells.",273,33,0.12087912087912088
9781910797853,chp1,The self-renewal of HSCs is a highly regulated process that provides a continuous source of blood cells in adult humans.,"Self-renewal. The second fundamental attribute of HSCs is the ability to self-renew to provide a continuous source of blood cells throughout the human lifespan. The ability to self-renew is maintained through a number of tightly regulated mechanisms that are gradually being elucidated. The incidence of uncontrolled proliferation (as occurs in cancer) is rare compared with the number of times the hematopoietic system has to respond by controlled proliferation to injury or infection. One way in which this is regulated is through the loss of self-renewal properties in differentiated cells such as neutrophils and monocytes. For example, vast numbers of neutrophils are drawn to sites of infection, but they have a limited lifespan and have to be replaced by upstream progenitors. This requires the HSCs to exit dormancy and generate intermediate progenitors (see Figure 1.1), which are able to divide rapidly and replenish these peripheral cells.",195,27,0.13846153846153847
9781910797853,chp1,The precursors of fully differentiated blood cells have intermediate properties between the final cells and the HSCs. Developmental potential becomes increasingly restricted.,"Identification of upstream progenitor cells. The precursors of fully differentiated neutrophils and erythrocytes bear intermediate properties between the final cells and the HSCs. They have an increasingly restricted developmental potential as they complete their development. Traditionally, these precursor cells have been identified by labeling cell surface markers with antibodies conjugated to fluorescent proteins, which can then be identified by flow cytometry. Cells sorted on the basis of these cell surface markers have been transplanted into irradiated mice, and only specific populations of cells have been found to develop from them. For example, when common lymphoid progenitors are transplanted into irradiated mice, they give rise only to lymphocytes (Figure 1.2a). Similarly, upstream intermediate progenitors of myeloid and erythroid cells have been identified. However, the exact lineages and potential of different intermediaries have been revised over the years.",189,29,0.15343915343915343
9781910797853,chp1,The lineage of hematopoietic cells has been extensively studied using flow cytometry and traditional transplantation techniques.,"More recent work based on single-cell analyses has revealed novel insights into the process of hematopoiesis (Figures 1.2b,c). Normal blood cells can be sorted into individual cells using flow cytometry and RNA extracted. From this, the expression levels of different genes can be identified using next-generation sequencing. From this information, in combination with traditional transplantation studies, the ultimate fate of these cells can be determined. These studies have further revised the models of hematopoiesis, with some suggesting that hematopoietic development is a continuous process rather than one involving sequential subpopulations with increasingly restricted lineage potential.",134,24,0.1791044776119403
9781910797853,chp1,Cytokines such as interferon-alpha and granulocyte-macrophage colony-stimulating factor provide signals to HSCs to proliferate and differentiate.,"The role of cytokine signaling. Cytokines provide a signal to cells to proliferate and differentiate. For example, dormant HSCs can be stimulated by the cytokine interferon-alpha (IFNalpha) to produce more proliferative oligopotent stem cells that can differentiate into other cells such as neutrophils. Other cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF), drive differentiation of progenitor cells into neutrophils and monocytes. Permissive versus instructive signaling. An ongoing debate on the role of cytokine signaling is whether cytokines merely provide a permissive environment for HSCs to differentiate into a specific role (permissive model) or have a more direct role, driving the HSCs down a specific differentiation lineage (instructive model).",187,36,0.1925133689839572
9781910797853,chp1,Transcription factors are also vital in the regulation of hematopoiesis.,"The role of specific transcription factors. Transcription factors are vital in the regulation of hematopoiesis. Evidence for this is seen through the disruption of hematopoiesis in both mouse models and in familial patterns of disease. Hematopoietic cells are exquisitely sensitive to subtle variations in expression levels of transcription factors. For example, a simple twofold increase in the levels of the transcription factor GATA binding protein 2 (GATA2) blocks differentiation of hematopoietic cells in mice. Powerful experimental data also show the ability of ectopically expressed transcription factors to transdifferentiate committed hematopoietic cells into different lineages (Figure 1.3).",145,17,0.11724137931034483
9781910797853,chp2,The main reason for the development of leukemia is the accumulation of gene mutations over time. Chromosomal translocations are common.,"Leukemia predominantly arises from acquired genetic abnormalities in the hematopoietic system. Gene mutations may occur at any stage of cell maturation, preventing normal maturation and/or leading to uncontrolled proliferation to the detriment of normal cell production. Exposure to radiation or carcinogens may cause gene mutations, but the most common reason for the development of leukemia is the accumulation of mutations associated with aging. Box 2.1 sets out some common terminology used when discussing the genetics of leukemia that, in conjunction with the karyotype shown in Figure 2.1, will help guide you through the following sections.",120,25,0.20833333333333334
9781910797853,chp2,The identification of chromosomal abnormalities aids treatment stratification in patients. New-generation sequencing technologies have revolutionized the discovery of mutations in leukemia.,"Implications of identifying mutations. The identification of chromosomal abnormalities in leukemias has resulted in appropriate treatment stratification for patients with these conditions. For example, in AML, chromosomal translocation t(8;21) or chromosomal inversion inv(16), which are associated with RUNX1 and its binding partner CBF beta, respectively, are known as core-binding factor AML and are associated with a good response to chemotherapy. In contrast, patients with a complex karyotype (a karyotype with multiple chromosomal mutations) or monosomy 5 or 7 (the presence of only one chromosome 5 or 7, rather than the normal pair) have a poor response to conventional cytotoxic chemotherapy and require further consolidation treatment such as allogeneic stem cell transplantation. In CLL, patients with mutations affecting the short arm of chromosome 17 (17p) have a poor treatment response to conventional chemotherapy and are often managed with novel therapies, for example Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib.",219,28,0.1278538812785388
9781910797853,chp2,"Prognosis depends on the genetic abnormalities involved, as well as other clinical factors.","Implications of identifying mutations. The identification of chromosomal abnormalities in leukemias has resulted in appropriate treatment stratification for patients with these conditions. For example, in AML, chromosomal translocation t(8;21) or chromosomal inversion inv(16), which are associated with RUNX1 and its binding partner CBF beta, respectively, are known as core-binding factor AML and are associated with a good response to chemotherapy. In contrast, patients with a complex karyotype (a karyotype with multiple chromosomal mutations) or monosomy 5 or 7 (the presence of only one chromosome 5 or 7, rather than the normal pair) have a poor response to conventional cytotoxic chemotherapy and require further consolidation treatment such as allogeneic stem cell transplantation. In CLL, patients with mutations affecting the short arm of chromosome 17 (17p) have a poor treatment response to conventional chemotherapy and are often managed with novel therapies, for example Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib.",219,17,0.0776255707762557
9781910797853,chp2,The acute leukemias are predominantly characterized by the uncontrolled growth of immature poorly differentiated cells that are blocked from further differentiation.,"The comprehensive nature of these studies has provided evidence for new paradigms in our understanding of these different diseases. For example, next-generation sequencing has identified mutations in whole new classes of genes. One such class comprises the genes responsible for the correct splicing of newly transcribed mRNA. These genes, such as U2AF1 and SRSF2, are frequently mutated in both AML and CLL. Knowledge of these genes has potentially important therapeutic implications, as they may become targets for new drugs. Characterization of the mutations found in large cohorts of patients with AML is providing insights into the molecular cooperativity between different mutations, and further studies may suggest how they interact. Mechanisms of leukemogenesis. CLL and CML are both characterized by an increased number of maturing cells. However, in both ALL and AML the leukemia is characterized by highly proliferative immature cells that are blocked from differentiating. Traditionally, in these acute leukemias, it has been hypothesized that two mutations in the regulatory mechanisms of hematopoiesis are required (Figure 2.4).",225,25,0.1111111111111111
9781910797853,chp2,The chronic leukemias are characterized by maturing proliferative later-stage cells.,"Mechanisms of leukemogenesis. CLL and CML are both characterized by an increased number of maturing cells. However, in both ALL and AML the leukemia is characterized by highly proliferative immature cells that are blocked from differentiating. Traditionally, in these acute leukemias, it has been hypothesized that two mutations in the regulatory mechanisms of hematopoiesis are required (Figure 2.4).",88,18,0.20454545454545456
9781910797853,chp2,Malignant clonal subpopulations identified at diagnosis have also been identified at relapse.,"In recent years, the use of next-generation genome sequencing has enabled unbiased characterization of these subpopulations through the identification of these mutations as clonal markers (Figure 2.5). Studies of paired samples in patients with AML at diagnosis, remission and relapse have shown that the clonal population at relapse comprises the same subpopulations that were present at diagnosis but not cleared during remission. This suggests that, to achieve cures, these subpopulations must also be eradicated.",96,17,0.17708333333333334
9781910797853,chp2,"The four main types of leukemia are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.","As discussed at the start of this chapter, there are four main types of leukemia: AML, ALL, CML and CLL. Acute myeloid leukemia. The underlying pathophysiology in AML is the maturational arrest of early-stage myeloid progenitor cells as a result of chromosomal translocations and other genetic and/or epigenetic abnormalities (as discussed earlier in this chapter). The prognosis for a patient with AML depends on the subtype of AML. French-American-British (FAB) classification. The traditional morphologically based classification of AML was based on the FAB criteria, which assigned patients to one of eight groups, designated M0-M7 based on morphological and cytochemical features (Table 2.1). Although the FAB classification has given way to classifications more reliant on recurrent genetic abnormalities, morphological findings remain a cornerstone of AML classification.",189,31,0.164021164021164
9781910797853,chp3,Acute myeloid leukemia (AML) is the most common acute leukemia in adults.,"Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of 4.2 new cases per 100 000 men and women per year in the USA between 2010 and 2014, and 3100 new cases in the UK in 2014. As such, this is a relatively uncommon cancer in comparison with many more common solid organ tumors: it accounts for less than 1% and 1.3% of all new cases of cancer in the UK and USA, respectively.",100,19,0.19
9781910797853,chp3,Acute lymphoblastic leukemia (ALL) most commonly affects younger people; over 50% of patients with ALL are under 20 years of age.,"Acute lymphoblastic leukemia. The number of new cases of acute lymphoblastic leukemia (ALL) was 1.7 per 100 000 men and women per year in the USA between 2010 and 2014, and there were 760 new cases in the UK in 2014. ALL commonly affects younger people, with over 50% of patients being under the age of 20 (see Figure 3.1). The median age of diagnosis is 15 years. However, there is a second, smaller peak of incidence in adults aged 55 to 64 years (see Figure 3.1). The management and prognoses of patients with ALL differs greatly between adults and children (see Chapter 5).",133,29,0.21804511278195488
9781910797853,chp3,"Age is the main risk factor for AML, chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL); the prevalence of these leukemias increases with age.","Genetic mutations. Like most cancers, the main risk factor for AML, CML and CLL is age, and so with an aging population the prevalence of these conditions increases. Despite the presence of certain etiologic factors, the major reason for the development of most leukemias is the accumulation of genetic mutations as a person ages. Many different gene mutations can lead to leukemia. Both AML and B-cell ALL can be subtyped on the basis of recurrent genetic mutations (see Chapter 2). CML is one of the few cancers in which most cases are caused by a single specific genetic mutation: chromosome translocation t(9;22), a cytogenetic abnormality known as the Philadelphia chromosome (see Figure 2.1). The presence of pre-existing populations of cells that place individuals at risk for developing leukemia has also long been recognized. A classic example is the identification of the RUNX1-ETO fusion protein in the blood of neonates, as identified by their Guthrie cards. This suggests that in some patients, RUNX1-ETO fusion occurs in utero, and pre-dates the development of frank leukemia.",235,41,0.17446808510638298
9781910797853,chp3,"The main risk factor for AML, CML and CLL is age, with recurrent genetic mutations accumulating over time.","Genetic mutations. Like most cancers, the main risk factor for AML, CML and CLL is age, and so with an aging population the prevalence of these conditions increases. Despite the presence of certain etiologic factors, the major reason for the development of most leukemias is the accumulation of genetic mutations as a person ages. Many different gene mutations can lead to leukemia. Both AML and B-cell ALL can be subtyped on the basis of recurrent genetic mutations (see Chapter 2). CML is one of the few cancers in which most cases are caused by a single specific genetic mutation: chromosome translocation t(9;22), a cytogenetic abnormality known as the Philadelphia chromosome (see Figure 2.1).",152,24,0.15789473684210525
9781910797853,chp3,"Predisposing conditions such as myelodysplastic syndrome and monoclonal B-cell lymphocytosis increase the risk of AML and CLL, respectively.","Myelodysplasia or myelodysplastic syndrome (MDS) is a heterogeneous group of hematopoietic clonal disorders of the bone marrow that results in one or more cytopenias. MDS is classically diagnosed on the basis of recognized morphological features affecting myeloid, erythroid or megakaryocytic cells on a peripheral blood film or bone marrow aspirate. The risk of developing AML from MDS is highly variable: prediction can be based on a number of scoring systems. One of the most widely used is the revised International Prognostic Scoring System, which takes into account several factors, including the severity of cytopenias, bone marrow blast count and cytogenetic risk. The risk of developing AML affects the overall survival of patients with MDS. Monoclonal B-cell lymphocytosis (MBL) is another example of a condition that pre-dates the onset of leukemia. It is defined by a clonal B-cell population of less than 5 x 10 /L. Patients with MBL are asymptomatic and have no lymphadenopathy or hepatosplenomegaly. In a prospective study of over 77 000 apparently healthy people over 60 years old, 45 patients eventually developed CLL. In virtually all cases, a preceding diagnosis of MBL was identified. MBL has a prevalence of approximately 5% in individuals over the age of 60, with an annual rate of transformation to CLL of 1%.",312,37,0.11858974358974358
9781910797853,chp3,"Clonal hematopoiesis of indeterminate potential (CHIP) is present in up to 10% of the population aged over 65. Although this increases the risk of hematologic malignancies, most individuals with CHIP do not develop a hematologic disorder.","Monoclonal B-cell lymphocytosis (MBL) is another example of a condition that pre-dates the onset of leukemia. It is defined by a clonal B-cell population of less than 5 x 10 /L. Patients with MBL are asymptomatic and have no lymphadenopathy or hepatosplenomegaly. In a prospective study of over 77 000 apparently healthy people over 60 years old, 45 patients eventually developed CLL. In virtually all cases, a preceding diagnosis of MBL was identified. MBL has a prevalence of approximately 5% in individuals over the age of 60, with an annual rate of transformation to CLL of 1%. Clonal hematopoiesis of indeterminate potential. A surprising finding in recent years has been the high prevalence of mutations associated with myeloid neoplasms (exempli gratia recurrent mutations in the epigenetic regulators DNMT3A, TET2 and ASXL1) in otherwise healthy individuals, the frequency of which increases with age. In one study in which exome sequencing was performed in over 12 000 patients without hematologic malignancies, 10% of patients over the age of 65 had at least one mutation suggesting clonal hematopoiesis. Patients with clonal hematopoiesis of indeterminate potential (CHIP) have an increased risk of hematologic malignancies, but it is important to emphasize that the majority of individuals with CHIP do not develop a hematologic disorder.",315,58,0.18412698412698414
9781910797853,chp3,"Down syndrome is associated with an increased risk of AML and ALL. The risk is greatest in early childhood, when transient abnormal myelopoiesis (TAM) develops. However, TAM spontaneously remits in most cases; only about 10% of cases, with additional genetic mutations, go on to develop AML.","Down syndrome is associated with an increased risk of both ALL and AML. The risk differs according to age, and is greatest in early childhood. Myeloid disorders associated with Down syndrome, including transient abnormal myelopoiesis (TAM) and AML, are characterized by a proliferation of megakaryocytes. Neonates and infants with TAM typically have an excess of blasts in the peripheral circulation, with varying clinical sequelae. In the majority of patients with TAM, blasts are cleared from the peripheral bloodstream and blood counts are normal within a few months. However, a subset of patients with TAM subsequently develop AML. All patients with TAM have an N-terminal-truncating mutation in the transcription factor gene GATA1. The accumulation of other gene mutations, including those that encode the cohesin complex, results in the development of AML (Figure 3.2). Inherited predisposition to acute myeloid leukemia. As described above, most cases of AML are sporadic, arising as a result of the steady accumulation of mutations in somatic cells. However, a small but increasingly well-recognized subset of patients with AML have a germline inherited genetic predisposition to AML. Indeed, in the latest revision of the World Health Organization's classification of hematopoietic diseases, 'myeloid neoplasms with germline predisposition' are classified as a separate subset of the disease (Table 3.1). The implications of diagnosing such cases are far reaching; genetic counseling for the patient's family may be necessary, and consideration should be given to the selection of donors for allogeneic stem cell transplantation. Patients with an inherited predisposition to AML present in a variety of ways: some have no other symptoms, some have other cytopenias, and some may have other organ dysfunction.",377,66,0.17506631299734748
9781910797853,chp3,"Although most cases of AML are sporadic, arising from the steady accumulation of genetic mutations with age, some individuals have a germline inherited genetic predisposition to the disease.","Inherited predisposition to acute myeloid leukemia. As described above, most cases of AML are sporadic, arising as a result of the steady accumulation of mutations in somatic cells. However, a small but increasingly well-recognized subset of patients with AML have a germline inherited genetic predisposition to AML. Indeed, in the latest revision of the World Health Organization's classification of hematopoietic diseases, 'myeloid neoplasms with germline predisposition' are classified as a separate subset of the disease (Table 3.1). The implications of diagnosing such cases are far reaching; genetic counseling for the patient's family may be necessary, and consideration should be given to the selection of donors for allogeneic stem cell transplantation. Patients with an inherited predisposition to AML present in a variety of ways: some have no other symptoms, some have other cytopenias, and some may have other organ dysfunction.",196,34,0.17346938775510204
9781910797853,chp3,"Environmental exposures to chemicals such as benzene, high-dose ionizing radiation and previous chemotherapy increase the risk of leukemia to varying degrees.","Environmental risk factors. Exposures to benzene, high-dose ionizing radiation and chemotherapeutics are known risk factors for leukemia to varying degrees. Patients may develop secondary AML after chemotherapy or radiotherapy for other malignancies. Those with previous exposure to alkylating agents, with or without radiation, often have a myelodysplastic phase before the development of AML, whereas those exposed to topoisomerase II inhibitors do not. These forms of AML are known as therapy-associated AML and patients tend to have adverse-risk cytogenetics.",120,27,0.225
9781910797853,chp4,"Many types of leukemia, including chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL), show no specific symptoms in the early stages and may be diagnosed incidentally during a physical examination or routine blood test.","The diagnosis of leukemia can begin with a patient presenting with non-specific symptoms that are consequences of pancytopenia. However, many types of leukemia show no obvious symptoms early in disease, and may be diagnosed incidentally during a physical examination or as a result of a routine blood test. Suspicion of either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) constitutes a medical emergency: assessment and a management plan should be instituted promptly. In general, the diagnostic workup for leukemia includes. history and physical examination. blood tests. bone marrow aspiration and biopsy. integrated review of flow cytometric, genetic and morphological results. Clinical presentation. Acute myeloid leukemia typically presents with signs and symptoms of bone marrow failure (Table 4.1). Patients may have symptoms of anemia, such as dyspnea or angina. Thrombocytopenia may result in bruising and bleeding. Neutropenia may present as sepsis or fever. The onset of symptoms occurs usually no more than a few months before diagnosis. Conversely, patients may be asymptomatic, with AML being diagnosed from a full blood count performed for other reasons.",247,47,0.1902834008097166
9781910797853,chp4,"Both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) can present with signs and symptoms of bone marrow failure, including those related to anemia, thrombocytopenia and neutropenia.","Acute myeloid leukemia typically presents with signs and symptoms of bone marrow failure (Table 4.1). Patients may have symptoms of anemia, such as dyspnea or angina. Thrombocytopenia may result in bruising and bleeding. Neutropenia may present as sepsis or fever. The onset of symptoms occurs usually no more than a few months before diagnosis. Conversely, patients may be asymptomatic, with AML being diagnosed from a full blood count performed for other reasons. Extramedullary disease. AML can also present as a soft-tissue swelling, known variably as extramedullary disease, granulocytic sarcoma or chloroma. Extramedullary disease can present without bone marrow involvement, and is associated with certain cytogenetic changes such as the t(8;21) chromosome translocation. Treatment for extramedullary disease is similar to that for AML that is confined to the bone marrow.",207,50,0.24154589371980675
9781910797853,chp4,"Diagnosis of leukemia is based on an integration of clinical, morphological, immunophenotypic and genetic findings.","As described above, many bone marrow disorders present with pancytopenia and its attendant signs and symptoms. The main diagnoses to consider in the differential diagnosis of pancytopenia due to acute myeloid or lymphoblastic leukemia are other hematologic cancers with marrow infiltration and bone marrow failure syndromes, such as aplastic anemia. Myeloproliferative disorders with bone marrow fibrosis can also present similarly. Rarely, pancytopenia caused by the displacement of hematopoietic bone marrow tissue by fibrosis, tumor or granuloma (called myelophthisis) may mimic an acute leukemia. Examples include solid organ cancers with extensive bone marrow involvement, and granulomatous disease such as tuberculosis. Morphological, immunophenotypic (or cytochemical), cytogenetic and molecular studies must be performed in every case of suspected leukemia. Information from these studies is important for the correct diagnosis and classification of the leukemia, as it informs the selection of treatment and determines prognosis. Morphological and immunophenotypic analyses remain the foundation of rapid initial assessment; from the results, specific cytogenetic and molecular genetic tests can be directed.",246,24,0.0975609756097561
9781910797853,chp4,The presence of blasts in a peripheral blood smear suggests an underlying hematologic disorder.,"Myeloblasts. The presence of myeloblasts - immature cells with large nuclei and nucleoli, and a scant rim of dark blue cytoplasm - suggests an underlying malignant hematologic disorder. Blasts containing Auer rods (a rod-like conglomeration of granules in the cytoplasm) are pathognomonic of AML.",77,17,0.22077922077922077
9781910797853,chp4,Myeloblasts containing Auer rods are pathognomonic for AML.,"Myeloblasts. The presence of myeloblasts - immature cells with large nuclei and nucleoli, and a scant rim of dark blue cytoplasm - suggests an underlying malignant hematologic disorder. Blasts containing Auer rods (a rod-like conglomeration of granules in the cytoplasm) are pathognomonic of AML.",77,17,0.22077922077922077
9781910797853,chp4,Flow cytometry can differentiate between ALL and AML on the basis of different cell surface markers.,"Immunophenotyping by flow cytometry differentiates precursor B-cell ALL from precursor T-cell ALL by demonstrating the presence of B-cell antigens and the absence of T-cell antigens. In addition, precursor B- and T-cell ALL are differentiated from AML by positivity for terminal deoxynucleotidyl transferase (TdT) and lack of staining for myeloperoxidase.",92,19,0.20652173913043478
9781910797853,chp4,"On immunophenotypic analysis, the presence of B-cell antigens in the absence of T-cell antigens differentiates B-cell ALL from T-cell ALL.","Immunophenotyping by flow cytometry differentiates precursor B-cell ALL from precursor T-cell ALL by demonstrating the presence of B-cell antigens and the absence of T-cell antigens. In addition, precursor B- and T-cell ALL are differentiated from AML by positivity for terminal deoxynucleotidyl transferase (TdT) and lack of staining for myeloperoxidase. Chronic myeloid leukemia. While CML is definitively diagnosed by the presence of the chromosome translocation t(9;22), also known as the Philadelphia chromosome (see below), examination of the peripheral blood and bone marrow helps to characterize the patient's disease phase (chronic stable phase, accelerated phase or blast phase). The staging of CML is discussed in more detail in Chapter 5.",171,38,0.2222222222222222
9781910797853,chp4,"CML is diagnosed by the presence of the chromosome translocation t(9;22), also known as the Philadelphia chromosome. The t(9;22) mutation also occurs in some cases of ALL.","Immunophenotyping by flow cytometry differentiates precursor B-cell ALL from precursor T-cell ALL by demonstrating the presence of B-cell antigens and the absence of T-cell antigens. In addition, precursor B- and T-cell ALL are differentiated from AML by positivity for terminal deoxynucleotidyl transferase (TdT) and lack of staining for myeloperoxidase. Chronic myeloid leukemia. While CML is definitively diagnosed by the presence of the chromosome translocation t(9;22), also known as the Philadelphia chromosome (see below), examination of the peripheral blood and bone marrow helps to characterize the patient's disease phase (chronic stable phase, accelerated phase or blast phase). The staging of CML is discussed in more detail in Chapter 5.",171,41,0.23976608187134502
9781910797853,chp4,Examination of bone marrow aspirate can confirm the diagnosis of leukemia.,"Morphology. LGLs are large (15-18 m), approximately twice the size of a normal red blood cell. They are characterized by abundant cytoplasm containing fine or coarse azurophilic granules and a reniform or round nucleus with a high nuclear to cytoplasmic ratio. LGLs comprise 10-15% of normal peripheral blood mononuclear cells. The absolute number of LGLs in the peripheral blood of healthy individuals is 200-400/L. The diagnosis can usually be made based on a morphological and immunophenotypic analysis of the peripheral blood, which demonstrates increased numbers of clonal LGLs of T-cell lineage. Bone marrow aspirate and/or biopsy may be required to confirm the diagnosis in some cases, especially those with low absolute numbers of circulating LGLs.",174,14,0.08045977011494253
9781910797853,chp4,Detection of recurring gene mutations in AML and ALL provides important genetic information about prognosis and informs the selection of targeted therapies.,"The detection of specific chromosome translocations/gene fusions enables a precise diagnosis of leukemia, while the detection of recurring gene mutations in AML and ALL provides important genetic information regarding prognosis and informs the selection of targeted therapies. Combining conventional cytogenetic analysis, FISH, microarray and next-generation sequencing (NGS) offers an informative genetic landscape of leukemia and enables personalized genetic-based treatment. Molecular methods, such as RT-PCR or NGS techniques, assess the entire cell population, whereas FISH provides analysis at the single cell level.",114,26,0.22807017543859648
9781910797853,chp4,"Certain cytogenetic abnormalities are associated with favorable responses to treatment, while others are associated with treatment failure.","The frequencies of recurring chromosome abnormalities in children and adults with ALL differ substantially. Up to 30% of B-cell ALL is not classified within any of the existing WHO subgroups (see page 33; Table 2.5) (id est they do not have recurring chromosome abnormalities, kinase-activating gene fusions or Philadelphia chromosome [Ph]-like B-cell ALL [see below]). However, a number of recurring cytogenetic abnormalities are associated with distinct immunologic phenotypes of ALL and characteristic outcomes. Certain abnormalities, such as t(4;11) and t(9;22), are associated with treatment failure even when using intensive chemotherapy. Conversely, t(12;21), t(1;19) and hyperdiploidy (50-60 chromosomes) are associated with more favorable outcomes.",165,21,0.12727272727272726
9781910797853,chp5,"Induction therapy for most patients with acute myeloid leukemia (AML) comprises intensive anthracycline/cytarabine (Ara-C) combination chemotherapy aimed at achieving a complete response (CR). However, almost all patients who achieve a CR after induction therapy will ultimately relapse without post-remission therapy.","Induction therapy in acute myeloid leukemia (AML) generally comprises intensive combination chemotherapy, aimed at achieving a complete response (CR) by rapidly reducing the number of leukemia cells and restoring normal bone marrow function. A CR is defined morphologically as fewer than 5% of blasts in a bone marrow aspirate, with recovery of blood counts to normal. Post-remission therapy, including chemotherapy, targeted therapies and autologous or allogeneic hematopoietic stem cell transplantation (HSCT) may be given to sustain the CR and achieve long-term disease-free survival. In the UK, most patients are offered access to a national clinical trial. Induction therapy. Intensive anthracycline/cytarabine (Ara-C)-based induction therapy constitutes the standard of care for most patients with AML. Exceptions are patients with acute promyelocytic leukemia (APML) for whom disease-specific treatments, such as all-trans retinoic acid or arsenic trioxide, are required, and frail or elderly patients in poor health who may require lower-intensity regimens (see below). The standard treatment involves daunorubicin and Ara-C in regimens such as 'DA 3+7' or 'DA 3+10'. These regimens usually entail hospitalization for at least 4 weeks while blood cell counts recover to normal, and complications of the disease and its treatment are managed (see Chapter 6).",300,67,0.22333333333333333
9781910797853,chp5,"Post-remission therapy for AML, comprising one or more courses of chemotherapy, or autologous or allogeneic hematopoietic stem cell transplantation (HSCT), is given to eliminate any residual disease and achieve a cure.","Induction therapy in acute myeloid leukemia (AML) generally comprises intensive combination chemotherapy, aimed at achieving a complete response (CR) by rapidly reducing the number of leukemia cells and restoring normal bone marrow function. A CR is defined morphologically as fewer than 5% of blasts in a bone marrow aspirate, with recovery of blood counts to normal. Post-remission therapy, including chemotherapy, targeted therapies and autologous or allogeneic hematopoietic stem cell transplantation (HSCT) may be given to sustain the CR and achieve long-term disease-free survival. In the UK, most patients are offered access to a national clinical trial. Induction therapy. Intensive anthracycline/cytarabine (Ara-C)-based induction therapy constitutes the standard of care for most patients with AML. Exceptions are patients with acute promyelocytic leukemia (APML) for whom disease-specific treatments, such as all-trans retinoic acid or arsenic trioxide, are required, and frail or elderly patients in poor health who may require lower-intensity regimens (see below). The standard treatment involves daunorubicin and Ara-C in regimens such as 'DA 3+7' or 'DA 3+10'. These regimens usually entail hospitalization for at least 4 weeks while blood cell counts recover to normal, and complications of the disease and its treatment are managed (see Chapter 6).",300,51,0.17
9781910797853,chp5,"The ideal donor for HSCT is a sibling with complete human leukocyte antigen (HLA) matching. Unrelated donors who are a good match or related donors with some matching may also be suitable, but the risk of graft-versus-host disease is increased.","For allogeneic HSCT, stem cell donors may be siblings or individuals unrelated to the patient; in some cases, donation from a twin may be possible (syngeneic transplantation) (Figure 5.1). Success of the procedure depends on the degree of human leukocyte antigen (HLA) matching (also known as tissue typing) between donor and host; there are many HLA markers. Stem cells from umbilical cord blood does not require as much HLA matching as that from adult circulating blood. Chances of graft-versus-host disease (GVHD) and graft rejection are reduced in well-matched recipients. An ideal donor would be a sibling completely matched at HLA-A, HLA-B, HLA-DR, HLA-C and HLA-DQ. Alternatively, unrelated donors with good HLA matching, or related donors with some HLA matching may be used; however, both are associated with an increased risk of GVHD. The graft-versus-tumor effect that is integral to allogeneic HSCT (in which donor T cells eliminate residual malignant cells in the host) diminishes the chances of tumor relapse.",246,55,0.22357723577235772
9781910797853,chp5,"Treatment for acute lymphoblastic leukemia (ALL) comprises chemotherapeutic induction, consolidation and maintenance therapy with central nervous system prophylaxis.","Emerging therapies. A number of emerging therapies are under evaluation for the treatment of AML. Various epigenetic therapies targeting both DNA and histone are currently in preclinical or Phase I development. The histone deacetylase inhibitor vorinostat has been evaluated in a Phase II study in patients with newly diagnosed AML. Preliminary data suggest that this agent is well tolerated and effective when added to standard therapy (idarubicin plus high-dose continuous infusion of Ara-C). Acute lymphoblastic leukemia. Treatment of acute lymphoblastic leukemia (ALL) is stratified according to age (< 15 years old; 15-39 years; > 39 years) and Philadelphia chromosome status (positive or negative). In general, ALL treatment consists of four components.",159,31,0.1949685534591195
9781910797853,chp5,"Treatment options for patients with chronic myeloid leukemia (CML) include disease control with tyrosine kinase inhibitors (TKIs) or palliative therapy with cytotoxic agents and, less commonly, HSCT. TKIs are the initial treatment of choice for almost all patients with newly diagnosed CML.","Improvements in the management of chronic stable disease in recent years have resulted in fewer patients (approximately 6% at 5 years) progressing to accelerated phase disease or blast crisis. Treatment options. Treatment decisions for patients with CML are complex because there are many, sometimes conflicting, therapeutic options. These include disease control using TKIs, allogeneic HSCT or palliative therapy with cytotoxic agents. Multiple factors will influence the choice of therapy in CML, including. the phase of CML. the response to treatment with TKIs (for patients in early phases). availability of a donor for HSCT. medical comorbidities affecting suitability for HSCT. Tyrosine kinase inhibitors target the active enzyme tyrosine kinase, which is implicated in the pathogenesis of CML. First- and second-generation oral TKIs include imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Although they may not cure the disease, they can achieve long-term control in most patients; as a result, they have become first-line treatment for almost all newly diagnosed patients with CML. Chronic phase. Imatinib was the first TKI approved for patients with chronic phase CML, but data from randomized trials in newly diagnosed patients have shown that more potent second-generation TKIs (exempli gratia dasatinib, nilotinib) produce faster and deeper responses than imatinib., However, these trials have not demonstrated improvements in overall survival. Long-term data show that the responses to imatinib have been very durable, with rates of progression being lower in successive years and with very few relapses after 3-4 years of follow-up.",359,67,0.18662952646239556
9781910797853,chp5,The standard of care for patients with newly diagnosed chronic lymphocytic leukemia (CLL) is observation rather than immediate treatment. Treatment is indicated for patients with more advanced or symptomatic disease to ameliorate symptoms and improve survival.,"Staging and when to treat. There are two main staging systems for chronic lymphocytic leukemia (CLL). The Rai staging system divides the disease into five stages; it is most often used in the USA. The Binet staging system divides the disease into three stages and is the preferred system in Europe (Table 5.5). CLL is an extremely heterogeneous disease, with certain subsets of patients having survival rates without treatment that are similar to the normal population. Hence, not all patients with CLL will require treatment at the time of diagnosis. Asymptomatic early-stage disease. Although highly variable, patients with asymptomatic early-stage CLL (Rai stage < 3, Binet stage A or B) have a median survival greater than 10 years. Observation rather than immediate treatment is the standard of care for newly diagnosed patients with early-stage asymptomatic CLL. Early initiation of chemotherapy has failed to show benefit, and may even increase mortality., Localized radiotherapy is usually offered to patients with localized (stage I) CLL. Symptomatic or advanced-stage disease. In contrast, patients with more advanced CLL, or those with symptoms or progressive disease, have a median survival without treatment between 18 months and 3 years. Treatment of the underlying CLL is indicated for patients who develop disease-related symptoms or evidence of progressive disease ('active disease'), and this can improve median survival to approximately 5-8 years.",297,47,0.15824915824915825
9781910797853,chp5,"Treatment decisions for patients with CML depend on the phase of the disease, response to TKI treatment, age and eligibility for HSCT.","There is no standard frontline treatment regimen for patients with symptomatic CLL: a wide variety of chemotherapy regimens are used, often combining nucleoside analogs (exempli gratia fludarabine), alkylating agents (exempli gratia cyclophosphamide) and biological agents (exempli gratia rituximab). Choice of treatment will depend on the person's age, disease risk and symptoms, as well as prognostic factors such as chromosome 17 or 11 deletions. Common treatment regimens are shown in Table 5.7; these may be used as first- or second-line options. For example, alemtuzumab, an anti-CD52 monoclonal antibody, is approved for first-line treatment of CLL and as salvage therapy in patients with fludarabine-refractory disease. It has also been shown to have a role in consolidation therapy for the elimination of MRD. Ofatumumab and obinutuzumab are anti-CD20 monoclonal antibodies approved for several indications in CLL.",228,29,0.12719298245614036
9781910797853,chp6,"Supportive care for patients with leukemia manages the effects of disease activity and progression, as well as the adverse effects of therapy.","While the overall prevalence of hematologic cancer is rising, so are survival rates; according to Cancer Research UK, leukemia survival in the UK has more than quadrupled in the past 40 years. As a consequence, supportive care has become increasingly important for patients with leukemia. This entails managing the effects of disease activity and progression, as well as the adverse effects of therapy (Table 6.1). This requires a multidisciplinary approach that includes clinical nurse specialists who can offer psychosocial support and continuity of care and can act as advocates for the patient to ensure that their needs are fully met.",119,25,0.21008403361344538
9781910797853,chp6,"Transfusion support, with or without the use of blood growth factors, may be required at many points in the disease process and becomes essential to continued survival in the later stages.","While the overall prevalence of hematologic cancer is rising, so are survival rates; according to Cancer Research UK, leukemia survival in the UK has more than quadrupled in the past 40 years. As a consequence, supportive care has become increasingly important for patients with leukemia. This entails managing the effects of disease activity and progression, as well as the adverse effects of therapy (Table 6.1). This requires a multidisciplinary approach that includes clinical nurse specialists who can offer psychosocial support and continuity of care and can act as advocates for the patient to ensure that their needs are fully met. Replacement of blood products (transfusion support). Blood transfusions are among the most important forms of supportive care for patients with leukemia. Blood product support may be necessary at many points in the disease process, and it becomes essential to continued survival in the later stages. Giving packed red blood cells is the fastest way to increase the oxygen-delivering capacity of the blood. Packed red blood cells should be given to patients with hemoglobin levels lower than 7-8 g/dL (higher if the patient has significant cardiovascular or respiratory compromise).",228,36,0.15789473684210525
9781910797853,chp6,The prevention and treatment of infection are of paramount importance.,"Limited clinical trial data suggest that the use of growth factors, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), accelerates neutrophil recovery and decreases infection risk in patients undergoing induction therapy. Such treatment may be considered in patients with leukemia at high risk of complications from infection. In practice, use of growth factors varies between centers, depending on the disease, the timing in relation to treatment and patient factors.",106,11,0.10377358490566038
9781910797853,chp6,It is important not to overlook the importance of cancer-related fatigue. The level and nature of fatigue should be regularly assessed.,"Cancer-related fatigue (CRF) can be defined as a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent event activity and interferes with usual functioning. CRF is almost universal in patients receiving cytotoxic chemotherapy. Patients usually recover after treatment, although some cancer survivors report that it can remain troublesome even after treatment. As such, it is important not to overlook the effect of CRF on patients' wellbeing.",107,25,0.2336448598130841
9781910797853,chp6,Failure to control chemotherapy-induced nausea and vomiting (CINV) on the first day of chemotherapy increases the risk of CINV on subsequent days and in subsequent cycles of chemotherapy. Well-established guidelines for the use of effective antiemetic regimens are available.,"The results of studies on the use of drug interventions to improve CRF have been conflicting, according to the population studies and outcome measures used. There is some evidence that psychostimulants may improve CRF, but large-scale trials are needed. Physical activity has been shown to be beneficial in individuals with CRF, but further research is required to determine the optimal type, intensity and timing of exercise regimens. Evidence for the effectiveness of psychosocial interventions in the management of CRF, including psychological, educational and support groups is limited and further studies are needed. Treatment of nausea and vomiting. Chemotherapy-induced nausea and vomiting (CINV) can result in severely debilitating weakness, weight loss, electrolyte imbalance, dehydration or anorexia; it is associated with a variety of complications, including esophageal tears and a decline in behavioral and mental status. Importantly, CINV can lead to patients refusing further courses of chemotherapy. Failure to control CINV on the first day of chemotherapy increases the risk of CINV on subsequent days and in subsequent cycles of chemotherapy. Increasingly effective antiemetic regimens have reduced the incidence of nausea and vomiting due to chemotherapy, and control can be enhanced by adherence to well-established antiemetic guidelines. The recommended approach to the prevention of nausea and vomiting depends on the emetic risk of the chemotherapeutic agents used (Table 6.3)., Antiemetics are usually given parenterally, either intravenously or subcutaneously. The use of syringe drivers may provide a more constant delivery of antiemetic medication.",328,54,0.16463414634146342
9781910797853,chp6,"Patients with leukemia may experience pain caused by the disease itself, complications of the disease, invasive diagnostic procedures, treatment effects or unrelated medical conditions. Management of pain therefore requires a multidisciplinary approach.","Patients with leukemia may experience pain caused by the disease itself, complications of the disease, invasive diagnostic procedures, treatment effects or unrelated medical conditions (Table 6.5). The management of pain in this setting requires a multidisciplinary approach, which should include the management of psychosocial factors that may augment pain, such as anxiety and depression, sleeplessness and financial problems. There are a number of simple pain-intensity screening tools that are quick and easy to administer (Figure 6.1). Prevention of pain. Painful short-duration procedures such as bone marrow aspiration and biopsy are usually performed under local anesthesia; however, pre-emptive analgesia with brief unconscious sedation or general anesthesia, under the guidance of an anesthetist, may be recommended in selected cases (exempli gratia for young children).",169,40,0.23668639053254437
9781910797853,chp6,"Surviving cancer can have a profound and lasting impact on patients, affecting both physical and mental health, professional and personal identity, sexuality and financial standing. Patients surviving leukemia may require support in a number of areas.","Certain leukemia treatments, such as some chemotherapy regimens or HSCT, can impair fertility, and this may be an important concern for younger patients wishing to start a family. While tyrosine kinase inhibitors such as imatinib are not known to impair fertility, data on their effects on reproductive potential are lacking. Before treatment, fertility issues should be raised with all patients with reproductive potential. Patients wishing to preserve their fertility should be counseled by a fertility specialist about their options. Table 6.6 lists recommendations for fertility preservation made by the International Society for Fertility Preservation. However, in most emergency circumstances, there may not be a safe means to explore these options as the patient may not be fit to travel to a fertility center. Support in survivorship - emotional health. The effects of living with cancer can be profound; mental health, professional and personal identity, sexuality and financial standing may all be affected. The US National Cancer Care Network has identified a number of areas where cancer survivors, including people living with leukemia, may require support. These include.",211,42,0.1990521327014218
9781910797853,chp6,The aim of palliative care is to provide the best possible quality of life for patients with advanced and untreatable disease and their families.,"It is important for healthcare teams to recognize advancing and untreatable disease and when specialist end of life care is needed. Retrospective studies in patients with leukemia and other hematologic malignancies have shown that in the last month of life patients experience bleeding, infections, pain, shortness of breath, CNS disturbances and fatigue. The aim of palliative care is to achieve the best possible quality of life for the patient by addressing their symptoms and psychosocial needs and building relationships with the patient and their family members in order to cultivate understanding of the illness and the prognosis.",117,29,0.24786324786324787
9781910797853,chp7,Sepsis should be treated immediately with broad-spectrum antibiotics; intravenous fluids and oxygen should be given as needed.,"Treatment. The maximum recommended dose of a broad-spectrum antimicrobial should be given immediately, together with intravenous fluids and oxygen as needed. The source of infection needs to be found, and additional antimicrobials against known infections should be administered as appropriate. It is important to assess for complications of sepsis to ensure timely referral to critical care services for further support if this is appropriate. Further antibiotic and admission management may be guided by the use of scoring systems to assess the risk of developing further complications.",104,24,0.23076923076923078
9781910797853,chp7,"The high risk of bleeding in uncontrolled acute promyelocytic leukemia (APML) represents a medical emergency. To prevent coagulopathy, anti-leukemic therapy should be initiated as soon as possible alongside meticulous supportive care.","Acute promyelocytic leukemia (APML) is a rare subtype of acute myeloid leukemia (AML). It is notable in the modern era, as disease-specific treatments such as all-trans retinoic acid (ATRA) or arsenic trioxide have had impressive results, with overall survival reaching over 95%. However, APML represents a medical emergency, with considerable early morbidity and mortality at the initial diagnosis. This is primarily due to the increased bleeding risk in uncontrolled APML. Trial data suggest an early death rate in the region of 5%, but in a population-based study, the early death rate was as high as 28%, particularly as a result of central nervous system hemorrhage. The coagulopathy seen in APML is due to the interaction of a number of different pathophysiological processes, including activation of the clotting system, increased fibrinolytic activity, cytokine release and non-specific proteolysis, leading to a form of disseminated intravascular coagulation (DIC) and hyperfibrinolysis. In DIC, increased fibrin deposition blocks small blood vessels; in turn, the increased clotting depletes the levels of platelets and clotting factors needed to control bleeding. Red blood cells are damaged by the microangiopathic process, resulting in the production of red cell fragments. In APML, it is the fibrinolytic activity that predominates, with the consumption of fibrinogen increasing the risk of bleeding (Figure 7.1).",319,48,0.15047021943573669
9781910797853,chp7,"Tumor lysis syndrome may arise spontaneously but is more frequent in the early days of chemotherapy, when massive numbers of tumor cells are being destroyed.","Tumor lysis syndrome may arise spontaneously as a result of the rapid turnover of leukemic cells, but it occurs more frequently in the first few days after chemotherapy is initiated. The destruction of large numbers of tumor cells results in the rapid release of intracellular metabolites into the extracellular space. This overwhelms homeostatic control mechanisms, leading to hyperuricemia, hyperphosphatemia, hyperkalemia and hypocalcemia. The earliest change is often hyperkalemia. Subsequent deposition of uric acid crystals in the renal tubules impairs the ability of the kidneys to maintain adequate homeostasis of the electrolytes, resulting in a downward spiral.",141,30,0.2127659574468085
9781910797853,chp7,All patients at risk of tumor lysis syndrome should be given intravenous fluids to maintain good diuresis.,"Prophylaxis. As a universal measure, all patients at risk of tumor lysis syndrome should be given at least 3 liters of fluid intravenously over 24 hours to maintain good diuresis. Alkalization of urine is not advisable as this may precipitate crystallization of xanthine and hypoxanthine in the nephrons. The choice of pharmaceutical prophylaxis depends on the patient's risk of tumor lysis syndrome. For intermediate-risk patients, allopurinol, typically at a dose of 300 mg daily for 7 days, is sufficient. In most high-risk adults, rasburicase should be used for prophylaxis at a single dose of 3 mg, although careful monitoring is needed to assess any need for re-dosing. Rasburicase is a recombinant urate oxidase that can help convert uric acid to allantoin, which is more readily excreted. Rasburicase should not be used in patients with glucose-6-phosphate dehydrogenase deficiency and it is not advisable to use allopurinol and rasburicase together. This is because allopurinol is a xanthine oxidase inhibitor and works upstream of rasburicase to prevent the production of uric acid (Figure 7.2).",275,22,0.08
9781910797853,chp7,"Both allopurinol and rasburicase can be used as prophylaxis in tumor lysis syndrome depending on the patient's risk level. However, they should not be used together.","The choice of pharmaceutical prophylaxis depends on the patient's risk of tumor lysis syndrome. For intermediate-risk patients, allopurinol, typically at a dose of 300 mg daily for 7 days, is sufficient. In most high-risk adults, rasburicase should be used for prophylaxis at a single dose of 3 mg, although careful monitoring is needed to assess any need for re-dosing. Rasburicase is a recombinant urate oxidase that can help convert uric acid to allantoin, which is more readily excreted. Rasburicase should not be used in patients with glucose-6-phosphate dehydrogenase deficiency and it is not advisable to use allopurinol and rasburicase together. This is because allopurinol is a xanthine oxidase inhibitor and works upstream of rasburicase to prevent the production of uric acid (Figure 7.2).",203,42,0.20689655172413793
9781910797853,chp7,"Hyperleukocytosis is a frequent finding in both chronic and acute leukemias, but leukostasis tends to be more common in patients with acute myeloid leukemia. Rapid reductions in white blood cell counts can be achieved with leukapheresis, but concomitant chemotherapy is needed to maintain leukodepletion.","Hyperleukocytosis - a marked elevation in leukemic cells in the peripheral blood - is a frequent finding in patients with both chronic and acute leukemias. However, the ability of patients to tolerate different WBC counts depends on the underlying type of leukemia; for example, patients with CLL may tolerate a far higher WBC count than those with AML. In AML, hyperleukocytosis is arbitrarily defined as leukemia cell counts greater than 100 x 10 /L; and it is more common in patients with monocytic subtypes. Leukostasis is a medical emergency. It is more commonly seen in patients with AML, but symptomatic leukostasis may also be associated with a blast crisis in chronic myeloid leukemia. Leukostasis occurs when WBC plugs form in very small blood vessels, potentially leading to reduced flow in the capillary beds and symptoms related to the affected organ. Pulmonary and neurological symptoms are most common. In some men, leukostasis may result in a painful priapism. Treatment. The management of leukostasis depends on whether the patient is symptomatic: patients may be hypoxic from pulmonary hemorrhage or confused from cerebral leukostasis. It may be difficult to exclude concomitant illnesses, such as pneumonia, that could also explain the clinical findings. Fundoscopy may identify retinal hemorrhages and engorgement of retinal vasculature.",298,72,0.24161073825503357
9781910797853,chp7,"Treatment with all-trans retinoic acid and arsenic trioxide has led to impressive improvements in survival rates in APML, but their use may be associated with the development of differentiation syndrome. This can be managed with intravenous dexamethasone, 10 mg twice a day.","The use of ATRA and arsenic trioxide in the treatment of APML has been associated with the development of differentiation syndrome, a potentially severe complication that can affect approximately 25% of patients during the induction phase of treatment. Although the pathogenesis of differentiation syndrome has not yet been fully elucidated, it appears that ATRA activates a cascade of mechanisms that lead to an inflammatory response, with damage to the endothelium and migration of leukocytes into the surrounding tissue. Differentiation syndrome is characterized by fever and features of cardiac failure, including dyspnea, weight gain, peripheral edema and pulmonary infiltrates; it may also result in renal failure. Hyperleukocytosis may also be present. In severe cases, patients may require organ support in an intensive care setting. It is important to be vigilant for differentiation syndrome because it is easily confused with concurrent illnesses, such as infections. Management of differentiation syndrome centers on the use of intravenous dexamethasone, 10 mg twice daily, until the syndrome settles. Although there is little evidence to support it, prophylactic corticosteroid treatment is commonly used, especially in patients at high risk of differentiation syndrome. Treatment with ATRA or arsenic trioxide is usually continued unless the syndrome is particularly severe (exempli gratia if the patient requires organ support), in which case treatment may be temporarily suspended while the syndrome is resolved.",282,58,0.20567375886524822
9781910797853,chp7,"An increased incidence of thromboses in patients with acute lymphoblastic leukemia is probably linked to treatment with regimens containing L -asparaginase. To help reduce the incidence of thromboses, placement of central venous catheters should be avoided during the induction phase of treatment with these regimens.","L -asparaginase is a vital component of pediatric and adult treatment protocols for acute lymphoblastic leukemia (ALL), and it has been part of the encouraging improvements in outcomes for patients with this leukemia. The increased incidence of thromboses in patients with ALL (5% in children and higher in adults) is likely to be linked to the use of L -asparaginase, as thromboses are not as strongly associated with regimens that do not contain this agent. Thromboses most frequently occur in the venous system, including critical sites such as the cerebral venous sinuses and pulmonary vessels. The mechanism of action underlying this increase in thromboses is multifactorial, including disruption of natural anticoagulants and activation of the coagulation cascade. L -asparaginase is particularly associated with a decrease in antithrombin, a natural anticoagulant that inhibits activated coagulation factors. Given the resultant prothrombotic state, which is worse during the initial stages of treatment, placement of central venous catheters should be avoided during induction treatment, as these may be a source of thromboses. The management of thromboses is predominantly based on the use of low molecular weight heparin (LMWH). However, as the anticoagulant mechanism of LMWH is dependent on antithrombin, the levels of which are affected by L-asparaginase, some clinicians also advocate the use of antithrombin infusions or other replacement products.",320,65,0.203125
9781910797907,chp1,Normal mature red blood cells (RBCs) rely on the breakdown of glucose via the glycolytic pathway to produce energy.,"Pyruvate kinase (PK) deficiency is the most common enzyme deficiency affecting the glycolytic pathway used by red blood cells (RBCs) to generate energy. PK is a tetrameric protein that catalyzes the conversion of phosphoenolpyruvate to pyruvate, one of two energy-generating steps in glycolysis. PK deficiency was first described in 1961. It is inherited in an autosomal recessive manner and presents as a congenital non-spherocytic hemolytic anemia.",113,27,0.23893805309734514
9781910797907,chp1,"Pyruvate kinase (PK) deficiency affects the penultimate step of the glycolytic pathway, impairing the conversion of phosphoenolpyruvate to pyruvate, and reducing the amount of energy produced by RBCs.","Pyruvate kinase (PK) deficiency is the most common enzyme deficiency affecting the glycolytic pathway used by red blood cells (RBCs) to generate energy. PK is a tetrameric protein that catalyzes the conversion of phosphoenolpyruvate to pyruvate, one of two energy-generating steps in glycolysis. PK deficiency was first described in 1961. It is inherited in an autosomal recessive manner and presents as a congenital non-spherocytic hemolytic anemia. To understand the impact of PK deficiency, it is necessary to review the overall metabolism in RBCs. Metabolic pathways in normal red blood cells. Mature RBCs lack a nucleus, ribosomes and mitochondria: as a result, they are incapable of cell division and protein synthesis, and are unable to generate energy through oxidative phosphorylation, as occurs in other cell types. Instead, RBCs rely on breaking down glucose to pyruvate and lactate to produce energy.",214,53,0.24766355140186916
9781910797907,chp1,PK deficiency is inherited in an autosomal recessive manner and is the most common glycolytic defect associated with hemolysis.,"Pyruvate kinase (PK) deficiency is the most common enzyme deficiency affecting the glycolytic pathway used by red blood cells (RBCs) to generate energy. PK is a tetrameric protein that catalyzes the conversion of phosphoenolpyruvate to pyruvate, one of two energy-generating steps in glycolysis. PK deficiency was first described in 1961. It is inherited in an autosomal recessive manner and presents as a congenital non-spherocytic hemolytic anemia.",113,27,0.23893805309734514
9781910797907,chp1,The hexose monophosphate shunt protects RBCs from oxidant damage.,"Hexose monophosphate shunt. The key product of the HMP shunt is NADPH, the reduced form of nicotinamide adenine dinucleotide phosphate. This cofactor plays a vital role in protecting RBCs from oxidant injury by assisting in the production of reduced glutathione. In RBCs, the reaction between hemoglobin and oxygen produces oxidants such as hydrogen peroxide and superoxide anion (O -). If allowed to accumulate, these oxidants will oxidize hemoglobin and other proteins, leading to a loss of function and ultimately cell death. Reduced glutathione is an intracellular reducing agent and is essential for the inactivation of these oxidants and thus for the protection of RBCs. The HMP shunt is the only source of NADPH in RBCs, and under conditions of increased oxidative stress the amount of glucose entering the shunt can rise significantly.",190,18,0.09473684210526316
9781910797907,chp2,Gaps remain in our understanding of the epidemiology of pyruvate kinase (PK) deficiency because many cases are believed to go unreported.,"Despite being the best studied of the glycolytic enzyme disorders, gaps remain in our understanding of pyruvate kinase (PK) deficiency. More than 600 cases of PK deficiency have been reported, mainly from Europe, the USA and Japan, but the disease occurs worldwide, and it is likely that many cases go unreported. This may be because affected individuals die before birth, or because cases are mild and do not require medical attention. Alternatively, some cases may not be properly recognized, or they may be misdiagnosed. Given that some cases may not present with any of the findings usually associated with the condition, there are likely to be more cases of PK deficiency than are published in the literature. Patient registries have now been developed for PK deficiency, which are helping to characterize the range of symptoms and complications arising from this disorder.",170,31,0.18235294117647058
9781910797907,chp2,Some mutations are seen more frequently in specific regions and populations.,"Despite being the best studied of the glycolytic enzyme disorders, gaps remain in our understanding of pyruvate kinase (PK) deficiency. More than 600 cases of PK deficiency have been reported, mainly from Europe, the USA and Japan, but the disease occurs worldwide, and it is likely that many cases go unreported. This may be because affected individuals die before birth, or because cases are mild and do not require medical attention. Alternatively, some cases may not be properly recognized, or they may be misdiagnosed. Given that some cases may not present with any of the findings usually associated with the condition, there are likely to be more cases of PK deficiency than are published in the literature. Patient registries have now been developed for PK deficiency, which are helping to characterize the range of symptoms and complications arising from this disorder.",170,12,0.07058823529411765
9781910797907,chp2,About one quarter of patients diagnosed with PK deficiency will have a previously unrecorded mutation in the PKLR gene.,"As discussed in Chapter 1, mutations in the PKLR gene on chromosome 1 are responsible for PK deficiency. More than 300 different mutations have been reported; most are very rare, occurring only once. Currently, about 25% of patients diagnosed with PK deficiency appear to have a previously unrecorded mutation. Although many of the mutations associated with PK deficiency are rare, a few are recorded more frequently (Table 2.1). The variability in how PK deficiency manifests is thought to reflect the heterogeneity of these causative mutations, as well as the fact that most individuals with PK deficiency will be compound heterozygotes (id est they will have a different mutation in each copy of the PKLR gene).",137,22,0.16058394160583941
9781910797907,chp2,Approximately 70% of mutations associated with PK deficiency are missense mutations.,"Approximately 70% of the mutations associated with PK deficiency are missense (M) mutations (id est a single nucleotide change resulting in the production of a different amino acid), while the others are more disruptive non-missense (NM) mutations - either nonsense or insertional mutations, deletions (such as the deletion of exon 11 found in the Romany population), or splicing abnormalities (see pages 43 -).",86,15,0.1744186046511628
9781910797907,chp2,Acquired PK deficiency very rarely can occur secondarily to other blood diseases.,"While almost all cases of PK deficiency are inherited and result from mutations in the PKLR gene, an acquired form of the deficiency can very rarely occur secondarily to other blood diseases, such as acute leukemia, myelodysplastic syndrome and refractory sideroblastic anemia. Acquired PK deficiency can also result from complications associated with chemotherapy.",72,16,0.2222222222222222
9781910797907,chp3,The differential diagnosis of pyruvate kinase deficiency includes a heterogeneous group of acquired and congenital hemolytic disorders.,"Pyruvate kinase (PK) deficiency is a chronic hemolytic anemia associated with acute exacerbations, varying degrees of severity and the potential to be diagnosed at any age. The differential diagnosis includes a heterogeneous group of hemolytic disorders, both acquired and congenital (Figure 3.1). Although most of these conditions are rare, the coexistence of two or more causes of hemolysis cannot be excluded without additional assessment, further complicating diagnosis. Many confounding factors can also complicate the clinical picture (id est concomitant iron or vitamin deficits, dysmyelopoiesis, liver or renal disease, chronic inflammation), underlining the need for a comprehensive clinical and laboratory evaluation of a patient presenting with a hemolytic disorder.",153,26,0.16993464052287582
9781910797907,chp3,The direct antiglobulin test (Coombs test) is the cornerstone of the diagnosis of autoimmune hemolytic anemias. False-positive and false-negative results should be taken into account.,"Autoimmune hemolytic anemias. The direct antiglobulin test (DAT, or Coombs test) is the cornerstone of the diagnosis of autoimmune hemolytic anemias (AIHAs). The DAT reveals the presence of anti-erythrocyte antibodies on red blood cells (RBCs). Diffferent DAT methods have varying sensitivities/specificities, levels of automation and availability in laboratories. The DAT tube utilizes the traditional agglutination technique, and is usually carried out using polyspecific reagents, although monospecific antisera (anti-immunoglobulin [Ig] G, anti-IgA, anti-IgM, anti-complement [C]) are advisable. Other methods include microcolumn DAT and solid-phase tests, which are suitable for automation and nowadays are available in most laboratories. The DAT tube is the most specific but least sensitive test, whereas microcolumn and solid-phase tests show reduced specificity but increased sensitivity. More sensitive techniques (id est flow cytometry, and enzyme-linked, radiolabeled and culture tests) are not routinely performed, and any positive result should be interpreted with caution given the low specificity of these techniques.",257,42,0.16342412451361868
9781910797907,chp3,A complex group of enzyme defects (mostly recessive) are diagnosed by testing the enzymatic activity in the peripheral blood and by confirming the causative mutation at a molecular level (homozygous or compound heterozygous).,"Hemolysis is primarily extravascular in the spleen in warm AIHAs, whereas it may also be intravascular in cold forms. Clinically, the level of RBC destruction by intravascular hemolysis has been calculated to be 200 mL of RBCs in 1 hour, more than ten times the level seen with extravascular hemolysis (Figure 3.2). Confounding factors. A positive DAT result may occur because of the presence of alloantibodies in recently transfused patients, as a result of delayed hemolytic transfusion reactions, in hemolytic disease of the newborn and in a small number of healthy blood donors (< 0.1%) and hospitalized patients (0.3-8%) with no clinical evidence of AIHA. Moreover, a false-positive DAT may be observed after the administration of various therapeutics (id est intravenous immunoglobulins, Rhesus immune globulins and antithymocyte globulin), as well as in diseases with elevated serum globulins or paraproteins.",222,47,0.21171171171171171
9781910797907,chp3,"Several infectious, microangiopathic, mechanical, toxic and pharmacological causes of acquired hemolytic anemias should also be considered.","Other acquired hemolytic anemias. There are several other causes of acquired hemolysis (see Figure 3.1a). The diagnostic work-up of all these conditions is beyond the scope of this book. However, alongside the patient's history and the serological and specific tests for the different diseases, it should be remembered that mechanical hemolysis is characterized by the presence of schistocytes (fragmented RBCs) on a blood smear examination, the early (and easy) detection of which may be crucial for prompt treatment and a consequent favorable prognosis.",118,29,0.2457627118644068
9781910797907,chp3,"Patient history and blood smear examination are fundamental in the diagnosis of congenital membrane defects, including hereditary spherocytosis, elliptocytosis and stomatocytosis.","Membrane defects. Examination of a blood smear is fundamental to guiding the differential diagnosis of congenital hemolytic anemias. A typical morphology is observed in most membrane defects, such as hereditary spherocytosis, hereditary elliptocytosis, hereditary stomatocytosis and hereditary pyropoikilocytosis. Hereditary spherocytosis is the most common form of membrane defect (Figure 3.3), with an estimated prevalence ranging from 1 in 2000 to 1 in 5000 in the general population. A dominant pattern of inheritance is seen in 75% of cases. Hereditary spherocytosis is due to a deficiency in the cytoskeletal proteins responsible for maintaining the biconcave morphology of RBCs. This defect results in reduced cell flexibility and premature destruction of spherocytes in the spleen. Typically, the osmotic fragility test, the acidified glycerol lysis test and flow cytometric analysis of eosin-5-maleimide-labeled RBCs are positive.",220,38,0.17272727272727273
9781910797907,chp3,Congenital dyserythropoietic anemias and hereditary pyropoikilocytosis are recessive anemias to be considered and diagnosed mainly by molecular analysis.,"Congenital dyserythropoietic anemias. It is also worth considering the complex group of congenital dyserythropoietic anemias, which comprise several autosomal recessive disorders characterized by distinct morphological abnormalities of marrow erythroblasts. Typically, these anemias have some hemolytic features but an inadequate reticulocytosis. There are several causative mutations that classify the major subgroups, including CDAN1, SEC23B, KIF23, KLF1 and GATA-1. Diagnosis of the congenital dyserythropoietic anemias requires bone marrow evaluation and molecular characterization in most patients. Enzyme defects. When RBC morphology is unremarkable, a congenital hemolytic anemia due to an erythrocyte enzyme defect is highly likely. As explained in Chapter 1, RBCs need to continuously break down glucose via the glycolytic pathway and the hexose monophosphate shunt (HMP). Hereditary deficiencies of all HMP and glycolytic enzymes have been identified (see Figure 3.1b). With the exception of glucose-6-phosphate dehydrogenase deficiency (G6PD) and the rare 3-phosphoglycerate kinase (PGK) deficiency, both of which are X-linked, all other enzyme deficiencies are inherited in an autosomal recessive fashion.",293,38,0.1296928327645051
9781910797907,chp4,"Pyruvate kinase (PK) deficiency should be considered in patients with signs/symptoms and laboratory findings of chronic hemolytic anemia (including those with mild anemia), reticulocytosis, jaundice, unconjugated hyperbilirubinemia, gallstones and splenomegaly.","Diagnosis of pyruvate kinase deficiency. The diagnosis of pyruvate kinase (PK) deficiency begins with an assessment of a patient's history, clinical signs/symptoms and laboratory markers of chronic hemolytic anemia. However, clinical symptoms can vary greatly between affected individuals. Most importantly, diagnosis is assisted by evidence of reduced PK enzyme activity together with the detection of compound heterozygous and homozygous mutations in the PKLR gene. As would be expected, patients with more severe anemia are diagnosed at a younger age, but PK deficiency can also be diagnosed later into adulthood. PK deficiency may be difficult to diagnose for several reasons. The clinical heterogeneity of the disease, which ranges from asymptomatic cases to life-threatening neonatal anemia, and even hydrops fetalis. As an autosomal recessive disorder there may be no family history to assist clinicians (id est the parents of an affected individual are most often hematologically normal and there may be no affected siblings). There are difficulties with the performance and interpretation of assays for PK enzymatic activity. Many different mutations in the PKLR gene have been associated with PK deficiency and about one-quarter of patients will have a novel mutation. The differential diagnoses include several other forms of hemolytic anemia, which may be unfamiliar to clinicians (see Chapter 3).",276,68,0.2463768115942029
9781910797907,chp4,The diagnosis of PK deficiency is made by measuring PK enzymatic activity in red blood cell lysates by spectrophotometric assay.,"Diagnosis of pyruvate kinase deficiency. The diagnosis of pyruvate kinase (PK) deficiency begins with an assessment of a patient's history, clinical signs/symptoms and laboratory markers of chronic hemolytic anemia. However, clinical symptoms can vary greatly between affected individuals. Most importantly, diagnosis is assisted by evidence of reduced PK enzyme activity together with the detection of compound heterozygous and homozygous mutations in the PKLR gene. As would be expected, patients with more severe anemia are diagnosed at a younger age, but PK deficiency can also be diagnosed later into adulthood.",124,28,0.22580645161290322
9781910797907,chp4,The diagnosis should be confirmed by the demonstration of known causative PKLR mutations in homozygous or compound heterozygous presentations.,"However, not all the mutations detected by DNA analysis can be immediately classified as causative until their pathogenic nature is confirmed by other functional tests. In fact, there are patients who are homozygous or compound heterozygous for PKLR mutations who show normal PK activity. Genetic testing will develop further with the use of whole-genome sequencing, although it will still be limited by the ability to interpret bioinformatic data. At present, most reference centers screen for PK deficiency by measuring PK enzymatic activity and then confirm suspected PK deficiency by DNA sequence analysis of the PKLR gene. In a few centers, screening for PK deficiency is initially performed by NGS panels and then (in the case of an identified novel mutation) confirmed by PK enzymatic activity.",157,26,0.16560509554140126
9781910797907,chp5,"The hemolytic anemia associated with pyruvate kinase (PK) deficiency can range from mild to severe, with hemoglobin levels typically in the range of 6-12 g/dL. It can be exacerbated by hemolytic episodes and aplastic crises.","Complications and monitoring. Pyruvate kinase (PK) deficiency can be associated with a range of complications (Table 5.1). Although complications are more frequent in patients with severe anemia and frequent transfusions, the likelihood of a given complication in an individual patient is not predictable based on hemoglobin and transfusion burden and thus all patients with PK deficiency require regular monitoring (Table 5.2). Main complications. Anemia. The hemolytic anemia due to PK deficiency varies from mild to severe, with hemoglobin levels typically in the range of 6-12 g/dL. Reticulocyte counts may be inappropriately low in children or increased as a reflection of the hemolysis. After splenectomy, reticulocyte counts will paradoxically rise to 30-70% of red blood cells (RBCs). In patients who receive regular blood transfusions, complete blood counts should be evaluated before transfusion. In those patients who do not receive transfusions on a regular basis, complete blood counts and a reticulocyte count should be monitored at least annually and with any significant worsening of baseline symptoms.",228,56,0.24561403508771928
9781910797907,chp5,Gallstones are a common complication of PK deficiency and the risk persists after splenectomy. Cholecystectomy should be considered at the time of splenectomy regardless of the presence of gallstones.,"Although splenectomy improves the anemia for most people with PK deficiency, it does not resolve the issue of jaundice or scleral icterus as the hemolytic process continues despite splenectomy. Thus, splenectomy should not be pursued to improve jaundice in patients with PK deficiency. Gallstones are a frequent complication in patients of all ages with PK deficiency because of the increased unconjugated bilirubin related to hemolysis. The risk of bilirubin gallstones is lifelong because hemolysis will continue after splenectomy. Therefore cholecystectomy should be considered concurrently with splenectomy, even in individuals who do not have evidence of gallstones, as almost half of patients who have a splenectomy only will ultimately go on to have a cholecystectomy.",169,41,0.24260355029585798
9781910797907,chp5,"Transfusion-independent iron loading can occur at any age and with any severity of anemia. Annual monitoring of iron is indicated in all patients with PK deficiency, regardless of transfusion status. Chelation may be intermittently prescribed.","Transfusion-related iron loading. The association between transfusions and iron loading is similar in PK deficiency to that seen in other transfusion-dependent red cell disorders. Regular ferritin monitoring before transfusions and annual MRI assessment are indicated in patients who receive transfusions, and ongoing chelation therapy is necessary in those who receive regular transfusions. Non-transfusion-related iron loading. Hemosiderosis also occurs frequently in individuals with PK deficiency in the absence of transfusions. Non-transfusion-related iron loading can occur at all ages and in patients with all hemoglobin levels. Although patients with both PK deficiency and hereditary hemochromatosis will have an increased risk of iron loading, ineffective erythropoiesis associated with PK deficiency is likely to be the main contributor to transfusion-independent iron loading in this hemolytic disorder. Although not confirmed, the mechanism may be similar to that seen in thalassemia intermedia, in which compensatory mechanisms to overcome chronic anemia include reduced hepcidin levels and increased gastrointestinal iron absorption. Given that iron loading occurs through the gastrointestinal route, patients with PK deficiency should avoid iron supplements, including multivitamins with iron, and excessive consumption of foods high in iron.",255,47,0.1843137254901961
9781910797907,chp5,"In pregnant women with PK deficiency, recommendations for management include close fetal monitoring, consideration of transfusions (because hemolysis is exacerbated) and avoidance of iron-containing supplements.","Non-transfusion-related iron loading. Hemosiderosis also occurs frequently in individuals with PK deficiency in the absence of transfusions. Non-transfusion-related iron loading can occur at all ages and in patients with all hemoglobin levels. Although patients with both PK deficiency and hereditary hemochromatosis will have an increased risk of iron loading, ineffective erythropoiesis associated with PK deficiency is likely to be the main contributor to transfusion-independent iron loading in this hemolytic disorder. Although not confirmed, the mechanism may be similar to that seen in thalassemia intermedia, in which compensatory mechanisms to overcome chronic anemia include reduced hepcidin levels and increased gastrointestinal iron absorption. Given that iron loading occurs through the gastrointestinal route, patients with PK deficiency should avoid iron supplements, including multivitamins with iron, and excessive consumption of foods high in iron.",185,35,0.1891891891891892
9781910797907,chp5,"Many patients with PK deficiency will have prenatal and neonatal complications including hyperbilirubinemia, prematurity, intrauterine growth retardation and perinatal anemia.","Neonatal hyperbilirubinemia. After birth many newborns with PK deficiency will develop hemolysis with significant hyperbilirubinemia, which is treated with phototherapy and/or simple or exchange transfusions. Jaundice in newborns with PK deficiency develops due to a combination of hemolysis and immaturity of the liver. Hyperbilirubinemia can lead to kernicterus of the newborn if untreated. Other complications. Approximately one-quarter of newborns with PK deficiency will have complications in utero or at the time of birth, including intrauterine growth retardation, hydrops fetalis, preterm birth, perinatal anemia and dermal extramedullary hematopoiesis (id est blueberry muffin rash). Severe hepatic disease leading to liver failure has been reported and is associated with a high rate of mortality.",185,37,0.2
9781910797907,chp5,"Other complications of PK deficiency can include low bone density, extramedullary hematopoiesis, pulmonary hypertension and leg ulcers.","Neonatal hyperbilirubinemia. After birth many newborns with PK deficiency will develop hemolysis with significant hyperbilirubinemia, which is treated with phototherapy and/or simple or exchange transfusions. Jaundice in newborns with PK deficiency develops due to a combination of hemolysis and immaturity of the liver. Hyperbilirubinemia can lead to kernicterus of the newborn if untreated. Other complications. Approximately one-quarter of newborns with PK deficiency will have complications in utero or at the time of birth, including intrauterine growth retardation, hydrops fetalis, preterm birth, perinatal anemia and dermal extramedullary hematopoiesis (id est blueberry muffin rash). Severe hepatic disease leading to liver failure has been reported and is associated with a high rate of mortality.",185,30,0.16216216216216217
9781910797907,chp6,"The decision for transfusion therapy relates to the patient's tolerance of anemia rather than an arbitrary level of hemoglobin. Some patients with PK deficiency may tolerate a lower level of hemoglobin than those with other anemias due to increased red cell 2,3-diphosphoglycerate.","Red blood cell (RBC) transfusions are frequently used to support patients with PK deficiency, particularly during the first months of life. However, transfusion thresholds and guidelines used in other red cell disorders, such as thalassemia major or intermedia, do not necessarily apply to PK deficiency. When to transfuse. There is no set standard with regard to transfusions for patients with PK deficiency because the degree of anemia and associated symptoms differ so much between affected individuals., The decision to opt for transfusion therapy is therefore based on a patient's tolerance of anemia rather than on an arbitrary level of hemoglobin. As explained in Chapter 1, an increase in red cell 2,3-diphosphoglycerate results in enhanced oxygen off-loading into the tissues. Consequently, patients may tolerate moderately severe anemia with few symptoms. When patients have a transfusion, the goal nadir hemoglobin level should also be based on symptoms rather than on a level extrapolated from guidelines used in other anemias. Many patients with PK deficiency will never need a transfusion or will only require intermittent, or unplanned, transfusions during hemolytic crises due to infections or an aplastic crisis associated with parvovirus infection. Others may remain on regular transfusion therapy until splenectomy is considered.",267,60,0.2247191011235955
9781910797907,chp6,Splenectomy is beneficial in increasing the hemoglobin level and decreasing the need for transfusions in most patients with PK deficiency.,"The benefits of splenectomy. Before splenectomy, the reticulocyte count may be inappropriately low or mildly to moderately increased (5-15%). After splenectomy, reticulocyte counts can be as high as 50-70% and, with the extended lifespan of PK-deficient reticulocytes in the absence of the spleen, hemoglobin levels increase by a median of 1.6 g/dL. Splenectomy partially ameliorates the anemia in most patients and is beneficial in decreasing the need for transfusions in 90% of patients. In patients who received regular transfusions before splenectomy, approximately 80% can discontinue transfusions altogether following surgery. However, in almost all patients, an incompletely compensated hemolytic process persists, in which mild anemia, reticulocytosis and indirect hyperbilirubinemia continue.",182,25,0.13736263736263737
9781910797907,chp6,The burden of transfusions in pyruvate kinase (PK) deficiency is quite variable and depends on both patient and provider factors.,"Patient selection. Preoperative assessment of red cell survival, splenic sequestration and/or spleen size is of no value in selecting patients for splenectomy. In part, this reflects the importance of the liver as a site of RBCl destruction. Low pre-splenectomy hemoglobin levels are associated with a poorer response to splenectomy in terms of the post-splenectomy hemoglobin rise and/or transfusion burden. The burden of transfusions in PK deficiency varies between patients. The decision whether to have a splenectomy to improve the anemia of PK deficiency is complex and depends on both the physician's and the patient's perspective of the potential benefits and risks. Recent guidelines recommend splenectomy in patients who are reliant on regular transfusions or are severely anemic. Splenectomy should also be considered in patients who receive intermittent transfusions with every infectious illness or who have symptomatic anemia.",187,28,0.1497326203208556
9781910797907,chp6,"Given the potential risks associated with splenectomy, physicians should participate in shared decision making with their patients to determine whether to pursue splenectomy and at what age.","Post-splenectomy sepsis. Splenectomy increases susceptibility to serious bacterial infections with encapsulated organisms, such as Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Capnocytophaga canimorsus. In the absence of a spleen, individuals are also at risk of severe babesiosis and malaria. With adequate vaccinations and prophylactic antibiotics, the absolute risk of a serious infection is very low. Nevertheless, because of these lifelong infectious risks, surgery should be avoided altogether or preferably delayed until at least 5 years of age. If splenectomy is needed at an earlier age, the benefits must be balanced against the risk of infection. Vaccination. Since the spleen is the primary site for the production of immunoglobulin M antibodies, which are required for opsonization of encapsulated organisms, vaccination prior to splenectomy is much preferred. Vaccination schedules are frequently updated based on new information and vaccine development. Therefore, physicians should refer to an updated website rather than to articles or books for a list and schedule of vaccinations before splenectomy. A useful website is www.cdc.gov/vaccines/schedules/index.html. It is recommended that all vaccines are given at least 2 weeks before splenectomy.",273,33,0.12087912087912088
9781910797907,chp6,The risk of post-splenectomy thrombosis in PK deficiency is similar (approximately 10%) to other non-malignant hematologic conditions.,"Post-splenectomy thrombosis. Many studies demonstrate an overall increased risk of thrombosis after splenectomy, including in otherwise healthy individuals. After splenectomy, the overall risk of thrombosis in PK deficiency is approximately 10%, including portal vein thrombosis, deep vein thrombosis, pulmonary embolism and central nervous system thrombosis. Although the etiology for the increased risk is not clear, some physicians recommend taking low-dose aspirin (acetylsalicylic acid) after splenectomy, particularly in patients with marked thrombocytosis, to potentially decrease this risk.",132,32,0.24242424242424243
9781912776139,ch1,ALS is primarily a progressive motor-predominant syndrome.,"ALS is a syndrome that arises from a neurodegenerative disorder of the motor system and its associated neuronal networks. In the USA, ALS is more readily recognized by the term Lou Gehrig's disease, named after the Yankees' baseball star of the 1930s who was known as the 'Iron Horse' for his durability and high tally of home runs. In the UK, the term motor neuron disease is used synonymously with ALS, but confusingly it is sometimes also used as an umbrella term that includes other, unrelated, disorders of the motor neuron, such as Kennedy's disease (X-linked spinobulbar muscular atrophy).",129,12,0.09302325581395349
9781912776139,ch1,"The initial regional patterns of body involvement vary, but generalized involvement over time is the norm.","ALS is a syndrome that arises from a neurodegenerative disorder of the motor system and its associated neuronal networks. In the USA, ALS is more readily recognized by the term Lou Gehrig's disease, named after the Yankees' baseball star of the 1930s who was known as the 'Iron Horse' for his durability and high tally of home runs. In the UK, the term motor neuron disease is used synonymously with ALS, but confusingly it is sometimes also used as an umbrella term that includes other, unrelated, disorders of the motor neuron, such as Kennedy's disease (X-linked spinobulbar muscular atrophy).",129,18,0.13953488372093023
9781912776139,ch1,"Amyotrophic lateral sclerosis (ALS) is not one disease, but a syndrome that overlaps with frontotemporal dementia.","Part of the persistent confusion around nomenclature arises from an array of terms in the literature that have been inconsistently used to delineate phenotypes across the spectrum of ALS; for example, progressive muscular atrophy, primary lateral sclerosis and progressive bulbar palsy. These terms are explained later in this chapter, but 'ALS' serves well as the single unifying term for what is now understood to be a multisystem, clinically heterogeneous syndrome that overlaps pathologically and genetically with frontotemporal dementia (FTD). In relation to the most obvious symptom, ALS has understandably found itself historically classified among the neuromuscular disorders. However, for clinical, histopathological and genetic reasons, it is now more rationally considered alongside the cerebral neurodegenerative disorders (Figure 1.1).",164,26,0.15853658536585366
9781912776139,ch1,There is significant variability in the clinical evidence of upper and lower motor neuron involvement.,'Paralysis' is the extreme end stage of the secondary muscular weakness that lies at the core of ALS. The site of onset and pattern of spread of weakness in ALS varies but is not random. It reflects dysfunction of a broader corticomotoneuronal system that encompasses the traditional nomenclature of upper motor neurons (UMNs) of the corticospinal tract and lower motor neurons (LMNs) arising from differentially vulnerable brainstem nuclei and the anterior horn cells of the spinal cord.,104,16,0.15384615384615385
9781912776139,ch1,Neuronal and glial cytoplasmic inclusions of transactive response DNA-binding protein with M r 43 kDa (TDP-43) are the consistent histopathological feature in nearly all cases.,"The mean age of onset of PLS is around 10 years younger than for typical ALS, usually with lower-limb or bulbar dysfunction. These cases have a profoundly different natural history of very slowly progressive weakness that may not be life shortening. Post mortem histopathology (and modern neuroimaging) of PLS has frequently demonstrated severe 'knife-edge' atrophy of the primary motor cortex. In contrast, and despite the more aggressive course and higher level of physical disability, ALS cases typically demonstrate limited macroscopic atrophy of the brain. Only a few cases of PLS have been examined using modern molecular histopathological phenotyping, with inconsistent reporting of the ALS-defining signature of cellular inclusions of transactive response DNA-binding protein with M r 43 kDa (TDP-43). Thus, unlike so-called PMA, justifiable debate persists as to whether PLS is part of the ALS spectrum; however, given the rarity of PLS compared to UMN-predominant forms of ALS (see below), this is not a major issue in clinical practice.",225,45,0.2
9781912776139,ch1,Symptom onset is focal and tends to spread contiguously.,Classification by site of first symptom onset. Individuals with ALS are strikingly able to define the timing and site of onset of their first symptoms (Table 1.2). The initial site of symptom onset typically retains the highest burden of progressive disability. Limb weakness tends to spread contiguously (contra- versus ipsilaterally).,66,14,0.21212121212121213
9781912776139,ch1,Variation in the speed of symptom progression is not closely tied to any single phenotypic classifier.,"Stratification by rate of progression. The major limitation of a unified TDP-43-based approach to the classification of ALS is the anatomic disconnection between the range of clinical phenotypes and rates of progression. Indeed, a common theme across all the ALS taxonomic systems discussed above is the strikingly slower-than-average rates of progression found in certain variants. For example, the bulbar onset of symptoms is under-represented among individuals with younger-onset disease. The molecular underpinnings for this remain obscure. Given that molecular taxonomies of ALS transcend or confound attempts to produce clinical criteria for these variants, supports the view that ALS is more usefully stratified in terms of rate of symptom progression rather than variable sites and patterns of symptom onset and spread. It is also one of the appealing aspects of a clinical staging approach to ALS akin to that in cancer (Table 1.3).",184,21,0.11413043478260869
9781912776139,ch2,Amyotrophic lateral sclerosis (ALS) is thought to involve a multistep pathogenesis with a variable mixture of predominantly genetic or environmentally mediated factors.,"Amyotrophic lateral sclerosis (ALS) is thought to occur in all regions of the world, but the epidemiology is based on data from the most socioeconomically developed countries, plus the study of atypical cases from geographically isolated populations, notably Guam, the Japanese Kii peninsula and West Papua, Indonesia. Incidence and prevalence. The annual incidence of ALS is 1-3 per 100 000, with a prevalence of 4-6 per 100 000 that equates to approximately 15 000 and 5000 cases in the USA and UK, respectively, at any given time. Although the incidence of ALS is not thought to be increasing, greater life expectancy and improved ascertainment mean that more cases are being recorded.",141,30,0.2127659574468085
9781912776139,ch2,The lifetime risk of developing ALS increases with age.,"An individual's risk of developing ALS increases with age, but the overall lifetime risk is estimated to be 1 in 400. Emerging data from China, the Indian subcontinent and Africa indicate a significantly younger age of first symptom onset in these populations. ALS case reports from the early 20th century in the European literature also had a consistently lower mean age, which has been attributed to reduced life expectancy at that time. Socioeconomic development, in particular dietary changes, may be an important contributor to the delay in symptom onset.",104,10,0.09615384615384616
9781912776139,ch2,Rodent modeling of ALS has been disappointing in terms of human therapeutic translation. Cellular models currently lack the ability to study neuronal network integrity.,"A preponderance of males has been traditionally reported in ALS at a ratio of 3:2, but this falls quickly to parity as the age of onset increases and, in some series, even appears to reverse independently of the longer mean survival of women. 'What is the cause of ALS?' This question has no single answer. Aging and a gradual loss of cellular tolerance is at the core of neurodegeneration. A common set of clinical endpoints is associated with an increasing array of upstream genetic and cellular mechanisms. A plot of log age of symptom onset versus log incidence supports a 'multiple-hit' mathematical model in which ALS occurs as a result of a range of perturbations over a lifetime. This is similar to accepted models of cancer, in which the monogenetic variants fulfill several 'hits' at baseline. An increasingly complex web of acquired environmental stressors may in turn operate through currently obscure epigenetic mechanisms.",187,27,0.1443850267379679
9781912776139,ch2,"A sizable body of epidemiological evidence, albeit mostly retrospectively acquired, supports a common clinical perception of premorbid athleticism and lower body mass index in ALS.","'What is the cause of ALS?' This question has no single answer. Aging and a gradual loss of cellular tolerance is at the core of neurodegeneration. A common set of clinical endpoints is associated with an increasing array of upstream genetic and cellular mechanisms. A plot of log age of symptom onset versus log incidence supports a 'multiple-hit' mathematical model in which ALS occurs as a result of a range of perturbations over a lifetime. This is similar to accepted models of cancer, in which the monogenetic variants fulfill several 'hits' at baseline. An increasingly complex web of acquired environmental stressors may in turn operate through currently obscure epigenetic mechanisms.",136,32,0.23529411764705882
9781912776139,ch2,Approximately 90% of cases appear to occur sporadically.,"Genetic factors. Most cases of ALS appear to arise sporadically; only 5-10% of individuals are known to have familial ALS, which usually affects a first-degree relative. Nevertheless, approximately 15% of all cases of ALS are associated with a variety of autosomal and largely dominant single nucleotide gene mutations or a repeat expansion (Figure 2.1).",74,13,0.17567567567567569
9781912776139,ch2,An intronic hexanucleotide GGGGCC repeat expansion in C9orf72 underpins around 10% of all cases of ALS in the Western hemisphere.,"An intronic hexanucleotide repeat expansion (HRE) in C9orf72 is now the commonest hereditary cause of both ALS and frontotemporal dementia (FTD), underpinning nearly 10% of both conditions. Specifically, in people with this mutation, there is a region in an intron of the C9orf72 gene in which the DNA nucleotide sequence GGGGCC repeats hundreds or thousands of times (compared with up to 30 repeats of the sequence in healthy individuals). There are important differences in the genotype frequency among familial cases across the world, however, with the C9orf72 HRE being uncommon in Asian populations.",134,33,0.2462686567164179
9781912776139,ch2,"Multiple and diverse cellular pathways, many involving cells adjacent to the motor neuron, are implicated in the pathogenesis of ALS.","In keeping with the 'multi-hit' hypothesis mentioned above, symptom onset tends to occur at an earlier age in genetically driven ALS. An extreme example of this is mutation in the FUS gene, which is linked to an often aggressive, typically lower motor neuron (LMN)-predominant form of ALS with symptom onset in the teenage years. For many of the genes linked to familial ALS, a broad range of clinical phenotypes (exempli gratia spinal versus bulbar onset) is still found in affected members of the same pedigree.",110,24,0.21818181818181817
9781912776139,ch2,RNA mishandling is a core theme underlying the aggregated TDP-43 signature that defines the ALS syndrome.,"RNA biology. The discovery of the predominantly RNA-binding protein TDP-43 as the cellular signature of nearly all cases of ALS was supported by the identification of mutations in the TARDBP gene, albeit in very rare cases of familial ALS. TDP-43 has a role in the regulation of more than one-quarter of all human genes, with extensive cross-species homology. It is therefore unsurprising that viable mutations of the parent gene represent fewer than 0.5% of all cases of ALS. However, further support for the concept of deranged RNA processing underlying ALS was provided by the discovery of another rare cause of familial ALS, namely mutations in another RNA-binding gene, FUS.",142,22,0.15492957746478872
9781912776139,ch3,The key symptom of amyotrophic lateral sclerosis (ALS) is painless weakness. A history of progression is essential for the diagnosis. The weakness is often asymmetric.,"The characteristic history of amyotrophic lateral sclerosis (ALS) is one of often insidious, yet always progressive, asymmetric weakness without prominent sensory symptoms. The most common complaints are of a weakness in one arm or leg, or a change in the voice. Individuals are often able to date the onset of symptoms to a specific month. While individuals often try to associate the onset of symptoms with other events (exempli gratia a viral infection or surgery), there is no firm epidemiological evidence to support a consistent trigger in this regard. Occasionally, an individual with ALS will perceive that the initial symptom came on overnight. Despite this assertion, they rarely seek acute services, unlike those who have a stroke, even though such individuals are frequently, and erroneously, referred for assessment as such.",159,34,0.2138364779874214
9781912776139,ch3,The individual symptoms reflect the body part affected and the balance between the burden of upper (UMN) and lower motor neuron (LMN) disease.,"Occasionally, an individual with ALS will perceive that the initial symptom came on overnight. Despite this assertion, they rarely seek acute services, unlike those who have a stroke, even though such individuals are frequently, and erroneously, referred for assessment as such. The history of progressive weakening is critical. In the early stages, symptoms may fluctuate from day to day or week to week. More rarely, an individual with ALS will report transient remission of weakness. In these cases, it is important to consider the broader overall trajectory of the condition to establish the clear presence of progression of weakness. Individual symptoms depend on the region affected and the relative burden of upper and lower motor neuron disease.",136,30,0.22058823529411764
9781912776139,ch3,"UMN disease causes slowness, stiffness, clumsiness and loss of fluidity of movement. Weakness is less pronounced and occurs in a pyramidal pattern. Tone may be increased, repetitive movements are slowed and reflexes are brisk. Speech may be strained, slowed and spastic. There may be pseudobulbar affect (emotional lability), dysphagia and a hyperactive gag response.","Atrophy can be best observed by comparing muscles side by side and looking for asymmetry, which is the more common pattern in ALS. The lateral intrinsic hand muscles, especially the first dorsal interossei, are typically more affected than the medial ones. This so-called 'split hand' in ALS is not easily explained in terms of peripheral or proximal limb innervation and may instead reflect the cortical organization associated with the uniquely opposable thumb in humans, or selective involvement of motor neuronal pools in the anterior horns of the cervical spinal cord (Figure 3.1). The tongue, quadriceps, tibialis anterior and calf muscles are also frequently affected by visible atrophy. Tongue atrophy in ALS is invariably symmetric (unlike atrophy in the limbs) (Figure 3.2). Fasciculation may be missed unless the individual is undressed to expose the upper chest, back and proximal arms and legs (see Case report 3.1). Individuals with ALS usually do not report fasciculation (unlike those with benign fasciculation). Fasciculation in the tongue can be difficult to distinguish from brief semi-voluntary movements, exaggerated by protrusion. It is best appreciated with the tongue relaxed, resting in the floor of the mouth, with the mouth gently opened. Muscle tone is reduced in LMN disease. This is not commonly a useful sign, as it only becomes apparent when weakness is advanced. Conversely, the increased tone seen in UMN disorders may be detectable before any weakness becomes apparent. 'Clasp-knife' spasticity may occur and there may be clonus, commonly at the ankles and, more rarely, at the jaw and occasionally at the patella or forearm. Repetitive movements are slowed in UMN disease. This is a crucial part of the examination in suspected ALS, and is best appreciated by asking the individual to.",384,84,0.21875
9781912776139,ch3,"LMN disease causes atrophy, fasciculation, weakness and cramps. Weakness may be profound and commonly affects muscles supplied by more than one myotome or peripheral nerve. Reflexes are reduced. Speech may be slurred or nasal. The tongue may be symmetrically atrophic and weak, with visible fasciculation.","Lower motor neuron weakness in a limb characteristically affects muscles supplied by more than one peripheral nerve or nerve root. Any muscles may be affected, but a common combination is to see weakness in the hand involving the median innervated abductor pollicis brevis (ask the individual to put their palms face up and point their thumbs to the ceiling) and weakness of the ulnar interossei (ask the individual to spread their fingers against resistance). Early 'finger drop' (distal upper-limb extensor weakness) is unusual for ALS and should prompt consideration of multifocal motor neuropathy with conduction block (see page 62). Proximal weakness in the arms may result in weakness of shoulder abduction or of flexion and extension at the elbow. Proximal arm weakness may become bilateral: the brachial amyotrophic diplegic phenotype ('flail arm' or 'man-in-a-barrel'; see page 18). When onset is in the leg, the ankle dorsiflexors are often involved early. Listening and watching for a foot drop and steppage gait can be a sensitive way to detect this, as can asking the individual to walk on their heels. Cramping on muscle strength testing, and occasionally when the patient bends to remove their socks or shoes, is a non-specific sign but often seen in ALS.",277,68,0.24548736462093862
9781912776139,ch3,"Approximately a third of cases start with weakness in an arm, a third with weakness in a leg and a quarter to one-third have bulbar onset.","Proximal weakness in the arms may result in weakness of shoulder abduction or of flexion and extension at the elbow. Proximal arm weakness may become bilateral: the brachial amyotrophic diplegic phenotype ('flail arm' or 'man-in-a-barrel'; see page 18). When onset is in the leg, the ankle dorsiflexors are often involved early. Listening and watching for a foot drop and steppage gait can be a sensitive way to detect this, as can asking the individual to walk on their heels. Cramping on muscle strength testing, and occasionally when the patient bends to remove their socks or shoes, is a non-specific sign but often seen in ALS.",148,32,0.21621621621621623
9781912776139,ch3,"More uncommon presentations include respiratory onset, a pure UMN syndrome (primary lateral sclerosis), and behavioral variant frontotemporal dementia.","Primary lateral sclerosis presentation. Approximately 3% of those diagnosed within the spectrum of ALS have a slowly progressive, pure UMN syndrome called primary lateral sclerosis (PLS) (see page 15). Weakness is far less prominent a symptom than in typical ALS. Instead, PLS tends to involve stiffness and poor balance, sometimes with falls. The symptoms most commonly start in the legs. In a minority with an initial bulbar presentation, common symptoms include a strained or forced voice and marked emotional lability. Distinguishing PLS from UMN-predominant ALS is challenging (see Chapter 4).",120,26,0.21666666666666667
9781912776139,ch4,"There is a significant multifactorial delay in the presentation of amyotrophic lateral sclerosis (ALS) to the neurologist, at which point the diagnosis can usually be made on clinical grounds alone.","Most cases of amyotrophic lateral sclerosis (ALS) are clinically obvious to the neurologist at first presentation. While there may be a clear rationale for investigations to exclude plausible differential diagnoses, it is often entirely possible to make a firm diagnosis of ALS on clinical grounds alone. While it is understandable that a clinician wishes to avoid wrongly diagnosing any serious illness, needless procrastination (even when portrayed as 'leaving no stone unturned') is particularly harmful to those with ALS when it increases the probability of unnecessary surgical intervention or delays physical and emotional support. The clinician should be wary of the publication bias for single case reports of atypical presentations of rare conditions. These may be interpreted as potential ALS mimics simply because of the presence of prominent bulbar symptoms or mixed lower (LMN) and upper motor neuron (UMN) signs, but which occur independently of each other anatomically.",182,39,0.21428571428571427
9781912776139,ch4,"The ALS spectrum comprises lower motor neuron-predominant, upper motor neuron (UMN)-predominant and symmetric limb syndromes.","Most cases of amyotrophic lateral sclerosis (ALS) are clinically obvious to the neurologist at first presentation. While there may be a clear rationale for investigations to exclude plausible differential diagnoses, it is often entirely possible to make a firm diagnosis of ALS on clinical grounds alone. While it is understandable that a clinician wishes to avoid wrongly diagnosing any serious illness, needless procrastination (even when portrayed as 'leaving no stone unturned') is particularly harmful to those with ALS when it increases the probability of unnecessary surgical intervention or delays physical and emotional support. The clinician should be wary of the publication bias for single case reports of atypical presentations of rare conditions. These may be interpreted as potential ALS mimics simply because of the presence of prominent bulbar symptoms or mixed lower (LMN) and upper motor neuron (UMN) signs, but which occur independently of each other anatomically.",182,30,0.16483516483516483
9781912776139,ch4,ALS is the most common cause of progressive dysarthria followed by dysphagia.,"Interval from symptom onset to diagnosis as a prognostic marker. The interval between symptom onset and a firm diagnosis of ALS is still one of the most robust prognostic markers: a shorter diagnostic latency infers a more aggressive course. As is seen in some types of cancer, more rapidly progressing cases of ALS present sooner to primary care, and symptoms are more quickly recognized as having a serious underlying neurological cause. It is the slowly progressive forms of ALS that are usually the most challenging diagnostically. Such cases tend to be those with a predominance of LMN or, more rarely, UMN clinical signs and often those with limited regional physical involvement (exempli gratia monomelic weakness).",141,17,0.12056737588652482
9781912776139,ch4,There are very few credible ALS mimic disorders (and even fewer that are reversible).,"Within ALS's axiomatic core of progressive weakness, there are clinical signs that may provide strong support for an ALS-spectrum disorder but can be easily overlooked (including behavioral and cognitive impairments), symptoms that should not put the clinician off diagnosing ALS when other clinical features fit, and symptoms and signs that should always prompt more thorough consideration of alternative diagnoses (Table 4.1).",78,16,0.20512820512820512
9781912776139,ch4,Fasciculation as a primary symptom and without associated weakness is nearly always benign.,"Fasciculation or cramps without weakness. Although fasciculation is an important clinical sign of ALS in someone presenting with progressive weakness, it is rarely reported in isolation by those with ALS before the formal diagnosis. A corollary of this observation is that when muscle fasciculation is the sole presenting complaint, in the absence of detectable weakness, it is nearly always part of the spectrum of normal human physiology (so-called benign fasciculation). Neuromyotonia (Isaacs' syndrome) is a very rare condition associated with generalized muscle fasciculation. Positive voltage-gated potassium channel antibodies are found in 50% of patients with this condition. Neuromyotonia has a characteristic appearance on electromyography.",148,17,0.11486486486486487
9781912776139,ch4,"Incidental spinal spondylosis is common among those with ALS and, if not carefully considered, it may lead to diagnostic delay and inappropriate surgical intervention.","Incidental spinal spondylosis. A frequent challenge in the age group presenting with ALS is incidental MRI evidence of cervical and lumbar spondylotic radiculopathy, sometimes with a degree of compressive myelopathy in the cervical region. Surgical procedures have been shown to significantly worsen the prognosis of ALS, providing an extra incentive to avoid unnecessary interventions. The spinal imaging undertaken as part of the usual work up for all those with limb-onset forms of ALS typically shows more extensive clinical or electromyography (EMG)-based myotome involvement than may be plausibly explained by spondylotic changes in the spine. While the absence of sphincter or sensory involvement is still compatible with significant spondylosis, weakness of neck flexion is a strong pointer to the diagnosis of ALS, along with any bulbar signs or abnormal reflexes above the neck.",182,31,0.17032967032967034
9781912776139,ch4,"Multifocal motor neuropathy with conduction block is much rarer than ALS and has a younger age of onset, most commonly manifesting as unilateral 'finger drop'.","Monomelic syndromes. The individual presenting with a slowly progressive LMN syndrome of weakness predominantly confined to a single limb is among the most challenging of diagnostic scenarios (Figure 4.4). Multifocal motor neuropathy with conduction block (MMN) is an autoimmune motor neuronopathy. It is much rarer than LMN-predominant forms of ALS. MMN typically has a slowly progressive or stepwise course and is not life shortening. The mean age of onset is significantly younger than ALS (40 versus 65 years) with a male predominance of 3:1. The most frequent presentation is unilateral 'finger drop', which commonly manifests by catching the middle fingers when retrieving items from trouser pockets or a handbag. Lower limb presentations have been reported but are rare (10%) (Table 4.2).",169,34,0.20118343195266272
9781912776139,ch4,"Primary lateral sclerosis is very rare, has a younger age of onset and has at least 4 years before it can be differentiated confidently from UMN-predominant forms of ALS, which progress more slowly.","Approximately 10% of cases in the broader ALS spectrum will have detectable clinical UMN signs only. Subtle symptoms of corticobulbar involvement such as emotionality and pathological yawning need to be actively queried. Early symptoms of postural dysequilibrium, sometimes with falls, is also an under-recognized feature in this group. Most UMN-only cases of progressive weakness will evolve into UMN-predominant ALS, which has a significantly slower-than-average rate of progression. Initially, however, there may be no detectable denervation, even on EMG, and the question of primary lateral sclerosis (PLS) arises. Primary lateral sclerosis is very rare, comprising fewer than 3% of all cases in the broader ALS spectrum. Differentiation from UMN-predominant ALS can be challenging (Table 4.3). At present, a firm diagnosis of PLS cannot be made until the individual is 4 years or more from symptom onset without clinical LMN signs (minor EMG evidence of denervation in the hands is acceptable).",215,41,0.19069767441860466
9781912776139,ch5,Amyotrophic lateral sclerosis (ALS) is fundamentally a clinical diagnosis. No investigations are mandatory or independently diagnostic.,"Amyotrophic lateral sclerosis (ALS) is a clinical diagnosis. There is no diagnostic test to confirm the disease and there are no mandatory investigations. In the advanced stages, the diagnosis can be made on the basis of. a history of progressive muscle weakness. the hallmark of mixed upper motor neuron (UMN) and lower motor neuron (LMN) signs in the bulbar region and limbs. However, many individuals will present before generalized physical involvement and will undergo a battery of investigations, including blood tests, brain and spine MRI, nerve conduction studies (NCS) and electromyography (EMG) to support the diagnosis and to exclude so-called 'ALS mimics', though these are rare. The risk of incidental findings that can result in diagnostic delay increases when investigations are not guided by the clinical syndrome (history and examination).",168,22,0.13095238095238096
9781912776139,ch5,"Most symptomatic individuals will have blood tests, brain and spinal MRI and neurophysiological testing during their diagnostic work up but there is risk of incidental findings that can lead to diagnostic delay.","the hallmark of mixed upper motor neuron (UMN) and lower motor neuron (LMN) signs in the bulbar region and limbs. However, many individuals will present before generalized physical involvement and will undergo a battery of investigations, including blood tests, brain and spine MRI, nerve conduction studies (NCS) and electromyography (EMG) to support the diagnosis and to exclude so-called 'ALS mimics', though these are rare. The risk of incidental findings that can result in diagnostic delay increases when investigations are not guided by the clinical syndrome (history and examination). Blood tests. Among the routine blood tests, the most pertinent to the symptoms of ALS and the differential diagnosis are: creatine kinase (CK), electrolytes and bone profile, thyroid-stimulating hormone and protein electrophoresis with immunofixation (serum and urine). Screening for HIV and human T-cell lymphotrophic virus (HTLV) may be indicated in clinically appropriate UMN-predominant cases. Apart from CK, these tests will be normal or negative in ALS. Moderate rises in CK (up to 500 U/L) are common in ALS due to denervation, but CK levels are also frequently normal. Occasionally, levels of up to 1500 U/L occur and should not be assumed to be indicative of primary muscle pathology if the clinical picture is otherwise typical for ALS.",282,37,0.13120567375886524
9781912776139,ch5,EMG can detect subclinical lower motor neuron disease and expedite diagnosis.,"the hallmark of mixed upper motor neuron (UMN) and lower motor neuron (LMN) signs in the bulbar region and limbs. However, many individuals will present before generalized physical involvement and will undergo a battery of investigations, including blood tests, brain and spine MRI, nerve conduction studies (NCS) and electromyography (EMG) to support the diagnosis and to exclude so-called 'ALS mimics', though these are rare. The risk of incidental findings that can result in diagnostic delay increases when investigations are not guided by the clinical syndrome (history and examination).",117,15,0.1282051282051282
9781912776139,ch5,"Investigations are usually performed to exclude plausible alternative diagnoses and, in the case of electromyography (EMG), to improve diagnostic certainty in body regions without clinical signs.","NCS are usually performed in conjunction with EMG to confirm LMN pathology, especially in regions of the body that do not yet show signs on examination, and to exclude other possible diagnoses. NCS may be normal in ALS, whereas EMG is not (except in the distinct, pure UMN disorder, primary lateral sclerosis). However, any abnormal EMG findings are not specific for ALS. ALS is a pure motor syndrome. The hallmark abnormalities therefore reflect loss of the motor nerves (denervation and reinnervation on EMG and, with adequate time, a reduction in the amplitude of the compound motor action potential [CMAP]) with normal sensory function (normal sensory nerve action potentials [SNAPs]).",143,35,0.24475524475524477
9781912776139,ch5,"Evidence of active denervation and chronic reinnervation in multiple myotomes on EMG is supportive, but not specific, for ALS.","NCS are usually performed in conjunction with EMG to confirm LMN pathology, especially in regions of the body that do not yet show signs on examination, and to exclude other possible diagnoses. NCS may be normal in ALS, whereas EMG is not (except in the distinct, pure UMN disorder, primary lateral sclerosis). However, any abnormal EMG findings are not specific for ALS. ALS is a pure motor syndrome. The hallmark abnormalities therefore reflect loss of the motor nerves (denervation and reinnervation on EMG and, with adequate time, a reduction in the amplitude of the compound motor action potential [CMAP]) with normal sensory function (normal sensory nerve action potentials [SNAPs]).",143,28,0.1958041958041958
9781912776139,ch5,"The El Escorial diagnostic criteria and subsequent modifications are intended for research purposes and do not predict the clinical course of the disease. The terms possible, probable and definite ALS should be avoided when counseling individuals.","Use of diagnostic criteria. For a diagnosis of ALS using any of the above criteria, evidence of chronic reinnervation must be present in the same muscle, as demonstrated by MUPs of increased amplitude, increased duration, or polyphasia, with or without reduced recruitment. From a physician's perspective, however, it should be remembered that these diagnostic criteria were intended for research purposes and not for clinical practice. The different categories do not reflect a clinical spectrum of disease progression. Individuals do not follow a clinical course that evolves from possible to definite and they may die from the disease having never progressed from the category of 'possible ALS'. The concept of possible, probable and definite ALS is therefore not helpful in explaining the diagnosis to individuals and does not predict their disease trajectory. These terms should therefore be avoided when counseling symptomatic individuals.",166,40,0.24096385542168675
9781912776139,ch6,A diagnostic biomarker of most immediate value in amyotrophic lateral sclerosis (ALS) would be one that can help the neurologist distinguish atypical (exempli gratia LMN-predominant) cases from other disease states for earlier therapeutic trial enrolment.,"Emerging diagnostic biomarkers. A biomarker is a 'characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathological processes or biological response to a therapeutic intervention'. As such, there are several different types of biomarker in ALS. Here, the discussion is limited to potential diagnostic biomarkers: that is, those that reliably distinguish people with ALS from individuals with weakness caused by other disease processes (disease controls). To date, no such biomarker has been adopted in routine international clinical practice. Leading candidates include biofluid markers, and novel electrodiagnostic and neuroimaging techniques. However, most of the development of biomarkers to date has used healthy controls as the comparator. The distinction of ALS from healthy is not the clinical question facing the physician. Furthermore, the rarity of ALS and its essentially sporadic nature sets the bar extremely high for a diagnostic test that can be applied in the primary care setting. Prospective application of existing biomarker candidates within a specialized clinical setting is required to ensure that they add value to the diagnostic process. Biofluid biomarkers.",222,55,0.24774774774774774
9781912776139,ch6,"Neurofilaments are a leading candidate, especially if the blood-based assays become sensitive enough to supersede the need for cerebrospinal fluid testing.","Neurofilaments, the building blocks for the key cytoskeletal components of nervous system cells, are a leading biological-fluid-based biomarker for ALS. Both neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) are structural proteins released into the cerebrospinal fluid (CSF) and thence to the peripheral blood in a wide range of pathological states that involve axonal breakdown, including ALS. They are relatively stable in biofluids and are easily detected by antibody-based immunoassays. Multiple studies have demonstrated higher CSF NfL and pNfH levels in patients with ALS than in healthy controls and, increasingly, also disease controls. Rising levels also predate the onset of symptoms by several months in studies following asymptomatic carriers of ALS-causing genetic mutations.",179,33,0.18435754189944134
9781912776139,ch6,Urinary p75 neurotrophin receptor (p75NTR) levels have also shown promise.,Neurotrophins are growth factors that promote neuronal cell differentiation and survival. The extracellular domain of the p75 neurotrophin receptor (p75NTR) is present in higher concentrations in the urine of patients with ALS than in healthy controls. It was shown to be highly sensitive and specific for the detection of spinal-onset ALS in a small study. Urinary concentrations of the p75NTR extracellular domain have also been shown to rise in genetically susceptible individuals as the disease becomes clinically apparent. The urinary concentrations continue to rise with disease progression.,115,20,0.17391304347826086
9781912776139,ch6,Threshold-tracking transcranial magnetic stimulation is sensitive to the cortical hyperexcitability that characterizes the syndrome of ALS.,"Transcranial magnetic stimulation (TMS) is a non-invasive tool used to demonstrate upper motor neuron (UMN) dysfunction. UMN pathology can be difficult to identify on clinical examination early in the disease and TMS may therefore be useful in identifying subclinical UMN disease, facilitating the early diagnosis of ALS. The technique uses a pulsed magnetic field directed at a small cortical area to induce local neuronal depolarization and hence the production of an action potential. Cortical hyperexcitability is important in the pathogenesis of ALS and can be demonstrated using a paired-pulse paradigm of threshold tracking. A reduction of short-interval intracortical inhibition is most prominent in the early stages of ALS. TMS has now been well validated in ALS and may prove to be an important diagnostic tool in clinical practice.",169,26,0.15384615384615385
9781912776139,ch6,Motor unit nerve estimation and electrical impedance myography are emerging developments beyond standard electromyography.,"Transcranial magnetic stimulation (TMS) is a non-invasive tool used to demonstrate upper motor neuron (UMN) dysfunction. UMN pathology can be difficult to identify on clinical examination early in the disease and TMS may therefore be useful in identifying subclinical UMN disease, facilitating the early diagnosis of ALS. The technique uses a pulsed magnetic field directed at a small cortical area to induce local neuronal depolarization and hence the production of an action potential. Cortical hyperexcitability is important in the pathogenesis of ALS and can be demonstrated using a paired-pulse paradigm of threshold tracking. A reduction of short-interval intracortical inhibition is most prominent in the early stages of ALS. TMS has now been well validated in ALS and may prove to be an important diagnostic tool in clinical practice. Other electrodiagnostic techniques. Motor unit number estimation, its surrogate motor unit number index and electrical impedance myography have all been used in the research setting to quantify lower motor neuron loss. None of these currently has diagnostic application over standard electromyography in ALS but they may prove useful in more objectively assessing disease progression and treatment response.",235,18,0.07659574468085106
9781912776139,ch6,Multimodal structural and functional brain imaging may provide more sensitive markers of broader motor system dysfunction in the longer term.,"DTI abnormalities have been consistently observed in the white matter tracts of individuals with ALS, particularly in the corticospinal tracts and corpus callosum, compared with healthy controls. However, DTI in isolation is neither sufficiently sensitive nor specific. Automated segmentation of gray matter volumes has demonstrated more subtle cortical involvement in ALS. A combination of these structural gray and white matter measures with blood oxygenation level-dependent functional MRI markers of brain activity holds promise for defining a more individualized 'signature' of ALS.",104,24,0.23076923076923078
9781912776153,chp1,"Cardiac cells have the unique ability to depolarize rhythmically; depolarization normally occurs in one direction from the top down, from atria to ventricles.","Conduction is the speed at which cells propagate electrical wavefronts. Cardiac cells have a unique ability to depolarize rhythmically. Normal depolarization within the heart occurs in one direction from the top (atria) downwards. The fibrous ring that supports the mitral and tricuspid valves is an electrical insulator, so depolarization can only travel from the atria to the ventricles via the specialized conducting tissues, unless an abnormal electrically active connection, such as an accessory pathway, is present. Different structures within the heart conduct at different rates (exempli gratia the His-Purkinje system conducts as rapidly as neural tissue [about 3 m/s], whereas conduction at the compact atrioventricular [AV] node is slower). The normal conduction pathway within the heart is described below (Figure 1.1).",178,35,0.19662921348314608
9781912776153,chp1,"The fibrous atrioventricular (AV) ring, which supports the mitral and tricuspid valves, behaves as an electrical insulator: conduction to the ventricles occurs only over the AV node, unless there is an abnormal or aberrant connection.","Conduction is the speed at which cells propagate electrical wavefronts. Cardiac cells have a unique ability to depolarize rhythmically. Normal depolarization within the heart occurs in one direction from the top (atria) downwards. The fibrous ring that supports the mitral and tricuspid valves is an electrical insulator, so depolarization can only travel from the atria to the ventricles via the specialized conducting tissues, unless an abnormal electrically active connection, such as an accessory pathway, is present. Different structures within the heart conduct at different rates (exempli gratia the His-Purkinje system conducts as rapidly as neural tissue [about 3 m/s], whereas conduction at the compact atrioventricular [AV] node is slower). The normal conduction pathway within the heart is described below (Figure 1.1). Atrial depolarization. Conduction originates with self-excitation of the sinoatrial (SA) node, which lies at the junction of the superior vena cava with the upper part of the right atrium. The SA node acts as the heart's pacemaker. A depolarization wavefront spreads down from the SA node to the base of the right atrium and simultaneously spreads to the left atrium over a band of muscle (Bachmann's bundle). The complete depolarization of the atria gives rise to the P wave on the surface electrocardiogram (ECG; see Figure 1.1). A normal P wave is less than 200 ms wide and smaller than 1 mV in amplitude. It has a low amplitude because the mass of the atria is considerably smaller than that of the ventricles, and it is wide because most of the depolarization of the atria occurs by relatively slow cell-to-cell conduction.",378,56,0.14814814814814814
9781912776153,chp1,The AV node has a decremental slowing effect on conduction.,"This slowing phenomenon of AV nodal tissue is known as decremental conduction and is characteristic of the AV node (accessory pathways very rarely demonstrate decrementation). Decremental conduction of the AV node is age related. The heart rate required to produce Wenckebach block decreases with age: for example, at 20-40 years of age, Wenckebach block occurs at 160-180 bpm, whereas over 70 years of age it occurs at approximately 120 bpm. Despite this relative slowing effect, it is still possible to maintain very rapid heart rates during tachycardia, emphasizing how complex conduction within the heart can be. The Wenckebach phenomenon is common at night, usually associated with autonomic tone; Holter monitoring (see page 57) often reveals frequent pauses during sleep in otherwise healthy young people. This type of AV block does not usually require treatment. Some antiarrhythmic drugs also slow AV nodal conduction and may cause Wenckebach phenomenon.",202,13,0.06435643564356436
9781912776153,chp1,"Wide- (broad-) complex tachycardias need further investigation, and patients should be referred for urgent assessment. They should be considered ventricular in origin until proven otherwise.","This slowing phenomenon of AV nodal tissue is known as decremental conduction and is characteristic of the AV node (accessory pathways very rarely demonstrate decrementation). Decremental conduction of the AV node is age related. The heart rate required to produce Wenckebach block decreases with age: for example, at 20-40 years of age, Wenckebach block occurs at 160-180 bpm, whereas over 70 years of age it occurs at approximately 120 bpm. Despite this relative slowing effect, it is still possible to maintain very rapid heart rates during tachycardia, emphasizing how complex conduction within the heart can be. The Wenckebach phenomenon is common at night, usually associated with autonomic tone; Holter monitoring (see page 57) often reveals frequent pauses during sleep in otherwise healthy young people. This type of AV block does not usually require treatment. Some antiarrhythmic drugs also slow AV nodal conduction and may cause Wenckebach phenomenon.",202,35,0.17326732673267325
9781912776153,chp1,Autonomic effects on the heart (sympathetic and parasympathetic stimuli) can significantly influence cardiac conduction.,"Although the heart muscle has intrinsic rhythmicity, an individual's heart rate is influenced by outside factors and can vary widely during the day, reflecting the relative balance between the sympathetic and parasympathetic nervous systems. The heart rate often varies with respiration, speeding up with inspiration and slowing with expiration. This is referred to as a sinus arrhythmia and is normal, particularly in young people (less than 40 years of age). In the 'flight or fight' response to danger, the sympathetic system activates the adrenal glands and releases epinephrine (adrenaline) into the circulation. This stimulates cardiac beta-adrenoreceptors, generally increasing cardiac conduction, heart rate and the force of contraction. Conversely, the parasympathetic system, via the vagus nerve, has a dampening effect, reducing the heart rate and force of contraction. Intracardiac conduction is slowed and, in certain patients, AV nodal conduction can be slowed significantly. Maneuvers that provoke a vagal response, such as carotid sinus massage or vomiting, may terminate arrhythmias that use the AV node as part of their mechanism (exempli gratia many supraventricular tachycardias; SVTs). Profound vagal activation usually produces a specific sequence of prodromal symptoms: for 1-2 minutes patients complain of feeling light-headed and nauseous, followed by sweating and worsening nausea; they may ultimately lose consciousness as a result of severe bradycardias or hypotension. Other factors such as thyroid hormones and pregnancy also affect heart rate.",325,24,0.07384615384615385
9781912776153,chp1,Narrow QRS complex arrhythmias signify depolarization of the ventricle over the usual His-Purkinje system.,"Narrow-complex tachycardia. A narrow QRS complex during an arrhythmia means that depolarization of the ventricles occurs via the specialized system of the AV node and the His-Purkinje system. This usually occurs during SVT and nearly always signifies a non-life-threatening arrhythmia. A narrow-complex tachycardia implies the presence of some sort of aberrant electrical pathway (exempli gratia an accessory pathway or slow/fast pathways) as the underlying mechanism or, less frequently, an atrial tachycardia.",120,28,0.23333333333333334
9781912776153,chp1,Most supraventricular tachycardias have narrow QRS complexes.,"SVT is a general term encompassing a number of arrhythmias that arise within the atria or AV node and produce a regular rapid heart rate. Most have narrow QRS complexes on the surface ECG, demonstrating that depolarization of the ventricles occurs over the His-Purkinje system.",64,14,0.21875
9781912776153,chp1,The substrate for an arrhythmia is an abnormal electrical pathway or a region of scarred myocardium. The trigger is an atrial or ventricular ectopic beat.,"During sinus rhythm the impulse spreads from the SA node in its usual manner and depolarizes both atria. Conduction is slowed through the AV node as normal, but it is not slowed through the accessory pathway. The impulse from the atria is therefore partly conducted to the ventricles via this route rather than only through the AV node and His-Purkinje system. This allows part of the ventricle to depolarize before it would otherwise do so (overt pre-excitation), resulting in a diagnostic abnormality on the surface ECG - fusion of the P wave with the initial part of the QRS complex, demonstrating depolarization from both normal AV node conduction and through the accessory pathway (Figure 1.4). This slurring of the upstroke of the initial part of the QRS deflection, called a delta wave, causes the QRS to be wider than normal. It can sometimes be confused with the appearance of bundle branch block, which also causes a broadening of the QRS because of abnormal depolarization of the ventricles. The delta wave vector can be used to determine the position of the accessory pathways. Sustained arrhythmia in WPW syndrome requires both an accessory pathway (the substrate) and a trigger, which is almost always an ectopic beat, either atrial or ventricular. These ectopic beats need to be critically timed in order to initiate the arrhythmia (Figure 1.5). The fact that people with accessory pathways have arrhythmias only now and again emphasizes the relative infrequency at which an ectopic beat falls at the critical time to allow the arrhythmia to start.",342,36,0.10526315789473684
9781912776153,chp1,Re-entry is the most frequent mechanism for arrhythmias.,"Atypical atrial flutter follows a different re-entry pathway that is not dependent on the cavotricuspid isthmus. It may occur after cardiac surgery (exempli gratia closure of an atrial septal defect) or left atrial flutter may occur after ablation for atrial fibrillation (AF). Atypical flutter can occur many years after surgery (exempli gratia in patients who have had previous surgery to correct a congenital defect), with the circuit rotating around the surgical scar.",111,14,0.12612612612612611
9781912776153,chp2,Patients with arrhythmias can present in a variety of ways.,"Patients with cardiac arrhythmias can present with symptoms of palpitations, shortness of breath, fatigue, syncope or presyncope, as well as chest pain. Patients may have no cardiac symptoms at all (exempli gratia with atrial fibrillation [AF] after a stroke, or as a finding at screening). Alternatively, patients may present with sudden cardiac death as their first symptom, usually as a result of ventricular fibrillation or tachycardia, and they may be resuscitated from a cardiac arrest, often out of hospital.",117,15,0.1282051282051282
9781912776153,chp2,Patients with palpitations and known structural cardiac disease should be evaluated without delay.,"Patients with cardiac arrhythmias can present with symptoms of palpitations, shortness of breath, fatigue, syncope or presyncope, as well as chest pain. Patients may have no cardiac symptoms at all (exempli gratia with atrial fibrillation [AF] after a stroke, or as a finding at screening). Alternatively, patients may present with sudden cardiac death as their first symptom, usually as a result of ventricular fibrillation or tachycardia, and they may be resuscitated from a cardiac arrest, often out of hospital.",117,17,0.1452991452991453
9781912776153,chp2,"Occasionally, it may be important for the patient to distinguish increased awareness of heart beat from true cardiac arrhythmias.","Palpitations are common in patients with any cardiac arrhythmia. When interviewing a patient with palpitations, it is important to determine whether the palpitations represent abnormal awareness of a normal heart beat or an actual cardiac rhythm disturbance (id est normal awareness of an abnormal beat). Try to get patients to be as clear as possible in their description, and ask them to tap out what they feel their heart is actually doing. Table 2.1 highlights some of the key questions to ask patients to help with the diagnosis.",106,25,0.2358490566037736
9781912776153,chp3,"Syncope can be benign, such as vasovagal (neurocardiogenic), although it may still be disabling for some patients with recurrent fainting spells. Syncope can also be serious with a potentially fatal outcome, such as ventricular arrhythmias or heart block.","Syncope is a significant healthcare problem, resulting in the need for clinical evaluation, whether acutely in the emergency room or later in the physician's office. On the one hand, syncope can be benign, such as vasovagal (neurocardiogenic) syncope, but on the other, it can be serious with a potentially fatal outcome, such as ventricular arrhythmias or heart block. In all of these situations, syncope is usually of considerable concern to the patient and may result in sequelae such as injury, restriction of driving, or even death. What is syncope?. Cerebral blood flow depends on maintenance of blood pressure, which in turn is directly related to both cardiac output and peripheral vascular resistance such that a drop in either may be associated with a fall or presyncope. Syncope is defined as a total loss of consciousness (sometimes also referred to as transient loss of consciousness), and presyncope is defined as a sensation patients describe when they feel they are about to lose consciousness but do not actually do so). Patients often use the term 'dizzy spell', which covers a multitude of etiologies, including vertigo and postural symptoms; a detailed history of what the patient actually feels is mandatory.",254,59,0.23228346456692914
9781912776153,chp3,Syncope with or without palpitations requires prompt referral.,"Syncope is a significant healthcare problem, resulting in the need for clinical evaluation, whether acutely in the emergency room or later in the physician's office. On the one hand, syncope can be benign, such as vasovagal (neurocardiogenic) syncope, but on the other, it can be serious with a potentially fatal outcome, such as ventricular arrhythmias or heart block. In all of these situations, syncope is usually of considerable concern to the patient and may result in sequelae such as injury, restriction of driving, or even death.",118,12,0.1016949152542373
9781912776153,chp3,Syncope is defined as a total loss of consciousness (sometimes also referred to as transient loss of consciousness or TLoC).,"Cerebral blood flow depends on maintenance of blood pressure, which in turn is directly related to both cardiac output and peripheral vascular resistance such that a drop in either may be associated with a fall or presyncope. Syncope is defined as a total loss of consciousness (sometimes also referred to as transient loss of consciousness), and presyncope is defined as a sensation patients describe when they feel they are about to lose consciousness but do not actually do so). Patients often use the term 'dizzy spell', which covers a multitude of etiologies, including vertigo and postural symptoms; a detailed history of what the patient actually feels is mandatory.",130,25,0.19230769230769232
9781912776153,chp3,Recurrent presyncope (the sensation patients describe when they feel they are about to lose consciousness) is common and may culminate in syncope over time.,"Although many patients are briefly disorientated on regaining consciousness, recovery is rapid and complete within a short period (usually minutes). It is unusual to have a prolonged period of unconsciousness (more than 5 minutes) with a cardiac cause, although witness description is notoriously unreliable. Patients are usually lucid quickly after an episode. Tonic-clonic seizure, although uncommon, can occur because of cerebral anoxia and does not exclude a cardiac cause. Urinary incontinence is rare. The desire to sleep afterwards is also uncommon. Syncope is much more common than epilepsy. Recurrent presyncope (the sensation patients describe when they feel they are about to lose consciousness) is common and may culminate in syncope over time. Presyncope occurs commonly in situations where the native cardiac pacemaker is impaired but not for long enough to produce syncope (exempli gratia sick sinus syndrome or carotid sinus hypersensitivity). Self-injury is variable. In some cases, symptoms may occur over many years before a diagnosis is made. In many cases, specific precipitating factors are uncommon. Presyncope needs to be differentiated from dizziness, which can include vertigo.",242,32,0.1322314049586777
9781912776153,chp3,"Syncope in patients with known structural heart disease, particularly impaired left ventricular function, carries a significantly worse prognosis with an increased risk of sudden death.","Syncope in patients with known structural heart disease, particularly impaired left ventricular (LV) function, carries a significantly worse prognosis with an increased risk of sudden death. Syncope may be due to sustained ventricular tachycardia (VT), or intermittent advanced heart block. These patients require urgent cardiological investigation. The differential diagnoses for the causes of falls and blackouts are shown in Table 3.3. Patients with cardiac syncope often do not remember the loss of consciousness and therefore only consider that they have had a fall. However, instances of sudden unheralded blackout without prodromal symptoms and with brief loss of consciousness are almost certainly cardiac in origin. Further investigations will help to ascertain whether the blackout has a cardiac cause.",149,31,0.2080536912751678
9781912776153,chp3,The differential diagnosis is complicated by the fact that patients with cardiac syncope often do not remember the loss of consciousness and therefore only consider that they have had a fall. Always try to find a witness to the incident.,"Syncope in patients with known structural heart disease, particularly impaired left ventricular (LV) function, carries a significantly worse prognosis with an increased risk of sudden death. Syncope may be due to sustained ventricular tachycardia (VT), or intermittent advanced heart block. These patients require urgent cardiological investigation. The differential diagnoses for the causes of falls and blackouts are shown in Table 3.3. Patients with cardiac syncope often do not remember the loss of consciousness and therefore only consider that they have had a fall. However, instances of sudden unheralded blackout without prodromal symptoms and with brief loss of consciousness are almost certainly cardiac in origin. Further investigations will help to ascertain whether the blackout has a cardiac cause. Clinical history. The clinical history remains of critical importance. The patient, and others present at the time of the syncope, can provide important details about the circumstances of the syncope. The following aspects should be reviewed and obtained prior to initiating a work-up.",203,43,0.21182266009852216
9781912776153,chp3,Instances of sudden unheralded blackout without prodromal symptoms and with brief loss of consciousness are almost certainly cardiac in origin.,"The differential diagnoses for the causes of falls and blackouts are shown in Table 3.3. Patients with cardiac syncope often do not remember the loss of consciousness and therefore only consider that they have had a fall. However, instances of sudden unheralded blackout without prodromal symptoms and with brief loss of consciousness are almost certainly cardiac in origin. Further investigations will help to ascertain whether the blackout has a cardiac cause. Clinical history. The clinical history remains of critical importance. The patient, and others present at the time of the syncope, can provide important details about the circumstances of the syncope. The following aspects should be reviewed and obtained prior to initiating a work-up.",139,27,0.19424460431654678
9781912776153,chp4,"Sudden cardiac death (SCD) represents a significant healthcare problem, accounting for more than 350 000 deaths in the USA alone every year, and an estimated 6 million deaths annually worldwide.","Sudden cardiac death (SCD), also known as sudden cardiac arrest, continues to represent a significant healthcare problem. There are more than 350 000 deaths every year from sudden cardiac arrest in the USA, accounting for more than 50% of all cardiovascular causes of death in the USA, and it is estimated that 6 million die from it annually worldwide. With increasing recognition of the condition and rapid application of resuscitation by bystanders, more people are surviving and making it to hospital. The reasons for this include: more widespread adoption of high-performance cardiopulmonary resuscitation (CPR) by emergency medical personnel; increasing the rates of CPR training for local residents; the practice of emergency services personnel giving CPR instructions to bystanders by phone; and increasing public access to automated external defibrillators as a result of their being carried in police and fire service vehicles. As a result, the overall survival rates of an out-of-hospital cardiac arrest have increased dramatically, particularly in some parts of the world, such as Seattle, where survival rates have increased significantly.",211,37,0.17535545023696683
9781912776153,chp4,"SCD is defined according to whether it was witnessed or not. If witnessed, unexpected death must have occurred within 1 hour after the onset of symptoms; if not, unexpected death must have occurred within 24 hours of the patient last being observed without symptoms.","Sudden cardiac death (SCD), also known as sudden cardiac arrest, continues to represent a significant healthcare problem. There are more than 350 000 deaths every year from sudden cardiac arrest in the USA, accounting for more than 50% of all cardiovascular causes of death in the USA, and it is estimated that 6 million die from it annually worldwide. With increasing recognition of the condition and rapid application of resuscitation by bystanders, more people are surviving and making it to hospital. The reasons for this include: more widespread adoption of high-performance cardiopulmonary resuscitation (CPR) by emergency medical personnel; increasing the rates of CPR training for local residents; the practice of emergency services personnel giving CPR instructions to bystanders by phone; and increasing public access to automated external defibrillators as a result of their being carried in police and fire service vehicles. As a result, the overall survival rates of an out-of-hospital cardiac arrest have increased dramatically, particularly in some parts of the world, such as Seattle, where survival rates have increased significantly. SCD is defined according to whether it was witnessed or not. If it was witnessed, unexpected death must have occurred within 1 hour after the onset of symptoms; if it was not witnessed, unexpected death must have occurred within 24 hours of the patient last being observed without symptoms.",266,50,0.18796992481203006
9781912776153,chp4,The overall survival rates of an out-of-hospital cardiac arrest have increased dramatically for reasons including: increasing recognition of the condition; more widespread adoption of high-performance cardiopulmonary resuscitation (CPR) by emergency medical personnel; increased rates of CPR training for local residents; emergency services personnel giving CPR instructions to bystanders by phone; and increasing public access to automated external defibrillators as a result of their being carried in police and fire service vehicles.,"Sudden cardiac death (SCD), also known as sudden cardiac arrest, continues to represent a significant healthcare problem. There are more than 350 000 deaths every year from sudden cardiac arrest in the USA, accounting for more than 50% of all cardiovascular causes of death in the USA, and it is estimated that 6 million die from it annually worldwide. With increasing recognition of the condition and rapid application of resuscitation by bystanders, more people are surviving and making it to hospital. The reasons for this include: more widespread adoption of high-performance cardiopulmonary resuscitation (CPR) by emergency medical personnel; increasing the rates of CPR training for local residents; the practice of emergency services personnel giving CPR instructions to bystanders by phone; and increasing public access to automated external defibrillators as a result of their being carried in police and fire service vehicles. As a result, the overall survival rates of an out-of-hospital cardiac arrest have increased dramatically, particularly in some parts of the world, such as Seattle, where survival rates have increased significantly. SCD is defined according to whether it was witnessed or not. If it was witnessed, unexpected death must have occurred within 1 hour after the onset of symptoms; if it was not witnessed, unexpected death must have occurred within 24 hours of the patient last being observed without symptoms. There are many potential causes of SCD (Table 4.1). SCD usually occurs in individuals with underlying cardiac disease and occurs more frequently with male sex and increasing age. In patients with ischemic heart disease, valvular or myocardial abnormalities, SCD can be the first presentation of the patient. An acute coronary syndrome can lead to ventricular fibrillation (VF) in a patient not previously known to have cardiac disease. Alternatively, a patient who has had coronary artery bypass graft surgery in the past may present years later with a new ischemic event leading to SCD. Metabolic causes associated with SCD include electrolyte abnormalities, and drugs and medication can also cause fatal rhythm disturbances (see Chapter 10). An increasing number of syndromes are recognized as being associated with SCD. Referred to as primary electric disorders or channelopathies, they generally have a genetic basis.",449,93,0.2071269487750557
9781912776153,chp4,SCD usually occurs in individuals with underlying cardiac disease and occurs more frequently with male sex and increasing age.,"There are many potential causes of SCD (Table 4.1). SCD usually occurs in individuals with underlying cardiac disease and occurs more frequently with male sex and increasing age. In patients with ischemic heart disease, valvular or myocardial abnormalities, SCD can be the first presentation of the patient. An acute coronary syndrome can lead to ventricular fibrillation (VF) in a patient not previously known to have cardiac disease. Alternatively, a patient who has had coronary artery bypass graft surgery in the past may present years later with a new ischemic event leading to SCD. Metabolic causes associated with SCD include electrolyte abnormalities, and drugs and medication can also cause fatal rhythm disturbances (see Chapter 10). An increasing number of syndromes are recognized as being associated with SCD. Referred to as primary electric disorders or channelopathies, they generally have a genetic basis.",183,21,0.11475409836065574
9781912776153,chp4,Other causes include: metabolic (such as electrolyte abnormalities); drugs and medication; genetic syndromes such as primary electrical disorders or channelopathies.,"There are many potential causes of SCD (Table 4.1). SCD usually occurs in individuals with underlying cardiac disease and occurs more frequently with male sex and increasing age. In patients with ischemic heart disease, valvular or myocardial abnormalities, SCD can be the first presentation of the patient. An acute coronary syndrome can lead to ventricular fibrillation (VF) in a patient not previously known to have cardiac disease. Alternatively, a patient who has had coronary artery bypass graft surgery in the past may present years later with a new ischemic event leading to SCD. Metabolic causes associated with SCD include electrolyte abnormalities, and drugs and medication can also cause fatal rhythm disturbances (see Chapter 10). An increasing number of syndromes are recognized as being associated with SCD. Referred to as primary electric disorders or channelopathies, they generally have a genetic basis.",183,30,0.16393442622950818
9781912776153,chp4,"In SCD in those aged under 35 years, approximately 80% have a structural abnormality, most commonly hypertrophic cardiomyopathy, very rarely coronary artery anomalies.","A structural abnormality, usually secondary to hypertrophic cardiomyopathy, is present in the majority (80%) of younger patients (aged <= 35 years) affected by SCD. Coronary artery anomalies occur rarely. Cardiac electrical disorders account for fewer than 10% of cases and include arrhythmogenic disorders such as long QT syndrome, arrhythmogenic right ventricular dysplasia, idiopathic VF and Brugada syndrome. Postmortem examination often reveals no evidence of demonstrable cardiac pathology; the death of the patient is often classified as of unknown etiology. Recent advances now involve a 'molecular' (genetic) postmortem.",138,34,0.2463768115942029
9781912776153,chp5,Performing an electrocardiogram (12-lead if possible) during symptoms is essential.,"Patients at risk of cardiac arrhythmias can often be determined by obtaining a history and physical examination, and by reviewing baseline tests. History taking. Relevant features include any history of previous myocardial infarction (MI) or cardiac surgery. In addition, any history to suggest the presence of structural heart disease, including hypertension or diabetes, makes an arrhythmia much more likely to be the cause of symptoms. A family history of sudden death is also relevant.",97,19,0.1958762886597938
9781912776153,chp5,The frequency of a patient's symptoms will determine the best non-invasive test to apply.,"Recording of a rhythm during symptoms is crucial to establishing the cause of palpitations. The frequency of symptoms will dictate the best investigation to carry out (Table 5.1). For example, in a patient who presents with a sustained arrhythmia and is not hemodynamically compromised, a 12-lead ECG is mandatory. However, digital recording of rhythm abnormalities has replaced the traditional ECG in many circumstances, especially when palpitations are infrequent.",94,19,0.20212765957446807
9781912776153,chp5,"Electrophysiological (EP) testing was initially conceived to provoke and identify cardiac arrhythmias. However, it is now performed infrequently solely as a diagnostic test; instead it is more often performed during an ablation procedure.","Electrophysiological study. Electrophysiological (EP) testing was conceived in the 1960s as a means to provoke and study a patient's cardiac arrhythmia. Many patients, particularly those with severe or life-threatening arrhythmias, require provocative procedures to induce the tachycardia. For example, if palpitations, ventricular ectopic beats or syncope have occurred in a patient who has previously had a myocardial infarction and has left ventricular dysfunction, an EP study can determine whether ventricular tachycardia is inducible and is likely to be the cause of the patient's symptoms. Abnormal recordings during an EP study may determine whether a pacemaker is required. However, the advent of digital recording methods, as well as the importance of left ventricular function in determining therapy, has meant that the EP study is now performed only infrequently to diagnose cardiac arrhythmias. Instead, the EP laboratory has become a site for treating cardiac arrhythmias with catheter ablation procedures or device implantation. The diagnostic EP study is still performed (Figure 5.3), but mainly in association with therapeutic procedures.",238,47,0.19747899159663865
9781912776153,chp5,Non-invasive monitoring can be performed repeatedly if needed. Digital and smartphone technologies will expand in use in future.,"Treadmill exercise testing. Treadmill exercise testing can be used to evaluate arrhythmias, and is occasionally a useful option, particularly in cases where symptoms occur under exercise conditions. Arrhythmias may occur during the exercise test, but there is often an even greater propensity for arrhythmias to occur during the recovery phase. This is particularly the case when automaticity is mostly responsible for the cardiac arrhythmias, such as patients with ventricular ectopy or ventricular tachycardia without overt heart disease. In these patients, the exercise test will not only be useful at provoking the cardiac arrhythmia, but will also assist in planning ablation, in view of the importance of the 12-lead morphology of ventricular tachycardia at predicting the region of the heart that requires mapping and ablation.",170,23,0.13529411764705881
9781912776153,chp5,Treadmill exercise testing can be useful to induce cardiac arrhythmias in selected patients.,"Treadmill exercise testing. Treadmill exercise testing can be used to evaluate arrhythmias, and is occasionally a useful option, particularly in cases where symptoms occur under exercise conditions. Arrhythmias may occur during the exercise test, but there is often an even greater propensity for arrhythmias to occur during the recovery phase. This is particularly the case when automaticity is mostly responsible for the cardiac arrhythmias, such as patients with ventricular ectopy or ventricular tachycardia without overt heart disease. In these patients, the exercise test will not only be useful at provoking the cardiac arrhythmia, but will also assist in planning ablation, in view of the importance of the 12-lead morphology of ventricular tachycardia at predicting the region of the heart that requires mapping and ablation.",170,19,0.11176470588235295
9781912776153,chp6,"Drug therapy can be useful to suppress symptoms initially, but is not curative.","Maintenance of sinus rhythm. The aim of antiarrhythmic drug therapy is to suppress the frequency of paroxysmal arrhythmias. The drugs are not curative, so treatment tends to be lifelong and the drugs must be taken daily (some of them three times daily). No drug taken orally is effective immediately, although some drugs can be useful when taken as soon as the arrhythmia begins. In cases where attacks are very infrequent, a small dose of a drug may be taken at the onset of symptoms (the so-called 'pill in the pocket' approach). However, this should not be repeated continuously if the arrhythmia fails to terminate, as pretreatment with a drug may complicate any subsequent aggressive treatment such as DC cardioversion in hospital. Table 6.3 summarizes the drugs that can be used for specific arrhythmias.",178,16,0.0898876404494382
9781912776153,chp6,Symptomatic patients should be considered for ablative therapy.,"Various brief arrhythmias may arise, especially ventricular and supraventricular premature beats, bradycardia and short periods of sinus arrest. Sinus arrest occurs more frequently in patients who have received multiple antiarrhythmic agents at the time of cardioversion. Ventricular tachycardia (VT) and VF can be precipitated in patients with hypokalemia or digitalis intoxication. Ideally, digoxin should be stopped for 48 hours before cardioversion. Transient ST segment elevation can appear on the ECG after cardioversion, and blood levels of creatine kinase-MB can rise without significant demonstrable myocardial damage.",133,12,0.09022556390977443
9781912776153,chp6,Radiofrequency (catheter) ablation can cure many types of arrhythmia.,"Age per se is not a contraindication to catheter ablation - results are generally similar in patients in their 80s to those in their teens. Caffeine has not been shown to be associated with easier induction of SVT during electrophysiological testing, and has not been demonstrated to be generally contraindicated in patients with cardiac arrhythmias. Alcohol can be detrimental, and may require abstinence or reduced consumption to prevent cardiac arrhythmias in selected patients. For most patients, exercise is to be encouraged, but in some (exempli gratia those with right ventricular outflow tract tachycardia or hypertrophic cardiomyopathy) strenuous exercise is contraindicated. Elite endurance athletes usually undergo major changes to the structure and autonomic regulation of their hearts and may develop arrhythmias (exempli gratia AF or right ventricular outflow tract tachycardia) or produce changes that resemble right ventricular dysplasia. Detraining may reduce arrhythmia burden in some of these patients.",217,18,0.08294930875576037
9781912776153,chp7,"Supraventricular tachycardias (SVTs) refer to a reciprocating regular tachycardia involving the atrioventricular (AV) node region, an accessory pathway or a discrete atrial substrate.","Supraventricular tachycardia (SVT) is a general term describing any rapid heart rate that originates above the ventricles. Although this can include atrial fibrillation (AF) and atrial flutter, as electrophysiology has improved our knowledge of mechanisms, it is now generally accepted that SVTs refer to a reciprocating regular tachycardia involving the atrioventricular (AV) node region in approximately 60% of cases, an accessory pathway in up to 30% of cases, and a discrete atrial substrate in about 10% of cases. Whereas atrioventricular nodal re-entrant tachycardia (AVNRT) or atrioventricular re-entrant tachycardia are re-entrant arrhythmias, atrial tachycardia is more commonly automatic and typically influenced by autonomic tone. Atrial tachycardias may arise from anywhere in the atria but the most common sites are in the right atrium along the crista terminalis (including the base of the atrial appendage), and in the left atrium in the pulmonary veins and around the mitral valve.",243,46,0.18930041152263374
9781912776153,chp7,"SVTs usually occur in young, otherwise healthy, adults, but may be seen at any age.","SVTs usually occur in young, otherwise healthy, adults, but can be seen at any age. There are surprisingly few data on the incidence of SVTs in the general population. In the USA, the prevalence is estimated to be 2.25 per 1000 persons, with an incidence of 35 per 100 000 person-years. This equates to approximately 89 000 new cases per year and a total of about 570 000 people with SVTs in the USA at any given time; the rate of presentation to the emergency room with a definite SVT was 0.05% per year over an 11-year period. Thus, SVTs are relatively infrequent.",132,21,0.1590909090909091
9781912776153,chp7,"Intervention is not usually needed if symptoms are infrequent and non-intrusive, providing a diagnosis of SVT has been confirmed.","No intervention. If symptoms are infrequent and non-intrusive (exempli gratia less than once or twice a year), and provided the diagnosis is confirmed, no treatment may be indicated and the patient can be reassured. Patients often develop successful ways of stopping their SVT, such as Valsalva maneuvers, deep breathing techniques, lying down or sleeping. The patient can be given the treatment options available, so that any increase in symptom frequency can be dealt with immediately. This advice applies only in the absence of ventricular pre-excitation. Patients with ventricular pre-excitation (as in Wolff-Parkinson-White syndrome) should be referred to a cardiologist for risk assessment, and generally most of these patients undergo catheter ablation.",156,28,0.1794871794871795
9781912776153,chp7,"Where ventricular pre-excitation is present on electrocardiography (exempli gratia patients with Wolff-Parkinson-White [WPW] syndrome), referral for cardiological assessment and risk profiling is strongly recommended. Regular antiarrhythmic therapy is not advised in asymptomatic WPW.","No intervention. If symptoms are infrequent and non-intrusive (exempli gratia less than once or twice a year), and provided the diagnosis is confirmed, no treatment may be indicated and the patient can be reassured. Patients often develop successful ways of stopping their SVT, such as Valsalva maneuvers, deep breathing techniques, lying down or sleeping. The patient can be given the treatment options available, so that any increase in symptom frequency can be dealt with immediately. This advice applies only in the absence of ventricular pre-excitation. Patients with ventricular pre-excitation (as in Wolff-Parkinson-White syndrome) should be referred to a cardiologist for risk assessment, and generally most of these patients undergo catheter ablation. Vagal maneuvers can terminate the arrhythmia by selective slowing of conduction through the AV node (Table 7.1). These maneuvers work variably - not at all in some patients - but should be tried as they are low risk and simple to perform. The safest and easiest to teach is the Valsalva maneuver, in which a patient strains against a closed glottis. Ask patients to imagine they are straining at stool, blowing hard with the mouth closed while pinching the nose or blowing into a straw. The forced expiration is maintained for 10 seconds and the tachycardia may terminate in the vagal phase on release of the breath hold.",292,65,0.2226027397260274
9781912776153,chp7,Pharmacological treatment is aimed at slowing conduction through the AV node and/or the accessory pathway.,"Pharmacological treatment. As discussed above, these arrhythmias use an accessory pathway (atrioventricular re-entrant tachycardia), or in the case of AVNRT a slow pathway, as part of the tachycardia in addition to the AV node (see Chapter 1). The tachycardia can be terminated by slowing conduction through the AV node and/or the pathway. Usually, antegrade depolarization of the ventricle occurs over the AV node.",103,21,0.20388349514563106
9781912776153,chp7,"In symptomatic patients with WPW syndrome, even if symptoms are minimal, ablation is recommended.","Flecainide should be avoided in patients with impaired left ventricular (LV) function or clinical heart failure, as the risk of proarrhythmia increases significantly. In these circumstances, an SVT can be converted to a potentially fatal arrhythmia - ventricular tachycardia (which can be incessant) or recurrent ventricular fibrillation. These risks are minimal when LV function is normal, as in the majority of patients with SVTs.",95,20,0.21052631578947367
9781912776153,chp7,"First-line treatment is catheter ablation; in the presence of normal ventricular function, antiarrhythmic agents are also considered (flecainide, propafenone or sotalol).","Propafenone has partial beta-blocking actions and is generally not recommended in patients with at least moderate asthma. It requires the same precautions as flecainide, as they are both in the same Vaughan Williams class (see Table 6.2). Propafenone should be avoided in any patient with impaired LV function. The usual dosage is 150 mg two to three times daily. Sotalol also has partial beta-blocking actions and should be avoided in patients with asthma. Treatment should be started at 80 mg twice daily and increased gradually. The maximum dosage is 320 mg twice daily. However, if 160 mg is ineffective, therapy should be changed as it is unlikely that a greater dose will be effective. Sotalol should be used with great caution in the presence of heart failure and is generally avoided in the elderly because of renal excretion. It is also used with caution in women as there is an increased risk of torsades de pointes.",193,43,0.22279792746113988
9781912776153,chp8,"Atypical atrial flutter usually includes right atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.","Atrial flutter is usually defined as a macro-entrant atrial rhythm (id est a circuit that covers a large area of the atrial myocardium), rotating counterclockwise, occasionally clockwise, within the right atrium (see Figure 1.9). Typical atrial flutter is defined as cavotricuspid isthmus- (CTI) dependent, whereas atypical flutter includes all other atrial flutters. Typical atrial flutter is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular block (an atrial rate of 300 beats per minute [bpm] and a regular ventricular response of 150 bpm related directly to the atrial rate), and characteristic flutter waves showing a saw-tooth aspect in the inferior leads, and a positive P wave in V1. A QRS rate of exactly 150 bpm should raise suspicion of atrial flutter. The diagnosis of typical or atypical atrial flutter is usually made by reviewing the electrocardiogram (ECG) showing the flutter waves.",229,33,0.14410480349344978
9781912776153,chp8,The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF).,"In typical atrial flutter, the circuit is critically dependent on the CTI, an area of slow conduction in the right atrium (see Figure 1.9). Other types of atrial flutter, referred to as atypical atrial flutter, occur mostly in patients with scarring in the atrium (exempli gratia after radiofrequency ablation or previous heart surgery, or those with structural heart disease). Electrocardiogram. Atrial flutter characteristically has a saw-tooth appearance of flutter waves on the baseline in the 12-lead ECG (see Figure 1.9). In common counterclockwise atrial flutter the P waves are inverted in the inferior ECG leads II, III and aVF. In clockwise atrial flutter (less common) the re-entry loop cycles in the opposite direction and thus the flutter waves are upright in II, III and aVF. Atypical atrial flutter includes all other types of atrial flutter on the 12-lead ECG.",218,27,0.12385321100917432
9781912776153,chp8,"Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment.","Complications. Apart from the usual complications associated with instrumentation of the venous circulation, very rarely heart block or cardiac tamponade or perforation of the inferior vena cava are reported. After ablation, the prognosis for patients with typical CTI-dependent atrial flutter is excellent. In patients with atypical atrial flutter, recurrences are more common because of scarring of the atria. Up to 30% of patients with either type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial flutter and AF often coexist.",129,25,0.1937984496124031
9781912776153,chp9,Atrial fibrillation (AF) is very common and is a major cause of morbidity and mortality.,"Lone AF (AF in the absence of cardiovascular disease) is more common in younger patients (younger than 60 years). It occurs in 30-45% of paroxysmal cases and 20-25% of persistent cases. Lone AF is more benign in terms of thromboembolism and mortality and has a favorable prognosis. However, the prognosis worsens with the development of cardiac abnormalities, with a consequent increase in thromboembolism and mortality.",99,22,0.2222222222222222
9781912776153,chp9,"It is vital to determine whether AF is paroxysmal, persistent, long-standing persistent or permanent because the treatment aims are different for each patient group.","Inappropriate heart rate. It is increasingly recognized that a persistently elevated ventricular rate (130 bpm or faster in one study) can adversely affect LV function, causing a dilated cardiomyopathy, referred to as a tachycardiomyopathy. Adequate rate control can partially or even completely reverse this process, and the elimination of alcohol may be necessary in these patients. In many cases, the ventricular rate is highly variable, often within a short time interval, which is known as the tachy-brady syndrome. It is often complex to manage, involving drugs that slow the rapid rates, which in turn can precipitate symptomatic bradycardias requiring electrical support in the form of a pacemaker. Quality of life. Many studies have shown impaired QoL in patients with AF. However, it is difficult to determine whether AF is solely responsible for reduced wellbeing, as these patients often have comorbidities and are receiving multiple drug treatments. Long-term oral anticoagulant therapy, which involves frequent blood testing and/or multiple drug interactions, also affects the QoL of patients with AF. A highly systematic approach to assessment of AF is required. detect AF and confirm diagnosis. identify the duration and type of AF.",258,32,0.12403100775193798
9781912776153,chp9,"AF ablation is still evolving as an interventional procedure, with the arrival of new mapping software and the continual evaluation of ablation methods and techniques.","Confirm diagnosis. If AF is suspected, an ECG should be performed immediately. Even a single-lead ECG is diagnostic, although a 12-lead ECG is always preferable. The key abnormality is a completely irregular, often rapid, ventricular response and loss of clear P waves, replaced by fibrillatory (or 'f') waves (Figure 9.2). The ventricular response depends on the functional properties of the AV node, which reflects vagal and sympathetic tone and, in many cases, depends on the effects of drugs. While a slow regular heart rate (exempli gratia 40 bpm) may indicate the presence of heart block, a slow but variable heart rate indicates a slow ventricular response during AF, and is often drug-related. Very rapid ventricular rates (over 200 bpm) associated with a wide QRS complex may indicate the presence of an accessory pathway, or bundle branch block.",190,30,0.15789473684210525
9781912776153,chp9,"Stroke risk and major bleeding risk in AF are multifactorial and can be assessed by the CHADS /CHA DS -VASc and HAS-BLED scores, respectively.","The risk of bleeding must be assessed before anticoagulation therapy is started. There are three recognized scoring systems to assess bleeding risk: HEMORR HAGES (H epatic or renal disease, E thanol abuse, M alignancy, O lder age, R educed platelet count or function, R e-bleeding, H ypertension, A nemia, G enetic factors, E xcessive fall risk and S troke); ATRIA (A nticoagulation and R isk factors I n A trial fibrillation); and HAS-BLED (H ypertension, A bnormal renal/liver function, S troke, B leeding history or predisposition, L abile international normalized ratio, E lderly and D rugs/alcohol). The HAS-BLED scoring system estimates the risk of major bleeding for patients on anticoagulant medication (Table 9.6). It can be used in conjunction with the CHA DS -VASc score (as described above) to determine if anticoagulation is in the best interest of the patient. For example, older people are at increased risk for anticoagulant-related bleeding and are therefore less likely to be treated with oral anticoagulation, even in situations for which efficacy is proven. A HAS-BLED score of 3 or higher is considered 'high risk', and such patients should be reviewed regularly.",298,38,0.12751677852348994
9781912776153,chp9,"In most patients, AF is not cured by ablation. In many patients, AF is a progressive condition that may be associated with long-term recurrences of AF after apparently successful ablation procedures.","Dronedarone is indicated for the treatment of AF in patients whose hearts have either returned to normal rhythm or who have undergone drug therapy or electric shock treatment to maintain normal rhythm. Although approved as recently as 2009, a study investigating the use of dronedarone in patients with permanent AF (PALLAS) in 2011 was stopped early because of a twofold increase in death, stroke and hospitalization for heart failure in patients receiving dronedarone compared with those taking a placebo. As patients with paroxysmal AF may develop persistent AF, there has been concern that dronedarone may continue to be used in all patients with AF regardless of type. Furthermore, concerns about liver toxicity, and the risks associated with the administration of dronedarone in patients with renal and heart failure, have limited the clinical use of this drug.",170,41,0.2411764705882353
9781912776153,chp9,Radiofrequency ablation is now the preferred option for many patients with AF.,"Wolff-Parkinson-White syndrome. Radiofrequency ablation of the accessory pathway is the treatment of choice for patients with pre-excitation syndromes and AF, and all patients should be referred urgently to a cardiologist for assessment. Antiarrhythmic drugs can be used, but calcium-channel blockers and digoxin should be avoided because of the risk of accelerating the ventricular rate during AF (especially if given intravenously). Beta-blockers do not decrease conduction over accessory pathways during pre-excited periods of AF.",111,15,0.13513513513513514
9781912776153,chp9,The direct oral anticoagulants are gradually replacing warfarin as first-line anticoagulant treatment for AF.,"Warfarin requires regular monitoring of the international normalized ratio, and drug and dietary interactions are common. If necessary, its anticoagulant effects can be quickly and effectively reversed with vitamin K (as well as plasma and/or prothrombin complex concentrates). Direct oral anticoagulants (DOACs) have recently been introduced for clinical use (Table 9.12). They have all shown non-inferiority compared with warfarin and a better safety profile, in particular less risk of intracranial hemorrhage (Figure 9.13). The recent introduction of specific antidotes to these drugs has further influenced both physicians and patients into using them. DOACs are gradually replacing warfarin in the majority of patients with AF.",156,27,0.17307692307692307
9781912776153,chp10,All patients with a wide-complex tachycardia need emergency referral and admission.,"In normal conduction, the QRS complex is narrow because of near simultaneous depolarization of the ventricles, with electrical activity in the ventricles normally completing in less than 100 ms (see Figure 1.1). This rapid ventricular activation can occur only if the specialized conduction tissue within the His-Purkinje network is functioning properly. A wide QRS can occur if. the specialized conducting tissue is not functioning normally - bundle branch block in which depolarization of the His-Purkinje system is still from the top down but the conduction system is damaged (exempli gratia atrial flutter with bundle branch block will be a wide-complex tachycardia).",143,17,0.11888111888111888
9781912776153,chp10,A wide regular QRS complex indicates ventricular tachycardia (VT) until proven otherwise.,"It is important that a patient is not made worse when treatment is initiated following the diagnosis. Sadly, some patients are occasionally made worse by treating a wide QRS tachycardia as if it were arising in the atria and being conducted with bundle branch block (aberration). Agents such as intravenous verapamil (which is long-acting) can prove disastrous if the rhythm is actually VT, although even adenosine (which is short-acting) can have deleterious effects. It is therefore generally safer to assume that all regular QRS tachycardias are VT and to initiate treatment on that basis in the first instance. (A patient with supraventricular tachycardia [SVT] treated for VT may not get better immediately but is unlikely to get worse.).",161,20,0.12422360248447205
9781912776153,chp10,Wide QRS tachycardia always requires further investigation and referral to an arrhythmia specialist.,"It is important that a patient is not made worse when treatment is initiated following the diagnosis. Sadly, some patients are occasionally made worse by treating a wide QRS tachycardia as if it were arising in the atria and being conducted with bundle branch block (aberration). Agents such as intravenous verapamil (which is long-acting) can prove disastrous if the rhythm is actually VT, although even adenosine (which is short-acting) can have deleterious effects. It is therefore generally safer to assume that all regular QRS tachycardias are VT and to initiate treatment on that basis in the first instance. (A patient with supraventricular tachycardia [SVT] treated for VT may not get better immediately but is unlikely to get worse.).",161,21,0.13043478260869565
9781912776153,chp10,VT may occur in a structurally normal heart and tends to show characteristic electrocardiogram and clinical features.,"If VT cannot be reliably sustained, then an alternative strategy is pace-mapping. The pattern of ventricular myocardial depolarization occurs in a particular way as it spreads from the focal source to the rest of the myocardium, producing a characteristic 12-lead ECG pattern. If a catheter is placed at this same site and pacing is performed, the 12-lead ECG morphology will look identical only if it is in the same place as the VT source. During ablation at the correct site there is often an accelerated burst of VT (automaticity), which is extinguished during continued ablation.",124,22,0.1774193548387097
9781912776153,chp10,"Catheter ablation is curative for normal heart VT, but palliative for scar-related VT.","Ablation. Unlike VTs in the normal heart, where catheter ablation is often curative, the procedure has been traditionally viewed as palliative in patients with structural heart disease, particularly in conditions such as arrhythmogenic right ventricular cardiomyopathy where there may be significant disease progression with time. However, catheter ablation can be effective at reducing or eliminating ICD shocks in patients with scar-related VT. In these patients, mapping and ablation are usually performed during sinus rhythm in order to avoid the prolonged hypotension usually present during VT, especially with underlying left ventricular dysfunction and general anesthesia. The ablation strategy is very different from SVT ablation (Table 10.1).",146,22,0.1506849315068493
9781912776153,chp11,"Several forms of congenital long QT syndrome have been described, the most well-characterized of which - LQT1, LQT2 and LQT3 - each have distinct clinical outcomes, ECG appearances and triggers.","Congenital long QT syndrome is an inherited disorder characterized by prolonged ventricular repolarization on the ECG and a propensity to ventricular arrhythmias. Syncope and sudden death may result from torsades de pointes. This VT with an undulating axis may degenerate into ventricular fibrillation (VF), leading to death. Torsades de pointes is typically initiated by sudden increases in sympathetic tone, such as that triggered by fright, stress or physical exertion. The prevalence of LQTS in the general population is approximately 1:4000 people, with the onset of symptoms typically occurring within the first two decades of life. Presentation may vary from merely prolongation of the QT interval being noted on the 12-lead ECG in an asymptomatic individual, to recurrent syncope or resuscitated sudden death. Many patients are initially labeled as having epilepsy. Several forms of congenital LQTS have been described; three forms have been well characterized (LQT1, LQT2, LQT3). These forms have distinct clinical outcomes, ECG appearances (Figure 11.1) and triggers. Most commonly, sudden death in LQT1 is seen after physical exertion (exempli gratia in athletes); in LQT2 sudden death or syncope is usually seen during emotional stress; and in LQT3 sudden death can occur during sleep.",291,49,0.16838487972508592
9781912776153,chp11,Most cases of acquired long QT syndrome are drug-related.,"Acquired long QT syndrome is most commonly either drug-induced or due to a profound biochemical abnormality, usually hypocalcemia or hypomagnesemia. Drugs that prolong the QT interval are shown in Table 11.1. It should be remembered that by their very action some antiarrhythmic drugs prolong the QT interval. This does not mean the drug should be stopped. As a rule, if the rate-corrected QT interval (see page 145) is greater than 500 ms, then it is advisable to withdraw treatment because of the unpredictable occurrence of torsades de pointes. Antiarrhythmic agents capable of prolonging the QT interval should not be used together. Large biochemical variations, particularly hypo- or hyperkalemia or hypocalcemia, should be avoided. Potassium levels should be checked regularly in patients on diuretic therapy and in those with intercurrent illness such as severe diarrhea.",195,13,0.06666666666666667
9781912776153,chp11,"Brugada syndrome is characterized by sudden death due to idiopathic ventricular fibrillation; ECG changes may be intermittent, but an abnormality resembling incomplete or complete right bundle branch block pattern with persistent ST elevation in the precordial chest leads (V1-V3) is diagnostic.","Brugada syndrome was first reported by the Brugada brothers in 1992. It is a rare syndrome characterized by sudden death due to idiopathic VF in an otherwise apparently structurally normal heart. More than 80 mutations in the sodium-channel gene have been identified in patients with Brugada syndrome. The arrhythmias are believed to be mainly due to differences in repolarization in regions of the epicardium at the right ventricular outflow tract, allowing re-entry to occur. The diagnostic ECG abnormality is shown in Figure 11.2. Brugada syndrome is known as Lai Tai in Thailand. In other parts of Asia (exempli gratia the Philippines, Japan), the condition is one of the most common causes of natural death in men younger than 50 years. An ICD is the treatment of choice in patients with syncope, resuscitated sudden death or inducible ventricular arrhythmias. Electrophysiological testing may be useful in asymptomatic cases (exempli gratia patients in whom Brugada syndrome is found incidentally) to assess the risk of sudden death. Confusingly, the ECG changes (postprandial, fever) are intermittent in some patients and a high index of suspicion is required to make the diagnosis. Patients with documented VF with an otherwise normal heart should undergo a provocation test using intravenous administration of a sodium-channel blocker such as ajmaline (a short-acting class I agent) or flecainide during 12-lead ECG recording. This brings out or exaggerates the ECG changes, confirming the diagnosis.",335,61,0.18208955223880596
9781912776153,chp11,ECG changes may be intermittent; a normal baseline ECG may not exclude these conditions.,"Confusingly, the ECG changes (postprandial, fever) are intermittent in some patients and a high index of suspicion is required to make the diagnosis. Patients with documented VF with an otherwise normal heart should undergo a provocation test using intravenous administration of a sodium-channel blocker such as ajmaline (a short-acting class I agent) or flecainide during 12-lead ECG recording. This brings out or exaggerates the ECG changes, confirming the diagnosis.",102,18,0.17647058823529413
9781912776153,chp11,Patients with known hypertrophic cardiomyopathy require cardiological assessment.,"Hypertrophic cardiomyopathy is a spectrum of disorders that affects myocardial structure, including asymmetric septal hypertrophy and idiopathic subaortic stenosis. Abnormal myocardial architecture and fiber disarray contribute to increased risk of VF in patients with hypertrophic cardiomyopathy. Five factors have been associated with an increased risk of sudden death, and such patients should be considered for an ICD.",91,15,0.16483516483516483
9781912776153,chp11,An arrhythmic cause should be considered in younger patients presenting with 'epilepsy' - a resting electrocardiogram (ECG) is mandatory.,"In the event of an unexplained sudden cardiac death, particularly at a young age, the possibility of a genetic cause should be considered and investigated as part of a 'molecular' postmortem (see page 50). Unfortunately, only a small percentage of carriers of an abnormal gene (exempli gratia Brugada syndrome) will have an abnormal ECG, and current clinical tests (exempli gratia MRI) are not sufficiently reliable to be clinically useful. However, genetic screening can be very helpful in conditions where the genetic basis is clear and testing is robust. Screening and counseling of family members should be carried out at specialized centers, with clear communication and referral systems in place between diagnostic testers, community healthcare providers, coroner services and affected families.",152,33,0.21710526315789475
9781912776153,chp11,"In many cases, screening of family members is mandatory and, if available, referral to a specialized genetics clinic should be made.","In the event of an unexplained sudden cardiac death, particularly at a young age, the possibility of a genetic cause should be considered and investigated as part of a 'molecular' postmortem (see page 50). Unfortunately, only a small percentage of carriers of an abnormal gene (exempli gratia Brugada syndrome) will have an abnormal ECG, and current clinical tests (exempli gratia MRI) are not sufficiently reliable to be clinically useful. However, genetic screening can be very helpful in conditions where the genetic basis is clear and testing is robust. Screening and counseling of family members should be carried out at specialized centers, with clear communication and referral systems in place between diagnostic testers, community healthcare providers, coroner services and affected families.",152,25,0.16447368421052633
9781912776153,chp12,Pacemakers are the treatment of choice in patients with symptomatic bradycardia.,"Heart failure. Traditionally, pacemakers were implanted exclusively for bradycardias. However, certain types of heart failure without bradycardia have now become an indication. In some cases of heart failure, the systolic contraction of the ventricles is not synchronous; parts of the left and right ventricles contract in an uncoordinated fashion, resulting in reduced cardiac output and functional mitral regurgitation. Often the QRS complex is broad, usually with a left bundle branch block morphology. Despite optimal pharmacological treatment with tolerated doses of beta-blockers, angiotensin-converting enzyme inhibitors, diuretics and spironolactone, with or without digoxin, some patients remain symptomatic with ongoing shortness of breath and tiredness. Cardiac resynchronization therapy (CRT), also referred to as biventricular pacing, should be considered in patients with the following inclusion criteria.",191,18,0.09424083769633508
9781912776153,chp12,Patients need regular review (usually annually) to check battery life and lead integrity.,"The lead body is incredibly resilient, flexing and twisting to accommodate daily cardiac contractions. Lead failure is rare (< 0.05% fracture per year) and lifespan is often 10-15 years. Fractures can occur within either the inner conducting core or the outer insulation and very rarely lead to sudden loss of pacing function. Contiguity is usually maintained even when a lead fractures internally. Lead embolization has never been reported, and internal lead erosion (id est through a large vein in the chest or through the heart) is very rare. Lead integrity can be assessed non-invasively via the pacemaker generator, previously on an annual basis, but newer devices are able to check lead function daily and even attempt automatic reprogramming to maintain safety. A broken lead requires replacement or, rarely, removal (see page 173). The pacing generator is not easily damaged, except perhaps by major trauma.",182,17,0.09340659340659341
9781912776153,chp12,Patients with pacemakers can live a near-normal life.,"Programmability. In modern pacemakers, the pacing rate can be altered and the power output adjusted. In more complex systems, both the atrial and ventricular channels can be programmed independently. The endocardial signal (internal electrocardiogram) can be recorded, and with some pacemakers the patient can externally trigger the pacemaker to store these signals when they are symptomatic, acting like a cardiomemo device. Older pacemakers are programmed non-invasively by placing a telemetry wand over the pacemaker and connecting this to a computer. Radiofrequency signals are used to alter the settings, a painless process that often takes 5-10 minutes to perform. However, current devices can be interrogated wirelessly, a development that has allowed pacemakers and defibrillators to be monitored continuously from the patient's home environment (see page 174).",178,14,0.07865168539325842
9781912776153,chp12,All implantable defibrillators have a back-up pacemaker.,Indications. Implantable cardioverter defibrillators (ICDs) are the treatment of choice for patients with life-threatening ventricular tachycardias (VTs). ICDs monitor heart rhythm and shock the heart if there is a rhythm problem. All ICDs have back-up pacemakers that prevent the heart from slowing down too much after a shock is delivered.,81,15,0.18518518518518517
9781912776207,ch1,"T cells develop in the thymus and are part of the innate and adaptive immune system. They recognize and respond to specific antigens, producing a tailored response to invading pathogens.","Innate immunity offers a rapid but non-specific defense. It comprises the physical epithelial barrier, complement activation, some T cells and natural killer (NK) cells, and phagocytic cells (neutrophils and macrophages) which engulf and remove pathogens. In the adaptive immune system, T and B cells recognize and respond to specific antigens, producing a tailored response to invading pathogens. Persistence of these 'experienced' T and B cells results in long-term immune memory. T cells develop from progenitors within the thymus gland. Mature T cells can be broadly classified into two types. T-helper cells, which are primarily involved in coordinating the immune response to an invading organism.",150,37,0.24666666666666667
9781912776207,ch1,Mature T cells express a surface T-cell receptor (TCR) that recognizes fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules.,"TCRs comprise two different protein chains (id est they are heterodimers), most often an alpha and beta subunit (alphabeta T cells). These alphabeta T cells recognize and bind foreign peptides presented by major histocompatibility complex (MHC) molecules on the cell surface of antigen-presenting cells. This MHC-antigen complex binds to alphabeta TCRs, while other co-stimulatory molecules (exempli gratia CD28) are activated, leading to alphabeta T-cell activation, proliferation, differentiation and apoptosis and cytokine release. About 5% of T cells express a gamma and delta TCR (gamma T cells). These cells have similarities with NK cells, with roles in both innate and adaptive immune responses. They are typically found at sites of antigen contact, such as the skin, spleen, liver, intestine and bone marrow. As a first line of defense after antigenic stimulus, gamma T cells release cytotoxic factors (perforins, granzyme B and TIA-1). The gamma TCR is expressed by several extranodal subtypes of PTCL (see Chapter 2).",245,37,0.1510204081632653
9781912776207,ch1,"Thymocytes do not express CD4 or CD8 initially (double-negative) but become double-positive during development, after which one molecule is downregulated. CD8 + T cells (cytotoxic T lymphocytes) recognize antigens presented by the MHC class I molecules found on nucleated cells. CD4 + T cells, of which there are several subtypes, recognize antigens presented by MHC class II molecules, which are only present on specialized antigen-presenting cells.","About 5% of T cells express a gamma and delta TCR (gamma T cells). These cells have similarities with NK cells, with roles in both innate and adaptive immune responses. They are typically found at sites of antigen contact, such as the skin, spleen, liver, intestine and bone marrow. As a first line of defense after antigenic stimulus, gamma T cells release cytotoxic factors (perforins, granzyme B and TIA-1). The gamma TCR is expressed by several extranodal subtypes of PTCL (see Chapter 2). CD4 and CD8. Lymphoid progenitor cells in the thymus undergo stepwise maturation (Figure 1.2). The developing cells, called thymocytes, do not initially express CD4 or CD8 (described as double negative); expression of CD4 and CD8 is driven by positive signals received during development, resulting in double-positive thymocytes. Double-positive cells also encounter self-antigens and those that exhibit self-reactivity undergo negative selection. Finally, either CD4 or CD8 is downregulated, resulting in single-positive cells. The naive CD4 + and CD8 + T cells enter the peripheral circulation from the thymus. CD8 + T cells recognize antigens presented by the MHC class I molecules found on nucleated cells. Once activated, the CD8 + T cells proliferate to produce cytotoxic T lymphocytes - a population of effector T cells which release the enzymes and toxins that induce apoptosis. CD4 + T cells recognize antigens presented by MHC class II molecules, which are only present on specialized antigen-presenting cells. Most of these cells are 'helper' subsets, which release cytokines, sending positive signals to other immune cells, predominantly B cells (Figure 1.3). A unique subset of CD4+ T cells, called T regulatory cells, restrain the immune response via various cytokine and signaling mechanisms, preventing aberrant or exaggerated immune activation. Follicular helper T cells provide essential support for B-cell immune responses.",440,103,0.2340909090909091
9781912776207,ch1,"Natural killer (NK) cells derive from the same common lymphoid progenitor as T cells but develop primarily in the bone marrow. They produce inflammatory cytokines and directly kill infected cells without prior priming or activation. While NK cells are typically considered part of the innate immune system, recent evidence suggests that they are also important in adaptive immunity.","CD4 + T cells recognize antigens presented by MHC class II molecules, which are only present on specialized antigen-presenting cells. Most of these cells are 'helper' subsets, which release cytokines, sending positive signals to other immune cells, predominantly B cells (Figure 1.3). A unique subset of CD4+ T cells, called T regulatory cells, restrain the immune response via various cytokine and signaling mechanisms, preventing aberrant or exaggerated immune activation. Follicular helper T cells provide essential support for B-cell immune responses. Our understanding of T-cell subsets has advanced significantly over recent years. The external signals (cytokines) that trigger polarized T-cell differentiation are being elucidated, as are the molecular mechanisms that alter T-cell behavior to produce specific effector functions. Furthermore, gene expression profiling is being used to define the molecular signatures of T-cell subsets. These insights are refining our understanding of PTCL subtypes and have allowed the cell of origin to be identified for some (see Chapter 2). Natural killer cells. NK cells are a type of lymphocyte derived from the same common lymphoid progenitor as B and T lymphocytes but develop primarily in the bone marrow. NK cells are typically considered part of the innate immune system because they rapidly produce inflammatory cytokines and directly kill infected cells without prior priming or activation. However, recent evidence suggests that NK cells are also important in adaptive immunity.",298,69,0.23154362416107382
9781912776207,ch2,"Extranodal PTCLs are less common than nodal PTCLs and include enteropathy-associated T-cell lymphoma (EATL), NK/T-cell lymphoma (ENKTCL) and hepatosplenic T-cell lymphoma (HSTCL).","Lymphomas arise from a single abnormal lymphocyte. Genetic changes within this lymphocyte lead to an accumulation of identical cells, known as a clonal population. The genetic changes that give rise to a clonal population may arise during different stages of the cell life cycle, which is important in classification. To date, the classification of T-cell lymphomas has been based largely on morphologic assessment, which contrasts with the B-cell lymphomas, for which certain entities are defined by distinct immunophenotypic profiles corresponding to specific maturation stages and recurrent chromosomal translocations. The classification of PTCLs is complicated by the diversity of the entities, a relative lack of pathognomonic molecular markers, and overlapping clinical and pathological features. Multiple genetic aberrations have been identified in T-cell lymphomas but few are entity defining. Two distinct subsets have been identified that span multiple histopathological groups. T-cell lymphomas arising from follicular helper T cells (Tfh) - angioimmunoblastic T-cell lymphoma (AITL), Tfh subtype of PTCL not otherwise specified (NOS), Tfh T-cell lymphoma. gamma T-cell lymphomas - primary cutaneous gamma T-cell lymphoma, hepatosplenic T-cell lymphoma (HSTCL).",280,62,0.22142857142857142
9781912776207,ch2,"Classification has been largely based on morphologic assessment, although the 2016 update to the WHO classification incorporated recent advances in the understanding of the cell of origin and the molecular signatures of particular types of PTCL. Genetic lesions are also being identified but few are entity-defining markers.","The classification of PTCLs is complicated by the diversity of the entities, a relative lack of pathognomonic molecular markers, and overlapping clinical and pathological features. Multiple genetic aberrations have been identified in T-cell lymphomas but few are entity defining. Two distinct subsets have been identified that span multiple histopathological groups. T-cell lymphomas arising from follicular helper T cells (Tfh) - angioimmunoblastic T-cell lymphoma (AITL), Tfh subtype of PTCL not otherwise specified (NOS), Tfh T-cell lymphoma. gamma T-cell lymphomas - primary cutaneous gamma T-cell lymphoma, hepatosplenic T-cell lymphoma (HSTCL). There is also evidence of plasticity in terms of cellular derivation (alphabeta, gamma, natural killer [NK]), particularly in the extranodal entities with a cytotoxic profile. WHO classification. The World Health Organization (WHO) classification of hematopoietic and lymphoid tumors divides PTCLs into nodal, extranodal and leukemic types, each with multiple disease entities (Table 2.1). The 2016 update incorporated advances in understanding of the cell of origin and the molecular signatures of particular types of PTCL (Table 2.2).",287,57,0.1986062717770035
9781912776207,ch2,"The World Health Organization (WHO) classifies PTCLs into nodal, extranodal and leukemia types, each with multiple disease entities.","gamma T-cell lymphomas - primary cutaneous gamma T-cell lymphoma, hepatosplenic T-cell lymphoma (HSTCL). There is also evidence of plasticity in terms of cellular derivation (alphabeta, gamma, natural killer [NK]), particularly in the extranodal entities with a cytotoxic profile. WHO classification. The World Health Organization (WHO) classification of hematopoietic and lymphoid tumors divides PTCLs into nodal, extranodal and leukemic types, each with multiple disease entities (Table 2.1). The 2016 update incorporated advances in understanding of the cell of origin and the molecular signatures of particular types of PTCL (Table 2.2).",159,31,0.1949685534591195
9781912776207,ch2,"PTCL not otherwise specified (PTCL-NOS) is the most common subtype, reflecting the need for more precise characterization of these lymphomas. Genetic analyses are helping to refine this category further.","PTCL-NOS refers to subtypes of PTCL that do not fit into the distinct entities described in this chapter and is in fact the most common category, accounting for 30-35% of cases of PTCL. This largely reflects the need to more precisely characterize these lymphomas. PTCL-NOS are predominantly considered to be nodal lymphomas, although extranodal involvement at presentation or relapse is common. The most common extranodal sites are the skin and gastrointestinal tract but the bone marrow, lungs and peripheral blood may also be involved. Morphology. Involvement at a node is often diffuse but can be interfollicular or paracortical, obscuring the normal architecture of the node; the number of high endothelial venules (post-capillary venous swellings where lymphocytes enter a lymph node from the blood) is also increased. Extensive immunophenotyping may be required to distinguish PTCL-NOS from AITL. The cytology in PTCL-NOS is often pleomorphic (Figure 2.1) - most cases comprise a mixed population of medium to large cells with a high proliferation rate. Clear cells are frequently present.",250,43,0.172
9781912776207,ch2,"The primary nodal PTCLs are anaplastic large-cell lymphoma (ALCL), which may be positive or negative for the fusion protein anaplastic lymphoma kinase (ALK + /ALK  ), and angioimmunoblastic T-cell lymphoma (AITL).","Morphology. Involvement at a node is often diffuse but can be interfollicular or paracortical, obscuring the normal architecture of the node; the number of high endothelial venules (post-capillary venous swellings where lymphocytes enter a lymph node from the blood) is also increased. Extensive immunophenotyping may be required to distinguish PTCL-NOS from AITL. The cytology in PTCL-NOS is often pleomorphic (Figure 2.1) - most cases comprise a mixed population of medium to large cells with a high proliferation rate. Clear cells are frequently present. Immunophenotypic features. The expression of pan T-cell antigens (id est those found on all T cells) by malignant cells is highly variable in PTCL-NOS, with reduced or no expression of CD5 and CD7 in up to 80% of cases. Loss of CD3 and CD2 expression is less common. The predominant immunophenotype in PTCL-NOS is CD3 +, CD4 +, with no cytotoxic markers. However, a subset expresses CD8 with cytotoxic markers (TIA-1, granzyme B and perforin) and CD56, and other subsets can show double positivity or double negativity for CD4 and CD8. The expression of CD52 varies widely (35-100%), and 32-58% of PTCL-NOS cases express CD30 (an activation marker for B and T cells). CD30 positivity is typically focal but with variable staining intensity, and thus can be difficult to distinguish from anaplastic lymphoma kinase (ALK)  anaplastic large-cell lymphoma (ALCL).",365,62,0.16986301369863013
9781912776207,ch2,The PTCLs are a group of highly heterogeneous aggressive malignancies that arise from the transformation of mature post-thymic T cells and natural killer cells.,"Immunophenotypic features. The expression of pan T-cell antigens (id est those found on all T cells) by malignant cells is highly variable in PTCL-NOS, with reduced or no expression of CD5 and CD7 in up to 80% of cases. Loss of CD3 and CD2 expression is less common. The predominant immunophenotype in PTCL-NOS is CD3 +, CD4 +, with no cytotoxic markers. However, a subset expresses CD8 with cytotoxic markers (TIA-1, granzyme B and perforin) and CD56, and other subsets can show double positivity or double negativity for CD4 and CD8. The expression of CD52 varies widely (35-100%), and 32-58% of PTCL-NOS cases express CD30 (an activation marker for B and T cells). CD30 positivity is typically focal but with variable staining intensity, and thus can be difficult to distinguish from anaplastic lymphoma kinase (ALK)  anaplastic large-cell lymphoma (ALCL).",233,35,0.15021459227467812
9781912776207,ch3,"T-cell lymphomas are rare, representing approximately 10% of all non-Hodgkin lymphomas.","While the incidence of lymphoid neoplasms as a whole appears to have plateaued in the USA during 1997-2006, this largely reflects slowing in the rate of increase of B-cell neoplasms, particularly in white men. Rates of T/NK-cell lymphoid neoplasms rose by 1.17% annually, and higher rates were seen in black men (2.2%) and Asian women (2.3%). The rate of PTCL increased by 3.78% over this time, with markedly greater increases in AITL (14%) and PTCL-NOS (5.5%). There was a decrease in the incidence of ALCL (2.0%) but this, and the concomitant increase in AITL, may have been related to changes in coding. In the UK, approximately 1000 people were diagnosed with PTCL in England and Wales in 2008, representing 10% of approximately 10 000 cases of non-Hodgkin lymphoma.",203,23,0.11330049261083744
9781912776207,ch3,PTCL subtypes display marked variation in geographic distribution; AITL and EATL are more frequent in Europe whereas ATLL is more common in Japan and the Caribbean basin and ENKTCL in South East Asia.,"PTCL-NOS is more common in North America but less common in Europe and East Asia. AITL is more common in Europe than in Asia or North America. For ALCL, the ALK + form is more common in North America whereas the ALK - form is more common in Europe. EATL is more common in areas with a high incidence of celiac disease - it accounts for 5.8% and 9.1% of PTCLs in North America and Europe, respectively, but only 1.9% in Asia. This reflects its close association with the DQ HLA that results in overt or silent celiac disease. EBV-associated lymphoproliferative T- and NK-cell neoplasms (exempli gratia ENKTCL) are more commonly seen in East Asian countries such as Korea and northern China, and in Native American populations from South and Central America.",190,46,0.24210526315789474
9781912776207,ch3,"Human T-cell lymphotropic virus type 1 is strongly implicated in lymphomagenesis in ATLL, and Epstein-Barr virus in ENKTCL.","EATL is more common in areas with a high incidence of celiac disease - it accounts for 5.8% and 9.1% of PTCLs in North America and Europe, respectively, but only 1.9% in Asia. This reflects its close association with the DQ HLA that results in overt or silent celiac disease. EBV-associated lymphoproliferative T- and NK-cell neoplasms (exempli gratia ENKTCL) are more commonly seen in East Asian countries such as Korea and northern China, and in Native American populations from South and Central America. The distribution of lymphomas associated with human T-cell lymphotropic virus type 1 (HTLV-1) reflects the distribution of the virus, notably Japan and the Caribbean basin (see below).",166,33,0.19879518072289157
9781912776207,ch4,Detailed immunophenotypic analysis is necessary to accurately diagnose PTCL subtypes.,"Accurate diagnosis and subtyping of PTCL is challenging but crucial, because it determines both prognosis and choice of therapy. The neoplastic nature of a given T-cell population is informed by its morphology, aberrant T-cell phenotype and clonality based on T-cell receptor (TCR) genotype (id est alphabeta versus gamma; see page 11). Accumulating evidence indicates that TCR genotype and the cell of origin influence tumor biology and clinical behavior, and are becoming increasingly clinically relevant as targeted therapeutic options emerge. Distinction between the PTCL subtypes requires consideration of the clinical picture, morphology, immunohistochemistry, flow cytometry, cytogenetics and molecular biology.",149,17,0.11409395973154363
9781912776207,ch4,PET scanning can be helpful to diagnose extranodal disease.,"Skin rash may be present, particularly in patients with PTCL-NOS or AITL. Patients with AITL may also present with hypotension, fevers, rash and vasculitis-like symptoms, due to tumor-related cytokine release.",54,13,0.24074074074074073
9781912776207,ch4,Epstein-Barr virus and CD30 are expressed in several subtypes of PTCL.,"The initial immunohistochemistry panel should include: CD20, CD10, CD3, CD30, CD4, CD8, CD7, CD2, CD56, CD21, CD23, BCL6, Ki-67, ALK, TCRB and TCRg. Epstein-Barr virus (EBV) encoding region (EBER) in situ hybridization (ISH) should be considered in cases suspected to be nasal ENKTCL. Molecular analysis should include TCR gene rearrangements, and fluorescence ISH to detect genetic alterations. DUSP22 and TP63 rearrangement studies should be considered in patients with ALK  ALCL, as this may affect prognosis.",149,20,0.1342281879194631
9781912776207,ch4,"Many patients with aggressive T-cell lymphomas present with systemic symptoms, and extranodal involvement is common.","The Ann Arbor staging system used to stage lymphomas (Table 4.4)is analogous to the tumor, nodes, metastases (TNM) system used for solid tumors. The clinical stage depends on where malignant tissue is identified and the presence of systemic B symptoms. PTCL is usually aggressive, and outcomes are generally poor compared with aggressive B-cell lymphomas. For example, the International T-cell Lymphoma study reported overall survival (OS) and failure-free survival of 10% at 10-15 years in patients with PTCL-NOS. Chemokine expression and proliferative signature have been shown to have prognostic significance (Table 4.5).",139,23,0.16546762589928057
9781912776207,ch4,The International Prognostic Index and the PTCL-specific index are useful prognostic tools.,"The International Prognostic Index (IPI) was developed in 1993 to identify factors that predict the prognosis of patients with aggressive NHL, as Ann Arbor stage alone did not adequately predict survival outcomes. The IPI has been shown to predict survival in patients with ALCL, AITL and PTCL-NOS, but not for other PTCL entities, and is the most commonly used prognostic index for T-cell lymphoma.",91,20,0.21978021978021978
9781912776207,ch5,"Insufficient understanding of the pathology of this heterogeneous group of rare diseases, together with a lack of randomized clinical trial data, has hindered progress in the treatment of PTCL, resulting in wide variation in practice.","PTCL is invariably fatal within a few months without treatment. Wherever possible, treatment aims to achieve long-term cure using chemotherapy and, in some situations, hemopoietic stem cell transplantation (see Chapter 7). First-line treatment offers the most realistic chance of achieving cure. Relapsed and refractory PTCL is associated with dire clinical outcomes. Conventional chemotherapy regimens showing activity in aggressive lymphomas (predominantly B-cell lymphomas) in the 1990s evolved to become the de facto standard of care for PTCL. Progress in developing specific treatments for PTCL has been hampered by the rarity of the diseases, the substantial clinical and biological heterogeneity of the subtypes, compounded by insufficient understanding of the molecular pathobiology, and a lack of the definitive clinical trial data from comparative studies that is needed to change practice. There is no standard 'one size fits all' treatment - the therapeutic approach varies across and within individual countries and for defined disease entities.",202,43,0.21287128712871287
9781912776207,ch5,The use of intensive treatment strategies for nodal PTCL does not appear to improve outcomes.,"CHOP chemotherapy (Table 5.1) became the backbone of treatment for aggressive non-Hodgkin lymphoma on the basis of large Phase III trials that confirmed activity and survival benefit compared with historic regimens. However, these trials mostly included patients with aggressive B-cell malignancies, and the superiority of CHOP over alternative chemotherapy regimens in PTCL has never been demonstrated prospectively. In fact, retrospective analysis of cases from the international T-cell Lymphoma Project did not show any survival benefit with anthracycline-based chemotherapy in patients with PTCL. Outcomes with CHOP are unsatisfactory for patients with PTCL: whilst initial complete responses are seen in 40-70% of patients, most develop refractory or relapsed disease, typically within 1-2 years of diagnosis.",169,19,0.11242603550295859
9781912776207,ch5,Extranodal PTCL has a dismal outcome with CHOP-based chemotherapy; alternative therapeutic chemotherapy strategies focused on distinct subtypes are therefore required.,"CHOP chemotherapy (Table 5.1) became the backbone of treatment for aggressive non-Hodgkin lymphoma on the basis of large Phase III trials that confirmed activity and survival benefit compared with historic regimens. However, these trials mostly included patients with aggressive B-cell malignancies, and the superiority of CHOP over alternative chemotherapy regimens in PTCL has never been demonstrated prospectively. In fact, retrospective analysis of cases from the international T-cell Lymphoma Project did not show any survival benefit with anthracycline-based chemotherapy in patients with PTCL. Outcomes with CHOP are unsatisfactory for patients with PTCL: whilst initial complete responses are seen in 40-70% of patients, most develop refractory or relapsed disease, typically within 1-2 years of diagnosis.",169,31,0.1834319526627219
9781912776207,ch5,"Improved survival with brentuximab vedotin in combination with CHP chemotherapy in the ECHELON-2 trial heralded a new treatment standard in ALCL; however, the benefit in other PTCL subtypes is unclear.","Brentuximab vedotin is a CD30-specific monoclonal antibody conjugated with the toxin monomethyl auristatin E (see pages 69-70), which is administered in combination with CHP chemotherapy (known as CHP + A). A large randomized Phase III trial (ECHELON-2) in patients with CD30 + PTCL (>= 10%, as assessed by local centers) recently evaluated the benefit of replacing the vincristine in CHOP with brentuximab vedotin, 1.8 mg/kg intravenously on day 1 of each 15-day cycle. The study met the primary endpoint, with CHP + A conferring a significantly improved PFS at 3 years compared with CHOP (57% vs 44%; p = 0.011) and a 34% decrease in all-cause mortality. In line with other studies of brentuximab vedotin, a correlation was not found between response and level of CD30 expression. Seventy percent of the trial participants had systemic ALCL, which does not reflect typical clinical practice but was a regulatory condition for the trial.",237,50,0.2109704641350211
9781912776207,ch6,Patients with relapsed and refractory PTCL who are not candidates for potentially curative allogeneic stem cell transplantation have poor outcomes with conventional chemotherapy regimens.,"Relapsed and refractory PTCL are associated with dismal outcomes, with median overall survival (OS) of 5.3 months reported in a population-based retrospective series of 163 patients from British Columbia. A recent prospective international registry study (the T Cell Project) reported survival outcomes from 633 patients with relapsed or refractory disease following frontline therapy: median OS was 11 months for those with relapsed disease and 5 months for those with refractory disease. Only 16% of this large cohort proceeded to stem cell transplantation. Given these outcomes, treatment within a clinical trial is recommended for patients with relapsed or refractory PTCL. Several novel agents have recently been approved for the treatment of relapsed and refractory PTCL, and studies are defining how these agents are best used (id est as monotherapy or in combination) to improve survival outcomes.",179,36,0.2011173184357542
9781912776207,ch6,A clinical trial should be regarded as the standard of care for patients with relapsed and refractory PTCL.,"Relapsed and refractory PTCL are associated with dismal outcomes, with median overall survival (OS) of 5.3 months reported in a population-based retrospective series of 163 patients from British Columbia. A recent prospective international registry study (the T Cell Project) reported survival outcomes from 633 patients with relapsed or refractory disease following frontline therapy: median OS was 11 months for those with relapsed disease and 5 months for those with refractory disease. Only 16% of this large cohort proceeded to stem cell transplantation. Given these outcomes, treatment within a clinical trial is recommended for patients with relapsed or refractory PTCL.",133,24,0.18045112781954886
9781912776207,ch6,Histone deacetylase inhibitors are often active in patients with AITL because of epigenetic mutations.,"Relapsed and refractory PTCL are associated with dismal outcomes, with median overall survival (OS) of 5.3 months reported in a population-based retrospective series of 163 patients from British Columbia. A recent prospective international registry study (the T Cell Project) reported survival outcomes from 633 patients with relapsed or refractory disease following frontline therapy: median OS was 11 months for those with relapsed disease and 5 months for those with refractory disease. Only 16% of this large cohort proceeded to stem cell transplantation. Given these outcomes, treatment within a clinical trial is recommended for patients with relapsed or refractory PTCL.",133,22,0.16541353383458646
9781912776207,ch6,"Single-agent therapies and novel agents have demonstrated activity in PTCL. Although the duration of response is typically short, these are options for patients who are not eligible for stem cell transplantation.","Decisions on the treatment of relapsed or refractory PTCL should first consider whether a patient is a candidate for potentially curative allogeneic stem cell transplantation (see Chapter 7). For these patients the National Comprehensive Cancer Network guidelines recommend either multi- or single-agent chemotherapy for salvage. Patients who are not candidates for transplant should receive single-agent therapy to provide palliative benefit with minimal toxicity. Multi-agent chemotherapy regimens for PTCL include conventional lymphoma salvage regimens such as ICE, DHAP and ESHAP (Table 6.1). Gemcitabine-based regimens have also shown activity, including GDP, GVD and GemOx. Single agents. Single agents approved for relapsed or refractory PTCL include pralatrexate, romidepsin and belinostat. Chidamide is a histone deacetylase (HDAC) inhibitor only approved in China and mogamulizumab is approved for human T-cell lymphotropic virus 1 (HTLV-1)-associated ATLL in Japan. Response rates seen with these treatments are presented in Table 6.2 and their administration and adverse effects in Table 6.3.",247,39,0.15789473684210525
9781912776207,ch6,Brentuximab vedotin is highly active in ALCL and has demonstrated activity in CD30-expressing subsets of PTCL. Neurotoxicity is a frequent adverse event and requires careful monitoring.,"Brentuximab vedotin is an immunoconjugate comprising a humanized CD30-specific antibody and the microtubule disrupting agent methylauristatin E (MMAE). It binds to the CD30 receptor and is internalized, where it liberates the MMAE fragment into the cytosol to disrupt the microtubule network and induce apoptosis. CD30 is expressed to a varying degree in PTCL, including in about 50% of PTCL-NOS cases, 20% of AITL, and most cases of EATL and ALCL (ALK  and ALK +). It is also thought that small amounts of MMAE are released by tumor cells and affect the tumor microenvironment, potentially explaining the activity of brentuximab vedotin in malignancies with low levels of CD30 expression. Efficacy and dosage. Brentuximab vedotin is approved in the USA for use in combination with chemotherapy (CHP + A) for previously untreated CD30-expressing subtypes of PTCL, irrespective of the degree of expression of CD30. In Europe, it is approved only for relapsed and refractory systemic ALCL. The standard dose is 1.8 mg/kg every 3 weeks.",263,44,0.16730038022813687
9781912776207,ch7,Autologous stem cell transplant (ASCT) as a consolidation strategy is an option for patients who achieve a complete response with front-line chemotherapy.,"The current standard of care for PTCL is anthracycline-based CHOP, followed by consolidation in first complete remission (CR1) with autologous stem cell transplantation (ASCT) in fit and eligible patients, given that remission tends to be short following induction chemotherapy. According to the National Comprehensive Cancer Network guidelines, ASCT is recommended for all patients except those with ALK + ALCL. Allogeneic stem cell transplantation (alloSCT) may be considered for patients with high-risk subtypes of PTCL (id est ENKTCL, ATLL and HSTCL).",127,30,0.23622047244094488
9781912776207,ch7,Phase II studies have shown that about 40% of patients who undergo ASCT at first remission are disease free at 5 years.,"The rarity and heterogeneity of PTCL have precluded a large randomized study to assess the best consolidation strategy (ASCT or alloSCT) after completing induction therapy, and studies comparing consolidation transplantation versus maintenance therapy have not been conducted. Prospective and retrospective Phase II studies are confounded by the highly selected populations of patients fit enough to tolerate transplantation and those in complete remission prior to transplant - a highly chemosensitive group. Retrospective series have not compared outcomes in patients who undergo transplant versus those who achieved similar responses but did not undergo transplant.",111,25,0.22522522522522523
9781912776207,ch7,"Complications from alloSCT include serious infections resulting from immune suppression, and chronic graft versus host disease.","Following induction chemotherapy to debulk disease burden, hematopoietic stem cells are harvested by apheresis and frozen. The patient then receives high-dose chemotherapy (HDT) to eradicate the residual malignant cell pool, but at the cost of partial or complete bone marrow ablation. The stored stem cells are then retransfused to replace the destroyed tissue and resume normal blood cell production. Autologous transplant allows rapid recovery of immune function, reducing the risk of infection during the immune-compromised period. In addition, the risk of graft versus host disease (GVHD) is low because the patient receives a transplant of their own cells.",134,21,0.15671641791044777
9781912776207,ch7,"In a randomized study, outcomes were similar with upfront ASCT and alloSCT, with more patients in the autologous arm relapsing and more in the allogeneic arm experiencing transplant-related morbidity and mortality.","Fossard and colleagues. In contrast to the studies above, this large multicenter retrospective study throws some doubt on the value or necessity of ASCT. This study compared outcomes with and without ASCT in 269 patients (aged <= 65 years) with PTCL-NOS (n = 78), AITL (n = 123) or ALK + ALCL (n = 68). CR was achieved with induction chemotherapy in 217 (81%) and PR in 52 (19%). Half the patients (n = 134) went on to ASCT (ITT). Comparison of the groups who did and did not receive transplant was based on a multivariate proportional hazard model, with propensity score matching to correct for sample selection bias. Neither method found a survival advantage in favor of ASCT, and no differences were identified between the groups in terms of response status, disease stage or risk category. Critics of this study point out the pitfalls of retrospective studies.",190,46,0.24210526315789474
9781912776207,ch7,Allogeneic stem cell transplantation (alloSCT) provides long-term disease control in patients with relapsed or refractory PTCL and as a front-line consolidation for patients with more aggressive PTCL subtypes.,"In summary, alloSCT offers long-term disease control in 30-55% of patients with relapsed/refractory PTCL but is associated with NRM rates of 12-36%. NRM rates are expected to be improved through high-resolution donor typing and improvements in antimicrobial and GVHD prophylaxis. AlloSCT at first remission. Data on alloSCT in CR1 are limited. Loirat and colleagues evaluated the feasibility of upfront alloSCT in advanced PTCL. In this ITT study, 29 of 49 patients (60%) proceeded to allograft. One- and 2-year OS rates after transplant were 76% and 72.5%, respectively and the TRM at 1 year was 8.2%. For patients who did not proceed to alloSCT, 2-year PFS was less than 30%. Corradini and colleagues have also reported findings from a prospective study of 64 patients who received chemoimmunotherapy followed by ASCT (n = 14) or alloSCT (n = 23) depending on donor availability following a conditioning regimen of fludarabine, cyclophosphamide and thiotepa. At the time of reporting, 16 of 23 patients were in CR, and seven had died (four from disease; three from toxicity).",270,48,0.17777777777777778
9781912776207,ch8,"Next-generation sequencing has identified distinct DNA mutations in AITL and Tfh-related lymphomas, and recurrent mutations in other PTCL subtypes. Whole-genome studies should provide further insight across all PTCL subtypes.","Next-generation sequencing (NGS) is a high-throughput method for detecting aberrations in DNA sequences: it can be used to interrogate a panel of specific genes (targeted), all coding regions of the genome (whole-exome sequencing; WES) or the entire genome (whole-genome sequencing; WGS). NGS research studies have identified distinct mutational signatures in AITL and Tfh-related lymphomas, and recurrent mutations in other PTCL subtypes (see Chapter 2). However, most studies have used targeted NGS or WES, providing only a limited view of the PTCL genome. Increasingly affordable sequencing platforms and improved bioinformatic pipelines will allow more PTCL cases to be interrogated by WGS, which should provide new mechanistic insights into the disease. Integrated multiomic analysis. The biology of PTCL is likely to extend beyond aberrations in the genetic sequence. Transcriptomic, epigenetic, methylation and metabolomic programs are likely to be key cellular drivers of PTCL. The integration of sequencing data with multiomic analysis is likely to be critical in identifying vulnerabilities for drug targeting. Alternative molecular approaches can map genome-wide chromatin accessibility, DNA-bound proteins such as enhancers, and methylated cytosine residues. Such analysis will be particularly relevant for PTCL cases in which current sequencing strategies do not detect a recurrent mutation.",294,50,0.17006802721088435
9781912776207,ch8,The integration of gene sequencing and multiomic analysis should help to identify vulnerabilities beyond aberrations of genetic sequences for drug targeting.,"Integrated multiomic analysis. The biology of PTCL is likely to extend beyond aberrations in the genetic sequence. Transcriptomic, epigenetic, methylation and metabolomic programs are likely to be key cellular drivers of PTCL. The integration of sequencing data with multiomic analysis is likely to be critical in identifying vulnerabilities for drug targeting. Alternative molecular approaches can map genome-wide chromatin accessibility, DNA-bound proteins such as enhancers, and methylated cytosine residues. Such analysis will be particularly relevant for PTCL cases in which current sequencing strategies do not detect a recurrent mutation.",122,25,0.20491803278688525
9781912776207,ch8,"The use of needle biopsies in patients with PTCL yield limits samples for molecular studies. However, circulating tumor DNA from peripheral blood may be an alternative.","Challenges to molecular studies. NGS studies, especially WES or WGS approaches, require adequate quality and quantity of tissue to produce robust data. Patients with PTCL are often unwell at presentation and frequently require urgent therapy, resulting in the use of needle biopsies (rather than surgical excision biopsy), which yield limited samples. Some subtypes of PTCL, particularly AITL, are characterized by a heavy stromal infiltrate with low tumor burden, rendering bulk sequencing relatively insensitive. Moreover, studies in other cancers have demonstrated significant intratumor heterogeneity, suggesting that single-site biopsies may fail to capture the global tumor mutational composition, representing a major barrier to genomic-driven treatment strategies.",147,33,0.22448979591836735
9781912776207,ch8,Patient-derived xenograft PTCL models may facilitate the development of new treatments and increase our understanding of PTCL biology.,"Bulk analysis generates an average profile of the whole cell population, including malignant and non-malignant cells, which does not adequately capture the complexity of a tumor and risks missing treatment-resistant subclones that will ultimately germinate relapse. However, technological developments enabling single cell analysis are allowing researchers to deconvolute bulk tumors and analyze cancers with greater resolution and accuracy (Figure 8.1). Single cell RNA and DNA sequencing can determine cancer evolution, provide insight into tumor heterogeneity and segregate and characterize stromal cells. Given that bulk sequencing of PTCL cases to date has been relatively insensitive, single cell analysis is likely to significantly advance our understanding of PTCL biology. Preclinical models. Advances in the treatment of PTCL have been significantly hampered by the paucity of relevant preclinical models. Only a relatively small number of PTCL cell lines are available, many of which are poorly characterized and are of limited value to preclinical testing. There is also a lack of genetically engineered mouse models that faithfully reflect human PTCL. Recent initiatives generating patient-derived xenograft PTCL models may facilitate discoveries into PTCL biology and the development of novel treatment strategies.",244,28,0.11475409836065574
9781912776207,ch8,"Given the high rates of chemoresistance and poor clinical outcomes for most patients with PTCL, novel precision medicine strategies are needed. A plethora of new drugs is in development, including monoclonal antibodies against T-cell receptors, cytokines and chemokines, small-molecule inhibitors, and agents that reverse epigenetic dysregulation.","A plethora of new drugs are being developed, including monoclonal antibodies against T-cell receptors, cytokines, and chemokines, small molecular inhibitors that target key T-cell pathways, and agents that reverse epigenetic dysregulation. It is unlikely that any single drug will be equally effective across all PTCL subtypes but a stratified approach may increase the likelihood of demonstrating a clear benefit in a subtype of PTCL, as illustrated in Figure 8.1. Disease rarity poses significant challenges, however. International collaboration, for example through the International Rare Cancer Initiative, will be essential to deliver practice-changing clinical trials for specific PTCL subtypes. Chimeric antigen receptor T-cell therapy represents a novel treatment strategy that may prove transformative across PTCL subtypes, as in other hematologic malignancies. Peripheral blood T cells apheresed from patients are engineered to express a modified antigen receptor that recognizes a cancer target (Figure 8.2). They are then reinfused. Upon engagement with the target cell, activation of CAR T cells triggers cytotoxicity of the cancer cell. This process is illustrated in Figure 8.3. CAR T cells have been developed for CD4, CD5, CD7 and CD30. However, some of these pan T-cell markers risk causing profound immunosuppression. An alternative approach is to develop CAR products against the T-cell receptor beta chain (TCRB). Peripheral T cells express two isoforms, TCRB1 and TCRB2, broadly evenly, but PTCL is clonally either TCRB1 or TCRB2. CAR products against these TCRB isoforms would therefore ensure that approximately half of the normal T-cell repertoire is preserved.",363,71,0.19559228650137742
9781912776238,ch1,"Biologics are typically proteins, ranging in size from simple proteins to large complex monoclonal antibodies. They are produced using living cell lines.","Biological medicines (biologics) are drugs derived or extracted from living systems, usually modified bacteria, fungi or animal cells; the three main categories are listed in Table 1.1. Biologics have been able to transform the outcomes of many previously hard-to-treat diseases, becoming an essential component in the treatment of diseases including diabetes, anemia, rheumatoid arthritis and cancer. This is reflected in the inclusion of biologics in the WHO list of essential medicines. These 'essential medicines' are those the WHO believes should be provided free, or at prices all citizens can afford; but this creates a problem. Biologics are inherently more expensive than past-generation medicines; they represent the result of costly investment in research and development and are manufactured using cellular-based technologies and utilizing gene expression. The combination of medical benefit but high costs for biologics creates the need for biosimilars.",186,30,0.16129032258064516
9781912776238,ch1,"The slight differences between batches of biologics, or between biologics and biosimilars, are evaluated and not expected to have any meaningful effect in clinical use.","Biological medicines (biologics) are drugs derived or extracted from living systems, usually modified bacteria, fungi or animal cells; the three main categories are listed in Table 1.1. Biologics have been able to transform the outcomes of many previously hard-to-treat diseases, becoming an essential component in the treatment of diseases including diabetes, anemia, rheumatoid arthritis and cancer. This is reflected in the inclusion of biologics in the WHO list of essential medicines. These 'essential medicines' are those the WHO believes should be provided free, or at prices all citizens can afford; but this creates a problem. Biologics are inherently more expensive than past-generation medicines; they represent the result of costly investment in research and development and are manufactured using cellular-based technologies and utilizing gene expression. The combination of medical benefit but high costs for biologics creates the need for biosimilars.",186,34,0.1827956989247312
9781912776238,ch1,"All biologics have inherent variability, which creates batch-to-batch variability for all products. Furthermore, biologics themselves show inherent variation between batches (microheterogeneity), such that no batch is identical to previous batches.","Microheterogeneity. Molecules made in living systems have inherent variability, even between batches of the same product, and this is known as microheterogeneity. The primary amino acid structure of the drug remains identical, but changes such as glycosylation occur to the protein after translation from RNA to protein sequence in the host cell. Modifications could occur at each potential site on a protein drug, and these can be altered by culture growth conditions such as temperature, nutrients and speed of stirring. The final product is often, then, a mixture of different structures (isoforms) of the drug; for example, epoetin alfa is a mixture of at least nine different isoforms of epoetin, with each isoform having potentially a different potency and half-life in the circulation. Thus, over time, a reference drug can never be considered to be a generic copy of its version at launch, as illustrated in Figure 1.2. This inherent variation is known as product drift (see Figure 1.3).",207,46,0.2222222222222222
9781912776238,ch1,"Biosimilars are highly similar, but not identical, to their reference (originator) biologic.","The manufacturing process can affect important aspects of the structure of a biological drug; a copied biologic can never therefore be entirely identical to the original reference product. Thus, the active substance of a biosimilar and its reference medicine is almost the same biological substance, but there may be minor differences as a result of their complex nature and production methods. Like the reference (originator) biologic, the biosimilar has a degree of natural variability. For a biosimilar to be approved, this variability, and any differences between the biosimilar and the reference biologic, have to have been shown not to affect safety or effectiveness.",124,22,0.1774193548387097
9781912776238,ch1,"Changes to manufacturing processes can introduce significant changes to the structure of a biologic; analytics tests (and, exceptionally, new clinical trials) are required to assure that safety and efficacy have not changed for these therapies.","The manufacturing process can affect important aspects of the structure of a biological drug; a copied biologic can never therefore be entirely identical to the original reference product. Thus, the active substance of a biosimilar and its reference medicine is almost the same biological substance, but there may be minor differences as a result of their complex nature and production methods. Like the reference (originator) biologic, the biosimilar has a degree of natural variability. For a biosimilar to be approved, this variability, and any differences between the biosimilar and the reference biologic, have to have been shown not to affect safety or effectiveness. In addition, manufacturing processes change frequently over the life of a biologic, adding to the potential for variability. A 2016 study of all European-approved originator monoclonal antibodies identified a mean of 11 changes with moderate or high potential risk of altering critical quality attributes (CQAs) per drug. Process change can result from advances in technology, such as higher yielding host cell systems, improvements in bioreactor design, scaling up of production to meet demand or if production is moved to a new manufacturing site. Changes in manufacturing risks the introduction of more significant variation in the tertiary structure of a biologic, known as 'step changes' (see Figure 1.3).",261,42,0.16091954022988506
9781912776238,ch2,Biologics have provided major advances in treatment of many chronic diseases but are a burden on health budgets that is predicted to increase with changing demographics. Biosimilars provide a lower-cost option to replace original-brand products.,"While discussion of costs may make some clinicians uncomfortable, attention to the health budget is a reality of modern medicine. Given aging populations and the rising prevalence of chronic conditions and cancers for which biologics are used, biologics represent a major demand on healthcare budgets that are already under pressure, and rationing measures are inevitably applied. However, just as the introduction of generic versions following patent expiry of small molecule drugs drove down prices, biosimilars can be expected to lower the prices of biologics. The substantial savings realized can improve patient access by allowing more patients to be treated from the same budget. Thus, biosimilars will enable stakeholders - including payers, clinicians and patients - to benefit from greater choice of treatment options, and more patients will have access to these treatments (Figure 2.1). The potential to reduce medicine costs today is significant; of the 12 bestselling global medicines of 2018, nine were biologics and six of those with total sales of US$54 billion face biosimilar competition now or in the near future (Table 2.2). If biosimilars of those six could be sold at 50% discount, savings would deliver US$28 billion a year to reinvest into global healthcare. Additional savings can be predicted - over the next 7 years a further 35 biologics face loss of patent and potential biosimilar competition.",272,46,0.16911764705882354
9781912776238,ch2,"In the era of biosimilars, payers, clinicians and patients can benefit from a greater choice of biologics and, through price reductions, access to these treatments can increase.","While discussion of costs may make some clinicians uncomfortable, attention to the health budget is a reality of modern medicine. Given aging populations and the rising prevalence of chronic conditions and cancers for which biologics are used, biologics represent a major demand on healthcare budgets that are already under pressure, and rationing measures are inevitably applied. However, just as the introduction of generic versions following patent expiry of small molecule drugs drove down prices, biosimilars can be expected to lower the prices of biologics. The substantial savings realized can improve patient access by allowing more patients to be treated from the same budget. Thus, biosimilars will enable stakeholders - including payers, clinicians and patients - to benefit from greater choice of treatment options, and more patients will have access to these treatments (Figure 2.1).",163,37,0.22699386503067484
9781912776238,ch2,"Prescribing a biosimilar is in keeping with the concept of rational prescribing, which includes a cost imperative.","Economics also sets the agenda for the evidence needed to use biosimilars in practice; while biosimilars must be clinically similar, they have no utility to health systems unless they can be economically different. The key driver of price reductions is competition between brands, with more brands marketed creating greater competition and thus discounts. To maximize price-volume discounts, pharmacy formulary managers will want to stock, ideally, only one preferred brand of each biologic; this mandates the use of biosimilars in extrapolated indications. Also, to maximize discounts over time, repeat tender process cycles will be needed - mandating that biologics and biosimilars can be switched between different brands as part of the typical 1-2-year competitive drug tender purchase cycle without excess risk to patients. Note that prescribing of biosimilars is entirely in keeping with the concept of rational prescribing, as defined by WHO: Medicine use is rational (appropriate, proper, correct) when patients receive the appropriate medicines, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost both to them and the community.",226,22,0.09734513274336283
9781912776238,ch4,'Evergreening' is a process by which manufacturers of originator products introduce minor changes to protect their drug development data from being made available to other companies.,"The manufacturers of original reference drugs are frequently accused of 'evergreening' to delay competition - maintaining data exclusivity through the introduction of minor changes to a product, such as a change to the dosing schedule from twice to once a day, which can potentially extend monopolies for years. This has particularly affected biosimilar development in the USA, where originators have tried to protect monopoly status well beyond the patent expiry of the drug itself through the creation of a 'patent thicket' of often dozens of secondary legal blocks to competitors. The first appearance of such tactics in biosimilar development was in 2015, when an originator biologic manufacturer described publicly its strategy: it listed 22 patents for various diseases or methods of treatment, 14 on the drug's formulation, 24 on its manufacturing practices and 15 other patents. The impact was to prolong US monopoly patent protection up to 2034 - while biosimilar versions of the same drug were approved and marketed in Europe by 2018.",195,32,0.1641025641025641
9781912776238,ch4,US state laws govern drug substitutions by the pharmacist.,"Within the USA, there can be state laws that govern how a medicine can be used. For biosimilars, this is principally ruling on the substitution of brands by pharmacists. Similar rulings were placed in the era when generic medicines were being introduced, and one of the key historic roles of pharmaceutical benefit schemes in the USA was to overturn many local state restrictions to create today's competitive American medicines market.",80,12,0.15
9781912776238,ch4,"In Europe, national patent laws may mean that one biosimilar, approved by the European Medicines Agency, is available with different names in different European countries - these are bioidenticals.","Europe has a specific legal problem, with one central regulator shared between 31 nations. Biosimilars are approved by the supranational European Medicines Agency, while patent laws can be national. As dates of patent filing may differ across the 31 nations, dates of expiry will differ as well. This explains the European need for 'bioidentical' drug brands for different nations - identical medicines sold under different brand names with different approved indications (some examples are listed in Table 4.1). Perhaps the best example of this is rituximab CTP10 (Celltrion), which is approved and marketed as Truxima, Ritemvia, Rituzena (previously Tuxella) and Blitzima. No such need for bioidentical medicines is required in the USA as one patent office and one regulator covers the same territory.",175,37,0.21142857142857144
9781912776238,ch5,"'Interchangeable' has different meanings in the USA and Europe. In the USA, interchangeability is the automatic substitution of prescriptions at a pharmacy level, whereas in Europe it refers to a physician-led decision, often at the level of the medicines formulary committee.","The ability to switch patients between different brands of the same biologic is critical for developing a competitive drug market to check costs. In Europe, regulators and clinical studies have supported the practicality of brand switching between originators and biosimilars as part of the annual drug tender process - which is the European definition of 'interchangeable'. To a European, 'interchangeable' means a physician-led process, often in the context of medicines formulary committee decisions. There is a second potential for brand switching, through 'automatic substitution' of prescriptions at a pharmacy level. This can occur when specialist biologics are dispensed through retail pharmacies - an unusual situation for most of Europe but more prevalent in the USA. Confusingly, in the USA, automatic substitution of prescriptions at a pharmacy level is called 'interchangeability'. In Australia, it is known as 'flagging'. The USA and Australia have specific regulatory requirements for biosimilars that can be substituted. Automatic substitution of drugs by pharmacists is considered to create price competition between manufacturers that will reduce costs and promote patient uptake, analogous to the effect of generic substitution with small molecule drugs (Figure 5.1).",237,55,0.2320675105485232
9781912776238,ch5,European regulators support the safety of biosimilar switching as part of an annual tender process.,"The ability to switch patients between different brands of the same biologic is critical for developing a competitive drug market to check costs. In Europe, regulators and clinical studies have supported the practicality of brand switching between originators and biosimilars as part of the annual drug tender process - which is the European definition of 'interchangeable'. To a European, 'interchangeable' means a physician-led process, often in the context of medicines formulary committee decisions.",95,17,0.17894736842105263
9781912776238,ch5,"In Europe, individual countries may have patent laws that prevent the extrapolation of indications for biosimilars, even if the indication has been approved by the European Medicines Agency. Similar regulations allowing for limited indications because of patent protection are also occurring in the US market.","The ability to switch patients between different brands of the same biologic is critical for developing a competitive drug market to check costs. In Europe, regulators and clinical studies have supported the practicality of brand switching between originators and biosimilars as part of the annual drug tender process - which is the European definition of 'interchangeable'. To a European, 'interchangeable' means a physician-led process, often in the context of medicines formulary committee decisions. There is a second potential for brand switching, through 'automatic substitution' of prescriptions at a pharmacy level. This can occur when specialist biologics are dispensed through retail pharmacies - an unusual situation for most of Europe but more prevalent in the USA. Confusingly, in the USA, automatic substitution of prescriptions at a pharmacy level is called 'interchangeability'. In Australia, it is known as 'flagging'. The USA and Australia have specific regulatory requirements for biosimilars that can be substituted. Automatic substitution of drugs by pharmacists is considered to create price competition between manufacturers that will reduce costs and promote patient uptake, analogous to the effect of generic substitution with small molecule drugs (Figure 5.1).",237,53,0.22362869198312235
9781912776238,ch5,Switching between biological drugs is a key mechanism for driving down costs.,"In its guidance for industry on biosimilar interchangeability, the FDA states that a switching study or studies will generally be expected to demonstrate that, 'for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch'. Currently, postmarketing data collected for a biosimilar, without corresponding data derived from an appropriately designed, prospective, controlled switching study or studies, would probably not be sufficient to support a demonstration of interchangeability.",126,14,0.1111111111111111
9781912776238,ch6,The risk of new or severe adverse events is likely to be lower with a biosimilar than with a novel biological agent.,"Safety data for a biosimilar are likely to be limited at the time of launch. However, experience to date indicates that the adverse event profiles of biosimilars match those of their originators. Indeed, safety monitoring within the European Union (EU) since the introduction of biosimilars has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines. The comparability studies performed on biosimilars mean that the risk of new or severe adverse events (type 2) is likely to be lower than with a novel biological agent.",117,24,0.20512820512820512
9781912776238,ch6,Adoption of the naming conventions and accurate reporting is key to effective surveillance and the identification of any rare adverse events that emerge post launch.,"Clinical studies on a biosimilar prior to authorization are generally limited and, as for any new drug, postmarketing surveillance is required to enable identification of any rare adverse effects. Biosimilars are subject to the same degree of post-approval pharmacovigilance as the originator biologic. Crucial to this is product naming, as biosimilars and originators share the same international non-propriety drug name (INN). In 2010, Europe updated its pharmacovigilance guidance requiring member states to encourage the use of brand names in prescribing, health records and adverse event reporting. This appears to have been successful. For example, product-specific attribution of epoetins is near 99%, and overall is 96%. However, such success has not been universal: for example, of 19 adverse event reports in the Australian Database of Adverse Event Notifications (DAEN) for filgrastim from 2011 to 2014, the full brand name was reported in only 11 (58%). This is an issue that affects originator medicines as well - in the USA, for example, brand name reporting for different insulins was only 84% in the MedWatch system.",241,27,0.11203319502074689
9781912776238,ch6,"Slight changes in a product can result in immunogenicity profile changes, but this applies to all biological medicines and not just biosimilars.","Clinical studies on a biosimilar prior to authorization are generally limited and, as for any new drug, postmarketing surveillance is required to enable identification of any rare adverse effects. Biosimilars are subject to the same degree of post-approval pharmacovigilance as the originator biologic. Crucial to this is product naming, as biosimilars and originators share the same international non-propriety drug name (INN). In 2010, Europe updated its pharmacovigilance guidance requiring member states to encourage the use of brand names in prescribing, health records and adverse event reporting. This appears to have been successful. For example, product-specific attribution of epoetins is near 99%, and overall is 96%. However, such success has not been universal: for example, of 19 adverse event reports in the Australian Database of Adverse Event Notifications (DAEN) for filgrastim from 2011 to 2014, the full brand name was reported in only 11 (58%). This is an issue that affects originator medicines as well - in the USA, for example, brand name reporting for different insulins was only 84% in the MedWatch system.",241,29,0.12033195020746888
9781912776238,ch6,"2D DataMatrix barcodes, with batch numbers and expiry dates, can be used to track biologics at all points in the supply chain.","In February 2019, a further step in the traceability of biologics was signaled in Europe with the final implementation of the Falsified Medicines Directive. Prior to full implementation, the European barcode standards could not automatically generate dynamic product information, such as batch numbers and expiry dates. This has been overcome by the introduction of 2D DataMatrix barcodes, which encode batch numbers and expiry dates. They are provided on both primary and secondary packaging, and inexpensive computer-readable laser scanners, as used for high street shops' stock control, can now track biologics through all points in the supply chain in different healthcare settings.",129,31,0.24031007751937986
9781912776238,ch7,'Intended-copy' biologics manufactured in countries with less stringent regulation than the EU and USA may not be true biosimilars and clinical equivalence cannot be assumed.,"'Intended-copy' biologics have arisen as a means of delivering affordable medicines in markets with less stringent regulatory pathways. Such medicines, while clinically active, may not be close enough to the originator molecule to be judged biosimilar in analytic or clinical testing. Without either a biosimilarity exercise or the security of a large-scale Phase III trial in each indication (for extrapolation cannot be approved in the absence of biosimilarity or a pivotal clinical trial), the safety and efficacy of such medicines cannot be predicted. For an idea of scale, 23 intended-copy biologics had been registered as generics in Mexico by 2011; in Russia, 20 epoetins, 53 interferons, 42 monoclonal antibody drugs, 61 insulins, 11 somatropins, 24 filgrastims and 55 heparin versions had been approved to 2015. While intended-copy biologics are unlikely to be encountered in clinical practice in the EU and USA, it should be borne in mind that such products have been misleadingly identified as biosimilars. Examples of clinical problems that have arisen following use of such products are described in the following sections. In the press, these products have been referred to as biosimilars; incidents such as these may fuel concerns with true biosimilars where such concerns are unfounded.",272,36,0.1323529411764706
9781912776238,ch7,Inaccurate use of terminology has clouded the distinction between biosimilars and intended-copy biologics.,"This is not to say that intended-copy drugs are bad medicines, just that they are not biosimilars, as understood by the WHO and many regulators. Indeed, the EMA has written that such drugs are not justified scientifically. The point is that intended-copy biologics, when approved, are inherently less predictable for real-world outcomes. While European experience of more than 50 biosimilars approved over more than a decade confirms the utility of the European regulator pathway, there is no such confirmation of the safety and efficacy of intended-copy biologics in regions such as Asia or South America. The following examples illustrate the problems that can arise with intended-copy biologics that have not been through the regulatory scrutiny of biosimilars. Such examples may also have tarnished the reputation of biosimilars and contributed to clinicians' concerns about equivalence, possibly exacerbated by the incorrect use of terminology in both the press and scientific journals.",190,23,0.12105263157894737
9781912776238,ch8,"A biosimilar may have effects that impact nursing time, patient comfort and ease of use, and these should be evaluated at the outset.","In the USA and Europe, decisions to include a drug in the formulary are usually made by a formulary committee, otherwise known as a pharmacy and therapeutics (PandT) or drug and therapeutics (DandT) committee. In these committees there are generally three groups to satisfy when choosing which drugs, brands and formulations to stock: pharmacists, physicians and payers. The final committee decision needs to ensure safety and effectiveness and economic feasibility of each choice. These committees also consider the impact of products on workflow and patient throughput, and the indications for the biosimilar within the organization. These next chapters explore many of the issues that drive these decisions: this one looks at primarily pharmaceutical issues and the following ones look at some of the clinical discussions that might arise when considering biosimilars for formulary inclusion.",166,27,0.16265060240963855
9781912776238,ch8,A number of product characteristics and manufacturer processes need to be considered when adopting a biosimilar.,"In the English National Health Service (NHS [England]), where 50% brand switching of biosimilar rituximab has been achieved in less than 6 months, there is now an established formula for managing this step for hematology and oncology through the NHS Cancer Vanguard. The Cancer Vanguard advocates forming a multidisciplinary steering group (Table 8.1) working in the therapy area to drive biosimilar switching and adoption within a health trust. Patients should be involved, and the Vanguard suggests convening a meeting or forum to introduce plans, listen to concerns and answer questions. Crucially, the Cancer Vanguard policy recognizes that brand switching entails extra immediate costs and it provides reimbursement for this if switching targets are met; this is typically a short-term target for 90% of new patients to be started on the best-value biological product within 3 months of its release and 80% of existing patients to be switched to a biosimilar within 12 months.",192,18,0.09375
9781912776238,ch8,Economic estimations should address the potential direct and indirect costs of the biosimilar versus the reference drug.,"The cost of the biosimilar versus the reference product should be considered in the context of financial arrangements that favor one product or the other. Is reimbursement support available? Are there government or commercial policies that favor biosimilars over the reference products? Differences in costs between biosimilars and their reference products should be carefully evaluated in the context of manufacturer assistance programs. If the biosimilar manufacturer does not provide an assistance program similar to that of the reference product, this may weaken the case for including the biosimilar.",101,20,0.19801980198019803
9781912776238,ch9,No biosimilar has been approved for which comparable immunogenicity in regulatory studies has not predicted real-world outcomes in more than 10 years of European experience.,"Immunogenicity. The immunogenicity of biosimilar epoetin was assessed for comparability in analytics and clinical confirmatory studies. This was supported by four large postmarketing studies with more than 4700 patients and pharmacovigilance with a total estimated population exposure (in the oncology and nephrology indication between 18 December 2007 and 30 November 2013) of 54 554 947 patient-days with over 35 000 000 patient-days' experience in the oncology indication. Furthermore, in over 10 years of European experience with biosimilars there has been no approval for which comparable immunogenicity in regulatory studies has not predicted real-world outcomes.",137,31,0.22627737226277372
9781912776238,ch9,"For epoetin, comparable composite outcomes were found in more than 13 000 patients treated with reference or biosimilar epoetins and erythropoiesis-stimulating agents, which reassured the regulator about the safety of biosimilar epoetin for symptomatic chemotherapy-induced anemia.","Immunogenicity. The immunogenicity of biosimilar epoetin was assessed for comparability in analytics and clinical confirmatory studies. This was supported by four large postmarketing studies with more than 4700 patients and pharmacovigilance with a total estimated population exposure (in the oncology and nephrology indication between 18 December 2007 and 30 November 2013) of 54 554 947 patient-days with over 35 000 000 patient-days' experience in the oncology indication. Furthermore, in over 10 years of European experience with biosimilars there has been no approval for which comparable immunogenicity in regulatory studies has not predicted real-world outcomes. For cancer chemotherapy. An updated meta-analysis of more than 60 randomized trials assessed for the REMS program showed that the association of poorer outcomes with epoetin was confined to off-label trials looking to extend approved indications rather than the core indication of treatment of symptomatic chemotherapy-induced anemia and avoidance of transfusion. The existence of a different safety profile between reference and biosimilar ESAs further to a potential unknown mechanism of toxicity was excluded through a population-based cohort study of more than 13 000 patients (8161 with chronic kidney disease [CKD] and 5309 in oncology); no differences in risk estimates for all-cause mortality, blood transfusion, major cardiovascular events (MACE) or blood dyscrasia (including PRCA) were found between patients on biosimilars or all originator epoetins or ESAs (Figure 9.1).",317,62,0.19558359621451105
9781912776238,ch9,"The design of the four-arm Pioneer study allowed data collection for participants who switched from originator to biosimilar filgrastim or vice versa on each round of chemotherapy, in anticipation of regulatory requirements to demonstrate interchangeability.","The Phase III Pioneer trial (EP06-302 in the ODAC documents) had a novel four-arm design (Table 9.4). Patient selection was typical for filgrastim use, supporting optimal dose density of chemotherapy in women with histologically proven breast cancer who were eligible for neoadjuvant or adjuvant treatment and who were given six cycles of TAC chemotherapy (docetaxel [Taxotere] at 75 mg/m, adriamycin at 50 mg/m and cyclophosphamide at 500 mg/m, all intravenously on day 1 of each 21-day cycle). Unlike a typical two-arm confirmatory clinical study, patients were randomized into four arms. Blood counts and toxicity could be compared between 192 patients split evenly into two groups on cycle 1. The first cycle of chemotherapy is typically the most sensitive to neutropenic fever, so this represents the best pharmacodynamic endpoint for discovering any clinical difference between the two versions of filgrastim. Over the full six cycles of the trial, there is a second potential comparison of efficacy and toxicity for both brands. This increases the total events studied, giving additional efficacy and safety data. The third comparison is between the 96 patients in arms 1 and 4 who remain on the same brand of filgrastim through chemotherapy and the 96 patients in arms 2 and 3, who switch brands on each alternate chemotherapy cycle; this explores whether brand switching leads to loss of efficacy or increased toxicity (especially immunogenicity), and anticipated the US regulator's requirement for clinical data to support a further label as an 'interchangeable biosimilar'.",327,45,0.13761467889908258
9781912776238,ch10,"Extension of patent protection, as occurs when a new indication is gained, can impede biosimilar developers from gaining an 'interchangeable' designation.","In autoimmune conditions. Given the key role of B cells in making antibodies, it is not surprising that rituximab also has a role in multiple autoimmune conditions. As volume-based tender pricing is of benefit, hematologists and oncologists may need to have joint drug formulary meetings with their colleagues in inflammatory disease to select brands for tenders that cover the maximal spread of indications. While biosimilar rituximab in Europe is approved for all indications, this is not the case in the USA where Celltrion sought approval for only the NHL indications and not the related one of chronic lymphocytic leukemia. This is further complicated in the USA as the reference rituximab, Rituxan (Genentech), was granted a new labeled indication for pemphigus vulgaris in 2018; this extends patent protection for this minor indication and could frustrate companies seeking a US 'interchangeable' designation.",193,30,0.15544041450777202
9781912776238,ch10,"Lack of a uniform approach to the design of clinical confirmatory trials, including differences in statistical design, disease and disease stage and participant characteristics, make it very difficult for clinicians to compare biosimilars.","The USA Biologics Price Competition and Innovation (BPCI) Act states that an application for a biosimilar product must include information from 'a clinical study or studies (including an assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity and potency in one or more conditions of use for which the reference product is licensed and for which licensure is sought for the biosimilar product'. This does not strictly imply that the clinical study has to be equivalent, in the same way that European regulators used the demonstrations of safety, purity and potency for trastuzumab reference product to explain the residual uncertainty left after the completion of the Phase III trial. Neoadjuvant or metastatic trial settings for trastuzumab biosimilars. There is a further issue over the choice of which settings to use for clinical confirmatory trials; for breast cancer, regulators accepted trials in both neoadjuvant treatment using pathology testing as an endpoint and metastatic disease using response rates on chemotherapy. Fundamentally, clinical trials are needed to resolve residual uncertainty over the earlier comparability assessments between a biosimilar and its reference. This ideally requires a pharmacodynamic endpoint that is sensitive to the drug function and reliable to measure.",253,41,0.16205533596837945
9781912776238,ch10,"Formulary decisions for long-duration drug tenders need to be forward thinking; if shorter-schedule treatments are adopted, might this impact on the relative merits of the biosimilar formulations approved?","Further doubt over the utility of trastuzumab and hyaluronidase-oysk comes from the Persephone trial, published in June 2019, which showed 6 months of adjuvant trastuzumab treatment to be non-inferior to the labeled 12-month schedule for HER2-positive early breast cancer. OS at 4 years was non-inferior at 94.8% (95% CI 93.7, 95.8) versus 93.8% (92.6, 94.9) with no statistical evidence of superiority of the 12-month arm for any outcome for all stratification factors. As clinical value is determined by the balance of efficacy and toxicity, this new schedule can be seen as more valuable, offering significantly less cardiotoxicity and fewer severe adverse events with no loss of efficacy. Formulary decisions for long-duration drug tenders need to think ahead; if shorter-schedule trastuzumab is to become adopted as a standard of care, the duration of trastuzumab monotherapy for adjuvant treatment will shorten significantly, making SC trastuzumab of lesser utility.",237,40,0.16877637130801687
9781912776238,ch10,"Biologics used in oncology settings have, as their trial endpoints, survival rates at 5 years. Confirmatory clinical trials for biosimilars tend to use disease response as an endpoint. This can be potentially problematic when the association between response and survival is weak, as with, for example, bevacizumab in bowel and gynecologic cancers.","This equivalence is reassuring for oncologists, though there are concerns regarding the unlicensed use of bevacizumab-ABP215 in ophthalmology. Bevacizumab is very similar to ranibizumab, another inhibitor of VEGF, which is licensed for the treatment of wet ARMD. As the cost per injection of bevacizumab for ARMD is about 12 times lower than that for ranibizumab, there is significant unlicensed use of bevacizumab in this indication. This off-label use is not without evidence: it is supported by clinical outcome data from the 2-year Comparison of wet-AMD Treatments Trials (CATT) in the USA (results published in 2012), the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) trial in the UK (2013) and a Cochrane review, which concluded that bevacizumab and ranibizumab were equally effective. Institutions such as the US Veterans Affairs and the UK National Health Service have endorsed this use based on these findings. It can be argued that the eye is an immune-privileged site, such that anti-drug antibodies are unlikely to be a problem; however, ocular immune privilege is not absolute and its mechanisms are still not completely understood. Such issues cannot be assessed by the drug regulators as use in wet ARMD is unlicensed. Problems such as this have previously been resolved by large-scale clinical studies, and these will probably be required in this context before bevacizumab-ABP215 can be used in this unlicensed setting.",344,76,0.22093023255813954
9781912776238,ch11,Health professionals and patients need support to understand the issues around biosimilars and to feel confident using them.,"Selection of biosimilars by formulary committees is just the first step to a successful biosimilar program; the economic benefits from biosimilars are only seen if they are used. This requires the assistance of all healthcare professionals and, most importantly, patients and their advocates. Experience in the European Union built up over the last 13 years indicates that even with one regulator and the support of the European Council, biosimilar uptake can vary dramatically between different countries and health systems.",95,21,0.22105263157894736
9781912776238,ch11,Go to the FastTest for this title FREE at karger.com/fastfacts,"Initial biosimilar programs were hampered because each hospital and clinic often had to work alone. This model was disrupted by the success of the Norwegian Health Service policy for introducing biosimilars of infliximab. Infliximab represented the greatest regulatory challenge for biosimilars for several reasons. It was the first monoclonal antibody. It was prescribed for at least six major indications requiring extrapolation for biosimilar approval. One key indication was rheumatoid disease, which is characterized by high rates of antibody formation against therapeutic antibodies; this is the most frequently identified reason for loss of efficacy in rheumatoid disease. Last, typical treatment schedules may cover many years, such that annual competitive drug tenders could drive regular brand switching for individual patients.",152,17,0.1118421052631579
9781912776238,ch11,"For best retention of the key issues, try taking the FastTest before and after reading","In England, the National Health Service (NHS) has achieved 50% switching rates for cancer therapeutic biosimilars in less than 6 months: this was achieved by investing in a program called the NHS Cancer Vanguard, in which health professionals provided physician and patient support throughout. Training and development of 'drug optimization pharmacists', who were hospital pharmacists, were key. Funding of health professional salaries for the program came as a gainshare agreement, through which the potential gains from biosimilar cost-savings were shared between payers and providers. As with the Norwegian model, each hospital's switching program was supported with clinical monitoring before and after switching, together with patient satisfaction surveys, while supportive education was provided from a central source. ,3.",148,17,0.11486486486486487
9781912776238,ch11,Many different support materials are available to help health professionals talk to colleagues and patients about biosimilars.,"Support materials. The European Council, in collaboration with the European Medicines Agency (EMA) has worked to improve understanding of biosimilars in the EU through shared patient and health professional education. A biosimilar guide for health professionals was released in English in 2017 and was translated to Dutch, French, German, Italian, Polish, Portuguese and Spanish in 2018, providing health professionals with comprehensive and easily understandable information summaries on both the science and the regulation underpinning the use of biosimilars.",98,20,0.20408163265306123
9781912776238,ch11,Approximate time 10 minutes,"For patients, the collaboration produced a document Questions and Answers on Biosimilars for Patients - this time in 23 languages - supported by a video version available in eight major European languages. The EMA also now publishes a public-friendly summary of each European Public Assessment Report (EPAR), which explains why each biosimilar medicine brand has been approved for use in Europe. All are available to use or adapt from one central website at the EMA (www.ema.europa.eu/en/medicines).",105,6,0.05714285714285714
9781912776238,ch11,Around half of European countries have incentives for physicians to prescribe biosimilars.,"Europe. The Belgian Health Care Knowledge Centre (KCE) explored drivers of biosimilar uptake and reported that approximately half of European countries have incentives for physicians to prescribe biosimilars. Prescribing targets and quotas have been used in the more centralized health systems of the UK, France, Belgium and Germany. In the more diverse insurance-based market of the Netherlands, limited reimbursement of reference medicines has been enforced by insurance companies. Austria and Norway rank choices about biologics with a clear best-value recommendation to follow unless the prescriber can provide a valid clinical reason not to use the cheapest product.",120,15,0.125
9781912776238,ch11,"The regulatory requirements for biosimilars mean that it may not be possible to compare a biosimilar with the originator or with other biosimilars. In this scenario, formulary decisions are driven by price and convenience.","Phase III clinical trials for biosimilars are designed to exclude any significant clinical difference. They are tailored for each drug and use sensitive patient populations and trial endpoints that may be different from the originator's pivotal study. As a result, it may be impossible to directly compare a biosimilar with the originator or, indeed, other biosimilars. Formulary decisions about the choice of biosimilar would then be driven by price and convenience, as is the case for generic drugs. This offers little opportunity to claim technical superiority of one biosimilar over another, as all versions of a drug will have been determined comparable. Only in the USA is there potential for brand differentiation between biosimilars and interchangeable biosimilars (see page 45), although this is not expected until after 2020, long after many of these drugs will have been launched. Different clinical trial designs may therefore offer the only opportunity for drug manufacturers to make claims of superiority of one trial approach over another that are of no interest to the regulator. The regulator requires only that equivalence has been shown in a suitably sensitive pharmacodynamic endpoint with the full approval based on the totality of the evidence. This can create problems in understanding biosimilarity, suggests Professor Pekka Kurki of the Finnish Medicines Agency, explaining that while regulators decide what constitutes a biosimilar based on analytic and non-clinical testing, as well as clinical trial data (the totality of evidence), clinicians consider only clinical testing - leaving them open to misunderstandings and misinformation that only better biosimilars education can overcome.",311,45,0.14469453376205788
9781912776276,chp2,"Although dopamine stimulation may cause Parkinson's disease psychosis (PDP), anticholinergics and amantadine cause identical symptoms.","The mechanisms underlying Parkinson's disease psychosis (PDP) are unknown. Psychotic symptoms are the result of particular interactions between medications and PD pathology. Medications used to treat the motor symptoms of PD, with the exception of the anticholinergic drugs, rarely cause psychosis when used in patients without PD. Furthermore, untreated PD patients only rarely develop psychotic symptoms. To date, almost all physiological studies of PDP have evaluated patients with visual hallucinations only, not other hallucinations or delusions, and it has yet to be elucidated whether particular brain structures or neurotransmitter alterations are involved. The complexity of the analysis lies in the variable pathology of PD and the variable treatment, plus the clinical and pathological overlap with dementia with Lewy bodies (DLB).",148,27,0.18243243243243243
9781912776276,chp2,Cholinergic mechanisms may be more important in both hallucinations and delusions arising in people with dementia with Lewy bodies.,"The mechanisms underlying Parkinson's disease psychosis (PDP) are unknown. Psychotic symptoms are the result of particular interactions between medications and PD pathology. Medications used to treat the motor symptoms of PD, with the exception of the anticholinergic drugs, rarely cause psychosis when used in patients without PD. Furthermore, untreated PD patients only rarely develop psychotic symptoms. To date, almost all physiological studies of PDP have evaluated patients with visual hallucinations only, not other hallucinations or delusions, and it has yet to be elucidated whether particular brain structures or neurotransmitter alterations are involved. The complexity of the analysis lies in the variable pathology of PD and the variable treatment, plus the clinical and pathological overlap with dementia with Lewy bodies (DLB).",148,23,0.1554054054054054
9781912776276,chp2,Psychotic symptoms are not simply related to drug levels in the brain; they also reflect the state of alertness.,"The association between psychotic symptoms and dopamine stimulation, either via dopamine itself or dopamine agonists, is clear, but there is no general dose-response relationship. Hallucinations are not generally associated with ON responses to medications, when brain levels of dopamine are likely to be at their peak, or with the occurrence of dyskinesias, which are usually an indication of high serum levels of dopamine. Indeed, many patients report that the hallucinations only occur at night, on awakening or during the evening, when dopamine levels are likely to be lower, and less commonly during the day. Some patients do, however, report an association with high dopamine levels.",129,23,0.17829457364341086
9781912776276,chp2,Psychosis is generally due to an interaction between PD medications and PD pathology.,"One pathophysiological hypothesis, akin to the dopamine theory of schizophrenia and as a theory to explain dyskinesia, is a supersensitive response to dopamine stimulation in the mesolimbic and mesocortical regions of the brain due to long-term dopamine deficiency. Problems with this theory include the, admittedly rare, reports of PDP in untreated patients and hallucinations in untreated patients with DLB, which many believe is simply a variant of PD and is often confused with it. In one study, 42% of patients with newly diagnosed PD who had never received any PD medications reported having had very minor and very transient psychotic symptoms months before the diagnosis; only 5% of an untreated age-matched control group without PD reported these.",147,15,0.10204081632653061
9781912776276,chp2,The importance of 5HT2A serotonin receptor stimulation is supported by the usefulness of pimavanserin as an antipsychotic drug.,"One pathophysiological hypothesis, akin to the dopamine theory of schizophrenia and as a theory to explain dyskinesia, is a supersensitive response to dopamine stimulation in the mesolimbic and mesocortical regions of the brain due to long-term dopamine deficiency. Problems with this theory include the, admittedly rare, reports of PDP in untreated patients and hallucinations in untreated patients with DLB, which many believe is simply a variant of PD and is often confused with it. In one study, 42% of patients with newly diagnosed PD who had never received any PD medications reported having had very minor and very transient psychotic symptoms months before the diagnosis; only 5% of an untreated age-matched control group without PD reported these.",147,28,0.19047619047619047
9781912776276,chp2,"Visual hallucinations in PDP have been linked to alterations in visual circuitry in the brain in both functional MRI and MRI connectivity studies, as well as to alterations in both dopamine and serotonin neurotransmitter circuits.","Low-stimulation environments. The occurrence of hallucinations is largely dependent on the state of alertness. They are more likely to occur in low-stimulation environments, such as when a patient is alone at home in the evening, watching TV, or when they awake at night to go to the bathroom, although they may occur in other settings. Visual processing abnormalities. The association between visual impairment and visual hallucinations underscores the importance of environment in the development of hallucinations., The phenomenology of visual hallucinations also indicates the variable nature of the underlying pathophysiology, as some patients only see their hallucinations in the dark and report that they resolve if they shine a light on them, whereas other patients report seeing the hallucinations only in the light. Functional MRI studies have demonstrated different responses to flashing lights or facial images in hallucinators compared to the responses of non-hallucinators, but numbers have been small and confirmatory studies are lacking.",184,39,0.21195652173913043
9781912776276,chp3,Impaired visual acuity or concurrent eye conditions may increase the risk of visual hallucinations and should be addressed.,"The major risk factor for PDP is medication (Table 3.2). All the medications that treat the motor symptoms of PD are associated with hallucinations, delusions and delirium. It is important to remember that medications not used directly in the treatment of PD, particularly anticholinergic medications typically used for overactive bladder symptoms, will also contribute to the occurrence of psychotic symptoms. Anxiolytics, hypnotics and tricyclic antidepressants are also potential contributors. Many patients with PD use marijuana derivatives for a wide spectrum of symptoms, including sleep problems, pain, tremor and anxiety. These may also contribute to psychotic symptoms. Some herbal supplements, particularly those that contain levodopa, such as Mucuna pruriens, may also be contributory.",155,21,0.13548387096774195
9781912776276,chp3,The study of genetic relationships with PDP is in its infancy and most genetic associations are not yet known.,"The major risk factor for PDP is medication (Table 3.2). All the medications that treat the motor symptoms of PD are associated with hallucinations, delusions and delirium. It is important to remember that medications not used directly in the treatment of PD, particularly anticholinergic medications typically used for overactive bladder symptoms, will also contribute to the occurrence of psychotic symptoms. Anxiolytics, hypnotics and tricyclic antidepressants are also potential contributors. Many patients with PD use marijuana derivatives for a wide spectrum of symptoms, including sleep problems, pain, tremor and anxiety. These may also contribute to psychotic symptoms. Some herbal supplements, particularly those that contain levodopa, such as Mucuna pruriens, may also be contributory.",155,21,0.13548387096774195
9781912776276,chp3,Cumulative anticholinergic load may be important in people on multiple medications.,"Combination therapies. Anticholinergics, amantadine, levodopa and dopamine agonists may cause PDP when used alone and are thought to be associated with increased risk when used in combination. Although unlikely, monoamine oxidase B (MAO-B) inhibitors may cause PDP when used alone. They are more likely to cause PDP when used as an adjunct to levodopa, where the main effect is an increase in levodopa serum levels and dopamine brain levels. Catechol- O -methyltransferase (COMT) inhibitors have little primary brain effect but may also cause PDP by increasing levodopa serum levels and brain dopamine levels. Cumulative anticholinergic load. In addition to drugs with overt anticholinergic effects, cumulative anticholinergic load may occur in people on multiple medications. Within the context of PD, cumulative anticholinergic load is associated with more rapid cognitive decline, and is likely to have an impact on visual hallucinations.",205,17,0.08292682926829269
9781912776276,chp3,"LRRK2, the most common monogenic cause of PD, generally confers a more benign prognosis than GBA -associated PD. People with PD and GBA mutations are at increased risk of dementia and psychosis.","PINK1, which encodes PTEN-induced putative kinase 1, is the most common recessive cause of early-onset PD. It is a mitochondrial-associated enzyme, and both homozygous and heterozygous carriers are at high risk of behavioral problems. In a study of 20 family members, three had psychotic features, but none with known PD, and the symptoms were thought to be schizophrenic in nature. Cases of psychosis in patients with PD who have PINK1 mutations are rarely reported. Serotonin genes. The 5HTTLPR polymorphic region in SLC6A4 (the gene that encodes the serotonin transporter) and the T102C polymorphism of HTR2A (the gene that encodes one of the receptors for serotonin) are both associated with psychosis in people with Alzheimer's disease., One preliminary study in people with DLB or Parkinson's disease dementia (PDD) with the 5HTTLPR transporter polymorphism suggested an increased risk for delusions but not hallucinations. However, one small study did not find any association between either of these polymorphisms and psychosis in people with PD in the absence of dementia. Specific GWAS focusing on PDP are needed to address this issue.",248,45,0.1814516129032258
9781912776276,chp3,"The medications commonly prescribed to people with PD can exacerbate or trigger psychosis, particularly visual hallucinations. For this reason, medications should always be reviewed in people developing PD psychosis (PDP).","Serotonin genes. The 5HTTLPR polymorphic region in SLC6A4 (the gene that encodes the serotonin transporter) and the T102C polymorphism of HTR2A (the gene that encodes one of the receptors for serotonin) are both associated with psychosis in people with Alzheimer's disease., One preliminary study in people with DLB or Parkinson's disease dementia (PDD) with the 5HTTLPR transporter polymorphism suggested an increased risk for delusions but not hallucinations. However, one small study did not find any association between either of these polymorphisms and psychosis in people with PD in the absence of dementia. Specific GWAS focusing on PDP are needed to address this issue. DiGeorge syndrome. The most common and probably the best studied of the rare genetic mutations is the microdeletion 22q11.2 syndrome, known as the DiGeorge syndrome, which can affect many different areas of the body. No or some behavioral problems may occur, including schizophrenia, autism, mood disorders and attention deficit disorder. An international group identified 45 patients with the microdeletion 22q11.2 who met clinical criteria for a diagnosis of PD. About 25% developed motor features after developing psychosis, so that their diagnosis was delayed by the confound of neuroleptic parkinsonism. An additional 21% developed psychotic symptoms after treatment with PD medications, but the distinction between PDP and schizophrenia was not made. Onset of motor symptoms occurred at a young age, with 75% being diagnosed under age 45. Aside from age and mildly higher than normal male predominance, the clinical features of PD were identical to the general PD population, including levodopa dyskinesias, positive dopamine transporter scans and dementia. Unfortunately, no descriptions of the psychosis or responses to antipsychotic medication were provided., No autopsy confirmation of PD could be found.",377,36,0.09549071618037135
9781912776276,chp4,"Behaviors associated with sleep may be difficult to distinguish from psychotic symptoms. Vivid dreams may be perceived as real, and brief episodes of dream continuation on awakening cannot always be distinguished from PDP.","While there are no validated diagnostic criteria for Parkinson's disease psychosis (PDP), it is important to distinguish PDP from other causes of psychosis. This is achieved by recognizing well-characterized clinical characteristics not shared by other psychotic syndromes, understanding the timing of onset and duration of PDP symptoms, and excluding differential diagnoses (Figure 4.1). Clinical characteristics. The most common psychotic symptoms in PDP are hallucinations, illusions, delusions and delusional misidentification (see page 7). Other psychotic manifestations, as are commonly present in primary psychiatric disorders, such as disorganized thinking, word salad, thought broadcasting, command hallucinations and passivity phenomena, with rare exception, do not occur. Although the psychotic symptoms are the same as those that occur in dementia with Lewy bodies (DLB), they usually occur in patients taking medications for their PD motor symptoms (see pages 24 -), and less frequently in untreated patients. In DLB, the symptoms are more severe, more persistent and often pre-date the use of these medications.",208,40,0.19230769230769232
9781912776276,chp4,"Patients with primary psychiatric disorders, such as schizophrenia, bipolar disease or major depression may have psychotic symptoms from these disorders rather than PDP.","Loose associations are not generally seen in PDP. Patients with PDP who have loose associations, as are typical in schizophrenia, are almost always demented or delirious. Delirium is defined as a mental state that is altered from baseline, with prominent disorientation and marked fluctuations in the level of consciousness and confusion, often accompanied by hallucinations. Patients with PDD typically have cognitive fluctuations, as are present in DLB, which will be associated with fluctuations in orientation and attention, but less so with level of consciousness. Neuropsychiatric comorbidities. Patients with PDP commonly experience other psychiatric comorbidities, such as anxiety, depression, irritability, agitation and aggression. Indeed, these comorbidities may pre-date motor symptoms in PD. Impulse control disorders are particularly prevalent in patients receiving dopamine agonists. These comorbidities may work synergistically with PDP, each making the other worse. It is therefore important that these comorbidities are assessed and managed accordingly.",207,28,0.13526570048309178
9781912776276,chp4,"Comorbid psychiatric problems such as depression and anxiety work synergistically with the psychosis, each making the other worse.","Neuropsychiatric comorbidities. Patients with PDP commonly experience other psychiatric comorbidities, such as anxiety, depression, irritability, agitation and aggression. Indeed, these comorbidities may pre-date motor symptoms in PD. Impulse control disorders are particularly prevalent in patients receiving dopamine agonists. These comorbidities may work synergistically with PDP, each making the other worse. It is therefore important that these comorbidities are assessed and managed accordingly.",100,23,0.23
9781912776276,chp4,"Parkinson's disease psychosis (PDP) typically manifests as visual hallucinations. Auditory, tactile and olfactory hallucinations are less common. Psychotic symptoms may be present as part of a delirium.","The International Parkinson and Movement Disorder Society formed a committee in 2008 to assess psychosis scales and make recommendations (Table 4.2). The most commonly used scales are modified from those used for decades in schizophrenia research (or in the case of the Neuropsychiatric Inventory, the assessment of dementia). However, there are notable differences in the syndromes. PDP primarily consists of visual hallucinations, whereas those in schizophrenia are primarily auditory. The delusions in PDP tend to be mundane, such as people living in the house, or simple paranoid ideas, such as infidelity or the belief they are being poisoned. They are not fantastic, like delusions of grandeur, having one's mind controlled by others, or being harmed by rays from aliens. In addition, negative symptoms of apathy, anhedonia and absent thought, although often present in PD are not part of the psychotic syndrome. However, they are central in psychiatric psychosis scales. Modified forms of the scales are therefore available that eliminate the items deemed to be irrelevant to PDP. Different studies have used different modifications of these scales, and other scales exist.",221,42,0.19004524886877827
9781912776276,chp4,The Clinical Global Impressions Scale is a simple short tool for assessing PDP in clinical practice; it reflects the actual clinical evaluation.,"In routine practice, the Clinical Global Impressions Scale (CGIS) is the simplest and shortest assessment tool, since it reflects the actual clinical evaluation. The physician simply scores on a scale of 1 to 7, where 1 is normal, 2 is borderline, and 3, 4 and 5-7 are mildly, moderately and severely mentally ill, respectively. The CGIS makes no distinctions between the presence of hallucinations and delusions, or the duration of the problem, but simply ascribes a single digit to how severely the disorder affects the patient. (CGIS-Improvement is a companion measure to the CGIS-severity scale described above, which assesses improvement after treatment is initiated on a similar seven-point scale [see Figure 5.1 ].).",152,27,0.17763157894736842
9781912776276,chp5,"The first approach to treatment is to look for contributing factors such as infection, metabolic disorders or non-PD-related psychoactive medications.","When non-PD medications cannot be reduced further, the medications used for PD motor function need to be considered. Although the most effective approach to PD medication reduction has yet to be evaluated, it is advisable to use the approach that epileptologists have been using for decades: use as few drugs as possible, possibly at higher doses, rather than more drugs at lower doses (Case report 5.2). Patients and families can often tell the doctor which medicines have been most helpful. If an increase in a particular drug, or the introduction of a new drug, is temporally related to the onset or increase in psychotic symptoms, then this would be a good place to start. If, on the other hand, the psychosis has arisen on a stable drug regimen, one should choose the drugs thought most likely to have the highest risk:benefit ratio. We recommend removal of anticholinergics first (benztropine, trihexyphenidyl and most medications for overactive bladder), followed by amantadine, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors and catechol- O -methyltransferase (COMT) inhibitors, with levodopa as the last choice (Case report 5.3). The COMT inhibitors have little brain penetration, so their behavioral side effects are almost purely related to their effect on levodopa levels, whereas the other drugs all have direct brain effects.",290,27,0.09310344827586207
9781912776276,chp5,"Quetiapine is widely used (on the basis of open-label reports) even though there is no clear evidence of efficacy and increasing evidence of adverse effects, including mortality risk.","Antipsychotics. Most of the atypical antipsychotic drugs have been used to treat PDP and have been the subjects of small clinical trials. These drugs are more commonly, and appropriately, labeled as second-generation antipsychotics (SGAs), defined most accurately as those introduced from clozapine onwards. The problem with the label of 'atypical' is the lack of consensus on what 'atypical' means. The main distinguishing characteristics that separate 'atypical' from 'typical' antipsychotics are the relative freedom from extrapyramidal side effects, and the pharmacological effect of blocking both dopamine D2 receptors and serotonin 5HT2A receptors. However, different drugs have different ratios of 5HT2A and D2 receptor blocking and it is difficult to define what 'relative' freedom from extrapyramidal side effects means. Recently, the term 'third generation' has been introduced to categorize antipsychotic drugs.",198,38,0.1919191919191919
9781912776276,chp5,"Although clozapine doses are one-tenth to one-hundredth of those used in schizophrenia, the risk of granulocytopenia and agranulocytosis is thought to be unchanged, so close blood monitoring is still required.","There was no association with the severity of dementia, as measured on the MMSE. Improvement was evident within 1 week of drug initiation. Although six subjects (10%) died within a few months of completing the trial, none of the deaths was ascribed to clozapine. Clozapine also has a beneficial effect on PD tremor and has been used to treat tremor that is otherwise drug refractory. Adverse events. Unfortunately, the lower dose used to treat PDP (one-tenth to one-hundredth of the dose used to treat schizophrenia) does not negate the need for weekly blood count monitoring, as the risk of granulocytopenia is independent of drug dose. Clozapine may cause neuroleptic malignant syndrome. In addition, there are rare reports of clozapine-induced tardive dyskinesia, but these all involve patients who had prior exposure to other neuroleptics. The most common side effect is the metabolic syndrome; however, weight gain hypertension, diabetes and hyperlipidemia appear to have threshold values that patients with PD rarely reach, so these problems are not usually seen.",238,53,0.22268907563025211
9781912776276,chp5,"Only clozapine and pimavanserin have proven efficacy for Parkinson's disease psychosis (PDP). While clozapine works quickly, pimavanserin requires 4-6 weeks to improve psychotic symptoms.","Pimavanserin. One of the criteria proposed for defining an antipsychotic as 'atypical' is the blocking effect on 5HT2A serotonin receptors. It is unclear why joint action against D2 dopamine and 5HT2A serotonin receptors leads to fewer extrapyramidal side effects, but multiple lines of evidence implicate serotonin in psychotic symptoms in PD, DLB and Alzheimer's disease. In addition, the antipsychotic effect of clozapine in patients with PDP occurs at such low doses that binding to the limbic D2 receptors is unlikely to be the mechanism by which psychotic symptoms improve; the blocking of 5HT2A receptors is a more likely explanation. These hypotheses have led to the search for drugs that specifically target the 5HT2A receptor only. Mechanism of action. The 5HT2A inverse agonist pimavanserin is a small molecule that blocks the basal activity of the receptor, unlike antagonists which inhibit stimulation but do not block the resting activity of the receptor. It has no effect on 5HT2B receptors and 40 times less activity on 5HT2C receptors than on 5HT2A. Unlike the SGAs, it has no affinity for dopamine or other neurotransmitter receptors. The serum half-life is around 57 hours and the median time to maximum serum level is 6 hours. The drug reaches steady state at 10-12 days for single daily dosing.",291,46,0.15807560137457044
9781912776276,chp5,"Cholinesterase inhibitors confer overall benefits in people with dementia with Lewy bodies and Parkinson's disease dementia, with some evidence of a specific beneficial effect in the treatment of psychosis. Further work is needed to determine potential benefits of cholinesterase inhibitor treatment for PDP in the absence of dementia.","Recent open-label reports. In two chart reviews at the same center (JHF), 41 patients were treated with pimavanserin. About 50% of parkinsonian patients with psychotic symptoms found pimavanserin to be useful and continued to take it. The drug was generally well tolerated, even when added to quetiapine, clozapine or dementia medications, and no difference in response was noted between patients with PDD and DLB., A chart review from a different clinic reviewed 16 cases of PDP and 1 of DLB; 14 of the patients with PD also had dementia. Overall, 5 of 8 on pimavanserin alone improved and 6 of 9 who were also taking atypical neuroleptic medications improved, allowing them to discontinue the atypical neuroleptic. Only 2 patients reported no benefit, and there were no significant side effects. Cholinesterase inhibitors. Studies in Europe and Japan have demonstrated the benefits of cholinesterase inhibitors on cognition, function and overall neuropsychiatric symptoms in people with DLB, and these have been confirmed in a meta-analysis. The European study demonstrated better overall treatment response in people with visual hallucinations, but only one of the Japanese studies specifically reported the impact on psychotic symptoms, highlighting modest but significant benefit with donepezil treatment. Importantly, psychotic symptoms were not required for inclusion, and therefore many participants did not have psychosis or did not have psychosis at a clinically significant threshold, making the results difficult to interpret. Thus, the effect of cholinesterase inhibitors on psychotic symptoms in DLB, particularly more severe symptoms at a clinically significant threshold, remains unknown.",341,62,0.18181818181818182
9781912776276,chp5,Trials of novel pharmacological and psychological treatment approaches are now being initiated; this is likely to be an evolving field over the next 5 years.,"The family should be counseled to avoid confrontation when refuting paranoid delusions, by being as gentle and supportive as possible without alienating or giving credence to the psychotic symptoms. Patients can usually be redirected to topics outside the psychotic focus. Future directions. Novel pharmacological and psychological interventions are starting to move forward into clinical trials. This is likely to gather momentum as the mechanistic understanding of symptoms improves through neuroimaging, the study of biomarkers and genome-wide association studies. More work is needed to implement best evidence-based practice in the clinic and to enable a more rational approach to prescribing that better balances benefits and potential harms.",128,29,0.2265625
9781912776276,chp6,Psychotic symptoms have been shown to be the single most important cause of nursing home placement in patients with PD.,"Psychosis has been reported as the single most important precipitant for nursing home placement,, with a consequent increase in mortality. In one study of 11 subjects placed in nursing homes, all died within a 2-year follow-up period. Although other studies have not confirmed this high mortality rate, follow up of 59 subjects 3 years after they had enrolled in the first double-blind trial of clozapine for the treatment of Parkinson's disease psychosis (PDP) found that 42% of survivors were in nursing homes. During the study, 88% of the subjects had been living at home, with only 12% in nursing homes. In total, 25% of the subjects (15) had died, 6 of whom had died within a few months of completing the trial; none of the deaths was thought to be related to adverse drug effects. The mean duration from baseline (defined as the end of their participation in the 4-month study) to death was 8.3 months. Causes of death included pneumonia, chronic obstructive pulmonary disease and myocardial infarction. Eight patients with mini-mental state examination score (MMSE) > 25 at entry were demented at follow up. Although all patients were treated at some point with clozapine, 37 of the 54 survivors continued to have psychotic symptoms beyond the first few months. Forty patients continued to be treated with antipsychotics, 23 on clozapine. Two subjects stopped clozapine because of granulocytopenia. No long-term follow up or short-term mortality was reported in the almost identical trial of clozapine that was performed in France.",334,22,0.0658682634730539
9781912776276,chp6,Healthcare costs have been found to be twice as high for patients with Parkinson's disease psychosis (PDP) than for those without psychosis.,"Studies of American healthcare costs have underscored the increased cost associated with PDP. A recent study reported that patients with PDP had yearly costs over twice as high as patients with PD but no psychosis, as well as an increased risk of falls (3 times higher) and twice the risk of fractures. A Medicare review (2000-2010) found that 75% of patients with PDP spent time in long-term care facilities, compared to 56% of patients with PD and no psychosis, and 36% of patients without PD. In addition, the patients with PDP stayed an average of 179 days, compared to 83 days for the non-psychotic patients and 22 days for the controls. The cost difference was $31 178 per year (PDP) versus $14 461 (non-psychotic).",163,28,0.17177914110429449
9781912776276,chp6,"Acute psychosis may require hospitalization. Causes for hospitalization include direct safety issues, both for the patient and their family.","A UK study of 7271 patients with PD (1994-2013) found that those with the disease required $3716 more for healthcare per year than age-matched controls without PD. In addition, patients with PD with greater disability, including psychosis, required an additional $1608 per year. Acute psychosis may require hospitalization, which is both costly and upsetting for the family. Causes for hospitalization include direct safety issues, both for the patient and their family, but also maintenance of a safe level of care, as caregivers are often unable to safely care for psychotic patients who might keep them awake all night or wander outdoors if unsupervised, even for short periods.",135,25,0.18518518518518517
9781912776276,chp6,"All antipsychotics carry a black box warning of increased mortality, which should be considered when making treatment plans.","The Food and Drug Administration (FDA) concluded that the deaths of patients receiving pimavanserin were likely to be due to underlying disease rather than drug effects. However, pimavanserin, like all other antipsychotic drugs, carries a black box warning of increased mortality. The warning for pimavanserin was purely derivative, based on data showing increased risk of death with antipsychotics, and did not take drug pharmacology into consideration. A 2-year chart review comparing mortality in 113 patients with PDP treated with pimavanserin with 505 who received quetiapine and 58 treated with both, found non-significant trends of increased mortality of 7.1%, 11.5% and 12.1%, respectively.",154,22,0.14285714285714285
9781912776276,chp6,"Although the FDA generally recommends that attempts be made to lower or discontinue antipsychotic use whenever possible, this should not apply to patients with PDP, whose psychotic symptoms generally worsen with time.","The Food and Drug Administration (FDA) concluded that the deaths of patients receiving pimavanserin were likely to be due to underlying disease rather than drug effects. However, pimavanserin, like all other antipsychotic drugs, carries a black box warning of increased mortality. The warning for pimavanserin was purely derivative, based on data showing increased risk of death with antipsychotics, and did not take drug pharmacology into consideration. A 2-year chart review comparing mortality in 113 patients with PDP treated with pimavanserin with 505 who received quetiapine and 58 treated with both, found non-significant trends of increased mortality of 7.1%, 11.5% and 12.1%, respectively. The increased mortality associated with the use of antipsychotic drugs must be considered when making treatment plans. However, as no medical disorder has been associated with the increased death rate, it has not been possible to identify a mechanism or even a risk profile to identify those at greatest risk. While the FDA has requested that attempts be made to lower or discontinue antipsychotic use whenever possible, and American nursing homes are graded on their reduction of antipsychotic drug use, this should not apply to patients with PDP, whose psychotic symptoms generally worsen with time.",265,39,0.1471698113207547
9781912776696,hh-4,"The type of statistical method used to analyze trial data depends on the type of endpoint being measured. Common endpoint types are continuous, score, binary, ordered categorical, count and time to event.","Endpoint types. The type of statistical method used to analyze trial data depends on the type of endpoint that is measured. Common endpoint types are. ordered categorical. time to event. Continuous endpoints are measured on a continuum of possible values over time: for example, a change in bone mineral density or blood pressure. Score endpoints are endpoints that arise from scales constructed to capture a discrete value for something that cannot be measured in a continuous way. Examples include scales that provide a score for quality of life or severity of depression. Count endpoints measure the number of items or events during a specified period: for example, the number of migraine headaches over 28 days. Binary endpoints represent a dichotomy: a 'yes or no' type of measurement (exempli gratia success/failure, progression/no progression, survival/death). A common example in oncology is responder versus non-responder, where a responder is a patient whose best response is a complete or partial response, and where a non-responder is a patient whose best response is stable disease or disease progression.",226,39,0.17256637168141592
9781912776696,hh-4,"Summary statistics provide a simple descriptive value for a data sample, which enables comparison of data sets. The mean (arithmetic average) is the most common measure used for continuous and score data with a normal or symmetric distribution. The median is the preferred measure for data with a skewed distribution. Proportions are compared for binary and ordered categorical endpoints.","Summary statistics provide a quick and simple description of a set of data values. Usually, the sample's average (mean), middle (median) or most common (mode) value is used. Mean. The mean is the arithmetic average, id est the sum of all values divided by the number of values. It is denoted by x. The mean is a good measure of comparison to use for sample groups with continuous and score endpoints, provided the endpoint data have a symmetric distribution (Figure 1.1a). The mean is also a good measure of comparison for samples with count endpoints, but these are usually calculated as means per unit of time to account for different observation periods for different patients. Median. When the data distribution is skewed (see Figure 1.1b, c), id est some of the values are a lot smaller or larger than the others, the mean is not usually the best measure of average. In these cases, the median is often the preferred measurement. The median is the middle value when the data values are placed in order from smallest to largest. It is sometimes denoted by x. Mode. The mode is the most common value (see Figure 1.1). It is used to describe the most frequently occurring outcome, but in general it is of limited value in clinical trials. Proportions. Comparing the means of binary endpoints makes no sense. Instead, proportions are compared; in this book the symbol r is used to denote a proportion.",306,72,0.23529411764705882
9781912776696,hh-4,The standard deviation is a measure of patient-to-patient variability.,Standard deviation (SD) is a measure of patient-to-patient variability. It is particularly important in the analysis of continuous and score endpoints. The SD is the average distance of all data values from the mean. It is not the simple average but a weighted average that gives rather more weight to the points well away from the mean.,68,14,0.20588235294117646
9781912776696,hh-4,The standard error is a measure of the extent of sampling variation.,"Standard error (SE) is a measure of the extent of the sampling variation. If the trial above was conducted 100 times, 100 values for the difference in the treatment means would be obtained. The SD associated with those 100 values is known as the SE. It is a measure of the inherent variability in the statistic being calculated.",65,13,0.2
9781912776696,hh-4,A 95% confidence interval is a range of values within which the true population value lies 95% of the time.,"The SE is an important measure, as it is used to calculate confidence intervals and p -values. Confidence intervals. As discussed above, the precise value for treatment difference can never be obtained, only an estimate of its value. However, an interval (a range of values) can be constructed around that estimate within which the true population value is likely to lie. The 95% confidence interval (CI) contains the true population value 95% of the time.",92,23,0.25
9781912776696,hh-4,The null hypothesis usually states that treatment effects are equal. The alternative hypothesis is that they are not equal. These hypotheses give two-sided p -values. One-sided p -values can be obtained when looking for differences only in one direction.,"In statistics, hypotheses are formulated to gain answers to questions of interest. To test for superiority, id est to demonstrate that treatments are different, the null hypothesis (H) is that the treatment effects (exempli gratia the mean effects) are equal. The alternative hypothesis (H) is that they are not equal. Null hypothesis (H):  = . Alternative hypothesis (H):   . where  is the mean value for treatment A and  is the mean value for treatment B. The p -value is a number between 0 and 1 that is a measure of how much evidence there is to accept or reject the null hypothesis (Table 1.1). Significance level. The conventional cut-off at which the p -value is deemed to be statistically significant is 0.05 or 5%. This is an entirely arbitrary cut-off that operationally seems to be a good compromise in terms of how strong the evidence needs to be before deciding in favor of differences. The cut-off at 5% is termed the significance level. If the p -value is above 0.05 then the difference is deemed to be non-significant and the null hypothesis is accepted.",240,49,0.20416666666666666
9781912776696,hh-4,"The p -value is a number between 0 and 1 that indicates whether to accept the null hypothesis or the alternative hypothesis. For two-sided testing, a p -value <= 0.05 shows that there is statistically significant evidence against the null hypothesis, id est there is a statistically significant difference between the treatments.","where  is the mean value for treatment A and  is the mean value for treatment B. The p -value is a number between 0 and 1 that is a measure of how much evidence there is to accept or reject the null hypothesis (Table 1.1). Significance level. The conventional cut-off at which the p -value is deemed to be statistically significant is 0.05 or 5%. This is an entirely arbitrary cut-off that operationally seems to be a good compromise in terms of how strong the evidence needs to be before deciding in favor of differences. The cut-off at 5% is termed the significance level. If the p -value is above 0.05 then the difference is deemed to be non-significant and the null hypothesis is accepted. Two-sided and one-sided p -values. The p -values discussed above are two-sided p -values as they detect differences in either direction, id est treatment A is better than treatment B or treatment B is better than treatment A. This is the way the hypotheses are set up; they ask the question, are the treatment means the same or are they different? In some cases, however, researchers may only be interested in detecting differences in favor of the experimental treatment.",253,62,0.2450592885375494
9781912776696,hh-4,"The odds ratio (OR) and relative risk (RR) are used to express the difference between binary endpoints. OR > 1 or RR > 1 indicates that the odds or risk of an event occurring, respectively, are higher in the treatment group.","Odds ratios (ORs) and relative risks (RRs) are used to express treatment differences when dealing with binary endpoints. The OR concept also extends to ordered categorical endpoints. An OR shows the odds of the binary outcome occurring after exposure to the experimental treatment compared with the corresponding odds of the binary outcome occurring on the control treatment. The RR is a similar measure that compares the risks of the binary outcome, rather than the odds. Interpreting OR and RR values. An OR of 1 corresponds to equal treatment effects. If the OR is greater than 1, the odds for the event are higher in the experimental group, and vice versa. In Example 1.5, an OR of 1.91 shows that the odds for neutropenia occurring in the experimental group (FCR) are 91% higher than the corresponding odds in the control group (FC). Likewise, an RR of 1 corresponds to equal treatment effects. If the RR is greater than 1, the risk is higher in the experimental group, and vice versa. In Example 1.5, an RR of 1.62 corresponds to a 62% increase in the risk of neutropenia in the FCR group.",242,50,0.2066115702479339
9781912776696,hh-4,"The two-sample t -test is used to analyze data with a normal or approximately normal distribution. Skewed data sets can be transformed (exempli gratia by log) before analysis with the t -test, or analyzed using a non-parametric Mann-Whitney U -test.","For comparison of two treatment means for continuous or score endpoints, the appropriate test is the two-sample t -test. For comparison of two proportions for a binary endpoint, it is the chi-square test. When comparing two hazard rates (by assessing whether the hazard ratio is equal to one), it is the logrank test (see Chapter 2). Normal versus non-normal data distribution. The t -test is used when the data are normally distributed, or approximately so, id est a bell-shaped distribution that is symmetric around the mean (see Figures 1.1a, 1.2). If the data distribution is substantially non-symmetric, strictly, the t -test does not apply and using it can result in an incorrect p -value. Alternatively, an attempt to recover normality may be made through a data transformation. Several transformations are possible, such as the log transformation in which the log of each data point is used in the analysis using the t -test. When normality cannot be recovered through a data transformation, a non-parametric test can be used to obtain the p -value. Instead of comparing the values of the raw data, either on the original scale or on a transformed scale, the data values are ranked and the ranks are compared. The non-parametric equivalent of the two-sample t -test is the Mann-Whitney U -test. The Mann-Whitney U -test takes the ranks of the data points in the two groups combined and compares the mean rank in treatment group 1 with the mean rank in treatment group 2.",321,60,0.18691588785046728
9781912776696,hh-5,"Typical examples of time-to-event analyses include overall survival, progression-free survival, disease-free survival and duration of response.","Time-to-event analyses include information from both censored and uncensored observations (see below). Censoring is a common feature of all time-to-event endpoints. A subject's time to event is said to be censored if the event of interest (death, disease progression etc.) has not occurred in that patient by the end of the follow-up period. A censored observation can also occur when information on a subject is known for a limited duration only (exempli gratia if a person drops out of a study before the end and is lost to follow-up).",119,28,0.23529411764705882
9781912776696,hh-5,Censoring is a common feature of all time-to-event endpoints. Observations are said to be censored when the event of interest has not happened by the end of the follow-up period.,"Censoring is a common feature of all time-to-event endpoints. A subject's time to event is said to be censored if the event of interest (death, disease progression etc.) has not occurred in that patient by the end of the follow-up period. A censored observation can also occur when information on a subject is known for a limited duration only (exempli gratia if a person drops out of a study before the end and is lost to follow-up). Example 1. In a study with a fixed 24-month follow-up, a subject who is still alive at month 24 will provide a censored value for OS. The OS for such a subject is considered to be at least as long as the duration of the study. Example 2. At the time of an interim analysis, some subjects may not have been in the study for very long. These subjects will provide censored values if the event of interest has not occurred during the limited follow-up.",198,42,0.21212121212121213
9781912776696,hh-5,Kaplan-Meier curves plot the probability of being event free over time. The curves from different treatment groups can be plotted against each other to show the differences in outcome.,"Kaplan-Meier survival curves are often used to compare the data between two groups of subjects. Figure 2.2 shows Kaplan-Meier curves for OS in a randomized study of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated either with or without trastuzumab. The Kaplan-Meier curve steps down at time points at which deaths occur, while censored observations are denoted by notches on the curve. In this study, the follow-up period ranged from 3 months to 74 months. The Kaplan-Meier curve plots the probability of being event free over time, with these probabilities being estimated from the data in the study. Note that the curve for patients who received trastuzumab is consistently above the curve for those who did not receive trastuzumab, indicating a higher survival probability in that group.",180,35,0.19444444444444445
9781912776696,hh-5,"Treatment differences are often expressed as a hazard ratio (HR). An HR of 1 means the risk in the two groups is the same. An HR > 1 means that the risk in one group is higher than the other, and vice versa.","The Kaplan-Meier curve plots the probability of being event free over time, with these probabilities being estimated from the data in the study. Note that the curve for patients who received trastuzumab is consistently above the curve for those who did not receive trastuzumab, indicating a higher survival probability in that group. For the rest of this chapter, for simplicity, let us assume that the event of interest is death. Median overall survival. The Kaplan-Meier curves can be used to obtain median survival times (Figure 2.3). The median survival time is the time point at which 50% of patients are estimated to be alive, and this can be found by drawing a horizontal line at the 50% line on the y -axis. Hazard ratio. Treatment differences are usually expressed as a hazard ratio (HR). In order to understand what an HR is, it is necessary to understand what a hazard rate is. Hazard rate is the probability that a subject will die within a given time interval among the subjects alive in that treatment group at the start of that interval. In a group of 1000 patients, suppose 10 die in month 1, 15 die in month 2 and 12 die in month 3.",248,49,0.1975806451612903
9781912776696,hh-5,"The logrank test compares the two Kaplan-Meier curves to provide a p -value for the difference in total survival experience of the two groups. This test can only be used if there is a constant HR, id est the Kaplan-Meier curves start together at time zero and then separate out gradually with time.","HRs are usually given in conjunction with a 95% CI, id est the range of values that is likely to include the true population value (see Chapter 1). This range can be used to measure the precision of the HR; the narrower the CI the more precise the HR estimate. Logrank test. While it is possible to compare the survival of patients in two different study groups at any given point in time on the Kaplan-Meier curves, this does not provide a comparison of the total survival experience of the two groups. The logrank test provides a p -value for the total survival experience of the treatment group compared with the control group by comparing the two Kaplan-Meier curves. It takes the whole follow-up period into account. A significant p -value (probabilities lower than 0.05 are usually considered significant, see Chapter 1) shows that there is sufficient evidence to declare treatment differences. The logrank test implicitly assumes that the HR is fairly constant. This will not always be the case and when the HR is not constant the logrank test does not provide an appropriate comparison of the Kaplan-Meier curves. Note that a constant HR manifests itself as Kaplan-Meier curves that start together at time zero but then separate out gradually with time (see Figure 2.2 for an example where this is the case).",270,64,0.23703703703703705
9781912776696,hh-5,"If the HR is not constant, a treatment difference can be expressed as the difference between two restricted mean survival times (which is equal to the area between two Kaplan-Meier curves).","The restricted mean survival time (RMST) is the mean survival time up to a certain point of follow-up, for example 10 years. If the RMST is 7 years, this means that the mean survival time in the 10-year period from the point of randomization is estimated to be 7 years. It is a straightforward statistic to calculate as it is the area under the curve (AUC) up to year 10 (Figure 2.5). Life expectancy difference. If the HR does not provide a suitable measure of treatment effect, for example if the HR is not constant, then a treatment difference can be expressed as the difference between two RMST values (the active RMST minus the control RMST). This is calculated as the area between the two Kaplan-Meier curves (Figure 2.6).",164,37,0.22560975609756098
9781912776696,hh-5,The stratified logrank and the Cox proportional hazards model are two ways of adjusting for imbalances in baseline factors.,"The principle of randomizing participants to two (or sometimes more) groups in a study is that, in theory, the two treatment groups are balanced in terms of factors that may influence the outcome. Any differences in outcomes between the two groups are then attributed to the difference in treatments. However, there are numerous baseline variables that may have a bearing on the outcome (exempli gratia patient characteristics such as age, sex and ethnicity, or stage or grade of tumor). It is therefore usually of value to adjust the analysis to account for any such differences in baseline factors. There are two ways to make such adjustments for time-to-event endpoints. The stratified logrank test can adjust for a small number of factors, while the Cox proportional hazards model is a modeling approach that can, in theory, adjust for many more factors simultaneously.",169,24,0.14201183431952663
9781912776696,hh-5,"Baseline variables that are important prognostic factors (exempli gratia age and stage of disease) should be taken into consideration in all statistical analyses, even in randomized studies.","The principle of randomizing participants to two (or sometimes more) groups in a study is that, in theory, the two treatment groups are balanced in terms of factors that may influence the outcome. Any differences in outcomes between the two groups are then attributed to the difference in treatments. However, there are numerous baseline variables that may have a bearing on the outcome (exempli gratia patient characteristics such as age, sex and ethnicity, or stage or grade of tumor). It is therefore usually of value to adjust the analysis to account for any such differences in baseline factors. There are two ways to make such adjustments for time-to-event endpoints. The stratified logrank test can adjust for a small number of factors, while the Cox proportional hazards model is a modeling approach that can, in theory, adjust for many more factors simultaneously.",169,36,0.21301775147928995
9781912776696,hh-6,Every trial has the potential to yield a false-positive or a false-negative result - the false positive is known as the type I error and the false negative the type II error.,"As discussed in Chapter 1, hypothesis testing involves the statement of a null hypothesis (exempli gratia that the frequencies of an event with two treatments are, in truth, equal) and the selection of a level of significance that indicates whether to reject or accept the null hypothesis (see page 16). In general, researchers are looking to reject the null hypothesis of equality in order to conclude in favor of treatment differences. The p -value framework, in which differences are significant when p <= 0.05 and non-significant when p > 0.05, is unfortunately not perfect in terms of ascertaining the truth. Sometimes the data through the p -value can be misleading. The two possible mistakes are the false positive and the false negative. The false positive occurs when the null hypothesis is true (id est there is no treatment difference) but the data give a significant p -value and a treatment difference is falsely declared. The false negative occurs when the alternative hypothesis is true (id est there is a treatment difference) but the data give a non-significant p -value and the difference between treatments is not detected. The false positive is more formally referred to as the type I error. The false negative is referred to as the type II error.",249,37,0.14859437751004015
9781912776696,hh-6,"Potential for the false positive is controlled at 5%, the significance level, while the false negative is controlled via the power.","Controlling the type I error. The probability of the type I error (false positive) is controlled generally at 5%, as determined by the level at which differences are declared statistically significant. For example, if the treatment means are truly identical, then there is a 5% probability of getting p <= 0.05. This is a consequence of the p -value definition: 5% of the time when there is no treatment effect, there will be a numerical difference in the sample means that is extreme enough to give p <= 0.05 by chance.",110,25,0.22727272727272727
9781912776696,hh-6,"Power is equal to 100%  type II error. The type II error is the false negative, missing a real difference, while the power is the true positive, capturing a real difference.","As examples, if the probability of the type II error is 10% then the power is 90%; if the trial is powered at 80%, then the probability of a type II error is 20%. The type II error is missing a true difference while the power is capturing a true difference; if there is a 10% chance of missing the bus, there is a 90% chance of catching the bus!. Real world implications. When considering type I and type II errors, medicines regulators are generally most concerned with the type I error, the false positive; they do not want to be registering drugs that do not work. They are less concerned with the false negative, the type II error. The type II error is more the sponsor's problem - a sponsor does not want to fail to demonstrate a treatment difference when, in truth, there is a treatment benefit for the experimental treatment.",174,38,0.21839080459770116
9781912776696,hh-6,"Power can be calculated at the planning stage, in advance of running the trial, by making various assumptions about, in particular, the magnitude of the treatment effect.","One good thing at the trial design stage is that the power of a study can be calculated in advance of running the trial by speculating about what might happen. Consider a cholesterol-lowering placebo-controlled trial with 50 patients per group, in which the primary endpoint is the change from baseline to month 6 (baseline  month 6). Assume that the Phase II data have shown a standard deviation (subject-to-subject variability) associated with the primary endpoint of 1.1 mmol/L and a 5% level test is being used. Table 3.1 shows the calculated power for a range of values for the true treatment difference. Note that when comparing means, the subject-to-subject variation in the endpoint impacts the power. If the variability in the endpoint is large, it is more difficult to 'see' differences in the means and vice versa when the variability is small.",179,32,0.1787709497206704
9781912776696,hh-6,"The sample size calculation is based on the requirement to detect a prespecified treatment difference, often referred to as the clinically relevant difference, with a certain level of power, usually 80%, or at least 90% in a Phase III pivotal trial.","Table 3.2 provides the values for power at the same specified levels of effect as in Table 3.1 after doubling the sample size to 100 patients per treatment group. All the values for power have increased. In particular, the power has increased from 62.3% to 89.5% at a treatment difference of 0.50 mmol/L. This is much more acceptable and is close to the generally acceptable level of 90% power for a Phase III pivotal trial. A sample size of 102 patients per treatment group would give the trial 90% power, while a sample size of 76 per treatment group would give the trial 80% power. This is the basis of sample size calculation. A level of effect of interest is specified and the sample size required to give, say, 90% power is then calculated. Formulas exist that can be used to calculate sample size for all the commonly occurring settings. To undertake the calculation, several parameters that impact sample size need to be specified.",197,49,0.24873096446700507
9781912776696,hh-6,"As many oncology studies are powered on a primary time-to-event endpoint - power being determined by the number of patients with events - many oncology studies are event driven, with the statistical analysis taking place once the required number of patients with events have been reported.","In many cases, the primary endpoint in an oncology trial is a time-to-event endpoint, such as OS or progression-free survival (PFS). The power of a study based on a time-to-event endpoint is determined not directly by the number of patients, but by the number of patients who experience the event being studied. For example, a trial in which 100 out of 1000 patients experienced the event has the same power as a trial in which 100 out of 300 patients had the event. Many oncology studies with a time-to-event primary endpoint are therefore event driven and the trial data are analyzed when the required number of events are observed in the two treatment groups combined. Calculating the sample size for a trial based on a time-to-event endpoint has an intermediate step as a consequence. First, calculate how many patients with events are needed for the required power. Then, considering the design, calculate how many patients need to be recruited to 'deliver' those events. The key elements of the design in this case are the rate of recruitment over the recruitment period and the length of follow-up.",232,56,0.2413793103448276
9781912776696,hh-6,"It is possible to increase the sample size if the event rate is lower than anticipated - if this is done in a blinded way, there is no statistical penalty or implication for the statistical method to be used for analysis.","The sponsor took the decision to increase the sample size (from 594), with 672 participants eventually being randomized. At the planned cut-off date for the final analysis, the number of PFS events observed was 318. Of course, it would have been possible to delay the cut-off date to achieve the required 329 events, but the sponsor decided against this course of action. The reduction in number of events led to a small reduction in the power of the study, but as the power had been set at a high level (95%) at the design stage it remained acceptable. Unblinded re-evaluation and adaptive designs. Undertaking a sample size re-evaluation based on blinded data is acceptable from a statistical perspective and does not cause any inflation in the false-positive potential for the trial (type I error). The US Food and Drug Administration (FDA) makes a clear distinction between blinded data looks and unblinded looks. It is possible to re-evaluate a sample size on the basis of unblinded data, perhaps having observed a smaller than expected treatment difference, but this would constitute an adaptive design and would affect the way in which the data could be analyzed in order to preserve the overall type I error for the comparison. Under these circumstances, it is important to plan for such an evaluation at the outset and consider carefully the implications for the statistical analysis once the trial eventually completes.",283,43,0.1519434628975265
9781912776696,hh-7,"The Bonferroni correction divides the 0.05 equally across all endpoints; for example, for four endpoints, the significance level for each endpoint would be 0.05/4 = 0.0125. The decision to do this must be made in the study protocol.","Suppose several different endpoints are being assessed; for example, objective response (partial response [PR] or complete response [CR]), clinical benefit (stable disease [SD], PR or CR), progression-free survival (PFS) and overall survival (OS). A general approach to control the type I error (alpha = 0.05) would be to divide it across the endpoints that are being considered. The Bonferroni correction divides the 0.05 equally across all endpoints. For the four endpoints mentioned above, the significance level for each endpoint would be 0.05/4 = 0.0125. Paying a price on the alpha in this way and using a reduced significance level enables researchers to draw confirmatory conclusions for the endpoints that are significant. For example, if two of the four endpoints are significant (p <= 0.0125) and two are non-significant (p > 0.0125) confirmatory conclusions can only be drawn about the two that are significant. For m tests, adjusted significant level = alpha/m. Making this correction will affect the power of the study (see Chapter 3 for a discussion on power). Achieving a significance level of 0.0125 is much more difficult than achieving a significance level of 0.05 and a larger sample size will be required.",271,57,0.21033210332103322
9781912776696,hh-7,"The overall type I error rate, known as the family-wise error rate must be controlled in every trial at 5%.","Non-equal division of the alpha. In certain situations, it may not make sense to divide the alpha equally. For example, in a study of patients with advanced prostate cancer, researchers may want the flexibility to draw confirmatory conclusions for both PFS and OS as co-primary endpoints. The Bonferroni correction would divide the 0.05 by 2 and assign a significance level of 0.025 to each endpoint. However, PFS is potentially the easier endpoint in terms of achieving statistical significance, possibly because there is likely to be a larger treatment effect on that endpoint or because, by definition, there will be more PFS events than OS events. In this case, it may make sense to assign a significance level of 0.01 for PFS and 0.04 for OS. Of course, researchers must decide how to divide the alpha at the trial design stage; it is not appropriate to decide on the alpha split once the data are available!.",193,24,0.12435233160621761
9781912776696,hh-7,"As several simultaneous statistical tests are usually conducted (exempli gratia for several different endpoints or time points, for the overall sample and several subgroups), the potential for a significant p -value to occur purely by chance increases.","Suppose the p -values for three different endpoints have been calculated and ordered from largest to smallest. If the largest p -value is <= 0.05, then all endpoints have p -values <= 0.05 and confirmatory conclusions can be drawn for all three endpoints (Case 1 in Example 4.1). If, however, the largest p -value is > 0.05, statistical significance cannot be declared for that endpoint. Instead, look to the endpoint with the second largest p -value. If that p -value is <= 0.025 (0.05/2) then that endpoint and the endpoint with the smallest p -value are statistically significant (Case 2 in Example 4.1). Finally, if the largest p -value is > 0.05 and the second largest p -value is > 0.025 (0.05/2), look to the endpoint with the smallest value. If that p -value is <= 0.017 (0.05/3) then that endpoint is statistically significant (Case 3 in Example 4.1).",218,47,0.21559633027522937
9781912776696,hh-7,"The Hochberg approach places the p -values in order, from largest to smallest, and then assigns a different significance level to each; for example, <= 0.05 to the largest, <= 0.025 (0.05/2) to the next and 0.017 (0.05/3) to the next, and so on.","Suppose the p -values for three different endpoints have been calculated and ordered from largest to smallest. If the largest p -value is <= 0.05, then all endpoints have p -values <= 0.05 and confirmatory conclusions can be drawn for all three endpoints (Case 1 in Example 4.1). If, however, the largest p -value is > 0.05, statistical significance cannot be declared for that endpoint. Instead, look to the endpoint with the second largest p -value. If that p -value is <= 0.025 (0.05/2) then that endpoint and the endpoint with the smallest p -value are statistically significant (Case 2 in Example 4.1). Finally, if the largest p -value is > 0.05 and the second largest p -value is > 0.025 (0.05/2), look to the endpoint with the smallest value. If that p -value is <= 0.017 (0.05/3) then that endpoint is statistically significant (Case 3 in Example 4.1). Hochberg versus Bonferroni. Note that if the Bonferroni correction is applied to Example 4.1, with an adjusted significance level of 0.017 for all three endpoints, the only statistically significant endpoint would be E in cases 2 and 3. In this sense, Hochberg always performs better than Bonferroni; it is more sensitive in terms of being able to pick up significant differences.",304,72,0.23684210526315788
9781912776696,hh-7,"In hierarchical testing (or closed testing), the endpoints of interest are ranked from most important to least important before the study begins. The endpoints are then tested in that order using 0.05 as the significance level. The statistical significance can only be claimed down to the first non-significant result.","In the approaches to multiple testing discussed above, paying a price on the alpha gives researchers the flexibility to cherry-pick significant p -values at a lower significance level. Hierarchical testing, or closed testing as it is sometimes called, places an alternative constraint on the testing to control the FWER at 5%. In hierarchical testing, the endpoints of interest are ranked from most important to least important before the study begins (id est the order of importance is prespecified in the study protocol). The endpoints are then tested in that order using 0.05 as the significance level, but the statistical significance can only be claimed down to the first non-significant result. In Example 4.2, OS in Case 2 (p = 0.013) and PFS in Case 3 (p = 0.033) both have p -values < 0.05 but these constitute exploratory findings only and are sometimes labeled as 'nominally significant'. Regulatory authorities would not allow these nominally significant p -values to be reported in the label. Estimated hazard ratios could be reported, but to avoid any misinterpretation of the statistics the p -values and confidence intervals would not be included. The hierarchical order. Clearly, it is important to get the hierarchical order correct, both in terms of clinical relevance and other practicalities. In general, it is more difficult to achieve statistical significance for OS than PFS, largely because there will be fewer OS events than PFS events at the time of the analysis. For this reason, PFS is usually placed higher up the hierarchy than OS, so that a non-significant result for OS does not preclude looking at PFS for statistical significance (Example 4.3).",341,60,0.17595307917888564
9781912776696,hh-7,"Attention should not be refocused on strong subgroup results because of the problem of multiplicity. If there is a good clinical argument that supports a strong effect in a subgroup, then that subgroup should be built into the confirmatory testing strategy from the beginning of the study.","It is not uncommon for a study to show an impressive treatment difference in a key subgroup but fail in terms of the primary endpoint. In this situation, it is generally not possible to refocus attention on the subgroup to make a confirmatory claim because of the problem of multiplicity. Treatment differences within subgroups will occur by chance and, especially when there are a lot of subgroups, they are almost inevitable. Remember that 1 in 40 p -values will be statistically significant in favor of the experimental treatment by chance. An 'interesting' result in a subgroup would therefore only constitute an exploratory finding. If a subgroup is particularly important, perhaps because of a good clinical argument that supports a strong effect in that subgroup, then that subgroup should be built into the confirmatory testing strategy from the beginning, for example by putting it within the prespecified hierarchy. Forest plots. If there is a treatment difference in favor of the experimental treatment, it is routine practice to produce a forest plot that displays the result overall and in subgroups (Figure 4.1). The main reason for looking at subgroups in this way is to assess the consistency of an observed treatment effect. The Committee for Medicinal Products for Human Use (CHMP) has provided a draft guideline on subgroup evaluation in which it explains how to interpret forest plots. If all of the point estimates (the hazard ratios shown in Figure 4.1) fall within the confidence interval (CI) for the overall treatment effect, then there is no evidence for heterogeneity. If a point estimate strays outside of the overall CI.",322,57,0.17701863354037267
9781912776696,hh-7,Forest plots are a good way of graphically displaying the results of subgroup analyses.,"It is not uncommon for a study to show an impressive treatment difference in a key subgroup but fail in terms of the primary endpoint. In this situation, it is generally not possible to refocus attention on the subgroup to make a confirmatory claim because of the problem of multiplicity. Treatment differences within subgroups will occur by chance and, especially when there are a lot of subgroups, they are almost inevitable. Remember that 1 in 40 p -values will be statistically significant in favor of the experimental treatment by chance. An 'interesting' result in a subgroup would therefore only constitute an exploratory finding.",123,17,0.13821138211382114
9781912776696,hh-8,Interim analyses assess the data for efficacy or for futility (or both) while the trial is ongoing and data are still accumulating.,"Conversely, if, at the interim stage, the drug demonstrates only limited efficacy potential, it may be prudent to stop the study and use the remaining budget and resources elsewhere in the company on a project that has greater potential for success. Disadvantages of interim analyses. There are several potential disadvantages of stopping trials early that must be considered at the trial design stage. Stopping a Phase II trial early could limit the amount of data available for other key aspects of the process such as the choice of, or justification for, the optimum dose. Stopping a Phase III trial early based on the evidence for the primary endpoint may limit the amount of data collected from secondary endpoints and safety, which ultimately may delay, or even prevent, approval for the new treatment.",152,27,0.17763157894736842
9781912776696,hh-8,"Interim analyses have predefined stopping rules for overwhelming efficacy of the experimental treatment, or futility if the experimental treatment does not appear to offer any efficacy advantage over the existing treatment (or against placebo).","Interim analyses for efficacy have stopping rules that trigger a conclusion of overwhelming efficacy for the experimental treatment. At each interim analysis, a p -value calculation compares the treatment groups for the primary endpoint. The p -value needs to be sufficiently small to draw a positive efficacy conclusion. This is an example of multiplicity in which repeated significance tests, id est interim analyses in addition to the primary analysis at the end of the study, have the potential to inflate the type I error and thus increase the chances of a false-positive claim (see Chapter 4). For example, there may be three p -value calculations for two interim analyses and a final analysis, each of which has the potential to be a false positive. As explained in Chapter 4, 0.05 cannot be used as the cut-off for statistical significance for each analysis if the family-wise error rate (FWER) is to be controlled at 5%. Instead, the type I error rate (alpha = 0.05) must be divided across the three analyses.",206,40,0.1941747572815534
9781912776696,hh-8,"Multiple analyses have the potential to inflate the type I probability error (multiplicity), increasing the chances of false-positive results. The type I error rate (alpha = 0.05) must therefore be divided across the interim analyses for efficacy.","Interim analyses for efficacy have stopping rules that trigger a conclusion of overwhelming efficacy for the experimental treatment. At each interim analysis, a p -value calculation compares the treatment groups for the primary endpoint. The p -value needs to be sufficiently small to draw a positive efficacy conclusion. This is an example of multiplicity in which repeated significance tests, id est interim analyses in addition to the primary analysis at the end of the study, have the potential to inflate the type I error and thus increase the chances of a false-positive claim (see Chapter 4). For example, there may be three p -value calculations for two interim analyses and a final analysis, each of which has the potential to be a false positive. As explained in Chapter 4, 0.05 cannot be used as the cut-off for statistical significance for each analysis if the family-wise error rate (FWER) is to be controlled at 5%. Instead, the type I error rate (alpha = 0.05) must be divided across the three analyses. Several schemes are used to break down the type I error rate for interim analyses. Provided the scheme is prespecified in the protocol, any of the following splits can be imposed on the design.",245,49,0.2
9781912776696,hh-8,"In most schemes to divide the alpha, a substantial amount of the 0.05 is left for the final analysis, with the interim analyses for efficacy having very stringent significance levels.","The most important analysis is the final analysis, so a substantial amount of the 0.05 should be left over for that final analysis. For two interim analyses and a final analysis, the division of the alpha (alpha = 0.05) is 0.0006, 0.014 and 0.045. Therefore, at the first interim analysis the adjusted significance level is 0.0006. This must be achieved to trigger a stopping decision for overwhelming evidence for efficacy. At the second interim analysis, the adjusted significance level is 0.014, which leaves a significance level of 0.045 for the final analysis. You will probably have recognized that the three adjusted significance levels used in the O'Brien-Fleming scheme do not add up to 0.05. In this situation, one plus one does not equal two - the adjusted alpha levels are not additive. This is because the analyses are correlated, id est the data for the first 200 patients is a subset of the data for the first 400 patients and the data for the first 400 patients is a subset of the data for the total 600 patients. The adjusted significance levels control the overall potential for the false positive (the FWER) at 0.05.",243,35,0.1440329218106996
9781912776696,hh-8,"There is usually only one interim analysis for futility, relatively early in the trial.","The objective here is to stop the study because it has no real chance of achieving the required level of statistical significance for the primary endpoint(s) if it were to run to completion. In general, a futility assessment takes place reasonably early in the trial, as stopping a study for futility potentially saves a sponsor's resources. There is usually only one interim analysis for futility, which for practical reasons may coincide with the first interim analysis for efficacy if such an analysis has been built into the study design, although this is not a requirement.",109,17,0.1559633027522936
9781912776696,hh-8,"The conditional power recalculates the power of the study based on the interim data under either the current trend or the original assumption. The former assumes the data in the interim analysis reflect the truth, whereas the latter assumes the original assumption about the data is correct.","Conditional power under the current trend assumes that the data observed so far (HR = 0.92) reflect the truth. If conditional power under the current trend is, for example, < 20%, and if the observed trend in each treatment arm continues for the remainder of the study, it can be argued that the trial is not worth continuing as there is such a small probability of a statistically significant result at trial completion. Conditional power under the original assumption. Alternatively, a more optimistic view is that the data observed so far do not reflect the truth and that the true HR is still 0.75. This increases the conditional power, but if it remains low (exempli gratia < 30%), then it could still be argued that it is not worth continuing the trial. In this instance, even with optimistic assumptions about the trends in the data moving forward, the probability for success remains low. Choice of cut-off for futility, as determined by the conditional power, is entirely at the discretion of the sponsor. Even a trial with a conditional power of 30% still has a 30% probability of success and the sponsor must decide whether this is something that is worth pursuing. Cut-off values for conditional power under the current trend are generally about 20% or 30%, but there are examples of sponsors using values as high as 50%.",269,52,0.19330855018587362
9781912776696,hh-9,"A stratified analysis (analysis of variance; ANOVA) gives a treatment effect, adjusting for baseline imbalances for continuous and score endpoints.","These stratified analyses (ANOVA for continuous and score endpoints, CMH test for binary endpoints and stratified logrank test for time-to-event endpoints) are routinely used to adjust for one or two baseline factors; for example, to adjust for two factors (exempli gratia age in three categories and sex), the data would need to be broken down into six categories according to the six combinations of age and sex. When adjusting for multiple baseline factors, however, the technique can break down. For example, to adjust for three baseline factors - age (< 50 vs 50 to < 60 vs >= 60), sex (male vs female) and baseline risk (ECOG 1 vs ECOG 2) - the data would need to be broken down into 12 (3 x 2 x 2) categories (strata), but there may not be any patients in the active treatment group who are, say, under 50 years, male and ECOG 1. If that is the case, a treatment difference for that category could not be obtained and the methodology described above would break down.",220,30,0.13636363636363635
9781912776696,hh-9,"The Cochran-Mantel-Haenszel test compares treatments, adjusting for baseline imbalances for a binary endpoint, while the stratified logrank test does the same for a time-to-event endpoint.","These stratified analyses (ANOVA for continuous and score endpoints, CMH test for binary endpoints and stratified logrank test for time-to-event endpoints) are routinely used to adjust for one or two baseline factors; for example, to adjust for two factors (exempli gratia age in three categories and sex), the data would need to be broken down into six categories according to the six combinations of age and sex. When adjusting for multiple baseline factors, however, the technique can break down. For example, to adjust for three baseline factors - age (< 50 vs 50 to < 60 vs >= 60), sex (male vs female) and baseline risk (ECOG 1 vs ECOG 2) - the data would need to be broken down into 12 (3 x 2 x 2) categories (strata), but there may not be any patients in the active treatment group who are, say, under 50 years, male and ECOG 1. If that is the case, a treatment difference for that category could not be obtained and the methodology described above would break down.",220,45,0.20454545454545456
9781912776696,hh-9,Linear regression (univariate analysis) and multiple regression (multivariate analysis) investigate the dependence of an outcome on baseline factors.,"Multiple regression analysis. Having considered the dependence of an outcome (time to disease progression) on a single baseline factor (size of primary tumor at baseline), this approach can be extended to look simultaneously at the dependence on multiple baseline factors. Although it is not possible to draw this as in Figures 6.1-6.3, the simple regression equation can be extended to a multiple regression equation by including additional x variables. For example, evaluating the dependence of time to disease progression (y) on three baseline factors rather than one: size of primary tumor (x), age (x) and sex (x). Note that sex is a binary variable (male/female) while the other two variables are numeric. Binary variables can be incorporated into the modeling framework by defining them with a so-called indicator variable.",161,26,0.16149068322981366
9781912776696,hh-9,These statistical models can be incorporated into a single modeling framework that models the mean for continuous and score endpoints. Patient-to-patient variation is assumed to follow a normal distribution.,"Why one equation? What are the advantages of fitting these baseline factors into one equation? Why not perform three separate regression analyses on each of the variables? The latter approach could be misleading if the baseline factors are correlated, which they usually will be. For example, age and size of primary tumor may be correlated, with older patients generally presenting with larger tumors. A simple regression analysis, with age as the single baseline factor, could well give a significant p -value suggesting a dependence, but this would be misleading. It is not age that drives outcome: age is correlated with the size of primary tumor and it is the size of the primary tumor that determines outcome. The only way to ensure this correlation is accounted for is to include all variables simultaneously in a multiple regression analysis. This technique sorts out the correlation and identifies where the true dependence lies.",168,36,0.21428571428571427
9781912776696,hh-9,Analysis of covariance (ANCOVA) is an extension of ANOVA that can adjust for continuous covariates and for several covariates simultaneously when comparing treatments.,"Analysis of covariance for a single covariate. Analysis of covariance (ANCOVA) is used to compare treatment groups while accounting for baseline imbalances. It is an extension of the ANOVA introduced earlier. Figure 6.4 is a scatter plot showing the relationship between time to disease progression and the size of the primary tumor (the covariate) in two groups (active treatment versus control [placebo]), each comprising 20 subjects. In this instance, a simple comparison of mean time to disease progression in the active treatment group versus the mean time to disease progression in the control group, ignoring the role of size of primary tumor, would be a perfectly valid approach. However, it would not be especially sensitive as those means would not be that different. As can be seen in Figure 6.4, there are patients in the active treatment group with large tumors whose outcomes are poor (time to disease progression of 15 months or less). There are also patients in the control group who are doing well (time to disease progression of over 20 months). Therefore, a straight comparison of mean times to disease progression would not be a good reflection of the separation between the two groups that is clearly visible in Figure 6.4.",244,32,0.13114754098360656
9781912776696,hh-9,ANCOVA can also be used to investigate treatment x covariate interactions.,"Second, ANCOVA assumes that the effect of tumor size on time to disease progression is linear; id est it can be described by a straight-line relationship. This may not always be the case. For example, patients with small tumors may have different outcomes from those with medium or large tumors, while patients with medium or large tumors may have very similar outcomes. This would show as a plateauing of the data and would violate the assumption of linearity. ANOVA, on the other hand, makes no assumptions regarding the underlying relationship between tumor size and time to disease progression and for that reason could be the preferred approach under some circumstances. The real advantage of ANCOVA, however, is its ability to incorporate multiple covariates, a setting in which ANOVA often breaks down, as discussed earlier. ANCOVA can also be used to investigate treatment x covariate interactions. These two aspects are discussed below.",183,15,0.08196721311475409
9781912776696,hh-9,The logistic model provides a corresponding framework for binary endpoints that models the odds for the event.,"Models for binary and time-to-event endpoints. The models discussed above work for continuous and score endpoints where the mean value is being modeled. When the endpoint is binary the corresponding model is called the logistic model. Logistic regression is the term used when looking at dependence. The model is expressed in terms of the log odds for the event on the left-hand side, while the right-hand side is exactly like the models discussed above.",93,20,0.21505376344086022
9781912776696,hh-9,The Cox model provides a corresponding framework for time-to-event endpoints that models the hazard rate.,log odds for the event = a + cz + bx. For this model it is easy to show that c is directly related to the odds ratio (OR) for treatment with natural logarithm (ln) c = OR. Cox regression for time-to-event endpoints (Cox proportional hazards model) is expressed in terms of the log hazard rate. When looking for dependence the model is expressed as.,86,21,0.2441860465116279
9781912776696,hh-10,Kaplan-Meier curves are used to display data on a time-to-event endpoint.,"Kaplan-Meier curves are discussed in Chapter 2 in conjunction with the analysis of time-to-event endpoints (see Figures 2.2 and 2.3). In this chapter, Figure 7.1 shows two sets of curves in the open-label ToGA trial, which compared treatment with trastuzumab and chemotherapy with chemotherapy alone in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer. The upper set of curves relate to overall survival (OS) while the lower set relate to progression-free survival (PFS).",125,20,0.16
9781912776696,hh-10,Cumulative incidence functions are used with a composite endpoint when there is interest in separating out the different components of the composite.,"In many settings, a researcher will be interested in a composite event, such as progression or death, and the associated composite endpoint of time to death or progression (PFS). In some circumstances, there may be interest in separating out the components of the composite endpoint. In this regard, it is convenient to think in terms of curves plotted in reverse (see Kaplan-Meier curves above) in order to calculate the probability of the event occurring by time t. Consider the events 'death without progression' and 'progression'. Cumulative incidence functions allow the components of the composite to be separated by estimating two separate curves.",124,25,0.20161290322580644
9781912776696,hh-10,"Forest plots display results for subgroups in a clinical trial, or across a series of trials in a meta-analysis.","To display results in subgroups within a trial, enabling an assessment of homogeneity of treatment effect. To present results across trials in a meta-analysis. Judging the homogeneity of effect is discussed in Chapter 4 (see Figure 4.1). In this chapter, Figure 7.3 displays data from the ToGA trial, comparing the effect of trastuzumab and chemotherapy with chemotherapy alone in terms of OS. The overall HR with its 95% confidence interval (CI) is shown, along with the HRs and 95% CIs for each subgroup.",115,24,0.20869565217391303
9781912776696,hh-10,"Concerning increases in laboratory parameters from baseline can be identified by plotting, relative to the normal range, the baseline value on the x -axis and the maximum value over time on the y -axis in trellis plots.","One potential source of bias is publication bias, as a study that gives a statistically significant result in favor of the experimental treatment is more likely to be reported, and accepted for publication, than a corresponding study that gives a non-significant result. If the focus is only on published studies, this could result in a biased view of the experimental treatment effect. The funnel plot helps to detect the presence of publication bias by plotting the treatment effect in each study (exempli gratia the HR or relative risk [RR]/risk ratio) on the x -axis against some function of the precision of the study (exempli gratia the number of events observed or the standard error of the log HR) on the y -axis. Smaller studies will have low precision and more variable results in terms of the observed treatment effect, and these will appear toward the foot of the plot, while larger studies with greater precision will give more consistent results and will appear toward the top of the plot.",198,45,0.22727272727272727
9781912776696,hh-10,The change in tumor burden from baseline over a treatment period or through to the end of follow-up at the individual patient level can be displayed in a waterfall plot. Swimmer plots also identify key events during treatment at the individual patient level.,"It is common for individual patients to be color coded according to the response evaluation criteria in solid tumors (RECIST): complete response, partial response, stable disease, progressive disease. Displaying waterfall plots for each treatment group, one on top of the other, or color coded on the same plot, can be a useful aid when comparing treatments. Swimmer plots. Swimmer plots also focus on individual patient data and display key events during treatment and follow-up, such as start of response, end of response, end of treatment, progression and death (Figure 7.7). The length of the bar in a swimmer plot is often the duration of follow-up, with different symbols representing the different events. Patients can be ordered according to the length of follow-up, so that the longest survivors appear at the top of the plot. Bars can also be color coded to differentiate treatment groups or tumor types, or separated appropriately as with waterfall plots (see Figure 7.7).",196,48,0.24489795918367346
9781912776696,hh-10,"Box and whisker plots look at the distribution of data and can be used for laboratory parameters, vital signs and QTc intervals over time or across different tumor types.","Finally, all data values outside of the lower and upper whiskers are marked on the plot and considered as outliers. Box and whisker plots are a useful way of displaying data over time or across visits. They can be used to compare an outcome across different tumor types or to highlight differences between treatments: for example, for a particular laboratory parameter (Figure 7.9). The horizontal line drawn within each box is the median value. For a laboratory parameter or vital sign measured over time, these medians can be joined across time within each treatment group to help pick up trends. Trends are much easier to identify in a plot than in a table, especially when comparing treatment groups.",136,34,0.25
9781912776696,hh-10,Relative risks for adverse events can be displayed for the most frequent adverse events to highlight where treatment differences lie.,"The events displayed in Figure 7.10 are the most frequent adverse events in two treatment groups and are potentially those of greatest concern. The circles and triangles on the left-hand side are the percentage incidence rates by treatment group, while the right-hand side shows the RR for each adverse event with 95% CIs. The events are ordered according to the value of the RR, so the adverse events with an increased risk are immediately apparent.",88,22,0.25
9781912776726,ch1,"IDH wild-type glioblastomas occur mostly in older people (50-70 years old). They generally have chromosome 7 gain and chromosome 10 loss, and in many cases, EGFR amplification and/or TERT promoter mutation.","IDH wild-type glioblastoma is the most common form of glioblastoma. It is generally understood to have chromosome 7 gain and chromosome 10 loss, and in most cases, EGFR amplification and/or TERT promoter mutation (see Table 1.1 and Figure 1.3). These tumors can occur in adults of any age, but arise most commonly in individuals of 50-70 years old. They arise from the hemispheres of the forebrain, most commonly involving the frontal, parietal and occipital lobes. While histological features vary, these tumors always have a poorly differentiated glial phenotype with microvascular proliferations and/or necrosis - the essential histological features of glioblastomas according to the WHO classification (see Figure 1.3). Precursor forms of IDH wild-type glioblastoma present on MRI as hyperperfused low-grade diffuse gliomas and do not show high-grade histological features (see Figure 1.3). Historically, these tumors were diagnosed as astrocytomas. The 2016 WHO classification describes them as IDH wild-type astrocytomas, but they are better described as glioblastoma precursor or early glioblastoma even though this term is not used by the WHO classification. These precursor forms carry the same mutations as glioblastoma and can therefore be considered as early manifestations of these tumors.",298,49,0.1644295302013423
9781912776726,ch1,"Many intrinsic brain tumors can be defined by their driver mutations, some of which are diagnostically and prognostically relevant. For example, the presence of an IDH mutation generally confers a better prognosis than no IDH mutation with chromosome 7 gain and chromosome 10 loss (as seen in early forms of glioblastoma or histological classic glioblastoma).","Oligodendrogliomas are also defined by the presence of an IDH mutation (see Table 1.1). These occur in low- and high-grade forms; the latter may have similar histological features to glioblastoma. Oligodendrogliomas occur in people in their 30s and 40s, are usually located in the frontal or parietal lobes, and are defined by the presence of an IDH mutation and loss of heterozygosity on chromosome arms 1p and 19q (1p/19q co-deletion). Oligodendrogliomas have functional ATRX and usually carry a TERT promoter mutation. Loss of heterozygosity 1p/19q does not occur in glioblastoma. An important diagnostic pitfall is the occasional presence of an oligodendroglioma-like component in a small proportion of glioblastomas (GBM-O), but this has no clinical relevance. An earlier study that reported such differences included a proportion of IDH -mutant glioblastomas, suggesting a better outcome in the GBM-O cohort. Subsequent large-scale molecular studies, analyzing data from nearly 1000 patients with glioblastoma, found a correlation with 7p and 10q status, but not with histological features. Histone H3.3 K27M-mutant glioblastoma has recently been recognized as a rare form of glioblastoma characterized by the K27M driver mutation in the histone H3.3 gene. This mutation results in abnormal chromatin remodeling and has a distinct gene expression profile. Tumors with this mutation are found in midline structures of the central nervous system, including the spinal cord, brainstem, midbrain and thalamus (see Table 1.1). They have non-specific histological features and do not always have high-grade features; nevertheless, the WHO 2016 classification categorizes them as grade IV tumors. H3.3 K27M-mutant glioblastomas are most commonly seen in children in the brainstem (so-called diffuse intrinsic pontine glioma), but adult forms are increasingly being recognized.",457,78,0.17067833698030635
9781912776726,ch1,IDH -mutant tumors may be astrocytomas or oligodendrogliomas. They occur in people aged 30-40 years and are usually located in the frontal lobe.,"Oligodendrogliomas are also defined by the presence of an IDH mutation (see Table 1.1). These occur in low- and high-grade forms; the latter may have similar histological features to glioblastoma. Oligodendrogliomas occur in people in their 30s and 40s, are usually located in the frontal or parietal lobes, and are defined by the presence of an IDH mutation and loss of heterozygosity on chromosome arms 1p and 19q (1p/19q co-deletion). Oligodendrogliomas have functional ATRX and usually carry a TERT promoter mutation. Loss of heterozygosity 1p/19q does not occur in glioblastoma.",159,39,0.24528301886792453
9781912776726,ch1,Gliomas in midline structures are highly likely to have a histone H3.3 K27M mutation.,"Histone H3.3 K27M-mutant glioblastoma has recently been recognized as a rare form of glioblastoma characterized by the K27M driver mutation in the histone H3.3 gene. This mutation results in abnormal chromatin remodeling and has a distinct gene expression profile. Tumors with this mutation are found in midline structures of the central nervous system, including the spinal cord, brainstem, midbrain and thalamus (see Table 1.1). They have non-specific histological features and do not always have high-grade features; nevertheless, the WHO 2016 classification categorizes them as grade IV tumors. H3.3 K27M-mutant glioblastomas are most commonly seen in children in the brainstem (so-called diffuse intrinsic pontine glioma), but adult forms are increasingly being recognized.",182,24,0.13186813186813187
9781912776726,ch1,MGMT promoter methylation increases chemosensitivity to temozolomide treatment.,"MGMT promoter methylation status. The resistance of glioma cells to alkylating agent chemotherapy (id est temozolomide - see pages 47 -) is mainly mediated by the DNA repair enzyme O -methylguanine-DNA methyltransferase (MGMT). Epigenetic silencing of the MGMT gene by promoter methylation in glioma cells occurs in about 50% of glioblastomas, increasing chemosensitivity. Patients whose tumors contain a methylated MGMT promoter therefore derive greater benefit from treatment with temozolomide than those with unmethylated- MGMT glioblastomas (see pages 48 -).",136,17,0.125
9781912776726,ch2,The signs and symptoms of glioblastoma result from direct compression and infiltration of the surrounding brain tissue and from the effects of increased intracranial pressure due to increasing tumor size and surrounding edema.,"The signs and symptoms of glioblastoma result from direct compression and infiltration of surrounding brain tissue and secondarily from the effects of raised intracranial pressure (ICP) due to the tumor and edema. There is no fixed pattern of symptom progression; specific signs and symptoms will vary from person to person depending on the area of the brain that is affected (see Typical locations, Table 1.1). Neurological deficit. Patients commonly experience focal neurological deficits such as hemiparesis, sensory loss or visual field defects, reflecting the location of the tumor. Patients with frontal tumors often present with cognitive deficits, a change in personality or a mood disorder and are often mistakenly diagnosed with a psychiatric disorder. Five percent of patients present with aphasia due to a tumor in the speech-dominant hemisphere, which may be mistaken for confusion or delirium. Patients with larger tumors may also experience incontinence and difficulties with gait due to mass effect.",197,42,0.2131979695431472
9781912776726,ch2,"Seizures and cognitive deficits tend to be seen throughout the trajectory of the disease. Headache and dizziness are more common in the early diagnostic phase, and nausea/vomiting, visual deficits and anorexia are more prevalent during treatment. Confusion, dysphagia, dyspnea, aphasia, drowsiness and fatigue are more prevalent at the end of life.","A systematic review identified symptom prevalence in patients at different stages of their glioma treatment. Glioblastoma is grade IV disease and so is not formally staged. The most common symptoms are shown in Table 2.1; other symptoms included alopecia, anorexia, anxiety/depression, constipation, diarrhea, dizziness, dyspepsia, gait disturbance, nausea/vomiting, pain, right-left confusion, sensory deficits, skin problems, urinary incontinence and visual defects. Eight of the ten most prevalent symptoms shown in Table 2.1 (excluding confusion and dysphagia) are included in at least two of the three assessment tools for patient-reported outcome measures: the brain cancer-specific European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20), the Functional Assessment of Cancer Therapy-Brain (FACT-Br), and the MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) module. These instruments are mostly used in clinical trials or research studies as a means of monitoring disease trajectory and the effect of treatments on quality of life and symptoms (Figure 2.1). They are important, as good symptom management has been shown to improve survival in other diseases such as lung cancer; however, symptoms are predominantly caused by the tumor, and to a lesser degree by the treatment. Note: these may occur at different phases in the disease trajectory (see Figure 2.1). Adapted from data in IJzerman-Korevaar et al. 2018.",325,79,0.24307692307692308
9781912776726,ch2,"The most prevalent symptoms of glioblastoma are neurological in nature. Apart from fatigue, the symptoms most commonly associated with end of life (exempli gratia anorexia, weight loss) in patients receiving palliative care for other forms of cancer are less common in patients with glioblastoma.","Eight of the ten most prevalent symptoms shown in Table 2.1 (excluding confusion and dysphagia) are included in at least two of the three assessment tools for patient-reported outcome measures: the brain cancer-specific European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20), the Functional Assessment of Cancer Therapy-Brain (FACT-Br), and the MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) module. These instruments are mostly used in clinical trials or research studies as a means of monitoring disease trajectory and the effect of treatments on quality of life and symptoms (Figure 2.1). They are important, as good symptom management has been shown to improve survival in other diseases such as lung cancer; however, symptoms are predominantly caused by the tumor, and to a lesser degree by the treatment. Note: these may occur at different phases in the disease trajectory (see Figure 2.1). Adapted from data in IJzerman-Korevaar et al. 2018. Confusion (40.3%), dysphagia (41.9%) and dyspnea (17.7%) are more prevalent at the end of life than during diagnosis, treatment and follow-up. A higher prevalence of confusion is seen at the end of life in patients with primary brain tumors than in patients with brain metastases or a general palliative care population. Aside from fatigue, the symptoms most commonly associated with end of life in cancer, such as anorexia and weight loss, tend to occur less often in patients with glioma than in other patients receiving palliative care. A study that compared 65 patients with glioblastoma at postsurgical baseline versus 130 age- and sex-matched healthy controls, reported that patients with glioblastoma frequently experience fatigue, suggesting that factors other than those related to radiotherapy or chemotherapy, such as depression and tumor localization, have a significant impact. Thus, patients require tailored symptom care at different times during the course of their disease.",422,65,0.15402843601895735
9781912776726,ch2,The trajectory of the disease varies widely from patient to patient depending on the location of the tumor and other patient- and treatment-related factors. Patients with glioblastoma should be treated on an individual basis according to their symptom burden at different phases of the disease course.,"Note: these may occur at different phases in the disease trajectory (see Figure 2.1). Adapted from data in IJzerman-Korevaar et al. 2018. Confusion (40.3%), dysphagia (41.9%) and dyspnea (17.7%) are more prevalent at the end of life than during diagnosis, treatment and follow-up. A higher prevalence of confusion is seen at the end of life in patients with primary brain tumors than in patients with brain metastases or a general palliative care population. Aside from fatigue, the symptoms most commonly associated with end of life in cancer, such as anorexia and weight loss, tend to occur less often in patients with glioma than in other patients receiving palliative care. A study that compared 65 patients with glioblastoma at postsurgical baseline versus 130 age- and sex-matched healthy controls, reported that patients with glioblastoma frequently experience fatigue, suggesting that factors other than those related to radiotherapy or chemotherapy, such as depression and tumor localization, have a significant impact. Thus, patients require tailored symptom care at different times during the course of their disease.",242,55,0.22727272727272727
9781912776726,ch3,It is important to recognize that gliomas that appear to be low-grade tumors histologically may carry mutations associated with higher-grade tumors.,"When assessing gliomas, it must be borne in mind that some tumors with the molecular profile of a glioblastoma (see below) may not have all high-grade features. It is increasingly apparent that diffuse infiltrating gliomas may not have high-grade features when diagnosed early. Likewise, the histone H3.3 K27M-mutant gliomas may not have any histological high-grade features but are defined as WHO grade IV. This is why a multidisciplinary approach is so important for the optimal diagnosis of patients with glioblastoma - the molecular analysis ensures a more robust classification.",130,29,0.2230769230769231
9781912776726,ch3,"The use of methylation arrays can add diagnostic information to brain tumors that are otherwise diagnostically difficult, or where conventional molecular tests do not give informative results.","Epigenetic changes. Many high-grade gliomas can be classified by a selection of the markers described above. However, some remain unclassifiable because of a lack of distinctive mutation patterns. Thus, a method has been developed that looks at epigenetic changes caused by a combination of mutations and the cell of origin. These epigenetic changes are identified from methylation patterns (which are a result of driver mutations), using a publicly accessible algorithm (www.molecularneuropathology.org). This method is widely used in the diagnosis of brain tumors with unusual or ambiguous histology and when conventional molecular testing is not diagnostically informative. A diagnostically useful copy number profile is also generated, which elucidates chromosomal changes and gene amplifications or losses (see Figure 1.3).",162,32,0.19753086419753085
9781912776726,ch3,"A variety of MRI features characterize glioblastoma, including solid contrast uptake and absence of enhancement.","The typical post-contrast appearance of glioblastoma on MRI is that of a (usually large) nodular rim-enhancing mass surrounding a central necrotic core. However, the diagnosis of glioblastoma can be complex, as any type of enhancement pattern can occur, including solid-patchy enhancement, thin rim enhancement resembling a cyst or, indeed, a total lack of enhancement (Figure 3.2). Because the early stages of primary glioblastoma are frequently non-enhancing, radiological descriptions of non-enhancing gliomas as 'low grade' can be misleading and are best avoided given that the WHO 2016 classification is now based on an integrated diagnosis.",145,21,0.14482758620689656
9781912776726,ch3,"Advanced modalities such as diffusion and perfusion MRI and magnetic resonance spectroscopy can support the characterization of gliomas, with a view to grading, genotyping and differential diagnosis.","As mentioned in previous chapters, the location of the tumor can support the diagnosis, as it indicates the likelihood of certain genotypes. For example, multifocality is thought to be more common in IDH wild-type gliomas than IDH -mutant low-grade gliomas. Given the propensity of glioblastoma for rapid spread along white matter tracts, it is often considered to be a multifocal disease, even though this is not consistently visible on imaging. Distant metastases, however, are virtually non-existent, so staging can be achieved from brain imaging only. Although spinal dissemination of glioblastoma is uncommon, if spinal drop metastases are suspected (exempli gratia on discovery of intracranial leptomeningeal disease), post-gadolinium spine imaging from the skull base to the sacrum (id est along the entire vertebral canal) should be considered as part of the diagnostic work-up.",198,38,0.1919191919191919
9781912776726,ch3,"Anatomic MRI is required for the identification, characterization and estimation of disease extent. Early glioblastoma can present as small, barely visible lesions.","Distinguishing glioblastoma from other diseases is often, but not always, straightforward (Figure 3.3). Anatomic MRI is essential for the diagnosis of glioblastoma, but it has limited sensitivity and specificity for the characterization of morphologically atypical lesions; for example, CNS lymphoma with central necrosis or with solitary metastases. In these cases, body imaging is usually requested before brain biopsy. Perfusion imaging techniques. The recommendations for performing advanced imaging techniques are less prescriptive than anatomic MRI, as there is a lack of high-level evidence for many of the more complex modalities. However, to improve the identification of malignant gliomas, recent European guidance recommends the addition of perfusion imaging for newly diagnosed non-gadolinium-enhancing masses. Perfusion MRI aims to identify neovascularization in brain tumors by analyzing (contrast-enhanced) blood flow through a volume of tissue over time. Several perfusion methods exist (Table 3.1).",211,31,0.14691943127962084
9781912776726,ch3,"Differential diagnoses may include metastatic disease, primary central nervous system lymphoma and therapy effects such as pseudoprogression and/or radiation necrosis.","Lower ADC values have been shown to correlate with higher glioma grades, corresponding to an increase in proliferative indices. Numerous studies have observed lower ADC values in IDH wild-type gliomas than IDH -mutant WHO grade II/III gliomas, specifically IDH -mutant 1p19q intact astrocytomas, which may show markedly increased ADC values ('facilitated diffusion'). To a limited extent, ADC measurements may also be valuable for differential diagnosis; for example, primary central nervous system lymphoma typically has lower ADC values than glioblastoma, but results can overlap for individual tumors. Other diffusion techniques. It remains unclear whether more elaborate diffusion techniques (exempli gratia diffusion kurtosis imaging, and multiexponential and compartmental diffusion models) could offer a diagnostic advantage over standard DWI for radiomic predictions.",178,31,0.17415730337078653
9781912776726,ch4,Patients with glioblastoma should be cared for by a multidisciplinary team.,"Patients with glioblastoma should be cared for by a multidisciplinary team that includes a neurosurgeon, neuropathologist, neuroradiologist, medical and radiation oncologists, and possibly a neurologist, together with allied health professionals such as physiotherapists, occupational therapists and social workers. Involvement of a supportive care team including specialist nursing care is also mandatory in the palliative setting.",87,19,0.21839080459770116
9781912776726,ch4,The initial therapeutic approach is surgical tumor debulking and biopsy; maximum tumor resection should be attempted if neurological function can be maintained.,"Surgery is the initial therapeutic approach for tumor debulking and to obtain tissue for diagnosis. The aim of surgery is maximum tumor resection while maintaining neurological function. Risk versus benefit. The neurosurgeon's preoperative assessment of the patient's prognosis - which will depend, among other things, on the location of the glioblastoma and the patient's performance status - will determine the extent of resection. For example, if the tumor is near or involves eloquent (exempli gratia language, motor, vision) areas of the brain, a subtotal resection or tissue biopsy only may be considered a more appropriate option than aggressive total resection. The consequences of surgically acquired neurological deficits (exempli gratia language, cognitive, motor, coordination and visual deficits) can be significant. If surgical resection is not safe because of the tumor location or impaired performance status, a biopsy should be obtained if feasible.",193,28,0.14507772020725387
9781912776726,ch4,"Functional MRI and diffusion tensor imaging are valuable for surgical planning in gliomas that are situated close to eloquent (exempli gratia language, motor, visual) regions of the brain.","Risk versus benefit. The neurosurgeon's preoperative assessment of the patient's prognosis - which will depend, among other things, on the location of the glioblastoma and the patient's performance status - will determine the extent of resection. For example, if the tumor is near or involves eloquent (exempli gratia language, motor, vision) areas of the brain, a subtotal resection or tissue biopsy only may be considered a more appropriate option than aggressive total resection. The consequences of surgically acquired neurological deficits (exempli gratia language, cognitive, motor, coordination and visual deficits) can be significant. If surgical resection is not safe because of the tumor location or impaired performance status, a biopsy should be obtained if feasible. Surgical planning. MRI helps to estimate the operability of tumors and facilitates surgical planning. High-resolution 3D volumetric imaging sequences can help to assess tumor resectability and the optimal operative trajectory. Anatomic MRI can be integrated into surgical navigation software, where appropriate, together with functional and tractography sequences.",224,41,0.18303571428571427
9781912776726,ch4,"The current standard of care is surgery followed by chemoradiotherapy (60 Gy radiotherapy over 6 weeks with concomitant temozolomide, 75 mg/m daily), followed by six cycles of adjuvant temozolomide, 150-200 mg/m on days 1-5 of each 28-day cycle.","Chemotherapy. Temozolomide is an imidazotetrazine-derived alkylating agent that is 100% bioavailable when taken orally, reaching peak plasma concentrations within 1 hour. Because of its small size and lipophilic properties, it can cross the blood-brain barrier. Temozolomide is administered orally at 75 mg/m daily during radiotherapy. After a duration of approximately 1 month, this is followed by six cycles of adjuvant temozolomide at 150-200 mg/m on days 1-5 of every 28-day cycle. Temozolomide acts by preventing DNA replication through alkyl group-mediated crosslinking of DNA. Clinical data. The standard of care described above is based on the results of the 2005 European Organisation for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) Clinical Trials Group CE3 randomized Phase III trial of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone in 573 patients with glioblastoma. In this trial, median OS was 14.6 months with radiotherapy plus temozolomide, and 12.1 months with radiotherapy alone. The unadjusted hazard ratio (HR) for death in the radiotherapy/temozolomide group was 0.63 (95% CI 0.52-0.75, p < 0.001). In patients whose tumors contained a methylated MGMT promoter (see page 18), median OS was significantly longer with temozolomide and radiotherapy than with radiotherapy alone (21.7 [95% CI 17.4-30.4] versus 15.3 [13.0-20.9] months; p > 0.007). The survival benefit in patients who received adjuvant temozolomide with radiotherapy continued to the 5-year follow-up, including in patients aged 60-70 years.",416,69,0.1658653846153846
9781912776726,ch4,Methylation of the MGMT promoter gene is the strongest predictor for outcome and benefit from temozolomide therapy.,"Clinical data. The standard of care described above is based on the results of the 2005 European Organisation for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) Clinical Trials Group CE3 randomized Phase III trial of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone in 573 patients with glioblastoma. In this trial, median OS was 14.6 months with radiotherapy plus temozolomide, and 12.1 months with radiotherapy alone. The unadjusted hazard ratio (HR) for death in the radiotherapy/temozolomide group was 0.63 (95% CI 0.52-0.75, p < 0.001). In patients whose tumors contained a methylated MGMT promoter (see page 18), median OS was significantly longer with temozolomide and radiotherapy than with radiotherapy alone (21.7 [95% CI 17.4-30.4] versus 15.3 [13.0-20.9] months; p > 0.007). The survival benefit in patients who received adjuvant temozolomide with radiotherapy continued to the 5-year follow-up, including in patients aged 60-70 years.",271,25,0.09225092250922509
9781912776726,ch4,"Prognostic factors associated with improved survival with the standard of care are younger age, better performance status, Mini-Mental State Examination score of at least 27 and no steroid treatment at baseline.","MGMT methylation status. In 2019, Hegi and colleagues reported a study that examined the optimal cut-off for definition of MGMT methylation based on four randomized trials involving 1725 patients with newly diagnosed glioblastoma who received standard radiotherapy and temozolomide. A cut-off of greater than 1.27 was identified as high MGMT methylation that would render a tumor more sensitive to temozolomide. The cut-off for 'truly unmethylated' tumors was -0.28 or lower; approximately 10% of tumors were in the 'gray zone' (< 0.28, <= 1.27). The authors concluded that low MGMT methylation status within the 'gray zone' may confer some sensitivity to temozolomide therapy and recommended that the lower safety margin should be used to select patients with unmethylated tumors for inclusion in trials that do not include temozolomide. At present, clinicians form their own opinions as to how to apply this in clinical practice. Other prognostic factors associated with improved survival in patients with glioblastoma receiving radiotherapy with concomitant and adjuvant temozolomide are younger age, better performance status, Mini-Mental State Examination score of 27 or higher and no steroid treatment at baseline.",270,39,0.14444444444444443
9781912776726,ch4,"MRI is the preferred method for following up patients. MRI scans are commonly performed every 3-4 months, unless the patient's clinical status dictates more frequent monitoring. Routine blood tests are not required for patients who are not receiving chemotherapy.","Serial magnetic resonance imaging is the preferred method of response assessment and long-term monitoring after surgery and/or adjuvant therapy. MRI scans are commonly performed every 3-4 months unless the clinical status of the patient (exempli gratia deteriorating symptoms) dictates more frequent monitoring. Conversely, some clinicians may wait several months longer to image (well patients) to minimize any confusion with the transient worsening associated with pseudoprogression or radiation necrosis or, indeed, the misleading improvement of a pseudoresponse to therapy. This process of imaging is fraught with complexity. Many technical parameters such as scanner hardware, multiple software settings, patient positioning, contrast dose and timing all may influence lesion conspicuity over time. Serial tumor measurements can vary according to scan angle and slice selection. For this reason, the technical parameters of serial MRI scans should be kept as constant as practicable to avoid missing or overestimating tumor changes over time. Volumetric (3D) imaging can be useful in support of serial tumor measurements, as this provides image reconstructions in all planes.",214,47,0.21962616822429906
9781912776726,ch4,"Therapy effects may manifest as transient worsening (pseudoprogression, radiation necrosis) or misleading improvement (pseudoresponse) of enhancing lesions. Interpretation of MRI scans after treatment can be complex. Treatment timing must be considered. In challenging cases, response assessment may benefit from physiological imaging techniques, including perfusion and PET imaging.","This process of imaging is fraught with complexity. Many technical parameters such as scanner hardware, multiple software settings, patient positioning, contrast dose and timing all may influence lesion conspicuity over time. Serial tumor measurements can vary according to scan angle and slice selection. For this reason, the technical parameters of serial MRI scans should be kept as constant as practicable to avoid missing or overestimating tumor changes over time. Volumetric (3D) imaging can be useful in support of serial tumor measurements, as this provides image reconstructions in all planes. Glioblastoma recurrence versus therapy effects. A problematic issue is the overlap that exists between structural and advanced imaging features of viable tumor and necrotic tissue. On conventional MRI sequences, the early (pseudoprogression; Figure 4.2) and late (radiation necrosis) effects of adjuvant therapy are often indistinguishable from a growing tumor, as both may appear as new or enlarging enhancing lesions due to breakdown of the blood-brain barrier. The true incidence of therapy effects is debatable, as it depends on the definition of a progressive lesion. This complexity is acknowledged in the Response Assessment in Neuro-Oncology (RANO) criteria, which take into consideration the timing of adjuvant therapy for glioblastoma serial monitoring. To date, the challenge of distinguishing between glioblastoma recurrence and therapy effects has not been completely resolved, not least because the two may coexist. However, several advanced imaging techniques are valuable in this context. Perfusion MRI can help to identify neovascular (viable) tumor (Figure 4.3), but difficulty may arise from intermediate values, and short-interval monitoring may be necessary unless a histological diagnosis is pursued.",359,70,0.19498607242339833
9781912776726,ch4,A standard of care has not been established for patients whose disease progresses after chemotherapy; enrolment into clinical trials is recommended if patients meet the inclusion criteria.,"Tumor recurrence after initial standard of care therapy is virtually inevitable. A standard of care has not been established for glioblastoma that progresses after chemotherapy. For patients who meet the inclusion criteria and are considered fit enough for further treatment, enrolment into clinical trials is recommended. Surgery may be considered, particularly if the tumor exerts a mass effect. Radiotherapy. Repeat radiotherapy may be considered for recurrent small tumors, although there is a lack of prospective comparative trials. The evidence supporting use of stereotactic radiotherapy in the recurrent setting is minimal. A Phase I multicenter dose-escalation study in 15 patients with recurrent glioblastoma or anaplastic astrocytoma showed that re-irradiation using hypofractionated stereotactic radiotherapy with concomitant bevacizumab (see below) was feasible and reasonably well tolerated; dose escalation up to 11 Gy x 3 was possible. Median OS was 13 months in the intent-to-treat population.",209,30,0.14354066985645933
9781912776726,ch4,Radiotherapy and temozolomide is suitable for fit elderly patients with glioblastoma.,"Management of glioblastoma in older patients (>= 65 years) can be challenging, given the poor prognosis, the likelihood of comorbidities and an increased risk of toxicity from radiotherapy on the aging brain. A recent trial in older patients (>= 65 years; n > 562) with newly diagnosed glioblastoma compared radiotherapy (40 Gy in 15 fractions) alone and with concomitant and adjuvant temozolomide (75 mg/m daily for 21 days, followed by 150-200 mg/m on days 1-5 of each 28-day cycle for up to 12 cycles or until disease progression). The addition of temozolomide to radiotherapy increased median OS from 7.6 to 9.3 months (HR for death 0.67 [95% CI 0.56-0.8]; p < 0.001), without compromising quality of life and with manageable chemotherapy-related side effects. Subgroup analysis showed that the benefit of chemoradiotherapy was particularly evident in patients with methylated MGMT status. Thus, combination therapy should be considered for fit elderly patients with glioblastoma.",238,22,0.09243697478991597
9781912776726,ch5,"Fatigue is one of the most common symptoms in patients with glioblastoma. If the patient is fit enough, then light-to-moderate exercise or physical therapy should be encouraged. Short-term steroids may be useful, provided patients are warned of the potential short-term adverse effects.","The treatment of glioblastoma includes recognizing and managing a host of disease- and treatment-related complications. This chapter focuses on several of the most common conditions associated with glioblastoma. More than half of patients with cancer who experience fatigue never tell their doctor about it, but as it is one of the most common symptoms experienced by patients with glioblastoma it is important to ascertain whether it is a problem. It may help if the patient keeps a 'fatigue diary', including a note of activities that make the fatigue better or worse. Anemia should be ruled out or treated, as appropriate. If the patient is fit enough, then a light to moderate level of exercise or physical therapy should be encouraged. Steroids can be prescribed, but patients should be made aware of the likely short-term adverse events, including raised glucose, thin skin, easy bruising, gastric irritation and the increased risk of infection. The pathophysiological development of depression and glioblastoma share several pathways, including altered regulation of the 5-hydroxytryptamine (serotonin) receptor, norepinephrine and cyclic adenosine monophosphate (cAMP).",242,60,0.24793388429752067
9781912776726,ch5,Selective serotonin-reuptake inhibitors are suitable treatment for patients with depression during glioblastoma treatment. These drugs do not appear to affect the toxicity of chemoradiotherapy or compromise survival.,"A systematic review of 42 observational studies involving 4089 patients with primary cerebral glioma (varying stages) reported a median frequency of depression at clinical interview of 15% (range 6-28%). Depression was associated with reduced physical function, cognitive impairment, reduced quality of life, caregiver distress and reduced likelihood of returning to work. The risk of depression was not affected by sex or older age, or with tumor location, histology, grade or extent of resection. The authors considered depression to be primarily a psychological response to the loss of health. The authors recommended the Hospital Anxiety and Depression Scale (HADS) as an accurate initial screening instrument for depression in glioma, although it may be difficult to apply in patients with hemiparesis, hemianopia, hemisensory neglect or dysphagia; all these conditions might skew the answers. Treatment. A retrospective study reported that almost 22% of 160 patients with glioblastoma took a selective serotonin-reuptake inhibitor during treatment for glioblastoma without affecting the toxicity of chemoradiotherapy or compromising survival. Careful antidepressant selection should be made under pharmacist and physician review to avoid potential adverse interactions.",244,41,0.1680327868852459
9781912776726,ch5,"The Hospital Anxiety and Depression Scale (HADS) can be used for the assessment of depression in patients with glioblastoma with the caveat that results may be skewed in patients with hemiparesis, hemianopia, hemisensory neglect or dysphagia.","A systematic review of 42 observational studies involving 4089 patients with primary cerebral glioma (varying stages) reported a median frequency of depression at clinical interview of 15% (range 6-28%). Depression was associated with reduced physical function, cognitive impairment, reduced quality of life, caregiver distress and reduced likelihood of returning to work. The risk of depression was not affected by sex or older age, or with tumor location, histology, grade or extent of resection. The authors considered depression to be primarily a psychological response to the loss of health. The authors recommended the Hospital Anxiety and Depression Scale (HADS) as an accurate initial screening instrument for depression in glioma, although it may be difficult to apply in patients with hemiparesis, hemianopia, hemisensory neglect or dysphagia; all these conditions might skew the answers. Treatment. A retrospective study reported that almost 22% of 160 patients with glioblastoma took a selective serotonin-reuptake inhibitor during treatment for glioblastoma without affecting the toxicity of chemoradiotherapy or compromising survival. Careful antidepressant selection should be made under pharmacist and physician review to avoid potential adverse interactions.",244,56,0.22950819672131148
9781912776726,ch5,"Although seizures are a common symptom in patients with glioblastoma, prophylactic use of antiepileptic drugs outside the perioperative phase is not advised. First-generation antiepileptic drugs may interact with other medications; the preferred antiepileptic agents are lamotrigine, levetiracetam, pregabalin and valproic acid.","Seizures are often the first symptom of a brain tumor and are likely to be caused by elevated levels of N -methyl- D -aspartate (NMDA) and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) extracellular glutamate receptors, and the formation of the oncometabolite 2-hydroxyglutarate, which resembles glutamate, in gliomas with IDH1 mutations. Localization of high-grade gliomas to the temporal lobe or cortex may also cause seizures. Surgical resection may induce seizures if, for example, the tumor is localized to the temporal lobe. Conversely, resection may reduce the incidence of seizures if they are being caused by edema or the mass effect of the tumor. In a retrospective analysis of 103 patients with glioblastoma, 22% (all with IDH1/2 wild-type glioblastoma) experienced seizures. Patients with seizures had smaller tumors, which caused less edema than non-epileptogenic tumors. Glutamate carrier systems were significantly upregulated in symptomatic compared with asymptomatic tumors, resulting in 'oversupply' of glutamate. The authors concluded that epileptogenic and non-epileptogenic tumors were morphologically different. Treatment. Antiepileptic drugs are recommended for patients who present with seizures, but prophylactic use outside the perioperative phase is not advised. The preferred agents are lamotrigine, levetiracetam, pregabalin and valproic acid. First-generation antiepileptic drugs such as phenytoin, carbamazepine and phenobarbital and their derivatives are strong inducers of liver metabolic enzymes and may interact with medications, including many commonly used chemotherapy agents, although not temozolomide.",390,82,0.21025641025641026
9781912776726,ch5,"Venous thromboembolism (VTE) is common in patients with intrinsic brain tumors. Glioma is not a contraindication to standard anticoagulation in patients with established thrombosis, but prophylactic anticoagulation is not recommended. Instead, clinicians and patients need to be vigilant for any signs or symptoms of VTE.","In a retrospective analysis of 103 patients with glioblastoma, 22% (all with IDH1/2 wild-type glioblastoma) experienced seizures. Patients with seizures had smaller tumors, which caused less edema than non-epileptogenic tumors. Glutamate carrier systems were significantly upregulated in symptomatic compared with asymptomatic tumors, resulting in 'oversupply' of glutamate. The authors concluded that epileptogenic and non-epileptogenic tumors were morphologically different. Treatment. Antiepileptic drugs are recommended for patients who present with seizures, but prophylactic use outside the perioperative phase is not advised. The preferred agents are lamotrigine, levetiracetam, pregabalin and valproic acid. First-generation antiepileptic drugs such as phenytoin, carbamazepine and phenobarbital and their derivatives are strong inducers of liver metabolic enzymes and may interact with medications, including many commonly used chemotherapy agents, although not temozolomide. Venous thromboembolism. Venous thromboembolism (VTE) is common in patients with intrinsic brain tumors, with an annual incidence of up to 20%. Risk factors include glioblastoma molecular subtype (exempli gratia patients with IDH1 -mutant glioblastoma have a lower incidence of VTE than those with an IDH wild-type tumor), paresis, neurological deficits, immobilization, surgery and steroid use. The risk of VTE is increased by a tumor-induced hypercoagulable state. As there is no evidence that anticoagulation therapy prevents VTE in these patients, prophylactic anticoagulation is not recommended, but vigilance for suspicious indicatory symptoms is required. Glioma is not a contraindication to standard anticoagulation in patients with established thrombosis.",409,77,0.1882640586797066
9781912776726,ch5,"Steroid treatment (usually dexamethasone, 8-16 mg per day) will decrease tumor-associated edema and improve symptoms. Lower doses may be equally effective.","The risk of VTE is increased by a tumor-induced hypercoagulable state. As there is no evidence that anticoagulation therapy prevents VTE in these patients, prophylactic anticoagulation is not recommended, but vigilance for suspicious indicatory symptoms is required. Glioma is not a contraindication to standard anticoagulation in patients with established thrombosis. Cerebral edema. Steroids can be used to decrease tumor-associated edema and improve clinical symptoms. Dexamethasone, 8-16 mg per day, is the usual choice, although lower doses may be equally effective. Physicians should make a clinical decision on the optimal starting dose of steroids after assessing the patient. Steroids are not indicated in the absence of edema-associated neurological deficits or if intracranial pressure is normal. Prolonged steroid use after resection is not recommended, and prophylaxis with steroids is not required during radiotherapy in asymptomatic patients.",209,37,0.17703349282296652
9781912776726,ch6,"Novel therapeutic management approaches for patients with glioblastoma are needed, but the selective targeting of oncogenic mutations that has transformed the therapeutic landscape in other cancers has yet to be exploited in the treatment of glioblastoma. The need to penetrate the blood-brain barrier is a complicating factor.","Emerging research and treatment. Glioblastoma is the most common primary brain tumor in adults but the prognosis with the current standard of care (see Chapter 4) remains poor, and novel therapeutic approaches are needed. Selective targeting of oncogenic mutations has transformed the therapeutic landscape in many solid and hematologic cancers but has yet to be exploited in glioblastoma. The need to penetrate the blood-brain barrier represents an additional challenge in this tumor type. This chapter discusses some potential novel therapeutic targets and describes how the IDH and BRAF mutations discussed in Chapter 1 are being targeted. Immunotherapies, such as checkpoint inhibitors and dendritic cell vaccination, as well as marizomib, a novel, irreversible and brain-penetrant pan-proteasome inhibitor, are also being evaluated in gliomas. Researchers are also examining the potential of immunosuppressive gene therapy and tumor-treating fields. IDH inhibitors. Mutations in the IDH gene result in the production of the oncometabolite 2-hydroxyglutarate (2HG), which induces epigenetic alterations such as DNA global and histone methylation (see page 11). Isoform-selective IDH inhibitors have been developed to suppress production of 2HG. Ivosidenib is a small-molecule inhibitor of IDH that is already approved for the treatment of acute myeloid leukemia. It is also being evaluated for the treatment of several IDH1 -mutant solid tumors, including glioma. Phase I data in 35 patients with non-enhancing glioma (grade II and III tumors) have shown ivosidenib to be well tolerated with no dose-limiting toxicities. It is currently also in Phase III trials for the treatment of cholangiocarcinoma where it has been shown to improve progression-free survival (PFS) (2.7 months) relative to placebo (1.4 months) in previously treated patients with IDH1 -mutant advanced cholangiocarcinoma (hazard ratio [HR] > 0.37 [95% CI 0.25-0.54]; p < 0.001). While the 6- and 12-month PFS rates with ivosidenib were 32.0% and 21.9%, respectively, none of the patients who received placebo were progression free for 6 months or more at data cut-off.",507,64,0.126232741617357
9781912776726,ch6,"Ivosidenib, a small-molecule IDH inhibitor, vemurafenib, an inhibitor of BRAF V600E, and marizomib, a pan-proteosome inhibitor, are currently in early trials in patients with brain tumors.","Mutations in the IDH gene result in the production of the oncometabolite 2-hydroxyglutarate (2HG), which induces epigenetic alterations such as DNA global and histone methylation (see page 11). Isoform-selective IDH inhibitors have been developed to suppress production of 2HG. Ivosidenib is a small-molecule inhibitor of IDH that is already approved for the treatment of acute myeloid leukemia. It is also being evaluated for the treatment of several IDH1 -mutant solid tumors, including glioma. Phase I data in 35 patients with non-enhancing glioma (grade II and III tumors) have shown ivosidenib to be well tolerated with no dose-limiting toxicities. It is currently also in Phase III trials for the treatment of cholangiocarcinoma where it has been shown to improve progression-free survival (PFS) (2.7 months) relative to placebo (1.4 months) in previously treated patients with IDH1 -mutant advanced cholangiocarcinoma (hazard ratio [HR] > 0.37 [95% CI 0.25-0.54]; p < 0.001). While the 6- and 12-month PFS rates with ivosidenib were 32.0% and 21.9%, respectively, none of the patients who received placebo were progression free for 6 months or more at data cut-off.",309,56,0.18122977346278318
9781912776726,ch6,Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of glioblastoma. The final survival results of a large Phase III trial are awaited.,"Dendritic cell immunotherapy is designed to enhance the individual's immune response to overcome tumor-derived immunosuppression. The vaccine contains the patient's own dendritic cells, pulsed with the patient's tumor lysate or peptides (obtained during surgical resection). Once the vaccine has been administered back to the patient, intradermally or subcutaneously, it activates T cells to cross the blood-brain barrier and target glioblastoma cells. Vaccination-related side effects include redness and itching at the site of injection. Serious adverse events such as neurotoxicity have been rare. An autologous tumor lysate-pulsed dendritic cell vaccine is being trialed across 80 centers in four countries in patients with newly diagnosed glioblastoma. All enrolled patients underwent surgery and standard of care chemoradiotherapy (see page 47) before receiving the vaccine (n > 232) or placebo (n > 99). Patients in both arms have continued to receive adjuvant temozolomide, and the vaccine or placebo has been administered by intradermal injection in the arm on days 0, 10 and 20, then months 2, 4, 8 and 12 and every 6 months thereafter (id est six times in year 1 and twice per year thereafter). The optimal timing of vaccination has yet to be determined, but it is thought that vaccination at the same time as treatment with adjuvant chemotherapy may increase the chemosensitivity of the tumor.",305,38,0.12459016393442623
9781912776726,ch6,The use of drug-induced interleukin-12 gene therapy is currently being evaluated in patients undergoing resection for recurrent high-grade glioma.,"Tumor-localized gene therapy is designed to control the production of the cytokine human interleukin-12 (hIL-12), which triggers the activation and expansion of T cells and is being investigated in patients undergoing resection for recurrent high-grade glioma. First, the hIL-12 gene vector that encodes IL-12 is injected into the tumor resection cavity. Patients are then treated with the oral compound veledimex, 20 mg, in capsule form, which activates IL-12 production. The preliminary results of a multicenter Phase I dose-escalation trial have shown a median OS of 12.7 months. In patients who also received low-dose steroids (>= 20 mg dexamethasone), the median OS was 17.8 months versus 6.4 months in patients who received high-dose steroids (< 20 mg dexamethasone). The treatment appears to be well tolerated: cytokine release syndrome correlated with the dose of veledimex and reversed promptly on discontinuation.",211,32,0.15165876777251186
9781912776818,hh-3,Thrombotic thrombocytopenic purpura (TTP) exists as immune-mediated (autoimmune) and congenital forms.,"Immune-mediated TTP. The reported annual incidence is 6 per million (UK TTP Registry) and 1.74 per million (Oklahoma TTP-HUS Registry). Individuals with iTTP tend to be young women; the median age is 43 years and there is a female predominance of 73%. The major ethnic groups affected by TTP in the UK are white (64%) and African-Caribbean (27%)., The etiology of most iTTP is primarily idiopathic (76%); secondary precipitants include infection, associated autoimmune disease, pregnancy, HIV and, rarely, drugs.",125,31,0.248
9781912776818,hh-3,TTP is mediated by a deficiency of ADAMTS13.,"Immune-mediated TTP results from an acquired deficiency of a cleaving protease for von Willebrand factor (VWF),, now identified as ADAMTS13. This severe deficiency of ADAMTS13 function can result in the accumulation of ultra-large VWF (UL-VWF) in the plasma, which tethers platelets and results in platelet-rich thrombi within the endothelial surface of the microcirculation (Figure 1.2). These microthrombi can affect multiple organ systems, leading to tissue injury and a MAHA.",117,13,0.1111111111111111
9781912776818,hh-3,"ADAMTS13 deficiency leads to accumulation of ultra-large von Willebrand factor, causing multisystem microthrombi.","Immune-mediated TTP results from an acquired deficiency of a cleaving protease for von Willebrand factor (VWF),, now identified as ADAMTS13. This severe deficiency of ADAMTS13 function can result in the accumulation of ultra-large VWF (UL-VWF) in the plasma, which tethers platelets and results in platelet-rich thrombi within the endothelial surface of the microcirculation (Figure 1.2). These microthrombi can affect multiple organ systems, leading to tissue injury and a MAHA.",117,27,0.23076923076923078
9781912776818,hh-3,"Congenital TTP has two incidence peaks, first in childhood and then in adulthood, typically in pregnancy.","There are typically two peaks seen in clinical presentation: one in childhood, with a median age of 3.5 years; and one in adulthood, which is typically related to pregnancy (median age 31 years) - in individuals who present in adulthood, 69% of cases are associated with pregnancy. The type of mutation identified has been shown to differ between age groups, with pre-spacer domain mutations (see Figure 1.1) leading to earlier symptom development in childhood.",95,22,0.23157894736842105
9781912776818,hh-4,Thrombotic thrombocytopenic purpura (TTP) usually presents acutely in previously healthy adults with diverse features resulting from microvascular thrombosis: (1) microangiopathic hemolytic anemia; (2) thrombocytopenia; and (3) end-organ damage.,"Various international and national TTP registries have allowed us to understand how TTP typically presents. The most common presentation of acute TTP is a previously healthy young to middle-aged adult with MAHA, severe thrombocytopenia and features of end-organ damage. There is a consensus that overall women are roughly twice as commonly affected by TTP as men, though Japanese data are unusual in showing a 1:1 ratio. There are a large variety of possible presenting symptoms, which can be categorized into those resulting from: (1) MAHA; (2) thrombocytopenia; (3) end-organ microvascular thrombosis; and (4) other (Figure 2.1). The frequencies of various symptoms at presentation according to data from six of the larger and more recently published registries are summarized in Table 2.1. - The end organs most commonly affected are the brain, heart, kidneys and gastrointestinal tract. Non-specific symptoms such as malaise, fatigue and weakness are common, and a non-specific prodrome may often precede the onset of the more specific features of hemolysis, thrombocytopenia or end-organ damage. In terms of end-organ manifestations, neurological symptoms appear to be the most predominant according to the published data, though these can be as subtle as headache and mild cognitive impairment. While the heart is probably the next most commonly involved organ, with an elevated cardiac troponin in approximately 60% of individuals,, this is usually subclinical and only a minority (10-14%), present with cardiac symptoms.",329,71,0.21580547112462006
9781912776818,hh-4,"The brain, heart, kidneys and gastrointestinal tract are the most commonly affected end organs. Neurological symptoms are the most common.","There are a large variety of possible presenting symptoms, which can be categorized into those resulting from: (1) MAHA; (2) thrombocytopenia; (3) end-organ microvascular thrombosis; and (4) other (Figure 2.1). The frequencies of various symptoms at presentation according to data from six of the larger and more recently published registries are summarized in Table 2.1. - The end organs most commonly affected are the brain, heart, kidneys and gastrointestinal tract.",108,25,0.23148148148148148
9781912776818,hh-4,Congenital TTP is a much more common cause of TTP in childhood/adolescence and in pregnancy than in non-pregnant adults.,"The presentation of cTTP is discussed on pages 18-20. The presentation of iTTP in children and adolescents was the subject of a French series of 45 cases. Girls were 2.5 times more commonly affected than boys, with an overall median age at onset of 13 years (range 4 months-17 years). In 56% of cases there was an underlying cause, such as infection (18%) or autoimmunity (17%). The clinical presentation mirrored that seen in adults, with MAHA and thrombocytopenia (usually severe) in all cases, fever in 36% and end-organ ischemic damage in 64%. The pattern of affected organs differed slightly from that in adults: renal insult was most common (42%), followed by brain (40%) and with cardiac injury in only 7%.",166,32,0.1927710843373494
9781912776818,hh-4,"Acute presentations of congenital TTP cannot generally be distinguished from immune-mediated TTP on the basis of presenting features, though some individuals have chronic subacute symptoms.","Late-onset cTTP accounted for 66% (23/35) of UK cases of pregnancy-associated initial presentations of TTP and 24% (10/42) of French cases. Both figures are much higher than the proportion of cTTP in adult-onset TTP in general (approximately 5%). As is the case in non-pregnancy presentations, congenital cases cannot be distinguished from immune cases on the basis of clinical features alone. However, certain features may be more suggestive of a congenital etiology. First, cTTP nearly always presents in the first pregnancy, whereas iTTP can present initially in subsequent pregnancies. Second, in congenital cases, overt TMA may be preceded by isolated thrombocytopenia in the second to third trimesters. Third, a predominance of neurological symptoms was described in UK congenital cases compared with immune-mediated cases.",184,35,0.19021739130434784
9781912776818,hh-4,"Pregnancy is a trigger for TTP, especially the congenital form. This should be considered as a potential cause for unexplained fetal growth restriction or stillbirth, unexplained thrombocytopenia in pregnancy and atypical/severe cases of pre-eclampsia/HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count).","Late-onset cTTP accounted for 66% (23/35) of UK cases of pregnancy-associated initial presentations of TTP and 24% (10/42) of French cases. Both figures are much higher than the proportion of cTTP in adult-onset TTP in general (approximately 5%). As is the case in non-pregnancy presentations, congenital cases cannot be distinguished from immune cases on the basis of clinical features alone. However, certain features may be more suggestive of a congenital etiology. First, cTTP nearly always presents in the first pregnancy, whereas iTTP can present initially in subsequent pregnancies. Second, in congenital cases, overt TMA may be preceded by isolated thrombocytopenia in the second to third trimesters. Third, a predominance of neurological symptoms was described in UK congenital cases compared with immune-mediated cases. Fetal outcomes are unfortunately poor in the index pregnancies because of impairment of the uteroplacental circulation by platelet thrombi and ischemia, which can lead to severe fetal growth restriction and fetal loss. Live birth rates range between 31% and 58%, - with the worst outcomes seen for women presenting in the second trimester. However, prophylactic treatment in known cases of cTTP and close monitoring in women who have previously had an episode of iTTP can vastly improve fetal outcomes. Differential diagnosis. Given the above, TTP (especially previously undiagnosed congenital disease) should be considered in the differential diagnosis of unexplained fetal growth restriction, unexplained second trimester pregnancy losses, unexplained thrombocytopenia in pregnancy (beyond the level expected for gestational thrombocytopenia, for example below 75 x 10 /L), 'atypical'/'severe' presentations of pre-eclampsia and in cases of HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count), with a low threshold for ADAMTS13 activity testing in all of these scenarios.",418,75,0.17942583732057416
9781912776818,hh-5,Individuals with hemolytic uremic syndrome and atypical hemolytic uremic syndrome typically present with more severe renal injury or renal failure compared with individuals with thrombotic thrombocytopenic purpura.,"HUS is defined by the simultaneous occurrence of TMA with acute kidney injury. Renal involvement is typically much more severe than with TTP and the patient often presents with oliguria or anuria. Traditionally, HUS was divided into diarrhea-positive and diarrhea-negative, but this is now known to be inaccurate as patients with aHUS may also present with diarrhea. A more accurate classification came about after better understanding of the pathophysiology that underpins a division into HUS (endothelial injury mediated by Shiga toxin) and secondary HUS or TMAs. Causes of secondary TMAs include severe infection with Streptococcus pneumoniae, HIV infection, drug toxicity (especially in people with cancer or following solid-organ transplant) and, rarely, autoimmune disorders such as systemic lupus erythematosus (SLE). STEC-HUS is the most common form of HUS. It is primarily caused by STEC infection (E. coli O157:H7) and less frequently by infection with Shigella dysenteriae type 1 or other E. coli subtypes. It can occur at any age, but it usually affects children younger than 5 years. It can occur sporadically or as an epidemic and is associated with ingestion of contaminated food or water. STEC colonizes the gut, damages the epithelium and secretes Shiga toxin (Stx), which gets delivered to target organs. The tendency to cause renal failure lies in the fact that renal cells have a surface rich in globotriaosylceramide (Gb3), which binds the pentameric B subunit of Stx. Stx is then endocytosed, its A subunit is released and apoptotic cell death occurs. Patients usually develop abdominal pain, diarrhea (often bloody), followed by an acute TMA and renal injury within 5-13 days after the onset of diarrhea. The TMA most commonly follows recovery from the acute diarrheal illness. ADAMTS13 levels should be normal in these cases. STEC can be recovered by culturing stool on selective media or it can be diagnosed through serologic testing. Treatment is usually supportive and includes intravenous fluids and transfusion support. Antibiotics early in the course of the STEC infection may actually increase the risk of HUS development. Antimotility agents and nephrotoxic drugs should be avoided.",490,49,0.1
9781912776818,hh-5,"Systemic disorders that can secondarily present with TMA findings include disseminated intravascular coagulation, sepsis/infection and autoimmune disorders (systemic lupus erythematosus).","HUS is defined by the simultaneous occurrence of TMA with acute kidney injury. Renal involvement is typically much more severe than with TTP and the patient often presents with oliguria or anuria. Traditionally, HUS was divided into diarrhea-positive and diarrhea-negative, but this is now known to be inaccurate as patients with aHUS may also present with diarrhea. A more accurate classification came about after better understanding of the pathophysiology that underpins a division into HUS (endothelial injury mediated by Shiga toxin) and secondary HUS or TMAs. Causes of secondary TMAs include severe infection with Streptococcus pneumoniae, HIV infection, drug toxicity (especially in people with cancer or following solid-organ transplant) and, rarely, autoimmune disorders such as systemic lupus erythematosus (SLE). STEC-HUS is the most common form of HUS. It is primarily caused by STEC infection (E. coli O157:H7) and less frequently by infection with Shigella dysenteriae type 1 or other E. coli subtypes. It can occur at any age, but it usually affects children younger than 5 years. It can occur sporadically or as an epidemic and is associated with ingestion of contaminated food or water. STEC colonizes the gut, damages the epithelium and secretes Shiga toxin (Stx), which gets delivered to target organs. The tendency to cause renal failure lies in the fact that renal cells have a surface rich in globotriaosylceramide (Gb3), which binds the pentameric B subunit of Stx. Stx is then endocytosed, its A subunit is released and apoptotic cell death occurs. Patients usually develop abdominal pain, diarrhea (often bloody), followed by an acute TMA and renal injury within 5-13 days after the onset of diarrhea. The TMA most commonly follows recovery from the acute diarrheal illness. ADAMTS13 levels should be normal in these cases. STEC can be recovered by culturing stool on selective media or it can be diagnosed through serologic testing. Treatment is usually supportive and includes intravenous fluids and transfusion support. Antibiotics early in the course of the STEC infection may actually increase the risk of HUS development. Antimotility agents and nephrotoxic drugs should be avoided.",490,44,0.08979591836734693
9781912776818,hh-5,"The thrombotic microangiopathies (TMAs) are a group of disorders that share common clinical characteristics and findings, but with differing pathobiologies that lead to the TMA presentation.","STEC-HUS is the most common form of HUS. It is primarily caused by STEC infection (E. coli O157:H7) and less frequently by infection with Shigella dysenteriae type 1 or other E. coli subtypes. It can occur at any age, but it usually affects children younger than 5 years. It can occur sporadically or as an epidemic and is associated with ingestion of contaminated food or water. STEC colonizes the gut, damages the epithelium and secretes Shiga toxin (Stx), which gets delivered to target organs. The tendency to cause renal failure lies in the fact that renal cells have a surface rich in globotriaosylceramide (Gb3), which binds the pentameric B subunit of Stx. Stx is then endocytosed, its A subunit is released and apoptotic cell death occurs. Patients usually develop abdominal pain, diarrhea (often bloody), followed by an acute TMA and renal injury within 5-13 days after the onset of diarrhea. The TMA most commonly follows recovery from the acute diarrheal illness. ADAMTS13 levels should be normal in these cases. STEC can be recovered by culturing stool on selective media or it can be diagnosed through serologic testing. Treatment is usually supportive and includes intravenous fluids and transfusion support. Antibiotics early in the course of the STEC infection may actually increase the risk of HUS development. Antimotility agents and nephrotoxic drugs should be avoided.",317,41,0.12933753943217666
9781912776818,hh-5,"Quinine, ciclosporin and tacrolimus can induce TMAs via an immune-mediated mechanism (quinine) or dose-dependent toxicity.","Quinine works via an immune mechanism that induces severe TMA, mainly in women, and it occurs suddenly - within a few hours of ingestion - causing constitutional symptoms, rash and oliguric renal failure. Injury occurs via quinine-dependent antibodies against platelets, endothelial and other cell types. ADAMTS13 levels are typically normal. Most patients recover normal renal function within several weeks simply by stopping the drug and with supportive care. Ciclosporin and tacrolimus can lead to the development of TMA via a direct dose-dependent toxicity. TMA can develop during the first few weeks of treatment and usually resolves with discontinuation of the drug. In many reports, ciclosporin- and tacrolimus-induced TMA occurred in patients who may have had an underlying diagnosis of aHUS with recurrence post-transplant, raising the question of whether this was a drug toxicity or a recurrence of an acute TMA, as can be seen post-transplant in aHUS patients.",212,34,0.16037735849056603
9781912776818,hh-5,"Diseases that present with significant thrombocytopenia mimicking a systemic TMA that should be considered in the differential diagnosis include myelodysplasia, megaloblastic anemia, heparin-induced thrombocytopenia and paroxysmal nocturnal hemoglobinuria.","Congenital TTP is much less common than iTTP. The prevalence is approximately 1 per million and cTTP accounts for a small percentage of TTP diagnoses. The suspicion for cTTP will also depend on age at presentation. The diagnosis of cTTP is made with the finding of undetectable ADAMTS13 activity (< 10 IU/dL) but with no clearly detectable inhibitor or anti-ADAMTS13 antibody. Mutation studies can then be used to confirm a cTTP diagnosis. In women of childbearing years, approximately 34% of newly diagnosed TTP cases during pregnancy will be cTTP, with pregnancy serving as the trigger for the acute TMA in individuals with previously undiagnosed congenital ADAMTS13 deficiency. During early childhood, the differential diagnosis includes STEC-HUS, aHUS and secondary TMA associated with diseases of early childhood. All young children should be tested for STEC because a significant number of children with STEC-HUS may not have the classic presentation with diarrhea. Other diseases associated with hemolysis and/or thrombocytopenia should be included in the differential for cTTP in young children, including immune thrombocytopenia (ITP) and hemolytic disease of the fetus and newborn. Immune thrombocytopenia is characterized by immune-mediated platelet destruction and impaired production. Childhood ITP is usually acute, often occurring after a viral infection or vaccination, and usually resolves spontaneously within weeks to months. TMA is not a common feature and anemia is not pronounced unless there is significant bleeding. Neurological findings are not common unless there is intracranial hemorrhage, which can happen in severe thrombocytopenia.",363,67,0.18457300275482094
9781912776818,hh-6,Plasma exchange should be started without delay in an individual presenting with microangiopathic hemolytic anemia and thrombocytopenia in the absence of any other identifiable cause.,"TTP is now defined by MAHA with moderate-to-severe thrombocytopenia and associated organ dysfunction (neurological, cardiac, gastrointestinal and renal involvement) without an alternative explanation. The diagnosis is confirmed by an ADAMTS13 activity level below 10 IU/dL. Table 4.1 lists the investigations that should be performed for an individual with a suspected diagnosis of TTP. Typical laboratory findings. Platelet consumption by platelet-rich thrombi results in thrombocytopenia. The median platelet count is typically 10-30 x 10 /L at presentation. Median hemoglobin levels on admission are 80-100 g/L, with evidence of MAHA (schistocytes in the blood film, low haptoglobin, raised reticulocyte counts and raised lactate dehydrogenase [LDH] levels). - The direct antiglobulin (Coombs) test is negative. Acute renal failure (requiring hemodialysis) is rare in immune-mediated TTP (iTTP), with a median creatinine level at presentation of 90 mol/L (1.0 mg/dL). Significant renal impairment usually points to a diagnosis of HUS. The coagulation screen (prothrombin time, activated partial thromboplastin time and fibrinogen) is usually normal as well.",287,40,0.13937282229965156
9781912776818,hh-6,"Immune-mediated TTP is often associated with organ involvement, typically neurological and cardiac. Both are markers of poor prognosis and may identify higher-risk patients.","TTP is now defined by MAHA with moderate-to-severe thrombocytopenia and associated organ dysfunction (neurological, cardiac, gastrointestinal and renal involvement) without an alternative explanation. The diagnosis is confirmed by an ADAMTS13 activity level below 10 IU/dL. Table 4.1 lists the investigations that should be performed for an individual with a suspected diagnosis of TTP. Typical laboratory findings. Platelet consumption by platelet-rich thrombi results in thrombocytopenia. The median platelet count is typically 10-30 x 10 /L at presentation. Median hemoglobin levels on admission are 80-100 g/L, with evidence of MAHA (schistocytes in the blood film, low haptoglobin, raised reticulocyte counts and raised lactate dehydrogenase [LDH] levels). - The direct antiglobulin (Coombs) test is negative. Acute renal failure (requiring hemodialysis) is rare in immune-mediated TTP (iTTP), with a median creatinine level at presentation of 90 mol/L (1.0 mg/dL). Significant renal impairment usually points to a diagnosis of HUS. The coagulation screen (prothrombin time, activated partial thromboplastin time and fibrinogen) is usually normal as well.",287,33,0.11498257839721254
9781912776818,hh-6,Untreated thrombotic thrombocytopenic purpura (TTP) is associated with a high mortality rate; TTP should be treated as a medical emergency.,"Typical laboratory findings. Platelet consumption by platelet-rich thrombi results in thrombocytopenia. The median platelet count is typically 10-30 x 10 /L at presentation. Median hemoglobin levels on admission are 80-100 g/L, with evidence of MAHA (schistocytes in the blood film, low haptoglobin, raised reticulocyte counts and raised lactate dehydrogenase [LDH] levels). - The direct antiglobulin (Coombs) test is negative. Acute renal failure (requiring hemodialysis) is rare in immune-mediated TTP (iTTP), with a median creatinine level at presentation of 90 mol/L (1.0 mg/dL). Significant renal impairment usually points to a diagnosis of HUS. The coagulation screen (prothrombin time, activated partial thromboplastin time and fibrinogen) is usually normal as well. Cardiac involvement is common in iTTP, with troponin being raised in 60% of cases. It is a sign of poor prognosis, being associated with a sevenfold increase in mortality rate compared with TTP patients with normal troponin levels. Neurological impairment is also common, with symptoms ranging from headaches and altered personality to strokes, seizures and a fluctuating level of consciousness, including coma. A reduced Glasgow Coma Scale (GCS) score is a worrying feature as it is associated with an increase in mortality. CT or MRI of the brain should be considered in these patients, but it is important that imaging on admission should not interrupt plasma exchange therapy.",341,37,0.10850439882697947
9781912776818,hh-6,Diagnosis of TTP is defined by an ADAMTS13 activity level below 10 IU/dL. A level of 10 IU/dL or higher is in keeping with atypical (complement-mediated) hemolytic uremic syndrome and other thrombotic microangiopathies.,"ADAMTS13 activity level below 10 IU/dL confirms the diagnosis of TTP. Samples taken immediately following plasma therapy may give a falsely elevated ADAMTS13 activity. However, it has been shown that in more than 78% of cases, samples taken after 3 days of plasma exchange still had an ADAMTS13 activity level below 10 IU/dL. The presence of an inhibitor on mixing studies or anti-ADAMTS13 IgG may help to confirm the diagnosis of iTTP in these situations. Other TMAs, by definition, will not have an ADAMTS13 activity below 10 IU/dL or the presence of significant anti-ADAMTS13 IgG. Congenital TTP (Upshaw-Schulman syndrome). A persistent deficiency (< 10 IU/dL) of ADAMTS13 activity, with no evidence of inhibitory autoantibodies, suggests a diagnosis of cTTP. Individuals can present in the neonatal period, childhood or adulthood, with presentation typically associated with a trigger, such as infection, vaccination or pregnancy. The diagnosis is confirmed by molecular demonstration of a pathogenic homozygous or compound heterozygous mutation in the ADAMTS13 gene (see chapter 1). Family members undergoing genetic testing should receive genetic counseling, as many mutations are of unknown significance - even if gene variants are detected, family members may be normal with no symptoms of TTP.",287,63,0.21951219512195122
9781912776818,hh-6,"Immune-mediated TTP is confirmed with elevated anti-ADAMTS13 IgG, whereas these antibodies are absent in congenital TTP.","ADAMTS13 activity level below 10 IU/dL confirms the diagnosis of TTP. Samples taken immediately following plasma therapy may give a falsely elevated ADAMTS13 activity. However, it has been shown that in more than 78% of cases, samples taken after 3 days of plasma exchange still had an ADAMTS13 activity level below 10 IU/dL. The presence of an inhibitor on mixing studies or anti-ADAMTS13 IgG may help to confirm the diagnosis of iTTP in these situations. Other TMAs, by definition, will not have an ADAMTS13 activity below 10 IU/dL or the presence of significant anti-ADAMTS13 IgG.",139,30,0.2158273381294964
9781912776818,hh-6,Pretreatment samples should be sent for ADAMTS13 activity and anti-ADAMTS13 immunoglobulin (Ig)G levels. Plasma exchange should be started immediately afterward.,"Congenital TTP (Upshaw-Schulman syndrome). A persistent deficiency (< 10 IU/dL) of ADAMTS13 activity, with no evidence of inhibitory autoantibodies, suggests a diagnosis of cTTP. Individuals can present in the neonatal period, childhood or adulthood, with presentation typically associated with a trigger, such as infection, vaccination or pregnancy. The diagnosis is confirmed by molecular demonstration of a pathogenic homozygous or compound heterozygous mutation in the ADAMTS13 gene (see chapter 1). Family members undergoing genetic testing should receive genetic counseling, as many mutations are of unknown significance - even if gene variants are detected, family members may be normal with no symptoms of TTP. Immune-mediated TTP can be categorized according to the presence (secondary iTTP) or absence (primary iTTP) of a precipitating factor. Both groups are defined by ADAMTS13 activity below 10 IU/dL and the presence of ADAMTS13 autoantibodies. Both also require immediate therapy with plasma exchange and steroids.",218,39,0.17889908256880735
9781912776818,hh-6,"Precipitating factors, such as HIV, autoimmune disease, drugs and pregnancy, should be excluded. Treatment should be tailored toward the underlying cause.","Immune-mediated TTP can be categorized according to the presence (secondary iTTP) or absence (primary iTTP) of a precipitating factor. Both groups are defined by ADAMTS13 activity below 10 IU/dL and the presence of ADAMTS13 autoantibodies. Both also require immediate therapy with plasma exchange and steroids. Primary iTTP accounts for approximately two-thirds of iTTP cases. The remainder are secondary TTPs, of which the commonest causes are autoimmune disorders, infection, pregnancy, HIV and drugs (Table 4.2). Treatment of secondary iTTP can be tailored toward the underlying precipitant: for example, discontinuation of the implicated drug or highly active antiretroviral therapies (HAART) in HIV-associated TTP.",158,30,0.189873417721519
9781912776818,hh-6,"Scoring systems such as PLASMIC can be a useful tool for predicting the likelihood of severe deficiency of ADAMTS13 activity, especially in settings where ADAMTS13 assays are not readily available. However, wherever possible, definitive confirmation of TTP should be based on analysis of ADAMTS13 activity.","Immune-mediated TTP can be categorized according to the presence (secondary iTTP) or absence (primary iTTP) of a precipitating factor. Both groups are defined by ADAMTS13 activity below 10 IU/dL and the presence of ADAMTS13 autoantibodies. Both also require immediate therapy with plasma exchange and steroids. Primary iTTP accounts for approximately two-thirds of iTTP cases. The remainder are secondary TTPs, of which the commonest causes are autoimmune disorders, infection, pregnancy, HIV and drugs (Table 4.2). Treatment of secondary iTTP can be tailored toward the underlying precipitant: for example, discontinuation of the implicated drug or highly active antiretroviral therapies (HAART) in HIV-associated TTP. Screening for severe ADAMTS13 deficiency. A number of scoring systems have been developed to help predict the likelihood of severe deficiency of ADAMTS13 activity and differentiate TTP from other TMAs. - One example is the PLASMIC score (Table 4.3), which is composed of seven elements: platelets, lysis, active cancer, stem-cell or organ transplant, mean cell volume (MCV), international normalized ratio (INR) and creatinine. In conjunction with clinical assessment, it calculates the risk of severe ADAMTS13 deficiency and therefore allows early rapid screening of patients who can benefit from plasma-based therapy.",290,64,0.2206896551724138
9781912776818,hh-7,"In patients presenting with a clinical picture consistent with an acute episode of thrombotic thrombocytopenic purpura (TTP), plasma exchange should be started empirically before the diagnosis is confirmed by ADAMTS13 activity testing.","Once a diagnosis of thrombotic thrombocytopenic purpura (TTP) is strongly suspected, treatment must be initiated as soon as possible. Delays in initiating treatment have been associated with early mortality. Therefore, the initial management for a patient with suspected TTP will typically involve empiric plasma exchange therapy, which should usually be started before the diagnosis is confirmed. Plasma exchange therapy. The introduction of plasma exchange therapy revolutionized the treatment of TTP. It remains the mainstay of acute TTP treatment. Nearly 90% of patients will survive an acute TTP episode with plasma exchange therapy whereas, in contrast, there was near uniform mortality prior to the discovery of its effectiveness in TTP. Because of this, it is imperative to start plasma exchange as soon as possible. It is hypothesized that plasma exchange works via repletion of the ADAMTS13 protease and/or the removal of the pathologic autoantibodies that inhibit ADAMTS13 function. The volume of exchange and replacement fluid used for the exchange can vary by institution, and it is not clear if there are material differences between replacement products. In general, in the acute phase, plasma exchange should be performed daily, with 1 to 1.5 plasma volume exchanges for the first few days; some centers use higher volume exchanges (1.5 plasma volume) for the initial days before dropping to one plasma volume exchanges thereafter for patients with a more severe presentation. For refractory or resistant cases, twice-daily exchanges can be considered, but this approach is less well supported by evidence.",320,50,0.15625
9781912776818,hh-7,Rituximab has an increasing role in the treatment of refractory and chronic relapsing TTP and may prevent future episodes by correcting the deficiency of ADAMTS13 activity.,"Rituximab has been used increasingly in recent years as more data have accumulated to demonstrate its efficacy in patients with refractory or relapsing TTP. Rituximab is most commonly given intravenously at a dose of 375 mg/m weekly for 4 weeks. It is typically given immediately after plasma exchange to minimize its clearance by the procedure. The efficacy of rituximab is based on its ability to clear the B cells that produce anti-ADAMTS13 immunoglobulin (Ig)G. At least 1-2 weeks are required for the rituximab to exert its effect and improve ADAMTS13 activity. The best available data suggest that it should be used in patients with refractory or poorly responding disease, as well as those with a prior history of relapses and a relapsing TTP phenotype. However, phase II trials of rituximab as a first-line treatment for TTP, in conjunction with plasma exchange and steroid, suggest that earlier upfront rituximab leads to shorter hospitalizations.",222,39,0.17567567567567569
9781912776818,hh-7,Many patients with congenital TTP require chronic plasma infusions as well as careful observations for chronic neurological and vascular complications.,"Rituximab has been used increasingly in recent years as more data have accumulated to demonstrate its efficacy in patients with refractory or relapsing TTP. Rituximab is most commonly given intravenously at a dose of 375 mg/m weekly for 4 weeks. It is typically given immediately after plasma exchange to minimize its clearance by the procedure. The efficacy of rituximab is based on its ability to clear the B cells that produce anti-ADAMTS13 immunoglobulin (Ig)G. At least 1-2 weeks are required for the rituximab to exert its effect and improve ADAMTS13 activity. The best available data suggest that it should be used in patients with refractory or poorly responding disease, as well as those with a prior history of relapses and a relapsing TTP phenotype. However, phase II trials of rituximab as a first-line treatment for TTP, in conjunction with plasma exchange and steroid, suggest that earlier upfront rituximab leads to shorter hospitalizations.",222,24,0.10810810810810811
9781912776818,hh-7,The development of caplacizumab as an adjunct to plasma exchange therapy has been shown to decrease the number of plasma exchange procedures required to achieve a normal platelet count and significantly decrease the risk for exacerbations of TTP.,"Caplacizumab is a nanobody (antibody fragment that has the structural and functional properties of naturally occurring heavy-chain-only antibodies) that targets the A1 domain of von Willebrand factor (VWF). By binding to VWF, caplacizumab blocks the ability of VWF to bind platelets, inhibiting the formation of microthrombi in TTP. It has no effect on the formation of autoantibodies to ADAMTS13. Caplacizumab was approved by both European Union and US regulatory authorities for the treatment of TTP in conjunction with plasma exchange and immune suppression. Trials have demonstrated a faster platelet response, but, more importantly, caplacizumab has been shown to significantly decrease the exacerbation rate (recurrence of TTP in the first month after stopping plasma exchange) after the acute TTP episode. This provides effective protection from recurrence for the patient until immunosuppressive therapy can improve the patient's ADAMTS13 activity.",213,47,0.22065727699530516
9781912776818,hh-7,Glucocorticoid therapy to suppress the production of anti-ADAMTS13 antibodies is an important adjunct to plasma exchange therapy.,"Prophylactic therapy requires the patient to have intravenous access and increases patient burden in travel time and costs, as well as potential transfusion reactions. Therefore, offering patients the alternative of close monitoring for symptoms without treatment is sometimes appropriate. Moreover, patients who were diagnosed by genetic testing of family members but who have never had an acute episode may need only close monitoring and not prophylactic plasma infusions. It is also appropriate to avoid prophylactic plasma infusions in patients who have had a clear trigger for their TTP episode (physiological stress or infection) that has been addressed and is no longer present. These patients may avoid the time commitment and potential complications associated with long-term plasma infusion therapy.",145,28,0.19310344827586207
9783318066241,ch1,The pathophysiology of acute pancreatitis (AP) is incompletely understood.,"Acute pancreatitis (AP) is a disease caused by acute inflammation of the pancreas. Recurrent AP refers to the development of at least two separate documented episodes of AP with a period of resolution in between, and the absence of definitive changes of chronic pancreatitis. Physiology of normal pancreatic function. The pancreas is an organ with important exocrine and endocrine functions, including being the main source of digestive enzymes. The exocrine pancreas consists of acinar and ductal cells (Figure 1.1).",108,16,0.14814814814814814
9783318066241,ch1,Initial acinar cell injury has several cellular consequences that promote local inflammation.,"Acinar and ductal secretion is controlled by complex neural (vagal innervation) and endocrine (cholecystokinin, secretin) regulation. Endocrine cells (clustered into the islets of Langerhans) are scattered along the exocrine tissue, and hormones such as insulin interact with acinar cells to further regulate exocrine secretion. The etiology of AP is discussed in detail in Chapter 2. However, the initial step in the pathogenesis of AP is acinar cell injury, which has several important consequences (Figure 1.3).",116,14,0.1206896551724138
9783318066241,ch1,AP may induce bacterial translocation. Viable bacteria in the bloodstream may colonize necrotic pancreatic and/or peripancreatic tissue resulting in infection.,"These local complications are frequently associated with pain, systemic inflammation, fluid sequestration and sometimes with compression of neighboring structures, leading to intolerance of an oral diet, thrombosis of peripancreatic veins, jaundice or infection. Infection is the consequence of early bacterial translocation due to a loss of the barrier function of the bowel: bacteria reach regional lymph nodes, the splanchnic vein system and then the necrotic tissue. Necrotizing pancreatitis (pancreatic gland and/or peripancreatic fat necrosis) is also associated with a higher risk of systemic inflammatory response syndrome leading to organ failure due to uncontrolled and unbalanced release of proinflammatory mediators. Fluid sequestration and loss of arteriolar tone may cause shock and kidney failure; respiratory failure is caused mainly by alveolar damage (acute respiratory distress syndrome) but also by pleural effusion, abdominal compartment syndrome and/or pain leading to respiratory restriction. Up to 50% of patients who develop persistent (> 48 hours in duration) shock, kidney failure and/or respiratory failure will die.",227,34,0.14977973568281938
9783318066241,ch1,"Severe local damage is associated with a systemic inflammatory response, which, when uncontrolled, may progress to organ failure.","Necrotizing pancreatitis (pancreatic gland and/or peripancreatic fat necrosis) is also associated with a higher risk of systemic inflammatory response syndrome leading to organ failure due to uncontrolled and unbalanced release of proinflammatory mediators. Fluid sequestration and loss of arteriolar tone may cause shock and kidney failure; respiratory failure is caused mainly by alveolar damage (acute respiratory distress syndrome) but also by pleural effusion, abdominal compartment syndrome and/or pain leading to respiratory restriction. Up to 50% of patients who develop persistent (> 48 hours in duration) shock, kidney failure and/or respiratory failure will die.",135,23,0.17037037037037037
9783318066241,ch2,Acute pancreatitis (AP) is a frequent cause of hospital admission and its incidence has been increasing in recent decades.,"The incidence of acute pancreatitis (AP) has increased in most regions of the world in recent decades. Data from the USA suggest that AP is the tenth most common gastrointestinal (including pancreatic and liver diseases) diagnosis reached in emergency department visits, the third most common cause of hospital admission due to gastrointestinal disease and the tenth leading cause of death from non-malignant gastrointestinal disease. The incidence of a first episode of AP ranges from 15 to 45 per 100 000 population per year. A nationwide prospective cohort study found that approximately 25% of total episodes of AP are due to recurrent disease.",117,24,0.20512820512820512
9783318066241,ch2,"Gallstones are the leading cause of AP in most countries, followed by alcohol. Hypertriglyceridemia and endoscopic retrograde cholangiopancreatography are also common causes.","The etiologies of AP are summarized in Table 2.1. Overall, the most frequent cause of AP is gallstones (45-55%) but the proportion varies widely from just 1 in every 4 patients in the USA to more than 80% in South America. Idiopathic cases of AP are the next most common (14-17%), followed by cases related to heavy alcohol consumption (14%), endoscopic retrograde cholangiopancreatography (ERCP; 12%) and hypertriglyceridemia (HTG; 5-10%), but, again, regional differences are important. Biliary stones. Gallstones are the most frequent cause of AP in many countries. Biliary stones are usually formed in the gallbladder and are most commonly composed of cholesterol crystals and calcium bilirubinate. Several risk factors for gallstones have been described, including ethnicity (native Americans), age, female sex, pregnancy, obesity, rapid weight loss, certain drugs (ceftriaxone, estrogens, statins and other lipid-lowering drugs) and prolonged fasting (id est total parenteral nutrition). Female sex, age between 50-60 years and increased levels of alanine aminotransferase at admission (more than two to three times the upper limit of normal) are independent predictors of a biliary etiology in AP.",280,39,0.1392857142857143
9783318066241,ch2,"Pancreatic adenocarcinoma must be ruled out in patients without an evident cause of AP who are aged more than 50 years, with weight loss and/or a recent diagnosis of diabetes.","Other obstructive etiologies. Solid as well as cystic tumors of the pancreas can induce AP. Red flags for pancreatic adenocarcinoma include age older than 50 years, weight loss and/or a recent diagnosis of diabetes. Pancreatic adenocarcinoma is associated with very poor outcomes. Intraductal papillary mucinous neoplasms may cause recurrent AP due to obstruction of the pancreatic ducts by mucin. Other obstructive causes of AP include periampullary duodenal diverticulum, while pancreatic duct strictures due to previous pancreatitis or trauma may induce recurrent AP and obstructive chronic pancreatitis. Sphincter of Oddi dysfunction may explain some cases of recurrent AP, but the evidence for endoscopic treatment for this disease is currently poorly elucidated. Other rare causes of obstructive pancreatitis are listed in Table 2.1.",187,42,0.22459893048128343
9783318066241,ch2,"Mutation in the PRSS1 gene is a rare cause of AP, with an autosomal dominant inheritance pattern. Other genetic mutations are generally considered as cofactors in the development of AP.","Cationic trypsinogen gene mutations. In 1996, the first genetic mutation leading to pancreatitis was described by David C. Whitcomb. In that landmark paper, Whitcomb described an Arg-His substitution at residue 117 of the cationic trypsinogen gene (PRSS1), which was associated with hereditary pancreatitis. Other mutations associated with pancreatitis have been described subsequently. Mutations in PRSS1 may promote autoactivation by direct or indirect (exempli gratia by making the trypsinogen molecule more resistant to degradation) mechanisms. PRSS1 mutations cause an autosomal dominant form of hereditary pancreatitis. Patients with hereditary pancreatitis due to PRSS1 mutations have an increased risk of pancreatitis during childhood, quick progression to chronic pancreatitis and a high probability of developing pancreatic cancer. PRSS1 mutations are very uncommon, and should be suspected in idiopathic recurrent pancreatitis starting in childhood (median age 10 years). It has been reported that a loss-of-function mutation (p.G191R variant) in the anionic trypsinogen gene (PRSS2) may be protective against pancreatitis.",238,39,0.1638655462184874
9783318066241,ch3,"The most frequent presentation of acute pancreatitis (AP) is severe epigastric pain radiating to the flanks and/or back, nausea and vomiting.","Most patients with AP have a severe epigastric pain radiating to the flanks and/or back, together with nausea and vomiting. Exceptions are patients under immunosuppression or sedation and patients with dementia, in whom the diagnosis may be challenging. Jaundice is frequently seen in cases of persistent choledocholithiasis, or more infrequently in patients with compression of the bile duct due to inflammation and/or collections (in these cases the jaundice usually develops days or weeks after presentation). Chills and high-grade fever associated with jaundice suggest acute cholangitis. Paralytic ileus may develop in some patients, and infrequently it may be persistent because of inflammatory or ischemic involvement of the bowel. Some patients with moderate-to-severe AP may develop reversible neuropsychiatric symptoms (exempli gratia delirium, hallucinations, convulsive and/or focal seizures) in the absence of organic triggers; this rare complication is known as pancreatic encephalopathy.",211,33,0.15639810426540285
9783318066241,ch3,Most patients are diagnosed based on typical pain and increased serum pancreatic enzyme activity greater than three times the upper limit of normal.,"Most patients with AP have amylase and/or lipase serum activity greater than three times the upper level of normal. The amylase increase is first detected 2-12 hours after the onset of symptoms of AP; the level peaks at 12-72 hours and usually normalizes within 5 days. Serum lipase levels increase within 4-8 hours after the onset of symptoms; they peak at 24 hours, and return to normal after 8-14 days. The half-life of lipase is longer than amylase, so patients with a delayed presentation in the emergency room may show normal amylase activity with increased lipase activity. Urinary trypsinogen-2 and urinary amylase are also increased in AP. There is no evidence supporting the superiority of any one serum or urinary test over another in terms of accuracy.",171,25,0.14619883040935672
9783318066241,ch3,Diseases other than AP may be associated with increased pancreatic enzyme serum activity. Differential diagnosis is important as most of these conditions require specific treatment.,"Increased serum pancreatic enzyme activity may also be due to other conditions (Table 3.1 and Table 3.2) and about 1 in 10 patients may be wrongly diagnosed as having AP by blood or urinary tests. As indicated in Table 3.1, any cause of acute abdomen may be associated with increased enzyme activity in blood; in general, the more elevated the pancreatic enzyme activity level, the greater the specificity for AP. In the emergency room, a CT scan is the most useful imaging test for diagnosing AP, followed by MRI; conventional ultrasonography is less reliable. CT/MRI to confirm the diagnosis of AP should be reserved for cases with atypical symptoms and/or those rare cases without an increase in pancreatic enzyme serum levels. Contrast enhancement is useful for differential diagnosis (especially to rule out acute mesenteric ischemia) and to detect necrosis (although an early CT scan may be falsely negative for pancreatic necrosis); however, but in cases of kidney failure or allergy, a CT scan without contrast enhancement can detect peripancreatic fat stranding or peripancreatic collections typical of AP. AP may be present regardless of a normal CT scan, MRI or ultrasonography.",248,31,0.125
9783318066241,ch3,"Abdominal imaging is useful for confirming the diagnosis of AP in atypical cases, ruling out other conditions.","In the emergency room, a CT scan is the most useful imaging test for diagnosing AP, followed by MRI; conventional ultrasonography is less reliable. CT/MRI to confirm the diagnosis of AP should be reserved for cases with atypical symptoms and/or those rare cases without an increase in pancreatic enzyme serum levels. Contrast enhancement is useful for differential diagnosis (especially to rule out acute mesenteric ischemia) and to detect necrosis (although an early CT scan may be falsely negative for pancreatic necrosis); however, but in cases of kidney failure or allergy, a CT scan without contrast enhancement can detect peripancreatic fat stranding or peripancreatic collections typical of AP. AP may be present regardless of a normal CT scan, MRI or ultrasonography.",162,23,0.1419753086419753
9783318066241,ch4,Comorbidity and obesity are baseline characteristics associated with worse outcomes.,"Comorbidity and obesity are important factors associated with an increased risk of persistent organ failure (OF) and mortality. Age has been classically identified as a prognostic factor but it is also a confounder, as older patients often also have increased comorbidity and obesity. Only extreme age seems independently associated with increased mortality.",68,14,0.20588235294117646
9783318066241,ch4,"Systemic inflammatory response syndrome, particularly when persistent (>= 48 hours), is associated with an increased frequency of local and systemic complications.","Local complications are associated with worse outcomes in terms of morbidity and mortality (due to their association with SIRS and persistent OF). CECT is the most commonly used imaging technique to detect local complications. However, CECT is associated with radiation exposure, so its use is inappropriate in patients with an obvious diagnosis of AP and predicted mild disease. CECT should be reserved for patients with an uncertain diagnosis and those who have predicted severe disease, persistent SIRS, the presence of signs or symptoms suggesting local complications (inability to resume oral feeding, persistent pain, palpable mass, fever, etc.) or who develop acute abdomen. Imaging before the third or fourth day may result in underestimation of local complications. Two historically important scoring systems - the Balthazar score and the CT score (Table 4.1) - have been developed for assessing the severity of local complications in AP on the basis of findings on CT imaging.",185,26,0.14054054054054055
9783318066241,ch4,Early increases in serum blood urea nitrogen or hematocrit are associated with worse outcomes.,"Organ failure. Early signs suggestive of OF, the most important marker of adverse outcomes, are shown in Table 4.2. OF, according to the revised Atlanta classification of AP (RAC), is defined by serum creatinine >= 1.9 mg/dL (or > 170 mol/l), a PaO /FIO <= 300 (the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen) and/or a systolic blood pressure <= 90 mmHg despite fluid resuscitation. The RAC defines transient OF as OF that is corrected within 48 hours, and persistent OF as OF lasting for more than 48 hours. Persistent OF is a marker of severe disease and is associated with maximum morbidity and a high risk of mortality (52% according to a large prospective cohort study), whereas transient OF is associated with increased morbidity but a low rate of mortality (7%). For these reasons, OF is considered a marker for a worse prognosis, not a predictor.",202,19,0.09405940594059406
9783318066241,ch4,"In general, scoring systems for predicting severity have a high negative predictive value and a low-to-moderate positive predictive value.","The accuracy of the different scoring systems according to a systematic review is shown in Table 4.3. Many scoring systems have low external validity because they were developed in referral centers with higher proportions of moderate-to-severe cases of AP. This gives a falsely high positive predictive value of the different methods for predicting severity compared with non-referral populations. In general, the predictors of severity have a high negative predictive value (as most patients will develop only mild disease) but a low-to-moderate positive predictive value. The personal experience of the authors suggests that SIRS, and especially persistent SIRS, is particularly useful in predicting severity.",132,25,0.1893939393939394
9783318066241,ch5,Early liquid peripancreatic collections without necrosis are called acute peripancreatic fluid collections (APFCs). APFCs lasting for more than 4 weeks develop an encapsulating wall and are known as pseudocysts.,"An APFC is defined as peripancreatic fluid (a homogeneous collection with fluid density with no intrapancreatic extension) associated with interstitial edematous pancreatitis with no associated peripancreatic necrosis. Therefore, this is typically a complication of interstitial AP. An acute necrotic collection is defined as a collection containing variable amounts of both fluid and necrosis (heterogeneous and non-liquid density of varying degrees) associated with necrotizing pancreatitis; the necrosis can involve the pancreatic parenchyma and/or the peripancreatic tissues. MRI and ultrasonography are more accurate in detecting solid necrotic tissue in collections than a CT scan (Figure 5.2). Collections persisting after 4 weeks. Collections that have not been reabsorbed over the first 4 weeks develop an encapsulating wall. According to the RAC, these mature collections can be classified in the following ways.",196,48,0.24489795918367346
9783318066241,ch5,Early collections associated with pancreatic and/or peripancreatic necrosis are called acute necrotic collections. Those lasting for more than 4 weeks and developing an encapsulating wall are known as walled-off necrosis.,"An APFC is defined as peripancreatic fluid (a homogeneous collection with fluid density with no intrapancreatic extension) associated with interstitial edematous pancreatitis with no associated peripancreatic necrosis. Therefore, this is typically a complication of interstitial AP. An acute necrotic collection is defined as a collection containing variable amounts of both fluid and necrosis (heterogeneous and non-liquid density of varying degrees) associated with necrotizing pancreatitis; the necrosis can involve the pancreatic parenchyma and/or the peripancreatic tissues. MRI and ultrasonography are more accurate in detecting solid necrotic tissue in collections than a CT scan (Figure 5.2). Collections persisting after 4 weeks. Collections that have not been reabsorbed over the first 4 weeks develop an encapsulating wall. According to the RAC, these mature collections can be classified in the following ways.",196,47,0.23979591836734693
9783318066241,ch5,"In the revised Atlanta classification, acute pancreatitis is defined as mild, moderately severe and severe.","The severity of AP should be classified at discharge according to whether local and systemic complications developed during the course of the disease. In the first Atlanta classification published in 1993, AP was divided into mild (no complications) and severe (local or systemic complications) forms. This classification had a homogeneous mild category, without morbidity or mortality, but the severe category was heterogeneous, mixing patients with increased morbidity with others with a life-threatening condition., However, local or 'mild' systemic complications (exacerbation of previous comorbidity, transient OF) are associated with increased morbidity but very low mortality and these patients are considered as having moderate disease. Patients with persistent OF have a high risk of mortality, indicating severe disease. The RAC therefore promotes a three-category classification (Table 5.2).",165,19,0.11515151515151516
9783318066241,ch5,"Mild disease is defined by the absence of complications, severe disease as persistent (> 48 hours) organ failure; patients with other local and systemic complications are classified as having moderately severe disease.","The severity of AP should be classified at discharge according to whether local and systemic complications developed during the course of the disease. In the first Atlanta classification published in 1993, AP was divided into mild (no complications) and severe (local or systemic complications) forms. This classification had a homogeneous mild category, without morbidity or mortality, but the severe category was heterogeneous, mixing patients with increased morbidity with others with a life-threatening condition., However, local or 'mild' systemic complications (exacerbation of previous comorbidity, transient OF) are associated with increased morbidity but very low mortality and these patients are considered as having moderate disease. Patients with persistent OF have a high risk of mortality, indicating severe disease. The RAC therefore promotes a three-category classification (Table 5.2). mild disease with an uneventful clinical course. moderately severe disease with increased morbidity but a low risk of mortality. severe disease with maximum morbidity and a high risk of mortality. From a simplistic point of view, mild disease is defined by the absence of complications, severe disease as persistent OF, and patients with other local and systemic complications as having moderately severe disease.",242,37,0.15289256198347106
9783318066241,ch5,Mild disease is associated with an uneventful disease course. Moderately severe disease results in increased morbidity and severe disease is associated with maximum morbidity and increased mortality.,"The severity of AP should be classified at discharge according to whether local and systemic complications developed during the course of the disease. In the first Atlanta classification published in 1993, AP was divided into mild (no complications) and severe (local or systemic complications) forms. This classification had a homogeneous mild category, without morbidity or mortality, but the severe category was heterogeneous, mixing patients with increased morbidity with others with a life-threatening condition., However, local or 'mild' systemic complications (exacerbation of previous comorbidity, transient OF) are associated with increased morbidity but very low mortality and these patients are considered as having moderate disease. Patients with persistent OF have a high risk of mortality, indicating severe disease. The RAC therefore promotes a three-category classification (Table 5.2).",165,35,0.21212121212121213
9783318066241,ch6,Opioids are safe in AP. Epidural analgesia may be used in refractory pain,"Patients with mild acute pancreatitis (AP) (65% of cases) have an uneventful disease course, with initial severe pain that improves quickly. In general terms, these patients are easily managed. In contrast, patients with moderate-to-severe AP may be challenging: they may require aggressive fluid resuscitation and they have prolonged pain and sometimes intolerance to oral refeeding. These patients may develop organ failure (OF) and be prone to late complications. This chapter addresses the early management of AP, focusing on the evidence underpinning each intervention.",112,21,0.1875
9783318066241,ch6,"Patients with acute pancreatitis (AP) must be carefully monitored to allow early detection of organ failure, particularly those patients with predicted severe disease.","However, local complications such as pancreatic necrosis are associated with fluid sequestration, as intravascular liquid leaks to the retroperitoneum. This results in hemoconcentration and it has been suggested that an increased hematocrit is in fact a marker for local complications, not their cause (reverse causation bias). In 2009 and 2010, two studies were published by the same research group., These were open-label randomized controlled trials (RCTs) comparing a more aggressive versus a moderate fluid volume administration (10-15 vs 5-10 mL/kg/hour) and a more rapid versus a slower hemodilution (hematocrit < 35% vs >= 35% at 48 hours) in patients with severe AP according to the classic 1993 Atlanta criteria (presence of local complications and/or organ failure). In both trials, the more aggressive approach was associated with worse outcomes, including decreased survival. These studies suggested that vigorous resuscitation is dangerous in patients with severe AP. The studies had some flaws, including being open-label single-center RCTs, with suboptimal randomization, an unexpectedly high rate of sepsis in patients with aggressive resuscitation and large differences in mortality between treatment groups despite a very small sample of patients, and they require validation.",261,29,0.1111111111111111
9783318066241,ch6,There is a lack of well-designed randomized clinical trials addressing the best fluid volume rate to improve outcomes.,"However, local complications such as pancreatic necrosis are associated with fluid sequestration, as intravascular liquid leaks to the retroperitoneum. This results in hemoconcentration and it has been suggested that an increased hematocrit is in fact a marker for local complications, not their cause (reverse causation bias). In 2009 and 2010, two studies were published by the same research group., These were open-label randomized controlled trials (RCTs) comparing a more aggressive versus a moderate fluid volume administration (10-15 vs 5-10 mL/kg/hour) and a more rapid versus a slower hemodilution (hematocrit < 35% vs >= 35% at 48 hours) in patients with severe AP according to the classic 1993 Atlanta criteria (presence of local complications and/or organ failure). In both trials, the more aggressive approach was associated with worse outcomes, including decreased survival. These studies suggested that vigorous resuscitation is dangerous in patients with severe AP. The studies had some flaws, including being open-label single-center RCTs, with suboptimal randomization, an unexpectedly high rate of sepsis in patients with aggressive resuscitation and large differences in mortality between treatment groups despite a very small sample of patients, and they require validation.",261,21,0.08045977011494253
9783318066241,ch6,Lactated Ringer's solution is associated with a decreased inflammatory response in AP when compared with normal saline.,"Fluid type. Both an open-label and a triple-blind RCT have demonstrated that fluid resuscitation using lactated Ringer's solution (a balanced salt solution) is associated with a decreased inflammatory response when compared with fluid resuscitation with normal saline (with a high chloride content). According to in vitro experiments, it seems that this anti-inflammatory effect depends on lactate. However, both studies included a small number of patients, and the influence of lactated Ringer's solution on important outcomes such as OF or mortality is unknown. In studies addressing other clinical scenarios, balanced fluids such as lactated Ringer's solution seem to be associated with a decreased need for blood products and a lower incidence of renal replacement therapy, hyperkalemia and postoperative infections when compared with normal saline. For the time being, it seems that lactated Ringer's solution is a good choice for fluid resuscitation in AP.",186,22,0.11827956989247312
9783318066241,ch6,Oral refeeding when abdominal pain subsides is recommended in all patients with pancreatitis. Tube feeding (either nasogastric or nasojejunal) is indicated from the fourth day when oral refeeding is not tolerated or the patient is sedated.,"However, placement of a nasojejunal tube is not easy, it is time-consuming and results in great patient discomfort. Furthermore, it has been shown that standard nasojejunal feeding does in fact stimulate pancreatic secretion. Three studies comparing a nasogastric versus a nasojejunal route found no difference in outcomes, so both feeding routes can be recommended, depending on the presence or absence of gastric outlet obstruction. In 2014, the Dutch Pancreatitis Study Group published an RCT in patients with predicted severe AP which compared early (within 24 hours) nasojejunal enteral nutrition versus on-demand nasojejunal enteral nutrition (the patients tried oral refeeding on the third day and enteral nutrition was given on the fourth day only to those who could not tolerate oral feeding). The study showed that on-demand oral feeding was not associated with worse outcomes, and only 31% of patients needed a nasojejunal tube. Overall, therefore, in patients with moderate-to-severe AP, oral refeeding on day 3 to 4 should be encouraged and nasogastric or nasojejunal tube feeding from day 4 should be reserved for patients who cannot tolerate oral refeeding or who are sedated. The nasojejunal route is indicated in patients with gastric outlet obstruction.",279,55,0.1971326164874552
9783318066241,ch6,Prophylactic antibiotics and early endoscopic retrograde cholangiopancreatography are not associated with improved outcomes.,"Early endoscopic retrograde cholangiopancreatography. Gallstone AP is associated with choledocholithiasis, but in most cases the stones are cleared to the duodenum spontaneously. The first single-center RCTs suggested a benefit for early endoscopic retrograde cholangiopancreatography (ERCP) in AP, but later, better designed RCTs which excluded patients with acute cholangitis, showed that regardless of severity and the presence of choledocholithiasis, patients undergoing ERCP within the first 72 hours do not have better outcomes., Patients with AP and acute cholangitis may benefit from early ERCP, as the first studies (those showing better outcomes for early ERCP) included patients with this complication. Preliminary data from a large Dutch multicenter study, the APEC trial, have confirmed the lack of benefits from early ERCP in AP.",188,25,0.13297872340425532
9783318066241,ch7,Infected pancreatic/peripancreatic necrosis is associated with increased morbidity and mortality.,"Together with the development of persistent OF, IPN is the most serious complication of AP. Table 7.1 compares the outcomes of sterile versus infected necrosis based on the findings of a nationwide prospective study. IPN was associated with higher morbidity (longer time to oral refeeding, prolonged hospitalization, greater need for intensive care unit admission, and almost all patients with IPN required invasive treatment) and mortality (34% vs 9%) than sterile necrosis. IPN is frequently associated with prolonged and expensive treatments, as reflected indirectly by the difference in duration of hospitalization (median 66 days vs 15 days in sterile necrosis; see Table 7.1).",136,22,0.16176470588235295
9783318066241,ch7,Symptomatic collections can be divided into symptomatic sterile collections and infected collections.,"Symptomatic collections can be divided into symptomatic sterile collections and infected collections. As acute peripancreatic fluid collections are usually sterile (they very rarely become infected), the term IPN is used here to refer to infected collections. Symptoms due to collections usually begin in the late phase of AP (beyond the first week after disease onset).",70,16,0.22857142857142856
9783318066241,ch7,Bulky sterile collections may become symptomatic or clinically relevant because of pain and/or compression of adjacent structures.,"Symptomatic sterile collections. Bulky sterile collections may become symptomatic or clinically relevant because of pain and/or compression of adjacent structures. Compression of the stomach or duodenum (Figure 7.1) may lead to early satiety, vomiting, refractory heartburn, regurgitation and an inability to resume oral feeding. Compression of the bile duct (Figure 7.2) may manifest as jaundice, while compression of the urinary tract (Figure 7.3) may (extremely rarely) result in hydronephrosis. Finally, compression of the peripancreatic veins leads to an increased risk of peripancreatic vein thrombosis, left-sided portal hypertension and a future risk of bleeding in cases of thrombosis due to development of esophageal-gastric varices.",175,22,0.12571428571428572
9783318066241,ch7,Sterile symptomatic collections are mostly managed non-invasively. Drainage is indicated in infected collections or in symptomatic sterile collections that persist despite initial conservative treatment.,"Indications for drainage. Generally speaking, sterile symptomatic collections can be managed conservatively. Only 1 in 10 patients or fewer with sterile necrotic collections require drainage due to symptoms, compared with almost all patients with IPN (see Table 7.1). Recent European Society of Gastrointestinal Endoscopy (ESGE) guidelines on endoscopic management of acute necrotizing pancreatitis suggest considering an invasive intervention after conservative treatment fails in patients with sterile necrosis and adjacent organ compression or persistent pain late in the course of the disease. The method for draining the collection, once the decision is taken, is similar to that for IPN (see Figure 7.5). Previously, FNA for Gram stain and culture was widely used to confirm IPN, as the treatment of choice was necrosectomy, a major and aggressive open surgical intervention. Now, minimally invasive methods for drainage are available, so obtaining a definitive diagnosis is less important. The ESGE guidelines recommend against routine percutaneous FNA in patients with suspected IPN, stating that its use should be restricted to cases with a suspicion of infection but with unclear clinical/imaging signs. In most cases direct drainage for diagnosis and treatment is encouraged when IPN is suspected and other sources of infection (central-line infection, pneumonia, urinary tract infections, Clostridium difficile infection, etc.) have been ruled out.",282,35,0.12411347517730496
9783318066241,ch7,"Currently, initial endoscopic drainage (plus/or percutaneous drainage in collections distant from the digestive tract) followed if needed by endoscopic necrosectomy seems the treatment of choice to drain collections. Video-assisted retroperitoneal debridement is a good alternative to endoscopic necrosectomy. Open necrosectomy should be avoided if possible.","In endoscopic necrosectomy, the endoscope is introduced into the collection cavity to remove the necrotic debris using devices such stone-retrieval baskets, polypectomy snares, etc. Evidence-based selection of drainage technique. Before 2010, the standard treatment of necrotic collections (all IPNs and those symptomatic collections refractory to conservative treatment) was open necrosectomy. A series of studies performed by the Dutch Pancreatitis Study Group shifted this towards a minimally invasive approach. In 2010, the group published a multicenter randomized controlled trial (RCT) comparing a step-up approach versus open necrosectomy for patients with IPN. The step-up approach comprised a first step of percutaneous or endoscopic transgastric drainage. The preferred route was through the left retroperitoneum, thereby facilitating minimally invasive retroperitoneal necrosectomy at a later stage, if necessary. If there was no clinical improvement after 72 hours and if the position of the drain (or drains) was inadequate or other fluid collections could be drained, a second drainage procedure was performed. If the second drainage procedure was not possible, or if there was no clinical improvement after an additional 72 hours, the second step, VARD with postoperative lavage, was performed. In the trial, 88 patients with IPN were randomized to either the step-up approach or to open necrosectomy. The step-up approach was associated with lower rates of.",308,74,0.24025974025974026
9783318066241,ch8,Abdominal compartment syndrome (ACS) is defined as a sustained intra-abdominal pressure > 20 mmHg that is associated with new organ dysfunction/failure.,"Moderate-to-severe acute pancreatitis (AP) is associated with increased vascular permeability (resulting in interstitial edema), retroperitoneal inflammation and collections and with paralytic ileus; it may also be associated with ascites. These factors increase IAP and may result in intra-abdominal hypertension (a sustained IAP >= 12 mmHg). Patients with intra-abdominal hypertension are at risk of developing organ failure (OF), as increased pressure in the abdomen may collapse blood vessels, resulting in gastrointestinal tract and kidney ischemia and decreased cardiac output. OF can also arise from organ compression resulting, for example, in difficulties expanding the lungs and decreased chest compliance. Abdominal compartment syndrome (ACS) is defined as a sustained increase in IAP (> 20 mmHg) that is associated with new organ dysfunction/failure.",178,36,0.20224719101123595
9783318066241,ch8,"When non-invasive measures fail in ACS, neuromuscular blockade with artificial respiration, percutaneous drainage or, finally, decompressive surgery may be indicated.","Very few randomized controlled trials (RCTs) have compared aggressive versus conservative treatment of pancreatitis-associated ACS. In critically ill patients with increasing IAP, some non-invasive measures may be useful. Nasogastric and colonic decompression via tubes should be used in cases of gastric or colonic dilatation. Neuromuscular blockade with artificial respiration decreases IAP by reducing abdominal musculature tone and increasing abdominal compliance. In cases of refractory intra-abdominal hypertension, and particularly in cases of organ dysfunction, percutaneous drainage of collections may decrease IAP and improve outcomes. Patients with no response can undergo abdominal decompression surgery (Figure 8.1). The indications, timing and technique for decompression surgery are a matter of debate, as there is no good-quality evidence from RCTs. Currently, midline laparostomy seems to be the method of choice.",189,35,0.18518518518518517
9783318066241,ch8,"Disconnected tail syndrome may be associated with bulky retroperitoneal collections, pancreatic ascites, pancreatic pleural effusion and/or pancreaticocutaneous fistula.","A healthy pancreas produces 1-4 liters of pancreatic juice per day. central pancreatic gland necrosis may result in complete transection of the main pancreatic duct, causing pancreatic juice to leak into the retroperitoneum (Figure 8.2). This complication is called disconnected tail syndrome (DTS) or disconnected pancreatic duct syndrome. DTS is associated with bulky retroperitoneal collections, pancreatic ascites, pancreatic pleural effusion (Figure 8.3) and/or pancreaticocutaneous fistula. Fluid obtained from these complications is typically rich in amylase and lipase. There are no good-quality RCTs addressing the management of DTS. The role of enteral or parenteral nutrition is unclear. Octreotide, a somatostatin analog that inhibits the secretion of pancreatic juice, does not seem to be useful in managing DTS. Endoscopic retrograde cholangiopancreatography together with pancreatic stenting of the disrupted duct will do little to solve the problem, as a necrotic collection is present and may become infected. In general, the recommended management is endoscopic transmural drainage of the necrotic collection if indicated (see page 67) using a long-term double-pigtail plastic stent. As discussed in Chapter 7 (see page 69), lumen-apposing metal stents (LAMS) left in place for more than 4 weeks may be associated with bleeding or may become embedded. However, in cases of DTS, early removal of the stent will probably result in the collection relapsing, so the use of LAMS in this kind of endoscopic drainage is discouraged. In cases of partial main pancreatic duct disruption, retrospective data suggest that bridging of the disruption using a transpapillary pancreatic stent may improve outcomes. In refractory cases, distal pancreatectomy or pancreaticojejunostomy may be needed.",409,37,0.09046454767726161
9783318066241,ch8,"If indicated, the treatment of choice for disconnected tail syndrome is long-term double-pigtail plastic stent drainage with or without transpapillary main pancreatic duct stenting.","There are no good-quality RCTs addressing the management of DTS. The role of enteral or parenteral nutrition is unclear. Octreotide, a somatostatin analog that inhibits the secretion of pancreatic juice, does not seem to be useful in managing DTS. Endoscopic retrograde cholangiopancreatography together with pancreatic stenting of the disrupted duct will do little to solve the problem, as a necrotic collection is present and may become infected. In general, the recommended management is endoscopic transmural drainage of the necrotic collection if indicated (see page 67) using a long-term double-pigtail plastic stent. As discussed in Chapter 7 (see page 69), lumen-apposing metal stents (LAMS) left in place for more than 4 weeks may be associated with bleeding or may become embedded. However, in cases of DTS, early removal of the stent will probably result in the collection relapsing, so the use of LAMS in this kind of endoscopic drainage is discouraged. In cases of partial main pancreatic duct disruption, retrospective data suggest that bridging of the disruption using a transpapillary pancreatic stent may improve outcomes. In refractory cases, distal pancreatectomy or pancreaticojejunostomy may be needed.",278,38,0.1366906474820144
9783318066241,ch8,A pancreatic pseudoaneurysm should be treated with selective angiographic embolization.,"There are no good-quality RCTs addressing the management of DTS. The role of enteral or parenteral nutrition is unclear. Octreotide, a somatostatin analog that inhibits the secretion of pancreatic juice, does not seem to be useful in managing DTS. Endoscopic retrograde cholangiopancreatography together with pancreatic stenting of the disrupted duct will do little to solve the problem, as a necrotic collection is present and may become infected. In general, the recommended management is endoscopic transmural drainage of the necrotic collection if indicated (see page 67) using a long-term double-pigtail plastic stent. As discussed in Chapter 7 (see page 69), lumen-apposing metal stents (LAMS) left in place for more than 4 weeks may be associated with bleeding or may become embedded. However, in cases of DTS, early removal of the stent will probably result in the collection relapsing, so the use of LAMS in this kind of endoscopic drainage is discouraged. In cases of partial main pancreatic duct disruption, retrospective data suggest that bridging of the disruption using a transpapillary pancreatic stent may improve outcomes. In refractory cases, distal pancreatectomy or pancreaticojejunostomy may be needed.",278,20,0.07194244604316546
9783318066241,ch8,"Although bleeding varices are uncommon, peripancreatic vein thrombosis should be diagnosed during the index hospital admission and patients should receive prompt anticoagulation therapy.","Although there are no RCTs and the benefits have not been properly studied, patients with acute PVT (diagnosed during index admission) should begin anticoagulation therapy unless contraindicated, although a retrospective study reported no differences in recanalization. The authors' personal experience suggests that early anticoagulation, first (during hospital stay) with low-molecular-weight heparin and then oral anticoagulation for 3-6 months, is safe and may be effective in solving the thrombosis and avoiding left-sided portal hypertension. Patients with well-established PVT (exempli gratia PVT diagnosed in an ambulatory control CT scan after discharge, and showing collateral circulation) will show little response to anticoagulation.",159,36,0.22641509433962265
9783318066241,ch9,The correct diagnosis of the etiology of acute pancreatitis (AP) is important to prevent recurrence.,"Correctly diagnosing the etiology of AP is important in guiding appropriate action to prevent the patient experiencing a recurrence. The etiology for most patients will be diagnosed during their index hospital admission by means of anamnesis (to determine possible drug, alcohol and tobacco abuse, etc.), laboratory findings (hypertriglyceridemia, hypercalcemia, etc.) and conventional ultrasonography (gallstones). Patients with an obscure etiology should undergo endoscopic ultrasonography, which can accurately diagnose gallbladder microlithiasis/sludge and pancreatic solid and cystic tumors. CT is also useful for detecting solid tumors, and MRI can diagnose cysts and ductal abnormalities. Genetic testing is usually performed in cases of otherwise idiopathic recurrent pancreatitis. Table 9.1 lists the imaging features that suggest autoimmune pancreatitis. Increased serum immunoglobulin G4 is associated with type I autoimmune pancreatitis but the sensitivity and specificity are far from perfect (frequent false-negative and -positive results). Manometry to diagnose sphincter of Oddi dysfunction is seldom used, and is available only in some very specialized tertiary referral centers.",237,21,0.08860759493670886
9783318066241,ch9,"Endoscopic ultrasonography is very useful in patients with an obscure etiology after anamnesis, laboratory findings and conventional ultrasonography.","Correctly diagnosing the etiology of AP is important in guiding appropriate action to prevent the patient experiencing a recurrence. The etiology for most patients will be diagnosed during their index hospital admission by means of anamnesis (to determine possible drug, alcohol and tobacco abuse, etc.), laboratory findings (hypertriglyceridemia, hypercalcemia, etc.) and conventional ultrasonography (gallstones). Patients with an obscure etiology should undergo endoscopic ultrasonography, which can accurately diagnose gallbladder microlithiasis/sludge and pancreatic solid and cystic tumors. CT is also useful for detecting solid tumors, and MRI can diagnose cysts and ductal abnormalities. Genetic testing is usually performed in cases of otherwise idiopathic recurrent pancreatitis. Table 9.1 lists the imaging features that suggest autoimmune pancreatitis. Increased serum immunoglobulin G4 is associated with type I autoimmune pancreatitis but the sensitivity and specificity are far from perfect (frequent false-negative and -positive results). Manometry to diagnose sphincter of Oddi dysfunction is seldom used, and is available only in some very specialized tertiary referral centers.",237,29,0.12236286919831224
9783318066241,ch9,"Diabetes, exocrine pancreatic insufficiency, recurrence and progression to chronic pancreatitis are frequent consequences of AP.","Exocrine pancreatic insufficiency. A systematic review showed a pooled prevalence of exocrine pancreatic insufficiency (EPI) subsequent to AP of 62% (95% confidence interval [CI] 39%, 82%), decreasing during follow-up to 35% (95%CI 27%, 43%). Again, risk factors for this complication were severe AP, necrotizing AP and alcohol-related AP. According to another systematic review, steatorrhea (a major symptom of EPI) subsequent to AP was present in 11% of patients at follow-up within 12 months, 33% at 12-36 months and 33% at 36 months or longer. In contrast, in patients undergoing a fecal elastase test (rather than fecal fat analysis) to define EPI, the prevalence of EPI decreased over the same period: 27%, 26% and 9%, respectively. Patients with clinical steatorrhea should receive pancreatic enzyme replacement treatment (PERT) directly. Patients with persistent decreased nutritional markers, new-onset dyspeptic symptoms or other possible signs or symptoms of EPI should undergo an indirect pancreatic function test or receive empiric PERT if a test is not available. Fecal elastase-1 is very useful as a screening test for EPI in this setting. EPI should be treated with enzymes; extrapolating from the United European Gastroenterology evidence-based guidelines on chronic pancreatitis, a minimum lipase dose of 40 000-50 000 PhU is recommended with main meals and half that dose with snacks.",320,25,0.078125
9783318066685,ch1,"Gene therapy involves the addition of nucleic acid-based products to a cell, either to compensate for a pathogenic loss of a protein or suppress the expression of a toxic protein.","The elucidation of the molecular basis of inherited diseases, from the discovery of the structure of DNA in 1953 to the sequencing of the human genome in 2002, has perhaps heralded a new age of genetic medicine, wherein it is now possible for the modern investigator or clinician to target the underlying disease mechanism. Gene-based therapy involves: (1) the addition or modification and subsequent expression of a new gene to provide a specific additional function to a cell; (2) the inoculation of nucleic acids for vaccination against foreign antigens; or (3) the general transfer of nucleic acids to modify the function of an endogenous gene to effect a direct or indirect clinical benefit. This transfer of genetic information, which may be transient or permanent, produces gene products for intercellular, intracellular or systemic uses that may affect endogenous genes, compensate for pathogenic genes or augment defective genes. It must be noted, though, that a formal definition for gene therapy is yet to be accepted by an international consortium and definitions may vary according to national regulatory agencies.",213,36,0.16901408450704225
9783318066685,ch1,"The transfer of genetic material may be transient or permanent, with non-viral and viral vectors, and it can be executed in an ex vivo context or directly in vivo.","The elucidation of the molecular basis of inherited diseases, from the discovery of the structure of DNA in 1953 to the sequencing of the human genome in 2002, has perhaps heralded a new age of genetic medicine, wherein it is now possible for the modern investigator or clinician to target the underlying disease mechanism. Gene-based therapy involves: (1) the addition or modification and subsequent expression of a new gene to provide a specific additional function to a cell; (2) the inoculation of nucleic acids for vaccination against foreign antigens; or (3) the general transfer of nucleic acids to modify the function of an endogenous gene to effect a direct or indirect clinical benefit. This transfer of genetic information, which may be transient or permanent, produces gene products for intercellular, intracellular or systemic uses that may affect endogenous genes, compensate for pathogenic genes or augment defective genes. It must be noted, though, that a formal definition for gene therapy is yet to be accepted by an international consortium and definitions may vary according to national regulatory agencies.",213,35,0.1643192488262911
9783318066685,ch1,Clinical translation of a gene therapy agent has many hurdles to overcome. These range from identifying the target gene and designing the drug for efficient specific delivery of the required levels of expression to considering the genotoxic and immunologic risks.,"The elucidation of the molecular basis of inherited diseases, from the discovery of the structure of DNA in 1953 to the sequencing of the human genome in 2002, has perhaps heralded a new age of genetic medicine, wherein it is now possible for the modern investigator or clinician to target the underlying disease mechanism. Gene-based therapy involves: (1) the addition or modification and subsequent expression of a new gene to provide a specific additional function to a cell; (2) the inoculation of nucleic acids for vaccination against foreign antigens; or (3) the general transfer of nucleic acids to modify the function of an endogenous gene to effect a direct or indirect clinical benefit. This transfer of genetic information, which may be transient or permanent, produces gene products for intercellular, intracellular or systemic uses that may affect endogenous genes, compensate for pathogenic genes or augment defective genes. It must be noted, though, that a formal definition for gene therapy is yet to be accepted by an international consortium and definitions may vary according to national regulatory agencies.",213,46,0.215962441314554
9783318066685,ch1,Monogenic diseases lend themselves to treatment using gene therapies. Ex vivo manipulation of hematopoietic stem cells is paving the way to clinical approvals.,"The elucidation of the molecular basis of inherited diseases, from the discovery of the structure of DNA in 1953 to the sequencing of the human genome in 2002, has perhaps heralded a new age of genetic medicine, wherein it is now possible for the modern investigator or clinician to target the underlying disease mechanism. Gene-based therapy involves: (1) the addition or modification and subsequent expression of a new gene to provide a specific additional function to a cell; (2) the inoculation of nucleic acids for vaccination against foreign antigens; or (3) the general transfer of nucleic acids to modify the function of an endogenous gene to effect a direct or indirect clinical benefit. This transfer of genetic information, which may be transient or permanent, produces gene products for intercellular, intracellular or systemic uses that may affect endogenous genes, compensate for pathogenic genes or augment defective genes. It must be noted, though, that a formal definition for gene therapy is yet to be accepted by an international consortium and definitions may vary according to national regulatory agencies.",213,31,0.14553990610328638
9783318066685,ch2,"Viral vector delivery has the advantage of persistence of transgene expression, though there are associated genotoxic and immunologic risks that limit efficacy and patient applicability.","Loss-of-function mutations usually show autosomal recessive or X-linked inheritance and result in severely reduced or complete absence of the functional protein so that disease results. It is possible to use gene therapy to compensate for the defective gene in a number of ways. Replacement of a defective copy of a gene. Gene addition, where the coding DNA of the affected gene is delivered to cells or a tissue, theoretically provides a therapy that would be applicable to all patients with a disease, irrespective of the mutation they possess. The complementary DNA (cDNA) is generally packaged with a promoter and polyadenylation signal (for termination of transcription) into a viral vector to enhance delivery into cells and provide longevity of expression. The delivery of naked DNA or DNA packaged into liposomes or endosomes is associated with low efficacy of delivery and rapid turnover.",172,34,0.19767441860465115
9783318066685,ch2,"Non-viral vector delivery, despite generally having safer outcomes than viral delivery, is limited by transient transgene expression and the need for re-administration, which may lead to accumulated toxicological issues.","More specific correction is possible through homology-directed repair (HDR), which requires the supply of donor DNA containing the desired insertion flanked by long arms of homology to drive recombination during cell division. Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) technology has led to an advance in the therapeutic potential of endonucleases in genetic disease through the development of base editing, RNA editing and exploitation of the alt-NHEJ pathway to drive targeted integration. Alt-NHEJ relies on short arms of homology to initiate end resection (as seen in HDR) prior to joining of the juxtaposed DNA ends (as seen in NHEJ). Of note here is the potential to use a catalytically inactive Cas protein 9 (Cas9), which normally acts as an RNA-guided endonuclease, tethered to transcriptional activators to upregulate expression of genes that could compensate for the mutated gene. This may also apply directly to mutations that affect the 5' untranslated region (UTR) of a gene.",228,42,0.18421052631578946
9783318066685,ch2,"Loss-of-function mutations can potentially be repaired through gene addition, exon skipping to restore the transcript reading frame, gene editing and upregulation of compensatory genes.","Treatable loss-of-function mutations may include pathogenic missense mutations and those that alter the transcript reading frame, bringing a premature stop or termination codon (PTC) into frame so that the transcript undergoes nonsense-mediated decay (NMD) and no functional protein is expressed. NMD is a surveillance pathway active during translation that guards against errors in gene expression; if a stop codon is further than 50 nucleotides upstream of an exon junction complex, binding of which normally denotes the position of splicing of two exons, the mRNA will be degraded. By designing antisense oligonucleotides to mask the exonic splicing enhancer (ESE) motifs of an out-of-frame exon that neighbors a loss-of-function deletion, it is possible to induce the splicing out of the target (mutated) exon so that the reading frame is restored and truncated but partially functional protein is expressed. This 'exon skipping' has been applied to a number of diseases as well as in the manipulation of alternative splicing for proteins that can be expressed as different isoforms.",230,35,0.15217391304347827
9783318066685,ch2,"Gain-of-function mutations can potentially be treated genetically through endonuclease-mediated gene editing, RNA interference using small interfering (si)RNA or short hairpin (sh)RNA, and antisense oligonucleotides targeting translation start codons, polyadenylation signals or out-of-frame exons.","LncRNAs and miRNAs interact in various ways to control gene expression (Figure 2.2). Briefly, miRNAs can trigger lncRNA decay, while lncRNAs can both generate miRNAs and act as miRNA sponges or decoys. Both bind the mRNA of target genes in a competitive manner. The miRNAs are suitable targets for therapeutic intervention to control gene expression. The delivery of an miRNA mimic to potentiate miRNA function will downregulate the target mRNA and so block the expression of a pathogenic gene. As an aside, therapeutic upregulation of a specific gene can be achieved through forced decrease of miRNA activity using miRNA antisense oligonucleotides (so-called antagomirs), among other strategies, to inhibit the interaction of miRNA with its target mRNA. Gene editing. Endonucleases can be used to disrupt a gene carrying a gain-of-function mutation so that expression is inhibited. This can be achieved by targeting similar sequences as those described for antisense oligonucleotides above. NHEJ repair of a DSB would have the potential to compromise the function of the promoter and/or enhancer, eliminate the transcription start site or translation start codon, disrupt the reading frame of the transcript or mutate the polyadenylation signal to reduce the export and stability of the RNA. Catalytically inactive Cas9, either on its own or tethered to transcriptional suppressors, can be guided to target the sequence around the transcription start site (TSS) of the mutated gene and so block its expression.",330,68,0.20606060606060606
9783318066685,ch2,Ex vivo and in situ in vivo gene therapies are - particularly for eye disorders - associated with enhanced safety and targeted efficacy relative to direct systemic in vivo therapy.,"Cellular gene therapy has been used most successfully in the treatment of blood diseases, as hematopoietic stem cells (HSCs) (either lymphocytes or stem and progenitor cells) are easy to harvest, manipulate in culture and transplant back into the patient. HSC gene therapy compares favorably to allogeneic hematopoietic cell transplantation and, as it can be applied to all patients - the need for an HLA-matched donor is removed - it eliminates the morbidity risks associated with graft versus host disease. It is also possible to exploit HSC gene therapy to engineer the cells to increase the therapeutic gene dosage, to specifically target diseased tissues or to become resistant to particular disease-causing pathogens. The plasticity of HSCs allows the ex vivo targeting of diseases associated with other tissues such as the heart and the brain. Hepatocytes, another adult stem cell type, have also been used for autologous ex vivo gene therapies for certain liver diseases. With the advent of cellular reprogramming and induced pluripotent stem cell technologies, ex vivo gene therapy is now being applied to other somatic stem and progenitor cell types, meaning a wider range of tissues can be targeted.",251,31,0.12350597609561753
9783318066685,ch2,Preclinical research is focused on improving the safety profiles and manufacturing costs of viral vectors.,"The infectivity and gene-shuttling capability of certain viral vectors, coupled with the ability to engineer the removal of viral genes that may cause harm, provides the basis for the use of viruses for gene delivery. Viral particles carry surface proteins that interact with particular receptors on target cells to trigger endocytotic uptake. Following endosomal trafficking, DNA is delivered into the nucleus for viral gene expression. Viral vector genome engineering involves replacing infectious viral genes with a therapeutic gene cassette, while retaining the signal sequences required for in vitro replication and packaging into producer cell lines. The most widely used viral vectors for preclinical and clinical gene therapy purposes are based on gammaretrovirus, lentivirus, adenovirus, adeno-associated virus (AAV) and herpes simplex virus (HSV). The key features and differences of these viral vectors are outlined in Table 2.2.",182,17,0.09340659340659341
9783318066685,ch3,Continued development of safer gene therapy vectors and protocols mitigates risks and makes gene therapy available to a broader patient population.,"The first clinical trial in human gene therapy was reviewed by the RAC and initiated at the NIH Clinical Center in 1990 (the goal of the trial was to treat immune-deficient children born with adenosine deaminase [ADA] deficiency using retroviral gene transfer to T cells). Over the years, major concerns about gene therapy included the (at least theoretical) possibility of germline transmission, the potential for severe immunotoxicities and the risk of insertional mutagenesis, among others. Conversely, the scientific and medical community's understanding of the risks related to gene transfer in patients has grown substantially over the past three decades and there is now a wealth of clinical trial and animal data. Senior leaders of the US Food and Drug Administration (FDA) and the NIH recently concluded that the risks of gene therapy should no longer be viewed as unique or unpredictable. Hence, the RAC's mission no longer includes scrutiny of gene therapy trials.",191,25,0.13089005235602094
9783318066685,ch3,"Some gene therapies have a risk of cancer development (due to insertional mutagenesis), toxicities, unwanted immune reactions or off-target effects. In each case, a risk-benefit analysis provides guidance for patient selection and potential protocol modifications.","X-linked severe combined immunodeficiency (SCID-X1) is caused by a lack of the common gamma chain that is critical for multiple cytokine receptors and therefore for the development of the immune system. It was reasoned that introducing this gene to HSCs should provide a selective advantage for gene-corrected cells, thus reconstituting the immune system without the need for a conditioning regimen. Two initial clinical trials in France and the UK utilized a gammaretroviral vector with long terminal repeat (LTR)-driven expression of the transgene for transduction of autologous CD34+ bone marrow cells. Following cell transplant to a total of 20 infants, the clinical outcome was remarkable. Two decades later, 18 of the 20 patients are alive and still show full or nearly full correction of T-cell immunodeficiency. However, six patients developed T-cell leukemia between 2.5 and 15 years after the cell transplant. While most patients were successfully treated with chemotherapy, one patient died as a result of the leukemia. Retroviral integration had caused the activation of proto-oncogenes such as LMO2. Therefore, the trials were suspended and novel vectors with an enhanced safety profile have been developed.",252,49,0.19444444444444445
9783318066685,ch3,Gene therapy is a relatively new type of medicine that is closely monitored and regulated.,"As a result of more extensive investigation of the innate immune response to adenoviral vectors, their use in gene therapy is now much more limited. In general, there are still concerns even with other vectors when systemic delivery of very high doses is required to achieve therapy. Here, administration of anti-inflammatory drugs may be warranted. Activation of complement has been observed in a few patients receiving high doses of AAV vectors, raising the need for appropriate intervention protocols. While, in general, the risk-benefit ratio is an important consideration, gene therapy protocols are also evolving and will include additional safety features as clinical experience is gained.",126,16,0.12698412698412698
9783318066685,ch3,"Although opinions on the ethical implications are diverse, the prevailing view on gene editing is that applications should, at least currently, be restricted to somatic cells because there are still many unknowns about this novel technology.","Gene therapy currently focuses on somatic gene transfer. However, especially with the development of gene-editing technologies, germline gene therapy is being discussed as a future possibility. Gene editing in embryos could theoretically be used to correct genetic defects, thus eliminating them not only from this individual but also from future generations, or to genetically 'enhance' people. These questions have sparked an ongoing ethical discussion and require answers not only from doctors and scientists but from society as a whole. The prevailing opinion among scientists is that, at least at the moment, there are too many question marks to even consider germline gene therapy until technologies are further developed and more experience with somatic gene editing has been obtained. Nonetheless, a claim was made by a scientist in China in late 2018 that two twin girls were gene edited to become resistant to HIV infection. Although it is not entirely clear that gene editing was indeed achieved, calls for global cooperation and oversight have been made. Even if the technology can be perfected, the unintended consequences of editing specific genes need to be considered. Moreover, a broader discussion in society of the ethical considerations surrounding the circumstances and goals of human gene editing is warranted.",233,42,0.18025751072961374
9783318066685,ch3,"The costs of gene therapy are high, but these therapies could actually provide healthcare systems with savings over time; outcomes-based pricing is one proposed model.","The cost of those gene therapies that are already approved range from several hundred thousand to more than 2 million dollars, posing a challenge to healthcare systems. However, one also needs to consider the costs of alternative treatments. Factor-replacement therapy in hemophilia typically costs $200 000-300 000 annually per patient. A gene therapy that lasts at least one decade would therefore substantially reduce treatment costs over time. For some rare diseases, there may not be any alternative treatment; costs to society related to the care of such patients over a lifetime may be greater than the expense of a gene therapy, particularly if a single administration of the drug is sufficient. In life-threatening genetic diseases or cancer, gene therapy may offer a unique possibility for a cure or substantially prolonged life.",153,30,0.19607843137254902
9783318066685,ch4,"Adeno-associated virus (AAV) gene therapies for Leber congenital amaurosis and spinal muscular atrophy are now approved medicines in the USA and rely on in vivo injection to, respectively, the subretinal space and systemic circulation.","4 Gene therapies with proven clinical efficacy. Several gene therapy drugs are now approved by the US Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA) to be marketed as medicines (Table 4.1). Others have shown strong efficacy in early clinical studies and are therefore being evaluated in Phase III trials. Examples of gene therapies with track records of clinical efficacy are described in the following sections and summarized in Table 4.2. Hereditary blindness. Prior to gene therapy, no treatment was available for certain forms of hereditary blindness. However, the ability of adeno-associated virus (AAV) vectors to transduce retinal cells on subretinal administration has enabled the development of therapies for such diseases. This effort ultimately led to the first gene therapy drug approved by the FDA for the treatment of a genetic disease in late 2017. Leber congenital amaurosis. In Leber congenital amaurosis type 2 (LCA2), mutations in the RPE65 gene prevent the expression of retinal pigment epithelium 65 kDa protein (RPE65), thereby impairing the process of visual photo-transduction and severely limiting vision. Inheritance is autosomal recessive. Affected infants typically already have decreased visual responsiveness at birth.",259,50,0.19305019305019305
9783318066685,ch4,"After initial setbacks, hematopoietic stem cell gene therapy, primarily based on lentiviral vectors, is being successfully developed for primary immune deficiencies and some lysosomal storage disorders. Globin disorders are a major next target for this approach.","Spinal muscular atrophy (SMA) is a genetic disease that causes death in infants. Loss of motor neurons leads to progressive muscle wasting, initially affecting arm, leg and respiratory muscles. The disease is caused by mutations in the SMN1 gene, which is autosomal recessive and encodes survival of motor neuron 1, telomeric (SMN1), a protein necessary for motor neuron survival. The SMN1 protein is important for the biogenesis and assembly of small nuclear ribonucleic particles (snRNPs), which are critical in messenger (m)RNA splicing (spliceosome assembly and pre-mRNA splicing). While SMN1 is ubiquitously expressed, its loss is particularly detrimental to motor neurons. Without functional motor neurons, the central nervous system (CNS) is unable to send signals to skeletal muscles, and babies born with this defect gradually become paralyzed. To correct this devastating defect, a gene therapy was developed based on systemic delivery of high doses of AAV9 expressing functional SMN1. This vector is capable of transducing motor neurons and effectively transduces the spinal cord after systemic administration. Moreover, it is also able to cross the blood-brain barrier and transduce cells in the brains of rhesus macaques, even in animals up to 3 years old. Nonetheless, it is thought that the most effective reversal of disease can be achieved early in life. Remarkably, all 15 babies treated by this gene therapy in the initial clinical trial are alive at age 20 months or older (these patients were expected to die within the first 2 years of life). Most can sit up, and some are even able to walk. The FDA has approved the systemic AAV gene therapy for SMN1-deficient children up to the age of 2 years.",369,52,0.14092140921409213
9783318066685,ch4,"Multiple gene therapies for hemophilia, based on hepatic AAV gene transfer, have elevated coagulation factor activities in patients to the normal or near normal range. These are now being evaluated in Phase III trials.","After preclinical efficacy and long-term follow-up studies in hemophilic mice and dogs and in non-human primates, followed by a series of early Phase I/II clinical trials and further preclinical development, there are now several AAV vectors in advanced clinical development for hemophilia. They all utilize hepatocyte-specific promoters but differ in capsid and also utilize different methods for vector production (such as transient transfection of human cells or baculovirus infection of insect cells). For FIX production, efficacy has been further improved by incorporation of a naturally occurring variant (FIX-Padua) that has an approximately eightfold higher enzymatic activity. Such vectors raised coagulation activity in patients with severe disease to around 30-50% of usual levels, close to the lower limit of the normal range. Thus, patients typically no longer require factor infusions, and dramatic reductions in annual bleeding rates (mostly none) are reported. These therapeutic benefits have persisted for at least 3 years, with more follow-up data pending. Notably, patients treated in an earlier trial with an AAV vector expressing FIX without the Padua mutation reached levels above 5% of normal that were sustained for at least 8 years. Two products expressing FIX-Padua have been developed. These are now being evaluated in Phase III clinical trials. Differences include capsids, vector genomes/expression cassette design, manufacturing systems and reported vector doses.",289,44,0.1522491349480969
9783318066685,ch4,"Gene therapy, using gene-modified cells or in vivo gene transfer, has now been successful for diverse diseases and modes of gene transfer.","CAR-T therapy for lymphoma and leukemia. Adoptive lymphocyte therapy using gene-modified autologous T cells is one of the technologies revolutionizing cancer therapy. T cells are harvested from the patient's blood and transduced with a chimeric antigen receptor (CAR) by ex vivo gene transfer using retroviral or lentiviral vectors (Figure 4.3). Early success has been shown with blood cancers. In pioneering work, CAR-T cells directed against the CD19 antigen were able to effectively kill lymphoma cells from patients refractory to conventional chemotherapy. CAR-T cells targeting CD19 are now approved by the FDA and the EMA for the treatment of several types of blood cancer. These include: relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults; and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.",194,27,0.13917525773195877
9783318066685,ch4,"Chimeric antigen receptor (CAR)-T cell therapies for blood cancers, targeting the CD19 antigen, are in use to treat relapsed or refractory diffuse large B-cell lymphoma in adults and B-cell acute lymphoblastic leukemia in children and young adults.","CAR-T therapy for lymphoma and leukemia. Adoptive lymphocyte therapy using gene-modified autologous T cells is one of the technologies revolutionizing cancer therapy. T cells are harvested from the patient's blood and transduced with a chimeric antigen receptor (CAR) by ex vivo gene transfer using retroviral or lentiviral vectors (Figure 4.3). Early success has been shown with blood cancers. In pioneering work, CAR-T cells directed against the CD19 antigen were able to effectively kill lymphoma cells from patients refractory to conventional chemotherapy. CAR-T cells targeting CD19 are now approved by the FDA and the EMA for the treatment of several types of blood cancer. These include: relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults; and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. CARs have a modular design and comprise an antibody-derived single-chain variable fragment (scFv, the extracellular binding domain that targets the intact tumor surface antigen), a hinge region, a transmembrane domain and intracellular signaling domains. Expression of the CAR re-directs the T cells to the tumor antigen and provides the signals required for T-cell activation on binding to the antigen. Importantly, targeting of the intact antigen via scFv binding is neither MHC restricted nor dependent on co-receptors or epitope processing. CARs are broadly classified by the number of co-stimulatory domains that have been incorporated into the intracellular portion of the molecule. First-generation CARs contained only CD3zed chain, while second- or third-generation CARs have CD3zed plus one or more co-stimulatory domains, respectively (Figure 4.4). Current commercial designs are based on second-generation CARs. Future (fourth) generation CARs are being developed with inducible signaling.",407,56,0.1375921375921376
9783318066685,ch5,The endonuclease-mediated double-strand break (DSB) in the DNA is repaired by two mechanisms: efficient but imprecise non-homologous end joining (NHEJ) or inefficient but precise homology-directed repair (HDR).,"Gene editing is the manipulation of the genetic material of a living cell or organism by the disruption, deletion, correction or insertion of a DNA sequence. Of fundamental importance to the genome editing discipline is the discovery that endogenous DNA repair machinery can be stimulated by the directed induction of DNA double-strand breaks (DSBs). Once made, DSBs activate one of the host cell's two main DNA repair systems: non-homologous end joining (NHEJ) or homology-directed recombination (HDR) (Figure 5.1). The NHEJ pathway operates throughout the cell cycle and repairs DSBs without a template via the typically imprecise direct ligation of broken strand ends. As NHEJ is prone to error, small insertions or deletions (indels) are introduced into the genomic sequence at the DSB site. In contrast, HDR machinery operates mainly during the S and G2 cell cycle phases, utilizes a donor template with homology sequences to DSB sites, which is naturally the sister chromatid, and directs efficient site-specific strand exchange and repair.",224,55,0.24553571428571427
9783318066685,ch5,"Ex vivo and in situ in vivo applications of gene editing are being tested in the clinic, with a number of systemic in vivo trials starting.","The MN gene-editing platform utilizes homing endonucleases, such as I- Cre I and I- Sce I, but re-engineers them to target novel specific genomic sites. The use of MNs for gene editing has shown promise in various studies. A particular strength of MNs is that their small size (they are the smallest of the programmable endonuclease classes) makes their delivery possible with all standard approaches. Nevertheless, the exploitation of this technology has been restricted, mainly as a result of the high degree of protein engineering required to generate MNs with novel target specificity.",123,28,0.22764227642276422
9783318066685,ch5,Engineered endonucleases can be designed to target virtually any DNA sequence of choice using bioinformatics tools.,"The TALEN system utilizes transcription activator-like effector (TALE) proteins from the plant pathogen Xanthomonas. Individual TALEs recognize DNA bases with a simple one-to-one cipher determining binding specificity - one type of TALE binds to only one DNA base. Each highly conserved TALE repeat binds a specific single DNA base pair, with two hypervariable amino acid residues conveying specificity. Four TALEs specific to different DNA bases can be coupled together in various orders to target diverse but particular DNA sequences. On this basis, novel DNA-binding proteins, with custom DNA-binding specificity, have been engineered by linking modular TALE repeats into long arrays. Subsequently, as with ZFs, TALEs have been fused to the Fok l restriction endonuclease domain, generating programmable TALENs that function as pairs for the introduction of DSBs. The TALENs system can be 'programmed' by engineering the TALE repeat sequence-specific targeting region. TALENs have been used to efficiently trigger both the NHEJ and HDR pathways in human cells. Perhaps the main strength of the TALENs platform is the virtually unlimited target sequence range it affords, with the only constraint being the need for a 5' T, specified by the constant N-terminal domain, for each array. A further strength is the comparative ease of engineering new arrays when compared with ZFNs and MNs.",301,24,0.07973421926910298
9783318066685,ch5,There are distinct advantages and disadvantages associated with each type of endonuclease.,"However, there are significant drawbacks that hamper the utility of the platform, particularly for in vivo delivery. The relatively large packaging size of each TALEN monomer, when compared with ZFNs and MNs, prohibits the packaging of a pair in a single viral vector with limited packaging capacity, such as an adeno-associated virus (AAV). Of further concern is the instability of the tandem repeats that comprise each TALEN monomer, with potential susceptibility to TALE rearrangement and increased difficulty in the viral packaging of repetitive sequences.",111,16,0.14414414414414414
9783318066685,ch5,NHEJ and HDR mechanisms can be exploited to repair loss-of-function mutations or disrupt gain-of-function mutations.,"HDR can be induced for precise and efficient gene correction of disease-causing mutations by targeted generation of a DSB along with the supply of an exogenous DNA repair template. Such a repair template should have homology to the break site and the correct sequence in place of the mutant. Therapeutic gene correction approaches have been in development for the repair of mutations causing a range of different human immunodeficiencies, including X-linked severe combined immunodeficiency. Similar strategies are under investigation as possible therapeutics for the correction of the underlying genetic defect in various other diseases, including: DMD, sickle cell disease, beta-thalassemia, cystic fibrosis and recessive dystrophic epidermolysis bullosa.",152,26,0.17105263157894737
9783318066685,ch6,Multiple gene therapies are showing efficacy in preclinical studies or early-phase trials.,"Clinical gene therapy is a very active field, with a large number of clinical trials, approaches and disease targets. It is not feasible to review all of these here. Newer technologies such as gene editing will undoubtedly shape the design of future gene therapies. In the meantime, there are already a number of promising candidates in early-phase clinical trials that may add to the success of those more advanced gene therapies summarized in chapter 4 (Table 6.1). Several examples are described in the following sections.",100,16,0.16
9783318066685,ch6,"Systemic delivery of adeno-associated virus (AAV) vectors using high-dose intravenous infusions are now being tested for the treatment of diseases that require gene transfer to multiple organs such as muscular dystrophies, lysosomal storage disorders and neuromuscular and neurodegenerative diseases.","X-linked myotubular myopathy (XLMTM) is a rare genetic neuromuscular disorder that has more recently been treated by systemic adeno-associated virus (AAV) vector delivery. Although results from more patients and longer-term follow-up data are still emerging, initial clinical trial results are quite remarkable. XLMTM is typically associated with severe muscle weakness. Symptoms are often already present at birth but may also develop later in infancy or early childhood. The defect is in a gene called MTM1 that encodes the enzyme myotubularin, which is required for the development and function of skeletal muscle. In addition to not being able to move on their own, boys born with the disease typically require assisted breathing and feeding. Approximately half of these children die within the first 1.5 years after birth. In a first clinical trial, nine patients aged from 8 months to 6 years were treated by systemic administration of a high dose of AAV8 vector, with the hope of widely transferring the MTM1 gene to muscle cells. Substantial restoration of myotubularin levels and improvements in muscle fiber development were observed on muscle biopsy. Impressively, at least four boys were able to sit up without help; three started to take steps with assistance. Some patients were able to vocalize sounds for the first time and eat food. These advances were presented at the 2019 annual meeting of the American Society of Gene and Cell Therapy.",297,64,0.21548821548821548
9783318066685,ch6,"Some of the most difficult targets are neurodegenerative diseases that require direct administration of vector into the brain and/or elimination of toxic gene products. In this case, the transgene may express a microRNA rather than a therapeutic protein to destroy the transcript for the endogenous toxic protein, such as in Huntington's disease.","Mutations in the ABCD1 gene cause an enzyme deficiency called adrenoleukodystrophy (ALD). As a consequence of the missing enzyme function, very-long-chain fatty acids accumulate, causing demyelination in the central nervous system (CNS) and the adrenal cortex. To initially test whether hematopoietic stem cell (HSC) gene transfer could treat this debilitating neurological disorder, two individuals with adrenoleukodystrophy were enrolled into a study. Lentiviral gene transfer was performed with autologous HSCs, and cells were transplanted following complete myeloablative conditioning. Impressively, these patients showed persistent therapeutic levels of aldolase protein for at least 3 years. Demyelination of the CNS was halted, resulting in stabilization of disease without any major safety complications. Cerebral ALD affects boys between ages 4 and 10 years, causing permanent disability; death occurs within 4-8 years of disease onset. The lentivirus/HSC approach is now being evaluated in such children in a Phase II/III trial. The absence of major functional disabilities at 24 months after transplantation serves as the primary efficacy endpoint for the study. Major functional disabilities include loss of ability to communicate, cortical blindness, need for tube feeding, total incontinence, wheelchair dependence and complete loss of voluntary movement. Among an initial group of 17 patients with median follow-up of 29.4 months, 15 were alive in 2017 with minimal clinical symptoms. As of early 2018, 29 individuals had received the gene therapy.",318,65,0.20440251572327045
9783318066685,ch6,"Advances in vector manufacturing, identification of viral capsids with suitable tropism and, in some cases, ability of the vector to cross the blood-brain barrier in young individuals have facilitated developments in AAV virus-mediated therapies.","Hope for treatment of this disease comes from preclinical studies using AAV vectors that express not a therapeutic protein but a micro (mi)RNA that targets the HTT messenger (m)RNA and induces its degradation (the miRNA machinery of post-transcriptional regulation has evolved to specifically eliminate unwanted gene expression in a given cell type) (Figure 6.1). For example, an AAV5-miHTT vector was able to decrease production of the huntingtin protein by more than 50% in areas of gene transfer in the brains of minipigs that had been injected with the vector. Intracranial injections led to dose-dependent vector distribution to the striatum, putamen and spreading to the cerebral cortex. These areas are affected by neuropathological changes at different stages of the disease. Using this approach, sustained lowering of huntingtin protein levels and functional improvements have been demonstrated in a mouse model of the disease. For clinical trial design, high-resolution MRI scans of people with Huntington's disease serve to identify injection sites for safe and hopefully efficient delivery of the vector to the desired target regions of the brain. A Phase I/II trial is under way.",237,46,0.1940928270042194
9783318066685,ch6,Hemopoietic stem cell gene transfer applications are being expanded to sickle cell disease and to certain central nervous system disorders.,"Hope for treatment of this disease comes from preclinical studies using AAV vectors that express not a therapeutic protein but a micro (mi)RNA that targets the HTT messenger (m)RNA and induces its degradation (the miRNA machinery of post-transcriptional regulation has evolved to specifically eliminate unwanted gene expression in a given cell type) (Figure 6.1). For example, an AAV5-miHTT vector was able to decrease production of the huntingtin protein by more than 50% in areas of gene transfer in the brains of minipigs that had been injected with the vector. Intracranial injections led to dose-dependent vector distribution to the striatum, putamen and spreading to the cerebral cortex. These areas are affected by neuropathological changes at different stages of the disease.",163,27,0.1656441717791411
9783318067095,ch1,Digital medicine is an emerging medical and scientific discipline concerned with the application of software and hardware to health through cycles of innovation and development of research-based evidence.,"What is digital medicine?. Digital medicine describes a field concerned with the use of technologies as tools for measurement and intervention in the service of human health. Digital medicine products are driven by high-quality hardware and software products that support health research and the practice of medicine broadly, including treatment, recovery, disease prevention and health promotion for individuals and across populations (Figure 1.1). Role of products. Digital medicine products can be used independently or in concert with pharmaceuticals, biologics, devices or other products to optimize patient care and health outcomes. Patients and healthcare providers are empowered with intelligent and accessible tools to address a wide range of conditions through high-quality, safe and effective measurements and data-driven interventions. Digital products are also used in health research to develop knowledge of the fundamental determinants of health and illness by examining biological, environmental and lifestyle factors. In observational and interventional research, digital technologies are increasingly used in the prevention and treatment of disease and to support health promotion.",196,31,0.15816326530612246
9783318067095,ch1,"Digital medicine products can be used for measurement and/or treatment, and in combination with existing diagnostics and therapeutics.","Digital medicine products can be used independently or in concert with pharmaceuticals, biologics, devices or other products to optimize patient care and health outcomes. Patients and healthcare providers are empowered with intelligent and accessible tools to address a wide range of conditions through high-quality, safe and effective measurements and data-driven interventions. Digital products are also used in health research to develop knowledge of the fundamental determinants of health and illness by examining biological, environmental and lifestyle factors. In observational and interventional research, digital technologies are increasingly used in the prevention and treatment of disease and to support health promotion.",117,24,0.20512820512820512
9783318067095,ch1,"These measurement advantages are applicable in clinical care and in the conduct of clinical research, where such measurements can be used as clinical endpoints or for other measurement and monitoring purposes such as establishing eligibility for a trial or detecting adverse effects of a treatment under study.","Digital medicine products can be used independently or in concert with pharmaceuticals, biologics, devices or other products to optimize patient care and health outcomes. Patients and healthcare providers are empowered with intelligent and accessible tools to address a wide range of conditions through high-quality, safe and effective measurements and data-driven interventions. Digital products are also used in health research to develop knowledge of the fundamental determinants of health and illness by examining biological, environmental and lifestyle factors. In observational and interventional research, digital technologies are increasingly used in the prevention and treatment of disease and to support health promotion. As a discipline, digital medicine encapsulates both broad professional expertise and responsibilities concerning the use of these digital tools. Digital medicine focuses on evidence generation to support the use of these technologies. Measurement products include digital biomarkers (exempli gratia using a vocal biomarker to track changes in tremor for a Parkinson's patient), electronic clinical outcome assessments (exempli gratia an electronic patient-reported outcome survey) and tools that measure adherence and safety (exempli gratia a wearable sensor that tracks falls and smart mirrors for passive monitoring in the home).",230,50,0.21739130434782608
9783318067095,ch1,"Measurement using digital products may enable more continuous, more precise and less biased information than traditional means of measurement in medicine.","Digital measures may enable more objective and precise screening for inclusion/exclusion in a clinical trial, which could expand the pool of eligible research participants, increase diversity of a trial population and decrease attrition between evaluation and enrollment by returning information to researchers faster. Digital measures may inform better decisions about whether to progress a drug from early phase trials to later, larger and more costly trials. These are known as 'go/no go' decisions. Digital measures may be particularly important to inform these decisions where current measures are subjective and/or where there is a high failure rate. For example, in Alzheimer's disease, digital cognitive assessments that afford more sensitive and frequent monitoring, but are not endorsed by health authorities yet, could enable better decision-making about which treatments to advance to the next phase of clinical development (Box 1.1).",164,24,0.14634146341463414
9783318067095,ch2,"Clinical research uses include interventional and non-interventional trials, although many practicalities and data management issues are yet to become commodities.","Clinical research may include some of the same activities as clinical care, but the primary purpose of clinical research is to develop a better understanding of factors influencing health and illness in people. The federal regulations define research as a 'systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge'. When a person (exempli gratia patient or healthy individual) volunteers to enroll in clinical research, they are called a research participant. There are rules and guidance that must be followed when conducting clinical research to make sure that research participants are protected from undue risks of harm. Clinical research comes in two broad subsets.",130,28,0.2153846153846154
9783318067095,ch2,"Digital medicine holds the promise of bringing complex medical measurements, observations and interventions outside the clinic.","Digital measurement in medicine will not replace clinics or clinicians entirely, nor would we want them to. The delivery of, for example, intravenous drugs or surgery, and the value that patients place on their relationship with their provider, cannot be replaced by digital tools. Nonetheless, when used appropriately, digital measurements can improve care by giving clinicians more complete information. Also, transferring some practices out of the clinic and into patients' regular lives - for example, passively measuring sleep quality with wearables instead of requiring overnight stays in clinics - can enhance access to care and reduce cost.",113,18,0.1592920353982301
9783318067095,ch2,Regulation of digital medicine varies widely across the globe.,"Digital measurement in medicine will not replace clinics or clinicians entirely, nor would we want them to. The delivery of, for example, intravenous drugs or surgery, and the value that patients place on their relationship with their provider, cannot be replaced by digital tools. Nonetheless, when used appropriately, digital measurements can improve care by giving clinicians more complete information. Also, transferring some practices out of the clinic and into patients' regular lives - for example, passively measuring sleep quality with wearables instead of requiring overnight stays in clinics - can enhance access to care and reduce cost.",113,11,0.09734513274336283
9783318067095,ch3,"The regulatory frameworks for digital tools are in flux, and developers should continue to read upcoming guidance, comment on the revisions in the public docket and engage in the process to improve regulatory decision-making.","Novel digital tools are being adopted at different rates in different stages of clinical trials, most likely because different trial stages are associated with different levels of risk to the sponsor. Phase III is an unlikely place to see novel measurements of any kind, as disrupting a large complex trial and risking the primary endpoint(s) could be expensive and harmful to the development process. In contrast, implementing exploratory efficacy measures in a small early-stage safety trial may be inexpensive and introduce minimal risk to the primary endpoint(s). Sponsors are now deploying digital tools in Phase I, II and III trials as digital measurements need to be relatively consistent in the early stages of trials to develop the necessary evidence both for internal decision-making and regulatory approval. The regulatory terms that describe tools, methods, materials or measures that can potentially facilitate the medical product's development are drug development tools (DDTs) or medical device development tools (MDDTs) ('tools' are different from 'devices' at the FDA). ,4 The FDA has also released a request for comments on prescription drug-use-related software (PDURS) for software that is developed for use with prescription drugs (including biological drug products), which may include, but is not limited to, tracking drug ingestion, calculating the appropriate dose, sending reminders to take the drug or providing information on how to use a drug.",273,40,0.14652014652014653
9783318067095,ch3,"Agencies such as the US Food and Drug Administration (FDA) regulate what manufacturers claim a product can do (rather than what a product actually does), which means that a product can be considered a 'device' (and regulated) or not a device (and not regulated) through only a change in words and no change to hardware or software.","The CDRH is often the point of contact for digital medicine developers who are building digital medical products such as 'software as a medical device' (SaMD). A 'device' is a term of art at the FDA, which means that it has a precise and specialized meaning. The CDRH is responsible for regulating digital 'devices' but not digital tools. As such, we limit our use of the term 'device' in this book to be consistent with the FDA's definition for a 'medical device' (see FDA 2013 and 2017). ,10. For the US market, it is important to distinguish that the FDA does not regulate what the product actually does, but rather what an organization claims the product does. For instance, let us say Product A and Product B are exactly the same mobile sensor technology, id est the same hardware, firmware and software/algorithm that produce a measurement. If Product A states that the intended use of this measurement is for a wellness purpose, it likely is not regulated. If Product B says the intended use of this measurement is to make a diagnosis, then it would be considered a 'device' and regulated by the FDA. This means that the exact same product can be developed and marketed either as a 'device' (and thus, regulated) or not a device (and unregulated) simply through a change of words, and no change in hardware or code.",281,70,0.2491103202846975
9783318067095,ch3,Digital measurement tools that are considered a 'device' are regulated by the FDA Center for Devices and Radiological Health (CDRH). Digital tools that support drug applications (exempli gratia those that capture digital endpoint data) are regulated by the FDA Center for Drug Evaluation and Research (CDER).,"The CDRH is often the point of contact for digital medicine developers who are building digital medical products such as 'software as a medical device' (SaMD). A 'device' is a term of art at the FDA, which means that it has a precise and specialized meaning. The CDRH is responsible for regulating digital 'devices' but not digital tools. As such, we limit our use of the term 'device' in this book to be consistent with the FDA's definition for a 'medical device' (see FDA 2013 and 2017). ,10. For the US market, it is important to distinguish that the FDA does not regulate what the product actually does, but rather what an organization claims the product does. For instance, let us say Product A and Product B are exactly the same mobile sensor technology, id est the same hardware, firmware and software/algorithm that produce a measurement. If Product A states that the intended use of this measurement is for a wellness purpose, it likely is not regulated. If Product B says the intended use of this measurement is to make a diagnosis, then it would be considered a 'device' and regulated by the FDA. This means that the exact same product can be developed and marketed either as a 'device' (and thus, regulated) or not a device (and unregulated) simply through a change of words, and no change in hardware or code.",281,61,0.21708185053380782
9783318067095,ch3,Increasingly more manufacturers of digital products are considering the 'de novo' regulatory pathway so they do not have to deal with predicates and can develop an application that better reflects the software's unique characteristics.,"The CDRH is often the point of contact for digital medicine developers who are building digital medical products such as 'software as a medical device' (SaMD). A 'device' is a term of art at the FDA, which means that it has a precise and specialized meaning. The CDRH is responsible for regulating digital 'devices' but not digital tools. As such, we limit our use of the term 'device' in this book to be consistent with the FDA's definition for a 'medical device' (see FDA 2013 and 2017). ,10. For the US market, it is important to distinguish that the FDA does not regulate what the product actually does, but rather what an organization claims the product does. For instance, let us say Product A and Product B are exactly the same mobile sensor technology, id est the same hardware, firmware and software/algorithm that produce a measurement. If Product A states that the intended use of this measurement is for a wellness purpose, it likely is not regulated. If Product B says the intended use of this measurement is to make a diagnosis, then it would be considered a 'device' and regulated by the FDA. This means that the exact same product can be developed and marketed either as a 'device' (and thus, regulated) or not a device (and unregulated) simply through a change of words, and no change in hardware or code.",281,42,0.1494661921708185
9783318067095,ch4,"The principles that guide the ethical conduct of biomedical and behavioral research include: respect for persons, beneficence, justice (Belmont Report) and respect for law and public interest (Menlo Report).","The development of the IRB peer review process stemmed from egregious acts whereby researchers disregarded the rights and welfare of research participants. One example, known as the 'Tuskegee Study of Untreated Syphilis in the Negro Male', was an observational study of the natural progression of syphilis initiated by the Public Health Services in 1932. ,2 At that time, there was no treatment for syphilis; however, after penicillin was developed, the study participants were not treated and the study continued for nearly 40 years. The National Research Act was passed in 1974; it involved creating a National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research with a goal of preventing future atrocities. It was this Commission that required the formation of IRBs and also wrote the Belmont Report. Published in 1979, the Belmont Report describes three guiding principles of ethical biomedical and behavioral research: respect for persons, beneficence and justice.",187,39,0.20855614973262032
9783318067095,ch4,"Knowing how to apply ethical principles is a responsibility of all stakeholders involved in digital health research, including technologists, researchers and ethics review boards.","Education. All these concerns suggest a need to better educate prospective participants - and yet, integrating these concepts into the consent process is not easy. Moving forward, this charge will require a commitment from the medical community to provide accessible public-facing educational modules. For example, one way to improve tech literacy might be to include a brief animation describing the difference between de-identification and anonymity when describing data-sharing practices, or an illustration of what it means to store data in a cloud. A participant may also think that if the study team has access to their health data in real time, 24/7, then that means someone is paying attention to them (which may not be the case). Clarifying these concepts is important and how best to do this will require experts in instructional design who can deliver creative educational content. One organization working to advance meaningful informed consent in digital health research is Sage Bionetworks; it has published a toolkit to assist researchers.",192,28,0.14583333333333334
9783318067095,ch5,"Globally, it is common to conduct an ethics review of behavioral and biomedical research; this is carried out by an institutional review board (IRB), a research ethics board or a research ethics committee.","Because of past harms associated with research involving human participants, there is an expectation and, in many cases, a regulatory requirement that an ethics committee review will take place in advance of the research commencing. In research supported by the US Department of Health and Human Services (HHS) or under US Food and Drug Administration (FDA) oversight, this is carried out by an institutional review board (IRB) registered with the federal Office for Human Research Protections (OHRP). These regulations were initiated in 1974 as part of the National Research Act. The involvement of an IRB in behavioral and biomedical research is common globally, though often by other names, such as a research ethics board (REB) or 'research ethics committee'. An IRB can be a part of the organization conducting the research (id est medical center or university) or operate as an independent fee-for-service entity. In the US, an IRB is required to have a minimum of five people, including scientists, non-scientists and someone who is unaffiliated with the organization. This membership convention has been adopted globally for organizations conducting FDA-regulated research under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice guidelines. ,3.",255,41,0.1607843137254902
9783318067095,ch5,Federal regulations and accepted ethical principles are in place to guide the conduct of research so that the science is rigorous and the participants are protected.,"The IRB is responsible for reviewing research that involves human participants to evaluate compliance with federal regulations and application of ethical principles. This review includes evaluating the probability and magnitude of potential harms to research participants and weighing these risks against the potential benefits of knowledge to be gained. The IRB also reviews the proposed research to make sure that participants selected to participate represent those most likely to benefit from its results. Moreover, the IRB wants to make sure that people who are invited to participate in research have a good understanding of the study purpose and what they will be asked to do. This process of sharing study information with a prospective participant is called informed consent and is a central tenet of biomedical research. Federal regulations and accepted ethical principles are in place to guide the conduct of research so that the science is rigorous and the participants are protected. In any research, an important step is to determine if people involved in the testing phase are considered to be human participants in the research. The federal regulations include definitions for what qualifies as 'research' and 'human subject' and address the responsibilities of the organization and research team.",219,27,0.1232876712328767
9783318067095,ch5,"While IRB approval is an important step in the process for identifying and mitigating risk in studies, it is truly the responsibility of developers, researchers and clinicians to be a part of the ethical decision-making process.","IRB application. Once the type of review is known, an IRB application is developed by the research team that includes a detailed research protocol and a draft of the informed consent document. The protocol will briefly describe the scientific literature that the study is building from, as well as the study aims, procedures, participant inclusion criteria, risks, benefits, risk management, data management, investigator qualifications and informed consent details. The IRB will review this protocol application to evaluate whether the risks are appropriate in relation to the potential contribution to science and benefits to people like those who participate in the study. Application of ethical principles. Researchers have applied these principles and relied on IRBs to help shape ethical research practices for nearly half a century. However, as digital products are increasingly used in health research and clinical care, all relevant stakeholders have a collective responsibility to think proactively about how to conduct digital health research ethically and responsibly. While IRB approval is an important step in the process for identifying and mitigating risk in studies, it is truly the responsibility of developers, researchers and clinicians to be a part of the ethical decision-making process. Simply stated, we cannot outsource ethics and hope for the best.",238,42,0.17647058823529413
9783318067095,ch5,"Because digital measurement methods are relatively new, accessing resources and asking questions at the protocol development phase are critical.","Of course, these regulations and ethical principles are sometimes difficult to put into practice. Because the use of digital methods is relatively new, accessing resources at the protocol development phase is important. Over the past few years, several initiatives have begun to address the ethical, legal and social implications (ELSI) of emerging technologies. A few focus specifically on artificial intelligence (AI) broadly (exempli gratia autonomous vehicles, facial recognition, city planning, future of work). AI initiatives presently underway (exempli gratia AI Now, A-100) are well-funded and global collaborative programs. Others addressing digital medicine technologies more specifically include the Connected and Open Research Ethics (CORE) initiative, MobileELSI research project, Sage Bionetworks and the Clinical Trials Transformation Initiative (CTTI), which are described in the following paragraphs.",169,21,0.1242603550295858
9783318067095,ch5,Terms of service and end user license agreements are not a substitute for informed consent.,"The takeaway message here is that ToS and end user license agreements (EULAs) are not a substitute for informed consent. People want the right to opt-in to being involved in biomedical research, and that is a clear call for respecting the ethical principle of 'respect for persons'. Yet, when we are doing work that is technically not research, what is our ethical obligation? In software development, the way user data have been treated has an emerging history of malfeasance. This practice likely results from the lack of universally agreed guidelines and standards. We strongly recommend the adoption of ethical principles to guide responsible practice when guidelines are lacking.",128,17,0.1328125
9783318067095,ch5,"Lack of guidelines and exploitation of consumer data have led to new regulations that speak to consent and privacy concerns, including the General Data Protection Regulations in the European Union and the California Consumer Privacy Act.","In response to the lack of guidelines and exploitation of consumer data, new regulations have emerged that speak to consent and privacy concerns. The General Data Protection Regulations (GDPR) were passed by the European Parliament in 2016 and took effect in April 2018. The GDPR were designed to harmonize European Union (EU) privacy laws, protect EU citizens' data privacy and change how organizations, regardless of where they are located, process and manage EU citizen data. An important change that the GDPR introduced was the need for companies to obtain explicit informed consent separate from a ToS or EULA. This shift from consumers being helpless data subjects to empowered actors in the digital data economy is moving to the US. In 2018, California passed the California Consumer Privacy Act (CCPA) which, when implemented in 2020, gives consumers control over their data and requires that companies like Facebook and Google explain what data they collect, what they do with the data, and who the data are shared with.",195,39,0.2
9783318067095,ch6,"As advances in technology enable digital tools to gather ever larger amounts of high-resolution personal health information, core principles of medical and research ethics must be integrated at every step, beginning in the design phase.","For example, there is a lot of excitement in the healthcare community about using these tools in postmarket monitoring, or surveillance, to track metrics like safety monitoring and efficacy. Although many of these surveillance techniques in healthcare are still in the early stages, security researchers in the tech world are understandably cautious. Put simply: personalized medicine holds great promise for humanity, but it is not possible to have personalized medicine without some amount of 'surveillance' - indeed, they go hand in hand. As de-identification gets more difficult with the vast amount of data generated for an individual, it is critical to understand, for an entity getting access to our data, who, what and when? Health insurers and data brokers have been vacuuming up personal details on individuals, to create predictions on health costs based on race, marital status, whether you pay your bills on time or even buy plus-size clothing. Similar data have been used to create 'health risk scores' for the opioid crisis, determining who gets access to what types of care. Many biases may not come to light until after more rigorous testing; for instance, researchers have found that Fitbits and other wearables may not accurately track heart rates in people of color. The biases in these types of algorithms are starting to become better documented, exacerbating health disparities - and yet our society lacks clear regulatory interventions or punishment for misuse. ,9.",280,40,0.14285714285714285
9783318067095,ch6,"The line between 'personalization' and 'surveillance' is thin. As a result, and given the near impossibility to 'de-identify' mass amounts of data, it becomes more and more important to know who has access to sensitive data and under what conditions.","For example, there is a lot of excitement in the healthcare community about using these tools in postmarket monitoring, or surveillance, to track metrics like safety monitoring and efficacy. Although many of these surveillance techniques in healthcare are still in the early stages, security researchers in the tech world are understandably cautious. Put simply: personalized medicine holds great promise for humanity, but it is not possible to have personalized medicine without some amount of 'surveillance' - indeed, they go hand in hand. As de-identification gets more difficult with the vast amount of data generated for an individual, it is critical to understand, for an entity getting access to our data, who, what and when? Health insurers and data brokers have been vacuuming up personal details on individuals, to create predictions on health costs based on race, marital status, whether you pay your bills on time or even buy plus-size clothing. Similar data have been used to create 'health risk scores' for the opioid crisis, determining who gets access to what types of care. Many biases may not come to light until after more rigorous testing; for instance, researchers have found that Fitbits and other wearables may not accurately track heart rates in people of color. The biases in these types of algorithms are starting to become better documented, exacerbating health disparities - and yet our society lacks clear regulatory interventions or punishment for misuse. ,9.",280,56,0.2
9783318067095,ch6,"Common practices in the consumer technology industry for obtaining agreement to corporate terms of service, including privacy policies, are not sufficient or appropriate for obtaining informed consent from users, be they patients receiving care or participants in health research. (When was the last time you read an end user license agreement for a website or app you use?)","For example, there is a lot of excitement in the healthcare community about using these tools in postmarket monitoring, or surveillance, to track metrics like safety monitoring and efficacy. Although many of these surveillance techniques in healthcare are still in the early stages, security researchers in the tech world are understandably cautious. Put simply: personalized medicine holds great promise for humanity, but it is not possible to have personalized medicine without some amount of 'surveillance' - indeed, they go hand in hand. As de-identification gets more difficult with the vast amount of data generated for an individual, it is critical to understand, for an entity getting access to our data, who, what and when? Health insurers and data brokers have been vacuuming up personal details on individuals, to create predictions on health costs based on race, marital status, whether you pay your bills on time or even buy plus-size clothing. Similar data have been used to create 'health risk scores' for the opioid crisis, determining who gets access to what types of care. Many biases may not come to light until after more rigorous testing; for instance, researchers have found that Fitbits and other wearables may not accurately track heart rates in people of color. The biases in these types of algorithms are starting to become better documented, exacerbating health disparities - and yet our society lacks clear regulatory interventions or punishment for misuse. ,9.",280,64,0.22857142857142856
9783318067095,ch6,"The field of digital medicine must develop innovative ways of ensuring that the values of respect, privacy and trust are not lost in the pursuit of better data. It is critical to ensure that the technologies are worthy of the trust we place in them.","For example, there is a lot of excitement in the healthcare community about using these tools in postmarket monitoring, or surveillance, to track metrics like safety monitoring and efficacy. Although many of these surveillance techniques in healthcare are still in the early stages, security researchers in the tech world are understandably cautious. Put simply: personalized medicine holds great promise for humanity, but it is not possible to have personalized medicine without some amount of 'surveillance' - indeed, they go hand in hand. As de-identification gets more difficult with the vast amount of data generated for an individual, it is critical to understand, for an entity getting access to our data, who, what and when? Health insurers and data brokers have been vacuuming up personal details on individuals, to create predictions on health costs based on race, marital status, whether you pay your bills on time or even buy plus-size clothing. Similar data have been used to create 'health risk scores' for the opioid crisis, determining who gets access to what types of care. Many biases may not come to light until after more rigorous testing; for instance, researchers have found that Fitbits and other wearables may not accurately track heart rates in people of color. The biases in these types of algorithms are starting to become better documented, exacerbating health disparities - and yet our society lacks clear regulatory interventions or punishment for misuse. ,9.",280,48,0.17142857142857143
9783318067095,ch7,"'Effective, unambiguous communication is essential for efficient translation of promising scientific discoveries into approved medical products' (US Food and Drug Administration, BEST framework). Today, many key terms and definitions have been used inconsistently, and this ambiguity makes it difficult to evaluate products and evidence.","Digital biomarkers and clinical outcomes. Are digital measures the same as digital biomarkers? In some cases, yes. But not always. Determining the best term boils down to what you are measuring and for what purpose. Although we worked hard to minimize jargon in this book, this section will have more technical terms because we strive to use the same language that regulators use to categorize types of measurements, and we want to arm readers with the right language and frameworks to work with regulatory bodies. The US Food and Drug Administration (FDA) and National Institutes of Health (NIH) came together in 2016 to create the BEST (Biomarkers, EndpointS and other Tools) glossary resource to help clarify terms in this confusing space (Figure 7.1). BEST defines an outcome as any 'measurable characteristic  that is influenced or affected by an individual's baseline state or an intervention as in a clinical trial or other exposure.'. Clinical outcome or biomarker?. The purpose of medicine is to improve health and reduce the risk of an early death. Outcomes are essential measures to determine whether the practice of medicine is working. Outcomes can be clinical outcomes or biomarkers (Box 7.1).",247,55,0.22267206477732793
9783318067095,ch7,"For many measurements, it can be helpful to think about whether the data were collected actively through human intervention (exempli gratia a clinician observing the patient, or a patient filling in a diary) or passively through a sensor.","The industry generally makes a distinction between a digitally collected COA and a non-digital one (exempli gratia a paper questionnaire) by putting an 'e' for 'electronic' in front of the acronym (exempli gratia PRO [patient-reported outcome] to ePRO, COA to eCOA). Interestingly, though, the lines between technology-based assessments and questionnaires have become blurry. If a wearable device monitored your sleep overnight and then in the morning asked when you went to bed - was that evidence from a sensor or a questionnaire? As technologies continue to advance, there is increasing discussion around where digital measurement tools fit within this framework. What if some of the human raters in the previous COA examples were replaced with technology? For example, a medically informed algorithm that processes movement data from a wearable to rate ataxia. The possibility of a fifth COA to describe digital clinical outcome assessments, and specifically those measurements made using technology, was proposed during a summer 2018 Public Workshop at the FDA, though no firm next step was defined.",217,47,0.21658986175115208
9783318067095,ch7,"If someone uses a term you don't know in a conversation, best practice is to ask the person to clarify what they mean. Many terms are still in early development and have loose definitions.","It takes far more work to make human assessments digital than to simply translate a paper questionnaire into an app and put an 'e' in front of the tool (exempli gratia PRO to ePRO). eCOAs have unique properties that offer new ways to measure outcomes. What matters is whether the concept being measured is directly meaningful to patients. Take, for example, multiple sclerosis (MS). 'Ability to go about my daily activities' is a meaningful aspect of health to MS patients. A PRO (or even an ePRO) could measure a person's ability to perform activities of daily living through a self-reported survey. Self-reported measures require the person to reflect on and assess their own ability, leading to data that are meaningful to that individual, but potentially fraught with person-to-person variability, and subject to recall bias. A PerfO (performance outcome) might measure the amount of time it takes a person to walk 25 m. This is easy to measure and may be correlated with the capacity to perform typical daily activities. This approach has the benefit of not relying on patient recall, but it is an imperfect measure of the real outcome of interest - the ability to perform daily living tasks in a natural environment.",248,38,0.1532258064516129
9783318067095,ch7,"Developing a common set of language around biomarkers, measurements, outcomes and other terms will streamline premarket discussions between regulators and industry, and also postmarket with patients and providers. The authors defined a first draft set of definitions, which we expect and hope will evolve as technologies and applications develop over time.","Composite measures. We can also combine multimodal data from sensors, questionnaires and other clinical data (exempli gratia lab test, genomic tests) to create composite measures or 'complex biomarkers'. A composite measure consists of several individual measures that are combined to reach a single interpretive readout. For example, you could use sensor, keyboard, voice and speech data from a smartphone to construct a composite measure for cognition, and augment that measure over time with genetic data to make it more multimodal. The need for a human intermediary. Over time, a useful distinction between metric types will be whether the measurement required action by a human intermediary to gather the data (Figure 7.3). At the passive end of the spectrum, human participation is minimal and sensors simply capture data as individuals engage in daily activities like eating and sleeping. At the active end of the spectrum, more action by the intermediary is required. This could include a patient entering information into an electronic sleep diary or performing a task like a cognitive test. Hybrids of these two measures that use multimodal assessments and combine active and passive measures will also be valuable. An example is using actigraphy to passively measure when an individual fell asleep, coupled with an ePRO asking the individual to self-report the time.",262,62,0.2366412213740458
9783318067095,ch7,"Most high-quality data sources will likely be 'multimodal', meaning that the data will come from multiple sensors.","The need for a human intermediary. Over time, a useful distinction between metric types will be whether the measurement required action by a human intermediary to gather the data (Figure 7.3). At the passive end of the spectrum, human participation is minimal and sensors simply capture data as individuals engage in daily activities like eating and sleeping. At the active end of the spectrum, more action by the intermediary is required. This could include a patient entering information into an electronic sleep diary or performing a task like a cognitive test. Hybrids of these two measures that use multimodal assessments and combine active and passive measures will also be valuable. An example is using actigraphy to passively measure when an individual fell asleep, coupled with an ePRO asking the individual to self-report the time.",156,25,0.16025641025641027
9783318067095,ch8,"DCTs have a number of potential benefits, including faster participant recruitment, improved participant retention in the trial, greater control and convenience for participants and increased diversity and inclusion (exempli gratia because it is easier to enroll in the first place).","Traditional clinical trials collect snippets of data when a participant visits the study site and represent a tiny snapshot of patients' lived experience with a disease or condition. Yet researchers, industry sponsors and regulators rely on this limited information to make life-or-death decisions and multibillion-dollar investments. Digital measurements will convert that snapshot into a movie, with the ability to collect near continuous data outside the physical confines of the clinical environment, such as in a person's home, using connected products, including smartphones, wearables, implantables and ingestible devices and sensors. Decentralized clinical trials. Digital tools enable new forms of research such as decentralized clinical trials (DCTs), which are conducted outside of the clinic to capture data about a study participant in their day-to-day life (Figure 8.2). DCTs have a number of potential benefits, including faster participant recruitment, improved participant retention in the trial, greater control and convenience for participants, increased diversity (exempli gratia because it is easier to enroll in the first place) and trial results that are more generalizable. ,3.",224,50,0.22321428571428573
9783318067095,ch8,"Decentralized clinical trials (DCTs), which are conducted in a study participant's home using digital tools, offer a way to make better-informed decisions about the efficacy of new therapies.","Decentralized clinical trials. Digital tools enable new forms of research such as decentralized clinical trials (DCTs), which are conducted outside of the clinic to capture data about a study participant in their day-to-day life (Figure 8.2). DCTs have a number of potential benefits, including faster participant recruitment, improved participant retention in the trial, greater control and convenience for participants, increased diversity (exempli gratia because it is easier to enroll in the first place) and trial results that are more generalizable. ,3. DCTs offer a way to make better-informed decisions about the efficacy of new therapies. More sensitive, objective measures from digital technologies coupled with a greater density of information - continuously sampling multiple times a day, not just once a quarter - will help the industry fail faster and win more efficiently.",171,40,0.23391812865497075
9783318067095,ch8,DCTs are characterized by two core questions: where are the data collected (exempli gratia how remote is the study?) and how are the data collected (exempli gratia how virtual is the study? How much of the data is collected using digital tools versus needing human interaction?)?,"Two features of data collection determine how 'decentralized' a clinical trial is: where and how the data are collected. Where are data collected? In traditional clinical trials, drugs, devices and therapies are administered in a clinic or research hospital. In newer direct-to-patient or remote trials, participant data are collected in the home or in the study participant's natural environment. How are the data collected? In the past, most data were collected via an intermediary - someone from the team would record information in a custom software system and/or case report form. As digital tools advance, we can collect more endpoint-supporting data at home via digital surveys and sensors, and study teams can 'visit' patients at home via telemedicine conference calls. This means that more of the data are participant-generated and collected 'virtually', without an intermediary. In context. A doctor who remote teleconferences with a patient would be conducting a 'remote trial', but they might collect the data manually through a survey, so the study would not be considered a 'virtual trial'. In contrast, a study team might collect all the data passively from a smartwatch in a clinic, and this study would be a 'virtual trial' from a data collection perspective, but not a 'remote trial' because the patient is in a centralized location.",272,61,0.22426470588235295
9783318067095,ch8,"Digital measurement tools collect real-world data only when used outside of a clinical trial. When data from these tools are collected as part of a clinical trial protocol, they are collecting data during activities of daily living. But it is incorrect to call these data 'real-world data' as this term has a specific regulatory meaning.","What are real-world data?. Real world is a term that is important to define as it is often misused. The regulatory definition of real-world data is the data collected outside of a traditional clinical study, such as a randomized controlled trial (RCT). These data sources include electronic health records (EHRs), claims and billing activities, product and disease registries, patient-generated data including in home-use settings, and data gathered from other sources that can inform on health status, such as mobile technologies. Real-world evidence is the evidence derived from real-world data. In the context of a traditional RCT, if study participants contribute to some measurements at home, such as pain measurement via an electronic patient-reported outcome (ePRO) or step count from a wearable sensor, many often mistakenly believe this would constitute real-world data. However, these measures would not constitute real-world data because the participants have been preselected for study entry by the inclusion and exclusion criteria of a given trial. They do not represent the overall population in a certain indication. Therefore, when working with clinical research, it is important to focus on the benefits of health-related data collected in natural settings - which may not be classified as 'real world' by a strict regulatory definition.",260,65,0.25
9783318067095,ch9,Analytic validation: does the device process the raw data to produce the measure of interest (exempli gratia convert raw accelerometry data to gait speed in a particular patient population)?,"Validation is the process of ensuring that the digital measurement tool is meeting its intended use by generating objective data that accurately represent the concept of interest - the specific way in which the patient feels, functions or survives - that it purports to be measuring. Validation answers the question 'did I build the right tool?' The concept of validation can be broken down as follows. Analytic validation. Is the algorithm processing the data to report the measurement of interest? For example, is the algorithm accurately processing raw accelerometry data to calculate gait speed in a particular patient population?. Clinical validation. Is the measurement of interest reflecting the concept of interest - the specific way in which the patient feels, functions or survives? For example, is gait speed a meaningful measure that reflects how a particular patient population feels, functions or survives?.",167,38,0.2275449101796407
9783318067095,ch9,"Verification evaluates the capture and transference of a sensor-generated signal into collected data. The goal of verification testing is to ensure that the sensor is accurate, precise, consistent and uniform. This usually does not require human subjects.","The process of verification evaluates the capture and transference of a sensor-generated signal into collected data. As verification studies typically happen at the bench without human subjects, they do not usually require ethics committee review. Validation almost always involves human subject testing; it is the process of ensuring that the output data from the technology are accurate against a gold standard (analytic validation) and an appropriate reflection of the clinical concept of interest (clinical validation). Answering the latter will often involve testing the technology with human participants, which may require an ethics committee review before testing (see chapter 5). Clinical validation has multiple dimensions. We will not go into all of them here, but one example is whether a change in your new measurement is regarded as meaningful by people with the disease. Do the results generated by the tool capture all aspects of the concept you are measuring? Do changes to measurement values predict certain clinical outcomes down the road? Does the measurement respond to an intervention that is well understood to have an effect on the property you are measuring in that population? Can the measure correctly identify those patients with and without the condition (sensitivity and specificity)? Likewise, does that property remain unchanged in circumstances when it should not change (exempli gratia in a different population or when there is no intervention)? Of particular note in the realm of digital medicine is the reliance on computational algorithms, the performance of which can improve over time given access to more representative datasets (see chapter 1). The regulatory framework to deal with such systems is under active development at the US Food and Drug Administration (FDA).",317,46,0.14511041009463724
9783318067095,ch9,Clinical validation: do changes to the measure of interest predict future clinical outcomes (exempli gratia is gait speed a marker of disease progression)?,"Clinical validation has multiple dimensions. We will not go into all of them here, but one example is whether a change in your new measurement is regarded as meaningful by people with the disease. Do the results generated by the tool capture all aspects of the concept you are measuring? Do changes to measurement values predict certain clinical outcomes down the road? Does the measurement respond to an intervention that is well understood to have an effect on the property you are measuring in that population? Can the measure correctly identify those patients with and without the condition (sensitivity and specificity)? Likewise, does that property remain unchanged in circumstances when it should not change (exempli gratia in a different population or when there is no intervention)? Of particular note in the realm of digital medicine is the reliance on computational algorithms, the performance of which can improve over time given access to more representative datasets (see chapter 1). The regulatory framework to deal with such systems is under active development at the US Food and Drug Administration (FDA).",200,31,0.155
9783318067095,ch9,"Validation ensures that the technology is measuring what it is intended to measure. It almost always requires human subjects. Validation comprises two types of testing:Analytic validation: does the device process the raw data to produce the measure of interest (exempli gratia convert raw accelerometry data to gait speed in a particular patient population)?Clinical validation: do changes to the measure of interest predict future clinical outcomes (exempli gratia is gait speed a marker of disease progression)?The level of validation associated with a digital measure should be sufficient to support its context of use, a regulatory term that refers to a description of how the tool is used and where it is applied.There is increasing overlap between clinical research and care. Digital biomarkers may initially be validated in the context of clinical research, and eventually transition to a validated digital diagnostic or a digital therapeutic.","Finally, many consider that the 6-minute walk test fails to demonstrate strong ecological validity, that is, it is a poor measure of how test performance predicts behaviors in real-world settings. Stellmann et al. offer an excellent exploration of the ecological validity of mobility outcomes, including the 6-minute walk test, in multiple sclerosis and consider the opportunities for digital tools to improve these measures. Regardless of the quality of a legacy standard, it is unlikely that a digital measurement will agree perfectly with the existing standard. In fact, for this reason, digital measures garner a lot of excitement: they may turn out to be more sensitive than traditional measures or be capable of measuring something researchers have never been able to measure before. Traditional measurements provide only a tiny snapshot of information about a patient's experience of their disease, and they are also fraught with confounders such as white coat syndrome, where a patient's feeling of anxiety in a medical environment results in an abnormally high reading when assessing blood pressure. In other instances, a digital assessment may measure an aspect of disease that has been inaccessible with traditional measures. For the DMD example, a more inclusive digital measurement could be of upper limb mobility, which can be applied to a much broader population of DMD patients. However, there would be little utility in trying to tether this new digital measure against the legacy standard of a 6-minute walk test. To summarize simply, if the test can be performed by a good engineer or physicist who flunked biology, then it is verification. If it requires medical knowledge, it is validation. When is something 'validated' enough?. The answer depends on the specific application. Tools need to be fit for purpose. The level of validation associated with a medical product development tool should be sufficient to support its context of use, a regulatory term that refers to a description of how the tool is used and where it is applied. The Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the FDA, has developed comprehensive recommendations and resources on developing digital measurement tools for use as clinical trial endpoints. This may be a valuable resource for anyone looking to understand the body of evidence that is required to support the use of a digital medicine tool in a clinical trial. Increasing overlap between clinical research and care. Historically, measures that support research (endpoints) and care (outcomes) were siloed. But that is changing: many clinically validated endpoints used in research will likely transition into clinical care. A number of companies are working toward a universal vision of human digital measurement across the continuum of research and clinical care. Clinical research provides a practical approach by which we can link (or validate) everyday behaviors and outcomes. Companies that develop digital biomarkers validate these tools through clinical research as a first step toward what may eventually become a validated digital diagnostic or a digital therapeutic. Similarly, a number of big tech companies are also developing digital measures for clinical settings. In 2018, the FDA cleared a 'software as a medical device' (SaMD) for the Apple Watch, which can determine the presence of atrial fibrillation, an abnormal heart condition. This clearance provides a regulatory pathway for companies to create more advanced diagnostics and interventions for the patient, at home, decentralized. There is crossover in use between research and routine care, such as the safety monitoring of trial participants during the course of a clinical study. However, even in such crossover cases, the clinical trial environment is by its nature more structured and controlled than the variety of settings and scenarios where clinical medicine is practiced.",724,175,0.24171270718232044
9783318067095,ch9,"The level of validation associated with a digital measure should be sufficient to support its context of use, a regulatory term that refers to a description of how the tool is used and where it is applied.","To summarize simply, if the test can be performed by a good engineer or physicist who flunked biology, then it is verification. If it requires medical knowledge, it is validation. When is something 'validated' enough?. The answer depends on the specific application. Tools need to be fit for purpose. The level of validation associated with a medical product development tool should be sufficient to support its context of use, a regulatory term that refers to a description of how the tool is used and where it is applied. The Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the FDA, has developed comprehensive recommendations and resources on developing digital measurement tools for use as clinical trial endpoints. This may be a valuable resource for anyone looking to understand the body of evidence that is required to support the use of a digital medicine tool in a clinical trial.",178,39,0.21910112359550563
9783318067095,ch9,"There is increasing overlap between clinical research and care. Digital biomarkers may initially be validated in the context of clinical research, and eventually transition to a validated digital diagnostic or a digital therapeutic.","The Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the FDA, has developed comprehensive recommendations and resources on developing digital measurement tools for use as clinical trial endpoints. This may be a valuable resource for anyone looking to understand the body of evidence that is required to support the use of a digital medicine tool in a clinical trial. Increasing overlap between clinical research and care. Historically, measures that support research (endpoints) and care (outcomes) were siloed. But that is changing: many clinically validated endpoints used in research will likely transition into clinical care. A number of companies are working toward a universal vision of human digital measurement across the continuum of research and clinical care. Clinical research provides a practical approach by which we can link (or validate) everyday behaviors and outcomes. Companies that develop digital biomarkers validate these tools through clinical research as a first step toward what may eventually become a validated digital diagnostic or a digital therapeutic.",198,37,0.18686868686868688
9783318068207,hh-3,DNA carries the genetic code in the form of sequences of codons; each codon codes for a specific amino acid or a stop signal.,"A codon is a sequence of three DNA or RNA nucleotides that matches a specific amino acid or stop signal during protein synthesis. DNA and RNA molecules are written in a language of four nucleotides; meanwhile, the language of proteins includes 20 amino acids. Codons provide the key that permits these two languages to be translated into each other. Each codon corresponds to a single amino acid (or stop signal), and the full set of codons is called the genetic code. A gene is a sequence of nucleotides in DNA or RNA that encodes the creation of a gene product, either RNA or protein. Genes are built up of DNA. Some genes act as instructions to make proteins. However, many genes do not code for proteins. In humans, genes can differ in size ranging from a few hundred DNA bases to more than 2 million bases. The Human Genome Project calculated that humans have between 20 000 and 25 000 genes. In most genes, coding regions (exons) are interrupted by non-coding regions (introns) (Figure 1.3).",219,28,0.1278538812785388
9783318068207,hh-3,"Non-coding DNA, which is much more abundant than coding DNA (99% versus 1%), has important functional roles; promoters, silencers, enhancers and insulators are examples of regulatory elements of non-coding DNA.","During transcription, the whole gene is copied into a pre-mRNA, which includes exons and introns. During the process of RNA splicing, introns are removed and exons linked to form a contiguous coding sequence. Non-coding DNA. Only about 1% of DNA is made up of protein-coding genes; the other 99% is non-coding. Although non-coding DNA does not provide instructions for making proteins, it is essential to the function of cells, particularly the control of gene activity. Non-coding DNA contains sequences that work as regulatory elements, determining when and where genes are turned on and off. Such elements provide sites for specialized proteins called transcription factors to bind and either activate or repress the process by which the information from genes is turned into proteins during transcription. These processes are very relevant in cancer genetics. Non-coding DNA contains many types of regulatory elements, including promoters, enhancers, silencers and insulators (Figure 1.4).",203,47,0.2315270935960591
9783318068207,hh-3,"Different types of genetic mutation occur. A mutation may result in the production of a protein with altered functional ability, or it may prevent the protein from being produced.","Repeat expansion. Nucleotide repeats are short DNA sequences that are repeated many times in a row. A trinucleotide repeat is composed of three-base-pair sequences, and a tetranucleotide repeat is composed up of four-base-pair sequences. A repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated. This type of mutation can cause the resulting protein to function inadequately. A point mutation or substitution is a genetic mutation in which a single nucleotide base is changed, inserted or deleted from a sequence of DNA or RNA. Point mutations have a variety of effects on the downstream protein product. These consequences can range from no effect (for example, synonymous mutations) to effects deleterious to protein production, composition and function. Point mutations in multiple tumor suppressor proteins cause cancer.",169,32,0.1893491124260355
9783318068207,hh-3,"The most frequent genetic alterations associated with cancer include: base substitutions, indels, copy number alterations, and rearrangements.","The comprehensive genomic profiling (CGP) approach distinguishes four classes of genomic alterations: base substitutions, insertions and deletions (indels), copy number alterations, and rearrangements (see Figure 1.5). Base substitutions/single-nucleotide variants are the simplest type of gene-level mutation. As one nucleotide is swapped for another during DNA replication, the overall number of nucleotides in the DNA is unchanged. The BRAF p.V600E mutation, which results in glutamic acid (E) being substituted for valine (V) at position 600 of the protein chain, is an example.",128,26,0.203125
9783318068207,hh-3,TP53 mutations are the most frequent mutations in patients with cancer. Mutations affect the ability of cellular tumor protein p53 to regulate cell division and survival.,"Tumor suppressor genes. TP53 is the gene that codes for cellular tumor protein p53. This tumor suppressor protein is a transcription factor that inhibits cell division or survival in response to several stresses. It is a critical failsafe mechanism of cellular anticancer defense. Tumor protein p53 regulates the expression of genes involved in cell cycle arrest, apoptosis, senescence, DNA repair and metabolism changes. In cancer, its usual roles are not carried out, so cells survive and proliferate and DNA damage accumulates. TP53 mutations are the most frequent mutations in patients with cancer, occurring in approximately half of all cancers. The mutations are common in ovarian, colon and esophageal cancers, and many other cancer types (as documented in the Catalogue Of Somatic Mutations In Cancer [COSMIC] database - see Useful resources).",174,31,0.1781609195402299
9783318068207,hh-3,Mutations affecting the MAPK signaling pathway are also implicated in cancers. Dysregulation of the pathway results in increased cell division and survival.,"The MAPK signaling pathway begins with the activation of a RAS family protein by receptor tyrosine kinases (RTKs; Figure 1.6). The activated RAS induces the membrane recruitment and activation of RAF kinases, which phosphorylate MEK, a separate protein kinase in the pathway. MEK phosphorylates ERK, which can, directly and indirectly, activate many transcription factors. The activation of these transcription factors by ERK leads to the expression of genes encoding proteins that regulate cell proliferation and survival.",108,27,0.25
9783318068207,hh-4,"Sanger sequencing, although groundbreaking, is labor intensive, time consuming and expensive, and hence it has been replaced with NGS.","The first major step in sequencing was the introduction, by Maxam and Gilbert, of chemical chain termination in 1977. This was followed closely - in the same year - by Sanger's dideoxy method, also known as the chain-termination method, which generated DNA strands of varying lengths that could be separated by electrophoresis (Figure 2.1). This method, which was the basis of the Human Genome Project, essentially allowed a net signal to be derived from a pool of molecules, to give a collective sequence. Many subsequent improvements allowed for commercialization and widespread use of Sanger sequencing but, as the need for high-throughput technology burgeoned, Sanger sequencing proved to be too labor intensive, time consuming and expensive for routine use.",154,26,0.16883116883116883
9783318068207,hh-4,The two major methods for NGS use the Illumina and Ion Torrent platforms. Illumina uses fluorescently tagged nucleotides while Ion Torrent detects a pH (voltage) change on nucleotide binding.,"Sequencing is performed using one of the two major platforms, Illumina or Ion Torrent. These are described below and summarized in Figure 2.3; the pros and cons of each platform are summarized in Table 2.1. The Illumina platform is based on the technique of bridge amplification and uses synthesis with fluorescent detection. DNA molecules of around 500 bp, with appropriate adapters ligated to each end, are utilized as substrates for repeated amplification reactions on a solid substrate that contains complementary oligonucleotide sequences. The oligonucleotides are spaced on the solid substrate, usually a glass slide, so that repeated rounds of amplification create clonal clusters of around 1000 copies of the oligonucleotide fragment. All four of the nucleotides, which are fluorescently tagged, are added and compete for the next space. The complementary tagged nucleotide will bind, but a blocker prevents the binding of more than one nucleotide per round; the remaining non-bound nucleotides are washed away.",201,41,0.20398009950248755
9783318068207,hh-4,It is vital that the results of NGS are considered in a clinical context. A result from an inadequate sample should not be interpreted as a negative result.,"The data from sequencing give numerous signals, many of which are low quality and need to be filtered out. The effect can be negated by sequencing both strands, with a positive result only being called if both strands show the variant. Information must be interpreted in the clinical context. A negative result needs to be interpreted in the light of sample adequacy. If there is inadequate tumor, the specimen should be regarded as inadequate rather than negative. Similarly, low or borderline levels need to be evaluated in the same light, depending on the depth of sequencing obtained. Novel abnormalities should be treated with reserve until databases have been populated with sufficient information to determine the pathogenicity of a mutation.",135,31,0.22962962962962963
9783318068207,hh-4,"Methods of single-molecule sequencing, although relatively error prone, have utility in the sequencing of large variants and transcript isoforms.","Oxford Nanopore technology does not require new molecule synthesis. Single-stranded DNA molecules are fed through minute pores in an electrically resistant membrane. Specialized proteins feed single-stranded DNA through the pores, which have current running through them. The molecule disrupts the current and from the pattern of disruption the DNA sequence can be inferred. Analytic devices can be plugged into a USB port and real-time DNA sequences can be read. While the Pacific Biosystems and Oxford Nanopore technologies are more prone to errors than NGS technologies, they are able to produce much longer reads. This improves the detection of large variants and transcript isoforms generated by alternative splicing, both of which are implicated in carcinogenesis.",148,27,0.18243243243243243
9783318068207,hh-5,"Comprehensive genomic profiles offer a complete evaluation of the genomic landscape of each tumor. The interpretation of the different variants reported, with attention focused on their clinical significance and usefulness for cancer patients, can support oncologists to make informed cancer treatment decisions.","The recent improvements in terms of available technologies and bioinformatics tools have allowed a better understanding of the pathobiology of different tumor types and the identification of several genomic alterations that may be targetable. CGP offers a complete evaluation of the genomic landscape of each tumor for both prognostic and predictive purposes, helping oncologists make decisions about cancer treatment. The adoption of broad NGS gene panels (Table 3.1) may support the administration of immunotherapy drugs in patients harboring high TMB (see page 45). Another potentially valuable approach is hybrid capture-based CGP, an ultra-sensitive assay that can be used to detect variants even in specimens with low tumor purity (a low proportion of tumor cells). The implementation of CGP in clinical practice is, however, limited by issues such as costs, turnaround time, sensitivity, specificity and bioinformatics pipelines. Despite increasing knowledge of the cancer molecular landscape, the clinical and pathological significance of several molecular variants, including SNVs, CNVs and indels, remains unknown and unexplored.",212,49,0.23113207547169812
9783318068207,hh-5,"The clinical and pathological significance of several molecular variants, including SNVs, CNVs and indels, remains unknown.","The adoption of broad NGS gene panels (Table 3.1) may support the administration of immunotherapy drugs in patients harboring high TMB (see page 45). Another potentially valuable approach is hybrid capture-based CGP, an ultra-sensitive assay that can be used to detect variants even in specimens with low tumor purity (a low proportion of tumor cells). The implementation of CGP in clinical practice is, however, limited by issues such as costs, turnaround time, sensitivity, specificity and bioinformatics pipelines. Despite increasing knowledge of the cancer molecular landscape, the clinical and pathological significance of several molecular variants, including SNVs, CNVs and indels, remains unknown and unexplored.",140,23,0.16428571428571428
9783318068207,hh-5,WES or wide gene panels may be employed to assess TMB status to guide immunotherapy decisions.,"Data interpretation potentially limits the usefulness of TMB analysis, regardless of the approach adopted (WES versus wide gene panels) and gene panel employed. In terms of prediction of suitability for immunotherapeutic regimens, it is important to analyze not only the total number but also the type of the detected mutations. While Rizvi et al. underlined the positive predictive value for immunotherapy when mutations in genes involved in DNA repair and replication are identified, Skoulidis et al. demonstrated that mutations in STK11 (also known as LKB1) were associated with resistance to immunotherapeutic drugs.",124,20,0.16129032258064516
9783318068207,hh-5,RNA-based molecular approaches play a pivotal role in the identification of targetable gene fusions and splice variants.,"Data interpretation potentially limits the usefulness of TMB analysis, regardless of the approach adopted (WES versus wide gene panels) and gene panel employed. In terms of prediction of suitability for immunotherapeutic regimens, it is important to analyze not only the total number but also the type of the detected mutations. While Rizvi et al. underlined the positive predictive value for immunotherapy when mutations in genes involved in DNA repair and replication are identified, Skoulidis et al. demonstrated that mutations in STK11 (also known as LKB1) were associated with resistance to immunotherapeutic drugs. Fusions and splice variants. RNA-based molecular approaches, such as reverse transcription PCR (RT-PCR), NGS and multiplex digital color-coded barcode technology, play a key role in identifying targetable gene fusions (Figure 3.3). These are chimeric genes generated from the fusion of two different genes belonging to the same or different chromosomes.",199,23,0.11557788944723618
9783318068207,hh-5,"Some therapies are indicated for MSI-H cancer, and others are in clinical trials. Careful attention should be paid to the accuracy of the MMR evaluation (IHC, PCR or NGS).","pairs of probes (reporter probe and capture probe), designed to be adjacent to one another along the target sequence of a transcript, are hybridized with mRNAs. excess probes are removed and the hybridized complex is bound to the surface of the sample cartridge. the probe/target complexes are aligned on the cartridge by an electric current and immobilized for data collection. the sample cartridge is scanned by a digital analyzer, and each color code is counted and tabulated. The nCounter system has a number of limitations, however. In particular, results generated by reading the color-coded barcodes are not directly usable for clinical purposes. Thus, additional data processing is required. Furthermore, careful attention needs to be paid to the design of the probe to avoid false-positive results.",159,39,0.24528301886792453
9783318068207,hh-6,"The FDA recognizes a pathway of three levels of biomarkers, based on the clinical evidence necessary to support NGS tests.","The FDA recognizes three levels of biomarkers and has commented on the analytic and clinical evidence necessary to support NGS tests for these biomarkers (Figure 4.1). Level 1, companion diagnostics. A companion diagnostic is a test that informs the safe and effective use of a corresponding therapy. For approval of the test, there should be evidence of its analytic validity for each specific biomarker and a clinical study that establishes either the link between the result of that test and patient outcomes or clinical concordance with a previously approved companion diagnostic.",107,24,0.22429906542056074
9783318068207,hh-6,"Multidisciplinary MTBs, comprising various medical disciplines, facilitate the incorporation of molecular diagnostics and interpretation of results into therapeutic decision-making for a patient with cancer.","Level 3, cancer mutations with potential clinical significance. These are mutations that do not fall within level 1 or 2. The variants are informational or used to direct patients toward clinical trials. Tests for these biomarkers should be supported by analytic validation and a clinical or mechanistic rationale for their inclusion in the panel. Molecular tumor boards. Approximately 9% of patients with metastatic cancer harbor targetable genomic alterations for optimal treatment selection with the standard treatments. An additional 27% of patients carry genomic abnormalities with convincing clinical evidence supporting the use of these alterations as predictive biomarkers for response to treatment outside of a therapy's registered indication. Multidisciplinary MTBs, sometimes called multidisciplinary meetings (MDMs) or multidisciplinary teams (MDTs) facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late-stage cancer. See Chapter 6 for further discussion.",178,33,0.1853932584269663
9783318068207,hh-6,"Precision medicine in oncology matches an individual patient to the correct treatment, based on the biological and molecular features of the patient's cancer.","Molecular tumor boards. Approximately 9% of patients with metastatic cancer harbor targetable genomic alterations for optimal treatment selection with the standard treatments. An additional 27% of patients carry genomic abnormalities with convincing clinical evidence supporting the use of these alterations as predictive biomarkers for response to treatment outside of a therapy's registered indication. Multidisciplinary MTBs, sometimes called multidisciplinary meetings (MDMs) or multidisciplinary teams (MDTs) facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late-stage cancer. See Chapter 6 for further discussion.",117,29,0.24786324786324787
9783318068207,hh-6,A basket trial is a biomarker-driven study in which a single treatment and single biomarker are tested in patients with different histologies.,"Traditionally, oncology Phase I clinical trials were conducted with a mixture of solid tumors, and Phase II and III oncology trials were histopathology based. A Phase II oncology study would be designed to answer the question: does a particular treatment at a selected dose in a particular tumor type (from histology) improve clinical outcome (response to treatment, PFS or overall survival)?. Recent developments in molecular profiling of tumors have led to the development of biomarker-driven clinical trials. These can be categorized as basket and umbrella trials, depending on the design (Figure 4.2). A basket trial tests a single treatment and a single biomarker (mutation X in Figure 4.2) in patients with different histologies. In an umbrella trial, participants have a single histology and multiple biomarkers are each matched to different treatments.",174,28,0.16091954022988506
9783318068207,hh-6,An umbrella trial is a biomarker-driven study in which participants with a single histology and multiple biomarkers are each matched to a particular treatment.,"Traditionally, oncology Phase I clinical trials were conducted with a mixture of solid tumors, and Phase II and III oncology trials were histopathology based. A Phase II oncology study would be designed to answer the question: does a particular treatment at a selected dose in a particular tumor type (from histology) improve clinical outcome (response to treatment, PFS or overall survival)?. Recent developments in molecular profiling of tumors have led to the development of biomarker-driven clinical trials. These can be categorized as basket and umbrella trials, depending on the design (Figure 4.2). A basket trial tests a single treatment and a single biomarker (mutation X in Figure 4.2) in patients with different histologies. In an umbrella trial, participants have a single histology and multiple biomarkers are each matched to different treatments.",174,30,0.1724137931034483
9783318068207,hh-7,"The molecular status of, at least, EGFR, ALK, ROS1 and BRAF must be tested in patients with advanced stage NSCLC to determine suitability for TKI therapy.","The second-generation EGFR TKI afatinib has also been shown to be more effective than chemotherapy in patients with EGFR mutations., More recently, patients receiving the third-generation EGFR TKI osimertinib have been shown to have a higher PFS (18.9 months versus 10.2 months) and a lower number of high-grade adverse events compared with those taking first-generation TKIs. ALK rearrangements occur in a limited number of patients with advanced stage NSCLC (3-5%). Despite the low number, patients with an ALK fusion have been shown to respond well to the first-generation anaplastic lymphoma kinase (ALK)- fusion TKI crizotinib when compared with chemotherapy (PFS 10.9 months versus 7.0 months and objective response rate [ORR] 74% versus 45%), with a significant improvement in quality of life.",186,39,0.20967741935483872
9783318068207,hh-7,PD-L1 expression also needs to be tested in patients with advanced NSCLC to guide immunotherapy decisions.,"The second-generation EGFR TKI afatinib has also been shown to be more effective than chemotherapy in patients with EGFR mutations., More recently, patients receiving the third-generation EGFR TKI osimertinib have been shown to have a higher PFS (18.9 months versus 10.2 months) and a lower number of high-grade adverse events compared with those taking first-generation TKIs. ALK rearrangements occur in a limited number of patients with advanced stage NSCLC (3-5%). Despite the low number, patients with an ALK fusion have been shown to respond well to the first-generation anaplastic lymphoma kinase (ALK)- fusion TKI crizotinib when compared with chemotherapy (PFS 10.9 months versus 7.0 months and objective response rate [ORR] 74% versus 45%), with a significant improvement in quality of life.",186,23,0.12365591397849462
9783318068207,hh-7,Knowledge of PD-L1 expression is also required to guide immunotherapy in TNBC.,"BRAF p.V600E. Identification of the BRAF p.V600E mutation is increasingly important as it supports treatment with dabrafenib plus trametinib in advanced stage NSCLC. Programmed death-ligand 1. In addition to the must test genes, the guidelines (see above) strongly recommend evaluating PD-L1 expression to inform immunotherapy decisions.",80,19,0.2375
9783318068207,hh-7,"The utility of assessing several other genes ( ESR1, AKT1, PTEN and HER2 ) and the value of assessing TMB are currently being investigated in breast cancer.","Primary breast cancer. Besides the classic biomarkers used by pathologists in every case of primary breast cancer, such as estrogen receptor (ER), progesterone receptor (PR) and HER2, which guide prognostication and treatment selection, gene expression profile assays have recently been incorporated into the biomarker assessment of early breast cancer. Commercially available genomic assays that provide these profiles include Oncotype DX, MammaPrint, Predictor Analysis of Microarrays 50 (PAM50), EndoPredict and Breast Cancer Index. Data from two large randomized clinical trials examining Oncotype DX and MammaPrint have yielded important evidence for use in discussions about potential benefit from chemotherapy in specific patient populations. When using the Oncotype DX assay, chemotherapy is not recommended for patients older than 50 years whose tumors have a recurrence score of less than 26. For those patients younger than 50 years whose tumors have a recurrence score of less than 16, there is little to no benefit from chemotherapy; however, clinicians may offer chemoendocrine therapy to those with a recurrence score in the range 16-25. In addition, oncologists may offer chemoendocrine therapy to any patient with recurrence score of 26-30. There are many guidelines published concerning the use of these assays.",266,37,0.13909774436090225
9783318068207,hh-7,"Individuals with advanced breast cancer should undergo molecular testing to assess, at least, PIK3CA (ER+ mBC), germinal BRCA mutations ( HER2  mBC), HER2 amplification, MSI and NTRK.","The genomic landscape of mBC is broad; alterations in multiple genes have been found, many with potentially actionable changes. Here, we will discuss only those classified as tier I-A (prospective randomized clinical trials show the alteration-drug match in a specific tumor type results in a clinically meaningful improvement in a survival endpoint) according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) or level 1 (FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication - see Chapter 4) by the precision oncology knowledge base OncoKB., These are PIK3CA mutations, germline BRCA1 / mutations, HER2 amplification, MSI and NTRK translocations. PIK3CA codes for the catalytic subunit of PI3K. A gain-of-function mutation can cause the activation of multiple downstream signaling cascades, including the PI3K/AKT/mTOR pathway that promotes cell survival and proliferation (see Figure 1.6). The Phase III randomized SOLAR-1 trial compared the combination of the PI3K inhibitor alpelisib and fulvestrant with fulvestrant alone in patients with HR-positive HER2 -negative mBC who had progressed on prior endocrine therapy. Participants receiving alpelisib-fulvestrant had superior PFS compared with those receiving fulvestrant alone, leading the FDA to approve alpelisib for HR-positive mBC. These findings stress the importance of clinical testing for the PIK3CA mutation in patients with HR-positive mBC who experience progression on first-line endocrine therapy. Alpelisib is now also authorized for use in the EU.",351,50,0.14245014245014245
9783318068207,hh-7,"Chromosomal instability accounts for around 85% of all CRCs, while MSI accounts for around 15%. CIMP, which shows overlap with the MSI pathway, is found in around 17% of CRCs.","chromosomal instability (CIN), which accounts for around 85% of all CRCs. MSI, which accounts for around 15% of CRCs. CpG island methylator (CIMP), which is found in 17% of CRCs and shows overlap with the MSI pathway. Chromosomal instability is characterized by alterations in chromosomes 17p and 18q. In addition, the tumors acquire mutations in oncogenes and tumor suppressors including APC, TP53, KRAS and BRAF. According to the Vogelstein model, there is initial inactivation of APC, followed by mutations of RAS with inactivation of the TP53 suppressor gene. The most clinically relevant pathways affected are the Wnt and MAPK pathways. Alterations in the Wnt signaling pathway, which occur in 93% of all CRC tumors, lead to cell proliferation. The MAPK pathway is activated by RTKs, such as EGFR, though it can be activated by other downstream signaling molecules, such as KRAS proto-oncogene, GTPase (KRAS), NRAS proto-oncogene, GTPase (NRAS) and BRAF, as well as ERK.",248,44,0.1774193548387097
9783318068207,hh-7,The minimum testing required to determine whether anti-EGFR therapy may be of benefit in CRC is extended RAS testing of KRAS and NRAS: codons 12 and 13 of exon 2; codons 59 and 61 of exon 3; and codons 117 and 146 of exon 4.,"CpG island methylator phenotype. The CIMP pathway is characterized by hypermethylation of CpG island loci and inactivation of suppressor genes. Sporadic MSI CRCs are associated with CIMP-associated methylation of the MLH1 promoter which, in turn, is associated with the presence of BRAF mutation. NGS testing for predictive biomarkers. EGFR activation of the RAS/RAF/MEK/ERK pathway (see Chapter 1) plays an important role in oncogenesis in CRC. Up to 50% of CRCs show activating mutations of KRAS. Anti-EGFR antibodies, such as cetuximab and panitumumab, can be beneficial in patients with metastatic CRC provided that there is no downstream mutation activating the RAS/RAF/MEK/ERK pathway. Initially, patients with codon 12/13 KRAS mutations did not benefit in clinical trials, and subsequently mutations in other codons of KRAS and in NRAS were also shown to confer resistance to antibody-based therapies., Thus, guidelines require an 'extended' RAS analysis be performed. At present, the minimum testing required to determine whether anti-EGFR therapy may be of benefit is this extended RAS testing of KRAS and NRAS.",269,61,0.22676579925650558
9783318068207,hh-7,"Melanoma is a highly mutated malignancy, with mutations - including BRAF, NRAS and KIT - documented in all melanoma subtypes.","Melanoma is a highly mutated malignancy, with mutations documented in all subtypes (Table 5.3)., The KIT mutation is associated with chronic sun damage. The BRAF mutation is present in 11% of patients with mucosal melanoma, NRAS mutation in 5% and KIT mutation in 15-20%. From a molecular point of view, uveal melanoma is a distinct condition characterized, in 50% of patients, by the presence of a GNAQ mutation. The presence of BRAF and NRAS mutations has not been described in uveal melanoma. The serine/threonine kinase BRAF is involved in the downstream signaling of the RTK and RAS proteins. Approximately half of melanomas show BRAF point mutations (Figure 5.2). In the majority of cases, a valine at position 600 is mutated to glutamic acid or lysine (BRAF p.V600E and BRAF p.V600K); both mutations are associated with kinase activation that results from relieving an intramolecular autoinhibitory interaction between the activation segment and P-loop of the protein.",239,32,0.13389121338912133
9783318068207,hh-7,"Approximately half of melanomas show BRAF point mutations. BRAF inhibitors can lead to remarkable early tumor responses in melanoma; however, these responses may be short.","BRAF inhibitors can lead to remarkable early tumor responses in melanoma, though these may be of short duration in some patients. Approximately 20% of patients with mutant BRAF melanoma show no response, and most patients treated with monotherapy relapse, with a median PFS of 8-9 months. Vemurafenib is an orally available small molecule kinase inhibitor with activity against BRAF with the p.V600E mutation; its indication is restricted to melanoma patients with a demonstrated BRAF p.V600E mutation by an FDA-approved test. This agent was approved by the FDA in 2011 and by the EMA in 2012. Vemurafenib has shown an improvement in PFS and overall survival in patients with unresectable or advanced melanoma.",160,34,0.2125
9783318068207,hh-7,Mucosal or acral melanomas with activating mutations or amplifications in KIT may be sensitive to c-KIT inhibitors.,"c-KIT inhibitors. Early data suggest that mucosal or acral melanomas with activating mutations or amplifications in KIT may be sensitive to a variety of c-KIT inhibitors. BRAF and MEK inhibitors in combination. In 2014, the combination of dabrafenib and trametinib received accelerated approval from the FDA for patients with unresectable or metastatic melanomas that carry the BRAF p.V600E or p.V600K mutation. The combination demonstrated improved durable response rates over single-agent dabrafenib. The treatment combination is also approved for use in the EU.",127,27,0.2125984251968504
9783318068207,hh-7,The combination of BRAF and MEK inhibitors has demonstrated improved durable response rates over a single-agent BRAF inhibitor.,"BRAF and MEK inhibitors in combination. In 2014, the combination of dabrafenib and trametinib received accelerated approval from the FDA for patients with unresectable or metastatic melanomas that carry the BRAF p.V600E or p.V600K mutation. The combination demonstrated improved durable response rates over single-agent dabrafenib. The treatment combination is also approved for use in the EU. In 2015, the combination of vemurafenib and cobimetinib was approved by the FDA and the EMA for metastatic melanomas that carry the BRAF p.V600E or p.V600K mutation.",136,24,0.17647058823529413
9783318068207,hh-7,"The majority of GISTs have KIT mutations that result in constitutive activation of the RTK, c-KIT.","Gastrointestinal stromal tumors. Around 80% of GISTs show mutations in KIT that result in constitutive activation of the RTK, c-KIT. Most commonly, there is mutation (SNV or indel) of exon 11, then exon 9, followed by exons 13 and 17 (Table 5.5). Up to 50% of KIT -mutation-negative GISTs have activating mutations of the PDGFRA gene, usually in exons 18, 12 and 14.",108,26,0.24074074074074073
9783318068207,hh-7,"Knowledge of mutations affecting KRAS, MET, RET and NTRK may also help select treatment for advanced NSCLC.","Initially, imatinib was the drug of choice, but the newer TKIs sunitinib and regorafenib have also shown efficacy, particularly for GISTs resistant to imatinib. Avapritinib was approved by the FDA in early 2020 for GIST harboring a PDGFRA exon 18 mutation, including the D842V mutation, while the kinase inhibitor ripretinib was approved later in the same year as fourth-line therapy for adults with an advanced GIST. Crenolanib, which selectively inhibits PDGFRA mutant protein, particularly that arising from PDGFRA D842 mutation, is in clinical trials for use in patients with GIST., The second- and third-generation TKIs dasatinib, nilotinib and ponatinib, which target BCR - ABL products, have shown limited results.",183,26,0.14207650273224043
9783318068207,hh-7,TKIs have some effectiveness in GISTs and non-GI sarcomas.,"Molecular targeting in other non-GIST sarcomas. Pazopanib, an oral anti-angiogenic drug targeting vascular endothelial growth factor receptor (VEGFR), PDGFR, fibroblast growth factor receptor (FGFR), c-KIT and many other tyrosine kinases, was associated with improved PFS in patients with soft-tissue sarcomas other than liposarcomas (mainly leiomyosarcoma and synovial sarcoma) in the Phase III PALETTE study. There is, however, no biomarker to guide its use. Other TKIs used for treating GISTs, such sorafenib, sunitinib and regorafenib, have some effect against non-GI sarcomas, particularly in tumors with PDGFRA mutations.",178,18,0.10112359550561797
9783318068207,hh-8,Different sample types (histological or cytological) have distinct advantages and disadvantages; these are a key issue in molecular analysis.,"In the era of personalized medicine, tissue samples (histological or cytological specimens) acquire a central role not only for morphological evaluation but also for molecular analyses. In this setting, careful attention should be paid to pre-analytic factors that can adversely affect the quality and quantity of nucleic acids in the sample, leading to uninterpretable molecular results. FFPE histological samples represent the gold standard starting material from which to extract nucleic acids for molecular analysis. FFPE specimens contain a high quantity of material for both morphological evaluation and ancillary techniques and do not require additional molecular validation, unlike cytological samples.",127,25,0.1968503937007874
9783318068207,hh-8,Laboratories should pay careful attention to costs and reimbursement systems for molecular analysis.,"Molecular reports are a crucial part of molecular laboratories' workflow. They should contain all relevant information to support the clinician's management of the patient, particularly regarding the best treatment choice., For this reason, the communication should be accurate and avoid any misinterpretation by molecular pathologists or clinicians, particularly oncologists or other physicians who request the molecular analysis.",72,15,0.20833333333333334
9783318068207,hh-8,Standardization in molecular reporting is very important.,"The increasing knowledge about genomic alterations involved in cancer development and the technological improvements represent a serious challenge for physicians making decisions about cancer treatment. In particular, clinicians may have had limited training in molecular biology while molecular pathologists may have low awareness of clinical management. To overcome these limitations, it is very important that challenging cases are brought to, and discussed by, MTBs.",73,9,0.1232876712328767
9783318068207,hh-8,Discussing a patient's results and management at an MTB meeting may help to overcome challenging issues.,"The increasing knowledge about genomic alterations involved in cancer development and the technological improvements represent a serious challenge for physicians making decisions about cancer treatment. In particular, clinicians may have had limited training in molecular biology while molecular pathologists may have low awareness of clinical management. To overcome these limitations, it is very important that challenging cases are brought to, and discussed by, MTBs. Molecular tumor boards are multidisciplinary groups of professionals involved in the management of cancer patients, such as molecular pathologists, clinicians, surgeons, radiologists, geneticists, bioinformaticians and biologists. There are 6-40 members at each meeting.",127,20,0.15748031496062992
